<SEC-DOCUMENT>0000950170-22-004794.txt : 20220328
<SEC-HEADER>0000950170-22-004794.hdr.sgml : 20220328
<ACCEPTANCE-DATETIME>20220328164446
ACCESSION NUMBER:		0000950170-22-004794
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		116
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220328
DATE AS OF CHANGE:		20220328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			4D Molecular Therapeutics Inc.
		CENTRAL INDEX KEY:			0001650648
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				473506994
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39782
		FILM NUMBER:		22776022

	BUSINESS ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5105052680

	MAIL ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	4D Molecular Therapeutics Inc
		DATE OF NAME CHANGE:	20150811
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>fdmt-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-28T16:37:23.0593+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:fdmt="http://www.4dmoleculartherapeutics.com/20211231" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_733a11db-f6c7-4a45-978b-b600cfb15731" name="dei:EntityCentralIndexKey" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be">0001650648</ix:nonNumeric><ix:nonNumeric id="F_6a54b9ee-b4de-4717-a1a2-a0f99f73deb0" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_c21f763e-80eb-484a-a941-fe0af17a7c0b" format="ixt-sec:durwordsen">three years</ix:nonNumeric><ix:nonNumeric id="F_80d41e98-685d-4c82-a966-93ef6194e666" name="fdmt:CollaborativeArrangementAdditionalResearchTerm" contextRef="C_e21eab0a-797b-4380-9011-1aea8fabc1b5" format="ixt-sec:durwordsen">three years</ix:nonNumeric><ix:nonFraction id="F_55f2fc27-7ef4-4149-a482-d2ca9293554a" name="fdmt:CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage" contextRef="C_2bc81db7-5978-41b8-8ad4-14969a57ecec" unitRef="U_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">300</ix:nonFraction><ix:nonFraction id="F_ae6a1cea-4dc5-429f-b6df-a8af5d5155a4" name="fdmt:ExpectedPaymentsPercentageToEqualActualAwardReceived" contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d" unitRef="U_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">600</ix:nonFraction><ix:nonNumeric id="F_c05559b7-51fa-4d3d-9739-b6c4a7e260ed" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_dcff2890-ab1b-4492-8304-4e459fc72f25">P3Y</ix:nonNumeric><ix:nonNumeric id="F_3340247d-416d-4f03-a381-b95a54629875" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_92bf420a-5530-4711-a7fd-253e4d577ba6">P1Y</ix:nonNumeric><ix:nonNumeric id="F_834220d8-b4e4-44b5-a1d2-6aff019d75c5" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" contextRef="C_2f32afd7-17e5-440d-95d7-e8e98ffe403b">http://fasb.org/us-gaap/2021-01-31#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonFraction id="F_ebac0ee9-675f-4dde-a1fd-3d4097e446f6" name="fdmt:CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived" contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d" unitRef="U_pure" decimals="2" scale="0" format="ixt:numdotdecimal">6.00</ix:nonFraction><ix:nonNumeric id="F_4716bf1b-08a4-4338-8ed0-e0aaa71272e5" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201807Member</ix:nonNumeric><ix:nonFraction id="F_0a20beb0-d4ab-4118-b999-4fa51b854c40" name="us-gaap:CommitmentsAndContingencies" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_8c0d535b-cead-44fa-bf8b-5dbc70a40b76" name="dei:AmendmentFlag" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be">false</ix:nonNumeric><ix:nonNumeric id="F_e0dbc496-2e08-4773-b4c2-4ca34dfb7a2f" name="dei:DocumentFiscalPeriodFocus" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be">FY</ix:nonNumeric><ix:nonNumeric id="F_f500242c-7c9c-43e7-8ba7-87e2388aa1db" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" contextRef="C_27c30b85-a010-4be5-a956-5fa66be6b6dc">http://fasb.org/us-gaap/2021-01-31#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonFraction id="F_93b3ec84-9a75-4877-a7e9-d3f6a374cf61" name="us-gaap:CommitmentsAndContingencies" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fdmt-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_e7d12ec2-7bb6-4ee6-9329-dfed184d0890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bc0fb33-e137-466b-afc1-ac2316dff7e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68203dba-eb94-47f4-bc69-28308c9e86fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">fdmt:CorporateBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87699b30-eed2-4ea5-86f4-0a39c1e5772e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:TwoThousandAndSeventeenRocheAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b9316bd-43bb-4236-afee-5dedacf34852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62a5478f-6648-41ef-8d95-7e857719eae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:TwoThousandAndSeventeenRocheAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ffdd2326-026c-4d95-8076-5a7d7c11f527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43895722-c889-4f5a-86ef-d1095b190b17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:MachineLearningSponsoredResearchAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d4c97fb-5c4e-482d-aa4f-d431fcdad1c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fcb58636-b558-407f-b0d5-265a83042f1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a392933-0525-4a24-bd80-f86924e2bcf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:AmendedUniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f3dd1a0-d4ca-4297-8f43-1b41c1131161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7e7e417-5edc-4abf-a76c-5be707bce23e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_100f6d0a-7eb4-409e-8987-51846785183e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c9ad16b-c408-4093-be43-5c9223652764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87f2bd8f-07bf-4e4e-8992-26041f581ddc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cddd6872-9bae-4abd-b89b-a8b4f291f7b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da021c91-4acb-426f-8a80-77705578bab8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46645de8-496d-4445-bcee-79e0f6a7e2e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:ChoroideremiaResearchFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:ChoroideremiaResearchFoundationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d15ccf5a-554c-4e09-bf6c-621fbf797861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29d03014-ea19-4d37-bd22-35b0ce14deba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dab250fb-28e0-4123-8e2b-eee2d878a7bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb67bb6e-bab1-4045-8de0-aaff307da3a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17493eda-6778-49b9-933d-bb5807fea6cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f311e2d1-83ec-4e94-91c6-bb50b44c9a4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7242b4b-b2c1-47e2-8a49-09fa5d802063"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c2f744e-0a59-4216-9244-12153c1d29c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc9158f0-cc85-4a61-9faf-16e23bce0c56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46bb51b8-c564-4f79-bb7b-808fc09a2915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3af24779-857a-4d8c-8ca2-daaa220bb8ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_debe135a-c35c-4564-ab5a-f34f314d29f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc671fd0-0ba3-4f31-87f7-95c143537ef9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aaf1e58d-3b1c-4821-9e56-aaa8b373ab63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0652071b-4c72-4479-b886-fe246ac1708e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f509df6f-30cd-48cb-a9e1-308f964642f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac7b6ce7-cd1a-4e4d-84ee-87d64c2d5f60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:MachineLearningSponsoredResearchAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4411f8c-40ed-48bd-b0d8-e6366fa6b2c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3efe0308-17fb-42e4-98f2-745c68439aa1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c922aa7a-0ebd-48c9-9a1f-066c43a04ba3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7407984c-b650-4ccb-99f5-f9cd63af7b7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:MachineLearningSponsoredResearchAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b63ba5ca-290b-449e-9c24-797545392bb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">fdmt:TwoThousandFourteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c21f763e-80eb-484a-a941-fe0af17a7c0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3286dd10-3afc-4496-bbd6-5ba1f0954a8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1001d586-4a93-4bdd-bca8-c247e6d58d1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7b36ed3-eaae-482f-82c3-37d423f79c62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da9eacae-140f-4ff4-bc19-21fffcc55707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8f5fd72-5501-4424-9c3c-155dadbc1f06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:AmendedUniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98081424-857b-49e5-aa11-1c55ddebeec0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc4d438d-ed76-4f51-85bd-a0b92d8c257e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af32b9d1-9efd-44e5-8ceb-eb4bf3e5244b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:AmendedUniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04e47ba0-ce07-4a2d-aa4a-280a066c7c65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0dd3438c-f8c5-4fe9-8672-19340e3bbb9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7421a1ac-23e5-447d-aabe-10f3efe826be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f96a58ac-dc2a-4623-8894-1ced49494bd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_216819a8-6057-48ea-a590-8f9225ba8a73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfd0d18e-816a-44fd-b58e-bba6ac6a812a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49564e79-c36e-4c78-aae6-91ada470dc34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_067e587d-dfef-4587-ad79-844c454aeb5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8c80726-14a0-4e92-b15c-36f91786d60a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:ConsultingServicesAndServicesAsBoardOfDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:CoFounderAndChiefScientificAdvisorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7958ed8e-8790-49e7-bfb6-54045eeb9eec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90284da0-93f6-431a-8c5e-011cfcb8f1f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbcc2364-ba79-4bc4-b41b-1b1dc9a8eede"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01872582-961a-450f-b5a8-ef39a9a60634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fc037ec-2e59-4454-98a8-7a703d7f1706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesA1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_542e8a0a-d3fd-48d5-aca9-2b0837fda539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0befc9ee-bbe3-4743-91fb-e5d8d3675f92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08032442-cecd-44e4-8446-5caefea14888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00c84e7f-1487-4fcb-b57c-626e653667be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fd3c166-54d6-4e85-a12d-b5c2352e23fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdb51331-8f19-40ce-b87c-0d9aa4e26603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0611f15-32cf-4702-b60f-3cf600264460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-24</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1dda0de-9512-4575-b09e-7dc96d5fda59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6961af42-3676-40b4-923b-b55bd4213555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0912072b-bcab-4ad8-a96b-b69214a4c085"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbf54024-6915-42de-b1f4-5893be4aa781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_963e934f-bc6b-4dc6-a918-158ec67c6212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:FundingAgreementProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_899d20dc-a0cb-4505-b8f0-3ed14460cfce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2757758c-223e-4e96-ad58-555f2a1537e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27c30b85-a010-4be5-a956-5fa66be6b6dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8cb6a3a-516a-44ff-a6c4-14639dae2312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:ConsultingServicesAndServicesAsBoardOfDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:CoFounderAndChiefScientificAdvisorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84f39b44-5422-454e-b43f-0e6094e9de94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f933dccb-0084-4f9e-bd98-0601bbc462d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3231fac-0339-4b86-8552-33d99ccf5b90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_528f45e3-d466-442e-aad5-49b6b3b7312c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68843b0d-f738-4525-bbf0-8acf1ea83427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b24504fe-8333-4d24-bea3-21f963c10bdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79e057b2-8bbb-4970-a6fe-1330e9256ec6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3baf353-2444-4e1a-a27d-448df6997e93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:NonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_614c9897-40b5-49d5-891b-2e8c91231c75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b1c1ec5-d872-44ae-8bb5-78aa34f73511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a794422-dee1-4707-8185-703c70506d97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfe98104-f350-4823-9e4e-dde161bbcd77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fdmt:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bf2311e-d3cd-40c5-9ad2-5823cd5dccbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76054bca-7f31-466a-af59-aee060457d1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e21eab0a-797b-4380-9011-1aea8fabc1b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:ChoroideremiaResearchFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:ChoroideremiaResearchFoundationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e90ff7ba-2215-4139-bfb3-bb512afebcb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f4f9f3d-c2a5-4a7a-b39c-2a675787b677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02f4bd8b-251b-482c-a9fc-56da777a2727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0ae8a23-d71e-4828-8ac8-78470326d77f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25a62ff3-b92c-4866-af5f-948e6635deba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44ba6365-051f-4e87-afa2-47586cb35c9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:ChoroideremiaResearchFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:ChoroideremiaResearchFoundationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_952d0fc8-cacf-4343-ad40-069f13b709dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_019809d7-3321-4394-ad06-f1dce3e3dcd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d9e57bc-9656-45fb-9e86-21e8155c0587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d12171a9-377c-49ef-adaa-5888c0e1ab2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201807Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0deaebff-c017-4132-ad32-5d55ae62b6b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:NonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5ffbd72-9ff1-4119-bcd0-b30265f21d41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92bf420a-5530-4711-a7fd-253e4d577ba6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1e25908-cccb-42b0-b877-3c97c0b0e8c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d24dc914-f653-4ead-88fd-297fac82aaf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5dc42fe3-b34c-426f-a35e-e9d6777af922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c273596-2f89-4f1e-8401-1a71be26008e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c926a8a-82fa-447e-b1e6-bbfe1e709a29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10bf4f98-2380-4a78-bf83-b60685bbda33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40669389-a7ad-4950-93fb-0a77d4c10a4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:FundingAgreementProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e28aeda-24d7-44f2-b175-686133e42282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:AmendedUniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_438b050d-f05e-45d9-947c-0d5a7c04e2ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1c116f5-4fc4-4134-a20b-4bb41e384479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67c79b0f-725f-4422-a99d-21b85901d3c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbdb060d-8326-4e8e-bfca-89985b0ee2d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c74490e-c642-49f7-a178-c5c00a711057"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aded6adf-76e7-4673-85fe-7c5fc3d77d2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_485d52ae-2831-49f8-b4f8-3e103c72940b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8da58ed6-e246-4eec-ba9a-77c486b0bfab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4b6884a-ce1d-4bbf-9756-4c19b608736e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e44911fe-c20f-4f88-b1c1-84fcf30c91f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2425f46-763c-4d4b-b2fc-1ca90612499e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f7ac562-47e8-4c80-b681-d3d1fbda0f72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_625a9586-f459-4552-b058-fb7510d5960c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22fd50bb-c8c9-4334-a1b4-281b0e9b354f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bc81db7-5978-41b8-8ad4-14969a57ecec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5292ea9b-5f9f-47a3-8950-e560df46b007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f91508fa-5dfa-4192-91eb-1afaa64ddaad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_778cb29d-d166-4215-968b-ce01bbf701d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46423923-3058-4aaf-ac32-c74922d40a3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2004132-d784-47b1-a1e9-3cd43319e93f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7974df26-e7b0-4ed8-86d9-17fbf7835f1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:TwoThousandAndSeventeenRocheAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_646334cd-512e-4567-85e0-49ec256638ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d804358-02f5-4c3e-b83a-38d656050858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:FundingAgreementProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b06fcf3-412c-465d-8612-1b6688ca22a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87233471-231c-4c4b-ba05-554ef259a531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38363b5b-dfc5-4de3-ad6d-69dec1df22bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7f143b1-ffa9-4263-bc77-01c55254624d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccccdee5-98b9-4eba-97f0-75b85fa9ed38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b92a1f3f-887c-4ea7-a989-5b92852b7259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e63d3fbd-6765-47dd-a387-c3545c1942c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_345dc4b4-ecea-45cf-b824-fa29a5f06694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3cb484d-807c-45d4-a35e-ca7c2f3f9313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6daa8ce8-a992-4249-a203-b1e888605ef4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0851c4dd-d51b-410e-9510-555127298972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71c68b91-969e-469a-ac31-ed7554ddc8fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf542ed1-e6b5-4685-8a2e-3f4a7e276ae0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a6c44c3-d641-4e5e-b729-a73d0337615b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f32afd7-17e5-440d-95d7-e8e98ffe403b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:TwoThousandAndSeventeenRocheAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_069b0a0c-065c-4686-838b-2ac26250f05e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ba7e920-3f27-47fd-a911-2a4a015a560f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_893705a7-019f-4880-8fba-130e464feaa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b2169b0-5a83-4d78-862e-5aacb257dffc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_369e8cc3-d5ce-4005-9fa7-8014c0cde676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_592a756d-a16a-4bd3-aad9-7318649c6f44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcff2890-ab1b-4492-8304-4e459fc72f25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e52d4eb1-67cf-418e-81c2-9f61ca8b3839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d63139e-3006-4754-b5ec-c678676f6695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7224f03c-f6e9-4042-a275-59c886ca1970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7f9066a-37f9-4184-9c45-03d0ffb6a47b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b47d4e9a-a1c9-42dc-ad5a-046908180aa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d724d8a1-6a4a-42cb-a720-853feca51dab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f51aa86-d6a8-4946-b9c6-489cfcc06d93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76372236-463c-49d8-950b-bfdd59d89a3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">fdmt:CorporateBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_156eea03-1e5f-4d20-bdd5-c6922ae709bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_649adcbd-b0e6-4117-97c9-7ba0549ac8dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd0116f7-4d6b-4e75-acbd-f547c6e71c2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a55673c8-51f2-4439-9f29-f4ac123dd97d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aee471bc-dfa2-486c-b5af-72c1159914db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f61ac2f-cef4-461c-a2ee-3967bbb25c65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a99aa56e-af3c-4d75-814c-006a1628cef5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47f11691-274e-42ed-9d35-7150a1a1bafe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74377b23-9b2b-42d3-bf22-b1ecef810775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201807Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78089c61-9c63-4f0e-ab4c-7158c1adabeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4af4886-82cd-4423-a392-44aee99ef576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_068f626d-cf83-45b9-9dba-b873304176e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1ec6218-dc19-4a0d-9c16-9e9cf05148c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d6bb9b3-6b6c-4b68-931a-aa92ca2d40c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fe951a6-989e-495f-bcdd-517a1a9d9539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fafc5e1-de72-42ab-a39e-911d607b5701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e916e9be-dd44-4775-b1f3-058f8afa1981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a504b7f3-7605-46fc-8597-53b18af6a1d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3050ecb2-11ee-4119-a548-6cdd89f1f561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c6ae4c6-838d-4e8a-a05e-7a077c423abd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf1c55da-f533-4e8b-9709-41e08427872a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_994128d2-ff7e-458c-a06e-3646a588a46f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4e47e36-ad9e-4007-bb25-cc82fae064e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcb74483-fa99-4ee5-a6ea-6a4843de5d40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fed81344-7c82-4eb4-9718-d25d585ff1e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20cd7796-d782-44fd-9c7c-a0d741c85cea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:FundingAgreementProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13f6e26c-4d62-4ef8-b29b-c168bba13d36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b3c671f-d9c2-479a-878e-5392aef7d177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17b5390d-b508-41a3-bec9-d59c6b3e03e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be527709-9a9f-4be1-8ea5-1064c24e61fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:ChoroideremiaResearchFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:ChoroideremiaResearchFoundationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5768aef4-f24f-4156-919c-885a554541d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8920c352-ac30-4ff7-8543-68d35ca73a38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80f31e89-ff18-484e-81fb-0a391abdc4b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe322eef-bf6e-4784-9f7d-22ae2b365638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2975534f-c7d6-40d2-b4f0-8396ed62ffe5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:AmendedUniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0620193-2d47-4e0f-b17c-1fa3385b38cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aad92407-2080-466e-ba91-9ebcedf0142e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_794002d9-a4fd-4194-b523-592564162f24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f63f746-5168-4906-b7e7-1be53b0dbc62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62df8820-e746-4de8-8b5d-7651c94d18fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4eaef891-9b88-429e-bd16-799664373d3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efc3ff61-873a-4027-8905-9906185f858f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddf9471b-7dbf-43eb-8802-d9844a6eb24a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_229b1105-6f81-4be3-bc0e-35524c07bfa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da1fd0ee-2a34-41fc-9e75-f7316c4ea264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_618215e0-a055-427d-9220-18bee23b39f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5af98ab-cbe3-47d9-a7e7-15b8be38cf21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdd81399-daf3-42e2-bc69-e7aaf154c086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26af25a4-cb52-44ca-92d6-ccc8fa01b65f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf4beef8-281b-4990-bced-f3548175f663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a196306-24e0-483e-8634-0a715c3d21e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b20ba5e2-9962-466b-938b-74b85690f0f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_925a7886-495a-4170-9b11-97befb205b58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2316f0b3-fa95-4376-836f-ea0ad0fecdf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fdmt:SeriesBFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_363a526b-afc7-4132-8b3a-387a13ab7bb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59d3639a-d9e5-4bdd-af89-ba17bedfea32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eab566a6-1468-49d2-aaec-a715d312418d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1784e7f0-ff83-48df-a30d-36b81c4f651d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fdmt:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36758c2d-4d20-4d3c-a68c-1ae0229d4cbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee124165-31e9-4e1d-8df3-5e051998cafd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:TwoThousandAndSeventeenRocheAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3e07726-b4be-4673-8ad2-8d4cb0def982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6589222f-c96b-40f8-a688-38fc97e550be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0a7f822-26e3-4aa6-b0cb-8635b7e734f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8a50303-fca8-4db7-8914-b41268aac3b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2f26722-25bb-4a09-88a3-02cae078cf69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_490d082b-4c24-4ebc-97b4-1f4ca133afe2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7aabaf7d-fcee-40ec-a3ce-91d93ae55155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5c170a8-c607-4fca-ab72-c7b6add90b77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b9c4496-5f5c-4b08-a9c6-6e3811f8ebe6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5ca12fb-9ded-49e2-8667-052f68f5cdfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77581bff-7745-4be8-a763-3227bbf42da1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">fdmt:TwoThousandFourteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6795eac3-18cb-415a-b6be-fd09406f11f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:ChoroideremiaResearchFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:ChoroideremiaResearchFoundationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84be53f3-486d-4f0d-90b0-07d7e83acbf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d34de791-bc33-4d58-b8e1-f57a6ba20191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650648</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Financial_Institution"><xbrli:measure>fdmt:Financial_Institution</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Agreement"><xbrli:measure>fdmt:Agreement</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>fdmt:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Installment"><xbrli:measure>fdmt:Installment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Security"><xbrli:measure>fdmt:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Arial;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Arial;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Arial;">FORM </span><span style="font-size:14.0pt;font-family:Arial;"><ix:nonNumeric id="F_8c758c1f-dfb8-4542-816c-a32f9c90553a" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Arial;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:14.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2120c39-db86-40b0-b219-e1b7c443f3c7" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_21fd7a81-9d01-434b-b342-d3862723514e" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_db524af4-03bf-4955-8693-e05682ace4ee" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">, </span><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_e0f6ca37-bb5b-4085-bdf1-d17252e38804" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2e208dd-3747-4c0d-a5f3-58d5e872b47e" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">Commission File Number </span><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_93f7ca44-1a2b-498f-8360-b67fff8944ac" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">001-39782</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:18.0pt;font-family:Arial;"><ix:nonNumeric id="F_b13aa42d-9504-4731-b73c-a15488a6ea06" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Arial;">4D Molecular Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Arial;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_0a54d246-f230-4797-b693-71096b90c938" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_7e5c9d5a-4d9e-4fdb-b552-db613dd4e0eb" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">47-3506994</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_803c9ecc-d1ae-4e87-95f0-248ca5b6ef1e" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">5858 Horton Street #455</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_c18e38c6-a2ae-4e7b-b400-132be7bb4b46" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">Emeryville</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">, </span><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_eb2d20b5-9bd6-467a-9ab1-135270c00d0b" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">CA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Arial;"><ix:nonNumeric id="F_7bcfe6bd-71de-4f53-997b-97018274b0f3" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Arial;">94608</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Arial;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Registrant&#x2019;s telephone number, including area code: </span><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_e2113554-ff7a-415c-89fd-20553fc4906a" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(510) </span></ix:nonNumeric></span><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_7b4abf3c-a825-467a-872b-10b398d21343" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">505-2680</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.793%;"></td>
    <td style="width:1.018%;"></td>
    <td style="width:20.396%;"></td>
    <td style="width:1.018%;"></td>
    <td style="width:38.774%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Trading Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_14608851-1aa5-452c-8f86-28c43ebef0db" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_fd3f339b-7c1d-4f4a-b9e3-dcf44ae74287" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">FDMT</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_1ac81c36-da6d-402d-8465-f41590886211" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_a1d5f151-1c8e-4e46-bc50-f40c4d3f9100" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_c824aee0-aec5-4ab0-b660-ed4cda10715c" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_9bb27839-1033-4e4e-a572-5730edc86128" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_126fbb44-6bc3-4886-8ba7-a294fd375ab6" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.759%;"></td>
    <td style="width:0.759%;"></td>
    <td style="width:54.759%;"></td>
    <td style="width:0.963%;"></td>
    <td style="width:20.417%;"></td>
    <td style="width:0.583%;"></td>
    <td style="width:1.759%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_b5f0e19f-6bd7-4f1f-8561-08158656bede" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1b489c9-789b-4ed6-8c28-f442007cf357" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99a6cafc-8ecc-4a18-bc9c-633a602a64fd" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_795bbfad-e288-49a3-95ca-2615a90ac4cd" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a700b803-d942-4b3e-9ae1-b730e3122663" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79079350-9729-48fe-9eae-c5509e61c972" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq Global Select Market on June 30, 2021 was $</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_d2dd9093-47cb-445d-872a-5302d567b86e" contextRef="C_6b06fcf3-412c-465d-8612-1b6688ca22a8" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">444,521,977</ix:nonFraction></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of March 28, 2022 was </span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_a963fb32-801c-4eff-b602-c2a1b466b744" contextRef="C_216819a8-6057-48ea-a590-8f9225ba8a73" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,237,496</ix:nonFraction></span></p>
  <div style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_cd94eb65-c4ac-4494-b4ef-81db04e4fba5" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Portions of the registrant&#x2019;s definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2021.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.003%;"></td>
    <td style="width:81.914%;"></td>
    <td style="width:7.083%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">115</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">115</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">115</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">115</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">116</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">130</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">132</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:7.2pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">132</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">134</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#aaaa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">136</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Annual Report on Form 10-K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential,&#x201d; &#x201c;positioned,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the success, cost and timing of our development activities, preclinical studies and clinical trials, including our clinical trials for 4D-310, 4D-150, 4D-125, 4D-110 and 4D-710</span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing of IND-enabling studies and results from such studies;</span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing and success of lead optimization for our product candidates in lead optimization;</span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the translation of our preclinical results and data into future clinical trials in humans; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing of any manufacturing runs for materials to be used in patient trials; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the number, size and design of our planned clinical trials, and what regulatory authorities may require to obtain marketing approval </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the potential effects of the COVID-19 pandemic on our preclinical and clinical programs and business; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing or likelihood of regulatory filings and approvals; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to obtain funding for our operations, including funding necessary to develop and commercialize our product candidates; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the rate and degree of market acceptance of our product candidates; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the success of competing products or platform technologies that are or may become available; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain approval; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">future agreements with third parties in connection with the commercialization of our product candidates; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to serve those markets; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">existing regulations and regulatory developments in the United States and foreign countries; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the expected potential benefits of strategic collaboration agreements, including our relationships with uniQure and Cystic Fibrosis Foundation (&#34;CFF&#34;), and our ability to attract collaborators with development, regulatory and commercialization expertise; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">potential claims relating to our intellectual property and third-party intellectual property; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the pricing and reimbursement of our product candidates, if approved; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our ability to attract and retain key managerial, scientific and medical personnel; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our financial performance; and</span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.653%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">These forward-looking statements are based on management&#x2019;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management&#x2019;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Annual Report on Form 10-K may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report on Form 10-K. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">iii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">usiness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="overview"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Overv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">iew</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are a clinical-stage gene therapy company pioneering the development of product candidates using our targeted and evolved AAV vectors. We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution, which combines the power of directed evolution with our approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. We believe key features of our targeted and evolved vectors will help us to potentially create targeted gene therapy product candidates with improved therapeutic profiles, and to address a broad range of both rare and large market diseases, including those that other gene therapies are unable to address.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have built a deep portfolio of gene therapy product candidates, with five product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa (&#34;XLRP&#34;), 4D-150 for the treatment of wet age-related macular degeneration (&#34;wet AMD&#34;), 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, and 4D-710 for the treatment of cystic fibrosis lung disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe we are positioned to create, develop, manufacture and, if approved, effectively commercialize targeted gene therapies that could transform the lives of patients suffering from debilitating diseases. <br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Our Product Candidate Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are developing a diverse pipeline of product candidates for both rare and large market diseases, including patient populations that other gene therapies are unable to address. Our initial product candidates are focused on the following therapeutic areas: ophthalmology, cardiology and pulmonology. Each of our product candidates leverages a targeted and evolved vector we invented through our Therapeutic Vector Evolution platform. Below is a summary of our wholly-owned product candidate pipeline:</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img227133604_0.jpg" alt="img227133604_0.jpg" style="width:624px;height:280px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Ophthalmology Pipeline: Intravitreal Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With our ophthalmology product strategy we plan to treat diseases that affect tissues throughout the retina. We are developing product candidates to treat tissues throughout the retina. Our retina product candidates, 4D-125, 4D-150 and 4D-110 utilize our targeted and evolved AAV vector, R100, which was invented for routine intravitreal injection, leading to transgene expression across the entire surface area of the retina and in the major cell layers of the retina.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Cardiology Pipeline: Intravenous Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With our cardiology product strategy, we plan to treat patient populations in both primary cardiomyopathies, that involve the heart only, as well as cardiomyopathies that are secondary to systemic diseases, such as lysosomal storage diseases. Our cardiology product candidate, 4D-310, utilizes our targeted and evolved AAV vector, C102, which was invented for routine low dose intravenous administration and delivery to the heart, leading to transgene expression in heart muscle cells throughout the organ. For lysosomal storage diseases involving the heart and other organs, including Fabry disease, our product candidates are designed for transgene expression both within the heart and in other targeted tissues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Pulmonology Pipeline: Aerosol Delivery Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With our pulmonology product strategy, we plan to treat diseases that affect the lungs. Our pulmonology product candidate, 4D-710, utilizes our targeted and evolved vector, A101, which was invented for aerosol delivery to all major regions within the lung, including airways and alveoli, and penetration of the mucus barrier for transduction of lung airway cells, overcoming potential barriers such as pre-existing AAV antibodies and other inhibitory proteins within the mucus barrier. A101 was designed to enable efficient airway and alveolar cell transduction and transgene expression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">The 4DMT Therapeutic Vector Evolution Platform: Evolved Vectors for Targeted Gene Therapy</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Gene therapy holds tremendous promise as a transformative therapeutic class. However, the majority of gene therapies have encountered limitations such as inflammation and toxicity, high dose requirements, limited efficacy and neutralization by pre-existing antibodies, due in part to their utilization of conventional AAV vectors that are naturally occurring and non-targeted. Through our Therapeutic Vector Evolution Platform we apply the principles of directed evolution to invent targeted and evolved vectors for the delivery of genes to specific tissue types to treat diseases involving those same target tissue(s). Our product candidates are designed and engineered to utilize our targeted and evolved vectors to potentially address the limitations encountered with gene therapies utilizing conventional AAV vectors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The first step of directed evolution involves the generation of massively diverse libraries of biological variants. Leveraging a wide range of molecular biology techniques, we have developed a collection of 40 distinct libraries that are comprised of approximately one billion synthetic capsid sequences. We next define a Target Vector Profile that identifies the optimal vector features for the specific tissue type(s) and related set of diseases we seek to target, with the goal of overcoming limitations encountered by conventional AAVs. We then deploy Therapeutic Vector Evolution with our capsid libraries in non-human primates (&#34;NHPs&#34;) and use competitive selection to identify targeted and evolved vectors from our libraries that demonstrate the strongest match to the Target Vector Profile. Subsequently, we characterize and evaluate a lead targeted and evolved vector for delivery and transgene expression through extensive studies in NHPs and human cell and organotypic tissue assays.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe our proprietary vectors will allow us to overcome known limitations of conventional AAV vectors, and to potentially address a broad range of diseases that affect both rare and large patient populations that cannot be addressed with conventional vectors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our proprietary Therapeutic Vector Evolution Platform is based on the principles of directed evolution. Directed evolution is a high-throughput platform approach that harnesses the power of evolution in order to create biologics with new and desirable characteristics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The first step in directed evolution is to generate massive genetic diversity. Starting with the genomes of multiple naturally occurring AAV variants, and their ancestral predecessors, we employ numerous molecular biology techniques to create our 40 distinct libraries comprising approximately one billion synthetic capsid sequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img227133604_1.jpg" alt="img227133604_1.jpg" style="width:605px;height:263px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Starting with our 40 distinct libraries comprising approximately one billion synthetic capsid sequences, we conduct Therapeutic Vector Evolution, including competitive selection, to identify targeted and evolved vectors that fit a Target Vector Profile. The illustration below highlights the Target Vector Profile design and subsequent selection process whereby competitive pressure is applied over a varying number of selection rounds for each program. Capsids with the best fitness for the Target Vector Profile are enriched at each round and are designated lead vectors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img227133604_2.jpg" alt="img227133604_2.jpg" style="width:612px;height:331px;" />&#160;</p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our co-founder Dr. David Schaffer, pioneered the use of directed evolution to create improved AAV capsids for use as gene therapy vectors at U.C. Berkeley over 20 years ago. Since the company's founding in 2013, we have developed and industrialized our Therapeutic Vector Evolution Platform to invent targeted and evolved vectors for use in human therapeutic products. In addition to the foundational libraries we in-licensed from U.C. Berkeley, we have created over 30 new libraries, which comprise approximately one billion proprietary synthetic capsid sequences. In addition, we have developed significant experience in performing Therapeutic Vector Evolution programs in NHPs, with over 14 capsid selections completed to date. We believe this will help us to develop product candidates to address a broad swath of diseases in rare and large patient populations, including those other gene therapies cannot address.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Diverse Libraries of Synthetic Capsid Sequences</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Each library results from the application of a different genetic diversification methodology, such as variable loop mutagenesis, random peptide insertion, random point mutagenesis, DNA shuffling and ancestral reconstruction, and is also defined by its starting material (AAV capsid gene sequences). We also apply bioinformatics, emerging technologies, and experience and know-how resulting from previous discovery programs to continually improve and expand our libraries and improve our ability to select customized targeted and evolved vectors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe the size and diversity of our proprietary synthetic capsid libraries represent a differentiating competitive advantage for us in the field of gene therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The Target Vector Profile Followed by Competitive Vector Selection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We employ a rigorous approach to inventing targeted and evolved vectors based on what we consider an optimal vector and product profile, which we term the Target Vector Profile. For any set of target diseases that affect the same tissue(s), this profile includes any combination of the following: the optimal route of administration for targeting the specific tissue(s), the optimal dose range, the desired distribution of vector transduction within the target organs, overall biodistribution and/or antibody resistance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We use our Therapeutic Vector Evolution Platform to select the &#x201c;fittest&#x201d; targeted and evolved capsid that best matches our Target Vector Profile. We achieve this through serial rounds of &#x201c;selection&#x201d;, or discovery, with each round of selection filtering down to fewer and fewer synthetic capsids from the original library. This funneling process is achieved by applying selective pressures&#x2014;forcing competition&#x2014;among all synthetic capsid variants in the library to achieve delivery to the target cells as defined in the Target Vector Profile. Each round is performed in a primate </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, sometimes in the presence of human antibodies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By the end of a typical Therapeutic Vector Evolution process, we will have identified approximately two to four targeted and evolved vectors, or hits, based on their frequency in the final pool of synthetic capsid sequences, in addition to numerous sequences present at lower frequencies. We believe this deliberate approach to selection </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> in NHPs and in human tissues should lead to identification of targeted and evolved vectors with a higher likelihood of therapeutic benefit in humans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Vector Invention Results to Date</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have completed unique vector selection programs or &#x201c;selection processes&#x201d; for specific proprietary synthetic capsids with specific Target Vector Profiles. Across our clinical development and discovery portfolio, we have utilized four different routes of administration: intravenous, intravitreal, aerosol, and intrathecal administrations. We have completed discovery programs targeting a diverse array of tissue types including various retinal cell types, heart and skeletal muscle tissues, different lung cell types, liver, brain, dorsal root ganglia, and synovial joints, resulting in over 300 unique targeted and evolved vectors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Characterization of Novel Vector Variant &#x201c;Hits&#x201d; and &#x201c;Leads&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Vector hits are typically characterized by three major criteria: manufacturing, human cell and human organotypic model transduction, and delivery to tissues in NHPs by the designated route of administration. Vector hits may also be evaluated for transduction in the presence of human antibodies. In order to perform characterization studies, vectors are armed with marker gene payloads such as enhanced green fluorescent protein (&#x201c;EGFP&#x201d;). After these hits have been evaluated, a lead vector is selected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Directed Evolution-Based Promoter and Transgene Discovery Platforms</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To complement our Therapeutic Vector Evolution Platform and modular development approach, we are generating next-generation optimized promoter elements and transgenes using a combination of directed evolution and proprietary algorithms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Currently available promoters may lack sufficient strength of expression and selectivity for clinical benefit of AAV gene therapies. In addition, for some AAV gene therapy products a smaller promoter region may be essential for the gene payload to fit in the AAV. Therefore, we believe there is a need for better promoters for many AAV products to enable or enhance their therapeutic benefit. We generate Target Promoter Profiles for any given product and disease target. This promoter profile includes target cell specificity and strength in order to maximize tolerability and/or biologic activity, as well as to account for any necessary size constraints. Our libraries of novel and diverse synthetic promoters have been engineered and currently comprise approximately ten million unique sequences. Our discovery platform identifies the best promoters within the libraries for a specific Target Promoter Profile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition to our synthetic promoters, we are developing next-generation optimized transgenes. Our discovery platform uses a high-throughput approach, harnessing both directed evolution and rational design algorithms, to identify novel transgenes that express therapeutic proteins. For example, we have developed transgenes to express RNAi in target cells of interest for treatment of disease. These transgene-expressed RNAi molecules, or ddRNAi, are anchored by a microRNA backbone that not only enhances stability and limits off-target effects, but also facilitates high expression within target cells and thereby may increase efficacy. Our technology allows us to knock down disease-causing transcripts, combining a design for a high degree of selectivity with the goal of long-term expression afforded by AAV-based gene therapy. <br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Our Product Candidate Pipeline</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><img src="img227133604_3.jpg" alt="img227133604_3.jpg" style="width:624px;height:280px;" /><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Ophthalmology Therapeutic Area</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Introduction</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are developing product candidates to treat severe ophthalmologic diseases. Our targeted and evolved vector, R100, is used in all three of our ophthalmology clinical stage product candidates and was invented for routine intravitreal injection, leading to transgene expression across the entire surface area of the retina, and in the major cell layers of the retina. We believe that the ability to use the same novel vector in all three product candidates will help inform the clinical development of subsequent product candidates using the same vector.<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">4D-125 for X-Linked Retinitis Pigmentosa (&#x201c;XLRP&#x201d;)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disease Background, Unmet Medical Need and Target Patient Population</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">XLRP is a rare inherited X-linked recessive genetic disorder that causes progressive vision loss and blindness. There are currently no approved therapies for XLRP. Seventy percent of cases are caused by mutations in the retinitis pigmentosa GTPase regulator (&#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">RPGR&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">) gene. The estimated worldwide prevalence of XLRP due to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">RPGR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> variants is approximately one in 25,600 people, which represents approximately 24,000 patients in the United States, and France, Germany, Italy, Spain and the United Kingdom (together, EU-5). It is characterized by dysfunction and degeneration of photoreceptors in the retina. Loss of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">RPGR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> function in retinal cells causes the progressive loss of rod and cone photoreceptors, leading to the progressive loss of vision. Symptoms of XLRP are initially night blindness, followed by loss of peripheral visual field, decreasing visual acuity and eventually blindness. While males are usually the most affected, approximately 25% of heterozygous females experience loss of vision.<br /><br />Our Solution</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are developing 4D-125 for the treatment of patients with XLRP with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">RPGR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> mutations. 4D-125 is designed to benefit patients at all stages of XLRP, including early stage patients whose entire viable retinas are not adequately treated by subretinal surgery. This product candidate is comprised of R100 and a codon-optimized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">RPGR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> transgene engineered for expression within human photoreceptors. In NHP models, we have observed widespread transduction and transgene expression across the entire retinal surface. We believe that 4D-125 has the potential to successfully treat XLRP patients at the earliest stages of their disease progression and ideally, slow or prevent progression and retain vision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Competition and Differentiation: AAV Gene Therapy for XLRP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Several companies are developing subretinal AAV gene therapies for patients with XLRP.  In Phase 1 and 2 trials, investigators have reported improvements in visual field function within the localized retina area receiving the treatment bleb in a subset of patients. These AAV gene therapies require invasive subretinal surgery, which has been associated with subretinal surgery-related adverse events. In addition, subretinal surgery results in transduction and direct treatment of only a small fraction of the retina and is, therefore, limited to patients with more advanced disease with a small remaining area of viable retinal cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe 4D-125 has the potential to be differentiated from other AAV gene therapies in clinical development, to our knowledge, on the basis of four features:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Safe and routine intravitreal route of administration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Product candidates that utilize conventional AAV vectors such as AAV2, must be administered by subretinal surgery for XLRP. Unlike those product candidates, R100, which is included in our product candidate 4D-125, was specifically invented for intravitreal injection. This easier and widely used route of administration may result in faster clinical trial enrollment and better efficacy.</span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Treatment of the entire retinal surface</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Unlike conventional AAV vectors administered by subretinal surgery, which treat only a small fraction of the retinal surface, 4D-125 can be used to treat the entire retinal surface following intravitreal injection, potentially broadening its therapeutic applicability. </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Feasibility of treating early stage patients</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: We believe it will be feasible to safely treat early stage patients before they start to lose their retinal function. 4D-125 is designed to treat the entire surface of the retina, including the periphery where degenerative diseases like XLRP start. In addition, intravitreal injection is recognized as a safe, simple and routinely used method of administering therapeutics. </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Commercial opportunity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Intravitreal injections are widely adopted by many practicing ophthalmologists and used to treat a number of ophthalmological indications. As a result, we believe 4D-125 has the potential for rapid market uptake, if approved. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preclinical Animal Model Pharmacology and Toxicology Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We completed a single dose IND-enabling toxicology and biodistribution study in 30 NHPs with 4D-125. 4D-125 was administered at doses of 1E11 vg/eye or 1E12 vg/eye by intravitreal injection. Animals were sacrificed at three weeks, three months or six months. No meaningful toxicities were reported anywhere in the body, including specifically within the retina. Mild, transient uveitis was observed, but no chronic inflammation was reported; all animals were under systemic immunosuppression during the study. We detected vector genomes and XLRP transgene RNA expression in all treated retinas at both dose levels; the genome and RNA levels were higher in the high dose animals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> model of the disease, XLRP patient photoreceptors were derived from XLRP-diseased white blood cells that had been reprogrammed into induced pluripotent stem cells. Diseased photoreceptors were transduced with 4D-125 and protein lysates were harvested 30 days post-transduction. 4D-125 transduced cells expressed significantly more transgene product (hRPGRorf15) than control cells. Moreover, this expressed protein was shown to be active as measured by glutamylation (GT335).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical Development: Phase 1/2 Clinical Trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4D-125 is currently being evaluated in a first-in-human, on-going Phase 1/2 dose escalation and dose expansion clinical trial. The primary objectives of this trial are to evaluate the safety and maximum tolerated dose of 4D-125. Secondary endpoints include assessments of biologic activity, including both visual field function and anatomical endpoints.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We reported initial clinical data on this program in October 2021. As of the data cutoff date of September 1, 2021, eight patients with clinically advanced XLRP due to RPGR gene mutation had been treated. A standard 3+3 dose escalation was used. Patients were enrolled in one of three dose cohorts: dose-escalation cohort 1 (3E11 vg/eye; n=3), dose-escalation cohort 2 (1E12 vg/eye n=3) and the dose expansion cohort (1E12vg/eye; n=2). Patients enrolled in the dose escalation cohorts of this first-in-human clinical trial had clinically-advanced XLRP, with patients having limited or no measurable remaining photoreceptor area or retinal sensitivity.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Two dose escalation patients (n=1 at 3E11 vg/eye; n=1 at 1E12 vg/eye) were evaluable for clinical activity defined as having both measurable ellipsoid-zone area (&#34;EZ Area&#34;) by spectral domain optical coherence tomography (&#34;SD-OCT&#34;) and retinal sensitivity by microperimetry in both the treated and untreated control eye with at least six months follow-up; dose expansion cohort patients (n=2) had not yet reached six months of follow-up.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img227133604_4.jpg" alt="img227133604_4.jpg" style="width:624px;height:226px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;font-style:italic;">*Month 4 &#x2013; Patient 5 unable to fixate in untreated eye at Month 6.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4D-125 was well-tolerated and did not result in dose-limiting toxicities. No serious adverse events were reported. Enrollment in the dose-expansion cohort is ongoing. We expect to enroll patients with less advanced disease than those enrolled in dose escalation, and whom we expect to be evaluable for clinical activity based on central reading center confirmation at screening.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">4D-150 for Wet AMD and Diabetic Retinopathy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disease Background, Unmet Medical Need and Target Patient Population</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Wet AMD is a type of macular degeneration where abnormal blood vessels (choroidal neovascularization or &#34;CNV&#34;) grow into the macula, the central area of the retina. As a consequence, CNV causes retina swelling and edema, and bleeding can occur and cause visual distortion and reduced acuity. The proliferation of abnormal blood vessels in the retina is stimulated by VEGF. This process distorts and can potentially destroy central vision and may progress to blindness without treatment. There are on average 200,000 new incidences of wet AMD per year in the United States alone. Wet AMD accounts for approximately 10% of all diagnosed cases of AMD, but it results in an estimated 90% of the legal blindness caused by all types of AMD. High expression levels of VEGF appear to play a causal role in the symptoms of wet AMD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Diabetes mellitus affects approximately 400 million adults worldwide and the prevalence is expected to increase by approximately 45% in the next decade. Diabetic eye disease, primarily diabetic retinopathy (&#x201c;DR&#x201d;), is a leading cause of vision loss and blindness in working-age adults and occurs due to the development of diabetic macular edema (&#x201c;DME&#x201d;; swelling, edema and hemorrhage in the central vision) and complications arising from proliferative diabetic retinopathy (&#34;PDR&#34;; retinal neovascularization causing bleeding and retinal detachment). The prevalence of diabetic retinopathy is high, affecting almost one-third of adults over 40 years of age with diabetes. In the United States approximately 4.2 million adults have DR and 655,000 have vision-threatening DR.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The current treatment paradigm for wet AMD and diabetic retinopathy, including DME, is intravitreal injection of patients with anti-VEGF proteins that inhibit the proliferation of new blood vessels, reducing edema and bleeding and allowing some visual acuity to be recovered. Most anti-VEGF therapies require repeated intravitreal injections in the office every few weeks to every few months to obtain full efficacy. When patients miss doses, they may experience accelerated vision decline. Based on current clinical experience, after several years of treatment, the early vision gains are frequently lost, and acuity declines are observed for reasons that may include variable treatment regimens and poor patient compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe these major retinal diseases are ideal candidate applications for gene therapy. There are multiple products on the market that validate the anti-VEGF therapeutic approach, and emerging randomized clinical trial data suggest that inhibiting additional molecular targets can extend the efficacy and durability of anti-VEGF alone. Delivering intravitreal therapies to the eye is routine, and there is an advantage for a single dose gene therapy that can provide long-term efficacy in patients for whom compliance, or treatment resistance, is a problem.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our Solution</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4D-150 is a dual-transgene, intravitreal gene therapy designed to inhibit four distinct angiogenic factors to prevent angiogenesis and reduce vascular permeability for the treatment of angiogenic diseases of the retina. These angiogenic diseases of the retina, including wet AMD and diabetic retinopathy, represent therapeutic markets of over $9.7 billion in annual global sales.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4D-150</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> is engineered for efficient intravitreal delivery to the retina of a payload expressing two transgenes that has the potential for greater efficacy and/or lower required doses versus therapies that target a single VEGF factor, including in patients refractory to currently approved anti-VEGF therapies. Intravitreal delivery of biologics to the eye is routine, and a single dose intravitreal gene therapy that could provide long-term efficacy in patients would be an advantage for patients who struggle with treatment burden and/or treatment resistance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Competition and Differentiation: AAV Gene Therapy for wet AMD and Diabetic Retinopathy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">AAV </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">gene therapy approaches are being developed by several companies to treat wet AMD by delivering a functional copy of an anti-angiogenic transgene by either subretinal or suprachoroidal injection with a conventional AAV vector, or intravitreal administration with a mouse-evolved vector. It remains to be demonstrated whether conventional AAVs or mouse-evolved vectors can deliver significant retinal coverage while limiting off-target effects. In comparison, our targeted and evolved vectors are designed and tested in NHPs whose eyes more closely resemble the anatomy of the human eye than  mouse eyes. We believe this provides comprehensive retinal coverage through less invasive and more commonly used intravitreal injections while delivering an improved tolerability profile with limited inflammation. To our knowledge, 4D-150 is the only AAV gene therapy asset in wet AMD and DR to utilize an intravitreal vector (such as R100) discovered through directed evolution in NHP. In addition, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">studies of R100 versus AAV2 have shown superior transduction by R100 in human retinal cells. We have not compared R100 to AAV2 in patients in clinical studies. R100 has been associated with a low inflammation profile and lack of adverse findings in 91 NHP eyes injected in GLP toxicology studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, to our knowledge, 4D-150 is the first gene therapy product candidate for the eye designed to implement three mechanisms of action by directly inhibiting four different angiogenic growth factor targets, including VEGF-A, -B and C- and PlGF. We therefore believe there is significant differentiation between our gene therapy product candidate and other AAV gene therapeutics in development in this therapeutic area.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe 4D-150 has the potential to be differentiated from approved agents, and those in clinical development, to our knowledge, on the basis of five features:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">1.</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Four distinct mechanisms-of-action</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: An intravitreal dose of 4D-150 should result in sustained anti-angiogenic effects through three distinct mechanisms of action. </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">2.</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">One-time therapy</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Unlike intravitreal protein therapeutics that require repeat dosing every few weeks for a patient&#x2019;s lifetime, 4D-150 is designed as a one-time dose. </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">3.</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Novel vector evolved in NHPs for efficient intravitreal delivery</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Unlike conventional AAV vectors such as AAV2 or the mouse-evolved AAV vector 7m8, R100 was specifically selected in NHPs from our collection of over one billion synthetic capsid sequences for use in humans.  </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">4.</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Low inflammation profile design</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Following intravitreal injection, R100 has shown a low inflammation profile and no significant adverse findings in three GLP toxicology studies, involving 91 NHP eyes, with two different 4DMT products utilizing the R100 vector (4D-110 and 4D-125). In addition, R100 vector-based product candidates 4D-125 and 4D-110 have been administered to patients at doses up to 1E12 vg/eye without dose-limiting toxicities observed to date. With respect to 4D-110 at the 1E12 vg/eye dose, pigment dispersion (iris transillumination) was observed in three patients in the 1E12 vg/eye cohort approximately 7 to 9 months following treatment. Two cases were asymptomatic and one patient reported mild glare. In each case the investigator described this as a Serious Adverse Event, but no hospitalization or medical intervention was initiated. </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">5.</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Commercial opportunity</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Intravitreal injections are widely adopted by many practicing ophthalmologists and used to treat a number of ophthalmological indications. As a result, we believe 4D-150 has the potential for rapid market uptake, if approved. Additionally, the low inflammation profile we have observed in our R100-based GLP toxicology studies, if reproduced in the clinic with 4D-150, may promote broad product adoption, if approved. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preclinical Animal Model Pharmacology and Toxicology Studies</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">carried out a proof-of-concept efficacy study in NHPs with 4D-150. In this study using the retinal laser-induced CNV model, we treated animals with intravitreal 4D-150 at doses of 1E11, 3E11 and 1E12 vg per eye. Animals received steroid treatment for 28 days following IVT administration of 4D-150 and remained off steroids for the remainder of the study. No adverse findings were reported. We demonstrated 100% suppression of CNV lesions 4-weeks after laser administration, the primary endpoint of the study, including at the lowest dose tested of 1E11 vg/eye. No uveitis or retinal abnormalities were reported at this 1E11 vg/eye dose level.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img227133604_5.jpg" alt="img227133604_5.jpg" style="width:458px;height:371px;" />&#160;</p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In an acute biodistribution study of 4D-150 in NHP, a single intravitreal injection resulted in both high levels of ocular aflibercept expression and VEGF-C miRNA expression within the retina at 4 weeks, with no evidence of uveitis or retinal abnormalities observed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical Development: Phase 1/2 Clinical Trial</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4D-150 is currently being evaluated in a first-in-human, on-going Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial and is expected to enroll approximately 60 adults with wet AMD. In the dose-escalation phase, multiple dose levels of 4D-150 will be examined in an open-label, 3+3 design with an initial dose of 3E10 vg/eye. In dose expansion, patients (n=50) will be randomized 2:2:1 to receive one of 2 dose levels of 4D-150 (n=20 for each dose level) or aflibercept (n=10). The primary endpoints of the study are safety and tolerability. Secondary endpoints include the number of supplemental aflibercept injections received and change from baseline in best corrected visual acuity (&#34;BCVA&#34;) over time. In January 2022, we announced the dosing of the first patient in this trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">4D-110 for Choroideremia</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disease Background, Unmet Medical Need and Target Patient Population</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Choroideremia is a monogenic blinding disease, affecting approximately 13,000 patients in the United States and EU-5. No products are approved currently for the treatment of this disease in the United States or European Union. This X-linked, progressive degenerative disease of the retina and choroid is caused exclusively by mutations in the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">CHM</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> gene that encodes for the REP1 protein. While choroideremia primarily affects men, some heterozygous females also suffer variable visual loss from the condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Choroideremia initially manifests as night-blindness and peripheral visual field defects, usually starting in the first two decades of life. The visual field begins to constrict relatively early in the disease&#x2019;s progression, which hinders patients&#x2019; ability to conduct daily activities such as driving. Many patients become blind by 30 years of age. A patient with advanced disease will be legally blind by virtue of poor visual acuity and minimal preserved visual field. Almost all mutations in the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">CHM</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> gene result in production of a non-functional REP1 protein. REP1 is essential for the activation (prenylation) of Ras-associated binding (&#x201c;Rab&#x201d;) proteins involved in intracellular vesicle trafficking.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our Solution</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are developing 4D-110 for the treatment of choroideremia. 4D-110 is designed for a single intravitreal injection and to benefit patients at all stages of disease, including early-stage patients whose entire viable retinas are not adequately treated by subretinal injection. 4D-110 contains the R100 vector and is engineered to deliver the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">CHM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">transgene, the dysfunctional gene in choroideremia, to human RPE cells safely. We believe that 4D-110 has the potential, if approved, to successfully treat choroideremia patients at the earliest stages of their disease progression and ideally, slow or prevent progression and retain vision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Competition and Differentiation: AAV Gene Therapy for Choroideremia</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Previously, subretinal conventional AAV gene therapy approaches were being developed to treat choroideremia. With the recent discontinuation of BIIB111, there is currently no direct competition for the choroideremia market. Subretinal administration requires an invasive surgical procedure, which has been associated with subretinal surgery-related adverse events. In addition, subretinal surgery results in transduction of only a small fraction of the retina and is therefore limited to patients with more advanced disease who have a small remaining area of viable retinal cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preclinical Animal Model Pharmacology and Toxicology Studies</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A total of 44 NHPs have been treated with 4D-110 on two GLP toxicology and biodistribution studies. No significant adverse effects or toxicities were reported.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We completed a single dose IND-enabling toxicology and biodistribution study in 27 NHPs dosed with 4D-110. 4D-110 was administered at doses of 1E11 vg/eye or 1E12 vg/eye by intravitreal injection. Animals were sacrificed at three weeks, three months or six months. No meaningful toxicities were reported anywhere in the body, including specifically within the retina. Mild, transient cortico-steroid responsive anterior uveitis was reported in a minority of treated NHP. No chronic inflammation was reported; all animals were under systemic immunosuppression during the study. We detected vector genomes and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">CHM/REP1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> transgene RNA expression in all treated retinas at both dose levels; the genome and RNA levels were higher in the high dose animals.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We subsequently completed a bilateral intravitreal 4D-110 GLP toxicology and biodistribution study in 17 NHPs dosed with 4D-110. 4D-110 was administered at doses of 3E11 vg/eye or 1E12 vg/eye by intravitreal injection. Animals were sacrificed at three weeks, 13 weeks and 26 weeks. No meaningful toxicities were reported anywhere in the body, including specifically within the retina.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Transient cortico-steroid responsive uveitis was reported. No chronic inflammation was reported; all animals were under systemic immunosuppression during the study. We detected vector genomes and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">CHM/REP1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">transgene RNA expression in treated retinas at both dose levels.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In preclinical pharmacology studies involving human choroideremia patient-derived RPE cells, 4D-110 led to functional REP1 protein expression that corrected RAB27A trafficking from the cytoplasm to the cell membrane. In similar fashion to normal RPE cells, 4D-110-treated diseased RPE cells derived from choroideremia patients had RAB27A protein associated with their cell membranes; this finding confirmed the functionality of the REP1 protein expressed from 4D-110. In contrast, in untreated diseased cells, RAB27A was demonstrated diffusely throughout the cytoplasm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical Development: Phase 1/2 Clinical Trial</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4D-110 is currently being studied in an ongoing Phase 1/2 dose escalation clinical trial in patients with choroideremia. The primary objectives of this trial are to evaluate the safety and maximum tolerated dose of 4D-110. Secondary endpoints include assessments of biologic activity, including both visual field function and anatomical endpoints.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We reported initial clinical data on this program in October 2021. As of the October 2021 data disclosure, six patients with clinically advanced choroideremia were treated. A standard 3+3 dose escalation design was used. Patients were enrolled in one of two dose cohorts: 3E11 vg/eye (cohort 1; n=3) and 1E12 vg/eye (cohort 2; n=3).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img227133604_6.jpg" alt="img227133604_6.jpg" style="width:624px;height:192px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;font-style:italic;">* Rate of progression normalized for same # months</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;font-style:italic;">+ Patient 2 latest evaluable scans 10 months</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At the 3E11 vg/eye dose (Cohort 1), 4D-110 was well-tolerated with no dose-limiting toxicities or serious adverse events. Initial signals of clinical activity were observed at this dose, through anatomical measurements of the retinal pigment epithelium (&#34;RPE&#34;) by fundus autofluorescence area and photoreceptors by ellipsoid zone area. At the 1E12 vg/eye dose, pigment dispersion (iris transillumination) was observed in three patients in the 1E12 vg/eye cohort approximately 7 to 9 months following treatment. Two cases were asymptomatic and one patient reported mild glare. In each case the investigator described this as a Serious Adverse Event, but no hospitalization or medical intervention was initiated.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Enrollment in the clinical trial is on-going at the 3E11 vg/eye dose level.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Cardiology Therapeutic Area</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Introduction</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are developing product candidates to treat cardiomyopathies. These target indications may include both primary cardiomyopathies that involve the heart exclusively, as with hypertrophic cardiomyopathies, or secondary cardiomyopathies that occur in the context of a systemic disease, as with lysosomal storage diseases. In the context of secondary cardiomyopathies, such as Fabry disease, we design and engineer the product to treat all diseased organs including the high unmet medical need in the heart. Our targeted and evolved vector, C102, used in all of our cardiology product candidates, was invented for low dose intravenous infusion, leading to transgene expression throughout the myocardium. We believe that this modular product approach, utilizing C102 for all of our cardiology product candidates, and switching the therapeutic transgene inserts, will help inform the clinical development of subsequent product candidates using the same vector.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">4D-310 for Fabry Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disease Background, Unmet Medical Need and Target Patient Population</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fabry disease is a monogenic disease caused by mutations in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GLA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> gene which encodes for the alpha-galactosidase A (&#x201c;AGA&#x201d;) enzyme, that result in the body&#x2019;s inability to produce sufficient AGA enzyme activity, causing the accumulation of toxic levels of sphingolipids, such as the substrate globotriaosylceramide-3 (&#x201c;lyso-Gb3&#x201d;), in critical organs, including the heart, kidney and blood vessels. The cardiomyopathy in Fabry disease is the leading cause of death, accounting for 54% of deaths. Substrate accumulation in the heart can lead to life-threatening heart failure, arrhythmias, and vascular blockages. Fabry disease is progressive and fatal, with an average life expectancy of approximately 50 years. Progression of the disease causes significant reduction in the quality of life and significant economic burden associated with greater patient needs for supportive care.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Annual worldwide sales of Fabry medicines were approximately $1.8 billion in 2021. We estimate the potential initial addressable male Fabry patient population in the United States and EU-5 to be up to 19,000 individuals, 57% of whom suffer from Classic Fabry disease. Of note, we estimate the prevalence of individuals with Fabry disease-associated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GLA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> mutations in the United States and EU-5 falls between 50,000 and 70,000 in the United States and the EU-5 based on recent newborn screening. Pre-treatment antibody titers to gene therapy, including 4D-310, may result in a reduction in the addressable patient population, if antibody titers at baseline are shown to be predictive of treatment response and/or tolerability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The current treatment paradigm for Fabry disease is bi-weekly infusion of AGA enzyme, a class of therapies broadly referred to as enzyme replacement therapies (&#x201c;ERT&#x201d;). For example, Fabrazyme received accelerated regulatory approval in 2003 in the United States based on improvements in a kidney interstitial capillary substrate biopsy endpoint, and received full approval in 2021.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition to high burdens of therapy due to the short-half life in the blood, patients on ERTs lack therapeutic concentrations of AGA in their blood for the majority of time between infusions, potentially limiting clinical benefit. AGA is normally produced within target cells themselves, but ERTs reportedly lack efficient uptake by parenchymal cells including cardiomyocytes. As a result, patients remain at risk of cardiac complications including death. Finally, antibodies develop to AGA in the majority of Classic Fabry disease patients after ERT which can reduce the therapeutic effect of ERT, leading to worse clinical outcomes than those patients on ERT who don't develop anti-AGA antibodies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Therefore, we believe cardiac-targeted treatment of Fabry disease is still an unmet medical need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our Solution</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are developing 4D-310 for the comprehensive systemic treatment of Fabry disease. 4D-310 is designed for an efficient, single low dose IV administration to benefit classic and late onset patients, including those who have previously received ERT. 4D-310 is comprised of C102 and is engineered with a codon-optimized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">GLA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> transgene under control of a ubiquitous promoter. 4D-310 is designed to generate both high, stable AGA activity in the blood, potentially resulting in cross correction of a broad range of critical organs, and to generate AGA activity via intracellular production within diseased cells including cardiomyocytes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe 4D-310 has the potential for &#x201c;mutation independent&#x201d; treatment of both &#x201c;classic&#x201d; (early onset, severe) as well as late-onset Fabry disease, both of which are often associated with cardiomyopathy. We believe reducing substrate in cardiomyocytes would represent a strategic advantage and significant opportunity in the treatment of Fabry-associated cardiomyopathy, which we believe remains a significant unmet medical need and is a leading cause of death in Fabry disease patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, AGA produced by 4D-310 within target cells themselves will not be exposed to serum antibodies against AGA. These antibodies develop following ERT in approximately 80% of Classic Fabry disease patients. We therefore have the potential to treat this patient population via intracellular production of AGA, in contrast to approaches that rely exclusively on delivery of AGA through the bloodstream.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Finally, single dose gene therapy treatment with 4D-310 may obviate biweekly ERT infusions in these patients, and/or every other day small molecule medicines for patients amenable to AGA chaperone therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Competition and Differentiation: AAV and Gene Therapy for Fabry Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Companies are developing liver-expressing AAV gene therapy for Fabry disease using conventional AAVs designed for expression from the liver only using liver-specific promoters. These product candidates are designed for the production and secretion of AGA enzyme for activity in the blood, as with ERT, but with more stable blood levels than achieved with intermittent ERT infusions. When administered as ERT in patients, the AGA protein has not been shown definitively to enter cardiomyocytes or other affected parenchymal cells. It is therefore unclear whether gene therapy-induced production of AGA from the liver, with secretion into the bloodstream, would result in effective correction in cardiac muscle cells or other affected parenchymal cells such as in the kidney.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe 4D-310 is the only gene therapy candidate designed specifically to express the AGA enzyme in cardiac tissues, as well as in other affected tissues in these patients, potentially addressing a major unmet medical need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe 4D-310 has the potential to be differentiated from approved agents and those in clinical development, to our knowledge, on the basis of four features:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Dual mechanisms-of-action</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: An IV dose of 4D-310 is designed to generate both stable sustained levels of AGA enzyme activity in blood and endothelial cells following secretion from the liver, plus high AGA levels directly within muscle cells throughout the heart. Preclinical data also suggest cells within the kidney, blood vessels and small intestine also produce intracellular AGA after 4D-310 treatment, albeit at significantly lower levels than in the heart. </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">One-time therapy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Unlike AGA chaperones that require dosing every other day for a patient&#x2019;s life, or IV ERT every two weeks for life, 4D-310 is designed as a single dose therapy. </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">AGA mutation-independent biologic activity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Unlike AGA chaperones that are only effective against specific AGA mutations present in a minority of Fabry patients, 4D-310 is designed to treat Fabry patients with any AGA mutation. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Resistance to AGA antibodies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: We believe that 4D-310 may be able to treat patients that have anti-AGA antibodies. Those antibodies develop in approximately 80% of Classic Fabry disease patients (early onset, severe disease) treated with ERT. This is in contrast to competing approaches that rely exclusively on AGA delivery through the bloodstream, that may be inhibited by these antibodies since AGA comes into contact with anti-AGA antibodies in the bloodstream that may inhibit delivery to target organs. Unlike ERT and gene therapies that are designed to rely exclusively on AGA production and secretion from the liver into the blood, 4D-310 is designed to include intracellular AGA production in target tissues themselves, thus avoiding AGA antibody contact and inhibition. We therefore plan to evaluate the treatment of patients with pre-existing AGA antibodies, potentially resulting in a larger addressable patient population. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The target product profile for 4D-310 is compared to competing technologies below. Many aspects of this profile have been supported by data generated to date with either the C102 vector or with 4D-310 itself.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img227133604_7.jpg" alt="img227133604_7.jpg" style="width:624px;height:320px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preclinical Animal Model Pharmacology and Toxicology Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We completed an IND-enabling GLP toxicology and biodistribution study of 4D-310 in normal mice. No meaningful toxicity was reported at doses up to 1.5E14 vg/kg, based both on in-life and histopathology assessments. This dose is 300% of the highest planned dose in our Phase 1/2 clinical trial. 4D-310-mediated AGA expression and/or AGA enzyme activity was observed in all target tissues tested, including heart, kidney, blood vessels, small intestine and blood.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pharmacology studies have been completed in Fabry disease knock-out mice. We observed that a single IV treatment with 4D-310 resulted in high stable blood concentrations and durable AGA production in target tissues, including the heart and kidney, and that toxic lyso-Gb3 metabolites were reduced significantly in all evaluated target tissues versus vehicle control. Efficacy was demonstrated with doses as low as 1E12 vg/kg. No adverse findings were observed in these knock-out animals at doses as high as 5E13 vg/kg.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We performed a dose-ranging toxicity and biodistribution study in NHPs. Doses of 3E12, 1E13 and 5E13 vg/kg were well-tolerated and resulted in AGA activity concentrations in blood equal to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> 1.9-fold, 3.4-fold and 70-fold</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> higher than pretreatment blood levels, respectively, within 14 days after treatment. NHPs used in this study were healthy and had normal baseline levels of AGA activity. No meaningful toxicity was noted clinically or with blood testing. Histopathology assessments were normal. Tissue analyses demonstrated dose-related 4D-310 genome delivery, RNA expression and AGA activity throughout the heart, especially within the left ventricle which is the key target tissue. AGA expression and enzymatic activity were also demonstrated within the kidney.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical Development: Phase 1/2 Clinical Trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are currently studying 4D-310 in an on-going Phase 1/2 dose-escalation and dose-expansion clinical program assessing intravenous 4D-310, 4DMT&#x2019;s targeted and evolved C102 vector-based product candidate designed for Fabry disease. The primary endpoint of these trials is safety and tolerability. Key secondary endpoints include change from baseline in serum AGA activity and serum lyso-Gb3. Exploratory endpoints include markers of biologic activity in the heart, including cardiac imaging parameters and quality of life. In the Asia-Pacific portion of the program, cardiac biopsies will also be assessed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In February 2022, we reported updated interim Phase 1/2 data from the on-going clinical trial. All three patients enrolled were patients with Classic Fabry disease, defined as having AGA activity &lt;5% of mean normal in peripheral blood white cells and having one or more clinical characteristics such as acroparesthesia, hypohidrosis, angiokeratoma or cornea verticillata.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Consistent with the Classic Fabry disease phenotype, all three patients had serum AGA activity below mean normal at baseline, ranging from 0 &#x2013; 0.42 nmol/hr/mL (population normal range: 4.44 &#x2013; 27.42 nmol/hr/mL; population mean normal 9.9 nmol/hr/mL).</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All three patients had prior experience on enzyme replacement therapy (&#34;ERT&#34;). Patients 1 and 3 were enrolled while receiving ERT (ON-ERT). Patient 2 had prior experience with ERT but was not receiving ERT (OFF-ERT) for approximately 13 months prior to dosing. Consistent with prior ERT use, each patient had positive baseline anti-AGA antibody titers:</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Patient 1: Baseline anti-AGA antibody titer 1:947</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Patient 2: Baseline anti-AGA antibody titer 1:99,900</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Patient 3: Baseline anti-AGA antibody titer 1:13,900</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Following 4D-310 infusion, mean serum AGA enzyme activity was within, or significantly above, the normal range in all three patients, despite pre-treatment anti-AGA antibody titer positivity in all patients. Lyso-Gb3 substrate concentrations in serum decreased significantly in Patient 2, who enrolled in the trial OFF-ERT and therefore with an elevated lyso-Gb3 level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Patients 1 and 3 demonstrated an increase in serum AGA enzyme activity significantly above the normal range at all timepoints through last follow-up.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img227133604_8.jpg" alt="img227133604_8.jpg" style="width:624px;height:260px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;font-style:italic;">Serum AGA activity: mean normal = 9.9 nmol/hr/ml; normal range: 4.44 &#x2013; 27.42 nmol/hr/mL</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Patient 2 entered the trial OFF-ERT but had prior ERT treatment that was stopped approximately 13 months prior to dosing. As a result, Patient 2 had a high baseline lyso-Gb3 level (101 ng/mL). Patient 2 also had the highest pre-treatment anti-AGA antibody titer of all three patients treated and of all patients screened to date (1:99,900).</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Patient 2 demonstrated a significant increase in serum AGA enzyme activity into the normal range. Lyso-Gb3 decreased significantly (&gt;50%) within the first four weeks and remained stable through week 12.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img227133604_9.jpg" alt="img227133604_9.jpg" style="width:624px;height:254px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;font-style:italic;">Serum AGA activity: mean normal = 9.9 nmol/hr/ml; normal range: 4.44 &#x2013; 27.42 nmol/hr/mL;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;font-style:italic;">Lyso-Gb3 normal range: &lt; 1.0 ng/mL</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;font-style:italic;">* = Patient 2 week 6 lyso-Gb3 datapoint not evaluable due to hemolysis</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preliminary clinical data evaluating biologic activity in the heart were also reported. Patient 1, who was the only patient who reached the initial 6-month cardiac MRI assessment, demonstrated encouraging signals of biologic activity in the heart on Native T1 and Global Longitudinal Strain.</span><img src="img227133604_10.jpg" alt="img227133604_10.jpg" style="width:624px;height:383px;" /></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4D-310 demonstrated a manageable safety profile in all three patients. No dose-limiting toxicities were observed and no serious adverse events were reported with Patient 1 and 3, and these patients did not have either atypical hemolytic uremic syndrome (&#34;aHUS&#34;) or liver toxicity, which are the two primary class-related toxicities associated with systemically administered AAV. Patient 2 developed transient, self-limited aHUS within approximately one week following treatment and was admitted to the hospital for observation and hydration and was discharged after four days. As a result of hospitalization, this event was classified as a serious adverse event.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Enrollment is on-going in both the Phase 1/2 dose-escalation and dose-expansion clinical program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Pulmonology Therapeutic Area</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Introduction</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are developing product candidates to treat lung diseases. Our targeted and evolved vector, A101, is used in all of our pulmonology disease product candidates and was invented for aerosol delivery, leading to transgene expression throughout all regions of the lung airways and alveoli, as well as resistance to pre-existing antibodies. We believe that this modular product approach, utilizing A101 for multiple product candidates by switching the therapeutic transgene insert, will help inform the clinical development of subsequent product candidates using the same vector.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our first pulmonology product candidate is 4D-710 for cystic fibrosis lung disease. This IND candidate has completed a non-GLP dose-ranging toxicology and biodistribution study in NHPs by aerosol delivery. No notable adverse effects were reported, and widespread biodistribution and transgene expression were observed throughout all lung segments tested in all NHPs. We have initiated an IND-enabling GLP toxicology and biodistribution study in NHPs. We are currently enrolling a Phase 1/2 clinical trial in patients with cystic fibrosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">4D-710 for Cystic Fibrosis Lung Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disease Background, Unmet Medical Need and Target Patient Population</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cystic fibrosis is the most common fatal inherited disease in the United States and results from mutations in the cystic fibrosis transmembrane conductance regulator (&#x201c;CFTR&#x201d;) gene. Cystic fibrosis causes impaired lung function, inflammation and bronchiectasis and is commonly associated with repeat and persistent lung infections due to the inability to clear thickened mucus from the lung, often resulting in frequent exacerbations and hospitalizations and eventual end-stage respiratory failure. There is no cure for cystic fibrosis, and the median age of death for patients is approximately 40 years in developed countries. Cystic fibrosis is considered a rare, or orphan, disease by both the FDA and the EMA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">According to the Cystic Fibrosis Foundation, more than 30,000 people in the United States and more than 70,000 people worldwide are living with cystic fibrosis, and approximately 1,000 new cases of cystic fibrosis are diagnosed in the United States each year. Patients with cystic fibrosis require lifelong treatment with multiple daily medications, frequent hospitalizations and, ultimately, lung transplants in some end-stage patients. The quality of life for cystic fibrosis patients is further compromised as a result of spending significant time on self-care every day and frequent outpatient doctor visits and hospitalizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Until recently, approved therapies to treat cystic fibrosis patients were only designed to treat the symptoms of cystic fibrosis, for example by preventing and controlling infections that occur in the lungs, rather than addressing the underlying cause of the disease. Accordingly, antibiotics are frequently used along with mucus-thinning drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">More recently, a new class of drugs called modulators target CFTR for patients with certain gene mutations. Several therapies from Vertex Pharmaceuticals Inc. have been approved for marketing in the United States and the European Union based on their ability to improve lung function in genetically defined subsets of cystic fibrosis patients. In 2019, the FDA approved triple drug therapy with Trikafta (elexacaftor/ivacaftor/tezacaftor), which Vertex believes would be applicable for up to 90% of cystic fibrosis patients, leaving at least 10% with no CFTR-targeted options. While these therapies improve lung function, reduce exacerbations and have extrapulmonary benefits, the magnitude of lung function improvement is variable, and these chronic therapies require daily dosing for the patient&#x2019;s lifetime. In addition, the existing cystic fibrosis drugs have been associated with tolerability issues, thus limiting their use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe there is a clinical need and market opportunity for a durable aerosolized therapy, delivered by breath-actuated nebulizer, that can restore normal CFTR function across all cystic fibrosis patient subgroups, including patients who are receiving combination CFTR-modulator therapies and/or do not have appreciable CFTR protein expression and are therefore not amenable to CFTR modulators. We expect to explore single agent therapy with 4D-710 initially in patients who are not amenable to CFTR modulators (estimated to include approximately 10% of all cystic fibrosis patients), and to explore single agent or combination therapy with CFTR modulators for the remaining approximately 90% of patients with cystic fibrosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our Solution</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are developing 4D-710 for the treatment of a broad range of patients with cystic fibrosis independent of their specific </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">CFTR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> mutation. 4D-710 is designed for efficient single dose aerosol delivery to the proximal and distal airways and alveoli, subsequent mucus barrier penetration, lung epithelial cell transduction, and resistance to pre-existing antibodies in humans. The intended result is to achieve CFTR expression within lung airway epithelial cells for correction of cystic fibrosis lung disease. 4D-710 is comprised of our targeted and evolved vector, A101, and a codon-optimized version of a synthetic truncated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">CFTR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> transgene</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> deltaR-CFTR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, which we refer to as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">microCFTR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">microCFTR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> is a construct that retains the most critical functional components of the full-size </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">CFTR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> gene and is small enough to fit within AAV vector packaging constraints.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe 4D-710 has the potential to treat a broad range of patients with cystic fibrosis independent of their specific </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">CFTR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> mutation. Initially we plan to focus on the approximately 10% of all patients who are not amenable to existing medicines targeting the CFTR protein as we believe these patients have the highest unmet medical need. In patients with CFTR mutations that are amenable to modulator medicines, while therapies demonstrate improvements in lung function, these modulators do not restore normal lung function in most patients. Further, these chronic therapies require daily dosing for the patient&#x2019;s lifetime. We therefore expect to eventually develop 4D-710 in this patient population, as a single agent and/or in combination with these CFTR modulator small molecule medicines.<br /><br />Competition and Differentiation: AAV Gene Therapy for Cystic Fibrosis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A number of biotechnology companies have pursued gene therapy solutions to treat cystic fibrosis. We believe these prior attempts to deliver AAV gene therapy to the lungs of cystic fibrosis patients have failed due to an inability of conventional AAV vectors to penetrate through the lung mucus barrier and transduce lung cells efficiently. Further, we believe antibody neutralization of AAV likely also played a role in the lack of efficacy, as the mucosal immune system actively transports large quantities of antibodies into all mucus secretions, including on the lung mucosa.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">While a number of companies are currently pursuing other gene therapy solutions utilizing liposomes, herpesvirus, lentivirus or conventional AAV vectors, these product candidates are in early stages of development. Moreover, they are not, to our knowledge, comprised of AAV vectors evolved in NHPs for aerosol delivery diffusely throughout the lung airways and alveoli. In addition, we believe these products were not designed for resistance to pre-existing antibodies to conventional AAVs, which is potentially a key requirement for successful delivery in the lung. As a result, to our knowledge, 4D-710 is the only AAV gene therapy product candidate in development designed specifically with a vector selected for aerosol delivery in NHPs, including humans, and with resistance to antibodies in the human population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe 4D-710 has the potential to be differentiated from approved agents, and those in clinical development to our knowledge, on the basis of four features:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Corrective mechanism-of-action</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: An aerosol dose of 4D-710 is designed to result in therapeutic levels of the CFTR protein directly within target cells lining the airway and alveoli. 4D-710 comprises a targeted and evolved vector invented for aerosol delivery, mucus barrier penetration and transduction of epithelial cells within the airways and alveoli of NHPs and humans. </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">One-time therapy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Unlike CFTR-targeted small molecules that require daily dosing for a patient&#x2019;s entire life, 4D-710 is designed for single or significantly less frequent dosing. </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">CFTR mutation-independent efficacy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Unlike CFTR-targeted small molecules that are only effective against specific mutations, 4D-710 is designed to be used in cystic fibrosis patients with any mutation, including in the approximately 10% of patients whose disease is not amenable to currently available medical therapy. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:2.406941836658923%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Resistance to AAV antibodies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: Unlike conventional AAV vectors, which are sensitive to anti-AAV antibody inhibition, 4D-710 utilizes A101, a vector invented for resistance to human antibody inhibition.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preclinical Proof-of-Concept Study with Evolved AAV for Aerosol Delivery in the Cystic Fibrosis Pig Model</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preclinical proof-of-concept studies have been conducted utilizing directed evolution to discover vectors for delivering a corrective </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">CFTR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> gene construct to cystic fibrosis lung tissue in a large animal model of cystic fibrosis, and in a human cystic fibrosis patient lung tissue model. Building on these previous proof-of-concept studies, our product candidate 4D-710 utilizes a vector, A101, that was evolved and selected in NHPs, which we believe is more relevant for human use. The product was designed to package the same </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">microCFTR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> transgene payload in this vector that was customized for use in humans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, directed evolution was used in an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> human organotypic air-liquid interface model of lung epithelium to select AAV2.5T, which we in-licensed with exclusive worldwide rights. In preclinical studies, AAV2.5T carrying </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">micro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CFTR transduced human lung epithelial tissue and resulted in expression of functional protein as suggested by increased chloride ion transport as compared to untreated control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe that these results demonstrate that a targeted and evolved vector can penetrate the mucus layer of diseased cystic fibrosis lungs and deliver functional CFTR protein in a well-validated large animal model of the disease, as well as in human cystic fibrosis patient-derived organotypic lung models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preclinical Animal Model Pharmacology and Toxicology Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In our NHP study of a single aerosol delivered dose of 4D-710 at two different dose levels, treatment resulted in widespread distribution, CFTR transgene expression throughout both proximal and distal airways and alveoli. No meaningful inflammation or adverse findings were reported on in-life examinations, hematology or clinical chemistry analyses, or lung histology analyses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Ex vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> studies demonstrated highly significant resistance to neutralization by human pooled antibody preparations, with human IVIG pooled from over 1,000 individuals.<br /><br />Clinical Development: Phase 1/2 Clinical Trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2021, we received clearance from the U.S. Food and Drug Administration (&#34;FDA&#34;) of an Investigational New Drug Application (&#34;IND&#34;) for 4D-710. We expect to dose the first patient in our Phase 1/2 clinical trial for 4D-710 in the first half of 2022. The Phase 1/2 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion trial of 4D-710 in patients (n=~18) with cystic fibrosis who are ineligible for CFTR modulator therapy or who have discontinued therapy due to adverse effects. The primary endpoint of the study is safety and tolerability. Secondary endpoints include assessments of clinical activity including lung function, plus transgene transfer and microCFTR expression as measured within bronchoscopic biopsies and brushings.<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are aware of several companies focused on developing gene therapies in various indications as well as companies addressing methods for modifying genes and regulating gene expression. We may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions with genetic medicine and other therapeutic approaches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With respect to 4D-125 for the treatment of XLRP, we consider our most direct AAV gene therapy competitors to be as follows: Applied Genetic Technologies Corporation (candidate administered by subretinal surgery in a Phase 1/2 clinical trial), Janssen Pharmaceuticals Inc. / MeiraGTx Holdings Plc (candidate administered by subretinal surgery enrolling a Phase 3 clinical trial).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With respect to 4D-110 for the treatment of choroideremia, we currently believe there are no gene therapies in development for this disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We consider our most direct competitors with respect to 4D-150 for the treatment of diabetic retinopathy and wet AMD to be Eylea (aflibercept) from Regeneron Pharmaceuticals Inc., which is the current wet AMD standard of care, and a combination of antibody-based programs including, but not limited to, Lucentis, Susvimo and Vabysmo from Roche, KSI-301 from Kodiak Sciences Inc. (missed primary endpoint in wet AMD), and OPT-302 from Opthea Limited, and gene-therapy based programs including ADVM-022 from Adverum Biotechnologies (discontinued in diabetic populations) and RGX-314 from RegenxBio Inc., which are both AAV-based programs in Phase 2 and Phase 3 studies, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We consider our most direct competitors with respect to 4D-310 for the treatment of Fabry disease to be Amicus Therapeutics, which has Galafold (migalastat) approved as a small molecule chaperone for specific mutations, and several gene therapy companies including Freeline Therapeutics Holdings Plc, which is in Phase 1 development of AAVS2-based FLT-190, and Sangamo, which is in Phase 1/2 development of AAV2/6-based ST-920. Other competitors include Sanofi Genzyme, Takeda Pharmaceutical Company Limited and Protalix BioTherapeutics, all of which either commercialize or develop enzyme replacement therapy for the treatment of Fabry disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We consider our most direct competitors with respect to 4D-710 for the treatment of cystic fibrosis lung disease to be Vertex, which has several approved CFTR modulators, as well as other gene therapy companies in preclinical development of cystic fibrosis programs, including Krystal Biotech Inc., Abeona Therapeutics Inc., Spirovant Sciences Inc. and Editas Medicine Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">CMC Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order to fulfill our strategy to maximize the robustness and internal control of our manufacturing processes from discovery and process development through to clinical-grade cGMP manufacturing, we have designed and are continually developing and scaling a robust in-house manufacturing platform for both GMP and non-GMP manufacturing. While many companies in the AAV gene therapy field in-license clinical trial material or manufacturing technologies from other companies or academic manufacturing centers, in contrast, our manufacturing processes were developed internally using internal technology transfers from our own process development labs. Our current in-house manufacturing capabilities include GMP manufacturing (upstream, downstream and fill/finish), production capabilities for clinical trials, IND-enabling GLP toxicology studies and research candidate production. In addition to our internal activities, we also collaborate with Contract Manufacturing Organizations (&#34;CMOs&#34;).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Current Good Manufacturing Practices (&#x201c;cGMP&#x201d;) Capabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our team has extensive experience with the manufacturing and analytical testing of numerous unique AAV capsids. Our team has internally manufactured over 150 unique AAV vectors, including both proprietary evolved 4DMT capsid variants and naturally occurring capsids. Our team has manufactured over 240 total lots of AAV vectors for research or clinical use. We have in-house cGMP manufacturing capabilities for clinical trial material production. Our manufacturing team has completed and released multiple lots of clinical trial material for our five product candidates in clinical development. This total also includes 15 lots of product candidate material for GLP toxicology and biodistribution studies. Leveraging internal testing capabilities in addition to qualified contract testing laboratories, we fully test and release our GLP and GMP lots for use in toxicology and clinical trials, respectively. We have developed and qualified assays for characterization, in-process testing and release and stability testing of our internally and externally manufactured proprietary AAV vectors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Process Development Capabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We use robust, scalable and transferable manufacturing unit operations throughout both the vector characterization process and product development, which are both platform-specific and product-specific. The upstream manufacturing step involves triple plasmid transfections in an adherent HEK293 mammalian production cell line. Downstream manufacturing steps for purification and concentration include multiple orthogonal column chromatography steps and tangential flow filtration. The downstream purification columns used in our process are from stable sources including General Electric. Using internally developed manufacturing processes and testing, we characterize our novel capsids and payloads. In addition, leveraging internal expertise and capabilities, we package and test our novel vectors with payloads using internally developed manufacturing processes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Manufacturing Facilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our manufacturing facilities are on site at company headquarters in Emeryville, California and include process development labs, an analytical development lab, and a cGMP manufacturing facility. These manufacturing facilities are also designed for production of material for GLP toxicology and biodistribution studies. In addition, we are currently building a second manufacturing facility to enable commercial-scale lot sizes under cGMP. Our cGMP facilities will be able to provide additional capacity for production of Phase 1 through Phase 3 clinical trials material. We expect to utilize commercial-scale bioreactors that are designed to manufacture higher titer clinical trial material lots. Our manufacturing facilities are also designed for production of material for GLP toxicology and biodistribution studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Manufacturing Team</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our team of approximately 40 highly trained individuals is led by our Chief Technical Officer and Chief Operating Officer, Dr. Fred Kamal, and includes Ph.D. scientists. Collectively, they have significant experience in viral vector manufacturing, chemistry-manufacturing-controls (&#x201c;CMC&#x201d;), regulatory affairs, analytical and process development, and quality assurance and controls. As of December 31, 2021, our team has submitted five INDs all of which have been granted clearance by the FDA enabling our clinical candidates to advance to Phase 1/2 clinical development. Our team also has experience prior to 4DMT with manufacturing multiple viral vectors from preclinical studies through to multiple Phase 3 trials. For example, Dr. Kamal helped to write and compile the AAV gene therapy BLA for Zolgensma (&#34;Novartis&#34;), the first AAV gene therapy approved for intravenous administration in infants and babies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, manufacturing and process discoveries, and other know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. In particular, our patent strategy includes the filing of patent applications covering unique gene sequences selected through our Therapeutic Vector Evolution process. We also rely on trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our product and lead optimization candidates were discovered by us utilizing our proprietary technology. We have filed several non-provisional and provisional patent applications, all owned by us, relating to our product and lead optimization candidates in the United States, certain foreign countries, and the World Intellectual Property Organization that are directed to compositions-of-matter, dosage unit forms, methods-of-treatment and medical use. We have also licensed several non-provisional patent applications, granted patents and international patent applications relating to our targeted and evolved vector, A101, which is used in 4D-710, and to other AAV-based technologies from U.C. Berkeley.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, our solely owned patent portfolio includes four granted U.S. patents and twenty-one granted foreign patents; each of these patents is expected to expire between May 2037 and April 2041, excluding any additional term from patent term adjustment or patent term extension if appropriate maintenance and other governmental fees are paid.  Our solely owned patent portfolio also includes eight pending U.S. non-provisional applications and sixty-three pending foreign applications. We expect that United States and European patents, if issued from pending applications in our solely owned portfolio, would expire between May 2037 and August 2041, excluding any additional term from patent term adjustment or patent term extension if appropriate maintenance and other governmental fees are paid. Additional patent term for the presently issued or later issued U.S. patents may be awarded as a result of the patent term extension provision of the Hatch-Waxman Amendments of 1984. In the European Union member countries, a supplementary protection certificate, if obtained, provides a maximum five years of market exclusivity. Our solely owned patent portfolio also includes one pending U.S. provisional patent application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> In other jurisdictions (currently, Australia, Bahrain, Brazil, Canada, Chile, China, Colombia, Costa Rica, Egypt, India, Indonesia, Iran, Israel, Japan, Korea, Kuwait, Malaysia, Mexico, New Zealand, Oman, Peru, Philippines, Qatar, Russia, Saudi Arabia, Singapore, South Africa, Taiwan, Thailand, United Arab Emirates, Ukraine and Vietnam), patents, if issued on pending applications in our solely owned patent portfolio, where applicable, relating to our product and lead optimization candidates, including composition of matter, dosage unit form, method-of-treatment and medical use, are expected to expire between May 2037 and August 2041, if the appropriate maintenance, renewal, annuity, and other government fees are paid. These patents and patent applications (if applicable), depending on the national laws, may benefit from extension of patent term in individual countries if regulatory approval of any of our product or lead optimization candidates is obtained in those countries. For example, in Japan, the term of a patent may be extended by a maximum of five years in certain circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, our in-licensed patent portfolio includes five granted U.S. patents and six granted foreign patents; each of these patents is expected to expire between June 2024 and May 2034, excluding any additional term from patent term adjustment or patent term extension if appropriate maintenance and other governmental fees are paid. Our in-licensed patent portfolio also includes four pending U.S. non-provisional patent applications and twenty-two pending foreign patent applications. We expect that United States and European patents, if issued from applications in our in-licensed portfolio would expire between June 2024 and June 2038, excluding any additional term from patent term adjustment or patent term extension if appropriate maintenance and other governmental fees are paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In other jurisdictions (currently, Australia, Brazil, Canada, China, Hong Kong, India, Japan, Korea and Mexico), patents, if issued on pending applications in our in-licensed patent portfolio, where applicable, relating to our product and lead optimization candidates, including composition of matter and various other patents, including dosage unit form, method-of-treatment and medical use patents are expected to expire between June 2024 and June 2038, if the appropriate maintenance, renewal, annuity, and other government fees are paid. These patents and patent applications (if applicable), depending on the national laws, may benefit from extension of patent term in individual countries if regulatory approval of any of our product or lead optimization candidates is obtained in those countries. For example, in Japan, the term of a patent may be extended by a maximum of five years in certain circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are effective for 20 years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office (&#x201c;USPTO&#x201d;) delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. The actual protection afforded by a patent varies on a product by product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We also protect our trade secrets and other proprietary technology and processes, in part, by confidentiality and invention assignment agreements with our employees, consultants, scientific advisors and other contractors. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, scientific advisors or other contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our commercial success will also depend in part on not infringing the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, alter our drugs or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have a material adverse impact on us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Strategic Collaborations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2017, we entered into a Collaboration and License Agreement (the &#x201c;2017 Roche Agreement&#x201d;), with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., collectively referred to as Roche. Under the Roche Agreement, we granted Roche an exclusive, sublicensable, worldwide license under certain intellectual property rights to research, develop, make, use, import, export, and sell products and constructs using our proprietary AAV vectors to treat ophthalmological diseases and disorders, excluding treatment and prevention of cancer and central nervous system conditions (but not retinal nerves) and delivery of DNA-directed RNA interference (the &#x201c;Roche Field&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At the effective date of the 2017 Roche Agreement, choroideremia was designated a Roche product class and the 4D-110 product was licensed to Roche. We were responsible for conducting research and development services prior to pivotal clinical studies, and Roche was responsible for conducting subsequent development and commercialization activities. In addition, Roche agreed to pay for research and development services we incur at an agreed upon full-time employee rate and certain third party costs, excluding costs associated with the manufacturing work for choroideremia.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the 2017 Roche Agreement, Roche had an option exercisable prior to pivotal clinical studies, to license 4D-125 (for the treatment of XLRP), which was not exercised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the 2017 Roche Agreement, we received a non-refundable upfront payment of $21.0 million as consideration. In addition, we were entitled to contingent payments including (i) $1.0 million for each Roche nominated product beyond the first three, (ii) up to $30.0 million upon exercise of the option to convert a product we nominated and developed prior to pivotal clinical studies, (iii) development milestone payments of up to $223.0 million, of which $86.0 million related to choroideremia and the rest related to other licensed products; and (iv) sales-based milestones of up to $123.0 million in connection with licensed products. Through December 31, 2021, we received $10.0 million for development milestone payments that are non-refundable. The 2017 Roche Agreement also included provisions that entitled us to receive royalty payments ranging from the mid-single digits to the mid-teens for the net sales of the licensed products, in each case subject to the reductions in accordance with the terms of the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In its accounting treatment, we identified a single combined performance obligation for the license, research services and participation in the joint steering committee and concluded that Roche&#x2019;s option did not represent a material right. We determined that the 2017 Roche Agreement did not include a significant financing component. We further concluded that the transaction price should not include the variable consideration related to the development milestones, which were considered to be constrained, as it was probable that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in the future. We excluded any consideration related to sales-based milestones, including royalties, which would be recognized when the related sales occur. The transaction price and estimated period of performance are re-evaluated at each reporting period and adjusted as needed to reflect changes in the scope of the project, reimbursable expenses and other conditions affecting variable consideration.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, we received from Roche notice of termination without cause of the 2017 Roche Agreement. The licenses granted by us to Roche under the 2017 Roche Agreement terminated in their entirety on September 16, 2021. Therefore, as of September 16, 2021, Roche no longer has a license for 4D-110 for the treatment of choroideremia or any other product class, and we are no longer entitled to receive any further milestones or royalties from Roche. In July 2021, we notified Roche of our election to continue development of choroideremia. As a result, in accordance with the terms of the agreement, all rights to 4D-110 data and intellectual property generated under the collaboration reverted to us. Under the 2017 Roche Agreement, if we are required to initiate a new Phase 1/2a clinical trial for 4D-110, we would not owe any royalty to Roche on net sales of 4D-110 following regulatory approval and commercialization. If, however, we obtain regulatory approval for and commercializes 4D-110, without being required to conduct a new Phase 1/2a clinical trial, we must pay Roche a mid-single digits percentage royalty on the net sales of 4D-110.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Collaboration and License Agreements with uniQure biopharma B.V.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In August 2019, we entered into an Amended and Restated Collaboration and License Agreement (the &#x201c;Amended and Restated uniQure Agreement&#x201d;) with uniQure biopharma B.V., now uniQure N.V. (&#x201c;uniQure&#x201d;), which amended and restated the Collaboration and License Agreement that we entered into with uniQure in January 2014.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Amended and Restated uniQure Agreement, we granted uniQure an exclusive, sublicensable, worldwide license under certain of our intellectual property rights, and other rights, to research, develop, make, use, and commercialize pre-selected AAV capsid variants (&#x201c;Selected Variants&#x201d;), and compounds and products containing such Selected Variants, using our proprietary AAV technology for delivery of gene therapy constructs to cells in the central nervous system and the liver (the &#x201c;uniQure Field&#x201d;). uniQure is solely responsible, at its cost and expense, to develop and commercialize the compounds and products containing the Selected Variants in accordance with the terms of the Amended and Restated uniQure Agreement. We retain all rights to all other AAV capsid variants, and compounds and products containing such AAV capsid variants, in the uniQure Field.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Also in August 2019, we entered into a separate Collaboration and License Agreement with uniQure (&#x201c;Second uniQure Agreement&#x201d;). Under the Second uniQure Agreement, the parties agreed to research and develop new AAV capsid variants that are not Selected Variants (New Variants) using our proprietary AAV technology for delivery of transgene constructs that affect certain targets (&#x201c;uniQure Targets&#x201d;) in the uniQure Field. We are responsible for the research of the New Variants, and uniQure is responsible for the development and commercialization of a certain number of compounds and products containing New Variants, that affect the uniQure Targets (&#x201c;Licensed Products&#x201d;). We granted uniQure an exclusive, sublicensable, worldwide license under certain of our intellectual property rights, and other rights, to research, develop, make, use, and commercialize the Licensed Products. We retain all rights to New Variants in the uniQure Field that affect targets other than the uniQure Targets. We also retain all rights to any new AAV capsid variants developed under the agreements that are not New Variants, and compounds and products containing such variants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under both the Amended and Restated uniQure Agreement and the Second uniQure Agreement, uniQure will be required to pay us royalties on worldwide annual net sales of licensed products at a mid-single digit percentage rate, subject to certain specified reductions. These royalties are payable on a product-by-product and country-by-country basis until the latest of ten years after the date of the first commercial sale of such product in such country, the expiration of the last-to-expire licensed patent right covering such product in such country (of which there are none), and the expiration of any applicable exclusivity granted by a regulatory authority in such country for such product (the &#x201c;uniQure Royalty Term&#x201d;). uniQure will also be required to pay us a portion of the amounts it receives for licensing or sublicensing to third parties our intellectual property rights licensed or other rights otherwise granted under the Amended and Restated uniQure Agreement, and a portion of the amounts it receives for licensing to third parties our intellectual property rights granted under the Second uniQure Agreement, each at a rate between mid-single digit to mid-twenties percentages, depending on the stage of development at which such third-party grant occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under both the Amended and Restated uniQure Agreement and the Second uniQure Agreement, under certain circumstances, we may propose to uniQure, and uniQure may grant to us, a non-exclusive right for us to develop and commercialize certain licensed products based on Selected Variants in the uniQure Field, or the New Variants in the uniQure Field to deliver transgene constructs that affect the uniQure Targets (&#x201c;4DMT Proposed Products&#x201d;). Pursuant to the Second uniQure Agreement, under certain circumstances, uniQure may propose to us, and we may grant to uniQure a non-exclusive right for uniQure to develop and commercialize certain licensed products using any new AAV capsid variants developed under the agreement that are not New Variants in the uniQure Field to deliver transgene constructs that affect targets other than the uniQure Targets (&#x201c;uniQure Proposed Products&#x201d;). If either party obtains the rights to develop and commercialize a 4DMT Proposed Product or a uniQure Proposed Product, as applicable, such party will be required to pay the other party royalties on worldwide annual net sales of such products at a mid-single digit percentage rate, subject to specified reductions. These royalties will be payable on a product-by-product basis during the uniQure Royalty Term for such products. The party receiving such license will also be required to pay the other party a portion of the amounts that it may receive for licensing or sublicensing to third parties rights for such 4DMT Proposed Products or uniQure Proposed Products, as applicable, at a rate between mid-single digit to mid-twenties percentages depending on the stage of development at which the sublicense is granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Each of the Amended and Restated uniQure Agreement and the Second uniQure Agreement will expire on the expiration of all payment obligations of the parties under such agreement. Each party may terminate either agreement for the other party&#x2019;s insolvency or bankruptcy. Each party may also terminate either agreement in its entirety in some circumstances or on an indication-by-indication basis if the other party fails to cure its material breach under the applicable agreement within 90 days of receiving notice, subject to an additional cure period in accordance with the terms of such agreement. uniQure may terminate either agreement upon 90 days&#x2019; prior written notice. If we terminate either agreement for uniQure&#x2019;s material breach, insolvency or bankruptcy or if uniQure terminates either agreement for convenience, the rights to the Selected Variants, and compounds and products containing such Selected Variants, or the uniQure New Variants, and compounds and products containing such uniQure New Variants, as applicable, generally revert back to us. If uniQure terminates either agreement for our material breach under the applicable agreement, insolvency or bankruptcy, uniQure may retain its rights to the intellectual property license grant under such agreement and uniQure&#x2019;s payment obligations will survive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Exclusive License and Agreements with The Regents of the University of California and The Trustees of the University of Pennsylvania</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2013, we entered into two Exclusive License and Bailment Agreements (the &#x201c;2013 UC Agreements&#x201d;) with The Regents of the University of California (the &#x201c;UC Regents&#x201d;) with one of the agreements covering AAV2 capsid mutants with novel properties for enhanced performance in gene therapy and the other covering AAV for enhanced gene delivery in the presence of neutralizing antibodies. Under both 2013 UC Agreements, the UC Regents granted us an exclusive, sublicensable license under certain patent rights to make, use, sell, offer to sell, and import products and services, and to practice methods in the United States and foreign countries where the licensed patent rights exist. The license grant under one of the 2013 UC Agreements is in all fields of use and the license grant under the other 2013 UC Agreement is in all fields of use, with the exception of the ophthalmic field. We agreed to certain general and specific diligence obligations under both 2013 UC Agreements in connection with the development, manufacture and sales of the licensed products, services and methods.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under each 2013 UC Agreement, we paid the UC Regents an upfront payment of $5,000. Further, at the closing of our Series A financing that was a qualified financing pursuant to the 2013 UC Agreements, we issued 311,812 shares of our common stock in aggregate under both agreements. Under each 2013 UC Agreement, we agreed to pay the UC Regents a specified annual license maintenance fee in each year in which we do not owe royalties to the UC Regents. We also agreed to pay the UC Regents a mid-teens to mid-twenties percentage range of any consideration, including royalties, we receive for the grant of a sublicense under the licensed patent rights under each 2013 UC Agreement, with the consideration payable to the UC Regents to not exceed such percentage range in the aggregate under both 2013 UC Agreements for the same sublicense grant. We may reduce any such sublicense consideration payable to UC Regents if we sublicense any of our own or third-party patent rights under the sublicense grant based on the relative value of the sublicensed patents. Upon the achievement of specified development and regulatory milestones by the first licensed product or method, we will be required to pay the UC Regents up to $3.1 million under each 2013 UC Agreement. We will also be required to pay the UC Regents a royalty on net sales of licensed products, services and methods covered by the patents licensed under the 2013 UC Agreements at a percentage in the low single-digit percentage rate, subject to certain specified reductions. Under the UC Agreements, a specified minimum annual royalty will also be due to the UC Regents beginning the first calendar year after the year in which any net sales of a licensed product first occur, such minimum royalty amount to increase on an annual basis, but not to exceed $0.1 million in the aggregate under both UC Agreements. Under each UC Agreement, royalties are payable until the expiration of the last-to-expire licensed patent right covering the licensed product, service or method, at which time the agreement shall expire. The UC Regents may terminate each of the 2013 UC Agreements if we fail to cure a breach of such UC Agreement within 60 days of notice. If we fail to meet our diligence obligations, the UC Regents has the right, under each 2013 UC Agreement, to either terminate the agreement or to reduce our exclusive license to a non-exclusive license, after giving us 60 days to cure or request arbitration. We may terminate either 2013 UC Agreement at-will in its entirety or with respect to any portion of the licensed patent rights upon 90 days prior written notice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In January 2019, the Company entered into an Exclusive License and Bailment Agreement (&#x201c;the 2019 UC Agreement&#x201d;) with the UC Regents to license patent rights related to certain retinal AAV variants. The UC Regents granted us an exclusive, sublicensable license to make, use, sell, offer to sell, and import products and services, and to practice methods in the United States and foreign countries where the licensed patent rights exist. The license grant under the 2019 UC Agreement is in all fields of use. We agreed to certain general and specific diligence obligations under the 2019 UC Agreement in connection with the development, manufacture and sales of the licensed products, services and methods.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the 2019 UC Agreement, we paid the UC Regents an upfront payment of $50,000 and agreed to pay a specified annual license maintenance fee in each year in which we do not owe royalties to the UC Regents. We also agreed to pay the UC Regents a mid-teens to mid-twenties percentage range of any consideration, including royalties, we receive for the grant of a sublicense under the licensed patent rights under the 2019 UC Agreement. We may reduce any such sublicense consideration payable to UC Regents if we sublicense any of our own or third-party patent rights under the sublicense grant based on the relative value of the sublicensed patents. Upon the achievement of specified development and regulatory milestones by the first licensed product or method, we will be required to pay the UC Regents up to $3.1 million under the 2019 UC Agreement. We will also be required to pay the UC Regents a royalty on net sales of licensed products, services and methods covered by the patents licensed under the 2019 UC Agreements at a percentage in the low single-digit percentage rate, subject to certain specified reductions. Under the 2019 UC Agreement, a specified minimum annual royalty will also be due to the UC Regents beginning the first calendar year after the year in which any net sales of a licensed product first occur, such minimum royalty amount to increase on an annual basis, but not to exceed $0.1 million in the aggregate. Under the 2019 UC Agreement, royalties are payable until the expiration of the last-to-expire licensed patent right covering the licensed product, service or method, at which time the agreement shall expire. The UC Regents may terminate the 2019 UC Agreement if we fail to cure a breach of the agreement within 60 days of notice. If we fail to meet our diligence obligations, the UC Regents has the right to either terminate the agreement or to reduce our exclusive license to a non-exclusive license, after giving us 60 days to cure or request arbitration. We may terminate either 2019 UC Agreement at-will in its entirety or with respect to any portion of the licensed patent rights upon 90 days prior written notice.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In July 2021, the Company entered into an Exclusive License Agreement (the &#34;UC/UPenn Agreement&#34;) with the UC Regents and the Trustees of the University of Pennsylvania (&#34;UPenn&#34;) to license intellectual property related to certain AAV vectors. The UC Regents and UPenn granted us an exclusive, sublicensable license to make, use, sell, offer to sell, and import products and services, and to practice methods in the United States and foreign countries where the licensed patent rights exist. The license grant under the UC/UPenn Agreement is in all therapeutic and prophylactic fields of use and excludes diagnostic uses. We agreed to certain general and specific diligence obligations under the UC/UPenn Agreement in connection with the development, manufacture and sales of the licensed products, services and methods. In July 2021, the Company paid a non-refundable license fee of $100,000 to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license maintenance fee of $10,000 on the one-year anniversary of the contract effective date and each year thereafter, except years for which the Company has paid royalties on the net sales of a licensed product. In addition, the Company is obligated to make certain contingent payments including (i) development sales milestones up to $3.9 million, (ii) low single digit percentage rate royalties on the net sales of its licensed products that consists of a minimum annual royalty of up to $0.1 million per year for the term of the Agreement beginning in the first calendar year after the year in which net sales first occurred and (iii) sublicense consideration in the mid-single digits to the low twenties percentage rate range on any future sublicensing arrangements the Company may enter into with third-party licensees, which we may reduce if we sublicense any of our own or third-party patent rights under the sublicense grant based on the relative value of the sublicensed patents. Under the UC/UPenn Agreement, royalties are payable until the expiration of the last-to-expire licensed patent right covering the licensed product, services or method, at which time the agreement shall expire. The UC Regents or UPenn may terminate the UC/UPenn Agreement if we fail to cure a breach of the agreement within 60 days of notice. If we fail to meet our diligence obligations, the UC Regents has the right to either terminate the agreement or to reduce our exclusive license to a non-exclusive license, after giving us 60 days to cure or request arbitration. We may terminate the UC/UPenn Agreement at-will in its entirety or with respect to any portion of the licensed patent rights upon 90 days prior written notice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Cystic Fibrosis Foundation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2016, we received a grant from Cystic Fibrosis Foundation (&#x201c;CFF&#x201d;) in the amount of $525,000 to support discovery and development of product candidates to treat cystic fibrosis. The grant was increased to $3.5 million in 2017 and was subsequently amended to allocate the $3.5 million to different milestones. The grant provides for repayment to CFF upon the commercialization of any product developed under the grant. The repayment is capped at nine times the grant actually paid to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2020, CFF made a $10.0 million investment in our Series C redeemable convertible preferred stock financing. In return for the investment, CFF received shares of our Series C redeemable convertible preferred stock, and we and CFF entered into a Funding Agreement (the Funding Agreement). Pursuant to the terms of the Funding Agreement, we agreed to use the proceeds of the CFF investment to support development of 4D-710, our product candidate for the treatment of cystic fibrosis, and to match CFF&#x2019;s support for the product candidate. As provided under the Funding Agreement, following acceptance by the FDA in October 2021 of our IND for 4D-710 (&#34;Acceptance&#34;), CFF made an additional $4.0 million investment (the &#34;Subsequent Investment&#34;), in exchange for 125,715 shares of the Company's common stock. We have agreed to use the additional $4.0 million from the Subsequent Investment to support development of 4D-710 and to match CFF's support of the product candidate. Under the terms of the Funding Agreement, neither the $10.0 million investment in the Series C redeemable convertible preferred stock nor the $4.0 million of funding upon Acceptance are restricted as to withdrawal or usage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biological product candidates such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">U.S. Biologics Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and other federal, state, local and foreign statutes and regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#x2019;s GLPs; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">submission to the FDA of an IND which must become effective before clinical trials may begin; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">approval by an IRB or ethics committee at each clinical site before the trial is commenced; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">satisfactory completion of an FDA Advisory Committee review, if applicable; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#x2019;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices (&#x201c;GCPs&#x201d;); and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical trials. The IND also includes results of animal and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition to the submission of an IND to the FDA, under the National Institutes of Health, or NIH, Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines), supervision of certain human gene transfer trials may also require evaluation and assessment by an institutional biosafety committee (&#x201c;IBC&#x201d;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to the public health or the environment, and such assessment may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phase 1&#x2014;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phase 2&#x2014;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phase 3&#x2014;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may also be made a condition to approval of the BLA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing suggesting a significant risk to humans exposed to the drug, and any clinically important increased rate of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">BLA Submission and Review by the FDA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators. The submission of a BLA requires payment of a substantial user fee to FDA, and the sponsor of an approved BLA is also subject to an annual program fee. A waiver of user fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#x2019;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the filing date. Priority review designation will direct overall attention and resources to the evaluation of applications for products that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#x2019;s continued safety, purity and potency. The FDA may also convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions regarding approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter (&#x201c;CRL&#x201d;). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy (&#x201c;REMS&#x201d;), to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase IV post-market studies and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#x2019;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new biological product candidates are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the application may be eligible for priority review. For a fast track product candidate, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application. A fast track designated product candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six months after the FDA accepts the application for filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2017, the FDA established the regenerative medicine advanced therapy (&#x201c;RMAT&#x201d;) designation as part of its implementation of the 21st Century Cures Act. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug or biologic that meets the following criteria: (i) the drug or biologic qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (ii) the drug or biologic is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii) preliminary clinical evidence indicates that the drug or biologic has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides all the benefits of breakthrough therapy designation, including more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Product candidates granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of clinical trial sites, including through expansion of trials to additional sites.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any marketing application for a drug or biologic submitted to the FDA for approval, including a product candidate with a fast track designation, RMAT designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product candidate is eligible for priority review if it is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. For original BLAs, priority review designation means the FDA&#x2019;s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review). Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#x2019;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a biologic or indication approved under accelerated approval on an expedited basis if, for example, the sponsor fails to conduct required post-marketing trials in a timely manner or if such trials fail to verify the predicted clinical benefit of the product.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fast Track designation, priority review, accelerated approval, RMAT designation and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Orphan Drug Designation and Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. We have obtained orphan drug designation for 4D-110 for the treatment of Choroideremia and for 4D-310 for the treatment of Fabry disease, and we plan to seek additional orphan drug designations for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Biologics are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">fines, warning letters, or untitled letters; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">clinical holds on clinical studies; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Biosimilars and Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Affordable Care Act, signed into law in 2010, includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#x201c;interchangeable&#x201d; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Other Healthcare Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, pricing reporting, data privacy and security, and transparency laws and regulations as well as similar foreign laws in the jurisdictions outside the U.S. For example, the federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute. The federal civil and criminal false claims laws, including the civil False Claims Act, prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. The federal Health Insurance Portability and Accountability Act of 1996 (&#x201c;HIPAA&#x201d;), created additional federal civil and criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation. The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians, certain other health care professionals beginning in 2022, and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives. Violation of any of such laws or any other governmental regulations that apply may result in significant penalties, including, without limitation, administrative civil and criminal penalties, damages, disgorgement fines, additional reporting requirements and oversight obligations, contractual damages, the curtailment or restructuring of operations, exclusion from participation in government healthcare programs and imprisonment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Data Privacy and Security Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pharmaceutical companies may be subject to domestic and foreign privacy, security and data breach notification laws, which are rapidly evolving in many jurisdictions worldwide. In the United States, federal and state health information laws may govern the collection, use, disclosure and protection of health-related and other personal information. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder, which impose obligations on &#x201c;covered entities,&#x201d; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#x201c;business associates&#x201d; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information or protected health information (&#34;PHI&#34;). State laws may be more stringent, broader in scope or offer greater individual rights with respect to health-related information than HIPAA and state laws may differ from each other, which may complicate compliance efforts. For example, California enacted the California Consumer Privacy Act (the &#x201c;CCPA&#x201d;) on June 28, 2018, which went into effect on January 1, 2020. The CCPA gives California residents expanded rights regarding their personal information. Although CCPA contains certain exceptions for health-related information, including PHI, such exceptions may not apply to all of our operations and processing activities. Further, the California Privacy Rights Act (&#x201c;CPRA&#x201d;), recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Virginia and Colorado have also enacted similar legislation to California increasing complexity of compliance with privacy laws. The majority of the provisions for these laws will go into effect in 2023, and additional compliance investment and potential business process changes may be required. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured PHI, a complaint about privacy practices or an audit by the Department of Health and Human Services (&#x201c;HHS&#x201d;) may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">European Union member states, the United Kingdom (&#34;UK&#34;), Switzerland and other jurisdictions have also adopted data protection laws and regulations, which impose significant compliance obligations. For example, the processing of personal data is governed in the European Economic Area (&#x201c;EEA&#x201d;) by the General Data Protection Regulation, or EU GDPR, and in the UK, by the UK data protection regime consisting primarily of the UK General Data Protection Regulation, or UK GDPR, and the UK Data Protection Act 2018, (collectively, the &#x201c;GDPR&#x201d;). The GDPR, together with national legislation, regulations and guidelines of the European Union and EEA member states and the UK governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the information provided to the individuals, the transfer of personal data out of the EEA or the UK, security breach notifications, security and confidentiality of the personal data and imposition of substantial potential fines for breaches of the data protection obligations. The law is also developing rapidly and, in July 2020, the Court of Justice of the European Union (&#34;CJEU&#34;) limited how organizations could lawfully transfer personal data from the EEA to the U.S. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in or from the EEA or UK. Guidance on implementation and compliance practices are often updated or otherwise revised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to make compliance efforts more challenging, and can result in investigations, proceedings, or actions that lead to significant penalties and restrictions on data processing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product, particularly for gene therapy products where the Centers for Medicare &amp; Medicaid Services (&#x201c;CMS&#x201d;) and other third-party payors in the United States have not yet established a uniform policy of coverage and reimbursement. Therefore, decisions. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#x2019;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of us placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payors&#x2019; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively the &#x201c;ACA&#x201d;) was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#x201c;branded prescription drugs&#x201d; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare &amp; Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA.  On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, absent additional Congressional action.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Employees and Human Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, we had 124 full-time employees. Of these employees, 92 are engaged in research and development. Our employees are not represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Facilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We lease approximately 54,000 square feet of office and laboratory space in Emeryville, California under leases that expire in September 2026 and December 2029. We believe that our facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Corporate Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We were formed on September 12, 2013 as a Delaware limited liability corporation under the name 4D Molecular Therapeutics, LLC. On March 11, 2015, 4D Molecular Therapeutics, Inc. was incorporated as a Delaware corporation. On March 20, 2015, 4D Molecular Therapeutics, LLC merged with 4D Molecular Therapeutics, Inc., with 4D Molecular Therapeutics, Inc. being the surviving entity. Our principal executive offices are located at 5858 Horton Street #455, Emeryville, California 94608, and our telephone number is (510) 505-2680.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Available Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our website address is www.4dmoleculartherapeutics.com. The information on, or that can be accessed through, our website is not part of this Annual Report on Form 10-K. The U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;) are also available free of charge on our investor relations website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and the section of this Annual Report on Form 10-K &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before deciding whether to invest in our common stock. If any of the following risks actually occur, our business, reputation, financial condition, results of operations, revenue and future prospects could be seriously harmed. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. Unless otherwise indicated, references to our business being seriously harmed in these risk factors and elsewhere will include harm to our business, reputation, financial condition, results of operations, revenue, future prospects and stock price. If our business is seriously harmed, the market price of our common stock could decline, and you could lose part or all of your investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risk Factor Summary</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. The following is a summary of the principal risks that could seriously harm our business, all of which are more fully described below. This summary should be read in conjunction with the other risk factors included in this &#x201c;Risk Factors&#x201d; section and should not be relied upon as an exhaustive summary of the material risks facing our business.</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are in the early stages of drug development and have a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have had recurring net losses, and we expect to continue to incur significant net losses for the foreseeable future.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All of our product candidates are based on a novel AAV gene therapy technology with which there is limited regulatory and clinical experience to date, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. Further, the regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied therapeutic modalities.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Gene therapies are novel, complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products or otherwise seriously harm our business.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Adverse public perception or regulatory scrutiny of gene therapy technology may negatively impact the developmental progress or commercial success of products that we develop alone or with collaborators.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, expensive, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our employees, independent contractors, consultants, research or commercial partners or collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by others, and the patent protection, prosecution and enforcement for some of our product candidates may be dependent on our licensors.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We are in the early stages of drug development and have a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are a clinical-stage gene therapy company pioneering the development of product candidates using our targeted and evolved AAV vectors. We commenced operations in September 2013, have no products approved for commercial sale and have not generated any product revenue. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. If our product candidates are not successfully developed and approved, we may never generate any product revenue. To date, we have not completed any clinical trials (including any pivotal clinical trial), obtained marketing approval for any product candidates, manufactured commercial scale quantities of any of our product candidates or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our limited operating history as a company and early stage of drug development make any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We have had recurring net losses, and we expect to continue to incur significant net losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have incurred recurring net losses, including net losses of $71.3 million and $56.7 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $207.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have devoted substantially all of our financial resources and efforts on research and development activities, including for our product candidates and our Therapeutic Vector Evolution platform. We do not expect to generate revenue from product sales for several years, if at all. We continue to incur significant research and development and other expenses related to our ongoing operations. The amount of our future net losses will depend, in part, on the level of our future expenditures and our ability to generate revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expect to continue to incur significant and increasingly higher expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">progress our current and any future product candidates through preclinical and clinical development; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">experience delays in our preclinical studies and clinical trials, whether current or planned, due to the novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic, or other factors; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">expand our manufacturing facilities and work with our contract manufacturers to scale up the manufacturing processes for our product candidates; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">continue our research and discovery activities; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">continue the development of our Therapeutic Vector Evolution platform; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">initiate and conduct additional preclinical, clinical or other studies for our product candidates; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">change or add additional contract manufacturers or suppliers; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">seek regulatory approvals and marketing authorizations for our product candidates; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establish sales, marketing and distribution infrastructure to commercialize any products for which we obtain approval; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">acquire or in-license product candidates, intellectual property and technologies; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">make milestone, royalty or other payments due under any current or future collaboration or license agreements; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">obtain, maintain, expand, protect and enforce our intellectual property portfolio; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">attract, hire and retain qualified personnel; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">experience any delays or encounter other issues related to our operations; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">meet the requirements and demands of being a public company;</span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">are adversely impacted by general economic conditions, such as rising inflation;</span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">defend against any product liability claims or other lawsuits related to our products; and </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">address the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#x2019; deficit and working capital. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time consuming, expensive and uncertain process that takes years to complete. Our operations have required substantial amounts of cash since inception. To date, we have financed our operations primarily through the sale of equity securities and to a lesser extent from cash received pursuant to our collaboration and license agreements. We have initiated clinical trials, which are ongoing, and have additional product candidates in preclinical development that may enter clinical development. Developing our product candidates is expensive, and we expect to continue to spend substantial amounts as we fund our early stage research projects, continue preclinical and clinical development of our product candidates and, in particular, advance our product candidates through clinical trials. Even if we are successful in developing our product candidates, obtaining regulatory approvals and launching and commercializing any product candidate will require substantial funding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, we had $315.4 million in cash and cash equivalents and marketable securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will allow us to fund our planned operations for at least one year from the date of the issuance of the financial statements included in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. Our ability to raise additional capital may be adversely impacted if global economic conditions worsen or if the COVID-19 pandemic, including the spread of any variant thereof, causes disruptions and volatility to credit and financial markets. If adequate funds are not available to us on a timely basis, we may be required to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities or eliminate one or more of our development programs altogether; or </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates, or reduce our flexibility in developing or maintaining our sales and marketing strategy. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to, or jointly own some aspects of, our product candidates or technologies that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and unless and until a product candidate is clinically tested, approved for commercialization and successfully marketed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We will be required to seek additional funding in the future and currently intend to do so through collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution, and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. Any of the above events could seriously harm our business and cause the price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on product candidates that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Due to the significant resources required for the development of our product candidates, in particular our product candidates in IND-enabling studies and those in clinical trials, we must decide which product candidates and indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain product candidates may subsequently also prove to be less than optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our product candidates or misread trends in the biopharmaceutical industry, in particular for ophthalmology, cardiology and pulmonology diseases, our business could be seriously harmed. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or collaboration partners; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing and cost of, and level of investment in research, development and commercialization activities, which may change from time to time; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing of receipt of approvals from regulatory authorities in the United States and internationally; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing and status of enrollment and safety and efficacy readouts for our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the cost of manufacturing, as well as building out our supply chain, which may vary depending on the quantity of production, the cost of continuing to establish and scale up our internal manufacturing capabilities, and the terms of any agreements we enter into with third-party suppliers; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">timing and amount of any option, milestone, royalty or other payments due under any current or future collaboration or license agreement; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">coverage and reimbursement policies with respect to our gene therapy product candidates and potential future drugs that compete with our products, if approved; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">expenditures that we may incur to acquire, develop or commercialize additional products and technologies; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the level of demand for our gene therapy products, if approved, which may vary significantly over time; and </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">future accounting pronouncements or changes in our accounting policies. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For example, most of our collaboration and license revenue for the year ended December 31, 2021 was from Roche. However, Roche terminated its collaboration and license agreement with us effective September 16, 2021. The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This variability and unpredictability could also result in our failing to meet the expectations of financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks Related to the Research, Discovery, Development and Commercialization of Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">All of our product candidates are based on a novel AAV gene therapy technology with which there is limited regulatory and clinical experience to date, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. Further, the regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied therapeutic modalities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">  </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All of our product candidates are based on gene therapy technology, and our future success depends on the successful development of this novel therapeutic approach. We cannot assure you that any development problems we or other gene therapy companies experience in the future related to gene therapy technology will not cause significant delays or unanticipated costs in the development of our product candidates, or that such development problems can be solved. In addition, the clinical study requirements of the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied therapeutic modalities. Further, as we are developing novel treatments for diseases in which there is limited clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, European Medicines Agency (&#x201c;EMA&#x201d;) or comparable foreign regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. To date, few gene therapy products have been approved by the FDA or comparable foreign regulatory authorities, which makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States, the European Union or other jurisdictions. Further, approvals by one regulatory agency may not be indicative of what other regulatory agencies may require for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Regulatory requirements governing gene therapy products have evolved and may continue to change in the future. For example, the FDA established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research (&#x201c;CBER&#x201d;) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. These and other regulatory review agencies, committees and advisory groups and the requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates or lead to significant post-approval limitations or restrictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The National Institutes of Health (&#x201c;NIH&#x201d;) Guidelines for Research Involving Recombinant DNA Molecules (&#x201c;NIH Guidelines&#x201d;) require supervision of human gene transfer trials, including evaluation and assessment by an Institutional Biosafety Committee (&#x201c;IBC&#x201d;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to the public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are subject to significant regulatory oversight by the FDA, and, in addition, the applicable IBC and Institutional Review Board (&#x201c;IRB&#x201d;), of each institution at which we or our collaborators conduct clinical trials of our product candidates, or a central IRB if appropriate, need to review and approve the proposed clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Similarly, the EMA governs the development of gene therapies in the European Union and may issue new guidelines concerning the development and marketing authorization for gene therapy products and require that we comply with these new guidelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Changes in applicable regulatory guidelines may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all and could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Adverse public perception or regulatory scrutiny of gene therapy technology may negatively impact the developmental progress or commercial success of product candidates that we develop alone or with collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The developmental and commercial success of our current product candidates, or any that we develop alone or with collaborators in the future, will depend in part on public acceptance of the use of gene therapy technology, including the use of AAVs, for the prevention or treatment of human diseases. Adverse public perception of gene therapies may negatively impact our ability to raise capital or enter into strategic agreements for the development of product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Gene therapy remains a novel technology. The commercial success of our gene therapy product candidates, if successfully developed and approved, may be adversely affected by claims that gene therapy is unsafe, unethical or immoral. This may lead to unfavorable public perception and the inability of any of our product candidates to gain the acceptance of the public or the medical community. Unfavorable public perceptions may also adversely impact our or our collaborators&#x2019; ability to enroll clinical trials for our product candidates. Moreover, success in commercializing any product candidates that receive regulatory approval will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of such product candidates in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Publicity of any adverse events in, or unfavorable results of, preclinical studies or clinical trials for any current or future product candidates, or with respect to the studies or trials of our competitors or of academic researchers utilizing similar technologies, even if not ultimately attributable to our technology or product candidates, could negatively influence public opinion. Negative public perception about the use of AAV technology in human therapeutics, whether related to our technology or a competitor&#x2019;s technology, could result in increased governmental regulation, delays in the development and commercialization of product candidates or decreased demand for the resulting products, any of which may seriously harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in previous trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Less common adverse effects may not become evident until investigational products are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If any serious adverse events occur, clinical trials or commercial distribution of any product candidates or products we develop alone or with collaborators could be suspended or terminated, and our business could be seriously harmed. Treatment-related side effects could also affect patient recruitment and the ability of enrolled patients to complete the trial or result in potential liability claims. Regulatory authorities could order us or our collaborators to cease further development of, deny approval of, or require us to cease selling any product candidates or products for any or all targeted indications. If we or our collaborators elect, or are required, to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be harmed, and our ability to generate product revenues from them or other product candidates that we develop may be delayed or eliminated. Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulatory authorities may require additional warnings on the label including &#x201c;boxed&#x201d; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may be required to create a Risk Evaluation and Mitigation Strategy (&#x201c;REMS&#x201d;), which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the product may become less competitive; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may be subject to fines, injunctions or the imposition of criminal penalties; </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:5.602%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.403652619758893%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our reputation may suffer. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We have no products approved for commercial sale, and we have never generated any revenue from product sales, and we may never generate product revenue or be profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have no products approved for commercial sale and have not generated any revenue from product sales. We do not anticipate generating any revenue from product sales until after we have successfully completed clinical development and received regulatory approval for the commercial sale of a product candidate, which will not occur for several years, if ever.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our ability to generate revenue and achieve profitability depends significantly on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">successfully completing research and preclinical and clinical development of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the COVID-19 pandemic, which has resulted in, and in the future may continue to result in delays to patient enrollment, patients discontinuing their treatment or follow up visits or changes to trial protocols; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development and clinical trials; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and any commercial demand for our product candidates; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">identifying, assessing, acquiring and/or developing new product candidates; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">launching and successfully commercializing product candidates for which we obtain marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign countries where our product candidates are commercialized; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">obtaining adequate reimbursement for our product candidates or procedures using our product candidates from payors; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the convenience and durability of our treatment or dosing regimen; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates, or any future product candidates, if approved, including relative to alternative and competing treatments; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">patient demand for any of our product candidates that may be approved; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">addressing any competing technological and market developments; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including patents, trade secrets and know-how; and </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">attracting, hiring and retaining qualified personnel. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA or foreign regulatory agencies, to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our collaborators&#x2019; clinical trials or the development of any of our product candidates. Even if one or more of our product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate and ongoing compliance efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Even if we are able to generate revenue from the sale of any approved products, we may not become profitable, and we will need to obtain additional funding through one or more equity or debt financings in order to continue operations. Revenue from the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price and whether we own the commercial rights for that territory. If the number of addressable patients is not as large as we anticipate, the indication approved by regulatory authorities is narrower than we expect, the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines or the price and available third-party reimbursement are lower than anticipated, we may not generate significant revenue from sales of such product candidate, even if approved. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations and cause a decline in the value of our common stock, all or any of which may seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Public health crises such as pandemics or similar outbreaks have affected and could continue to seriously and adversely affect our preclinical and clinical trials, business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In response to the COVID-19 pandemic, &#x201c;shelter in place&#x201d; orders and other public health guidance measures were implemented, and may be implemented again to the extent eased, across much of the United States and Europe, including in the locations of our offices, clinical trial sites, key vendors and partners. We expect that our clinical development program timelines will be negatively affected by COVID-19, which could seriously harm our business. Further, due to &#x201c;shelter in place&#x201d; orders and other public health guidance measures, we have implemented a work-from-home policy for all staff members excluding those working in certain laboratory and manufacturing functions and those necessary to maintain minimum basic operations. Such &#x201c;shelter in place&#x201d; orders could be further extended due to the spread of more contagious and virulent COVID-19 variants. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay or otherwise seriously harm our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories will be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a result of the COVID-19 pandemic, or similar pandemics, and related &#x201c;shelter in place&#x201d; orders and other public health guidance measures, we have, and may in the future, experience disruptions that could seriously harm our business. Disruptions due to the COVID-19 pandemic that have and may in the future impact our business include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays or difficulties in enrolling patients in our clinical trials;</span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;</span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations imposed on travel; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">recommendations by federal, state or local governments, employers and others or interruptions of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical trial endpoints; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at CROs and vendors; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, raw materials shortages, production slowdowns or stoppages and disruptions in delivery systems; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and preclinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">These and other factors arising from the COVID-19 pandemic could worsen in countries that are already afflicted with COVID-19, could continue to spread to additional countries or could return to countries where the pandemic has been partially contained, each of which could further adversely impact our ability to conduct clinical trials and our business generally, and could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The COVID-19 pandemic continues to rapidly evolve, including the spread of new variants that have proven to be more contagious and deadly. The extent to which the COVID-19 pandemic may affect our clinical trials, business, financial condition and results of operations will depend on future developments (such as the prevalence of new variants, difficulties in the vaccine rollout or reluctance of individuals to get inoculated), which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and results of operations and could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical trials will be initiated or conducted as planned or completed on schedule, if at all. For example, in the first half of 2019 a manufacturing batch of our product candidate 4D-110 produced at a CMO failed to meet the specifications required for use in our planned clinical trial due to an issue identified with one of the plasmids used in the manufacturing process. As a result, we delayed the initiation of our planned first-in-human trial of 4D-110 until July 2020, so that we could produce the clinical-grade material required for the trial using our in-house manufacturing facility. We also cannot be sure that submission of an IND or a clinical trial application (&#x201c;CTA&#x201d;) will result in the FDA or other regulatory authority, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could delay, suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays in reaching a consensus with regulatory agencies on study design or implementation of the clinical trials; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adverse impacts from the COVID-19 pandemic as further described elsewhere in these risk factors; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays or failure in obtaining regulatory authorization to commence a trial; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays in reaching agreement on acceptable terms with prospective contract research organizations (&#x201c;CROs&#x201d;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">refusal of the FDA to accept data from clinical trials in geographies outside the United States; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays in identifying, recruiting and training suitable clinical investigators; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays in identifying, recruiting, and enrolling patients who meet the requirements of our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays in obtaining required IRB approval at each clinical trial site; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">insufficient or inadequate supply or quality of product candidates or other materials necessary for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND or amendment, CTA or amendment, or equivalent foreign application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; or a negative finding from an inspection of our clinical trial operations or study sites; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">developments on trials conducted by competitors for related technology that raise FDA or foreign regulatory authority concerns about risk to patients of the technology broadly; or if the FDA or a foreign regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its stated objectives; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">difficulty collaborating with patient groups and investigators; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">failure by our CROs, other third parties, or us to adhere to clinical trial protocols; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">failure to perform in accordance with the FDA&#x2019;s or any other regulatory authority&#x2019;s good clinical practice requirements (&#x201c;GCPs&#x201d;) or applicable regulatory guidelines in other countries; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the cost of clinical trials of our product candidates being greater than we anticipate; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization (&#x201c;CMO&#x201d;) or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">third parties being unwilling or unable to satisfy their contractual obligations to us; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adverse public perception or regulatory scrutiny of gene therapy technology may negatively impact the developmental progress or commercial success of products that we develop alone or with collaborators.</span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Patient enrollment, a determinative factor in the timing of clinical trials, is affected by many factors including the severity of and difficulty of diagnosing the disease under investigation, knowledge of the disease in the medical community and availability of effective diagnostic methods, size and distribution of the patient population and process for identifying subjects, access of patients to medical professionals experienced in their disease, our ability to effectively disseminate information about our clinical trials to the patient population and access of patients to such information, eligibility and exclusion criteria for the trial in question, design of the trial protocol, availability, efficacy of, and our ability to compete with approved and standard of care therapies or other clinical trials for the disease or condition under investigation, perceived risks and benefits of the product candidate under trial or testing, availability of genetic testing for potential patients, efforts to facilitate timely enrollment in clinical trials, patient referral practices of physicians, ability to obtain and maintain subject consent, the risk that enrolled subjects will drop out before completion of the trial, the ability to monitor patients adequately during and after treatment, the time and financial commitments required of patients to enroll in our trials beyond the costs covered by the company, and the proximity and availability of and access to clinical trial sites for prospective patients. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required, or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates and could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The limited number of patients who have the diseases for which our product candidates are being studied may make it more difficult for us to enroll or complete clinical trials or may result in findings in our clinical trials that do not reach levels of statistical significance sufficient for marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Most of the conditions for which we plan to evaluate our current product candidates in clinical trials are rare genetic diseases. Accordingly, there are limited patient pools from which to draw for clinical trials. In addition to the rarity of these diseases, the eligibility criteria of our clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their disease is either severe enough or not too advanced to include them in a trial. We or our collaborators may not be able to initiate or continue clinical trials on a timely basis or at all for any of our product candidates if we or our collaborators are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. Similarly, because most of the conditions we intend to treat are rare in nature, we plan to design and conduct clinical trials utilizing a small number of patients in order to evaluate the safety and therapeutic activity of our product candidates. Conducting trials in smaller subject populations increases the risk that any safety or efficacy issues observed in only a few patients could prevent such trials from reaching statistical significance or otherwise meeting their specified endpoints, which could require us to conduct additional clinical trials, or delay or prevent our product candidates from receiving regulatory approval, which would seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized or if they will ever be successfully commercialized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are at an early stage of development of our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our product candidates may not successfully complete preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">delays in our clinical development plans due to the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it does not meet applicable regulatory criteria; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our competitors may develop therapeutics that render our product candidates obsolete or less attractive; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our competitors may develop platform technologies that render our Therapeutic Vector Evolution platform technology obsolete or less attractive; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the product candidates and Therapeutic Vector Evolution platform technology that we develop may not be sufficiently covered by intellectual property for which we hold exclusive rights or may be covered by third-party patents or other intellectual property or exclusive rights; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If any of these events occur, we or our collaborators may be forced to abandon our development efforts for a product candidate or candidates, which would seriously harm our business. Failure of a product candidate may occur at any stage of preclinical or clinical development, and, because our product candidates and our Therapeutic Vector Evolution platform technology are in an early stage of development, there is a relatively higher risk of failure and we may never succeed in developing marketable products or generating product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may not be successful in our efforts to further develop our Therapeutic Vector Evolution platform technology and current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product candidates is in the early stages of development and will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates or if we do not meet the clinical endpoints with statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If any of our product candidates successfully completes clinical trials, we generally plan to seek regulatory approval to market our product candidates in the United States, the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would seriously harm our business. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, purity, potency, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. We may also rely on our collaborators or collaboration partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product candidates. We cannot be sure that our collaborators or collaboration partners will conduct these activities successfully or do so within the timeframe we desire. Even if we (or our collaborators or collaboration partners) are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. Failure to obtain approval for our product candidates in multiple jurisdictions will seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. Any approval we may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The ability of the FDA to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#x2019;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#x2019;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Separately, in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing facilities, and subsequently, on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we or our collaborators must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Further, because our product candidates are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our ongoing and planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Interim, &#x201c;top-line&#x201d; and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">From time to time, we may publicly disclose top-line or preliminary data from preclinical studies  and  clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or &#x201c;top-line&#x201d; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, top-line or interim data and final data could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may not be successful in our efforts to continue to create a pipeline of product candidates or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates, our commercial opportunity may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">One of our strategies is to identify and pursue preclinical and clinical development and commercialization of additional product candidates through our Therapeutic Vector Evolution platform technology. Our Therapeutic Vector Evolution platform technology may not produce a pipeline of viable product candidates, or our competitors may develop platform technologies that render our Therapeutic Vector Evolution platform technology obsolete or less attractive. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make them unmarketable or unlikely to receive marketing approval. Identifying, developing and obtaining regulatory approval and commercializing additional product candidates will require substantial funding and is prone to the risks of failure inherent in drug development. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunity may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of the indications for which we have product candidates, including XLRP, choroideremia, Fabry disease, wet AMD, and cystic fibrosis lung disease. Certain of our competitors have commercially approved products for the treatment of the diseases that we are pursuing or may pursue in the future, including Biogen, Roche, Sanofi, Takeda and Vertex. These drugs are well established therapies and are widely accepted by physicians, patients and third-party payors, which may make it difficult to convince these parties to switch to our product candidates. Companies that we are aware are developing therapeutics in the ophthalmology, cardiology and pulmonology disease areas include large companies with significant financial resources, such as Allergan, Biogen, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and Vertex, and biopharmaceutical companies such as Abeona, Adverum, AGTC, Amicus, Avrobio, Freeline, Kodiak Sciences, Krystal, MeiraGTx, RegenxBio, Sangamo, and Spirovant. In addition to competition from other companies targeting ophthalmology, cardiology and pulmonology, any products we may develop may also face competition from other types of therapies, such as gene-editing therapies and drug delivery devices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of ophthalmology, cardiology and pulmonology indications, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing against competitors any product candidates we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Factors that may inhibit our efforts to commercialize any approved product on our own include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, compliance, customer service, medical affairs and other support personnel; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our inability to recruit and build a commercial infrastructure due to the impacts of COVID-19; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">unforeseen costs and expenses associated with creating an independent commercialization organization. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved and our business would be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials and published in peer-reviewed journals; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the potential and perceived advantages compared to alternative treatments; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the ability to offer our products for sale at competitive prices; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the ability to offer appropriate patient access programs, such as co-pay assistance; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">sufficient third-party coverage or reimbursement; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the extent to which physicians recommend our products to their patients; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">convenience and ease of dosing and administration compared to alternative treatments; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the clinical indications for which the product candidate is approved by FDA, EMA or other regulatory agencies; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">product labeling or product insert requirements of the FDA, EMA or other comparable foreign regulatory authorities, including any limitations, contraindications or warnings contained in a product&#x2019;s approved labeling; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">restrictions on how the product is distributed; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the timing of market introduction of competitive products; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">publicity concerning our products or competing products and treatments; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the strength of marketing and distribution support; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the prevalence and severity of any side effects. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable and our business could be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks Related to Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Gene therapies are novel, complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products or otherwise seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We currently have a development, manufacturing and testing agreement and cooperation agreement with Catalent to manufacture supplies of our product candidates in the future. Our product candidates require processing steps that are more complex than those required for most chemical and protein pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we employ multiple steps to control our manufacturing process to assure that the process works and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory, which could delay or prevent the initiation of clinical trials or receipt of regulatory approvals. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. For example, in the first half of 2019, a manufacturing batch of our product candidate 4D-110 produced at a CMO failed to meet the specifications required for use in our planned clinical trial due to an issue identified with one of the plasmids used in the manufacturing process. As a result, we delayed the initiation of our planned first-in-human trial of 4D-110 until July 2020, so that we could produce the clinical-grade material required for the trial using our in-house manufacturing facility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, FDA and other comparable foreign regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or other comparable foreign regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches which could be costly to us and otherwise seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to operate our manufacturing process which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies, which could limit our access to additional attractive development programs. Problems in third-party manufacturing process or facilities also could restrict our ability to meet market demand for our products. Additionally, should our agreement with Catalent or agreements with other parties with whom we have manufacturing agreements be terminated for any reason, there are a limited number of manufacturers who would be suitable replacements, and it would take a significant amount of time to transition the manufacturing to a replacement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Delays in obtaining regulatory approval of our manufacturing process or disruptions in our manufacturing process may delay or disrupt our commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Before we can begin to commercially manufacture our product candidates in third-party or our own facilities, we must obtain regulatory approval from the FDA to market our product using the manufacturing process and facility we proposed in our marketing application. In addition, we must pass a pre-approval inspection of our manufacturing facility by the FDA before any of our product candidates can obtain marketing approval, if ever. In order to obtain approval of a BLA for our product candidates, we will need to ensure that all of our manufacturing processes, methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any products that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Delays in developing our manufacturing capabilities or failure to achieve operating efficiencies from it may require us to devote additional resources and management time to manufacturing operations and may delay our product development timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have a small operational manufacturing facility that we are using to manufacture clinical trial material. In addition, we have leased and are building out approximately 17,000 square feet of space primarily for our second manufacturing facility in Emeryville, California, a large portion of which we plan to devote to manufacturing activities for our clinical trials under cGMP. We commenced construction of this additional space in July 2021. We may face delays in the production of clinical supply at our manufacturing facility and cannot guarantee when our facility will be able to produce sufficient quantities of product candidates needed to support our planned clinical trials. Any delays in developing our internal manufacturing capabilities, including any delays due to the COVID-19 pandemic, may disrupt or delay the supply of our product candidates if we have not maintained a sufficient back-up supply of such product candidates through third-party manufacturers. Moreover, changing manufacturing facilities during the clinical development process may also require that we or our collaborators conduct additional studies, make notifications to regulatory authorities, make additional filings to regulatory authorities, and obtain regulatory authority approval for the new facilities, which may be delayed or which we may never receive. We will further need to comply with the FDA&#x2019;s and applicable foreign regulatory authorities&#x2019; cGMP requirements for the production of product candidates for clinical trials and, if approved, commercial supply, and will be subject to FDA and comparable foreign regulatory authority inspection. These requirements include the qualification and validation of our manufacturing equipment and processes. We may not be able to develop or acquire the internal expertise and resources necessary for compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order to develop internal manufacturing expertise, we may be forced to devote greater resources and management time than anticipated, particularly in areas relating to operations, quality, regulatory, facilities and information technology. We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to operate our manufacturing processes. If we experience unanticipated employee shortage or turnover in any of these areas, we may not be able to effectively manage our ongoing manufacturing operations and we may not achieve the operating efficiencies that we anticipate from developing these capabilities, which may negatively affect our product development timeline or result in difficulties in maintaining compliance with applicable regulatory requirements. Any such problems could result in the delay, prevention or impairment of clinical development and commercialization of our product candidates and would seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We currently rely and expect to continue to rely on third parties to conduct product manufacturing for certain of our product candidates, and these third parties may not perform satisfactorily.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Although we are in process of expanding internal manufacturing capabilities, we currently rely, and expect to continue to rely, on third parties for the production of some of our preclinical study and planned clinical trial materials and, therefore, we can control only certain aspects of their activities. The facilities used by us and our contract manufacturers to manufacture certain of our product candidates must be reviewed by the FDA pursuant to inspections that will be conducted after we submit our BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the cGMPs for manufacture of our products. If we or our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to obtain and/or maintain regulatory approval for our products as manufactured at their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, we rely on additional third parties to manufacture plasmids used in the manufacture of our product candidates and to perform quality testing, and reliance on these third parties entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">reduced control for certain aspects of manufacturing activities; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">termination or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">disruptions to the operations of our third-party manufacturers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or service provider. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future product candidates. Some of these events could be the basis for FDA or European Union Member State regulatory authority action, including injunction, recall, seizure or total or partial suspension of product manufacture.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Any contamination in our manufacturing process, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our research studies, preclinical, and clinical development or marketing schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Some of the raw materials required in our manufacturing process, such as plasmids, are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We rely on third-party suppliers for the raw materials required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality and delivery schedules. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our competitors who are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any interruption in supply of raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supplier in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, expensive, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We and any collaborators are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. We have not submitted for or obtained regulatory approval for any product candidate. We and any collaborators must complete additional preclinical or nonclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans to the satisfaction of the regulatory authorities before we will be able to obtain these approvals, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the FDA or comparable foreign regulatory authorities may disagree with the design, implementation or results of our or our collaborators&#x2019; clinical trials; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the FDA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use of our products; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we or our collaborators may be unable to demonstrate to the FDA, or comparable foreign regulatory authorities that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the FDA or comparable foreign regulatory authorities may disagree with our or our collaborators&#x2019; interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our or our collaborators&#x2019; clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, even if we or our collaborators were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a REMS. Regulatory authorities may not approve the price we or our collaborators intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may in the future seek an accelerated approval for one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#x2019;s agreement to conduct, in a diligent manner, additional post- approval confirmatory studies to verify and describe the drug&#x2019;s clinical benefit. If such post-approval studies fail to confirm the drug&#x2019;s clinical benefit, the FDA may withdraw its approval of the drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Even if we or our collaborators obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If one of our product candidates is approved, it will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post- market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Manufacturers and manufacturers&#x2019; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#x2019;s approved label. As such, we may not promote our products &#x201c;off-label&#x201d; for indications or uses for which they do not have approval, though we may share truthful and not misleading information that is otherwise consistent with our product&#x2019;s FDA approved labeling. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval or label restrictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">issue warning letters; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">impose civil or criminal penalties; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">suspend or withdraw regulatory approval; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">suspend any of our clinical trials; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">refuse to approve pending applications or supplements to approved applications submitted by us; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">impose restrictions on our operations, including closing our contract manufacturers&#x2019; facilities; or </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">seize or detain products, or require a product recall. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, our business will be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We have received Fast Track designation for 4D-310 for the treatment of Fabry disease to improve pain, disability and organ dysfunction, and for 4D-125 for the treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including XLRP and we may seek Fast Track designation for certain future product candidates. However, we may not be able to obtain such designations, and there is no guarantee that 4D-310 or 4D-125 will experience a faster regulatory review or obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this disease condition, the product sponsor may apply for Fast Track designation. The sponsor of a Fast Track product has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. We have received Fast Track designation for 4D-310 for the treatment of Fabry disease to improve pain, disability and organ dysfunction,  and for 4D-125 for the treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including XLRP and we may receive Fast Track designation for other product candidates in the future; however, we may not experience a faster development, review or approval process, and receipt of the designation does not increase the likelihood that the FDA will approve 4D-310 or 4D-125 for any indication. In addition, the FDA may rescind the Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We have received orphan drug designation for 4D-110 for the treatment of choroideremia and for 4D-310 for the treatment of Fabry disease, and we may seek orphan drug designation for certain future product candidates. However, we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have received orphan drug designation in the United States for 4D-110 for the treatment of choroideremia and for 4D-310 for the treatment of Fabry disease. Although we may seek orphan product designation for some or all of our other product candidates, we may never receive such designations. Under the Orphan Drug Act, the FDA may designate a drug or biologic product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Orphan drug designation must be requested before submitting a BLA. In the European Union, the EMA&#x2019;s Committee for Orphan Medicinal Products (&#x201c;COMP&#x201d;), grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity for the orphan patient population. Exclusive marketing rights in the United States may also be unavailable if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Even if we obtain orphan drug designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If the product candidates that we or our collaborators may develop receive regulatory approval in the United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for such product candidate and seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or our collaborators&#x2019; ability to develop, manufacture, promote and sell product candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to market and sell product candidates in the European Union and many other jurisdictions, we and our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or our collaborators fail to comply with the regulatory requirements in international markets or to obtain all required marketing approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and to commercialize our product candidates and may affect the prices we may set</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively the &#x201c;ACA&#x201d;) was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting &#x201c;transfers of value&#x201d; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an increase to the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and an extension the rebate program to individuals enrolled in Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a licensure framework for follow-on biologic products; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establishment of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services (CMS) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since its enactment, there have been judicial, U.S. Congressional and executive branch challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. At the federal level, the former Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures and could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could seriously harm our business. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. Prescription drugs and biological products that are in violation of these requirements will be included on a public list. These reforms could reduce the ultimate demand for our product candidates or put pressure on our product pricing and could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or judicial action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such products at competitive prices which would seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid and Veterans Affairs (&#x201c;VA&#x201d;) hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, other third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. For gene therapy and other products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, that the level of reimbursement will be sufficient.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the medicine is approved by the FDA, EMA or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell any products effectively, if approved, or generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We currently do not have a marketing or sales organization. In order to commercialize any product, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In advance of any of our product candidates receiving regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time-consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses and our business would be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties and seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil federal False Claims Act, which can be enforced through civil whistleblower or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">qui tam </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">actions, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by engaging in impermissible marketing practices, such as the off-label promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the federal Health Insurance Portability and Accountability Act of 1996 (&#x201c;HIPAA&#x201d;), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to certain payments and other transfers of value to physicians (as defined by statute), certain other non-physician practitioners (including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants, and certified nurse midwives) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">similar healthcare laws in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may also be subject to additional federal laws, such as the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof, and federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including certain of our advisory board arrangements with physicians, some of whom are compensated in the form of stock or stock options, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We use and generate materials that may expose us to material liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our research programs involve the use of hazardous materials and chemicals. We are subject to foreign, federal, state and local environmental and health and safety laws and regulations governing, among other matters, the use, manufacture, handling, storage and disposal of hazardous materials and waste products such as human tissue samples that may have the potential to transmit diseases. We may incur significant costs to comply with these current or future environmental and health and safety laws and regulations. In addition, we cannot completely eliminate the risk of contamination or injury from hazardous materials and may incur material liability as a result of such contamination or injury. In the event of an accident, an injured party may seek to hold us liable for any damages that result. Any liability could exceed the limits or fall outside the coverage of our workers&#x2019; compensation, property and business interruption insurance and we may not be able to maintain insurance on acceptable terms, if at all. We currently carry no insurance specifically covering environmental claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Animal Welfare Act (&#x201c;AWA&#x201d;) is the federal law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom we contract are subject to registration, inspections and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks Related to Our Reliance on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, clinical data assessments and analysis organizations, medical institutions and clinical investigators, to conduct some aspects of our research, preclinical testing and clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our reliance on these third parties for research and development activities reduces our control over these activities, but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCP for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and to post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our product candidates, producing additional losses and depriving us of potential product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may depend on collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have sought, and may in the future seek third-party collaborators for the research, development and commercialization of certain of the product candidates we may develop. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional, national and international pharmaceutical companies, biotechnology companies and academic institutions. If we enter into any such arrangements with any third parties, we will likely have shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#x2019; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Collaborations involving our product candidates we may develop, pose the following risks to us:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to our product candidates or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may own or co-own intellectual property covering our product candidates that result from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">disputes may arise with respect to the ownership of intellectual property developed pursuant to collaborations; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may decide not to pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#x2019;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of such product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may undergo a change of control and the new owners may decide to take the collaboration in a direction which is not in our best interest; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may become party to a business combination transaction and the continued pursuit and emphasis on our development or commercialization program by the resulting entity under our existing collaboration could be delayed, diminished or terminated; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, devices, materials, know-how or intellectual property of the collaborator relating to our products and product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders, or disrupt our management and business; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or our Therapeutic Vector Evolution platform technology; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may face significant competition in seeking appropriate collaborations. Recent business combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate or delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we enter into collaborations to develop and potentially commercialize any product candidates, we may not be able to realize the benefit of such transactions if we or our collaborator elect not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#x2019;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Any collaborator may also be subject to many of the risks relating to product development, regulatory approval, and commercialization described in this &#x201c;Risk Factors&#x201d; section, and any negative impact on our collaborators may adversely affect us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. Further, we have two granted patents (U.S. patent nos. 10,883,117 and 11,136,557) and four pending patent applications (U.S. patent application nos. 16/315,032, 16/486,681, 17/107,461 and 17,468,290), that were made with government support, that may be subject, under certain circumstances, to march-in-rights under 35 U.S.C. 203, which is a right that allows the government, in certain limited circumstances, to force a party with a license to intellectual property funded, at least in part, by the government, to grant a license to such property to another entity. U.S. patent no. 11,136,557 was made with the support of U.C. Berkeley and relates to our A101 vector. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We and our licensors have applied, and we intend to continue applying, for patents covering aspects of our product candidates, proprietary technologies and their uses that we deem appropriate. However, we may not be able to apply for patents on certain aspects of our current or future product candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent coverage we obtain may not be sufficient to prevent substantial competition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our actual or potential future collaborators or licensors will be successful in protecting our product candidates, proprietary technologies and their uses by obtaining and defending patents. These risks and uncertainties include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the U.S. Patent and Trademark Office (&#x201c;USPTO&#x201d;) and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">patent applications may not result in any patents being issued; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March 16, 2013; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. Moreover, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents, if issued, patents obtained by our collaborators or the patent rights that we license from others, may be challenged in the courts or patent offices in the United States and abroad. Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical products or product candidates, or limit the duration of the patent protection of our product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#x2019;s or potential competitor&#x2019;s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering our product candidates are invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our product candidates, our competitive position could be harmed or we could be required to incur significant expenses to enforce or defend our rights. If we initiate lawsuits to protect or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any of our pending patent applications or those of our licensors may issue as patents; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">others will not or may not be able to make, use, offer to sell, or sell products that are the same as or similar to our own but that are not covered by the claims of the patents that we own or license; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we or our licensors were the first to make the inventions covered by each of the patents and pending patent applications that we own or license; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we or our licensors were the first to file patent applications for these inventions; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">others will not develop similar or alternative technologies that do not infringe the patents we own or license; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any of the patents we own or license will be found to ultimately be valid and enforceable; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable products or will provide us with any competitive advantages; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a third party may not challenge the patents we own or license and, if challenged, a court would hold that such patents are valid, enforceable and infringed; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may develop or in-license additional proprietary technologies that are patentable; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the patents of others will not have an adverse effect on our business; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we will develop additional proprietary technologies or product candidates that are separately patentable; or </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our commercial activities or products will not infringe upon the patents of others. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Where we obtain licenses from or collaborate with third parties, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furthermore, our owned and in-licensed intellectual property rights may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our in-licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The lives of our patents may not be sufficient to effectively protect our product candidates and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent life has expired, we may be open to competition. In addition, although upon issuance in the United States a patent&#x2019;s life can be extended based on certain delays caused by the USPTO and clinical development, this extension can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. If we do not have sufficient patent life to protect our product candidates, proprietary technologies and their uses, our business would be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business would be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. We have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees and consultants. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant, collaborator or customer or third party from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our product candidates that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. Trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Though our agreements with third parties typically restrict the ability of our employees, collaborators, licensors, third-party contractors and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Because from time to time we have relied on, and in future expect to rely on third parties in the development, manufacture, and distribution of our product candidates and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by others, and the patent protection, prosecution and enforcement for some of our product candidates may be dependent on our licensors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We currently are reliant upon licenses of certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology, including technology related to our product candidates. For example, we rely on our exclusive license agreements with U.C. Berkeley for all of our rights with respect to the intellectual property covering certain compositions of matter and methods of use of certain AAV variants related to our research candidates in lead optimization stage. These and other licenses we may enter into in the future may not provide adequate rights to use such intellectual property and technology in all relevant fields of use or in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. As a result, we may not be able to develop and commercialize our technology and product candidates in fields of use and territories for which we are not granted rights pursuant to such licenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Licenses to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In some circumstances, we may not have the right to control the preparation, filing, prosecution and enforcement of patent applications, or to maintain the patents, covering technology that we license from third parties. In addition, some of our agreements with our licensors require us to obtain consent from the licensor before we can enforce patent rights, and our licensor may withhold such consent or may not provide it on a timely basis. Therefore, we cannot be certain that our licensors or collaborators will prosecute, maintain, enforce and defend such intellectual property rights in a manner consistent with the best interests of our business, including by taking reasonable measures to protect the confidentiality of know-how and trade secrets, or by paying all applicable prosecution and maintenance fees related to intellectual property registrations for any of our product candidates. We also cannot be certain that our licensors have drafted or prosecuted the patents and patent applications licensed to us in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our current licenses, and our future licenses likely will, impose various royalty payments, milestones, and other obligations on us. If we fail to comply with any of these obligations, we may be required to pay damages and the licensor may have the right to terminate the license. Termination by the licensor would cause us to lose valuable rights, and could prevent us from developing and commercializing our product candidates and proprietary technologies. Our business would be seriously harmed if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any current or future licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#x2019;s rights. In addition, while we cannot currently determine the amount of royalty obligations we would be required to pay on the sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in product candidates that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize any product candidates, we may be unable to achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If our trademarks and trade names, whether registered in the future or unregistered now, are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any trademarks we may register in the future or any current unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names, to the extent any are registered, to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">others may be able to make gene therapy products that are similar to our product candidates or utilize similar gene therapy technology but that are not covered by the claims of the patents that we own or have exclusively licensed; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">it is possible that our pending patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we may not develop additional proprietary technologies that are patentable; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the patents of others may have an adverse effect on our business. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Should any of these events occur, they could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any future collaborations that we enter into may not be successful, such as our collaboration agreement with Pfizer that was terminated in 2018, with AstraZeneca that concluded in 2020 without AstraZeneca exercising its option and with Roche that was terminated without cause effective September 2021. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators could independently develop, or develop with third parties, products and product candidates that compete directly or indirectly with our product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a collaborator with marketing, manufacturing and distribution rights to one or more products and product candidates may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future product candidates or that results in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborations may be terminated, and, if terminated, may adversely affect the price of our common stock and may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">collaborators may own or co-own intellectual property covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a collaborator&#x2019;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks Related to Our Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We conduct our operations at our facilities in Emeryville, California, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region, and doing so may be costly and difficult.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock option grants. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. In addition, our employees are employed at-will, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract, incentivize and retain quality personnel on acceptable terms, or at all, it could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, we had 124 full-time employees. As our development plans and strategies develop, and as we transition into operating as a public company, we must add a significant number of additional managerial, operational, financial and other personnel. Future growth will impose significant added responsibilities on members of management, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">identifying, recruiting, integrating, retaining and motivating additional employees; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to contractors and other third parties; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">expanding our operational, financial and management controls, reporting systems and procedures; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">managing increasing operational and managerial complexity. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Portions of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials more costly to operate. Furthermore, a severe or prolonged economic downturn, including a recession or depression resulting from the current COVID-19 pandemic or other factors could result in a variety of risks to our business, including weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption, including any international trade disputes, could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. Any of the foregoing could seriously harm our business, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we engage in acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">increased operating expenses and cash requirements; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the assumption of indebtedness or contingent liabilities; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the issuance of our equity securities which would result in dilution to our stockholders; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the diversion of our management&#x2019;s attention from our existing product candidates and initiatives in pursuing such an acquisition or strategic partnership; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, if we undertake such a transaction, we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our information technology systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches and other disruptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have experienced certain cyberattacks from time to time, but we do not believe that any such incidents have been material. Despite the implementation of security measures, our internal information technology systems and those of our collaborators, future CROs and other contractors and consultants may be vulnerable to damage from computer viruses, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, denial or degradation of service attacks, unauthorized access or use, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. As a result of the COVID-19 pandemic, we and our third party service providers and partners may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may experience security breaches that may remain undetected for an extended period. Our third party service providers and partners are also subject to these heightened risks. The costs to us to investigate and mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive position. Although to our knowledge we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information or other similar disruptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If a security breach or other incident were to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of clinical trial data or personal data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media, and other parties pursuant to privacy and security laws. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their information technology systems could also seriously harm our business. Any security compromise affecting us, our partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures, and lead to regulatory scrutiny. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary or personal information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Business disruptions could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our operations, and those of our CROs, CMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All of our operations including our corporate headquarters are located in multiple facilities in Emeryville, California. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, earthquake and other natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business could be seriously harmed by such delays and interruption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the United States and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder, imposes, among other things, certain standards on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates that perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities, and their covered subcontractors. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, California enacted the CCPA on June 28, 2018, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the CPRA, recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area (&#x201c;EEA&#x201d;). Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#x20ac;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. For example, in July 2020, the CJEU limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on use of the standard contractual clauses. The European Commission has issued new SCCs that account for the CJEU's decision and we will be required to implement the new SCCs within the relevant timeframes. The new SCCs apply only to the transfer of personal data outside of the EEA and not the UK; the UK's Information Commissioner's Office launched a public consultation on its draft revised data transfers mechanisms in August 2021. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. Inability to transfer personal information from the European Union, Switzerland or UK to the United States or elsewhere, may restrict our activities in those jurisdictions and limit our ability to provide our products and services in those jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Further, from January 1, 2021, companies have had to comply with the GDPR and also the United Kingdom GDPR, or the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#x20ac;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the UK and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term. These changes may lead to additional costs and increase our overall risk exposure. The European Commission has adopted an adequacy decision in favor of the UK, enabling data transfers from EU member states to the UK without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews or extends that decision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under Sections 382 and 383 of the United States Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), if a corporation undergoes an &#x201c;ownership change&#x201d; (generally defined as a greater than 50-percentage-point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards (&#x201c;NOLs&#x201d;) and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our ability to utilize our pre-change NOLs or other pre-change tax attributes if we undergo a future ownership change. We have experienced ownership changes in the past. We may also experience ownership changes as a result of any future shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our NOLs and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation. We will be unable to use our NOLs or other tax attributes if we do not attain profitability sufficient to offset our available NOLs or other tax attributes prior to their expiration, to the extent subject to expiration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Changes in tax laws or regulations that are applied adversely to us or our customers may seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Risks Related to Ownership of Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">The market price of our common stock may be volatile, which could result in substantial losses for investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Some of the factors that may cause the market price of our common stock to fluctuate include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">results from, and any delays in, our clinical trials for our clinical-stage product candidates or any other future clinical development programs, including any delays related to the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the success of existing or new competitive products or technologies; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">commencement or termination of collaborations for our product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">failure or discontinuation of any of our product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">failure to develop our Therapeutic Vector Evolution platform technology; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">regulatory or legal developments in the United States and other countries, including sanctions imposed by either the U.S. or foreign governments;</span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the commencement of litigation; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the level of expenses related to any of the research programs or product candidates that we may develop; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the results of our efforts to develop additional product candidates or products; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">announcement or expectation of additional financing efforts; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">sales of our common stock by us, our insiders, or other stockholders; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">expiration of market standoff or lock-up agreements; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the impact of political instability, natural disasters, war and/or events of terrorism, such as the military conflict between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other countries such as China; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">general economic, industry, and market conditions; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the other factors described in this &#x201c;Risk Factors&#x201d; section. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Further, the stock market in general has been highly volatile due to the COVID-19 pandemic and political uncertainty in the United States. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Since the completion of our initial public offering (&#x201c;IPO&#x201d;) in December 2020, the price of our common stock has been volatile, and we expect such volatility to continue. Following periods of such volatility in the market price of a company&#x2019;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#x2019;s attention and resources from our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We currently have research coverage by three financial analysts. If one or more of these analysts should drop research coverage of us or if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could reduce the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Further, shares issued upon the exercise of stock options outstanding under our equity incentive plans, or pursuant to future awards granted under those plans, will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any applicable market standoff and lock-up agreements, and Rule 144 and Rule 701 under the Securities Act of 1933, as amended (the Securities Act).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Moreover, holders of an aggregate of 11.6 million shares of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We will seek additional capital through one or a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional capital through the sale of equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Insiders have substantial influence over us, which could limit your ability to affect the outcome of key transactions, including a change of control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our directors, executive officers, holders of more than 5% of our outstanding stock and their respective affiliates beneficially own shares representing approximately 46.7% of our outstanding common stock as of December 31, 2021. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We are an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company&#x201d; and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are an &#x201c;emerging growth company,&#x201d; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an &#x201c;emerging growth company&#x201d; the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) December 31, 2025, (2) the last day of the year in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the year in which we are deemed to be a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Even after we no longer qualify as an &#x201c;emerging growth company,&#x201d; we may still qualify as a &#x201c;smaller reporting company,&#x201d; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including, among other things, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, presenting only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and reduced disclosure obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We will incur significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Select Market and the rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations have and will likely continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#x2019; and officers&#x2019; insurance, on acceptable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (&#x201c;Section 404&#x201d;) and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Beginning with this annual report, Section 404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404. Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal controls over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or, when required to do so, our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we will be required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend in part on CROs to provide timely and accurate notice of their costs to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our Company may deem advantageous. These provisions, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">eliminate cumulative voting in the election of directors; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">provide that our directors may be removed only for cause; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">prohibit stockholders from calling a special meeting of stockholders; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">provide for a staggered board, which will result in only a few directors being up for re-election in each calendar year; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">authorize our board of directors, by a majority vote, to amend the bylaws; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of our common stock to amend many of the provisions described above; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">limit the liability of, and provide indemnification to, our directors and officers. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, Section 203 of the General Corporation Law of the State of Delaware (&#x201c;DGCL&#x201d;) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any provision of our certificate of incorporation, bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#x2019;s conduct was unlawful. </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law. </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification. </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws will also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws precludes stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision that will be contained in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">General Risk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Any legal proceedings or claims against us could be costly and time-consuming to defend and could harm our reputation regardless of the outcome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We may in the future become subject to legal proceedings and claims that arise in the ordinary course of business, such as disputes or employment claims made by our current or former employees. Any litigation, whether meritorious or not, could harm our reputation, will increase our costs and may divert management&#x2019;s attention, time and resources, which may in turn seriously harm our business. Insurance might not cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims, and might not continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs and could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to cease commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">decreased or interrupted demand for our products; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">substantial monetary awards to trial participants or patients; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">injury to our reputation; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">withdrawal of clinical trial participants and inability to continue clinical trials; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">costs to defend the related litigation; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a diversion of management&#x2019;s time and our resources; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">loss of revenue; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">exhaustion of any available insurance and our capital resources; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the inability to commercialize any product candidate; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a decline in our share price. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our employees, independent contractors, consultants, research or commercial partners or collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, research or commercial partners or other collaborators, including the foundations we work with, and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA, EMA and other comparable foreign regulatory authorities; provide true, complete and accurate information to the FDA, EMA and other comparable foreign regulatory authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could seriously harm our business, including the imposition of significant fines or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Reliance on third parties to conduct clinical trials, assist in research and development and to manufacture our product candidates, will at times require us to share trade secrets with them. We seek to protect our proprietary technology by in part entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may fail to comply with any of our obligations under existing or future agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are party to various agreements that we depend on to operate our business. Our rights to use currently licensed intellectual property, or intellectual property to be licensed in the future, are or will be subject to the continuation of and our compliance with the terms of these agreements. These agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations which could lead to disputes, including but not limited to those regarding:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the extent to which our proprietary technology and product candidates infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the sublicensing of patent and other rights; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us or our counterparties, alone or jointly; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the scope and duration of our payment obligations; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">rights upon termination of such agreement; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the scope and duration of exclusivity obligations of each party to the agreement. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The resolution of any contractual interpretation dispute that may arise, if unfavorable to us, could seriously harm our business. Such resolution could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial or other obligations under the relevant agreement, or decrease the third party&#x2019;s financial or other obligations under the relevant agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If disputes over intellectual property rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or future license agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from selling our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. We cannot assure you that our operations do not, or will not in the future, infringe existing or future patents or other proprietary rights of third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Third parties may have or obtain patents or other proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products, if any, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> review proceedings and post-grant review proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#x2019;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our product candidates. As a result, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates, and cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming and could:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">result in costly litigation; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">divert the time and attention of our technical personnel and management; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">cause development delays; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">require us to pay the attorney&#x2019;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing; and/or </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Although no third party has asserted a claim of patent infringement against us as of the date of this report, others may hold proprietary rights that could prevent our product candidates or any future products from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidates or proprietary technologies could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market our product candidates or any future products. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be time-consuming and a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Even if such licenses are available, we could incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins, and the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. In addition, we cannot be certain that we could redesign our product candidates or proprietary technologies to avoid infringement, if necessary, or on a cost-effective basis. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates or any future products which could seriously harm our business. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. Also, we may be obligated under our agreements with our collaborators, licensors, suppliers and others to indemnify and hold them harmless for damages arising from intellectual property infringement by us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court or administrative tribunal may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in foreign patent offices and may result in the revocation, cancellation, or amendment of any foreign patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we could lose at least part, and perhaps all, of the patent protection on an affected product candidate. Such a loss of patent protection would seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO, or equivalent actions brought in foreign jurisdictions, may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be seriously harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace and seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and licenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We currently have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, license or use these proprietary rights. We may be unable to acquire or license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have collaborated with, and are currently collaborating with, U.S. academic institutions and may in the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business could be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we, our employees or consultants have wrongfully used or disclosed alleged confidential information or trade secrets of their former or concurrent employers or former or current clients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As is common in the biotechnology and biopharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees or consultants, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer or former or current client. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, which could seriously harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our agreements with employees and consultants provide that any inventions conceived by an individual in the course of rendering services to us shall be our exclusive property. Although our policy is to have all such individuals complete these agreements, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. The assignment of intellectual property may not be self-executing and despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. We may also be subject to claims that former employees, consultants, or other third parties have an ownership interest in our patents or other intellectual property. In addition, we may face claims by third parties that our agreements with employees or consultants obligating them to assign intellectual property to us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could seriously harm our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">If we do not obtain patent term extension for our product candidates, our business may be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Depending upon the timing, duration and specifics of FDA marketing approval of any of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration of the applicable product, and our business may be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our patent rights may be affected by developments or uncertainty in the U.S. or foreign patent statutes, patent case laws, USPTO rules and regulations or in the rules and regulations of foreign patent offices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There are a number of recent changes to the U.S. patent laws that may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, on September 16, 2011, the Leahy-Smith America Invents Act (&#x201c;Leahy-Smith Act&#x201d;) was signed into law. The Leahy-Smith Act includes a number of significant changes to the U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#x201c;first to file&#x201d; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings including opposition, derivation, reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. This could have a negative impact on some of our intellectual property and could increase uncertainties surrounding obtaining and enforcement or defense of our issued patents. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future. Similarly, statutory or judicial changes to the patent laws of other countries may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Filing, prosecuting and defending all current and future patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our business may be seriously harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ reputable professionals and rely on such third parties to help us comply with these requirements and effect payment of these fees with respect to the patents and patent applications that we own, and if we license intellectual property we may have to rely upon our licensors to comply with these requirements and effect payment of these fees with respect to any patents and patent applications that we license. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Our business could be negatively impacted by corporate citizenship and ESG matters and or our reporting of such matters.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Institutional, individual, and other investors, proxy advisory services, regulatory authorities, consumers and other stakeholders are increasingly focused on environmental, social and governance (&#34;ESG&#34;) practices of companies. As we look to respond to evolving standards for identifying, measuring, and reporting ESG metrics, our efforts may result in a significant increase in costs and may nevertheless not meet investor or other stakeholder expectations and evolving standards or regulatory requirements, which may negatively impact our financial results, our reputation, our ability to attract or retain employees, our attractiveness as an investment or business partner, or expose us to government enforcement actions, private litigation, and actions by stockholders or stakeholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 1B. Unresolved</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">operties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our corporate headquarters are located in Emeryville, California, where we lease approximately 54,000 square feet of office, research and development, engineering and laboratory space pursuant to lease agreements that expire in September 2026 and December 2029. We believe that our facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are not currently a party to any material legal proceedings.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a liability for such matters when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. Regardless of outcome litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ety Disclosures.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our common stock has been listed on the Nasdaq Global Select Market under the symbol &#x201c;FDMT&#x201d; since December 11, 2020. Prior to this date, there was no public market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Holders of Common Stock</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of March 28, 2022, there were approximately 24 holders of record of our common stock. The approximate number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in &#x201c;street name&#x201d; or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Stock Performance Graph</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="s163797164"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The following graph is not &#x201c;soliciting material&#x201d; or deemed &#x201c;filed&#x201d; with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that Section, and shall not be deemed incorporated by reference into any filing of 4D Molecular Therapeutics Inc. under the Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following graph compares the cumulative total stockholder return on our common stock with the cumulative total return of the Nasdaq Composite Index and the Nasdaq Biotechnology Index for an investment of $100, between December 11, 2020 (the date of our IPO) and December 31, 2021. The stockholder returns shown in the graph below are based on historical results and are not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img227133604_11.jpg" alt="img227133604_11.jpg" style="width:624px;height:310px;" />&#160;</p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Dividend Policy</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have never declared or paid any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors.</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2021, 45,000 warrants were exercised using the net settlement election, resulting in the issuance of 43,030 shares of our common stock. The issuance of warrants and securities in this transaction were deemed to be exempt from registration under the Securities Act, in reliance on Section 4(a)(2) of the Securities Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Use of Proceeds from Initial Public Offering</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On December 15, 2020, we closed our IPO, in which we issued and sold 9,660,000 shares of common stock at a price to the public of $23.00 per share. We received net proceeds of $204.7 million, after deducting underwriting discounts and commissions of $15.6 million and offering costs of $1.9 million.</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None of the expenses associated with the IPO were paid to directors, officers, or persons owning 10% or more of any class of equity securities, or to their associates, or to our affiliates, other than payments in the ordinary course of business to officers for salaries. Goldman Sachs &amp; Co. LLC, BofA Securities and Evercore ISI acted as book-running managers for the offering.</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Shares of our common stock began trading on the Nasdaq Global Select Market on December 11, 2020. The shares were registered under the Securities Act on a Registration Statement on Form S-1 (File No. 333-250150), which was declared effective by the SEC on December 11, 2020.</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus dated December 11, 2020, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Purchases of Equity Securities by the Issuer and Affiliated Purchases</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 6. [</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Reserved]</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Part II. Item 6 is no longer required pursuant to certain amendments to Regulation S-K that eliminated Item 301.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included elsewhere in this Annual Report on Form 10-K (this &#x201c;report&#x201d;). This discussion and analysis and other parts of this report contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are a clinical-stage gene therapy company pioneering the development of product candidates using our targeted and evolved AAV vectors. We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution, which combines the power of directed evolution with our approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. Our targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, of transducing diseased cells in target tissues efficiently, of having reduced immunogenicity and, where relevant, of having resistance to pre-existing antibodies. We believe these key design features will help us to potentially create targeted gene therapy product candidates with improved therapeutic profiles, and address a broad range of diseases from rare to large patient populations, including those that other gene therapies are unable to address. Each of our product candidates is created with our targeted and evolved AAV vectors. Our platform is designed to be modular, in that an evolved vector invented for a given set of diseases can be equipped with different transgene payloads to treat other diseases affecting the same tissue types. We believe this modularity will help inform the clinical development of subsequent product candidates using the same vector.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have built a deep portfolio of gene therapy product candidates initially focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). We have four product candidates that are in clinical trials: 4D-150 for the treatment of wet AMD in a Phase 1/2 clinical trial, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP) in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1/2 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. In addition, an IND has been cleared by the U.S. Food and Drug Administration (FDA) 4D-710 for the treatment of cystic fibrosis lung disease, and we are actively enrolling patients for such trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have funded our operations primarily through the sale and issuance of equity securities and </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">to a lesser extent from cash received pursuant to our collaboration and license agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2021, we completed our second underwritten public offering (the &#34;Follow-on Offering&#34;) in which 4,750,000 shares of our common stock were sold at an offering price of $25.00 per share pursuant to an effective Registration Statement on Form S-1. The net proceeds from the Follow-on Offering were $111.1 million after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2021, we had cash, cash equivalents and marketable securities of $315.4 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have incurred significant operating losses and expect that our operating losses will increase significantly as we, among other things, continue to advance our product candidates through preclinical and clinical development, seek regulatory approval, and prepare for, and, if approved, proceed to commercialization; broaden and improve our platform; acquire, discover, validate and develop additional product candidates; maintain, protect and enforce our intellectual property portfolio; and hire additional personnel. In addition, we expect to incur additional costs associated with operating as a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our net losses were $71.3 million and $56.7 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $207.0 million. We do not expect positive cash flows from operations in the foreseeable future. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not have any products approved for sale and have not generated any revenue from product sales since our inception. Our ability to generate product revenue will depend on the successful development, regulatory approval and eventual commercialization of one or more of our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We will require substantial additional funding to support our continuing operations and further the development of our product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which could include income from collaborations, strategic partnerships or other strategic arrangements, for the foreseeable future. Adequate funding may not be available when needed or on terms acceptable to us, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic and otherwise. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The global COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the COVID-19 situation closely. The extent of the impact of the COVID-19 pandemic on our business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on our clinical trial enrollment, trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and the majority of our employees working remotely. We will continue to actively monitor the rapidly evolving situation related to the COVID-19 pandemic and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. At this point, the extent to which the COVID-19 pandemic may affect our business, operations and clinical development timelines and plans, including the resulting impact on our expenditures and capital needs, remains uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Components of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our revenue to date has been generated through payments from our collaboration and license agreements, primarily from upfront and milestone payments and expense reimbursement. We have not generated any revenue from the sale of approved products and do not expect to do so for the foreseeable future. The primary drivers for revenue consist of the following:</span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.406941836658923%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Roche: In November 2017, we entered into a collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, &#x201c;Roche&#x201d;). We received an upfront payment of $21.0 million in 2017, are reimbursed for our internal and third-party costs and were entitled to contingent payments, including milestone payments. In 2020, we received milestone payments totaling $10.0 million, which were comprised of a $5.0 million milestone payment upon the release of clinical trial material for our Phase 1 clinical trial for 4D-110 to treat choroideremia in the second quarter of 2020 and an additional $5.0 million milestone payment upon dosing our first patient in the trial in the third quarter of 2020. We began recognizing revenue related to this agreement in 2017. In June 2021, we received notice of termination of the collaboration and license agreement from Roche. The termination became effective on September 16, 2021.  We recognized $17.2 million of revenue from Roche in 2021, of which amount $2.9 million represented expense reimbursement and $14.3 million represented recognition of previously deferred revenue. See Note 7 to our financial statements included elsewhere in this report for further discussion regarding the accounting treatment of this agreement.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">uniQure: In August 2019, we amended our agreement with uniQure and entered into a separate new collaboration and license agreement with uniQure. Neither party was required to pay monetary consideration in connection with the amendment or new agreement. We determined the incremental transaction price of the amendment and new agreement to be $5.1 million and recorded the amount as deferred revenue. We began recognizing revenue related to this in 2020 and expect to recognize revenue over the next one to two years. See Note 7 to our financial statements included elsewhere in this report for further discussion regarding the accounting treatment of this transaction. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Future collaboration and license revenue is highly dependent on the successful development and commercialization of products by our collaboration partners, which is uncertain, and revenue may fluctuate significantly from period to period. Additionally, we may never receive the consideration from our license agreements that is contemplated for option fees, development and sales-based milestone payments or royalties on sales of licensed products, given the contingent nature of these payments. We expect that our collaboration and license revenue in 2022 will primarily be from uniQure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our research and development expenses primarily consist of costs incurred for the discovery and preclinical and clinical development of our product candidates. These expenses include salaries and personnel-related costs, including stock-based compensation of our scientific personnel performing research and development activities; laboratory supplies; research materials; fees paid to CROs to execute preclinical studies and clinical trials; fees paid to CMOs to manufacture materials for preclinical studies and clinical trials; fees related to obtaining technology licenses; consulting costs; costs related to seeking regulatory approval of our product candidates; and allocated facility-related costs, information technology costs, depreciation expense and other overhead.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expense all research and development costs in the periods in which they are incurred. We have entered into various agreements with CROs and CMOs. Costs of certain activities are recognized based on an evaluation of the progress to completion of specific tasks. Payments made prior to the receipt of goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses and other current assets on our balance sheet. The capitalized amounts are recognized as expense as the goods are delivered or the related services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not allocate our costs by product candidate, as a significant amount of research and development expenses includes internal costs, such as salary  and other personnel related expenses, laboratory supplies and allocated overhead, and external costs, such as fees paid to third parties to conduct research and development activities on our behalf, none of which are tracked by product candidate. In particular, with respect to internal costs, several of our departments support multiple product candidate research and development programs, and therefore the costs cannot be allocated to a particular product candidate or development program.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At this time, we cannot reasonably estimate or know the nature, timing or estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, and incur expenses associated with hiring additional personnel to support our research and development efforts. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. See the section titled &#x201c;Risk Factors&#x201d; for additional risks regarding regulatory development and approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">General and Administrative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our general and administrative expenses consist primarily of personnel-related expenses, including salaries, employee benefit costs and stock-based compensation expense for our personnel in executive, finance and accounting, human resources, business development and other administrative functions. General and administrative expenses also include professional fees for legal, patent, consulting, accounting and tax services, allocated overhead, including rent, equipment, depreciation, information technology costs and utilities, and other general operating expenses not otherwise classified as research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expect our general and administrative expenses to increase as a result of increased personnel-related costs, patent costs for our product candidates, consulting, legal and accounting services associated with maintaining compliance with stock exchange listing and requirements of the SEC, investor relations costs, director and officer insurance premiums and other costs associated with being a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Other Income (Expense)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our other income (expense) primarily consists of interest income earned on our cash equivalents, and marketable securities and adjustments for the change in the fair value of our derivative liability which must be remeasured at each reporting period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes our results of operations for the periods indicated (dollars in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.945%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.541%;"></td>
    <td style="width:9.002%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.541%;"></td>
    <td style="width:9.002%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.541%;"></td>
    <td style="width:9.002%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:9.912%;"></td>
    <td style="width:2.462%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">$ Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">% Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Revenue:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,038</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13,612</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,426</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">33</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Operating Expenses:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">61,360</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">53,038</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,322</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">28,011</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,238</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,773</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">62</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">89,371</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">70,276</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,095</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(71,333</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(56,664</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(14,669</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Other Income (Expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(29</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">-155</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(71,317</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(56,693</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(14,624</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Revenue for the year ended December 31, 2021 increased $4.4 million, or 33%, from the year ended December 31, 2020 primarily attributable to a $4.3 million increase in revenue recognized under our collaboration and license agreement with Roche.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table provides a breakout of research and development expenses for the periods indicated (dollars in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.713%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:1.542%;"></td>
    <td style="width:8.929%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:1.542%;"></td>
    <td style="width:8.983%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:1.542%;"></td>
    <td style="width:8.983%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:11.328%;"></td>
    <td style="width:2.452%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">$ Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">% Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development trials and consumables expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26,335</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29,455</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(3,120</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">-11</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Payroll and personnel expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26,448</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,064</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,384</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">65</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Facilities and other research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,577</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,519</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,058</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">61,360</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">53,038</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,322</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development expenses for the year ended December 31, 2021 increased $8.3 million, or 16%, from the year ended December 31, 2020. The increase was attributable to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a $3.1 million decrease in research and development trials and consumable expenses, which was mainly attributable to a $7.2 million decrease in development activities for 4D-310 manufacturing; offset by a $1.1 million increase in selection and validation expense attributable to 4D-710 and 4D-150 IND enabling studies in 2021 and a $2.9 million increase in clinical trial expenses primarily attributable to the start-up of 4D-710 and 4D-150 Phase 1/2 trials during the second half of 2021. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a $10.4 million increase in payroll and personnel expenses due to an increased headcount of research and development personnel, including a $1.0 million increase in bonus expense along with a $4.2 million increase in employee stock-based compensation expense; and</span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a $1.1 million increase in facilities and other research and development expenses primarily for allocated overhead, including rent, equipment, depreciation, information technology costs and utilities. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative expenses for the year ended December 31, 2021 increased $10.8 million, or 62%, from the year ended December 31, 2020. The increase was primarily due to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a $4.6 million increase in employee and nonemployee stock-based compensation expense and a $1.5 million increase for other personnel costs; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a $2.7 million increase for director and officer insurance as we went public in December 2020; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a $1.3 million increase for employee recruiting incurred to support the increase in hiring activity. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have funded our operations primarily through the sale and issuance of our equity securities, including from the sale of our common stock in our IPO and Follow-on Offering and the sale of our Series A, Series A-1, Series B and Series C redeemable preferred stock, and to a lesser extent from cash received pursuant to our collaboration and license agreements.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2020, we completed our IPO. We issued and sold 9,660,000 shares of common stock at a price to the public of $23.00 per share. The aggregate net proceeds from our IPO were $204.7 million after deducting underwriting discounts and commissions and other offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2021, we completed our Follow-on Offering in which 4,750,000 shares of our common stock were sold at an offering price of $25.00 per share. The net proceeds from the Follow-on Offering were $111.1 million after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2021, we had cash, cash equivalents and marketable securities of $315.4 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Future Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have experienced recurring net losses and had an accumulated deficit of $207.0 million at December 31, 2021. Our transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and those of our collaboration partners and achieving a level of revenue adequate to support our cost structure. We expect to continue to incur losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We expect that our research and development and general and administrative expenses will continue to increase for the foreseeable future. Additionally, we expect our capital expenditures will increase significantly in the future for costs associated with building additional manufacturing capacity. As a result, we will need significant additional capital to fund our operations, which we may obtain through one or more equity offerings, debt financings or other third-party funding, including potential strategic alliances and licensing or collaboration arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Because of the numerous risks and uncertainties associated with the development and commercialization of gene therapy product candidates, we are unable to estimate the amount of increased capital we will need to raise to support our operations and the outlays and operating expenditures necessary to complete the development of our product candidates and build additional manufacturing capacity, and we may use our available capital resources sooner than we currently expect.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the progress of our current and future product candidates through preclinical and clinical development; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">potential delays in our preclinical studies and clinical trials, whether current or planned, due to the COVID-19 pandemic, or other factors; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">expanding our manufacturing facilities and working with our contract manufacturers to scale up the manufacturing processes for our product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">continuing our research and discovery activities; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">continuing the development of our Therapeutic Vector Evolution platform; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">initiating and conducting additional preclinical, clinical or other studies for our product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">changing or adding additional contract manufacturers or suppliers; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">seeking regulatory approvals and marketing authorizations for our product candidates; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">establishing sales, marketing and distribution infrastructure to commercialize any products for which we obtain approval; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">acquiring or in-licensing product candidates, intellectual property and technologies; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">making milestone, royalty or other payments due under any current or future collaboration or license agreements; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">obtaining, maintaining, expanding, protecting and enforcing our intellectual property portfolio; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">attracting, hiring and retaining qualified personnel; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">potential delays or other issues related to our operations; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">meeting the requirements and demands of being a public company; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">defending against any product liability claims or other lawsuits related to our products; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We believe that our existing cash and cash equivalents will allow us to fund our planned operations for at least one year from the date of the issuance of the financial statements for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have based our estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing sooner than currently projected, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. See the section titled &#x201c;Risk Factors&#x201d; for additional risks associated with our substantial capital requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not have any committed external sources of funds. Accordingly, we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources to complete the clinical development for the product candidates in treatment of Fabry disease, XLRP, choroideremia, wet AMD, cystic fibrosis or any other indication we may pursue. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter would result in fixed payment obligations and may involve agreements that include grants of security interests on our assets and restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, granting liens over our assets, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. Any debt financing or additional equity that we raise may contain terms that could adversely affect our common stockholders. Further, additional funds may not be available when we need them, on terms that are acceptable to us, or at all. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If we are unable to obtain additional funding, we expect to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or investment in internal manufacturing capabilities, which could adversely affect our business. If we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to future revenue streams or product candidates or grant licenses on terms that may not be favorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Summary Statement of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following is a summary of cash flows for the periods indicated below (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:64.986%;"></td>
    <td style="width:1.574%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:12.699%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.574%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:12.689%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.574%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="8" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Year Ended<br />December 31,</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(69,134</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(50,909</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(172,680</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(1,000</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">118,089</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">278,983</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(123,725</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">227,074</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Net Cash Used in Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021, net cash used in operating activities of $69.1 million was attributable to a net loss of  $71.3 million partially offset by a change of $17.7 million in noncash charges and by a net change of $15.5 million in our operating assets and liabilities. The noncash charges primarily consisted of stock-based compensation expense of $13.8 million, depreciation and amortization of $1.5 million and the amortization of operating lease right-of-use assets of $1.5 million.  The change in operating assets and liabilities was primarily due to a $14.7 million decrease in deferred revenue and a $4.2 million increase in prepaid expenses and other current assets primarily offset by a $2.3 million increase in accounts payable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net cash used in operating activities was $50.9 million for the year ended December 31, 2020. This was primarily due to the net loss of $56.7 million and an increase in prepaid expenses of $2.6 million, which were partially offset by stock-based compensation expense of $5.0 million and depreciation and amortization expense of $1.4 million and an increase in accrued and other liabilities of $1.9 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Net Cash Used in Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021, net cash used in investing activities was $172.7 million, consisting of purchases of marketable securities of $168.6 million, as well as purchases of property and equipment of $9.1 million, offset by the maturities of marketable securities of $5.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net cash used in investing activities was $1.0 million for the year ended December 31, 2020, all of which was used to purchase property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Net Cash Provided by Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the year ended December 31, 2021, net cash provided by financing activities of $118.1 million was primarily comprised of $114.3 million in net proceeds from offerings, as well as proceeds received from the issuance of common stock upon exercise of stock options and warrants of $3.4 million.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net cash provided by financing activities was $279.0 million for the year ended December 31, 2020, which was primarily due to $205.7 million of proceeds from our IPO net of paid underwriting discounts and commissions and offering costs in December 2021 and $72.5 million of net proceeds received from the issuance of our Series C redeemable convertible preferred stock in April and June 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Contractual Obligations, Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our commitments include obligations under vendor contracts to provide research services and other purchase commitments with our vendors. In the normal course of business, we enter into services agreements with contract research organizations, contract manufacturing organizations and other third parties. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of the services to be provided. These amounts are not fixed and determinable.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021, our principal commitments consisted of obligations under our operating lease for our headquarters. Please see note 9 to our financial statements included elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenue and expenses during the reported periods. We evaluate these estimates and assumptions on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our significant accounting policies are described in Note 2 to our financial statements included elsewhere in this report. We believe the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements and understanding and evaluating our reported financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We determine revenue recognition for arrangements within the scope of ASC 606 by performing the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our revenue is primarily derived through our license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses to our technology, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to us under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to us for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products. Arrangements that include upfront payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until performance obligations are met. The event-based milestone payments, royalties and cost reimbursements represent variable consideration, and we use the most likely amount method to estimate this variable consideration. Royalty payments are recognized when earned or as the sales occur. We record cost reimbursements as accounts receivable when right to consideration is unconditional.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. We allocate the total transaction price to each performance obligation based on the estimated selling price and recognize revenue when, or as, the performance obligation is satisfied. We include the unconstrained amount of estimated variable consideration in the transaction price. At the end of each reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We estimate our accrued research and development expenses as of each balance sheet date. This process involves reviewing contracts and purchase orders with service providers, identifying services that have been performed on our behalf and estimating the level of service performed, the expected remaining period of performance and the associated expenses incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. Depending on the timing of payments to the service providers and the estimated expenses incurred, we may record net prepaid or accrued research and development expenses relating to these costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Examples of estimated accrued research and development expenses include fees paid to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CROs in connection with preclinical development and clinical studies; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CMOs and other vendors related to process development and manufacturing of materials for use in preclinical development and clinical studies. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our understanding of the status and timing of services performed relative to the actual status and timing may vary and may result in us reporting changes in estimates in any particular period. To date, there have been no material differences from our estimates to the amounts actually incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Stock-Based Compensation Expense</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We use a fair value-based method to account for all stock-based compensation arrangements with employees and nonemployees including stock options and stock awards. Our determination of the fair value of stock options on the date of grant utilizes the Black-Scholes option pricing model.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The fair value of the option granted is recognized on a straight-line basis over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period, which usually is the vesting period. Prior to January 1, 2020, the stock-based compensation expense for nonemployees was subject to remeasurement until the related vesting conditions were met. Effective January 1, 2020, the measurement date for nonemployee awards is the date of grant without changes in the fair value of the award. We account for forfeitures as they occur for both employees and nonemployees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Estimates of the fair value of equity awards as of the grant date using valuation models such as the Black-Scholes option pricing model are affected by assumptions with a number of complex variables.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Changes in the following assumptions can materially affect the estimate of fair value and ultimately how much stock-based compensation expense is recognized; and the resulting change in fair value, if any, is recognized in our statements of operations during the period the related services are rendered. These inputs are subjective and generally require significant analysis and judgment to develop:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;The expected term for employee options is calculated using the simplified method as we do not have sufficient historical information to provide a basis for estimate. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.</span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;For all stock options granted to date, the expected volatility was estimated based on a study of publicly traded industry peer companies as we did not have sufficient trading history for our common stock. We selected the peer group based on similarities in industry, stage of development, size and financial leverage with our principal business operations. For each grant, we measured historical volatility over a period equivalent to the expected term. </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Risk-Free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues whose term is similar in duration to the expected term of the respective stock option. </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;We have not paid and do not currently anticipate paying any dividends on our common stock. Accordingly, we have estimated the dividend yield to be zero. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Common Stock Valuations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to our IPO in December 2020, the estimated fair value of the common stock underlying our stock options and stock awards was determined at each grant date by our board of directors, with assistance from management and external appraisers. All options to purchase shares of our common stock were intended to be exercisable at a price per share not less than the per-share fair value of our common stock underlying those options on the date of grant. The approach to estimate the fair value of our common stock was consistent with the methods outlined in the American Institute of Certified Public Accountants&#x2019; Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Subsequent to our IPO, the fair value of our common stock is determined based on its closing market price as reported on the Nasdaq Global Select Market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the financial statement reporting and tax basis of our assets and liabilities. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We account for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Our policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (IRS) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Off-Balance Sheet Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Since our inception, we have not engaged in any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">JOBS Act</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, while we are an emerging growth company, we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We will remain an emerging growth company until the earlier of (i) December 31, 2025, (ii) the last day of the year in which we have total annual gross revenue of at least $1.07 billion, (iii) the last day of the year in which we are deemed to be a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year, or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we will present only two years of audited financial statements for any interim period, and related management&#x2019;s discussion and analysis of financial condition and results of operations; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we will avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (the &#x201c;Sarbanes-Oxley Act&#x201d;); </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we will provide less extensive disclosure about our executive compensation arrangements; </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we will not require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements; and </span></div></div>
  <div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">we will take advantage of extended transition periods to comply with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a result, the information in this report in the future may be different than what you might receive from other public reporting companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">See Note 2 to our financial statements included elsewhere in this report for information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 7A. Quantitative and Qualitat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ive Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Interest Rate Sensitivity and Effects of Inflation</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of December 31, 2021, we had cash, cash equivalents and marketable securities of $315.4 million, consisting of bank deposits, interest-bearing money market funds, and marketable securities, for which the fair value would be affected by changes in the general level of U.S. interest rates. However, due to the short-term maturities of our cash equivalents and marketable securities, an immediate 10% change in interest rates would not have a material effect on the fair value of our cash equivalents or marketable securities.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We do not believe that inflation or interest rate changes have had a significant impact on our results of operations for any periods presented herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">s and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The financial statements required by this item are set forth beginning on page F-1 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">4D Molecular Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Index to Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:90.0%;"></td>
    <td style="width:10.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Page</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Report of Independent Registered Public Accounting Firm (PCAOB ID </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_c8b9a81d-f9d6-4847-9e5b-418ef2b8311e" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">238</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_operations_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Statements of Operations</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Statements of Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_redeemable_convertible_prefer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Statements of Redeemable Convertible Preferred Stock and Stockholders</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">' Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#n4d_molecular_rapeutics_inc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 9. Changes in and Disagreements With Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 9A. Controls</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Management&#x2019;s Evaluation of our Disclosure Controls and Procedures</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We maintain &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#x2019;s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial and accounting officers, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our management, with the participation of our principal executive officer and principal financial and accounting officer, evaluated the effectiveness of our disclosure controls and procedures at the end of the period covered by this Annual Report on Form 10-K. Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Management has assessed the effectiveness of our internal control over financial reporting based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013 framework). Based on our evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Annual Report on Form-10K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for &#34;emerging growth companies&#34;.</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:5.507%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There has been no change in our internal control over financial reporting during the quarter ended December 31, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 9B. Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Not Applicable. <br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Not Applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PART III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information required by this item will be contained in our definitive proxy statement to be filed with the SEC in connection with the Annual Meeting within 120 days after December 31, 2021 (the &#x201c;Proxy Statement&#x201d;) and is incorporated in this Annual Report on Form 10-K by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.</span></p>
  <p style="margin-left:5.667%;text-indent:-2.462%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.3987843299494%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The financial statements schedules and exhibits filed as part of this Annual Report on Form 10-K are as follows:</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.4773548660176474%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial Statements; </span></div></div>
  <p style="margin-left:7.867%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Reference is made to the financial statements included in Item 8 of Part II hereof.</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.4773548660176474%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:7.867%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All financial statement schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.4773548660176474%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exhibits </span></div></div>
  <p style="margin-left:7.867%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The exhibits required to be filed as part of this report are listed in the Exhibit List attached hereto and are incorporated herein by reference.</span></p>
  <p style="margin-left:5.667%;text-indent:-2.462%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Exhibit Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.452%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:52.933%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:8.992%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:8.007%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:8.007%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:7.579%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Incorporated by Reference</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Herewith</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#160;&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520318186/d13863dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Amended and Restated Certificate of Incorporation, as currently in effect.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/15/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#160;&#160;3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520318186/d13863dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Amended and Restated Bylaws, as currently in effect.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/15/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#160;&#160;4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fdmt-ex4_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Description of Securities of the Registrant.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#160;&#160;4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Form of Common Stock Certificate.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#160;&#160;4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex43.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Amended and Restated Investors&#x2019; Rights Agreement, dated as of April  29, 2020, among the Registrant and the investors party thereto.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.1(a)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520296146/d69563dex101a.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">2015 Equity Incentive Plan.</span><span style="color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">11/17/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.1(a)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.1(b)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520296146/d69563dex101b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Form of Stock Option Agreement under 2015 Equity Incentive Plan.</span><span style="color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">11/17/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.1(b)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.2(a)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001650648/000119312520318232/d28592dex992a.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">2020 Incentive Award Plan.</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/15/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">99.2(a)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.2(b)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex102b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.2(b)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.2(c)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex102c.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2020 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.2(c)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.2(d)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex102d.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2020 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.2(d)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.3#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001650648/000119312520318232/d28592dex993.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">2020 Employee Stock Purchase Plan.</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/15/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">99.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.4&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Form of Indemnification Agreement for directors and officers.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.5&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520296146/d69563dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Collaboration and License Agreement, dated November 16, 2017, among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.</span><span style="color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">11/17/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.6&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520296146/d69563dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Amended and Restated Collaboration and License Agreement, dated August 6, 2019, between the Registrant and uniQure biopharma B.V.</span><span style="color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">11/17/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.7&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520296146/d69563dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Collaboration and License Agreement, dated August 6, 2019, by and between the Registrant and uniQure biopharma B.V.</span><span style="color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">11/17/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.8&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Exclusive License and Bailment Agreement, dated December  19, 2013, between the Registrant and The Regents of the University of California.</span><span style="color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.9&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Exclusive License and Bailment Agreement, dated December  19, 2013, between the Registrant and The Regents of the University of California.</span><span style="color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.10#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Offer Letter, dated March 20, 2015 between David Kirn, M.D. and the Registrant.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.11#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Employment Agreement, dated January 15, 2019 between Peter Francis, M.D., Ph.D. and the Registrant.</span><span style="color:rgba(0,0,238,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.12#&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Offer Letter, dated January 4, 2019 between August Moretti and the Registrant.</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12/7/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.13#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001650648/000119312521282451/d151012dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Change in Control and Severance Agreement, dated September 22, 2021, by and between David Kirn and 4D Molecular Therapeutics, Inc.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">9/24/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.14#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001650648/000119312521282451/d151012dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Change in Control and Severance Agreement, dated September 22, 2021, by and between August Moretti and 4D Molecular Therapeutics, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">9/24/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.15#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001650648/000119312521282451/d151012dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Change in Control and Severance Agreement, dated September 22, 2021, by and between Robert Stephen Fishman and 4D Molecular Therapeutics, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">9/24/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.452%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:52.933%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:8.992%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:8.007%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:8.007%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:7.579%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.16#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1650648/000095017021004086/fdmt-ex10_4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Change in Control and Severance Agreement, dated September 22, 2021, by and between Fred Kamal and 4D Molecular Therapeutics, Inc.</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">11/10/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fdmt-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Power of Attorney (included on the signature page of this Form 10-K).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fdmt-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Certification of the Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fdmt-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Certification of the Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">32.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="fdmt-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:8.0pt;font-family:Arial;">Certifications of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Arial;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Arial;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Arial;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"># Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#134; Certain confidential portions (indicated by brackets and asterisks) have been omitted form this exhibit.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">* The certifications attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of 4D Molecular Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="aaaa"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Item 16. For</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">m 10-K Summary</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SIGNATURES</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.219%;"></td>
    <td style="width:4.122%;"></td>
    <td style="width:5.15%;"></td>
    <td style="width:45.508%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">4D Molecular Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Date: March 28, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ David Kirn</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">David Kirn, M.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Chief Executive Officer and Director</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Duly Authorized Officer and Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Power o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">f Attorney</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Kirn and August Moretti, jointly and severally, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.981%;"></td>
    <td style="width:1.036%;"></td>
    <td style="width:43.301%;"></td>
    <td style="width:1.036%;"></td>
    <td style="width:21.645%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ David Kirn</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Chief Executive Officer and Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">David Kirn, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ August J. Moretti</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">August J. Moretti</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ John F. Milligan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Executive Chairman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">John F. Milligan, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Jacob Chacko</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jacob Chacko, M.D., MBA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Susannah Gray</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Susannah Gray, MBA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Nancy Miller-Rich</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Nancy Miller-Rich</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Charles P. Theuer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Charles P. Theuer, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ Shawn Cline Tomasello</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Shawn Cline Tomasello, MBA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Report of Independent Regist</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ered Public Accounting Firm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Board of Directors and Stockholders of 4D Molecular Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Opinion on the Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have audited the accompanying balance sheets of 4D Molecular Therapeutics, Inc. (the &#x201c;Company&#x201d;) as of December 31, 2021 and 2020, and the related statements of operations, of comprehensive loss, of redeemable convertible preferred stock and stockholders&#x2019; equity (deficit) and of cash flows for the years then ended, including the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Change in Accounting Principle</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As discussed in Note 2 to the financial statements, the Company changed the manner in which it accounts for leases in 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#x201c;PCAOB&#x201d;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_ea0bbe00-a1b8-46eb-82e3-dc7059774599" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">PricewaterhouseCoopers LLP</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_1155a061-e79a-4b44-b3da-dcba6f552735" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">San Jose, California </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:Arial;"></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 28, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We have served as the Company&#x2019;s auditor since 2016.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">4D Molecular Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Balance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(In thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.042%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:12.932%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:12.932%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">As of December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9ef6ec5d-eb1b-4011-b463-bc7d76439dab" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">153,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_73009d48-a65b-4bb4-b4f8-c2605576a1e5" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,726</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e96745ef-b254-4806-9e54-d308b4fde89f" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,776</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4552fc33-a749-4fdb-b493-6926e46e26c1" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3acb4d83-caba-4aa5-8baa-ed510f7c74c9" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5ebe6eb7-213b-4bd4-9deb-de7de72d5a53" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,486</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prepaid expenses and other current assets (includes $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8f36cc29-eebb-4527-bf38-3531e67ee3cf" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="fdmt:PrepaidExpensesToRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">285</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_843b448a-fef8-4825-8349-e1a136c2d07a" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="fdmt:PrepaidExpensesToRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;at December 31, 2021 and 2020, respectively, attributable to related parties)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_821b5776-38ac-4f39-838f-97b829c7e5d3" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,456</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_760cd2e6-25c0-4542-8209-cac7d48b74e3" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a1c99670-5981-43db-b652-ba4a2c2b430f" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">256,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ef250ea9-60e7-41ca-86f1-69ac37445bc0" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">282,656</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities, long-term</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bd482ac1-1b69-4a5d-96fa-f2fc30564156" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,652</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_83d22ee1-9c84-4f1c-b5a5-6edae9370ac0" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4af589bd-75ee-47ac-b02b-109a5ddc8733" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,391</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_13ee1ac5-d47f-4518-9d19-d8404ccefa82" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,073</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease right-of-use assets, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_38cd9612-4e50-4b88-95eb-0dc6840bd622" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,562</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_85aa135f-84ed-4d22-8eed-63690ca12097" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_deb0a672-d3f3-4831-90bf-4ffaec512fd0" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">602</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f8519ad6-8193-4cba-a730-0379b7dcfa60" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">602</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0e63fef6-3ce5-4438-887d-3fa422727a12" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ac5a880c-9dc2-42b9-bf6f-0054a871d466" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">288,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Liabilities and Stockholders&#x2019; Equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accounts payable (includes $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f2bc8380-21fc-48c9-8540-ce86fe924833" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AccountsPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b4830cef-a489-4daf-aa7a-806e17f4b0c6" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AccountsPayableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">173</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;at December 31, 2021 and 2020, respectively, attributable to related parties)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9839a857-4fed-4827-ada0-68b36f2f037c" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7f4947af-198c-4dad-902a-9c7f193668cf" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,787</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued and other current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f8a37433-cca0-4e5e-a4c6-f72efbf4cfb0" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,744</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1aa2d613-8adb-4a23-bc34-946311cd2787" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_51aa7dac-ae86-45af-869f-4ea8fd27fde5" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,599</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_18508c12-3101-46a7-90fd-4a0c5cc96874" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,586</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities, current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d6e8644d-450d-4033-903c-6ad3fe497362" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0ecba942-a403-4469-8783-f2dec0e69e87" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_66a86161-e92a-4def-a75f-1f65bb8b34db" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fbc09b35-4825-452e-ac9c-58d3744d2fcc" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,744</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6c34d7e4-af8a-4404-a939-bd712ae6e1a7" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,491</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b4f58eb3-00f4-480e-a79c-68fae7a8d6c7" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,226</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_704014ee-8e1b-416c-a75f-5e0baea6447e" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9639dcca-64ba-4246-904d-21a8391a0341" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DerivativeLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities, long-term portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_71574c71-a657-4286-ad8b-c2401e4bce67" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_97c02a72-9f70-4ee2-b072-585dbb252dc4" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a9b5e48b-6e00-4842-8a21-6b3831ebd96a" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fa962fd7-6ad2-4dd3-af8b-6d8a877459b1" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a9088b00-83ee-41df-8cf3-a0c6da12f968" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,380</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3c4d9a06-4035-4803-a4c7-cc63af894cde" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_0a20beb0-d4ab-4118-b999-4fa51b854c40;"><span style="-sec-ix-hidden:F_93b3ec84-9a75-4877-a7e9-d3f6a374cf61;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ee5c0499-20ca-437d-a8e1-ab52ac1d0b47" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_c498d275-d3c0-433d-9f79-a121914de6f8" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;par value, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_328fa102-5209-401a-a474-463b648b124f" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_79810407-3071-43ec-b222-91808e03afc1" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;shares authorized at December 31, 2021 and 2020; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_68a8d48f-6d25-4206-8344-005658f7cb00" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_898d5ce7-becc-4623-b305-2638e09a71ae" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_24ba14f3-13b2-49af-a2df-3dec8ca2b4a8" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_260b4f51-0464-4674-91a2-3813bf81b6f1" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;shares issued and outstanding at December 31, 2021 and 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b2121f3b-48a1-4a40-881f-c65258efc934" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_49c17aa8-18bb-4f7c-b2aa-30e3a9a6fa45" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Common stock, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4d3ff223-661c-44f2-a303-3a571f035f74" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_f2da90ab-421e-41d2-b41c-421f173f16da" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;par value, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_219b44ea-fa7a-43f8-995d-31717ba44eb1" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_7a82e37b-61f6-4107-b1ec-875825c6c0c5" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;shares authorized at December 31, 2021 and 2020; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_32542280-9e10-457b-8f5e-9bb92036e89a" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_ecd9cda3-00ab-4818-bddc-b1bea83d7380" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,224,524</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_350bebd4-4cdb-408f-9486-63659dd8acf3" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_7f63d232-c14b-40a6-8ebc-15a7c026fb1a" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,681,983</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;shares issued and outstanding at December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ff70f8a4-1fc1-47e7-8ad6-f2451768f5f7" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_341978d0-d9fc-4160-942d-5791e9c716e2" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fe9d06fc-13bb-4a7e-8aab-61f6808bb451" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">526,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_134b30f9-bfe2-4e85-a7ac-d4de6b76ee0c" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">392,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_eb00ac19-d7cf-4214-af1b-8ba69763307b" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">423</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4e91d547-dd96-45f9-9ae7-a9907e17e697" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7e0cbf04-7359-4940-8308-849c70e78129" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">206,996</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_98800575-c943-45cd-9d94-92fef8cdde4b" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">135,679</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_09cd29b3-cf7a-44cf-8daf-57144ab13502" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">319,107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b9e4c39d-e158-457f-ab32-8f934b782a8c" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">256,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dcaed8b0-78f6-4bfd-8493-aabd0aae74a7" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cb6d42e3-a08a-4d7f-adc8-261126dbf41c" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">288,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The accompanying notes are an integral part of these financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">4D Molecular Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_operations_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Statements of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(In thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:64.929%;"></td>
    <td style="width:1.574%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:12.74%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.574%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:12.707%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.574%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Revenue:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Collaboration and license revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_16a70b68-4741-4547-b101-2c92340c8106" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,038</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0f843b23-c918-4578-8c9d-29c5310154f7" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Collaboration and license revenue, related parties</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2858da6d-989b-4eb2-9dbb-7cffdd09eafb" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="3" decimals="-3">249</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c0fb7d62-3592-4460-9fbd-9d19dfa864cd" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,038</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9e4cfacf-a854-4a2c-a9e5-d894cb34c95c" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,612</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development (includes $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fdefe76c-957a-4d47-b07c-878d40ac0665" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:ResearchAndDevelopmentExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">935</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2a820835-f123-485b-b655-c33977290e4c" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:ResearchAndDevelopmentExpenseRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">579</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;for the years ended December 31, 2021 and 2020, respectively, attributable to related parties)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a3ef7496-fc39-4612-b6f8-b3470dd13130" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ed281fd7-3d59-4f82-82d7-06d33916415d" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,038</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5289144c-50fc-4268-9f05-9a5356b5bd9f" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,011</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d5a52127-c8ab-4b0b-a29c-78cee41b3e8e" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d2cbce8f-3960-4144-8ba3-1c337ccffbd1" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f25e10fb-0d98-466d-930b-5d9d866940d5" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,276</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6825c3f9-c00d-459b-a238-29b9cddd84bd" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">71,333</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_538f9354-6992-4ba5-966c-f703bd8d99ec" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cca0bb5f-3b87-480e-95e7-0e19ea8044c9" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">137</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_73b1983c-98e8-459a-9c40-eb50ac7b91df" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_12c708a5-488f-4c33-a143-e08fe685840f" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">121</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3b46cd8b-4bb6-4337-91bf-00afd516b565" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5b8d1df7-479d-4142-863e-eea5e25704b7" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_831f169e-3d90-4c22-be76-906cae96978a" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-">29</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b836a7ed-76a4-4fd7-86e2-40abeb0c0d86" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">71,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5d302a98-2e2a-446e-8abc-eef753bc474a" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b1763703-a5e1-4af1-85a8-496a52265d54" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.57</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d38e1038-38ca-4a80-8f8d-467fc6b0845e" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">8.82</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ca10a9dd-36eb-4b72-b55c-0574d2c9bc33" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,730,420</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_beb98568-917a-452d-86f4-d620d7cc7a83" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,430,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The accompanying notes are an integral part of these financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">4D Molecular Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Statements of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(In thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.904%;"></td>
    <td style="width:1.981%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:16.626%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.981%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:16.626%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.981%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5052d1e9-f2d7-42ed-b510-fd1c3ab80b04" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">71,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4b29a9e6-827f-4bf6-b2e3-e739d836f51e" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Other comprehensive loss:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Gross unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_875dcb21-a2a9-4d87-b877-0fb48110e5c0" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">423</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4d2d80d3-ccdc-4401-b1f4-70bd9b20a3da" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_775ca217-7f09-4e93-a99d-daa28c47406c" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">71,740</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_066313ec-7a12-418e-8734-93c41e3fb5d3" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">4D Molecular Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_redeemable_convertible_prefer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Statements of Redeemable Convertible Pre</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ferred Stock and Stockholders&#x2019; Equity (Deficit)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(In thousands, except share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Arial;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.437%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:0.459%;"></td>
    <td style="width:8.642%;"></td>
    <td style="width:0.563%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:0.918%;"></td>
    <td style="width:8.28%;"></td>
    <td style="width:0.563%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:0.459%;"></td>
    <td style="width:8.704%;"></td>
    <td style="width:0.459%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:0.918%;"></td>
    <td style="width:8.357%;"></td>
    <td style="width:0.459%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:0.918%;"></td>
    <td style="width:7.001%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:9.045%;"></td>
    <td style="width:0.563%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:0.918%;"></td>
    <td style="width:8.28%;"></td>
    <td style="width:0.563%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:0.918%;"></td>
    <td style="width:9.003%;"></td>
    <td style="width:0.563%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Redeemable<br />Convertible<br />Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Additional<br />Paid-In</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Accumulated Other Comprehensive</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Total<br />Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Equity<br />(Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Balances at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_95d1bf0e-afc9-413b-92c3-2e240571b44c" contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,375,631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_8b2b9800-71c0-4107-804b-8e9e1f09d645" contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_778251da-7f3e-436f-a0ec-58d43c39ef1e" contextRef="C_59d3639a-d9e5-4bdd-af89-ba17bedfea32" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,178,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_86d7f767-e739-4e87-b3c5-9e581c8e627a" contextRef="C_59d3639a-d9e5-4bdd-af89-ba17bedfea32" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_cbad1918-c147-409e-9d17-e30efdf4ccb0" contextRef="C_5c9ad16b-c408-4093-be43-5c9223652764" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_64681f15-0a86-40ed-99fa-7f3bcfab48c7" contextRef="C_4eaef891-9b88-429e-bd16-799664373d3a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">79,025</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_bcb4c23f-bae1-43a8-85a8-38accfd24304" contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">72,970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_4716bf1b-08a4-4338-8ed0-e0aaa71272e5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Cumulative effect of adoption of ASU 2018-07</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_af3eb39f-82d0-4f09-93f3-3a377dcd944a" contextRef="C_e90ff7ba-2215-4139-bfb3-bb512afebcb1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_5753ec4a-42a2-4e50-b27b-4481ce0fe590" contextRef="C_01872582-961a-450f-b5a8-ef39a9a60634" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Issuance of redeemable convertible preferred stock, net of $</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_edabdf86-8cf6-4de5-85f5-79f83b3be576" contextRef="C_e7f9066a-37f9-4184-9c45-03d0ffb6a47b" name="fdmt:IssuanceCostForIssuanceOfPreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,138</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#160;of issuance cost</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_d82786bf-b805-4233-94b3-667354f02c35" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,200,353</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_466cf6da-22fa-499d-821c-80e6caa0f5ac" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,468</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Conversion of redeemable convertible preferred stock into common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_3361a183-b28f-4dfb-bc23-9a3d911f3dee" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">11,575,984</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_e953f3db-f640-445c-bd82-32c6125579bd" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">175,448</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_205013e9-d44f-42a5-b036-beafeb7838f9" contextRef="C_528f45e3-d466-442e-aad5-49b6b3b7312c" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,575,984</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_d49461ea-961d-47b2-843c-5340f3d04c62" contextRef="C_528f45e3-d466-442e-aad5-49b6b3b7312c" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_8dfedcc7-2819-4e13-9dd1-f2935bc713ef" contextRef="C_6daa8ce8-a992-4249-a203-b1e888605ef4" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_f001d20c-3f30-41fa-9787-266a369ea52e" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,448</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Issuance of common stock upon initial public offering, net of $</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_998925c7-22cd-49bb-a436-e658ba2f6ced" contextRef="C_ccccdee5-98b9-4eba-97f0-75b85fa9ed38" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,468</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#160;issuance cost</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_9da8814c-aba7-4bc4-af0e-b239b90e4395" contextRef="C_528f45e3-d466-442e-aad5-49b6b3b7312c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,660,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_38ec4b97-0dd6-4cce-a584-c73ae3428958" contextRef="C_528f45e3-d466-442e-aad5-49b6b3b7312c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_c6a3bb06-ffa4-4800-96f6-3e6beea8196e" contextRef="C_6daa8ce8-a992-4249-a203-b1e888605ef4" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">204,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_fc02aceb-91b9-44d4-9385-614cb4afe219" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">204,713</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_9687b4dd-6ed9-43e4-9f49-d8ccf1345536" contextRef="C_528f45e3-d466-442e-aad5-49b6b3b7312c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">267,044</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_e8f8e559-57fb-41e3-9bdb-19b4e3f9467b" contextRef="C_6daa8ce8-a992-4249-a203-b1e888605ef4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_8e2f3434-d5f2-4389-a478-535ec89ac28d" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_8ace2c54-73ec-4c68-921f-7218e714e0e0" contextRef="C_6daa8ce8-a992-4249-a203-b1e888605ef4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,984</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_1c5d2f18-a2d8-4d58-b371-d9049af7e505" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,984</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Vesting of common stock warrant issued for services</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_a128fc37-397e-43ed-8ddd-e301395b3c9e" contextRef="C_6daa8ce8-a992-4249-a203-b1e888605ef4" name="fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_be8d6eea-20c6-46b9-b888-365dacbd6a79" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_a740c526-61de-4176-9f98-722593a4aff0" contextRef="C_5d6bb9b3-6b6c-4b68-931a-aa92ca2d40c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_df5aa19e-2693-482b-b8a8-b8632257b53b" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Balances at December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_cd8a7423-36a8-4ace-9075-b37b973d2fbf" contextRef="C_fbf54024-6915-42de-b1f4-5893be4aa781" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,681,983</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_0a5bf724-403e-4849-8945-082d927f1923" contextRef="C_fbf54024-6915-42de-b1f4-5893be4aa781" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_bab6bc6b-d73e-4dae-9245-58a22554d4f0" contextRef="C_aee471bc-dfa2-486c-b5af-72c1159914db" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">392,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_1539584c-be12-4d64-b9e8-3723b130bddf" contextRef="C_5768aef4-f24f-4156-919c-885a554541d5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">135,679</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_3c1dd694-48fd-46c7-b1b0-511024ddfb88" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">256,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Issuance of common stock upon exercise of stock options and warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_5fda0b5a-07e3-497f-88c3-8cdd65d59fdd" contextRef="C_0851c4dd-d51b-410e-9510-555127298972" name="fdmt:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">646,417</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_bc9f3625-c704-436c-9b8f-075b7d0490d2" contextRef="C_618215e0-a055-427d-9220-18bee23b39f3" name="fdmt:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,905</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_2b4ac02e-c067-42f1-a645-0a530a2c1131" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,905</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Issuance of common stock upon offerings, net of $</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_93fcfd8f-93d9-4465-a963-9599621d8741" contextRef="C_f0ae8a23-d71e-4828-8ac8-78470326d77f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,660</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#160;issuance cost</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_22c814a8-8c9f-4969-b0c0-e120baaaac70" contextRef="C_0851c4dd-d51b-410e-9510-555127298972" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,875,715</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_e496b63c-9f4b-4289-926e-fabae69d5a2f" contextRef="C_618215e0-a055-427d-9220-18bee23b39f3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,090</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_57b480e5-92ed-4da7-9de3-2580497b8c5e" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,090</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Issuance of common stock warrant</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_82e167e3-43c2-490b-a82e-65d421746000" contextRef="C_618215e0-a055-427d-9220-18bee23b39f3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_d591de63-22bb-45cf-bf59-cf5797ae118c" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_ef9141a5-6567-4508-8b43-63dee76630f5" contextRef="C_618215e0-a055-427d-9220-18bee23b39f3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,799</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_afeac895-87e7-404e-9357-87fb430e4184" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,799</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Issuance of common stock - 2020 ESPP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_95899568-9c4a-4000-bd98-d72a4f76a854" contextRef="C_0851c4dd-d51b-410e-9510-555127298972" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,409</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_ea702d82-aef4-4b70-ad42-98b22cbffaca" contextRef="C_618215e0-a055-427d-9220-18bee23b39f3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_197aef14-fdb1-4604-89f6-9167d76e5364" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Vesting of common stock warrants issued for services</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_a1098e52-2da8-406c-9d90-a6346d66c2c2" contextRef="C_618215e0-a055-427d-9220-18bee23b39f3" name="fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_99ee8035-f798-4204-b9dc-ef873d4e8064" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Gross unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_da6a174f-5a5f-4047-848f-49edfd53cd1d" contextRef="C_36758c2d-4d20-4d3c-a68c-1ae0229d4cbf" name="fdmt:StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">423</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_b6a387ff-cefc-4299-a75b-300d1beeffaa" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">423</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_f048bbb4-e46b-4b82-b527-49a917726b0b" contextRef="C_f0a7f822-26e3-4aa6-b0cb-8635b7e734f0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">71,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_dddc44b5-384c-40e0-b97d-9004500bd530" contextRef="C_36758c2d-4d20-4d3c-a68c-1ae0229d4cbf" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">71,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Arial;">Balances at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_75fba49c-6d60-4f36-a680-0d5507dc5cc5" contextRef="C_e7d12ec2-7bb6-4ee6-9329-dfed184d0890" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,224,524</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_e1b46946-0630-43ed-9a5c-bb2d97514196" contextRef="C_e7d12ec2-7bb6-4ee6-9329-dfed184d0890" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_ceb5e751-838d-4fe0-a68f-1e6373b51186" contextRef="C_25a62ff3-b92c-4866-af5f-948e6635deba" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">526,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_eab079eb-6246-4bf0-9ee0-3d094a16d891" contextRef="C_0d9e57bc-9656-45fb-9e86-21e8155c0587" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">423</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">(</span><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_e149291c-1b66-46d2-8810-a4d0c41cef55" contextRef="C_ddf9471b-7dbf-43eb-8802-d9844a6eb24a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">206,996</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Arial;"><ix:nonFraction id="F_cede5a0e-8486-4bc4-8a05-6fe6520b8ac3" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">319,107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">4D Molecular Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Statements of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">(In thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:69.593%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.542%;"></td>
    <td style="width:10.31%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.403%;"></td>
    <td style="width:1.542%;"></td>
    <td style="width:12.762%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_17f3398b-6e10-4b6f-a3d2-93fdc5e37bc7" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">71,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4b54a8f8-92e0-4f97-b682-587f340eea84" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Adjustments to reconcile net loss to net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bf97d07e-70ad-4585-94db-fb2be6dd7fde" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,799</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2b23a302-e658-4891-be7a-bb0c7c995da1" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,984</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Vesting of common stock warrant in return for services</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3d401fbc-8d16-4319-9040-858f324889e0" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:VestingOfCommonStockWarrantInReturnForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_296079e7-c6dc-4af0-8069-151bde26217b" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:VestingOfCommonStockWarrantInReturnForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6745954d-6b42-4d10-8447-6392552e1634" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c8ccf5b6-5117-46b1-b5b8-f40a8f03272a" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_363b4ffd-634f-47a2-8bfc-e87c0e0309c9" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c8e7a293-17b0-4308-9e69-cc93e089e2c1" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,443</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Amortization of right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f03a1748-df8b-47e1-b244-182ae7126024" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,497</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_683ef2e3-2a62-49e9-8678-2b035b75e84a" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net amortization (accretion) of premium (discount) on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_600d0e5f-d236-428f-b603-f1071e9cacb3" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_634cee6d-1786-4ee7-925f-263577737236" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Changes in operating assets and liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a4b11d83-0eea-4f92-89bd-c15e92301350" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dcf9f88c-d70f-4596-9b01-bf2b72783dcc" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2406e37c-8c16-4a16-ba7d-dae858b16319" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,225</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8f03f0b5-9407-4deb-baf7-722cd0c0f255" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,566</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e5a05990-cfbd-462a-b4c2-35ccf5ec3020" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d183a228-22d8-4c01-9a91-93a678e8f6bc" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_aa609f83-4b27-49e2-80d2-fc82372599a3" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,285</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8c979293-bed0-41fa-918a-f701b82740a0" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued and other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fa556346-9db4-4d4e-8545-ba8a40870dbb" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">689</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0d3080c9-04d5-4a1f-8a86-4b59e8cbda13" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,899</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6470a674-b335-422f-9ae0-71892e737ee4" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14,722</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3468c623-c389-4c37-ae3a-9e566724f1c4" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1afe67c1-f7ef-45d1-923f-5c0a3bd6dfa9" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_23b662d7-ee15-46f7-b584-f6e9f867b045" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_eec84e61-7b5a-4467-9963-1afc18b8b358" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,134</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7ce7346a-7848-4d2b-b217-dcca60a05356" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Acquisition of property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2970d8ff-6335-4d3a-8a84-b90c0b7ad58e" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0cbcf1bd-93ed-406b-8020-f7e4ace9f228" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Purchase of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a397e40e-d021-4ae5-a603-aa8dcd176e91" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168,570</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9e8013eb-ed84-41c5-ad8a-1c7a1341673e" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f15362c9-27ec-42e7-af79-23b89b37af75" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e0fc954a-1f67-4d3a-a245-52c87ced6dff" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_05f148f4-7013-4b1b-978f-6b6672b263f1" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">172,680</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_db0757a0-bb52-414d-9729-384512581adb" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of redeemable convertible preferred stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_40deb337-2327-4a0e-adcd-eec697672c26" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c0705481-f3c8-4a99-a570-995fb67b75e1" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,468</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock upon offerings, net of issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2045a30d-45f1-42f0-b873-c8646e04658d" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_96cf3e01-b2e0-46a5-826a-a67448d5f111" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205,658</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock upon exercise of stock options and warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a58a5b6c-eb7b-4bbd-9219-4f3fc72f7357" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0bb835a4-70b7-4475-95a5-5ac5ed60e2fd" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock through 2020 ESPP</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_efe915f9-951f-403f-ab7d-19c419197097" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_aa9b40d7-7ed3-4825-9d40-9ec0b6117e0e" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bca50794-69b2-4874-b08d-73920782b186" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">118,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_74cd8161-3ea9-4cd4-a300-77059189bdbe" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">278,983</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c6f2eda3-a295-413a-bba0-79466abc0c7b" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">123,725</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_073ec1d4-3448-4d4c-aef3-91cef8091639" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227,074</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents, beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_63811ad8-af6d-4f21-8aa8-9698f02036dc" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,726</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e6e47979-0054-4b3a-ae8b-6402729c9c7b" contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,652</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Cash and cash equivalents, end of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1f0f9155-34e9-41f3-af03-18c536fbaaa1" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">153,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_51fd2d35-21b1-4e68-90ab-0e188c09d281" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,726</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Supplemental disclosures of noncash investing and financing information</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Conversion of redeemable convertible preferred stock into common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bcdd71b9-c76a-4d8a-b2d0-ef736f4308fc" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3da348cb-1f94-43e8-bca4-b8e8832ace15" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,448</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Purchases of property and equipment in accounts payable and accrued and other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bb738f70-9d4f-4c5c-8427-e6b7ced8a8f5" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,199</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0467ac83-f6a3-4c6e-9a7d-cd8d0177c83f" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">466</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unpaid offering costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6622f66c-7d96-4cfd-901a-be77e76894fc" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:UnpaidOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_35da2291-98d6-41df-af7f-1263ab35d5a9" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:UnpaidOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">946</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Decrease in right-of-use assets due to reduction in operating lease liabilities upon modification</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c476d981-505a-4c87-80db-130aef56d407" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_930e5a09-aa3a-4614-bf4f-d72c1ebfb668" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock warrant to settle liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_439d75a7-6318-4c60-80a5-cdf702869129" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:NonCashIssuanceOfCommonStockWarrantToSettleLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a0ebca19-dc83-405d-94c4-caee06b13c78" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:NonCashIssuanceOfCommonStockWarrantToSettleLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Receivable for common stock issued upon exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d470c919-49d0-4868-9c56-79c732a7ba8d" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">545</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6ebfdeac-1cf7-402e-83aa-d7c29be6d23a" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="n4d_molecular_rapeutics_inc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">4D Molecular Ther</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">apeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Notes to Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_bed3f420-911d-473c-8614-beb03a0163c3" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">1. The Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4D Molecular Therapeutics, Inc. (the &#x201c;Company&#x201d;) was formed as a limited liability company in September 2013 under the name 4D Molecular Therapeutics, LLC. The Company changed its name and converted into a corporation which was incorporated in the state of Delaware in March 2015. The Company is a clinical-stage gene therapy company pioneering the development of product candidates using its targeted and evolved adeno-associated viruses (&#x201c;AAV&#x201d;) vectors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Initial Public Offering</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2020, the Company sold and issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_70c1c2d0-48f9-48d5-936e-1084cee77c9d" contextRef="C_542e8a0a-d3fd-48d5-aca9-2b0837fda539" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,660,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock at a price to the public of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_112c47f6-9cb2-4ddb-b5b9-73f78e3f034b" contextRef="C_625a9586-f459-4552-b058-fb7510d5960c" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">23.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, which included shares sold upon the underwriters&#x2019; exercise of their overallotment option to purchase </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c56af0a3-7585-4660-b511-f29f3816064f" contextRef="C_aded6adf-76e7-4673-85fe-7c5fc3d77d2f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,260,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> additional shares. The Company received an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_97e48f20-c30f-4289-ba99-0929d1ced977" contextRef="C_542e8a0a-d3fd-48d5-aca9-2b0837fda539" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">204.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in net proceeds, after deducting underwriting discounts and commissions and offering costs.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon the closing of the Company's initial public offering in December 2020 (the &#34;IPO&#34;), all outstanding shares of redeemable convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6d42bf06-bfb6-4cb7-8400-6df2bcece467" contextRef="C_625a9586-f459-4552-b058-fb7510d5960c" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,575,984</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock. Subsequent to the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c552ad4d-2795-436c-9f92-23e48fafc32d" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of redeemable convertible preferred stock outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Follow On Public Offering</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2021, the Company completed its second underwritten public offering (&#34;Follow-on Offering&#34;) in which </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f15601e4-440b-4aa0-9d38-1f13643ab2f1" contextRef="C_cfe98104-f350-4823-9e4e-dde161bbcd77" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,750,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock were sold at an offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_05ceffe3-fc14-4694-bc81-4a3701e52495" contextRef="C_cfe98104-f350-4823-9e4e-dde161bbcd77" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">25.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share pursuant to an effective Registration Statement on Form S-1. The net proceeds from the Follow-on Offering were $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3febee93-63a2-43a5-bcb2-5fdac31ff5e0" contextRef="C_1784e7f0-ff83-48df-a30d-36b81c4f651d" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">111.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, after deducting underwriting discounts and commissions and offering expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Liquidity</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has incurred significant losses and negative cash flows from operations and had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_de846564-ce98-4b40-ac46-174a1e4a3a7a" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">207.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as of December 31, 2021. The Company believes that its cash and cash equivalents and marketable securities as of December 31, 2021 are sufficient for the Company to fund planned operations for at least one year from the issuance date of these financial statements for the year ended December 31, 2021. The Company has historically financed its operations primarily through the sale of equity securities, and to a lesser extent, from cash received pursuant to its collaboration and license agreements. To date, none of the Company&#x2019;s product candidates have been approved for sale, and therefore, the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows from operations to continue for the foreseeable future. The Company plans to raise additional funding as required based on the status of its clinical trials and projected cash flows. There can be no assurance that, in the event the Company requires additional financing, such financing will be available on terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company&#x2019;s ability to achieve its business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_76434f64-2f3e-41e6-ad78-f04bec8f8cbc" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_5f706d85-74d6-40cd-a2d5-30ccec818052" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true" continuedAt="F_5f706d85-74d6-40cd-a2d5-30ccec818052_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_5f706d85-74d6-40cd-a2d5-30ccec818052_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&#x201c;U.S. GAAP&#x201d;).</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_47b94927-5f3a-48f9-a4b0-10b67039d1b1" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_47b94927-5f3a-48f9-a4b0-10b67039d1b1_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Use of Estimates and Judgements</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgements that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the contract term, transaction price and costs of collaboration agreements, as well as estimates of the fair value of common stock (prior to the IPO), stock options and derivative instruments and income tax uncertainties. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_47b94927-5f3a-48f9-a4b0-10b67039d1b1_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Due to the coronavirus (&#x201c;COVID-19&#x201d;) pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2021. While there was not a material impact to the Company&#x2019;s financial statements as of December 31, 2021, these estimates may change, as new events occur and additional information is obtained, as well as other factors related to the COVID-19 pandemic that could result in material impacts to the financial statements in future reporting periods.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_f02c00ce-9bda-4cdc-adbb-e3c86fc2a83f" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_f02c00ce-9bda-4cdc-adbb-e3c86fc2a83f_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company operates and manages its business as </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b3e3bf98-175c-433e-9e02-75f1ea0223ee" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fb2b5f1b-d1cc-4cda-b81e-48ab4bbdaf89" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> reportable and operating segment. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on a company-wide basis for purposes of allocating resources and assessing financial performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_f02c00ce-9bda-4cdc-adbb-e3c86fc2a83f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of and for the years ended December 31, 2021 and 2020, all of the Company&#x2019;s long-lived assets were located in the United States and all revenue was earned in the United States.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_3d222116-8ebb-4272-9c8b-ae6aa3472ad2" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable securities and accounts receivable. The Company&#x2019;s cash is held at </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d75f49a0-09b9-409d-9660-19bdf9bddade" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:NumberOfFinancialInstitutionsWhereCashIsHeld" unitRef="U_Financial_Institution" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> financial institutions in the United States of America. The Company&#x2019;s cash equivalents are invested in money market funds. The Company also invests in U.S. Treasuries, commercial paper and corporate bonds. The Company has not experienced any losses on its deposits of cash and cash equivalents. Such deposits may, at times, exceed federally insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_52658ab4-9dcb-4fc9-9931-b37e94899a4e" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s partners in collaboration and license agreements who represent 10% or more of the Company&#x2019;s total revenue are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.91%;"></td>
          <td style="width:1.606%;"></td>
          <td style="width:14.636%;"></td>
          <td style="width:1.606%;"></td>
          <td style="width:14.636%;"></td>
          <td style="width:1.606%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer A</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c315e224-3334-42e8-b3ff-f3a923b0dd1f" contextRef="C_d724d8a1-6a4a-42cb-a720-853feca51dab" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">95</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4e92f9e4-aed5-41dd-9457-d8843225c087" contextRef="C_fcb58636-b558-407f-b0d5-265a83042f1a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">95</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer B</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">*</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">*</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_63b655be-eeb3-4839-a5bc-e8a73733cb3e" contextRef="C_f5ca12fb-9ded-49e2-8667-052f68f5cdfa" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">95</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2d6d595a-d754-4ec1-ad4a-2896c69e0caf" contextRef="C_a2f26722-25bb-4a09-88a3-02cae078cf69" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">95</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">* Less than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a36221e3-6ec8-44e1-99b2-acd3d5310c83" contextRef="C_f0620193-2d47-4e0f-b17c-1fa3385b38cb" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2"><ix:nonFraction id="F_822c6c43-5009-4e2c-abc1-4c7922292457" contextRef="C_794002d9-a4fd-4194-b523-592564162f24" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2">10</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8</span></p>
         <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s partners in collaboration and license agreements who represent 10% or more of the Company&#x2019;s total accounts receivable are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.974%;"></td>
          <td style="width:1.627%;"></td>
          <td style="width:14.881%;"></td>
          <td style="width:1.627%;"></td>
          <td style="width:14.891%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer A</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5e2188bb-23fb-4e09-ad62-8a39633dfd2c" contextRef="C_6f61ac2f-cef4-461c-a2ee-3967bbb25c65" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9c17a54d-ce22-4680-9486-76bd26a7a69b" contextRef="C_778cb29d-d166-4215-968b-ce01bbf701d9" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2">74</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer B</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5a0c7063-c709-47de-b120-f26fa75ff765" contextRef="C_cddd6872-9bae-4abd-b89b-a8b4f291f7b6" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_731d2ca9-18be-4434-8aa2-934c3eb8e831" contextRef="C_f7242b4b-b2c1-47e2-8a49-09fa5d802063" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2">26</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a8e0eea3-359f-4399-8f34-b0862122ca67" contextRef="C_a99aa56e-af3c-4d75-814c-006a1628cef5" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ba492083-6a8c-423c-953d-da44bb65a469" contextRef="C_e52d4eb1-67cf-418e-81c2-9f61ca8b3839" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_78713a05-2d89-483c-9e11-2e24ef5abe49" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s total revenues by geographic region, based on the location of the customer, are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.036%;"></td>
          <td style="width:1.584%;"></td>
          <td style="width:1.531%;"></td>
          <td style="width:12.793%;"></td>
          <td style="width:0.771%;"></td>
          <td style="width:1.584%;"></td>
          <td style="width:1.531%;"></td>
          <td style="width:12.665%;"></td>
          <td style="width:0.921%;"></td>
          <td style="width:1.584%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Netherlands</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_295d5a45-74fc-4fbf-860c-4783852ab931" contextRef="C_02f4bd8b-251b-482c-a9fc-56da777a2727" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">736</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9766a248-13f7-4bcc-8bb1-691730967285" contextRef="C_dc4d438d-ed76-4f51-85bd-a0b92d8c257e" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">742</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Switzerland</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7172464d-a32f-4317-9800-3e4225c71518" contextRef="C_3286dd10-3afc-4496-bbd6-5ba1f0954a8a" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,181</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8b628310-7ddd-412c-904a-82b95801687c" contextRef="C_c5ffbd72-9ff1-4119-bcd0-b30265f21d41" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,897</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">United States</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_25b67bbc-c7b6-419c-8df4-8ed46d798afb" contextRef="C_069b0a0c-065c-4686-838b-2ac26250f05e" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">121</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e0ee81d2-8ef0-409a-80fa-cef2d0d1cf3d" contextRef="C_d15ccf5a-554c-4e09-bf6c-621fbf797861" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total revenue</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_437322d0-39e6-4933-a981-cce1ad61b387" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,038</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ec1c70c8-3779-4073-91ec-f1d0c19c0467" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,612</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_a9129cf4-11d8-4a33-b626-b755d653227a" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_a9129cf4-11d8-4a33-b626-b755d653227a_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_a9129cf4-11d8-4a33-b626-b755d653227a_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist of money market funds.<br /><br /></span></ix:continuation></span><span style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_83e61aea-dc91-4533-b1de-4f5abbe7515a" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:MarketableSecuritiesPolicy" escape="true" continuedAt="F_83e61aea-dc91-4533-b1de-4f5abbe7515a_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Marketable Securities</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:continuation id="F_83e61aea-dc91-4533-b1de-4f5abbe7515a_1"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities consist of commercial paper, corporate bonds and U.S. Treasuries and are included in current and noncurrent assets.  The Company classifies its marketable securities as available-for-sale and carries them at fair value on its balance sheet. Fair value is estimated using independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses on the marketable securities are reported as a component of stockholders' equity (deficit) in accumulated other comprehensive loss.  The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the statements of operations. Realized gains and losses are included in interest income on the statements of operations.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company periodically evaluates its marketable securities to assess whether those with unrealized loss positions are other than temporarily impaired.  The Company considers various factors in determining whether to recognize an impairment charge.  If the Company determines that the decline in an investment's fair value is other-than-temporary, the difference is recognized as an impairment loss in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p></ix:continuation></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_3f0ce859-6405-40b9-a126-21a7480810de" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:OtherRisksAndUncertaintiesPolicyPolicyTextBlock" escape="true" continuedAt="F_3f0ce859-6405-40b9-a126-21a7480810de_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Other Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (&#x201c;CMOs&#x201d;) and contract research organizations (&#x201c;CROs&#x201d;), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_3f0ce859-6405-40b9-a126-21a7480810de_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The extent of the impact of the COVID-19 pandemic on the Company&#x2019;s business will depend upon the duration and spread of the outbreak and the extent and severity of the impact on the Company&#x2019;s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. The extent to which the coronavirus outbreak may materially impact the Company&#x2019;s financial condition, liquidity or results of operations is uncertain.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_bb85694a-773c-451d-96eb-68a4d3c75873" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true" continuedAt="F_bb85694a-773c-451d-96eb-68a4d3c75873_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a basis for considering such assumptions, a three-level fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Level 1 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014; Observable inputs that reflect unadjusted quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date. </span></div></div><div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Level 2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></div><div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Level 3 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></div></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_bb85694a-773c-451d-96eb-68a4d3c75873_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for transfers of financial instruments between levels of the fair value hierarchy on the date of the event or change in circumstance that caused the transfer.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_c955f0f1-5b10-4ce1-a290-adc659f018a5" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Accounts Receivable&#x2014;Allowance for Doubtful Accounts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company regularly reviews accounts receivable for collectability and establishes an allowance for probable credit losses and writes off uncollectible accounts as necessary. The Company has determined that </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2709e1e4-0c80-4cb6-bf23-eb322dcbaed3" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_70523b3e-eca5-445c-8e58-c35325190fa5" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> allowance was required at December 31, 2021 and 2020. The Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0f25b56f-73e8-4307-b6d0-96495c942b18" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e0579170-242e-408a-b5d9-1554494e923f" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t have any write-offs relating to uncollectible accounts receivable during the years ended December 31, 2021 and 2020.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_8e363fa5-cfa4-4ce1-9422-338896c3ecd6" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_8e363fa5-cfa4-4ce1-9422-338896c3ecd6_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_8e363fa5-cfa4-4ce1-9422-338896c3ecd6_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over the estimated useful lives of assets, ranging from </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_c05559b7-51fa-4d3d-9739-b6c4a7e260ed;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_675a4ae8-4148-430e-94aa-73dfbba394f8" contextRef="C_0dd3438c-f8c5-4fe9-8672-19340e3bbb9d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Leasehold improvements are amortized over the shorter of the useful life of the assets or the lease term. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected within operating expenses in the statements of operations. Maintenance and repairs are charged to expense as incurred.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_2e88f646-2267-4b72-a39d-bfa8ba5532d8" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true" continuedAt="F_2e88f646-2267-4b72-a39d-bfa8ba5532d8_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_2e88f646-2267-4b72-a39d-bfa8ba5532d8_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is typically measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_54c4da89-0077-4548-a7ff-b5ec4e2635d4" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_72162fdc-baa0-4f86-867d-67b12834921d" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> such impairments of long-lived assets in the years ended December 31, 2021 and 2020.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_9d619e6d-8170-46af-ac77-70885b6e34c6" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" escape="true" continuedAt="F_9d619e6d-8170-46af-ac77-70885b6e34c6_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Redeemable Convertible Preferred Stock</span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_9d619e6d-8170-46af-ac77-70885b6e34c6_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance costs. The redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company's control, such as a merger or consolidation, sale, lease, or license of substantially all of the Company's assets (each, a &#34;deemed liquidation event&#34;), the convertible preferred stock would become redeemable at the option of the holders of a majority of the outstanding series of redeemable convertible preferred stock. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the liquidation preference of such shares because a deemed liquidation event obligating the Company to pay the liquidation preference did not occur. All outstanding shares of the redeemable convertible preferred stock converted into common stock upon the close of the IPO in December 2020.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_562e6988-4c03-42eb-8b72-116c19e4a2a0" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:CommonStockWarrantsPolicyPolicyTextBlock" escape="true" continuedAt="F_562e6988-4c03-42eb-8b72-116c19e4a2a0_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Common Stock Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_562e6988-4c03-42eb-8b72-116c19e4a2a0_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for common stock warrants which meet the definition of a derivative as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement. Common stock warrants classified as liabilities are initially recorded at fair value and remeasured at fair value each balance sheet date with the offset adjustments recorded in other income (expense), net within the statements of operations. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_09ce9f64-0d9f-4cda-bdc3-8bc66e673ac0" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Leases</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On December 31, 2021, the Company </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_0f5ac6e0-6fa4-49fa-aee9-4b27ed1621ca" contextRef="C_f1c116f5-4fc4-4134-a20b-4bb41e384479" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, Leases (Topic 842), (&#34;ASC 842&#34;) using the alternative modified retrospective approach effective as of January 1, 2021 to recognize a cumulative-effect adjustment on the effective date and to not adjust financial information and disclosures required under the new lease standards for comparative prior periods.  The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. Additionally, the Company has elected not to separate lease and non-lease components and not to recognize leases with an initial term of twelve months or less.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under ASC 842, at contract inception, the Company determines if an arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the obligation to make lease payments arising from the lease. Operating lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent the Company's obligation to make payments arising from the lease. Operating right-of-use assets and liabilities are recognized at the commencement date of the lease and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates, or abatements the Company expects to receive from the lessor. The Company records amortization of operating right-of-use assets and accretion of lease liabilities as a single lease cost on a straight-line basis over the lease term. No lease renewal options are recognized as part of the right-of-use assets and lease liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company's operating leases are presented in the balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent based on the discounted lease payments to be made within the proceeding twelve months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As the Company&#x2019;s leases do not provide an implicit rate , the Company uses its incremental borrowing rate to discount lease payments. The incremental borrowing rate represents an estimated rate of interest that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon adoption of the new lease standard effective </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_415e1179-f1d6-4afc-89c7-1c162e3fc552" contextRef="C_f1c116f5-4fc4-4134-a20b-4bb41e384479" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company recognized operating lease right-of-use assets of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_870c293b-e9be-4a1e-9170-a5ef71c62fed" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, and current and noncurrent operating lease liabilities of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5a0c13a1-26b9-4743-b870-9591a8d447b2" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f209fac4-c68e-4732-8c87-7fc6792c856f" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. In connection with the adoption of this standard, deferred rent of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0cb620c3-24dc-4e31-81c0-ea78c0dc979c" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:DeferredRentCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and lease incentive liability of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ff144a0b-0036-4e3c-85cc-50fb55dde7c5" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="fdmt:LeaseIncentiveLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which were previously recorded in prepaid expenses and other current assets, accrued and other current liabilities and other liabilities on the balance sheet as of December 31, 2020, were derecognized. The adoption of the standard did </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_36718d4b-f62a-425c-8ff5-45e6abdfa4e4" contextRef="C_f1c116f5-4fc4-4134-a20b-4bb41e384479" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t have an impact on the Company's statements of operations or comprehensive loss, stockholders' equity or cash flows. </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_1877c7ea-b2c0-4a7f-9fdc-22f8380a0447" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" escape="true" continuedAt="F_1877c7ea-b2c0-4a7f-9fdc-22f8380a0447_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The impact of adoption of the new lease standard as of January 1, 2021 is summarized as follows:<br /></span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:11.0pt;font-family:Arial;"><ix:continuation id="F_1877c7ea-b2c0-4a7f-9fdc-22f8380a0447_1">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:51.033%;"></td>
          <td style="width:1.584%;"></td>
          <td style="width:1.531%;"></td>
          <td style="width:12.889%;"></td>
          <td style="width:0.91%;"></td>
          <td style="width:1.584%;"></td>
          <td style="width:1.531%;"></td>
          <td style="width:12.954%;"></td>
          <td style="width:0.91%;"></td>
          <td style="width:1.584%;"></td>
          <td style="width:1.531%;"></td>
          <td style="width:11.048%;"></td>
          <td style="width:0.91%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31, 2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">ASC 842 Adjustments</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">January 1, 2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease right-of-use assets</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_77dc7ec8-9fc5-4dcb-aa46-f53a772a0c49" contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,537</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5779ffb2-00b6-43b4-b6f3-8a9c89f85681" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,537</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prepaid expenses and other current assets</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f39e4ad5-2e33-492c-98ca-fafb86a78dfd" contextRef="C_438b050d-f05e-45d9-947c-0d5a7c04e2ae" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,444</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0ca447dc-be13-455d-8412-6547baeda813" contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_17bd87b8-ac43-4969-97a7-07a129cd3375" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,230</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued and other current liabilities</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2edf9549-7efb-4e5c-a947-6cf572a620b0" contextRef="C_438b050d-f05e-45d9-947c-0d5a7c04e2ae" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,371</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5872c5e9-9dda-4171-b983-f4fa555083a5" contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">68</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_56a6a51e-8e37-41d3-ac30-101421d34844" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,303</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other liabilities</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fa884c6f-dd8c-4cdd-a775-fb613655cfa3" contextRef="C_438b050d-f05e-45d9-947c-0d5a7c04e2ae" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,852</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2dd525c3-4820-4565-839c-8cc06c398e61" contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,696</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_22712606-2562-4749-a11f-4d5d29c3b741" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities, current</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_10b752ce-d4f3-4154-a2a5-42dcfecc232d" contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,029</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a2ac1917-5f61-4781-aa98-669623bb6afe" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,029</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities, long-term</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1f9b0dd6-4f5d-45f0-9f6c-6f292acc4c87" contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,058</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a4ab81f9-30cd-4d0e-92d9-980fd22ffbdb" contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,058</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12</span></p>
         <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_c04fc13c-d23f-4125-b673-8208f0fd8e3c" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company determines revenue recognition for arrangements within the scope of Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606) (&#34;ASC 606&#34;) by performing the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#x2019;s revenue is primarily derived through its license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses to the Company&#x2019;s technology, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products. Arrangements that include upfront payments are recorded as deferred revenue upon receipt or when due and are recognized as revenue as performance conditions are met. The event-based milestone payments, royalties and cost reimbursements represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration. Royalty payments are recognized when earned or as the sales occur. The Company records cost reimbursements as accounts receivable when right to consideration is unconditional.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company allocates the total transaction price to each performance obligation based on the estimated standalone selling price and recognizes revenue when, or as, the performance obligation is satisfied. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. At the end of each reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_5a7a95ce-2ca6-476a-b61a-418690276e5f" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_5a7a95ce-2ca6-476a-b61a-418690276e5f_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Costs related to research, design and development of programs are charged to research and development expense as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses including stock-based compensation, materials, laboratory supplies, outside services and allocated overhead, including rent, insurance, repairs and maintenance, depreciation and utilities. The Company expenses all research and development costs in the period in which they are incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_5a7a95ce-2ca6-476a-b61a-418690276e5f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_c2e99626-29df-498c-a001-e8521b090101" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:AccruedResearchAndDevelopmentPolicyPolicyTextBlock" escape="true" continuedAt="F_c2e99626-29df-498c-a001-e8521b090101_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Accrued Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_c2e99626-29df-498c-a001-e8521b090101_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has entered into various agreements with CROs and CMOs. The Company&#x2019;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_3d5027b5-a189-4e91-8c40-822b8bc6c50b" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_0377fe78-6be8-415c-bdb6-eac7a5ba6008" contextRef="C_74377b23-9b2b-42d3-bf22-b1ecef810775" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2020</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_9b4b7ad6-4d74-4e57-b5f0-8a2a25a1921f" contextRef="C_74377b23-9b2b-42d3-bf22-b1ecef810775" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> ASU 2018-07, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees. As of January 1, 2020, the Company accounts for stock-based compensation for stock options granted to employees, directors and nonemployees as measured at grant date, based on the fair value of the award. The Company measures the fair value of awards granted using the Black-Scholes option pricing model and recognizes the expense in the statements of operations over the requisite service period, generally </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_2f5cd243-2d01-42cd-af05-9945e2439ddd" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, using the straight-line method. Forfeitures are accounted for as they occur. The Company&#x2019;s policy for issuing stock upon stock option exercise is to issue new common stock.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the adoption of ASU 2018-07 on January 1, 2020, stock-based compensation expense related to stock options granted to nonemployees was recognized based on the vesting date fair value of options as the stock options were earned. The Company remeasured the stock-based compensation at each reporting period end with the resulting change in fair value being recognized in the statements of operations over the period the related services were rendered. The Company estimated the service period for the options based on the time that would be required to satisfy the service condition, assuming the service condition would be satisfied. Stock-based compensation expense was recognized over the estimated service period but was accelerated if the performance condition was achieved earlier than estimated.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_14e61a14-59ac-45e1-beac-0c55dc193526" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_14e61a14-59ac-45e1-beac-0c55dc193526_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&#x2019;s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_14e61a14-59ac-45e1-beac-0c55dc193526_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_1b89a74f-aea6-4816-8938-16429b158797" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:DerivativesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Embedded Derivative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as a separate financial instrument. An embedded derivative exists in the award agreement with the Cystic Fibrosis Foundation (&#x201c;CFF&#x201d;). As described in Note 16, the embedded derivative has been bifurcated and is classified as a liability on the balance sheet and separately accounted for at its fair value. The derivative liability is subject to remeasurement to fair value each reporting period. Changes in the fair value of the derivative liability are recognized as a component of other income (expense), net within the statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_29668eae-60a3-4f71-8502-e2fa88dd5e15" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:DeferredOfferingCostsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company capitalizes certain legal, accounting and other third-party fees that are directly related to the Company&#x2019;s in-process financings, until such financings are consummated. After consummation of the financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. In the event that a planned offering does not occur or is significantly delayed, all related deferred offering costs will be expensed immediately within the Company&#x2019;s statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_fd29ab8f-5304-4597-9a3c-57f22ba560f2" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_fd29ab8f-5304-4597-9a3c-57f22ba560f2_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Net Loss Per Share, Basic and Diluted</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for companies with participating securities. The Company considers all series of redeemable convertible preferred stock to be participating securities as the holders are entitled to receive non-cumulative dividends on a pari passu basis in the event the dividend is paid on common shares. Under the two-class method, the net loss is not allocated to the redeemable convertible preferred stock as the holders of redeemable convertible preferred stock do not have a contractual obligation to share in losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_fd29ab8f-5304-4597-9a3c-57f22ba560f2_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. Diluted net loss per share is computed by giving effect to all potentially dilutive common shares outstanding for the period. For purposes of this calculation, redeemable convertible preferred shares, stock options to acquire shares of common stock, common stock warrants, and unvested common stock subject to repurchase, are considered potentially dilutive common shares, but have been excluded from the calculation of diluted net loss per share as their effect is antidilutive.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_86afb6fc-f3c9-4308-b670-e1a217eea66d" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">New Accounting Pronouncements Recently Adopted</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2018, the Financial Accounting Standards Board (&#34;FASB&#34;) issued Accounting Standards Update (&#34;ASU&#34;) No. 2018-07, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This ASU aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payment to employees. Under this ASU, the measurement of equity-classified nonemployee awards is fixed at the grant date, which may lower their cost and reduce volatility in the statements of operations. The transition method provided by this ASU is on a modified retrospective basis, which recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020, with early adoption permitted, but no earlier than a company's adoption date of ASC 606. The Company </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_8afe6547-d9b4-449e-b532-6e3b6ae28643" contextRef="C_74377b23-9b2b-42d3-bf22-b1ecef810775" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> this guidance effective </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_ae3db6a7-f5b7-4977-bf80-68dd4c194314" contextRef="C_74377b23-9b2b-42d3-bf22-b1ecef810775" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2020</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> using the modified retrospective method. The Company recorded a less than $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_87273bce-e748-4d01-9cfa-249c4a8ab7e9" contextRef="C_d12171a9-377c-49ef-adaa-5888c0e1ab2e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million cumulative-effect adjustment reflected as a decrease to the opening balance of accumulated deficit and a decrease to additional paid-in capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. This ASU clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606, Revenue from Contracts with Customers, when the counterparty is a customer. This ASU also precludes an entity from presenting consideration received from a transaction as revenue from contracts with customers if the counterparty is not a customer for that transaction.  This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.  Early adoption is permitted for entities that have adopted ASC 606, Revenue from Contracts with Customers. The Company </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_6a06ecc0-6a12-4099-ae89-c69fdc7c2a14" contextRef="C_80f31e89-ff18-484e-81fb-0a391abdc4b5" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> this ASU on </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_f8998a26-4bee-452d-a3e7-c05f2344c75d" contextRef="C_80f31e89-ff18-484e-81fb-0a391abdc4b5" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The adoption of this ASU did </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_ebd9718c-220f-4f47-822d-44e0d96779a3" contextRef="C_80f31e89-ff18-484e-81fb-0a391abdc4b5" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">not</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> result in a material impact on the Company&#x2019;s financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. This ASU affects general principles within Topic 740 and is meant to simplify the accounting for income taxes by removing certain exceptions to the general framework. The ASU adds guidance to reduce complexity in certain areas, including recognizing a franchise (or similar) tax that is partially based on income as an income-based tax and incremental amounts incurred as a non-income-based tax and recognizing deferred taxes for tax goodwill. ASU 2019-12 also created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, other comprehensive income). The amendments in ASU 2019-12 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022.  Early adoption of the amendments is permitted.  The Company </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_b6120b54-7815-42b1-b788-c67bd005f9f9" contextRef="C_2757758c-223e-4e96-ad58-555f2a1537e5" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> ASU 2019-12 effective </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_1a8d9dc2-be20-4b0b-a66f-cae81d9d541a" contextRef="C_2757758c-223e-4e96-ad58-555f2a1537e5" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> on a prospective basis. The adoption of this ASU did </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_2057bb8d-aa41-4d56-9e2c-712f7345aea1" contextRef="C_2757758c-223e-4e96-ad58-555f2a1537e5" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">not</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> result in a material impact on the Company's financial statements and related disclosures.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In February 2016, the FASB issued ASU No. 2016-02,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. The classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than twelve months regardless of whether it is an operating or financing lease and (ii) lease expense in its statements of operations for operating leases and amortization and interest expense in its statements of operations for financing leases. Leases with a term of twelve months or less may be accounted for similar to existing guidance for operating leases under Topic 840. In July 2018, the FASB issued ASU No. 2018-11, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">See earlier disclosure in this footnote on the impact on the Company of the adoption of this standard in 2021. <br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">New Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As an &#x201c;emerging growth company,&#x201d; the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, as clarified in subsequent amendments. ASU 2016-13 changes the impairment model for certain financial instruments. The new model is a forward-looking expected loss model and will apply to financial assets subject to credit losses and measured at amortized cost and certain off-balance sheet credit exposures. This includes loans, held-to-maturity debt securities, loan commitments, financial guarantees and net investments in leases, as well as trade receivables. For available-for-sale debt securities with unrealized losses, credit losses will be measured in a manner similar to today, except that the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. In October 2019, the FASB voted to delay the effective date of this standard. Topic 326 will be effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_a70d6e6e-2e4e-4169-82fe-03abb35142b7" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_7a7d14ac-1160-44c0-a07b-e14813fb31d2" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following tables represent the Company&#x2019;s fair value hierarchy for financial assets and financial liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.298%;"></td>
        <td style="width:1.167%;"></td>
        <td style="width:1.231%;"></td>
        <td style="width:9.441%;"></td>
        <td style="width:0.61%;"></td>
        <td style="width:1.167%;"></td>
        <td style="width:1.231%;"></td>
        <td style="width:9.473%;"></td>
        <td style="width:0.61%;"></td>
        <td style="width:1.167%;"></td>
        <td style="width:1.231%;"></td>
        <td style="width:9.398%;"></td>
        <td style="width:0.61%;"></td>
        <td style="width:1.167%;"></td>
        <td style="width:1.231%;"></td>
        <td style="width:11.357%;"></td>
        <td style="width:0.61%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Basis for Fair Value Measurements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Fair Value as of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_eece758d-219a-454f-a048-416b47dacc10" contextRef="C_08032442-cecd-44e4-8446-5caefea14888" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_e2b4f108-4b18-4558-a85d-61093c3fe587" contextRef="C_7c926a8a-82fa-447e-b1e6-bbfe1e709a29" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_95c68307-0f3b-41e0-a44e-943614e9ef66" contextRef="C_cd0116f7-4d6b-4e75-acbd-f547c6e71c2d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_66ce8725-4dbc-450f-a87c-f46c90086e01" contextRef="C_100f6d0a-7eb4-409e-8987-51846785183e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_20239b20-27f0-44b3-82cc-0b700a441e30" contextRef="C_13f6e26c-4d62-4ef8-b29b-c168bba13d36" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,864</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_794705e0-8ff4-4f91-8ec8-9d0f9ae1b459" contextRef="C_7958ed8e-8790-49e7-bfb6-54045eeb9eec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,864</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">US Treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_1330bced-4632-44a1-8aa3-b8deaad814c7" contextRef="C_8da58ed6-e246-4eec-ba9a-77c486b0bfab" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,029</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_4e21f6cd-221f-4967-8c48-0f828c758886" contextRef="C_38363b5b-dfc5-4de3-ad6d-69dec1df22bb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,029</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_96a8af96-45bd-4113-9341-edc7006c95b3" contextRef="C_9bf2311e-d3cd-40c5-9ad2-5823cd5dccbb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_66686ca2-a2f8-4f90-8945-2e40fa3920ef" contextRef="C_62df8820-e746-4de8-8b5d-7651c94d18fb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162,428</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_c03f00a0-b08d-457c-bab2-3e3aa2de8232" contextRef="C_d1ec6218-dc19-4a0d-9c16-9e9cf05148c8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">198,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Derivative liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_7c25756b-c286-4799-a792-5a52456cdb86" contextRef="C_994128d2-ff7e-458c-a06e-3646a588a46f" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_6d699bd1-bf0f-4214-a905-3ac5de36a706" contextRef="C_369e8cc3-d5ce-4005-9fa7-8014c0cde676" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8c380f83-6695-4ae5-b676-7c580bad0c28" contextRef="C_345dc4b4-ecea-45cf-b824-fa29a5f06694" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8fe85478-23f9-4411-80cb-513a09f9db79" contextRef="C_d1ec6218-dc19-4a0d-9c16-9e9cf05148c8" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.829%;"></td>
        <td style="width:0.803%;"></td>
        <td style="width:1.359%;"></td>
        <td style="width:8.765%;"></td>
        <td style="width:0.621%;"></td>
        <td style="width:0.824%;"></td>
        <td style="width:1.359%;"></td>
        <td style="width:8.776%;"></td>
        <td style="width:0.621%;"></td>
        <td style="width:0.824%;"></td>
        <td style="width:1.359%;"></td>
        <td style="width:8.797%;"></td>
        <td style="width:0.621%;"></td>
        <td style="width:0.824%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.618%;"></td>
        <td style="width:0.621%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Basis for Fair Value Measurements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Fair Value as of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_e666337a-d985-4ad0-9946-3062364ee5e0" contextRef="C_8bc0fb33-e137-466b-afc1-ac2316dff7e2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,726</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_3347c77a-17c9-4669-bf3d-59792d575dd4" contextRef="C_8920c352-ac30-4ff7-8543-68d35ca73a38" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,726</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_2cbb0232-b875-4893-aecb-065c9c6335fe" contextRef="C_fdb51331-8f19-40ce-b87c-0d9aa4e26603" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,726</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_44bfd050-a485-47fa-95f5-ebc80998874c" contextRef="C_f8a50303-fca8-4db7-8914-b41268aac3b6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,726</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Derivative liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_6c1e8f8c-037f-4371-9c77-cd7639c49a8f" contextRef="C_cf542ed1-e6b5-4685-8a2e-3f4a7e276ae0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3">122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_616dabd7-a3c8-4455-82a7-a3c044a76e98" contextRef="C_c2004132-d784-47b1-a1e9-3cd43319e93f" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3">122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_3a08b74f-dd13-42fb-8781-94631be1b3c5" contextRef="C_592a756d-a16a-4bd3-aad9-7318649c6f44" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3">122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9fecdd7d-4c5f-4f42-844d-8441626f6619" contextRef="C_f8a50303-fca8-4db7-8914-b41268aac3b6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3">122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 3 Inputs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability was determined using a present value analysis with multiple scenarios. In determining the fair value of the derivative liability, the inputs impacting fair value include the change of control payment to CFF, the probability of a change of control event, the product status at time of a change of control event and the discount rate. See Note 16 for further discussion on embedded derivative.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d96d6cc7-7fa3-488b-bd41-cb63a32e0e2b" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4c261d4e-368b-42ac-8c6a-2a8e3675d5ad" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b7737a8d-9e0f-4d61-b56f-2b0dae001f55" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_946c7bb1-391f-41f8-9fcb-446c1cf240b9" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_aa1f5762-11ce-4834-bc32-056f80ca0a69" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7f9b05b0-6e25-412e-9002-30d7a3806d0b" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ffe0e8bb-b63c-49f1-9e49-862d12479cb6" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_657dda11-ba9e-43e0-880c-843920b032d8" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_640984bf-62c9-4a61-9966-2b1ea9d6c6d6" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3dd539b0-8293-4867-8fe6-6d1b2ff3bd95" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c2ac31b2-eab9-45c1-a5c5-f086e2328d69" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_56f671de-d2f0-42c5-bb18-3079f8eaed5b" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_76b2e04a-aa89-4b4b-9dce-a95d19e7d7ac" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_52dcd69c-b69f-42b4-bcec-1c2d04647662" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_acf19322-a0d9-457e-af34-e628d1bf5668" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_55dca056-426b-4179-a39a-b9b0157546ba" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> transfers between Level 1, 2 and 3 during the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_c5f1172b-4daa-48a1-ab0d-e8c81756082c" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3 derivative liability (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.79%;"></td>
        <td style="width:1.934%;"></td>
        <td style="width:1.53%;"></td>
        <td style="width:15.971%;"></td>
        <td style="width:0.776%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_565387fc-1f11-4535-a087-97c315334703" contextRef="C_78089c61-9c63-4f0e-ab4c-7158c1adabeb" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">101</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value included in other income (expense), net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2f4e1365-c6f8-4624-a284-8a75e3f3f441" contextRef="C_2f32afd7-17e5-440d-95d7-e8e98ffe403b" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_834220d8-b4e4-44b5-a1d2-6aff019d75c5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2020</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5934655e-2cfe-400c-9f9b-a19955703029" contextRef="C_04e47ba0-ce07-4a2d-aa4a-280a066c7c65" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3">122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value included in other income (expense), net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_00545f07-352b-463a-91f1-c3a2033eed4e" contextRef="C_27c30b85-a010-4be5-a956-5fa66be6b6dc" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3">92</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_f500242c-7c9c-43e7-8ba7-87e2388aa1db;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2021</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c0b77032-9726-4f39-89ba-4b641b518e5a" contextRef="C_2b9316bd-43bb-4236-afee-5dedacf34852" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_39a0b535-179b-4c81-b8be-945a298c6658" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">4. Marketable Securities</span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_58697145-69f6-4dec-af5a-1187f89bd43d" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2021 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.349%;"></td>
        <td style="width:1.296%;"></td>
        <td style="width:1.542%;"></td>
        <td style="width:9.412%;"></td>
        <td style="width:0.782%;"></td>
        <td style="width:1.296%;"></td>
        <td style="width:1.542%;"></td>
        <td style="width:9.412%;"></td>
        <td style="width:0.782%;"></td>
        <td style="width:1.296%;"></td>
        <td style="width:1.542%;"></td>
        <td style="width:9.294%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.296%;"></td>
        <td style="width:1.542%;"></td>
        <td style="width:14.916%;"></td>
        <td style="width:0.782%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Amortized Cost Basis</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Fair Value as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_acf47efb-6f86-45e9-89f3-174701a88ab4" contextRef="C_2fe951a6-989e-495f-bcdd-517a1a9d9539" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,471</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8d697f24-7a48-4f9f-bda9-25d74c6e5724" contextRef="C_2fe951a6-989e-495f-bcdd-517a1a9d9539" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a32e7274-59f5-49d6-807b-397d3d97c8fd" contextRef="C_2fe951a6-989e-495f-bcdd-517a1a9d9539" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2c86e72c-ed31-4c79-b43c-d351222c5ce3" contextRef="C_2fe951a6-989e-495f-bcdd-517a1a9d9539" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,467</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9c1e15b8-9bbe-437f-b720-59af03ee1be9" contextRef="C_76372236-463c-49d8-950b-bfdd59d89a3a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,315</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5777a1eb-20ab-41b9-9d59-f965eb606aed" contextRef="C_76372236-463c-49d8-950b-bfdd59d89a3a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5e8c418c-ecf1-476b-a27e-3d2eef0bc390" contextRef="C_76372236-463c-49d8-950b-bfdd59d89a3a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d02f6fd2-9a57-44d0-9720-be839497ab5e" contextRef="C_76372236-463c-49d8-950b-bfdd59d89a3a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,236</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">US Treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2dd3f335-4f88-41af-8039-c2eff5d3dedd" contextRef="C_29d03014-ea19-4d37-bd22-35b0ce14deba" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,082</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_94da40a3-79b6-4cbf-9e8b-170b4ecf532f" contextRef="C_29d03014-ea19-4d37-bd22-35b0ce14deba" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1beb79f7-0505-46c7-b880-88ca16ee5c71" contextRef="C_29d03014-ea19-4d37-bd22-35b0ce14deba" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8a618b24-5973-404b-8e40-3dbc80eebfd4" contextRef="C_29d03014-ea19-4d37-bd22-35b0ce14deba" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,073</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d1e02b35-f13c-414b-b491-e1262b9f3d22" contextRef="C_f91508fa-5dfa-4192-91eb-1afaa64ddaad" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,868</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_badcafc5-f028-453a-ab20-5a15853b7122" contextRef="C_f91508fa-5dfa-4192-91eb-1afaa64ddaad" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ed4c4d5a-a449-4675-9ad1-7c5c03f3dca2" contextRef="C_f91508fa-5dfa-4192-91eb-1afaa64ddaad" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9efae3e9-9716-4191-af11-c396228ba39d" contextRef="C_f91508fa-5dfa-4192-91eb-1afaa64ddaad" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,776</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6d3495b9-56da-44cd-8d72-55fa69108d76" contextRef="C_068f626d-cf83-45b9-9dba-b873304176e4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_52001d2a-112a-4462-afe3-8a53ac496a85" contextRef="C_068f626d-cf83-45b9-9dba-b873304176e4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dfb08330-e8e0-4ade-b149-ddf947dc931a" contextRef="C_068f626d-cf83-45b9-9dba-b873304176e4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a5c13558-0b77-485b-853f-1dfeacf40106" contextRef="C_068f626d-cf83-45b9-9dba-b873304176e4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,068</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_45596eed-d30b-4637-95ce-67d7529538c1" contextRef="C_68203dba-eb94-47f4-bc69-28308c9e86fa" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,821</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b7eef666-7d8d-4b68-913e-36337e87f6ba" contextRef="C_68203dba-eb94-47f4-bc69-28308c9e86fa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_741f37e6-ad9a-4018-b40c-c639995949c1" contextRef="C_68203dba-eb94-47f4-bc69-28308c9e86fa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">193</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9a4f25b3-82c2-41be-af84-ce2ce8345d9b" contextRef="C_68203dba-eb94-47f4-bc69-28308c9e86fa" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,628</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">US Treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_34d63828-e0f4-434f-8785-b2d4d3f99865" contextRef="C_debe135a-c35c-4564-ab5a-f34f314d29f1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,073</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_806b951f-de22-4499-a026-812fda71c81b" contextRef="C_debe135a-c35c-4564-ab5a-f34f314d29f1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c2047d46-92ab-45c7-b31f-2fd205342934" contextRef="C_debe135a-c35c-4564-ab5a-f34f314d29f1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a3b4be7e-e2be-4811-8ba0-95feb01cb2ba" contextRef="C_debe135a-c35c-4564-ab5a-f34f314d29f1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,956</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c4aee31d-a584-47a5-88dd-78b550ee5177" contextRef="C_8c2f744e-0a59-4216-9244-12153c1d29c6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,983</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1a1a3c22-a7f7-4213-b859-641cdd2d009a" contextRef="C_8c2f744e-0a59-4216-9244-12153c1d29c6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_136ae332-b7ae-4ccf-b9e8-b8ee0aed4ec6" contextRef="C_8c2f744e-0a59-4216-9244-12153c1d29c6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">331</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8fece251-4bed-4358-934d-059fa34ea245" contextRef="C_8c2f744e-0a59-4216-9244-12153c1d29c6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,652</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All marketable securities held as of December 31, 2021, had contractual maturities of less than </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_694af594-1a34-4c5f-95a8-392ff0f1341f" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:MaximumMaturityPeriodOfMarketableSecurities" format="ixt-sec:durwordsen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. There have been </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2f640658-cc2d-4483-96ac-c7b2a6b7a471" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7c780d68-61f9-45a6-82b6-945ab49ea0cb" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> realized gains or losses on marketable securities for the periods presented. </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_00696bbe-24b7-4fd5-a8cc-43f9f13d5cc3" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="fdmt:NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen">None</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of the Company's investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c2581108-3cf1-49a9-805c-17b6078868b7" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> recognition of any other-than-temporary impairment in the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2020, the Company had </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2fe2679f-b9ca-4e6b-90a4-0c8afd8cafca" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:MarketableSecurities" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> marketable securities.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_aba3aec0-88c8-4703-840e-967578a53f9c" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true" continuedAt="F_aba3aec0-88c8-4703-840e-967578a53f9c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">5. Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_36343d28-7e40-45d2-a0e3-f34f89552e2e" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.113%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:12.901%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:12.891%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Machinery and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5748f19f-a978-4799-8fbc-f05959f0e922" contextRef="C_3f51aa86-d6a8-4946-b9c6-489cfcc06d93" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,971</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_795e023e-81b0-4c9f-9a5c-f1065d0defab" contextRef="C_90284da0-93f6-431a-8c5e-011cfcb8f1f0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,911</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5f6246d7-548a-4f6f-91a0-123dcc04a084" contextRef="C_5292ea9b-5f9f-47a3-8950-e560df46b007" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,527</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_eb5a2c8c-f654-483b-a10e-a7d2ff62a29b" contextRef="C_6ba7e920-3f27-47fd-a911-2a4a015a560f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,527</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a1828676-76c1-4752-9077-9ca69abda5c4" contextRef="C_17b5390d-b508-41a3-bec9-d59c6b3e03e3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">566</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_74f19de8-0821-43dd-9d05-d0e935d3a174" contextRef="C_6961af42-3676-40b4-923b-b55bd4213555" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">473</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Office equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2e2841d1-09cf-49c6-b8b0-02dafa7e6c4d" contextRef="C_cf4beef8-281b-4990-bced-f3548175f663" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_88dad22a-4d6a-4fe9-8757-22ef90305030" contextRef="C_3f63f746-5168-4906-b7e7-1be53b0dbc62" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">101</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2409ef14-33fc-4001-a181-5ab63ff607a9" contextRef="C_4d4c97fb-5c4e-482d-aa4f-d431fcdad1c2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">421</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b73ede35-4271-46ce-98fd-ecf731ebb30a" contextRef="C_d3e07726-b4be-4673-8ad2-8d4cb0def982" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">366</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Construction in progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f7183df3-07ff-479c-b0d2-e853ddc37a8b" contextRef="C_952d0fc8-cacf-4343-ad40-069f13b709dc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,066</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0c0b794f-3ac3-43ad-8797-23eecff0adef" contextRef="C_e4411f8c-40ed-48bd-b0d8-e6366fa6b2c1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">539</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_960a3f23-6ef5-4b75-be61-9fbdc5b8ec71" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,716</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f532e56c-cb0f-46c1-a184-5b1385328637" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,917</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f386f56e-0b53-4aee-bf34-7dd67698151a" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,325</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_64e848bd-64d4-4921-a9d1-2fb6a1712a09" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,844</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ac75612a-a25e-4716-a8f6-cd3346fe0cfc" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,391</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_04ae9e2f-6f60-49e6-b4c1-a857298070db" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,073</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_aba3aec0-88c8-4703-840e-967578a53f9c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All property and equipment are maintained in the United States. Depreciation expense was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7669eb2a-2cb4-4f8a-af82-fe376dfb8303" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_abb19189-810d-4076-87e1-578828e87f9c" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended December 31, 2021 and 2020, respectively.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_78d2c7e6-8d9a-4d68-8da9-37aeed21d3d5" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:AccruedAndOtherLiabilitiesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">6. Accrued and Other Liabilities, Current and Noncurrent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_b838bb5a-4dc2-4c62-8b08-ad2913352a4f" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.149%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:13.018%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:13.018%;"></td>
        <td style="width:0.771%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1e9e1b10-73f3-4b8c-816e-f21b9ee18ed1" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,994</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c90cae74-7ead-4e7e-97ee-fe95f748d3f6" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,437</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued clinical and preclinical study costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_404cc476-3eb9-4133-95c6-117a573de24d" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="fdmt:AccruedClinicalAndPreclinicalStudyCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">407</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c3bd6e68-57e6-49f4-b8b2-01c122b4521f" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="fdmt:AccruedClinicalAndPreclinicalStudyCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">869</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Consulting and professional</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0a85d99e-cba3-49d7-9793-7620ab6d0a67" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_78899f5c-57a1-4694-9fa6-a613c25c13f8" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,574</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9f5a68e6-a77b-45de-971d-507dbe65cec1" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,770</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_801f33ad-8654-4cb6-90d7-bec3369734aa" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">491</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total accrued and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7d8a74fb-6f40-427a-b48b-4c3619217eca" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,744</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f113044e-1316-45c2-b018-8bb907809208" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_f806c27a-0604-4739-ac64-ec4ae157b084" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other liabilities, noncurrent consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.178%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:12.987%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:13.019%;"></td>
        <td style="width:0.771%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred rent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e029cb3a-1862-481d-98e1-d88467c20239" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DeferredRentCreditNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,237</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b7d744a0-27c4-4e4b-8f0b-0ca427f3d4c1" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OtherSundryLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7b17fb0b-350f-461f-82a3-8111dc7f3210" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:OtherSundryLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">615</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total other liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1059bdde-12bb-411a-8126-fb267e0cb8cd" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_90b312f2-f006-4010-97d0-70ce830b9769" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,852</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_cf81e5e6-a277-41d0-b76f-b7ab581e7242" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">7. Research and Collaboration Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_5b07e23f-85c5-4a03-8be1-aaded0327e33" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:ScheduleOfCollaborationAndLicenseRevenueTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Collaboration and license revenue for each period was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.014%;"></td>
        <td style="width:1.584%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:12.804%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:1.584%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:12.675%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.584%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">uniQure</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fc216c33-542d-4737-9a42-62104d828e21" contextRef="C_0c74490e-c642-49f7-a178-c5c00a711057" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">736</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cbef46ec-792f-4da9-995c-e47bae11a32b" contextRef="C_10bf4f98-2380-4a78-bf83-b60685bbda33" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">742</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Roche</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c1531654-9e7c-4e85-afd6-a45beeeb743d" contextRef="C_efc3ff61-873a-4027-8905-9906185f858f" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_72d27bf0-1b8d-4c90-a9b8-adffdf447be2" contextRef="C_7224f03c-f6e9-4042-a275-59c886ca1970" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,897</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CFF</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e3051771-0a68-43f0-bc4e-14a80ef7d7d5" contextRef="C_bc671fd0-0ba3-4f31-87f7-95c143537ef9" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">121</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cbcc57d5-c980-4e00-a01c-6a56ce30cc11" contextRef="C_f311e2d1-83ec-4e94-91c6-bb50b44c9a4a" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_49d20e62-d675-4001-859d-29840e9ea6a8" contextRef="C_dfd0d18e-816a-44fd-b58e-bba6ac6a812a" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,038</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_62db0d10-1569-4f3b-90b6-e9c8884de1a8" contextRef="C_46bb51b8-c564-4f79-bb7b-808fc09a2915" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_3fa9c27c-c36e-49dd-aa8b-e9c67363a8da" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:DeferredRevenueByArrangementDisclosureTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred revenue for each period was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.124%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:13.019%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:13.041%;"></td>
        <td style="width:0.771%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Deferred Revenue <br />as of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">uniQure</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_da584672-5c48-477d-87fe-1b3c5e99214e" contextRef="C_019809d7-3321-4394-ad06-f1dce3e3dcd3" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,661</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3b87ec64-3b54-4624-a58b-3e87ce82c969" contextRef="C_d7e7e417-5edc-4abf-a76c-5be707bce23e" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Roche</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d4d92cfa-88d1-4bae-97d3-1f93950481bf" contextRef="C_fb67bb6e-bab1-4045-8de0-aaff307da3a9" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,318</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CFF</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2a55cdff-3b25-4fec-b873-461932621d46" contextRef="C_b3cb484d-807c-45d4-a35e-ca7c2f3f9313" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,429</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1ed6c1a5-bc9b-4533-a21a-6ae2dbee883c" contextRef="C_84be53f3-486d-4f0d-90b0-07d7e83acbf6" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_09501158-5bdf-4c85-aa6a-a115b9b1b586" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,090</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_800ba7cf-728a-4b1e-9a47-0c949e4836a9" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,812</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The total amount of revenue in the year ended December 31, 2021, which was included in deferred revenue at January 1, 2021, was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a6257806-6f91-4a8b-9d36-89e3a2a3a8e9" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The total amount of revenue in the year ended December 31, 2020, which was included in deferred revenue at January 1, 2020, was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f1c744b0-108b-4c74-ba71-6a06fdd75114" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">uniQure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In January 2014, the Company and uniQure biopharma B.V. (&#x201c;uniQure&#x201d;) entered into a Collaboration and License Agreement (the &#x201c;uniQure Agreement&#x201d;) to collaborate on the discovery and non-clinical research activities related to the Company&#x2019;s Therapeutic Vector Evolution platform in order to generate and validate vectors for gene delivery to treat diseases within the central nervous system and liver (together, the &#x201c;uniQure Field&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The uniQure Agreement provided uniQure with a research license as well as an exclusive development and commercialization license for each project variant selected for further development. The initial research term is </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_bb29245f-b4b9-483b-a085-2af4e50f44e2" contextRef="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b" name="fdmt:CollaborativeArrangementInitialResearchTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> with an option for uniQure to extend the research term one time for an additional year. Once the Company&#x2019;s research plan has concluded, uniQure is solely responsible for the continued development, manufacturing and commercialization of the project variants as potential product candidates. In October 2016, uniQure exercised its option to extend the research term for an additional year to January 2018. The Company was also required to work exclusively with uniQure in the uniQure Field (the &#x201c;uniQure Exclusivity Clause&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the uniQure Agreement, the Company received upfront payments of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6ab1d663-3b33-4749-9c26-788062e40063" contextRef="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b" name="fdmt:CollaborationArrangementsUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, and was entitled to receive (i) contingent payments for the achievement of research and development milestones of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8de4e11a-6828-4ca5-bf30-bfbea03e10c2" contextRef="C_e3231fac-0339-4b86-8552-33d99ccf5b90" name="fdmt:CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for each licensed product selected under the arrangement, and (ii) royalties in the single digit range on future sales of the potential product candidates and sublicense consideration in the low teens to low thirties range on any future sublicensing arrangements. The Company also received capped research and development service fees based on contractual full-time employee rates per year. In connection with the performance obligations under the uniQure Agreement, the founders of 4D Molecular Therapeutics, LLC received equity options to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_21ce308a-63e3-4144-a6bb-c96d3d0e027d" contextRef="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b" name="fdmt:OptionsToPurchaseOrdinaryShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">609,744</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of uniQure ordinary shares that vest over the initial </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_5503e1ff-f02e-4778-bfde-0646259dce92" contextRef="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b" name="fdmt:VestingPeriodOfShareAwards" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> term of the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The upfront payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f2ab2148-948c-4517-af8c-90f59b0a8b46" contextRef="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b" name="fdmt:CollaborationArrangementsUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was recorded as deferred revenue and was recognized on a ratable basis over the estimated performance period of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_a7385807-61f0-4cb2-9c70-b6d343847868" contextRef="C_0912072b-bcab-4ad8-a96b-b69214a4c085" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Payments and reimbursements for research costs were recognized on an as-incurred basis. The options to purchase uniQure shares were deemed to be a noncash component of the arrangement consideration, as the vesting of options is linked to the uniQure Agreement and there is a requirement for the holders of the options to provide services under the agreement. The fair value of the uniQure options, which was estimated to be $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3375892e-4452-41e2-bba2-6d9a34dbf3f4" contextRef="C_98081424-857b-49e5-aa11-1c55ddebeec0" name="fdmt:FairValueOfOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, was recognized ratably as revenue over the estimated performance period of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_b9c50cad-48ef-4f7f-8629-89184360247d" contextRef="C_0912072b-bcab-4ad8-a96b-b69214a4c085" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and the associated compensation expense related to the stock options were recorded as research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In August 2019, the Company and uniQure entered into an Amended and Restated Collaboration and License Agreement (the &#x201c;Amended uniQure Agreement&#x201d;), which amended and restated the uniQure Agreement, and a separate Collaboration and License Agreement (the &#x201c;Second uniQure Agreement&#x201d;). Under these agreements, the Company agreed to transfer incremental rights and services to uniQure in exchange for uniQure eliminating the uniQure Exclusivity Clause and transferring other rights back to the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Amended uniQure Agreement, uniQure continues to have an exclusive license to select AAV capsid variants (the &#x201c;Selected Variants&#x201d;) in the uniQure Field. uniQure continues to be solely responsible, at its cost, to develop and commercialize the compounds and products containing the Selected Variants. The amended uniQure Agreement eliminated the uniQure Exclusivity Clause in the uniQure Agreement. Furthermore, the contingent payments that the Company was entitled to from uniQure for the achievement of research and development milestones of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1744dcc9-e611-47c6-b496-de94829fc3a2" contextRef="C_af32b9d1-9efd-44e5-8ceb-eb4bf3e5244b" name="fdmt:ContingentPaymentsEliminated" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for each licensed product selected under the uniQure Agreement were eliminated and sublicense consideration on any future sublicensing arrangements was reduced from the low teens to low thirties percentages to mid-single digit to mid-twenties percentages.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Second uniQure Agreement, the parties agreed to research and develop new AAV capsid variants (the &#x201c;New Variants&#x201d;) that are not Selected Variants that affect certain targets selected by uniQure (the &#x201c;uniQure Targets&#x201d;) in the uniQure Field. The Company is solely responsible, at its cost, for the research of the New Variants. The Company granted uniQure an exclusive license to a certain number of the New Variants (the &#x201c;uniQure New Variants&#x201d;) that affect the uniQure Targets. uniQure is solely responsible, at its cost, to develop and commercialize the compounds and products containing the uniQure New Variants that affect the uniQure Targets (the &#x201c;Licensed Products&#x201d;). The Company retains all rights to New Variants in the uniQure Field that affect targets other than the uniQure Targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under both the Amended uniQure Agreement and the Second uniQure Agreement, uniQure will be required to pay the Company royalties on worldwide annual net sales of Licensed Products at a mid-single digit percentage rate, subject to certain specified reductions. uniQure will also be required to pay the Company sublicensing consideration for sublicensing the Company&#x2019;s intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties at a rate between the mid-single digit to mid-twenties. The Company has reciprocal obligations, at the same percentage rates as uniQure, to pay uniQure royalties and sublicensing consideration for sublicensing certain intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company concluded that the Amended uniQure Agreement and the Second uniQure Agreement should be accounted for as one combined contract that should be accounted for as a separate contract from the uniQure Agreement given that the incremental licensed intellectual property rights and research and development services are distinct from the rights and services previously transferred to uniQure under the uniQure Agreement and the transaction price increased by an amount that equals the standalone selling price of the incremental rights and services to be transferred to uniQure under the Amended uniQure Agreement and Second uniQure Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Neither party was required to pay monetary consideration in connection with the execution of the Amended uniQure Agreement or the Second uniQure Agreement or for subsequent performance by the parties under those agreements, notwithstanding the potential future royalty and sublicense consideration described above. The fair value of the non-monetary consideration given by uniQure to the Company, for the intellectual property right is $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9d9ce441-b867-4d97-a011-7525776c151c" contextRef="C_490d082b-4c24-4ebc-97b4-1f4ca133afe2" name="fdmt:FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. This intellectual property right is considered to be an in-process research and development asset with no alternative future use and, accordingly, was written off as acquired in-process research and development expense in the year ended December 31, 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The incremental transaction price described in the paragraph above was recorded as deferred revenue given that the Company identified one single combined performance obligation under ASC 606, which includes the licenses to the New Variants, research services and participation in the joint steering committee (&#x201c;JSC&#x201d;). Revenue is being recognized using the input method based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligation. Based on the current estimated timelines, the deferred revenue is expected to be recognized as revenue over approximately </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_3340247d-416d-4f03-a381-b95a54629875;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_34edb21a-11fd-4948-ab7d-f57cd0dde3e3" contextRef="C_6589222f-c96b-40f8-a688-38fc97e550be" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> from December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company determined the transaction price using the risk adjusted net present value analysis (&#x201c;rNPV&#x201d;) methodology to value the elimination of the uniQure exclusivity clause and other material rights received by the Company, including the potential royalties the Company would receive from uniQure. The rNPVs incorporate estimates and assumptions including the number of products the Company and uniQure would develop, the risk-adjusted probability of successfully developing a biopharmaceutical product, the probability that uniQure will develop a product, the research and development costs, the potential worldwide sales and associated commercialization costs, corporate tax rate, and discount rate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During each of the years ended December 31, 2021 and 2020 the Company recognized revenue of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_51ca3e43-41ec-405d-be55-67cdc1b581e4" contextRef="C_2975534f-c7d6-40d2-b4f0-8396ed62ffe5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_c95f5f4a-ab7b-4a69-82fb-e2d27822e3a6" contextRef="C_d8f5fd72-5501-4424-9c3c-155dadbc1f06" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million under the Amended uniQure Agreement and the Second uniQure Agreement. As of December 31, 2021 and 2020, deferred revenue relating to uniQure was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2f2ae6ed-bd7b-4b9a-880d-93b8a63bc9ec" contextRef="C_019809d7-3321-4394-ad06-f1dce3e3dcd3" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e789f3e6-e2bb-4a46-8aaf-1f7daf1a71a3" contextRef="C_d7e7e417-5edc-4abf-a76c-5be707bce23e" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. There were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5481060e-da52-49be-b43f-99401d939fc8" contextRef="C_019809d7-3321-4394-ad06-f1dce3e3dcd3" name="us-gaap:DueFromRelatedParties" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_776464d6-8401-4f7d-8b59-3b28b3e8fa3f" contextRef="C_d7e7e417-5edc-4abf-a76c-5be707bce23e" name="us-gaap:DueFromRelatedParties" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> amounts due from uniQure under the uniQure Agreement, Amended uniQure Agreement or Second uniQure Agreement as of December 31, 2021 and 2020. As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d7d93f51-73ee-40d1-9307-c692d5fbc307" contextRef="C_4a392933-0525-4a24-bd80-f86924e2bcf6" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e01080ae-67f4-43da-90a9-1f15165ef8f1" contextRef="C_0e28aeda-24d7-44f2-b175-686133e42282" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CRF</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2015, the Company entered into a research funding and collaboration agreement (the &#x201c;CRF Agreement&#x201d;) with the Choroideremia Research Foundation (&#x201c;CRF&#x201d;), a non-profit organization dedicated to finding a cure for choroideremia, a rare inherited disorder that causes progressive vision loss, ultimately leading to complete blindness. The goal of the CRF Agreement is for CRF to contribute funding to help with the advancement of the Company&#x2019;s choroideremia research program. The Company is responsible for all decision making and execution of any and all of the related activities to be completed in its sole discretion. The initial term of the CRF Research Plan is </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_c41616fa-c147-4043-8a4b-14ebde92c61b" contextRef="C_e21eab0a-797b-4380-9011-1aea8fabc1b5" name="fdmt:CollaborativeArrangementInitialResearchTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The agreement includes contribution by the Company to CRF of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8ee68137-e2b3-4015-acb4-d0fe59b6ea4c" contextRef="C_44ba6365-051f-4e87-afa2-47586cb35c9d" name="fdmt:CollaborativeArrangementContributionUponDevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million upon certain development or approval milestones. The overall arrangement has automatic extensions of up to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_80d41e98-685d-4c82-a966-93ef6194e666;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> additional years. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0849f39d-5c73-42e1-895e-bf3e8c90a7e0" contextRef="C_6795eac3-18cb-415a-b6be-fd09406f11f7" name="fdmt:CollaborativeArrangementAchievedMilestones" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> milestones have been achieved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Revenue was fully recognized for this agreement in the year ended December 31, 2017. There was </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_603c5045-732b-402e-9f02-9dbde56318f8" contextRef="C_46645de8-496d-4445-bcee-79e0f6a7e2e5" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4126d7d8-0d1e-4590-8c51-f16515b4566f" contextRef="C_be527709-9a9f-4be1-8ea5-1064c24e61fb" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> deferred revenue relating to the CRF Agreement as of December 31, 2021 and 2020. </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d25478d7-4607-4780-b0d5-1e72ca9b4ef5" contextRef="C_46645de8-496d-4445-bcee-79e0f6a7e2e5" name="us-gaap:DueFromRelatedParties" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_781891e8-144d-4d35-8b28-93f085967666" contextRef="C_be527709-9a9f-4be1-8ea5-1064c24e61fb" name="us-gaap:DueFromRelatedParties" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_27be9389-24d8-4eba-979f-3ab79156651d" contextRef="C_46645de8-496d-4445-bcee-79e0f6a7e2e5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bcf6bb67-7818-452c-8e80-4343bc62a03d" contextRef="C_be527709-9a9f-4be1-8ea5-1064c24e61fb" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> amount was due from or to CRF under the CRF Agreement as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Roche</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2017, the Company entered into a collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, &#x201c;Roche&#x201d;) to discover and develop products containing optimized next generation AAV Vectors focused on ophthalmological diseases and disorders excluding select criteria (the &#x201c;2017 Roche Agreement&#x201d;). The Company and Roche both have the ability to nominate products to discover, develop and commercialize.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At the effective date of the 2017 Roche Agreement, choroideremia was designated a Roche product class and the 4D-110 product was licensed to Roche. The Company was responsible for conducting research and development services prior to pivotal clinical studies, and Roche was responsible for conducting subsequent development and commercialization activities. In addition, Roche agreed to pay for research and development services at the agreed upon full-time employee rate for work performed for choroideremia under the 2017 Roche Agreement, and certain external costs, except for the costs associated with the manufacturing work for choroideremia.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the 2017 Roche Agreement, Roche had an option, exercisable prior to pivotal clinical studies, to license 4D-125 (for the treatment of XLRP), which was not exercised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the 2017 Roche Agreement, the Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_35e7ed47-d744-4780-87d9-84fb083135ce" contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0" name="fdmt:CollaborationArrangementsNonRefundableUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as consideration. In addition, the Company was entitled to contingent payments including (i) $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a34f90ab-cc58-4dd8-a619-bf07b026c321" contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0" name="fdmt:CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for each Roche nominated product beyond the first three, (ii) up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c261faf2-96ed-4321-a39f-bad4ca819af6" contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0" name="fdmt:CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million upon exercise of the option to convert a product the Company nominated and developed prior to pivotal clinical studies, (iii) development milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9ba89443-94cc-4815-8476-92c355d0e6ec" contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0" name="fdmt:CollaborationArrangementsMaximumDevelopmentMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">223.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, of which $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_be6f3545-19eb-4ecb-94ad-db1f36669595" contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0" name="fdmt:CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">86.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million related to choroideremia and the rest related to other licensed products; and (iv) sales-based milestones of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cf296114-2d59-42d8-953c-58d272335f94" contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0" name="fdmt:CollaborativeArrangementMaximumSalesBasedMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">123.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in connection with licensed products. Through December 31, 2021, the Company received $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_439d306c-91d8-40d5-9a77-e14e42d5ab33" contextRef="C_62a5478f-6648-41ef-8d95-7e857719eae5" name="fdmt:CollaborationArrangementsNonRefundableDevelopmentMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for development milestone payments that are non-refundable. The 2017 Roche Agreement also included provisions that entitled the Company to receive royalty payments ranging from the mid-single digits to the mid-teens for the net sales of the licensed products, in each case subject to the reductions in accordance with the terms of the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company identified a single combined performance obligation for the license, research services and participation in the JSC and concluded that Roche&#x2019;s option did not represent a material right. The Company&#x2019;s contract with Roche did not include a significant financing component. The Company further concluded that the transaction price should not include the variable consideration related to development milestones as they were considered to be constrained as it was probable that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in the future. The Company excluded any consideration related to sales-based milestones, including royalties, which would be recognized when the related sales occur. The transaction price and estimated period of performance are re-evaluated at each reporting period and adjusted as needed to reflect changes in the scope of the project, reimbursable expenses and other conditions affecting variable consideration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the Company received from Roche notice of termination without cause of the 2017 Roche Agreement. The licenses granted by the Company to Roche under the 2017 Roche Agreement terminated in their entirety on September 16, 2021. Therefore, as of September 16, 2021, Roche no longer has a license for 4D-110 for the treatment of choroideremia or any other product class, and the Company is no longer entitled to receive any further milestones or royalties from Roche. In July 2021, the Company notified Roche of the Company&#x2019;s election to continue development of choroideremia. As a result, in accordance with the terms of the agreement, all rights to 4D-110 data and intellectual property generated under the collaboration reverted to the Company. Under the 2017 Roche Agreement, if the Company is required to initiate a new Phase 1/2a clinical trial for 4D-110, the Company would not owe any royalty to Roche on net sales of 4D-110. If, however, the Company moves directly to a pivotal trial of 4D-110, without first being required to conduct a new Phase 1/2a clinical trial, the Company must pay Roche a mid-single digits percentage royalty on the net sales of 4D-110.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a result of the termination of the 2017 Roche Agreement, an adjustment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_045e178a-da5e-4269-b282-2f7d1b9848dd" contextRef="C_62a5478f-6648-41ef-8d95-7e857719eae5" name="fdmt:CollaborativeArrangementAdjustmentToTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was made to the transaction price to reflect the decrease in reimbursable costs for the year ended December 31, 2021. The decrease in the transaction price and total budgeted costs for the remaining performance obligation resulted in an $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1d138d56-dcf7-4c37-9bfb-0ebd22566f97" contextRef="C_62a5478f-6648-41ef-8d95-7e857719eae5" name="fdmt:IncreaseDecreaseInContractWithCustomerRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million increase in revenue recognized in the year ended December 31, 2021 related to the performance obligation partially satisfied prior to January 1, 2021. For the year ended December 31, 2020, an adjustment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9c344b02-b591-4c5b-9084-ee0ef12102ee" contextRef="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0" name="fdmt:CollaborativeArrangementAdjustmentToTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was made to the transaction price to reflect an increase of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_eafeeb0e-5692-4de3-abd8-1555548a06f1" contextRef="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0" name="fdmt:CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in the scope of the project and expected reimbursable costs and the addition of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_35599517-32e7-4952-92b8-17161479664e" contextRef="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0" name="fdmt:CollaborativeArrangementAdditionOfVariableConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of variable consideration as the uncertainty associated with two development milestones was resolved. The adjustments to the transaction price and total budgeted costs in 2020 resulted in a $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c2a58457-236e-4191-a615-1c63ecfb345c" contextRef="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0" name="fdmt:IncreaseDecreaseInContractWithCustomerRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million increase in revenue recognized in the year ended December 31, 2020 related to performance obligations partially satisfied in periods prior to January 1, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the years ended December 31, 2021 and 2020, the Company recognized revenue of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ebcb2ba1-1d65-4c2d-8d42-f5fe63308b07" contextRef="C_62a5478f-6648-41ef-8d95-7e857719eae5" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e2cca2c2-e8d6-45a0-8bab-1c73716d19c9" contextRef="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million from Roche, respectively. As of December 31, 2021 and 2020, deferred revenue relating to the Roche Agreement was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e6b4c719-df5d-46b9-99eb-e6c6cccd1033" contextRef="C_7974df26-e7b0-4ed8-86d9-17fbf7835f1a" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_11b4f6e5-2b58-4d98-bc93-5a029921eddb" contextRef="C_ee124165-31e9-4e1d-8df3-5e051998cafd" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5">14.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. Accounts receivable from Roche under this agreement as of December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_acd2c390-cb2b-4158-a132-527f3ab2de40" contextRef="C_7974df26-e7b0-4ed8-86d9-17fbf7835f1a" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bc4fe13c-c5df-4196-842e-193f3a8487de" contextRef="C_ee124165-31e9-4e1d-8df3-5e051998cafd" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4840b47f-dfb6-450d-84ae-a6ffa49b4059" contextRef="C_7974df26-e7b0-4ed8-86d9-17fbf7835f1a" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1ee36f20-2ec5-4623-85b1-ce74bd4e0053" contextRef="C_ee124165-31e9-4e1d-8df3-5e051998cafd" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5">25.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CFF</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In September 2016, the Company entered into an award agreement for the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program with CFF, a non-profit organization dedicated to finding a cure for cystic fibrosis, an inherited disorder that causes disease in the pulmonary airways leading to morbidity and mortality. Under this agreement, CFF contributes funding to help advance the Company&#x2019;s CF research program. The agreement was subsequently amended in September 2017, August 2018 and February 2021 (all four agreements are collectively referred to as the &#x201c;CFF Agreement&#x201d;). The total amount of the award under the CFF Agreement is $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ec0017c0-21b7-4f93-b355-f7953dab236d" contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5">3.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. As of December 31, 2021 and 2020, the Company achieved milestones totaling $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_20a801fb-0f30-40b6-9620-329f76b43c9b" contextRef="C_d34de791-bc33-4d58-b8e1-f57a6ba20191" name="fdmt:CollaborativeArrangementAchievedMilestones" unitRef="U_USD" scale="6" decimals="-5">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8e534614-2d73-4e1a-9101-a6a352a38a9e" contextRef="C_067e587d-dfef-4587-ad79-844c454aeb5e" name="fdmt:CollaborativeArrangementAchievedMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million under the CFF Agreement, respectively. The remaining award amount will be paid by CFF based on achievement of certain development milestones by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company expects to make payments to CFF equal to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_ae6a1cea-4dc5-429f-b6df-a8af5d5155a4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">six</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> times the actual award received by the Company in </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_54b939ab-17e8-4113-8a78-cd314b453408" contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d" name="fdmt:NumberOfInstallmentsToPayActualAward" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> installments within the first </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_16a62b7d-6633-4ac4-a53e-8b745e5bd40f" contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d" name="fdmt:ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of the first commercial sale of a product developed under this agreement. The Company also has agreed to make future sales-based milestone payments to CFF of up to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_55f2fc27-7ef4-4149-a482-d2ca9293554a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> times the actual award received upon achieving specified commercialization milestones with respect to the first of any product developed utilizing any compound covered under the CFF Agreement. The CFF Agreement also requires the Company to pay to CFF royalties of a mid-single digit percentage, up to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_ebac0ee9-675f-4dde-a1fd-3d4097e446f6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">six</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> times the actual award received, on any amounts received by the Company from the sale, license or transfer to a third-party of rights in the technology developed as a result of this collaboration. Any such royalty payments shall be credited against the payments owed by the Company upon first commercial sale. In the event of a change of control of the Company, CFF will receive certain payments, depending on the timing of the change of control and the size of the transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To date, the Company has not developed a commercial product in connection with the CFF Agreement, and it has not licensed, sold or otherwise transferred to another party the product developed under the CFF Agreement or the underlying technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If at any time prior to the first commercial sale of a product developed as a result of the CFF Agreement, the Company ceases to use commercially reasonable efforts to develop or commercialize any product under the CFF Agreement for a continuous period of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_21d691c5-9ef9-4aa2-82e2-0fe3a5c32434" contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d" name="fdmt:ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">180</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> consecutive days and fails to present a reasonable plan to resume commercially reasonable efforts, the Company will grant to CFF an irrevocable, exclusive worldwide interruption license under all of the Company&#x2019;s interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under ASC 606, the Company identified one performance obligation within the CFF grant agreement for research activities. The Company&#x2019;s contract with CFF does not include a significant financing component.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company concluded that the transaction price should not include the variable consideration related to future research milestones as they were considered to be constrained as it is probable that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in the future. The Company re-evaluates the transaction price and estimated period of performance at each reporting period. For the year ended December 31, 2021, an adjustment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7b9a1e31-c89d-4599-9491-e3ecec645de2" contextRef="C_d34de791-bc33-4d58-b8e1-f57a6ba20191" name="fdmt:CollaborativeArrangementTransactionPriceAdjustment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was made to the transaction price to reflect the achievement of the fourth milestone related to demonstrating GFP expression and determining a cell specific expression profile in human and NHP upper airway ALI cultures following apical transduction under the CFF Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the years ended December 31, 2021 and 2020, the Company recognized revenue of  $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f39a574e-cccd-44ee-a928-67f6f5800b02" contextRef="C_d34de791-bc33-4d58-b8e1-f57a6ba20191" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1d3606c1-bcdd-43bd-b69a-dc8e6022d176" contextRef="C_067e587d-dfef-4587-ad79-844c454aeb5e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">) million, respectively. As of December 31, 2021 and 2020, deferred revenue relating to the CFF Agreement was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e5e1b3a1-5de2-4d25-9a89-baebcb56c79a" contextRef="C_1001d586-4a93-4bdd-bca8-c247e6d58d1e" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c76260f4-db2f-47af-8e72-c69c6eed6dc4" contextRef="C_4a794422-dee1-4707-8185-703c70506d97" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. Accounts receivable from CFF under the CFF Agreement as of December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_149c6150-1ec6-4319-a0a6-0bd5074f9c2b" contextRef="C_1001d586-4a93-4bdd-bca8-c247e6d58d1e" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e5d18d0e-775c-4bf0-ac07-f3b9f65f31d6" contextRef="C_4a794422-dee1-4707-8185-703c70506d97" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_89f5f052-4365-4b8b-9abe-a79e4cdef12d" contextRef="C_1001d586-4a93-4bdd-bca8-c247e6d58d1e" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ff381a6a-0ed5-475e-b0c8-1b0fb83d274d" contextRef="C_4a794422-dee1-4707-8185-703c70506d97" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. Based on current timelines, the deferred revenue is expected to be recognized as revenue over the next </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_6a54b9ee-b4de-4717-a1a2-a0f99f73deb0;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_5dad5432-6235-4f6d-b59d-c2c3bc02404a" contextRef="C_b4e47e36-ad9e-4007-bb25-cc82fae064e6" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> as the Company performs research services through the completion of IND-enabling studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The obligation to make payments to CFF upon a change of control meets the definition of an embedded derivative that is required to be bifurcated and separately accounted for as a derivative liability. See Note 16 for further discussion of the embedded derivative.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_b0f29c8d-e2e6-4bac-9c12-c8d77ba7ef47" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:LicenseArrangementsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">8. License Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has exclusive, worldwide license agreements (the &#x201c;UC Agreements&#x201d;) with the Regents of the University of California (the &#x201c;UC Regents&#x201d;) relating to the use of certain patents and intellectual property surrounding its core technologies, including Therapeutic Vector Evolution. Pursuant to each of the UC Agreements executed prior to January 2019, the Company was obligated to pay a (i) non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6d187497-f3c7-4faf-a0f6-14f971a18fbe" contextRef="C_cc9158f0-cc85-4a61-9faf-16e23bce0c56" name="fdmt:NonRefundableLicenseFeePayableUponExecution" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> upon execution, (ii) a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_06c07edf-49ee-4f7d-8b43-0d6eb95b8b38" contextRef="C_cc9158f0-cc85-4a61-9faf-16e23bce0c56" name="fdmt:NonRefundableLicenseFeePayableEveryYearAfterExecution" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents, (iii) reimbursement of domestic and foreign patent filing, prosecution and maintenance fees, and (iv) either $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_45380fa2-e155-4f73-a2ea-5df730d35bf9" contextRef="C_cc9158f0-cc85-4a61-9faf-16e23bce0c56" name="fdmt:AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> or issuance of a </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b0e8f5e4-e08b-48cf-bf69-a9d35ef8eb42" contextRef="C_cc9158f0-cc85-4a61-9faf-16e23bce0c56" name="fdmt:PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption" unitRef="U_pure" scale="-2" decimals="2">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% equity interest in the Company upon the closing of the first qualified financing at the option of the UC Regents. The Company&#x2019;s first qualified financing occurred in 2015 and at the election of the UC Regents, the Company issued the UC Regents in January 2016 an amount of common stock equal to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7af32fc2-7432-45ab-8077-78e611c5043d" contextRef="C_b7f143b1-ffa9-4263-bc77-01c55254624d" name="fdmt:PercentageOfEquityInterestsIssuedAsCommonStock" unitRef="U_pure" scale="-2" decimals="2">6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the equity interests in the Company pursuant to the applicable clause in each of the UC Agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to an agreement with the UC Regents executed in January 2019 the Company paid a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b5858459-8280-408f-808c-9d2ee8279148" contextRef="C_47f11691-274e-42ed-9d35-7150a1a1bafe" name="fdmt:AmountsPaidNonRefundableLicenseFees" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_94170475-5ebe-4a1f-8859-988a0eee0f75" contextRef="C_47f11691-274e-42ed-9d35-7150a1a1bafe" name="fdmt:AmountObligatedToPayNonRefundableLicenseFeeAnnually" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> on the one-year anniversary of the contract effective date and each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8dda1be6-1f92-4b9b-b801-41052de7f133" contextRef="C_aaf1e58d-3b1c-4821-9e56-aaa8b373ab63" name="fdmt:DevelopmentMilestones" unitRef="U_USD" scale="6" decimals="INF">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, (ii) low single digit royalties on the net sales of its developed products that consists of a minimum annual royalty of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_98ee2840-e3dd-4f77-97a7-67b97ed12e24" contextRef="C_bbcc2364-ba79-4bc4-b41b-1b1dc9a8eede" name="fdmt:AnnualRoyalty" unitRef="U_USD" scale="6" decimals="INF">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million per year for the term of the Agreement beginning in the first calendar year after the year in which net sales first occurred, and (iii) sublicense consideration in the mid-teens to the mid-twenties-range on any future sublicensing arrangements the Company may enter into with third-party licensees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In July 2021, the Company entered into an exclusive license agreement with the UC Regents and the Trustees of the University Pennsylvania to license intellectual property related to certain vectors. In July 2021, the Company paid a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_83750204-8583-4a51-ad60-30ddbd7dfe72" contextRef="C_b92a1f3f-887c-4ea7-a989-5b92852b7259" name="fdmt:AmountsPaidNonRefundableLicenseFees" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">100,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license maintenance fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e95c3816-4630-45d9-a62f-3b84b33e3728" contextRef="C_b92a1f3f-887c-4ea7-a989-5b92852b7259" name="fdmt:AmountObligatedToPayNonRefundableLicenseFeeAnnually" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> on the one-year anniversary of the contract effective date and each year thereafter, except years for which the Company has paid royalties on the net sales of a licensed product. In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a25ce4a3-d176-4aa9-8432-2f01122204c7" contextRef="C_485d52ae-2831-49f8-b4f8-3e103c72940b" name="fdmt:DevelopmentMilestones" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">3.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, (ii) low single digit percentage rate royalties on the net sales of its licensed products that consists of a minimum annual royalty of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4dfed9be-8669-4789-a977-c2ad06332087" contextRef="C_00c84e7f-1487-4fcb-b57c-626e653667be" name="fdmt:AnnualRoyalty" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million per year for the term of the Agreement beginning in the first calendar year after the year in which net sales first occurred and (iii) sublicense consideration in the mid-single digits to the low twenties percentage rate range on any future sublicensing arrangements the Company may enter into with third-party licensees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the years ended December 31, 2021 and 2020, the Company incurred expenses of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1a88edb7-a1b8-49cc-b9d4-119f57aae794" contextRef="C_bcb74483-fa99-4ee5-a6ea-6a4843de5d40" name="fdmt:IncurredExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6ef6f1df-d176-47e8-951b-a28abf0120f3" contextRef="C_71c68b91-969e-469a-ac31-ed7554ddc8fc" name="fdmt:IncurredExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, under the provisions of the outstanding license arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_9b2a5aa3-d027-4c8f-97cd-a0f2660d40a6" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">9. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Operating Lease Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the adoption of ASC 842, the Company recognized rent expense for its operating leases on a straight-line basis over the noncancelable lease term and recorded the difference between rent payments and the straight-line rent expense was recorded as a deferred rent liability. As of December 31, 2020, the Company performed an evaluation of its other contracts with customers and suppliers in accordance with ASC 842 and determined that, except for the leases described below, none of the Company&#x2019;s contracts contain a material lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">5980 Horton Street Building Lease</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In May 2015, the Company executed a lease agreement for office and laboratory space in Emeryville, California. In January 2016, the Company executed the first amendment to the lease agreement for additional rentable office and laboratory space which extended the lease term to </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_512ed984-a676-4540-9b0f-1f26dd34fa27" contextRef="C_9a196306-24e0-483e-8634-0a715c3d21e0" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 31, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and updated the option to renew the lease at market rent from the prior additional term of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_c5eac9d3-379b-4226-ab04-ab746879c995" contextRef="C_a504b7f3-7605-46fc-8597-53b18af6a1d1" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_8019d16d-a0ad-4207-8c22-af641cdb0936" contextRef="C_68843b0d-f738-4525-bbf0-8acf1ea83427" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. In October 2018, the Company executed a second amendment to extend the lease to </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_b70744d4-5b3c-4188-8438-d328a427f269" contextRef="C_5b1c1ec5-d872-44ae-8bb5-78aa34f73511" name="fdmt:OperatingLeaseTermExtendedExpirationPeriod" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">September 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Additionally, the second amendment provided a tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_663b1d4f-27de-4cbb-8951-fa4d001b3d5e" contextRef="C_4fafc5e1-de72-42ab-a39e-911d607b5701" name="us-gaap:PaymentsForTenantImprovements" unitRef="U_USD" scale="6" decimals="-5">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which was paid to the Company in November 2018.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The 5980 Horton Street Building Lease is considered an operating lease under ASC 842 as it does not meet the criteria of a finance lease. As of December 31, 2021, the operating lease right-of-use asset and operating lease liability was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e5e52f91-2fba-4d50-bc54-51a34279db67" contextRef="C_6c273596-2f89-4f1e-8401-1a71be26008e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dde76680-63b8-463c-ac54-646be6db78bd" contextRef="C_6c273596-2f89-4f1e-8401-1a71be26008e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. The discount rate used to determine the lease liability was </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e5c0aead-7561-4e73-abdf-d14351675cee" contextRef="C_6c273596-2f89-4f1e-8401-1a71be26008e" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">5858 Horton Street Building Lease and Expansion</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2018, the Company executed a second lease agreement for additional office and laboratory space in Emeryville, California. </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_b783d2e6-4887-4e59-9cc5-e6bcb35c29ca" contextRef="C_e1dda0de-9512-4575-b09e-7dc96d5fda59" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The new lease has an initial term of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_981b6188-1663-4e7b-846f-616cbc5bf3d6" contextRef="C_156eea03-1e5f-4d20-bdd5-c6922ae709bd" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">87</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> months beginning on the rent commencement date with the </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_6b5d5b95-995e-42ae-b8b0-eae77b551c08" contextRef="C_6b9c4496-5f5c-4b08-a9c6-6e3811f8ebe6" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">option to renew</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> the lease for one additional term of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_cc3e33b1-5198-402b-9d22-db74b655531b" contextRef="C_156eea03-1e5f-4d20-bdd5-c6922ae709bd" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> at market rent. </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company did not have to pay rent until October 2019. This lease agreement also provided for a tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dde7ced3-6273-4875-b1ea-c1eb62fc61dd" contextRef="C_3b2169b0-5a83-4d78-862e-5aacb257dffc" name="us-gaap:PaymentsForTenantImprovements" unitRef="U_USD" scale="6" decimals="-5">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which was paid to the Company in December 2019. The Company amortizes the tenant improvement allowance on a straight-line basis over the remaining term of the lease as a reduction of rent expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In May 2019, the Company amended the second lease agreement executed in October 2018 to add additional office and laboratory space (the &#34;Expansion&#34;). The amendment extended the term of the lease to December 31, 2029. The Company did not have to pay rent until December 2019. The lease agreement also included a tenant improvement allowance, which was increased to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a31d4b82-8121-45ca-b189-385c89d1c3ae" contextRef="C_a5af98ab-cbe3-47d9-a7e7-15b8be38cf21" name="us-gaap:PaymentsForTenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in February 2021 pursuant to a second amendment to the second lease agreement. In November 2021, the Company received the first installment of this tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_840c1ffc-e82a-42d5-ac69-68e84567fa1a" contextRef="C_cdd81399-daf3-42e2-bc69-e7aaf154c086" name="us-gaap:PaymentsForTenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The tenant improvement allowance funds improvements to the additional office and laboratory space, which the Company has determined to be lessee owned. The allowance is treated as a reduction of lease payments used to measure the lease liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The 5858 Horton Street Building Lease and Expansion is considered an operating lease under ASC 842 as it does not meet the criteria of a finance lease. As of December 31, 2021, the operating lease right-of-use asset and operating lease liability was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_eb80e1a9-4743-4bc1-92b8-0f249e024730" contextRef="C_b4b6884a-ce1d-4bbf-9756-4c19b608736e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5dede44c-b1dc-4943-9282-e180338b95e8" contextRef="C_b4b6884a-ce1d-4bbf-9756-4c19b608736e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. The discount rate used to determine the lease liability was </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4b3c73f4-0c10-4dcb-a80a-8b1136b6011e" contextRef="C_b4b6884a-ce1d-4bbf-9756-4c19b608736e" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total operating lease expense for the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_60dff6bc-f09e-4bd5-8bb2-835a1160da55" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. Cash paid for amounts included in the measurement of lease liabilities was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ca7dd366-656d-42e4-896e-f3a8c7a81842" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the year ended December 31, 2021.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Neither of the leases include a general option for the Company to terminate the leases.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_920c49b0-f0be-480b-88c8-aef07c35dc8a" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the components of lease expense for the year ended December 31, 2021, which are included in operating expenses in the Company&#x2019;s statements of operations (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.996%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:20.34%;"></td>
        <td style="width:0.78%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ef6cee05-aeda-43bd-be7b-101434b7b0e6" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,631</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_49dce5b4-d1b4-4c37-843b-5571a1045de6" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">914</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_43b94020-5236-43ed-a070-b7a843e7ec80" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,545</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Variable lease payments include amounts relating to common area maintenance and are recognized in the statements of operations as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_64377ffd-064c-430a-9d1b-bf2f03744d47" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes supplemental information related to operating leases for the year ended December 31, 2021:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.004%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.998%;"></td>
        <td style="width:18.536%;"></td>
        <td style="width:2.457%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average remaining lease term (in years):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_943e8fb4-225d-4fb1-bc5a-9a8fe0b43609" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average discount rate:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c192ff88-e188-4180-b0a6-4d62572fff3b" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_a2870369-0371-4ac0-a239-310ab7a95696" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the maturities of lease liabilities as of December 31, 2021 (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.996%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.538%;"></td>
        <td style="width:20.543%;"></td>
        <td style="width:0.919%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_471209be-32b3-4f8b-9ef8-6db6cfc161a9" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,230</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6cdeda0f-2acb-4a66-8f14-5a3352205151" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,058</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6d0c68f4-a4f5-4338-9135-d08a20b9162a" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2b5d867d-100c-4015-abf2-3eec68c317dc" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5b34a016-8184-46ff-96e7-24be2500f296" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,135</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_572f979e-faf6-466a-a5cf-c516166e304d" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,686</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c7b4faf0-f78d-4862-bdea-69f213df6396" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: Amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bd0558df-510e-4edd-81b5-3079f091b1e2" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,054</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1546f684-c45b-4fb6-a03c-2abe02eb0ae9" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,448</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: Current portion of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9bc9f3b1-ab11-4a22-bba1-faad915e3d60" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,231</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Long-term portion of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5142529a-c1b9-4b2f-a4b3-cf12b2e23908" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Indemnification Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions, such as with vendors and other parties. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently maintains directors&#x2019; and officers&#x2019; liability insurance that would generally enable it to recover a portion of any future amounts paid. The Company believes the estimated fair value of its indemnification agreements in excess of applicable insurance coverage is not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Legal Proceedings</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. There are no material legal proceedings outstanding at December 31, 2021.  See Note 14 for details of a settlement with a former employee in April 2021.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_1844990d-6eb5-4b0c-b17c-31545d840c2d" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">10. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6e121d45-1019-4ada-99e3-ce7d54debfe1" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_68bcae6c-40a3-4a5d-bc79-3bcd2bb3a85a" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t record any income tax expense during the years ended December 31, 2021 and 2020. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company&#x2019;s ability to realize these assets. All losses before income taxes arose in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_cec1d1ab-26df-4adb-abc9-fa0b5724938d" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The effective tax rate of the Company&#x2019;s income tax expense (benefit) differs from the federal statutory rate as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.429%;"></td>
        <td style="width:1.563%;"></td>
        <td style="width:0.76%;"></td>
        <td style="width:11.297%;"></td>
        <td style="width:3.384%;"></td>
        <td style="width:1.563%;"></td>
        <td style="width:0.76%;"></td>
        <td style="width:11.297%;"></td>
        <td style="width:3.384%;"></td>
        <td style="width:1.563%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_81f64c70-6f6f-4377-9082-7ad6cb5753bb" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a93ec866-2d29-40d3-ba09-8ba416800945" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research tax credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_354c2613-7e65-4d19-9faa-5ec38e534c38" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ffe8ece5-4926-459a-87e4-dfd5182ecdfb" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3">2.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a88ca701-2786-42a8-bf6b-041a2914cd91" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ed2aea53-7465-47ea-866d-888cdce312a5" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-">1.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6e5ad598-8086-4ca6-9232-66b5b3263fe0" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">23.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4a220096-9315-45b1-85bc-090d86919ee6" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-">22.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bdd83099-c679-4806-95d8-9c48cdfe2957" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0fff3ebf-6cf6-4787-af0c-a5cdf02b5a9a" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">28</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_ee9df346-49a7-46dd-b246-a0a59b76b1bf" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The tax effects of temporary differences that give rise to significant components of the deferred taxes are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.081%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:12.912%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:12.912%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Deferred Tax Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bf4c4b95-f618-4643-9ef3-c5920f25c41a" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_46cc3001-e2af-4283-a5e7-760fbcec2867" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,132</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f67e5cdd-9d15-4b86-829f-6e2e2c1d7483" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d17427a3-ac44-4cd2-ad96-5ef0416a6235" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1a30dfe8-b40c-4dbe-9a34-7ae763b51027" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">993</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1da83b6e-0c59-41ad-b9a3-b495524ad9d1" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,111</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_adc4195a-e627-4717-92fb-00338f557329" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,078</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ea914ef5-d076-4bdf-aa0f-43954da85d01" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,018</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4234f2ca-6452-40ad-b541-30f72f9dbee2" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a1351eab-56e9-4cac-94ad-84bb24d7150f" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Intangible asset basis</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0ed4c5f2-5c79-44d6-9fb8-7ccde2e2b3e1" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">907</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c6d52395-f8e9-42dc-a804-48668350fe6c" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">977</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c107e1ba-4445-443e-921d-40548857d7bd" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="fdmt:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,460</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e211ea3d-36bc-4893-8db8-36f116851f78" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,288</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b9e5b6fd-804e-4a05-9ae3-bc047ad7632b" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,811</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Deferred Tax Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ac748a02-2e95-4c50-8c50-14090fd9defb" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="fdmt:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,064</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6fea1618-a8d7-4865-b223-6ca2ff9796fd" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">992</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6bfcdfe3-2ede-4523-9420-d898ce545feb" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,056</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b3485fd6-9cc3-46fa-8b83-121457e2d946" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,232</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_69943c47-909c-4b2d-b2a1-5aae5395d830" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,811</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total net deferred tax</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Income Taxes,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#x2019;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ba3e45e4-c843-4a03-b565-b757ccb365cd" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million during 2021 and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3bc8955f-1ca2-4635-a50d-c9268b6701cf" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million during the year ended December 31, 2020. The increase in the valuation allowance for each of the years ended December 31, 2021 and 2020 was primarily driven by net losses incurred, stock-based compensation expense and tax credits generated within the U.S.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company had net operating loss (&#x201c;NOL&#x201d;) carryforwards of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_213e6572-891f-4bc6-ab50-80acdb31db3e" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">177.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_538d6b66-6a1f-4e6c-8220-59523b6dafb1" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as of December 31, 2021 and 2020, respectively, available to reduce future taxable income, if any, for federal income tax purposes. $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4dc0a330-8513-4d4a-a447-80e2e7ec2261" contextRef="C_da1fd0ee-2a34-41fc-9e75-f7316c4ea264" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of the federal NOL carryforwards expire in </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_6add8906-6c62-4b1f-a4eb-63af932bc43a" contextRef="C_3af24779-857a-4d8c-8ca2-daaa220bb8ed" name="fdmt:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2037</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and the remaining $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0c8ac0d4-a356-4ef8-baa9-c75f74235c39" contextRef="C_da1fd0ee-2a34-41fc-9e75-f7316c4ea264" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">168.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million carryforward indefinitely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">29</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021 and 2020, the Company had federal research and development credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0ae6d2c6-c363-4d4e-952c-19b79577b4c1" contextRef="C_da1fd0ee-2a34-41fc-9e75-f7316c4ea264" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fb6d18e2-a296-4237-b43f-5e07e6c6407e" contextRef="C_a7b36ed3-eaae-482f-82c3-37d423f79c62" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, and state research and development credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c4d61fe1-6511-4d6e-9e38-a78ee90130b4" contextRef="C_3efe0308-17fb-42e4-98f2-745c68439aa1" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d97da949-d676-433b-946e-0da846a6d48b" contextRef="C_49564e79-c36e-4c78-aae6-91ada470dc34" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. The federal credit carryforwards begin expiring in </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_fcb9177c-acaa-4e8b-bdb3-ab21a0719493" contextRef="C_3af24779-857a-4d8c-8ca2-daaa220bb8ed" name="fdmt:TaxCreditCarryforwardBeginningExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and the state credits carryforward </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_749f4c31-27ad-4bfc-b161-87102a3a8004" contextRef="C_0befc9ee-bbe3-4743-91fb-e5d8d3675f92" name="fdmt:TaxCreditCarryforwardExpirationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">indefinitely</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Utilization of the NOL carryforwards and research credit carryforwards may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in the expiration of the NOL and tax credit carryforwards before they are utilized. The Company has experienced ownership changes in the past as a result of its Series B redeemable convertible preferred stock financing. As a result of the ownership changes, some of the tax attribute carryforwards may be permanently limited as they will expire unused and such amounts are excluded from our NOLs as of December 31, 2021. Subsequent ownership changes may result in additional limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_9a4315ba-6950-4ad5-9ffb-ff354bbf877e" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The reconciliation of the beginning and ending unrecognized tax benefits amounts is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.722%;"></td>
        <td style="width:1.927%;"></td>
        <td style="width:1.542%;"></td>
        <td style="width:16.039%;"></td>
        <td style="width:0.771%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Unrecognized<br />Income Tax<br />Benefits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cc0709f7-adef-4c4c-a506-ebd855713b0a" contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,566</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for current year tax positions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_70a8f81b-7711-40aa-a6b5-764bd1fd3a8d" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,729</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for tax positions of prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9292fffd-8152-41b4-8807-c66c71ab7b26" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cd410d17-8ea1-4990-aca8-8332de9d367e" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b1666a41-061d-4574-abac-2695459aba6a" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,219</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for tax positions of prior years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b227918f-8816-4acb-bd6c-f22d83bee72f" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6d4fa379-c897-410b-9cbd-d7b897516feb" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,586</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The entire amount of the unrecognized tax benefits would not impact the Company&#x2019;s effective tax rate if recognized. During the years ended December 31, 2021 and 2020, the Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_553c5206-d5b0-4a1e-b032-f337bee1c918" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c42afef0-1e6c-45ea-ba4f-f59cc4b0a81f" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will materially increase or decrease during the next 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company files income tax returns in the U.S. federal and California tax jurisdictions. In general, the Company is no longer subject to tax examination by the Internal Revenue Service or state taxing authorities for years before 2017. Although the federal and state statutes are closed for purposes of assessing additional income tax in those prior years, the taxing authorities may still make adjustments to the NOL and credit carryforwards used in open years. Therefore, the tax statutes should be considered open as it relates to the NOL and credit carryforwards used in open years. The Company has no ongoing income tax examinations by tax authorities at this time.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was signed into law. </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_ed8f9a8f-0481-4321-b5cf-b39baab1990b" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:CARESActReliefDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The CARES Act changed certain provisions of the Tax Act. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminated the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021 and increased the amount of interest expense that may be deducted to 50% of adjusted taxable income for taxable years beginning in 2019 or 2020.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> The Company evaluated the impact of the CARES act on its tax provision and concluded that there was not a material impact.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On December 21, 2020, the U.S. president signed into law the Consolidated Appropriations Act, 2021 which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant. The Company evaluated the impact of the Consolidated Appropriations Act, 2021 on its tax provision and concluded that there was not a material impact.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On March 11, 2021, the American Rescue Plan Act was signed into law and contained provisions relating to extending the Employee Retention Tax Credit, additional funding for the PPP loan and Economic Injury Disaster Loans, as well as expanding the covered employees under Section 162(m) for tax years beginning after December 31, 2026. The Company does not expect the American Rescue Plan will have a material impact to its current income tax provision.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On November 15, 2021, the Infrastructure Investment and Jobs Act was signed into law and contained several tax provisions including changes to the Employee Retention Tax Credit after September 30, 2021. The Company does not expect the Infrastructure Investment and Jobs Act will have a material impact to its income tax provision.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_9be8fbde-8236-49d1-9c0a-b7b35f4e84f6" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:TemporaryEquityDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">11. Redeemable Convertible Preferred Stock</span></p><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_9bed7306-e8ac-47f6-9b61-3a810db78a9e" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:TemporaryEquityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2019, redeemable convertible preferred stock consisted of the following (in thousands, except per share and share amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:14.981%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:12.006%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.541%;"></td>
        <td style="width:11.985%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:16.982%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.541%;"></td>
        <td style="width:11.996%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:2.675%;"></td>
        <td style="width:14.446%;"></td>
        <td style="width:0.781%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Shares<br />Authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Original<br />Issuance price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Shares Issued<br />and Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Liquidation<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Proceeds Net of<br />Issuance cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_90347b89-3ed1-42e4-ac8f-1893c7636f44" contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">909,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fdc45cf8-0289-4e83-a98d-9f3de404a82e" contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">7.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f82b029d-ec64-40cf-a0c7-68ec0f3b0a25" contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_3501e2fe-8c6e-4915-b0bc-36f78d6cdd54" contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">909,312</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dbc7d53a-dde8-4c4e-9ad7-f4fac87bb4a4" contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,001</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0d00704b-eb8f-4ec2-9b1a-25ddcdf36bb6" contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,960</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Series A-1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_45599f15-b200-4f20-aec8-8de31392f6dd" contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,311,687</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b4e1ff7e-0cb2-4681-8919-cfd17e3ee577" contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">8.84</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2ad1f5ef-d8b6-4b7a-83ba-e05ce7d8acfa" contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_495b6c7b-c270-4b49-a489-0d7a3af8a7d6" contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,311,687</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ee77f994-d63e-43b1-b4f3-f7c14f2c676a" contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6aaaca1f-eeeb-4246-a1bc-f462836a6a1f" contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,548</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Series B</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0ca8d32d-4d91-40e0-857e-ab8f94729d48" contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,154,639</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5c69965b-d250-441e-9c4f-cb3aa92f567f" contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">17.46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a74128ef-2fc6-456c-8ea5-c8ffd5b0ed99" contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_155fb8a1-fefa-442d-ac5b-b7d4797692e8" contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,154,632</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d5d6856a-474e-441f-be30-529ec96240d5" contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_661ab383-328e-4013-8bd8-a61e684803b3" contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,472</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d6867444-bf83-4ad5-bdfe-c21b55f4f7ef" contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,375,638</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_35a4b7af-742c-417f-80ab-bfc334fded49" contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_8e81bef4-5659-477b-974a-023613db582f" contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,375,631</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_03701b7d-da35-4fee-94c5-686428f73e66" contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,596</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e37777d5-0d12-4dfb-9859-2d908ffc1df5" contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April and June of 2020, the Company issued a total of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fa2d0b54-42b7-4d16-b63e-e9367c167d4f" contextRef="C_893705a7-019f-4880-8fba-130e464feaa6" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,200,353</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series C redeemable convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8dfdcedb-406d-40ab-aea8-a06c5db22731" contextRef="C_893705a7-019f-4880-8fba-130e464feaa6" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">18.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for net proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d4110d5e-701c-4e0c-a0a3-981a9672d63d" contextRef="C_b20ba5e2-9962-466b-938b-74b85690f0f0" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">72.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. Upon the closing of the Company's IPO on December 15, 2020, all outstanding redeemable convertible preferred stock automatically converted into shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. There were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f3739e33-d3f4-4f2b-8774-6c87ccd17eea" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9e6231ea-e398-4095-b6a1-1e695c8b0912" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of redeemable convertible preferred stock outstanding as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Funding Agreement with CFF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2014; In April 2020, CFF made a $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4bcdc944-bc1e-4513-a2f8-d2442cf15ffd" contextRef="C_40669389-a7ad-4950-93fb-0a77d4c10a4c" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million investment in the Company's Series C redeemable convertible preferred stock financing. In return for the investment, CFF received shares of Series C redeemable convertible preferred stock, and the Company and CFF entered into a Funding Agreement (&#34;the Funding Agreement&#34;). Pursuant to the terms of the Funding Agreement, except in the event of a technical failure, the $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_73c30aa9-1063-406e-8e7c-552912ece342" contextRef="C_40669389-a7ad-4950-93fb-0a77d4c10a4c" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million received from CFF will be used to advance the development program for 4D-710, the Company's lead product in cystic fibrosis, or any other therapeutic approved by the Program Advisory Group (&#34;PAG&#34;) to alleviate pulmonary complications of cystic fibrosis (&#34;the Funding Agreement Product&#34;).</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CFF committed to provide an additional $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a85bef32-742b-4851-b99c-fc60ea6fb2e7" contextRef="C_5d804358-02f5-4c3e-b83a-38d656050858" name="fdmt:AdditionalFundingCommitted" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of funding upon acceptance of an Investigational New Drug (&#34;IND&#34;) application or its equivalent to allow for human testing of the Funding Agreement Product (&#34;Acceptance&#34;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The IND was cleared by the U.S. Food and Drug Administration in October 2021, and CFF made the additional investment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e0d9a29f-d089-431d-964a-038512ff5420" contextRef="C_20cd7796-d782-44fd-9c7c-a0d741c85cea" name="fdmt:AdditionalInvestmentInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in cash for the issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2e9f1b3d-a50c-4a9b-b83e-aa283999c35f" contextRef="C_963e934f-bc6b-4dc6-a918-158ec67c6212" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">125,715</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock to CFF.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">31</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Except in the event of a technical failure, the Company is committed to providing an amount equal to the funding provided by CFF to be used solely to advance the Funding Agreement Product. A technical failure is defined as a determination by the Company, after consultation with and approval of the PAG that (i) the Funding Agreement Product has failed to reach its intended endpoints due to safety issues, lack of sufficient transgene expression and/or efficacy, each despite commercially reasonable efforts and (iii) the exercise of further commercially reasonable efforts is unlikely to correct such failure. Under the terms of the Funding Agreement, neither the $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_157ea075-404c-4a49-8d91-c9be59ca797b" contextRef="C_40669389-a7ad-4950-93fb-0a77d4c10a4c" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million investment in the Series C redeemable convertible preferred stock, which converted to common stock as of December 31, 2020, nor the $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_afedce41-1e99-4b54-84a9-edc96f25b09b" contextRef="C_5d804358-02f5-4c3e-b83a-38d656050858" name="fdmt:AdditionalFundingCommitted" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of funding upon Acceptance are restricted as to withdrawal or usage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_e4367f43-6b98-408c-9632-981eb7837618" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">12. Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of each of December 31, 2021 and 2020, the Company&#x2019;s certificate of incorporation authorized the Company to issue </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1b48eaee-274c-48b6-9f49-38b47b262447" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_1faac0f2-2b25-4eb9-89fa-5483a626a81e" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock, at the par value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3835f731-dbaf-43f6-9953-797a2863a48a" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_635ea2bf-8a3e-426b-94ec-74205487d6dd" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share. The holder of each share of common stock is entitled to </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_6c1d29ac-cbb0-40c0-b696-92d096d0891d" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one vote per share</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Common stockholders are entitled to dividends if and when declared by the board of directors, subject to the prior rights of the redeemable preferred stockholders. As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d890d2ac-436a-4287-843f-f12cfc667cd2" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:DividendsCommonStock" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e4097c81-3392-4867-bfbd-757a3d58458b" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:DividendsCommonStock" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> dividends on common stock had been declared by the board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_df8237d6-e583-4b1d-9b83-56325f48cbc6" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:ScheduleOfCommonShareReservedForFutureIssuance" escape="true" continuedAt="F_df8237d6-e583-4b1d-9b83-56325f48cbc6_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021 and 2020, the Company has reserved common stock, on an as-converted basis, for future issuance as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:continuation id="F_df8237d6-e583-4b1d-9b83-56325f48cbc6_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.356%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:13.674%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:0.771%;"></td>
        <td style="width:13.674%;"></td>
        <td style="width:0.771%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock under the 2020 Equity Incentive Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_58f70912-13ae-4a98-82c5-b0aeb0a7c49c" contextRef="C_84f39b44-5422-454e-b43f-0e6094e9de94" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,690,097</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5ba942a7-c6d6-4326-a9cf-b9099d0cb8a4" contextRef="C_b47d4e9a-a1c9-42dc-ad5a-046908180aa8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,606,546</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock under the Employee Stock Share Purchase Plan</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_badac09f-5f0a-43d1-9bfc-e59f568c6961" contextRef="C_22fd50bb-c8c9-4334-a1b4-281b0e9b354f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">498,747</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_405a79d0-772f-4907-a40d-cdd7a0dc791e" contextRef="C_79e057b2-8bbb-4970-a6fe-1330e9256ec6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">252,337</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercise of options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f4711f51-d646-4188-a831-2d36c24c8c96" contextRef="C_0fd3c166-54d6-4e85-a12d-b5c2352e23fe" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,881,274</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_32e8ac8f-ebf4-40d7-a448-1f73fc7f1e3d" contextRef="C_229b1105-6f81-4be3-bc0e-35524c07bfa6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,194,113</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercise of common stock warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c271f282-2bd1-4060-9f3a-bf73de7c1d4b" contextRef="C_614c9897-40b5-49d5-891b-2e8c91231c75" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">53,669</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_343c317f-558d-455f-a684-d3272c80167a" contextRef="C_76054bca-7f31-466a-af59-aee060457d1c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">98,669</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total common stock reserved</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_40354756-5166-4581-bf96-d516d0245d0f" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,123,787</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c12c46b1-b9e0-4d06-bddd-c184664b1db9" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,151,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_76728b4c-ca3d-4490-a5b5-b52bde14682c" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">13. Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020 Incentive Award Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2020, the Company adopted the 2020 Incentive Award Plan (&#x201c;2020 Plan&#x201d;), which became effective on December 10, 2020. The 2020 Plan initially reserved </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c0574c5e-1f66-4721-954f-1548b42fe9db" contextRef="C_5f7ac562-47e8-4c80-b681-d3d1fbda0f72" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,606,546</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance bonus awards, performance stock units, dividend equivalents or other stock or cash based award granted to employees, directors and consultants of the Company. The number of shares reserved for future issuance under the 2020 Plan will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_04e86558-d168-42e0-a2f2-c02d46d0d989" contextRef="C_c922aa7a-0ebd-48c9-9a1f-066c43a04ba3" name="fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_54c129e6-b10e-482d-b547-99edbb2592b6" contextRef="C_87233471-231c-4c4b-ba05-554ef259a531" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock may be issued upon the exercise of incentive stock options. In 2021, an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0eb64582-f34d-4088-84ec-22ff84d6d3a7" contextRef="C_da9eacae-140f-4ff4-bc19-21fffcc55707" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,334,099</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock became available for issuance under the 2020 Plan, as a result of the operation of the automatic annual increase provision. All options are exercisable over a period not to exceed the contractual term of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_052bc20d-6a5a-496f-8d12-242f5cf32f87" contextRef="C_7aabaf7d-fcee-40ec-a3ce-91d93ae55155" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> from the date the stock options were issued. As of December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_13afcfda-6b6c-41a7-8dc8-381798f9bc35" contextRef="C_da9eacae-140f-4ff4-bc19-21fffcc55707" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,690,097</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares available for grant under the 2020 Plan.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Following the effectiveness of the 2020 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the &#x201c;2015 Plan&#x201d;). However, the 2015 Plan continues to govern the terms of options that remain outstanding under the 2015 Plan.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2015 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The 2015 Plan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">provided for grants of stock options, stock appreciation rights, restricted stock and restricted stock unit awards to employees, directors and consultants of the Company. As of December 31, 2021, options to purchase </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9ab9d2ce-08c0-425c-9248-4a2c60ff456b" contextRef="C_87699b30-eed2-4ea5-86f4-0a39c1e5772e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,519,217</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock were outstanding under the 2015 Plan. All options are exercisable over a period not to exceed the contractual term of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_e6d054fb-905b-4130-89d5-73e1d679f4af" contextRef="C_a55673c8-51f2-4439-9f29-f4ac123dd97d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> from the date the stock options were issued and are granted at prices not less than the estimated fair market value of the Company&#x2019;s common stock on the grant date as determined by the board of directors. If an individual owns stock representing more than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5b373e00-f692-45c3-98c9-8b6ee11c8551" contextRef="C_a55673c8-51f2-4439-9f29-f4ac123dd97d" name="fdmt:MinimumPercentageOfOutstandingSharesHeldByIndividual" unitRef="U_pure" scale="-2" decimals="INF">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the Company&#x2019;s outstanding shares, the exercise price of each share shall be at least </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_16491420-d581-4d04-a16f-f342e75a92b7" contextRef="C_a55673c8-51f2-4439-9f29-f4ac123dd97d" name="fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum" unitRef="U_pure" scale="-2" decimals="INF">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the fair market value on the date of grant.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_6a0423ad-96fb-4e69-9acd-0fe51f74d50e" contextRef="C_87699b30-eed2-4ea5-86f4-0a39c1e5772e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> additional grants will be made under the 2015 Plan, and all outstanding grants under the 2015 Plan that are repurchased, forfeited, expire or are cancelled are returned back to the 2015 Plan and are not available for grant under the 2020 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Employee Stock Purchase Plan</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2020, the Company adopted the 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;). Under the 2020 ESPP, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3c5418f8-d2d0-478e-8b65-b8b640fc96f8" contextRef="C_87f2bd8f-07bf-4e4e-8992-26041f581ddc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">252,337</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock were initially reserved for employee purchases of the Company's common stock under terms and provisions established by the Company's board of directors and approved by the Company's stockholders. The number of shares reserved for future issuance under the 2020 ESPP will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d5ed3b90-c9ca-4737-afa4-a0b781b54fb4" contextRef="C_a0611f15-32cf-4702-b60f-3cf600264460" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c4531022-101c-46e6-ab8d-8dd3388e6824" contextRef="C_26af25a4-cb52-44ca-92d6-ccc8fa01b65f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares the Company's common stock may be issued under the 2020 ESPP. On March 28, 2022, an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1fbcc6a3-c783-45da-9cb9-570a560742f7" contextRef="C_bbdb060d-8326-4e8e-bfca-89985b0ee2d1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">25,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock became available for future issuance under the 2020 ESPP, as a result of the operation of this automatic annual increase provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">   </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the 2020 ESPP the Company's employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d8115124-ebe2-40da-92cb-0dc34fd5d609" contextRef="C_5dc42fe3-b34c-426f-a35e-e9d6777af922" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2020 ESPP provides for a series of overlapping </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_590c5746-1d09-42cc-908c-46fab70f964a" contextRef="C_5dc42fe3-b34c-426f-a35e-e9d6777af922" name="fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">24-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> offering periods comprising four </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_db277b06-2014-48c1-a3d7-40bd3a2919f3" contextRef="C_5dc42fe3-b34c-426f-a35e-e9d6777af922" name="fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">six-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> purchase periods. The initial offering period under the 2020 ESPP is longer than 24 months, commencing February 15, 2021 and ending on May 14, 2023. Contributions under the 2020 ESPP are limited to a maximum of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0bca7b3e-26fe-459e-8d9d-117f96eb47cc" contextRef="C_87f2bd8f-07bf-4e4e-8992-26041f581ddc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of an employee's eligible compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_e50467e6-ed6f-4185-9c5d-2ab353119547" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the stock options activity for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.854%;"></td>
        <td style="width:0.225%;"></td>
        <td style="width:1.167%;"></td>
        <td style="width:10.332%;"></td>
        <td style="width:0.867%;"></td>
        <td style="width:0.225%;"></td>
        <td style="width:1.435%;"></td>
        <td style="width:11.274%;"></td>
        <td style="width:0.867%;"></td>
        <td style="width:0.225%;"></td>
        <td style="width:1.349%;"></td>
        <td style="width:9.251%;"></td>
        <td style="width:0.61%;"></td>
        <td style="width:0.225%;"></td>
        <td style="width:1.349%;"></td>
        <td style="width:10.632%;"></td>
        <td style="width:0.61%;"></td>
        <td style="width:0.225%;"></td>
        <td style="width:1.638%;"></td>
        <td style="width:13.03%;"></td>
        <td style="width:0.61%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Number of<br />Shares<br />Available<br />for Grant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Number of<br />Shares<br />Underlying<br />Outstanding<br />Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Weighted-<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term<br />(in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Aggregate<br />Intrinsic<br />Value<br />(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Balances at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_496c064a-a099-494d-9dcf-209ddaf9e905" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,606,546</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_c37d5d8f-2ca5-43ab-9aea-93ee955ac292" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,194,113</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_05cf165e-ee79-4098-a436-4acca00dd4cf" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.05</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_1c01fc38-cdb4-4342-9d8c-2d0768373af9" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">8.46</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9d46f5f5-fa42-4fca-8f99-5f6bf3e1896f" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_828bef5a-856c-4ab2-9522-8d019081d451" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,334,099</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_00ae9c83-ac57-4065-a641-1ba3e730372c" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,566,150</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_5ac50414-b0af-4b5f-9384-95c3d78cec3f" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,566,150</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_bc116b5e-cbca-4f75-aa4f-0ec08e36affc" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">34.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_d803e3b5-6c8a-4969-9fc1-59201e3eba24" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">563,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_1bce6bc1-0889-47b3-bbab-24852aa2b466" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">6.26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_5e17d572-2b9f-44d7-b06e-590aa839d4a2" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,324</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_d982f946-efbe-4468-b162-474a42f8c06d" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,324</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_10373e25-5cfe-41b2-8d18-e622d6d97cc0" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">36.33</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_6fc103a4-fed4-429d-bb67-ee5c4d5f1439" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">311,278</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_49c0dab8-9044-42c2-8ddb-c05cf11b1cbb" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">311,278</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_c6960332-df40-4aef-b711-dd38291e2827" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">29.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Balances at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_9659f0a8-a870-4e0d-b8c6-6931f68cd69e" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,690,097</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_62d0707b-064a-4344-bf16-426aed159729" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,881,274</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8bcd202d-61fd-4ecd-9646-76d077c4ee75" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">19.86</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_ec932bff-78c4-41e2-9c81-853571879787" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">7.97</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_f46325b0-074d-4aeb-93d1-ff4ee76778e3" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,666</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Shares exercisable, December 31,<br />&#160;&#160;&#160;2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_8fd5ac3c-0206-496c-9a2a-8f4cce32bebb" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,592,139</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_4a48654e-208e-4a09-ac09-ce7f5bfa8d58" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_07237b00-8582-4bcc-a26c-8d89bb49f05d" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">7.07</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_781a4cff-f8a7-4adf-a77f-64a1912419cb" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Shares vested and expected to <br />&#160;&#160;&#160;vest, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_ffb2923d-3435-409e-a02b-2ccd407787c7" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,881,274</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_2e016c50-ae7d-4303-8d95-133f525767d2" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">19.86</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><ix:nonNumeric id="F_5fc5a0a8-abe9-4c9f-9453-1fb21c5d4bdd" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">7.97</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"><ix:nonFraction id="F_3d17a2f5-337d-4563-b59b-b9d5f4972206" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,666</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">33</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_177f7628-9184-4ff2-a315-55fa67f4b4d2" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table is a summary of stock compensation expense for employees and nonemployees by function (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.671%;"></td>
        <td style="width:1.424%;"></td>
        <td style="width:1.541%;"></td>
        <td style="width:12.706%;"></td>
        <td style="width:0.781%;"></td>
        <td style="width:1.424%;"></td>
        <td style="width:1.541%;"></td>
        <td style="width:12.706%;"></td>
        <td style="width:0.781%;"></td>
        <td style="width:1.424%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dcfc7b83-583e-4092-8b87-1e37e299c72c" contextRef="C_e63d3fbd-6765-47dd-a387-c3545c1942c5" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,847</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_45a96e4f-8dad-4d50-b80a-32dd88c92fc0" contextRef="C_e44911fe-c20f-4f88-b1c1-84fcf30c91f4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,670</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1f138c00-c53b-49a2-8b41-71d5732a1f14" contextRef="C_649adcbd-b0e6-4117-97c9-7ba0549ac8dd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,952</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9c7ffd73-fe00-431f-9777-de895db5a6e8" contextRef="C_7d63139e-3006-4754-b5ec-c678676f6695" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,314</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dd3bed8d-cf1c-49e2-a389-7e28c44e31f4" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,799</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a3108fc0-d185-4523-aec4-f007dad60079" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the years ended December 31, 2021 and 2020 the Company granted </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_99c77ba9-dc1c-48b1-a5bf-6cc313d6a748" contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,521,150</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9fa66707-4410-4827-bf24-81eafe676da3" contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,267,743</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> stock options to employees with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2c6a4420-df8f-46fd-ba3e-5ed766459cf4" contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">34.46</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fe9a2032-9160-42f7-b57c-4535ba4ad8d7" contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.84</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, respectively and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b818a15c-1dc9-42db-ac5e-28be4e38edf9" contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2d2d58f0-ea4a-400f-87a3-7366f46532ca" contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">54,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> stock options to nonemployees with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_55ff7fbd-b2b0-4266-84e3-ae6480ff83e7" contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">47.42</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1691a14c-afa9-4cc7-a8bc-b199d27cb68c" contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.05</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, respectively. The total fair value of options vested during the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f0e0b9a7-9a4b-406d-b6d3-86cde1319384" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_a0c48a39-206d-4334-9c04-acc05ca2ee27" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. As of December 31, 2021, the unrecognized stock-based compensation expense of unvested options was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e52647e9-32a3-42d6-99f1-d0658392ef81" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and is expected to be recognized over a weighted-average period of</span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_669f6064-583c-483d-92dd-91cb9cdc3fa4" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> 2.7 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation expense recorded for employee options was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f3221b54-143d-446a-9b3b-3c2b8f8a994a" contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_af6f4f13-33e9-42d3-ad96-52fe8b66d35a" contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended December 31, 2021 and 2020, respectively. Stock-based compensation expense recorded for nonemployee consultants was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b7d7b276-23c4-48d9-a264-75f77be91fa6" contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3b40fe98-1924-4baa-8543-47aeb2d0690f" contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the Company&#x2019;s IPO, the fair value of the shares of common stock underlying the stock options was estimated by the board of directors at various dates considering the Company&#x2019;s most recently available third-party valuations of common stock as well as a number of objective and subjective factors including valuation of comparable companies, sales of redeemable convertible preferred stock, operating and financial performance and general and industry specific economic outlook, amongst other factors. The fair value was determined in accordance with the guidance provided by the American Institute of Certified Public Accountants&#x2019; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Subsequent to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock is determined based on its closing market price on the respective grant date.</span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_854479c6-2140-40a8-8a73-dd3e9b8e0829" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company estimates the fair value of employee and nonemployee stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of the Company's stock options was estimated using the following assumptions for the years ended December 31, 2021 and 2020.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:18.506%;"></td>
        <td style="width:1.242%;"></td>
        <td style="width:18.506%;"></td>
        <td style="width:1.242%;"></td>
        <td style="width:1.242%;"></td>
        <td style="width:18.517%;"></td>
        <td style="width:1.242%;"></td>
        <td style="width:18.506%;"></td>
        <td style="width:1.242%;"></td>
        <td style="width:1.242%;"></td>
        <td style="width:18.517%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31, 2020</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Employee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Nonemployee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Employee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Nonemployee</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_61de5221-0c2a-456e-b7be-c068fa8cd96d" contextRef="C_f96a58ac-dc2a-4623-8894-1ced49494bd0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_e493bee0-9c9c-4372-a7cc-0aff96b2d78f" contextRef="C_fed81344-7c82-4eb4-9718-d25d585ff1e5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_957dc219-ec33-418c-83a8-c80567cd9a79" contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_305765d3-6d5f-43e6-b533-c1a564003f2b" contextRef="C_e916e9be-dd44-4775-b1f3-058f8afa1981" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.5 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#x2013; </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_4d95ecc3-37a8-486f-892e-1d98caf2e372" contextRef="C_8c6ae4c6-838d-4e8a-a05e-7a077c423abd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_fa478f47-5395-44ae-985d-9009ba747561" contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.0 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_426c593d-6a6d-4e00-97b0-2fe27fd70079" contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">80.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b6e5ac3f-3ae9-4f39-a9fc-0a492dde3077" contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">84.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_07da280a-0bdc-43be-ac17-3a608ffd1b86" contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">83.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_90faf74a-abeb-4088-b7c4-ae400bb8b1f2" contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">82.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9489f985-ee5f-454e-b9ba-446dcc45eeb6" contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">83.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0039717a-b07f-46e9-b982-add6980fce4f" contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">82.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_afa25bb4-9a99-47c3-ab49-54693a5ae10a" contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">83.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_053c9414-8a85-4864-90fe-32d2af2ffe78" contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9ada536e-1e01-4a3e-b13b-61daf88c96d4" contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_136b2db5-993b-42c5-9c57-f0a8c8ca732e" contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_857d842e-4d2a-433a-9026-87d12a2a0026" contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4b5d37b2-b81c-494f-901f-660647ce1e07" contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f7b150ff-c2f4-42ea-97ec-e2a6ba7f60cb" contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e6efed02-1999-44be-80ae-14a6f58da712" contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ec9f4360-a4ba-4cba-bd4b-b84ea9a99719" contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fdaa87a1-7480-4360-b17b-b3d5b6a0b4a2" contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e3a7eaaf-799b-4f5a-8b89-dd67830d3fe0" contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_dfeb1404-9982-41c3-8b49-2c2e8dd0bf7b" contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.  The expected term for employee options is calculated using the simplified method as the Company does not have sufficient historical information to provide a basis for estimate. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The expected term for nonemployee options is the contractual term of the options.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">34</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.  The expected volatility was estimated based on a study of publicly traded peer companies as the Company did not have sufficient trading history for its common stock. The Company selected the peer group based on similarities in industry, stage of development, size and financial leverage with the Company&#x2019;s principal business operations. For each grant, the Company measured historical volatility over a period equivalent to the expected term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Risk-free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.  The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues whose term is similar in duration to the expected term of the respective stock option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.  The Company has not paid and does not anticipate paying any dividends on its common stock in the future. Accordingly, the Company has estimated the dividend yield to be </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e2686b15-3389-418f-b548-b6b36486a7f7" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen"><ix:nonFraction id="F_360591e1-ba9b-425a-bc0c-495c0c2ee93c" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_a76e48fb-f377-4379-9c74-d99097280acb" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:CommonStockWarrantsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">14. Common Stock Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2016, the Company issued a warrant for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cf4ece7a-b144-4a6e-aa9b-cb0cda812926" contextRef="C_da021c91-4acb-426f-8a80-77705578bab8" name="fdmt:NumberOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company&#x2019;s common stock to a service provider with an exercise price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_36bfef34-d72c-4f3a-8c71-1958d3636c10" contextRef="C_aad92407-2080-466e-ba91-9ebcedf0142e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">1.14</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, of which </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8ad85cf0-d9eb-4646-8d8d-71d941b07228" contextRef="C_f1e25908-cccb-42b0-b877-3c97c0b0e8c4" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> warrant shares become exercisable upon completion of an offering of securities in a private placement by the Company with net proceeds in excess of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_25d0135f-bfd5-4426-b1c1-b04252625462" contextRef="C_da021c91-4acb-426f-8a80-77705578bab8" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cf738967-ad02-4559-8a24-e36cee95e949" contextRef="C_925a7886-495a-4170-9b11-97befb205b58" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> warrant shares become exercisable upon completion of an IPO by the Company. The warrant expires in </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_b43cbaba-7d1d-4cb9-88c1-2595d2fd1beb" contextRef="C_da021c91-4acb-426f-8a80-77705578bab8" name="fdmt:WarrantExpiresYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model. </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_cf9f2c13-8b4d-4f34-80e2-ff5593f91f71" contextRef="C_2316f0b3-fa95-4376-836f-ea0ad0fecdf7" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of these warrant shares became exercisable upon the completion of the Series B financing in 2018 and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2258bf9e-a29c-42dd-885f-c3e0ae4f7655" contextRef="C_925a7886-495a-4170-9b11-97befb205b58" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of these warrants became exercisable upon completion of the IPO in 2020. </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_19a44626-93f7-43ac-9fff-bae9bb3d1672" contextRef="C_3050ecb2-11ee-4119-a548-6cdd89f1f561" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of this warrant were exercised in October 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In May 2018, the Company issued a warrant for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_48eabb48-818a-4090-a5d3-b9b450fe939c" contextRef="C_4a6c44c3-d641-4e5e-b729-a73d0337615b" name="fdmt:NumberOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">23,669</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company&#x2019;s common stock to a service provider with an exercise price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_111bd410-c6a2-4460-baf8-75ed917b6187" contextRef="C_0652071b-4c72-4479-b886-fe246ac1708e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">3.19</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model, expires in </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_d8d851a7-ba2e-402c-a1e6-eea4984e033c" contextRef="C_4a6c44c3-d641-4e5e-b729-a73d0337615b" name="fdmt:WarrantExpiresYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and upon issuance was fully vested.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2020, the Company issued a warrant for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_5f7af4c6-5118-4ff6-838f-9d5a18a205b8" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:NumberOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company&#x2019;s common stock to a service provider with an exercise price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_b40e2aaa-0dcf-4b64-897f-487846e3f655" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">18.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share. This warrant vests over a period of </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_f7d89bce-c595-465e-801e-487ab7fde171" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:WarrantVestsOverPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and expires in </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_f3a818c8-76f7-492b-b1c5-715124f9682c" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:WarrantExpiresYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2027</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2021, the Company issued a warrant for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2b16d311-cfd6-4a69-bb8b-b8f6d600cb35" contextRef="C_5b3c671f-d9c2-479a-878e-5392aef7d177" name="fdmt:NumberOfWarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">40,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company&#x2019;s common stock to a former employee with an exercise price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_e4145173-c1f7-41b5-a8ca-8ac12f3f1387" contextRef="C_f933dccb-0084-4f9e-bd98-0601bbc462d4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">9.41</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share as a result of a settlement agreement with such former employee. The warrant was exercised in </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_14fd1429-0b08-4de4-b6c7-2937a32e2fa4" contextRef="C_5b3c671f-d9c2-479a-878e-5392aef7d177" name="fdmt:WarrantExercisedMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">May 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The Company previously recorded an accrual within accrued and other current liabilities within the balance sheet at December 31, 2020 to accrue for the settlement and the related expense was recognized in general and administrative expenses for the year ended December 31, 2020. Upon the issuance of the warrant in April 2021 in connection with the settlement, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_f3caa09d-aeef-4dd6-9790-e125dbb660f3" contextRef="C_899d20dc-a0cb-4505-b8f0-3ed14460cfce" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was reclassified from accrued and other current liabilities to additional paid-in capital within the balance sheet as of December 31, 2021.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">35</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company recorded less than $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7c213d2a-24d8-48dc-b8d7-2028b01f8ccf" contextRef="C_0dd3438c-f8c5-4fe9-8672-19340e3bbb9d" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_04cd2c97-9d04-4ece-a9f9-6039458dcb87" contextRef="C_363a526b-afc7-4132-8b3a-387a13ab7bb1" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million expense for the above warrants, within operating expenses in the statements of operations during each of the years ended December 31, 2021 and 2020.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_d146a0d7-1e73-45f4-8580-1cfb2b0039cb" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">15. Net Loss Per Share, Basic and Diluted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_e86ebf83-868e-4d11-b907-756b88e5c5fc" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.422%;"></td>
        <td style="width:1.692%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:13.276%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.552%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:12.602%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.552%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Numerator</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_00c66517-1c87-4257-8fa4-2c90f3e94a2f" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">71,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_fd36e61f-d69f-4e26-ae74-1af7f2887bad" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,693</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Denominator</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average shares outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_046945ff-23c5-4d1e-8263-b467f14aa219" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,730,420</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_8d8c7574-3f14-467b-999a-6d5dbdb31dda" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,430,555</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_c144d0e8-02e3-426f-9334-d75d53a103fd" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,730,420</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_effe1611-6b84-4e59-9acf-bf3f791dbecb" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,430,555</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_16efc342-c84d-4c68-87fd-0438f959c8a8" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.57</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3029ef58-fd5c-446f-b09a-6a4fbbe8e9de" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">8.82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:12.0pt;font-family:Arial;"><ix:nonNumeric id="F_3fe7230d-a99a-47bf-907d-c2507ba08f52" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.98%;"></td>
        <td style="width:2.997%;"></td>
        <td style="width:0.76%;"></td>
        <td style="width:13.509%;"></td>
        <td style="width:0.76%;"></td>
        <td style="width:1.552%;"></td>
        <td style="width:0.76%;"></td>
        <td style="width:13.37%;"></td>
        <td style="width:0.76%;"></td>
        <td style="width:1.552%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_216b4514-b963-4362-824f-dd6afd9ff072" contextRef="C_fe322eef-bf6e-4784-9f7d-22ae2b365638" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,881,274</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_3ce97aa2-73aa-439b-8d72-e6274e3f2dc5" contextRef="C_2f3dd1a0-d4ca-4297-8f43-1b41c1131161" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,194,113</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4560a767-9e61-405d-b3ad-7314aefc1e43" contextRef="C_17493eda-6778-49b9-933d-bb5807fea6cc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">53,669</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_39d2f24f-5edf-4f65-92e1-5823999e95f4" contextRef="C_e4af4886-82cd-4423-a392-44aee99ef576" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">98,669</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_bae366ad-a64a-4aaa-b68f-72a3fc0d1f06" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,934,943</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_727b394a-67ad-4f62-8381-f57f2b017012" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,292,782</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_7ea07b3c-2d84-4d28-a8bb-ccb23ae7ac22" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">16. Derivative Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company identified an embedded derivative resulting from the change of control provision in the CFF Agreement. Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as separate financial instruments. At the inception of the derivative in 2017, the Company recognized this derivative as a liability and revenue was reduced by the initial fair value of the derivative liability. The Company remeasures the derivative liability to fair value at each reporting period and records the change in fair value of the derivative liability as other income (expense), net. The Company uses a present value analysis with multiple scenarios, which incorporates assumptions and estimates to value the derivative instrument. The Company assesses these assumptions and estimates on a periodic basis as additional information impacting the assumptions is obtained. Estimates and assumptions impacting the fair value measurement include the change of control payment to CFF (range of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_1806b053-9601-4457-b12e-a95b1a9e431b" contextRef="C_d2425f46-763c-4d4b-b2fc-1ca90612499e" name="fdmt:FairValueAssumptionsChangeOfControlPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_992aa15d-d04d-405d-9986-dad451b30f79" contextRef="C_dcff2890-ab1b-4492-8304-4e459fc72f25" name="fdmt:FairValueAssumptionsChangeOfControlPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_d5aa5939-58aa-49c9-8d5b-5a25f8a0860a" contextRef="C_363a526b-afc7-4132-8b3a-387a13ab7bb1" name="fdmt:FairValueAssumptionsChangeOfControlPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_9ed848ef-cfe6-431e-a3cf-8a7645a2c0d7" contextRef="C_0dd3438c-f8c5-4fe9-8672-19340e3bbb9d" name="fdmt:FairValueAssumptionsChangeOfControlPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.6</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million at December 31, 2021 and December 31, 2020), the probability of a change of control event, the probability of the product achieving development or commercial status at time of change of control (range of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ec956af1-710d-43f5-b529-7e13219368ac" contextRef="C_dcff2890-ab1b-4492-8304-4e459fc72f25" name="fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_9c28d668-515d-44a5-924b-197a757e33a4" contextRef="C_0dd3438c-f8c5-4fe9-8672-19340e3bbb9d" name="fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">17.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% at December 31, 2021 and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ebcefe0e-192e-486e-8fbb-d664d3958740" contextRef="C_d2425f46-763c-4d4b-b2fc-1ca90612499e" name="fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0041cc01-cbec-4daa-9909-d9ebf3ebf242" contextRef="C_363a526b-afc7-4132-8b3a-387a13ab7bb1" name="fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">12.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% at December 31, 2020) and the discount rate (</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4b5b37cc-0b6d-45e5-8f6b-d87663c05141" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="fdmt:FairValueAssumptionsProbabilityOfChangeInControlDiscountRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_91681762-6fc8-46eb-8a1d-5ab01fb3fa37" contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e" name="fdmt:FairValueAssumptionsProbabilityOfChangeInControlDiscountRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">14.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% at December 31, 2021 and December 31, 2020). The Company determined the estimated fair value of this liability as of the inception date of the CFF Agreement and concluded that the amount was immaterial. The Company determined the fair value of this derivative liability was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2bea9d2e-e238-4f8d-aa5e-ed62a7acbe96" contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2885585a-5b36-4898-b750-329bf360e1b5" contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as of December 31, 2021 and 2020, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_c647d8eb-7c02-4779-8dad-49bfc5871506" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">17. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the years ended December 31, 2021 and 2020, the Company paid $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_01ae6d35-49cc-4fb6-9f5a-6498eeec310b" contextRef="C_f8c80726-14a0-4e92-b15c-36f91786d60a" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">85,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ad5fd97f-c0ce-4dc3-a32b-b02de3ba60da" contextRef="C_d8cb6a3a-516a-44ff-a6c4-14639dae2312" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">93,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, respectively, to David Schaffer, Ph.D., the co-founder, director and Chief Scientific Advisor of the Company for consulting services. In April 2019, the Company entered into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ebbf6a89-7e4a-4875-935b-75c9a84314dd" contextRef="C_dab250fb-28e0-4123-8e2b-eee2d878a7bb" name="fdmt:NumberOfAgreementsEntered" unitRef="U_Agreement" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> sponsored research agreements (&#x201c;SRAs&#x201d;) with the UC Regents to conduct research in a research facility on the U.C. Berkeley campus, under the direction of Dr. Schaffer. The SRAs have a </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_50642d9e-a892-4dd8-a263-16882493d220" contextRef="C_dab250fb-28e0-4123-8e2b-eee2d878a7bb" name="fdmt:TermOfAgreement" format="ixt-sec:durwordsen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three year</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> term ending in May 2022. Under the SRAs, the Company has an option to license (on a royalty-bearing basis) all intellectual property generated under the SRAs. The total amount the Company is committed to pay to the UC Regents under the SRAs is $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_78a4896c-7091-430b-8283-b7e38521887f" contextRef="C_5f4f9f3d-c2a5-4a7a-b39c-2a675787b677" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which was fully paid as of December 31, 2021. In March 2021, the Company entered into another sponsored research agreement with the UC Regents to conduct research in laboratories on the U.C. Berkeley campus that are under the direction of Dr. Schaffer and another U.C. Berkeley professor covering investigations into how machine learning approaches may enhance AAV capsid engineering (the &#x201c;Machine Learning SRA&#x201d;). Pursuant to the Machine Learning SRA, the Company has committed to pay the UC Regents a total of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_0edfea58-ee21-4211-a06d-1ee4d56d004a" contextRef="C_43895722-c889-4f5a-86ef-d1095b190b17" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, of which $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_4d4345f3-0145-481b-8cd0-79fc79d1034f" contextRef="C_7407984c-b650-4ccb-99f5-f9cd63af7b7b" name="us-gaap:RelatedPartyCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was paid as of December 31, 2021. The Machine Learning SRA has a </span><span style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_18904104-e407-4848-8f27-3210390c8abe" contextRef="C_ac7b6ce7-cd1a-4e4d-84ee-87d64c2d5f60" name="fdmt:TermOfAgreement" format="ixt-sec:durwordsen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> term ending in 2024. Any patent prosecution costs incurred under the SRAs will also be borne by the Company. The Company can terminate the SRAs for convenience and without cause with 60 days&#x2019; notice. While the Machine Learning SRA is between the Company and the UC Regents, the payments under the SRA will be used to fund the lab under the direction of Dr. Schaffer. As of December 31, 2021 and 2020, accounts payable to the UC Regents related to the SRAs and Machine Learning SRA was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_96bc063e-3b4a-4057-9038-efa0abd74eca" contextRef="C_646334cd-512e-4567-85e0-49ec256638ec" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_ee0aa60e-857a-40cc-9f40-e7d9ceac7ef6" contextRef="C_ffdd2326-026c-4d95-8076-5a7d7c11f527" name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. In the years ended December 31, 2021 and 2020, the Company recorded $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_151ba881-1651-415b-b366-c426aa7c9d40" contextRef="C_67c79b0f-725f-4422-a99d-21b85901d3c0" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_7372a372-b9ff-4200-a7ef-a503edcba042" contextRef="C_d24dc914-f653-4ead-88fd-297fac82aaf8" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, of expense related to SRAs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In August 2019, the Company and uniQure entered into the amended uniQure Agreement and the Second uniQure Agreement. Under these agreements, the Company agreed to transfer incremental rights and services to uniQure in exchange for uniQure eliminating the exclusivity clause in the uniQure Agreement and transferring other rights back to the Company. Further details and the accounting for these agreements is discussed in Note 7. As of June 17, 2020, uniQure was no longer a related party of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Arial;"><ix:nonNumeric id="F_38de6bd6-f2d9-4031-ac42-19667999398f" contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be" name="us-gaap:DefinedContributionPlanTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">18. 401(k) Plan</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2014, the Company adopted a 401(k) plan for all employees who have met certain eligibility requirements. The 401(k) plan allows employees to make pre-tax and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company made contributions to the Plan for eligible participants, and recorded contribution expenses of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_2b53fabe-30c9-4c9f-9b4d-0616474cc422" contextRef="C_b63ba5ca-290b-449e-9c24-797545392bb5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><ix:nonFraction id="F_20c03885-a2df-4c40-abdf-1cd4636d02e4" contextRef="C_77581bff-7745-4be8-a763-3227bbf42da1" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5">0.4</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>fdmt-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES REGISTERED PURSUANT<br>TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	As of December 31, 2021, 4D Molecular Therapeutics, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation, our amended and restated bylaws, the amended and restated investors&#x2019; rights agreement to which we and certain of our stockholders are parties, and the Delaware General Corporation Law. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws, and amended and restated investors&#x2019; rights agreement, each of which is incorporated herein by reference as an exhibit to the Annual Report on Form 10-K filed with the Securities and Exchange Commission, of which this Exhibit 4.1 is a part.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Authorized Capital Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our authorized capital stock consists of 300,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. Unless our board of directors determines otherwise, we will issue all shares of our capital stock in uncertificated form.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	As of December 31, 2021, there were approximately 31 stockholders of record of our common stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Voting Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 66 2/3% of the voting power of all of the then outstanding voting stock is required to take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to amending our amended and restated bylaws, the classified board and director liability.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividends</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rights and Preferences</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fully Paid and Nonassessable</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	All of our outstanding shares of common stock are fully paid and nonassessable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Redeemable Convertible Preferred Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of our common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control or other corporate action. As of December 31, 2021, no shares of preferred stock are outstanding, and we have no present plan to issue any shares of preferred stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registration Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Under our amended and restated investors&#x2019; rights agreement, based on the number of shares outstanding as of December 31, 2021, the holders of 11.6 million shares of our common stock, or their transferees, have the right to require us to register their shares under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) so that those shares may be publicly resold, and the holders of 11.6 million shares of our common stock, or their transferees, have the right to include their shares in any registration statement we file, in each case as described below.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Demand Registration Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Based on the number of shares outstanding as of December 31, 2021, the holders of 11.6 million shares of our common stock (on an as-converted basis), or their transferees, are entitled to certain demand registration rights. The holders of at least 50% of these shares can, on not more than two occasions, request that we register all or a portion of their shares if the aggregate price to the public of the shares offered is at least $30.0 million (before deductions of underwriters&#x2019; commissions and expenses).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Piggyback Registration Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Based on the number of shares outstanding as of December 31, 2021, in the event that we determine to register any of our securities under the Securities Act (subject to certain exceptions), either for our own account or for the account of other security holders, the holders of 11.6 million shares of our common stock (on an as-converted basis), or their transferees, will be entitled to certain &#x201c;piggyback&#x201d; registration rights allowing the holders to include their shares in such registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, other than with respect to a registration related to employee benefit plans, the offer and sale of debt securities, or corporate reorganizations or certain other transactions, the holders of these shares are entitled to notice of the registration and have the right, subject to limitations that the underwriters may impose on the number of shares included in the registration, to include their shares in the registration. In an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions, to exclude or limit the number of shares such holders may include.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Form S-3 Registration Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Based on the number of shares outstanding as of December 31, 2021, the holders of 11.6 million shares of our common stock (on an as-converted basis), or their transferees, are entitled to certain Form S-3 registration rights. The holders of at least 30% of these registrable securities then outstanding can make a written request that we register their shares on Form S-3 if we are eligible to file a registration statement on Form S-3 and if the aggregate price to the public of the shares offered is at least $5.0 million (before deductions of underwriters&#x2019; commissions and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses). These stockholders may make an unlimited number of requests for registration on Form S-3, but in no event shall we be required to file more than two registrations on Form S-3 in any given twelve-month period.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expenses of Registration</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	We will pay the registration expenses of the holders of the shares registered pursuant to the demand, piggyback and Form S-3 registration rights described above, including the expenses in an amount not to exceed $25,000 of one special counsel for the selling holders.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expiration of Registration Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The demand, piggyback and Form S-3 registration rights described above will expire, with respect to any particular stockholder, upon the earlier of December 10, 2025 or when that stockholder can sell all of its shares under Rule 144 of the Securities Act during any three-month period (and without the requirement for us to be in compliance with the current public information required under Section c(1) of Rule 144 of the Securities Act).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and Restated Bylaws and Delaware Law</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Certain provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Delaware Anti-Takeover Statute</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	We are subject to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed &#x201c;interested stockholders&#x201d; from engaging in a &#x201c;business combination&#x201d; with a publicly-held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Undesignated Preferred Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The ability to authorize undesignated preferred stock will make it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Special Stockholder Meetings</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our amended and restated bylaws provide that a special meeting of stockholders may be called at any time by our board of directors, or our President or Chief Executive Officer, but such special meetings may not be called by our stockholders or any other person or persons.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our amended and restated bylaws established advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stockholder Action by Written Consent</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our amended and restated certificate of incorporation and our amended and restated bylaws do not provide for the right of stockholders to act by written consent without a meeting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Classified Board; Election and Removal of Directors; Filling Vacancies</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our board of directors is divided into three classes. The directors in each class serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of our common stock outstanding are able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board of directors, may only be filled by a resolution of our board of directors unless our board of directors determines that such vacancies shall be filled by our stockholders. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Choice of Forum</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our amended and restated certificate of incorporation and amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our stockholders; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time); or any action asserting a claim against us that is governed by the internal affairs doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	If any action the subject matter of which is within the scope described above is filed in a court other than a court located within the State of Delaware (a &#x201c;Foreign Action&#x201d;), in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state and federal courts located within the State</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and amended and restated bylaws and having service of process made upon such stockholder in any such action by service upon such stockholder&#x2019;s counsel in the Foreign Action as agent for such stockholder. Although our amended and restated certificate of incorporation and amended and restated bylaws contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amendment of Charter Provisions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The amendment of any of the above provisions in our amended and restated certificate of incorporation, except for the provision making it possible for our board of directors to issue undesignated preferred stock, requires approval by a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Limitations of Liability and Indemnification Matters</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any breach of the director&#x2019;s duty of loyalty to us or our stockholders;<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any transaction from which the director derived an improper personal benefit.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Each of our amended and restated certificate of incorporation and amended and restated bylaws provides that we are required to indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Our amended and restated bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys&#x2019; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors&#x2019; and officers&#x2019; liability insurance.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder&#x2019;s investment may be adversely affected to the extent that we pay the costs of settlement and damages.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Listing</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our common stock is listed on the Nasdaq Global Select Market under the symbol &#x201c;FDMT.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfer Agent and Registrar</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent and registrar&#x2019;s address is 6201 15th Avenue, Brooklyn, New York 11219.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>fdmt-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-254701 and 333-251370) of 4D Molecular Therapeutics, Inc. of our report dated March 28, 2022 relating to the financial statements, which appears in this Form 10-K.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ PricewaterhouseCoopers LLP <br>San Jose, California<br>March 28, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>fdmt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PURSUANT TO RULES 13a-14(a) AND</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">15d-14(a) UNDER THE EXCHANGE ACT OF 1934,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">I, David Kirn, certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">I have reviewed this Annual Report on Form 10-K of 4D Molecular Therapeutics, Inc.;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:46.004%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Dated: March 28, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;/s/ David Kirn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">David Kirn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>fdmt-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">I, August J. Moretti, certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">I have reviewed this Annual Report on Form 10-K of 4D Molecular Therapeutics, Inc.;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.571084182443509%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Arial;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:46.004%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Dated: March 28, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;/s/ August Moretti</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">August J. Moretti</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>fdmt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">AS ADOPTED PURSUANT TO SECTION 906</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In connection with the Annual Report on Form 10-K (the &#x201c;Annual Report&#x201d;) of 4D Molecular Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2021, David Kirn, as Chief Executive Officer of the Company, and August J. Moretti, as Chief Financial Officer of the Company, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the Company&#x2019;s Annual Report for the year ended December 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:3.447919145106397%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">the information contained in such Annual Report fairly presents, in all material respects, the financial condition and results of operations of 4D Molecular Therapeutics, Inc.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Dated: March 28, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.692%;"></td>
    <td style="width:92.308%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ David Kirn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">David Kirn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Dated: March 28, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.692%;"></td>
    <td style="width:92.308%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">/s/ August J. Moretti</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">August J. Moretti</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img227133604_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $8 G # 2(  A$! Q$!_\0
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MU;JY6RDNLKM5PH4(9/E!\LGCFM73I6NJ:?Y[-]O+0R4ZM[.H_P!.G^>IF?\
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M[CG^M5OYV?5__#T#]H'_ *&#1_\ P30T?\/0/V@?^A@T?_P30U\H44?5Z/\
M(ON#ZU6_G9]7_P##T#]H'_H8-'_\$T-'_#T#]H'_ *&#1_\ P30U\H44?5Z/
M\B^X/K5;^=GV3XH_X*5?'K2)-*$'B#2<7.F6UT^[1X3\[IEL>V:Q?^'H'[0/
M_0P:/_X)H:^=_'G^N\/_ /8#LO\ T77,5,</1M\"^XN>)K*32DSZO_X>@?M
M_P#0P:/_ .":&C_AZ!^T#_T,&C_^":&OE"BJ^KT?Y%]Q'UJM_.SZO_X>@?M
M_P#0P:/_ .":&C_AZ!^T#_T,&C_^":&OE"BCZO1_D7W!]:K?SL^K_P#AZ!^T
M#_T,&C_^":&C_AZ!^T#_ -#!H_\ X)H:^4**/J]'^1?<'UJM_.SZO_X>@?M
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MT-?*%%5]7H_R+[B?K5;^=GU?_P /0/V@?^A@T?\ \$T-'_#T#]H'_H8-'_\
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MKC_[%U'_ *!]W_WX?_"M(TZMO>CKZ&$ZE*_NR_$I45=_L74?^@?=_P#?A_\
M"C^Q=1_Z!]W_ -^'_P *OV<_Y61[2'\R*+-M4MZ#->L_$/PKX!^&$/\ PC%_
MI^N:KXL&FV]Y-K$-_%!9PSSP).D<=N8F,D:K(H+EP6.2, #/GVF^#]?UJ\6T
MT[0M3U"Z<$K;VME++(P R2%523@5ZQ'>?&\>&[;1)O!.L7T%K;"RM[N^\'_:
M+R&W'2%+AX#($'0#/ .!@<5A43C9/3\#JHM23:U_$ZN7]D--/\/_  GU#4K;
M686US5+&R\2;H@D<*7N)+8VSE<$B(%7SG#E15?PE^RWH&M>*)O-U&\U7P;=7
M^GQZ-J]H%C:>&:]%O/%*"K".XB!VLG9L-RK#/+:;-\=]*\5:MXBM_#WB[^UM
M5E2:\FET":1)'299D8(T152KHI7:!C&!QQ3/!_\ PO7P'9W5IH?A[Q=96=SJ
M-OJ\ML= FDB-W ^^*7:T1 (/7'## .0*YO?WYEO_ ):?+I]WF=/NVMRO;_/7
MYZ&_X%^#7P^^+U]%-H,.OZ':6&M0Z5JEEJ%[#=>9'.DQBE@F6),.&A(:-E/R
MG(/!J*'X0_#[6-8\-^"8(=>LO%NL>&K?6(=8>\BFLOM,EF;DQO;^4&2+ *[Q
M(2O!((JK?Z]\?+Z^TJZ7PMX@L/[+N6O;6WTWPE]DMUN&4H9FBBMU1WVL1N8$
M@' IW_"0?'Q=!M])C\*:]!;PV,>F"X@\(>7=M:1J%6!K@6_FM'M 4J6PPX.1
MQ2M.WQ?CY?YZE7CS7Y7]WG_EH:GB?]G'3/AG\.O OB_Q'HGB'4(;P10:_:PS
M+9+%-=Q^=9F"5HW!58\K("#\XQD9K:?X&_#>X\3?$ZSL=)U@V_@R^@TU8]4\
M6V>GK=N\TJ-*9Y8 BX6,8CP223SQ7F=UI/QJOKWQ)=7/ACQ=<3>(B#J?FZ%<
M,LY$JS*=IBPA5U4@J!C&!@'%:NEWOQRTG5O$NHKX-UJ]N/$EPMUJJZEX0^UQ
M7$JLS*_ERV[*I!=B-H'6F^9Z\RZ]?3_@_>A+EVY'TZ>O_ /%+I52ZF5!M178
M*-X? SP-PX/U'6HZ[2?X/_$2XGDE?P#XG#R,7(30KE5R3G@"/ 'L*9_PIGXA
M?]"#XI_\$EU_\;KI4HVW.1PE?1,=\'/!ME\0?B5HWA_49)HK*\,PD>W8+(-L
M+N,$@CJH[5ZQ'^S/HNIZOX0DT?4[[4-,N-*L[CQ':_*+K3+BXL3<1R+QAK=V
MPH?'RL"K<E2?.?#'P_\ BIX-UVUUG1_!7BFTU*UW&&;^P;A]NY2AX:,@_*Q'
M([UNZ1#\<M \30^(-.\.^+[/5H],71Q/'H,X#68@$ A9?*VLOE@#D$Y /49K
M*;;^&7]:FL(V5I1?]6-RZ^$O@+4M8B\%Z;%K]CXN?PQ%KD6K3WL4]C+.=.6]
MDBDA$2M%&1N4.';:0I((S3O&WPE\!_"6TNM9UVWUSQ!8W5_'IVF:=9WT=JR%
M;*VN)Y9YS$_.ZY"HBJ,@$D\<TM4UCX\ZMX:?0I?"FOPV<MA'I<TUIX2,%U-:
M1HJ+!)<) )73:JJ06Y &<TZPUCX[6=UJDTW@_7-5BU-H9;JSU7PDUW;/)#$(
MHI1%) 55U10NY0"0,'-1[UW[VGKY_AH:KELO==_3R_'74M?"7]G"#XM>!?''
MB?3+'7/(@ED@\.0(%E$DD,9N)TN9%4 ?N0(U8  R2+QVJ]I_PR^%_BB\^%EE
MINC>)M,E\:"6>2:XUJ&<6L<4\T3(%%LNYF\H$-D8ST-<G>6_QPO-5T346\->
M+(+K1;A[NP-KX?F@2"9Y?-9PB1!22^.HZ #H *;%8_&NWUG0=5B\)^)XKW06
MF?37C\.2A;<RRO+)A1#M(+RN<$$#.!@ "A\S?Q?CY?C=V8+E2MR._I_5K&UI
MWPO^'^F^)O!W@/7(O$-SXH\26MC*^N6%S$MM8RWJJT"I;&,M.BATWMO4GYMN
M-O.RG[+.EWFL> ;33]4NM0FN!9CQ781%?.LTGN'A%W;''S097:202C%<Y# C
M"T/6OCUX=T.RTRR\*>(%_L^!K6PU"7PJTM_8PMG,<%RT!DC7YFP%;Y<G;BLS
M08?CEX8\4:!XCTKP[XOL=:T*T2PL+J'0IP8[=0P$;#RL.N';.X'.><T/FOI+
MKW]?^!_2U5H\MN5[=O0\AN(Q%<2QCHKLHS['%,7[R_45V+?!OXANS,? 7BDE
MCD_\22Z_^-TB_!GXA;A_Q0/BGK_T!+K_ .-UT*4>YR\DK['7ZAX&T[5-=\=>
M*/$6NW.@^'M/U9; '3[7[3=75U*'=8HT+HH 2-V9F8 8  )-=;X7_9+7Q7:W
M=Y#XPG?0W6RFTW4H],+0FWN8IW$]V&F7[,D;6[H_W\'D9&,T;[2?B;X3\7^,
MK2W^&VJ>(= U:]\RYTW5?#MU<6LKH3Y<J[55E==S ,C#AB#D&L?Q?#\9/&VE
MWNF:CX#UU-.N+BUG2TM/#=Q#%;+;Q2100PJ$PD:K*_R\Y)R23DUS-R:]V5MO
MTO\ ,ZU&/VHM[]_ZL6H?@7X6U*R\)_V-XZU2XNO$EM>W5O%<:((8TCM1+YNY
MA<-R6B(&!R&R<=*O:A^R/=:;9ZIJ)\7:7)H]IH/]JPS(O[^>[6U2XDL/(W;E
M=$;<9#\FTJ1DMMK"TG3_ (P:+_PC7V;P'KX_X1ZVN[6QW^';DXCN3(9=_P G
MS']Z^#VX]*233_C!+XHU+7V\!Z__ &AJ&F-I$Y_X1ZYV>0;=;<X79PWEHOS>
MO-5>6MI?EY_I87+#3W'^/D7YO@-X5TNX\=6NJ^-=2LIO"/F"[N%T)7M9'SMM
MXED-P#YDK<!=O&&)X4FH+/\ 9UCL_"?@7Q#XAUN\TRQ\23+;SI::6;B33WF.
M;(L&=%=9D61LAOE"]#FN@U#Q5\7=:TN\L-7^#<>L0WFHS:K,U[X1O"[7,BA"
MY*D9PH"KG[HSCJ<T+_Q%\>]5FU'[;X7\4W=C>-;,NES:'=M96AMY$> V\)7;
M%L\M5&W^$L#G)I1E.ZO+MV^?]>2"4(6TB^O?Y$,G[-^F:AJFLPZ-XPDET[0]
M6GTW5+[4=+,'D);P3SW$ZHDKEU58"%7@L6'2HO"O[/N@?$2 :GX:\<^3H$8N
MH;R\U[3C:O97$5NT\8D5)''E2JK#S QV8.Y>.7:5??&[1=0OKVS\$:]'-?:S
M)KERK>&KATEFDCDCDC960@PNDTBF,C!!J:^U#XO3:>^F:;\+K[P[HKV]U ^E
MZ3X7NHX':XB\J65MP9FDV?*I+$*. !DYF]2WQ:V\M[:_CL5RT[_"[7\]K_Y;
MGG?C3X7ZEX!\/Z=>:ONM=2N-1OM.GTZ2/#0-;B$[M^<.'$P((XP 02#7&5ZW
MXITCXQ^-/"OAGP]K'@SQ->6'AQ)HM/=M N?.6.0IE'D\O+A0BA<_= QTQCE?
M^%,_$+_H0?%/_@DNO_C==$9:>\T<TX._NQ=CK-+\%6/C:[N5OI)X_P"R_ L>
MIP>0P&Z6-(PH;(.5^<YQS79>,?V8]$T?QCXO.BZI?:MX.TRVO4ANVVK<6>H6
M[QJUK= # )#,RL,"1<$<A@.9U;P5\4?#MQ9-HW@_Q/$;SPU;Z9=E-#G?=$R+
MYD9S&<'*CIR,5#;Q_'.UU'Q9>P^'?%\4_BM&36@N@SA+P&0299/*V@A@""H!
M'('!-97=TU+2WXFTHZ23B[W-OQG\(?!.J:Q\2?#W@JS\16?B#P5)(P6_NXKZ
M'4XDNDMF50D2-%*6D0JOS!N5ZXJ#3?@CIFE_!:77_$.D7UOXI_M.]T][6^UR
MWTIK011P,A%I-'YMPQ\XDJA!P%]:9XTUCX]>/;&[M-4\+>(8H+VX6[O!IGA,
MV+7<RG<KS-! C2$,2PW$X//7FJ.GQ_&K3O"4WAO_ (0O7+W2I)I;D#4?";7<
M\<LJHLCQS2P-(C$1IRK#&T8I1YE&SDNG4<N5N\8OKT.E\<_LTZ+H'B;QK-HF
MIWVL>$-(TW4GAN6"K<VFHVJ*3:70 QSDLK# D0@C!# ;6H?L>QZ#K7PBMM4B
MUB"VUZ_@TCQ&TJB$0W<L:SJ+9RI&SRG*%CG#PR5PFDW'QXT/7O$FL67AWQ9%
M>^) 1JX;P]*\5Y\XD^>(PE.& (P..1T)IN@2?';PSKFHZQ8^'O%W]H:A>QZC
M<R7&@33B2YCE,J2[7B*A@[-T'1B.A(I+GT]]=/\ @_G^"&^37W'U_P"!_7FS
M9^*OP%\.^$?!^N^(M,DO$A@TS3KRVB_M*WU&V2::\DMYXA=PJ$GVJB-\N"C/
MM.<59L?V<?#6L>"%N8M<N=-\1WNFZ+-I2WKI]CN+V\2Z=[>1L#RPWV<+&Q.
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MR_RWM^19E]3^NUE67O>U=]_ANKK3Y_Y[7N^'O@O/XD\.6$MKJ_\ Q4NH6?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!_KI/_GT_P#P)?\ R)^PW_"?W7_0G>(_^_,'_P >H_X3^Z_Z$[Q'_P!^8/\
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MM_C1_J=#_GZO_ 7_ /)!_KI/_GT__ E_\B?L-_PG]U_T)WB/_OS!_P#'J/\
MA/[K_H3O$?\ WY@_^/5^//VVY_Y^9O\ OZW^-'VVY_Y^9O\ OZW^-'^IT/\
MGZO_  %__)!_KI/_ )]/_P "7_R)^PW_  G]U_T)WB/_ +\P?_'J/^$_NO\
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M27_/I_\ @2_^1/V#_P"%@W7_ $)WB3_OQ!_\>H_X6#=?]"=XD_[\0?\ QZO
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M:3\*_%FE:7KL4GB;1=4O-6NOM<T]]H)<2,>"LB^?\RJ@15 P%"#KDUVWP_\
M"$?@'P9I/A^*Y>\2PA$0GD4*7Y))"CA1DG"CH,#M6O\ Z9_TP_\ 'J/],_Z8
M?^/4ZN*JUHN,WHW?9+966R[!2PM*C)3@M4FMV]W=[OJRU157_3/^F'_CU'^F
M?],/_'JY#K+5%5?],_Z8?^/4?Z9_TP_\>H H^+M+U+6_#M[8:3JQT._N$\M-
M16$2O "?F9%) W8S@G@'!P<8KRS4_P!FBUM?#FM:!X6UR30-&U:UC6XLYX#=
MK]MCD1UO,EU/F/LQ)S^\.&R""3[#_IG_ $P_\>H_TS_IA_X]0!Y-K7P E^(&
MHQ7WCS6+'7KF#3[BQMWL=+^R&V:22&2.XB+2R%)8VBX8'O[<[W@CX0Q>'O%.
MI>)M;NK3Q%XBO8;.,ZC)IZ121M##Y3,ARQ7?]X@$ $FN[_TS_IA_X]1_IG_3
M#_QZC;1 6J*J_P"F?],/_'J/],_Z8?\ CU %JBJO^F?],/\ QZC_ $S_ *8?
M^/4 6J*J_P"F?],/_'J/],_Z8?\ CU 'XP>)_P#D9M8_Z_9__1C5FYK]$KS3
M?V8C>7!NV\%_:_,;SM]PX;S,G=GYNN<U%_9O[+7]_P $_P#@2_\ \57[3'B-
M**7U:I_X"?B,^&7*3?UJG_X$?GEFC-?H;_9O[+7]_P $_P#@2_\ \51_9O[+
M7]_P3_X$O_\ %5?^LB_Z!:G_ ("1_JO+_H*I_P#@1^>6:,U^AO\ 9O[+7]_P
M3_X$O_\ %4?V;^RU_?\ !/\ X$O_ /%4?ZR+_H%J?^ A_JO+_H*I_P#@1^>6
M:,U^AO\ 9O[+7]_P3_X$O_\ %4?V;^RU_?\ !/\ X$O_ /%4?ZR+_H%J?^ A
M_JO+_H*I_P#@1^>6:,U^AO\ 9O[+7]_P3_X$O_\ %4?V;^RU_?\ !/\ X$O_
M /%4?ZR+_H%J?^ A_JO+_H*I_P#@1^>5&:_0F+3?V7,-N?P3]XX_TA^G_?52
M?V;^RU_?\$_^!+__ !5+_61?] M3_P !#_5>7_053_\  C\\LT9K]#?[-_9:
M_O\ @G_P)?\ ^*H_LW]EK^_X)_\  E__ (JG_K(O^@6I_P" A_JO+_H*I_\
M@1^>6:,U^AO]F_LM?W_!/_@2_P#\51_9O[+7]_P3_P"!+_\ Q5'^LB_Z!:G_
M ("'^J\O^@JG_P"!'YY9HS7Z&_V;^RU_?\$_^!+_ /Q5']F_LM?W_!/_ ($O
M_P#%4?ZR+_H%J?\ @(?ZKR_Z"J?_ ($?GEFC-?H;_9O[+7]_P3_X$O\ _%4?
MV;^RU_?\$_\ @2__ ,51_K(O^@6I_P" A_JO+_H*I_\ @1^>5&:_0I=-_9<\
MU\OX)VX&/](?W_VJ?_9O[+7]_P $_P#@2_\ \52_UD7_ $"U/_ 0_P!5W_T%
M4_\ P(_/+-&:_0W^S?V6O[_@G_P)?_XJC^S?V6O[_@G_ ,"7_P#BJ?\ K(O^
M@6I_X"'^J\O^@JG_ .!'YY9HR/6OT-_LW]EK^_X)_P# E_\ XJI;/3?V7_MD
M'DMX(,WF+Y8:X8C=D8SEL=?7BE_K(O\ H%J?^ @N%W_T%4__  (\H_9 _9+F
M\5W-AXZ\86\EOHL+K/IFGOE7NV!RLK]Q&#@@?Q=>G7] *IPK<K$@B%L(@H"A
M,XQVQ[4[_3/^F'_CU?E>9YE6S2NZM7;HNB7];L_6<KRNAE5!4:._5]6_ZV1:
MHJK_ *9_TP_\>H_TS_IA_P"/5Y![ K?\A"+_ *Y-_-:LUG-]K^W1_P"IW>6W
M][U6I_\ 3/\ IA_X]0!:HJK_ *9_TP_\>H_TS_IA_P"/4 6J*J_Z9_TP_P#'
MJ/\ 3/\ IA_X]0!:HJK_ *9_TP_\>H_TS_IA_P"/4 6J*J_Z9_TP_P#'J/\
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MJF7?WOO#_6[,O[OW'Z&_\-Z?"O\ Y\?$'_@NM_\ XJC_ (;T^%?_ #X^(/\
MP76__P 57YY44?ZJ9=_>^\/];LR_N_<?H;_PWI\*_P#GQ\0?^"ZW_P#BJ/\
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M$%LKGJVP=6/]YLGWKGZ**4(1IQY8*R'4J3JRYIN["BBBK,SWS]AG_DY'0/\
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MHOD?V?IMG9&"W%I$UO J%(0<B,$#A0>=O3-2S1Z?;[!*+>,OG;O(&[ R<>N
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M 'XE_P#BZ/\ AX1XX_Z%KPS_ -^)?_BZ/K&??\^(?^!/_,/J_#__ #_G_P"
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MO1V5%<;_ ,+=\+_\_EW_ ."VZ_\ C='_  MWPO\ \_EW_P""VZ_^-T?5J_\
M(_N8?6J'_/Q?>C\B/$__ ",VL?\ 7[/_ .C&K-KZ3U;]D=]2U:^NU\<V*+<7
M$DP4Z+?Y 9BV/]5[U5_X8[D_Z'RP_P#!+?\ _P ;K]YAF^"44G/_ ,EE_D?S
M_4R;&RFVH+?^:/\ F?.U%?1/_#'<G_0^6'_@EO\ _P"-T?\ #'<G_0^6'_@E
MO_\ XW5_VQ@OY_\ R67^1']BX[^1?^!1_P SYVHKZ)_X8[D_Z'RP_P#!+?\
M_P ;H_X8[D_Z'RP_\$M__P#&Z/[8P7\__DLO\@_L7'?R+_P*/^9\[45]$_\
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M#Y8?^"6__P#C=']L8+^?_P EE_D']BX[^1?^!1_S/G:D;&TYZ5]%?\,=R?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+QM_T3R3_P '-O1_PF7C;_HGDG_@YMZ[RBCF7\J_'_,/;0_Y]+_R;_Y(X/\
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M<@_LO ?] \/_  %?Y'N__#<_QT_Z*!=_^ =K_P#&J/\ AN?XZ?\ 10+O_P
M[7_XU7A%%'U>C_(ON0?V7@/^@>'_ ("O\CW9?VY?CFN<?$"[Y.?^/.U_^-4O
M_#<_QT_Z*!=_^ =K_P#&J\(HH^KT?Y%]R%_96 _Z!X?^ K_(]W_X;G^.G_10
M+O\ \ [7_P"-4?\ #<_QT_Z*!=_^ =K_ /&J\(HH^KT?Y%]R'_9> _Z!X?\
M@*_R/=_^&Y_CI_T4"[_\ [7_ .-4?\-S_'3_ **!=_\ @':__&J\(HH^KT?Y
M%]R#^R\!_P! \/\ P%?Y'N__  W/\=/^B@7?_@':_P#QJC_AN?XZ?]% N_\
MP#M?_C5>$44?5Z/\B^Y!_9> _P"@>'_@*_R/=_\ AN?XZ?\ 10+O_P  [7_X
MU1_PW/\ '3_HH%W_ . =K_\ &J\(HH^KT?Y%]R#^R\!_T#P_\!7^1[L/VY?C
MF&+?\+ N\GK_ *':_P#QJE_X;G^.G_10+O\ \ [7_P"-5X111]7H_P B^Y"_
MLK ?] \/_ 8_Y'N__#<_QT_Z*!=_^ =K_P#&J/\ AN?XZ?\ 10+O_P  [7_X
MU7A%%'U>C_(ON0_[+P'_ $#P_P# 5_D>[_\ #<_QT_Z*!=_^ =K_ /&JDM_V
M[/CG;W$<I\>W$H1@WER65J5;!S@CRNAKP2BCZO1_D7W(7]E9?_T#P_\  5_D
M?M#^RO\ M4Z%^TCX5W+Y>F^+;&,?VEI&[IV\V+/+1D_BI.#V)]UK\B_V$?@)
MXU^(GQ-L/%NC:A=>&-!T.X#7.M0C#3'^*VC!X<L.&SE0#SDD _KI7R>,HPHU
M7&F_^ ?AO$. PV7XUTL-.Z>MOY?+^M>X4445P'S!6;_D(1?]<F_FM6:K-_R$
M(O\ KDW\UJS0 4444 %%%% !1110 4444 5KO_66W_77_P!E:K-5KO\ UEM_
MUU_]E:K- 'C'QZ_:Q\"? &SECU>^_M/7@NZ/1-/(>X.>A?G$8/JW/H#6G\#_
M -I;P/\ 'S2TF\.ZD(M3$8>?1[S$=U#ZG;GYU']Y<CZ=*^"/VIO UW\/OVB/
M%'B7Q1HKKH.O7RO:7UQ;^;:R)Y:+@/@JK@@_*<'BMK]C?X>Z_P")/CC!XW\,
MZ.MGI-A97T":A-;E+)9GA9(1@8W_ #D;@G.,\BOKY97A5@?;*3O:][Z7[?UJ
M?(1S3%?7O8N.E[6L[V[_ -:'Z*ZYXY\.>&4NGU?7],TM;41M<&\NXXO)$A(C
M+[B-NXJP&>N#CI4>D_$#POKVF?VCIGB/2=0T_P T0&ZM;V.2(2'@(65B-Q].
MM?%.L_ SXJ^&/$WB&]U/3X/&$-SJOAW5-5OK&VFEN-3:"ZD>0P([[1L7 :/&
MT+L"@<UZ7K'P[U3XB?$:]\36'@B]\,^%[J'3]-O+"\A2WGU1UNO,>X>%&.Q8
MHRRAVPQW$8P!7F+ T+I.KH^NGET^;^[7K;MQ&8XFG1G4ITKR2=HZZ[]5?LK^
MNE^OTUJGB+2M#*C4=2M+ LC2 7,ZQY5?O-R>@R,GWJKI?CCP[K=XEIIVO:;?
M73@LL%M=QR.0!DD*#FO.K7X3R^'_ (D>%[\S7WB",1WD-S?7["3R8/+400GM
M@?-SC+')-=)\+_#+Z+/XJDN=.6T>;7;J:V<QJ"T+!-K*1_"<&N6='#PI\T9W
M=K]NK6V_2YC0QV8UL2J=2BH1YFGN]%&,KW5EK>W9-;L[RBBBO-/J#\AO^"CG
M_)U&M_\ 7A9?^B17S%7TY_P4<8?\-4:YS_RX67_HD5\Q[AZU]QA?X$/1'])Y
M+_R+</\ X(_D>R:#XU\*^.?">@^'O$DUUH6K:+;-96.H),/L,T1D:3;,NQFC
M?+D>9\RD!<A<9JC?^'K;P'X@LVU&6]L89P=IGMUGMKN!QM?RYHG*R*5)Y KR
MG</6NF\+_$35/"]K)IX,&J:',V^?1]23SK60_P!X+G*-_MH5;WKHO.,>6+T[
M'H.-6G!PI2]UWT]=[/\ KU1TNK^%;+Q%XL'AO0[C4]<&FAK:&WT^PP<*29)9
M&=P$!8DECP!CTK0TV]\)?!F:[O-/N+K7/&$EI<6216UXDEA:+-$T3^;($Q.P
M5R0L9VA@#O.,5RWBKXJ:EXBM[JQLK>U\.:+<R&6;3=)#(D[DYW3.Q+RG/]]B
M!V KC=P]:YU2<_XC...%G6BEB'IV[^K7Y+[PZ<44;AZT;AZUU'K'TO\ \$Z?
M^3K/#G_7G??^D[U^O]?D!_P3I/\ QE9X<_Z\[[_TG>OU_KY3-/XZ]/\ ,_#^
M-/\ D91_P+\V%%%%>0?!!1110 4444 %%%% ''?&#P;>_$#X:Z]X>TV>WMK^
M^@"0RW6[RE8,K#=M!./E[5Y]XM^$'C;XH1W=UXHU'0K&[M]/GL=*L]*$SPH\
MYC\R::1P&8[8PH4* ,DDGC'N5% 'SCX@_9S\1ZGJ7B.:TGTBRT^ZUB#6(-.6
M1F^U2J\AE,LK1%D5@ZL(R)56121@'%-M_P!G7Q';ZQH+K'H#:3IMG+:FT>>4
MR2)+:S0R1R3B$22*#(NT[E 48" @&OI"BETY?Z[!UN?,$G[,/B6YT?0+>\N=
M+NTL8+JP.GQW+6Z06\DL;Q.LRP$O*HC"L^Q&;@[L@D_3D2F.-%)R5 &2<T^B
MJN*P4444AA1110!\4:A_P2X\#ZQJ%U?R>,/$"/=3/.RJD& 68L0/D]Z@_P"'
M4_@7_H<O$7_?,'_Q%?;4.1"@/!Q4E=OUW$?SGT:XBS5*RKO\/\CXA_X=3^!?
M^AR\1?\ ?,'_ ,11_P .I_ O_0Y>(O\ OF#_ .(K[>HI_7L1_./_ %CS;_G^
M_P /\CXA_P"'4_@7_H<O$7_?,'_Q%'_#J?P+_P!#EXB_[Y@_^(K[>HH^O8C^
M</\ 6/-O^?[_  _R/B'_ (=3^!?^AR\1?]\P?_$4?\.I_ O_ $.7B+_OF#_X
MBOMZBCZ]B/YP_P!8\V_Y_O\ #_(^(?\ AU/X%_Z'+Q%_WS!_\11_PZG\"_\
M0Y>(O^^8/_B*^WJ*/KV(_G#_ %CS;_G^_P /\CX<@_X)6^!)@_\ Q67B+Y7*
M_<@[?\ J7_AU/X%_Z'+Q%_WS!_\ $5]JV((6;(Q^];^=6:/KV(_G#_6/-O\
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M<Z%C],UPESX3U"S\5'PY-X>T1-8\P1?9SI-EC<5W#YO+QC'>O4_C/JUCX?\
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M4?\ "D_"?_/OJ?\ X.[[_P"/5W=%'M)]V'UJO_S\?WLX3_A2?A/_ )]]3_\
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M?_'J/^%)^$_^??4__!W??_'J[NBCVD^[#ZU7_P"?C^]G"?\ "D_"?_/OJ?\
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M_P \8_\ OD46K=U]S_S#W^YD_P#";^'O^@YI_P#X$I_C1_PF_A[_ *#FG_\
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ML/\ SQC_ .^11:MW7W/_ ##W^YD_\)OX>_Z#FG_^!*?XT?\ ";^'O^@YI_\
MX$I_C6M]EA_YXQ_]\BC[+#_SQC_[Y%%JW=?<_P#,/?[F3_PF_A[_ *#FG_\
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M0 4444 5F_Y"$7_7)OYK5FJS?\A"+_KDW\UJS0 4444 %%%% !1110 4444
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M ,_.C?\ @/+_ /%T44>Q7\S^\.7S#R_%?_/SHW_@/+_\71Y?BO\ Y^=&_P#
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M_P# >7_XNCR_%?\ S\Z-_P" \O\ \7111[%?S/[PY?,3R_%?_/SHW_@/+_\
=%UOQ;_+3S"IDP-VT8&>^/:BBM(PY.K?S&E8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img227133604_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_1.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %UR^68 X0DE-! 0      #@< 5H  QLE1QP"   "   < @4 )#1$351?
M,D$M1V5N97)A=&EN9T1I=F5R<VET>5\R,#(P,3 P.3A"24T$)0      $'-1
M1W[1N\:U:/OP6Z=DML,X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  5 !3 #4 ,0 P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              R@   <_          $
M 0             '/P   R@                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   R@     4F=H=&QO;F<   <_    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    "#A"24T$#      ,IP    $   "@    1@
M >   (-    ,BP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 1@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M  ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !
M! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S
M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($
M! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*2
M0U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M]$S;.IOLLQJ\,/QW0/7%P:2T@;]M<;FV?3_X-93L=S'SEXKZ"2UQW9P#(U:7
M/;[-K=K?S*_?_P 8NF0+\+#R'!V12RTB(WM#OHG<SZ7[FYVS^N_]]&U. S&%
MA>RBEUM@DM:S.U<(:-[G,?O;ZF_]+_V[_.V+1P;>KU>ECV8)92WVFUU[;7@3
M^=I7OY5VGI^#19ZM-#&62X[F@ R[Z9_M_GJPE:E)))(*<;J.+DW9I>W$LL96
M6&NVO(].3]%_Z/\ X/\ S/W/TF]Z'AU=3P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6-2"-<)LT=75,--O--% 6%//-K(W!1"7BTE0A12"D)WC[%$@2)G!/N,3G,$
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MU(UE.KRMFL]K?W6-NDE5Y=\8DZ]L#2SNV[UP]3/24.YE*LH!()R4) V@@D&
M(V@B(B,142/_ *HXZG[//GR\S5+XES+LAR$&-V^+VE6192V2YB[8B=N,-6ZA
M5^6RQ>*?DFR3MPQS,VJB5R"E+?;*2[RE)R-BK3YP_FH>6LYEGK@DRN5W4XE\
M;]^\D(2E8*MQV)*0E*AN)VI(3"3A,)@#%!M(!$ <C@ [I,@>O,Q.?,D41S5L
M/D(FD003>)C0!LHQ?R?LW=3\- DRKG5UEZ/B9BMG>5]*+1FLIK(9C(VM+)0C
M>SH2\^Y"5=-;6W6EA;?!42EP$)(5]:0ELM@A76$%38@_5\.,82D1'!B (ZS!
M\^)^%=?G8)@RH7JAQ]1P[2JHXND=C:YXXJV-$UQLUY@*O"WR-J;;'E8K+V4N
MTM"5*<AK(BS@(.:"+C'!'0=@&SCL1+[BDJ)<4HH#B5J43X5*6D$*4<2I"Q$@
MDCUH=J1T ZP!P/AQ'W36F:KUL;AJ,RGLV4JMR]%SK:J_=#J36WF[7=C;[\=.
MHXYJ4Y:8Z.QO.N8N_."FIE'JREK:Q=I=J(Q%<ABJJM",TI0E]2BEO=N0E8,+
MB$)2MU8!W ;0 M1 ,$[CR<R8Y/'PZP)^X9\OA5?57(6TXM'KEEK*%-AJ7A2]
M5/'-7*>@258'%F0,H1U1K-8K$179.M1DO3YRQQ>9JM K)-HM@HW:756-EE&B
M:DLDC04N24PHE:"N!D+0G<HF1X5)!;)&2)3(Z4D'U@_?75P3;MIN9D<D3.$:
MU 2S"XL2HY%GR8>L]/A<AQ<W,W:2.5Q/6JEUZ)R+&/IVQ7R3>FBWL\S\?9IN
M0>F(K8E5WU3B76P@.*B/JI[U*E(X !0E:E-F$I$$),!.( H ,D1GT'QZ9GUF
MMV+\H[15)W(EBQ.O1V3V"I<:6_Y"K5(?0];D*+B9!_#Q38<H)5QE4[C!XY;.
MY*-9,X6RS2-706?-DT6:9G!=0I+L)2K>052E!),*<B2$$R"K&XP"8$U C*L>
MIQP/=F/?\,1427FU^C?%M6<Z7.K87F?G(T>S2T9D,,-*VB6R%CLE9CHV[3-J
M?15*E)AK5&53L,=#7*6NQ(Z-C(B3)#6!RU0.=H%P)NLM@N@,K2DHW* 0O*D!
M,D &02G;,D2,T&V)QF3Q]OP_3'E4[96L.UJI.<?9AR>UQZXG558UOBBU!54[
MG=91=&.EIB*;8V:UV'G;=.+-8B5G95HA4F3X[2,D95^0B31T[6/;2EQ6\)W0
M,N & ./KR0.@YR8'E4XQ\(QY9^&*C*2RQL?O&9*[+2U>KUJS7"5JN3T1;)#
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MZZ\U'Q;P%F3.466?-T4W*IU#4!:TQM4I,%2A"B(4H *4(."H !1&2  >!4D
MX(!&,$ @@<#/0=*D4  H 4H   '  'P /L#\&J:D8 'E6NE*:4II2FE*T$.?
MZ?L#^\(Z@B1'Z^1^XFE8.JGLAW)X34VW77%,16)%W5);(V3LPXM>V6.81RV<
MH3;_ +@<7XKO5>EE5 CE%+RRR)4:%D=,ATP!G6*7/)@7U385'F>;AEP.]X%R
MK8AM0@GN>\0M84.5%,>#Q1'AZP+109!!  R9!DJ V@CH!U)SY^M>A7=@N?\
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MJVWQ:FP$<QV_T+=RPI=^&[1#IEE^<R]AK-.&\7QL;!)HDE*FDK#Y=4F[L]M
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M%0+B^9E:063!QA.7F*LU*QUA+9]D*L/XZ&:Y8K28)VB7W#V205DDY]R4()G
M,&B8.$W<J\J7;MMLEU:7)2EH*1OVD+6[<I.-IP P ).%$]( @*E6WWY] $G_
M /='7^FO8J>\+.$G=L8-LDDI.+,:JW:VX<N&2XO&=SR%1[]G.B;@[EA"1I4;
M9VEUBB8+A[HVK<!+T*;OK"UQ[RSW3V*--OYBK^&M%"F$@+#:BM82EP()"5!H
MMI7N*2)5!)"H,C:3$< N<@&)(GU!(X$_[S%95=8U5TTI32E-*4TI32E-*4TI
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI3D/MTI32E-*4TI32E-*4
MY#[=*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI4%7K;CB[
M(%Y99+DT+I7KVUC(V"=V;'&4<F8KDK'7X9^]DXBOW(^-[;5D[I"1+^2E',7&
MVE.6;1IY65*Q(W3DWY'%8<6E.P$%,E4*2E4$B"05 E,CR(X'D*1]WP_7W52E
MVV;[><B8Y'%5NHR\G336C*MS4;$M5O82ZMDS;'Y)B<HR2UECIUK8U36V+RYD
M"/?-U94[5%G/"W9(-DHZ+*RJ0\ZVO>A<* 0 821""DHP04^$H21CD3R3,%*3
MT'7I^4"#\2"<\]>:DW(6':CDVL1E0L+Z]Q<)$G3["=#R=D;&;YRV(P6C#1LK
M+8]M%9E9B)68KJ)+Q<H]=L%502=F0\8@@NG0E90HJ 22>JD)7UW#"PH"" 1'
MNXQ0@'FH0)L1VUL',>[J]6MF/7$3+S<Q&+8NROE7&"\>>Q4C&>.I>+8N*%<Z
M\NTKSFH8>QO$DKC91*%:^S#5XS8H/W#UTYK+[J@0I94"4DA0"@2E2U"9!F%.
M+/KN,R(AM',9\^/(?F 'PJKE-H^"3(T..0K,\PJV-SP3BLX]C,A9$C<8'DJU
M:E+U"3MDQJRM2%'N5D9W13VL/9+;!34X_L2368DI!Z_9M%T([YS)D2K=*MB-
M\+2$J&_;N"2D1M!"1D@ DR@??/QSG[ZN4U;J::4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FGNI6&[*SK>O4\TY]W%8\HEDDXBR4C-6"\05EH
MK9K1*QS[&N-T;?B*_P _AT]5;0R$#,YCHV6HJ#M+6TNW]OC<V42-=1:$:G'R
M),UOV=:&&EJB%M..'PHG>YM<1WAZ!&TF?JPHCC-LA>Y1$'"@),'\7;'3F>.G
M.>)SC+SNNA,LC0KTXR(ZQ="9$N,)"9:JF'H^6L&07 5S!-DQ["W!I"5&PPE5
MQN^?W/,E;GLBP]2B&B0T"+9OKI5)IJ]=6>T$M%L*3^ZD)*D+< 2E(4X%E/!*
MX#92F22"<&015F8/$<CS]1F/S2/6*C&H9@WQ.ZY1I6Z0MN0FY+(] A;UC^JX
MEM+6U13J18.T,AQD)>[/@L<8H8UKLFXBY*)F7YI.-DXN-G&*.X]:2<Q";FM3
M;.Y0 !3W:E)47D&0)VE2 X(61RB09_N*H$Q*NN,]$DCCS\O/UZQ7E8MM>]"H
M8H=)V>1S[:G5'Q)CMI(!.8ZB5,CS65[=GC)-*O\ )M+"IB6UK66OXIQ]"U>Y
M$;5G'%^?V*NR+.6BAL17T<UD"@PIP!(2 IQ7"X2$AI)$[EH "EE0DJ&1@X-2
MJ8,>0X&?(_T9]]>CB"<W@'Q'N2RK*T6=J^X*VUG!AJ^VDJ'(KMGEFAX)*L6!
M^RJ#M.,&1(U1*I(2\<U+&ID455[18U,42H2M+'>6Z006Y672E8F"I4#=) @0
M!R8C),FDJV?R@#$^?N@?FS50S>2]\$+;<D0O@IYS!U.8CX@SQCBB9L\T\QF;
M(N.84,N8W<Q&,8K']HR%\E[J^6VP8Z0NE[D3VM5HC!XOC6-76J]GH"62&XR5
M)$[EI2-\&4K,C:F8$PG$^(2"*?%*I,#I )\L^G7K\)KQ<FY@WL1:&1!Q)#Y1
MM,M%5ZU.<:L+5@A)G#67'[7;#*6FNY)GY@*M6%6^<76Y--A3#8E(E N%H00B
MC8?09.SY&8U(;:.WO-B1N2%%#P)W=ZD*2!N5]%W6X[X5)@]Y^*9S."3(,>$B
M  8*I_&G[0>/*IY"Z;S(N^DQ^^>9"L%;)EJ3I+2W5C%<7"66?IUIQAA"P1^0
MG%L=XWMF(8RKXKN5QRS$2$9)A0IFTMZI&(0UHLEIJ4W4K[&QD@$0GP;CN<!@
MA3HV!(()*@EL\F)DP% 4E6WS.,\'&28QSQ$#TP8JF\<7C>/5L=X^GYESF6UP
ME$QGM 2O<-:L/)O\GVB;L>0IN'W1OW39M4HRU6N<Q_5J^R1B(ZK0AI9]$2:M
MK,M=Y.;@Y125I84M824IW.W 3"H0E "2P I1/A429*B<#D&:#= F9A,CC.9G
MR/J(Z>E>+*9 WIY,Q/FV%F&^<\5Y#EL+9I<8 84?%+&./9K(0,OIUE6[WE]4
M+$WQK=(Q"-H#&GPAYNAO)0Z[2>8R=J>V($:[ 2TE;:@$+ 6@.)4X F/#(&02
MDF=RA@"<XI*LX(@8@2#G]?O)]-DAD#=_6ELCKTN RT>#E'5KF<<VU?!H2UWR
M5DJ.P)MD'$E;R=5GM9@4*;1;C:GV7(V_VHL!CII#2U32@7EWQJXCSC-5);8.
MV2DG!<3WJ4A* XZ%[%GZS@2&]B?'N!F%8H=V?+I',P,'TF<X]]7280LNZ5WE
MYJCE9-^I0+5';I'+F+4I#&(BL>OL8Y_J51P<RB[.S:MI"4+DC%-@L=C%>PK/
MC61M664[7DXMLC+DD;*PT$'NR2I)9$J4"5;T+4X8 &$*VI,8& <S4C=^-CT'
M'O\ ?\:O?U9JJFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2H'W![A*
M'MRI)[A=7*[EV_7")I]/B>PM:+S9EP$&4!7F:RB20JJG,F9_*/EFD) L14E)
MR081R"K@NQTO2[K5KGN+8)2E"2[</N':S;,)/C>>4<!*092E,NNJ&QM"E0#B
MW5RBV2GP..O.J[NWMVA+MPZ02&VQ@)P)4XX4--)\3CB$R:QED]*[D=7PO9VS
MTY3QQ$SM"CGJRE.IWWBL8W(8!V]="2BTN@XC *H<H$61,Z4,6/.B\5[+\![(
M GY\?P5 _M4V1X4A:^=6'U6X7Q,& )D52!J\2;&SX!(.I.&"8P8TWH<3QZQF
MMJ7I7LCKBB"&VJEJ^*.B1KQGJS%[XO%56T?TBIMY)V_'NFSMND*H$[!FQU'O
MAD%&ZJU1[#V(!)UU^ "3^U5O^*)5CYYGPC) !)X -(U?/[!L_AJ+D<>?S;Z'
MD_T5N1]+!D%<"BGMKJ!^ZLR0;@3.ME^Z%),%5(T"=W;ZCT ];MGC@AENV5 K
M4Z;LS=99LFM![#62>=<N ?%,Z4W V0%@SJ\>$J2#$_6!$YB@JU8?\BLNG.IN
M"9]VEGW>==LGI7+D8#";;M60(4B:G63-%@4 R2[(THW4*4V"T3B"T0DO)%+P
M"A$41;K$3?G3:&I5V'M@0!K+A))!'S<T% I<#2H'SH1(<4E')&XS,":@N:L#
MG3[/X:B\9_\ TP#[2/M@'MD]*S92@45]OT$4ID>^8Q,N3AP33!H$H83!\C9#
M&$L*<DL(% 3=DWA  9,IV18/8FWZ:PYDD *L&TDD**,?M@<=X"F2>9.$B:=Y
MJO6RM4?_ #[A^.=/'V5Z+3TJ$VLL5)Q@6+; (.!5,&3Y=;L%9MTWSTQNC%7O
ME:QRS=\;M=0KD7(@U!9V1=NE;5V+9 )&KJ/$38MI!"CM!DZAF5 I^_BG?:B,
MFSML<@7CL\3ULH^/P&:E&%](5+2W(*X=CV9DU%TERCD*16[)V8D!_P ]..R
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MZ*;;NG5(4T;5&/"<\8.?./..L5-:N<C8^9UIE<W=[IS6GR93'CK6YL\*A6Y
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M"JB,'<%5ZM*4E_&GC%JSCBGS=8KTRP%\J*BI.% ^&4A(*I)(2$X@F<1Y29-
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M4]%Q4 QCZS(Q!XE)ZU?232RMJDBZLSE[,"A*@N-JG XHCH%-I00DD=5$J/N
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M9%<"0L9],,Z/)BI^,C>2&[P GBKW^+Z=9,&22U,XG(0F9/!P9&#@FM+<:2A
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MN2OU:=P"R4U*$,:LOY5=!=@C)O\ 'M$55;%2AW"#^OVET)V B)600 ".\PH
M\P!( Z D9DU&T')G@#GR\X.3Q]E5I+;+L4/\/57!4;(VJKXZI5_E;[5XZO!3
MTI"N&DK/8[2SK-4EY.GRDA1H.L+V5U$4V1HBU8NE6K[*-BH>VMDD5SN:>^7W
MG>F"O:$DD'("0D2 0#@"9!!.8F:F!!3T@CK.>N.M>4ML:Q86'KT;$VG)-??U
M"%@(FJV2)F*V:<@7%9S 7-L/.-0E:E*0SN4;V\IFJR,M#R,,]KZJT6]B5SJG
M=&COG 3A*@HG=N$\I*3Y< @B#(('E2/N_1%;J=L9Q'2B5_U?.9"?+UV9H4\W
M=R\Y#NW3V3QY8LNVB(7DE4*ZU!P9]*YKMYI@4BMQ=)(PQ&PLCM'*CZI5PZLJ
M)VC<EQ, " '$M @9, =R@#RB>IH0#TY_W_GJB8;T;&W> ;S#2*]I&R<S3J?5
MU7PQ^-5[1'2U$IE*HM:O<'?E\=*9!A+2SA\?5EPK'QUI0H;R6;O9!U2U3RD@
M1Q*KEU9&X_5*B "0/$I2R-H(3&Y:HD3&)B*@) X']/E^:!]E72XAP]&8@:W8
MK2UW"ZR^0[PZR%;+)=G%>6EY&QO*Y6:LJHFC5JY58-@Q)%5.)(W8,(9LW;'!
M8$2D1.FBE:6LKVR$@(1L2 "( )/4GJ23YFI B?4S]P']%2]JFIII2FE*:4II
M2FE*:4II2FE*:4IP'GY!Y_'\/X_MTI5FK?>OCQ/)4W0[!3;_ %" BLC7W$S+
M+5@)1/DZG<@XUQK)Y=MM?9$B+U*7N,(QQ] V6>1F[/28"O.2UV29)RH/UHIM
M(WO9U! 6"V2I#:R@%05M6ONTD!20)"L0"2.2(DBDK (&<DCC$@2<\#XQ7BTG
M?ACS)N.<7W''6-LMW"YY;5OY:OA!I$4N'RHQ:XMFT8&_2=M+:KU 4&HQ-;>R
M%?!P_G;XS1>'M5791?CI.::L1E=LMM:T*4VD-[%%>2@[TA20D@$J*@3P#$*Z
MI- H$ B<B1B#\9B#[Z]YAO/I#W*/R''H.2&N8DI^APLACD6]'D9R):6^DQ-_
MGK7).X.\RU?;TS&$%,L6U^LQ9E6.+87<76JBI;9NQ5IC,0;=8;#DH[LI4H*S
M!VJ*-H! .]2@2E,21XB ,TW"?4&.).1/2<1UXKE2WN86&1W$,'A+:Q#;A,U:
M#L+D8 LG[=R%RFI.EP+?%["#?2LQ:W;[*4#9,1(1BD;&2SC(M?D(AJQ79*QT
MF^=PX>ZP"'9*3(A(2-RBLG"0$C<2>$P:C>DE0ZI@'UD2(\QF/(&1YUW9+=42
MI(453)F"\PXN6R3DA[C6HL;*YPW-.W\BRQ)D_,;B:<#CS+EV:QT,2NXHGXLY
M'[E";]?OX5OZF&-7?2D=0EH**@A;:@A.]02% )E:$Y*DI!)4XDR!&9W8J28$
MP?Z>"?7RBHZA?2.;>YO'6)LF((WM&&S!4KI/PD0>M(.K=#V:CV;'5(>XJGJQ
M&RKZ4-DR9NN3ZO5JQ!P24Y'3D@N+MI-##/(B4DKGLSH4XG:);V[B"((6E2]P
M/5("%;CT(CF@4-H4.#$<@P?2.F?+W=:NNQI>;/>H^1>VC#^0,/.&;PC=G%9#
MDL724A,M%$"JA)L38MR1DB/;M2F$6ZC:8?Q<F18@_< H]*QK2TA)A*TK&9*0
MH#K@;@/M@@]#4@SR(/O!_6#-27P ? -4U--*4TI6(;TB"%[7SA@TM%R7'XT=
M?)1F'U@^D+_'T$DDS]JL3]Q-)W(%$C]2)0%Q.$03, I*,$U%"'(/).KT8-'1
MM0+K"WXU/3-NQI3I0?9M3)G:1M"X")\B8XSM>SAM$Z^#=V2KM'S/?QLMC<%M
M?MNE[00% H#BO 3$9R1@&RP[+<:<6X*;I:NTY;F,YZ-QU8Z6@]KI642-V2&6
M!C& C:"' 4 %X\,42E+RH>[^P@,6CIX(/LKA/$P>?K$[#@X$UZ0%Z/D_,SQ5
M$8T=Z2D\&(_&=4M@$X 0 /#7%X+<@' .-T=69@*SH' EW(U?[A*)2%?@3EN4
M1]GVXMI!L'4F8BLB<IU! XF-,6<>&S<(($$VCLF,@X$#>93B(V]8J^ES1-O_
M !"^KKM^9W85!, '!^D*"F1U2<X)/&9AN0*5?O[I:LSY<E(N)=R57$8Y,5T1
MD3)"+80 T$OX6-;IG*8RI)=8@JHB)1&(M! %HX1!_P"2NR?R>@^L/$3_ ">*
MOH=T0E'[0W+FU0""-$N<K4DD3 SWP4\Z 9">Y3P0!6P['<D"BIS;H*FD;J,(
MH%W(UDI2*]T@KM_)$!*DSE01JY!]_EJ]4,/2;I(8$V9YM'8Z'V9V(/AG'4H)
M<$=0!.!5T.Z#!![/W0VQ)^8;HSX!M6/H]LEA*;R"""LRJ9(/'X+<H<6H%W0U
M-4Y6R8%3-N3K( [4%V<P=8 B03"I+B:F <G:)X)N4"(B?D--MG!_8KLR1'LK
MGU0($X_( =S)W'/G5_O=")('9N\D[0 G0+DC:4 J64]WE?= 7: /"E:UR-H
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MQ-.-FZ==:BBFH=-]'JJ-P!V"Y@A2M0 /T3*( P>_\(!*I/T)@()WF<0H;L$
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M4N/Y(/VXJ56ZZ#I%)PV627073(LBLBH55)5)0H'3434()B*$.40,0Y1$IBB
M@(@.MVE25I2I"@M"A*5)5N24G(4%20H'H02"#(Q6,002""",$$00?(@\5S:J
MJ*:4II2J/N-^J- 8$DK;-M(=LL8R;8BO=7>OEB%ZS(1T8T3<24DN5/J5.BP:
M.54T2'64(5(ACA@7^IV&F-=]?W35LUF%.+ *B(\*4 EQ9S)"$*@9,"KK3+KZ
MMK2%+,@&!X1)@;E'PC.,D5VZM<:S=8PDQ5IEE,QYSBD=5JI]*V<%*!E&;]JH
M";N/?(@( NQ?(-W: B *HD'RU797]GJ#*;BRN&KAE<PMM4P1RE:3"FU@\H6
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MWP8>SHY:U15VICW*1@43<8ZMSANW>OUT#&(X-4)HHIQ5P; )#K A'*(V!HU
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M9#*RIFW1MHI2H.$1%$'6)K /=,J48Y!-X48(.DCB115BGZ9S(&-5T6B0@02
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MPD"_8B.8'TG (#:?)I2AT,[3RF5S*+*$VSTXX!R<%%<1V(RYR*B20165_(
M,X6CDEI=Z("83V9!FOP00%(8V6D8U)X$R#^RF<2DI@'O9@*,3B6RKBKZ?8L#
MY[NIC:1\YV\;E)@)C<1L4I26R."@J!($BMGK7*I3-C'VS4XA"M2"H9/$5B[B
M( N:3/X01K_Q)%G3FTNH$SA<E%7'8 ![1JBBT(/[9O$S !NF8/AV23WOY7A/
M_-<G%7P;(*QK=Y(!3_QI;@_4"5 'G:%I+!!P6!L$B*Y(N3RNF\9E<;9Z:U*1
M3A8[+$5B2.V(U,9XY.Q,:OEZ%&C%5*1AC")!+/N'JW"@*E3"DHLR%1J3Q!&)
MNF 2H@ 3#IP2"%8C8$S5PFP*#&O79G<L ZG;A!2H^%13U+BVULN@Y++: HA,
M5.M3>Y&#L@YP+5(\4EB L#+&LVV*V!D)P=F9=<*4 \""S<801Y(4SJ1Y4."H
M &&XED2!?N\$8?;4#NSDA2IG._,CPB<16O?39$*_;JY,[B =18653, D.))D
M8/AF-L2 *N-K;FX@0WB<50+/HZ"&!O2I-(I!12!%<A &-#Z-LNLDT8>1^B-6
M=EY,(ZPEAK$7CB@)Y<1U(CDGD253^,!Z&M,ZFVB!J3JN9F[0>3CZJUX.2?4
MU<'75)X!("]+BVPB!0,"5?=)$*8I00,7WFI>"$7 &R7GR$?[G'D!M8RPC,/J
M401^.DYF?.9@R2.L$Y-:IX,D8O'#R0"XDS!P9Q,QSU/NFIWKQWA@3[L2@VY
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M)O2P$8I3#(Y-+U!SQ\@.>@$.?,.0-C0A@'CX@8I3!R(&#D-;H=E]9@>"Q/\
M_>=%]W\8'XY.?3%:?\)-*&"J]F8QI.K'C_Y(5K\]' 7Z)Y-_Q YX_FV^K_WZ
MG\%]8S]'8_\ ?.C=/+]G]?UBGX2Z3^5??]T:M_J5:_/0P%^B>3?\0.>?YMOJ
M_C^OZGX+ZQ^]V/\ WSHOK_T_]<1UI^$NE?E7W_=&K?ZE429']*9L@P\\C(_)
MN4K=37TRV6?1;:7P+N"(J]:-U00671!#%BX"FDL()F$3%$#"'E]>ME8_)]VL
MU-*UZ?IUM=I:(2XIK5M$5L*N K]LDQNZ8@YK67_;WLKIBD(U#4'[1;B2IM+N
MEZNE2TI(!*8L23!(GWCS%>EC?TF>S/,+.3?XRR-=+DSA7+=I*KP^!-P!R,G+
MI(ZS=%<5\7-Q ZR29SEZ>OW2B(B CQJW?=@^U&F*0B_L+:T4\DK;#FK:*DK2
M#M*D_MBH$ XGS\ZN6/;GLSJ:5KL+ZXNDMJ"7"UI>K*VJ(D _L$9(S5TV+,SX
M\S&SFG=!EW[\*W))1,XQFJU:*?-QKUPS1D&@NX&X0T#-)M'S-=-9@_!@9@^
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M=@Y)^BZ@ @P_C">  !F "9$XU>K.6X=/RZU%4$7"XE*G*6!QX,6@D[9.M2.
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MV=<E* B110>KW^GRZBA]0=D/B'N=S[XX@&.I0S"8D#R(S)GG.2>!^FM:\N9
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MBJ*@3S YSM!+]Z(:\<[U26BUNE3D+W* 4$A.0E1,#QCH8D&/?T&W<M)R,$?
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MM5N!W*\/$XK:MN%-LAQ2N]/=!6]E)<W@B0I 2!ND$$0!NZ#I5NV%X&>IM\Q
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MJ=D!&()VTC%FBL!*H7DQR;^R<6WHE\I&T_MII\@I"CX;+55B)(B=L&,^_ .
MM_V?6;14Q.F:@G/!_9>E*@@>J1[@3TF+5#HXC(*?-2RJ7E$XF\-<! 2_<A1$
M6XA2R@*Q4A [ Q^@1M@O2CT"!7*F*7GS^.DYR D\<X&[[N>3B(&X3J*C!#B?
M+B2(XZ\_'%<!D,1"8PC4,JE'O/>?!W(X 02ID[HL!&DD\BD,4U; XD(:3&5
MO8X ZL%]T8+@D>8STYE7/G_NJZG4E<=XCRRDS[Y!@9\YQ7"HCB 2.1-4,K@
M+*=?@;DH)RB#AN!AB^*20P F<2! @0"%/&#-]0H '0H+[V?$@^]$Q]IG,R9S
M$?"\F_49(<9D9G8?7F", _ #%;3H8@$ZO-/RB @901[-R,*'(.D0$$?RD<>&
M*H)4V(E*!0J1GQQ A@%L9W[T_61'HB#]H5^OYKXOW<?2-1Y[#/.(@SG/D8D>
M4<0)8@*9L'L?E(!%!,2@K=![/^B)BAXL?8@P<]T#$5%4!6&C^'/P("#8([Y\
M\K$?^[,_:<9SUY]*NIU!^" \SR>6^//\8\?&(S KDBT,0E>,A3J&50-U)=(R
M5Q,"0AXHX$"2*:D"44A.42376)NFMA'#PJ G03=\\!]9'O*8X^/I,>_.!5_Y
MP?Z.-3_U1/)C/BS_ %P#U$U55#&@ W%"M9&+],VZ?6%G.=3DQG I^L &J ($
M'@X3GWY  (P!%4..BV7'""=Z>#PDGCUW<U0J]N"#+C,F<=V#CWE7EQSTB0<3
M]6TJ3T<H0MQ( @@ >*FS*'X%L<2]?$"3Z04^H9$"=0>M 9E$3&Y.6R'7#SF)
MC$1!\Y@SCSZY$36.NX>5RMH@?R!SZ03CW?T5/-?+7RB0$(Z?( D+TBO(B<P!
MVAX#GU:0>X)!$RO \^L> Y'[_5I3BB2.D\9\_?6,MYT@^)&#& <^D2,\0.GI
M4V08,@!/LH/"<@40$ZXG'R* @/FB0#>0B'//YMUE^KD8DJ\ICR_3( ]?=.)C
M#6I<Y4#(/3[B,\GW^IQB1"<=)0#X<!\1Y^K[?K_']>J*M5NTI32E-*4TI32E
M-*5B2RQX8N6,NE< F"SNPK(-%#'$JR::,/$*/E$!$Q4RFZ%4B',K[AVWBR=:
M?28Y?G#M8I".TFN[M@6X^E#942-B$L,*64[2#O4HI2E60"' *Z^Q!5:VD?5#
M9"OBJ>O(D'TD=3BH!+.LRG.Q;,RD\<0J)%':W<$'Q0ZF:H&(1,R)A<\H&515
M1(F@Y5Y)[O7KDFKUI$LM6Z4]ZT9<=(6>^D[0D3LY^KCB 21-9RF5$EPO+*09
M"4 ) 2.>HS$^XD@>E!OKE..T#A(RCYQ$PQ>ZG%JN%08*/#J*"S;'9]8(*];H
MQG+DBI>XHU;N@Z^L $=:O4+E?>*>>=4RP"2P%%*.].&T%*2!X5'>H$1""F,D
M5FH8:2$AMOQK@A2H*C$S).0<5";NQ"V?$?+B9P!E#BZ()^3N4' '2>)'4$>>
MIP@JJF)^H# *G4 @;6@%R&W4NK,@J/>E(RI*X#H\(,%: 1Q@A,# (S C=M3,
M"4  \<C!QYXP!]]9K?1ZIBE@!5/N%6*2_P!K!)<OWCA 2QAF[DGVIN$!373$
M/(4U"B'QU]1?),DI[(M)E)C4+\!29 6.\20L2 86""G&$[>LUPO:$[M0GK[.
MP#Z$),_?)QC,R:[.\HR((XS%P4PM4Y2RJNP((E,+9)I&'6*0W( "AR%%-,1$
M %4Y"@(".L?Y4 #8Z,%B6Q>O%T2!*$V_!)Q!6$@^4STJ-%!F\@$GNV@".?KK
MZ]!T\_/$&K!+ ^8QS]1<Z:QUS&3=(HE'I:HDX$2 U5%8RHI$.0OAC*I*D! I
M2"FX*8C@?%W'6&G''7&E.*5L6AH+'=Y2%!)(Y X,'C@]*Z-+;JP A:6^DJ22
MJ<<$8_\ =Z<3Q5#25QF8]8Z< Z6BDY5,O02/.9 ZA55 +V@.F)>@Z+A-1#N-
MR-C*]OJ.'2?SQ']4N$*";50MFWDA1#("5$2KZRR1D$R.""23 )JM-FRL#OT]
M^09^E,H!3F0CB#(F0?/&:AJT3QEUU"F<'7*@ I>(44%0[A0!$R[DQU/>.9=8
M5%"F.(F!(4TQ$P$+K07CI6HA3A6(V*4HRIP_54LGJHB23R8 YK:-(2$@ )0F
M)2E.$($8"1P ! Q\*N>V!OO'[D(U<.3&)C^VM''GSPHT6@2H&X   H*-3I)E
M 0Y,H@L;GS'7HOR1N%[M67 9(T>^;5!F%(=M=I/62D@@\$[NH-:;M$ -./2'
MVN>N%\0  (^'ES697+O]BC)W^U]<_P#DY):^CM8$Z3J@\]/O/\G<KB;<Q<,'
MR>:/_P!::P]R*L>C#LSJIK%.U5%)[V#_ )N]<%66(14IU  @-6P-2""1B'.H
M+E(.@PBN3Y8<5;I89+B7"4QWP:6D%[>92252 $H*0<?5&<DSVVU:G%[5""H@
M!0.V3C,=/..F>>*'?V<4&Y7$:D1HXCC% BO(G631,H94BJ:A>@1(FY$P&3=>
M* !<)$ PE* !8<U$);4JV80RMH$[ECO'MI( .[*01SQQ&,5=1:[B \M:IGP@
MA#) C!!\4&<"< $5&UDMDJ^;'7E))\]</S&[8.G"ATT6:1QZQ12,84TB.'2?
M0!4B)](-5 $H@H(:T]W>OO-%5P\IY;Y@)6J0&T&)B=H*R!,"" 3@ 5EL6[2%
M MH0V$&82D22001N^M$&<Y/V5"<[+=V+F69C!R+)TZ0 .!#O-FZIE2?'R [0
MRYA H"*BB2!?/R$-.I94AQK\7:5)SC<F)$$PDQ $&#]7SK.;2=Z21,DS $\<
MDXZ>9XXF"3],F1V3:1HL<Q>(E<-'5HQ:BX0/R)%45,@U(IR' ! >D0'SX$!^
ML!YU]\Z>I2'4K02%(M;M0(G!]B?\B//K(]*\:OTA;.Q0W!5U9@C$?VXQS/3S
MC,<0<UZGR9T;@0"LQO'G\07Y\_\ [74^WWO\(7\=LQ\,>?3K3V*UB.X;&/(G
MGX_K%0M2MHFWK$%VR;E['6-(ZOY*R8I+2MQM:4E8)"0F'KYIVUBD;24L]CX]
MN)$DDTVL6R9MR 7D$A,8PFS[G7M7U"WT_3KV^6[8V.QJU94EE(:1WA<VA8:"
MU#<HJ\:S$0,8K7LZ%I=B_>WUI:):O+P*6^Z''5=XKN]DA"W5-I.W\AM/K)JA
M\?Q43?)K!]=G3.)FK1^UBL6)"""3?)0:DO(N:S'MYA[',G:+*1=!'LG*$4XD
M$G/A43/QCA2,X>G4J?>=MEZA<6_T3B]6N&B\&PE9">]4I 4H&$^)"E!$\I*C
MM*=U3+3%TBS:>276TZ<RX&RI10">["5D)4/$0%!)<Q"3M@@U&VZST5FUK=Q(
M5*7NK:[TJ7IS&1C&$AC:P1L0=_'R;ANZ5:RS:PP%I8."MG+<%VBS9HS=IBLN
MF=RJB<J1.G[*?*?VK['>VC2W;-]%\&2\W?VW?@*8*RA32D+96@^,@G<1@>$'
M-<IVM^3#LKVS3:#5;>Z979=Z&'+&Y5;KVO;-Z5R'4*2=@(E((,YC%6D?];U[
M*_U0=Q_[L<=?S4:[?_TB>WW[WHG\SNO]>KB/_1S[ ?ONN_S]C_4J?];U;*_U
M0=Q_[L<=?S4:C_TB>WW[WHO\SN<?_P#=^>G_ *.?8#]]UW^?L?ZE54T?T#VT
MS'-PK=[JF2=Q+2QU.7:3D*Z<VC&KQ!&08*E6;'69KXG%!RF!P#J25 2&#R$-
M:_5?EV[9ZQ876F7UOHKMI>LEA] M;E"BV5)40%B]*DF4@^''F.(V.D_(1V,T
M34;75+!_6D7EFYWK"UWENM*5[5(DH-F$J$*/)P0(J\N9VA5:O1$I/SFX#+D5
M#0D<\EI>2>)8819QT;'ME';YZZ6-B,"I-VC9%5=94P@4B9#'-Y!K@6^TC[JT
M--Z/I[CKBDMMH0K4U+6XLA*4) U#*E*("0!DD"O05]G&&FU..:I?H0V@K6M0
ML $I0"5*439'  )))/'-038JMMRJ) ]J=T>=*XY]GXZU*14WCZLQ<^WKLI*3
M,.TF'==>[>D)UFR![7Y8[Q5W'(^K8YNE,R(-(=ZP?N=DU?:J^0&=#TIX%]=L
ME;5X^MI3Z$-N*;2\G5RTI6UU 2$K/>+);;W.)4@8+NG:8RDJ>UC4FMK:'E)<
MMK=+B6EK6VEPMG3.\"-S:MQ*? D!:]J5))N%^95%& HESEF82'#S$K;#(& H
MAY&((XA,'/F @)@,'U\#\-:O\*'4Y3I6F)4#(43J)*2)&-U^0)F% I(4DE)$
M$UL#V894(.HZ@H0>EB)D&""+(9'*2"(,*!D U+E7VRX8IE2A*C#U( 85V':Q
M#*04DI,D^9-F@5(CY279.FKLLHH8HN3O69FJA7)S*-RH>X0FK?UO5;AQUUVZ
M65.K4I0A!1"B?!L*8V 0D!1/A'C),D[)G1M.8:0TFV$-H2D+*E*7X1 45!6X
MKZD@?6^J ( BK#DT]L%GVN2\I(.):6D-I-Z>2D@\7,Y>/7[B=VY>)=/5U#*+
M+.W+E)P==98QE5G!5SJ&%0#B$WB4I3J>Q"6T#56@A"0 A*2B]*$H B$ 'P#H
M#U3MI9K*C9*4LK4=.<45J,J60NU2I2OY1(A74D&<R!>B8>"B/ CY? /C^+[.
M?WM:DG'E[Q^?C^BMIP/<.GITX_HK"5->D4S^ED3%-3AZO1A@\K)W!VO/M<;V
M6S5_$!*RQ%\V@,FV@,TU8Q)YZIU0A3DK41WIQNY;),$Q3.DGZ;;]B]*.GWUR
MY<W!>L/9DAHWS+"K\.@A2K%!L+H*2@@'O%/%*AT'UCYU<=K]21>V5LU;6_=W
MG?[G?9WGA8EJ(]K/M=N1N2?JH;)&#)X$U_.MSQ^GO;W_ (LK9_T@=8'X.:3_
M  35?Y];?[*K,_"#4OW_ $W^:7'^T,T^=9GC]/>WO[/[&=L_Z0/[_P =/P<T
MG^":K_/K;_95/P@U+]_TW^:7'^T*?.MSQ^GO;W_BRMG_ $@=/P<TG^!ZMG_I
MMM_LJGS_ *E^_:=_-+CSGCYP_4>E/G6YX_3WM[_Q96S_ *0.GX.:3_!-5_GM
MM_LJGX0:E^_Z;_-+CT'\8_U\GSJ8]O6XS(>0,J+8[N;_ !I86SJBSMO:2-#@
MYFMO89:O3M5B#-95C)WF^)/V<T2T&.S>)NH91DXAET0;2I7JBL7J-:T:TL;1
M%S;)NV9?2R6[IQIT.!2%+46UH8M\IV@*3W9C=];,5M=(U>ZO;I5L_P"RN ,J
M=WVR'6R@I4E(2XAQUX0H*E*@Y)((VB":N#W#9)DL/85R3DZ(BV<S)4FJ2D\S
MCY)9PWC%'#1 >VXEEVI#N48=@8_CYA9$O<1C&SM4ATSD*H7E'W2PQ<7 8?NC
M;6MW="TM4[KN\-K:O7(L[1,*!N[M3*;>W!2O<\XA.Q1(!Z6-RFF^\:8[Y^WM
M_:'R1;VWM-PU;^TW)!24VUOWO?W"@I)2RVM6X1(POE])EN;$H"$OMLX'S\L=
MWD0][S\A'/0"(>?D(_$.!^O7S"?^$O<(.W^Q1K/AA)[SM.\E<@ '<D]C5%*I
M!E),@S,&17LO]A]HY';S2B"21&CM$1F0".T8! XW#!B08R=W]4QW.?5+;;!\
M_P!3J]?4/P\L]?7YA]8A]FI1_P )A]2@D_)5JZ9*1([3N*Y4 9!['I/7I/PJ
ME7R/-PK_ .WFF I251\S(S'0QVDZ_=S$5S9E])AN6Q=04;DPG=L\^[4D(ID:
M*-CJ[M@(6027445%9#/KI4?#BD!>D6X%,)N3&((<:^RODML])^4+5;+3[S2M
M<T9N[TD:D7AJ5N^6W"REWN(=T5E*AXBF3L.-VV3M'S/\I&M:EV$TJYU&UO=(
MUARWU/YO#)M'6 MOO"WWQ4WJ]PI)Q)3M4"8!5P:M%_JXV[/] -LG[B<B_P ]
M(?;\/Q_L?0G]@GLKQ\YZ_G']L:?Y>?S=C/Z)ZUX3_9Z[1_Q/HL9Z7I/$\"ZR
M?3KP,U=]MJ]);N6SO$6B3EY[;/3CUZ18,44"XYNS[QI7K9=P=83.\_QXI=D4
M@)TE*J'O\B)>.D>$[7?)OV?[,W%DRRK7+[VIA;JR+RQ'=*2YM"/H]+43(D@D
M ?GKO>QWRBZ[VG8OGKAK2-/]E?0TV%6UZ>]2MH+[P;]11$&01\" 9-7G8<SS
M?;A8CR2[*'N%GC\GL:1+N<8/WT/3[E$6'%5NN:,6XKUTO-D@ZW::A)5N)DY-
MTSLKA\6N/FZS)$I["XA'/G6KZ7:66UMI3K3#]J7T"^"5W-HMJXMVBL.,,LEY
MFX2ZI")8 +J'00.Y#U>B:7J-Q>*4XM+;CK5R&5*LE%%O<I<9N'-I:>>=#3S!
M;2I7TRCW:VSNAWNJO9]09(L9CC8[.QIL:H4 ]2T#K?2WQ,50CN[6&.3[B"Z8
M@($A:C7I)DH(BA-J])%-<X%VS1EMHW"_WRY)2@9Y1;M+D*&9[Q]U"I +=;\M
MW+O[HZ&4$#P6X!<ZR%/N @IS@(9;4""0X< TS2<8TPK^_E7B#2)R7A4HNYF3
MEYJ17YJM4,)G4G*OGD@[.!C&Z3N72IP+P0! A2E+E/WUV$VP2[W8]F3X6DH;
M1^Z.D?1MH2GG,1CH:Q[>RMBJX*FMZA<N>)Q:W%90V#*EK43/J9\ZK[Y-*-^E
MF,_:7_Y[6/[?>_PA?V#CG\^:RO8[7]X1]A]WGY8I\FE&_2S&?M+_ //:>WWO
M2X7/7 J/8K7]X;^S^NJ)R1MPPSEJB6G&M]HL=-4VYQ+B"LD25Y+1HR,4[Z0<
MM/'1;]E(M2K%+T&59NVZX%$0(J41YUDV>MZK873%[:WBVKFW<#K3FQM>U8QN
M"7$+03!.%I4#U%6+O2=.O;9ZTN;5#C#Z"VZW*T[T'.W<A2%#_LJ2?(BH&W 8
MHQY@O9!F"@XLJ[&G4NOT"2&*@HY=\NV:%*JU$P@K(NGCQ0X]!.HZSE4YN/,P
MZR[&[N]6UQFXOWUW%Q<%X..KV[E;K=X$;4)2VD&2(2D#.16NU&UM-)T*Y:LV
MD6]O;-H<2VG<H)2VZV3E96M1P/KJ4H^<U@5N$Y'-*O$,7)G#=03$EY]1D4BC
ME9PY,?U>R5(L9%/AC"NV3M%R*Q@:N)Y=H=LH(<(]=I>EE3A*$@I5]7<  I*8
MWE,I6G<#_)CK(Q/E>KZH#;-!:E)4 ';A2)65J7]5"_&E21L*5 A6X[TX(42+
M?BV]F\3E:XW2,LI*I^*B ,@DEUS485=2-;*HK+2JYW$BV6?1*!XYW&F4?2#4
MXI "11+Z"Q8V]N+=]JV2>[6EM]5T0_\ 1.IVNJ2AM+" 6X2I)4EV!.49K@3=
MO7/M%JJX< >\;";5(94EYJ5M(*EK>7N<27&Y;<92%.I!D)$04ZR#<I55E78>
M5>-_&.TVC%JU?+HJF</3IH 4\FZ<'?@@8W1UE</O"H$*8QBII@<P;MS0M+>?
M^<KVQM+BZ8;E%PZPT5-I2 4(2E#:4P#&T *63 WJF*P;;5]43;C2[*]NV+=]
MV%V[3[@+BU*"7"\7''%228/TT#"BVD23!>1;<A(29D63E1>+BD"Q48LL<XG<
M-T#JJ.'YP4]\JDO(K/995,XB9%1\9 #""0<=/IU@6F0IP!+[Y4MP) "05 )0
MD 9"4HVI .!$1D"L6[<[YP)03W+">Z;@DA02H++D$DDJ62N3))R#)FNKCJ9]
M?W##(][N/:CF/'489+S$YJ]/WF-?,CD#R $8V?"23=*J<&%6Q1Z)3"4H 6UJ
MC7L]MK7A"47FBZ@Z5   7#%BZA2#'Y;.PIYD-*/(-;C2OIWM(69WV6KV#91S
M+-Q?-J0H \['2I*^-I<3@$S7Z"[V@U&2=KOW\$R=O7)P4<.%@5$ZIND"]1NE
M0 $0 H!R !Y!^/GX[1=W3:$MH=4A"9A(@@29,DY/IG'NBOJQ5K;K65K:2I2N
M5&9/PX^//G75^32C?I9C/VE_^>U7[?>_PA7V"H]CM?WA'V']-/DTHWZ68S]I
M?_GM3[?>_P (7]@_7H*>QVO[PC[#^GU-1#%;/=N4-FY_N-88QC$<S2$=&0ZM
MT-*3ZKA&,AVQ6C!JRBU)8\&S*FD7E15O&)N7!S"=PNH/2!<]WM%K3VFMZ.Y?
MN+TUMUQY-L4-;2X]!<4I?==Z9( "2X4B, =<!O0=):U!S546:$W[C:&E/A;H
M);;$(3L#G=8 PH-A48).:MQW?-;JZS_B$E+C49)R3#N6A>D6A82:[2!KIB0"
M.2IS<=()('8G 9(ID"I*N%&)&8&%1PD);25[- O8Y^=+'K&38:L!QF).?,?&
M<;4_:/G*R-N 3\W:D%%24J FXTPI@*ZX)Q/''40P6%ST(MORE,&G0CP8Q:-C
M]4&(? >@"U@!7\$7ILQ 1$A5W#LT:G]U)',?5=\H\-J \\'[JHWZBG^YI,]
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MIV8)464J[J\8;"9 [O8M-PE,05M2X1 [@J!6>KL]78?4$/%-NX<[E#<TI4S
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M\6]P0!];: >)C.7W(A"IUE@F0.")W/&!"AYCP4F1ZD4H?;\  /X=?35H '%
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MW[]VJ)0+W7+MU'*N%U!* !UJJ',( '(CP&KZ+FX0 $7#Z4IPD)><"1&/" H
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M>M20@&1<20>"E:HC(^JJ<>9P 9]^A*M52=':R:@GVU!%(7$/;B D#<PJ- =
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M95%5A.I%(F1$#OT#/T4"%192#0@" \=VB[#Z%VD^ENK?V>]3&R^M8;>Q,!T
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M9LD1!!%,!Y B*292IID#ZB%* !JDE1)*E%1/))))/F9S/.9-5       0
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M4QO_ !C !A^)@ >0UW0UZQ(&W6%)$1'<7Z,C!\*&EH2)R$A2HQ)F17%_,FH
MF-.)'0^U6QQSDJ>2HD<$E(R..M:_-EO/ZTDW^$\"?SCZGY^L?XX/^*U'_04^
M9=0_BT_SFU_T]/FRWK]:2;_">!/YQ]/GVQS^W*O3Z+4<?_X,_KTQ3YEU'^+3
M_.;7_3T^;+>OUI)P_P#O+ GXOU1_M_?T.NV/\<J'_P /4?\ 5_//NQQ3YEU#
M^+3_ #JU_HN*BB^[-MP=@NF*)NFX85I%4J4]+2&1ZCZLVYS09+AWD5X2.A_6
MSO)B;FN^K7W4[\2R35.L*P',4%&J &S[;M)HC=M?M7-V;I^Y:0BUN#\Y-&U<
M2M!4YM%LM*BI(4F(C,]36'<=GM;<N+)QA@,,6[A7<6\V;@N$%*AW>Y=V2D!2
M@H'D$<YK)KM'QC><;0=U3M5>-1H>;L#%[5Z$,Y'30P:+6*3:2TEVH)]*5R#]
M?/@*J$+ R3QF(,@FWAT9B;DVR/$=H+ZTOG[=5LHNN-H<#]T&BR'=RTEI&U:$
M+<+:0075I2M14$0$H23U^A65U9,O)N$]TA:FRU;]Z'MA2F%KW!2DH"SM(;0H
MI3MW3N415WFM!6^JC*F'$A>_]E<SC^W6*N'\6LFX^K;?WLC_ ,QVL:W^M<_W
MRO\ \MJJSUC5DTTI32E-*5&^4\08SS;5'=(RM2H"\UAX8%31D\Q(Z!H\(4Y$
M).)=E%-]"S#0%%!8S,0Z92C$YQ.T>(G][678ZA?:9<)NM/N7K6X3 [QI91N2
M""4N) V.()^LVXE:%0)36%?Z=9:I;+M-0M6;NW7,MO("PDD$;D*,*0H G:M"
MDJ3T(KYS=X7H8,AU,LG<-J4PZR-6T@.Y6Q1:Y%FTO<:E[QU256TNQ8P]J;(E
M,'9C;"K#SA$4S $U8WZB:!O;.S/RK6KRD6G:1M%J[*0C4;=I2K941FZMTDK8
M&XA2GK9+B KZ[*4DUXGVE^2=UD.W?9QQ5PVH*+FFW3@[T D*BUN" %Q&&WU)
M4N".\43%87(' FX',MG@\)8[Q3>Y_)L-(S[6P4]Q"NX)[3!4=L@,YNQ[ $8Q
MI#(W2/#RS.(INY.!4VZCE=5!)3TI6N:#IB;W5;O4;-NR<5;JM[Q"VKA-W#"=
MPM!;I4NX5.-K(6I)!2X&RDBN%8T/6M179Z6Q97J[MI+Z7K5;2F%6LNF#=%Y8
M0PG$A3BPA:2GNRHD"OH(V:>@AQK0C1%_W<2L;F"Y)BB]0Q;#"Z)BB#6X*<$)
MY=RBTE<@ND3\@JD\0AZP?J4;.8*82 CP_CW:?Y6M0U#?:]GFU:99G<DWCAW:
M@Z"3*FH*FK,$<=V%OI.4/M&4GV#LY\F=C8 7&M+3J#Y"?V(@$62(@PYN'>W)
MD1XBVRI)VJ97 57T!P\-$5Z+80D#&1\+#131O'Q<1$LFT;%QK!HD5!JRCX]F
MDBT9,VR)")-VS=)-%%(A4TR%*4 UY"M;CJUNNK6ZZXHK<<6I2EK6HDE2U*)4
MI1)RI1))R2:]0;;0TA+;:$MMH2$H;0E*4(2D0$H2D )2!@   #@"O2U35=-*
M4TI32E8V-WSQ@SS_ (A._KC>Q$4P]EI)-)PLZ1!LHI<L3(I"4S5NX,8KQ=9%
MDN4X%)X9=?J$2"H)=GL2O0+S< 8U:PR>@^;]7)SR.(^/!KFM8>2SJ=BI3(=!
MT_4DP9A,OZ9DP#S_ $5"P3]9.*(IXUCU162'L"H^F@[H*\L42J]4:!0[\@FK
M%+ 8R8>KT" <I6_0<VI[I'Y(ZY@^\^OJ?MBL8W3.5>QG;//TG)'$1('2>,9K
M0+!6#F+VL:QZO=.IV.Z\FQ[YG?"+4RPGBBAS(K(KMW@'$O*#=(5C=!4Q&.[3
M@@0!T@^<3Z=!/2J1>6_2TP><KSR!P.IQ6HV"K*E.">-8Y;NK)%2*J]F1*Z.Z
M5*JS!?JB_@^1;N'+P3E$.^T;BL=,X)\W T"./2#.0>O'6<^4 U0JY8B?8S G
M@N'!XF4_T\ ^>-#6*K]1S!CAB<H^_P!P7TV!C$4$'R2@@:,$W6M'IJ2:OD8?
M6"*(F ''2EJKN 8&#/J?T\^^*"[M\39IR 097)'UI..8!.>H,\9!8JN7M";'
M+$O2B7DQ'LV HIE.,A]%S& /N1IB3!1 2?DFH803\2(EU6&  <3GS!P.G)/3
M(\^*H5>,X/L28ZGQ$\R<;?*?B<USL[#6".4!/C=BW%,W48R3R:Y;@V'Q3DR?
MY&%+]Q,U4G[42G*(.UE!3$RQSE"H, <1^O3 ]*@7;(("K)(\_"X8ZR"$Q,'$
MXF?=4HP,U #T!["-&ADE2@J5-S* #<S43"Y%$? !QX(54A:"41#J=+=HYNHW
M LDR01G@3,F/,^LSZ5F(N&5$1:>1F5<CDB1B"3U]?6I?AI**$I@&K-VXE$I#
M@5=_P!TDP15 I1:< 1!91)LD/!R]A57H,).L I[I4]!GSG[/,CB,'TSG+0\T
M>68QYJ'$0#CW"9\_C+4*[9")0+!I(FZ Y JCDP<@ HF*(&;A[I%ON< Y_,?@
M ICU:C8?,<]/O@Y^'VUE(<0"DAJ,<Y.(@3/)DQD<9P*E>)42,!0*U*3D $.!
M4'RXZ/[8@<!U 8@ (AP0/AT@ ZA8B,G,G,<_J?OQR:S&R#G;$1CC[9GX^X3Q
M)JG5%95-*4TI32E-*4TI32E-*4TI32E-*4TI6TQRD*)CF I0 1$QAX* !YB(
MB/D  'F(CJ"H#DP!DD\ 9,D\ 0"2>D9I5J62MT]8KJCF&H*2-XL*9SME'J*Y
MB5*+< '2(.)5 ISS3A)01 T?! X+W2*-7LG%+% =<#K_ &^TS2][%C&J7I.Q
M*&E 6K2E#'>OIW;\_B-)69)!4D9&VM-)>?A;TL,X/$NJ!XA'2<"3P,P8-646
M++F1)*=3G9"]6 DNW/UE-!R+F'BHPX](^%B(9JL>,,U;F*(&]:H2ZLD8!2EG
M,FT!(@>37G:_77[Y%VO4'4/-'+;"BQ;M$D0VAL%3:VP G<I0+CA)"H0%$[UN
MRMVVBTAA"P?"2Z@*6KS5NS"H/AB/*KB,<[R4V2S>%RZV*1%0"@UOD"S5.R61
M$>A,\_ ( N[8JB("5P_A@>-.^"AEHN';)B8.]T+Y2V'%IM-=2&'(2$W["%%A
MV2 DNLC<JW41XE%*EI2"=Z&R*U=SHBX*[0[DC'=+,.3,0GH1[X,<U?5#S418
M(UG,0<HPF(I^B#AE)1CI%\Q=H&YX5;NFRBJ*J8B AU$.8.HI@YY 0#U5AYFX
M:2\P\V^TX-R'6EI<;4">4J22DCI .#BM$M"FU%"TE"Q@I4"%#W@YKU-7JIII
M2FE*:4II2J#R/^=QG_?MC+_*34]9-I^ZK_O:]_R-^L:Z_<D?WS9_Y8Q5>:QJ
MR::4II2FE*:4II2FE*:4II2FE*:4II2M!$  1'X?7J#@=?@)/V $TJR\N^7%
MSOJ7@:=EFR0QU%0C;!$5!DG$S35-0R9)**&:GX>17C7?2*K%XM'H)O6IDGC7
MNM5T%E.A_!G4DX<5:,K_ !FG+E(<0>J5@ PH'!$X/-:'\(M.SM]I<2# <2R2
MA8_*0HJ&Y)S!  ,&.*W?/<HOZFF:?W*5[_/+3\&[_P#?K'^=)_S:?A%8?D77
M^(__ (ZI.Y^D2POCV&]H;E2\S0D0+Q!CXQ2F13D@NG0*"BD";"T.E^5"HJ")
MNWT!T"!C%Y+SD6O8W6+YWN;7V)YR"O8+QM,I3E7URE//G Y\JQ;OM=H]BWWU
MTJ[:;D)*O97%B5<?4"B9])JEJ7Z4O;?D.8&OTV!S'-2Y6:\@9DC0VK8Q6;8Z
M)%EA5?V!LAP0RZ0=(*]8]?)2B &$,FZ[!]H+)GO[INS9:"@G=[<PH2KC]S6J
M.(SUP.M8UKVYT"^=#-J[>..;2K:+)]'A')^D0GCK''6I5^>W10\ODTS5Y>7G
M5*]S^S^7+XZUWX-W_5ZQ_G2?\T_G-;/\(K#\FZ/_ ,#_ /C%2+BS<U0\K6M>
MDQL/=ZS920+VS,X^X5SU8E*PL7(147+.HZ2CWTO$J*QCV=ADW3%P_;2(IR2#
MENS7:INEF^'>Z/=V#(N'BPMKO$M%3#R7-BUAQ2 M(A0"@VN%;2D%)!4"4SE6
M>KV=\\IAGO4NA"G EUHH"T(*$J*%922DN(E,A4*D @$B9;E;H*A5:=N5G=*,
MH&MQKF5DW"#1W(.2MFI!,9-I'QZ#E_(/5S=*#-@Q;.'CUTJDU:HJKK)IFP&&
M'+EYJW92%.O+2VA)(2"5$"2HD!*1,J42$I$J40 36=</MVS+C[Q*6FD*<6H
MJ(2D3A(!4I1("4I2"I2B G) -L8;SZ)QY8\R^(?4/L[6RB(?'GI4N)%"\AY]
M)R%.7X&*40$-;D=F]1(GO+6#Q%P#*3P1]&9G&9(SSR!JOG^Q_)N<3/T)$1R#
M*@<09QTJGB[_ '#1K4>C%@,@FNJ<(6RGJ(-*2-E)73//5Q9XT&%[&2+#B_\
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M[GK20?/ZPP(DG)@CI4D0LOE<1(*]CB2_2<=(3]65%$"B;ME4$E@.!Q8!U>(
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MYIZO KZP@Z=U_7K4X_,C8?K@<Y_[SP3_ #(ZU7X6.?Q/I7^-UH?8!JX ]P
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MY.X=.UE3:C4M3?U-QI3K;+*&4J2TS;I6&T!1E1EUQUQ2U$"5K<4HI2E,[4I
MVFGZ:SIR'$M+==4ZH+<=>*"M92(2(;0VVE(DD)0A*94HQ)),QZUU;"J4K(</
MKD/VVLX_\7J\'\6K[WU;8>5ND?\ ^1VL=@0;CUN%'_Z&_P#?55ZL5D4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*5C'WGMZRXSYAT+-,S\.@7#^73-3P,2$LHX
M5"W8I45!=,7;0$C-DDQ=,5.LYB2*350B9S)@0^<X4C0+K<HI_;C3O\BU7X>H
MZ@BN*[3I8.H:;W[MPTGV'5 /9V@X5$NZ;&[\G:8*>"5'!Q4!J1>*4^@1NV0"
M"1,WFC2"E[?0V*N8R C.?1'23,#UK_K<V=R[*4QU>P7G0IN<*/$>L 1P#'W]
M9K2;=/!@W=Y)!R+%48'F%'D<=-TX)P-/5>*2=7Y=K^3MJ.C"+>C GVQ2(0ZG
MA1"<,"0-2J K$CR8&[M9XJF*IEA*2H%H@0I6/+TSYF(Q$9Y /E:*--4K-Y>9
M!G;8J"CP1M(/(D;#G,Y/3:,7BDA5>;K?B=*AQ-X>CD3,D**R!#@R#UX<2>%,
M<J,:8@* V9KR"915!8QB7-S>86L<=)GT\)/H)SSQ5'=::D']EWF2<"Q5 @@D
M0%& "8;&=J-R1,8W&BL4@HIQ<[T4>H_N)T5,$BB5<C<Q2 ,\(=E(YRL6Q>1*
MG"*.693'(<5BU!;?Y:N8X&>.#]V,CR$U'=Z9)!N[V)@CV$E)E0$?6!4W)@B9
M+.X>HT]5XI$S< NE[,/8*0H'HJ8IG 7@MR@X TZ'/4KS'G(;I$U<!)F(=LOB
M#5A;1GQ*/EUD?9TR!Z"J0UI@@>UWTB8)L53]>()W$I03X0G@VR4)QMW'FCXO
M%1G#7MW.^*&$4Q*5S1B=M7N+BB0KOJG"%.5<Y!:R '$G>B46S<XI$2[IZ@XD
M'ZQ4/7'^\^<1U/%6TM:6DI/M5\?% FQ5@D[85X@-L@Q$0QW:1P5&5Z['X[Z4
M>Q:[BN!U&XE%Y4P*94515!('/,H/65QTG]8G'I*N"+3K%+ME[EP.!41)S'3_
M '_U?"MFRC3Q 3=7>2D@FR5P09"O(*GQDD<)GZIJ:X%I4.@>S/6-7J[)A,M
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MDK2A^\=0BU96M*D(<=2M25A)0KD=7NWK#3+^]MV@^]:VKKS32IA:T#P@P"2
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MU4B*>K $JA0.FJBX((]3$HJD.8JH=X3H./I [;1-,. $NL%846TK(W)9"DJ
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M)\I\O+/NS3<V/QTB/Y0_3ZC[O2NTW5C7I1.T<M712FZ3&:KHJE PE^],*)C
M B0?(!X-TCR'U#J""(*@1C$B!&<P<'XR/OJJ4JX(,^1].A!\B8(\\5WCE*8.
M#CP'/V\<^0CQ^'R 1X^P!^KG5) ,3(@X(,=1\#F,&:JF/S?=^BO(]:5]/E,9
M.(*)!$HE,]9 8! 1Y W*O(" \@//F _'SU6$KB E<>@/'V>542W,[DR/Y0Z>
M>>??FM?7%?#R"5APY'ZGS(.1^'U*_'RT[M9_$7F. KGX=3_0/*A6WB5(GI*D
M_=GSIZYKWZ*PWV?]G,?C]GYK^#][\&FQ?Y"O+ZI_14=XU^6W_A)]?7U/VFGK
MBO#_ *:PP\\_!\Q\_(1'_MOU>8CQ]FFQ?Y*OL/Z*D+0>%I\L*'EZ'RK7US7_
M -%8?_?[+_G=-B_R5?X)_13<C\M/^'']/K^N*[R!VBQ2K-54%4U??(H@HFHF
M?I'I$Q#)B8IN!Y()BB/UE$?JU200<S(&0>DF4R#D1!V_&I&W!$9DB(R1@F>I
MR 3GI7:TJJJ:KX</+6/]U93C_P !P8?P &KSW#/HRG_QN&K+/+WJ\K_P-BJE
MU9J]32E-*4TI32E-*4TI32E-*4TI32E-*4TI6.3=F6QFW 8C+7;6VJBOR/96
M,Y7<SKR#\64EWQ&JV1*HT61\0FDZ326>$4$>A@#LZ?!_/63=%?X/W&QQ+9^>
M=./B5MXLM5@^ON]_/%<OK2'EZEIX9?#!%AJ2E;GEM!82_ID"$D;@).Z> <1U
MB,4,E@+<$\R,0%(A0)W\A3?'418[E(SL1>\"!9 ZJKH3#UA!BV$H@J!U!YG]
MD=+ELGG]T5\,0<?IGT.$;>^&?G%'\[>Z9]9&<GI]M<9&^2R] IYE8E[:@=KQ
M&09SR*B8RK(70 ]   BRK@9;@"E!H=GV>@PK">?IQ$W*.I_=#D#S_IXQGK5!
M8OYCYP1 F9NW3)F1(^\^G&3D"&3$RB">8V0"11$S<7&09WZ/PXBFU*Z K[D"
M%05=$E")=)!='CP  2,H4U0+^3[2DF1/TL9G X/Q$8@#BH+%^D%/SBB)_A;H
M@<=5 ]<X))B*T!#)0<E#,;44Q*4I2J7^;!4$R)"V2 W#T [P,#JD==' !-BV
M @ GRF,@/3E]"AY=Y,C(@@ >8Z\CJ*MJ9ON%:HD  R!>. E,01,QNVS'/C@B
MM!2R3REU9C:<"B0J@)Y FQ,/)/"&[/4]XZQBRII%ZP$WM "I!-V (F%</'^Z
MM&#P'%&9G(D>HSB2"*@,ZAC]M41 F+MR8@QU.=I$G@K!@=*YFB.23.$N]F)F
M<HF5!<K:_P X)U.\4B#@J '>"43&:%03C@4*(!*E= 8!3!,H7 'A$.(.1)WD
MQS)F, 1B3@@\T[F^!$:FB#R1>.=3D"5 $P,<0>>E2=!I7O@HN<GLW!E%#=P4
M+G+JE-W1#Q16P'=CR)^A#U:!N2#T.RGYX3Z;H"Q'TB"1!@+)Y\L9,]/29S%9
M335](G4$'*3_ &VX>>0G/, ;<<R3)S4M1!;28#>(O#=P)AY$Q+'(' 3'X.MT
M"=P(B47!$S->D?-F#@3B*@@8+H2X,E8_PIG[_LCJ<XK/;1<@G==)QB>_43D9
M)*E' Q$08)G,5*D029ZB]RQ(K<\"/3+.5"F-U=P1X%00Z!5X,3XCX3@?OO/5
MQ&Z1)F9',R?02?U]*SD!Z([])3'[X8\^@$C=CKCUJ4(DCH )UOB+  %\_$**
M<\#SR/(C\3"(\#_VL2"(\@/-^8$%,'SCSX^//NCCRRVTK!$N3)Z+)XF.?7GT
M/J)JO5%9E-*4TI32E-*4TI32E-*4TI32E-*4TI32E05E[;MC7,S<ZEDBAC[$
M1 J#*XP(HQ]E:)I]0I(*.Q060E&*9CG,6.F&S]D0RAU$$47 E7+S':#LCHO:
M-M2;^V2+@(*&;UB&KQG.X;7 (6D*)5W;P6V2?J@@*&=9ZA<V2@6EDHGQ-*RV
MH3)$?BD\;DP1,S-8N[?L)SLQM!8"M*5VT5R36("-U5D4H%I%-DU#B<UBA'"S
MR70<@0P FG (V-%P/!Q69]1TT/$;_P"27M"W?JMK"XM;FQ?*0F_N'$M&W:#B
M2H/,)25*>"1""V"A9!!**ZEGM%9EE2W4N-.I  80DK2I0&2APF1)P=YZ"9Z7
MO8(V,XMQ(JPL5D33R1?6W:<%FYYDF$+#O2#UE5K5;4,Y:L54#\&1DY!:2F$U
M ,HV>LDS^&)Z?V6^330NSH1<O(^=-3V@JN[M"5-MKCZS%N=S:%#(#BMSD2$E
M"3MK17^MW5YN;0>X8)/@03O6/^=7R> =J83)(@\F]H X  ^SRUZ*! CGX1]U
M:6M=32FE*:4II2J!M-S=Q;D(&O5^:G;2[*B$<D:$GFM71%P8X"\F;CZI6K[%
M@P334=2"*+YS,G23!K&Q;V2<M&:]QMM*CN6M"&P#OA:"\0(@(9W!PR3"5;=D
MDRH02+#CI3X6T*6X=H2"A81DQ*G-I0 .J9W1D#*9[=0IZ=:(]?OGIYRU3AD5
MK'8UT006D%4.YX5BR; HL6)KT2"ZR,'!-U5$&"2SARX6?S$A+2TC4\Z7"D)
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M=-6+YPN@S=J)E;J>LZ9<LV>H6EU<-K=99>2I:6X[Q/1+J)*05LJAU"%$)6I
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M3]N#7@)_X)?RUSGMKHPF?_7O:$?=W0 ^&!5 Y.]$9NNN%*EJ] XAQ1$2KT[
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M;Y?=3\)K?^+]2_P;'_7Z?/BB/A\WO<!^+JP'_!\O.I_!6XB?G728\_VTC_\
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M\6>,'R!(B##G*74;JQ5%&-YAW"T(!(=3K*54_/C@$2+OQ2DTN )RQ06/R4P
M UA"S^(D$](ZYZ^^/]]4%6H D?-S?BF?V&O\H#=E1( /B!Z@$Q0/E3Y2#Y*H
MH#"F ]1J$'2DIWA#DXB^]T"O^J7-[I_R,4(IW!-[FJ^Z7B4)^SX\R3SCSCUJ
MDN:B2 --;!B ?8U0-I@'ZW*B-W0@'W1R,S91,NB 8JBVY1,!2G5H8%!$!4$K
M<RH@_/T@V=]QZZ$2G K1=,X>9^D)#*NB!UY&.IZ&?L]P%4A>H"#\W-B3 !LE
M2(,C\8F 023@Q!$U)4'\H @D"F.8]J'60$RFIX(B@41/X<ROW:8H S'O>*,
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M,<U=A\Q2JC_JY;@O\-XO_FFUS1[2W9))L]-)))_M=SK_ /'KIOP<MOX;J?\
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M;ULJ>'<NG(NX1D%BN.FX8G45*0L?$2QNZU22,];]PJ!0=-T#%,<Q0 NR/_\
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MW^SZGS;#G"]Y"RPZJRN3SY=IPT*=G)>5/ U-(U3L,=/51E7FI;#0X"LPB!;
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M7R^_\(I)4#V<0F"1 [&WPVP3@_2*@C@^(YFM_P#5 MU_ZM__ !!Q7_F+J?P
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MYX[ML1B9$HQ,9XXG-:F#<2)U1]E& E,8P@92EU45^GND4 RG35N!743 SEX
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MTFK2M/>) ]E,G&5HQQUZ>_/N\PP&.![QQS%'*F$A%!6]E5"#U*-#2!W72"H
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M@@YP!T'H.,=)FR!2:@1+MOR+ATEX$J0D _O"0/K\O= $/K^\$P>9A'60"",
MGS/P/I,<'/E6.H%)E4CJ!^?G.>A&8(X ,5X7[TOGSP !R <<\!\>/J_%]6HJ
MH<?HS]_7WUNTJ::4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*T$> $?LU!XQ_3_ $9I
M5O9,]&=@#F-QW:WD>L(J,7AG]7:"]:"(]AZ5JXF@<H)NDNE=%)R1)R1(Y/$(
MHK=:1-P-(7PJZMDJ 3N22Z2DE*502&R) 4)SS/OK5?.B3)1;/*3*@E14T@*
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M]=#+-E?;]I40I#0P(_YP^O4<&I='.4AS_8RM7Q^J7J7\/KH>?XP_?P?F=?\
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MBB> Z02(I'IS!S%0 G:6>TM9/LP/)^M=>><S)])!D1YQ5'S([B-53"LY;8$
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M8E2$B .N@!-T!:(U4X3<MJF2-SUN3/XW & N4YSUXY%'9;<?VON!S'[2:H0
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M!0!6(H)"B#YF[/9_8>JY_P#OAN1 C!^;*A7;OM2LJ*G-%&\+P-(4(+@2%_\
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MZK=V/_G!GKG]CCK^N8&(YV@U9V-ZK$D8!39J'0\_LG\T9R<YJOH_$96 @);
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)2FE*:4II2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img227133604_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_2.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &>J^9C0X0DE-! 0      #\< 5H  QLE1QP"   "   < @4 *S1$351?
M,D(M4W5R=FEV86Q/9D9I='1E<W1?4W1Y;&5$979?,C R,# Y,3@ .$))300E
M       0!X\/WAV#9,VGS)9'*+K!"CA"24T$.@     !"P   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4    % !# &$ ;@!O &X ( !4 %, -0 Q #  ,  @ ',
M90!R &D 90!S       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!!X       0     .$))300:
M      ,U    !@             #]@  !U,          0
M           !              =3   #]@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   #]@    !29VAT;&]N9P  !U,    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   _8     4F=H=&QO;F<   =3     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    %.$))300,      \M     0
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MX;O=MWU?HW?V5'-R,ND-^S8KLK<';MCV,+2(V?SQ:WW*Q76RI@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M]WHJ-AH^AI,(WL"CLP-;4UU5LJ/%:"8\&S1UB/E8:9P(PYKB!LQ*X(\7A"!
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MG:0U+*_,JJP$ J[L&,6-#;6<2"*6P*:Q7-2<ITLJ>^1?=YD>KM&<_I$^63G
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M8K_6KF?4CIVUM!ZJZ2DN\%#ZFNPK6SUS/6+M9,S=KI.F>O\ $ST5Q88I\?\
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M>V&=U5:3M*"C"N[2MHI= \Z[I:P\X&LMQ8+&Q:7D+B4$MJ4DOS/%&IP_=D&
M$).#D=QN#M0J#GU!!P<;'X5.\#Z8^O>L]=LM9D+7L*O@W1-H=>XN;L#3G=>+
M9V]?451ML#C#+">F!M' 4=>/$</ V>)C)E:[W3RJ[!I'? ;0=/0A &QN<$YW
MW.>GGZ8D*!G'<YWR<'SWJ*D^DS% 3].U^1+N\YENK^E+'TZL#J]3J:+2LZO;
M'@K#*RTVUS]I7Z@'5Y30]7Y5P5JEI$XFML]/]9+,23 U[F-ALZ6U2B4ZE!!8
M!ANIV.0QSTWQC%,;_(C[?7/I65ZU],F7ZQ['J-C0EV+JG)=>[3(9H2WM[C2:
M(Z_[=[(&[0[EVVNU&A,L;:]NMCH\]D"(9)BE^B>'=(W_  4\(.MEI69"AQNZ
MN<  >%2BJ -@%#'&/.H"@';ICIZG&^?D*V>YKK*G%*<'XXI6K.>]&'IUS]81
M2OZ]K])53]8C].L!V4L^L'"Z^AMM==ST=;'=R&-KEM+';7<MV>&D-C<,;4P'
ME3PTE6P78)I!@AL8<2# QAA@ ^1P .H[>M1@9R>I&#\/U_?7PJ/1?T+4#!0.
MSUK;O%O;^^L#='HKF_.TZZ[JVEZ=VE)L2+4LI=7E=GB<[11:O,7;3*:[O*>K
MTQ@C[^N"L((YTH&[G  & , !7+@@=B&.01OVZ&A53V_?Y=:U5N>J_P!'*L>\
MJ+WU$#RF];C4^"MW:/U>:V[O.BPL_P!R==W];EJ272]C69O7\H7<W6_7-?[B
M&MMX[V@J,HIK8',JG[>9=8!T:5?Q;01A9? R-J(7+AT9@1D#22>^3&%! [@[
M;G()WVP=O3Y=:V3.L_2QUF)T)LM[WWFD3.0:FPZ;W?:7=U>:7L!-]6?3V]@+
MIM%?M;N0IJ:T%BKS?GL!@ )*WZ6:*'Z=7Z@L[EPL;'M(J1GPL#D @ Z2.P.,
MG.2,5)P,;X\LD;^8W^WS'G7$[4L?1-%VCL"^T>P.H,[W!K/3_<=<:>2[W]%G
M]H[H(UNBV%I"HY%N,8#FDB'T6@?=QP1MC'KBC?K$'KU="7G%!H632) 1A"0L
MF0-QCZW8CK3;.=LD#OOCM\ONJ(6_2/I4Q?6T>DU7>&TI<_U-?V>4KNY[OU)[
M"CTO61AIE!B+OK6'LR+65I570V%U2Y^HMNNK<XFD)U 54013+H0*PD7,23,^
M%C1FD7)C$(.M=SJ*'.6'\_L =\9%,#UV]3\]\]-JOO$=;])[.IZRWF5M$[+S
M^;P.[Q6*U!VYN.S -#CNR2\R_:-N-'?W.BGW3[HO$5$9%I>V5L4GTQ@[2$C)
M)C?KU,,CZI.DE0, $9TX QC&3C&*8&WI^/U[YZY JO?^ GZ?):2XS-E7;[19
ML[!;'K.AS^O[:[/V-)UWB][E3L1J*KK*KT^LM0<,09DK([-AW-+!#>4V>)GS
MU-9 4,TM8_,3S Z@X5M2L2JJ-11@PS@#.XSN3ON<]*@(H[;=AD[9^.?QC&.M
M7]C^J<9@M-M]7E@)ZJQ[%ESQNN&@-)6HM+K-4L.:"TBU3Y'!CZ(S.@TM)<VX
M\<15Q79W/PV#IW58\B:R6( )R%U:<]0&.IAGJ1G<#H,G'4YRQ5C\BE.*4XI7
MA4\HJ(OC^OBE:/Q_H^N@'X>/K:U)[3T>$"IM?GJ'+:7M?;75/E:;==:=@]1Z
M2NRPIEJ]*,4W"]F:FJ9&&YGT\LE:; L954#+%N]XFU,X90S8U,J*"2K(ZY(\
MF13Z_;F"H(P1D;]SWZ_X_94OJO15T.%+;%WE1INP;+1UNOI=7;=G[?5]A6>L
MI-OEJC%7E+?E:BVL5*IDR](#4UM1 P6LK&..+#$C/L[$LG'G2X #!0""NE=.
MD@DZA@[,2=V]!D&FE?(?WXQ^/W[UE*GT@]'U6?FIEH+&WMB=QD>R"^P-#>65
MYV<7ML)/D)<I?D;^PGETLA52/@\I5,C4]!BZ:K_"SX"PS3XRAED)SJ &EETJ
M $TL""-/3OG[.^]0%4 @#8[G_'K]IKAT?HTZ*S;<+'1T5Q70]?4/5V<I8!]+
M=M@- Z6V$.XZPET,/UGQ7]AD+U#OPRRLF3'?AMS<U4\\P!\D"#-*VK+DZBY.
M1G',4*V/0XSC]PJ0H'8=,'U_7]^:B%=Z!^E*_KUG5'ZR=[%]<1529F+&D=^]
MLPT$>*E!FJ[+!H!6ZH"*7'7-7*VNM*,A)H)A8(&PN'D8LKI,\I<N.4')/CY*
MEQG!RK$Y5P1E7_1/04P#U).^=R3^/QFMU88F011PQ,9''$QL<;(VHQC&,1&M
M8QC41K&M:B(UK41$1$1$1$YJ^_S/F3U)]2=S4U].*4XI3BE:.U?Z/CH"NPU7
MUH43VGH<)G\IIL1ELSJ>U]M?UF1RNOZQU_3]]39>$^UD6F%*P.WNZAB".:\>
M1*XZ%[2ZT22/<UQ,TC2ED#LX=BL:J682<P$X\CVQCO@=*@* , ;#H/+T'IC:
MI#5>A?T] NMY[B@T>ZL-)FMIC]7;=C[?6[NTU.9WF=R.2O*2[+T=P<^:LAS>
M'SM52 BH('1,&++K(![&UM##,3--L0X725*Z$50"K,X.!UW8]^OI@!@?=CJ>
MGXZ^=9^+T>='_@FAJ["BL[VWU&MQ.\M]]?WMG;=ER;+KD/"@XK1"[TJ=VCK[
M'/1];Y"8)P!H\/U=;,7/#-/96;RQEESE7T^"1  -@DBLK@#IN'8]-B1CH*!0
M.WF?M_P%8^H]%'0- )U\#39VWKA.M<YU/E:" ;3WK&'5/1G8=-VAU.W2M^N5
M-(9B==3O)IS[1)S(P+S35,DTE??'CRRT\S,[E\M(92[%5R3*I5\;  $$C  '
M3N :$ YR.ZGYKN#Y]0#N?NJ,TWH(Z4I>L1NFH]'WJ7UB#1"8\''D]^]L15(N
M#@IGYPK ,AKM2 Z3&6U"YE79TA#IH9AQQI(7CDP1SH,SE@Y$>H'.H1J"2>[9
MSDYW!VP2:@J",'/VG[O*MTAX(18(!1XHX1QH8X((8F)'%%#"QL<44;&^&LCC
M8UK&,;]FM1$3[)S5\?Q^NLJ^W%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O"_E]D\_G]OM]_LOV^_V3SR#G;'F
M,_"E=/5_^CRWNAHK30$=A;H#LV7U>;7L/$+7:+ MH^GNH]WZ^Z3U%Z2_Z\&+
MP)@Y6VM\-DLO?S"]B_K_  ":,*6BK@PP"BPI[R72JP!C&CW81MMEGD%DT(+9
M887FD9T8. &ZC-:RF?TB#D'(/8,#CIY#OG[,"I#T9Z<_4-Z;G(\#I[J_NATG
M4&6]/JSW'8OZI'QUW6.Q[-/JMS*3<9K;^S&=TU>Z"U_8^4'6:]R'8$%T)6U.
MYH2*8FKPEE2;(U/$.8TN%7*@R! 0N#J)CT:5)/B7!.&+$R 023@DCMV(^/GT
MV'89SVJ]WZ.'MVJZ0[\P0^ZM;+27OH\QG1> J*+93YSK'6:VKZU[-RU@#?YH
MV$R<7)YFPUU56822U,D+KJ*OKE(=,0#,LFPW:&:*14*!;B25C@%PK.K+I88R
MV <G&-V&V34@$8WW"A=OGGK\OVY[V#V'TEZG+;KCN'J.@ZH/&AL?5Y7^H['=
MCYGM?KZFM+:A!]56)[B_"Z,*^$L_U<V$>3KK:6L,TE4920W-= ,9%/$5'&_"
M-XM2R,XR(#%H=&8*>3(BGP[$*Q7&^03D# -&!8$#;=3G)&0""1T[@$=\@[]:
M[*^GP].!UKD0MF/I1=.+6?!<0['09O5:?ZF(F=C9+K0Y"MJ,U:&SP)%.\BHK
M A4;(R+X&R1R*M5L:CC!&>H&!\AV'D*R_ JR>12G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4K'6UJ#25Y-G93H.&*Q'2R^R25WERHR...&%DDT\\TCF0
MCCP1R3D3R1P0QOED8U<D1I'5$&68X Z#."=V.%4 #)9B% ZFL'=8T:1SA4&I
MB 2<>B@$L3T  ))Z"J4L^VK=55U=7UU8*UKY?J+"*>[*6)BN\MF!"L*<,>?V
MM61/I[NS&^/[O)C>CV,Z4?#AIR[%C@9"G0-1QLI"3.PR=(9HD)(^K@BN6_$F
MR J*FK&EF',R#MN!)$BGJ3B5U'0L,$CEU?;!D3VMT%>(X1KU;/95<9D$T3?,
MOF9U&2\R1T$+89%F:-;&63E5OTU3.U)',2\-(QRF.HKD(X!#';;F#1H/8"2-
M$).#*I #3%Q(DGF*NE Q=DSJ55 );E@R*RX._*FD< 9$9!VNR">(F&(B"2.:
M&>-DL4L3VR121R-1S)(Y&^6O8]JHYKVJK7-5%:JHJ+SF$$$@@@@X(.Q!'4$=
MB*ZH((!!!! ((((((R,$;$>HKZ\BIIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2JL[TWEAU9TEW%V=4""'VO7/5G8.\K 3X#2@3+#(9*WT 0AHU;)#8DB$$
MUT4), $L1LT+WQBR,G=&Y,D&IE7^<P'4#J0.IV'Q.PZFH)P"?($_9]OZJJ&D
M]3E!1!B5/8)>DT&NF92E/FQOI_[CR->D6QT&@S6(K)\YJ6:&[J;?0768MJP!
MEG911FRQ06'QA518Q4C0Q/A 49.=3J<!?K;C VR.G44SMGK\-ZRTWJUZEC,C
MKHQNQC#_ '5@AH8/5VZ+FIKV[TNGQE-E[SX:-T=3H;/5X^]HA0C)(X?J(0C)
MBHJFVJK S+E/U\(&Y!+*,@8)(WW !!ID?CM\?+Y^OD:EMCZB>H:3)9/<Z#9@
M9W,[7Q^ GZ 6RIY'.:COJXK00X2(JBEJ)&/&O&W<5>VF*8X>S<+*B,6Y8<(X
MIQ26:#AUE->301<V6.%=3JI(">#.IB['$:1AY)"<(K$$5YOVD]L?9CV/@L[K
MVGXW9<%MK^Y]TMKB^=HH&FT:W,DP#1P00H-4]U<&&V@4J9I8PZYPU'WD/JNX
M<QA\K-0:#%:;J72]B!:NL)D,4HRAV5-EV05Y8Y#ZTNJGCL29D*B21)I((Y!"
M)1I$<_H2\"DMN!WO$KH36][9<<MN#RV,T9B:,SV-S=LTJNHD256@"<L@,H;Q
M*&V'F[+\H-KQ7V[X/[,\(?A_$^"<9]AN)^U]IQRRNQ<I.>'\=X;P=8K62!GM
M;BTF6^:5;F-V5S$#&SQN&.LW8'K8UV#]2MAU,5E\B_ U&XZJQ]K>&?K8#;5X
M?9E( 9+IS=$P(S"586>L3HX'U=V=56=W&^(>H;/*TH@;U'#/86#B7LPG&4O;
MD<0GX=QR_MK-([61)Y.#S:!9);BX7B,DES$'D:>&VEBMM'TRA22ORSVH_+UQ
M7V9_*I<>Q<W ^%O[.6/M![#\#O\ C$\W&+:>U@]LK5G/%Y^(#AT_L[90<,NN
M5"++B?$+&[XF9EBL=4O6;=,>JO7]G[;K+,'YC.UPFWJ.^K*Q)#DL7$!OZD['
M%Q55$#\YCXWQV84TA=@^:-[D+:UH[8(55%H\;]D8.$\.XG>)>2S/8-[,*B-&
M%64<?X1)Q&4[*#B"11'&=0#(=?CZUW?8?\LG$/:WVA]E.#3<%L;.'VB@_*I)
M--%=S2RVS_D\]L;;V9MQ&K($D7B,$QNI]1!AF7EH= !:>4GJ T5GF?55?2T=
M+%+T#I]W0T([''I'=0Y' 56N'FN7/G61DI19\HQ#06PL8-&Q(D63S*ZC=>SD
M5O+[(QBX=E]I;&SNY"=&8#<\5NN',D8 WTBW#@,6.HG)QX1Z/AOY2;N_L/RQ
MWC<.M8V_)EQSC?"+)!)<%>))PGV3X5[1)-=L4#Q&:;B#VSB%,)&B,NLY9JFH
M?55W-V0V 3JKKGKH^RRG4O5'9O9<VWV%UF ISNS,9#LX,MB(0::[D1D0#I$;
MI;\N.K#(<P,R%[X9B'=>]]DN"\'+OQCBO$(X[KCG&N$<+6PL(KIS#P>^:Q:\
MO7FN;959Y= %K"AE9-4JD96,^*X/^6+VU]L#R/8KV2]F[JXX-["^Q/M?[4R>
MT/M'>\%@]]]LN!Q^T%OP3@4=MP?B;RQQ6',U\9XA+;V45RT=LT<ACGE2N)/T
MD<+"KJQ(P3ZO$E]+9O>9/2V"&NBJ^P-1FM%<46'VSH96QP@Z"TSQU+278+18
M)S1X87N5+<2<?KR?DMN%CCBCX@+CB<?'[_AEWP^*(!I>&\.N;2&ZXE8$L997
MMX[I)Y[9X-21<R12WNTZ#R*?_BMLFGN[V?V9GL/9:X]@. >TW!^/WD^([7VE
M]HN$<7XGPSV9]HD7$=E%Q&;A4UAP_BD$KVTMXL<#LKWUH3V(]5ZTS?=7];[J
MP&&"/VF"Q^M.##^50Q#-'GJZX)&%^=\LWTT$QCXH/FDDE^)C?D>]_ER_-^,V
M*\,XOQ7AJ2&9.'<2OK%)CHS*MI=2VZR'ELR9<1ACH9DW\+$8-?IOV-XY+[3^
MR'LK[2SP1VLWM#[-\#XY-;1,[16\O%N&6M_)!&T@#M'"]P8T9P'*J"P!)J>\
MYM>DIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4JE>VB9IB<S3LD6."66RM9U]KG,?*"T2O$AG8CV))"];B>9K'N1&D##D,
M7Y(&<ZW"HU<S2,H.D)& ?]8L6P?,&-<8SD$Y&.O(XI(1RD!*Y+NQ4G4= "JH
M\P1(Q/P'6J8M(56J+GE=)+\4$RP.\J]'O2-[G.=\<:K)X5SE<_WLC<CDE)8L
MB*V'M[$@+@[8(![G8'IN>F,?J KC$#);<=-]P3D  8STZ;>7V5D4&>U(XX)G
MPQR^Y4<JJK/D>KF.9Y>V&;VM61SWQRN>2K6-B=(V)9%CQ(!!4[@@C?U^&/A\
M*#6HU $  C(R-\;8/?!&QVWP<=,WAU*:^;-$USU\I1W!E8.OM]C4#E@$N088
MXD54@B$#MX X(&JK((1XXH_V&-YY_B40CN%*@ 2Q+)\U9XCGN3JB;).Y.YW.
M:]!PV0O;X)),<A3H1@%$E7R&-,B@ # Z#'06ARA70IQ2G%*I'U,$7HGIQ[^*
MR\]N-IQNE.U2,V3GY38;Z"_APE_)3S4DM8YME';Q6#1WUKZ]S3F&M@<(Y"$C
M7F4942Q%MU$B9'7(SN,?#/D/6H/0X\JU*MNQY<9JEO?3?<:C1=9IDIJ[LS2;
M#^5;M'K'!:*PW>  R>NKP+F\BOKJ>ERQ?99NSH.OM)6@Q@C4-GMRZ$:$&X3(
M*<$2  ALJ 55B#G8G!&YQC(.VPZFH)TGH=\9SG8#'[\^N:P6D]7/J&JAA64^
M(S-T6=F"RJTZ#J_LQ:XL8'M6UQI/<-[6_K:S2Y#KF7!#@=D4^3@J]>?:,^LS
MYW8E"XO.VUW(C0G<D=L%AY @#H"<Y!.Q'D<&I!)';S^7[#]HK>/HO8ZS>]89
MO4[:/+IHK%;AA9&+BT(^8L1P;VSKJRWJ!M0/#<"CW%6('9.$EFM!19RI8*R^
MT-8P.Z.P8 ,0,D#ID 'IY D??3/X_5Z[_OJW>8U-.*4XI3BE.*4XI3BE8#5Y
M>BW&6TN+U "6F9U]!<Y?15BD%B)8T6@KB:FW 4L"<4X5#*\L@=2 B1RX4D^0
M>>&9K)&@<$8ZC<?*E1S3=5X;7NO9;ZH((*T8F3#LSPKN^I+-K,)<V>AR!-5:
M4=G6V%!:9^[N+"SKKFA)K;>(J9CU.<@PJ0@2,#.P).X'?;]0 Z?93\?C\?"H
M=6=6]*9(RNHQ 81[6YO*3Z9MCJ-'<7=WIL59Z3M.L)LK&WNK"UN+X2PO-'KK
M ZW**L;EALT]U/8C-'C9.IB,[D8VVV .VVVW3%0!CH>YS\^N<8\^_P"ZK,IL
MUF,A1#T58"+748\I,(XI,TA,22WMG(20/\]C,1-*MC:GN]D$DSTDFGC'A8C4
MAB:#,"&!(88((."-/0@C!\/GU%0R(X*NBNK JP90P*L &4@@@A@ "#L0!FL%
M7Y/$7&HJNT:D(>>["RMAB*JX%(/@'BS<]R.?85D5:DT5:K%MJD9Z$N!^JC^G
M2*$AHSGQOMGB%ZUC)PTW$ALIKM+^6 X(>[2)X4G8D:BXBD=.IV<[9S7'_P##
MW!QQVV]I%L(EXU:<'GX!;WJM(IAX1<W=M?36*0+(+81R75I;2Z^29%,*JKA"
M5-+VWI]]-?9?9^PT-C5!Z7L>HL\8=OJN+<ZJ04:RK:@0G#R:W#!:2/,S2LIA
MQ3*B*VHGLE@\&L9*^221_5L_:KV@X?81\.M+WW>TCCO882+6S:X2*_5H[U(K
MQ[9KN-+E&9)1'.N02!CK7D^,_DF]@/:#CDWM'QC@37W$[FZX1>78DXKQE.'W
MMSP(H>$37_!XN(Q<'OFX>T:M;>]V$VALL 6+%HM6]$>DKL!F,&S:16:UHW9]
MIC"\9VGOZHB4,K=Q1=HS 7&7UP9%D'!NRH0K>*0PN"J.E& 'C&@6*%<U]KO:
M&,W&;N*0726$5PESP_A]S$Z<.MUM[ &&XM98EY$"A%8('<9:1G9F<U9_R.?D
M\N%X:!P:[M6X1+Q^;AT_#/:#VDX1=6TGM/Q)N+\> N^&<6M+ITXEQ!C<3Q22
MO"A"QPQQ1HL:YW.^E_TZ:6,C=9JLNK2MW@)1A5G6=J]H24&N!N:%,[-9E5L>
MR2EN$M:'V#_B4P<KRHFPG13RS+"7R3[7<>:"WMFN;8Q6846>OAG#&FM%CO&O
MT2WN3:&X@C2[=IECAEC1=3(JB-BAE/R.^P$=_P 3XE'POB:7/&FG?C")[4>U
M2V?%9+GAJ<'GEXAP[\]'A][-+PV..T>XNK:69UCCD:0RHDBYW2>D3H'6#9D6
M]Z\%*9D<O48FFF&OM-6&.Q] /&)49NZ.K;D0S4508\?QM#TL]K#)[Y))D?-+
M+(^+3VP]IK$W36W%9E:\NYN(3ATMYD'$)V+RWD"3PRK;W#NS'F0<I@2,$8&(
MXK^1G\F?&XN%0\2]E+29.#<$LO9JR:*[XE9S/[/</B2&SX-?SV5[;R\4X=!'
M&JI:\3>\B&7?!>1RV7-Z$Z0E(TF=.QM1\G96%J<C<T7R'1UMGB.NF#UM-7 5
M<!+*NC'S?ZP"-!FI8:P\>:<0B(E9@X)!Z<?M#QR%K"2/B5P)N&W]SQ.RFU?2
MQ7]X4-W<M*?I93/RU#I*\D9P1I =L]B?\F_L-<P\=MI_9KA[VOM)P3A?L[QF
MS*R"SN^#<$BN(>$64=HLJV]FO#TN9#:R64=M-"XBD60/#$R6I@8,G7Y"DH,/
M(,[+X\>7!U<(A9!\5<F!*GQAE*XTN6<L@FA/HBJ4R0N>8KZP"="99)D>]W.N
MKF:[N;B[N7,EQ=3RW$\A 4R33NTTCD* HUNS-A0%&<  ;5ZKA?#;'@W#>'\'
MX9 +;AO";&TX;P^V#.XM[&QMX[6T@#R/)(PB@BCC#2.[L%RSLV29AS15ZG%*
M<4IQ2G%*<4IQ2G%*K3M+N'K;I7,3;'M#55^1SL),833K!)Y'E'31RRP@5P0D
M1!]F?+#!/-&'7C$DOB@GD;$K(GJWJ<'X+Q3C]ZG#N$64U]=N-0BBT@*FI4,D
MLCLD4,2LZ!I972-2RZF!->6]L/;;V4]@."R^T/MCQRRX!P>&18#>7K/]+<R)
M))%:VL$*2W-W=2I%(T5M:PS3.(W*H51B* NOTA7HISNRZYZ_NO4AUE7Z[M@>
M K"U,MXC_P 2A+GD# =8G0PRUN9?9'PS5E7#J#*::SM(9JX&,@V*2!O3_P#!
M?M6(N)S'@'$UCX._+XCKMV1[=]"R:>6^F24B-TD/)63$;I(<1LK&O8?E!]B>
M*P<&N>&^T_"+ZV]H(!<\(N+:[2:&\A+-'J61,K$1*DD)6<Q,)HY(2.:C(/B?
M^D1]$M94=D7Q_J0ZU&J>IU1-L9);2HP1'D#A1/I(T&6;81SV!0]8-)CXKYA-
MI-'70.D,>R%V*>QWM1)+P^%.!W[2<4Q[DHB!$@.=Y&U:;; !<BY,)5 7(" D
M76]L/9A8^(RMQJQ"<*R+XF7>+!5?"N-4X+LJ P+*&D81J2Y"UC6_I*?0D\'K
M.Q;ZGNK7!=O>%PL[;MSFF,^:<5TMZU!U?BX(CQB*R>;:MS\4%K#)63.C.C?
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MOZJ%&^%V6AQMZ-98P$TB]"QE937=6S$VWP4EC%H([&5\AM(!"_6",-GJ=P<
MX/?8[#.VXZ>1S4[[;_'UZ>GQ\L].E:1KTSZKXKQ,=H+B8VQV%-VMI,[94'J(
M[GIL[@-%+GNB,\)<)8P9TBZ) SVP@U.HR&,T%IHG6M=?7D]A8-L6V<1&S,9!
M(&,%1NJDD9;)(S@' Q^[8" #WQU[9_7D?#&XP!5J&=">II^AU)4&V:5E2[S3
M6C*4WNCLH*\V(=SV%U_I):4N_I:0,' 5+\O0Z//9F+'Y^&QRM=8+F#[/1 '$
MWZ8Y3 ZYZ9TK@8!'0'Q'.,Y/KUVJ<=?7X_OVZGIC&:VH]/\ @[SK?K,3+Z*
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M;._NKN:M5CK&6J&!B!K!*R".$(.O%@:-)').85,8PF:8AC71BC_1?:#VIO\
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M'!;:\7B[0$);>[*]Q-+:+%'!Q%[B%,1NH=R\37::A) $+@2R?.U]N^&^V?M
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MS*W]_9M;\4"64-TZ7 MXREW)9K*\T42B8,K,(GY32!%;2=?+V)I^7_[I6]+
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MTEAH\9;]EDTX1]E^MFZL!]=)0Z[3Z*&H.N$M=(,5+;Y/-3M*(_!WXMS,%2I
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M;U,E]9+)';2W$*RW"MRX7< RJ?"<9ZYW '<Y !/3%:#KDLO.VN7KK$:QREL
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MSQ.^2.!"LEA8RO9V5RVI71YM+/<L48'.BXC$@TI(K(K*^V5W4#WM184Q<ID
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M\TMK>63ZBCH,_'7K86EA'6GW$L32KFQIJ,"&"LJK$N4NXMZT3VC_ $\<\AI
M@T^R.+FL09%B1%UO*Y.A%U*N65$DD;+,H CC=MR< ;UJEDY87P,[.VE40#4S
M:6; 9F1%\*DDLP&VQSUBBUO;FI^5MC=U'6-5+'X8-E60:[9>YRN<R=='I*N/
M*53T8YL156S$Z9K'L5XFC<CD<W:&M(QX8I+E\]9V:"$'<'$4$AFD'0HQN801
ML\ R16DK=R'!D2V3_P"$JS3'<$?23)RDVR&06\AZ%9@1OG:#K#&Y^R;?1U;K
M?3M@<,FLTYQVHU+!Y%\S"C7U^386-<!*_P#G7559.%4QR*JP Q-\-36]Q-(N
MAGTQY!Y,:1PQ @8!Y<2JK,  -;ZG.,EB22=D<$49U!,O_2.[RR')R0))&9@N
M=]"Z4'0+C $_1C6_DU$\)X3^I.:<#&,#'E^SX;#:M_X_'VU[<FE.00#L:5#M
MMC =I51"2E$U-M6&17&:TE<V#\8S-^+%/")<5;R(Y85E;"22$<&3%-7W-.;8
MT=N*9461P<^V*4Q,2 &5E*R1DG3(AQE6P1Y JP(9& 92& -:IHEE4;Z70ZHY
M !JC< @,I/H2"#LRDJP*D@X7![(ZW?99K5CC5.[S,8B:&M&=-] :.8LS:[3Y
MQ2'RSDYB^^E)D DDFGGK#(+#/64SK6H-\IHUC(D1S)!*&>-R,%0#XHI@ %2:
M(Y5EPH=0LJC0ZUA!*SZHY $FCTAT!8@YR0\;,,LC#!!WTDF,G6C592*CD147
MRB_=%YK!R,^>^X(/S!W'P.]6/Q^/W]Z\\4HJ^/SY!( R=A2L:7<5($XHQUD"
M&0<YS H"BH1Y3)&.C:^,6.5['3O:Z:)KF1(]R.EC14\O:BYJK.&**S!!ERH)
MT#S;'U1ZG%8-)&A4.ZJ7.E Q"ZVQG"YQJ..PR:R2*B_=/O\ [^?]7,,@]"#6
M=.32G%*<4IQ2L5=6<5172FR)[W_*(&)"KGL0FQLC1ZRK#65D4WP?6V1@@GU#
MV+"/\WSD.C@CDD;(4L<#R)/H "6/4=%!/4=*Q=M*DYQN -\;L0H&2"!DD#<8
MW[=:Z>?5I^D9 P)VBP&"S<':.RKS+K-6I%J'?U71./MH*]^7V&3U!CR ;#ON
MUJ+G\=&)IZ2MSN/B<QU3<75'JZ*5C_I'LM^3ZYXRL-W?7*\-X=((V4%[>3BM
MU&XYL4D%L6*V:3(4 FEYQPP:..1&+5\H]MORH</]F1+:VUO+Q/B:,Z:$BG3A
MUM*"8V2XN@H%T8W!+01,C'<%U8"NEO9[K>=X:R7>]T;6[V,M$R:6.<I0P:;*
M@&N6.',]=Y<.&#.Y=UDV*.K'2MKI+4T,7\4U!]ZVK/L$^Y6'!N'>SUNMIP>R
M$,ETNA&?+33.&#O<75SB.66*)?%)%*PB1BJ1*LDD1/YNXK[2\:]K[M[OC=_*
MW#[71*\$'+AL[?42L=O# H;^$SE2$YI=P-<C@Q0OIJ317L]L;*9(V*!OMC@&
M#&1[1  H&)$( (R1\DC1QH6MC:LLDL\SD?.5/.3+-,_N001V\>E279LL[N5Y
MLKMC6\C# +.P)V\(72B?1J@KSUQ(US*TK* ,+#&BYY<<*#3%%$"<A$0*N_B8
M@NY+LQ/ <0+K01,[8*Q+FOECER-E)+\#U)AF^K&I)3/DB<#,TQ%+S%K#)'/5
MW$GT[Y8Q3XC::G*AM9)9M DM)PR7]NH0['"M<I$X9)5=2!<1$:I(LN2>6^KM
M6)-P(H5F:"]A&JPN]?);62Q>U=T(,*%R?=95;5%*-"8BF1(=V/3S^E&[?Z@/
MK\YW2->=T9<*!U"%LAY:P?U$XJK?8UYDU94:K0QK5]B5?U=8(I&>W[QK<^5K
MGV&W-B@'J7> ]H?R8<,XCS+S@<L/"[ELS>[N'?@EV-#9<",-<6+%3J5EU1 $
M,%2/+'ZU[+_E7XG9%+/VB@EXA;)B!>(0J1Q.WPWBCF$F8;O2WULZ')4KEI<*
M?TE=$>H+']Z9JGUF-O!M%G;^?11 VB59^1LZNTJ;&-\F+TF*TY#=55:FHI30
M)K&601 #TBGMX(JRNLJ6 SX)Q+A=YPFYEM+V)H9X0A9=:S))&Y(2>&XB)AEB
MD8,J\LD@C!9B#C]"<,XK:<6MH[NRF6>WE)". T;*ZX9XI(7 DCE164D,!D$'
M R,VGO8D+SZU;U5(;RUH*(QB*J?/6W%[7 6XR.3[L4FIF-@]Z*CF?)[F.1Z(
MJ5[/^4:\X,,,\Z==I(H7DB;;^;*B$?L&:L7I^@T=1-+!"PS@&.:>.*4'XQNR
M[;C.1TJ:(GA$1/W)X_NY6JW6G?K"U9%;F<QD!9EA_6FS)L;)K5\*349A!)E$
M7[HYJ/N;.D*<]OV<P)\#T6.9S5]7[(68GXA-=, 5M(E*D[@33<Q8SWWTK(!M
ML3J'B4&O*>UMV8;"*V5L&\E*,!U:*,!Y!L1L?#GTR.Y!Z_U7[>4_)//C^'\/
MX(OW\JOY_FG\4^WT@Y&QZGK\0"WF1M@#IT/EU^<GOL.G?O\ 'T_O^?7OZCK<
MH[254Y2?%\8ES7-&B:]6LCK+(%(/D\(JNE]YQ2.D7PUSG.;&C6>&I[WV;C6&
M"4!F^D"2,<[L2BL$_P!D$YR.IQW.:\=QYWE>%SD<LNJ*"<="Q; /UB/"<_HY
MP-B:L_T_'O\ P#""J82&R*F$KC(&/<\8FQJA9*B>&9OR-B<UQ@\Z02^V1Z2?
M%[6(^17LY7%XV!N<J&=9-F.1A=.H_K]?/KTZO#9 R6^EB%*X*CH6Q]NV>X.=
M^G6MNXI2QIAS 29 K $L4^N-B55F"L:\F(VO-B3RB+*$:..3&CG>Q9(F^_RW
MRB^4ECBG22&0!XID,4F=ARG&EP.V<98$#J!MMD>@BED@D2:)BCQ.LD9'9U.1
MD=P3@%3L03U)-=Q6%T@O86#S>F2&.*+0T8I1U?(U)F"&30K#:U4[7J]DJ@'-
M+KYV^9(WO'>B.D8J.7XK=VS6EW<6S$J]O-)%D;$Z'.AA@[$C2^WG7V2TG6\M
M;>Y4AEGBCDVW&64%UWWV)93GRJ#844>KCTG1M[[B0Z2J?^J;B9III+GJRV^6
MNK@I9YOYV8W(R?4XZR<Z<TU]8)FK^T,4[2I&S;(S9BOHSAC)F4J .7=1,'U8
M7H)!B5!A06YB(NF,L=4:J1+83+E#&RH&)/,M9%*:=1.2T>\;[MA3&S-JD %C
M88TVPR.>+LG_ "V3ZH*.RE5$3Y;$>!@Q\OA%7PDI<,TB)Y7PCD3ROCRN%W&L
M5U<1IC0LKZ #D!"=2#??92 ,DD@9)R:VV;M):P2.29'B363U9@N&)Q@9)!)P
M ,G;:I7RO5FG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KY2K,C56%(U=X_*17(B_
M_P!/&0-SG'?'6H.>V/G44LKNW"218Q0)48CE\N>0SSX153[KX^Z^/ZOS3\OO
MXAG1>HD(_P!503Y=,@^?;'KY[4AEDQI,0!./$Q&/CM^,;9JOK/L_0@(OBDK7
M^/S]Q!#4;X\*Y7+]E1&(DCG*B._9AF5J.5K4=I>\MTZQW./,JB@?$EO//;.V
M,9JTG#+A\8FM\G./#(0/+)&0>V_?(JM;?U#["M\JS(4[T:GE5E/):GA'-1_W
M:Y?M%X(=(Y41/:$6K?<Z.-LV@\4LQD-'<9'3!B/V[[=SWVQUJTG ;Z3ZMQ9X
M/0D2C/Z\=1Y]:JRX]8_8%:DBQ=;TI#V.2-L2VA+9'S+[$6!$65&_,U[G0K&Y
MS56:&5K5<WXWOU'CG#QUMN('M@>[YSW_ $OC^ZK\?L?Q67ZMYPP;$_\ MC$
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M *>2*2(B-%C0A\)$"H.DCW1MV#C?"2=K?BN,XSHMO3?&OU%/_ ?'/_?^#:L
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MR.]W''JB,A=5DDL;I%9L9:,8&EE8R.+V@21Y.:G*B$LOT,K(JZ8F*\U$,;2
M3Q-H4LVDLV"%;3+NU/5=F\!6YZQSM.FZCT/7P_:(\D%G)1"LQ1^NZ^QM18_*
M15V!2E75CV)7EUP<H,"/KZ>]D((')%&%+U67")KOFZGY')NA9LIC$C>\>ZW=
MRR'$J* B6K:W#, 74 $$L-EQQ".W9%"<P-:3WADUA%6*%X(^FEG)=ILKA=*A
M&+,"45Z?NO7#KEP&VVN*Z6HKPGI[(C6?=M)I^US<HF)W\6CT^5TG55+94_5^
MX;J=)F+3)FF&FF!9>M*SEQE;X1[H= + SH0^S\!N[:UN>(O$+Z9UL);>Q%R+
MBU$4<T=\R27MKRH)TDT(-<C">.6)AJ1L5$XN\JRM%:@FV2-;H27&CDW4D[0-
M:Y6*35)%I,CDA?HWA901(*VTZQ['O-?9[?)[+,560W. .S\%W4T.G*V- 77:
M?/B7E1=4>@.S.-L#*^8AUQ1R-L<Q3EQVF>LG-&D!D"+)XMS:K"D$\,IFM[D2
M\MWBY,JO#(4DCEC$DJA@IBDRDDB%90H<NKA>G!,\AECEBY4L3(" _,C='165
MXWTHV-6N,JZ(X:,L5TLA:W>4S\,U8K4KLWO/J_'>H'K'*66[Q4&SFRF[IQLH
M=JZ2MMTM-3;];.H!3H##(Y*U+>*M/GKE(C^ILV!$0TX=F=\ 1'3M;"[N+*YG
M2";W>-XI'G$4C)H1+@OHTJW,9?#J (5 P>5HX@\D?,NN(6MO=6\#31&XEUHD
M)E17+,T0&K6RJBD$X9CEF 2-7E9(WV!2LUWTJ&+IHF6GM:[\.;5BNSON5%5T
M+F*C;YZ)[E8TF.Y@7RR*9P2HD@LM+F6X\(@9T.D:VE*W&,>(AD(MUR=_%"^G
MH'QXJL\NXQJYX5\'"! 8,]1J# SL1C TS(#]8KU4\^JT@QDKZZQ8RIO1WM81
M4SSMD>]'_(L!==.K8_Q*M+;#+(*7'%&_Q'*.8.&>,6&/@T>D!D8RQ-NL@4@C
MS60$G0XV# G&X92T;*QVI*&)1QRY5ZQE@<[D!D.VM#C(8#S! 96427F%;:<4
MIQ2O#D]R*B_O_P _^OBE4C;#R]26Q^L 29_6MP639[BIA;)(W&VQLSISM[4C
M,<Y8J(Z>20K>U8T2PP$R3;@:* IVMEN;2+[YHC)/O:C3;L20)U5=*VS]BX4
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MB]?9B2V0"N L9XI2 W*/)&G+HDFNH89;A%CGGLX6GC(;(D*L 6##"Z@,X.&
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MMF<&KWHK=Y$Z%QGXF4L:?LO 30#(GP,R2,J\_I._$+HYZ^"49\]A<;9;+],
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MW$TQ#&^W\2C1B,<Z2 ?C<6:TEO;J>S1DM9[JXEMXRBH%MVD.A3&H\&,85<#
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M2*UJN\<XEXX>[N64Y#3RG/GEV.1_JG]'R&!7=LE*6ELI&G3!$,8Q@:%P".Q
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M64F0&5XM_H;>=B,@55E8R6I/A+T3B!*FYA("N(GL7ZV>ILWS!EE1_6R"UK[
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M[,Z#S$J+-Y5$Y#*5WSJ0L45P#I9@-3 9PPP/YRJ?+-9*^H@$%6QJ9&QJ4$D
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M $F!<*.D;9\<7_TD@KN? R$G)K5"Y\43DF2(@%C_ )Q",I(-SLPRI_UT< 8
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M&R:UJM:D9X[?Y]&-;%%80GB0^YHJ.=QN'73J)K.Z8^^V3K%*Q4CWB,ZO=[T
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MX8FHQC?<Y7/>J-1/<][G2/=Y>]SGJKEULQ9BS$EF.23W)_';:MJJ$4*HPJC
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M3*,>YV0Z["] _G[GZ4; JV?(!NFDXV&]& +ZX/U#"25-;22L]0#GRUU0;+8
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M9'&H[;*D>#@G-<$RS=/!"2%/\Z8@AB!CI&A*@@G+,XZ@5#-81%;U&OT+T24
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M5&#>.D^E%L!@Y8D)\-ECE/6.,<.5B*KOK%)FC#49OF52U^G:BR?;F#HZ.8L
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MU:Q70Z.OJ+O=U\4:OF?:0]@'$R11S@Q\X!(EL[@EF+Q30RE0"1R2)HI)&R,
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MM_Y]QL#[,8WZ@9SG-='V>"!N-: X XL@',SJ'^1>#9!R3GIUR<^9ZG8^S_\
M*UBO_5UV?_[R]1<KK_))O]XM?_3NZ[C?RJ+_ .1<?^I;?+\;]JL7E>M].*4X
MI3BE8+264M54DDC,28Z1&!U@[U5L9-J=-&'6P2N145L+S)XOJ)$7^9'2:9W[
M,;E3.--;J"<*,LYR!A%!+=>N%!(&02P '6M<KZ$)QDG"J.N68Z5&!O\ 6(SY
M#)[5%/I/YN'(5Y,P]13 PNU%JDRQ&%R$,6?Z#ZR-\<@]C:HZ6UO3T]I4 A,;
MX'Q$VD)PFPM@^\%09)6^A0YT@@X!*D$%4.%52"N0058 J=! (-NK82-!S7SA
MB",L-0^JS;L[ A@#D,I(8>@+J]X\>NN6CU6<IP4DS8)$;1X  /A6-M[,.L;$
M#-*#D06N#8CIZ^LE? OPEV1H(^3*VHV\9,LTKE9G!R7<GQQ*V<L@8$R'(5W7
M6=2J';$: />7 CAA3,*G8*@ TR%<>%M.R  LJG PS,B_2BLA]X2EM\K6T=.<
MJ U*JBE36$+63"6EPUCE;$UH\\)]+7>9/CCG%M37,L4&$JYD7W8<L9,DJ 2L
M5(55)R8X2<$G*Z99 !DJR1DQZGE1-[RW,; BB;,2!LES@@22@'R.8XCG 8/(
M!)A(LWAU9'B<H]SFM:F9I997JY$;[GU@TLLKG+X1/<YSI'N541557+^:\UW(
MQ<W"#'AN)D !S@"1E51CR& !UQBMMLV;6!SG+01N<[')168D'ODG/J:]<E(B
M9H(R6-1H['Z^\^.3]A!(+L\RZA&D1WCV() <P=Z?9K?B5$\(GCD7&TSH-S&5
MBVSXVB18BP&,GF,K-GS).!V6QS CG82!IAJ(&E9G:4*1G "*P7K@ 8SL:^'7
MIHI^0IC1Y&J\Z*>P+B]JQ/'L;$P@^R$DA>C7PRBGDD0/A<U%C=&K4141%79>
MJ8[J6-M.4;EJ000ZQJ$5U.3J#*H;4"<YSMTK"Q<26D,@)\:ZV!&&5I&+%&&,
MAE9BI!WR._6IKRKD'H0?G5NG (.XI3DTIQ2H?JFL&EHKJ7VM%JK1C;*1R^WV
M5UC&\3Y'.548R$2T6JL"I'JC(10IIW*GQ(O-T.6$L0QF2,Z/]M/'@=-W0/&H
M&[%]/>JUQX3%*?JQR#7U^I)X,[=D<H[?S0NH["OHL\8.L9(0C8X;VH%K@B'.
M1$0^I(LSG@*KD^TI81\A(S6KXD96E^[PK(T?"X:W(7<Q2/(V 3]&ZQ+J) P
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M+'5D@' ) &2<,0<8.<XZ55:\M4SJF4:3ACXB =]B0".QSY$8ZU]&;#/2L22
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M7&P7?PX[>N:V0L__ "M8K_U==G_^\O47-*_R2;_>+7_T[NNRW\JB_P!WG_\
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MA-=DCT*VH'Q&58?$':JD8_AET0!M#:KG;.0;AB//HRGRW\\U!;"*2TS&]/\
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M["^U]O"EQ+[/<26&19'CDY2D2)#%)/,T8#ZI!%!#+,X0$JD;G&5(K.;3UO\
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MY;(JZ9C7-3Y56?S]GMBM45%^HD1^6"-@2 =\;_OVVV]1GY5'A).UM >Q\/\
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M8JB/"[':-'5%96/@5P=95':1/B4X:*7WA4>1&B$5PB#5($4NR2QH/KNA9@R
M%G4CE@NJI)054-$K!98+NO*K\K9XJ\G4.+ZR.V8!99_,MN!S6%?XM5]3F?CN
MLX6!]?67PDKV%S!EMEE[,LN9&YD,BO<QW<>''*:!Y([B;DO&5S(PGE!AE0Z&
M@?#*)$(KCQ)A%"RHPMI+.0LA#),J26]NLRN"= ,4+\Z%P76=<JQC(U;<M_R4
M_A^2?V)]D1?Z_P#?^OGG02<Y.3D_?N/N/K^P>D'0?#\?C;X"O;DU-0C3(XN_
MP]:QZ>&WAEV7$JIX>%44=C%&OM^ZK\5W9TDR+X1K7L;Y5'*U'68"%BO7(!)@
M2) 3N'DFC;(&.K11S*=SL2>QQ3N 7GLD!( G>9@.C)'!*N#Z"66%AMU4;YKV
MPRM@ N*E$5KZ34Z(-S?OXCA.LI;^MB8BHGB.*IN:^.-&_L-:U&-^S?"3=C+Q
M2;?36UN_UM1+)&L,K$D Y::*1C_M4LL+'+$/\S<W$?3 "M*TT8'8A898U!'\
MT_*:\JU<KX%2I /.0OY0123+Y7PGB-CGKY7^Q%X U,J;Y)7IY%@#\?A6+'2K
M-Y*3]@S6D9N?GK:[*QQVL<AE75X_4U]9*V<%7M-"H82\LZ,>0\W4W6M9BIJB
MG#KZR&.B'>7=G-*.%K83.IQ$W%T\]]9PXOX+N\D@P0PF93="6&8MIBM+*2.[
M;G32R.><(6C$8BD*^:%NL4=M!)-E(X;.09!4@$6WT0(+-/--[H8XHT0&-7=Y
M"S<O5LOA11=!':;V<>2(G90@01"%M@4NMSU1$3#74Q\;%FCA-C-,N+"T"5[W
M 6%D363.D<#[W<_WN.YM;1().9;QJ\B,-0#S3%><Y5PK*Z\N*!@Z*RF#Q*K9
M%=NUBR\MXR-'+<K$-+@"2**(.8HFP2 ZO)+(X!(5Y&4,P4&H%D]51=0SG]:[
M2\J\[2T21D=<6MY81A"V>$,5Z5U%&?8RP,(M<*1 1FR!6SFE_JW!D;FP*E-O
M)TCS$4LXU11R2L=I%C5G97 [A0?K ZL[ $D=,&O2R6=WQ9EOK&WGNYI5/O\
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MW\I/ZQ/^W^JFKA_]#>?\S!_9*?2=R_T@ZS_T-U'^WO&JW_FR?UD?_;IJX?\
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M_MTU</\ Z&\_YF#^R4^D[E_I!UG_ *&ZC_;WC5;^4G]9']OU*:N'_P!#>?\
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M%5->$UB.?[W:!4^ZH@[ 7KY^ZI\221JCWJJ1)&GCRZ506?E)XYK*[]7WWV(
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M1?\ )V!+9'S6MJBIX61MC92D3!R2I\[*I*X.5?(C42(<A6GD!YL[%BN<LJ*
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M/*N@;^TG[[<0Q:WDFV6$%MN-P)7:8L/7^"A?@Q[XJI,=5U9QGH/>+CXM$J1
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MSE\FI K$\,^ZK\CF^/'V7Q^RWPC$\_GS:GJ&)[8SZ8QV'QZ@=*NV_4;3?(G
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M<.&DC87(EM4N1)A"#&H]IT*L<R,94?%*UR(L14GF 21&D3HL4;DY:G^K'_\
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M00Q&S98Y. IY((U$H%SC'-C)^H2+B\5F&^+3.,?Q9'3(R<VXQWR<_9C<K<5
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M1J[U\ZFE:;C?M'*XCU-Q2T!Y2A4 7V=X$HP !V49) );)[[[V&_].,_^:_\
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MB%(5<GEVUC;*(XX><%DCC2.%M$:O<R:RA+>>+R7),MW(TI099V90 ,G$<:*
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M-]3!*4L835(DA(1"(9)5>^.=/E8J/_:YSQPCA2ZM/#;!0QRP6TMP&.2V6 C
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MC1'KL29'.!L^D,8VVD4,Q4%DZA20<-G!P<$@4R//\9Q^NN078!@LA>63 /\
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MR)%9&0L'0G+M[0R[OF1O:]HZ2 &$\@:/(QR&P(3HB<B+7D@MS'U8U\7J CJ
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M_P"F]G_V/G?']?V_#?W\>Z7?^E;K^HL/[)30_P#3/_PQ_P#13\ T/[MM9_\
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MJGSP$$,1S;RN<QR,&5)&2L<B.'(>OTXI"1%%_P""0S<T7&.6"2H EA8EE+
M3(2<+@C;]([)]=ME-1W'3ZR]?/4,'Y=>AKH_OI;&LU>_JHJXZ>:J[/[++OPV
M02M(&)L.P+VVJE):V.24<5]:ZJLJPF:%L)T!;S0I"*\R":3\:^TL=]:<>XS
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MJ-D5%8 &,UZ(U)/D5C%;]EM[5(  &9VT(A9MEPBZ04B33##D8U+!'&AQLH&
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MT8!2&&6^NZ0[[ZY-T.@+T1 FHQD=7!D]=^HL-)0,K2*34;8ZGH"K"_9//=7
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2?$DECEB2?,G)H!C85(^12O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img227133604_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $8 G # 2(  A$! Q$!_\0
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MU;JY6RDNLKM5PH4(9/E!\LGCFM73I6NJ:?Y[-]O+0R4ZM[.H_P!.G^>IF?\
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M[CG^M5OYV?5__#T#]H'_ *&#1_\ P30T?\/0/V@?^A@T?_P30U\H44?5Z/\
M(ON#ZU6_G9]7_P##T#]H'_H8-'_\$T-'_#T#]H'_ *&#1_\ P30U\H44?5Z/
M\B^X/K5;^=GV3XH_X*5?'K2)-*$'B#2<7.F6UT^[1X3\[IEL>V:Q?^'H'[0/
M_0P:/_X)H:^=_'G^N\/_ /8#LO\ T77,5,</1M\"^XN>)K*32DSZO_X>@?M
M_P#0P:/_ .":&C_AZ!^T#_T,&C_^":&OE"BJ^KT?Y%]Q'UJM_.SZO_X>@?M
M_P#0P:/_ .":&C_AZ!^T#_T,&C_^":&OE"BCZO1_D7W!]:K?SL^K_P#AZ!^T
M#_T,&C_^":&C_AZ!^T#_ -#!H_\ X)H:^4**/J]'^1?<'UJM_.SZO_X>@?M
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MT-?*%%5]7H_R+[B?K5;^=GU?_P /0/V@?^A@T?\ \$T-'_#T#]H'_H8-'_\
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MKC_[%U'_ *!]W_WX?_"M(TZMO>CKZ&$ZE*_NR_$I45=_L74?^@?=_P#?A_\
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MM.<59L?V<?#6L>"%N8M<N=-\1WNFZ+-I2WKI]CN+V\2Z=[>1L#RPWV<+&Q.
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MR_RWM^19E]3^NUE67O>U=]_ANKK3Y_Y[7N^'O@O/XD\.6$MKJ_\ Q4NH6?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!_KI/_GT_P#P)?\ R)^PW_"?W7_0G>(_^_,'_P >H_X3^Z_Z$[Q'_P!^8/\
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MM_C1_J=#_GZO_ 7_ /)!_KI/_GT__ E_\B?L-_PG]U_T)WB/_OS!_P#'J/\
MA/[K_H3O$?\ WY@_^/5^//VVY_Y^9O\ OZW^-'VVY_Y^9O\ OZW^-'^IT/\
MGZO_  %__)!_KI/_ )]/_P "7_R)^PW_  G]U_T)WB/_ +\P?_'J/^$_NO\
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M27_/I_\ @2_^1/V#_P"%@W7_ $)WB3_OQ!_\>H_X6#=?]"=XD_[\0?\ QZO
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M:3\*_%FE:7KL4GB;1=4O-6NOM<T]]H)<2,>"LB^?\RJ@15 P%"#KDUVWP_\
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M_O\ @G_P)?\ ^*H_LW]EK^_X)_\  E__ (JG_K(O^@6I_P" A_JO+_H*I_\
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MJ/\ 3/\ IA_X]0!:HJK_ *9_TP_\>H_TS_IA_P"/4 6J*J_Z9_TP_P#'J/\
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MJF7?WOO#_6[,O[OW'Z&_\-Z?"O\ Y\?$'_@NM_\ XJC_ (;T^%?_ #X^(/\
MP76__P 57YY44?ZJ9=_>^\/];LR_N_<?H;_PWI\*_P#GQ\0?^"ZW_P#BJ/\
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M$%LKGJVP=6/]YLGWKGZ**4(1IQY8*R'4J3JRYIN["BBBK,SWS]AG_DY'0/\
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MHOD?V?IMG9&"W%I$UO J%(0<B,$#A0>=O3-2S1Z?;[!*+>,OG;O(&[ R<>N
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M 'XE_P#BZ/\ AX1XX_Z%KPS_ -^)?_BZ/K&??\^(?^!/_,/J_#__ #_G_P"
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MO1V5%<;_ ,+=\+_\_EW_ ."VZ_\ C='_  MWPO\ \_EW_P""VZ_^-T?5J_\
M(_N8?6J'_/Q?>C\B/$__ ",VL?\ 7[/_ .C&K-KZ3U;]D=]2U:^NU\<V*+<7
M$DP4Z+?Y 9BV/]5[U5_X8[D_Z'RP_P#!+?\ _P ;K]YAF^"44G/_ ,EE_D?S
M_4R;&RFVH+?^:/\ F?.U%?1/_#'<G_0^6'_@EO\ _P"-T?\ #'<G_0^6'_@E
MO_\ XW5_VQ@OY_\ R67^1']BX[^1?^!1_P SYVHKZ)_X8[D_Z'RP_P#!+?\
M_P ;H_X8[D_Z'RP_\$M__P#&Z/[8P7\__DLO\@_L7'?R+_P*/^9\[45]$_\
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M#Y8?^"6__P#C=']L8+^?_P EE_D']BX[^1?^!1_S/G:D;&TYZ5]%?\,=R?\
M0^6'_@EO_P#XW7I?P(_9M\&?#_Q8NO>,=>'B22S*O8V5OH]XL*R#GS) T?S$
M<8'3/)[5A6SS"4J<IQ;DUT497?X&]#(<95J1A-**?5R6GXGM?[&MGX]L_A7"
MGC=SY9$9TJ*YS]KCM<':)2>W]T'D#KV ]\KAH_BSX86ZG<WEWM8+C_B6W7;/
M_3.I_P#A;OA?_G\N_P#P6W7_ ,;K\4Q4:^*KSKNDX\SO9)V/W'"RP^%H0H*L
MI<JM=M7.RHKC?^%N^%_^?R[_ /!;=?\ QNC_ (6[X7_Y_+O_ ,%MU_\ &ZY?
MJU?^1_<SK^M4/^?B^]'945QO_"W?"_\ S^7?_@MNO_C='_"W?"__ #^7?_@M
MNO\ XW1]6K_R/[F'UJA_S\7WH[*BN-_X6[X7_P"?R[_\%MU_\;H_X6[X7_Y_
M+O\ \%MU_P#&Z/JU?^1_<P^M4/\ GXOO1V5%<;_PMWPO_P _EW_X+;K_ .-T
M?\+=\+_\_EW_ ."VZ_\ C='U:O\ R/[F'UJA_P _%]Z.I;_D(1?]<F_FM6:X
M=OBSX8-Y&_VR[VB-@?\ B6W7JO\ TS]JF_X6[X7_ .?R[_\ !;=?_&Z/JU?^
M1_<P^M4/^?B^]'945QO_  MWPO\ \_EW_P""VZ_^-T?\+=\+_P#/Y=_^"VZ_
M^-T?5J_\C^YA]:H?\_%]Z.RHKC?^%N^%_P#G\N__  6W7_QNC_A;OA?_ )_+
MO_P6W7_QNCZM7_D?W,/K5#_GXOO1V5%<;_PMWPO_ ,_EW_X+;K_XW1_PMWPO
M_P _EW_X+;K_ .-T?5J_\C^YA]:H?\_%]Z.RHKC?^%N^%_\ G\N__!;=?_&Z
M/^%N^%_^?R[_ /!;=?\ QNCZM7_D?W,/K5#_ )^+[T=3=_ZRV_ZZ_P#LK59K
MA[CXM>&)'@(O+OY9-Q_XEMUZ'_IG4W_"W?"__/Y=_P#@MNO_ (W1]6K_ ,C^
MYA]:H?\ /Q?>C\U?VGK27Q-^U#XQM/%M[>SZ?'=+#I]M-.R>3"8T(* ]$+9Z
M<'DUL?L9R:AX7_:,AB\*G4+O1?[-OFN=)AN/EN62%C$')(4;G "EL $CFOM3
MXN:1\(OCAHRZ?XMLIKXQ_P#'O>QZ;=1W5L?6.41;E^G0]P:T/AK-\+/A'H2:
M3X5LGTNVP/,D32[II9V ^])(8]SGZGZ8KZR682>#]A[&5[<MK:>O]?>?)1P$
M8XSV_MH\O-S7NK^G_!_ ^4_&/CSQ_<>)/%,'Q!M-<T:.]U/PR]^BW\4-EHUJ
M]W,'A5HIBWENF09!\S%6+[1MKT>XOH'\<:AHWPW\2:I=?#^4:<MU>17\UU!8
MZD]WM"VLTC,23$2SH&*C"G@G%?1LWQ0\'W&\2RS2A\!M^E7)W8Z9_=4L?Q4\
M(PPK$D\Z1+]U%TNY"CZ#RJ\]8FJFFJ#5NFMNG2WEI_5^K$8.EB*,Z+Q"]Y-7
MNKZWZIKOK_5N'N-"\377Q&\+6OB[5OMD%]#?6QL]->2" QQQJ1*VT@^8Y.X\
MX7@"MKX/>%[*'5/$U[F\DN+#6[JRMC->S2*D(5,+M9R#C)Y()YKHC\6O"K,&
M-U=%EZ'^S+K(_P#(="_%KPJF=MU=+DY.-,NN3Z_ZNN6I4Q,Z?LU3:TMHFENW
MM;L[&6'RO!4<2L0ZJDU)R]YJ3^&*^)N^C3DNU[)([.BN-_X6]X6'_+Y=_P#@
MMNO_ (W7703)<P1S1DF.10ZD@@X(R.#R*\F=*I3^.+7JCZR%6G4^"2?HS\M_
MVRO MOX^_;2URRO;UM-TJTT2+4M0NHH_,D2V@M3))L3(W.0N%!(&2,\5\^V6
MC> ?&WC7PIHGAVT\1:4FHZK!8W;:E=P7!,,DBIO0I$FU^3P0PZ<U[W^VIK'B
M+0?VVKR^\+1/<:S%86OEVZP"99HS;$2H\9!#HR;PRG@J37A&O>/M2TW5=!UB
MU\#:'X1DTO5#<Q-8V,J":Z@9"R.9)&8JAVY12 ,^M?68>_)3[61_0>5JL\%0
M47O35M;6=GNNOEZ=.O4>#?@5X=UI#9ZA>ZDFIZSK6HZ+H;VYC$,+VD0?S+@%
M27#L\:84KCYFR>!7)>+O!WA9/A;H_BO01JUE/-J+Z7-;ZM)%(+LI"DCSP[%7
M:JLVTJ=V-R_-G-'AWX\>(?#-CJEO;VVFSRW5W<7]M=W%N6FTVXG0QS26QW *
M60@?,& VJ1@C-4O&'Q8G\9^$M$T"X\.:#81:/ EM:WEA;RI<"-2Q(),I4EV8
MLQVY)YS6L8U4U=]O^#_7S/4A2Q:K*4W>-^_37I_X#\TWUN<+M'I1M'I1178>
MV&T>E&T>E%% 'TO_ ,$Z0/\ AJSPYQ_RYWW_ *3O7Z>-\;M&F\17&E:=I.O:
MW%:W7V*[U32],>>RMYP0&1I!U*D_-M#!>^,&OS#_ ."=/_)UGAS_ *\[[_TG
M>OT?\&^'/'_PS:;PUI.E:)K'AMM1GN[35KG4)()[>&>=II(Y81$WF.K2.%96
M 8;<[3FOF<PC%U]>R\NI^.<60IRS!N6ZA&RO;K*[^6FGGY';0_$S0)_B1<>!
M4NF/B&#3UU)X=AV>47VXW=-PX)7KA@>]<GH?[2W@_7M(UK4435K*'2].EU=D
MO=/>)KFSC8JTT&>)%W+C@YR1QR*Y6U^ /B>U\06_CG_A(Y'\8?V\^K3:6TJ_
MV=Y,F('@5O*\SBU"J"3C>@.*YW1_V7?$'A/P;JEAI4]C<7VO^';O1]46\NI7
M6&<F1[>2W=E)2,ERLD8"K]U@,J<^>H4>766OZ_Y'S$,-E^TJFON]>NO-TVMJ
MON/6-)^/OAS4#<QWMEK7AZ[AL9=2CM-:TV2VDN;>)=TC0Y^60J,94'(R.,<T
MFI?'W0+:>"#3M,U[Q'<-9PW]Q%HFFO<M9PS)OB,V,!69>0@RV!G'2N6U;X;^
M//B(MBWB&UT/08=%TR]@L+6PO9+M[FZGM'MP\LC11^7&JNWRA6))!SQ@O\,^
M!_B#\*9[L^'M.T3Q';ZO:V;7$=Y?O:-9WD-I%;.0PB?S86$*$#"L#GKG@<*6
MMGKZ_KZ&?L,':]_>[<RM>_\ -:VVN^^GD_1/"_Q2\.>--4MK+1;TW[7.EQZO
M%-'&1&UN\C1@Y/1MR,"I&1CFN;O?VB_"UC>73&VUF70K2Y-I<^)(=.D?3(95
M;8P:8?PJ_P K. 4!SEN#7(>$/A3XZ^%OB:PU'2K71O$PGTEK;4I+B^DL-MU)
M?3W4K1((9,QYG(4$@X44L?PS^(FD_#O4/A=I]OH4OARYCN+*'Q+/=.)X;*9G
M+![7R\/,JNR@[PK$!CCD4>SIWT=UZ^8?5L&JCM.\=+>\EI]I[;K2RM=WV9WN
MN?&W1M(\17>C6FEZ[XAN+#8-0ET/37NHK(LH95D9?XMI#;5W, 02.13[[XW^
M%].U"[TV>6Z76+>_@TY=+^S-]JN))@&B>*/J\97<V_H!&^<;37G6O?"CQ_X9
MT?Q9X<\%O;RZ7KER;ZRU8:Q+I]]IEPT:(V\K$_G1[HPPP02"5(Q@UWW_  K>
M\F^*WA+Q7=?8[IM)T"YTRXNG'^D/-(\!#+\OW<)+W&-_3DTN6EIK_5K_ )Z?
MCJ92HX2,4[WT?76Z2>JZ7=U;?\WZ-1117(>*%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+QM_T3R3_P '-O1_PF7C;_HGDG_@YMZ[RBCF7\J_'_,/;0_Y]+_R;_Y(X/\
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M<@_LO ?] \/_  %?Y'N__#<_QT_Z*!=_^ =K_P#&J/\ AN?XZ?\ 10+O_P
M[7_XU7A%%'U>C_(ON0?V7@/^@>'_ ("O\CW9?VY?CFN<?$"[Y.?^/.U_^-4O
M_#<_QT_Z*!=_^ =K_P#&J\(HH^KT?Y%]R%_96 _Z!X?^ K_(]W_X;G^.G_10
M+O\ \ [7_P"-4?\ #<_QT_Z*!=_^ =K_ /&J\(HH^KT?Y%]R'_9> _Z!X?\
M@*_R/=_^&Y_CI_T4"[_\ [7_ .-4?\-S_'3_ **!=_\ @':__&J\(HH^KT?Y
M%]R#^R\!_P! \/\ P%?Y'N__  W/\=/^B@7?_@':_P#QJC_AN?XZ?]% N_\
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MBOMZBCZ]B/YP_P!8\V_Y_O\ #_(^(?\ AU/X%_Z'+Q%_WS!_\11_PZG\"_\
M0Y>(O^^8/_B*^WJ*/KV(_G#_ %CS;_G^_P /\CX<@_X)6^!)@_\ Q67B+Y7*
M_<@[?\ J7_AU/X%_Z'+Q%_WS!_\ $5]JV((6;(Q^];^=6:/KV(_G#_6/-O\
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M<Z%C],UPESX3U"S\5'PY-X>T1-8\P1?9SI-EC<5W#YO+QC'>O4_C/JUCX?\
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M4?\ "D_"?_/OJ?\ X.[[_P"/5W=%'M)]V'UJO_S\?WLX3_A2?A/_ )]]3_\
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M?_'J/^%)^$_^??4__!W??_'J[NBCVD^[#ZU7_P"?C^]G"?\ "D_"?_/OJ?\
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M_P \8_\ OD46K=U]S_S#W^YD_P#";^'O^@YI_P#X$I_C1_PF_A[_ *#FG_\
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ML/\ SQC_ .^11:MW7W/_ ##W^YD_\)OX>_Z#FG_^!*?XT?\ ";^'O^@YI_\
MX$I_C6M]EA_YXQ_]\BC[+#_SQC_[Y%%JW=?<_P#,/?[F3_PF_A[_ *#FG_\
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M0 4444 5F_Y"$7_7)OYK5FJS?\A"+_KDW\UJS0 4444 %%%% !1110 4444
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M ,_.C?\ @/+_ /%T44>Q7\S^\.7S#R_%?_/SHW_@/+_\71Y?BO\ Y^=&_P#
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M_P# >7_XNCR_%?\ S\Z-_P" \O\ \7111[%?S/[PY?,3R_%?_/SHW_@/+_\
=%UOQ;_+3S"IDP-VT8&>^/:BBM(PY.K?S&E8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img227133604_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_4.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %K ^D# 2(  A$! Q$!_\0
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M9ZP60,0K82WQD=\5Z=7E_CC_ )+U\+_^O/6?_1=M7J% !1110 4444 %%%%
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M+&34;_QM'?2S0^+;W7=/THZD9+#+2[H+AH5.TR $XST[BMS]I?XF>)?"NH>
M_!_A.\@T;6/&6IM8#6[B$3+8QJ%W,J-\K.=XP#QP>Y!&7X_\*^-O@[\*_'OB
M"/XGZWXA%OH%Q)##J=O;^9!=* 4FCD1%(  8;""#NSGB@#N&_9V\'MH\^F&&
M\-K-XE/BQQ]I.?MY</NS_<R/NU@_ [X4ZKH?Q(^)?Q \3:9;Z;K?B34!#9V\
M,B2>581*%C)9>-\F 6'J@JE\/_VA=0N)+;PYK?AF]BUU?"</B.UFDO8"-1A
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M_P"+LQ^F*\RT?]J^V\6W-AH%IH-W9^)[AM5AU6R6Y1I-$%F"&ED)7#;B4"\
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MVD7.KZ/_ &A=-?7NEV.HR1V%S<,,-*\&=NX\$XP"0,@TEO\ L^^#+?X4Z?\
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MQ@%>F  ,5N>"_ASI'PWC\12:'#<,^M:E-K%TDTY<O<2*H;:6^Z#L7BO(+O\
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MGJGB&'XE?%SPKK7BC4O%-KX>O;"&RN-4\OS566W,CYV*HZGTZ 5[W0 4444
M%%>;Z]-\7EUB[&BV?@E]*\P_9FO[N\6<IVWA8BH/T)%4/M'QR_Y\?A]_X&WW
M_P :H ]7HKRC[1\<O^?'X??^!M]_\:H^T?'+_GQ^'W_@;??_ !J@#U>BO*/M
M'QR_Y\?A]_X&WW_QJC[1\<O^?'X??^!M]_\ &J /5Z*\H^T?'+_GQ^'W_@;?
M?_&J/M'QR_Y\?A]_X&WW_P :H ]7HKR=KKXXJ,FP^'W7'_'[??\ QJE^T?'+
M_GQ^'W_@;??_ !J@#U>BO*/M'QR_Y\?A]_X&WW_QJC[1\<O^?'X??^!M]_\
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M-=V\*A8UF62-U+ #[X56YZXIOVCXY?\ /C\/O_ V^_\ C5'VCXY?\^/P^_\
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M\JYC7@@]^:X+3_V:[CQG\3/BO-XLEUBQ\*:UJ5C-!8V=]'';ZK#% @(F507
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MUQG( W IUYXJ/[1\<O\ GQ^'W_@;??\ QJC[1\<O^?'X??\ @;??_&J .?\
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MML(!((.!GBO=M#FO+G1[274+&/3;UXP9;.*83+"W]P.  V/4 4 7J\S\(_\
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MM#2_TNVADUJ:RN@+6V=XP^[+G*HP.Y2W4$5Y%\=OA1KOBCXM:7XEL_A_X?\
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M?=(/T-+71_JSE7_/G_R:7^9S_P"M&;_\_O\ R6/^1]P?\/*4_P"B?G_P;_\
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MFE_F'^M&;_\ /[_R6/\ D?</_#RE/^B?G_P;_P#VBC_AY2G_ $3\_P#@W_\
MM%?#](6"XR0,T?ZLY5_SY_\ )I?YB_UHS?\ Y_?^2Q_R/N'_ (>4I_T3\_\
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M/_@W_P#M%?#]%'^K.5?\^?\ R:7^8?ZT9O\ \_O_ "6/^1]P?\/*4_Z)^?\
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M_P"B?G_P;_\ VBC_ (>4I_T3\_\ @W_^T5\/T4?ZLY5_SY_\FE_F'^M&;_\
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M*O\ GS_Y-+_,/]:,W_Y_?^2Q_P C[@_X>4I_T3\_^#?_ .T4?\/*4_Z)^?\
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M_P"1]P?\/*4_Z)^?_!O_ /:*/^'E*?\ 1/S_ .#?_P"T5\/T4?ZLY5_SY_\
M)I?YA_K1F_\ S^_\EC_D?<'_  \I3_HGY_\ !O\ _:*/^'E*?]$_/_@W_P#M
M%?#]%'^K.5?\^?\ R:7^8?ZT9O\ \_O_ "6/^1]P?\/*4_Z)^?\ P;__ &BC
M_AY2G_1/S_X-_P#[17P_11_JSE7_ #Y_\FE_F'^M&;_\_O\ R6/^1]P?\/*4
M_P"B?G_P;_\ VBC_ (>4I_T3\_\ @W_^T5\/T4?ZLY5_SY_\FE_F'^M&;_\
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M_K%5D=E8Y/0#BN<TK]H!O^$-T3P]XE\%^'_&<6@@II5UJJR"2V0\^6VQAYB
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH L:?\ \?UO_P!=%_G7[9U^)FG_ /'];_\
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M7WLZ?]7*'_/Q_<C\T_\ A5_C/_H4->_\%DW_ ,31_P *O\9_]"AKW_@LF_\
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MXT?VA=?\_4__ '];_&C^WZ__ #[7WL/]7*'_ #\?W(_-/_A5_C/_ *%#7O\
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M'X7^- 2#X/U_/_8,F_\ B:/^%7^,_P#H4->_\%DW_P 37Z::E?W7]I78%U.
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MYI_\*O\ &?\ T*&O?^"R;_XFC_A5_C/_ *%#7O\ P63?_$U^EG]H77_/U/\
M]_6_QH_M"Z_Y^I_^_K?XT?V_7_Y]K[V'^KE#_GX_N1^:?_"K_&?_ $*&O?\
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MXS_Z%#7O_!9-_P#$U^EG]H77_/U/_P!_6_QH_M"Z_P"?J?\ [^M_C1_;]?\
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M63?_ !-?I9_:%U_S]3_]_6_QH_M"Z_Y^I_\ OZW^-']OU_\ GVOO8?ZN4/\
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MX6?\CM9_]<;C_P!$O7HR_='TKY/,_P#>O^W5^<CZK+?]V_[>?Y1%HHHKRSU
MKC'^+6@0_%+_ (5_<236VO/9I>0&50(;@-D^6C9Y<!2=I R <9P:[.O$-8\"
M6'Q"^,_Q"TK4/.MP=%TB:UO[8[)[.X1[@I-"_9U//Z'@USUI3CR\G5FU.,97
MYNWZH[S2?BUH&N_$S5/ UA)-=:OI=K]JNYHU!MXSN53%OSS(-RD@#C/)SQ7:
M%2,9!&>E?.>M^%[SX;^-+K3? UK))JEEX!NFM'9?,EGN3>*SRL3]^5B6;GJV
M.U3:/K&GQZ]I"^ _$.LZ['/IEX_B-+VZGN%A MV,<LOF_P"HN/.PH1=N06^7
M S6$<1*.DUK?^O\ @FTJ,7K#;^ON\CZ&VMZ'TZ5@^)?&%EX7&C&Y26==6U*+
M2X&MP& E?=@L<_=&TYQD^U>*?#^QO;%?@_-_:^MW,OBC1;F'6/M>H32";%H)
M$8 MB-U;@,NT\\D]:Y#PII>BR_##X>:':7]]'KR>);&/6H$O9S<6<@>X7&')
M$)(S]W&<Y]Z3Q,NB_K3_ #&L.KZO^M?\CZW92IP1@UA3^,+.W\<V7A1HICJ-
MWI\NI1R!1Y0CCD5&!.<[LN,<8QGFN3^$:SZ7XB^(.@"ZO+G2])U6%;!;Z=YW
MBCDMHY&02.2S+O)(R3C.*CU16_X:6\.MM;;_ ,(K>C=CC/VJ'C-;NHW%-=[&
M"IKF:?:_X7)Y/CEHMOXLAT6ZTK7;*TN+XZ9!KMS8%-/FNP2/)60G.200&*[2
M1P:]&KY]^)GQC\'ZU\4--\)ZOKL&FZ)X>O(=0OG>&5S>WJ',%M'L4C:C$.['
MN%4=Z^@LYYHHU.=R5[V'5ARJ+M:X4445TF 5PWA__DLGC;_L&Z5_[<UW-<-X
M?_Y+)XV_[!NE?^W-8S^*/K^AI':7I^J.YHHHK8S"BBB@ HHKG/'%UXLL]-A?
MP?IND:GJ!EQ+%K-W);Q+'@\AD5B6SCC'3-3*7*KC2N[$VN>,;+0?$7AS1;B.
M9[K79IH;9HU!1&BB,C;R3D#:., \T>-O&FF> /#L^LZJTOV>-TBCAMXS)-/*
M[!8XHT'+.S$ "N(\=?:I/B;\&WNXDCNOM5\;A8"7C1S8MN 8CE<Y )ZU5^-F
MNVDT.E7UH9=1'@SQ%8ZCK5I:PN\D,!1_GVX^?:'#_+GA37-*JTIOMM]R.B--
M-Q7?_-HV-/\ CEI&I:/)-%I&M1ZW'J":2WAN>V6/41=.A=(RC-L * N&+;<
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M-$&:)4<DAHC\AP<=.AR!Z%733ESQ4C"<>6304445H0%%%% '!>*/^2Q^ /\
MKTU7_P!%PUWM<%XH_P"2Q^ /^O35?_1<-=[6-/XI^OZ(TG\,?3]6%<=KWQ8\
M/^&?B%HG@W4YY+35-9MVGLII% @=@VT1%L\.3G (P<8SG KL:\9\=>#M,\>?
M'6/1-:M6N=-NO!TRL5RK1N+R,JZ./NNI 8$<@BE6E**7)O<=*,9-\VQZ5J'B
MZSTWQAHWAR6.8WVJV]S<PNJCRU6#9O#'.03O&, ]ZW=IP#@XKYML]0\:Z?\
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M_P ^=S_X$#_XFKYG_*_P_P R>5?S+\?\BC15[SM,_P"?.Y_\"!_\31YVF?\
M/G<_^! _^)HYG_*_P_S#E7\R_'_(H?6EJ]YVF?\ /G<_^! _^)H\[3/^?.Y_
M\"!_\31S/^5_A_F'*OYE^/\ D4:.G2KWG:9_SYW/_@0/_B:/.TS_ )\[G_P(
M'_Q-',_Y7^'^8<J_F7X_Y%&BKWG:9_SYW/\ X$#_ .)H\[3/^?.Y_P# @?\
MQ-',_P"5_A_F'*OYE^/^11HJ]YVF?\^=S_X$#_XFCSM,_P"?.Y_\"!_\31S/
M^5_A_F'*OYE^/^11HJ]YVF?\^=S_ .! _P#B:/.TS_GSN?\ P('_ ,31S/\
ME?X?YARK^9?C_D>:>*/^2Q^ /^O35?\ T7#7>US/B*ZT)?BKX(273+Y[MK74
MO(F6\4(@"1;PR[/F)XQR,8[UVGG:9_SYW/\ X$#_ .)K&$GS2]U[^79>9I**
MM'WEMY]WY%&BKWG:9_SYW/\ X$#_ .)H\[3/^?.Y_P# @?\ Q-;<S_E?X?YF
M?*OYE^/^11HW'GGKUJ]YVF?\^=S_ .! _P#B:/.TS_GSN?\ P('_ ,31S/\
ME?X?YARK^9?C_D4:*O>=IG_/G<_^! _^)H\[3/\ GSN?_ @?_$T<S_E?X?YA
MRK^9?C_D4:-Q]:O>=IG_ #YW/_@0/_B:/.TS_GSN?_ @?_$T<S_E?X?YARK^
M9?C_ )%')HR:O>=IG_/G<_\ @0/_ (FCSM,_Y\[G_P "!_\ $T<S_E?X?YAR
MK^9?C_D4=QZYYHZ5>\[3/^?.Y_\  @?_ !-'G:9_SYW/_@0/_B:.9_RO\/\
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MS_X$#_XFCSM,_P"?.Y_\"!_\31S/^5_A_F'*OYE^/^11HJ]YVF?\^=S_ .!
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MI4BK_$MEW[+R*-%7O.TS_GSN?_ @?_$T>=IG_/G<_P#@0/\ XFM>9_RO\/\
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M_B:.9_RO\/\ ,.1?S+\?\BB23R>315[SM,_Y\[G_ ,"!_P#$T>=IG_/G<_\
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M_L9M*_\ 2E:[VN"^,G_(#\._]C-I7_I2M%;X&%+XT=ZWWC10WWC16QD%%%%
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M?IXFO@GB:+5673XMMRX4M$9Q\J8 (V'Z&E.OR\O*MPC2YE*[V]/\SZMH +'
M&37F.C_&Y=>DT2QL]"GF\07DU]#?:2MPHDT_[)D2EF(P<OY:KT!\P'(P:XOX
MB?%9_&'P]\;Z2]I'I6L:+-IC3?V?J:7D6R6ZCP!+&!AQM963''J<TY8B"5U_
M6EPC0FW9K^KV/H*BO.]:^,D6E>'_ !MJYTF21?#6KC2FA$X!N"6A'F [?E'[
M[IS]WWJ67XJ/8?$VP\(:CI,=H=2>>.RN$U&*6=O*0OOEMU&Z)'4':Q)SQD#-
M5[:&FI/LI]COR"IP1@T$%3@C!KP3X'?$?5-#\ ^!+76]"F71M4N'TVVUP7ZS
MNT[2R&/S8L;D5B"H;<><9 S69X!^-]IX$^&O@W2)1;7NLW=G=7K-JNJI91+"
MMU(@S+(&W.QX50/X3D@"LEBH63>FG^7^9H\/.[2UL_\ /_(^CJ*P_ _B^Q\?
M>$=+\0Z<)%L]0A\U$E #IR0RG'&001D<'&16Y76FI*Z.=IQ=F26_^N7_ #VK
MVRO$[?\ UR_Y[5[97S^;;P^?Z'O95M/Y?J?'WQ$_Y'G7O^OZ?_T8U<[5SQAX
MGL-7\4ZK>VTC-;W%U++&60@E6<D<?0UC_P!K6_\ >/Y&OJ,/QAPY&C!/,*2=
ME_R\CV]3X_$<-9W*M-K!U+7?V)=_0N453_M:W_O'\C1_:UO_ 'C^1KH_URX;
M_P"AA1_\&1_S,/\ 5G//^@*I_P" 2_R."N?@+H5WXDN-=DU37O[1N)UGE=-0
M*!R#E5("CY1C 7TKTHG))JE_:UO_ 'C^1H_M:W_O'\C7/1XJX6H7=+'45??]
MY'_,WJY!Q!7M[3"57;;W)?Y%RBJ?]K6_]X_D:/[6M_[Q_(UT?ZY<-_\ 0PH_
M^#(_YF'^K.>?] 53_P  E_D=Q\+/^1VL_P#KC<?^B7KT9?NCZ5Y!X#\7:9H/
MB>WO;V9H[=(YE+*A8Y:-E' ]R*[-?BAX>VC_ $J7_OPW^%?,YAQ7D%3$<T,=
M2:LOMQ[OS/I,OX?S>G0Y9X2HG=_8EV7D=;17)_\ "T/#W_/U+_WX;_"C_A:'
MA[_GZE_[\-_A7G_ZT9%_T&T__ X_YGH?V%FO_0+/_P !E_D=97/Z?X,MM/\
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M =<<FJ?_  M#P]_S]2_]^&_PH_X6AX>_Y^I?^_#?X5?^LN0VM]=I_P#@<?\
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M4MK\5/#D-U#(]U*$216)\AN@()[5<N*,CL_]MI_^!Q_S)CD6:W7^RS_\!?\
MD=?J7_(2O/\ KL__ *$:KUS-Y\5O#D]Y<2I=RE'D9E/D-T))':H?^%H>'O\
MGZE_[\-_A2CQ1D?*O]MI_P#@<?\ ,)9%FO,_]EG_ . O_(ZRBN3_ .%H>'O^
M?J7_ +\-_A1_PM#P]_S]2_\ ?AO\*O\ UHR+_H-I_P#@<?\ ,G^PLU_Z!9_^
M R_R.LJKJ&EV6K0B&_LK:_A#;A'=0K*H/KA@1FN=_P"%H>'O^?J7_OPW^%'_
M  M#P]_S]2_]^&_PI?ZT9$]'C:?_ (''_,?]A9K_ - L_P#P&7^19U[P+8Z]
MJOA6^,CV?_".W;7EK!;JJQN3"T6QACA0KDC&.@KF_'GP/TWQUKESJ8US6=".
MH6J6.KV^E3K''JENI.V.7*DC 9EW*0<$C-;?_"T/#W_/U+_WX;_"C_A:'A[_
M )^I?^_#?X5E+B/A^2:>,I?^!Q_S+CDN;Q=UAJG_ ("_\A^H> UO]+UK2EUB
M_L])U#3TTV&QM=B)I\:H4+0';D,RD [B>@QBK\GA>&'P@/#VEW$NC6L=FMC!
M-9@>9!&%"@ID8#;1U['FLW_A:'A[_GZE_P"_#?X4?\+0\/?\_4O_ 'X;_"J_
MUER#_H-I_P#@<?\ ,7]B9M_T#3_\ ?\ D9.I?!/1KRZB%K>7FE:4UO:6MYI5
MIL\F\BM7WP*Q92R[6ZE""W?UKT)F+,2>IKD_^%H>'O\ GZE_[\-_A1_PM#P]
M_P _4O\ WX;_  HCQ+D$?AQE+_P./^82R3-Y;X:I_P" O_(ZRBN3_P"%H>'O
M^?J7_OPW^%'_  M#P]_S]2_]^&_PK3_6C(O^@VG_ .!Q_P R/["S7_H%G_X#
M+_(ZRBN3_P"%H>'O^?J7_OPW^%'_  M#P]_S]2_]^&_PH_UHR+_H-I_^!Q_S
M#^PLU_Z!9_\ @,O\C.\4?\EC\ ?]>FJ_^BX:[VO*-<\8:7??$;PEK$,LC6&G
M6]_'<R&-@5:5(PF!U.2I^E=7_P +0\/?\_4O_?AO\*RAQ/D:E*^-I[_SQ[+S
M-)9'FMH_[+/;^5]WY'645R?_  M#P]_S]2_]^&_PH_X6AX>_Y^I?^_#?X5K_
M *T9%_T&T_\ P./^9G_86:_] L__  &7^1UE%<G_ ,+0\/?\_4O_ 'X;_"C_
M (6AX>_Y^I?^_#?X4?ZT9%_T&T__  ./^8?V%FO_ $"S_P# 9?Y'653O-%T[
M4+B&XN].L[NXAYBFN+=)'CYS\I8$CGGBN?\ ^%H>'O\ GZE_[\-_A1_PM#P]
M_P _4O\ WX;_  I/BC(GOC:7_@<?\Q_V%FO_ $"S_P# 9?Y'/67P#T:R\61:
MH-5U:71X=1;6(/#,DRG3X;UB29U7;N^\2P4MM#'.*T]>^&^JZUIMO;P_$'Q+
MI5U%//*;ZR: 221R-D1,IC*E4'"G&X#N:O?\+0\/?\_4O_?AO\*/^%H>'O\
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MG_K1D7_0;3_\#C_F']A9K_T"S_\  9?Y'645R?\ PM#P]_S]2_\ ?AO\*/\
MA:'A[_GZE_[\-_A1_K1D7_0;3_\  X_YA_86:_\ 0+/_ ,!E_D=96!XY\%Z?
M\0?#-SHFIF:."5DD2>U?9-!*C!HY8V[,K $&J7_"T/#W_/U+_P!^&_PH_P"%
MH>'O^?J7_OPW^%3+B?(9*SQM/_P./^8UD>;1=UA9_P#@,O\ (9\/_AQ;^ _[
M3N9-5U#Q#K>J2))?:QJKJUQ/L7;&N% 5549PH'<GO77UR?\ PM#P]_S]2_\
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M_P!Q_P"177X2>'X_$GB_7(XIH=0\46:V5])"^PJ@0H3&1RK,""3ZJIKD[/\
M9KTNUTV_L3XBU22"]LK*QE406T2[;6421,%2,#=Q@^N23DUVG_"T/#W_ #]2
M_P#?AO\ "C_A:'A[_GZE_P"_#?X4GQ%P\_\ F,I?^!QZ_,I9/G"VPU3_ ,!?
M3Y'/^)_@;:>))O$*+XBU;3=+UV[CU"]TVU$)B>Y0I\X9D+@-Y:Y0'!(S1%\"
MM/M_&R>)(-<U*&=-7EUA;=4@*^9+&4E0R&/>R$'@%OE'"XKH/^%H>'O^?J7_
M +\-_A1_PM#P]_S]2_\ ?AO\*7^L/#U[_7*?_@<?\P_L?.+6^K3_ / '_D87
MAGX(V?A]M%MY]?U35M&T.Y-YI>DW*PI#;S98J[,B!I2N]MNXX!.:98? NST.
MQT-=%U_4M)U32;::R34HXX96GMY)3*8Y8Y$*, YRIP"/QKH/^%H>'O\ GZE_
M[\-_A1_PM#P]_P _4O\ WX;_  H_UBX?_P"@RG_X''_,/['SC_H&G_X _P#(
MWM%TUM'TJVLWO;G47B7#75XRF64DDDMM '?H  !@5>KD_P#A:'A[_GZE_P"_
M#?X4?\+0\/?\_4O_ 'X;_"MUQ1D25OKM/_P./^9E_86:O_F%G_X"_P#(["W_
M -<O^>U>V5\T6OQ.\/O<(HNI<DX'[AO\*^EZX\1FF!S*SP5:-3EWY6G:^U[=
M['H83 XK!<WUFE*%]N9-7^\^$K6-6\[*@_O&[>]6/*3^Z/RJ&S_Y;?\ 71JL
M5]SP71IRX<P+<5_#CT\CX'BFI-9YBTF_CE^8WRD_NC\J/*3^Z/RIU%?:>PI?
MR+[D?+^TG_,QOE)_='Y4>4G]T?E7GUS\2M8T7QUH^A:UX>AM+/69Y(+&ZMKX
M3297G=)'M&T$8Z$XS7H=<]'ZM6YE"*]UV>EOS1O5C7H\KF]U=:W_ "8WRD_N
MC\J/*3^Z/RIU%='L*7\B^Y&'M)_S,Z+X>P1OXG0-&K#[+=<,H(_U#U,MO%M'
M[M.G]T4SX=_\C0G_ %ZW7_HAZG3[J_2O(K4:7UB7NK9=/.1ZM&I/V"]Y[O\
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M "5+Q;_UX:;_ .UZYZE&ESP]U;]O)F].I/EGJ]OU1UGV>+_GFG_?(H^SQ?\
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MM WV"UG-M%>%@5N77B0H/[JM\N[N0V.G.M71&G1DKJ*^XYY2J1=FV,^SQ?\
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M_/-/^^11]GB_YYI_WR*?11[&E_*ON#VD_P"9C/L\7_/-/^^11]GB_P">:?\
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MT_\ (]1_X9<E_P"AG;_P$_\ LZ/^&7)?^AG;_P !/_LZ\N_X:\\;?\\-*_\
M =__ (NC_AKSQM_SPTK_ ,!W_P#BZ/\ 4O$_\_)_^#ZO_P D'_$4\B_Y]_\
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M&;;[_H;9/_ 4_P#Q=>2?\->>-O\ GAI7_@.__P 71_PUYXV_YX:5_P" [_\
MQ='^I%?^>?\ X.J__)!_Q%7)/Y/_ "C3_P CUO\ X9MOO^AMD_\  4__ !=+
M'^SCJ$,BR1^+Y$=2&5A:G((Y!^_7D?\ PUYXV_YX:5_X#O\ _%T?\->>-O\
MGAI7_@.__P 71_J17_GG_P"#JO\ \D'_ !%;)/Y/_*-/_(]=D_9RU&:1Y)/%
M\LDCL69FM3EB>23\]-_X9MOO^AMD_P# 4_\ Q=>2?\->>-O^>&E?^ [_ /Q=
M'_#7GC;_ )X:5_X#O_\ %T?ZD5_YY_\ @ZK_ /)#_P"(K9)_)_Y1I_Y'K?\
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MI7_@._\ \71_J17_ )Y_^#JO_P D'_$5<D_D_P#*-/\ R/6_^&;;[_H;9/\
MP%/_ ,71_P ,VWW_ $-LG_@*?_BZ\D_X:\\;?\\-*_\  =__ (NC_AKSQM_S
MPTK_ ,!W_P#BZ/\ 4BO_ #S_ /!U7_Y(/^(JY)_)_P"4:?\ D>H3?LN37&HV
MEZ_B;?<6RR+%,UH=\8< ,%_>=\#/TJW_ ,,VWW_0VR?^ I_^+KR3_AKSQM_S
MPTK_ ,!W_P#BZ/\ AKSQM_SPTK_P'?\ ^+H_U(K?SS_\'5?_ )(?_$5LD_D_
M\HT_\CUO_AFV^_Z&V3_P%/\ \71_PS;??]#;)_X"G_XNO)/^&O/&W_/#2O\
MP'?_ .+H_P"&O/&W_/#2O_ =_P#XNC_4BO\ SS_\'5?_ )(7_$5<D_D_\HT_
M\CUO_AFV^_Z&V3_P%/\ \71_PS;??]#;)_X"G_XNO)/^&O/&W_/#2O\ P'?_
M .+H_P"&O/&W_/#2O_ =_P#XNC_4BO\ SS_\'5?_ )(/^(JY)_)_Y1I_Y'K?
M_#-M]_T-LG_@*?\ XNC_ (9MOO\ H;9/_ 4__%UY)_PUYXV_YX:5_P" [_\
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M6O\ AFV]_P"ALD_\!3_\74MQ^SMJ=U('G\8S2N%5 S6QR%484??Z  "O(/\
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MU7_Y(/\ B*N2?R?^4:?^1ZW_ ,,VWW_0VR?^ I_^+H_X9MOO^AMD_P# 4_\
MQ=>2?\->>-O^>&E?^ [_ /Q='_#7GC;_ )X:5_X#O_\ %T?ZD5_YY_\ @ZK_
M /)!_P 15R3^3_RC3_R/6_\ AFV^_P"AMD_\!3_\71_PS;??]#;)_P" I_\
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M3_P%/_Q=>2?\->>-O^>&E?\ @.__ ,71_P ->>-O^>&E?^ [_P#Q='^I%?\
MGG_X.J__ "0?\15R3^3_ ,HT_P#(];_X9MOO^AMD_P# 4_\ Q='_  S;??\
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M?ZD5_P">?_@ZK_\ )!_Q%7)/Y/\ RC3_ ,CUO_AFV^_Z&V3_ ,!3_P#%T?\
M#-M]_P!#;)_X"G_XNO)/^&O/&W_/#2O_  '?_P"+H_X:\\;?\\-*_P# =_\
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MN*_#+P/X3\"Q:WXIEU&XGAUBYTR1-.<#[3L=U!4'A0 NX\\XQWJ&YL/!ND_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>@_U?S?_ *!:G_@$O\CS&BO3O^&;_'O_ $"[?_P.A_\ BJ/^&;_'O_0+M_\
MP.A_^*H^O87_ )^Q^]!_J_F__0+4_P# )?Y'F-%>G?\ #-_CW_H%V_\ X'0_
M_%4?\,W^/?\ H%V__@=#_P#%4?7L+_S]C]Z#_5_-_P#H%J?^ 2_R/,:*]._X
M9O\ 'O\ T"[?_P #H?\ XJE7]FWQ\S #2[?)./\ C^A_^*I?7L+_ ,_8_>@_
MU?S?_H$J?^ 2_P CS"BO3V_9M\?(Q4Z7;Y!P?].A_P#BJ3_AF_Q[_P! NW_\
M#H?_ (JCZ]A?^?L?O0?ZOYO_ - E3_P"7^1YC17IW_#-_CW_ *!=O_X'0_\
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M\W_Z!:G_ (!+_(\QHKT[_AF_Q[_T"[?_ ,#H?_BJ/^&;_'O_ $"[?_P.A_\
MBJ/KV%_Y^Q^]!_J_F_\ T"U/_ )?Y'F-%>G?\,W^/?\ H%V__@=#_P#%4?\
M#-_CW_H%V_\ X'0__%4?7L+_ ,_8_>@_U?S?_H%J?^ 2_P CS&BO3O\ AF_Q
M[_T"[?\ \#H?_BJ/^&;_ ![_ - NW_\  Z'_ .*H^O87_G['[T'^K^;_ /0+
M4_\  )?Y'F-%>G?\,W^/?^@7;_\ @=#_ /%4?\,W^/?^@7;_ /@=#_\ %4?7
ML+_S]C]Z#_5_-_\ H%J?^ 2_R/,:*]._X9O\>_\ 0+M__ Z'_P"*ITG[-?CZ
M-@#I=OG /_']#W_X%2^O87_G['[T/_5_-_\ H$J?^ 2_R/+Z*]._X9O\>_\
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M]II=I]*-I]*J,5%61E4J.K)R8E%+M/I1M/I5F8E<!X9_Y+AX^_[!6C_SNJ]
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MZ_\ #G7OB9JOBS5(/"H\$07OA*ZT!+2^D@\V_N9#NB=UA9D6.+!"L3N_>'@
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M=;YM.9ETR0VZS D$&4< 9'4UZA4QX=RF7PTO_)I__)&M3/LXHV52I:_>,?\
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M;#(." 1^(I?ZNY5_SZ_\FG_\D4\_S5*[J?\ DL?_ )$Q/^$%N?\ H:=;_P#
MBC_A!;G_ *&G6_\ P(KJJ6G_ *N97_SZ_P#)I_\ R1'^L69_\_?_ "6/_P B
M<I_P@MS_ -#3K?\ X$4?\(+<_P#0TZW_ .!%;.D>(M.UZXU2"QN//ETNZ-E>
M+M8>5,%5BG(YX93D9'-:)(5220J@9))P /4T?ZN95_SZ_P#)I_\ R0WQ#FBT
M=7_R6/\ \B<K_P (+<_]#3K?_@11_P (+<_]#3K?_@16OX;\3Z3XPTL:EHM_
M%J>GF1XEN8,E&9&VMM..0".HX/8UIT?ZN95_SZ_\FG_\D-\09I%V=7_R6/\
M\B<K_P (+<_]#3K?_@11_P (+<_]#3K?_@17544?ZN97_P ^O_)I_P#R0O\
M6+-/^?O_ )+'_P"1.5_X06Y_Z&G6_P#P(KE])\.3W'Q'\3Z:-<U*)K.RL)3>
M1S$33>9YWRN>X79\OIN:O4JXCP__ ,ED\;_]@S2?_;FI?#F5W7[K_P FG_\
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M-=([M54XB=EW!"V,%MI!(!R,C.,U>JO]7,J_Y]?^33_^2,O]8<T6]7_R6/\
M\B<K_P (+<_]#3K?_@11_P (+<_]#3K?_@17544?ZN97_P ^O_)I_P#R0?ZQ
M9I_S]_\ )8__ ")RO_""W/\ T-.M_P#@14EMX!N)KF%/^$JUQ=SJN1<<C)KI
MJGL/^/ZV_P"NJ?\ H0I/AS*[?PO_ ":?_P D5'B',W)+VO\ Y+'_ .1.3O/
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MII]]J$^XQ6MK)*!(\FT@A,85CD<,>17HI\,Z.UG=V9TFQ-I=N)+BW^SIY<S
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M&'/"Y]37G.H?%)=#^&E]XU^)/@N/PQ<Z3+(+32[R>*\DF=D 3RF P&<DKCJ
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M/SKJPBD?:HPJY93P!P!VK5L-"TW2OLWV+3K6S^RP?98/(A5/)AR#Y:8'RKD
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MM/\ #7[0W@C5=>N[?3]*;1]1M;2\O'$<,5X7B8@NW"LT0;&>H!%<?\,?A_\
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MK>6?] *_\#J?_)'D/_"8:O\ ]";J_P#WR?\ XFC_ (3#5_\ H3=7_P"^3_\
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MO;CZT;CZT?V?FG_0?+_P73_^1#ZWEG_0"O\ P.I_\D>0_P#"8:O_ -";J_\
MWR?_ (FC_A,-7_Z$W5_^^3_\37KVX^M&X^M']GYI_P!!\O\ P73_ /D0^MY9
M_P! *_\  ZG_ ,D>0_\ "8:O_P!";J__ 'R?_B:YC2=<U"W^(WB;44\/7\T]
MU96$4EBBGS;<1^=M=^.C[CC_ '#7T+N/K7G_ (9_Y+AX^_[!6C_SNJEY?F=U
M_M\O_!=/_P"1-88O+>67^PK;^>IW7]XP?^$PU?\ Z$W5_P#OD_\ Q-'_  F&
MK_\ 0FZO_P!\G_XFO7MQ]:-Q]:K^S\T_Z#Y?^"Z?_P B9?6\L_Z 5_X'4_\
MDCR'_A,-7_Z$W5_^^3_\31_PF&K_ /0FZO\ ]\G_ .)KU[<?6C<?6C^S\T_Z
M#Y?^"Z?_ ,B'UO+/^@%?^!U/_DCR'_A,-7_Z$W5_^^3_ /$T?\)AJ_\ T)NK
M_P#?)_\ B:]>W'UHW'UH_L_-/^@^7_@NG_\ (A];RS_H!7_@=3_Y(\A_X3#5
M_P#H3=7_ .^3_P#$T?\ "8:O_P!";J__ 'R?_B:]>W'UHW'UH_L_-/\ H/E_
MX+I__(A];RS_ * 5_P"!U/\ Y(\A_P"$PU?_ *$W5_\ OD__ !-'_"8:O_T)
MNK_]\G_XFO7MQ]:-Q]:/[/S3_H/E_P""Z?\ \B'UO+/^@%?^!U/_ )(\A_X3
M#5_^A-U?_OD__$T?\)AJ_P#T)NK_ /?)_P#B:]>W'UHW'UH_L_-/^@^7_@NG
M_P#(A];RS_H!7_@=3_Y(\A_X3#5_^A-U?_OD_P#Q-'_"8:O_ -";J_\ WR?_
M (FO7MQ]:-Q]:/[/S3_H/E_X+I__ "(?6\L_Z 5_X'4_^2/(?^$PU?\ Z$W5
M_P#OD_\ Q-26_C35X;B*3_A#-8;:ZMM"GG!SC[M>M;CZT^W8_:(N?XQ_.D\O
MS.W^_P O_!=/_P"1*CB\LYE_L*_\#J?_ "1Y'=^-M7FNIY#X+UA-\C-M*G(R
M<X^[47_"8:O_ -";J_\ WR?_ (FO8[IC]JFY_C;^=1;CZT++\SM_O\O_  73
M_P#D0GB\LYG_ +"O_ ZG_P D>0_\)AJ__0FZO_WR?_B:/^$PU?\ Z$W5_P#O
MD_\ Q->O;CZT;CZT_P"S\T_Z#Y?^"Z?_ ,B3];RS_H!7_@=3_P"2/(?^$PU?
M_H3=7_[Y/_Q-'_"8:O\ ]";J_P#WR?\ XFO7MQ]:-Q]:/[/S3_H/E_X+I_\
MR(?6\L_Z 5_X'4_^2/(?^$PU?_H3=7_[Y/\ \31_PF&K_P#0FZO_ -\G_P")
MKU[<?6C<?6C^S\T_Z#Y?^"Z?_P B'UO+/^@%?^!U/_DCR'_A,-7_ .A-U?\
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M^S\T_P"@^7_@NG_\B'UO+/\ H!7_ ('4_P#DCR'_ (3#5_\ H3=7_P"^3_\
M$URGQ&UK4-9TO1XKCP_?Z6L.M6%TLERIQ*\<P985X'S.?E'N:^B=Q]:\Z^.!
M_P")#X8_[&K2/_2I:B67YG;_ '^7_@NG_P#(FM+%Y;SJV"7_ ('4_P#DC&/C
M'5R3_P 4;J__ 'R?_B:/^$PU?_H3=7_[Y/\ \37K[,=QY[TFX^M7_9^:?]!\
MO_!=/_Y$R^MY9_T K_P.I_\ )'D/_"8:O_T)NK_]\G_XFC_A,-7_ .A-U?\
M[Y/_ ,37KVX^M&X^M']GYI_T'R_\%T__ )$/K>6?] *_\#J?_)'D/_"8:O\
M]";J_P#WR?\ XFC_ (3#5_\ H3=7_P"^3_\ $UZ]N/K1N/K1_9^:?]!\O_!=
M/_Y$/K>6?] *_P# ZG_R1Y#_ ,)AJ_\ T)NK_P#?)_\ B:/^$PU?_H3=7_[Y
M/_Q->O;CZT;CZT?V?FG_ $'R_P#!=/\ ^1#ZWEG_ $ K_P #J?\ R1Y#_P )
MAJ__ $)NK_\ ?)_^)H_X3#5_^A-U?_OD_P#Q->O;CZT;CZT?V?FG_0?+_P %
MT_\ Y$/K>6?] *_\#J?_ "1Y#_PF&K_]";J__?)_^)H_X3#5_P#H3=7_ .^3
M_P#$UZ]N/K1N/K1_9^:?]!\O_!=/_P"1#ZWEG_0"O_ ZG_R1Y#_PF&K_ /0F
MZO\ ]\G_ .)H_P"$PU?_ *$W5_\ OD__ !->O;CZT;CZT?V?FG_0?+_P73_^
M1#ZWEG_0"O\ P.I_\D>0_P#"8:O_ -";J_\ WR?_ (FC_A,-7_Z$W5_^^3_\
M37KVX^M&X^M']GYI_P!!\O\ P73_ /D0^MY9_P! *_\  ZG_ ,D>53^.M7DL
M;2'_ (0K6%$6_P"<J<-DYX^7M5;_ (3#5_\ H3=7_P"^3_\ $U[/.3]BM>?[
M_P#.JVX^M3'+\SM_O\O_  73_P#D32IB\MYM<$ME]NIV7]X\A_X3#5_^A-U?
M_OD__$T?\)AJ_P#T)NK_ /?)_P#B:]>W'UHW'UJO[/S3_H/E_P""Z?\ \B9_
M6\L_Z 5_X'4_^2/(?^$PU?\ Z$W5_P#OD_\ Q-'_  F&K_\ 0FZO_P!\G_XF
MO7MQ]:-Q]:/[/S3_ *#Y?^"Z?_R(?6\L_P"@%?\ @=3_ .2/(?\ A,-7_P"A
M-U?_ +Y/_P 31_PF&K_]";J__?)_^)KU[<?6C<?6C^S\T_Z#Y?\ @NG_ /(A
M];RS_H!7_@=3_P"2/(?^$PU?_H3=7_[Y/_Q-'_"8:O\ ]";J_P#WR?\ XFO7
MMQ]:-Q]:/[/S3_H/E_X+I_\ R(?6\L_Z 5_X'4_^2/(?^$PU?_H3=7_[Y/\
M\31_PF&K_P#0FZO_ -\G_P")KU[<?6C<?6C^S\T_Z#Y?^"Z?_P B'UO+/^@%
M?^!U/_DCR'_A,-7_ .A-U?\ [Y/_ ,31_P )AJ__ $)NK_\ ?)_^)KU[<?6C
M<?6C^S\T_P"@^7_@NG_\B'UO+/\ H!7_ ('4_P#DCR'_ (3#5_\ H3=7_P"^
M3_\ $T?\)AJ__0FZO_WR?_B:]>W'UHW'UH_L_-/^@^7_ (+I_P#R(?6\L_Z
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MO]\?SK5[')'XD+=?\?4W^^W\ZBJ6Z_X^IO\ ?;^=141V0Y_$PHHHID!1110
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M26UM+V\N^AZ=%\2O#=GH.K7M[XALY(]!$46K72JRK%(Z(RG;@G#AU*A<YW
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MXG>%?#[0"_URV@,]C_:<0&Y]]MN51*-H/!9T4=V+8 ->7? WP=XX\)Z?X?\
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M9=V]A]MU?3[KQ)I=PVV"^2WF61+E.#MG4+M)_C7@\@5SRYKMH[Z7LFHJ>_\
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M_P"&8_A]_P ^.L_^%+J?_P D4?\ #,?P^_Y\=9_\*74__DBCZTNP?V/+^?\
M V_+?^ZWY4>6_P#=;\JQ/^&8_A]_SXZS_P"%+J?_ ,D4?\,Q_#[_ )\=9_\
M"EU/_P"2*/K2[!_8\OY_P-ORW_NM^526\;_:(OE;[X[>]8'_  S'\/O^?'6?
M_"EU/_Y(H_X9D^'XY%EK(/\ V,NI_P#R12^M+L4LHDFGS_@=!=1O]JF^5OOM
MV]ZB\M_[K?E6(?V9?A^3DV6LD_\ 8RZG_P#)%'_#,?P^_P"?'6?_  I=3_\
MDBA8I6V"642DV^?\#;\M_P"ZWY4>6_\ =;\JQ/\ AF/X??\ /CK/_A2ZG_\
M)%'_  S'\/O^?'6?_"EU/_Y(I_6EV)_L>7\_X&WY;_W6_*CRW_NM^58G_#,?
MP^_Y\=9_\*74_P#Y(H_X9C^'W_/CK/\ X4NI_P#R11]:78/['E_/^!M^6_\
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M\#;\M_[K?E1Y;_W6_*L3_AF/X??\^.L_^%+J?_R11_PS'\/O^?'6?_"EU/\
M^2*/K2[!_8\OY_P-ORW_ +K?E1Y;_P!UORK$_P"&8_A]_P ^.L_^%+J?_P D
M4?\ #,?P^_Y\=9_\*74__DBCZTNP?V/+^?\  V_+?^ZWY4>6_P#=;\JQ/^&8
M_A]_SXZS_P"%+J?_ ,D4?\,Q_#[_ )\=9_\ "EU/_P"2*/K2[!_8\OY_P-OR
MW_NM^5'EO_=;\JQ/^&8_A]_SXZS_ .%+J?\ \D4?\,Q_#[_GQUG_ ,*74_\
MY(H^M+L']CR_G_ V_+?^ZWY4>6_]UORK$_X9C^'W_/CK/_A2ZG_\D4?\,Q_#
M[_GQUG_PI=3_ /DBCZTNP?V/+^?\#;\M_P"ZWY59U"-O/7Y6_P!6G;_9%<W_
M ,,Q_#[_ )\=9_\ "EU/_P"2*4_LR_#]NMEK1^OB74__ )(I?6E>]BUE,E%Q
MY]_(VO+?^ZWY4>6_]UORK$_X9C^'W_/CK/\ X4NI_P#R11_PS'\/O^?'6?\
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M8I+H7+*92=^?MT[*QM^6_P#=;\J/+?\ NM^58G_#,?P^_P"?'6?_  I=3_\
MDBC_ (9C^'W_ #XZS_X4NI__ "13^M+L1_8\OY_P-ORW_NM^5'EO_=;\JQ/^
M&8_A]_SXZS_X4NI__)%'_#,?P^_Y\=9_\*74_P#Y(H^M+L']CR_G_ V_+?\
MNM^5'EO_ '6_*L3_ (9C^'W_ #XZS_X4NI__ "11_P ,Q_#[_GQUG_PI=3_^
M2*/K2[!_8\OY_P #;\M_[K?E1Y;_ -UORK$_X9C^'W_/CK/_ (4NI_\ R11_
MPS'\/O\ GQUG_P *74__ )(H^M+L']CR_G_ V_+?^ZWY4>6_]UORK$_X9C^'
MW_/CK/\ X4NI_P#R11_PS'\/O^?'6?\ PI=3_P#DBCZTNP?V/+^?\#;\M_[K
M?E1Y;_W6_*L3_AF/X??\^.L_^%+J?_R11_PS'\/O^?'6?_"EU/\ ^2*/K2[!
M_8\OY_P-ORW_ +K?E1Y;_P!UORK$_P"&8_A]_P ^.L_^%+J?_P D4?\ #,?P
M^_Y\=9_\*74__DBCZTNP?V/+^?\  WH8V\P?*W0]O:NVKRV+]FCP!#(DBV.L
?;E.1GQ'J1'Y&XP:]2KFK5?:VT/4P6#>$YKN]['__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img227133604_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %S <H# 2(  A$! Q$!_\0
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MT*TL%U";2?%MK)X7U!+%IT: R3PN+@2QG]QLM1J/S_*2YB4,#BO%O&NA^/\
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MBMR]S?-)!.P1I2V$B78IPJEG;'S*%(< ]?HHHH **** "BBB@ HHHH ****
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MCAHNIV/B30;.6YU".&*74EMHVN@D4@D10[*> 01@]F/K4'_"2?&__HGGP_\
M_"\OO_E-1_PDGQO_ .B>?#__ ,+R^_\ E-0!?\>?!:U\?0R:=<^(M9L/"]U9
MQV%_X;LS;_8KRW1B?+;?$SH'4F-_+==R<=@:ZCQ-X/M/%,V@R7$LT)T?48]2
M@6' #2)'(@5L@_+B0],'@<UQ'_"2?&__ *)Y\/\ _P +R^_^4U'_  DGQO\
M^B>?#_\ \+R^_P#E-0!ZK17E7_"2?&__ *)Y\/\ _P +R^_^4U'_  DGQO\
M^B>?#_\ \+R^_P#E-0!ZK17E7_"2?&__ *)Y\/\ _P +R^_^4U'_  DGQO\
M^B>?#_\ \+R^_P#E-0!ZK17E7_"2?&__ *)Y\/\ _P +R^_^4U'_  DGQO\
M^B>?#_\ \+R^_P#E-0!ZK17E7_"2?&__ *)Y\/\ _P +R^_^4U'_  DGQO\
M^B>?#_\ \+R^_P#E-0!ZK17E7_"2?&__ *)Y\/\ _P +R^_^4U'_  DGQO\
M^B>?#_\ \+R^_P#E-0!ZK17E7_"2?&__ *)Y\/\ _P +R^_^4U'_  DGQO\
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MC!AP'^A?!.GG2?">E6!T.P\-"T@6W32=*</:6J)\JI"0B#RPH&WY%P,?*.E
M&W1110 5Y5\&_P#DHOQV_P"QSMO_ %'M&KU6O*O@W_R47X[?]CG;?^H]HU '
MJM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_B)9_%;P/9>)+*WDM$FEN;6:VE.6AN+>XDMYX\]&"RPR*&'#  ]Z .MHHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7-_$;Q1J?@WP5JNLZ-X:O\ QAJEK&#;:)IKQ1SW3LP4
M*&D9551NW,2<A58@,<*>DKRC]J;5=4T7X"^*KW2KN33FC2W%]?02O%):Z>;F
M);Z9)$(9'2U-PX=>5*@CI0!P'P_T&^O?%MK\1?B;H?B#Q#X[BB*:?8V]BQTG
MPZKC#Q643-\TISM>Z<>:XR!Y:'RQ]$Z/J7]L:;#=_9+JR\S/[B\C\N5<,1\R
MYXSC/T(K NOA_P"#-0^'L?AF;1-)E\&I!&8[ Q)]D2-")(W4=!M95=7'(8!@
M01FN1_91UK5O$'P \*7VL7=QJ4CK<QV>H7<AEFO=/2YE2QN9'))=Y;58)"YY
M8N20"<4 >M4444 %>5?!O_DHOQV_['.V_P#4>T:O5:\J^#?_ "47X[?]CG;?
M^H]HU 'D7[?W_(%\&_\ 7Q=?^@QU\9U]F?M_?\@7P;_U\77_ *#'7QG7VF6_
M[M'Y_F?,8[^._D=+\,_^2D>%/^PM:?\ HY*_5FORF^&?_)2/"G_86M/_ $<E
M?JS7EYQ\</0]#+?@D?#7BV\G7Q5K($T@'VV;^,_\]&K*^V7'_/>3_OLUH>+O
M^1KUK_K]F_\ 1C5DUW02Y5H<,F^9GT3^RO-)-9^(_,=GQ)!C<2>TE>[UX+^R
MG_QY^)/^NEO_ "DKWJOG,7_&D>[A_P"%$****Y#H"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2O>J\%_93_X\_$G_ %TM_P"4E>]5\UB_X\CW</\ PHA1117(=(4444 %%%%
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MK(\3^+M%\%Z>E]KNIVVE6LD@A22YD"[Y""0BCJS85C@<X4GH#0!KUY5\&_\
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M!T? OQ8\+_$S4/$EIX:U2/5O^$?O?[.OKBW^: 7&P,R))T?;G:Q7(#!EZJ0
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M3\">![336F1;JXM/&MY/-%$6&]TC;24#L%R0I= 2 "RYR/2Z "BBB@ HHHH
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M/X>K\+?A_IOAXWO]I74;SW=[?>68Q=7EQ/)<7,P0LQ17FED8)N;:& R<5V-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img227133604_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_6.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $> Z # 2(  A$! Q$!_\0
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M#;(C@JR\^H)&<8G[2GQ\E^!/A[19-,T1O$OB+6KX65AI*2%&EP"788!/'RC
M'5Q0![#17FOPD^.>A_$SX-Z=\0;B>VT6P>!FO_M$X$=E(AVR*SMC !'!.,@@
M]ZZ!?BMX+>#4)AXMT4PZ?;QW=Y)_:$6+>&0 QR2'=\JL""">N1ZT =517-0?
M$SPC=>%I/$L7BC1Y/#L9(?55OHC:J1U!DW;0?;-7O"_C#0O&VEC4O#VL6.N:
M>6*?:M/N$GCW#JNY21GVH UZ*** "O-/VE+RXL/@1XVN+6>6UN(]/=DF@D*.
MAR.0P.0?I7I=>7_M/?\ )O\ XY_[!K_S% 'J%%%% !1110 4444 %%%% !11
M7RUI_P"T]\4/&'C3QGHW@WX8Z;K=IX:U2739KJ?7H[9F*NP5MK@=0N>,XH ^
MI:*^??$W[36K>%=<\<:3>>&;=;OPOX2C\12J+PL'F95W09"XV@DC>,YQTYKI
M?!OQQN/$6K>&TO[/1],TO4_",7B6XGDUB,7-LS %E^SD!C$H)_>\#CM0!Z[1
M7*>&OBQX*\9ZE_9^@>+=$UJ_\OSOLMAJ$4TFS^]M5B<58T7XC^%/$>K:AI>E
M>)=)U+4M/!:[L[6]CDE@ ."756RH!X.>E '1T5R^@_$[PIXNDU&#P[XET;7;
MNQ5FG@L=0BE,6,CY]I.T9XR:YSP3\:=-OOA7IGC+QAJ/A[PS#=.\;20ZU#<V
M882,BA+@$*Y(7D#H<CM0!Z717D_P#^.0^-K>-GBL[:"ST'7)M*MKFTN?/2\B
M3!68' 'S @\9'/6N&^-_[07Q2^#L>OZS+\-=*N/!VG2[8=6GU^*-YT)"H1%@
MMN)(&T F@#Z1HKRSX3_%^]\1_".T\=^/;+3? EK>+]HBCN;T;$MR!Y;R.X4*
M6Y('H5[G ZL?%#P>WA8>)1XIT=O#V\1?VJM]&;;>2 %\S=MSD@8SWH ZBBL'
MP]X^\,^+9-031/$.EZN^GOY=XMC>1S&W;GA]I.WH>OH:C\+_ !$\*^.)[N'P
M[XDTG79K-MMQ'IU['.T1SCY@I..: .BHKR']I+X\2? GPOI-SI^C'Q'X@UC4
M$L-.TE)"C3L1EB, GC@<#JRUH_!WX[:-\4O@W9>/KF2WT.T$4G]I)<3 )8R1
MDB17=L8 QG)QPP- 'IM%<K#\5O!<\-[+'XMT1XK*UCOKIQJ$6(+>0 QRO\WR
MHP(PQX.1ZU+9_$SPCJ'A>7Q);>*-'G\/PDB35([Z(VR$'!#2;MH/L30!TM%8
MWA7QEH'CC33J'AW6M/UVQ#F,W.G7*3QAAU4E20#[5R.M?%PI\8-,^'VBV"ZC
M?K9MJFLW4DA2/3[0?*G0'=*[D +Q@<F@#T>BOE+X7_M1?%KXN:>NK>'OA3I=
MSHGVQK-[I_$,<3*5(#'8X#' ([<U<^-?[2WQ4^"MGK&M:I\,=)7PM:WC6UKJ
M,GB&,272ER(B(@"VYE&XKCCGT)H ^H:*\?\ ^%WZIX9_9UN?B7XST*'0[V.Q
M-\FCQW!<_/@01,S*,.Y9,C'R[O4&L_\ 9H_:.G^/%AXAMM4T'_A%O$VC2Q^=
MI<DI<^3+&&BEY53@_-QCH >] 'N%%>=_"#XM?\+''B'2]1L%T;Q5X<OFL-5T
MU)?-1&Y,<L;8!:.1?F4D ]1CCGT2@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO$G@C0-:US1O$FI6NW5- :2:SU".1HY(592)%)4C<C#JC9!P.,B@#\_?A)\
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M9%_\>KTRB@#S/_A=D_\ T3GQS_X+(O\ X]1_PNR?_HG/CG_P61?_ !ZO3**
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M -$Y\<_^"R+_ ./5Z910!YG_ ,+LG_Z)SXY_\%D7_P >H_X79/\ ]$Y\<_\
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MYG_PNR?_ *)SXY_\%D7_ ,>H_P"%V3_]$Y\<_P#@LB_^/5Z910!YG_PNR?\
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M_P#1.?'/_@LB_P#CU'_"[)_^B<^.?_!9%_\ 'J],HH \S_X79/\ ]$Y\<_\
M@LB_^/4?\+LG_P"B<^.?_!9%_P#'J],HH \S_P"%V3_]$Y\<_P#@LB_^/4?\
M+LG_ .B<^.?_  61?_'J],HH \S_ .%V3_\ 1.?'/_@LB_\ CU'_  NR?_HG
M/CG_ ,%D7_QZO3** /,_^%V3_P#1.?'/_@LB_P#CU'_"[)_^B<^.?_!9%_\
M'J],HH \S_X79/\ ]$Y\<_\ @LB_^/4?\+LG_P"B<^.?_!9%_P#'J],HH \S
M_P"%V3_]$Y\<_P#@LB_^/4?\+LG_ .B<^.?_  61?_'J],HH \S_ .%V3_\
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M_P#@LB_^/4?\+LG_ .B<^.?_  61?_'J],HH \S_ .%V3_\ 1.?'/_@LB_\
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M\6://I$,Z6TM\E['Y4<KL%1&;.%)+#&>N15#5OCOX T;P=>>*9?%6FSZ%:7
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MZ?HHHH *X_XQ_P#)(?''_8"OO_2=Z["N/^,?_)(?''_8"OO_ $G>@#1^'_\
MR(7AO_L&6W_HI:WZP/A__P B%X;_ .P9;?\ HI:WZ "BBB@ KY?^)'[7GC+X
M8^(K/3=3^#%^(]3U(Z9I5R=;A OI-^U-JB,[=V5.#TSUKZ@KYL_:_P#!6O\
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M9SY>=W3VK"TOXO>#]:\::KX4M-?L9-=TUXXI[0SH&,CJS>6@)R[*%^8+G;D
M\Y%?$WQ)\&>.]2^-,'B*V^%5[8)H7C9+TMH.AQF74+7S2[7+7QD\R9W/_+,
M1H#R1P!Z-X3^&-YX9^-7Q2MS\-[F#5/$DS7?AGQ=#ID,EMI326\FYVGSNA8.
MXR%R2<\="0#ZRL?$FD:GJ5UIUGJME=ZA:_\ 'Q:P7"/+#_OH#E?Q%>=?&/\
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M5;G/J7[,WA^/1;SXD7%CX9N_"NA:AX@6YTVRNM.:PS%]DMT9EA8#:-ZOV]:
M)(?CAXVUSQSXAT;PU\,1K>D:'JO]E76KOK\-MAPD<C,(6CW'"RJ>#SZU[/\
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MP.N3'G=C\*PO#WQ>\(>*?%6K^'--UZRN-8TNX^RSVHG0.TNS>RH,Y?:/O8&
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MQ"$#GU3]E_03H.A^-C#X>NO#.E7OBF[N]-L+JQ:R*VS1PA2L) *+D-@8'0T
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M  \HM/\ H0)?_!N/_C%?2KAO-9)-4?QC_F?,2XFRF+:=;_R67^1]JT5\5?\
M#RBT_P"A E_\&X_^,4?\/*+3_H0)?_!N/_C%/_5K-?\ GS_Y-'_,G_6?*/\
MG]_Y++_(^U:*^*O^'E%I_P!"!+_X-Q_\8H_X>46G_0@2_P#@W'_QBC_5K-?^
M?/\ Y-'_ ##_ %GRC_G]_P"2R_R/M6BOBK_AY1:?]"!+_P"#<?\ QBC_ (>4
M6G_0@2_^#<?_ !BC_5K-?^?/_DT?\P_UGRC_ )_?^2R_R/M6BOBK_AY1:?\
M0@2_^#<?_&*/^'E%I_T($O\ X-Q_\8H_U:S7_GS_ .31_P P_P!9\H_Y_?\
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M'\9?\%"+3Q9X1US0_P#A!Y;;^T[&>R\_^U WE^9&R;L>2,XW9QGM1_JUFO\
MSY_\FC_F'^L^4?\ /[_R67^1]G?#_P#Y$+PW_P!@RV_]%+6_7PWX?_X**6FA
M:#INF_\ ""2S?8[:*W\S^U0-VQ N<>3QG%7_ /AY1:?]"!+_ .#<?_&*/]6L
MU_Y\_P#DT?\ ,/\ 6?*/^?W_ )++_(^U:*^*O^'E%I_T($O_ (-Q_P#&*/\
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MU_Y\_P#DT?\ ,/\ 6?*/^?W_ )++_(^U:*^*O^'E%I_T($O_ (-Q_P#&*/\
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M^?/_ )-'_,/]9\H_Y_?^2R_R/M6BOBK_ (>46G_0@2_^#<?_ !BC_AY1:?\
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MG_R:/^8?ZSY1_P _O_)9?Y'VK17Q5_P\HM/^A E_\&X_^,4?\/*+3_H0)?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<?\ XY1_PP^__0Y+_P""X_\ QROJBBC^UL;_ #_@O\@_L7 _\^_Q?^9\K_\
M##[_ /0Y+_X+C_\ '*/^&'W_ .AR7_P7'_XY7U111_:V-_G_  7^0?V+@?\
MGW^+_P SY7_X8??_ *')?_!<?_CE'_##[_\ 0Y+_ ."X_P#QROJBBC^UL;_/
M^"_R#^Q<#_S[_%_YGRO_ ,,/O_T.2_\ @N/_ ,<H_P"&'W_Z')?_  7'_P".
M5]444?VMC?Y_P7^0?V+@?^??XO\ S/E?_AA]_P#H<E_\%Q_^.4?\,/O_ -#D
MO_@N/_QROJBBC^UL;_/^"_R#^Q<#_P ^_P 7_F?*_P#PP^__ $.2_P#@N/\
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MH_X8??\ Z')?_!<?_CE?5%%']K8W^?\ !?Y!_8N!_P"??XO_ #/E?_AA]_\
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MY+_X+C_\<H_X8??_ *')?_!<?_CE?5%%']K8W^?\%_D']BX'_GW^+_S/E?\
MX8??_H<E_P#!<?\ XY1_PP^__0Y+_P""X_\ QROJBBC^UL;_ #_@O\@_L7 _
M\^_Q?^9\K_\ ##[_ /0Y+_X+C_\ '*Q/''[(_P#PA/@_5]?D\5?:X]/@,[0)
M8;2^"!@$R<=:^PZX/X\_\D9\8_\ 8/;_ -"6LZF<8Z,&U4_!?Y%T\DP$II.G
MU[O_ #/%&_8>=21_PF:_^"X__'*3_AA]_P#H<E_\%Q_^.5]4M]XTE:?VMC?Y
M_P %_D1_8N!_Y]_B_P#,^5_^&'W_ .AR7_P7'_XY1_PP^_\ T.2_^"X__'*^
MJ**/[6QO\_X+_(/[%P/_ #[_ !?^9\K_ /##[_\ 0Y+_ ."X_P#QRC_AA]_^
MAR7_ ,%Q_P#CE?5%%']K8W^?\%_D']BX'_GW^+_S/E?_ (8??_H<E_\ !<?_
M (Y1_P ,/O\ ]#DO_@N/_P <KZHHH_M;&_S_ (+_ "#^Q<#_ ,^_Q?\ F?*_
M_##[_P#0Y+_X+C_\<H_X8??_ *')?_!<?_CE?5%%']K8W^?\%_D']BX'_GW^
M+_S/E?\ X8??_H<E_P#!<?\ XY1_PP^__0Y+_P""X_\ QROJBBC^UL;_ #_@
MO\@_L7 _\^_Q?^9\K_\ ##[_ /0Y+_X+C_\ '*/^&'W_ .AR7_P7'_XY7U11
M1_:V-_G_  7^0?V+@?\ GW^+_P SY7_X8??_ *')?_!<?_CE'_##[_\ 0Y+_
M ."X_P#QROJBBC^UL;_/^"_R#^Q<#_S[_%_YGRO_ ,,/O_T.2_\ @N/_ ,<H
M_P"&'W_Z')?_  7'_P".5]444?VMC?Y_P7^0?V+@?^??XO\ S/E?_AA]_P#H
M<E_\%Q_^.4?\,/O_ -#DO_@N/_QROJBBC^UL;_/^"_R#^Q<#_P ^_P 7_F?+
M]A^PG)?7<< \:JA;/S'32>@)_P">GM5<?L/N>?\ A,E_\%Q_^.5]<>'_ /D,
M6_T?_P! :LY?NCZ5"SC&\[7M.BZ+S\BWDN Y$_9]7U?EYGRQ_P ,/O\ ]#DO
M_@N/_P <H_X8??\ Z')?_!<?_CE?5%%7_:V-_G_!?Y$?V+@?^??XO_,^5_\
MAA]_^AR7_P %Q_\ CE'_  P^_P#T.2_^"X__ !ROJBBC^UL;_/\ @O\ (/[%
MP/\ S[_%_P"9\K_\,/O_ -#DO_@N/_QRC_AA]_\ H<E_\%Q_^.5]444?VMC?
MY_P7^0?V+@?^??XO_,^5_P#AA]_^AR7_ ,%Q_P#CE'_##[_]#DO_ (+C_P#'
M*^J**/[6QO\ /^"_R#^Q<#_S[_%_YGRO_P ,/O\ ]#DO_@N/_P <H_X8??\
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M?^ABO<]6_P"0M??]=Y/_ $(U\SFW\6'H_P!#Z7*OX4_5?J5:***\4]D****
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MCO.A(:.W(+W!4]B8U*@]M^:B<U"+DRH1<Y**/258.H92&4C(93D&C<-Q7(W
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M\_\ @#C27.X2?X?\$^E5<2+E6##IE3D4M>7Z/J3^%OC]JWAB,[=*U_21KMM
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M@?XT?VL?^?*Q_P"_ _QJC11[./8/:2[E[^UC_P ^5C_WX'^-']K'_GRL?^_
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MC_SY6/\ WX'^-><:/\:O"6M>%]:U^*^GMK+1N+^&]M9(+F E0R Q. V7!&T
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M]_UWD_\ 0C7S.;?Q8>C_ $/I<J_A3]5^I5HHHKQ3V0HHHH .M%><_M'3/;_
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M% !1110!\9_M->'?$'PJ\1>-M=TU-)UC3?B/##I'V6Z)-]#-@#$"#[PX!SG
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MI:YKXF?\DV\6?]@B[_\ 1+U%3X65'XD7_"/_ "*.A?\ 8/M__12UK5D^$?\
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M=0HXP5ADGD>+_P <93^-9T)S;BI/=/\ !EUHQ2DUT:_%:GJM%%%=QR!1110
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M-I1I\\.7;3\R_P#$;XD:EX4\)^%I=,M;.;7?$EW:Z=:M?.R6D$LR;S)(1SM
M!PHY)P,UA6?Q0\86L?CC1=2LM*NO%GA*&WU)_P"S@_V;4;-P7*HK'=%+M1U
M)(SM/0UUWBK0M)U7X4FT\1:!-XAL;?3HI9=*AB+SR/'&I"Q@$$2 CC!!!KAO
M@?\ #./X8>$/%WB75],CT&[UQ7O9M+\YI1I]I'&WEPO(Q)9]NYG.?O-CM1+V
MO.K/2WW:?YBC[/V;NM;_ 'Z_Y'KWA_7;+Q1H.G:QILOGZ?J%O'=6\G]Y'4,/
MQP:T*\S_ &9]/NM+^ ?@>WO59)_[/678_54=F=!_WRRUZ9793DY04GU1S5(J
M,W%= HHHK0@**** "MOP5_R,EK]&_D:Q*V_!7_(R6OT;^1KGQ'\&?HS?#_QH
M>J_,\8^)W_)0_$'_ %]M_(5S%?7FH?#/POJU]/>7>BV\]U,V^21LY8^IYJO_
M ,*C\'_] "U_\>_QKOH<2X:E2A3<)722Z=%ZG!6X;Q52K.:G&S;?7J_0^2Z*
M^M/^%1^#_P#H 6O_ (]_C1_PJ/P?_P! "U_\>_QK;_6G"_R2_#_,Q_U8Q?\
M/'\?\CY+HKZT_P"%1^#_ /H 6O\ X]_C1_PJ/P?_ - "U_\ 'O\ &C_6G"_R
M2_#_ ##_ %8Q?\\?Q_R/DNBOK3_A4?@__H 6O_CW^-'_  J/P?\ ] "U_P#'
MO\:/]:<+_)+\/\P_U8Q?\\?Q_P CY+HKZT_X5'X/_P"@!:_^/?XT?\*C\'_]
M "U_\>_QH_UIPO\ )+\/\P_U8Q?\\?Q_R/E72?\ D+Z?_P!?,7_H8KW/5O\
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MI'_0/A_[YH_X172/^@?#_P!\T?VI2_E8?V75[K\?\CR6BO6O^$5TC_H'P_\
M?-'_  BND?\ 0/A_[YH_M2E_*P_LNKW7X_Y'DM8_BSPM9^,-&;3KTR1@2QW$
M-Q"0);>:-@T<J'LRL ?S!X)KW+_A%=(_Z!\/_?-'_"*Z1_T#X?\ OFD\SI25
MG%@LMK)W4E^/^1Y(N=HW'<V.6QC/O2EB>IS7K7_"*Z1_T#X?^^:/^$5TC_H'
MP_\ ?-/^U*7\K#^RZO=?C_D>2Y-&3U[UZU_PBND?] ^'_OFC_A%=(_Z!\/\
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MND?] ^'_ +YJ/[3I\SEROI^I7]FU>5*ZZ_IY'DM%>M?\(KI'_0/A_P"^:/\
MA%=(_P"@?#_WS5_VI2_E9/\ 9=7NOQ_R/):*]:_X172/^@?#_P!\T?\ "*Z1
M_P! ^'_OFC^U*7\K#^RZO=?C_D>2T5ZU_P (KI'_ $#X?^^:/^$5TC_H'P_]
M\T?VI2_E8?V75[K\?\CPSQ5X5L_%VFQ6MTTD,EO<1WEK=0$"6WGC;*2(2.HY
M!!X()!ZULUZU_P (KI'_ $#X?^^:/^$5TC_H'P_]\TO[3I7ORL/[,K6MS+\?
M\CR6C)Z]Z]:_X172/^@?#_WS1_PBND?] ^'_ +YI_P!J4OY6+^RZO=?C_D>2
MUD>*O#=MXPT.?2+V25+"Y*BYCA.TS1A@6B)[*P&UL<D$CO7N/_"*Z1_T#X?^
M^:/^$5TC_H'P_P#?-)YI2DK.+&LLK)W4E^/^1Y&B+&BHBJB* JJHP% X  ["
MG5ZU_P (KI'_ $#X?^^:/^$5TC_H'P_]\T_[4I?RL/[+J_S+\?\ (\EHKUK_
M (172/\ H'P_]\T?\(KI'_0/A_[YH_M2E_*P_LNKW7X_Y'DM%>M?\(KI'_0/
MA_[YH_X172/^@?#_ -\T?VI2_E8?V75[K\?\CR6MOP5_R,EK]&_D:[__ (17
M2/\ H'P_]\U-:^'].L9UF@LXHI5Z,J\BLJN94ZE.4%%ZHTI9=5A4C)M:,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img227133604_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %  G # 2(  A$! Q$!_\0
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M* "BBB@ HHHH **** (X9#(&)&,,5_(U)4%K]V3_ *Z-_.IZ "BBB@ HHHH
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M85C]_'!H ^UJ*^7?[+^+LEY\3_$=_J7BMTTT*-#\,Z3]EA6^9["(2M&\BO\
M=F+[1DA65OOY%>56_CCXL:7+X4\/>+Y?B%IPOO$.I^6ND^3)J5Y8?V>LL$<;
M,/WACE#EBRJ0/R !][T5\=> [[XS:A\6/ O@_P 0>)[B*6]T>S\2^)X8W3S]
M.^SM)$+<;!M5;HF$N!_%'-MP*^Q: "BBB@ HHHH *CDD*RQJ!PV<_E4E03?\
M?$'U;^5 '*:E<?$!=0N1I]CX:DL0Y\AKF]N%E*=BP$1 /T)JO]I^)G_0.\)_
M^!]S_P#&:[JB@#A?M/Q,_P"@=X3_ / ^Y_\ C-'VGXF?] [PG_X'W/\ \9KN
MJ* .%^T_$S_H'>$__ ^Y_P#C-'VGXF?] [PG_P"!]S_\9KNJ* .%^T_$S_H'
M>$__  /N?_C-'VGXF?\ 0.\)_P#@?<__ !FNZHH X7[3\3/^@=X3_P# ^Y_^
M,U%_:'Q*^T>3_9WA3=LW_P#'_=>N/^>-=_5/_F,#_KA_[-0!R/VGXF?] [PG
M_P"!]S_\9H^T_$S_ *!WA/\ \#[G_P",UW5% '"_:?B9_P! [PG_ .!]S_\
M&:/M/Q,_Z!WA/_P/N?\ XS7=44 <+]I^)G_0.\)_^!]S_P#&:/M/Q,_Z!WA/
M_P #[G_XS7=44 <+]I^)G_0.\)_^!]S_ /&:/M/Q,_Z!WA/_ ,#[G_XS7=44
M <+]I^)G_0.\)_\ @?<__&:/M/Q,_P"@=X3_ / ^Y_\ C-=U10!POVGXF?\
M0.\)_P#@?<__ !FC[3\3/^@=X3_\#[G_ .,UW5% '"_:?B9_T#O"?_@?<_\
MQFC[3\3/^@=X3_\  ^Y_^,UW5% '"_:?B9_T#O"?_@?<_P#QFC[3\3/^@=X3
M_P# ^Y_^,UW5% '"_:?B9_T#O"?_ ('W/_QFC[3\3/\ H'>$_P#P/N?_ (S7
M=44 <+]I^)G_ $#O"?\ X'W/_P 9H^T_$S_H'>$__ ^Y_P#C-=U10!POVGXF
M?] [PG_X'W/_ ,9H^T_$S_H'>$__  /N?_C-=U10!P,-Q\2MK[=.\)_?;/\
MI]UUS_UQJ3[3\3/^@=X3_P# ^Y_^,UV=K]V3_KHW\ZGH X7[3\3/^@=X3_\
M ^Y_^,T?:?B9_P! [PG_ .!]S_\ &:\J^+7[05WX/^->FVEM=7D?A?0&@AU]
M(M,FF@F:[."SW"H4A^S1^5,=S+D2GTK/UCXD70L_$/C;7OB'KN@Q:/XAFTG_
M (1_P]96]Q%I\4<[1H;N-HGD?S559"^Y0!*NWL2 >R_:?B9_T#O"?_@?<_\
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M/B6)%7^SO">2"?\ C_NNV/\ IC[UWE0O_P ?47^XW\UH XO[3\3/^@=X3_\
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MR7$@624A%V2% N55F Z9R*]GH \UN/$7Q&MKAXFTWPJ67K_Q,+KTS_SPJ/\
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MT=\/QX\UWPE_;\+:CH6DMK6IW"\VMI;@KG?-]T-AU;;UPPJC^T!\';GXQ?\
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ME.8UVR 9S))^S??_ &V[NY'TW4+NZU"_>ZNY9I(+B]M)],%J(I)47<I,JAR
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MEQ\I_>  $Y() S@U2^,G@^]^(7PJ\5>&M-E@AO\ 5-/FM8)+IB(E=EP"Q )
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M-_X!I_A1_P *3\ _]"=HW_@&G^%=M10!Q/\ PI/P#_T)VC?^ :?X4?\ "D_
M/_0G:-_X!I_A7;44 <3_ ,*3\ _]"=HW_@&G^%'_  I/P#_T)VC?^ :?X5VU
M% '%CX+^ U4J/".CA3U7[(F/Y4W_ (4GX!_Z$[1O_ -/\*[:B@#B?^%)^ ?^
MA.T;_P  T_PH_P"%)^ ?^A.T;_P#3_"NVHH XG_A2?@'_H3M&_\  -/\*/\
MA2?@'_H3M&_\ T_PKMJ* .)_X4GX!_Z$[1O_  #3_"C_ (4GX!_Z$[1O_ -/
M\*ZR^U2STO[/]LNX+3[1,MO#Y\BIYDK?=1<GEC@X Y.*=!J%K=75S;0W,,MS
M;%1/#'(&>(L-RA@.5R.1GJ* .1_X4GX!_P"A.T;_ , T_P */^%)^ ?^A.T;
M_P  T_PKMJ* .)_X4GX!_P"A.T;_ , T_P */^%)^ ?^A.T;_P  T_PKK[.^
MMM0A\ZUN(KF'>T?F0N'7<K%67([A@01V((J>@#B?^%)^ ?\ H3M&_P# -/\
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MA787DI@M)Y%^\B,PS["J'A/4IM9\+Z/J%QM\^ZLX9Y-@P-S(&.!Z9- '/?\
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M_P#\8H_X5_=_]#QXK_\  JW_ /C%'UJO_P _G]\@]A2_Y\K[D<%_PQ7\$O\
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M10 4444 %%%% !1110 4444 %%%% !7->,?B-X;\ _8AKVKVNGO>31P0Q2R
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MO_R11_PL/4/^A \6?]^+7_Y(K&QJ=E17&_\ "P]0_P"A \6?]^+7_P"2*/\
MA8>H?]"!XL_[\6O_ ,D46 [*BN-_X6'J'_0@>+/^_%K_ /)%'_"PK_\ Z$'Q
M9_WXM?\ Y(HL!V5:7A__ (_S_N'^8KEO"6O3>)_#MGJD^E7FBRW 8FQOPHFC
MPQ )P2,'&X>Q%=3X?_X_S_N'^8J);,J.Z.DHHHKD.D**** "BBB@ HHHH *I
M_P#,8'_7#_V:KE4)(Q)JX#;O]1_"Q'\7M0!?HJ'[+'ZO_P!_&_QH^RQ^K_\
M?QO\: )J*A^RQ^K_ /?QO\:/LL?J_P#W\;_&@":BH?LL?J__ '\;_&C[+'ZO
M_P!_&_QH FHJ'[+'ZO\ ]_&_QH^RQ^K_ /?QO\: )J*A^RQ^K_\ ?QO\:/LL
M?J__ '\;_&@":BH?LL?J_P#W\;_&C[+'ZO\ ]_&_QH FHJ'[+'ZO_P!_&_QH
M^RQ^K_\ ?QO\: )J*A^RQ^K_ /?QO\:/LL?J_P#W\;_&@":BH?LL?J__ '\;
M_&C[+'ZO_P!_&_QH FHJ'[+'ZO\ ]_&_QH^RQ^K_ /?QO\: )J*A^RQ^K_\
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M^XW\UH^RQ^K_ /?QO\:B:U3[5$,O]UO^6C>J^]2,;K6DP:]H]]IEUO\ LUY
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MHMSK%I=Q06*ZI;B=K"6S26)TL)(6DC+,JOEID'S'_5MT.X5[A]JA_P">L?\
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MU]KM6TH(UVWR[I$<O\BL<8 ! QU->Q?:H?\ GK'_ -]"C[5#_P ]8_\ OH4
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M!(]LI$:R$GIBO4O$'Q5^(-_^SUX1\6V5B- \07FI64>L*-+FN?L=J;GRYY1
M3OVA1N(Y(4G!Z,,/PK\8/AA\+[K7=0T+P7J=CH^G^'+'4[G5[5H[E(K.6280
M6\:^<V$#*Y"1?)DG '4]_8_M0>$KKQA;^%YK'7=/UF0HLMO>:>4:V:0.8EE
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ML;>:.1I(9[4 -;M&[ %ML;+&20#NB:N_H A^T'_GC)^0_P :/M!_YXR?D/\
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M\>LO^Z?Y5-0!#]H/_/&3\A_C1]H/_/&3\A_C4U% $/V@_P#/&3\A_C1]H/\
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MB;DG:4VVGRD9S@8 )./7[KPU87VGWMA<Z7IMQ8WKF2ZMI;96CG8D$LZD88G
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M;Y?R%=V"  0<"MK2_AQX:T34K>^L-)AM+FWDDEB:(L C21QQ/A<X *0QKC&
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MY3PUXFT?Q"]L%,ZZ7?Q7)B#9VEMC';G!QGK@UT58^@^#= \*M,VB:'INCM.
M)386D<!DQG&[8!G&3U]36Q3CS6][<FM[+VC]A?E\[7_ ****HP"H7_X^HO\
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M/_!7!_\ $4?\*I\$_P#0G:!_X*X/_B* -G_A(])_Z"EG_P"!"?XT?\)'I/\
MT%+/_P "$_QK&_X53X)_Z$[0/_!7!_\ $4?\*I\$_P#0G:!_X*X/_B* -G_A
M(])_Z"EG_P"!"?XT?\)'I/\ T%+/_P "$_QK&_X53X)_Z$[0/_!7!_\ $4?\
M*I\$_P#0G:!_X*X/_B* -G_A(])_Z"EG_P"!"?XT?\)'I/\ T%+/_P "$_QK
M&_X53X)_Z$[0/_!7!_\ $4?\*I\$_P#0G:!_X*X/_B* -G_A(])_Z"EG_P"!
M"?XT?\)'I/\ T%+/_P "$_QK&_X53X)_Z$[0/_!7!_\ $4?\*I\$_P#0G:!_
MX*X/_B* -G_A(])_Z"EG_P"!"?XT?\)'I/\ T%+/_P "$_QK&_X53X)_Z$[0
M/_!7!_\ $4?\*I\$_P#0G:!_X*X/_B* -G_A(])_Z"EG_P"!"?XT?\)'I/\
MT%+/_P "$_QK&_X53X)_Z$[0/_!7!_\ $4?\*I\$_P#0G:!_X*X/_B* -G_A
M(])_Z"EG_P"!"?XT?\)'I/\ T%+/_P "$_QK&_X53X)_Z$[0/_!7!_\ $4?\
M*I\$_P#0G:!_X*X/_B* -2W\0Z4JOG4[+[['_CX3U^M2_P#"1Z3_ -!2S_\
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MO">H]ZR_^%4^"?\ H3M _P#!7!_\143?"OP3]HC7_A#M P58_P#(+@]1_L4
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MK?PA_P!"EH/_ (*X/_B*6H]#6_MK3?\ H)67_@3'_C1_;6F_]!*R_P# F/\
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MC## 'AE8=.WI7C_P)^"7BGX7^(8KW5M=74+6;1FM;Z$7UQ/YM[]LEE28"7@
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M6[LS:3VT,UJRA3!)&&0@=!M/&*ADT/3I8[6-]/M72U8-;JT*D0D="@Q\I^E
M'QUX4_:7\5^%9M2U;5+B;Q7:6FD3S-8O-'  1KEY;^?D)N.R&)1M4,Q"<*3D
MU]@^&M<A\3>'=*UBW*M;ZA:Q7<9C)*E70,,$@'&#W /L*=-X>TJXC:.73+.2
M-AAD>W0@C<6Y&/[Q)^IS5]5"J !@#@ 4 +5"1G&K#8H8^1_$V/XOI5^N?\5:
MP_A_3]7U2.)9I+'3)KE8V. Y0%@">P.* -K?/_SR3_OX?\*-\_\ SR3_ +^'
M_"O O O[3TVK6^G3>(;6PT^VDE+75U&L\7EP&P-T'6*51(?G!C!P0Y!VY/%>
M@S?'?PC;6WF37&H12QF3[19MI=S]IM$C5&DDGB\O=%&JR1L78!<.I!.: .\W
MS_\ /)/^_A_PHWS_ //)/^_A_P *X33?B]I_B#XD67AK2$:]M'M;V6?4?)D6
M'S('@39%(5V2X,S!MI.TJ!ZU7U#]HCP'I=NLL^L2<@%HTM)GD3F0,&4+E2GD
MR%@>5 !(Y&0#T/?/_P \D_[^'_"C?/\ \\D_[^'_  KAHOCIX/N+F."&]N9W
MEU7^QHO*L9V$MT%+,B$)A@H5B6' QUZ5B:E^TAX66ZM/[.O4NK&.[DCU&X>&
M51#;I;7,WGQ?+^]7=;,N5R#S[9 /5-\__/)/^_A_PHWS_P#/)/\ OX?\*J^'
M]<M?$VBV6JV7F_9+N,2Q>?$T3E3T)5@"/QK0H AWS_\ /)/^_A_PHWS_ //)
M/^_A_P *FHH AWS_ //)/^_A_P *-\__ #R3_OX?\*FHH AWS_\ /)/^_A_P
MHWS_ //)/^_A_P *FHH AWS_ //)/^_A_P *-\__ #R3_OX?\*FHH AWS_\
M/)/^_A_PHWS_ //)/^_A_P *FHH AWS_ //)/^_A_P *-\__ #R3_OX?\*FH
MH AWS_\ /)/^_A_PHWS_ //)/^_A_P *FHH IVK3;9,1I_K&_C/K]*FWS_\
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MIYEI=V3P3("1N1LJPR.G!-<[_P (3XJ_Z*+JG_@NL?\ XS57_A"_%']I;?\
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M?\(3XJ_Z*+JG_@NL?_C-48G<5"__ !]1?[C?S6N-_P"$)\5?]%%U3_P76/\
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M1QN1A@J>X-<3_P (3XJ_Z*+JG_@NL?\ XS1_PA/BK_HHNJ?^"ZQ_^,T <O\
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MQD]L*1GYC6DNE>)K7PV+2TGM8M6$RS27<CEHY68[YL+M)"[B54>@'(H I_\
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MY/\ XJN[HH X3_A1G@3_ *%RV_[[D_\ BJ/^%&>!/^A<MO\ ON3_ .*KNZ*
M.$_X49X$_P"A<MO^^Y/_ (JC_A1G@3_H7+;_ +[D_P#BJ[NB@#A/^%&>!/\
MH7+;_ON3_P"*H_X49X$_Z%RV_P"^Y/\ XJN[HH X3_A1G@3_ *%RV_[[D_\
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5[IXS$TL1;)4D$CD^H'Y5U%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img227133604_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_8.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &D _$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ ID<,<.[RT5-S%FVC&2>I/O3Z\%^(7[(^B^/O%FI^([OQ[X[TB2\;
MS'M=+U^2VM8L#'R(!A1Q0!ZI\3]0NM)^&OBR^LIFM[RVTF[F@F3[R.L+E6'N
M" :\Z_8W\4:K\0OV6?AUKGB6]DUG5M1TM)KNZN@&:9][?,W;/ _*ODOQ+_PR
M_8W&H:+J7[1?CR\4![:YC@U^[N86!RKH62(JW<'!K[:_9XTGPAH/P5\(Z?X!
MNY;_ ,'6]DJ:9<3EB\D.3@G< >N>H% 'HM%%(6"@DG '4T +133(HCWE@$QG
M=GC'KFB.19$#HP=&&0RG(- #J*8LT<DCHKJSI]Y002OUI] !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %<Y\1[.SU#X>^)K;4;]M+L)M,N8[B^0D&WC,3!I!_NC)_"NCKD_%=QI_C;
MPSXI\.:?=:;JFHO9SV<VGR7 (5GC*A)0IW*#GTSB@#XL_9A_:%O/#/P%\'Z3
MHO[.7C#Q'IEC:?9H-9TK3K=;;4%1BHN$$C!OW@ 8Y'4GK7V_X UZ;Q/X-TG5
M;C0+SPO-=0B1M'U!%6>U.3\CA20#]*^5_A;X;_:V^%?P[T'PC:Z/\,-1M=&M
M5LX+FXOKQ9&C7A P5<9"X&1UQ7U5X%E\1S>$=+?Q=!I]MXD:$&^BTMV>V63/
M(C+?,1TZT ;U?#'_  4,^/GB>\^'_P 0/ GPRD,;Z!I7VWQAXA1RJ:= Y CL
MHV'_ "\2YR0/NH#GK7W,PW*1T^E?!G[6'_!/[P/I?P/^)>O>#--\4:AXRO8W
MOEM8-7N9_METTBEF>'=B0X+<$'I0!N_%A[SXM^-?V?/@C+J=[IWA;6- .O\
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ML5N+&X,RG!\O<WG;=V<<[<>U:0CSNUTO4UIP51V<DO4[Z.^MY+J2V2>)[B,
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MEMP/RD=*]2_9O^-/B+XY:UX[U:6UL;;P1I^J-INAS0QL)KK83OD=BQ!&"F,
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MQVJC-"PS_P \WK]1,C&<\5GB:"HR7*[Q>QRYQEL,OJ1=&3E3FKIO?1V:^_\
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MMK!90B*WAC@B'2.)0JC\!4M<#M?0^9GR\SY-O,****1 4444 %%%% !1110
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MDX?:#GHH]*5#!NM24KZRDHQ]>K?X??Y#K8M4:KC;2,7)^G2WX_TSZ_HKXO\
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M]FOXE7WQ@^ O@;QEJD4<.I:QI<5Q=+$,)YN,.5']TD$CV(H ]+HHHH ****
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M<MG_ &5&/J*^]/A;\%/!?P7TN2Q\(:%;Z2DV//F7+33$="[GD_RK[ZIF7U'
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MM:5J5?M]F7IV?]>9^G5%>#?LX?MA>#?VA;&*U@F71/%2)F?1;IQN8CJT+?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>,_$+X]:!X#UC4M ^)^D7'ASPS>
M!H;7Q#<(9M+O(F7!261!^X?DC;)@'J#7LU07UC;:G:2VMY;Q7=K*NV2&= Z.
M/0J>"* /EV'X-_L?75H+J/3?AJT#+NWB^MP"/7_65UW@7X[>!YYM,\"?!C21
MXLL]/9;>6715*:3I4(;YM]R1L+#DB-"S'VK:NOV._@??:P=4G^%7A22_+^89
MCI<7+>N,8_2O4]&T/3O#NGQV&E6%KIEC']RVLX5BC7Z*H % %ZBBB@ HHHH
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MF6EUJFIZ4MC?PWZR:9<&%I&C.0CD=5/<5V%?*/Q*_:L^#GQ \(^&+H?%*_\
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M** /D#_@J[_R93XM_P"ORP_]*4KZ/^#G_)(? _\ V K'_P!)TKYP_P""KO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM=?6LE[D79=?7YF\E^[B[+KKU?KKIY:(6BBBLC **** "BBB@ HHHH ****
M.<\<?#GPQ\2=)?3?$^AV6MV;#'EW<(8K[J>JGW!KXT^*W_!,NVCO&UKX5>)+
MCP_J$9WQZ??2L4#?],YE^=?QS]:^[J*[\-CL1A'^ZE9=NGW'IX/,L5@7^XG9
M=MU]Q^:^D_M2?'_]EG4(M(^*/AZX\1Z*AVK=7@^=E_Z9W2 JW4<-D_2OK'X-
M_MI?#'XS"&VL]971-:DX_LO5R(9"WHC9VO\ @<^U>V:KI-CKEC+9:E9V]_9S
M#;);W,2R1N/0J1@U\G?&3_@FYX!\=>=?^$9I/!6KMEA'"#+9LW;,9.5Y_NG\
M*]+ZQ@,9_'A[.7>.WS7^1Z_UK+,PTQ-/V4_YH_#\X_Y'UVK!E!!R#R"*6OS.
M75/VF_V,)@MU'-XP\&PM]Y]U[;;,]F_UD/ [\"OH+X,_\%%_AU\13!8^(S)X
M+UA\+MO3OM7;@?+*!QR?X@/K6%;*JT(^THM5(=XZ_>MSFQ&28BG#VV':JP[Q
MU^];GU?15>QU"UU2TBNK.YAN[:4;HYH'#HX]0PX(JQ7BGS^VC"BBB@04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !6)XX\-_P#"8>#==T'SVM?[3L9[/SDZ
MQ^9&5W?AFMNB@#X^\,?L_P#Q8^'_ ,&?ATGAJS\*)X_\(V-QH-W87C-_9NKZ
M>^0K%E7<C A),$<DN#UKZ#^ G@'4OA;\&_"/A36+]-3U32K!+>YNH@=C/R2$
MSSM&=HSV J[\3/C!X*^#>@R:QXT\2Z?X=L$!(>\F"O)CLB?><^R@FKOPY\?Z
M3\4O!.D>*]!>:71M5A^T6DEQ$8G>,D@,5/(SC/- '24444 %%%% !1110!\@
M?\%7?^3*?%O_ %^6'_I2E?1_P<_Y)#X'_P"P%8_^DZ5\X?\ !5W_ ),I\6_]
M?EA_Z4I7T?\ !S_DD/@?_L!6/_I.E '84444 %%%% $%[;&\LY[<32VYEC:/
MSH6VNF1C<I[$=17QA\9OV/[7P?I/@6U\)ZWXZO[>?QE9/>6ZZDTR6J2,YFO
M%0;)%.#YIZ9YK[6HK>E6G1=XGI8+,*V!GS4GIU7??_,^6/%'B*?X/_M776OW
MOASQ7K^B3>"[72HK[2=+EOV:9;EV(D91][:,D^I]ZMZH?$?[4_CGP81X2UCP
MC\//"^K1ZY<77B*#[+=:E=1 ^3'%!DL(P22S-C.>,$<_3E%7[?9J.J5KG3_:
M2BHSC3_>*/+S7\K72[V]3S/0_AWXTT?Q]=:_??$O4=:T)GGDC\-2:;;QQ(K
M[$$JC>=F1@GKCFO O$&I/\:OC1\/M7\(?#;Q3X.\::;K,-QX@U[5M.-G''I\
M:E9;>23=B;>,*H&>![U]DT4H5W%MVUM;M^6YG0S&5&3J.*<K65O=5K-:J*2E
MOU[*YX9^TQH.I:WXA^#,FGZ?<WR6/C>SNKIK>)G$$*I(&D? ^51D9)XJM^T!
MI^J^#_B?\._BGI^C7_B#3M"%YINL6.EP>==+;7" +,B#E@CKD@<X->^44HUG
M'E5MKK[R*6.E35-<MU%27JI7OZ;Z'@O[.^C:KXC^('Q'^*>J:1?:!!XHFM+7
M2M/U*+RKE;.VBV"61.JF1B3M/( ]P:]Y)"@D]!2UB>.-:'AOP7KVK,<"QL)[
MG/\ N1LW]*B4G5GMV7Z')B\1[>;JM622279)67X(_(OP_"GQ<_;FC+ S6^H>
M+&E)Z_NTF+?D%2OV'U"Z:RL+FX2"2Y>&-I%@B^_(0"=J^YZ5^3O_  3HT%_%
M'[4$.J2)YB6%I=7KD]F8;%/YO7ZQ:A>#3["YNC%).(8VD\N%=SO@$X4=R<<"
MOI<_E:O3HK:,4>IF:]CA\)AG]FG%OUEJSF_A?XVN_B'X+LM=OO#VH>%KBX9P
MVF:FH$T>UBH)QV.,CZUUE<I\,?'R_$SP;9^($T?4M"6X9U^PZM"89TVL5R5]
M#C(KJZ^:JKEG)6MKMV/GJ;YH)WOY]PHHHK(T"BBB@ KYV_;ZTW1;S]F7Q1/J
M^F_VA+:B-[*11\UO<%PJR ]@,G/J#BOHFL;QEX1TKQ]X7U/P]K=L+S2M1@:W
MN(2<94CL>Q'4'U%=.&JJC6A4?1IF&(INM2E375-'X/>&_B1XJ\'7$,VB>(M4
MTJ2$,L1M;N2/8#U  /&:_07]AO\ 8^\,>(/">D?%7QA(WB?5=29[BUL[M2T,
M!61EWN&_UCDKGG@>A-4X_P#@E%8CQEYS^.)6\+^9N^S"T N]O]W?G;[9V_A7
MW5X3\*Z9X'\,Z;H&C6RV>EZ= MO;PK_"JC'XD]2>Y)KZ[-LWHU*2A@Y:RW:5
MM.Q\MEF5U85'/%1T6RO?7N:@AC4(!&H"<(,#Y?IZ5\%?MG_LG:EX3UT_&7X4
MK+IVK6,OVW4K"P&UE8')N8@/_'U[Y)]17WQ2,H92K %2,$'H:^6PF+J8.K[2
M'S71KLSZ3%86&*I\D_D^J?<^>?V0?VL=,_:*\*K:7S16/C73XP+^Q!P)P.//
MB']T]Q_"3Z8KZ'K\[/VMOV9]<^ OC)/C1\)O,L;>VG^TZA96H_X\V)^:0*.L
M+9(9>@SZ=/JC]EO]IK1?VC_!*WD!CLO$EFJIJ>E[N8FZ>8GK&W8]NAKNQN$I
MN'US"?PWNOY7V?EV./!XJ:G]5Q/QK9_S+N>UT445X9[ 4444 %%%% ''?$SQ
M]>?#_3]+N;+PSJ7B=KR_BLGATQ06@5S@RMG^$5V%<A\2OB,GPWT_3+I]#U77
M!?7\5CY>DVYF:+><>8X[(.YKL*UDO<B^7OKW_P"&-Y1M3B^6U[Z]_P#A@HHH
MK(P"BBB@ HHHH **** "BBB@ HHHH **** &NBR(R.H96&"K#((]*^??C/\
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M-YVPI QPH.WKC^';_"V0#ZKHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^#?VP/VJ/B[
M\/\ XGIX-M[*/X4?#ZYE6'_A9UWI\NIIM95)*(@*Q$$D?.#TR<5]Y5SVI>(/
M"^J:])X,O[[3+S5[BT-T^AW#I)+);[MI=H3DE,\9(QF@#\X?@#\'? ^M?MZ6
M,5WXM?XX6#>#%UR/7=>N$OT-VTH&]%Y5 !]U#RN:_3R*)((UCC18XU&%51@
M>@%?!7Q8^ _[/O@3XC7VN?#SXOZ-\!OBA9EHI5L=4@2 L0"8Y[1VQM;() QF
MOL[X6KXBC^'NA#Q9JMAKOB'[,IN]3TM-EM=-U$L:]@PP<>] '54444 %%%%
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MG2OEO_@J9X3T/2/V,O%EQ8Z+IUG<"[L0)K>TC1QFY3."!D5]2?!S_DD/@?\
M[ 5C_P"DZ4 =A1110 4444 %%%% !1110 4444 %>2>)/@)<77C+6O$GA7QS
MKG@F\UP1'58=.BMYXKEXT")(!-&QC?8 ,J1G XS7K=?.?[9W[2&O_LX^'/#6
MH:#I]A?RZG>26\JWZN0H5 PQM8>M=%",YS4*>[/4RVGB:^(5#"VYIZ:VL^NM
M].E_4]D^&?PZTCX3^!],\*Z$LPTVP5@C7#[Y'9W9W=FXRS.S,< #G@"OB'_@
MJ_XC7[+X!T -AR]S?$>V%0?UK[YT6\?4='L;N1562>".5E7H"R@G'YU^8'_!
M2S5IO$W[1NB>'HAYAM-.MX$4?WYI&;'UY%>SDD74QZE+I=_U]YT97&6)S2C[
M5W?-S-^EY?FC[F_8Z\,_\(I^S3X#LRNUY=/%V_'>5C)_[-7K]]>0Z?97%U<N
M(K>"-I97;HJJ,D_D*H>$M'C\.^%='TN%=D5G9PVZKZ!4"_TK0O;B"TLYY[IT
MCMHHV>5Y/NJ@&6)]L9KQ:U3VM:4WU;?WL\O$U76K3J]VW][.?^'7COP[\2/"
M=KKWA:[CO=%G9UBECC*#*L588(&.0:Z:N;^'OB;PQXN\*VNI^$+FSN]!D+K#
M)8*%BR&(8  #'.:Z2HJ+EFTDUY/?YG'3=X)MW]-@HHHK,T"BBB@ HHHH ***
M* "BBB@ HHHH R_%'AC2_&?A^_T36K*+4-+OHFAN+:9<JZG^OOV-?B9\2K_4
MO@;\6/&OAKP1XCUC2])MM0DME,-T\+R*C';OVD9(R1DU^X]?%?[4?_!/%/C#
MXUO/&'A+6K?1M5U!@][97L;&&63H9%9>5)[C!!/I7TN28VEA:DH8AVC)?*Y\
M_F^$J8BG&=%>\OOL>(?LS_\ !1G4_ASH=UHOQ#CU+Q9:QX:PO8W5KF/U1V8C
M<O<$DD<_A[5_P]4^'_\ T*OB#_R#_P#%5VW[/'[!'@KX1Z%=#Q/:V/C;7+PJ
M9+B\M088%'\$2MGOU8\GCI7KG_#-_P +?^B?^'O_  7Q_P"%:XK$Y5.M*2I-
M^:=E]QGAL/F4*48NHEY-7?WGS<O_  52^'Y8 ^%O$ &>3^YX_P#'JTO^'HGP
MO_Z!.O?]^$_^*KWV3]FOX5S1LC_#[P\588(^P1_X52_X93^#_P#T3GP]_P"
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ME^:P"A5SU"JH&>^":]+-EEJPL?JUN;I;>WG_ ,'4X,M>/>(E]8OR];[7\O\
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MTVXK)<0 1C SR0>*_&33[^YTN_M[RSGDMKN"19(IHF*NC Y!!'0@U^A?A_\
M:7_:KFT#3)+/]G"+Q!:O:Q-%JSZEY+7BE!B8IO&TL.<>]>WQ1D^*A'"?5ZR5
M."Y6G'5O=N]]+_@:YS'"Y=A:<*M-S=FHOFM9][6U^_R/J;Q]\2+'X>I9M>V-
M]>?:BP7['%OVX]3GBH/!_C^Q^*&GZI!96VI:9Y:>4TL\?EL-X(#(>>17S?\
M\-)?M:=_V6+<_P#<9_\ LZAO/VC/VM[BSGAB_9=AMY)(V194U@90D8##Y^U?
M#K+L9]8]I[5<G\MOU]==CXUX[!?5?9^Q?M/YN;3?^6W;3?S/8=)\;:5\"=/C
M\&W<GB;Q//8DNVI7B"1Y-YW8W<9 SBO4?"_B:W\5^'X-7MH+BW@F#$17,>R0
M8.#Q^%?&'P^^-/[87@WPM;:5J7[.Q\2W<3R,VHWFJJDCAF+!<!^ ,X'L*Z/_
M (:2_:T_Z-8@_P#!S_\ 9UH\OQKQ-2I5KJ<6W;W;=>__  "'C<#]5ITJ-!PF
MK7?->^G:VGWL]M;]HS0UO#;_ -BZYN\SR\_91USC.,YKT#Q)XD@\+^'Y]7N(
M+B>"%5<Q6\>Z0YQCC\:^4O\ AI+]K/\ Z-7M\_\ 88'_ ,77(:A^W=^T+I/Q
M+TOX?7?[.EC#XQU2U:]L]);5W,DT*ABS@[MN!L?J>QKGI99CHQFJE92;V]VU
MO\SHKYAE\YP=&@XI?$N:]_G96_$^KO"?QOTGQAKMOI5MI6K6\T^=LEQ !&,#
M/)!XK9\>_$>Q^'L=H][97UY]I+!?L<6_;CU/:OF?_AI+]K/M^RQ;CZ:S_P#9
MT?\ #27[6G_1K%N?^XS_ /9THY9CE1<)5DY])<NWROK]X3S#+WB(U(X=JFMX
M\^K_ .WK:=.A]+> ?B58?$(7GV*QO[/[+MW?;(M@;/H<\UE>+_C9I/@W79M*
MNM+U6YFB"DR6\ ,9R,\$GFOG[_AI+]K3M^RQ;C_N,_\ V='_  TE^UG_ -&L
M6Y^NL_\ V=$LLQSHJ"K)3ZRY=_E_P0CF&7K$2J2P[=/I'GU7_;UM?N/JSPMX
MFM_%GA^#5[:WN+:"8,1%<Q[)!@\\5P#_ +1FAI>&W.BZYN$GEY^RCKG&<9S7
MB7_#27[6G_1K$'_@Y_\ LZ/^&DOVL_\ HU>W_P#!P/\ XNG5RS'2C%4ZRBUN
M^6]_ET"AF&7PG-UJ#E%[+FM;YV=_P/JWQ)XD@\,^'Y]7N(+B>"%%<Q6\>Z0Y
MQV_&N0\)_'#2?%^NV^E6VE:M;S3YVR7$ $8P,\D'BOE+3_V\/VA=5^)FI_#V
MU_9TL9O&6F6JWMYI(U=_,B@8*5<DMMP=Z=#_ !"NO_X:2_:S_P"C5[<?36?_
M +.JJY;C)58RIU4HK=6O?Y]#.CC\#"C*%6BY3>SYK6[:6=_O/ICQ[\1K'X>P
MVDE[97UX+HL%^QQ;]N/[Q[4WP#\2K#XA?;/L5C?V?V7;N^V1; V?0YYKYI_X
M:2_:T_Z-8MS_ -QG_P"SH_X:2_:T[?LL6X_[C/\ ]G3_ +-QGM^?VJY/Y;?K
MZZ[!]?P7U;V?L7[3^;FTW_EMVTW\SZ!\8?&S2O!FNS:5=:7JMS-$%)DMX 8S
MD9X)/-=5X3\3V_B_08-6MH+BV@FW8BNH]D@P<'BOE3_AI+]K/_HUBW/_ '&?
M_LZ/^&DOVM/^C6(/_!S_ /9TJ>6XR-64JE5.+V5K6^?7[@K8_!2H1A2HN,UO
M+FO?OI;3[SVV;]HS0X;Q[<Z+KA99#'N%L.N<9QG->@^(?$<'AOP]<:Q/!<3P
M0QB0Q6\>Z0@XX _&OE'_ (:2_:S_ .C5[?\ \' _^+KD/!_[=_[0OC[Q1XF\
M.Z!^SI8ZGK7AJ=;;5[./5W#6DC%@%;<P!)VMT)Z5-++<=%352LI-[>[:W^9=
M?,,OG*#HT'%+XES7O^"M^)]6^%?CCI'B[7K;2K;2M6MYK@D+)<0 (,#/)!XK
M;\>_$2Q^'L%I+>V5]>"Y9E46<6_;CU]*^9O^&DOVL_\ HUBW'TUG_P"SH_X:
M2_:T_P"C6+<_]QG_ .SI1RS'*BX2K)SZ/EV^77[QSS#+WB(SAAVJ:WCSW;_[
M>MI]Q[7)?6/[05C%:6-]XC\+'2;V&^:6WQ"9]I/[LGG*GN*U_&/QJTKP7KDN
MEW6EZK=31JK&2V@!0Y&>"3S7RMX^^,W[8GC#3;*UTW]GE_#<EO>17,D]GJJL
MTJ(<F(YDX#=":Z?_ (:2_:T_Z-8MS]=9_P#LZVJ9?CY86%)8B/.F]>7]//UZ
M>9K_ &CE_M>>5%NGK:'-JMM>:VM^Q]5^$_%%OXOT&#5K6WN+:"7=B*ZCV2#!
MQTK@9OVC-#AO'MSHNN%ED,9(MAU!QG&<UXE_PTE^UI_T:Q!_X.?_ +.C_AI+
M]K/_ *-7M\_]A@?_ !=95<LQTH15.LHM;OEO?Y=#*AF&7PJ3E6H.47\*YK6^
M=G?\#ZN\0>(X/#OAZ?6)X+B>"&,2&*"/=(0<< ?C7'>%?CEI'BW7K;2K;2M6
MMYK@D+)<0 (,#/)!XKY2^&G[>7[0GQBT_4[[P=^SK8Z[:Z;>/I]W)!J[J(KA
M0"T9W,.0".G'-=A_PTE^UG_T:Q;CZ:S_ /9U57+<9*I&5.JE%;JU[_/H9T<?
M@849QJT7*;V?-:WRL[_>?3/CWXB6/P]M[26]LKZ\%RQ519Q;]N!W/:HO /Q,
ML/B$UXME8W]F;4*6-Y%L#9]#GGI7S7_PTE^UI_T:Q;GZZS_]G1_PTE^UIV_9
M8MQ_W&?_ +.G_9N,]OS^U7)_+;]?7R!8_!?5O9NB_:?S<VF_\MNVF_F?07C'
MXU:5X+UR72[K2]4NIHU5C);0 QG(SP2>:ZGPGXHM_&&@P:M:P7%M!+N CNH]
MD@P<'BOE3_AI+]K/_HUBW/UUG_[.C_AI+]K3_HUB#_P<_P#V=%/+<9&K*4ZJ
M<'LK6M\^OW!5Q^"E0C"G1<9K>7->_P K:?>>W7'[1>AV][);'1=;+)(8R1;#
MJ#C.,YKT#7O$4'A_P[/K$\%Q-;PQ"4Q0Q[I2#CC;Z\U\D:G^U)^U7H^FW>H7
MG[+MK!:6L3SS3-K'"(JEF;A^P!-8/PW_ &X/VC?B]X2MO$_@_P#9PLM<T&Z9
MTAO8-894<HQ5@ S \$$=.U11RW'14_:UE)O;W;6_S+KYA@)R@Z-!Q2^+WKW_
M  5OQ/J/PM\<](\6:[:Z5;Z5JUO-<$JLD\ "+QGD@\"M[QY\0[+X?6MK/>V5
M]>+<.446<6_;@9Y]*^9?^&DOVM/^C6+<?36?_LZ/^&DOVM.G_#+%N?\ N,__
M &=*&68Y490E63GT?+M\NOWCGF&7RKQG##M4UO'GO?\ [>MI]Q]*> ?B=I_Q
M"DO$LK'4+,VP5F-Y%L#9]#GK6=XR^-&E>"=<?2[K3-4NID17,EM!F,Y]"3S7
MSY_PTE^UI_T:Q;C_ +C/_P!G1_PTE^UF>O[+%N?KK/\ ]G0\LQSHJ"K+G_FY
M?T_X(1S#+UB'4EAVZ?2//JGWYK?H?57A'Q3;>,M!AU:UM[FV@D+ 1W4>R08.
M#Q7!W'[16AV]Y+;'1=;9HY#&6%L.2#C.,YKQ'_AI+]K3_HUB#_P<_P#V=8WC
M/]L3]IKX>^%M3\2>(?V9K/3-$TV$W%W>2ZN2L48ZL0&)[]A3JY9CI0BJ=91:
MW?+>_P N@4<PR^%2<JM!RB]ESVM\[._X'V1KGB*#0?#L^LS07$UO#$)3%#'N
ME(.. OKS7&>%_CII'BO7+72K?2=6MYK@[5DGMP$7C/)!X%?-GA#]L#]IWQ[X
M7TSQ%H'[,UKJ>BZG MS:7<>L$+-$PRK %@<'W%:__#27[6?_ $:Q;C_N,_\
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M'UIM,N],U2ZF5%<R6L 9.>P)/-?/7_#27[6G;]EBW'_<9_\ LZ/^&DOVL_\
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MFN6VK)-  BG&>2#P*\%_X:2_:T_Z-9@_\'/_ -G2?\-)?M9_]&L6_P"&L_\
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MX->+7S2G1YK1<K24=+:RM=K5K9;OY'L4<MJ5N6\E&\7+6^D;V3T3W>WWGO\
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M?A%RWJQUVU6O0%@<4[VI2TWT>AZ'17%>'_C%X4\3Z\NCV&I;[V12T(DB=%G
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MW4JR<I/JS1HHHK(Q"BBB@ K(\6>$])\=>'+_ $'7;&/4=)OHC#<6TH^5U/\
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MP1NAE+RMB3/<JR=>N17N7[">EWVC?L@_"JTU**2"[718W,<OW@K,S)_XZRT
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M4@D%K<H,G;(.'4@Y!JG\'_VG['XY?%+Q7H'A3P_?7OA#P^#;R>,B0ME<WJL
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M"?X2#[8KI/@[\%_"GP(\'IX:\(6#6=CYK7$\T\K37%U,WWY99&Y=SW)KN:*
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M<U+10 4444 %>5_&[]G/P[\=FTN;5M7\1Z#?:;O%O?>&M6DL)PKXW*S+]X'
MX(KU2B@#S?X=_L\^ _AC\-[WP-H^B)+H&H^:=22_<W$NH/*,2R3NW,C,.I/Z
M5Y]\.?V#_A?\-?&6F>(K/^WM6;1G9]%TS6M7EN['2&/>VA;A"!P,YQ7T310
M4444 %%%% #)8Q-&Z-]U@5./>O+O O[-'@7P'\%[CX5P6$VK>#;G[0)[35I?
M/:03.7<%L#^)CCTXKU2B@#Q+X*_L@^ ?@7XEG\0Z,=9UC6VM186U]XAU*2^E
ML;4'/V>W+_ZN/IP/3K7MM%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!XTCDW%+>WU!]UB<?PK'A/Q(]* /TO\ %'CKP_X*;3%UW5[72GU2Z6QLEN9
MIN)V^[&@_B8^@K=KY%NH_P#AH3]O2",XN/"/P?T_S6[QR:U=KP/0F.(=.QP:
MW/%G[;GD^*/$VG>!?AMX@^(NF>%YWM=9UC3)X(8(YT&9881(P,SIW"CUYH ^
MGJ2O =>_;4\!Z;\$_"WQ%TQ+_P 0Q>*IDLM$T33X@;Z\NR2&MPI.%9"K!B3@
M8^E1_"G]K-?'/Q*_X5WXM\$:O\._%]S8OJ.GVNI30W$-_ O#^7+$Q&Y>ZGWH
M ]I\(^--"\?:*NK^'-5M=9TQI'A%U9R!XRZ,5=<CN&!!^E;5? ?[(?QZT/X
M_L5Z/J&H6UQJVM:IXDU6RT7P_IX#7>J737L@6*)?YL>%'6O>/C!^U==_";4O
M 'A@> M2\1?$#QA!)-;^'["ZB18/+4&17G<A21G''4@T ?0E%<E\+?'5W\1O
M!=GKE_X9U;P?>S,Z3:-K4:I<P,K%3G:2"#C((/((KK: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img227133604_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #^ G # 2(  A$! Q$!_\0
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M_KB__H)H \]_9A_Y-N^%G_8KZ9_Z2QUZ;7BW[-=Y.O[.GPN E8#_ (1C3?\
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M".2WBF8-)$CL 5!902 >H_&H8=+LK=;98K."(6P(@"1*/*R,';Q\N1Z5:HH
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MW)))/<DF@#S#]FS_ )-U^%W;_BF--_\ 29*]'KSC]FW_ )-U^%W_ &+&F_\
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MOER>OR)S\HK0\,^!=+^'/@Z[TK2/M31'SKF:YO;E[FYN)GR6DEE<EG8\<D]
M!T KJZJ:M_R"[S_KB_\ Z": /&_V;?\ DW7X7?\ 8L:;_P"DR5Z/7G'[-O\
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M^!9@^XO\NW#'!H ^@_%OPWT/QQJ%I=:Q;R77V>SO-/$/F%8Y(;I%296 ZY5
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M;D94@$=P001ZB@#S#]FW_DW7X7?]BQIO_I,E>CUYS^S;_P FZ_"[_L6--_\
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M5]H 5RJL!O"@ -UP!7K5%7&<H.\78WHXBMAY.5&;BWIH[?D>(C]FW4/"WS>
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M %%%% !1110!Q'Q:^(F@_#GP_:2^([Y])TS5KL:6VI>>EO'9F2*1O->5B!&
M(VPW7<4 !)%>+_L8Z?8:1<^)+&*[UJ:XCLK.:SCU32X=/3^S99KN6WE6..1S
MOD=KAF\W8^-A,:YY^F+RQM]1MVM[NWBNH&QNBF0.IP<C(/'! /X4^.WBBEEE
M2)$EEP9'50"^!@9/? H DJIJW_(*O?\ KB__ *":MU4U;_D%7O\ UQ?_ -!-
M 'GO[,/_ ";=\+/^Q7TS_P!)8Z]-KS+]F'_DV[X6?]BOIG_I+'7IM !1110
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M5VALG: 4_P#A%_C5_P!%"\&_^$=<_P#RQH_X1?XU?]%"\&_^$=<__+&O5Z*
M/F?POXM^-WB3XS>._ ;>+/!UK'X8LM,O%U+_ (1.Z87?VL3DKL^W@+L\@<AC
MG?VQ7H/_  B_QJ_Z*%X-_P#".N?_ )8U3^&_QZNO'7QF\7>"I='@L[/2//\
MLM\DTK//Y,R129W1+&WS./\ 5/)Y>-LFUB!7L= 'E'_"+_&K_HH7@W_PCKG_
M .6-<?\ #G6/C;X]/B@/XQ\&Z=_8NNW6C+GPE=/YXAV?O>=0&-V[ISTZFO9?
MB-XHD\#_  ^\3^(XK=;N71],N=02W=BJRF*)I I.#@';C/O7!^'?C=?ZQ\6S
MX8FT6WAT69Y[&VODNF:X:\@MH+B4/%L"K$4N JL&))0Y #"@"?\ X1?XU?\
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M'3P+)XGTZ&.WM/[1N[..-+A)F"Q3,B,Y4D!F0*Y7)V[P,F@#T2BBB@ HHHH
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M3W![4ZB@# M? ?AZS&@^3H]I&="4)IC",9M%$1B 0]0/+8K]#6_110 4444
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M1*% 7/T1 3U(1020HQTE% !5#5]#L->BMH]0M8[M+>YBNXED&=DT;!XW'NK
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M,QW_ #YE]S/=Z*\(_P"&V/A3_P!!>^_\%L__ ,31_P -L?"G_H+WW_@MG_\
MB:/J]7^5_<']F8[_ )\R^YGN]%>$?\-L?"G_ *"]]_X+9_\ XFC_ (;8^%/_
M $%[[_P6S_\ Q-'U>K_*_N#^S,=_SYE]S/=Z*\(_X;8^%/\ T%[[_P %L_\
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MF8[_ )\R^YGN]%>$?\-L?"G_ *"]]_X+9_\ XFC_ (;8^%/_ $%[[_P6S_\
MQ-'U>K_*_N#^S,=_SYE]S/=Z*\(_X;8^%/\ T%[[_P %L_\ \31_PVQ\*?\
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MXP>&_#.F:#;Z;IDTFF/<O#=3N\RW"Q-(A9W8*!O8 K@\\FO3_P#AWKX@Z_\
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M1110 4444 %%<UXS\&2^+UM%B\2:YX>^SEB3HL\<1ESCA]\;YQCC&.IKF/\
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MKS/_ (4M=_\ 12O''_@?;_\ QBC_ (4M=_\ 12O''_@?;_\ QB@#TRBO,_\
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M_P",4?\ "EKO_HI7CC_P/M__ (Q0!Z917F?_  I:[_Z*5XX_\#[?_P",4?\
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MKS/_ (4M=_\ 12O''_@?;_\ QBC_ (4M=_\ 12O''_@?;_\ QB@#TRBO,_\
MA2UW_P!%*\<?^!]O_P#&*/\ A2UW_P!%*\<?^!]O_P#&* /3**\S_P"%+7?_
M $4KQQ_X'V__ ,8H_P"%+7?_ $4KQQ_X'V__ ,8H ],HKS/_ (4M=_\ 12O'
M'_@?;_\ QBC_ (4M=_\ 12O''_@?;_\ QB@#TRBL+P?X7D\)Z=+:2ZYJVOL\
KIE^T:Q,DLJY &T%$4;>,].I-;M !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img227133604_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_10.jpg
M_]C_X  02D9)1@ ! 0$!( $@  #_X1":17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0>.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO92!$86UB
M<F]S;P    'J'  '   (#   "&H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BK_P  1" '0 O0# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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MZ_:^&/#]SK%_'-);VP4NL*@N<L%X!('4^M6]/O8]2TRVOH%98KF)94#@!@&
M(SCOS7CEQXIU/Q7^S_K]SK95[JVN%MRXC$9<!XSEE' //:O5?"?_ ")NC?\
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M%C;CKL5F88_\='ZT[7^ZX:VOYV/3J***D84444 %%%% !1110 4444 %%%%
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MG%2:-K7]K7>JP?9_)_LZ\-KNW[O,PBMNZ#'WL8YZ4;_=^'],-OZZ_P!(SH_
M>F1^(=(UE9[O[1I%H+2!2Z[&0*RY8;<DX8]"/I46G_#O2=-\,:MH4%Q>M:ZJ
M[O.[NA=2P .TA<#IW!KJZKW]U]ATVYN]GF>1$TFS.-VT$XSVZ4I/1M_UU&D[
MI(Y2Z^%^BW-GHT"W>I6\FC)Y=M<V]P(Y2O<%@OZ@ U%!\)]!MHM6BBNM4":J
MA696N]P7/5AD'+>[;CR?6MG2?%<6H:';ZE<65Q;12:>+]WQNB1>I3?QEAUQ@
M<56L_%=]>SZ;;QZ5 MQJ,1NXT:].([8;?F<B/A_G'R#(_P!JJ:=VOZ_K0E6L
MG_7]:FYI&F0Z-HUIIMJTCPVD*PHTA!8A1@9P ,_A7(>)O@_X9\4:M+J5V;VU
MNICNE>VF \PXQR&# =.V*[NBD]7=C6BLCF;+X?>';#PG<^';>R/V&ZYGW.2\
MC<?,6]1@8QTQ6>OPLTG_ (1>YT*;4]8N+:X$:[Y[L.\2HVY40%=JKGT6NVHH
MW#96,C6/#.GZYX7?0=0$C6C1K'N5L.-N-K XQD$ ],>U<[#\)=$COM/O'U'6
MII[!=B22W[$NF,!"<<*!D87:,$YS7<T4[ZW%;2QR#?#71VA\0QFYOL>('#W7
M[Q/D(8M\GR\<D]<U-J/P_P!*U/0]%TJ>XO%@T9XWMV1U#,4&!N)7!_ "NIHI
M;?A^&PWKO_5R*ZMH[RSFM9QNBFC:-QZ@C!K@OAB)?#GV_P %:K\MS8RO-:,W
M N+=CD,OK@YSZ9KJ]<UW^QKK28?L_G?VC>K:9W[?+RK-NZ'/W>G'6K]_=?8=
M-N;O9YGD1-)LSC=M!.,]NE*ZC>73^F.S=H_/]#A=;^"?A'6;YKI8[K3G=BSK
M92JJL3_LLK ?ABMG2OAUX?T3P[?Z1ID$L,>H0F&YG\S=*X((SD\#&3T&/:JV
MB>-M5O= N=;UKPP^F:;%9_:X98[U+AIUQNP% !7CGFKD7BV41W$-U81KJ">4
M(((;GS$G,H)0!]HP<*2WR\ 9Y%5RV7**]WS')?\ #/GA7_H(:Q_W^B_^-UL:
MM\(/#.LZ;86MT;U9+&W6VBN8Y@)#&IR 005[GG;WKIK[7[>PNH;>48=G EW!
ME"*49MRDCY^5QA>Y_"I+36([G5I;!HVBE6%+B+>"#)$W&<$ @A@05/3CUI;Z
M!MJ<YI/A;PQ\+-#OM2MQ(-L>9KFXD#22 =$' ')P  !DXJ'X6^'KS2M(OM6U
MB+R=1UNY-W+$1@QJ22JD=CR3CWKNJ*=WN*VE@HHHI#"BBB@ HHHH **** "B
MBB@ HHHH **** "FR[O)?R_O;3M^M.HI-75@/*AN_P"%0>'?-SYW]JV_G9Z^
M9]I^?/ONS6UXQ\*Z1I?A?Q5K%E:A+R\L9/,;.0O&6VC^'<<$XZD5UNFZ8NF2
M78@D_P!'GF,ZP[?]4S<O@^A/S8[$G\+U-ZI^?ZI?Y M&OZV;/)/%/_'KXC_[
M%:V_]#>M+[+!I?B>UBTZ);:.]\.S27*QC F==FUV]6&X_,>>:])HHEK?SO\
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MA<*N.2""<UZE133M_7I_D#U_KU_S/,;>TM+#Q!XUBL(+*V\0S%GTP%42=PT
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M!<ZI<K!&S;4!!9G;^ZJC)8^P!-7JC:"%[B.=XD::,,J2%064'&0#VS@9^@H
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M?+9R"\L(+0PW<QV<B?=,S,RMSN*YZ]C4>F:/Y7P9L-0TBWQJ3V<2RW"HSRF
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MY@N))&"CH6':H_$'B'XL^']5\+?\)#<^%[?3]1\06EA-_8\<SRR+(QW(?.!
M4J#RN&SC!ZT >R4444 %%%% !1110 45FZOXCT/P_P"3_;VLZ?IGG[O*^VW2
M0^9MQG;N(SC(SCU%7+.]M=1LX[O3[F&ZMI1NCF@D#HX]0PX- $U%%5AJ5BRR
M,M[;D1LZN1*OR%/O@\\%>_IWH LT4R&:.XA2:"198I%#HZ,"K*1D$$=0:?0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4C*K?>4'ZBEHH \3F\=31^']=N-4\1I!J,FG[X;)4C1K.Y$LB^0J8W'
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M]=L-5@U"YO+>,/'/9R^7+%* &Q_"X&<[6P<$]<'TJ[0 4444 %%%% !1110
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M-T?\-!_#'_H9O_)"Y_\ C= 'I-%>;?\ #0?PQ_Z&;_R0N?\ XW1_PT'\,?\
MH9O_ "0N?_C= 'I-%>;?\-!_#'_H9O\ R0N?_C='_#0?PQ_Z&;_R0N?_ (W0
M!Z317FW_  T'\,?^AF_\D+G_ .-T?\-!_#'_ *&;_P D+G_XW0!Z37D&M?\
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MI>#O&^JR:;X8UC[==Q0F=X_LLT>$#*I.70#JR\9SS0!UM%%% !1110 4444
M%%%% '*?$O3;K5_ =W96,,TTTDL&%@'SX$J$D?0 G\*J?\*QM?\ H9_%/_@W
M?_"NVKC;GQE?MXX31[*RMQ91W0LY[B:0^896@:8;4'&T #))[\#O0NP^ATVD
MZ<NDZ7#8I<W-TL(($UW*9)&R<_,QZ]:-8,XT.^-HS).+>3RF5-Y#;3@A>_/:
MJ?A36W\1>&K;4I8EBDD+HZHV5W(Y0D'N"5R*NZLUVNC7K:: ;P0.8 >\FT[?
MUQ2J;.X0^)'E/A6VT"%=(2?2/&4=^IB#F6.Z$2R<9)YVA<^V,5[#7B^FMX?C
M70[GPS?7,WC":YA6]5IY&FD^8>>)T)P% W=0,$#%>T5I+;Y_U8A;_P!?B5-4
MU2RT73)M0U.<06L(!>0J6QD@   $DDD  <DFLNP\<>'-3T.]U>UU2,65@2+M
MYD:%K<@9(=' 93CU'/:M;4;^STO3;B_U.>.WM+:,RRRR'"HJ\DFO"+_4M.\1
M^&?$/BJWU"SN#J.JZ??7FF6UPDLL&G6\J*&E122&(R[ ]!@=J@H]J\/^)]'\
M46LMQH=W]H2%_+E5HGB>-L @,C@,,@@C(Y'2N,^,G_,A?]CGIW_M2JUG9VWC
MKQUXP?0]:N[;2[BQL+:35-%N@CM<1N\A\N4 C(0JK8SPV*YOQSX _P"$5U7P
M/??\)9XHUGS/%MA#]GUC4OM$2Y9CO"[1AOEQGT)]: /=J*** "BBB@#YP_:&
M_P"2@V/_ &"X_P#T;+7E5>J_M#?\E!L?^P7'_P"C9:\JKUZ/\-'WF7_[K#T"
MBBBMCN"BBB@ HHHH **** /N2BBBO"/S4**** "BBB@ HHHH **** "BBB@
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MM>55ZK^T-_R4&Q_[!<?_ *-EKRJO7H_PT?>9?_NL/0****V.X**** "BBB@
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ML?P1_P!#EX?_ /!I!_\ %5Y!_P (GX<_Z &E_P#@%'_A1_PB?AS_ * &E_\
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MV+S;/S=NW/F9\_9MSQC=NS_#CFI&UF^6._8>&M48VKA84$EKF\!8C='F;
MW?O-AP> 3Q6O10!D1:S?223*_AK5(A':B=7>2UQ*^T'R5Q,3OR2N6PF5/S8P
M22ZS?1R0JGAK5)1):F=G22UQ$^TGR6S,#OR N5RF6'S8R1KT4 9"ZS?-'8,?
M#6J*;IRLR&2US9@,!NDQ-@@@[OW>\X'(!XJ/^WM1_LK[7_PB>L>=YWE?8O-L
M_-V[<^9GS]FW/&-V[/\ #CFMNB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6N4_X5_JO_/Q9_\ ?;?_ !->B44 >=_\*_U7_GXL_P#OMO\ XFC_ (5_JO\
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M55@M4>1BV,X\QF[_ ,)[<5V-WJEU?>$9-1\-6TES<SV^ZSCF'D%BW"L1(/E
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MC5)1*B!L?=4J  <_*,9JUJ&EZC<^*-(U"UU.2WL;,3"ZLPWRW.Y<)D8_A/-
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M\O\ @G.>(?&WB**\M]-M=.M;._AUBS@N!]M+QRP3%BH#>5D$[2&^48[%JU]
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M%_P?N"7Q-+Y?>_\ @?>9]IXKU*XUWQ%:2:3M32[**YM8 ^9IR_F\-SM7/EC
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M&AO%?_0/T;_OQ+_\<H^K5 _L?%=E]Y]'T5\X?\-#>*_^@?HW_?B7_P".4?\
M#0WBO_H'Z-_WXE_^.4?5J@?V/BNR^\^CZ*^</^&AO%?_ $#]&_[\2_\ QRC_
M (:&\5_] _1O^_$O_P <H^K5 _L?%=E]Y]'T5\X?\-#>*_\ H'Z-_P!^)?\
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MSM9_Y]K#_OV__P 70!ZG17EG_"SM9_Y]K#_OV_\ \71_PL[6?^?:P_[]O_\
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MVL_\^UA_W[?_ .+H ]3HKRS_ (6=K/\ S[6'_?M__BZ/^%G:S_S[6'_?M_\
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MZ]S_ .A+7N)N=(L_#_AZYU1;YIXD=X%MBH4X?/S$\^G2O*Q'\1_+\CX?-?\
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M/4->^"^MS:DVEWMI;P(EGIMFB++I^UMOF,.H'&[J2>>U<UIW_)!=9_[#$/\
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M1&0[*F"2I!#  >I'-+I?^MD_U'UL:O\ PA/A7_H6='_\ (O_ (FC_A"?"O\
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M;^7_  /\PEI;S_X/^1T__"$^%?\ H6='_P# "+_XFC_A"?"O_0LZ/_X 1?\
MQ-;E% '%^$/"'AJY\#Z%/<^'M*FFETZW>222RC9G8QJ222N22>];'_"$^%?^
MA9T?_P  (O\ XFCP3_R3_P /?]@NV_\ 12UR7QX2"3X9%+NVFN[=M1M!+;P
MF25?.7** 0<D<#!'6EV^7XC.M_X0GPK_ -"SH_\ X 1?_$T?\(3X5_Z%G1__
M   B_P#B:\Y^%,FGZ;XDUJR\.Z1J_A^R>SCDM/#^M"6.:1U+;YD\PL IW*IP
MQYY('&>L3XA-!#XACU'3(WU#0;5;J:VTR[^U!T8-A0Q1"'^0Y4KP,')S5-6_
M,2NW8VO^$)\*_P#0LZ/_ . $7_Q-'_"$^%?^A9T?_P  (O\ XFLJ7Q\EAX-A
MUW5H]-A2YECBMG@U19+:0O\ =)G94V@<[B5XP<;N,\UXB\96GBOP1=10RZ?)
M<V6J:<)O[-OEO("&N8RI64*N>AR"H((],$B3<K>:7Y?YAH=U_P (3X5_Z%G1
M_P#P B_^)H_X0GPK_P!"SH__ ( 1?_$UR\GCN32-6N[:&PN+Z2Z\2KI2K/??
M+&6MU?<GR?*@_N<\DG/.*O-\1X+#2M8EUZTBL+W2+R*SGB%V&@+RA3&PF94P
MI#@DLHQ@\'NNE_3\;?YH.MOZZ_Y,VO\ A"?"O_0LZ/\ ^ $7_P 31_PA/A7_
M *%G1_\ P B_^)JGX0\;VGBJ>\M(YM-DN[-4>4Z7J O8"K[MN) J\_*<@J".
M.H.:ZBFTT!A_\(3X5_Z%G1__   B_P#B:/\ A"?"O_0LZ/\ ^ $7_P 36Y7@
MOQ0LOL/B37M8\1Z#X@U"6* 2Z#JVG7!2#3@L8!#'>H1O,R>0Q;( !J;ZC2N>
MO?\ "$^%?^A9T?\ \ (O_B:/^$)\*_\ 0LZ/_P" $7_Q-<OXQDNY?#/@B34U
MVWCZSI[7 ])#][]<U5^*7BN2TUO3/#<=GK%W:W$+W>HQ:-;/-<S0J0HB7;C:
M&8G<V1\JD9YJFK.WFU]R3)3OKY)_>VCLO^$)\*_]"SH__@!%_P#$T?\ "$^%
M?^A9T?\ \ (O_B:M>'=8T_7O#]IJ.CNS6<J8C#J59=IVE6!Y!!!!![BN;U/X
MC6UAXQL=*6SU-K>2.X-PPT.]9]\90+Y>(_G7YFRRAATY&1D>CL-:JYM?\(3X
M5_Z%G1__   B_P#B:/\ A"?"O_0LZ/\ ^ $7_P 36PL@N+421A@)$W*'0HW(
M[@X(/L>:\2^$GAVS\(>*$T[7O!\^@^)KNUG\C4_M_P!HCO4# O\ *K%$894X
MQT'6DM[!IRW/5?\ A"?"O_0LZ/\ ^ $7_P 31_PA/A7_ *%G1_\ P B_^)KB
M=/\ !MAX6^*>CKX4N;MKV:&:;7VGNY)OM$6W$;R!B0',GW<8X#8'%>I4^B8=
M;#(((K:WC@MHDAAB4)''&H544#   X  [4^BBD 4444 %%%% !17SKX^L]$N
M?B]XH?5O"6OZ_>Q6EJ;&XT>.4BRD\MOF<QL-O.T@X;[IXKTR+Q?>:%\--,UD
M/8ZU:VU@KWM_+?&W,K(N'\M60EI,J?E8ISP2#T%K'F_KJ-KWN5?UM_F=]17)
M77C=_P#A*+#1M.T^*4WEFMZLEW=_9S*A.-L*[6\QQU*DK@$<\UG:[\5])T36
M;VTEGTI8M-<)>+<ZJD-R3M#?N8"I,F PZLN3D#-.SO87]?>=]17EFIZHNG>(
MO%UXC7!5KW1U!M;CR6(<JOWL'Y>>1CD9&1G-:M]\2;JS/B2=="22P\-W0AO)
MOMN)&CV*Y=$V8)&[[I8=.#GBA*Z_KR_S0=+G?45P6O?%;2M&U:ZM!/I6VP17
MNEO-52VG;<@<"&)@3(=I'4H,G ).<=S;SQW5M%/"VZ.5 Z-Z@C(I=+@24444
M %%%9K>)-#36QHS:SIZZH>EB;I///&[_ %>=W3GITH TJ*XC1O\ DMOB?_L%
M6'_H4U<KH_Q#L]0^(UQJ&NV^M)9I>OIFESK:2"PMR&\LM))P#)(^0."%&!D9
M--*[2[@]$WV_RN>PT45XSXB^(MAJOQ(\/16GB+3H-)LM7-O-#]LC#SN(GS(X
MSE45L*N>K$G^[26LE$'HF^Q[-1110!AW?_)0-)_[!=[_ .C;6MRL.[_Y*!I/
M_8+O?_1MK6Y0 45\R>*+329?'?CBX?PQX@N]=CO@+'7--CG,&GGR4^:1HVXV
M\L1L8XKVC5_&[Z!H%CK++8W^C-#$TM_]N\N2;?@;H8MA#]<X+*?3--*\4^]O
MQ!Z.WK^!V=%<O=>+YH_'2>'+33X786Z7+R7-WY+2(Q(_<)M/FE<?-EEQD=<U
MDZI\6-)TS6[JTDN-*6WLKC[/<B;58X[LMQDQV^"74$XY92<' /&4M;('H=]1
M7E<.I?V9<>(Y@;C][XQM8?\ 1[CRB=ZVZ\G!RO/*\9'&1UK3C^)UR;2ZU*;0
MECTJSUE]*N)Q>[I01*(UD6/9A@2PR"P([;J:5TK=;?DG_P"W(3=K_P!=_P#)
MGH-%<#KOQ7TG1-9O;26?2EBTUPEXMSJJ0W).T-^Y@*DR8##JRY.0,UWJ.LD:
MNARK#(/J*72X]G86BH[BXAM+:2XNI8X88E+R2R,%5% R22>  .]9#ZYI.O>&
MM1N-#U2RU*%(9$>2SN$F56V9P2I(!P1Q4R=HM]AQ5VEW-NBN%\%Z9;ZQ\#=!
ML+[[0;>;28!*MM(T;NH0$J&4@C.,<$'FLCX*-9I#XBM=(@U'3-.M[Y$MM%U/
M>)[ >6"<AR2 YR0,G]:UE&TY1[?YV)3O%2[GJ-%>6_$SP9IQ9_$5O=7G_"63
M7,4.BR"[D7RI"5 C2,';M(#,V0>-Q->G%S#;;YLL43+^6A8G YP!DGZ#FH^S
M<?6Q)17$:?\ $>VO?&E[I)L]46VC@MV@8Z'>K)O=I V_,?RK\JX8A1][DX..
MLU73XM5TJXL;EIEAG0I(8)#&Y7N PY&1QD<T.Z5PZV+=%>5?!H:?;ZIXFL=#
MM=2T?3;::$0Z)J@D$UL2I+28<DA7/09/W2>]+\9?'4.G:'J7A[3=:L]/U(V$
MD\[R7*)(J8.V.-2<M(YXXZ#)ZXR2TM;J.*N[,]4HK-\/7EM?^&].N;&XBN8'
MMTV2PN'5L  X(X/(K2IR5FT1%\R3"BBBD4%%%% !1110 4444 %%%% !6%XU
M\-'Q?X-U#05O/L1O8P@N/*\SR\,#G;D9Z>M;9$F>&7'^[_\ 7I,2?WE_[Y_^
MO2>HT[.Z//\ 3OAOKLVH0W?C'QQ=:Z]G'(M@L.GQ6:V[NA0R?)G<P5CC/2KN
M@^!-0T.^CNXM9M/,33!I_P"YTWRQ\KEDDP9&&>3N_O=1MKL\2?WE_P"^?_KT
M8D_O+_WS_P#7JK_U]_\ FQ=+?U_6AQEK\.@+756OM0C%[J-U#>>;I]K]FA@F
MBP4D6(N_S$@;B6.ZKNI>&M:U_P +WND:]K-C(UP8_+GL]->'8%<,<JTS[L[>
MQ&/>NFQ)_>7_ +Y_^O1B3^\O_?/_ ->D!Q>K_#G^U6U4_P!J>5_:&K6FI?\
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M1S0RJ4DBD4,KJ1@@@\$$=JSK;PWI.F:1=:?H>G66E0W*L'6SMDB4L5V[BJ@
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M5[-[:6[N3I4=RTD<:<#[[  LQP.#T;TJ'0?B+XENKK1]5UJPT:+PWX@N5M[
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MCN\N-V4$+)M^; SSCFN7\*ZU\0YO'DNB^+5\,M:V]F+F=](2X+(S,5C4F1L
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ME_T*6L?]_;/_ .2*W** ,/\ M_4O^A2UC_O[9_\ R11_;^I?]"EK'_?VS_\
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%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img227133604_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img227133604_11.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ('!!4# 2(  A$! Q$!_\0
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M"/\ X(K7_P"-UWU% ' _\,__  N_Z)MX1_\ !%:__&Z/^&?_ (7?]$V\(_\
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M_P#C==]10!P/_#/_ ,+O^B;>$?\ P16O_P ;H_X9_P#A=_T3;PC_ ."*U_\
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M_!%:_P#QNC_AG_X7?]$V\(_^"*U_^-UWU% ' _\ #/\ \+O^B;>$?_!%:_\
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M_P#"[_HFWA'_ ,$5K_\ &Z/^&?\ X7?]$V\(_P#@BM?_ (W7?44 <#_PS_\
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M_P"B;>$?_!%:_P#QNC_AG_X7?]$V\(_^"*U_^-UWU% 'YT?\%)OAOX1\&?\
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M>QS(PD9YEA<2PI&=L9W_ 'L4[X]^!?%S_&K6?'?A[PW>ZQ=^'= TG4-*6W
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M)-(\1-=#2M5LM3-K)Y5P+.X27R7_ +K[2=I]C6E7SG\&?@M:_"WXV6=QX?\
M"$/AGP_-X!LK.\DL;98(9;Z.Y;Y9=OWY@C'+-EB#R37T90 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P7_P %3/\
MFF/_ '%/_;2BC_@J9_S3'_N*?^VE% 'UM^S_ /\ )!OAM_V+6F_^DL==]7 _
ML_\ _)!OAM_V+6F_^DL==]0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!61X+^ /Q'N/!_Q \+:=X5U+2]#G\'3:-81^-(=)6_2Z1D-O:P7ME\TUKA9
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M33JK:IJEM"4\J;RFW9DP.6C/7_EJG]X5X1X$^#_C+PK^T1:RZ'X+U33?#/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X+_X*F?\TQ_[
MBG_MI11_P5,_YIC_ -Q3_P!M** /K;]G_P#Y(-\-O^Q:TW_TECKOJX']G_\
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M&B0AC*D;[/G(+8&0N<=J /3Z*** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /@O_@J9_P TQ_[BG_MI11_P5,_YIC_W%/\ VTHH ^MO
MV?\ _D@WPV_[%K3?_26.N^K@?V?_ /D@WPV_[%K3?_26.N^H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /@O_@J9_S3'_N*?^VE%'_!4S_FF/\
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M%_T+5K_WT_\ \51_PHGP%_T+5K_WT_\ \50!WM%<%_PHGP%_T+5K_P!]/_\
M%4?\*)\!?]"U:_\ ?3__ !5 '>T5P7_"B? 7_0M6O_?3_P#Q5'_"B? 7_0M6
MO_?3_P#Q5 '>T5P7_"B? 7_0M6O_ 'T__P 51_PHGP%_T+5K_P!]/_\ %4 =
M[17!?\*)\!?]"U:_]]/_ /%4?\*)\!?]"U:_]]/_ /%4 =[17!?\*)\!?]"U
M:_\ ?3__ !5'_"B? 7_0M6O_ 'T__P 50!WM%<%_PHGP%_T+5K_WT_\ \51_
MPHGP%_T+5K_WT_\ \50!WM%<%_PHGP%_T+5K_P!]/_\ %4?\*)\!?]"U:_\
M?3__ !5 '>T5P7_"B? 7_0M6O_?3_P#Q5'_"B? 7_0M6O_?3_P#Q5 '>T5P7
M_"B? 7_0M6O_ 'T__P 51_PHGP%_T+5K_P!]/_\ %4 =[17!?\*)\!?]"U:_
M]]/_ /%4?\*)\!?]"U:_]]/_ /%4 =[17!?\*)\!?]"U:_\ ?3__ !5'_"B?
M 7_0M6O_ 'T__P 50!WM%<%_PHGP%_T+5K_WT_\ \51_PHGP%_T+5K_WT_\
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M?\*)\!?]"U:_]]/_ /%4?\*)\!?]"U:_]]/_ /%4 =[17!?\*)\!?]"U:_\
M?3__ !5'_"B? 7_0M6O_ 'T__P 50!WM%<%_PHGP%_T+5K_WT_\ \51_PHGP
M%_T+5K_WT_\ \50!WM%<%_PHGP%_T+5K_P!]/_\ %4?\*)\!?]"U:_\ ?3__
M !5 '>T5P7_"B? 7_0M6O_?3_P#Q5'_"B? 7_0M6O_?3_P#Q5 '>T5P7_"B?
M 7_0M6O_ 'T__P 51_PHGP%_T+5K_P!]/_\ %4 =[17!?\*)\!?]"U:_]]/_
M /%4?\*)\!?]"U:_]]/_ /%4 =[17!?\*)\!?]"U:_\ ?3__ !5'_"B? 7_0
MM6O_ 'T__P 50!WM%<%_PHGP%_T+5K_WT_\ \51_PHGP%_T+5K_WT_\ \50!
MWM%<%_PHGP%_T+5K_P!]/_\ %4?\*)\!?]"U:_\ ?3__ !5 '>T5P7_"B? 7
M_0M6O_?3_P#Q5'_"B? 7_0M6O_?3_P#Q5 '>T5P7_"B? 7_0M6O_ 'T__P 5
M1_PHGP%_T+5K_P!]/_\ %4 =[17!?\*)\!?]"U:_]]/_ /%4?\*)\!?]"U:_
M]]/_ /%4 =[17!?\*)\!?]"U:_\ ?3__ !5'_"B? 7_0M6O_ 'T__P 50!WM
M%<%_PHGP%_T+5K_WT_\ \51_PHGP%_T+5K_WT_\ \50!WM%<%_PHGP%_T+5K
M_P!]/_\ %4?\*)\!?]"U:_\ ?3__ !5 '>T5P7_"B? 7_0M6O_?3_P#Q5'_"
MB? 7_0M6O_?3_P#Q5 '>T5P7_"B? 7_0M6O_ 'T__P 51_PHGP%_T+5K_P!]
M/_\ %4 =[17!?\*)\!?]"U:_]]/_ /%4?\*)\!?]"U:_]]/_ /%4 =[17!?\
M*)\!?]"U:_\ ?3__ !5'_"B? 7_0M6O_ 'T__P 50!WM%<%_PHGP%_T+5K_W
MT_\ \51_PHGP%_T+5K_WT_\ \50!WM%<%_PHGP%_T+5K_P!]/_\ %4?\*)\!
M?]"U:_\ ?3__ !5 '>T5P7_"B? 7_0M6O_?3_P#Q5'_"B? 7_0M6O_?3_P#Q
M5 '>T5P7_"B? 7_0M6O_ 'T__P 51_PHGP%_T+5K_P!]/_\ %4 =[17!?\*)
M\!?]"U:_]]/_ /%4?\*)\!?]"U:_]]/_ /%4 =[17!?\*)\!?]"U:_\ ?3__
M !5'_"B? 7_0M6O_ 'T__P 50!WM%<%_PHGP%_T+5K_WT_\ \51_PHGP%_T+
M5K_WT_\ \50!WM%>+?%KX/\ @[0?AIXDU"PT&WM;VVLI)(9HW<,C <$?-UKV
M:'_4Q_[H_E0!\'?\%3/^:8_]Q3_VTHH_X*F?\TQ_[BG_ +:44 ?6W[/_ /R0
M;X;?]BUIO_I+'7?5P/[/_P#R0;X;?]BUIO\ Z2QUWU !1110 4444 %>1?M"
M?\?7PK_['>P_]%7%>NUY%^T)_P ?7PK_ .QWL/\ T5<4 >NT444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK_H9U_\  2;_ .(IDW[7WPKA4$>(S)SC"6DQ/_H-=1_PH7X=?]"7HW_@(O\
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M,?<V,\X'' KCPN%J4:G-+8^CSW/<'F&$]C0O>Z>J]?,ZRBBBO8/SPX?XX?\
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M'_4_9/\ EC]W'SXSS7T;XE_8]^$/B[Q7J7B75?"/GZWJ5Q]JN[N/4KR$S2@
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M"O\ ['>P_P#15Q0!N?\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\
M(]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >
M??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$
M7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\
M*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1
M_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?
M^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PH
MQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@
MT4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >??\
M"5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0
M--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_
M "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )
M5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A T
MW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\
M(]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >
M??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$
M7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\
M*,?_ "/1_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1
M_P )5\1?^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?
M^A TW_PHQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PH
MQ_\ (]>@T4 >??\ "5?$7_H0--_\*,?_ "/1_P )5\1?^A TW_PHQ_\ (]=[
M<7$5K$TLTJ0Q+U>1@H'XFJ?_  D6E?\ 03L_^_Z?XTKHI1E+9''?\)5\1?\
MH0--_P#"C'_R/1_PE7Q%_P"A TW_ ,*,?_(]>@*P900<@\@BEIDGGW_"5?$7
M_H0--_\ "C'_ ,CT?\)5\1?^A TW_P *,?\ R/7H-% 'GW_"5?$7_H0--_\
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M^(O_ $(&F_\ A1C_ .1Z/^$J^(O_ $(&F_\ A1C_ .1Z]!HH \^_X2KXB_\
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MDEYI=_;:C:N,K-:RK(A_$&O(/'7C/X5^.K<P:[I!USC"RBQ;S%_W9.&'X&O
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M15++GC.<G('&?:NZHKR:&4X3#R<X0U?=M_F9JG&.J1R$_P (_!UQG?H%J/\
M<#+_ "(K.N/@1X*GSC23%_USG<?UKT"BNF6!PLOBI1^Y%<L>QY?-^SGX/D^X
ME[#_ +MR3_,&J4G[->@J2;?5-3MS[2(?_917KM%8/*L"_P#ETOR)]G'L>.']
MGEX6S:^+]4@]!R?Y,*/^%,^++7_CS\?7J>F_S/Z/7L=%1_9.#7PQ:])2_P P
M]G$\"\9:;X\^'NAR:I<^-Q-"K*BQD$N[$]!N!^OT!KS+P;XVUKPOK4EQI=W&
MEU?,(Y3<@,CDMG+9Z')Z^YKZ_P!2TFQUB%8K^SM[V)6W*EQ$L@!]0".M9_\
MP@_AP$$:#IF?^O2/_"O*Q.2UIUHSH57%+:[;?GK<SE2=[IGF_P#PGGQ/TK(O
M?!\-ZJ]7MLY/_?+'^5'_  O^\T]@NK>#M2M#W*YP/^^E%>Q#C@<"@C/!&17J
M_4\3'^'B'\TG^B-.6721Y;9_M'>$[C G%]9MW$D&['_?)-;]C\8_!NH8":[;
MQL?X9@T?\Q727GA[2]0!%UIMG<@_\]8%;^8KG[[X0^#]0R9-!M58_P 40,9_
M\=(HY,RAM.$O5-?DV'O]S=L_$^CZB ;75;*XST\JX1OY&M)6#*"#D'N*\PO?
MV=?"-T28DO+1NWE7&<?]] UF']GN6Q8MI7BW4K)NP.2!_P!\L*/K&/A\5!/T
ME_FD%Y]CV.H+R]@TZUEN;J9+>WB7<\LC851ZDUY&?AW\2M+YL/&BW2KT6YW<
M_P#?0;^=>?\ Q.\4^-K&W;PWXDO;299E69UM0NXJ#P&( QDC.".U<V(S:6&I
MN=6C*+Z7M:_JF3*IRK5'U$K!E#*<@\@BEKYX\!_%;QO=:/%8:5HL&MK8(L32
MDMY@7^'=\WH.OM72-\4/B)%]_P !.WIL\S_ UI3SC#U(*=I:_P!UO\4AJHFC
MV.BO'U^+GC.//F_#V^Q_LK)U_P"^*=_PN[7H?]?\/]6&.#M#]?\ OW6O]K81
M;MK_ +=E_D/VD3UZBO(E^/EPG^O\%ZQ%C[WRMQ^:BG#]H:S3_7>&]8B]?W8X
M'KSBC^U\#_S\_!_Y![2/<];HKRB/]HO0F^_I6K1_6%3_ .S597]H7PRV=UOJ
MB?6U_P#KU2S; O\ Y>H/:0[GIU%>*:E^T)9R^+M%CT[S!HNXI?-/%L;+< C/
M("]??->U A@"#D&NG#8RCBW)497Y2HR4MA:***[2CA_CA_R2'Q=_V#I?Y5VL
M/^IC_P!T?RKBOC@"?A#XNP,_\2Z7_P!!KM8?]3'_ +H_E0!\'?\ !4S_ )IC
M_P!Q3_VTHH_X*F?\TQ_[BG_MI10!];?L_P#_ "0;X;?]BUIO_I+'6?\ &CP;
MK'BS6OAA/I5K]IAT;Q9!J=\WF*GE6ZVMS&7PQ&[YI$&!D\].#6A^S_\ \D&^
M&W_8M:;_ .DL==]0!\H?$3X;?$V$_%7P%X>\*0:OX=^(VHF]B\4MJ4,,>D+/
M!#!=K<0,?,=E$3-'Y:L&W ';@U2@^$/Q)MM%@^#J>%8O^$,A\6IK8\;?VE!Y
M?]G+J O_ "?L^?.^T[QY7W=F/FW]J^O** /"OBOIOC?5M?\ "/CK0?!<U]J?
M@S6K^'^P9]0MHI=5L)H&@-Q!(7\M&)*.J2E#A6!VG%>:>&?AU\5/AW\0KCXQ
M1^!EU[6O$<VI1ZIX-L]6MH[G3[>8VOV4K/(5AD=1:#S0&Q^]^4MMY^P** /-
M/V=? >L_#OX6VFG^(_LZ>(+R]O=7U"&TD\R&">[NI;AH4? W!/-V;L<[<]ZX
M7]I;X9^&]7U_X=:C=V$DMY?>,;"">07<Z!D\F88"JX ^Z.0 :^A:\B_:$_X^
MOA7_ -CO8?\ HJXH VO^% ^!?^@1<?\ @SNO_CM'_"@? O\ T"+C_P &=U_\
M=KT.B@#SS_A0/@7_ *!%Q_X,[K_X[7CGQL^#.G:+XHT"Z\.Z/?NL5O,9%C>X
MNE#$J%/S%MIP&Z8Z^PKZFHKCQF'^MT)4>:U^I<9SA?D=FTU\GH_P/C3P_P""
M-:U+Q-HEG-I=_#8S7L<=VS6TBXA)PQ#$?*1P<U] Q_L^>$8^L5Y)_O7+?TKT
MJBO+PF2X;#P<:B4WW:,%3CRJ+2T/.U^ G@U5P;&=O=KE_P#&IU^!O@I&S_8^
M?]ZXE(_]"KO:*]!9?@UM1C]R'R1['$I\%_!<8(_L*%O]Z1S_ .S5,OPA\&KC
M'A^T./4$_P!:["BK^I85;4H_<A\L>QQ\_P '_!=RH63PW8L <\1X_E5&;X"_
M#^X?>_A>R+8Q_$/ZUWU%:+"T%M37W(.5=CYDN_V<_$*WES_9UGI>GV+2LT-M
M'<N5C4DD 94FNT\"?L_Z='ILZ^*M-2:_\W*36FI7*ATP."%=0,=.!TKV>BN#
M#970PE9UZ;=WY]R8TU%W1YY_PH'P+_T"+C_P9W7_ ,=H_P"% ^!?^@1<?^#.
MZ_\ CM>AT5[!H>>?\*!\"_\ 0(N/_!G=?_':/^% ^!?^@1<?^#.Z_P#CM>AT
M4 >>?\*!\"_] BX_\&=U_P#':/\ A0/@7_H$7'_@SNO_ ([7H=% 'GG_  H'
MP+_T"+C_ ,&=U_\ ':/^% ^!?^@1<?\ @SNO_CM>AT4 >>?\*!\"_P#0(N/_
M  9W7_QVC_A0/@7_ *!%Q_X,[K_X[7H=% 'GG_"@? O_ $"+C_P9W7_QVC_A
M0/@7_H$7'_@SNO\ X[7H=% 'GG_"@? O_0(N/_!G=?\ QVC_ (4#X%_Z!%Q_
MX,[K_P".UZ'10!YY_P *!\"_] BX_P#!G=?_ !VC_A0/@7_H$7'_ (,[O_X[
M7H=% 'GG_"@? QY.DW!/_83N_P#X[1_PH'P+_P! BX_\&=U_\=KT.B@#SS_A
M0/@7_H$7'_@SNO\ X[1_PH'P+_T"+C_P9W7_ ,=KT.B@#SS_ (4#X%_Z!%Q_
MX,[K_P".T?\ "@? O_0)N/\ P9W?_P =KT.B@#SQ_@!X%D7#Z/,X]&U*Z/\
M[5J&R_9Q^&^GWGVJ'PK;?:/^>DDLLA_\><UZ3142A&:M)7 ^3_%OP]\07_B3
M4)M,\(W=EI_FE8(88@%V#@'KWQG\:]*^%/PQTW4/#,L'B?PDD-_%(4,EW'S,
MAY!Z]1T_"O9J*\##Y)0H5W6;YKWT:5M?D8QI*+N>8W7[-/PSO)_.E\)VOF_W
MDFE3^3BIXOV>/A_;J!%H3QCT2_N1_*2O1Z*]^-.$/A5C6QYZWP#\#,I4Z3<%
M3P5.IW6/_1M<[K7[(WPNU;2WM(/#BZ2[,7^U6$KI+N/4DDG=_P "!KV2BMX5
M)TWS0=F4I-;'QWXI_9&\;>%YH;KPGXDD\26-J#Y6DZE=S0 *>2-JR"-OK\IK
M%T[Q[X;\'WRZ?\3OAEJOA^X)Q]LL[Z\,3>X1I>1_NLU?;U5-4TFRUNSDM-0L
MX+ZUD&&AN(Q(A^H(Q79]:C4_CP4O/9FG/S?$CQOP7X3^"_Q&@#Z#)%J38R;?
M^U;H2K]8VD##\J3P[X+^#/BSQ-JWA_2HH[S5=,(%S FHW/'KM/F8;!X.,X/!
MKG_BY^Q_H.J:;<ZIX%@.@>(X?WD4,,S)!-CJH&?W9/8C ![8KXZT.XUKP+XP
MANTFN_#^I:9=K'/<F)BUJQ;#!U[\9^4_>&:ZJ."H8F,I4YOT9I&G&:;3/T2_
MX4!X%_Z!$_\ X,KK_P".T?\ "@? O_0(N/\ P9W7_P =KLO#NL6GB#0['4;&
M^AU*UN(5=+N#[DO'W@.W/;MTK1KQFK.S.8\\_P"% ^!?^@1<?^#.Z_\ CM'_
M  H'P+_T"+C_ ,&=U_\ ':]#HI >>?\ "@? O_0(N/\ P9W7_P =H_X4#X&'
M32;@?]Q.[_\ CM>AT4 >??\ "A/ _P#T"KG_ ,&=W_\ ':YC7/V:=/O-0:32
MM2?2;(@8M662XPW=MTDA//MCI7M%%<V(PU+%P]G65UZM?D3**DK,\:\/_LVZ
M;8WI;5]0DU>R*$?9E\VVPW&&W1RC)&".<]371?\ "@? O_0(N/\ P9W7_P =
MKT.BC#X>EA:?LJ*M'YO\PC%15D>>?\*!\"_] BX_\&=U_P#':/\ A0/@7_H$
M7'_@SNO_ ([7H=%=)1YY_P *!\"_] BX_P#!G=?_ !VC_A0/@7_H$7'_ (,[
MK_X[7H=% 'GG_"@? O\ T"+C_P &=U_\=H_X4#X%_P"@1<?^#.Z_^.UZ'10!
MYY_PH'P+_P! BX_\&=U_\=H_X4#X%_Z!%Q_X,[K_ ..UZ'10!YY_PH'P+_T"
M+C_P9W7_ ,=H_P"% ^!?^@1<?^#.Z_\ CM>AT4 >>?\ "@? O_0(N/\ P9W7
M_P =H_X4#X%_Z!%Q_P"#.Z_^.UZ'10!YY_PH'P+_ - BX_\ !G=?_':/^% ^
M!?\ H$7'_@SNO_CM>AT4 >>?\*!\"_\ 0(N/_!G=?_':/^% ^!?^@1<?^#.Z
M_P#CM>AT4 >>?\*!\"_] BX_\&=U_P#':/\ A0/@7_H$7'_@SNO_ ([7H=%
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M+_T"+C_P9W7_ ,=H_P"% ^!?^@1<?^#.Z_\ CM>AT4 >>?\ "@? O_0(N/\
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M3LO9T_\ 07%1_P#"@? O_0(N/_!G=?\ QVO0Z*JG3A1CR4XI+RT!)+1'GO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]_X'Z;_\E4?\)_XH_P"B9:]_X'Z;_P#)5 '>45P?_"?^*/\ HF6O?^!^F_\
MR51_PG_BC_HF6O?^!^F__)5 '>45P?\ PG_BC_HF6O?^!^F__)5'_"?^*/\
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M>=_M"?\ 'U\*_P#L=[#_ -%7%>NUY%^T)_Q]?"O_ +'>P_\ 15Q0!Z[1110
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MX->B5\%_M:Z7!X#^*C3^'+&_\.MJ=FQN[JW<Q07A?[XCV^WWQW)!QW/K4?\
M;;49_$MG^C-X_O/=>Y]Z45\3_!#]L*7P9X>31_&-K?:M96N([;4K<!Y43'$<
MFXC=CL<YQQS7O7AW]K#X8^(@H7Q&NGR-QY>H0O"?S(V_K6%7!5Z3:Y;KNB94
MY1Z'KU%96C>*M%\11J^E:M8ZDC#(-K<))_(UJUPM-:,R"BBBD 4444 %%%%
M!1110 4444 %%%% !1110 45'/<16L+S32+#$@W-)(P55'J2>E>'?$/]KSP?
MX3G;3M"$OB[6B=B6^F\Q;NF#)@Y^BAJVIT:E9VIJY48N6Q[K7E7Q*_:6\#?#
M/S8+K4QJFJ+Q_9^FXED#>C'.U/Q.?:O*?^$5^-WQ^^;7K]?A]X8F_P"7* %9
MG3T*@[S_ ,#91[5ZI\-?V9? WPU\NXM]-&K:HO)U#4@)7#>JKC:GX#/O75[*
MC1_BRN^R_5_Y%\L8_$SRH^+OC;\?OD\/:>O@#PQ+Q]NN"5F=3W#$;C_P!0/>
MNV^'O[(7A#PK<+J.OM-XOUICO>?43F+=UR(\G/U8M7NU%3+%SMRTERKR_5[@
MZCVCH1V]O%:0I#!$D,,8VI'&H55'H .E2445PF04444 ,EB2:-HY$62-AAE8
M9!'H17G'B_\ 9S^'?C;S'O\ PS:P7#];BQ!MY/K\F ?Q!KTJBM(5)TW>#L--
MK8^8[O\ 8]U/PK</=_#WQ_JF@S9RMO<L2GT+(1G\5-1?\)3^T1\,SC5-"LO'
M.GQ\>=: -*0._P FUL_5#7U#177]<G+2JE+U6OWFGM']I7/G/0/VV/#+7(LO
M%6AZMX5O0<.)H3*@/?H P_[YKV+PI\4_"/CB-6T/Q%I^H,W_ "RCG D_[X.&
M_2M77_">B^*K8V^LZ39ZI"1C;=P+)^61Q7C'C+]C+P'KT<T^C0W/AS4=I,+V
M<[&)7QP2C9XS_=(-%\+4W3@_O7^8>Y+R/8-2\<:#I'B33M O=5MK;6=05FM;
M.1\22@=<#^6>N#C-;E?EKXP\'^+?#/CS^P]7BO9?$D<B1V[*[R23<XC:)NI'
MH1T]L5]0Z;\;_C+\-]/MX/&'P\N-<M8$"OJ%KGS6 [NR;U+?@*ZJV7\L8NG-
M._HON+E1M:S/JFBOGWP[^VQX#U*18-7AU+P[<YPRW=OO13]4R?S KUCPS\4_
M"'C!5.C>)--OV;I''<*)/^^"0P_*O.J8>M3^.+1DX2CNCJJ***YR HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A_C
MA_R2'Q=_V#I?Y5VL/^IC_P!T?RKBOCA_R2'Q=_V#I?Y5VL/^IC_W1_*@#X._
MX*F?\TQ_[BG_ +:44?\ !4S_ )IC_P!Q3_VTHH ^MOV?_P#D@WPV_P"Q:TW_
M -)8Z[ZN!_9__P"2#?#;_L6M-_\ 26.N^H \6E_:;M6\:2:98^"/%.J^&;?5
MAH5SXOLK:*2PAO=XC9-@D\YXTD(1YEC**P8$_*34#?M6:.OC;^S#X7\0#PK_
M &W_ ,(U_P )IY4/]F?VEO\ +\G'F>;L\S]UYWE^7O\ EW5\\6?[/^L>&_&=
MQH]A\-M>?XB+XQ?6-+^)T=ZHT^VTN2^^T.I?S0RCR6EA:T\LAV);G=FNQN/"
M'CB71G^"Z^!-56W;QO\ VX/&!\DZ4-+_ +5_M'S-_F;_ +1_RQ\K9G=\V<4
M?0'Q8^,L?PSO=#TBP\-:MXS\4:V9C8:'HODK*\<*JTTSR32)'&BAE&6899U
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M,K"%X[;6;J&)!Y,XRD:R!4;C[R@'D\\F@#Z!HK@_^%-Z3_T'/%O_ (5&H?\
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M4WI/_0<\6_\ A4:A_P#'J .\HK@_^%-Z3_T'/%O_ (5&H?\ QZC_ (4WI/\
MT'/%O_A4:A_\>H [RBN#_P"%-Z3_ -!SQ;_X5&H?_'J/^%-Z3_T'/%O_ (5&
MH?\ QZ@#O**X/_A3>D_]!SQ;_P"%1J'_ ,>H_P"%-Z3_ -!SQ;_X5&H?_'J
M.\HK@_\ A3>D_P#0<\6_^%1J'_QZC_A3>D_]!SQ;_P"%1J'_ ,>H [RBN#_X
M4WI/_0<\6_\ A4:A_P#'J/\ A3>D_P#0<\6_^%1J'_QZ@#O**X/_ (4WI/\
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MFB1O^6EM%Y#?7,>*F_X4WI/_ $'/%O\ X5&H?_'J/^%-Z3_T'/%O_A4:A_\
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MA_\ 'J .\HK@_P#A3>D_]!SQ;_X5&H?_ !ZC_A3>D_\ 0<\6_P#A4:A_\>H
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M9^*[5>MQIX!<CN?W9_F@KV/_ (4WI/\ T'/%O_A4:A_\>H_X4WI/_0<\6_\
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M9WUQ:SW%K#//:N9())(PS1,1@E21\IP2.*M444 %%%% !1110 4444 %%%%
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M>1?M"?\ 'U\*_P#L=[#_ -%7% 'KM%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>&O#]UI6I:W?R>'[][&ZO'@>VBBA$\9#H@-PSD*1G:H/&0?)O 5[XG^,^O\
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MC+_P71__ !VC_A;\O_0A>,O_  71_P#QVO0Z* ///^%OR_\ 0A>,O_!='_\
M':/^%OR_]"%XR_\ !='_ /':]#HH \\_X6_+_P!"%XR_\%T?_P =H_X6_+_T
M(7C+_P %T?\ \=KT.B@#SS_A;\O_ $(7C+_P71__ !VC_A;\O_0A>,O_  71
M_P#QVO0Z* ///^%OR_\ 0A>,O_!='_\ ':/^%OR_]"%XR_\ !='_ /':]#HH
M \\_X6_+_P!"%XR_\%T?_P =H_X6_+_T(7C+_P %T?\ \=KT.B@#SS_A;\O_
M $(7C+_P71__ !VC_A;\O_0A>,O_  71_P#QVO0Z* ///^%OR_\ 0A>,O_!=
M'_\ ':/^%OR_]"%XR_\ !='_ /':]#HH \\_X6_+_P!"%XR_\%T?_P =H_X6
M_+_T(7C+_P %T?\ \=KT.B@#SS_A;\O_ $(7C+_P71__ !VC_A;\O_0A>,O_
M  71_P#QVO0Z* ///^%OR_\ 0A>,O_!='_\ ':/^%OR_]"%XR_\ !='_ /':
M]#HH \\_X6_+_P!"%XR_\%T?_P =H_X6_+_T(7C+_P %T?\ \=KT.B@#SS_A
M;\O_ $(7C+_P71__ !VC_A;\O_0A>,O_  71_P#QVO0Z* ///^%OR_\ 0A>,
MO_!='_\ ':/^%OR_]"%XR_\ !='_ /':]#HH \\_X6_+_P!"%XR_\%T?_P =
MH_X6_+_T(7C+_P %T?\ \=KT.B@#SS_A;\O_ $(7C+_P71__ !VC_A;\O_0A
M>,O_  71_P#QVO0Z* ///^%OR_\ 0A>,O_!='_\ ':/^%OR_]"%XR_\ !='_
M /':]#HH \\_X6_+_P!"%XR_\%T?_P =H_X6_+_T(7C+_P %T?\ \=KT.B@#
MSS_A;\O_ $(7C+_P71__ !VC_A;\O_0A>,O_  71_P#QVO0Z* ///^%OR_\
M0A>,O_!='_\ ':/^%OR_]"%XR_\ !='_ /':]#HH \\_X6_+_P!"%XR_\%T?
M_P =H_X6_+_T(7C+_P %T?\ \=KT.B@#SS_A;\O_ $(7C+_P71__ !VC_A;\
MO_0A>,O_  71_P#QVO0Z* ///^%OR_\ 0A>,O_!='_\ ':/^%OR_]"%XR_\
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MR_\ !='_ /':]#HH \\_X6_+_P!"%XR_\%T?_P =H_X6_+_T(7C+_P %T?\
M\=KT.B@#SS_A;\O_ $(7C+_P71__ !VC_A;\O_0A>,O_  71_P#QVJ>E_%;Q
M+XDMY;W1?A]=W^F?:9[>&ZDU2VB,OE2O$S;"V5!9#@'G&*N?\)SXZ_Z)G<?^
M#JT_QH /^%OR_P#0A>,O_!='_P#':/\ A;\O_0A>,O\ P71__':/^$Y\=?\
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M.O\ HF=Q_P"#JT_QH /^%OR_]"%XR_\ !='_ /':/^%OR_\ 0A>,O_!='_\
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M+_P71_\ QVC_ (3GQU_T3.X_\'5I_C1_PG/CK_HF=Q_X.K3_ !H /^%OR_\
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M_P!3'_NC^5 'P=_P5,_YIC_W%/\ VTHH_P""IG_-,?\ N*?^VE% 'UM^S_\
M\D&^&W_8M:;_ .DL==]7 _L__P#)!OAM_P!BUIO_ *2QUWU !1110 4444 %
M>1?M"?\ 'U\*_P#L=[#_ -%7%>NUY%^T)_Q]?"O_ +'>P_\ 15Q0!Z[1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU)KE?AK\6O']YXX\.V_BWXH_\(YXNOM02#4/A]XF\+#3[!D+-O@L+S9NFE"
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MG,BA-+MH\>5=229VM'<;H_*VY+;FR!L;'L5 !1110 5P?P3_ .1$?_L,ZO\
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MX$VO_P CT?\ "I[W_HH?C#_P)M?_ )'KT&B@#S[_ (5/>_\ 10_&'_@3:_\
MR/1_PJ>]_P"BA^,/_ FU_P#D>O0:* //O^%3WO\ T4/QA_X$VO\ \CT?\*GO
M?^BA^,/_  )M?_D>O0:* //O^%3WO_10_&'_ ($VO_R/1_PJ>]_Z*'XP_P#
MFU_^1Z]!HH \^_X5/>_]%#\8?^!-K_\ (]'_  J>]_Z*'XP_\";7_P"1Z]!H
MH \^_P"%3WO_ $4/QA_X$VO_ ,CT?\*GO?\ HH?C#_P)M?\ Y'KT&B@#S[_A
M4][_ -%#\8?^!-K_ /(]'_"I[W_HH?C#_P ";7_Y'KT&B@#S[_A4][_T4/QA
M_P"!-K_\CT?\*GO?^BA^,/\ P)M?_D>O0:* //O^%3WO_10_&'_@3:__ "/1
M_P *GO?^BA^,/_ FU_\ D>O0:* //O\ A4][_P!%#\8?^!-K_P#(]'_"I[W_
M **'XP_\";7_ .1Z]!HH \^_X5/>_P#10_&'_@3:_P#R/1_PJ>]_Z*'XP_\
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M_P#10_&'_@3:_P#R/1_PJ>]_Z*'XP_\  FU_^1Z]!HH \^_X5/>_]%#\8?\
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M?LT?$"&;Q3I>G_&231_!GB+4[[4+G3;'PY"M_$MW*TDL<5XTK;3\Y ?RR1V
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M5@2N#+Y,2QQ@DY.U0HYXK"\8_LXQ>+M-^)UHVORVH\;R:>[NMJ&^Q_98H8P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \N^$NN6GAGX.?VG?N8[2VO=2>1E4L<?;YQP![D4?
M\-'^#O\ GI>_^ Q_QJY\#8([GX7V\4T:RQ/?ZD&1U!4C[?<<$&NQ_P"$6T7_
M *!%A_X#)_A7!B(8J4E[":2\TW^J(ES=#RRX_:/TO_A)K0013-H7DM]HD:'$
MOF'[NT9Z#'_CWM6M_P -'>#O^>E[_P" Q_QJC=?LV:-=7,T[:OJ >1V<[1$
M"3G@;:]&M?".CV]M%$VF6<S1H%,CVT>YL#&3@=37DX>&;R<O:2BOE?\ )Z&<
M?:=3Y]_:$^*_B?Q!X?\  %U\)=5:VUJ;Q6D#VET@2+4%CM+B=K.7/191&%W
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M^+O^P=+_ "KM8?\ 4Q_[H_E7%?'#_DD/B[_L'2_RKM8?]3'_ +H_E0!\'?\
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M "-1_P -0> /^>_B#_PE-5_^1J /6**\G_X:@\ ?\]_$'_A*:K_\C4?\-0>
M/^>_B#_PE-5_^1J /6**\G_X:@\ ?\]_$'_A*:K_ /(U'_#4'@#_ )[^(/\
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M '_/?Q!_X2FJ_P#R-0!ZQ17D_P#PU!X _P">_B#_ ,)35?\ Y&H_X:@\ ?\
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ML9[Y/$%C?2P(\]K_ ,(OJC>3(5!9,BVYP<C/M5O_ (:@\ ?\]_$'_A*:K_\
M(U 'K%%>3_\ #4'@#_GOX@_\)35?_D:C_AJ#P!_SW\0?^$IJO_R-0!ZQ17D_
M_#4'@#_GOX@_\)35?_D:C_AJ#P!_SW\0?^$IJO\ \C4 >L45Y/\ \-0> /\
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M_P#D:@#UBBO)_P#AJ#P!_P ]_$'_ (2FJ_\ R-1_PU!X _Y[^(/_  E-5_\
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M (:@\ ?\]_$'_A*:K_\ (U9>A?M7^$;YM2_M&U\0:<(;R2&V_P"*8U1_M$
MVR\6W&<G@\\4 =3_ ,*AG_Z'_P 9?^!\7_QFC_A4,_\ T/\ XR_\#XO_ (S6
M5_PU!X _Y[^(/_"4U7_Y&H_X:@\ ?\]_$'_A*:K_ /(U &K_ ,*AG_Z'_P 9
M?^!\7_QFC_A4,_\ T/\ XR_\#XO_ (S65_PU!X _Y[^(/_"4U7_Y&H_X:@\
M?\]_$'_A*:K_ /(U &K_ ,*AG_Z'_P 9?^!\7_QFC_A4,_\ T/\ XR_\#XO_
M (S65_PU!X _Y[^(/_"4U7_Y&H_X:@\ ?\]_$'_A*:K_ /(U &K_ ,*AG_Z'
M_P 9?^!\7_QFC_A4,_\ T/\ XR_\#XO_ (S65_PU!X _Y[^(/_"4U7_Y&JAX
M@_:L\&V&@ZE<Z9#X@U+48;:22VLO^$7U1/M$H4E(]QML#<P R>F: .D_X5#/
M_P!#_P",O_ ^+_XS1_PJ&?\ Z'_QE_X'Q?\ QFLB']J+P$T2,\OB!'*@LO\
MPBNJ\'T_X]J=_P -0> /^>_B#_PE-5_^1J -7_A4,_\ T/\ XR_\#XO_ (S1
M_P *AG_Z'_QE_P"!\7_QFLK_ (:@\ ?\]_$'_A*:K_\ (U'_  U!X _Y[^(/
M_"4U7_Y&H U?^%0S_P#0_P#C+_P/B_\ C-'_  J&?_H?_&7_ ('Q?_&:RO\
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M\&D64US<PQR33&>\E\R:2265Y9'9L#)+NQZ=ZX'_ (:@\ ?\]_$'_A*:K_\
M(U'_  U!X _Y[^(/_"4U7_Y&H Z#XX?\DA\7?]@Z7^5=K#_J8_\ ='\J^>OC
M%^T5X3UWX5^*M/T6'Q#J>L7&G31V=F/#&IH9Y2IV)N:W &3@9)P,U]!VI9K:
M(LNQM@ROH<=* /A#_@J9_P TQ_[BG_MI11_P5,_YIC_W%/\ VTHH ^MOV?\
M_D@WPV_[%K3?_26.N^K@?V?_ /D@WPV_[%K3?_26.N^H *\+/[*>GGQG]M/B
M[7?^$,_MS_A)O^$)_<?8/[2\SS?-W^7YWE^;^]\G?LW_ #8[5[I10!Y%XZ^
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M#XD^)O"LNEWGAWX>7,*W7A=K1GNM8LS:0W4UQ'<;_P!VQCF;R@$(8Q$-][@
M^G**H:#K=GXET/3M7TZ9;G3]0MH[NVF7I)%(H9&'U!!J_0 4444 %%%% !15
M"]U[3=.^U"ZO[:!K6!KF=9)5#1Q*,F1AG(48Z]*\+U/]L;03X?UB[T[P[X@@
MN?\ A'+[Q'X?EUBQ^S6FO6]M$)&:W<,6QAHVPZHQ1PP!% 'T'17S]\.?BEXS
MT'QQX*T3QQJ^E>)=)\>:6]_HNLZ78FS%O>1Q+-)9LN]PZ-"QDCDR&/E.&!X-
M?0- !1110 4444 %%(S!023@#DDUQOQ!^+&A_#OP[8ZK<?:-7;4KR/3M,L=(
M03W&H73[BL,(R%)PCL26"@(Q) % '9T5\V?$;]I7Q3KGPDUS4OA=X.U*7QKH
M^IO8ZGI6N0)&=+^SQK<W'G;796\R#"Q%"P9IHSV./?/!_BG3_''A/1O$6E2^
M?IFK6<-];2?WHY$#J?K@B@#7HHHH **** "BBH+F]M[/R_M$\4'F.(T\QPNY
MCT49ZD^E $]%>0?$O]IKP_\ #76M9TY]#\0^(?\ A'[2*_U^ZT.R6:'1[>0$
MK).6=23L5I"D8=@BEB.F<>;XX>)+7]H[0=#N='6U^&&NV;:?I>M2XW7NK"$7
M8:/!_P!0;?>@)P6D1@.E 'N]%%% !1110 4444 %%4KK6K"Q2\:>]@B%G$9[
MG=(,PQ@$[F'88!.3Z5Y!X=_:JT+Q-?VUM;>%O%,"ZII5SK'AZ>YL%1-?AA0.
MPM?WA;>RLC*L@0LK CO@ ]LHKQS]F?XH>*?B!X?\0Z;X_P!/MM'\>>'M5DM-
M2T^U.4CBE5;BT((ZCR)HU+#JT;U['0 4444 %%%% !139)%C1G=@B*,EF. !
MZFN*^(GQ=T3X=Z1I-W+%>:Y=ZS=K8Z5INBQK<7%_.59]L8W!<!$=F9F"JJDD
MT =O17S3\3/VG/$E[\)[CQ%\-?"&I7.LZ1J4\?B"PUBW6-])AL@LU[%* Q!E
MDBPL6PL'\U6!P*^B-#UJS\2:)I^KZ=.MSI]_;QW5M,AR)(G4,C#V((- %ZBB
MB@ HHHH ***AN+RWM&B6>>.%IG\N,2.%+L>BC/4^PH FHKQSXB?M0^&_ASK6
MN6<^C:_K-EX=$+>(=6TFS66UT995#J9R75FPC+(PC5RJ$,<<"LZU^,_BF#]I
MJ#PMJVBC2_A]K%E-9Z#J,P'FWVIVZK/,PP3B%H9"$SU-O(>A% 'NE%%% !11
M10 4444 %%9NI^)-+T>PU.]O=0M[>VTN!KF]D:0?Z/&JEV9P.0 H)^@KR+0?
MVJM*\132VUKX-\6V][=:+-KVA6]]8)"VO6\6W(MOWA(<^9&=D@1MLBG'7 ![
M?17D'[,GQ+\3?$+P/J%KX\M;73_B!X>U.?2M=L[(YA248EB9/56AEB(;H3G%
M>OT %%%% !1110 44R25(8WDD=8XT!9F8X  ZDGTKB?B'\7=(^'UKHG^BWWB
M'5-=G-MI.DZ+&LUQ?.L;2.4W,J!%169G9@H ZY(! .YHKYF^)G[4NNR_"VQ\
M8_#SPMJ%S#I>ISOXK@U:W6*72+.QD']H02+N/^D%20@4L" S9P.?I*QOH-3L
M;>\M95GM;B-98I4.5=& *L/8@B@">BBB@ HHHH ***@GO;>UDACFGBADF;9$
MLCA2[=<*#U/TH GHKQKQQ^U-X8\":]JMG<:3KVHZ3H=W;V.N>(-/LUDL-)FF
MV;$F<N&) EB9_+5]@=2V*IZ#\9/%3?M+7_@_Q!H9T7P;JEE-'X8NKA0)[VZL
MRIO&."<(Z3*8\\E8';H: /<:*** "BBB@ HHHH **Q]>\8:+X9T/6=7U+4K>
MVT[1K>2ZU"8ON^S1HA=F<#)&%!.,9KRK3?VH+;7/[4L+/P/XKM?$:Z*VNZ/I
M&I6<<,FLVX98PT)$C!2'DB#+)M9!(I(ZX /;:*\I_9K^(NO_ !#^&[?\)C%:
MVWCG0[^XT7Q!;V8Q"EY"_6/_ &'C:*13Z.*]6H **** "BBB@ HIDTT=M#)-
M-(L44:EGD<@*H')))Z"N"^('QHT?P'+HUG#8:IXKUG6$EFL-)\.P)<W$\,04
MRS99U18UWH-S.,EU R3B@#T"BOF[XN?M+:[_ ,*D\,_$'X7Z)-K7A[S6U;7K
MN\A\HV>EVLFV^@*-\PNLAT"XX,4A)^49^BK&^M]3L;>\M95GM;B-9HI4.5=&
M *L#Z$$&@">BBB@ HHHH ***KW&H6MG-!#/<PP37#;88Y) K2$=0H)Y/TH L
M45X]?_M2>$[#Q>='.GZ[-ID>LKX>G\316&=*@U%F""V>7=NSYA$9<(4#G:6!
MS5#P_P#%_P 6_P##2NH^$?$>B#1?!VJ6<R>%[B?;Y]Y<V;*;QVP3A'69&C!Y
M*P.V.: /<**** "BBB@ HHHH **YOQA\1/#O@7PSK>OZQJ<,&FZ-'YEZT9\U
MXNRKL7+%F) "XR20!7 V/[14?B#3_%MGIG@OQ-;>--$T^._A\+ZM9I;W=[',
M66"2(B1D,;2(RLV[*%6W 8H ]BHKRG]FGXAZ_P#$#X;E?&*VT7CK0K^XT3Q#
M#9C$*WD+<L@_N/&T4B^JR"O5J "BBB@ HHHH ^"_^"IG_-,?^XI_[:44?\%3
M/^:8_P#<4_\ ;2B@#ZV_9_\ ^2#?#;_L6M-_])8Z[ZN!_9__ .2#?#;_ +%K
M3?\ TECKOJ "BBB@ HJF=8L!J<FG?;;?^T(X!=/:>:OFK"6*B0IG(4E6&<8R
M#Z5XOX3_ &I;7Q=XD\+6J^%-6TOPUXPENK7PWXEN7A,5]-#'))AH0QDB5TBE
M="X^8)R%R,@'NE<[JWQ!\/Z'XST#PG?:G#;^(=>BN)M.L6SON$@56F(_W0P/
M/]*^8_'7BKXD:S\(?AK\8XM<CBTGPG9V^OZYI5C&RS:L^\17H<#Y1%';-/(J
M@$EP.FT&NW_:2^&ME=:&/C#X4TY]7\=>')+'6;*>W9II+JRMV9IK6$9.%E@F
MN!M0?.S(3D@8 -?7/&OQ!^(7BJY\,^#_ +/X6L=-URZT_5_$C11WDEO#%:6\
M\/EPR$+OF:XVY(8*L;<988\6T37O^%M:S\'M6^*]IIGBSPMJTGB#PM'>7-J%
MTZ[OEN-ME?"!B51KF"WF53V9\(?G%>M:Y\/_ !AXNT/XX:=X9N%\.3>+C:RZ
M/JU\K!!YMA!#.^U?G5@(V'0$-CTK;\ _L_36/@V?PWX]URV\:Z')906$/AV/
M28;32;&&+&Q8(ANDR,##O(S?*,8Q0!\U:QX@?PW\*=4^%OV#6-9.H>-KOP=J
M&LZ'827^I76BVL2SB-V0%GF^SR1V09SA1DD_*:]L?X6^+O&UQ>>,?":?\*HO
MO$.FC0]8T'Q%91WPFM(@ZVUT$@F"Q7")(Z@%V4J0K#Y17NOA/P?HG@/0;?1?
M#VEVNCZ5;Y,=K9QA$!)RS8'4DDDD\DG)K8H P/ '@ZT^'?@7P[X5T^226QT/
M3K?38))CEVCAC6-2V.Y"C-;]%<%\0OC)HO@7PA8:Y;I)XE.JWT6E:39Z.Z2/
M?W<C,J1(Y8(.5<LS, H1B>F* .]HKY^D_:&U?7I-.T^+1[CP?XBL?%]OX=US
M2]0\JY$:W%K))!)'(A*NCEH&##!X92!7$1V?BK]F_P"(?A?5?$E[XIU_PC?6
M,>D^*O$\NJ?:;6XU:ZFB2"X6S>0M:Q)(63=$  )XUVD*6H ]PUKXX:&_P_\
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MQ3U6'XE+-<1W,4-QID-E:V#(N%6UCC^:,#)&XNS$<9QG(!\W:QX[U+Q'\ _
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M@*HC4!$7!"UZQ\._A#X+^$MM>0>#_#>G^'H[QP\_V*+:9,9V@GKM7)PO1<G
M&: /*/V5X[^^^'T^@ZOX)UVTL]0BGO\ 5]>\10)9G5]0NG+W6RT+&58R78*9
M%7Y548/6O5_A'X!D^%GPU\/^$7U:;6TT6V%E#>W$81VA0D1*0"?N1[$SWVY[
MUU]% !169XH\2:?X.\-ZMKVJS?9M+TNTEO;J;:6V11H7=L#DX53P*\B\-_M#
M77CZR\1Z7#X7UCP;X@3PV?$.D-JH@F6YM9%=89OW3N%8.HS$^",CKS@ ]PK
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M +BG_MI11_P5,_YIC_W%/_;2B@#ZV_9__P"2#?#;_L6M-_\ 26.N^K@?V?\
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M.)/$=[<ZW=1R7\>JOH4VJS/I37L>W9<?9B=N\%4('W-RAMN1FO4:* "BBB@
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M[^U9[.ZU36=7U9XWU#6M<O&N[VZ\M2L2NYP B*2%50 ,DXR23W"J%4 # '
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^"_\ @J9_S3'_ +BG_MI11_P5
M,_YIC_W%/_;2B@#ZV_9__P"2#?#;_L6M-_\ 26.N^K@?V?\ _D@WPV_[%K3?
M_26.N^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@O_@J9_P T
MQ_[BG_MI11_P5,_YIC_W%/\ VTHH ^MOV?\ _D@WPV_[%K3?_26.N^K@?V?_
M /D@WPV_[%K3?_26.N^H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@=_T._\ Y2;[_P",4?\ #=GP._Z'?_RDWW_QBBB@ _X;L^!W_0[_ /E)OO\
MXQ1_PW9\#O\ H=__ "DWW_QBBB@ _P"&[/@=_P!#O_Y2;[_XQ1_PW9\#O^AW
M_P#*3??_ !BBB@ _X;L^!W_0[_\ E)OO_C%'_#=GP._Z'?\ \I-]_P#&***
M#_ANSX'?]#O_ .4F^_\ C%'_  W9\#O^AW_\I-]_\8HHH /^&[/@=_T._P#Y
M2;[_ .,4?\-V? [_ *'?_P I-]_\8HHH /\ ANSX'?\ 0[_^4F^_^,4?\-V?
M [_H=_\ RDWW_P 8HHH /^&[/@=_T.__ )2;[_XQ1_PW9\#O^AW_ /*3??\
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MH /^&[/@=_T._P#Y2;[_ .,4?\-V? [_ *'?_P I-]_\8HHH /\ ANSX'?\
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M?_RDWW_QBBB@ _X;L^!W_0[_ /E)OO\ XQ1_PW9\#O\ H=__ "DWW_QBBB@
M_P"&[/@=_P!#O_Y2;[_XQ1_PW9\#O^AW_P#*3??_ !BBB@ _X;L^!W_0[_\
ME)OO_C%'_#=GP._Z'?\ \I-]_P#&*** #_ANSX'?]#O_ .4F^_\ C%'_  W9
M\#O^AW_\I-]_\8HHH /^&[/@=_T._P#Y2;[_ .,4?\-V? [_ *'?_P I-]_\
M8HHH /\ ANSX'?\ 0[_^4F^_^,4?\-V? [_H=_\ RDWW_P 8HHH /^&[/@=_
MT.__ )2;[_XQ1_PW9\#O^AW_ /*3??\ QBBB@ _X;L^!W_0[_P#E)OO_ (Q1
M_P -V? [_H=__*3??_&*** #_ANSX'?]#O\ ^4F^_P#C%'_#=GP._P"AW_\
M*3??_&*** #_ (;L^!W_ $.__E)OO_C%'_#=GP._Z'?_ ,I-]_\ &*** #_A
MNSX'?]#O_P"4F^_^,4?\-V? [_H=_P#RDWW_ ,8HHH /^&[/@=_T._\ Y2;[
M_P",4?\ #=GP._Z'?_RDWW_QBBB@ _X;L^!W_0[_ /E)OO\ XQ1_PW9\#O\
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:]H?:/]!N8MF_[-M_UD:YSL;IGI1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>fdmt-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-28T16:37:34.3394+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="fdmt-20211231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="fdmt-20211231.xsd#DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1" xlink:href="fdmt-20211231.xsd#StatementStatementsOfOperations1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" xlink:href="fdmt-20211231.xsd#StatementStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="fdmt-20211231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" xlink:href="fdmt-20211231.xsd#DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails" xlink:href="fdmt-20211231.xsd#DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="fdmt-20211231.xsd#DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="fdmt-20211231.xsd#DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromRelatedParties" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fdmt_VestingOfCommonStockWarrantInReturnForServices" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="13" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="14" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="15" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="16" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="17" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_VestingOfCommonStockWarrantInReturnForServices" xlink:label="fdmt_VestingOfCommonStockWarrantInReturnForServices"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants" xlink:label="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fdmt_AccruedClinicalAndPreclinicalStudyCosts" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AccruedClinicalAndPreclinicalStudyCosts" xlink:label="fdmt_AccruedClinicalAndPreclinicalStudyCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="0" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>fdmt-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-28T16:37:33.8969+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="fdmt-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="fdmt-20211231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="fdmt-20211231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1" xlink:href="fdmt-20211231.xsd#StatementStatementsOfOperations1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical" xlink:href="fdmt-20211231.xsd#StatementStatementsOfOperationsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" xlink:href="fdmt-20211231.xsd#StatementStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="fdmt-20211231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="fdmt-20211231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="fdmt-20211231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompany" xlink:href="fdmt-20211231.xsd#Role_DisclosureTheCompany" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="fdmt-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="fdmt-20211231.xsd#DisclosureMarketableSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="fdmt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrent" xlink:href="fdmt-20211231.xsd#Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrent" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangements" xlink:href="fdmt-20211231.xsd#Role_DisclosureLicenseArrangements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="fdmt-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:href="fdmt-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="fdmt-20211231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrants" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommonStockWarrants" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted1" xlink:href="fdmt-20211231.xsd#DisclosureNetLossPerShareBasicAndDiluted1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiability" xlink:href="fdmt-20211231.xsd#Role_DisclosureDerivativeLiability" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="fdmt-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlan" xlink:href="fdmt-20211231.xsd#Role_Disclosure401KPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="fdmt-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="fdmt-20211231.xsd#DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="fdmt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentTables" xlink:href="fdmt-20211231.xsd#Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="fdmt-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables" xlink:href="fdmt-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="fdmt-20211231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables" xlink:href="fdmt-20211231.xsd#DisclosureNetLossPerShareBasicAndDilutedTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureTheCompanyAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails" xlink:href="fdmt-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails" xlink:href="fdmt-20211231.xsd#DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" xlink:href="fdmt-20211231.xsd#DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureLicenseArrangementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails" xlink:href="fdmt-20211231.xsd#DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails" xlink:href="fdmt-20211231.xsd#DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="fdmt-20211231.xsd#DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingUnrecognizedTaxBenefitsDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="fdmt-20211231.xsd#DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="fdmt-20211231.xsd#DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_Disclosure401KPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_PrepaidExpensesToRelatedPartiesCurrent" xlink:label="fdmt_PrepaidExpensesToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="fdmt_PrepaidExpensesToRelatedPartiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromRelatedParties" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndDevelopmentExpenseRelatedParty" xlink:label="fdmt_ResearchAndDevelopmentExpenseRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="fdmt_ResearchAndDevelopmentExpenseRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" xlink:label="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities" xlink:label="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_24"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_25"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_27"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IssuanceCostForIssuanceOfPreferredStock" xlink:label="fdmt_IssuanceCostForIssuanceOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_IssuanceCostForIssuanceOfPreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_VestingOfCommonStockWarrantInReturnForServices" xlink:label="fdmt_VestingOfCommonStockWarrantInReturnForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UnpaidOfferingCosts" xlink:label="fdmt_UnpaidOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants" xlink:label="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability" xlink:label="fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fdmt_VestingOfCommonStockWarrantInReturnForServices" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fdmt_UnpaidOfferingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompany" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrent" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AccruedAndOtherLiabilitiesTextBlock" xlink:label="fdmt_AccruedAndOtherLiabilitiesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="fdmt_AccruedAndOtherLiabilitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LicenseArrangementsAbstract" xlink:label="fdmt_LicenseArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LicenseArrangementsTextBlock" xlink:label="fdmt_LicenseArrangementsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_LicenseArrangementsAbstract" xlink:to="fdmt_LicenseArrangementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityDisclosureTextBlock" xlink:label="fdmt_TemporaryEquityDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="fdmt_TemporaryEquityDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrants" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CommonStockWarrantsTextBlock" xlink:label="fdmt_CommonStockWarrantsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="fdmt_CommonStockWarrantsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiability" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CommonStockWarrantsPolicyPolicyTextBlock" xlink:label="fdmt_CommonStockWarrantsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock" xlink:label="fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DeferredOfferingCostsPolicyPolicyTextBlock" xlink:label="fdmt_DeferredOfferingCostsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fdmt_CommonStockWarrantsPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fdmt_DeferredOfferingCostsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock" xlink:label="fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ScheduleOfCommonShareReservedForFutureIssuance" xlink:label="fdmt_ScheduleOfCommonShareReservedForFutureIssuance"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="fdmt_ScheduleOfCommonShareReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OrganizationAndNatureOfBusinessTable" xlink:label="fdmt_OrganizationAndNatureOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:label="fdmt_OrganizationAndNatureOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FollowOnPublicOfferingMember" xlink:label="fdmt_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fdmt_OrganizationAndNatureOfBusinessTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_OrganizationAndNatureOfBusinessTable" xlink:to="fdmt_OrganizationAndNatureOfBusinessLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fdmt_FollowOnPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_SharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201807Member" xlink:label="us-gaap_AccountingStandardsUpdate201807Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld" xlink:label="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LeaseIncentiveLiability" xlink:label="fdmt_LeaseIncentiveLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fdmt_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201807Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRentCredit" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fdmt_LeaseIncentiveLiability" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquity" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerAMember" xlink:label="fdmt_CustomerAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerBMember" xlink:label="fdmt_CustomerBMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerMember" xlink:label="fdmt_CustomerMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="fdmt_CustomerAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="fdmt_CustomerBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="fdmt_CustomerMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerBMember" xlink:label="fdmt_CustomerBMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="fdmt_CustomerBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL" xlink:label="country_NL"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_NL" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CH" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RestatementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShortTermMarketableSecuritiesMember" xlink:label="fdmt_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LongTermMarketableSecuritiesMember" xlink:label="fdmt_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fdmt_ShortTermMarketableSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fdmt_LongTermMarketableSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShortTermMarketableSecuritiesMember" xlink:label="fdmt_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LongTermMarketableSecuritiesMember" xlink:label="fdmt_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CorporateBondMember" xlink:label="fdmt_CorporateBondMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fdmt_ShortTermMarketableSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fdmt_LongTermMarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="fdmt_CorporateBondMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear" xlink:label="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_MaximumMaturityPeriodOfMarketableSecurities" xlink:label="fdmt_MaximumMaturityPeriodOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fdmt_MaximumMaturityPeriodOfMarketableSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AccruedClinicalAndPreclinicalStudyCosts" xlink:label="fdmt_AccruedClinicalAndPreclinicalStudyCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="fdmt_AccruedClinicalAndPreclinicalStudyCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureBiopharmaBVMember" xlink:label="fdmt_UniQureBiopharmaBVMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationAndLicenseRevenueMember" xlink:label="fdmt_CollaborationAndLicenseRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_UniQureBiopharmaBVMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fdmt_CollaborationAndLicenseRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_CysticFibrosisFoundationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureBiopharmaBVMember" xlink:label="fdmt_UniQureBiopharmaBVMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_UniQureBiopharmaBVMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_CysticFibrosisFoundationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureAgreementMember" xlink:label="fdmt_UniQureAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureBiopharmaBVMember" xlink:label="fdmt_UniQureBiopharmaBVMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementInitialResearchTerm" xlink:label="fdmt_CollaborativeArrangementInitialResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmendedUniQureAgreementMember" xlink:label="fdmt_AmendedUniQureAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsUpfrontPaymentReceived" xlink:label="fdmt_CollaborationArrangementsUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct" xlink:label="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ContingentPaymentsEliminated" xlink:label="fdmt_ContingentPaymentsEliminated"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OptionsToPurchaseOrdinaryShares" xlink:label="fdmt_OptionsToPurchaseOrdinaryShares"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_VestingPeriodOfShareAwards" xlink:label="fdmt_VestingPeriodOfShareAwards"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueOfOptions" xlink:label="fdmt_FairValueOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight" xlink:label="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_UniQureAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_UniQureBiopharmaBVMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementInitialResearchTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_AmendedUniQureAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsUpfrontPaymentReceived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_ContingentPaymentsEliminated" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_OptionsToPurchaseOrdinaryShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_VestingPeriodOfShareAwards" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_FairValueOfOptions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureBiopharmaBVMember" xlink:label="fdmt_UniQureBiopharmaBVMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureAgreementMember" xlink:label="fdmt_UniQureAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_UniQureBiopharmaBVMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_UniQureAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ChoroideremiaResearchFoundationMember" xlink:label="fdmt_ChoroideremiaResearchFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementInitialResearchTerm" xlink:label="fdmt_CollaborativeArrangementInitialResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ChoroideremiaResearchFoundationAgreementMember" xlink:label="fdmt_ChoroideremiaResearchFoundationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone" xlink:label="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAdditionalResearchTerm" xlink:label="fdmt_CollaborativeArrangementAdditionalResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAchievedMilestones" xlink:label="fdmt_CollaborativeArrangementAchievedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_ChoroideremiaResearchFoundationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementInitialResearchTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_ChoroideremiaResearchFoundationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementAdditionalResearchTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementAchievedMilestones" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandAndSeventeenRocheAgreementMember" xlink:label="fdmt_TwoThousandAndSeventeenRocheAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived" xlink:label="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree" xlink:label="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct" xlink:label="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments" xlink:label="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia" xlink:label="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments" xlink:label="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments" xlink:label="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAdjustmentToTransactionPrice" xlink:label="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts" xlink:label="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAdditionOfVariableConsideration" xlink:label="fdmt_CollaborativeArrangementAdditionOfVariableConsideration"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized" xlink:label="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_TwoThousandAndSeventeenRocheAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementAdditionOfVariableConsideration" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandAndSeventeenRocheAgreementMember" xlink:label="fdmt_TwoThousandAndSeventeenRocheAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_TwoThousandAndSeventeenRocheAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAchievedMilestones" xlink:label="fdmt_CollaborativeArrangementAchievedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived" xlink:label="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfInstallmentsToPayActualAward" xlink:label="fdmt_NumberOfInstallmentsToPayActualAward"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct" xlink:label="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage" xlink:label="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived" xlink:label="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct" xlink:label="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementTransactionPriceAdjustment" xlink:label="fdmt_CollaborativeArrangementTransactionPriceAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_CysticFibrosisFoundationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementAchievedMilestones" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_NumberOfInstallmentsToPayActualAward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementTransactionPriceAdjustment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_CysticFibrosisFoundationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LicenseArrangementsAbstract" xlink:label="fdmt_LicenseArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UCAgreementsMember" xlink:label="fdmt_UCAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonRefundableLicenseFeePayableUponExecution" xlink:label="fdmt_NonRefundableLicenseFeePayableUponExecution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution" xlink:label="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption" xlink:label="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption" xlink:label="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_PercentageOfEquityInterestsIssuedAsCommonStock" xlink:label="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmountsPaidNonRefundableLicenseFees" xlink:label="fdmt_AmountsPaidNonRefundableLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually" xlink:label="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DevelopmentMilestones" xlink:label="fdmt_DevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AnnualRoyalty" xlink:label="fdmt_AnnualRoyalty"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IncurredExpenses" xlink:label="fdmt_IncurredExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_LicenseArrangementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fdmt_UCAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_NonRefundableLicenseFeePayableUponExecution" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_AmountsPaidNonRefundableLicenseFees" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_DevelopmentMilestones" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_AnnualRoyalty" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_IncurredExpenses" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_BuildingLeaseMember" xlink:label="fdmt_BuildingLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CommitmentAndContingenciesTable" xlink:label="fdmt_CommitmentAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CommitmentAndContingenciesLineItems" xlink:label="fdmt_CommitmentAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_BuildingLeaseAndExpansionMember" xlink:label="fdmt_BuildingLeaseAndExpansionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OperatingLeaseTermExtendedExpirationPeriod" xlink:label="fdmt_OperatingLeaseTermExtendedExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="fdmt_BuildingLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fdmt_CommitmentAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_PaymentsForTenantImprovements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="fdmt_BuildingLeaseAndExpansionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesTable" xlink:to="fdmt_CommitmentAndContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="fdmt_OperatingLeaseTermExtendedExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OperatingLossCarryforwardsExpirationYear" xlink:label="fdmt_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TaxCreditCarryforwardExpirationDescription" xlink:label="fdmt_TaxCreditCarryforwardExpirationDescription"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TaxCreditCarryforwardBeginningExpirationYear" xlink:label="fdmt_TaxCreditCarryforwardBeginningExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CARESActReliefDescription" xlink:label="fdmt_CARESActReliefDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fdmt_OperatingLossCarryforwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fdmt_TaxCreditCarryforwardExpirationDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fdmt_TaxCreditCarryforwardBeginningExpirationYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fdmt_CARESActReliefDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FundingAgreementProductMember" xlink:label="fdmt_FundingAgreementProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AdditionalFundingCommitted" xlink:label="fdmt_AdditionalFundingCommitted"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AdditionalInvestmentInCash" xlink:label="fdmt_AdditionalInvestmentInCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fdmt_SeriesCRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_CysticFibrosisFoundationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_FundingAgreementProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fdmt_AdditionalFundingCommitted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fdmt_AdditionalInvestmentInCash" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fdmt_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fdmt_SeriesBRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_DividendsCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="fdmt_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fdmt_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandTwentyIncentiveAwardPlanMember" xlink:label="fdmt_TwoThousandTwentyIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_EmployeeMember" xlink:label="fdmt_EmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonemployeeMember" xlink:label="fdmt_NonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="fdmt_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:label="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fdmt_TwoThousandTwentyIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fdmt_EmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fdmt_NonemployeeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fdmt_TwoThousandFifteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_EmployeeMember" xlink:label="fdmt_EmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonemployeeMember" xlink:label="fdmt_NonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fdmt_EmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fdmt_NonemployeeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfWarrantsIssued" xlink:label="fdmt_NumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesBFinancingMember" xlink:label="fdmt_SeriesBFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_WarrantExpiresYear" xlink:label="fdmt_WarrantExpiresYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_WarrantVestsOverPeriod" xlink:label="fdmt_WarrantVestsOverPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_WarrantExercisedMonthAndYear" xlink:label="fdmt_WarrantExercisedMonthAndYear"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="fdmt_NumberOfWarrantsIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="fdmt_SeriesBFinancingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="fdmt_WarrantExpiresYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="fdmt_WarrantVestsOverPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="fdmt_WarrantExercisedMonthAndYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueAssumptionsChangeOfControlPayment" xlink:label="fdmt_FairValueAssumptionsChangeOfControlPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="fdmt_FairValueAssumptionsChangeOfControlPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_DerivativeLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember" xlink:label="fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CoFounderAndChiefScientificAdvisorMember" xlink:label="fdmt_CoFounderAndChiefScientificAdvisorMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SponsoredResearchAgreementsMember" xlink:label="fdmt_SponsoredResearchAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfAgreementsEntered" xlink:label="fdmt_NumberOfAgreementsEntered"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UCRegentsMember" xlink:label="fdmt_UCRegentsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_MachineLearningSponsoredResearchAgreementMember" xlink:label="fdmt_MachineLearningSponsoredResearchAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TermOfAgreement" xlink:label="fdmt_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember" xlink:label="fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyCosts" xlink:label="us-gaap_RelatedPartyCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fdmt_CoFounderAndChiefScientificAdvisorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fdmt_SponsoredResearchAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fdmt_NumberOfAgreementsEntered" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fdmt_UCRegentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fdmt_MachineLearningSponsoredResearchAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fdmt_TermOfAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandFourteenPlanMember" xlink:label="fdmt_TwoThousandFourteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="fdmt_TwoThousandFourteenPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>fdmt-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-28T16:37:29.6860+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.4dmoleculartherapeutics.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:fdmt="http://www.4dmoleculartherapeutics.com/20211231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fdmt-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fdmt-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fdmt-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fdmt-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" id="DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1" id="StatementStatementsOfOperations1">
        <link:definition>100040 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical" id="StatementStatementsOfOperationsParenthetical">
        <link:definition>100050 - Statement - Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" id="StatementStatementsOfComprehensiveLoss">
        <link:definition>100060 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100080 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100090 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompany" id="Role_DisclosureTheCompany">
        <link:definition>100100 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100110 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>100130 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100140 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrent" id="Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrent">
        <link:definition>100150 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements" id="Role_DisclosureResearchAndCollaborationArrangements">
        <link:definition>100160 - Disclosure - Research and Collaboration Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangements" id="Role_DisclosureLicenseArrangements">
        <link:definition>100170 - Disclosure - License Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100180 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100190 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" id="Role_DisclosureRedeemableConvertiblePreferredStock">
        <link:definition>100200 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100210 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100220 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrants" id="Role_DisclosureCommonStockWarrants">
        <link:definition>100230 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted1" id="DisclosureNetLossPerShareBasicAndDiluted1">
        <link:definition>100240 - Disclosure - Net Loss Per Share, Basic and Diluted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiability" id="Role_DisclosureDerivativeLiability">
        <link:definition>100250 - Disclosure - Derivative Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100260 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlan" id="Role_Disclosure401KPlan">
        <link:definition>100270 - Disclosure - 401(K) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100300 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>100310 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100320 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentTables" id="Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentTables">
        <link:definition>100330 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables" id="Role_DisclosureResearchAndCollaborationArrangementsTables">
        <link:definition>100340 - Disclosure - Research and Collaboration Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100350 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100360 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables" id="Role_DisclosureRedeemableConvertiblePreferredStockTables">
        <link:definition>100370 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100380 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100390 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables" id="DisclosureNetLossPerShareBasicAndDilutedTables">
        <link:definition>100400 - Disclosure - Net Loss Per Share, Basic and Diluted (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" id="Role_DisclosureTheCompanyAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - The Company - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails">
        <link:definition>100430 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical">
        <link:definition>100440 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails">
        <link:definition>100450 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails">
        <link:definition>100460 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impact of Adoption of New Accounting Standard (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100470 - Disclosure - Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails" id="DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails">
        <link:definition>100490 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" id="DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails">
        <link:definition>100500 - Disclosure - Marketable Securities - Summary of Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Marketable Securities (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100520 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails">
        <link:definition>100540 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent - Summary of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails" id="Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails">
        <link:definition>100550 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent - Summary of Other Liabilities, Noncurrent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails" id="Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails">
        <link:definition>100560 - Disclosure - Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" id="Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails">
        <link:definition>100570 - Disclosure - Research and Collaboration Arrangements - Summary of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1" id="Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1">
        <link:definition>100590 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Research and Collaboration Arrangements - CRF Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Research and Collaboration Arrangements - Roche Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1" id="Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1">
        <link:definition>100620 - Disclosure - Research and Collaboration Arrangements - Roche Agreement - Additional Information (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1" id="Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1">
        <link:definition>100640 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" id="Role_DisclosureLicenseArrangementsAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - License Arrangements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails" id="DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails">
        <link:definition>100670 - Disclosure - Commitments and Contingencies - summary of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails" id="DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails">
        <link:definition>100680 - Disclosure - Commitments and Contingencies - Summary of Supplemental Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>100690 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails">
        <link:definition>100700 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Income Tax Expense (Benefit) Differs from Federal Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails">
        <link:definition>100710 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences to Significant Components of Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100720 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingUnrecognizedTaxBenefitsDetails">
        <link:definition>100730 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100740 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails" id="Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails">
        <link:definition>100750 - Disclosure - Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100760 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails" id="Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails">
        <link:definition>100770 - Disclosure - Common Stock - Schedule of Common Share Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100780 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails">
        <link:definition>100790 - Disclosure - Stock-based Compensation - Summary of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails">
        <link:definition>100800 - Disclosure - Stock-based Compensation - Summary of Stock Compensation Expense for Employees and Nonemployees by Function (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails">
        <link:definition>100810 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" id="Role_DisclosureCommonStockWarrantsAdditionalInformationDetails">
        <link:definition>100820 - Disclosure - Common Stock Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100830 - Disclosure - Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>100840 - Disclosure - Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" id="Role_DisclosureDerivativeLiabilityAdditionalInformationDetails">
        <link:definition>100850 - Disclosure - Derivative Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100860 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" id="Role_Disclosure401KPlanAdditionalInformationDetails">
        <link:definition>100870 - Disclosure - 401(K) Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="fdmt_LicenseArrangementsAbstract" name="LicenseArrangementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_ResearchAndCollaborationArrangementsAbstract" name="ResearchAndCollaborationArrangementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_AccruedClinicalAndPreclinicalStudyCosts" name="AccruedClinicalAndPreclinicalStudyCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct" name="ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_AdditionalFundingCommitted" name="AdditionalFundingCommitted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_AdditionalInvestmentInCash" name="AdditionalInvestmentInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" name="AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually" name="AmountObligatedToPayNonRefundableLicenseFeeAnnually" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption" name="AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_AmountsPaidNonRefundableLicenseFees" name="AmountsPaidNonRefundableLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_AnnualRoyalty" name="AnnualRoyalty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_CARESActReliefDescription" name="CARESActReliefDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree" name="CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia" name="CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct" name="CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments" name="CollaborationArrangementsMaximumDevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments" name="CollaborationArrangementsNonRefundableDevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived" name="CollaborationArrangementsNonRefundableUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_CollaborationArrangementsUpfrontPaymentReceived" name="CollaborationArrangementsUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_CollaborativeArrangementAchievedMilestones" name="CollaborativeArrangementAchievedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_CollaborativeArrangementAdditionalResearchTerm" name="CollaborativeArrangementAdditionalResearchTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_CollaborativeArrangementAdditionOfVariableConsideration" name="CollaborativeArrangementAdditionOfVariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice" name="CollaborativeArrangementAdjustmentToTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone" name="CollaborativeArrangementContributionUponDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts" name="CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_CollaborativeArrangementInitialResearchTerm" name="CollaborativeArrangementInitialResearchTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments" name="CollaborativeArrangementMaximumSalesBasedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct" name="CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage" name="CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived" name="CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_CollaborativeArrangementTransactionPriceAdjustment" name="CollaborativeArrangementTransactionPriceAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_ContingentPaymentsEliminated" name="ContingentPaymentsEliminated" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct" name="ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_DevelopmentMilestones" name="DevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived" name="ExpectedPaymentsPercentageToEqualActualAwardReceived" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_FairValueAssumptionsChangeOfControlPayment" name="FairValueAssumptionsChangeOfControlPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate" name="FairValueAssumptionsProbabilityOfChangeInControlDiscountRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" name="FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight" name="FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_FairValueOfOptions" name="FairValueOfOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized" name="IncreaseDecreaseInContractWithCustomerRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_IncurredExpenses" name="IncurredExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_IssuanceCostForIssuanceOfPreferredStock" name="IssuanceCostForIssuanceOfPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants" name="IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_LeaseIncentiveLiability" name="LeaseIncentiveLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_MaximumMaturityPeriodOfMarketableSecurities" name="MaximumMaturityPeriodOfMarketableSecurities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual" name="MinimumPercentageOfOutstandingSharesHeldByIndividual" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability" name="NonCashIssuanceOfCommonStockWarrantToSettleLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution" name="NonRefundableLicenseFeePayableEveryYearAfterExecution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_NonRefundableLicenseFeePayableUponExecution" name="NonRefundableLicenseFeePayableUponExecution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_NumberOfAgreementsEntered" name="NumberOfAgreementsEntered" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld" name="NumberOfFinancialInstitutionsWhereCashIsHeld" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_NumberOfInstallmentsToPayActualAward" name="NumberOfInstallmentsToPayActualAward" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear" name="NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_NumberOfWarrantsIssued" name="NumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_OperatingLeaseTermExtendedExpirationPeriod" name="OperatingLeaseTermExtendedExpirationPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_OptionsToPurchaseOrdinaryShares" name="OptionsToPurchaseOrdinaryShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock" name="PercentageOfEquityInterestsIssuedAsCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption" name="PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_PrepaidExpensesToRelatedPartiesCurrent" name="PrepaidExpensesToRelatedPartiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_ResearchAndDevelopmentExpenseRelatedParty" name="ResearchAndDevelopmentExpenseRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_ScheduleOfCommonShareReservedForFutureIssuance" name="ScheduleOfCommonShareReservedForFutureIssuance" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities" name="StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" name="StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_TaxCreditCarryforwardBeginningExpirationYear" name="TaxCreditCarryforwardBeginningExpirationYear" type="dtr-types:gYearListItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_TaxCreditCarryforwardExpirationDescription" name="TaxCreditCarryforwardExpirationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_TermOfAgreement" name="TermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_UnpaidOfferingCosts" name="UnpaidOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="fdmt_VestingOfCommonStockWarrantInReturnForServices" name="VestingOfCommonStockWarrantInReturnForServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="fdmt_VestingPeriodOfShareAwards" name="VestingPeriodOfShareAwards" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_WarrantExercisedMonthAndYear" name="WarrantExercisedMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_WarrantExpiresYear" name="WarrantExpiresYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_WarrantVestsOverPeriod" name="WarrantVestsOverPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_CommitmentAndContingenciesLineItems" name="CommitmentAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_OrganizationAndNatureOfBusinessLineItems" name="OrganizationAndNatureOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_AmendedUniQureAgreementMember" name="AmendedUniQureAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_BuildingLeaseAndExpansionMember" name="BuildingLeaseAndExpansionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_BuildingLeaseMember" name="BuildingLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_ChoroideremiaResearchFoundationAgreementMember" name="ChoroideremiaResearchFoundationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_ChoroideremiaResearchFoundationMember" name="ChoroideremiaResearchFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_CoFounderAndChiefScientificAdvisorMember" name="CoFounderAndChiefScientificAdvisorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_CollaborationAndLicenseRevenueMember" name="CollaborationAndLicenseRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember" name="ConsultingServicesAndServicesAsBoardOfDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_CorporateBondMember" name="CorporateBondMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_CustomerAMember" name="CustomerAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_CustomerBMember" name="CustomerBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_CustomerMember" name="CustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_CysticFibrosisFoundationMember" name="CysticFibrosisFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_EmployeeMember" name="EmployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" name="FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_FundingAgreementProductMember" name="FundingAgreementProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_LongTermMarketableSecuritiesMember" name="LongTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_MachineLearningSponsoredResearchAgreementMember" name="MachineLearningSponsoredResearchAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_NonemployeeMember" name="NonemployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember" name="SeriesA1RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_SeriesBFinancingMember" name="SeriesBFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_ShortTermMarketableSecuritiesMember" name="ShortTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember" name="SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_SponsoredResearchAgreementsMember" name="SponsoredResearchAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_TwoThousandAndSeventeenRocheAgreementMember" name="TwoThousandAndSeventeenRocheAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_TwoThousandFifteenEquityIncentivePlanMember" name="TwoThousandFifteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_TwoThousandFourteenPlanMember" name="TwoThousandFourteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_TwoThousandTwentyIncentiveAwardPlanMember" name="TwoThousandTwentyIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_UCAgreementsMember" name="UCAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_UCRegentsMember" name="UCRegentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_UniQureAgreementMember" name="UniQureAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_UniQureBiopharmaBVMember" name="UniQureBiopharmaBVMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock" name="AccruedResearchAndDevelopmentPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_CommonStockWarrantsPolicyPolicyTextBlock" name="CommonStockWarrantsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_DeferredOfferingCostsPolicyPolicyTextBlock" name="DeferredOfferingCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock" name="OtherRisksAndUncertaintiesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" name="RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_CommitmentAndContingenciesTable" name="CommitmentAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_OrganizationAndNatureOfBusinessTable" name="OrganizationAndNatureOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock" name="ScheduleOfCollaborationAndLicenseRevenueTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_AccruedAndOtherLiabilitiesTextBlock" name="AccruedAndOtherLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_CommonStockWarrantsTextBlock" name="CommonStockWarrantsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_LicenseArrangementsTextBlock" name="LicenseArrangementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="fdmt_TemporaryEquityDisclosureTextBlock" name="TemporaryEquityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>fdmt-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-28T16:37:34.1036+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="fdmt-20211231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="fdmt-20211231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureTheCompanyAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails" xlink:href="fdmt-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails" xlink:href="fdmt-20211231.xsd#DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" xlink:href="fdmt-20211231.xsd#DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1" xlink:href="fdmt-20211231.xsd#Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureLicenseArrangementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureCommonStockWarrantsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="fdmt-20211231.xsd#DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureDerivativeLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails" xlink:href="fdmt-20211231.xsd#Role_Disclosure401KPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" xlink:label="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities" xlink:label="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IssuanceCostForIssuanceOfPreferredStock" xlink:label="fdmt_IssuanceCostForIssuanceOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fdmt_IssuanceCostForIssuanceOfPreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:label="fdmt_OrganizationAndNatureOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OrganizationAndNatureOfBusinessTable" xlink:label="fdmt_OrganizationAndNatureOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FollowOnPublicOfferingMember" xlink:label="fdmt_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="fdmt_OrganizationAndNatureOfBusinessTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fdmt_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fdmt_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fdmt_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201807Member" xlink:label="us-gaap_AccountingStandardsUpdate201807Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld" xlink:label="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LeaseIncentiveLiability" xlink:label="fdmt_LeaseIncentiveLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fdmt_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201807Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRentCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fdmt_LeaseIncentiveLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerAMember" xlink:label="fdmt_CustomerAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerBMember" xlink:label="fdmt_CustomerBMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerMember" xlink:label="fdmt_CustomerMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="fdmt_CustomerAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="fdmt_CustomerBMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="fdmt_CustomerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerBMember" xlink:label="fdmt_CustomerBMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="fdmt_CustomerBMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL" xlink:label="country_NL"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_NL" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CH" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShortTermMarketableSecuritiesMember" xlink:label="fdmt_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LongTermMarketableSecuritiesMember" xlink:label="fdmt_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fdmt_ShortTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fdmt_LongTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShortTermMarketableSecuritiesMember" xlink:label="fdmt_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CorporateBondMember" xlink:label="fdmt_CorporateBondMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LongTermMarketableSecuritiesMember" xlink:label="fdmt_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fdmt_ShortTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="fdmt_CorporateBondMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fdmt_LongTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear" xlink:label="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_MaximumMaturityPeriodOfMarketableSecurities" xlink:label="fdmt_MaximumMaturityPeriodOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fdmt_MaximumMaturityPeriodOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationAndLicenseRevenueMember" xlink:label="fdmt_CollaborationAndLicenseRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureBiopharmaBVMember" xlink:label="fdmt_UniQureBiopharmaBVMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fdmt_CollaborationAndLicenseRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_UniQureBiopharmaBVMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_CysticFibrosisFoundationMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureBiopharmaBVMember" xlink:label="fdmt_UniQureBiopharmaBVMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_UniQureBiopharmaBVMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_CysticFibrosisFoundationMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureBiopharmaBVMember" xlink:label="fdmt_UniQureBiopharmaBVMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureAgreementMember" xlink:label="fdmt_UniQureAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmendedUniQureAgreementMember" xlink:label="fdmt_AmendedUniQureAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementInitialResearchTerm" xlink:label="fdmt_CollaborativeArrangementInitialResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsUpfrontPaymentReceived" xlink:label="fdmt_CollaborationArrangementsUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct" xlink:label="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ContingentPaymentsEliminated" xlink:label="fdmt_ContingentPaymentsEliminated"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OptionsToPurchaseOrdinaryShares" xlink:label="fdmt_OptionsToPurchaseOrdinaryShares"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_VestingPeriodOfShareAwards" xlink:label="fdmt_VestingPeriodOfShareAwards"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueOfOptions" xlink:label="fdmt_FairValueOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight" xlink:label="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_UniQureBiopharmaBVMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_UniQureAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_AmendedUniQureAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementInitialResearchTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsUpfrontPaymentReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_ContingentPaymentsEliminated" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_OptionsToPurchaseOrdinaryShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_VestingPeriodOfShareAwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_FairValueOfOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DueFromRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureBiopharmaBVMember" xlink:label="fdmt_UniQureBiopharmaBVMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureAgreementMember" xlink:label="fdmt_UniQureAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_UniQureBiopharmaBVMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_UniQureAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ChoroideremiaResearchFoundationMember" xlink:label="fdmt_ChoroideremiaResearchFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ChoroideremiaResearchFoundationAgreementMember" xlink:label="fdmt_ChoroideremiaResearchFoundationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementInitialResearchTerm" xlink:label="fdmt_CollaborativeArrangementInitialResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone" xlink:label="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAdditionalResearchTerm" xlink:label="fdmt_CollaborativeArrangementAdditionalResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAchievedMilestones" xlink:label="fdmt_CollaborativeArrangementAchievedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_ChoroideremiaResearchFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_ChoroideremiaResearchFoundationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementInitialResearchTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementAdditionalResearchTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementAchievedMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DueFromRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived" xlink:label="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandAndSeventeenRocheAgreementMember" xlink:label="fdmt_TwoThousandAndSeventeenRocheAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree" xlink:label="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct" xlink:label="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments" xlink:label="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia" xlink:label="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments" xlink:label="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments" xlink:label="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAdjustmentToTransactionPrice" xlink:label="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts" xlink:label="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAdditionOfVariableConsideration" xlink:label="fdmt_CollaborativeArrangementAdditionOfVariableConsideration"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized" xlink:label="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_TwoThousandAndSeventeenRocheAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementAdditionOfVariableConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandAndSeventeenRocheAgreementMember" xlink:label="fdmt_TwoThousandAndSeventeenRocheAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_TwoThousandAndSeventeenRocheAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAchievedMilestones" xlink:label="fdmt_CollaborativeArrangementAchievedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived" xlink:label="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfInstallmentsToPayActualAward" xlink:label="fdmt_NumberOfInstallmentsToPayActualAward"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct" xlink:label="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage" xlink:label="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived" xlink:label="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct" xlink:label="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementTransactionPriceAdjustment" xlink:label="fdmt_CollaborativeArrangementTransactionPriceAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_CysticFibrosisFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementAchievedMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_NumberOfInstallmentsToPayActualAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fdmt_CollaborativeArrangementTransactionPriceAdjustment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_CysticFibrosisFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UCAgreementsMember" xlink:label="fdmt_UCAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonRefundableLicenseFeePayableUponExecution" xlink:label="fdmt_NonRefundableLicenseFeePayableUponExecution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution" xlink:label="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption" xlink:label="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption" xlink:label="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_PercentageOfEquityInterestsIssuedAsCommonStock" xlink:label="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmountsPaidNonRefundableLicenseFees" xlink:label="fdmt_AmountsPaidNonRefundableLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually" xlink:label="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DevelopmentMilestones" xlink:label="fdmt_DevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AnnualRoyalty" xlink:label="fdmt_AnnualRoyalty"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IncurredExpenses" xlink:label="fdmt_IncurredExpenses"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fdmt_UCAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_NonRefundableLicenseFeePayableUponExecution" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_AmountsPaidNonRefundableLicenseFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_DevelopmentMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_AnnualRoyalty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="fdmt_IncurredExpenses" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CommitmentAndContingenciesLineItems" xlink:label="fdmt_CommitmentAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CommitmentAndContingenciesTable" xlink:label="fdmt_CommitmentAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_BuildingLeaseMember" xlink:label="fdmt_BuildingLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_BuildingLeaseAndExpansionMember" xlink:label="fdmt_BuildingLeaseAndExpansionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OperatingLeaseTermExtendedExpirationPeriod" xlink:label="fdmt_OperatingLeaseTermExtendedExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="fdmt_CommitmentAndContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="fdmt_BuildingLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fdmt_CommitmentAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fdmt_CommitmentAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_PaymentsForTenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="fdmt_BuildingLeaseAndExpansionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="fdmt_OperatingLeaseTermExtendedExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OperatingLossCarryforwardsExpirationYear" xlink:label="fdmt_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TaxCreditCarryforwardExpirationDescription" xlink:label="fdmt_TaxCreditCarryforwardExpirationDescription"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TaxCreditCarryforwardBeginningExpirationYear" xlink:label="fdmt_TaxCreditCarryforwardBeginningExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CARESActReliefDescription" xlink:label="fdmt_CARESActReliefDescription"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fdmt_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fdmt_TaxCreditCarryforwardExpirationDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fdmt_TaxCreditCarryforwardBeginningExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="fdmt_CARESActReliefDescription" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FundingAgreementProductMember" xlink:label="fdmt_FundingAgreementProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AdditionalFundingCommitted" xlink:label="fdmt_AdditionalFundingCommitted"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AdditionalInvestmentInCash" xlink:label="fdmt_AdditionalInvestmentInCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fdmt_CysticFibrosisFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fdmt_FundingAgreementProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fdmt_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fdmt_AdditionalFundingCommitted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="fdmt_AdditionalInvestmentInCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fdmt_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="fdmt_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="fdmt_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fdmt_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandTwentyIncentiveAwardPlanMember" xlink:label="fdmt_TwoThousandTwentyIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_EmployeeMember" xlink:label="fdmt_EmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonemployeeMember" xlink:label="fdmt_NonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="fdmt_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:label="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fdmt_TwoThousandTwentyIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fdmt_EmployeeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fdmt_NonemployeeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fdmt_TwoThousandFifteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_EmployeeMember" xlink:label="fdmt_EmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonemployeeMember" xlink:label="fdmt_NonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fdmt_EmployeeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="fdmt_NonemployeeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesBFinancingMember" xlink:label="fdmt_SeriesBFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfWarrantsIssued" xlink:label="fdmt_NumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_WarrantExpiresYear" xlink:label="fdmt_WarrantExpiresYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_WarrantVestsOverPeriod" xlink:label="fdmt_WarrantVestsOverPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_WarrantExercisedMonthAndYear" xlink:label="fdmt_WarrantExercisedMonthAndYear"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="fdmt_SeriesBFinancingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="fdmt_NumberOfWarrantsIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="fdmt_WarrantExpiresYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="fdmt_WarrantVestsOverPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="fdmt_WarrantExercisedMonthAndYear" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueAssumptionsChangeOfControlPayment" xlink:label="fdmt_FairValueAssumptionsChangeOfControlPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="fdmt_FairValueAssumptionsChangeOfControlPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember" xlink:label="fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CoFounderAndChiefScientificAdvisorMember" xlink:label="fdmt_CoFounderAndChiefScientificAdvisorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfAgreementsEntered" xlink:label="fdmt_NumberOfAgreementsEntered"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SponsoredResearchAgreementsMember" xlink:label="fdmt_SponsoredResearchAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UCRegentsMember" xlink:label="fdmt_UCRegentsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TermOfAgreement" xlink:label="fdmt_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_MachineLearningSponsoredResearchAgreementMember" xlink:label="fdmt_MachineLearningSponsoredResearchAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember" xlink:label="fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyCosts" xlink:label="us-gaap_RelatedPartyCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fdmt_CoFounderAndChiefScientificAdvisorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fdmt_NumberOfAgreementsEntered" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fdmt_SponsoredResearchAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fdmt_UCRegentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fdmt_TermOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fdmt_MachineLearningSponsoredResearchAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandFourteenPlanMember" xlink:label="fdmt_TwoThousandFourteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="fdmt_TwoThousandFourteenPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201807Member" xlink:label="us-gaap_AccountingStandardsUpdate201807Member"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201807Member" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>fdmt-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-28T16:37:33.3129+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_EmployeeMember" xlink:label="fdmt_EmployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureBiopharmaBVMember" xlink:label="fdmt_UniQureBiopharmaBVMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants" xlink:label="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LicenseArrangementsTextBlock" xlink:label="fdmt_LicenseArrangementsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AdditionalFundingCommitted" xlink:label="fdmt_AdditionalFundingCommitted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAdjustmentToTransactionPrice" xlink:label="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfInstallmentsToPayActualAward" xlink:label="fdmt_NumberOfInstallmentsToPayActualAward"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandAndSeventeenRocheAgreementMember" xlink:label="fdmt_TwoThousandAndSeventeenRocheAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LeaseIncentiveLiability" xlink:label="fdmt_LeaseIncentiveLiability"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmountsPaidNonRefundableLicenseFees" xlink:label="fdmt_AmountsPaidNonRefundableLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FollowOnPublicOfferingMember" xlink:label="fdmt_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonRefundableLicenseFeePayableUponExecution" xlink:label="fdmt_NonRefundableLicenseFeePayableUponExecution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived" xlink:label="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfAgreementsEntered" xlink:label="fdmt_NumberOfAgreementsEntered"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_PercentageOfEquityInterestsIssuedAsCommonStock" xlink:label="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ScheduleOfCommonShareReservedForFutureIssuance" xlink:label="fdmt_ScheduleOfCommonShareReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AccruedClinicalAndPreclinicalStudyCosts" xlink:label="fdmt_AccruedClinicalAndPreclinicalStudyCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UnpaidOfferingCosts" xlink:label="fdmt_UnpaidOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OperatingLossCarryforwardsExpirationYear" xlink:label="fdmt_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UCAgreementsMember" xlink:label="fdmt_UCAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually" xlink:label="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201807Member" xlink:label="us-gaap_AccountingStandardsUpdate201807Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts" xlink:label="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ContingentPaymentsEliminated" xlink:label="fdmt_ContingentPaymentsEliminated"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_WarrantExpiresYear" xlink:label="fdmt_WarrantExpiresYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CorporateBondMember" xlink:label="fdmt_CorporateBondMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree" xlink:label="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_MachineLearningSponsoredResearchAgreementMember" xlink:label="fdmt_MachineLearningSponsoredResearchAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementInitialResearchTerm" xlink:label="fdmt_CollaborativeArrangementInitialResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_VestingPeriodOfShareAwards" xlink:label="fdmt_VestingPeriodOfShareAwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandTwentyIncentiveAwardPlanMember" xlink:label="fdmt_TwoThousandTwentyIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IssuanceCostForIssuanceOfPreferredStock" xlink:label="fdmt_IssuanceCostForIssuanceOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AdditionalInvestmentInCash" xlink:label="fdmt_AdditionalInvestmentInCash"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LongTermMarketableSecuritiesMember" xlink:label="fdmt_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="fdmt_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL" xlink:label="country_NL"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IncurredExpenses" xlink:label="fdmt_IncurredExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OrganizationAndNatureOfBusinessTable" xlink:label="fdmt_OrganizationAndNatureOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAdditionOfVariableConsideration" xlink:label="fdmt_CollaborativeArrangementAdditionOfVariableConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UniQureAgreementMember" xlink:label="fdmt_UniQureAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DeferredOfferingCostsPolicyPolicyTextBlock" xlink:label="fdmt_DeferredOfferingCostsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_UCRegentsMember" xlink:label="fdmt_UCRegentsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ChoroideremiaResearchFoundationAgreementMember" xlink:label="fdmt_ChoroideremiaResearchFoundationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_MaximumMaturityPeriodOfMarketableSecurities" xlink:label="fdmt_MaximumMaturityPeriodOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized" xlink:label="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight" xlink:label="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_WarrantExercisedMonthAndYear" xlink:label="fdmt_WarrantExercisedMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CysticFibrosisFoundationMember" xlink:label="fdmt_CysticFibrosisFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments" xlink:label="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsUpfrontPaymentReceived" xlink:label="fdmt_CollaborationArrangementsUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct" xlink:label="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_BuildingLeaseAndExpansionMember" xlink:label="fdmt_BuildingLeaseAndExpansionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia" xlink:label="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_PrepaidExpensesToRelatedPartiesCurrent" xlink:label="fdmt_PrepaidExpensesToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:label="fdmt_OrganizationAndNatureOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption" xlink:label="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerAMember" xlink:label="fdmt_CustomerAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct" xlink:label="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandFourteenPlanMember" xlink:label="fdmt_TwoThousandFourteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived" xlink:label="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_VestingOfCommonStockWarrantInReturnForServices" xlink:label="fdmt_VestingOfCommonStockWarrantInReturnForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct" xlink:label="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" xlink:label="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CoFounderAndChiefScientificAdvisorMember" xlink:label="fdmt_CoFounderAndChiefScientificAdvisorMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CommonStockWarrantsTextBlock" xlink:label="fdmt_CommonStockWarrantsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear" xlink:label="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived" xlink:label="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="fdmt_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueOfOptions" xlink:label="fdmt_FairValueOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock" xlink:label="fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationAndLicenseRevenueMember" xlink:label="fdmt_CollaborationAndLicenseRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock" xlink:label="fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:label="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CARESActReliefDescription" xlink:label="fdmt_CARESActReliefDescription"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAchievedMilestones" xlink:label="fdmt_CollaborativeArrangementAchievedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities" xlink:label="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementAdditionalResearchTerm" xlink:label="fdmt_CollaborativeArrangementAdditionalResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesBFinancingMember" xlink:label="fdmt_SeriesBFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FundingAgreementProductMember" xlink:label="fdmt_FundingAgreementProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_WarrantVestsOverPeriod" xlink:label="fdmt_WarrantVestsOverPeriod"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TaxCreditCarryforwardExpirationDescription" xlink:label="fdmt_TaxCreditCarryforwardExpirationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SponsoredResearchAgreementsMember" xlink:label="fdmt_SponsoredResearchAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments" xlink:label="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption" xlink:label="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember" xlink:label="fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CommitmentAndContingenciesLineItems" xlink:label="fdmt_CommitmentAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementTransactionPriceAdjustment" xlink:label="fdmt_CollaborativeArrangementTransactionPriceAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="fdmt_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability" xlink:label="fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AmendedUniQureAgreementMember" xlink:label="fdmt_AmendedUniQureAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueAssumptionsChangeOfControlPayment" xlink:label="fdmt_FairValueAssumptionsChangeOfControlPayment"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyCosts" xlink:label="us-gaap_RelatedPartyCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld" xlink:label="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct" xlink:label="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_LicenseArrangementsAbstract" xlink:label="fdmt_LicenseArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ResearchAndDevelopmentExpenseRelatedParty" xlink:label="fdmt_ResearchAndDevelopmentExpenseRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_BuildingLeaseMember" xlink:label="fdmt_BuildingLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ShortTermMarketableSecuritiesMember" xlink:label="fdmt_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonemployeeMember" xlink:label="fdmt_NonemployeeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NumberOfWarrantsIssued" xlink:label="fdmt_NumberOfWarrantsIssued"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CommitmentAndContingenciesTable" xlink:label="fdmt_CommitmentAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage" xlink:label="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerBMember" xlink:label="fdmt_CustomerBMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember" xlink:label="fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution" xlink:label="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CommonStockWarrantsPolicyPolicyTextBlock" xlink:label="fdmt_CommonStockWarrantsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments" xlink:label="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_ChoroideremiaResearchFoundationMember" xlink:label="fdmt_ChoroideremiaResearchFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TaxCreditCarryforwardBeginningExpirationYear" xlink:label="fdmt_TaxCreditCarryforwardBeginningExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityDisclosureTextBlock" xlink:label="fdmt_TemporaryEquityDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_DevelopmentMilestones" xlink:label="fdmt_DevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AccruedAndOtherLiabilitiesTextBlock" xlink:label="fdmt_AccruedAndOtherLiabilitiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone" xlink:label="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_AnnualRoyalty" xlink:label="fdmt_AnnualRoyalty"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OptionsToPurchaseOrdinaryShares" xlink:label="fdmt_OptionsToPurchaseOrdinaryShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_TermOfAgreement" xlink:label="fdmt_TermOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_OperatingLeaseTermExtendedExpirationPeriod" xlink:label="fdmt_OperatingLeaseTermExtendedExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="fdmt-20211231.xsd#fdmt_CustomerMember" xlink:label="fdmt_CustomerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairments of long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_EmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease extended term date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UniQureBiopharmaBVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">uniQure biopharma B.V.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UniQureBiopharmaBVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Uni Qure Biopharma B V [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UniQureBiopharmaBVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">uniQure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Transfers into Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Level 1 to Level 2 transfers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options and warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon exercise of stock options and warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock upon Exercise of Stock Options and Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LicenseArrangementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License arrangements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LicenseArrangementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Arrangements [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LicenseArrangementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AdditionalFundingCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional funding upon acceptance of investigational New Drug application</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AdditionalFundingCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional funding committed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AdditionalFundingCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Funding Committed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Available for Grant, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Available for Grant, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement adjustment to transaction price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Adjustment To Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement adjustment to transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 300,000,000 shares authorized at December 31, 2021 and 2020; 32,224,524 and 26,681,983 shares issued and outstanding at December 31, 2021 and 2020, respectively.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period, Accounting Standards Update, Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfInstallmentsToPayActualAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of installments to pay actual award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfInstallmentsToPayActualAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Installments To Pay Actual Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfInstallmentsToPayActualAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of installments to pay actual award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandAndSeventeenRocheAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and seventeen Roche agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandAndSeventeenRocheAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Seventeen Roche Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandAndSeventeenRocheAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Roche Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LeaseIncentiveLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease incentive liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LeaseIncentiveLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Incentive Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LeaseIncentiveLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease incentive liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmountsPaidNonRefundableLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount paid non-refundable license fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmountsPaidNonRefundableLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amounts Paid Non Refundable License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmountsPaidNonRefundableLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount paid non-refundable license fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares converted, number of common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number shares issued upon conversion of redeemable convertible preferred shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized losses on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standard Update ("ASU") 2018-18</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2018-18 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options and warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options And Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value stock options and warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license revenue, related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-On Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow on public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (in years), Shares exercisable, December 31,2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonRefundableLicenseFeePayableUponExecution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable license fee payable upon execution.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonRefundableLicenseFeePayableUponExecution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable License Fee Payable Upon Execution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonRefundableLicenseFeePayableUponExecution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable license fee payable upon execution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangements royalties percentage on actual award received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements Royalties Percentage On Actual Award Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties percentage on actual award received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total net deferred tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasuries</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle accounting standards update, adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfAgreementsEntered_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of agreements entered.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfAgreementsEntered_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Agreements Entered</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfAgreementsEntered_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of sponsored research agreements entered</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of equity interests issued as common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Equity Interests Issued As Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of equity interests issued as common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ScheduleOfCommonShareReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common share reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ScheduleOfCommonShareReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Share Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ScheduleOfCommonShareReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Share Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon initial public offering, net of issuance cost (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares sold and issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AccruedClinicalAndPreclinicalStudyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical and preclinical study costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AccruedClinicalAndPreclinicalStudyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical And Preclinical Study Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AccruedClinicalAndPreclinicalStudyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical and preclinical study costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock - 2020 ESPP (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UnpaidOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UnpaidOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UnpaidOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle accounting standards update, immaterial effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable and accrued and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies line items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UCAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">UC Agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UCAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U C Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UCAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UC Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate number of shares of common stock outstanding reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Liabilities Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount obligated to pay a non-refundable license fee annually.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Obligated To Pay Non Refundable License Fee Annually</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable license fee payable annually</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease, right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease, right-of-use assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use ("ROU") assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201807Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standard Update ("ASU") 2018-07</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201807Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2018-07 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement by Share Based Payment Award Shares Available for Grant Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Shares Available for Grant Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Options expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement adjustment to transaction price due to increase in project scope and expected reimbursable costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement adjustment to transaction price due to increase in project scope and expected reimbursable costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Increase Of Project Scope And Expected Reimbursable Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ContingentPaymentsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payments eliminated</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ContingentPaymentsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Payments Eliminated</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ContingentPaymentsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent payments eliminated.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other liabilities, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_WarrantExpiresYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant expires year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_WarrantExpiresYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Expires Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_WarrantExpiresYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, Transfers out of Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standard Update ("ASU") 2019-12</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Embedded Derivative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Concentration Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CorporateBondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CorporateBondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate bond.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CorporateBondMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payment for each nominated product beyond the first three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangements Contingent Payment For Each Nominated Product Beyond First Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration arrangements contingent payment for each nominated product beyond the first three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Beginning and Ending Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates and Judgements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Current portion of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization (accretion) of premium (discount) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development (includes $935 and $579 for the years ended December 31, 2021, and 2020, respectively, attributable to related parties)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_MachineLearningSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machine Learning SRA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_MachineLearningSponsoredResearchAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machine Learning Sponsored Research Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementInitialResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, initial research term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementInitialResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Initial Research Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementInitialResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement, initial research term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_VestingPeriodOfShareAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting period of share awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_VestingPeriodOfShareAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Period Of Share Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_VestingPeriodOfShareAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty incentive award plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Incentive Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Incentive Award Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IssuanceCostForIssuanceOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance cost for issuance of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IssuanceCostForIssuanceOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Cost For Issuance Of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IssuanceCostForIssuanceOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance cost for issuance of preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AdditionalInvestmentInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional investment in cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AdditionalInvestmentInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional investment in cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AdditionalInvestmentInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Investment in Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, estimated performance period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease existence of option to renew term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_NL_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NETHERLANDS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_NL_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Netherlands</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IncurredExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incurred expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IncurredExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incurred Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IncurredExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incurred expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award duration purchase period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Duration Purchase Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duration of purchase period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, Transfers into Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OrganizationAndNatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and nature of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OrganizationAndNatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OrganizationAndNatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Nature Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, Level 2 to Level 1 Transfers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts payable (includes $0 and $173 at December 31, 2021 and 2020, respectively, attributable to related parties)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAdditionOfVariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement adjustment to transaction price due to variable consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAdditionOfVariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement adjustment to transaction price due to variable consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAdditionOfVariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Addition Of Variable Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for current year tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders&#8217; Equity (Deficit), ending balances (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders&#8217; Equity (Deficit), beginning balances (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in-capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UniQureAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">uniQure Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UniQureAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Uni Qure Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UniQureAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">uniQure Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value, 10,000,000 shares authorized at December 31, 2021 2020; no shares issued and outstanding at December 31, 2021 and 2020, respectively.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease liabilities, long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease liabilities, long -term portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term portion of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due from Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due from related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due from Related Parties, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UCRegentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">UC Regents.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UCRegentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U C Regents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_UCRegentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UC Regents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock outstanding increased annually for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Increased Annually For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award percentage of outstanding stock increased annually for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Receivable, after Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Receivable, after Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (in years), Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash investing and financing information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ChoroideremiaResearchFoundationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Choroideremia Research Foundation Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ChoroideremiaResearchFoundationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Choroideremia Research Foundation Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ChoroideremiaResearchFoundationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRF Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_MaximumMaturityPeriodOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum Maturity Period of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_MaximumMaturityPeriodOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum maturity period of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_MaximumMaturityPeriodOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Maturity Period of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in revenue recognized related to performance obligations partially satisfied in the beginning of the current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in revenue recognized related to performance obligations partially satisfied in the beginning of the current year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Shares vested and expected to vest, December 31,2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of non monetary consideration of intellectual property right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Non Monetary Consideration Of Intellectual Property Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of non monetary consideration of intellectual property right.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable for common stock issued upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in redeemable convertible preferred stock financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_WarrantExercisedMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercised month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_WarrantExercisedMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Exercised Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_WarrantExercisedMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant exercised month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon initial public offering, issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CysticFibrosisFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cystic Fibrosis Foundation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CysticFibrosisFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cystic Fibrosis Foundation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CysticFibrosisFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CFF</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturities of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum sales-based milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Maximum Sales Based Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement maximum sales-based milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangements Upfront Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration arrangements upfront payment received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Tax Rate of Income Tax Expense (Benefit) Differs from Federal Statutory Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock, net of $3,138 of issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Underlying Outstanding Options, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Underlying Outstanding Options, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement research and development milestones entitled to receive for each licensed product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Research And Development Milestones Entitled To Receive For Each Licensed Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payments entitled to receive for achievement of research and development milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Redeemable Convertible Preferred Stock, ending balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Redeemable Convertible Preferred Stock, beginning balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, $0.0001 par value; 0 and 7,375,638 shares authorized shares at December 31, 2020 and 2019, respectively; 0 and 7,375,631 shares issued and outstanding at December 31, 2020 and 2019, respectively. Liquidation value of $0 and $108,596 at December 31, 2020 and 2019, respectively.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds Net of Issuance Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration and license revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Options authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_BuildingLeaseAndExpansionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">5858 Horton Street Building Lease and Expansion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_BuildingLeaseAndExpansionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Building Lease and Expansion [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_BuildingLeaseAndExpansionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Building lease and expansion.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone payments relating to Choroideremia</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangements Development Milestone Payments Relating To Choroideremia</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration arrangements development milestone payments relating to Choroideremia.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Previously Reported</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Previously Reported [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award requisite service period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_PrepaidExpensesToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses to related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_PrepaidExpensesToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses To Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_PrepaidExpensesToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses to related parties current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research tax credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Amount representing interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OrganizationAndNatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and nature of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OrganizationAndNatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OrganizationAndNatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Nature Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of equity interest upon closing of first qualified financing at option of UC Regents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of equity interest upon closing of first qualified financing at option.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of equity interest upon closing of first qualified financing at option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer A.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer A</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for doubtful accounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum contingent payment upon exercise of the option to convert a product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangements Maximum Contingent Payment Upon Exercise Of Option To Convert A Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration arrangements maximum contingent payment upon exercise of the option to convert a product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ASC 842 Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standard Update ("ASU") 2016-02</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders&#8217; Equity (Deficit), ending balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders&#8217; Equity (Deficit), beginning balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity attributable to parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandFourteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 401(k) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandFourteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandFourteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award stock overlapping offering period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Stock Overlapping Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock overlapping offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original Issuance Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Temporary equity, shares issued price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Overallotment Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Tax Effects of Temporary Differences to Significant Components of Deferred Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrant shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other risks and uncertainties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Risks And Uncertainties Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(K) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected payments percentage to equal actual award received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Payments Percentage To Equal Actual Award Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected payments percentage to equal actual award received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Impact of Adoption of New Accounting Standard</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_VestingOfCommonStockWarrantInReturnForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of common stock warrant in return for services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_VestingOfCommonStockWarrantInReturnForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Common Stock Warrant In Return For Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_VestingOfCommonStockWarrantInReturnForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of common stock warrant in return for services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock, net of $3,138 of issuance cost (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Continuous period where the Company ceases to develop or commercialize any product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Continuous Period Where Company Ceases To Develop Or Commercialize Any Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Continuous period where the Company ceases to develop or commercialize any product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Disclosure [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of common stock warrants issued for services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital vesting of stock warrant issued for services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Vesting Of Stock Warrant Issued For Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance, deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write-offs relating to uncollectible accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon initial public offering, net of issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CoFounderAndChiefScientificAdvisorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Co-founder and Chief Scientific Advisor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CoFounderAndChiefScientificAdvisorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Co Founder And Chief Scientific Advisor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CoFounderAndChiefScientificAdvisorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">David Schaffer, PhD,</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommonStockWarrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommonStockWarrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommonStockWarrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of marketable securities unrealized loss position more than one year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of marketable securities unrealized loss position more than one year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Marketable Securities Unrealized Loss Position More Than One Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payments received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangements Non Refundable Upfront Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration arrangements non-refundable upfront payment received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets (includes $285 and $169 at December 31, 2021 and 2020, respectively, attributable to related parties)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award exercise price as percentage of fair market value minimum.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Exercise Price As Percentage Of Fair Market Value Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price as percentage of fair market value, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease initial term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Shares exercisable, December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum contributions of employee's eligible compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease in right-of-use assets due to reduction in operating lease liabilities upon modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in right-of-use assets due to reduction in operating lease liabilities upon modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties related to unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenues by Geographic Region</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other-than-temporary impairment on investment in debt securities available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationAndLicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and License Revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationAndLicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationAndLicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of collaboration and license revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaboration And License Revenue Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Collaboration and License Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award shares available for grant grants in period gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Available for Grant, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of outstanding shares held by individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Outstanding Shares Held By Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of outstanding shares held by individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement total amount of award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CARESActReliefDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES Act Relief description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CARESActReliefDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act Relief Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CARESActReliefDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act, relief description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAchievedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement achieved milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAchievedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Achieved Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAchievedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement achieved milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value net unrealized gain (loss) on sale of marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Net Unrealized Gain (Loss) on Sale of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value conversion of convertible securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options and warrants (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options And Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options and warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Shares vested and expected to vest, December 31,2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, liquidation preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liquidation Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Collaboration Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate amount of transaction price allocated to remaining performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount of the transaction price remaining performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining performance obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAdditionalResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement additional research term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAdditionalResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Additional Research Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementAdditionalResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement additional research term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to renew term description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesBFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesBFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesBFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CH_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SWITZERLAND</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CH_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Switzerland</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Compensation Expense for Employees and Nonemployees by Function</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FundingAgreementProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding Agreement Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FundingAgreementProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding agreement product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FundingAgreementProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Agreement Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Collaboration Arrangements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ResearchAndCollaborationArrangementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Collaboration Arrangements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_WarrantVestsOverPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant vests over period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_WarrantVestsOverPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Vests Over Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_WarrantVestsOverPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award shares available for grant forfeitures in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Options forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Fair Value of Level 3 Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TaxCreditCarryforwardExpirationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TaxCreditCarryforwardExpirationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TaxCreditCarryforwardExpirationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, expiration description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable&#8212;Allowance for Doubtful Accounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ASC 842 Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsored Research Agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SRAs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable development milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangements Non Refundable Development Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration arrangements non-refundable development milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Shares exercisable, December 31,2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assumptions probability of change in control event percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Probability Of Change In Control Event Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in control event percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (in years), Shares vested and expected to vest, December 31,2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount obligated to pay upon closing first qualified financing at option.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Obligated To Pay Upon Closing First Qualified Financing At Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount obligated to pay upon closing first qualified financing at option of UC Regents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant shares exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SRAs and Machine Learning SRA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Agreements And Machine Learning Sponsored Research Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment and contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommitmentAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementTransactionPriceAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement transaction price adjustment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementTransactionPriceAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Transaction Price Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementTransactionPriceAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement transaction price adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Redeemable Convertible Preferred Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Shares vested and expected to vest, December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrant to settle liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash Issuance Of Common Stock Warrant to settle liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non cash Issuance Of Common Stock Warrant to settle liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable to related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmendedUniQureAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended uniQure agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmendedUniQureAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Uni Qure Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AmendedUniQureAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended uniQure Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueAssumptionsChangeOfControlPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assumptions change of control payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueAssumptionsChangeOfControlPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Change Of Control Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueAssumptionsChangeOfControlPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change of control payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">F Hoffmann La Roche Ltd And Hoffmann La Roche Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assumptions probability of change in control discount rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Probability Of Change In Control Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in control discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available for Sale Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from offering of securities in a private placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation, expected to be recognized over weighted-average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of financial institutions where cash is held.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Financial Institutions Where Cash Is Held</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of financial institutions cash is held</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Sundry Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward indefinitely</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Actual award payment period upon first commercial sale of product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Actual Award Payment Period Upon First Commercial Sale Of Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Actual award payment period upon first commercial sale of product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrant in connection with settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle accounting standards update, adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LicenseArrangementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License arrangements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_LicenseArrangementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Arrangements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares authorized and reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized and reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock sold and issued price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares priced under public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ResearchAndDevelopmentExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ResearchAndDevelopmentExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ResearchAndDevelopmentExpenseRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense, related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Present value of future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting and professional</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock through 2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_BuildingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">5980 Horton Street Building Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_BuildingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">5980 Horton Street Building Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_BuildingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Building lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Redeemable Convertible Preferred Stock, ending balances (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Redeemable Convertible Preferred Stock, beginning balances (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding shares of redeemable convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Transfers out of Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Nonemployee Consultants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonemployee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonemployee [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonemployee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Warrants Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment and contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommitmentAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Operating Lease Right-of-Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities, operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangements future sales based milestone payments percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements Future Sales Based Milestone Payments Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future sales-based milestone payments percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer B.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer B</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Services and Services as Board of Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Services And Services As Board Of Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable license fee payable upon execution every year after execution.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable License Fee Payable Every Year After Execution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable license fee payable upon execution every year thereafter until sales of a licensed product and payment of royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommonStockWarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommonStockWarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CommonStockWarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock dividend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum development milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangements Maximum Development Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration arrangements maximum development milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Level 2 to Level 1 transfers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due to Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ChoroideremiaResearchFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Choroideremia Research Foundation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ChoroideremiaResearchFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Choroideremia Research Foundation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_ChoroideremiaResearchFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRF</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TaxCreditCarryforwardBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward beginning expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TaxCreditCarryforwardBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Beginning Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TaxCreditCarryforwardBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward beginning expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares conversion of convertible securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value included in other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_DevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AccruedAndOtherLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and other liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AccruedAndOtherLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued And Other Liabilities [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AccruedAndOtherLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Liabilities, Current and Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement contribution upon development milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Contribution Upon Development Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement contribution upon development milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock - 2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AnnualRoyalty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual royalty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AnnualRoyalty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Royalty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_AnnualRoyalty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual royalty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OptionsToPurchaseOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase ordinary shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OptionsToPurchaseOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OptionsToPurchaseOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_TermOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation of unvested options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OperatingLeaseTermExtendedExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease term extended expiration period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OperatingLeaseTermExtendedExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Term Extended Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_OperatingLeaseTermExtendedExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease extended term period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, Level 1 to Level 2 transfers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Share Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="fdmt_CustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Shares exercisable, December 31,2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee purchase price of common stock as percentage of fair market value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Concentration of Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions of prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon offerings, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_EmployeeMember" xlink:to="fdmt_EmployeeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_UniQureBiopharmaBVMember" xlink:to="fdmt_UniQureBiopharmaBVMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants" xlink:to="fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_LicenseArrangementsTextBlock" xlink:to="fdmt_LicenseArrangementsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AdditionalFundingCommitted" xlink:to="fdmt_AdditionalFundingCommitted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice" xlink:to="fdmt_CollaborativeArrangementAdjustmentToTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_NumberOfInstallmentsToPayActualAward" xlink:to="fdmt_NumberOfInstallmentsToPayActualAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TwoThousandAndSeventeenRocheAgreementMember" xlink:to="fdmt_TwoThousandAndSeventeenRocheAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_LeaseIncentiveLiability" xlink:to="fdmt_LeaseIncentiveLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AmountsPaidNonRefundableLicenseFees" xlink:to="fdmt_AmountsPaidNonRefundableLicenseFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201818Member" xlink:to="us-gaap_AccountingStandardsUpdate201818Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:to="fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_FollowOnPublicOfferingMember" xlink:to="fdmt_FollowOnPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_NonRefundableLicenseFeePayableUponExecution" xlink:to="fdmt_NonRefundableLicenseFeePayableUponExecution_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived" xlink:to="fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_NumberOfAgreementsEntered" xlink:to="fdmt_NumberOfAgreementsEntered_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock" xlink:to="fdmt_PercentageOfEquityInterestsIssuedAsCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ScheduleOfCommonShareReservedForFutureIssuance" xlink:to="fdmt_ScheduleOfCommonShareReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AccruedClinicalAndPreclinicalStudyCosts" xlink:to="fdmt_AccruedClinicalAndPreclinicalStudyCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_UnpaidOfferingCosts" xlink:to="fdmt_UnpaidOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_OperatingLossCarryforwardsExpirationYear" xlink:to="fdmt_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fdmt_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_UCAgreementsMember" xlink:to="fdmt_UCAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually" xlink:to="fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201807Member" xlink:to="us-gaap_AccountingStandardsUpdate201807Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts" xlink:to="fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ContingentPaymentsEliminated" xlink:to="fdmt_ContingentPaymentsEliminated_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_WarrantExpiresYear" xlink:to="fdmt_WarrantExpiresYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CorporateBondMember" xlink:to="fdmt_CorporateBondMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree" xlink:to="fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="fdmt_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_MachineLearningSponsoredResearchAgreementMember" xlink:to="fdmt_MachineLearningSponsoredResearchAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementInitialResearchTerm" xlink:to="fdmt_CollaborativeArrangementInitialResearchTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_VestingPeriodOfShareAwards" xlink:to="fdmt_VestingPeriodOfShareAwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TwoThousandTwentyIncentiveAwardPlanMember" xlink:to="fdmt_TwoThousandTwentyIncentiveAwardPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_IssuanceCostForIssuanceOfPreferredStock" xlink:to="fdmt_IssuanceCostForIssuanceOfPreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AdditionalInvestmentInCash" xlink:to="fdmt_AdditionalInvestmentInCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_LongTermMarketableSecuritiesMember" xlink:to="fdmt_LongTermMarketableSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="fdmt_TwoThousandFifteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_IncurredExpenses" xlink:to="fdmt_IncurredExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_OrganizationAndNatureOfBusinessTable" xlink:to="fdmt_OrganizationAndNatureOfBusinessTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementAdditionOfVariableConsideration" xlink:to="fdmt_CollaborativeArrangementAdditionOfVariableConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_UniQureAgreementMember" xlink:to="fdmt_UniQureAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_DeferredOfferingCostsPolicyPolicyTextBlock" xlink:to="fdmt_DeferredOfferingCostsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_UCRegentsMember" xlink:to="fdmt_UCRegentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:to="us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ChoroideremiaResearchFoundationAgreementMember" xlink:to="fdmt_ChoroideremiaResearchFoundationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_DerivativeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_MaximumMaturityPeriodOfMarketableSecurities" xlink:to="fdmt_MaximumMaturityPeriodOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized" xlink:to="fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight" xlink:to="fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="fdmt_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_WarrantExercisedMonthAndYear" xlink:to="fdmt_WarrantExercisedMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CysticFibrosisFoundationMember" xlink:to="fdmt_CysticFibrosisFoundationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments" xlink:to="fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborationArrangementsUpfrontPaymentReceived" xlink:to="fdmt_CollaborationArrangementsUpfrontPaymentReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct" xlink:to="fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_BuildingLeaseAndExpansionMember" xlink:to="fdmt_BuildingLeaseAndExpansionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia" xlink:to="fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_PrepaidExpensesToRelatedPartiesCurrent" xlink:to="fdmt_PrepaidExpensesToRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_OrganizationAndNatureOfBusinessLineItems" xlink:to="fdmt_OrganizationAndNatureOfBusinessLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption" xlink:to="fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CustomerAMember" xlink:to="fdmt_CustomerAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct" xlink:to="fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TwoThousandFourteenPlanMember" xlink:to="fdmt_TwoThousandFourteenPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived" xlink:to="fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_VestingOfCommonStockWarrantInReturnForServices" xlink:to="fdmt_VestingOfCommonStockWarrantInReturnForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct" xlink:to="fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices" xlink:to="fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CoFounderAndChiefScientificAdvisorMember" xlink:to="fdmt_CoFounderAndChiefScientificAdvisorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CommonStockWarrantsTextBlock" xlink:to="fdmt_CommonStockWarrantsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear" xlink:to="fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived" xlink:to="fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="fdmt_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_FairValueOfOptions" xlink:to="fdmt_FairValueOfOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock" xlink:to="fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForTenantImprovements" xlink:to="us-gaap_PaymentsForTenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborationAndLicenseRevenueMember" xlink:to="fdmt_CollaborationAndLicenseRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock" xlink:to="fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:to="fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CARESActReliefDescription" xlink:to="fdmt_CARESActReliefDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementAchievedMilestones" xlink:to="fdmt_CollaborativeArrangementAchievedMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities" xlink:to="fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:to="fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementAdditionalResearchTerm" xlink:to="fdmt_CollaborativeArrangementAdditionalResearchTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_SeriesBFinancingMember" xlink:to="fdmt_SeriesBFinancingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_FundingAgreementProductMember" xlink:to="fdmt_FundingAgreementProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ResearchAndCollaborationArrangementsAbstract" xlink:to="fdmt_ResearchAndCollaborationArrangementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_WarrantVestsOverPeriod" xlink:to="fdmt_WarrantVestsOverPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod" xlink:to="fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TaxCreditCarryforwardExpirationDescription" xlink:to="fdmt_TaxCreditCarryforwardExpirationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_SponsoredResearchAgreementsMember" xlink:to="fdmt_SponsoredResearchAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments" xlink:to="fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage" xlink:to="fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption" xlink:to="fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember" xlink:to="fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:to="fdmt_SeriesA1RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CommitmentAndContingenciesLineItems" xlink:to="fdmt_CommitmentAndContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementTransactionPriceAdjustment" xlink:to="fdmt_CollaborativeArrangementTransactionPriceAdjustment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="fdmt_SeriesCRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="fdmt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability" xlink:to="fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AmendedUniQureAgreementMember" xlink:to="fdmt_AmendedUniQureAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_FairValueAssumptionsChangeOfControlPayment" xlink:to="fdmt_FairValueAssumptionsChangeOfControlPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember" xlink:to="fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate" xlink:to="fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyCosts" xlink:to="us-gaap_RelatedPartyCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld" xlink:to="fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct" xlink:to="fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_LicenseArrangementsAbstract" xlink:to="fdmt_LicenseArrangementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ResearchAndDevelopmentExpenseRelatedParty" xlink:to="fdmt_ResearchAndDevelopmentExpenseRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_SummaryOfSignificantAccountingPoliciesTable" xlink:to="fdmt_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_BuildingLeaseMember" xlink:to="fdmt_BuildingLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ShortTermMarketableSecuritiesMember" xlink:to="fdmt_ShortTermMarketableSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_NonemployeeMember" xlink:to="fdmt_NonemployeeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_NumberOfWarrantsIssued" xlink:to="fdmt_NumberOfWarrantsIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CommitmentAndContingenciesTable" xlink:to="fdmt_CommitmentAndContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage" xlink:to="fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CustomerBMember" xlink:to="fdmt_CustomerBMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember" xlink:to="fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution" xlink:to="fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CommonStockWarrantsPolicyPolicyTextBlock" xlink:to="fdmt_CommonStockWarrantsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments" xlink:to="fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_ChoroideremiaResearchFoundationMember" xlink:to="fdmt_ChoroideremiaResearchFoundationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TaxCreditCarryforwardBeginningExpirationYear" xlink:to="fdmt_TaxCreditCarryforwardBeginningExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TemporaryEquityDisclosureTextBlock" xlink:to="fdmt_TemporaryEquityDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_DevelopmentMilestones" xlink:to="fdmt_DevelopmentMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AccruedAndOtherLiabilitiesTextBlock" xlink:to="fdmt_AccruedAndOtherLiabilitiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone" xlink:to="fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_AnnualRoyalty" xlink:to="fdmt_AnnualRoyalty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_OptionsToPurchaseOrdinaryShares" xlink:to="fdmt_OptionsToPurchaseOrdinaryShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_TermOfAgreement" xlink:to="fdmt_TermOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_OperatingLeaseTermExtendedExpirationPeriod" xlink:to="fdmt_OperatingLeaseTermExtendedExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fdmt_CustomerMember" xlink:to="fdmt_CustomerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576528248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">4D Molecular Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001650648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,237,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,521,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3506994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5858 Horton Street #455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(510) <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">505-2680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FDMT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Portions of the registrant&#8217;s definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2021.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578512200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 153,001<span></span>
</td>
<td class="nump">$ 276,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">94,776<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets (includes $285 and $169 at December 31, 2021 and 2020, respectively, attributable to related parties)</a></td>
<td class="nump">8,456<span></span>
</td>
<td class="nump">4,444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">256,280<span></span>
</td>
<td class="nump">282,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">67,652<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,391<span></span>
</td>
<td class="nump">5,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets, net</a></td>
<td class="nump">14,562<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">353,487<span></span>
</td>
<td class="nump">288,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable (includes $0 and $173 at December 31, 2021 and 2020, respectively, attributable to related parties)</a></td>
<td class="nump">4,764<span></span>
</td>
<td class="nump">1,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">7,744<span></span>
</td>
<td class="nump">8,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,599<span></span>
</td>
<td class="nump">6,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,338<span></span>
</td>
<td class="nump">16,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">2,491<span></span>
</td>
<td class="nump">13,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long -term portion</a></td>
<td class="nump">15,217<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">34,380<span></span>
</td>
<td class="nump">31,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000,000 shares authorized at December 31, 2021 2020; no shares issued and outstanding at December 31, 2021 and 2020, respectively.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 300,000,000 shares authorized at December 31, 2021 and 2020; 32,224,524 and 26,681,983 shares issued and outstanding at December 31, 2021 and 2020, respectively.</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">526,523<span></span>
</td>
<td class="nump">392,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(423)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(206,996)<span></span>
</td>
<td class="num">(135,679)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">319,107<span></span>
</td>
<td class="nump">256,387<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 353,487<span></span>
</td>
<td class="nump">$ 288,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576330776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_PrepaidExpensesToRelatedPartiesCurrent', window );">Prepaid expenses to related parties</a></td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable to related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">32,224,524<span></span>
</td>
<td class="nump">26,681,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">32,224,524<span></span>
</td>
<td class="nump">26,681,983<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_PrepaidExpensesToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses to related parties current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_PrepaidExpensesToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051579732696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 18,038<span></span>
</td>
<td class="nump">$ 13,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Collaboration and license revenue, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">18,038<span></span>
</td>
<td class="nump">13,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development (includes $935 and $579 for the years ended December 31, 2021, and 2020, respectively, attributable to related parties)</a></td>
<td class="nump">61,360<span></span>
</td>
<td class="nump">53,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">28,011<span></span>
</td>
<td class="nump">17,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">89,371<span></span>
</td>
<td class="nump">70,276<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(71,333)<span></span>
</td>
<td class="num">(56,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (71,317)<span></span>
</td>
<td class="num">$ (56,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (2.57)<span></span>
</td>
<td class="num">$ (8.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</a></td>
<td class="nump">27,730,420<span></span>
</td>
<td class="nump">6,430,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577424632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ResearchAndDevelopmentExpenseRelatedParty', window );">Research and development expense, related party</a></td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ResearchAndDevelopmentExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ResearchAndDevelopmentExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578454328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (71,317)<span></span>
</td>
<td class="num">$ (56,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Gross unrealized loss on marketable securities</a></td>
<td class="num">(423)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (71,740)<span></span>
</td>
<td class="num">$ (56,693)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573905960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders&#8217; Equity (Deficit), beginning balances at Dec. 31, 2019</a></td>
<td class="num">$ (72,970)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 6,054<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (79,025)<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable Convertible Preferred Stock, beginning balances (in shares) at Dec. 31, 2019</a></td>
<td class="nump">7,375,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable Convertible Preferred Stock, beginning balances at Dec. 31, 2019</a></td>
<td class="nump">$ 102,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders&#8217; Equity (Deficit), beginning balances (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,178,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standard Update ("ASU") 2018-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of redeemable convertible preferred stock, net of $3,138 of issuance cost</a></td>
<td class="nump">$ 72,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of redeemable convertible preferred stock, net of $3,138 of issuance cost (in shares)</a></td>
<td class="nump">4,200,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock</a></td>
<td class="nump">$ 175,448<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">175,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,575,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock</a></td>
<td class="num">$ (175,448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock (in shares)</a></td>
<td class="num">(11,575,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance cost</a></td>
<td class="nump">$ 204,713<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">204,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices', window );">Vesting of common stock warrants issued for services</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(56,693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders&#8217; Equity (Deficit), ending balances at Dec. 31, 2020</a></td>
<td class="nump">$ 256,387<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">392,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable Convertible Preferred Stock, ending balances (in shares) at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders&#8217; Equity (Deficit), ending balances (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,681,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Issuance of common stock upon exercise of stock options and warrants</a></td>
<td class="nump">$ 3,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Issuance of common stock upon exercise of stock options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance cost</a></td>
<td class="nump">$ 115,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,875,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">563,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrant</a></td>
<td class="nump">$ 1,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">13,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock - 2020 ESPP</a></td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock - 2020 ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices', window );">Vesting of common stock warrants issued for services</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities', window );">Gross unrealized loss on marketable securities</a></td>
<td class="num">(423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(71,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,317)<span></span>
</td>
<td class="num">(71,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders&#8217; Equity (Deficit), ending balances at Dec. 31, 2021</a></td>
<td class="nump">$ 319,107<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 526,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (423)<span></span>
</td>
<td class="num">$ (206,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable Convertible Preferred Stock, ending balances (in shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders&#8217; Equity (Deficit), ending balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,224,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital vesting of stock warrant issued for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options and warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value net unrealized gain (loss) on sale of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock options and warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period value conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576357160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock upon initial public offering, issuance cost</a></td>
<td class="nump">$ 7,660<span></span>
</td>
<td class="nump">$ 17,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_IssuanceCostForIssuanceOfPreferredStock', window );">Issuance cost for issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_IssuanceCostForIssuanceOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance cost for issuance of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_IssuanceCostForIssuanceOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578343032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (71,317)<span></span>
</td>
<td class="num">$ (56,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">13,799<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_VestingOfCommonStockWarrantInReturnForServices', window );">Vesting of common stock warrant in return for services</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,523<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization (accretion) of premium (discount) on marketable securities</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,439<span></span>
</td>
<td class="num">(508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,225)<span></span>
</td>
<td class="num">(2,566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,285<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(14,722)<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(69,134)<span></span>
</td>
<td class="num">(50,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">(9,110)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(168,570)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(172,680)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock upon offerings, net of issuance costs</a></td>
<td class="nump">114,296<span></span>
</td>
<td class="nump">205,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants', window );">Issuance of common stock upon exercise of stock options and warrants</a></td>
<td class="nump">3,360<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Issuance of common stock through 2020 ESPP</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">118,089<span></span>
</td>
<td class="nump">278,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(123,725)<span></span>
</td>
<td class="nump">227,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">276,726<span></span>
</td>
<td class="nump">49,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">153,001<span></span>
</td>
<td class="nump">276,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock into common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">175,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued and other liabilities</a></td>
<td class="nump">2,199<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_UnpaidOfferingCosts', window );">Unpaid offering costs</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Decrease in right-of-use assets due to reduction in operating lease liabilities upon modification</a></td>
<td class="num">(478)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability', window );">Issuance of common stock warrant to settle liability</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Receivable for common stock issued upon exercise of stock options</a></td>
<td class="nump">$ 545<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash Issuance Of Common Stock Warrant to settle liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_UnpaidOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_UnpaidOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_VestingOfCommonStockWarrantInReturnForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting of common stock warrant in return for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_VestingOfCommonStockWarrantInReturnForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582509480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">1. The Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4D Molecular Therapeutics, Inc. (the &#8220;Company&#8221;) was formed as a limited liability company in September 2013 under the name 4D Molecular Therapeutics, LLC. The Company changed its name and converted into a corporation which was incorporated in the state of Delaware in March 2015. The Company is a clinical-stage gene therapy company pioneering the development of product candidates using its targeted and evolved adeno-associated viruses (&#8220;AAV&#8221;) vectors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Initial Public Offering</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2020, the Company sold and issued </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9,660,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock at a price to the public of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, which included shares sold upon the underwriters&#8217; exercise of their overallotment option to purchase </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,260,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> additional shares. The Company received an aggregate of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">204.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in net proceeds, after deducting underwriting discounts and commissions and offering costs.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon the closing of the Company's initial public offering in December 2020 (the "IPO"), all outstanding shares of redeemable convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11,575,984</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock. Subsequent to the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of redeemable convertible preferred stock outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Follow On Public Offering</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2021, the Company completed its second underwritten public offering ("Follow-on Offering") in which </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,750,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock were sold at an offering price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share pursuant to an effective Registration Statement on Form S-1. The net proceeds from the Follow-on Offering were $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">111.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, after deducting underwriting discounts and commissions and offering expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Liquidity</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has incurred significant losses and negative cash flows from operations and had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">207.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as of December 31, 2021. The Company believes that its cash and cash equivalents and marketable securities as of December 31, 2021 are sufficient for the Company to fund planned operations for at least one year from the issuance date of these financial statements for the year ended December 31, 2021. The Company has historically financed its operations primarily through the sale of equity securities, and to a lesser extent, from cash received pursuant to its collaboration and license agreements. To date, none of the Company&#8217;s product candidates have been approved for sale, and therefore, the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows from operations to continue for the foreseeable future. The Company plans to raise additional funding as required based on the status of its clinical trials and projected cash flows. There can be no assurance that, in the event the Company requires additional financing, such financing will be available on terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company&#8217;s ability to achieve its business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582453144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;).</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Use of Estimates and Judgements</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgements that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the contract term, transaction price and costs of collaboration agreements, as well as estimates of the fair value of common stock (prior to the IPO), stock options and derivative instruments and income tax uncertainties. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Due to the coronavirus (&#8220;COVID-19&#8221;) pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2021. While there was not a material impact to the Company&#8217;s financial statements as of December 31, 2021, these estimates may change, as new events occur and additional information is obtained, as well as other factors related to the COVID-19 pandemic that could result in material impacts to the financial statements in future reporting periods.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company operates and manages its business as </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> reportable and operating segment. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on a company-wide basis for purposes of allocating resources and assessing financial performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of and for the years ended December 31, 2021 and 2020, all of the Company&#8217;s long-lived assets were located in the United States and all revenue was earned in the United States.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable securities and accounts receivable. The Company&#8217;s cash is held at </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> financial institutions in the United States of America. The Company&#8217;s cash equivalents are invested in money market funds. The Company also invests in U.S. Treasuries, commercial paper and corporate bonds. The Company has not experienced any losses on its deposits of cash and cash equivalents. Such deposits may, at times, exceed federally insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s partners in collaboration and license agreements who represent 10% or more of the Company&#8217;s total revenue are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.91%;"/>
          <td style="width:1.606%;"/>
          <td style="width:14.636%;"/>
          <td style="width:1.606%;"/>
          <td style="width:14.636%;"/>
          <td style="width:1.606%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer A</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer B</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">*</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">*</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">* Less than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s partners in collaboration and license agreements who represent 10% or more of the Company&#8217;s total accounts receivable are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.974%;"/>
          <td style="width:1.627%;"/>
          <td style="width:14.881%;"/>
          <td style="width:1.627%;"/>
          <td style="width:14.891%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer A</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer B</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s total revenues by geographic region, based on the location of the customer, are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.036%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.793%;"/>
          <td style="width:0.771%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.665%;"/>
          <td style="width:0.921%;"/>
          <td style="width:1.584%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Netherlands</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">736</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">742</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Switzerland</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,181</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,897</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">United States</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">121</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total revenue</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,038</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13,612</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist of money market funds.<br/><br/></span></span><span style="font-size:12.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Marketable Securities</span></span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities consist of commercial paper, corporate bonds and U.S. Treasuries and are included in current and noncurrent assets.  The Company classifies its marketable securities as available-for-sale and carries them at fair value on its balance sheet. Fair value is estimated using independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses on the marketable securities are reported as a component of stockholders' equity (deficit) in accumulated other comprehensive loss.  The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the statements of operations. Realized gains and losses are included in interest income on the statements of operations.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company periodically evaluates its marketable securities to assess whether those with unrealized loss positions are other than temporarily impaired.  The Company considers various factors in determining whether to recognize an impairment charge.  If the Company determines that the decline in an investment's fair value is other-than-temporary, the difference is recognized as an impairment loss in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Other Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (&#8220;CMOs&#8221;) and contract research organizations (&#8220;CROs&#8221;), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The extent of the impact of the COVID-19 pandemic on the Company&#8217;s business will depend upon the duration and spread of the outbreak and the extent and severity of the impact on the Company&#8217;s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. The extent to which the coronavirus outbreak may materially impact the Company&#8217;s financial condition, liquidity or results of operations is uncertain.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a basis for considering such assumptions, a three-level fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Level 1 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212; Observable inputs that reflect unadjusted quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date. </span></div></div><div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Level 2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></div><div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Level 3 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></div></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for transfers of financial instruments between levels of the fair value hierarchy on the date of the event or change in circumstance that caused the transfer.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Accounts Receivable&#8212;Allowance for Doubtful Accounts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company regularly reviews accounts receivable for collectability and establishes an allowance for probable credit losses and writes off uncollectible accounts as necessary. The Company has determined that </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> allowance was required at December 31, 2021 and 2020. The Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t have any write-offs relating to uncollectible accounts receivable during the years ended December 31, 2021 and 2020.</span></p></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over the estimated useful lives of assets, ranging from </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_c05559b7-51fa-4d3d-9739-b6c4a7e260ed;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Leasehold improvements are amortized over the shorter of the useful life of the assets or the lease term. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected within operating expenses in the statements of operations. Maintenance and repairs are charged to expense as incurred.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is typically measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> such impairments of long-lived assets in the years ended December 31, 2021 and 2020.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Redeemable Convertible Preferred Stock</span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance costs. The redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company's control, such as a merger or consolidation, sale, lease, or license of substantially all of the Company's assets (each, a "deemed liquidation event"), the convertible preferred stock would become redeemable at the option of the holders of a majority of the outstanding series of redeemable convertible preferred stock. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the liquidation preference of such shares because a deemed liquidation event obligating the Company to pay the liquidation preference did not occur. All outstanding shares of the redeemable convertible preferred stock converted into common stock upon the close of the IPO in December 2020.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Common Stock Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for common stock warrants which meet the definition of a derivative as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement. Common stock warrants classified as liabilities are initially recorded at fair value and remeasured at fair value each balance sheet date with the offset adjustments recorded in other income (expense), net within the statements of operations. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Leases</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On December 31, 2021, the Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, Leases (Topic 842), ("ASC 842") using the alternative modified retrospective approach effective as of January 1, 2021 to recognize a cumulative-effect adjustment on the effective date and to not adjust financial information and disclosures required under the new lease standards for comparative prior periods.  The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. Additionally, the Company has elected not to separate lease and non-lease components and not to recognize leases with an initial term of twelve months or less.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under ASC 842, at contract inception, the Company determines if an arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the obligation to make lease payments arising from the lease. Operating lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent the Company's obligation to make payments arising from the lease. Operating right-of-use assets and liabilities are recognized at the commencement date of the lease and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates, or abatements the Company expects to receive from the lessor. The Company records amortization of operating right-of-use assets and accretion of lease liabilities as a single lease cost on a straight-line basis over the lease term. No lease renewal options are recognized as part of the right-of-use assets and lease liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company's operating leases are presented in the balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent based on the discounted lease payments to be made within the proceeding twelve months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As the Company&#8217;s leases do not provide an implicit rate , the Company uses its incremental borrowing rate to discount lease payments. The incremental borrowing rate represents an estimated rate of interest that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon adoption of the new lease standard effective </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company recognized operating lease right-of-use assets of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, and current and noncurrent operating lease liabilities of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. In connection with the adoption of this standard, deferred rent of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and lease incentive liability of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which were previously recorded in prepaid expenses and other current assets, accrued and other current liabilities and other liabilities on the balance sheet as of December 31, 2020, were derecognized. The adoption of the standard did </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t have an impact on the Company's statements of operations or comprehensive loss, stockholders' equity or cash flows. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The impact of adoption of the new lease standard as of January 1, 2021 is summarized as follows:<br/></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:11.0pt;font-family:Arial;">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:51.033%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.889%;"/>
          <td style="width:0.91%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.954%;"/>
          <td style="width:0.91%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:11.048%;"/>
          <td style="width:0.91%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31, 2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">ASC 842 Adjustments</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">January 1, 2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease right-of-use assets</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,537</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,537</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prepaid expenses and other current assets</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,444</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">214</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,230</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued and other current liabilities</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,371</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">68</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,303</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other liabilities</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,852</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,696</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">156</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities, current</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,029</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,029</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities, long-term</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,058</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,058</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company determines revenue recognition for arrangements within the scope of Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606") by performing the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s revenue is primarily derived through its license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses to the Company&#8217;s technology, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products. Arrangements that include upfront payments are recorded as deferred revenue upon receipt or when due and are recognized as revenue as performance conditions are met. The event-based milestone payments, royalties and cost reimbursements represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration. Royalty payments are recognized when earned or as the sales occur. The Company records cost reimbursements as accounts receivable when right to consideration is unconditional.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company allocates the total transaction price to each performance obligation based on the estimated standalone selling price and recognizes revenue when, or as, the performance obligation is satisfied. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. At the end of each reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized.</span></p></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Costs related to research, design and development of programs are charged to research and development expense as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses including stock-based compensation, materials, laboratory supplies, outside services and allocated overhead, including rent, insurance, repairs and maintenance, depreciation and utilities. The Company expenses all research and development costs in the period in which they are incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Accrued Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has entered into various agreements with CROs and CMOs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> ASU 2018-07, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees. As of January 1, 2020, the Company accounts for stock-based compensation for stock options granted to employees, directors and nonemployees as measured at grant date, based on the fair value of the award. The Company measures the fair value of awards granted using the Black-Scholes option pricing model and recognizes the expense in the statements of operations over the requisite service period, generally </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, using the straight-line method. Forfeitures are accounted for as they occur. The Company&#8217;s policy for issuing stock upon stock option exercise is to issue new common stock.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the adoption of ASU 2018-07 on January 1, 2020, stock-based compensation expense related to stock options granted to nonemployees was recognized based on the vesting date fair value of options as the stock options were earned. The Company remeasured the stock-based compensation at each reporting period end with the resulting change in fair value being recognized in the statements of operations over the period the related services were rendered. The Company estimated the service period for the options based on the time that would be required to satisfy the service condition, assuming the service condition would be satisfied. Stock-based compensation expense was recognized over the estimated service period but was accelerated if the performance condition was achieved earlier than estimated.</span></p></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&#8217;s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Embedded Derivative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as a separate financial instrument. An embedded derivative exists in the award agreement with the Cystic Fibrosis Foundation (&#8220;CFF&#8221;). As described in Note 16, the embedded derivative has been bifurcated and is classified as a liability on the balance sheet and separately accounted for at its fair value. The derivative liability is subject to remeasurement to fair value each reporting period. Changes in the fair value of the derivative liability are recognized as a component of other income (expense), net within the statements of operations.</span></p></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company capitalizes certain legal, accounting and other third-party fees that are directly related to the Company&#8217;s in-process financings, until such financings are consummated. After consummation of the financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. In the event that a planned offering does not occur or is significantly delayed, all related deferred offering costs will be expensed immediately within the Company&#8217;s statements of operations.</span></p></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Net Loss Per Share, Basic and Diluted</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for companies with participating securities. The Company considers all series of redeemable convertible preferred stock to be participating securities as the holders are entitled to receive non-cumulative dividends on a pari passu basis in the event the dividend is paid on common shares. Under the two-class method, the net loss is not allocated to the redeemable convertible preferred stock as the holders of redeemable convertible preferred stock do not have a contractual obligation to share in losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. Diluted net loss per share is computed by giving effect to all potentially dilutive common shares outstanding for the period. For purposes of this calculation, redeemable convertible preferred shares, stock options to acquire shares of common stock, common stock warrants, and unvested common stock subject to repurchase, are considered potentially dilutive common shares, but have been excluded from the calculation of diluted net loss per share as their effect is antidilutive.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">New Accounting Pronouncements Recently Adopted</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2018-07, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This ASU aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payment to employees. Under this ASU, the measurement of equity-classified nonemployee awards is fixed at the grant date, which may lower their cost and reduce volatility in the statements of operations. The transition method provided by this ASU is on a modified retrospective basis, which recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020, with early adoption permitted, but no earlier than a company's adoption date of ASC 606. The Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> this guidance effective </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> using the modified retrospective method. The Company recorded a less than $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million cumulative-effect adjustment reflected as a decrease to the opening balance of accumulated deficit and a decrease to additional paid-in capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. This ASU clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606, Revenue from Contracts with Customers, when the counterparty is a customer. This ASU also precludes an entity from presenting consideration received from a transaction as revenue from contracts with customers if the counterparty is not a customer for that transaction.  This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.  Early adoption is permitted for entities that have adopted ASC 606, Revenue from Contracts with Customers. The Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> this ASU on </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The adoption of this ASU did </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">not</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> result in a material impact on the Company&#8217;s financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. This ASU affects general principles within Topic 740 and is meant to simplify the accounting for income taxes by removing certain exceptions to the general framework. The ASU adds guidance to reduce complexity in certain areas, including recognizing a franchise (or similar) tax that is partially based on income as an income-based tax and incremental amounts incurred as a non-income-based tax and recognizing deferred taxes for tax goodwill. ASU 2019-12 also created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, other comprehensive income). The amendments in ASU 2019-12 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022.  Early adoption of the amendments is permitted.  The Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> ASU 2019-12 effective </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> on a prospective basis. The adoption of this ASU did </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">not</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> result in a material impact on the Company's financial statements and related disclosures.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In February 2016, the FASB issued ASU No. 2016-02,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. The classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than twelve months regardless of whether it is an operating or financing lease and (ii) lease expense in its statements of operations for operating leases and amortization and interest expense in its statements of operations for financing leases. Leases with a term of twelve months or less may be accounted for similar to existing guidance for operating leases under Topic 840. In July 2018, the FASB issued ASU No. 2018-11, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">See earlier disclosure in this footnote on the impact on the Company of the adoption of this standard in 2021. <br/><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">New Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As an &#8220;emerging growth company,&#8221; the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, as clarified in subsequent amendments. ASU 2016-13 changes the impairment model for certain financial instruments. The new model is a forward-looking expected loss model and will apply to financial assets subject to credit losses and measured at amortized cost and certain off-balance sheet credit exposures. This includes loans, held-to-maturity debt securities, loan commitments, financial guarantees and net investments in leases, as well as trade receivables. For available-for-sale debt securities with unrealized losses, credit losses will be measured in a manner similar to today, except that the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. In October 2019, the FASB voted to delay the effective date of this standard. Topic 326 will be effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051579882600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following tables represent the Company&#8217;s fair value hierarchy for financial assets and financial liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.298%;"/>
        <td style="width:1.167%;"/>
        <td style="width:1.231%;"/>
        <td style="width:9.441%;"/>
        <td style="width:0.61%;"/>
        <td style="width:1.167%;"/>
        <td style="width:1.231%;"/>
        <td style="width:9.473%;"/>
        <td style="width:0.61%;"/>
        <td style="width:1.167%;"/>
        <td style="width:1.231%;"/>
        <td style="width:9.398%;"/>
        <td style="width:0.61%;"/>
        <td style="width:1.167%;"/>
        <td style="width:1.231%;"/>
        <td style="width:11.357%;"/>
        <td style="width:0.61%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Basis for Fair Value Measurements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Fair Value as of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">36,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">36,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">37,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">37,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">94,864</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">94,864</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">US Treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">30,029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">30,029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">36,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">162,428</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">198,984</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Derivative liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">214</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">214</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.829%;"/>
        <td style="width:0.803%;"/>
        <td style="width:1.359%;"/>
        <td style="width:8.765%;"/>
        <td style="width:0.621%;"/>
        <td style="width:0.824%;"/>
        <td style="width:1.359%;"/>
        <td style="width:8.776%;"/>
        <td style="width:0.621%;"/>
        <td style="width:0.824%;"/>
        <td style="width:1.359%;"/>
        <td style="width:8.797%;"/>
        <td style="width:0.621%;"/>
        <td style="width:0.824%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.618%;"/>
        <td style="width:0.621%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Basis for Fair Value Measurements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Fair Value as of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">276,726</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">276,726</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">276,726</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">276,726</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Derivative liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">122</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">122</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Level 3 Inputs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability was determined using a present value analysis with multiple scenarios. In determining the fair value of the derivative liability, the inputs impacting fair value include the change of control payment to CFF, the probability of a change of control event, the product status at time of a change of control event and the discount rate. See Note 16 for further discussion on embedded derivative.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> transfers between Level 1, 2 and 3 during the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3 derivative liability (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.79%;"/>
        <td style="width:1.934%;"/>
        <td style="width:1.53%;"/>
        <td style="width:15.971%;"/>
        <td style="width:0.776%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value included in other income (expense), net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_834220d8-b4e4-44b5-a1d2-6aff019d75c5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2020</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value included in other income (expense), net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">92</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_f500242c-7c9c-43e7-8ba7-87e2388aa1db;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2021</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">214</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582617800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">4. Marketable Securities</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2021 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.349%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.542%;"/>
        <td style="width:9.412%;"/>
        <td style="width:0.782%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.542%;"/>
        <td style="width:9.412%;"/>
        <td style="width:0.782%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.542%;"/>
        <td style="width:9.294%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.542%;"/>
        <td style="width:14.916%;"/>
        <td style="width:0.782%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Amortized Cost Basis</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Fair Value as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,471</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,467</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">57,315</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">57,236</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">US Treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,082</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,073</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">94,868</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">92</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">94,776</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,068</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37,821</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">193</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37,628</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">US Treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25,073</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">117</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">24,956</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">67,983</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">331</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">67,652</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All marketable securities held as of December 31, 2021, had contractual maturities of less than </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two years</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. There have been </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> realized gains or losses on marketable securities for the periods presented. </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">None</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of the Company's investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> recognition of any other-than-temporary impairment in the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2020, the Company had </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> marketable securities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582642120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">5. Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.113%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.901%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.891%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Machinery and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,971</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,911</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,527</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,527</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">566</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">473</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Office equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">165</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">421</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">366</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Construction in progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,066</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">539</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,716</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,917</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,325</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,844</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14,391</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,073</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">All property and equipment are maintained in the United States. Depreciation expense was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended December 31, 2021 and 2020, respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582505976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Liabilities, Current and Noncurrent<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AccruedAndOtherLiabilitiesTextBlock', window );">Accrued and Other Liabilities, Current and Noncurrent</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">6. Accrued and Other Liabilities, Current and Noncurrent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.149%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.018%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.018%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,994</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued clinical and preclinical study costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">407</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">869</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Consulting and professional</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,574</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,770</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">491</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total accrued and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,744</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other liabilities, noncurrent consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.178%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.987%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.019%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred rent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,237</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">615</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total other liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_AccruedAndOtherLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_AccruedAndOtherLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582679592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ResearchAndCollaborationArrangementsAbstract', window );"><strong>Research And Collaboration Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research and Collaboration Arrangements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">7. Research and Collaboration Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Collaboration and license revenue for each period was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.014%;"/>
        <td style="width:1.584%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.804%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.584%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.675%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.584%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">uniQure</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">736</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">742</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Roche</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,181</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,897</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CFF</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">121</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,038</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13,612</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred revenue for each period was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.124%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.019%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.041%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Deferred Revenue <br/>as of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">uniQure</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,661</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Roche</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14,318</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CFF</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,429</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,098</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,090</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,812</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The total amount of revenue in the year ended December 31, 2021, which was included in deferred revenue at January 1, 2021, was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The total amount of revenue in the year ended December 31, 2020, which was included in deferred revenue at January 1, 2020, was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">uniQure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In January 2014, the Company and uniQure biopharma B.V. (&#8220;uniQure&#8221;) entered into a Collaboration and License Agreement (the &#8220;uniQure Agreement&#8221;) to collaborate on the discovery and non-clinical research activities related to the Company&#8217;s Therapeutic Vector Evolution platform in order to generate and validate vectors for gene delivery to treat diseases within the central nervous system and liver (together, the &#8220;uniQure Field&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The uniQure Agreement provided uniQure with a research license as well as an exclusive development and commercialization license for each project variant selected for further development. The initial research term is </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> with an option for uniQure to extend the research term one time for an additional year. Once the Company&#8217;s research plan has concluded, uniQure is solely responsible for the continued development, manufacturing and commercialization of the project variants as potential product candidates. In October 2016, uniQure exercised its option to extend the research term for an additional year to January 2018. The Company was also required to work exclusively with uniQure in the uniQure Field (the &#8220;uniQure Exclusivity Clause&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the uniQure Agreement, the Company received upfront payments of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, and was entitled to receive (i) contingent payments for the achievement of research and development milestones of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for each licensed product selected under the arrangement, and (ii) royalties in the single digit range on future sales of the potential product candidates and sublicense consideration in the low teens to low thirties range on any future sublicensing arrangements. The Company also received capped research and development service fees based on contractual full-time employee rates per year. In connection with the performance obligations under the uniQure Agreement, the founders of 4D Molecular Therapeutics, LLC received equity options to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">609,744</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of uniQure ordinary shares that vest over the initial </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> term of the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The upfront payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was recorded as deferred revenue and was recognized on a ratable basis over the estimated performance period of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Payments and reimbursements for research costs were recognized on an as-incurred basis. The options to purchase uniQure shares were deemed to be a noncash component of the arrangement consideration, as the vesting of options is linked to the uniQure Agreement and there is a requirement for the holders of the options to provide services under the agreement. The fair value of the uniQure options, which was estimated to be $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, was recognized ratably as revenue over the estimated performance period of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and the associated compensation expense related to the stock options were recorded as research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In August 2019, the Company and uniQure entered into an Amended and Restated Collaboration and License Agreement (the &#8220;Amended uniQure Agreement&#8221;), which amended and restated the uniQure Agreement, and a separate Collaboration and License Agreement (the &#8220;Second uniQure Agreement&#8221;). Under these agreements, the Company agreed to transfer incremental rights and services to uniQure in exchange for uniQure eliminating the uniQure Exclusivity Clause and transferring other rights back to the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Amended uniQure Agreement, uniQure continues to have an exclusive license to select AAV capsid variants (the &#8220;Selected Variants&#8221;) in the uniQure Field. uniQure continues to be solely responsible, at its cost, to develop and commercialize the compounds and products containing the Selected Variants. The amended uniQure Agreement eliminated the uniQure Exclusivity Clause in the uniQure Agreement. Furthermore, the contingent payments that the Company was entitled to from uniQure for the achievement of research and development milestones of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for each licensed product selected under the uniQure Agreement were eliminated and sublicense consideration on any future sublicensing arrangements was reduced from the low teens to low thirties percentages to mid-single digit to mid-twenties percentages.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the Second uniQure Agreement, the parties agreed to research and develop new AAV capsid variants (the &#8220;New Variants&#8221;) that are not Selected Variants that affect certain targets selected by uniQure (the &#8220;uniQure Targets&#8221;) in the uniQure Field. The Company is solely responsible, at its cost, for the research of the New Variants. The Company granted uniQure an exclusive license to a certain number of the New Variants (the &#8220;uniQure New Variants&#8221;) that affect the uniQure Targets. uniQure is solely responsible, at its cost, to develop and commercialize the compounds and products containing the uniQure New Variants that affect the uniQure Targets (the &#8220;Licensed Products&#8221;). The Company retains all rights to New Variants in the uniQure Field that affect targets other than the uniQure Targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under both the Amended uniQure Agreement and the Second uniQure Agreement, uniQure will be required to pay the Company royalties on worldwide annual net sales of Licensed Products at a mid-single digit percentage rate, subject to certain specified reductions. uniQure will also be required to pay the Company sublicensing consideration for sublicensing the Company&#8217;s intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties at a rate between the mid-single digit to mid-twenties. The Company has reciprocal obligations, at the same percentage rates as uniQure, to pay uniQure royalties and sublicensing consideration for sublicensing certain intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company concluded that the Amended uniQure Agreement and the Second uniQure Agreement should be accounted for as one combined contract that should be accounted for as a separate contract from the uniQure Agreement given that the incremental licensed intellectual property rights and research and development services are distinct from the rights and services previously transferred to uniQure under the uniQure Agreement and the transaction price increased by an amount that equals the standalone selling price of the incremental rights and services to be transferred to uniQure under the Amended uniQure Agreement and Second uniQure Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Neither party was required to pay monetary consideration in connection with the execution of the Amended uniQure Agreement or the Second uniQure Agreement or for subsequent performance by the parties under those agreements, notwithstanding the potential future royalty and sublicense consideration described above. The fair value of the non-monetary consideration given by uniQure to the Company, for the intellectual property right is $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. This intellectual property right is considered to be an in-process research and development asset with no alternative future use and, accordingly, was written off as acquired in-process research and development expense in the year ended December 31, 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The incremental transaction price described in the paragraph above was recorded as deferred revenue given that the Company identified one single combined performance obligation under ASC 606, which includes the licenses to the New Variants, research services and participation in the joint steering committee (&#8220;JSC&#8221;). Revenue is being recognized using the input method based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligation. Based on the current estimated timelines, the deferred revenue is expected to be recognized as revenue over approximately </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_3340247d-416d-4f03-a381-b95a54629875;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> from December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company determined the transaction price using the risk adjusted net present value analysis (&#8220;rNPV&#8221;) methodology to value the elimination of the uniQure exclusivity clause and other material rights received by the Company, including the potential royalties the Company would receive from uniQure. The rNPVs incorporate estimates and assumptions including the number of products the Company and uniQure would develop, the risk-adjusted probability of successfully developing a biopharmaceutical product, the probability that uniQure will develop a product, the research and development costs, the potential worldwide sales and associated commercialization costs, corporate tax rate, and discount rate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During each of the years ended December 31, 2021 and 2020 the Company recognized revenue of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million under the Amended uniQure Agreement and the Second uniQure Agreement. As of December 31, 2021 and 2020, deferred revenue relating to uniQure was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. There were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> amounts due from uniQure under the uniQure Agreement, Amended uniQure Agreement or Second uniQure Agreement as of December 31, 2021 and 2020. As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CRF</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2015, the Company entered into a research funding and collaboration agreement (the &#8220;CRF Agreement&#8221;) with the Choroideremia Research Foundation (&#8220;CRF&#8221;), a non-profit organization dedicated to finding a cure for choroideremia, a rare inherited disorder that causes progressive vision loss, ultimately leading to complete blindness. The goal of the CRF Agreement is for CRF to contribute funding to help with the advancement of the Company&#8217;s choroideremia research program. The Company is responsible for all decision making and execution of any and all of the related activities to be completed in its sole discretion. The initial term of the CRF Research Plan is </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The agreement includes contribution by the Company to CRF of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million upon certain development or approval milestones. The overall arrangement has automatic extensions of up to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_80d41e98-685d-4c82-a966-93ef6194e666;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> additional years. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> milestones have been achieved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Revenue was fully recognized for this agreement in the year ended December 31, 2017. There was </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> deferred revenue relating to the CRF Agreement as of December 31, 2021 and 2020. </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> amount was due from or to CRF under the CRF Agreement as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Roche</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2017, the Company entered into a collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, &#8220;Roche&#8221;) to discover and develop products containing optimized next generation AAV Vectors focused on ophthalmological diseases and disorders excluding select criteria (the &#8220;2017 Roche Agreement&#8221;). The Company and Roche both have the ability to nominate products to discover, develop and commercialize.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">At the effective date of the 2017 Roche Agreement, choroideremia was designated a Roche product class and the 4D-110 product was licensed to Roche. The Company was responsible for conducting research and development services prior to pivotal clinical studies, and Roche was responsible for conducting subsequent development and commercialization activities. In addition, Roche agreed to pay for research and development services at the agreed upon full-time employee rate for work performed for choroideremia under the 2017 Roche Agreement, and certain external costs, except for the costs associated with the manufacturing work for choroideremia.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the 2017 Roche Agreement, Roche had an option, exercisable prior to pivotal clinical studies, to license 4D-125 (for the treatment of XLRP), which was not exercised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to the 2017 Roche Agreement, the Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as consideration. In addition, the Company was entitled to contingent payments including (i) $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for each Roche nominated product beyond the first three, (ii) up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million upon exercise of the option to convert a product the Company nominated and developed prior to pivotal clinical studies, (iii) development milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">223.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, of which $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">86.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million related to choroideremia and the rest related to other licensed products; and (iv) sales-based milestones of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">123.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in connection with licensed products. Through December 31, 2021, the Company received $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for development milestone payments that are non-refundable. The 2017 Roche Agreement also included provisions that entitled the Company to receive royalty payments ranging from the mid-single digits to the mid-teens for the net sales of the licensed products, in each case subject to the reductions in accordance with the terms of the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company identified a single combined performance obligation for the license, research services and participation in the JSC and concluded that Roche&#8217;s option did not represent a material right. The Company&#8217;s contract with Roche did not include a significant financing component. The Company further concluded that the transaction price should not include the variable consideration related to development milestones as they were considered to be constrained as it was probable that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in the future. The Company excluded any consideration related to sales-based milestones, including royalties, which would be recognized when the related sales occur. The transaction price and estimated period of performance are re-evaluated at each reporting period and adjusted as needed to reflect changes in the scope of the project, reimbursable expenses and other conditions affecting variable consideration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2021, the Company received from Roche notice of termination without cause of the 2017 Roche Agreement. The licenses granted by the Company to Roche under the 2017 Roche Agreement terminated in their entirety on September 16, 2021. Therefore, as of September 16, 2021, Roche no longer has a license for 4D-110 for the treatment of choroideremia or any other product class, and the Company is no longer entitled to receive any further milestones or royalties from Roche. In July 2021, the Company notified Roche of the Company&#8217;s election to continue development of choroideremia. As a result, in accordance with the terms of the agreement, all rights to 4D-110 data and intellectual property generated under the collaboration reverted to the Company. Under the 2017 Roche Agreement, if the Company is required to initiate a new Phase 1/2a clinical trial for 4D-110, the Company would not owe any royalty to Roche on net sales of 4D-110. If, however, the Company moves directly to a pivotal trial of 4D-110, without first being required to conduct a new Phase 1/2a clinical trial, the Company must pay Roche a mid-single digits percentage royalty on the net sales of 4D-110.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a result of the termination of the 2017 Roche Agreement, an adjustment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was made to the transaction price to reflect the decrease in reimbursable costs for the year ended December 31, 2021. The decrease in the transaction price and total budgeted costs for the remaining performance obligation resulted in an $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million increase in revenue recognized in the year ended December 31, 2021 related to the performance obligation partially satisfied prior to January 1, 2021. For the year ended December 31, 2020, an adjustment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was made to the transaction price to reflect an increase of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in the scope of the project and expected reimbursable costs and the addition of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of variable consideration as the uncertainty associated with two development milestones was resolved. The adjustments to the transaction price and total budgeted costs in 2020 resulted in a $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million increase in revenue recognized in the year ended December 31, 2020 related to performance obligations partially satisfied in periods prior to January 1, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the years ended December 31, 2021 and 2020, the Company recognized revenue of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million from Roche, respectively. As of December 31, 2021 and 2020, deferred revenue relating to the Roche Agreement was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. Accounts receivable from Roche under this agreement as of December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CFF</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In September 2016, the Company entered into an award agreement for the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program with CFF, a non-profit organization dedicated to finding a cure for cystic fibrosis, an inherited disorder that causes disease in the pulmonary airways leading to morbidity and mortality. Under this agreement, CFF contributes funding to help advance the Company&#8217;s CF research program. The agreement was subsequently amended in September 2017, August 2018 and February 2021 (all four agreements are collectively referred to as the &#8220;CFF Agreement&#8221;). The total amount of the award under the CFF Agreement is $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. As of December 31, 2021 and 2020, the Company achieved milestones totaling $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million under the CFF Agreement, respectively. The remaining award amount will be paid by CFF based on achievement of certain development milestones by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company expects to make payments to CFF equal to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_ae6a1cea-4dc5-429f-b6df-a8af5d5155a4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">six</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> times the actual award received by the Company in </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> installments within the first </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of the first commercial sale of a product developed under this agreement. The Company also has agreed to make future sales-based milestone payments to CFF of up to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_55f2fc27-7ef4-4149-a482-d2ca9293554a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> times the actual award received upon achieving specified commercialization milestones with respect to the first of any product developed utilizing any compound covered under the CFF Agreement. The CFF Agreement also requires the Company to pay to CFF royalties of a mid-single digit percentage, up to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_ebac0ee9-675f-4dde-a1fd-3d4097e446f6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">six</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> times the actual award received, on any amounts received by the Company from the sale, license or transfer to a third-party of rights in the technology developed as a result of this collaboration. Any such royalty payments shall be credited against the payments owed by the Company upon first commercial sale. In the event of a change of control of the Company, CFF will receive certain payments, depending on the timing of the change of control and the size of the transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">To date, the Company has not developed a commercial product in connection with the CFF Agreement, and it has not licensed, sold or otherwise transferred to another party the product developed under the CFF Agreement or the underlying technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If at any time prior to the first commercial sale of a product developed as a result of the CFF Agreement, the Company ceases to use commercially reasonable efforts to develop or commercialize any product under the CFF Agreement for a continuous period of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">180</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> consecutive days and fails to present a reasonable plan to resume commercially reasonable efforts, the Company will grant to CFF an irrevocable, exclusive worldwide interruption license under all of the Company&#8217;s interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under ASC 606, the Company identified one performance obligation within the CFF grant agreement for research activities. The Company&#8217;s contract with CFF does not include a significant financing component.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company concluded that the transaction price should not include the variable consideration related to future research milestones as they were considered to be constrained as it is probable that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in the future. The Company re-evaluates the transaction price and estimated period of performance at each reporting period. For the year ended December 31, 2021, an adjustment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was made to the transaction price to reflect the achievement of the fourth milestone related to demonstrating GFP expression and determining a cell specific expression profile in human and NHP upper airway ALI cultures following apical transduction under the CFF Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the years ended December 31, 2021 and 2020, the Company recognized revenue of  $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">) million, respectively. As of December 31, 2021 and 2020, deferred revenue relating to the CFF Agreement was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. Accounts receivable from CFF under the CFF Agreement as of December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. Based on current timelines, the deferred revenue is expected to be recognized as revenue over the next </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_6a54b9ee-b4de-4717-a1a2-a0f99f73deb0;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> as the Company performs research services through the completion of IND-enabling studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The obligation to make payments to CFF upon a change of control meets the definition of an embedded derivative that is required to be bifurcated and separately accounted for as a derivative liability. See Note 16 for further discussion of the embedded derivative.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ResearchAndCollaborationArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Collaboration Arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ResearchAndCollaborationArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582696152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_LicenseArrangementsAbstract', window );"><strong>License Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_LicenseArrangementsTextBlock', window );">License Arrangements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">8. License Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has exclusive, worldwide license agreements (the &#8220;UC Agreements&#8221;) with the Regents of the University of California (the &#8220;UC Regents&#8221;) relating to the use of certain patents and intellectual property surrounding its core technologies, including Therapeutic Vector Evolution. Pursuant to each of the UC Agreements executed prior to January 2019, the Company was obligated to pay a (i) non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> upon execution, (ii) a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents, (iii) reimbursement of domestic and foreign patent filing, prosecution and maintenance fees, and (iv) either $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> or issuance of a </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% equity interest in the Company upon the closing of the first qualified financing at the option of the UC Regents. The Company&#8217;s first qualified financing occurred in 2015 and at the election of the UC Regents, the Company issued the UC Regents in January 2016 an amount of common stock equal to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the equity interests in the Company pursuant to the applicable clause in each of the UC Agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Pursuant to an agreement with the UC Regents executed in January 2019 the Company paid a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> on the one-year anniversary of the contract effective date and each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, (ii) low single digit royalties on the net sales of its developed products that consists of a minimum annual royalty of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million per year for the term of the Agreement beginning in the first calendar year after the year in which net sales first occurred, and (iii) sublicense consideration in the mid-teens to the mid-twenties-range on any future sublicensing arrangements the Company may enter into with third-party licensees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In July 2021, the Company entered into an exclusive license agreement with the UC Regents and the Trustees of the University Pennsylvania to license intellectual property related to certain vectors. In July 2021, the Company paid a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license maintenance fee of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> on the one-year anniversary of the contract effective date and each year thereafter, except years for which the Company has paid royalties on the net sales of a licensed product. In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, (ii) low single digit percentage rate royalties on the net sales of its licensed products that consists of a minimum annual royalty of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million per year for the term of the Agreement beginning in the first calendar year after the year in which net sales first occurred and (iii) sublicense consideration in the mid-single digits to the low twenties percentage rate range on any future sublicensing arrangements the Company may enter into with third-party licensees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the years ended December 31, 2021 and 2020, the Company incurred expenses of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, under the provisions of the outstanding license arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_LicenseArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_LicenseArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_LicenseArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_LicenseArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582668408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">9. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Operating Lease Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the adoption of ASC 842, the Company recognized rent expense for its operating leases on a straight-line basis over the noncancelable lease term and recorded the difference between rent payments and the straight-line rent expense was recorded as a deferred rent liability. As of December 31, 2020, the Company performed an evaluation of its other contracts with customers and suppliers in accordance with ASC 842 and determined that, except for the leases described below, none of the Company&#8217;s contracts contain a material lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">5980 Horton Street Building Lease</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In May 2015, the Company executed a lease agreement for office and laboratory space in Emeryville, California. In January 2016, the Company executed the first amendment to the lease agreement for additional rentable office and laboratory space which extended the lease term to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">March 31, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and updated the option to renew the lease at market rent from the prior additional term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. In October 2018, the Company executed a second amendment to extend the lease to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">September 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Additionally, the second amendment provided a tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which was paid to the Company in November 2018.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The 5980 Horton Street Building Lease is considered an operating lease under ASC 842 as it does not meet the criteria of a finance lease. As of December 31, 2021, the operating lease right-of-use asset and operating lease liability was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. The discount rate used to determine the lease liability was </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">5858 Horton Street Building Lease and Expansion</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In October 2018, the Company executed a second lease agreement for additional office and laboratory space in Emeryville, California. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The new lease has an initial term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">87</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> months beginning on the rent commencement date with the </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">option to renew</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> the lease for one additional term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> at market rent. </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company did not have to pay rent until October 2019. This lease agreement also provided for a tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which was paid to the Company in December 2019. The Company amortizes the tenant improvement allowance on a straight-line basis over the remaining term of the lease as a reduction of rent expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In May 2019, the Company amended the second lease agreement executed in October 2018 to add additional office and laboratory space (the "Expansion"). The amendment extended the term of the lease to December 31, 2029. The Company did not have to pay rent until December 2019. The lease agreement also included a tenant improvement allowance, which was increased to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in February 2021 pursuant to a second amendment to the second lease agreement. In November 2021, the Company received the first installment of this tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. The tenant improvement allowance funds improvements to the additional office and laboratory space, which the Company has determined to be lessee owned. The allowance is treated as a reduction of lease payments used to measure the lease liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The 5858 Horton Street Building Lease and Expansion is considered an operating lease under ASC 842 as it does not meet the criteria of a finance lease. As of December 31, 2021, the operating lease right-of-use asset and operating lease liability was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. The discount rate used to determine the lease liability was </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total operating lease expense for the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. Cash paid for amounts included in the measurement of lease liabilities was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the year ended December 31, 2021.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Neither of the leases include a general option for the Company to terminate the leases.</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the components of lease expense for the year ended December 31, 2021, which are included in operating expenses in the Company&#8217;s statements of operations (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.996%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.88%;"/>
        <td style="width:20.34%;"/>
        <td style="width:0.78%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">914</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,545</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Variable lease payments include amounts relating to common area maintenance and are recognized in the statements of operations as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes supplemental information related to operating leases for the year ended December 31, 2021:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.998%;"/>
        <td style="width:18.536%;"/>
        <td style="width:2.457%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average remaining lease term (in years):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average discount rate:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the maturities of lease liabilities as of December 31, 2021 (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.996%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.538%;"/>
        <td style="width:20.543%;"/>
        <td style="width:0.919%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,058</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,149</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,244</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,686</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: Amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,054</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,448</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: Current portion of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,231</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Long-term portion of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15,217</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Indemnification Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions, such as with vendors and other parties. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently maintains directors&#8217; and officers&#8217; liability insurance that would generally enable it to recover a portion of any future amounts paid. The Company believes the estimated fair value of its indemnification agreements in excess of applicable insurance coverage is not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Legal Proceedings</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. There are no material legal proceedings outstanding at December 31, 2021.  See Note 14 for details of a settlement with a former employee in April 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051579848856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">10. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t record any income tax expense during the years ended December 31, 2021 and 2020. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company&#8217;s ability to realize these assets. All losses before income taxes arose in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The effective tax rate of the Company&#8217;s income tax expense (benefit) differs from the federal statutory rate as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.429%;"/>
        <td style="width:1.563%;"/>
        <td style="width:0.76%;"/>
        <td style="width:11.297%;"/>
        <td style="width:3.384%;"/>
        <td style="width:1.563%;"/>
        <td style="width:0.76%;"/>
        <td style="width:11.297%;"/>
        <td style="width:3.384%;"/>
        <td style="width:1.563%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research tax credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The tax effects of temporary differences that give rise to significant components of the deferred taxes are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.081%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.912%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.912%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Deferred Tax Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37,295</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21,132</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">937</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">993</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,111</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,078</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,018</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,618</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,151</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Intangible asset basis</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">907</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">977</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,460</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">54,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,811</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Deferred Tax Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,064</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">992</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,056</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">50,232</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,811</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total net deferred tax</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Income Taxes,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million during 2021 and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million during the year ended December 31, 2020. The increase in the valuation allowance for each of the years ended December 31, 2021 and 2020 was primarily driven by net losses incurred, stock-based compensation expense and tax credits generated within the U.S.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company had net operating loss (&#8220;NOL&#8221;) carryforwards of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">177.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as of December 31, 2021 and 2020, respectively, available to reduce future taxable income, if any, for federal income tax purposes. $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of the federal NOL carryforwards expire in </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2037</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and the remaining $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">168.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million carryforward indefinitely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021 and 2020, the Company had federal research and development credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, and state research and development credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. The federal credit carryforwards begin expiring in </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and the state credits carryforward </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">indefinitely</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Utilization of the NOL carryforwards and research credit carryforwards may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in the expiration of the NOL and tax credit carryforwards before they are utilized. The Company has experienced ownership changes in the past as a result of its Series B redeemable convertible preferred stock financing. As a result of the ownership changes, some of the tax attribute carryforwards may be permanently limited as they will expire unused and such amounts are excluded from our NOLs as of December 31, 2021. Subsequent ownership changes may result in additional limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The reconciliation of the beginning and ending unrecognized tax benefits amounts is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.722%;"/>
        <td style="width:1.927%;"/>
        <td style="width:1.542%;"/>
        <td style="width:16.039%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Unrecognized<br/>Income Tax<br/>Benefits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,566</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for current year tax positions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,729</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for tax positions of prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">72</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,367</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,219</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for tax positions of prior years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The entire amount of the unrecognized tax benefits would not impact the Company&#8217;s effective tax rate if recognized. During the years ended December 31, 2021 and 2020, the Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will materially increase or decrease during the next 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company files income tax returns in the U.S. federal and California tax jurisdictions. In general, the Company is no longer subject to tax examination by the Internal Revenue Service or state taxing authorities for years before 2017. Although the federal and state statutes are closed for purposes of assessing additional income tax in those prior years, the taxing authorities may still make adjustments to the NOL and credit carryforwards used in open years. Therefore, the tax statutes should be considered open as it relates to the NOL and credit carryforwards used in open years. The Company has no ongoing income tax examinations by tax authorities at this time.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The CARES Act changed certain provisions of the Tax Act. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminated the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021 and increased the amount of interest expense that may be deducted to 50% of adjusted taxable income for taxable years beginning in 2019 or 2020.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> The Company evaluated the impact of the CARES act on its tax provision and concluded that there was not a material impact.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On December 21, 2020, the U.S. president signed into law the Consolidated Appropriations Act, 2021 which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant. The Company evaluated the impact of the Consolidated Appropriations Act, 2021 on its tax provision and concluded that there was not a material impact.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On March 11, 2021, the American Rescue Plan Act was signed into law and contained provisions relating to extending the Employee Retention Tax Credit, additional funding for the PPP loan and Economic Injury Disaster Loans, as well as expanding the covered employees under Section 162(m) for tax years beginning after December 31, 2026. The Company does not expect the American Rescue Plan will have a material impact to its current income tax provision.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On November 15, 2021, the Infrastructure Investment and Jobs Act was signed into law and contained several tax provisions including changes to the Employee Retention Tax Credit after September 30, 2021. The Company does not expect the Infrastructure Investment and Jobs Act will have a material impact to its income tax provision.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582646936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_TemporaryEquityDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">11. Redeemable Convertible Preferred Stock</span></p><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2019, redeemable convertible preferred stock consisted of the following (in thousands, except per share and share amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:14.981%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:12.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.541%;"/>
        <td style="width:11.985%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:16.982%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.541%;"/>
        <td style="width:11.996%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:2.675%;"/>
        <td style="width:14.446%;"/>
        <td style="width:0.781%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Shares<br/>Authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Original<br/>Issuance price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Shares Issued<br/>and Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Liquidation<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Proceeds Net of<br/>Issuance cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">909,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">909,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,001</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,960</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Series A-1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,311,687</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.84</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,311,687</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11,595</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11,548</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Series B</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,154,639</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,154,632</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">90,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">84,472</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,375,638</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,375,631</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">108,596</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">102,980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April and June of 2020, the Company issued a total of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,200,353</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of Series C redeemable convertible preferred stock at $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share for net proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">72.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million. Upon the closing of the Company's IPO on December 15, 2020, all outstanding redeemable convertible preferred stock automatically converted into shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. There were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of redeemable convertible preferred stock outstanding as of December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Funding Agreement with CFF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212; In April 2020, CFF made a $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million investment in the Company's Series C redeemable convertible preferred stock financing. In return for the investment, CFF received shares of Series C redeemable convertible preferred stock, and the Company and CFF entered into a Funding Agreement ("the Funding Agreement"). Pursuant to the terms of the Funding Agreement, except in the event of a technical failure, the $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million received from CFF will be used to advance the development program for 4D-710, the Company's lead product in cystic fibrosis, or any other therapeutic approved by the Program Advisory Group ("PAG") to alleviate pulmonary complications of cystic fibrosis ("the Funding Agreement Product").</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CFF committed to provide an additional $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of funding upon acceptance of an Investigational New Drug ("IND") application or its equivalent to allow for human testing of the Funding Agreement Product ("Acceptance").</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The IND was cleared by the U.S. Food and Drug Administration in October 2021, and CFF made the additional investment of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million in cash for the issuance of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">125,715</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock to CFF.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Except in the event of a technical failure, the Company is committed to providing an amount equal to the funding provided by CFF to be used solely to advance the Funding Agreement Product. A technical failure is defined as a determination by the Company, after consultation with and approval of the PAG that (i) the Funding Agreement Product has failed to reach its intended endpoints due to safety issues, lack of sufficient transgene expression and/or efficacy, each despite commercially reasonable efforts and (iii) the exercise of further commercially reasonable efforts is unlikely to correct such failure. Under the terms of the Funding Agreement, neither the $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million investment in the Series C redeemable convertible preferred stock, which converted to common stock as of December 31, 2020, nor the $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million of funding upon Acceptance are restricted as to withdrawal or usage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_TemporaryEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_TemporaryEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582648952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">12. Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of each of December 31, 2021 and 2020, the Company&#8217;s certificate of incorporation authorized the Company to issue </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">300,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock, at the par value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share. The holder of each share of common stock is entitled to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one vote per share</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Common stockholders are entitled to dividends if and when declared by the board of directors, subject to the prior rights of the redeemable preferred stockholders. As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> dividends on common stock had been declared by the board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021 and 2020, the Company has reserved common stock, on an as-converted basis, for future issuance as follows: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.356%;"/>
        <td style="width:1.606%;"/>
        <td style="width:0.771%;"/>
        <td style="width:13.674%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.606%;"/>
        <td style="width:0.771%;"/>
        <td style="width:13.674%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock under the 2020 Equity Incentive Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,690,097</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,606,546</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock under the Employee Stock Share Purchase Plan</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">498,747</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">252,337</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercise of options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,881,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,194,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercise of common stock warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">53,669</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">98,669</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total common stock reserved</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,123,787</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,151,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051579863272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">13. Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2020 Incentive Award Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2020, the Company adopted the 2020 Incentive Award Plan (&#8220;2020 Plan&#8221;), which became effective on December 10, 2020. The 2020 Plan initially reserved </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,606,546</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance bonus awards, performance stock units, dividend equivalents or other stock or cash based award granted to employees, directors and consultants of the Company. The number of shares reserved for future issuance under the 2020 Plan will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock may be issued upon the exercise of incentive stock options. In 2021, an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,334,099</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock became available for issuance under the 2020 Plan, as a result of the operation of the automatic annual increase provision. All options are exercisable over a period not to exceed the contractual term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> from the date the stock options were issued. As of December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,690,097</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares available for grant under the 2020 Plan.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Following the effectiveness of the 2020 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;). However, the 2015 Plan continues to govern the terms of options that remain outstanding under the 2015 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">2015 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The 2015 Plan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">provided for grants of stock options, stock appreciation rights, restricted stock and restricted stock unit awards to employees, directors and consultants of the Company. As of December 31, 2021, options to purchase </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,519,217</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock were outstanding under the 2015 Plan. All options are exercisable over a period not to exceed the contractual term of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> from the date the stock options were issued and are granted at prices not less than the estimated fair market value of the Company&#8217;s common stock on the grant date as determined by the board of directors. If an individual owns stock representing more than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the Company&#8217;s outstanding shares, the exercise price of each share shall be at least </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the fair market value on the date of grant.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> additional grants will be made under the 2015 Plan, and all outstanding grants under the 2015 Plan that are repurchased, forfeited, expire or are cancelled are returned back to the 2015 Plan and are not available for grant under the 2020 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Employee Stock Purchase Plan</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2020, the Company adopted the 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;). Under the 2020 ESPP, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">252,337</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company's common stock were initially reserved for employee purchases of the Company's common stock under terms and provisions established by the Company's board of directors and approved by the Company's stockholders. The number of shares reserved for future issuance under the 2020 ESPP will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares the Company's common stock may be issued under the 2020 ESPP. On March 28, 2022, an additional </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of common stock became available for future issuance under the 2020 ESPP, as a result of the operation of this automatic annual increase provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">   </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under the 2020 ESPP the Company's employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2020 ESPP provides for a series of overlapping </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">24-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> offering periods comprising four </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">six-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> purchase periods. The initial offering period under the 2020 ESPP is longer than 24 months, commencing February 15, 2021 and ending on May 14, 2023. Contributions under the 2020 ESPP are limited to a maximum of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of an employee's eligible compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the stock options activity for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.854%;"/>
        <td style="width:0.225%;"/>
        <td style="width:1.167%;"/>
        <td style="width:10.332%;"/>
        <td style="width:0.867%;"/>
        <td style="width:0.225%;"/>
        <td style="width:1.435%;"/>
        <td style="width:11.274%;"/>
        <td style="width:0.867%;"/>
        <td style="width:0.225%;"/>
        <td style="width:1.349%;"/>
        <td style="width:9.251%;"/>
        <td style="width:0.61%;"/>
        <td style="width:0.225%;"/>
        <td style="width:1.349%;"/>
        <td style="width:10.632%;"/>
        <td style="width:0.61%;"/>
        <td style="width:0.225%;"/>
        <td style="width:1.638%;"/>
        <td style="width:13.03%;"/>
        <td style="width:0.61%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Number of<br/>Shares<br/>Available<br/>for Grant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Balances at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">2,606,546</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">3,194,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">11.05</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">8.46</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">97,105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">1,334,099</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">1,566,150</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">1,566,150</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">34.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">563,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">6.26</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">4,324</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">4,324</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">36.33</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">311,278</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">311,278</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">29.17</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Balances at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">2,690,097</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">3,881,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">19.86</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">7.97</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">24,666</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Shares exercisable, December 31,<br/>&#160;&#160;&#160;2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">1,592,139</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12.75</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">7.07</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">17,280</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Shares vested and expected to <br/>&#160;&#160;&#160;vest, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">3,881,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">19.86</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">7.97</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">24,666</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table is a summary of stock compensation expense for employees and nonemployees by function (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.671%;"/>
        <td style="width:1.424%;"/>
        <td style="width:1.541%;"/>
        <td style="width:12.706%;"/>
        <td style="width:0.781%;"/>
        <td style="width:1.424%;"/>
        <td style="width:1.541%;"/>
        <td style="width:12.706%;"/>
        <td style="width:0.781%;"/>
        <td style="width:1.424%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,847</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,670</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,952</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,314</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13,799</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,984</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the years ended December 31, 2021 and 2020 the Company granted </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,521,150</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,267,743</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> stock options to employees with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">34.46</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11.84</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, respectively and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">54,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> stock options to nonemployees with a weighted-average grant date fair value of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">47.42</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11.05</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, respectively. The total fair value of options vested during the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. As of December 31, 2021, the unrecognized stock-based compensation expense of unvested options was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and is expected to be recognized over a weighted-average period of</span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> 2.7 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation expense recorded for employee options was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended December 31, 2021 and 2020, respectively. Stock-based compensation expense recorded for nonemployee consultants was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the Company&#8217;s IPO, the fair value of the shares of common stock underlying the stock options was estimated by the board of directors at various dates considering the Company&#8217;s most recently available third-party valuations of common stock as well as a number of objective and subjective factors including valuation of comparable companies, sales of redeemable convertible preferred stock, operating and financial performance and general and industry specific economic outlook, amongst other factors. The fair value was determined in accordance with the guidance provided by the American Institute of Certified Public Accountants&#8217; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Subsequent to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on its closing market price on the respective grant date.</span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company estimates the fair value of employee and nonemployee stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of the Company's stock options was estimated using the following assumptions for the years ended December 31, 2021 and 2020.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:18.506%;"/>
        <td style="width:1.242%;"/>
        <td style="width:18.506%;"/>
        <td style="width:1.242%;"/>
        <td style="width:1.242%;"/>
        <td style="width:18.517%;"/>
        <td style="width:1.242%;"/>
        <td style="width:18.506%;"/>
        <td style="width:1.242%;"/>
        <td style="width:1.242%;"/>
        <td style="width:18.517%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31, 2020</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Employee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Nonemployee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Employee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Nonemployee</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.5 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8211; </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.0 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">80.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">84.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">83.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">82.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">83.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">82.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">83.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.  The expected term for employee options is calculated using the simplified method as the Company does not have sufficient historical information to provide a basis for estimate. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The expected term for nonemployee options is the contractual term of the options.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.  The expected volatility was estimated based on a study of publicly traded peer companies as the Company did not have sufficient trading history for its common stock. The Company selected the peer group based on similarities in industry, stage of development, size and financial leverage with the Company&#8217;s principal business operations. For each grant, the Company measured historical volatility over a period equivalent to the expected term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Risk-free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.  The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues whose term is similar in duration to the expected term of the respective stock option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.  The Company has not paid and does not anticipate paying any dividends on its common stock in the future. Accordingly, the Company has estimated the dividend yield to be </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582645176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CommonStockWarrantsTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">14. Common Stock Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2016, the Company issued a warrant for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company&#8217;s common stock to a service provider with an exercise price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share, of which </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> warrant shares become exercisable upon completion of an offering of securities in a private placement by the Company with net proceeds in excess of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> warrant shares become exercisable upon completion of an IPO by the Company. The warrant expires in </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model. </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of these warrant shares became exercisable upon the completion of the Series B financing in 2018 and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of these warrants became exercisable upon completion of the IPO in 2020. </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">45,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of this warrant were exercised in October 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In May 2018, the Company issued a warrant for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23,669</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company&#8217;s common stock to a service provider with an exercise price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model, expires in </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and upon issuance was fully vested.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2020, the Company issued a warrant for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">30,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company&#8217;s common stock to a service provider with an exercise price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share. This warrant vests over a period of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and expires in </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2027</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In April 2021, the Company issued a warrant for </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">40,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shares of the Company&#8217;s common stock to a former employee with an exercise price of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9.41</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> per share as a result of a settlement agreement with such former employee. The warrant was exercised in </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">May 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The Company previously recorded an accrual within accrued and other current liabilities within the balance sheet at December 31, 2020 to accrue for the settlement and the related expense was recognized in general and administrative expenses for the year ended December 31, 2020. Upon the issuance of the warrant in April 2021 in connection with the settlement, $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was reclassified from accrued and other current liabilities to additional paid-in capital within the balance sheet as of December 31, 2021.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company recorded less than $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million expense for the above warrants, within operating expenses in the statements of operations during each of the years ended December 31, 2021 and 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CommonStockWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CommonStockWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582696152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share, Basic and Diluted<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share, Basic and Diluted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">15. Net Loss Per Share, Basic and Diluted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.422%;"/>
        <td style="width:1.692%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.276%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.552%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.602%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.552%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Numerator</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">71,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">56,693</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Denominator</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average shares outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27,730,420</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,430,555</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27,730,420</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,430,555</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.57</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.82</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.98%;"/>
        <td style="width:2.997%;"/>
        <td style="width:0.76%;"/>
        <td style="width:13.509%;"/>
        <td style="width:0.76%;"/>
        <td style="width:1.552%;"/>
        <td style="width:0.76%;"/>
        <td style="width:13.37%;"/>
        <td style="width:0.76%;"/>
        <td style="width:1.552%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,881,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,194,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">53,669</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">98,669</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,934,943</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,292,782</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582483656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Liability</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">16. Derivative Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company identified an embedded derivative resulting from the change of control provision in the CFF Agreement. Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as separate financial instruments. At the inception of the derivative in 2017, the Company recognized this derivative as a liability and revenue was reduced by the initial fair value of the derivative liability. The Company remeasures the derivative liability to fair value at each reporting period and records the change in fair value of the derivative liability as other income (expense), net. The Company uses a present value analysis with multiple scenarios, which incorporates assumptions and estimates to value the derivative instrument. The Company assesses these assumptions and estimates on a periodic basis as additional information impacting the assumptions is obtained. Estimates and assumptions impacting the fair value measurement include the change of control payment to CFF (range of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million at December 31, 2021 and December 31, 2020), the probability of a change of control event, the probability of the product achieving development or commercial status at time of change of control (range of </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% at December 31, 2021 and </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% at December 31, 2020) and the discount rate (</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% at December 31, 2021 and December 31, 2020). The Company determined the estimated fair value of this liability as of the inception date of the CFF Agreement and concluded that the amount was immaterial. The Company determined the fair value of this derivative liability was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million as of December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051579850552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">17. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">During the years ended December 31, 2021 and 2020, the Company paid $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">85,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">93,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, respectively, to David Schaffer, Ph.D., the co-founder, director and Chief Scientific Advisor of the Company for consulting services. In April 2019, the Company entered into </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> sponsored research agreements (&#8220;SRAs&#8221;) with the UC Regents to conduct research in a research facility on the U.C. Berkeley campus, under the direction of Dr. Schaffer. The SRAs have a </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three year</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> term ending in May 2022. Under the SRAs, the Company has an option to license (on a royalty-bearing basis) all intellectual property generated under the SRAs. The total amount the Company is committed to pay to the UC Regents under the SRAs is $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which was fully paid as of December 31, 2021. In March 2021, the Company entered into another sponsored research agreement with the UC Regents to conduct research in laboratories on the U.C. Berkeley campus that are under the direction of Dr. Schaffer and another U.C. Berkeley professor covering investigations into how machine learning approaches may enhance AAV capsid engineering (the &#8220;Machine Learning SRA&#8221;). Pursuant to the Machine Learning SRA, the Company has committed to pay the UC Regents a total of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, of which $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million was paid as of December 31, 2021. The Machine Learning SRA has a </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three-year</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> term ending in 2024. Any patent prosecution costs incurred under the SRAs will also be borne by the Company. The Company can terminate the SRAs for convenience and without cause with 60 days&#8217; notice. While the Machine Learning SRA is between the Company and the UC Regents, the payments under the SRA will be used to fund the lab under the direction of Dr. Schaffer. As of December 31, 2021 and 2020, accounts payable to the UC Regents related to the SRAs and Machine Learning SRA was $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. In the years ended December 31, 2021 and 2020, the Company recorded $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively, of expense related to SRAs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In August 2019, the Company and uniQure entered into the amended uniQure Agreement and the Second uniQure Agreement. Under these agreements, the Company agreed to transfer incremental rights and services to uniQure in exchange for uniQure eliminating the exclusivity clause in the uniQure Agreement and transferring other rights back to the Company. Further details and the accounting for these agreements is discussed in Note 7. As of June 17, 2020, uniQure was no longer a related party of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582676728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(K) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">401(K) Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">18. 401(k) Plan</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In 2014, the Company adopted a 401(k) plan for all employees who have met certain eligibility requirements. The 401(k) plan allows employees to make pre-tax and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company made contributions to the Plan for eligible participants, and recorded contribution expenses of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578280344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Judgements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Use of Estimates and Judgements</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgements that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the contract term, transaction price and costs of collaboration agreements, as well as estimates of the fair value of common stock (prior to the IPO), stock options and derivative instruments and income tax uncertainties. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Due to the coronavirus (&#8220;COVID-19&#8221;) pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2021. While there was not a material impact to the Company&#8217;s financial statements as of December 31, 2021, these estimates may change, as new events occur and additional information is obtained, as well as other factors related to the COVID-19 pandemic that could result in material impacts to the financial statements in future reporting periods.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company operates and manages its business as </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> reportable and operating segment. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on a company-wide basis for purposes of allocating resources and assessing financial performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of and for the years ended December 31, 2021 and 2020, all of the Company&#8217;s long-lived assets were located in the United States and all revenue was earned in the United States.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable securities and accounts receivable. The Company&#8217;s cash is held at </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> financial institutions in the United States of America. The Company&#8217;s cash equivalents are invested in money market funds. The Company also invests in U.S. Treasuries, commercial paper and corporate bonds. The Company has not experienced any losses on its deposits of cash and cash equivalents. Such deposits may, at times, exceed federally insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s partners in collaboration and license agreements who represent 10% or more of the Company&#8217;s total revenue are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.91%;"/>
          <td style="width:1.606%;"/>
          <td style="width:14.636%;"/>
          <td style="width:1.606%;"/>
          <td style="width:14.636%;"/>
          <td style="width:1.606%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer A</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer B</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">*</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">*</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">* Less than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s partners in collaboration and license agreements who represent 10% or more of the Company&#8217;s total accounts receivable are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.974%;"/>
          <td style="width:1.627%;"/>
          <td style="width:14.881%;"/>
          <td style="width:1.627%;"/>
          <td style="width:14.891%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer A</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer B</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:12.0pt;font-family:Arial;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s total revenues by geographic region, based on the location of the customer, are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.036%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.793%;"/>
          <td style="width:0.771%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.665%;"/>
          <td style="width:0.921%;"/>
          <td style="width:1.584%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Netherlands</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">736</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">742</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Switzerland</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,181</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,897</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">United States</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">121</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total revenue</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,038</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13,612</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist of money market funds.<br/><br/></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Marketable Securities</span><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities consist of commercial paper, corporate bonds and U.S. Treasuries and are included in current and noncurrent assets.  The Company classifies its marketable securities as available-for-sale and carries them at fair value on its balance sheet. Fair value is estimated using independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses on the marketable securities are reported as a component of stockholders' equity (deficit) in accumulated other comprehensive loss.  The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the statements of operations. Realized gains and losses are included in interest income on the statements of operations.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company periodically evaluates its marketable securities to assess whether those with unrealized loss positions are other than temporarily impaired.  The Company considers various factors in determining whether to recognize an impairment charge.  If the Company determines that the decline in an investment's fair value is other-than-temporary, the difference is recognized as an impairment loss in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock', window );">Other Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Other Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (&#8220;CMOs&#8221;) and contract research organizations (&#8220;CROs&#8221;), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The extent of the impact of the COVID-19 pandemic on the Company&#8217;s business will depend upon the duration and spread of the outbreak and the extent and severity of the impact on the Company&#8217;s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. The extent to which the coronavirus outbreak may materially impact the Company&#8217;s financial condition, liquidity or results of operations is uncertain.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a basis for considering such assumptions, a three-level fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Level 1 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212; Observable inputs that reflect unadjusted quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date. </span></div></div><div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Level 2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></div><div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Level 3 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></div><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for transfers of financial instruments between levels of the fair value hierarchy on the date of the event or change in circumstance that caused the transfer.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable&#8212;Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Accounts Receivable&#8212;Allowance for Doubtful Accounts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company regularly reviews accounts receivable for collectability and establishes an allowance for probable credit losses and writes off uncollectible accounts as necessary. The Company has determined that </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> allowance was required at December 31, 2021 and 2020. The Company did </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t have any write-offs relating to uncollectible accounts receivable during the years ended December 31, 2021 and 2020.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over the estimated useful lives of assets, ranging from </span><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_c05559b7-51fa-4d3d-9739-b6c4a7e260ed;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> to </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Leasehold improvements are amortized over the shorter of the useful life of the assets or the lease term. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected within operating expenses in the statements of operations. Maintenance and repairs are charged to expense as incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is typically measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> such impairments of long-lived assets in the years ended December 31, 2021 and 2020.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Redeemable Convertible Preferred Stock</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance costs. The redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company's control, such as a merger or consolidation, sale, lease, or license of substantially all of the Company's assets (each, a "deemed liquidation event"), the convertible preferred stock would become redeemable at the option of the holders of a majority of the outstanding series of redeemable convertible preferred stock. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the liquidation preference of such shares because a deemed liquidation event obligating the Company to pay the liquidation preference did not occur. All outstanding shares of the redeemable convertible preferred stock converted into common stock upon the close of the IPO in December 2020.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CommonStockWarrantsPolicyPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Common Stock Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for common stock warrants which meet the definition of a derivative as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement. Common stock warrants classified as liabilities are initially recorded at fair value and remeasured at fair value each balance sheet date with the offset adjustments recorded in other income (expense), net within the statements of operations. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Leases</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">On December 31, 2021, the Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, Leases (Topic 842), ("ASC 842") using the alternative modified retrospective approach effective as of January 1, 2021 to recognize a cumulative-effect adjustment on the effective date and to not adjust financial information and disclosures required under the new lease standards for comparative prior periods.  The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. Additionally, the Company has elected not to separate lease and non-lease components and not to recognize leases with an initial term of twelve months or less.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Under ASC 842, at contract inception, the Company determines if an arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the obligation to make lease payments arising from the lease. Operating lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent the Company's obligation to make payments arising from the lease. Operating right-of-use assets and liabilities are recognized at the commencement date of the lease and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates, or abatements the Company expects to receive from the lessor. The Company records amortization of operating right-of-use assets and accretion of lease liabilities as a single lease cost on a straight-line basis over the lease term. No lease renewal options are recognized as part of the right-of-use assets and lease liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company's operating leases are presented in the balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent based on the discounted lease payments to be made within the proceeding twelve months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As the Company&#8217;s leases do not provide an implicit rate , the Company uses its incremental borrowing rate to discount lease payments. The incremental borrowing rate represents an estimated rate of interest that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon adoption of the new lease standard effective </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company recognized operating lease right-of-use assets of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, and current and noncurrent operating lease liabilities of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, respectively. In connection with the adoption of this standard, deferred rent of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million and lease incentive liability of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million, which were previously recorded in prepaid expenses and other current assets, accrued and other current liabilities and other liabilities on the balance sheet as of December 31, 2020, were derecognized. The adoption of the standard did </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">t have an impact on the Company's statements of operations or comprehensive loss, stockholders' equity or cash flows. </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The impact of adoption of the new lease standard as of January 1, 2021 is summarized as follows:<br/></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</span></p><div style="font-size:11.0pt;font-family:Arial;">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:51.033%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.889%;"/>
          <td style="width:0.91%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.954%;"/>
          <td style="width:0.91%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:11.048%;"/>
          <td style="width:0.91%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31, 2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">ASC 842 Adjustments</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">January 1, 2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease right-of-use assets</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,537</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,537</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prepaid expenses and other current assets</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,444</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">214</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,230</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued and other current liabilities</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,371</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">68</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,303</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other liabilities</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,852</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,696</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">156</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities, current</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,029</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,029</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities, long-term</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,058</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,058</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company determines revenue recognition for arrangements within the scope of Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606") by performing the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s revenue is primarily derived through its license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses to the Company&#8217;s technology, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products. Arrangements that include upfront payments are recorded as deferred revenue upon receipt or when due and are recognized as revenue as performance conditions are met. The event-based milestone payments, royalties and cost reimbursements represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration. Royalty payments are recognized when earned or as the sales occur. The Company records cost reimbursements as accounts receivable when right to consideration is unconditional.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company allocates the total transaction price to each performance obligation based on the estimated standalone selling price and recognizes revenue when, or as, the performance obligation is satisfied. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. At the end of each reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Costs related to research, design and development of programs are charged to research and development expense as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses including stock-based compensation, materials, laboratory supplies, outside services and allocated overhead, including rent, insurance, repairs and maintenance, depreciation and utilities. The Company expenses all research and development costs in the period in which they are incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock', window );">Accrued Research and Development</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Accrued Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has entered into various agreements with CROs and CMOs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, the Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> ASU 2018-07, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees. As of January 1, 2020, the Company accounts for stock-based compensation for stock options granted to employees, directors and nonemployees as measured at grant date, based on the fair value of the award. The Company measures the fair value of awards granted using the Black-Scholes option pricing model and recognizes the expense in the statements of operations over the requisite service period, generally </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, using the straight-line method. Forfeitures are accounted for as they occur. The Company&#8217;s policy for issuing stock upon stock option exercise is to issue new common stock.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the adoption of ASU 2018-07 on January 1, 2020, stock-based compensation expense related to stock options granted to nonemployees was recognized based on the vesting date fair value of options as the stock options were earned. The Company remeasured the stock-based compensation at each reporting period end with the resulting change in fair value being recognized in the statements of operations over the period the related services were rendered. The Company estimated the service period for the options based on the time that would be required to satisfy the service condition, assuming the service condition would be satisfied. Stock-based compensation expense was recognized over the estimated service period but was accelerated if the performance condition was achieved earlier than estimated.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&#8217;s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Embedded Derivative</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Embedded Derivative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as a separate financial instrument. An embedded derivative exists in the award agreement with the Cystic Fibrosis Foundation (&#8220;CFF&#8221;). As described in Note 16, the embedded derivative has been bifurcated and is classified as a liability on the balance sheet and separately accounted for at its fair value. The derivative liability is subject to remeasurement to fair value each reporting period. Changes in the fair value of the derivative liability are recognized as a component of other income (expense), net within the statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_DeferredOfferingCostsPolicyPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company capitalizes certain legal, accounting and other third-party fees that are directly related to the Company&#8217;s in-process financings, until such financings are consummated. After consummation of the financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. In the event that a planned offering does not occur or is significantly delayed, all related deferred offering costs will be expensed immediately within the Company&#8217;s statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share, Basic and Diluted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Net Loss Per Share, Basic and Diluted</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for companies with participating securities. The Company considers all series of redeemable convertible preferred stock to be participating securities as the holders are entitled to receive non-cumulative dividends on a pari passu basis in the event the dividend is paid on common shares. Under the two-class method, the net loss is not allocated to the redeemable convertible preferred stock as the holders of redeemable convertible preferred stock do not have a contractual obligation to share in losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. Diluted net loss per share is computed by giving effect to all potentially dilutive common shares outstanding for the period. For purposes of this calculation, redeemable convertible preferred shares, stock options to acquire shares of common stock, common stock warrants, and unvested common stock subject to repurchase, are considered potentially dilutive common shares, but have been excluded from the calculation of diluted net loss per share as their effect is antidilutive.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">New Accounting Pronouncements Recently Adopted</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2018-07, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This ASU aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payment to employees. Under this ASU, the measurement of equity-classified nonemployee awards is fixed at the grant date, which may lower their cost and reduce volatility in the statements of operations. The transition method provided by this ASU is on a modified retrospective basis, which recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020, with early adoption permitted, but no earlier than a company's adoption date of ASC 606. The Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> this guidance effective </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> using the modified retrospective method. The Company recorded a less than $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> million cumulative-effect adjustment reflected as a decrease to the opening balance of accumulated deficit and a decrease to additional paid-in capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. This ASU clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606, Revenue from Contracts with Customers, when the counterparty is a customer. This ASU also precludes an entity from presenting consideration received from a transaction as revenue from contracts with customers if the counterparty is not a customer for that transaction.  This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.  Early adoption is permitted for entities that have adopted ASC 606, Revenue from Contracts with Customers. The Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> this ASU on </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The adoption of this ASU did </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">not</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> result in a material impact on the Company&#8217;s financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. This ASU affects general principles within Topic 740 and is meant to simplify the accounting for income taxes by removing certain exceptions to the general framework. The ASU adds guidance to reduce complexity in certain areas, including recognizing a franchise (or similar) tax that is partially based on income as an income-based tax and incremental amounts incurred as a non-income-based tax and recognizing deferred taxes for tax goodwill. ASU 2019-12 also created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, other comprehensive income). The amendments in ASU 2019-12 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022.  Early adoption of the amendments is permitted.  The Company </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> ASU 2019-12 effective </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> on a prospective basis. The adoption of this ASU did </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">not</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> result in a material impact on the Company's financial statements and related disclosures.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In February 2016, the FASB issued ASU No. 2016-02,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. The classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than twelve months regardless of whether it is an operating or financing lease and (ii) lease expense in its statements of operations for operating leases and amortization and interest expense in its statements of operations for financing leases. Leases with a term of twelve months or less may be accounted for similar to existing guidance for operating leases under Topic 840. In July 2018, the FASB issued ASU No. 2018-11, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">See earlier disclosure in this footnote on the impact on the Company of the adoption of this standard in 2021. <br/><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">New Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As an &#8220;emerging growth company,&#8221; the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;">Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, as clarified in subsequent amendments. ASU 2016-13 changes the impairment model for certain financial instruments. The new model is a forward-looking expected loss model and will apply to financial assets subject to credit losses and measured at amortized cost and certain off-balance sheet credit exposures. This includes loans, held-to-maturity debt securities, loan commitments, financial guarantees and net investments in leases, as well as trade receivables. For available-for-sale debt securities with unrealized losses, credit losses will be measured in a manner similar to today, except that the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. In October 2019, the FASB voted to delay the effective date of this standard. Topic 326 will be effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CommonStockWarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CommonStockWarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_DeferredOfferingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_DeferredOfferingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051671043272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s partners in collaboration and license agreements who represent 10% or more of the Company&#8217;s total revenue are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.91%;"/>
          <td style="width:1.606%;"/>
          <td style="width:14.636%;"/>
          <td style="width:1.606%;"/>
          <td style="width:14.636%;"/>
          <td style="width:1.606%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer A</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer B</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">*</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">*</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">* Less than </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s partners in collaboration and license agreements who represent 10% or more of the Company&#8217;s total accounts receivable are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.974%;"/>
          <td style="width:1.627%;"/>
          <td style="width:14.881%;"/>
          <td style="width:1.627%;"/>
          <td style="width:14.891%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer A</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Customer B</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues by Geographic Region</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company&#8217;s total revenues by geographic region, based on the location of the customer, are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.036%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.793%;"/>
          <td style="width:0.771%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.665%;"/>
          <td style="width:0.921%;"/>
          <td style="width:1.584%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Netherlands</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">736</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">742</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Switzerland</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,181</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,897</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">United States</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">121</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total revenue</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,038</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13,612</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of Impact of Adoption of New Accounting Standard</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The impact of adoption of the new lease standard as of January 1, 2021 is summarized as follows:<br/></span>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:51.033%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.889%;"/>
          <td style="width:0.91%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:12.954%;"/>
          <td style="width:0.91%;"/>
          <td style="width:1.584%;"/>
          <td style="width:1.531%;"/>
          <td style="width:11.048%;"/>
          <td style="width:0.91%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31, 2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">ASC 842 Adjustments</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">January 1, 2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease right-of-use assets</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,537</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,537</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prepaid expenses and other current assets</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,444</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">214</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,230</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued and other current liabilities</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,371</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">68</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,303</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other liabilities</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,852</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,696</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">156</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities, current</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,029</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,029</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities, long-term</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,058</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,058</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e725-108305<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578338728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following tables represent the Company&#8217;s fair value hierarchy for financial assets and financial liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.298%;"/>
        <td style="width:1.167%;"/>
        <td style="width:1.231%;"/>
        <td style="width:9.441%;"/>
        <td style="width:0.61%;"/>
        <td style="width:1.167%;"/>
        <td style="width:1.231%;"/>
        <td style="width:9.473%;"/>
        <td style="width:0.61%;"/>
        <td style="width:1.167%;"/>
        <td style="width:1.231%;"/>
        <td style="width:9.398%;"/>
        <td style="width:0.61%;"/>
        <td style="width:1.167%;"/>
        <td style="width:1.231%;"/>
        <td style="width:11.357%;"/>
        <td style="width:0.61%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Basis for Fair Value Measurements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Fair Value as of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">36,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">36,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">37,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">37,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">94,864</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">94,864</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">US Treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">30,029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">30,029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">36,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">162,428</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">198,984</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Derivative liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">214</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">214</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.829%;"/>
        <td style="width:0.803%;"/>
        <td style="width:1.359%;"/>
        <td style="width:8.765%;"/>
        <td style="width:0.621%;"/>
        <td style="width:0.824%;"/>
        <td style="width:1.359%;"/>
        <td style="width:8.776%;"/>
        <td style="width:0.621%;"/>
        <td style="width:0.824%;"/>
        <td style="width:1.359%;"/>
        <td style="width:8.797%;"/>
        <td style="width:0.621%;"/>
        <td style="width:0.824%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.618%;"/>
        <td style="width:0.621%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Basis for Fair Value Measurements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Fair Value as of</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">276,726</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">276,726</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">276,726</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">276,726</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Derivative liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">122</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">122</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Level 3 Derivative Liability</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level 3 derivative liability (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.79%;"/>
        <td style="width:1.934%;"/>
        <td style="width:1.53%;"/>
        <td style="width:15.971%;"/>
        <td style="width:0.776%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value included in other income (expense), net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_834220d8-b4e4-44b5-a1d2-6aff019d75c5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2020</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">122</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Change in fair value included in other income (expense), net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">92</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Arial;"><span style="-sec-ix-hidden:F_f500242c-7c9c-43e7-8ba7-87e2388aa1db;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2021</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">214</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582699352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available for Sale Securities</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2021 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.349%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.542%;"/>
        <td style="width:9.412%;"/>
        <td style="width:0.782%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.542%;"/>
        <td style="width:9.412%;"/>
        <td style="width:0.782%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.542%;"/>
        <td style="width:9.294%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.542%;"/>
        <td style="width:14.916%;"/>
        <td style="width:0.782%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Amortized Cost Basis</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Gross Unrealized Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Gross Unrealized Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Fair Value as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,471</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,467</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">57,315</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">57,236</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">US Treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,082</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,073</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">94,868</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">92</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">94,776</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,068</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37,821</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">193</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37,628</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">US Treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">25,073</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">117</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">24,956</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">67,983</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">331</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">67,652</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582454872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net, consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.113%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.901%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.891%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Machinery and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,971</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,911</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,527</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,527</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">566</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">473</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Office equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">165</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">101</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">421</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">366</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Construction in progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">10,066</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">539</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,716</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,917</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,325</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,844</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14,391</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,073</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576605112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Liabilities, Current and Noncurrent (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.149%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.018%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.018%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,994</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Accrued clinical and preclinical study costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">407</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">869</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Consulting and professional</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,574</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,770</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">491</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total accrued and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,744</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Summary of Other Liabilities, Noncurrent</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other liabilities, noncurrent consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.178%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.987%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.019%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred rent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,237</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">615</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total other liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">120</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576349240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ResearchAndCollaborationArrangementsAbstract', window );"><strong>Research And Collaboration Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock', window );">Summary of Collaboration and License Revenue</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Collaboration and license revenue for each period was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.014%;"/>
        <td style="width:1.584%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.804%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.584%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.675%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.584%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">uniQure</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">736</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">742</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Roche</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17,181</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">12,897</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CFF</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">121</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">18,038</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13,612</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Summary of Deferred Revenue</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred revenue for each period was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.124%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.019%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.041%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Deferred Revenue <br/>as of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">uniQure</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,661</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Roche</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">14,318</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">CFF</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,429</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,098</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,090</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">19,812</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ResearchAndCollaborationArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Collaboration Arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ResearchAndCollaborationArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of collaboration and license revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578277064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Components of Lease Expense</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the components of lease expense for the year ended December 31, 2021, which are included in operating expenses in the Company&#8217;s statements of operations (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.996%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.88%;"/>
        <td style="width:20.34%;"/>
        <td style="width:0.78%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">914</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,545</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Summary of Supplemental Information Related to Leases</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes supplemental information related to operating leases for the year ended December 31, 2021:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.004%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.998%;"/>
        <td style="width:18.536%;"/>
        <td style="width:2.457%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average remaining lease term (in years):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average discount rate:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the maturities of lease liabilities as of December 31, 2021 (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.996%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.538%;"/>
        <td style="width:20.543%;"/>
        <td style="width:0.919%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,058</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,149</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,244</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,686</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: Amount representing interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,054</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">16,448</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: Current portion of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,231</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Long-term portion of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">15,217</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051583478328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Tax Rate of Income Tax Expense (Benefit) Differs from Federal Statutory Rate</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The effective tax rate of the Company&#8217;s income tax expense (benefit) differs from the federal statutory rate as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.429%;"/>
        <td style="width:1.563%;"/>
        <td style="width:0.76%;"/>
        <td style="width:11.297%;"/>
        <td style="width:3.384%;"/>
        <td style="width:1.563%;"/>
        <td style="width:0.76%;"/>
        <td style="width:11.297%;"/>
        <td style="width:3.384%;"/>
        <td style="width:1.563%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research tax credit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">23.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">22.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Tax Effects of Temporary Differences to Significant Components of Deferred Taxes</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The tax effects of temporary differences that give rise to significant components of the deferred taxes are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.081%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.912%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.912%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Deferred Tax Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">37,295</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">21,132</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">937</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">993</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,111</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8,078</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,018</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,618</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,151</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Intangible asset basis</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">907</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">977</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,460</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">54,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,811</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Deferred Tax Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,064</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">992</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,056</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">50,232</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">32,811</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total net deferred tax</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Beginning and Ending Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The reconciliation of the beginning and ending unrecognized tax benefits amounts is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.722%;"/>
        <td style="width:1.927%;"/>
        <td style="width:1.542%;"/>
        <td style="width:16.039%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Unrecognized<br/>Income Tax<br/>Benefits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,566</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for current year tax positions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,729</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for tax positions of prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">72</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,367</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for current year tax positions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,219</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Additions for tax positions of prior years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582467544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Summary of Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2019, redeemable convertible preferred stock consisted of the following (in thousands, except per share and share amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:14.981%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:12.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.541%;"/>
        <td style="width:11.985%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:16.982%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.541%;"/>
        <td style="width:11.996%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.006%;"/>
        <td style="width:2.675%;"/>
        <td style="width:14.446%;"/>
        <td style="width:0.781%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Shares<br/>Authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Original<br/>Issuance price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Shares Issued<br/>and Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Liquidation<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Proceeds Net of<br/>Issuance cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">909,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">909,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,001</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,960</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Series A-1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,311,687</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.84</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1,311,687</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11,595</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">11,548</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Series B</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,154,639</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">17.46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5,154,632</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">90,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">84,472</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,375,638</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,375,631</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">108,596</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">102,980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051662800184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ScheduleOfCommonShareReservedForFutureIssuance', window );">Schedule of Common Share Reserved for Future Issuance</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021 and 2020, the Company has reserved common stock, on an as-converted basis, for future issuance as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.356%;"/>
        <td style="width:1.606%;"/>
        <td style="width:0.771%;"/>
        <td style="width:13.674%;"/>
        <td style="width:0.771%;"/>
        <td style="width:1.606%;"/>
        <td style="width:0.771%;"/>
        <td style="width:13.674%;"/>
        <td style="width:0.771%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock under the 2020 Equity Incentive Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,690,097</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,606,546</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Issuance of common stock under the Employee Stock Share Purchase Plan</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">498,747</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">252,337</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercise of options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,881,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,194,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exercise of common stock warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">53,669</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">98,669</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total common stock reserved</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">7,123,787</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,151,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ScheduleOfCommonShareReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common share reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ScheduleOfCommonShareReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051662810856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table summarizes the stock options activity for the year ended December 31, 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.854%;"/>
        <td style="width:0.225%;"/>
        <td style="width:1.167%;"/>
        <td style="width:10.332%;"/>
        <td style="width:0.867%;"/>
        <td style="width:0.225%;"/>
        <td style="width:1.435%;"/>
        <td style="width:11.274%;"/>
        <td style="width:0.867%;"/>
        <td style="width:0.225%;"/>
        <td style="width:1.349%;"/>
        <td style="width:9.251%;"/>
        <td style="width:0.61%;"/>
        <td style="width:0.225%;"/>
        <td style="width:1.349%;"/>
        <td style="width:10.632%;"/>
        <td style="width:0.61%;"/>
        <td style="width:0.225%;"/>
        <td style="width:1.638%;"/>
        <td style="width:13.03%;"/>
        <td style="width:0.61%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Number of<br/>Shares<br/>Available<br/>for Grant</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Balances at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">2,606,546</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">3,194,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">11.05</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">8.46</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">97,105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">1,334,099</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">1,566,150</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">1,566,150</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">34.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">563,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">6.26</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">4,324</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">4,324</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">36.33</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Options forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">311,278</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">(</span><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">311,278</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">29.17</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Balances at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">2,690,097</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">3,881,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">19.86</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">7.97</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">24,666</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Shares exercisable, December 31,<br/>&#160;&#160;&#160;2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">1,592,139</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">12.75</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">7.07</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">17,280</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">Shares vested and expected to <br/>&#160;&#160;&#160;vest, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">3,881,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">19.86</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">7.97</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;">24,666</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Compensation Expense for Employees and Nonemployees by Function</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table is a summary of stock compensation expense for employees and nonemployees by function (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.671%;"/>
        <td style="width:1.424%;"/>
        <td style="width:1.541%;"/>
        <td style="width:12.706%;"/>
        <td style="width:0.781%;"/>
        <td style="width:1.424%;"/>
        <td style="width:1.541%;"/>
        <td style="width:12.706%;"/>
        <td style="width:0.781%;"/>
        <td style="width:1.424%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,847</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,670</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,952</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2,314</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">13,799</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">4,984</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company estimates the fair value of employee and nonemployee stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of the Company's stock options was estimated using the following assumptions for the years ended December 31, 2021 and 2020.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:18.506%;"/>
        <td style="width:1.242%;"/>
        <td style="width:18.506%;"/>
        <td style="width:1.242%;"/>
        <td style="width:1.242%;"/>
        <td style="width:18.517%;"/>
        <td style="width:1.242%;"/>
        <td style="width:18.506%;"/>
        <td style="width:1.242%;"/>
        <td style="width:1.242%;"/>
        <td style="width:18.517%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31, 2020</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Employee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Nonemployee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Employee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Nonemployee</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">5.5 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#8211; </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.3 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6.0 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">80.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">84.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">83.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">82.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">83.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">82.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">83.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% &#8211; </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576351240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share, Basic and Diluted (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.422%;"/>
        <td style="width:1.692%;"/>
        <td style="width:1.531%;"/>
        <td style="width:13.276%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.552%;"/>
        <td style="width:1.531%;"/>
        <td style="width:12.602%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.552%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Numerator</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">71,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">56,693</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Denominator</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average shares outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27,730,420</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,430,555</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">27,730,420</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">6,430,555</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">2.57</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">(</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">8.82</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.98%;"/>
        <td style="width:2.997%;"/>
        <td style="width:0.76%;"/>
        <td style="width:13.509%;"/>
        <td style="width:0.76%;"/>
        <td style="width:1.552%;"/>
        <td style="width:0.76%;"/>
        <td style="width:13.37%;"/>
        <td style="width:0.76%;"/>
        <td style="width:1.552%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,881,274</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,194,113</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">53,669</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">98,669</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,934,943</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">3,292,782</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577981704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization And Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,296<span></span>
</td>
<td class="nump">$ 205,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Outstanding shares of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,375,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,679<span></span>
</td>
<td class="nump">$ 206,996<span></span>
</td>
<td class="nump">$ 135,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization And Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold and issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,875,715<span></span>
</td>
<td class="nump">9,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization And Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold and issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock sold and issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number shares issued upon conversion of redeemable convertible preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,575,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,575,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Exercise of Overallotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization And Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold and issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Follow-On Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization And Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock sold and issued price per share</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs</a></td>
<td class="nump">$ 111,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares priced under public offering</a></td>
<td class="nump">4,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_OrganizationAndNatureOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and nature of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_OrganizationAndNatureOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fdmt_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fdmt_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573537080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>Financial_Institution</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld', window );">Number of financial institutions cash is held | Financial_Institution</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs relating to uncollectible accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairments of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets</a></td>
<td class="nump">$ 14,562,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 16,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">1,231,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,029,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long -term portion</a></td>
<td class="nump">15,217,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_LeaseIncentiveLiability', window );">Lease incentive liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent</a></td>
<td class="nump">319,107,000<span></span>
</td>
<td class="nump">256,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (72,970,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent</a></td>
<td class="nump">$ 526,523,000<span></span>
</td>
<td class="nump">392,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,054,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standard Update ("ASU") 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201807Member', window );">Accounting Standard Update ("ASU") 2018-07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member', window );">Accounting Standard Update ("ASU") 2018-18</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">Accounting Standard Update ("ASU") 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Accounting Standard Update ("ASU") 2018-07 | Additional Paid-in Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_LeaseIncentiveLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease incentive liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_LeaseIncentiveLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of financial institutions where cash is held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201807Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201807Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576675544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer Concentration Risk | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer Concentration Risk | Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Credit Concentration Risk | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Credit Concentration Risk | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Credit Concentration Risk | Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=fdmt_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=fdmt_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=fdmt_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=fdmt_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=fdmt_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=fdmt_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051580254312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Customer Concentration Risk | Customer B | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=fdmt_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=fdmt_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582747992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 18,038<span></span>
</td>
<td class="nump">$ 13,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">Netherlands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">17,181<span></span>
</td>
<td class="nump">12,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573451672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Impact of Adoption of New Accounting Standard (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets</a></td>
<td class="nump">$ 14,562<span></span>
</td>
<td class="nump">$ 16,537<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,456<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
<td class="nump">4,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="num">(7,744)<span></span>
</td>
<td class="num">(8,303)<span></span>
</td>
<td class="num">(8,371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
<td class="num">(1,852)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="num">(1,231)<span></span>
</td>
<td class="num">(2,029)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term</a></td>
<td class="num">$ (15,217)<span></span>
</td>
<td class="num">(16,058)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,852)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember', window );">Revision of Prior Period, Accounting Standards Update, Adjustment | ASC 842 Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578175512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value on Recurring Basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 198,984<span></span>
</td>
<td class="nump">$ 276,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">94,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">30,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">37,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">36,556<span></span>
</td>
<td class="nump">276,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">36,556<span></span>
</td>
<td class="nump">276,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">36,556<span></span>
</td>
<td class="nump">276,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">162,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">94,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">30,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">37,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578076072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Assets, Level 1 to Level 2 transfers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Assets, Level 2 to Level 1 Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Assets, Transfers into Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Assets, Transfers out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Liabilities, Level 1 to Level 2 transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Liabilities, Level 2 to Level 1 transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Liabilities, Transfers into Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Liabilities, Transfers out of Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051580165576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Derivative Liability (Details) - Derivative Liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value included in other income (expense), net</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List]</a></td>
<td class="text">Other income (expense), net<span></span>
</td>
<td class="text">Other income (expense), net<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577047928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Available for Sale Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fdmt_ShortTermMarketableSecuritiesMember', window );">Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 94,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">94,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fdmt_ShortTermMarketableSecuritiesMember', window );">Short-term Marketable Securities | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">32,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">32,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fdmt_ShortTermMarketableSecuritiesMember', window );">Short-term Marketable Securities | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">57,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">57,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fdmt_ShortTermMarketableSecuritiesMember', window );">Short-term Marketable Securities | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">5,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">5,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fdmt_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">67,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">67,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fdmt_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">5,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">5,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fdmt_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">37,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">37,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fdmt_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | US Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">25,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 24,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=fdmt_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=fdmt_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=fdmt_CorporateBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=fdmt_CorporateBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=fdmt_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=fdmt_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051583634216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains on marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses on marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear', window );">Number of marketable securities unrealized loss position more than one year | Security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings', window );">Other-than-temporary impairment on investment in debt securities available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_MaximumMaturityPeriodOfMarketableSecurities', window );">Maximum Maturity Period of Marketable Securities</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_MaximumMaturityPeriodOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum maturity period of marketable securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_MaximumMaturityPeriodOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of marketable securities unrealized loss position more than one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578105096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 19,716<span></span>
</td>
<td class="nump">$ 8,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(5,325)<span></span>
</td>
<td class="num">(3,844)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,391<span></span>
</td>
<td class="nump">5,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">5,971<span></span>
</td>
<td class="nump">4,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,527<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 10,066<span></span>
</td>
<td class="nump">$ 539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051662628600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576415640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Liabilities, Current and Noncurrent - Summary of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 3,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AccruedClinicalAndPreclinicalStudyCosts', window );">Accrued clinical and preclinical study costs</a></td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Consulting and professional</a></td>
<td class="nump">1,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 7,744<span></span>
</td>
<td class="nump">$ 8,303<span></span>
</td>
<td class="nump">$ 8,371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_AccruedClinicalAndPreclinicalStudyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and preclinical study costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_AccruedClinicalAndPreclinicalStudyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573508664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Liabilities, Current and Noncurrent - Summary of Other Liabilities, Noncurrent (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other payable</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other liabilities, noncurrent</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 1,852<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577915432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 18,038<span></span>
</td>
<td class="nump">$ 13,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fdmt_CollaborationAndLicenseRevenueMember', window );">Collaboration and License Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Collaboration and license revenue</a></td>
<td class="nump">18,038<span></span>
</td>
<td class="nump">13,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fdmt_CollaborationAndLicenseRevenueMember', window );">Collaboration and License Revenue | uniQure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Collaboration and license revenue</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fdmt_CollaborationAndLicenseRevenueMember', window );">Collaboration and License Revenue | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Collaboration and license revenue</a></td>
<td class="nump">17,181<span></span>
</td>
<td class="nump">12,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fdmt_CollaborationAndLicenseRevenueMember', window );">Collaboration and License Revenue | CFF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fdmt_CollaborationAndLicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fdmt_CollaborationAndLicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578271592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research and Collaboration Arrangements - Summary of Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total deferred revenue</a></td>
<td class="nump">$ 5,090<span></span>
</td>
<td class="nump">$ 19,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember', window );">uniQure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total deferred revenue</a></td>
<td class="nump">3,661<span></span>
</td>
<td class="nump">4,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember', window );">CFF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total deferred revenue</a></td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="nump">$ 1,098<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573816312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Arrangements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,090,000<span></span>
</td>
<td class="nump">$ 19,812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember', window );">uniQure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,661,000<span></span>
</td>
<td class="nump">4,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember', window );">uniQure | uniQure Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementInitialResearchTerm', window );">Collaborative arrangement, initial research term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborationArrangementsUpfrontPaymentReceived', window );">Upfront payments received</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_OptionsToPurchaseOrdinaryShares', window );">Options to purchase ordinary shares</a></td>
<td class="nump">609,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_VestingPeriodOfShareAwards', window );">Ordinary shares vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_FairValueOfOptions', window );">Fair value of options</a></td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight', window );">Fair value of non monetary consideration of intellectual property right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember', window );">uniQure | uniQure Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, estimated performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember', window );">uniQure | uniQure Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct', window );">Contingent payments entitled to receive for achievement of research and development milestones</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, estimated performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember', window );">uniQure | Amended uniQure Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember', window );">uniQure | Amended uniQure Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ContingentPaymentsEliminated', window );">Contingent payments eliminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborationArrangementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration arrangements upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborationArrangementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementInitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, initial research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementInitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement research and development milestones entitled to receive for each licensed product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ContingentPaymentsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments eliminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ContingentPaymentsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of non monetary consideration of intellectual property right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_FairValueOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_FairValueOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_OptionsToPurchaseOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to purchase ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_OptionsToPurchaseOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_VestingPeriodOfShareAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting period of share awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_VestingPeriodOfShareAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fdmt_UniQureAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fdmt_UniQureAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fdmt_AmendedUniQureAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fdmt_AmendedUniQureAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582538920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research and Collaboration Arrangements - Additional Information (Details 1)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember', window );">uniQure | uniQure Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, estimated performance period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_UniQureBiopharmaBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fdmt_UniQureAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fdmt_UniQureAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573869736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Arrangements - CRF Agreement - Additional Information (Details) - CRF - CRF Agreement - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementInitialResearchTerm', window );">Collaborative arrangement, initial research term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone', window );">Collaborative arrangement contribution upon development milestone</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementAdditionalResearchTerm', window );">Collaborative arrangement additional research term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementAchievedMilestones', window );">Collaborative arrangement achieved milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementAchievedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement achieved milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementAchievedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementAdditionalResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement additional research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementAdditionalResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement contribution upon development milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementInitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, initial research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementInitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_ChoroideremiaResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_ChoroideremiaResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fdmt_ChoroideremiaResearchFoundationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fdmt_ChoroideremiaResearchFoundationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577980552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Arrangements - Roche Agreement - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,038<span></span>
</td>
<td class="nump">$ 13,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember', window );">Roche | 2017 Roche Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived', window );">Non-refundable upfront payments received</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree', window );">Contingent payment for each nominated product beyond the first three</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct', window );">Maximum contingent payment upon exercise of the option to convert a product</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments', window );">Maximum development milestone payments</a></td>
<td class="nump">223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia', window );">Development milestone payments relating to Choroideremia</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments', window );">Maximum sales-based milestone payments</a></td>
<td class="nump">$ 123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments', window );">Non-refundable development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementAdjustmentToTransactionPrice', window );">Collaborative arrangement adjustment to transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts', window );">Collaborative arrangement adjustment to transaction price due to increase in project scope and expected reimbursable costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementAdditionOfVariableConsideration', window );">Collaborative arrangement adjustment to transaction price due to variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized', window );">Increase in revenue recognized related to performance obligations partially satisfied in the beginning of the current year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="nump">12,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Aggregate amount of transaction price allocated to remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration arrangements contingent payment for each nominated product beyond the first three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration arrangements development milestone payments relating to Choroideremia.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration arrangements maximum contingent payment upon exercise of the option to convert a product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration arrangements maximum development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration arrangements non-refundable development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration arrangements non-refundable upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementAdditionOfVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement adjustment to transaction price due to variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementAdditionOfVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementAdjustmentToTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement adjustment to transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementAdjustmentToTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement adjustment to transaction price due to increase in project scope and expected reimbursable costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement maximum sales-based milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in revenue recognized related to performance obligations partially satisfied in the beginning of the current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130534-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fdmt_TwoThousandAndSeventeenRocheAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fdmt_TwoThousandAndSeventeenRocheAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577020600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Arrangements - CFF - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,038<span></span>
</td>
<td class="nump">$ 13,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Estimated fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fdmt_CysticFibrosisFoundationMember', window );">CFF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaborative arrangement total amount of award</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementAchievedMilestones', window );">Collaborative arrangement achieved milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived', window );">Expected payments percentage to equal actual award received</a></td>
<td class="nump">600.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_NumberOfInstallmentsToPayActualAward', window );">Number of installments to pay actual award | Installment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct', window );">Actual award payment period upon first commercial sale of product</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived', window );">Royalties percentage on actual award received</a></td>
<td class="nump">600.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct', window );">Continuous period where the Company ceases to develop or commercialize any product</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementTransactionPriceAdjustment', window );">Collaborative arrangement transaction price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fdmt_CysticFibrosisFoundationMember', window );">CFF | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage', window );">Future sales-based milestone payments percentage</a></td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actual award payment period upon first commercial sale of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementAchievedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement achieved milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementAchievedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementTransactionPriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementTransactionPriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements future sales based milestone payments percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements royalties percentage on actual award received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Continuous period where the Company ceases to develop or commercialize any product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected payments percentage to equal actual award received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_NumberOfInstallmentsToPayActualAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of installments to pay actual award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_NumberOfInstallmentsToPayActualAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130534-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fdmt_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fdmt_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577415768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research and Collaboration Arrangements - CFF - Additional Information (Details 1) - CFF - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fdmt_CysticFibrosisFoundationMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, estimated performance period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fdmt_CysticFibrosisFoundationMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, estimated performance period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fdmt_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fdmt_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577994296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Arrangements - Additional Information (Details) - UC Agreements - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_NonRefundableLicenseFeePayableUponExecution', window );">Non-refundable license fee payable upon execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution', window );">Non-refundable license fee payable upon execution every year thereafter until sales of a licensed product and payment of royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption', window );">Amount obligated to pay upon closing first qualified financing at option of UC Regents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption', window );">Percentage of equity interest upon closing of first qualified financing at option of UC Regents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_PercentageOfEquityInterestsIssuedAsCommonStock', window );">Percentage of equity interests issued as common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AmountsPaidNonRefundableLicenseFees', window );">Amount paid non-refundable license fees</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually', window );">Non-refundable license fee payable annually</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_IncurredExpenses', window );">Incurred expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fdmt_UCAgreementsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fdmt_UCAgreementsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AnnualRoyalty', window );">Annual royalty</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount obligated to pay a non-refundable license fee annually.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount obligated to pay upon closing first qualified financing at option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_AmountsPaidNonRefundableLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid non-refundable license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_AmountsPaidNonRefundableLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_AnnualRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_AnnualRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_DevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_DevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_IncurredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incurred expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_IncurredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable license fee payable upon execution every year after execution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_NonRefundableLicenseFeePayableUponExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable license fee payable upon execution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_NonRefundableLicenseFeePayableUponExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity interest upon closing of first qualified financing at option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_PercentageOfEquityInterestsIssuedAsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity interests issued as common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_PercentageOfEquityInterestsIssuedAsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fdmt_UCAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fdmt_UCAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051574218904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use ("ROU") assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,562<span></span>
</td>
<td class="nump">$ 16,537<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=fdmt_BuildingLeaseMember', window );">5980 Horton Street Building Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease extended term date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_OperatingLeaseTermExtendedExpirationPeriod', window );">Lease extended term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use ("ROU") assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=fdmt_BuildingLeaseAndExpansionMember', window );">5858 Horton Street Building Lease and Expansion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use ("ROU") assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Lease initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">87 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease option to renew term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The new lease has an initial term of 87 months beginning on the rent commencement date with the option to renew the lease for one additional term of five years at market rent. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease existence of option to renew term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 5980 Horton Street Building Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 5980 Horton Street Building Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_OperatingLeaseTermExtendedExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease term extended expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_OperatingLeaseTermExtendedExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=fdmt_BuildingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=fdmt_BuildingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=fdmt_BuildingLeaseAndExpansionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=fdmt_BuildingLeaseAndExpansionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576391224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - summary of Components of Lease Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 3,545<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051582591448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Supplemental Information Related to Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Weighted-average discount rate</a></td>
<td class="nump">7.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576419816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">3,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">3,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">3,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">3,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">22,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amount representing interest</a></td>
<td class="num">(6,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">16,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liabilities</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">$ 2,029<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">$ 15,217<span></span>
</td>
<td class="nump">$ 16,058<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051580593496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Tax Rate of Income Tax Expense (Benefit) Differs from Federal Statutory Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Research tax credit</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(23.50%)<span></span>
</td>
<td class="num">(22.10%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573420440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Tax Effects of Temporary Differences to Significant Components of Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 37,295<span></span>
</td>
<td class="nump">$ 21,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other accrued liabilities</a></td>
<td class="nump">937<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">3,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research tax credits</a></td>
<td class="nump">8,078<span></span>
</td>
<td class="nump">6,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">2,618<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible asset basis</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">3,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">54,288<span></span>
</td>
<td class="nump">32,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(3,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(4,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">$ (50,232)<span></span>
</td>
<td class="num">$ (32,811)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, operating lease right-of-use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051665094920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance, deferred tax asset</a></td>
<td class="nump">17,400,000<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">177,500,000<span></span>
</td>
<td class="nump">100,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_CARESActReliefDescription', window );">CARES Act, relief description</a></td>
<td class="text">The CARES Act changed certain provisions of the Tax Act. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminated the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021 and increased the amount of interest expense that may be deducted to 50% of adjusted taxable income for taxable years beginning in 2019 or 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards, expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforward indefinitely</a></td>
<td class="nump">$ 168,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_TaxCreditCarryforwardBeginningExpirationYear', window );">Tax credit carryforward beginning expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_TaxCreditCarryforwardExpirationDescription', window );">Tax credit carryforward, expiration description</a></td>
<td class="text">indefinitely<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_CARESActReliefDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Relief description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_CARESActReliefDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_TaxCreditCarryforwardBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward beginning expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_TaxCreditCarryforwardBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_TaxCreditCarryforwardExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_TaxCreditCarryforwardExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577957448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Beginning and Ending Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 3,367<span></span>
</td>
<td class="nump">$ 1,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for current year tax positions</a></td>
<td class="nump">2,219<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 5,586<span></span>
</td>
<td class="nump">$ 3,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573747240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,375,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 72,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Outstanding shares of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,375,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,875,715<span></span>
</td>
<td class="nump">9,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fdmt_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Temporary equity, shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fdmt_FundingAgreementProductMember', window );">Funding Agreement Product | CFF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AdditionalFundingCommitted', window );">Additional funding upon acceptance of investigational New Drug application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_AdditionalInvestmentInCash', window );">Additional investment in cash</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fdmt_FundingAgreementProductMember', window );">Funding Agreement Product | CFF | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase shares of common stock</a></td>
<td class="nump">125,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fdmt_FundingAgreementProductMember', window );">Funding Agreement Product | CFF | Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Investment in redeemable convertible preferred stock financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_AdditionalFundingCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional funding committed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_AdditionalFundingCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_AdditionalInvestmentInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional investment in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_AdditionalInvestmentInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fdmt_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fdmt_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fdmt_FundingAgreementProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fdmt_FundingAgreementProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fdmt_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578382840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,375,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,375,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,375,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Proceeds Net of Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fdmt_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Original Issuance Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Proceeds Net of Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fdmt_SeriesA1RedeemableConvertiblePreferredStockMember', window );">Series A-1 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,311,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Original Issuance Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,311,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,311,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Proceeds Net of Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=fdmt_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,154,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Original Issuance Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,154,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,154,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Proceeds Net of Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fdmt_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fdmt_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fdmt_SeriesA1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fdmt_SeriesA1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=fdmt_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=fdmt_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051576330600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">one vote per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Common stock dividend</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573542216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Common Share Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">7,123,787<span></span>
</td>
<td class="nump">6,151,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">2,690,097<span></span>
</td>
<td class="nump">2,606,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Share Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">498,747<span></span>
</td>
<td class="nump">252,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">3,881,274<span></span>
</td>
<td class="nump">3,194,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="nump">53,669<span></span>
</td>
<td class="nump">98,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051572914056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,151,665<span></span>
</td>
<td class="nump">7,123,787<span></span>
</td>
<td class="nump">6,151,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,606,546<span></span>
</td>
<td class="nump">2,690,097<span></span>
</td>
<td class="nump">2,606,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,194,113<span></span>
</td>
<td class="nump">3,881,274<span></span>
</td>
<td class="nump">3,194,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,566,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation of unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation, expected to be recognized over weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,799<span></span>
</td>
<td class="nump">$ 4,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=fdmt_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,521,150<span></span>
</td>
<td class="nump">1,267,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.46<span></span>
</td>
<td class="nump">$ 11.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=fdmt_NonemployeeMember', window );">Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.42<span></span>
</td>
<td class="nump">$ 11.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyIncentiveAwardPlanMember', window );">2020 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,606,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,606,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance', window );">Percentage of common stock outstanding increased annually for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,690,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized and reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,334,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyIncentiveAwardPlanMember', window );">2020 Incentive Award Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fdmt_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,519,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual', window );">Minimum percentage of outstanding shares held by individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum', window );">Exercise price as percentage of fair market value, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of aggregate number of shares of common stock outstanding reserved for future issuance</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized and reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,337<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employee purchase price of common stock as percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod', window );">Common stock overlapping offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod', window );">Duration of purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of maximum contributions of employee's eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of outstanding shares held by individual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award duration purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award exercise price as percentage of fair market value minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award percentage of outstanding stock increased annually for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award stock overlapping offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=fdmt_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=fdmt_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=fdmt_NonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=fdmt_NonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fdmt_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fdmt_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578186072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of Shares Available for Grant, Beginning Balance</a></td>
<td class="nump">2,606,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of Shares Available for Grant, Options authorized</a></td>
<td class="nump">1,334,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross', window );">Number of Shares Available for Grant, Options granted</a></td>
<td class="num">(1,566,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod', window );">Number of Shares Available for Grant, Options expired</a></td>
<td class="nump">4,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod', window );">Number of Shares Available for Grant, Options forfeited</a></td>
<td class="nump">311,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of Shares Available for Grant, Ending Balance</a></td>
<td class="nump">2,690,097<span></span>
</td>
<td class="nump">2,606,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Beginning Balance</a></td>
<td class="nump">3,194,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Underlying Outstanding Options, granted</a></td>
<td class="nump">1,566,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Underlying Outstanding Options, exercised</a></td>
<td class="num">(563,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares Underlying Outstanding Options, expired</a></td>
<td class="num">(4,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares Underlying Outstanding Options, forfeited</a></td>
<td class="num">(311,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Ending Balance</a></td>
<td class="nump">3,881,274<span></span>
</td>
<td class="nump">3,194,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Underlying Outstanding Options, Shares exercisable, December 31, 2021</a></td>
<td class="nump">1,592,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Shares vested and expected to vest, December 31, 2021</a></td>
<td class="nump">3,881,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 11.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">34.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">6.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired</a></td>
<td class="nump">36.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="nump">29.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Ending Balance</a></td>
<td class="nump">19.86<span></span>
</td>
<td class="nump">$ 11.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Shares exercisable, December 31,2021</a></td>
<td class="nump">12.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Shares vested and expected to vest, December 31,2021</a></td>
<td class="nump">$ 19.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (in years), Outstanding</a></td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
<td class="text">8 years 5 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (in years), Shares exercisable, December 31,2021</a></td>
<td class="text">7 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (in years), Shares vested and expected to vest, December 31,2021</a></td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Balance</a></td>
<td class="nump">$ 24,666<span></span>
</td>
<td class="nump">$ 97,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Shares exercisable, December 31,2021</a></td>
<td class="nump">17,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Shares vested and expected to vest, December 31,2021</a></td>
<td class="nump">$ 24,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Shares Available for Grant Expirations In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award shares available for grant forfeitures in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award shares available for grant grants in period gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051580193976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Compensation Expense for Employees and Nonemployees by Function (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 13,799<span></span>
</td>
<td class="nump">$ 4,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,847<span></span>
</td>
<td class="nump">2,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,952<span></span>
</td>
<td class="nump">$ 2,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573556344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=fdmt_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">82.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">84.30%<span></span>
</td>
<td class="nump">83.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=fdmt_NonemployeeMember', window );">Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=fdmt_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=fdmt_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=fdmt_NonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=fdmt_NonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573600328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_NumberOfWarrantsIssued', window );">Number of warrants issued</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">23,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 9.41<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrant in connection with settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from offering of securities in a private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_WarrantExpiresYear', window );">Warrant expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2027<span></span>
</td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_WarrantVestsOverPeriod', window );">Warrant vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_WarrantExercisedMonthAndYear', window );">Warrant exercised month and year</a></td>
<td class="text">2021-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrant in connection with settlement</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=fdmt_SeriesBFinancingMember', window );">Series B Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_WarrantExercisedMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant exercised month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_WarrantExercisedMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_WarrantExpiresYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant expires year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_WarrantExpiresYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_WarrantVestsOverPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant vests over period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_WarrantVestsOverPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=fdmt_SeriesBFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=fdmt_SeriesBFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573813144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (71,317)<span></span>
</td>
<td class="num">$ (56,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted-average shares outstanding</a></td>
<td class="nump">27,730,420<span></span>
</td>
<td class="nump">6,430,555<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</a></td>
<td class="nump">27,730,420<span></span>
</td>
<td class="nump">6,430,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (2.57)<span></span>
</td>
<td class="num">$ (8.82)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577466696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">3,934,943<span></span>
</td>
<td class="nump">3,292,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">3,881,274<span></span>
</td>
<td class="nump">3,194,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">53,669<span></span>
</td>
<td class="nump">98,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051578134280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate', window );">Change in control discount rate</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Estimated fair value of derivative liability</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_FairValueAssumptionsChangeOfControlPayment', window );">Change of control payment</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage', window );">Change in control event percentage</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_FairValueAssumptionsChangeOfControlPayment', window );">Change of control payment</a></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage', window );">Change in control event percentage</a></td>
<td class="nump">17.20%<span></span>
</td>
<td class="nump">12.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_FairValueAssumptionsChangeOfControlPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assumptions change of control payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_FairValueAssumptionsChangeOfControlPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assumptions probability of change in control discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assumptions probability of change in control event percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051573488104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>Agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fdmt_CoFounderAndChiefScientificAdvisorMember', window );">David Schaffer, PhD, | Consulting Services and Services as Board of Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">$ 93,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fdmt_UCRegentsMember', window );">UC Regents | SRAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_NumberOfAgreementsEntered', window );">Number of sponsored research agreements entered | Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_TermOfAgreement', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fdmt_UCRegentsMember', window );">UC Regents | Machine Learning SRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fdmt_TermOfAgreement', window );">Agreement term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount due to related party</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Payment to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fdmt_UCRegentsMember', window );">UC Regents | SRAs and Machine Learning SRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_NumberOfAgreementsEntered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of agreements entered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_NumberOfAgreementsEntered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fdmt_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fdmt_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fdmt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fdmt_CoFounderAndChiefScientificAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fdmt_CoFounderAndChiefScientificAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fdmt_UCRegentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fdmt_UCRegentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=fdmt_SponsoredResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=fdmt_SponsoredResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=fdmt_MachineLearningSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=fdmt_MachineLearningSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140051577582920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(K) Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=fdmt_TwoThousandFourteenPlanMember', window );">2014 401(k) Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=fdmt_TwoThousandFourteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=fdmt_TwoThousandFourteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>fdmt-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:fdmt="http://www.4dmoleculartherapeutics.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fdmt-20211231.xsd" xlink:type="simple"/>
    <context id="C_e7d12ec2-7bb6-4ee6-9329-dfed184d0890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8bc0fb33-e137-466b-afc1-ac2316dff7e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_68203dba-eb94-47f4-bc69-28308c9e86fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">fdmt:CorporateBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_87699b30-eed2-4ea5-86f4-0a39c1e5772e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:TwoThousandAndSeventeenRocheAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2b9316bd-43bb-4236-afee-5dedacf34852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_62a5478f-6648-41ef-8d95-7e857719eae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:TwoThousandAndSeventeenRocheAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ffdd2326-026c-4d95-8076-5a7d7c11f527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_43895722-c889-4f5a-86ef-d1095b190b17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:MachineLearningSponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_4d4c97fb-5c4e-482d-aa4f-d431fcdad1c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fcb58636-b558-407f-b0d5-265a83042f1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4a392933-0525-4a24-bd80-f86924e2bcf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:AmendedUniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2f3dd1a0-d4ca-4297-8f43-1b41c1131161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d7e7e417-5edc-4abf-a76c-5be707bce23e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_100f6d0a-7eb4-409e-8987-51846785183e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5c9ad16b-c408-4093-be43-5c9223652764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_87f2bd8f-07bf-4e4e-8992-26041f581ddc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cddd6872-9bae-4abd-b89b-a8b4f291f7b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_da021c91-4acb-426f-8a80-77705578bab8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="C_46645de8-496d-4445-bcee-79e0f6a7e2e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:ChoroideremiaResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:ChoroideremiaResearchFoundationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d15ccf5a-554c-4e09-bf6c-621fbf797861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_29d03014-ea19-4d37-bd22-35b0ce14deba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dab250fb-28e0-4123-8e2b-eee2d878a7bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_fb67bb6e-bab1-4045-8de0-aaff307da3a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_17493eda-6778-49b9-933d-bb5807fea6cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f311e2d1-83ec-4e94-91c6-bb50b44c9a4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f7242b4b-b2c1-47e2-8a49-09fa5d802063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8c2f744e-0a59-4216-9244-12153c1d29c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cc9158f0-cc85-4a61-9faf-16e23bce0c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_46bb51b8-c564-4f79-bb7b-808fc09a2915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3af24779-857a-4d8c-8ca2-daaa220bb8ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_debe135a-c35c-4564-ab5a-f34f314d29f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bc671fd0-0ba3-4f31-87f7-95c143537ef9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aaf1e58d-3b1c-4821-9e56-aaa8b373ab63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0652071b-4c72-4479-b886-fe246ac1708e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_f509df6f-30cd-48cb-a9e1-308f964642f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ac7b6ce7-cd1a-4e4d-84ee-87d64c2d5f60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:MachineLearningSponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_e4411f8c-40ed-48bd-b0d8-e6366fa6b2c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3efe0308-17fb-42e4-98f2-745c68439aa1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c922aa7a-0ebd-48c9-9a1f-066c43a04ba3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7407984c-b650-4ccb-99f5-f9cd63af7b7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:MachineLearningSponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b63ba5ca-290b-449e-9c24-797545392bb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">fdmt:TwoThousandFourteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c21f763e-80eb-484a-a941-fe0af17a7c0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3286dd10-3afc-4496-bbd6-5ba1f0954a8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1001d586-4a93-4bdd-bca8-c247e6d58d1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a7b36ed3-eaae-482f-82c3-37d423f79c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_da9eacae-140f-4ff4-bc19-21fffcc55707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d8f5fd72-5501-4424-9c3c-155dadbc1f06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:AmendedUniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_98081424-857b-49e5-aa11-1c55ddebeec0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="C_dc4d438d-ed76-4f51-85bd-a0b92d8c257e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_af32b9d1-9efd-44e5-8ceb-eb4bf3e5244b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:AmendedUniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="C_04e47ba0-ce07-4a2d-aa4a-280a066c7c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0dd3438c-f8c5-4fe9-8672-19340e3bbb9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7421a1ac-23e5-447d-aabe-10f3efe826be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f96a58ac-dc2a-4623-8894-1ced49494bd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_216819a8-6057-48ea-a590-8f9225ba8a73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <instant>2022-03-28</instant>
        </period>
    </context>
    <context id="C_dfd0d18e-816a-44fd-b58e-bba6ac6a812a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_49564e79-c36e-4c78-aae6-91ada470dc34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_067e587d-dfef-4587-ad79-844c454aeb5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f8c80726-14a0-4e92-b15c-36f91786d60a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:ConsultingServicesAndServicesAsBoardOfDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:CoFounderAndChiefScientificAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_7958ed8e-8790-49e7-bfb6-54045eeb9eec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_90284da0-93f6-431a-8c5e-011cfcb8f1f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_bbcc2364-ba79-4bc4-b41b-1b1dc9a8eede">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_01872582-961a-450f-b5a8-ef39a9a60634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_8fc037ec-2e59-4454-98a8-7a703d7f1706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesA1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_542e8a0a-d3fd-48d5-aca9-2b0837fda539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0befc9ee-bbe3-4743-91fb-e5d8d3675f92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_08032442-cecd-44e4-8446-5caefea14888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_00c84e7f-1487-4fcb-b57c-626e653667be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_0fd3c166-54d6-4e85-a12d-b5c2352e23fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fdb51331-8f19-40ce-b87c-0d9aa4e26603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a0611f15-32cf-4702-b60f-3cf600264460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-24</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="C_e1dda0de-9512-4575-b09e-7dc96d5fda59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6961af42-3676-40b4-923b-b55bd4213555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1874832c-8de4-4a7f-a27f-f1dc966227e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_0912072b-bcab-4ad8-a96b-b69214a4c085">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="C_fbf54024-6915-42de-b1f4-5893be4aa781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_963e934f-bc6b-4dc6-a918-158ec67c6212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:FundingAgreementProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_899d20dc-a0cb-4505-b8f0-3ed14460cfce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_2757758c-223e-4e96-ad58-555f2a1537e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_27c30b85-a010-4be5-a956-5fa66be6b6dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d8cb6a3a-516a-44ff-a6c4-14639dae2312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:ConsultingServicesAndServicesAsBoardOfDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:CoFounderAndChiefScientificAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_84f39b44-5422-454e-b43f-0e6094e9de94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f933dccb-0084-4f9e-bd98-0601bbc462d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_e3231fac-0339-4b86-8552-33d99ccf5b90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="C_528f45e3-d466-442e-aad5-49b6b3b7312c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_68843b0d-f738-4525-bbf0-8acf1ea83427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="C_b24504fe-8333-4d24-bea3-21f963c10bdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_79e057b2-8bbb-4970-a6fe-1330e9256ec6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d3baf353-2444-4e1a-a27d-448df6997e93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:NonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_614c9897-40b5-49d5-891b-2e8c91231c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5b1c1ec5-d872-44ae-8bb5-78aa34f73511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="C_4a794422-dee1-4707-8185-703c70506d97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cfe98104-f350-4823-9e4e-dde161bbcd77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fdmt:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_9bf2311e-d3cd-40c5-9ad2-5823cd5dccbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_76054bca-7f31-466a-af59-aee060457d1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e21eab0a-797b-4380-9011-1aea8fabc1b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:ChoroideremiaResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:ChoroideremiaResearchFoundationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="C_e90ff7ba-2215-4139-bfb3-bb512afebcb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_5f4f9f3d-c2a5-4a7a-b39c-2a675787b677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_02f4bd8b-251b-482c-a9fc-56da777a2727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f0ae8a23-d71e-4828-8ac8-78470326d77f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_25a62ff3-b92c-4866-af5f-948e6635deba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_44ba6365-051f-4e87-afa2-47586cb35c9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:ChoroideremiaResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:ChoroideremiaResearchFoundationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="C_c809c8ab-34c1-45aa-9199-72b4b861d30e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_952d0fc8-cacf-4343-ad40-069f13b709dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_019809d7-3321-4394-ad06-f1dce3e3dcd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0d9e57bc-9656-45fb-9e86-21e8155c0587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d12171a9-377c-49ef-adaa-5888c0e1ab2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201807Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0deaebff-c017-4132-ad32-5d55ae62b6b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:NonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c5ffbd72-9ff1-4119-bcd0-b30265f21d41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_92bf420a-5530-4711-a7fd-253e4d577ba6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f1e25908-cccb-42b0-b877-3c97c0b0e8c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_d24dc914-f653-4ead-88fd-297fac82aaf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5dc42fe3-b34c-426f-a35e-e9d6777af922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6c273596-2f89-4f1e-8401-1a71be26008e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7c926a8a-82fa-447e-b1e6-bbfe1e709a29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_10bf4f98-2380-4a78-bf83-b60685bbda33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_40669389-a7ad-4950-93fb-0a77d4c10a4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:FundingAgreementProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_0e28aeda-24d7-44f2-b175-686133e42282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:AmendedUniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_438b050d-f05e-45d9-947c-0d5a7c04e2ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f1c116f5-4fc4-4134-a20b-4bb41e384479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_034d1a9d-6368-4975-b6f6-9934f04efcc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_67c79b0f-725f-4422-a99d-21b85901d3c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bbdb060d-8326-4e8e-bfca-89985b0ee2d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="C_0c74490e-c642-49f7-a178-c5c00a711057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aded6adf-76e7-4673-85fe-7c5fc3d77d2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_485d52ae-2831-49f8-b4f8-3e103c72940b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_8da58ed6-e246-4eec-ba9a-77c486b0bfab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b4b6884a-ce1d-4bbf-9756-4c19b608736e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e44911fe-c20f-4f88-b1c1-84fcf30c91f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d2425f46-763c-4d4b-b2fc-1ca90612499e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5f7ac562-47e8-4c80-b681-d3d1fbda0f72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_625a9586-f459-4552-b058-fb7510d5960c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_22fd50bb-c8c9-4334-a1b4-281b0e9b354f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2bc81db7-5978-41b8-8ad4-14969a57ecec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_5292ea9b-5f9f-47a3-8950-e560df46b007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f91508fa-5dfa-4192-91eb-1afaa64ddaad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_778cb29d-d166-4215-968b-ce01bbf701d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_46423923-3058-4aaf-ac32-c74922d40a3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c2004132-d784-47b1-a1e9-3cd43319e93f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7974df26-e7b0-4ed8-86d9-17fbf7835f1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:TwoThousandAndSeventeenRocheAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_646334cd-512e-4567-85e0-49ec256638ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">fdmt:SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fdmt:UCRegentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5d804358-02f5-4c3e-b83a-38d656050858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:FundingAgreementProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_6b06fcf3-412c-465d-8612-1b6688ca22a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_87233471-231c-4c4b-ba05-554ef259a531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_38363b5b-dfc5-4de3-ad6d-69dec1df22bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b7f143b1-ffa9-4263-bc77-01c55254624d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="C_ccccdee5-98b9-4eba-97f0-75b85fa9ed38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b92a1f3f-887c-4ea7-a989-5b92852b7259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e63d3fbd-6765-47dd-a387-c3545c1942c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_345dc4b4-ecea-45cf-b824-fa29a5f06694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b3cb484d-807c-45d4-a35e-ca7c2f3f9313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6daa8ce8-a992-4249-a203-b1e888605ef4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0851c4dd-d51b-410e-9510-555127298972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_71c68b91-969e-469a-ac31-ed7554ddc8fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_cf542ed1-e6b5-4685-8a2e-3f4a7e276ae0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4a6c44c3-d641-4e5e-b729-a73d0337615b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_2f32afd7-17e5-440d-95d7-e8e98ffe403b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:TwoThousandAndSeventeenRocheAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_069b0a0c-065c-4686-838b-2ac26250f05e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6ba7e920-3f27-47fd-a911-2a4a015a560f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_893705a7-019f-4880-8fba-130e464feaa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_3b2169b0-5a83-4d78-862e-5aacb257dffc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_369e8cc3-d5ce-4005-9fa7-8014c0cde676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_592a756d-a16a-4bd3-aad9-7318649c6f44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_dcff2890-ab1b-4492-8304-4e459fc72f25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e52d4eb1-67cf-418e-81c2-9f61ca8b3839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="C_7d63139e-3006-4754-b5ec-c678676f6695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7224f03c-f6e9-4042-a275-59c886ca1970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e7f9066a-37f9-4184-9c45-03d0ffb6a47b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b47d4e9a-a1c9-42dc-ad5a-046908180aa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d724d8a1-6a4a-42cb-a720-853feca51dab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3f51aa86-d6a8-4946-b9c6-489cfcc06d93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_76372236-463c-49d8-950b-bfdd59d89a3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">fdmt:CorporateBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_156eea03-1e5f-4d20-bdd5-c6922ae709bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="C_649adcbd-b0e6-4117-97c9-7ba0549ac8dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cd0116f7-4d6b-4e75-acbd-f547c6e71c2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a55673c8-51f2-4439-9f29-f4ac123dd97d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aee471bc-dfa2-486c-b5af-72c1159914db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6f61ac2f-cef4-461c-a2ee-3967bbb25c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a99aa56e-af3c-4d75-814c-006a1628cef5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_47f11691-274e-42ed-9d35-7150a1a1bafe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_74377b23-9b2b-42d3-bf22-b1ecef810775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201807Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_78089c61-9c63-4f0e-ab4c-7158c1adabeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_e4af4886-82cd-4423-a392-44aee99ef576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_068f626d-cf83-45b9-9dba-b873304176e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d1ec6218-dc19-4a0d-9c16-9e9cf05148c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5d6bb9b3-6b6c-4b68-931a-aa92ca2d40c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2fe951a6-989e-495f-bcdd-517a1a9d9539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fdmt:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4fafc5e1-de72-42ab-a39e-911d607b5701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_e916e9be-dd44-4775-b1f3-058f8afa1981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a504b7f3-7605-46fc-8597-53b18af6a1d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="C_3050ecb2-11ee-4119-a548-6cdd89f1f561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_8c6ae4c6-838d-4e8a-a05e-7a077c423abd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_bf1c55da-f533-4e8b-9709-41e08427872a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_994128d2-ff7e-458c-a06e-3646a588a46f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b4e47e36-ad9e-4007-bb25-cc82fae064e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bcb74483-fa99-4ee5-a6ea-6a4843de5d40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fdmt:UCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fed81344-7c82-4eb4-9718-d25d585ff1e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fdmt:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20cd7796-d782-44fd-9c7c-a0d741c85cea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:FundingAgreementProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_13f6e26c-4d62-4ef8-b29b-c168bba13d36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5b3c671f-d9c2-479a-878e-5392aef7d177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_17b5390d-b508-41a3-bec9-d59c6b3e03e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_be527709-9a9f-4be1-8ea5-1064c24e61fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:ChoroideremiaResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:ChoroideremiaResearchFoundationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5768aef4-f24f-4156-919c-885a554541d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_8920c352-ac30-4ff7-8543-68d35ca73a38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_80f31e89-ff18-484e-81fb-0a391abdc4b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fe322eef-bf6e-4784-9f7d-22ae2b365638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2975534f-c7d6-40d2-b4f0-8396ed62ffe5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:AmendedUniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f0620193-2d47-4e0f-b17c-1fa3385b38cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aad92407-2080-466e-ba91-9ebcedf0142e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_794002d9-a4fd-4194-b523-592564162f24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3f63f746-5168-4906-b7e7-1be53b0dbc62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_62df8820-e746-4de8-8b5d-7651c94d18fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4eaef891-9b88-429e-bd16-799664373d3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_efc3ff61-873a-4027-8905-9906185f858f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fdmt:CollaborationAndLicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ddf9471b-7dbf-43eb-8802-d9844a6eb24a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_229b1105-6f81-4be3-bc0e-35524c07bfa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_da1fd0ee-2a34-41fc-9e75-f7316c4ea264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_618215e0-a055-427d-9220-18bee23b39f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a5af98ab-cbe3-47d9-a7e7-15b8be38cf21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_cdd81399-daf3-42e2-bc69-e7aaf154c086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_26af25a4-cb52-44ca-92d6-ccc8fa01b65f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="C_cf4beef8-281b-4990-bced-f3548175f663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9a196306-24e0-483e-8634-0a715c3d21e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="C_b20ba5e2-9962-466b-938b-74b85690f0f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_925a7886-495a-4170-9b11-97befb205b58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2316f0b3-fa95-4376-836f-ea0ad0fecdf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">fdmt:SeriesBFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_363a526b-afc7-4132-8b3a-387a13ab7bb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_59d3639a-d9e5-4bdd-af89-ba17bedfea32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_eab566a6-1468-49d2-aaec-a715d312418d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_1784e7f0-ff83-48df-a30d-36b81c4f651d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fdmt:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_36758c2d-4d20-4d3c-a68c-1ae0229d4cbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ee124165-31e9-4e1d-8df3-5e051998cafd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:TwoThousandAndSeventeenRocheAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d3e07726-b4be-4673-8ad2-8d4cb0def982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6589222f-c96b-40f8-a688-38fc97e550be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f0a7f822-26e3-4aa6-b0cb-8635b7e734f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f8a50303-fca8-4db7-8914-b41268aac3b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a2f26722-25bb-4a09-88a3-02cae078cf69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_490d082b-4c24-4ebc-97b4-1f4ca133afe2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:UniQureBiopharmaBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:UniQureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="C_7aabaf7d-fcee-40ec-a3ce-91d93ae55155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fdmt:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e5c170a8-c607-4fca-ab72-c7b6add90b77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fdmt:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_6b9c4496-5f5c-4b08-a9c6-6e3811f8ebe6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fdmt:BuildingLeaseAndExpansionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="C_f5ca12fb-9ded-49e2-8667-052f68f5cdfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fdmt:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_77581bff-7745-4be8-a763-3227bbf42da1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">fdmt:TwoThousandFourteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6795eac3-18cb-415a-b6be-fd09406f11f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:ChoroideremiaResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:ChoroideremiaResearchFoundationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_84be53f3-486d-4f0d-90b0-07d7e83acbf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d34de791-bc33-4d58-b8e1-f57a6ba20191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650648</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fdmt:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_Financial_Institution">
        <measure>fdmt:Financial_Institution</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Agreement">
        <measure>fdmt:Agreement</measure>
    </unit>
    <unit id="U_Segment">
        <measure>fdmt:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Installment">
        <measure>fdmt:Installment</measure>
    </unit>
    <unit id="U_Security">
        <measure>fdmt:Security</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_733a11db-f6c7-4a45-978b-b600cfb15731">0001650648</dei:EntityCentralIndexKey>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_c21f763e-80eb-484a-a941-fe0af17a7c0b"
      id="F_6a54b9ee-b4de-4717-a1a2-a0f99f73deb0">P3Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <fdmt:CollaborativeArrangementAdditionalResearchTerm
      contextRef="C_e21eab0a-797b-4380-9011-1aea8fabc1b5"
      id="F_80d41e98-685d-4c82-a966-93ef6194e666">P3Y</fdmt:CollaborativeArrangementAdditionalResearchTerm>
    <fdmt:CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage
      contextRef="C_2bc81db7-5978-41b8-8ad4-14969a57ecec"
      decimals="2"
      id="F_55f2fc27-7ef4-4149-a482-d2ca9293554a"
      unitRef="U_pure">3</fdmt:CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage>
    <fdmt:ExpectedPaymentsPercentageToEqualActualAwardReceived
      contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d"
      decimals="2"
      id="F_ae6a1cea-4dc5-429f-b6df-a8af5d5155a4"
      unitRef="U_pure">6</fdmt:ExpectedPaymentsPercentageToEqualActualAwardReceived>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_dcff2890-ab1b-4492-8304-4e459fc72f25"
      id="F_c05559b7-51fa-4d3d-9739-b6c4a7e260ed">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_92bf420a-5530-4711-a7fd-253e4d577ba6"
      id="F_3340247d-416d-4f03-a381-b95a54629875">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="C_2f32afd7-17e5-440d-95d7-e8e98ffe403b"
      id="F_834220d8-b4e4-44b5-a1d2-6aff019d75c5">http://fasb.org/us-gaap/2021-01-31#OtherNonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <fdmt:CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived
      contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d"
      decimals="2"
      id="F_ebac0ee9-675f-4dde-a1fd-3d4097e446f6"
      unitRef="U_pure">6.00</fdmt:CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      id="F_4716bf1b-08a4-4338-8ed0-e0aaa71272e5">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201807Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      id="F_0a20beb0-d4ab-4118-b999-4fa51b854c40"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_8c0d535b-cead-44fa-bf8b-5dbc70a40b76">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_e0dbc496-2e08-4773-b4c2-4ca34dfb7a2f">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="C_27c30b85-a010-4be5-a956-5fa66be6b6dc"
      id="F_f500242c-7c9c-43e7-8ba7-87e2388aa1db">http://fasb.org/us-gaap/2021-01-31#OtherNonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      id="F_93b3ec84-9a75-4877-a7e9-d3f6a374cf61"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_8c758c1f-dfb8-4542-816c-a32f9c90553a">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_c2120c39-db86-40b0-b219-e1b7c443f3c7">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_21fd7a81-9d01-434b-b342-d3862723514e">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_db524af4-03bf-4955-8693-e05682ace4ee">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_e0f6ca37-bb5b-4085-bdf1-d17252e38804">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_a2e208dd-3747-4c0d-a5f3-58d5e872b47e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_93f7ca44-1a2b-498f-8360-b67fff8944ac">001-39782</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_b13aa42d-9504-4731-b73c-a15488a6ea06">4D Molecular Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_0a54d246-f230-4797-b693-71096b90c938">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_7e5c9d5a-4d9e-4fdb-b552-db613dd4e0eb">47-3506994</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_803c9ecc-d1ae-4e87-95f0-248ca5b6ef1e">5858 Horton Street #455</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_c18e38c6-a2ae-4e7b-b400-132be7bb4b46">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_eb2d20b5-9bd6-467a-9ab1-135270c00d0b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_7bcfe6bd-71de-4f53-997b-97018274b0f3">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_e2113554-ff7a-415c-89fd-20553fc4906a">(510) </dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_7b4abf3c-a825-467a-872b-10b398d21343">505-2680</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_14608851-1aa5-452c-8f86-28c43ebef0db">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_fd3f339b-7c1d-4f4a-b9e3-dcf44ae74287">FDMT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_1ac81c36-da6d-402d-8465-f41590886211">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_a1d5f151-1c8e-4e46-bc50-f40c4d3f9100">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_c824aee0-aec5-4ab0-b660-ed4cda10715c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_9bb27839-1033-4e4e-a572-5730edc86128">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_126fbb44-6bc3-4886-8ba7-a294fd375ab6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_b5f0e19f-6bd7-4f1f-8561-08158656bede">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_f1b489c9-789b-4ed6-8c28-f442007cf357">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_99a6cafc-8ecc-4a18-bc9c-633a602a64fd">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_795bbfad-e288-49a3-95ca-2615a90ac4cd">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_a700b803-d942-4b3e-9ae1-b730e3122663">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_79079350-9729-48fe-9eae-c5509e61c972">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_6b06fcf3-412c-465d-8612-1b6688ca22a8"
      decimals="0"
      id="F_d2dd9093-47cb-445d-872a-5302d567b86e"
      unitRef="U_USD">444521977</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_216819a8-6057-48ea-a590-8f9225ba8a73"
      decimals="INF"
      id="F_a963fb32-801c-4eff-b602-c2a1b466b744"
      unitRef="U_shares">32237496</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_cd94eb65-c4ac-4494-b4ef-81db04e4fba5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Portions of the registrant&#x2019;s definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_c8b9a81d-f9d6-4847-9e5b-418ef2b8311e">238</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_ea0bbe00-a1b8-46eb-82e3-dc7059774599">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_1155a061-e79a-4b44-b3da-dcba6f552735">San Jose, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_9ef6ec5d-eb1b-4011-b463-bc7d76439dab"
      unitRef="U_USD">153001000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_73009d48-a65b-4bb4-b4f8-c2605576a1e5"
      unitRef="U_USD">276726000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_e96745ef-b254-4806-9e54-d308b4fde89f"
      unitRef="U_USD">94776000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_4552fc33-a749-4fdb-b493-6926e46e26c1"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_3acb4d83-caba-4aa5-8baa-ed510f7c74c9"
      unitRef="U_USD">47000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_5ebe6eb7-213b-4bd4-9deb-de7de72d5a53"
      unitRef="U_USD">1486000</us-gaap:AccountsReceivableNetCurrent>
    <fdmt:PrepaidExpensesToRelatedPartiesCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_8f36cc29-eebb-4527-bf38-3531e67ee3cf"
      unitRef="U_USD">285000</fdmt:PrepaidExpensesToRelatedPartiesCurrent>
    <fdmt:PrepaidExpensesToRelatedPartiesCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_843b448a-fef8-4825-8349-e1a136c2d07a"
      unitRef="U_USD">169000</fdmt:PrepaidExpensesToRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_821b5776-38ac-4f39-838f-97b829c7e5d3"
      unitRef="U_USD">8456000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_760cd2e6-25c0-4542-8209-cac7d48b74e3"
      unitRef="U_USD">4444000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_a1c99670-5981-43db-b652-ba4a2c2b430f"
      unitRef="U_USD">256280000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_ef250ea9-60e7-41ca-86f1-69ac37445bc0"
      unitRef="U_USD">282656000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_bd482ac1-1b69-4a5d-96fa-f2fc30564156"
      unitRef="U_USD">67652000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_83d22ee1-9c84-4f1c-b5a5-6edae9370ac0"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_4af589bd-75ee-47ac-b02b-109a5ddc8733"
      unitRef="U_USD">14391000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_13ee1ac5-d47f-4518-9d19-d8404ccefa82"
      unitRef="U_USD">5073000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_38cd9612-4e50-4b88-95eb-0dc6840bd622"
      unitRef="U_USD">14562000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_85aa135f-84ed-4d22-8eed-63690ca12097"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_deb0a672-d3f3-4831-90bf-4ffaec512fd0"
      unitRef="U_USD">602000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_f8519ad6-8193-4cba-a730-0379b7dcfa60"
      unitRef="U_USD">602000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_0e63fef6-3ce5-4438-887d-3fa422727a12"
      unitRef="U_USD">353487000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_ac5a880c-9dc2-42b9-bf6f-0054a871d466"
      unitRef="U_USD">288331000</us-gaap:Assets>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_f2bc8380-21fc-48c9-8540-ce86fe924833"
      unitRef="U_USD">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_b4830cef-a489-4daf-aa7a-806e17f4b0c6"
      unitRef="U_USD">173000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_9839a857-4fed-4827-ada0-68b36f2f037c"
      unitRef="U_USD">4764000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_7f4947af-198c-4dad-902a-9c7f193668cf"
      unitRef="U_USD">1787000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_f8a37433-cca0-4e5e-a4c6-f72efbf4cfb0"
      unitRef="U_USD">7744000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_1aa2d613-8adb-4a23-bc34-946311cd2787"
      unitRef="U_USD">8371000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_51aa7dac-ae86-45af-869f-4ea8fd27fde5"
      unitRef="U_USD">2599000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_18508c12-3101-46a7-90fd-4a0c5cc96874"
      unitRef="U_USD">6586000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_d6e8644d-450d-4033-903c-6ad3fe497362"
      unitRef="U_USD">1231000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_0ecba942-a403-4469-8783-f2dec0e69e87"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_66a86161-e92a-4def-a75f-1f65bb8b34db"
      unitRef="U_USD">16338000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_fbc09b35-4825-452e-ac9c-58d3744d2fcc"
      unitRef="U_USD">16744000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_6c34d7e4-af8a-4404-a939-bd712ae6e1a7"
      unitRef="U_USD">2491000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_b4f58eb3-00f4-480e-a79c-68fae7a8d6c7"
      unitRef="U_USD">13226000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_704014ee-8e1b-416c-a75f-5e0baea6447e"
      unitRef="U_USD">214000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_9639dcca-64ba-4246-904d-21a8391a0341"
      unitRef="U_USD">122000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_71574c71-a657-4286-ad8b-c2401e4bce67"
      unitRef="U_USD">15217000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_97c02a72-9f70-4ee2-b072-585dbb252dc4"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_a9b5e48b-6e00-4842-8a21-6b3831ebd96a"
      unitRef="U_USD">120000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_fa962fd7-6ad2-4dd3-af8b-6d8a877459b1"
      unitRef="U_USD">1852000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_a9088b00-83ee-41df-8cf3-a0c6da12f968"
      unitRef="U_USD">34380000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_3c4d9a06-4035-4803-a4c7-cc63af894cde"
      unitRef="U_USD">31944000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_ee5c0499-20ca-437d-a8e1-ab52ac1d0b47"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_c498d275-d3c0-433d-9f79-a121914de6f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_328fa102-5209-401a-a474-463b648b124f"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_79810407-3071-43ec-b222-91808e03afc1"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_68a8d48f-6d25-4206-8344-005658f7cb00"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_898d5ce7-becc-4623-b305-2638e09a71ae"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_24ba14f3-13b2-49af-a2df-3dec8ca2b4a8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_260b4f51-0464-4674-91a2-3813bf81b6f1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_b2121f3b-48a1-4a40-881f-c65258efc934"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_49c17aa8-18bb-4f7c-b2aa-30e3a9a6fa45"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_4d3ff223-661c-44f2-a303-3a571f035f74"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_f2da90ab-421e-41d2-b41c-421f173f16da"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_219b44ea-fa7a-43f8-995d-31717ba44eb1"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_7a82e37b-61f6-4107-b1ec-875825c6c0c5"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_32542280-9e10-457b-8f5e-9bb92036e89a"
      unitRef="U_shares">32224524</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_ecd9cda3-00ab-4818-bddc-b1bea83d7380"
      unitRef="U_shares">32224524</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_350bebd4-4cdb-408f-9486-63659dd8acf3"
      unitRef="U_shares">26681983</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_7f63d232-c14b-40a6-8ebc-15a7c026fb1a"
      unitRef="U_shares">26681983</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_ff70f8a4-1fc1-47e7-8ad6-f2451768f5f7"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_341978d0-d9fc-4160-942d-5791e9c716e2"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_fe9d06fc-13bb-4a7e-8aab-61f6808bb451"
      unitRef="U_USD">526523000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_134b30f9-bfe2-4e85-a7ac-d4de6b76ee0c"
      unitRef="U_USD">392063000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_eb00ac19-d7cf-4214-af1b-8ba69763307b"
      unitRef="U_USD">-423000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_4e91d547-dd96-45f9-9ae7-a9907e17e697"
      unitRef="U_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_7e0cbf04-7359-4940-8308-849c70e78129"
      unitRef="U_USD">-206996000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_98800575-c943-45cd-9d94-92fef8cdde4b"
      unitRef="U_USD">-135679000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_09cd29b3-cf7a-44cf-8daf-57144ab13502"
      unitRef="U_USD">319107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_b9e4c39d-e158-457f-ab32-8f934b782a8c"
      unitRef="U_USD">256387000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_dcaed8b0-78f6-4bfd-8493-aabd0aae74a7"
      unitRef="U_USD">353487000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_cb6d42e3-a08a-4d7f-adc8-261126dbf41c"
      unitRef="U_USD">288331000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_16a70b68-4741-4547-b101-2c92340c8106"
      unitRef="U_USD">18038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_0f843b23-c918-4578-8c9d-29c5310154f7"
      unitRef="U_USD">13363000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_2858da6d-989b-4eb2-9dbb-7cffdd09eafb"
      unitRef="U_USD">249000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:Revenues
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_c0fb7d62-3592-4460-9fbd-9d19dfa864cd"
      unitRef="U_USD">18038000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_9e4cfacf-a854-4a2c-a9e5-d894cb34c95c"
      unitRef="U_USD">13612000</us-gaap:Revenues>
    <fdmt:ResearchAndDevelopmentExpenseRelatedParty
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_fdefe76c-957a-4d47-b07c-878d40ac0665"
      unitRef="U_USD">935000</fdmt:ResearchAndDevelopmentExpenseRelatedParty>
    <fdmt:ResearchAndDevelopmentExpenseRelatedParty
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_2a820835-f123-485b-b655-c33977290e4c"
      unitRef="U_USD">579000</fdmt:ResearchAndDevelopmentExpenseRelatedParty>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_a3ef7496-fc39-4612-b6f8-b3470dd13130"
      unitRef="U_USD">61360000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_ed281fd7-3d59-4f82-82d7-06d33916415d"
      unitRef="U_USD">53038000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_5289144c-50fc-4268-9f05-9a5356b5bd9f"
      unitRef="U_USD">28011000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_d5a52127-c8ab-4b0b-a29c-78cee41b3e8e"
      unitRef="U_USD">17238000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_d2cbce8f-3960-4144-8ba3-1c337ccffbd1"
      unitRef="U_USD">89371000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_f25e10fb-0d98-466d-930b-5d9d866940d5"
      unitRef="U_USD">70276000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_6825c3f9-c00d-459b-a238-29b9cddd84bd"
      unitRef="U_USD">-71333000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_538f9354-6992-4ba5-966c-f703bd8d99ec"
      unitRef="U_USD">-56664000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_cca0bb5f-3b87-480e-95e7-0e19ea8044c9"
      unitRef="U_USD">137000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_73b1983c-98e8-459a-9c40-eb50ac7b91df"
      unitRef="U_USD">152000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_12c708a5-488f-4c33-a143-e08fe685840f"
      unitRef="U_USD">-121000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_3b46cd8b-4bb6-4337-91bf-00afd516b565"
      unitRef="U_USD">-181000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_5b8d1df7-479d-4142-863e-eea5e25704b7"
      unitRef="U_USD">16000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_831f169e-3d90-4c22-be76-906cae96978a"
      unitRef="U_USD">-29000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_b836a7ed-76a4-4fd7-86e2-40abeb0c0d86"
      unitRef="U_USD">-71317000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_5d302a98-2e2a-446e-8abc-eef753bc474a"
      unitRef="U_USD">-56693000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="2"
      id="F_b1763703-a5e1-4af1-85a8-496a52265d54"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.57</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="2"
      id="F_d38e1038-38ca-4a80-8f8d-467fc6b0845e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-8.82</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="0"
      id="F_ca10a9dd-36eb-4b72-b55c-0574d2c9bc33"
      unitRef="U_shares">27730420</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="0"
      id="F_beb98568-917a-452d-86f4-d620d7cc7a83"
      unitRef="U_shares">6430555</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_5052d1e9-f2d7-42ed-b510-fd1c3ab80b04"
      unitRef="U_USD">-71317000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_4b29a9e6-827f-4bf6-b2e3-e739d836f51e"
      unitRef="U_USD">-56693000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_875dcb21-a2a9-4d87-b877-0fb48110e5c0"
      unitRef="U_USD">-423000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_4d2d80d3-ccdc-4401-b1f4-70bd9b20a3da"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_775ca217-7f09-4e93-a99d-daa28c47406c"
      unitRef="U_USD">-71740000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_066313ec-7a12-418e-8734-93c41e3fb5d3"
      unitRef="U_USD">-56693000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"
      decimals="INF"
      id="F_95d1bf0e-afc9-413b-92c3-2e240571b44c"
      unitRef="U_shares">7375631</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"
      decimals="-3"
      id="F_8b2b9800-71c0-4107-804b-8e9e1f09d645"
      unitRef="U_USD">102980000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_59d3639a-d9e5-4bdd-af89-ba17bedfea32"
      decimals="INF"
      id="F_778251da-7f3e-436f-a0ec-58d43c39ef1e"
      unitRef="U_shares">5178955</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_59d3639a-d9e5-4bdd-af89-ba17bedfea32"
      decimals="-3"
      id="F_86d7f767-e739-4e87-b3c5-9e581c8e627a"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5c9ad16b-c408-4093-be43-5c9223652764"
      decimals="-3"
      id="F_cbad1918-c147-409e-9d17-e30efdf4ccb0"
      unitRef="U_USD">6054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4eaef891-9b88-429e-bd16-799664373d3a"
      decimals="-3"
      id="F_64681f15-0a86-40ed-99fa-7f3bcfab48c7"
      unitRef="U_USD">-79025000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"
      decimals="-3"
      id="F_bcb4c23f-bae1-43a8-85a8-38accfd24304"
      unitRef="U_USD">-72970000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e90ff7ba-2215-4139-bfb3-bb512afebcb1"
      decimals="-3"
      id="F_af3eb39f-82d0-4f09-93f3-3a377dcd944a"
      unitRef="U_USD">-39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_01872582-961a-450f-b5a8-ef39a9a60634"
      decimals="-3"
      id="F_5753ec4a-42a2-4e50-b27b-4481ce0fe590"
      unitRef="U_USD">39000</us-gaap:StockholdersEquity>
    <fdmt:IssuanceCostForIssuanceOfPreferredStock
      contextRef="C_e7f9066a-37f9-4184-9c45-03d0ffb6a47b"
      decimals="-3"
      id="F_edabdf86-8cf6-4de5-85f5-79f83b3be576"
      unitRef="U_USD">3138000</fdmt:IssuanceCostForIssuanceOfPreferredStock>
    <fdmt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_d82786bf-b805-4233-94b3-667354f02c35"
      unitRef="U_shares">4200353</fdmt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_466cf6da-22fa-499d-821c-80e6caa0f5ac"
      unitRef="U_USD">72468000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <fdmt:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_3361a183-b28f-4dfb-bc23-9a3d911f3dee"
      unitRef="U_shares">-11575984</fdmt:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <fdmt:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_e953f3db-f640-445c-bd82-32c6125579bd"
      unitRef="U_USD">-175448000</fdmt:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_528f45e3-d466-442e-aad5-49b6b3b7312c"
      decimals="INF"
      id="F_205013e9-d44f-42a5-b036-beafeb7838f9"
      unitRef="U_shares">11575984</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_528f45e3-d466-442e-aad5-49b6b3b7312c"
      decimals="-3"
      id="F_d49461ea-961d-47b2-843c-5340f3d04c62"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_6daa8ce8-a992-4249-a203-b1e888605ef4"
      decimals="-3"
      id="F_8dfedcc7-2819-4e13-9dd1-f2935bc713ef"
      unitRef="U_USD">175447000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_f001d20c-3f30-41fa-9787-266a369ea52e"
      unitRef="U_USD">175448000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_ccccdee5-98b9-4eba-97f0-75b85fa9ed38"
      decimals="-3"
      id="F_998925c7-22cd-49bb-a436-e658ba2f6ced"
      unitRef="U_USD">17468000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_528f45e3-d466-442e-aad5-49b6b3b7312c"
      decimals="INF"
      id="F_9da8814c-aba7-4bc4-af0e-b239b90e4395"
      unitRef="U_shares">9660000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_528f45e3-d466-442e-aad5-49b6b3b7312c"
      decimals="-3"
      id="F_38ec4b97-0dd6-4cce-a584-c73ae3428958"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6daa8ce8-a992-4249-a203-b1e888605ef4"
      decimals="-3"
      id="F_c6a3bb06-ffa4-4800-96f6-3e6beea8196e"
      unitRef="U_USD">204712000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_fc02aceb-91b9-44d4-9385-614cb4afe219"
      unitRef="U_USD">204713000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_528f45e3-d466-442e-aad5-49b6b3b7312c"
      decimals="INF"
      id="F_9687b4dd-6ed9-43e4-9f49-d8ccf1345536"
      unitRef="U_shares">267044</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6daa8ce8-a992-4249-a203-b1e888605ef4"
      decimals="-3"
      id="F_e8f8e559-57fb-41e3-9bdb-19b4e3f9467b"
      unitRef="U_USD">857000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_8e2f3434-d5f2-4389-a478-535ec89ac28d"
      unitRef="U_USD">857000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6daa8ce8-a992-4249-a203-b1e888605ef4"
      decimals="-3"
      id="F_8ace2c54-73ec-4c68-921f-7218e714e0e0"
      unitRef="U_USD">4984000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_1c5d2f18-a2d8-4d58-b371-d9049af7e505"
      unitRef="U_USD">4984000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices
      contextRef="C_6daa8ce8-a992-4249-a203-b1e888605ef4"
      decimals="-3"
      id="F_a128fc37-397e-43ed-8ddd-e301395b3c9e"
      unitRef="U_USD">48000</fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices>
    <fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_be8d6eea-20c6-46b9-b888-365dacbd6a79"
      unitRef="U_USD">48000</fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="C_5d6bb9b3-6b6c-4b68-931a-aa92ca2d40c7"
      decimals="-3"
      id="F_a740c526-61de-4176-9f98-722593a4aff0"
      unitRef="U_USD">-56693000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_df5aa19e-2693-482b-b8a8-b8632257b53b"
      unitRef="U_USD">-56693000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_fbf54024-6915-42de-b1f4-5893be4aa781"
      decimals="INF"
      id="F_cd8a7423-36a8-4ace-9075-b37b973d2fbf"
      unitRef="U_shares">26681983</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_fbf54024-6915-42de-b1f4-5893be4aa781"
      decimals="-3"
      id="F_0a5bf724-403e-4849-8945-082d927f1923"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aee471bc-dfa2-486c-b5af-72c1159914db"
      decimals="-3"
      id="F_bab6bc6b-d73e-4dae-9245-58a22554d4f0"
      unitRef="U_USD">392063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5768aef4-f24f-4156-919c-885a554541d5"
      decimals="-3"
      id="F_1539584c-be12-4d64-b9e8-3723b130bddf"
      unitRef="U_USD">-135679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_3c1dd694-48fd-46c7-b1b0-511024ddfb88"
      unitRef="U_USD">256387000</us-gaap:StockholdersEquity>
    <fdmt:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised
      contextRef="C_0851c4dd-d51b-410e-9510-555127298972"
      decimals="INF"
      id="F_5fda0b5a-07e3-497f-88c3-8cdd65d59fdd"
      unitRef="U_shares">646417</fdmt:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
    <fdmt:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="C_618215e0-a055-427d-9220-18bee23b39f3"
      decimals="-3"
      id="F_bc9f3625-c704-436c-9b8f-075b7d0490d2"
      unitRef="U_USD">3905000</fdmt:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <fdmt:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_2b4ac02e-c067-42f1-a645-0a530a2c1131"
      unitRef="U_USD">3905000</fdmt:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_f0ae8a23-d71e-4828-8ac8-78470326d77f"
      decimals="-3"
      id="F_93fcfd8f-93d9-4465-a963-9599621d8741"
      unitRef="U_USD">7660000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0851c4dd-d51b-410e-9510-555127298972"
      decimals="INF"
      id="F_22c814a8-8c9f-4969-b0c0-e120baaaac70"
      unitRef="U_shares">4875715</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_618215e0-a055-427d-9220-18bee23b39f3"
      decimals="-3"
      id="F_e496b63c-9f4b-4289-926e-fabae69d5a2f"
      unitRef="U_USD">115090000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_57b480e5-92ed-4da7-9de3-2580497b8c5e"
      unitRef="U_USD">115090000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_618215e0-a055-427d-9220-18bee23b39f3"
      decimals="-3"
      id="F_82e167e3-43c2-490b-a82e-65d421746000"
      unitRef="U_USD">1146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_d591de63-22bb-45cf-bf59-cf5797ae118c"
      unitRef="U_USD">1146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_618215e0-a055-427d-9220-18bee23b39f3"
      decimals="-3"
      id="F_ef9141a5-6567-4508-8b43-63dee76630f5"
      unitRef="U_USD">13799000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_afeac895-87e7-404e-9357-87fb430e4184"
      unitRef="U_USD">13799000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0851c4dd-d51b-410e-9510-555127298972"
      decimals="INF"
      id="F_95899568-9c4a-4000-bd98-d72a4f76a854"
      unitRef="U_shares">20409</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_618215e0-a055-427d-9220-18bee23b39f3"
      decimals="-3"
      id="F_ea702d82-aef4-4b70-ad42-98b22cbffaca"
      unitRef="U_USD">433000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_197aef14-fdb1-4604-89f6-9167d76e5364"
      unitRef="U_USD">433000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices
      contextRef="C_618215e0-a055-427d-9220-18bee23b39f3"
      decimals="-3"
      id="F_a1098e52-2da8-406c-9d90-a6346d66c2c2"
      unitRef="U_USD">87000</fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices>
    <fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_99ee8035-f798-4204-b9dc-ef873d4e8064"
      unitRef="U_USD">87000</fdmt:AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices>
    <fdmt:StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities
      contextRef="C_36758c2d-4d20-4d3c-a68c-1ae0229d4cbf"
      decimals="-3"
      id="F_da6a174f-5a5f-4047-848f-49edfd53cd1d"
      unitRef="U_USD">-423000</fdmt:StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities>
    <fdmt:StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_b6a387ff-cefc-4299-a75b-300d1beeffaa"
      unitRef="U_USD">-423000</fdmt:StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="C_f0a7f822-26e3-4aa6-b0cb-8635b7e734f0"
      decimals="-3"
      id="F_f048bbb4-e46b-4b82-b527-49a917726b0b"
      unitRef="U_USD">-71317000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_36758c2d-4d20-4d3c-a68c-1ae0229d4cbf"
      decimals="-3"
      id="F_dddc44b5-384c-40e0-b97d-9004500bd530"
      unitRef="U_USD">-71317000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_e7d12ec2-7bb6-4ee6-9329-dfed184d0890"
      decimals="INF"
      id="F_75fba49c-6d60-4f36-a680-0d5507dc5cc5"
      unitRef="U_shares">32224524</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e7d12ec2-7bb6-4ee6-9329-dfed184d0890"
      decimals="-3"
      id="F_e1b46946-0630-43ed-9a5c-bb2d97514196"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_25a62ff3-b92c-4866-af5f-948e6635deba"
      decimals="-3"
      id="F_ceb5e751-838d-4fe0-a68f-1e6373b51186"
      unitRef="U_USD">526523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0d9e57bc-9656-45fb-9e86-21e8155c0587"
      decimals="-3"
      id="F_eab079eb-6246-4bf0-9ee0-3d094a16d891"
      unitRef="U_USD">-423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ddf9471b-7dbf-43eb-8802-d9844a6eb24a"
      decimals="-3"
      id="F_e149291c-1b66-46d2-8810-a4d0c41cef55"
      unitRef="U_USD">-206996000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_cede5a0e-8486-4bc4-8a05-6fe6520b8ac3"
      unitRef="U_USD">319107000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_17f3398b-6e10-4b6f-a3d2-93fdc5e37bc7"
      unitRef="U_USD">-71317000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_4b54a8f8-92e0-4f97-b682-587f340eea84"
      unitRef="U_USD">-56693000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_bf97d07e-70ad-4585-94db-fb2be6dd7fde"
      unitRef="U_USD">13799000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_2b23a302-e658-4891-be7a-bb0c7c995da1"
      unitRef="U_USD">4984000</us-gaap:ShareBasedCompensation>
    <fdmt:VestingOfCommonStockWarrantInReturnForServices
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_3d401fbc-8d16-4319-9040-858f324889e0"
      unitRef="U_USD">87000</fdmt:VestingOfCommonStockWarrantInReturnForServices>
    <fdmt:VestingOfCommonStockWarrantInReturnForServices
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_296079e7-c6dc-4af0-8069-151bde26217b"
      unitRef="U_USD">48000</fdmt:VestingOfCommonStockWarrantInReturnForServices>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_6745954d-6b42-4d10-8447-6392552e1634"
      unitRef="U_USD">92000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_c8ccf5b6-5117-46b1-b5b8-f40a8f03272a"
      unitRef="U_USD">21000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_363b4ffd-634f-47a2-8bfc-e87c0e0309c9"
      unitRef="U_USD">1523000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_c8e7a293-17b0-4308-9e69-cc93e089e2c1"
      unitRef="U_USD">1443000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_f03a1748-df8b-47e1-b244-182ae7126024"
      unitRef="U_USD">1497000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_683ef2e3-2a62-49e9-8678-2b035b75e84a"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_600d0e5f-d236-428f-b603-f1071e9cacb3"
      unitRef="U_USD">-719000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_634cee6d-1786-4ee7-925f-263577737236"
      unitRef="U_USD">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_a4b11d83-0eea-4f92-89bd-c15e92301350"
      unitRef="U_USD">-1439000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_dcf9f88c-d70f-4596-9b01-bf2b72783dcc"
      unitRef="U_USD">508000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_2406e37c-8c16-4a16-ba7d-dae858b16319"
      unitRef="U_USD">4225000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_8f03f0b5-9407-4deb-baf7-722cd0c0f255"
      unitRef="U_USD">2566000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_e5a05990-cfbd-462a-b4c2-35ccf5ec3020"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_d183a228-22d8-4c01-9a91-93a678e8f6bc"
      unitRef="U_USD">-75000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_aa609f83-4b27-49e2-80d2-fc82372599a3"
      unitRef="U_USD">2285000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_8c979293-bed0-41fa-918a-f701b82740a0"
      unitRef="U_USD">43000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_fa556346-9db4-4d4e-8545-ba8a40870dbb"
      unitRef="U_USD">689000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_0d3080c9-04d5-4a1f-8a86-4b59e8cbda13"
      unitRef="U_USD">1899000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_6470a674-b335-422f-9ae0-71892e737ee4"
      unitRef="U_USD">-14722000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_3468c623-c389-4c37-ae3a-9e566724f1c4"
      unitRef="U_USD">345000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_1afe67c1-f7ef-45d1-923f-5c0a3bd6dfa9"
      unitRef="U_USD">-1000000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_23b662d7-ee15-46f7-b584-f6e9f867b045"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_eec84e61-7b5a-4467-9963-1afc18b8b358"
      unitRef="U_USD">-69134000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_7ce7346a-7848-4d2b-b217-dcca60a05356"
      unitRef="U_USD">-50909000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_2970d8ff-6335-4d3a-8a84-b90c0b7ad58e"
      unitRef="U_USD">9110000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_0cbcf1bd-93ed-406b-8020-f7e4ace9f228"
      unitRef="U_USD">1000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_a397e40e-d021-4ae5-a603-aa8dcd176e91"
      unitRef="U_USD">168570000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_9e8013eb-ed84-41c5-ad8a-1c7a1341673e"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_f15362c9-27ec-42e7-af79-23b89b37af75"
      unitRef="U_USD">5000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_e0fc954a-1f67-4d3a-a245-52c87ced6dff"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_05f148f4-7013-4b1b-978f-6b6672b263f1"
      unitRef="U_USD">-172680000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_db0757a0-bb52-414d-9729-384512581adb"
      unitRef="U_USD">-1000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_40deb337-2327-4a0e-adcd-eec697672c26"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_c0705481-f3c8-4a99-a570-995fb67b75e1"
      unitRef="U_USD">72468000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_2045a30d-45f1-42f0-b873-c8646e04658d"
      unitRef="U_USD">114296000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_96cf3e01-b2e0-46a5-826a-a67448d5f111"
      unitRef="U_USD">205658000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <fdmt:IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_a58a5b6c-eb7b-4bbd-9219-4f3fc72f7357"
      unitRef="U_USD">3360000</fdmt:IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants>
    <fdmt:IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_0bb835a4-70b7-4475-95a5-5ac5ed60e2fd"
      unitRef="U_USD">857000</fdmt:IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_efe915f9-951f-403f-ab7d-19c419197097"
      unitRef="U_USD">433000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_aa9b40d7-7ed3-4825-9d40-9ec0b6117e0e"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_bca50794-69b2-4874-b08d-73920782b186"
      unitRef="U_USD">118089000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_74cd8161-3ea9-4cd4-a300-77059189bdbe"
      unitRef="U_USD">278983000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_c6f2eda3-a295-413a-bba0-79466abc0c7b"
      unitRef="U_USD">-123725000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_073ec1d4-3448-4d4c-aef3-91cef8091639"
      unitRef="U_USD">227074000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_63811ad8-af6d-4f21-8aa8-9698f02036dc"
      unitRef="U_USD">276726000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"
      decimals="-3"
      id="F_e6e47979-0054-4b3a-ae8b-6402729c9c7b"
      unitRef="U_USD">49652000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_1f0f9155-34e9-41f3-af03-18c536fbaaa1"
      unitRef="U_USD">153001000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_51fd2d35-21b1-4e68-90ab-0e188c09d281"
      unitRef="U_USD">276726000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_bcdd71b9-c76a-4d8a-b2d0-ef736f4308fc"
      unitRef="U_USD">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_3da348cb-1f94-43e8-bca4-b8e8832ace15"
      unitRef="U_USD">175448000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_bb738f70-9d4f-4c5c-8427-e6b7ced8a8f5"
      unitRef="U_USD">2199000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_0467ac83-f6a3-4c6e-9a7d-cd8d0177c83f"
      unitRef="U_USD">466000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <fdmt:UnpaidOfferingCosts
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_6622f66c-7d96-4cfd-901a-be77e76894fc"
      unitRef="U_USD">152000</fdmt:UnpaidOfferingCosts>
    <fdmt:UnpaidOfferingCosts
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_35da2291-98d6-41df-af7f-1263ab35d5a9"
      unitRef="U_USD">946000</fdmt:UnpaidOfferingCosts>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_c476d981-505a-4c87-80db-130aef56d407"
      unitRef="U_USD">478000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_930e5a09-aa3a-4614-bf4f-d72c1ebfb668"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <fdmt:NonCashIssuanceOfCommonStockWarrantToSettleLiability
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_439d75a7-6318-4c60-80a5-cdf702869129"
      unitRef="U_USD">1146000</fdmt:NonCashIssuanceOfCommonStockWarrantToSettleLiability>
    <fdmt:NonCashIssuanceOfCommonStockWarrantToSettleLiability
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_a0ebca19-dc83-405d-94c4-caee06b13c78"
      unitRef="U_USD">0</fdmt:NonCashIssuanceOfCommonStockWarrantToSettleLiability>
    <us-gaap:StockIssued1
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_d470c919-49d0-4868-9c56-79c732a7ba8d"
      unitRef="U_USD">545000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_6ebfdeac-1cf7-402e-83aa-d7c29be6d23a"
      unitRef="U_USD">0</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_bed3f420-911d-473c-8614-beb03a0163c3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;1. The Company&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4D Molecular Therapeutics, Inc. (the &#x201c;Company&#x201d;) was formed as a limited liability company in September 2013 under the name 4D Molecular Therapeutics, LLC. The Company changed its name and converted into a corporation which was incorporated in the state of Delaware in March 2015. The Company is a clinical-stage gene therapy company pioneering the development of product candidates using its targeted and evolved adeno-associated viruses (&#x201c;AAV&#x201d;) vectors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In December 2020, the Company sold and issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9,660,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock at a price to the public of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;23.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share, which included shares sold upon the underwriters&#x2019; exercise of their overallotment option to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,260,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; additional shares. The Company received an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;204.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in net proceeds, after deducting underwriting discounts and commissions and offering costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Upon the closing of the Company's initial public offering in December 2020 (the "IPO"), all outstanding shares of redeemable convertible preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11,575,984&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock. Subsequent to the closing of the IPO, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of redeemable convertible preferred stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Follow On Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In November 2021, the Company completed its second underwritten public offering ("Follow-on Offering") in which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,750,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company's common stock were sold at an offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;25.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share pursuant to an effective Registration Statement on Form S-1. The net proceeds from the Follow-on Offering were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;111.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has incurred significant losses and negative cash flows from operations and had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;207.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as of December 31, 2021. The Company believes that its cash and cash equivalents and marketable securities as of December 31, 2021 are sufficient for the Company to fund planned operations for at least one year from the issuance date of these financial statements for the year ended December 31, 2021. The Company has historically financed its operations primarily through the sale of equity securities, and to a lesser extent, from cash received pursuant to its collaboration and license agreements. To date, none of the Company&#x2019;s product candidates have been approved for sale, and therefore, the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows from operations to continue for the foreseeable future. The Company plans to raise additional funding as required based on the status of its clinical trials and projected cash flows. There can be no assurance that, in the event the Company requires additional financing, such financing will be available on terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company&#x2019;s ability to achieve its business objectives.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_542e8a0a-d3fd-48d5-aca9-2b0837fda539"
      decimals="INF"
      id="F_70c1c2d0-48f9-48d5-936e-1084cee77c9d"
      unitRef="U_shares">9660000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_625a9586-f459-4552-b058-fb7510d5960c"
      decimals="INF"
      id="F_112c47f6-9cb2-4ddb-b5b9-73f78e3f034b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_aded6adf-76e7-4673-85fe-7c5fc3d77d2f"
      decimals="INF"
      id="F_c56af0a3-7585-4660-b511-f29f3816064f"
      unitRef="U_shares">1260000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_542e8a0a-d3fd-48d5-aca9-2b0837fda539"
      decimals="-5"
      id="F_97e48f20-c30f-4289-ba99-0929d1ced977"
      unitRef="U_USD">204700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_625a9586-f459-4552-b058-fb7510d5960c"
      decimals="INF"
      id="F_6d42bf06-bfb6-4cb7-8400-6df2bcece467"
      unitRef="U_shares">11575984</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="INF"
      id="F_c552ad4d-2795-436c-9f92-23e48fafc32d"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="C_cfe98104-f350-4823-9e4e-dde161bbcd77"
      decimals="INF"
      id="F_f15601e4-440b-4aa0-9d38-1f13643ab2f1"
      unitRef="U_shares">4750000</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_cfe98104-f350-4823-9e4e-dde161bbcd77"
      decimals="2"
      id="F_05ceffe3-fc14-4694-bc81-4a3701e52495"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_1784e7f0-ff83-48df-a30d-36b81c4f651d"
      decimals="-5"
      id="F_3febee93-63a2-43a5-bcb2-5fdac31ff5e0"
      unitRef="U_USD">111100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-5"
      id="F_de846564-ce98-4b40-ac46-174a1e4a3a7a"
      unitRef="U_USD">-207000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_76434f64-2f3e-41e6-ad78-f04bec8f8cbc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Use of Estimates and Judgements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgements that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the contract term, transaction price and costs of collaboration agreements, as well as estimates of the fair value of common stock (prior to the IPO), stock options and derivative instruments and income tax uncertainties. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Due to the coronavirus (&#x201c;COVID-19&#x201d;) pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2021. While there was not a material impact to the Company&#x2019;s financial statements as of December 31, 2021, these estimates may change, as new events occur and additional information is obtained, as well as other factors related to the COVID-19 pandemic that could result in material impacts to the financial statements in future reporting periods.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; reportable and operating segment. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on a company-wide basis for purposes of allocating resources and assessing financial performance.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of and for the years ended December 31, 2021 and 2020, all of the Company&#x2019;s long-lived assets were located in the United States and all revenue was earned in the United States.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable securities and accounts receivable. The Company&#x2019;s cash is held at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; financial institutions in the United States of America. The Company&#x2019;s cash equivalents are invested in money market funds. The Company also invests in U.S. Treasuries, commercial paper and corporate bonds. The Company has not experienced any losses on its deposits of cash and cash equivalents. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s partners in collaboration and license agreements who represent 10% or more of the Company&#x2019;s total revenue are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.91%;"/&gt;
          &lt;td style="width:1.606%;"/&gt;
          &lt;td style="width:14.636%;"/&gt;
          &lt;td style="width:1.606%;"/&gt;
          &lt;td style="width:14.636%;"/&gt;
          &lt;td style="width:1.606%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:66.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;* Less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s partners in collaboration and license agreements who represent 10% or more of the Company&#x2019;s total accounts receivable are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.974%;"/&gt;
          &lt;td style="width:1.627%;"/&gt;
          &lt;td style="width:14.881%;"/&gt;
          &lt;td style="width:1.627%;"/&gt;
          &lt;td style="width:14.891%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;74&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s total revenues by geographic region, based on the location of the customer, are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.036%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.793%;"/&gt;
          &lt;td style="width:0.771%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.665%;"/&gt;
          &lt;td style="width:0.921%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Netherlands&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Switzerland&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist of money market funds.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Marketable Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Marketable securities consist of commercial paper, corporate bonds and U.S. Treasuries and are included in current and noncurrent assets.  The Company classifies its marketable securities as available-for-sale and carries them at fair value on its balance sheet. Fair value is estimated using independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses on the marketable securities are reported as a component of stockholders' equity (deficit) in accumulated other comprehensive loss.  The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the statements of operations. Realized gains and losses are included in interest income on the statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company periodically evaluates its marketable securities to assess whether those with unrealized loss positions are other than temporarily impaired.  The Company considers various factors in determining whether to recognize an impairment charge.  If the Company determines that the decline in an investment's fair value is other-than-temporary, the difference is recognized as an impairment loss in the statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Other Risks and Uncertainties&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (&#x201c;CMOs&#x201d;) and contract research organizations (&#x201c;CROs&#x201d;), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The extent of the impact of the COVID-19 pandemic on the Company&#x2019;s business will depend upon the duration and spread of the outbreak and the extent and severity of the impact on the Company&#x2019;s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. The extent to which the coronavirus outbreak may materially impact the Company&#x2019;s financial condition, liquidity or results of operations is uncertain.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As a basis for considering such assumptions, a three-level fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Level 1 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014; Observable inputs that reflect unadjusted quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Level 2 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Level 3 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company accounts for transfers of financial instruments between levels of the fair value hierarchy on the date of the event or change in circumstance that caused the transfer.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Accounts Receivable&#x2014;Allowance for Doubtful Accounts&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company regularly reviews accounts receivable for collectability and establishes an allowance for probable credit losses and writes off uncollectible accounts as necessary. The Company has determined that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; allowance was required at December 31, 2021 and 2020. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;t have any write-offs relating to uncollectible accounts receivable during the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over the estimated useful lives of assets, ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_c05559b7-51fa-4d3d-9739-b6c4a7e260ed;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. Leasehold improvements are amortized over the shorter of the useful life of the assets or the lease term. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected within operating expenses in the statements of operations. Maintenance and repairs are charged to expense as incurred.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is typically measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; such impairments of long-lived assets in the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance costs. The redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company's control, such as a merger or consolidation, sale, lease, or license of substantially all of the Company's assets (each, a "deemed liquidation event"), the convertible preferred stock would become redeemable at the option of the holders of a majority of the outstanding series of redeemable convertible preferred stock. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the liquidation preference of such shares because a deemed liquidation event obligating the Company to pay the liquidation preference did not occur. All outstanding shares of the redeemable convertible preferred stock converted into common stock upon the close of the IPO in December 2020.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Common Stock Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company accounts for common stock warrants which meet the definition of a derivative as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement. Common stock warrants classified as liabilities are initially recorded at fair value and remeasured at fair value each balance sheet date with the offset adjustments recorded in other income (expense), net within the statements of operations. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;On December 31, 2021, the Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, Leases (Topic 842), ("ASC 842") using the alternative modified retrospective approach effective as of January 1, 2021 to recognize a cumulative-effect adjustment on the effective date and to not adjust financial information and disclosures required under the new lease standards for comparative prior periods.  The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. Additionally, the Company has elected not to separate lease and non-lease components and not to recognize leases with an initial term of twelve months or less.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Under ASC 842, at contract inception, the Company determines if an arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the obligation to make lease payments arising from the lease. Operating lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent the Company's obligation to make payments arising from the lease. Operating right-of-use assets and liabilities are recognized at the commencement date of the lease and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates, or abatements the Company expects to receive from the lessor. The Company records amortization of operating right-of-use assets and accretion of lease liabilities as a single lease cost on a straight-line basis over the lease term. No lease renewal options are recognized as part of the right-of-use assets and lease liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company's operating leases are presented in the balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent based on the discounted lease payments to be made within the proceeding twelve months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As the Company&#x2019;s leases do not provide an implicit rate , the Company uses its incremental borrowing rate to discount lease payments. The incremental borrowing rate represents an estimated rate of interest that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Upon adoption of the new lease standard effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, the Company recognized operating lease right-of-use assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, and current and noncurrent operating lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. In connection with the adoption of this standard, deferred rent of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and lease incentive liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, which were previously recorded in prepaid expenses and other current assets, accrued and other current liabilities and other liabilities on the balance sheet as of December 31, 2020, were derecognized. The adoption of the standard did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;t have an impact on the Company's statements of operations or comprehensive loss, stockholders' equity or cash flows. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The impact of adoption of the new lease standard as of January 1, 2021 is summarized as follows:&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Arial;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:51.033%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.889%;"/&gt;
          &lt;td style="width:0.91%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.954%;"/&gt;
          &lt;td style="width:0.91%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:11.048%;"/&gt;
          &lt;td style="width:0.91%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;ASC 842 Adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease liabilities, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company determines revenue recognition for arrangements within the scope of Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606") by performing the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s revenue is primarily derived through its license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses to the Company&#x2019;s technology, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products. Arrangements that include upfront payments are recorded as deferred revenue upon receipt or when due and are recognized as revenue as performance conditions are met. The event-based milestone payments, royalties and cost reimbursements represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration. Royalty payments are recognized when earned or as the sales occur. The Company records cost reimbursements as accounts receivable when right to consideration is unconditional.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company allocates the total transaction price to each performance obligation based on the estimated standalone selling price and recognizes revenue when, or as, the performance obligation is satisfied. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. At the end of each reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Costs related to research, design and development of programs are charged to research and development expense as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses including stock-based compensation, materials, laboratory supplies, outside services and allocated overhead, including rent, insurance, repairs and maintenance, depreciation and utilities. The Company expenses all research and development costs in the period in which they are incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Accrued Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has entered into various agreements with CROs and CMOs. The Company&#x2019;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, the Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; ASU 2018-07, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees. As of January 1, 2020, the Company accounts for stock-based compensation for stock options granted to employees, directors and nonemployees as measured at grant date, based on the fair value of the award. The Company measures the fair value of awards granted using the Black-Scholes option pricing model and recognizes the expense in the statements of operations over the requisite service period, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, using the straight-line method. Forfeitures are accounted for as they occur. The Company&#x2019;s policy for issuing stock upon stock option exercise is to issue new common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prior to the adoption of ASU 2018-07 on January 1, 2020, stock-based compensation expense related to stock options granted to nonemployees was recognized based on the vesting date fair value of options as the stock options were earned. The Company remeasured the stock-based compensation at each reporting period end with the resulting change in fair value being recognized in the statements of operations over the period the related services were rendered. The Company estimated the service period for the options based on the time that would be required to satisfy the service condition, assuming the service condition would be satisfied. Stock-based compensation expense was recognized over the estimated service period but was accelerated if the performance condition was achieved earlier than estimated.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&#x2019;s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Embedded Derivative&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as a separate financial instrument. An embedded derivative exists in the award agreement with the Cystic Fibrosis Foundation (&#x201c;CFF&#x201d;). As described in Note 16, the embedded derivative has been bifurcated and is classified as a liability on the balance sheet and separately accounted for at its fair value. The derivative liability is subject to remeasurement to fair value each reporting period. Changes in the fair value of the derivative liability are recognized as a component of other income (expense), net within the statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company capitalizes certain legal, accounting and other third-party fees that are directly related to the Company&#x2019;s in-process financings, until such financings are consummated. After consummation of the financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. In the event that a planned offering does not occur or is significantly delayed, all related deferred offering costs will be expensed immediately within the Company&#x2019;s statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Net Loss Per Share, Basic and Diluted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company calculates basic and diluted net loss per share in conformity with the two-class method required for companies with participating securities. The Company considers all series of redeemable convertible preferred stock to be participating securities as the holders are entitled to receive non-cumulative dividends on a pari passu basis in the event the dividend is paid on common shares. Under the two-class method, the net loss is not allocated to the redeemable convertible preferred stock as the holders of redeemable convertible preferred stock do not have a contractual obligation to share in losses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. Diluted net loss per share is computed by giving effect to all potentially dilutive common shares outstanding for the period. For purposes of this calculation, redeemable convertible preferred shares, stock options to acquire shares of common stock, common stock warrants, and unvested common stock subject to repurchase, are considered potentially dilutive common shares, but have been excluded from the calculation of diluted net loss per share as their effect is antidilutive.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;New Accounting Pronouncements Recently Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2018-07, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;This ASU aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payment to employees. Under this ASU, the measurement of equity-classified nonemployee awards is fixed at the grant date, which may lower their cost and reduce volatility in the statements of operations. The transition method provided by this ASU is on a modified retrospective basis, which recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020, with early adoption permitted, but no earlier than a company's adoption date of ASC 606. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; this guidance effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; using the modified retrospective method. The Company recorded a less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million cumulative-effect adjustment reflected as a decrease to the opening balance of accumulated deficit and a decrease to additional paid-in capital&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. This ASU clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606, Revenue from Contracts with Customers, when the counterparty is a customer. This ASU also precludes an entity from presenting consideration received from a transaction as revenue from contracts with customers if the counterparty is not a customer for that transaction.  This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.  Early adoption is permitted for entities that have adopted ASC 606, Revenue from Contracts with Customers. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; this ASU on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. The adoption of this ASU did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;not&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; result in a material impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. This ASU affects general principles within Topic 740 and is meant to simplify the accounting for income taxes by removing certain exceptions to the general framework. The ASU adds guidance to reduce complexity in certain areas, including recognizing a franchise (or similar) tax that is partially based on income as an income-based tax and incremental amounts incurred as a non-income-based tax and recognizing deferred taxes for tax goodwill. ASU 2019-12 also created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, other comprehensive income). The amendments in ASU 2019-12 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022.  Early adoption of the amendments is permitted.  The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; ASU 2019-12 effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; on a prospective basis. The adoption of this ASU did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;not&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; result in a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In February 2016, the FASB issued ASU No. 2016-02,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. The classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than twelve months regardless of whether it is an operating or financing lease and (ii) lease expense in its statements of operations for operating leases and amortization and interest expense in its statements of operations for financing leases. Leases with a term of twelve months or less may be accounted for similar to existing guidance for operating leases under Topic 840. In July 2018, the FASB issued ASU No. 2018-11, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;See earlier disclosure in this footnote on the impact on the Company of the adoption of this standard in 2021. &lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As an &#x201c;emerging growth company,&#x201d; the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, as clarified in subsequent amendments. ASU 2016-13 changes the impairment model for certain financial instruments. The new model is a forward-looking expected loss model and will apply to financial assets subject to credit losses and measured at amortized cost and certain off-balance sheet credit exposures. This includes loans, held-to-maturity debt securities, loan commitments, financial guarantees and net investments in leases, as well as trade receivables. For available-for-sale debt securities with unrealized losses, credit losses will be measured in a manner similar to today, except that the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. In October 2019, the FASB voted to delay the effective date of this standard. Topic 326 will be effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_5f706d85-74d6-40cd-a2d5-30ccec818052">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_47b94927-5f3a-48f9-a4b0-10b67039d1b1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Use of Estimates and Judgements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgements that affect the reported amounts of assets, liabilities, revenue and expenses; and disclosure of contingent assets and liabilities as of the date of the financial statements. Such estimates include the determination of useful lives for property and equipment, the contract term, transaction price and costs of collaboration agreements, as well as estimates of the fair value of common stock (prior to the IPO), stock options and derivative instruments and income tax uncertainties. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Due to the coronavirus (&#x201c;COVID-19&#x201d;) pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2021. While there was not a material impact to the Company&#x2019;s financial statements as of December 31, 2021, these estimates may change, as new events occur and additional information is obtained, as well as other factors related to the COVID-19 pandemic that could result in material impacts to the financial statements in future reporting periods.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_f02c00ce-9bda-4cdc-adbb-e3c86fc2a83f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; reportable and operating segment. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on a company-wide basis for purposes of allocating resources and assessing financial performance.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of and for the years ended December 31, 2021 and 2020, all of the Company&#x2019;s long-lived assets were located in the United States and all revenue was earned in the United States.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_b3e3bf98-175c-433e-9e02-75f1ea0223ee"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_fb2b5f1b-d1cc-4cda-b81e-48ab4bbdaf89"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_3d222116-8ebb-4272-9c8b-ae6aa3472ad2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, marketable securities and accounts receivable. The Company&#x2019;s cash is held at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; financial institutions in the United States of America. The Company&#x2019;s cash equivalents are invested in money market funds. The Company also invests in U.S. Treasuries, commercial paper and corporate bonds. The Company has not experienced any losses on its deposits of cash and cash equivalents. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s partners in collaboration and license agreements who represent 10% or more of the Company&#x2019;s total revenue are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.91%;"/&gt;
          &lt;td style="width:1.606%;"/&gt;
          &lt;td style="width:14.636%;"/&gt;
          &lt;td style="width:1.606%;"/&gt;
          &lt;td style="width:14.636%;"/&gt;
          &lt;td style="width:1.606%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:66.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;* Less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s partners in collaboration and license agreements who represent 10% or more of the Company&#x2019;s total accounts receivable are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.974%;"/&gt;
          &lt;td style="width:1.627%;"/&gt;
          &lt;td style="width:14.881%;"/&gt;
          &lt;td style="width:1.627%;"/&gt;
          &lt;td style="width:14.891%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;74&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s total revenues by geographic region, based on the location of the customer, are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.036%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.793%;"/&gt;
          &lt;td style="width:0.771%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.665%;"/&gt;
          &lt;td style="width:0.921%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Netherlands&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Switzerland&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <fdmt:NumberOfFinancialInstitutionsWhereCashIsHeld
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_d75f49a0-09b9-409d-9660-19bdf9bddade"
      unitRef="U_Financial_Institution">2</fdmt:NumberOfFinancialInstitutionsWhereCashIsHeld>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_52658ab4-9dcb-4fc9-9931-b37e94899a4e">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s partners in collaboration and license agreements who represent 10% or more of the Company&#x2019;s total revenue are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.91%;"/&gt;
          &lt;td style="width:1.606%;"/&gt;
          &lt;td style="width:14.636%;"/&gt;
          &lt;td style="width:1.606%;"/&gt;
          &lt;td style="width:14.636%;"/&gt;
          &lt;td style="width:1.606%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:66.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;* Less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s partners in collaboration and license agreements who represent 10% or more of the Company&#x2019;s total accounts receivable are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.974%;"/&gt;
          &lt;td style="width:1.627%;"/&gt;
          &lt;td style="width:14.881%;"/&gt;
          &lt;td style="width:1.627%;"/&gt;
          &lt;td style="width:14.891%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;74&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_d724d8a1-6a4a-42cb-a720-853feca51dab"
      decimals="2"
      id="F_c315e224-3334-42e8-b3ff-f3a923b0dd1f"
      unitRef="U_pure">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_fcb58636-b558-407f-b0d5-265a83042f1a"
      decimals="2"
      id="F_4e92f9e4-aed5-41dd-9457-d8843225c087"
      unitRef="U_pure">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_f5ca12fb-9ded-49e2-8667-052f68f5cdfa"
      decimals="2"
      id="F_63b655be-eeb3-4839-a5bc-e8a73733cb3e"
      unitRef="U_pure">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_a2f26722-25bb-4a09-88a3-02cae078cf69"
      decimals="2"
      id="F_2d6d595a-d754-4ec1-ad4a-2896c69e0caf"
      unitRef="U_pure">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_f0620193-2d47-4e0f-b17c-1fa3385b38cb"
      decimals="2"
      id="F_a36221e3-6ec8-44e1-99b2-acd3d5310c83"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_794002d9-a4fd-4194-b523-592564162f24"
      decimals="2"
      id="F_822c6c43-5009-4e2c-abc1-4c7922292457"
      unitRef="U_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_6f61ac2f-cef4-461c-a2ee-3967bbb25c65"
      decimals="2"
      id="F_5e2188bb-23fb-4e09-ad62-8a39633dfd2c"
      unitRef="U_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_778cb29d-d166-4215-968b-ce01bbf701d9"
      decimals="2"
      id="F_9c17a54d-ce22-4680-9486-76bd26a7a69b"
      unitRef="U_pure">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_cddd6872-9bae-4abd-b89b-a8b4f291f7b6"
      decimals="2"
      id="F_5a0c7063-c709-47de-b120-f26fa75ff765"
      unitRef="U_pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_f7242b4b-b2c1-47e2-8a49-09fa5d802063"
      decimals="2"
      id="F_731d2ca9-18be-4434-8aa2-934c3eb8e831"
      unitRef="U_pure">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_a99aa56e-af3c-4d75-814c-006a1628cef5"
      decimals="2"
      id="F_a8e0eea3-359f-4399-8f34-b0862122ca67"
      unitRef="U_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_e52d4eb1-67cf-418e-81c2-9f61ca8b3839"
      decimals="2"
      id="F_ba492083-6a8c-423c-953d-da44bb65a469"
      unitRef="U_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_78713a05-2d89-483c-9e11-2e24ef5abe49">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s total revenues by geographic region, based on the location of the customer, are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.036%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.793%;"/&gt;
          &lt;td style="width:0.771%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.665%;"/&gt;
          &lt;td style="width:0.921%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Netherlands&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Switzerland&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_02f4bd8b-251b-482c-a9fc-56da777a2727"
      decimals="-3"
      id="F_295d5a45-74fc-4fbf-860c-4783852ab931"
      unitRef="U_USD">736000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_dc4d438d-ed76-4f51-85bd-a0b92d8c257e"
      decimals="-3"
      id="F_9766a248-13f7-4bcc-8bb1-691730967285"
      unitRef="U_USD">742000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_3286dd10-3afc-4496-bbd6-5ba1f0954a8a"
      decimals="-3"
      id="F_7172464d-a32f-4317-9800-3e4225c71518"
      unitRef="U_USD">17181000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_c5ffbd72-9ff1-4119-bcd0-b30265f21d41"
      decimals="-3"
      id="F_8b628310-7ddd-412c-904a-82b95801687c"
      unitRef="U_USD">12897000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_069b0a0c-065c-4686-838b-2ac26250f05e"
      decimals="-3"
      id="F_25b67bbc-c7b6-419c-8df4-8ed46d798afb"
      unitRef="U_USD">121000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_d15ccf5a-554c-4e09-bf6c-621fbf797861"
      decimals="-3"
      id="F_e0ee81d2-8ef0-409a-80fa-cef2d0d1cf3d"
      unitRef="U_USD">-27000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_437322d0-39e6-4933-a981-cce1ad61b387"
      unitRef="U_USD">18038000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_ec1c70c8-3779-4073-91ec-f1d0c19c0467"
      unitRef="U_USD">13612000</us-gaap:Revenues>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_a9129cf4-11d8-4a33-b626-b755d653227a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist of money market funds.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_83e61aea-dc91-4533-b1de-4f5abbe7515a">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Marketable Securities&lt;/span&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Marketable securities consist of commercial paper, corporate bonds and U.S. Treasuries and are included in current and noncurrent assets.  The Company classifies its marketable securities as available-for-sale and carries them at fair value on its balance sheet. Fair value is estimated using independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses on the marketable securities are reported as a component of stockholders' equity (deficit) in accumulated other comprehensive loss.  The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the statements of operations. Realized gains and losses are included in interest income on the statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company periodically evaluates its marketable securities to assess whether those with unrealized loss positions are other than temporarily impaired.  The Company considers various factors in determining whether to recognize an impairment charge.  If the Company determines that the decline in an investment's fair value is other-than-temporary, the difference is recognized as an impairment loss in the statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <fdmt:OtherRisksAndUncertaintiesPolicyPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_3f0ce859-6405-40b9-a126-21a7480810de">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Other Risks and Uncertainties&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, suppliers for key raw materials, contract manufacturing organizations (&#x201c;CMOs&#x201d;) and contract research organizations (&#x201c;CROs&#x201d;), compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties (including for clinical trials and some aspects of research and preclinical testing).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The extent of the impact of the COVID-19 pandemic on the Company&#x2019;s business will depend upon the duration and spread of the outbreak and the extent and severity of the impact on the Company&#x2019;s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. The extent to which the coronavirus outbreak may materially impact the Company&#x2019;s financial condition, liquidity or results of operations is uncertain.&lt;/span&gt;</fdmt:OtherRisksAndUncertaintiesPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_bb85694a-773c-451d-96eb-68a4d3c75873">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As a basis for considering such assumptions, a three-level fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Level 1 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014; Observable inputs that reflect unadjusted quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Level 2 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:5.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4053088526814586%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Level 3 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company accounts for transfers of financial instruments between levels of the fair value hierarchy on the date of the event or change in circumstance that caused the transfer.&lt;/span&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_c955f0f1-5b10-4ce1-a290-adc659f018a5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Accounts Receivable&#x2014;Allowance for Doubtful Accounts&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company regularly reviews accounts receivable for collectability and establishes an allowance for probable credit losses and writes off uncollectible accounts as necessary. The Company has determined that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; allowance was required at December 31, 2021 and 2020. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;t have any write-offs relating to uncollectible accounts receivable during the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_2709e1e4-0c80-4cb6-bf23-eb322dcbaed3"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_70523b3e-eca5-445c-8e58-c35325190fa5"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_0f25b56f-73e8-4307-b6d0-96495c942b18"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_e0579170-242e-408a-b5d9-1554494e923f"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_8e363fa5-cfa4-4ce1-9422-338896c3ecd6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment are stated at cost less accumulated depreciation for acquired assets. Depreciation is computed using the straight-line method over the estimated useful lives of assets, ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_c05559b7-51fa-4d3d-9739-b6c4a7e260ed;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. Leasehold improvements are amortized over the shorter of the useful life of the assets or the lease term. Upon sale or retirement of assets, the costs and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected within operating expenses in the statements of operations. Maintenance and repairs are charged to expense as incurred.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0dd3438c-f8c5-4fe9-8672-19340e3bbb9d"
      id="F_675a4ae8-4148-430e-94aa-73dfbba394f8">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_2e88f646-2267-4b72-a39d-bfa8ba5532d8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows, which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is typically measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; such impairments of long-lived assets in the years ended December 31, 2021 and 2020.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_54c4da89-0077-4548-a7ff-b5ec4e2635d4"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_72162fdc-baa0-4f86-867d-67b12834921d"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <fdmt:RedeemableConvertiblePreferredStockPolicyPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_9d619e6d-8170-46af-ac77-70885b6e34c6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance costs. The redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company's control, such as a merger or consolidation, sale, lease, or license of substantially all of the Company's assets (each, a "deemed liquidation event"), the convertible preferred stock would become redeemable at the option of the holders of a majority of the outstanding series of redeemable convertible preferred stock. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the liquidation preference of such shares because a deemed liquidation event obligating the Company to pay the liquidation preference did not occur. All outstanding shares of the redeemable convertible preferred stock converted into common stock upon the close of the IPO in December 2020.&lt;/span&gt;</fdmt:RedeemableConvertiblePreferredStockPolicyPolicyTextBlock>
    <fdmt:CommonStockWarrantsPolicyPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_562e6988-4c03-42eb-8b72-116c19e4a2a0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Common Stock Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company accounts for common stock warrants which meet the definition of a derivative as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement. Common stock warrants classified as liabilities are initially recorded at fair value and remeasured at fair value each balance sheet date with the offset adjustments recorded in other income (expense), net within the statements of operations. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.&lt;/span&gt;</fdmt:CommonStockWarrantsPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_09ce9f64-0d9f-4cda-bdc3-8bc66e673ac0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;On December 31, 2021, the Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, Leases (Topic 842), ("ASC 842") using the alternative modified retrospective approach effective as of January 1, 2021 to recognize a cumulative-effect adjustment on the effective date and to not adjust financial information and disclosures required under the new lease standards for comparative prior periods.  The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. Additionally, the Company has elected not to separate lease and non-lease components and not to recognize leases with an initial term of twelve months or less.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Under ASC 842, at contract inception, the Company determines if an arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the obligation to make lease payments arising from the lease. Operating lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and operating lease liabilities represent the Company's obligation to make payments arising from the lease. Operating right-of-use assets and liabilities are recognized at the commencement date of the lease and are measured at the present value of the fixed payments due over the expected lease term less the present value of any incentives, rebates, or abatements the Company expects to receive from the lessor. The Company records amortization of operating right-of-use assets and accretion of lease liabilities as a single lease cost on a straight-line basis over the lease term. No lease renewal options are recognized as part of the right-of-use assets and lease liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company's operating leases are presented in the balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent based on the discounted lease payments to be made within the proceeding twelve months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As the Company&#x2019;s leases do not provide an implicit rate , the Company uses its incremental borrowing rate to discount lease payments. The incremental borrowing rate represents an estimated rate of interest that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Upon adoption of the new lease standard effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, the Company recognized operating lease right-of-use assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, and current and noncurrent operating lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. In connection with the adoption of this standard, deferred rent of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and lease incentive liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, which were previously recorded in prepaid expenses and other current assets, accrued and other current liabilities and other liabilities on the balance sheet as of December 31, 2020, were derecognized. The adoption of the standard did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;t have an impact on the Company's statements of operations or comprehensive loss, stockholders' equity or cash flows. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The impact of adoption of the new lease standard as of January 1, 2021 is summarized as follows:&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Arial;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:51.033%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.889%;"/&gt;
          &lt;td style="width:0.91%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.954%;"/&gt;
          &lt;td style="width:0.91%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:11.048%;"/&gt;
          &lt;td style="width:0.91%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;ASC 842 Adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease liabilities, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_f1c116f5-4fc4-4134-a20b-4bb41e384479"
      id="F_0f5ac6e0-6fa4-49fa-aee9-4b27ed1621ca">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_f1c116f5-4fc4-4134-a20b-4bb41e384479"
      id="F_415e1179-f1d6-4afc-89c7-1c162e3fc552">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-5"
      id="F_870c293b-e9be-4a1e-9170-a5ef71c62fed"
      unitRef="U_USD">16500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-5"
      id="F_5a0c13a1-26b9-4743-b870-9591a8d447b2"
      unitRef="U_USD">2000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-5"
      id="F_f209fac4-c68e-4732-8c87-7fc6792c856f"
      unitRef="U_USD">16100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCredit
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-5"
      id="F_0cb620c3-24dc-4e31-81c0-ea78c0dc979c"
      unitRef="U_USD">1000000.0</us-gaap:DeferredRentCredit>
    <fdmt:LeaseIncentiveLiability
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-5"
      id="F_ff144a0b-0036-4e3c-85cc-50fb55dde7c5"
      unitRef="U_USD">500000</fdmt:LeaseIncentiveLiability>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_f1c116f5-4fc4-4134-a20b-4bb41e384479"
      id="F_36718d4b-f62a-425c-8ff5-45e6abdfa4e4">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_1877c7ea-b2c0-4a7f-9fdc-22f8380a0447">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The impact of adoption of the new lease standard as of January 1, 2021 is summarized as follows:&lt;br/&gt;&lt;/span&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:51.033%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.889%;"/&gt;
          &lt;td style="width:0.91%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:12.954%;"/&gt;
          &lt;td style="width:0.91%;"/&gt;
          &lt;td style="width:1.584%;"/&gt;
          &lt;td style="width:1.531%;"/&gt;
          &lt;td style="width:11.048%;"/&gt;
          &lt;td style="width:0.91%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;ASC 842 Adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease liabilities, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc"
      decimals="-3"
      id="F_77dc7ec8-9fc5-4dcb-aa46-f53a772a0c49"
      unitRef="U_USD">16537000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-3"
      id="F_5779ffb2-00b6-43b4-b6f3-8a9c89f85681"
      unitRef="U_USD">16537000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_438b050d-f05e-45d9-947c-0d5a7c04e2ae"
      decimals="-3"
      id="F_f39e4ad5-2e33-492c-98ca-fafb86a78dfd"
      unitRef="U_USD">4444000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc"
      decimals="-3"
      id="F_0ca447dc-be13-455d-8412-6547baeda813"
      unitRef="U_USD">-214000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-3"
      id="F_17bd87b8-ac43-4969-97a7-07a129cd3375"
      unitRef="U_USD">4230000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_438b050d-f05e-45d9-947c-0d5a7c04e2ae"
      decimals="-3"
      id="F_2edf9549-7efb-4e5c-a947-6cf572a620b0"
      unitRef="U_USD">8371000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc"
      decimals="-3"
      id="F_5872c5e9-9dda-4171-b983-f4fa555083a5"
      unitRef="U_USD">-68000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-3"
      id="F_56a6a51e-8e37-41d3-ac30-101421d34844"
      unitRef="U_USD">8303000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_438b050d-f05e-45d9-947c-0d5a7c04e2ae"
      decimals="-3"
      id="F_fa884c6f-dd8c-4cdd-a775-fb613655cfa3"
      unitRef="U_USD">1852000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc"
      decimals="-3"
      id="F_2dd525c3-4820-4565-839c-8cc06c398e61"
      unitRef="U_USD">-1696000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-3"
      id="F_22712606-2562-4749-a11f-4d5d29c3b741"
      unitRef="U_USD">156000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc"
      decimals="-3"
      id="F_10b752ce-d4f3-4154-a2a5-42dcfecc232d"
      unitRef="U_USD">2029000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-3"
      id="F_a2ac1917-5f61-4781-aa98-669623bb6afe"
      unitRef="U_USD">2029000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b24504fe-8333-4d24-bea3-21f963c10bdc"
      decimals="-3"
      id="F_1f9b0dd6-4f5d-45f0-9f6c-6f292acc4c87"
      unitRef="U_USD">16058000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1874832c-8de4-4a7f-a27f-f1dc966227e4"
      decimals="-3"
      id="F_a4ab81f9-30cd-4d0e-92d9-980fd22ffbdb"
      unitRef="U_USD">16058000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_c04fc13c-d23f-4125-b673-8208f0fd8e3c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company determines revenue recognition for arrangements within the scope of Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606") by performing the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company&#x2019;s revenue is primarily derived through its license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses to the Company&#x2019;s technology, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products. Arrangements that include upfront payments are recorded as deferred revenue upon receipt or when due and are recognized as revenue as performance conditions are met. The event-based milestone payments, royalties and cost reimbursements represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration. Royalty payments are recognized when earned or as the sales occur. The Company records cost reimbursements as accounts receivable when right to consideration is unconditional.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company allocates the total transaction price to each performance obligation based on the estimated standalone selling price and recognizes revenue when, or as, the performance obligation is satisfied. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. At the end of each reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_5a7a95ce-2ca6-476a-b61a-418690276e5f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Costs related to research, design and development of programs are charged to research and development expense as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses including stock-based compensation, materials, laboratory supplies, outside services and allocated overhead, including rent, insurance, repairs and maintenance, depreciation and utilities. The Company expenses all research and development costs in the period in which they are incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <fdmt:AccruedResearchAndDevelopmentPolicyPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_c2e99626-29df-498c-a001-e8521b090101">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Accrued Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has entered into various agreements with CROs and CMOs. The Company&#x2019;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered.&lt;/span&gt;</fdmt:AccruedResearchAndDevelopmentPolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_3d5027b5-a189-4e91-8c40-822b8bc6c50b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, the Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; ASU 2018-07, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees. As of January 1, 2020, the Company accounts for stock-based compensation for stock options granted to employees, directors and nonemployees as measured at grant date, based on the fair value of the award. The Company measures the fair value of awards granted using the Black-Scholes option pricing model and recognizes the expense in the statements of operations over the requisite service period, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, using the straight-line method. Forfeitures are accounted for as they occur. The Company&#x2019;s policy for issuing stock upon stock option exercise is to issue new common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prior to the adoption of ASU 2018-07 on January 1, 2020, stock-based compensation expense related to stock options granted to nonemployees was recognized based on the vesting date fair value of options as the stock options were earned. The Company remeasured the stock-based compensation at each reporting period end with the resulting change in fair value being recognized in the statements of operations over the period the related services were rendered. The Company estimated the service period for the options based on the time that would be required to satisfy the service condition, assuming the service condition would be satisfied. Stock-based compensation expense was recognized over the estimated service period but was accelerated if the performance condition was achieved earlier than estimated.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_74377b23-9b2b-42d3-bf22-b1ecef810775"
      id="F_0377fe78-6be8-415c-bdb6-eac7a5ba6008">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_74377b23-9b2b-42d3-bf22-b1ecef810775"
      id="F_9b4b7ad6-4d74-4e57-b5f0-8a2a25a1921f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_2f5cd243-2d01-42cd-af05-9945e2439ddd">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_14e61a14-59ac-45e1-beac-0c55dc193526">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&#x2019;s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_1b89a74f-aea6-4816-8938-16429b158797">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Embedded Derivative&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as a separate financial instrument. An embedded derivative exists in the award agreement with the Cystic Fibrosis Foundation (&#x201c;CFF&#x201d;). As described in Note 16, the embedded derivative has been bifurcated and is classified as a liability on the balance sheet and separately accounted for at its fair value. The derivative liability is subject to remeasurement to fair value each reporting period. Changes in the fair value of the derivative liability are recognized as a component of other income (expense), net within the statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <fdmt:DeferredOfferingCostsPolicyPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_29668eae-60a3-4f71-8502-e2fa88dd5e15">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company capitalizes certain legal, accounting and other third-party fees that are directly related to the Company&#x2019;s in-process financings, until such financings are consummated. After consummation of the financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. In the event that a planned offering does not occur or is significantly delayed, all related deferred offering costs will be expensed immediately within the Company&#x2019;s statements of operations.&lt;/span&gt;&lt;/p&gt;</fdmt:DeferredOfferingCostsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_fd29ab8f-5304-4597-9a3c-57f22ba560f2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Net Loss Per Share, Basic and Diluted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company calculates basic and diluted net loss per share in conformity with the two-class method required for companies with participating securities. The Company considers all series of redeemable convertible preferred stock to be participating securities as the holders are entitled to receive non-cumulative dividends on a pari passu basis in the event the dividend is paid on common shares. Under the two-class method, the net loss is not allocated to the redeemable convertible preferred stock as the holders of redeemable convertible preferred stock do not have a contractual obligation to share in losses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. Diluted net loss per share is computed by giving effect to all potentially dilutive common shares outstanding for the period. For purposes of this calculation, redeemable convertible preferred shares, stock options to acquire shares of common stock, common stock warrants, and unvested common stock subject to repurchase, are considered potentially dilutive common shares, but have been excluded from the calculation of diluted net loss per share as their effect is antidilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_86afb6fc-f3c9-4308-b670-e1a217eea66d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;New Accounting Pronouncements Recently Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2018-07, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;This ASU aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payment to employees. Under this ASU, the measurement of equity-classified nonemployee awards is fixed at the grant date, which may lower their cost and reduce volatility in the statements of operations. The transition method provided by this ASU is on a modified retrospective basis, which recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020, with early adoption permitted, but no earlier than a company's adoption date of ASC 606. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; this guidance effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; using the modified retrospective method. The Company recorded a less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million cumulative-effect adjustment reflected as a decrease to the opening balance of accumulated deficit and a decrease to additional paid-in capital&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. This ASU clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606, Revenue from Contracts with Customers, when the counterparty is a customer. This ASU also precludes an entity from presenting consideration received from a transaction as revenue from contracts with customers if the counterparty is not a customer for that transaction.  This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.  Early adoption is permitted for entities that have adopted ASC 606, Revenue from Contracts with Customers. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; this ASU on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. The adoption of this ASU did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;not&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; result in a material impact on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. This ASU affects general principles within Topic 740 and is meant to simplify the accounting for income taxes by removing certain exceptions to the general framework. The ASU adds guidance to reduce complexity in certain areas, including recognizing a franchise (or similar) tax that is partially based on income as an income-based tax and incremental amounts incurred as a non-income-based tax and recognizing deferred taxes for tax goodwill. ASU 2019-12 also created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, other comprehensive income). The amendments in ASU 2019-12 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022.  Early adoption of the amendments is permitted.  The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; ASU 2019-12 effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; on a prospective basis. The adoption of this ASU did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;not&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; result in a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In February 2016, the FASB issued ASU No. 2016-02,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, as subsequently amended, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840, Leases. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. The classification will determine the recognition pattern of lease expense over the term of the lease. In addition, a lessee is required to record (i) a right-of-use asset and a lease liability on its balance sheet for all leases with accounting lease terms of more than twelve months regardless of whether it is an operating or financing lease and (ii) lease expense in its statements of operations for operating leases and amortization and interest expense in its statements of operations for financing leases. Leases with a term of twelve months or less may be accounted for similar to existing guidance for operating leases under Topic 840. In July 2018, the FASB issued ASU No. 2018-11, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative period presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;See earlier disclosure in this footnote on the impact on the Company of the adoption of this standard in 2021. &lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As an &#x201c;emerging growth company,&#x201d; the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, as clarified in subsequent amendments. ASU 2016-13 changes the impairment model for certain financial instruments. The new model is a forward-looking expected loss model and will apply to financial assets subject to credit losses and measured at amortized cost and certain off-balance sheet credit exposures. This includes loans, held-to-maturity debt securities, loan commitments, financial guarantees and net investments in leases, as well as trade receivables. For available-for-sale debt securities with unrealized losses, credit losses will be measured in a manner similar to today, except that the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. In October 2019, the FASB voted to delay the effective date of this standard. Topic 326 will be effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_74377b23-9b2b-42d3-bf22-b1ecef810775"
      id="F_8afe6547-d9b4-449e-b532-6e3b6ae28643">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_74377b23-9b2b-42d3-bf22-b1ecef810775"
      id="F_ae3db6a7-f5b7-4977-bf80-68dd4c194314">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:StockholdersEquity
      contextRef="C_d12171a9-377c-49ef-adaa-5888c0e1ab2e"
      decimals="-5"
      id="F_87273bce-e748-4d01-9cfa-249c4a8ab7e9"
      unitRef="U_USD">100000</us-gaap:StockholdersEquity>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_80f31e89-ff18-484e-81fb-0a391abdc4b5"
      id="F_6a06ecc0-6a12-4099-ae89-c69fdc7c2a14">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_80f31e89-ff18-484e-81fb-0a391abdc4b5"
      id="F_f8998a26-4bee-452d-a3e7-c05f2344c75d">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_80f31e89-ff18-484e-81fb-0a391abdc4b5"
      id="F_ebd9718c-220f-4f47-822d-44e0d96779a3">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_2757758c-223e-4e96-ad58-555f2a1537e5"
      id="F_b6120b54-7815-42b1-b788-c67bd005f9f9">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_2757758c-223e-4e96-ad58-555f2a1537e5"
      id="F_1a8d9dc2-be20-4b0b-a66f-cae81d9d541a">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_2757758c-223e-4e96-ad58-555f2a1537e5"
      id="F_2057bb8d-aa41-4d56-9e2c-712f7345aea1">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_a70d6e6e-2e4e-4169-82fe-03abb35142b7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following tables represent the Company&#x2019;s fair value hierarchy for financial assets and financial liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.298%;"/&gt;
        &lt;td style="width:1.167%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:9.441%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:1.167%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:9.473%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:1.167%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:9.398%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:1.167%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:11.357%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Basis for Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Fair Value as of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;36,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;36,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;37,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;37,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;94,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;94,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;US Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;30,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;30,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;36,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;162,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;198,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.829%;"/&gt;
        &lt;td style="width:0.803%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:8.765%;"/&gt;
        &lt;td style="width:0.621%;"/&gt;
        &lt;td style="width:0.824%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:8.776%;"/&gt;
        &lt;td style="width:0.621%;"/&gt;
        &lt;td style="width:0.824%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:8.797%;"/&gt;
        &lt;td style="width:0.621%;"/&gt;
        &lt;td style="width:0.824%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.618%;"/&gt;
        &lt;td style="width:0.621%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Basis for Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Fair Value as of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;276,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;276,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;276,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;276,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Level 3 Inputs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability was determined using a present value analysis with multiple scenarios. In determining the fair value of the derivative liability, the inputs impacting fair value include the change of control payment to CFF, the probability of a change of control event, the product status at time of a change of control event and the discount rate. See Note 16 for further discussion on embedded derivative.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; transfers between Level 1, 2 and 3 during the periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3 derivative liability (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.79%;"/&gt;
        &lt;td style="width:1.934%;"/&gt;
        &lt;td style="width:1.53%;"/&gt;
        &lt;td style="width:15.971%;"/&gt;
        &lt;td style="width:0.776%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Change in fair value included in other income (expense), net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_834220d8-b4e4-44b5-a1d2-6aff019d75c5;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Change in fair value included in other income (expense), net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_f500242c-7c9c-43e7-8ba7-87e2388aa1db;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_7a7d14ac-1160-44c0-a07b-e14813fb31d2">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following tables represent the Company&#x2019;s fair value hierarchy for financial assets and financial liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.298%;"/&gt;
        &lt;td style="width:1.167%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:9.441%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:1.167%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:9.473%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:1.167%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:9.398%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:1.167%;"/&gt;
        &lt;td style="width:1.231%;"/&gt;
        &lt;td style="width:11.357%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Basis for Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Fair Value as of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;36,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;36,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;37,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;37,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;94,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;94,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;US Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;30,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;30,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;36,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;162,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;198,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.829%;"/&gt;
        &lt;td style="width:0.803%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:8.765%;"/&gt;
        &lt;td style="width:0.621%;"/&gt;
        &lt;td style="width:0.824%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:8.776%;"/&gt;
        &lt;td style="width:0.621%;"/&gt;
        &lt;td style="width:0.824%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:8.797%;"/&gt;
        &lt;td style="width:0.621%;"/&gt;
        &lt;td style="width:0.824%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.618%;"/&gt;
        &lt;td style="width:0.621%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Basis for Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Fair Value as of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;276,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;276,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;276,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;276,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Derivative liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_08032442-cecd-44e4-8446-5caefea14888"
      decimals="-3"
      id="F_eece758d-219a-454f-a048-416b47dacc10"
      unitRef="U_USD">36556000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7c926a8a-82fa-447e-b1e6-bbfe1e709a29"
      decimals="-3"
      id="F_e2b4f108-4b18-4558-a85d-61093c3fe587"
      unitRef="U_USD">36556000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cd0116f7-4d6b-4e75-acbd-f547c6e71c2d"
      decimals="-3"
      id="F_95c68307-0f3b-41e0-a44e-943614e9ef66"
      unitRef="U_USD">37535000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_100f6d0a-7eb4-409e-8987-51846785183e"
      decimals="-3"
      id="F_66ce8725-4dbc-450f-a87c-f46c90086e01"
      unitRef="U_USD">37535000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_13f6e26c-4d62-4ef8-b29b-c168bba13d36"
      decimals="-3"
      id="F_20239b20-27f0-44b3-82cc-0b700a441e30"
      unitRef="U_USD">94864000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7958ed8e-8790-49e7-bfb6-54045eeb9eec"
      decimals="-3"
      id="F_794705e0-8ff4-4f91-8ec8-9d0f9ae1b459"
      unitRef="U_USD">94864000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8da58ed6-e246-4eec-ba9a-77c486b0bfab"
      decimals="-3"
      id="F_1330bced-4632-44a1-8aa3-b8deaad814c7"
      unitRef="U_USD">30029000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_38363b5b-dfc5-4de3-ad6d-69dec1df22bb"
      decimals="-3"
      id="F_4e21f6cd-221f-4967-8c48-0f828c758886"
      unitRef="U_USD">30029000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9bf2311e-d3cd-40c5-9ad2-5823cd5dccbb"
      decimals="-3"
      id="F_96a8af96-45bd-4113-9341-edc7006c95b3"
      unitRef="U_USD">36556000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_62df8820-e746-4de8-8b5d-7651c94d18fb"
      decimals="-3"
      id="F_66686ca2-a2f8-4f90-8945-2e40fa3920ef"
      unitRef="U_USD">162428000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d1ec6218-dc19-4a0d-9c16-9e9cf05148c8"
      decimals="-3"
      id="F_c03f00a0-b08d-457c-bab2-3e3aa2de8232"
      unitRef="U_USD">198984000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_994128d2-ff7e-458c-a06e-3646a588a46f"
      decimals="-3"
      id="F_7c25756b-c286-4799-a792-5a52456cdb86"
      unitRef="U_USD">214000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_369e8cc3-d5ce-4005-9fa7-8014c0cde676"
      decimals="-3"
      id="F_6d699bd1-bf0f-4214-a905-3ac5de36a706"
      unitRef="U_USD">214000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_345dc4b4-ecea-45cf-b824-fa29a5f06694"
      decimals="-3"
      id="F_8c380f83-6695-4ae5-b676-7c580bad0c28"
      unitRef="U_USD">214000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_d1ec6218-dc19-4a0d-9c16-9e9cf05148c8"
      decimals="-3"
      id="F_8fe85478-23f9-4411-80cb-513a09f9db79"
      unitRef="U_USD">214000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8bc0fb33-e137-466b-afc1-ac2316dff7e2"
      decimals="-3"
      id="F_e666337a-d985-4ad0-9946-3062364ee5e0"
      unitRef="U_USD">276726000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8920c352-ac30-4ff7-8543-68d35ca73a38"
      decimals="-3"
      id="F_3347c77a-17c9-4669-bf3d-59792d575dd4"
      unitRef="U_USD">276726000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fdb51331-8f19-40ce-b87c-0d9aa4e26603"
      decimals="-3"
      id="F_2cbb0232-b875-4893-aecb-065c9c6335fe"
      unitRef="U_USD">276726000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f8a50303-fca8-4db7-8914-b41268aac3b6"
      decimals="-3"
      id="F_44bfd050-a485-47fa-95f5-ebc80998874c"
      unitRef="U_USD">276726000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_cf542ed1-e6b5-4685-8a2e-3f4a7e276ae0"
      decimals="-3"
      id="F_6c1e8f8c-037f-4371-9c77-cd7639c49a8f"
      unitRef="U_USD">122000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_c2004132-d784-47b1-a1e9-3cd43319e93f"
      decimals="-3"
      id="F_616dabd7-a3c8-4455-82a7-a3c044a76e98"
      unitRef="U_USD">122000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_592a756d-a16a-4bd3-aad9-7318649c6f44"
      decimals="-3"
      id="F_3a08b74f-dd13-42fb-8781-94631be1b3c5"
      unitRef="U_USD">122000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_f8a50303-fca8-4db7-8914-b41268aac3b6"
      decimals="-3"
      id="F_9fecdd7d-4c5f-4f42-844d-8441626f6619"
      unitRef="U_USD">122000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_d96d6cc7-7fa3-488b-bd41-cb63a32e0e2b"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_4c261d4e-368b-42ac-8c6a-2a8e3675d5ad"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_b7737a8d-9e0f-4d61-b56f-2b0dae001f55"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_946c7bb1-391f-41f8-9fcb-446c1cf240b9"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_aa1f5762-11ce-4834-bc32-056f80ca0a69"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_7f9b05b0-6e25-412e-9002-30d7a3806d0b"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_ffe0e8bb-b63c-49f1-9e49-862d12479cb6"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_657dda11-ba9e-43e0-880c-843920b032d8"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_640984bf-62c9-4a61-9966-2b1ea9d6c6d6"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_3dd539b0-8293-4867-8fe6-6d1b2ff3bd95"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_c2ac31b2-eab9-45c1-a5c5-f086e2328d69"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_56f671de-d2f0-42c5-bb18-3079f8eaed5b"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_76b2e04a-aa89-4b4b-9dce-a95d19e7d7ac"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_52dcd69c-b69f-42b4-bcec-1c2d04647662"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_acf19322-a0d9-457e-af34-e628d1bf5668"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_55dca056-426b-4179-a39a-b9b0157546ba"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_c5f1172b-4daa-48a1-ab0d-e8c81756082c">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level 3 derivative liability (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.79%;"/&gt;
        &lt;td style="width:1.934%;"/&gt;
        &lt;td style="width:1.53%;"/&gt;
        &lt;td style="width:15.971%;"/&gt;
        &lt;td style="width:0.776%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Change in fair value included in other income (expense), net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_834220d8-b4e4-44b5-a1d2-6aff019d75c5;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Change in fair value included in other income (expense), net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_f500242c-7c9c-43e7-8ba7-87e2388aa1db;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_78089c61-9c63-4f0e-ab4c-7158c1adabeb"
      decimals="-3"
      id="F_565387fc-1f11-4535-a087-97c315334703"
      unitRef="U_USD">101000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_2f32afd7-17e5-440d-95d7-e8e98ffe403b"
      decimals="-3"
      id="F_2f4e1365-c6f8-4624-a284-8a75e3f3f441"
      unitRef="U_USD">21000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_04e47ba0-ce07-4a2d-aa4a-280a066c7c65"
      decimals="-3"
      id="F_5934655e-2cfe-400c-9f9b-a19955703029"
      unitRef="U_USD">122000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_27c30b85-a010-4be5-a956-5fa66be6b6dc"
      decimals="-3"
      id="F_00545f07-352b-463a-91f1-c3a2033eed4e"
      unitRef="U_USD">92000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_2b9316bd-43bb-4236-afee-5dedacf34852"
      decimals="-3"
      id="F_c0b77032-9726-4f39-89ba-4b641b518e5a"
      unitRef="U_USD">214000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_39a0b535-179b-4c81-b8be-945a298c6658">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;4. Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2021 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.349%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.542%;"/&gt;
        &lt;td style="width:9.412%;"/&gt;
        &lt;td style="width:0.782%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.542%;"/&gt;
        &lt;td style="width:9.412%;"/&gt;
        &lt;td style="width:0.782%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.542%;"/&gt;
        &lt;td style="width:9.294%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.542%;"/&gt;
        &lt;td style="width:14.916%;"/&gt;
        &lt;td style="width:0.782%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Amortized Cost Basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Fair Value as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;57,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;57,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;US Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;94,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;94,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;37,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;37,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;US Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;25,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;24,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;67,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;67,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;All marketable securities held as of December 31, 2021, had contractual maturities of less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. There have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; realized gains or losses on marketable securities for the periods presented. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;None&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; of the Company's investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; recognition of any other-than-temporary impairment in the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2020, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_58697145-69f6-4dec-af5a-1187f89bd43d">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2021 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.349%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.542%;"/&gt;
        &lt;td style="width:9.412%;"/&gt;
        &lt;td style="width:0.782%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.542%;"/&gt;
        &lt;td style="width:9.412%;"/&gt;
        &lt;td style="width:0.782%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.542%;"/&gt;
        &lt;td style="width:9.294%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.542%;"/&gt;
        &lt;td style="width:14.916%;"/&gt;
        &lt;td style="width:0.782%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Amortized Cost Basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Fair Value as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;57,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;57,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;US Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;94,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;94,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;37,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;37,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;US Treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;25,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;24,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;67,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;67,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2fe951a6-989e-495f-bcdd-517a1a9d9539"
      decimals="-3"
      id="F_acf47efb-6f86-45e9-89f3-174701a88ab4"
      unitRef="U_USD">32471000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_2fe951a6-989e-495f-bcdd-517a1a9d9539"
      decimals="-3"
      id="F_8d697f24-7a48-4f9f-bda9-25d74c6e5724"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2fe951a6-989e-495f-bcdd-517a1a9d9539"
      decimals="-3"
      id="F_a32e7274-59f5-49d6-807b-397d3d97c8fd"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2fe951a6-989e-495f-bcdd-517a1a9d9539"
      decimals="-3"
      id="F_2c86e72c-ed31-4c79-b43c-d351222c5ce3"
      unitRef="U_USD">32467000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_76372236-463c-49d8-950b-bfdd59d89a3a"
      decimals="-3"
      id="F_9c1e15b8-9bbe-437f-b720-59af03ee1be9"
      unitRef="U_USD">57315000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_76372236-463c-49d8-950b-bfdd59d89a3a"
      decimals="-3"
      id="F_5777a1eb-20ab-41b9-9d59-f965eb606aed"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_76372236-463c-49d8-950b-bfdd59d89a3a"
      decimals="-3"
      id="F_5e8c418c-ecf1-476b-a27e-3d2eef0bc390"
      unitRef="U_USD">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_76372236-463c-49d8-950b-bfdd59d89a3a"
      decimals="-3"
      id="F_d02f6fd2-9a57-44d0-9720-be839497ab5e"
      unitRef="U_USD">57236000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_29d03014-ea19-4d37-bd22-35b0ce14deba"
      decimals="-3"
      id="F_2dd3f335-4f88-41af-8039-c2eff5d3dedd"
      unitRef="U_USD">5082000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_29d03014-ea19-4d37-bd22-35b0ce14deba"
      decimals="-3"
      id="F_94da40a3-79b6-4cbf-9e8b-170b4ecf532f"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_29d03014-ea19-4d37-bd22-35b0ce14deba"
      decimals="-3"
      id="F_1beb79f7-0505-46c7-b880-88ca16ee5c71"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_29d03014-ea19-4d37-bd22-35b0ce14deba"
      decimals="-3"
      id="F_8a618b24-5973-404b-8e40-3dbc80eebfd4"
      unitRef="U_USD">5073000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f91508fa-5dfa-4192-91eb-1afaa64ddaad"
      decimals="-3"
      id="F_d1e02b35-f13c-414b-b491-e1262b9f3d22"
      unitRef="U_USD">94868000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f91508fa-5dfa-4192-91eb-1afaa64ddaad"
      decimals="-3"
      id="F_badcafc5-f028-453a-ab20-5a15853b7122"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f91508fa-5dfa-4192-91eb-1afaa64ddaad"
      decimals="-3"
      id="F_ed4c4d5a-a449-4675-9ad1-7c5c03f3dca2"
      unitRef="U_USD">92000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f91508fa-5dfa-4192-91eb-1afaa64ddaad"
      decimals="-3"
      id="F_9efae3e9-9716-4191-af11-c396228ba39d"
      unitRef="U_USD">94776000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_068f626d-cf83-45b9-9dba-b873304176e4"
      decimals="-3"
      id="F_6d3495b9-56da-44cd-8d72-55fa69108d76"
      unitRef="U_USD">5089000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_068f626d-cf83-45b9-9dba-b873304176e4"
      decimals="-3"
      id="F_52001d2a-112a-4462-afe3-8a53ac496a85"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_068f626d-cf83-45b9-9dba-b873304176e4"
      decimals="-3"
      id="F_dfb08330-e8e0-4ade-b149-ddf947dc931a"
      unitRef="U_USD">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_068f626d-cf83-45b9-9dba-b873304176e4"
      decimals="-3"
      id="F_a5c13558-0b77-485b-853f-1dfeacf40106"
      unitRef="U_USD">5068000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_68203dba-eb94-47f4-bc69-28308c9e86fa"
      decimals="-3"
      id="F_45596eed-d30b-4637-95ce-67d7529538c1"
      unitRef="U_USD">37821000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_68203dba-eb94-47f4-bc69-28308c9e86fa"
      decimals="-3"
      id="F_b7eef666-7d8d-4b68-913e-36337e87f6ba"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_68203dba-eb94-47f4-bc69-28308c9e86fa"
      decimals="-3"
      id="F_741f37e6-ad9a-4018-b40c-c639995949c1"
      unitRef="U_USD">193000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_68203dba-eb94-47f4-bc69-28308c9e86fa"
      decimals="-3"
      id="F_9a4f25b3-82c2-41be-af84-ce2ce8345d9b"
      unitRef="U_USD">37628000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_debe135a-c35c-4564-ab5a-f34f314d29f1"
      decimals="-3"
      id="F_34d63828-e0f4-434f-8785-b2d4d3f99865"
      unitRef="U_USD">25073000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_debe135a-c35c-4564-ab5a-f34f314d29f1"
      decimals="-3"
      id="F_806b951f-de22-4499-a026-812fda71c81b"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_debe135a-c35c-4564-ab5a-f34f314d29f1"
      decimals="-3"
      id="F_c2047d46-92ab-45c7-b31f-2fd205342934"
      unitRef="U_USD">117000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_debe135a-c35c-4564-ab5a-f34f314d29f1"
      decimals="-3"
      id="F_a3b4be7e-e2be-4811-8ba0-95feb01cb2ba"
      unitRef="U_USD">24956000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8c2f744e-0a59-4216-9244-12153c1d29c6"
      decimals="-3"
      id="F_c4aee31d-a584-47a5-88dd-78b550ee5177"
      unitRef="U_USD">67983000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8c2f744e-0a59-4216-9244-12153c1d29c6"
      decimals="-3"
      id="F_1a1a3c22-a7f7-4213-b859-641cdd2d009a"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8c2f744e-0a59-4216-9244-12153c1d29c6"
      decimals="-3"
      id="F_136ae332-b7ae-4ccf-b9e8-b8ee0aed4ec6"
      unitRef="U_USD">331000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8c2f744e-0a59-4216-9244-12153c1d29c6"
      decimals="-3"
      id="F_8fece251-4bed-4358-934d-059fa34ea245"
      unitRef="U_USD">67652000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fdmt:MaximumMaturityPeriodOfMarketableSecurities
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_694af594-1a34-4c5f-95a8-392ff0f1341f">P2Y</fdmt:MaximumMaturityPeriodOfMarketableSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_2f640658-cc2d-4483-96ac-c7b2a6b7a471"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_7c780d68-61f9-45a6-82b6-945ab49ea0cb"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <fdmt:NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_00696bbe-24b7-4fd5-a8cc-43f9f13d5cc3"
      unitRef="U_Security">0</fdmt:NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_c2581108-3cf1-49a9-805c-17b6078868b7"
      unitRef="U_USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:MarketableSecurities
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_2fe2679f-b9ca-4e6b-90a4-0c8afd8cafca"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_aba3aec0-88c8-4703-840e-967578a53f9c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;5. Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.113%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.901%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.891%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;14,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;All property and equipment are maintained in the United States. Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_36343d28-7e40-45d2-a0e3-f34f89552e2e">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.113%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.901%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.891%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;14,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3f51aa86-d6a8-4946-b9c6-489cfcc06d93"
      decimals="-3"
      id="F_5748f19f-a978-4799-8fbc-f05959f0e922"
      unitRef="U_USD">5971000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_90284da0-93f6-431a-8c5e-011cfcb8f1f0"
      decimals="-3"
      id="F_795e023e-81b0-4c9f-9a5c-f1065d0defab"
      unitRef="U_USD">4911000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5292ea9b-5f9f-47a3-8950-e560df46b007"
      decimals="-3"
      id="F_5f6246d7-548a-4f6f-91a0-123dcc04a084"
      unitRef="U_USD">2527000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6ba7e920-3f27-47fd-a911-2a4a015a560f"
      decimals="-3"
      id="F_eb5a2c8c-f654-483b-a10e-a7d2ff62a29b"
      unitRef="U_USD">2527000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_17b5390d-b508-41a3-bec9-d59c6b3e03e3"
      decimals="-3"
      id="F_a1828676-76c1-4752-9077-9ca69abda5c4"
      unitRef="U_USD">566000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6961af42-3676-40b4-923b-b55bd4213555"
      decimals="-3"
      id="F_74f19de8-0821-43dd-9d05-d0e935d3a174"
      unitRef="U_USD">473000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cf4beef8-281b-4990-bced-f3548175f663"
      decimals="-3"
      id="F_2e2841d1-09cf-49c6-b8b0-02dafa7e6c4d"
      unitRef="U_USD">165000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3f63f746-5168-4906-b7e7-1be53b0dbc62"
      decimals="-3"
      id="F_88dad22a-4d6a-4fe9-8757-22ef90305030"
      unitRef="U_USD">101000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4d4c97fb-5c4e-482d-aa4f-d431fcdad1c2"
      decimals="-3"
      id="F_2409ef14-33fc-4001-a181-5ab63ff607a9"
      unitRef="U_USD">421000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d3e07726-b4be-4673-8ad2-8d4cb0def982"
      decimals="-3"
      id="F_b73ede35-4271-46ce-98fd-ecf731ebb30a"
      unitRef="U_USD">366000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_952d0fc8-cacf-4343-ad40-069f13b709dc"
      decimals="-3"
      id="F_f7183df3-07ff-479c-b0d2-e853ddc37a8b"
      unitRef="U_USD">10066000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e4411f8c-40ed-48bd-b0d8-e6366fa6b2c1"
      decimals="-3"
      id="F_0c0b794f-3ac3-43ad-8797-23eecff0adef"
      unitRef="U_USD">539000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_960a3f23-6ef5-4b75-be61-9fbdc5b8ec71"
      unitRef="U_USD">19716000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_f532e56c-cb0f-46c1-a184-5b1385328637"
      unitRef="U_USD">8917000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_f386f56e-0b53-4aee-bf34-7dd67698151a"
      unitRef="U_USD">5325000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_64e848bd-64d4-4921-a9d1-2fb6a1712a09"
      unitRef="U_USD">3844000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_ac75612a-a25e-4716-a8f6-cd3346fe0cfc"
      unitRef="U_USD">14391000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_04ae9e2f-6f60-49e6-b4c1-a857298070db"
      unitRef="U_USD">5073000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-5"
      id="F_7669eb2a-2cb4-4f8a-af82-fe376dfb8303"
      unitRef="U_USD">1500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-5"
      id="F_abb19189-810d-4076-87e1-578828e87f9c"
      unitRef="U_USD">1400000</us-gaap:Depreciation>
    <fdmt:AccruedAndOtherLiabilitiesTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_78d2c7e6-8d9a-4d68-8da9-37aeed21d3d5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;6. Accrued and Other Liabilities, Current and Noncurrent&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.149%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.018%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.018%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued clinical and preclinical study costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Consulting and professional&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total accrued and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other liabilities, noncurrent consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.178%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.987%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.019%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred rent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total other liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</fdmt:AccruedAndOtherLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_b838bb5a-4dc2-4c62-8b08-ad2913352a4f">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.149%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.018%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.018%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Accrued clinical and preclinical study costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Consulting and professional&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total accrued and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_1e9e1b10-73f3-4b8c-816e-f21b9ee18ed1"
      unitRef="U_USD">3994000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_c90cae74-7ead-4e7e-97ee-fe95f748d3f6"
      unitRef="U_USD">3437000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <fdmt:AccruedClinicalAndPreclinicalStudyCosts
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_404cc476-3eb9-4133-95c6-117a573de24d"
      unitRef="U_USD">407000</fdmt:AccruedClinicalAndPreclinicalStudyCosts>
    <fdmt:AccruedClinicalAndPreclinicalStudyCosts
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_c3bd6e68-57e6-49f4-b8b2-01c122b4521f"
      unitRef="U_USD">869000</fdmt:AccruedClinicalAndPreclinicalStudyCosts>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_0a85d99e-cba3-49d7-9793-7620ab6d0a67"
      unitRef="U_USD">1573000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_78899f5c-57a1-4694-9fa6-a613c25c13f8"
      unitRef="U_USD">3574000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_9f5a68e6-a77b-45de-971d-507dbe65cec1"
      unitRef="U_USD">1770000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_801f33ad-8654-4cb6-90d7-bec3369734aa"
      unitRef="U_USD">491000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_7d8a74fb-6f40-427a-b48b-4c3619217eca"
      unitRef="U_USD">7744000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_f113044e-1316-45c2-b018-8bb907809208"
      unitRef="U_USD">8371000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_f806c27a-0604-4739-ac64-ec4ae157b084">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other liabilities, noncurrent consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.178%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.987%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.019%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred rent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total other liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_e029cb3a-1862-481d-98e1-d88467c20239"
      unitRef="U_USD">1237000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_b7d744a0-27c4-4e4b-8f0b-0ca427f3d4c1"
      unitRef="U_USD">120000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_7b17fb0b-350f-461f-82a3-8111dc7f3210"
      unitRef="U_USD">615000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_1059bdde-12bb-411a-8126-fb267e0cb8cd"
      unitRef="U_USD">120000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_90b312f2-f006-4010-97d0-70ce830b9769"
      unitRef="U_USD">1852000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_cf81e5e6-a277-41d0-b76f-b7ab581e7242">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;7. Research and Collaboration Arrangements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Collaboration and license revenue for each period was as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.014%;"/&gt;
        &lt;td style="width:1.584%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.804%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.584%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.675%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.584%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;uniQure&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Roche&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;CFF&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred revenue for each period was as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.124%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.019%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.041%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Deferred Revenue &lt;br/&gt;as of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;uniQure&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Roche&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;14,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;CFF&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The total amount of revenue in the year ended December 31, 2021, which was included in deferred revenue at January 1, 2021, was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;15.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The total amount of revenue in the year ended December 31, 2020, which was included in deferred revenue at January 1, 2020, was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;uniQure&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In January 2014, the Company and uniQure biopharma B.V. (&#x201c;uniQure&#x201d;) entered into a Collaboration and License Agreement (the &#x201c;uniQure Agreement&#x201d;) to collaborate on the discovery and non-clinical research activities related to the Company&#x2019;s Therapeutic Vector Evolution platform in order to generate and validate vectors for gene delivery to treat diseases within the central nervous system and liver (together, the &#x201c;uniQure Field&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The uniQure Agreement provided uniQure with a research license as well as an exclusive development and commercialization license for each project variant selected for further development. The initial research term is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; with an option for uniQure to extend the research term one time for an additional year. Once the Company&#x2019;s research plan has concluded, uniQure is solely responsible for the continued development, manufacturing and commercialization of the project variants as potential product candidates. In October 2016, uniQure exercised its option to extend the research term for an additional year to January 2018. The Company was also required to work exclusively with uniQure in the uniQure Field (the &#x201c;uniQure Exclusivity Clause&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Pursuant to the uniQure Agreement, the Company received upfront payments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, and was entitled to receive (i) contingent payments for the achievement of research and development milestones of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for each licensed product selected under the arrangement, and (ii) royalties in the single digit range on future sales of the potential product candidates and sublicense consideration in the low teens to low thirties range on any future sublicensing arrangements. The Company also received capped research and development service fees based on contractual full-time employee rates per year. In connection with the performance obligations under the uniQure Agreement, the founders of 4D Molecular Therapeutics, LLC received equity options to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;609,744&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; of uniQure ordinary shares that vest over the initial &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; term of the agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million was recorded as deferred revenue and was recognized on a ratable basis over the estimated performance period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. Payments and reimbursements for research costs were recognized on an as-incurred basis. The options to purchase uniQure shares were deemed to be a noncash component of the arrangement consideration, as the vesting of options is linked to the uniQure Agreement and there is a requirement for the holders of the options to provide services under the agreement. The fair value of the uniQure options, which was estimated to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, was recognized ratably as revenue over the estimated performance period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and the associated compensation expense related to the stock options were recorded as research and development expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In August 2019, the Company and uniQure entered into an Amended and Restated Collaboration and License Agreement (the &#x201c;Amended uniQure Agreement&#x201d;), which amended and restated the uniQure Agreement, and a separate Collaboration and License Agreement (the &#x201c;Second uniQure Agreement&#x201d;). Under these agreements, the Company agreed to transfer incremental rights and services to uniQure in exchange for uniQure eliminating the uniQure Exclusivity Clause and transferring other rights back to the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Under the Amended uniQure Agreement, uniQure continues to have an exclusive license to select AAV capsid variants (the &#x201c;Selected Variants&#x201d;) in the uniQure Field. uniQure continues to be solely responsible, at its cost, to develop and commercialize the compounds and products containing the Selected Variants. The amended uniQure Agreement eliminated the uniQure Exclusivity Clause in the uniQure Agreement. Furthermore, the contingent payments that the Company was entitled to from uniQure for the achievement of research and development milestones of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for each licensed product selected under the uniQure Agreement were eliminated and sublicense consideration on any future sublicensing arrangements was reduced from the low teens to low thirties percentages to mid-single digit to mid-twenties percentages.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Under the Second uniQure Agreement, the parties agreed to research and develop new AAV capsid variants (the &#x201c;New Variants&#x201d;) that are not Selected Variants that affect certain targets selected by uniQure (the &#x201c;uniQure Targets&#x201d;) in the uniQure Field. The Company is solely responsible, at its cost, for the research of the New Variants. The Company granted uniQure an exclusive license to a certain number of the New Variants (the &#x201c;uniQure New Variants&#x201d;) that affect the uniQure Targets. uniQure is solely responsible, at its cost, to develop and commercialize the compounds and products containing the uniQure New Variants that affect the uniQure Targets (the &#x201c;Licensed Products&#x201d;). The Company retains all rights to New Variants in the uniQure Field that affect targets other than the uniQure Targets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Under both the Amended uniQure Agreement and the Second uniQure Agreement, uniQure will be required to pay the Company royalties on worldwide annual net sales of Licensed Products at a mid-single digit percentage rate, subject to certain specified reductions. uniQure will also be required to pay the Company sublicensing consideration for sublicensing the Company&#x2019;s intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties at a rate between the mid-single digit to mid-twenties. The Company has reciprocal obligations, at the same percentage rates as uniQure, to pay uniQure royalties and sublicensing consideration for sublicensing certain intellectual property rights licensed under the Amended uniQure Agreement or the Second uniQure Agreement to third parties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company concluded that the Amended uniQure Agreement and the Second uniQure Agreement should be accounted for as one combined contract that should be accounted for as a separate contract from the uniQure Agreement given that the incremental licensed intellectual property rights and research and development services are distinct from the rights and services previously transferred to uniQure under the uniQure Agreement and the transaction price increased by an amount that equals the standalone selling price of the incremental rights and services to be transferred to uniQure under the Amended uniQure Agreement and Second uniQure Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Neither party was required to pay monetary consideration in connection with the execution of the Amended uniQure Agreement or the Second uniQure Agreement or for subsequent performance by the parties under those agreements, notwithstanding the potential future royalty and sublicense consideration described above. The fair value of the non-monetary consideration given by uniQure to the Company, for the intellectual property right is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. This intellectual property right is considered to be an in-process research and development asset with no alternative future use and, accordingly, was written off as acquired in-process research and development expense in the year ended December 31, 2019.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The incremental transaction price described in the paragraph above was recorded as deferred revenue given that the Company identified one single combined performance obligation under ASC 606, which includes the licenses to the New Variants, research services and participation in the joint steering committee (&#x201c;JSC&#x201d;). Revenue is being recognized using the input method based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligation. Based on the current estimated timelines, the deferred revenue is expected to be recognized as revenue over approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_3340247d-416d-4f03-a381-b95a54629875;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; from December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company determined the transaction price using the risk adjusted net present value analysis (&#x201c;rNPV&#x201d;) methodology to value the elimination of the uniQure exclusivity clause and other material rights received by the Company, including the potential royalties the Company would receive from uniQure. The rNPVs incorporate estimates and assumptions including the number of products the Company and uniQure would develop, the risk-adjusted probability of successfully developing a biopharmaceutical product, the probability that uniQure will develop a product, the research and development costs, the potential worldwide sales and associated commercialization costs, corporate tax rate, and discount rate.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During each of the years ended December 31, 2021 and 2020 the Company recognized revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million under the Amended uniQure Agreement and the Second uniQure Agreement. As of December 31, 2021 and 2020, deferred revenue relating to uniQure was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; amounts due from uniQure under the uniQure Agreement, Amended uniQure Agreement or Second uniQure Agreement as of December 31, 2021 and 2020. As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;CRF&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In November 2015, the Company entered into a research funding and collaboration agreement (the &#x201c;CRF Agreement&#x201d;) with the Choroideremia Research Foundation (&#x201c;CRF&#x201d;), a non-profit organization dedicated to finding a cure for choroideremia, a rare inherited disorder that causes progressive vision loss, ultimately leading to complete blindness. The goal of the CRF Agreement is for CRF to contribute funding to help with the advancement of the Company&#x2019;s choroideremia research program. The Company is responsible for all decision making and execution of any and all of the related activities to be completed in its sole discretion. The initial term of the CRF Research Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. The agreement includes contribution by the Company to CRF of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million upon certain development or approval milestones. The overall arrangement has automatic extensions of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_80d41e98-685d-4c82-a966-93ef6194e666;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; additional years. As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; milestones have been achieved.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Revenue was fully recognized for this agreement in the year ended December 31, 2017. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; deferred revenue relating to the CRF Agreement as of December 31, 2021 and 2020. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; amount was due from or to CRF under the CRF Agreement as of December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Roche&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In November 2017, the Company entered into a collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, &#x201c;Roche&#x201d;) to discover and develop products containing optimized next generation AAV Vectors focused on ophthalmological diseases and disorders excluding select criteria (the &#x201c;2017 Roche Agreement&#x201d;). The Company and Roche both have the ability to nominate products to discover, develop and commercialize.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;At the effective date of the 2017 Roche Agreement, choroideremia was designated a Roche product class and the 4D-110 product was licensed to Roche. The Company was responsible for conducting research and development services prior to pivotal clinical studies, and Roche was responsible for conducting subsequent development and commercialization activities. In addition, Roche agreed to pay for research and development services at the agreed upon full-time employee rate for work performed for choroideremia under the 2017 Roche Agreement, and certain external costs, except for the costs associated with the manufacturing work for choroideremia.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Under the 2017 Roche Agreement, Roche had an option, exercisable prior to pivotal clinical studies, to license 4D-125 (for the treatment of XLRP), which was not exercised.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Pursuant to the 2017 Roche Agreement, the Company received a non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as consideration. In addition, the Company was entitled to contingent payments including (i) $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for each Roche nominated product beyond the first three, (ii) up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million upon exercise of the option to convert a product the Company nominated and developed prior to pivotal clinical studies, (iii) development milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;223.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;86.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million related to choroideremia and the rest related to other licensed products; and (iv) sales-based milestones of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;123.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in connection with licensed products. Through December 31, 2021, the Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for development milestone payments that are non-refundable. The 2017 Roche Agreement also included provisions that entitled the Company to receive royalty payments ranging from the mid-single digits to the mid-teens for the net sales of the licensed products, in each case subject to the reductions in accordance with the terms of the agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company identified a single combined performance obligation for the license, research services and participation in the JSC and concluded that Roche&#x2019;s option did not represent a material right. The Company&#x2019;s contract with Roche did not include a significant financing component. The Company further concluded that the transaction price should not include the variable consideration related to development milestones as they were considered to be constrained as it was probable that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in the future. The Company excluded any consideration related to sales-based milestones, including royalties, which would be recognized when the related sales occur. The transaction price and estimated period of performance are re-evaluated at each reporting period and adjusted as needed to reflect changes in the scope of the project, reimbursable expenses and other conditions affecting variable consideration.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In June 2021, the Company received from Roche notice of termination without cause of the 2017 Roche Agreement. The licenses granted by the Company to Roche under the 2017 Roche Agreement terminated in their entirety on September 16, 2021. Therefore, as of September 16, 2021, Roche no longer has a license for 4D-110 for the treatment of choroideremia or any other product class, and the Company is no longer entitled to receive any further milestones or royalties from Roche. In July 2021, the Company notified Roche of the Company&#x2019;s election to continue development of choroideremia. As a result, in accordance with the terms of the agreement, all rights to 4D-110 data and intellectual property generated under the collaboration reverted to the Company. Under the 2017 Roche Agreement, if the Company is required to initiate a new Phase 1/2a clinical trial for 4D-110, the Company would not owe any royalty to Roche on net sales of 4D-110. If, however, the Company moves directly to a pivotal trial of 4D-110, without first being required to conduct a new Phase 1/2a clinical trial, the Company must pay Roche a mid-single digits percentage royalty on the net sales of 4D-110.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As a result of the termination of the 2017 Roche Agreement, an adjustment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million was made to the transaction price to reflect the decrease in reimbursable costs for the year ended December 31, 2021. The decrease in the transaction price and total budgeted costs for the remaining performance obligation resulted in an $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million increase in revenue recognized in the year ended December 31, 2021 related to the performance obligation partially satisfied prior to January 1, 2021. For the year ended December 31, 2020, an adjustment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million was made to the transaction price to reflect an increase of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in the scope of the project and expected reimbursable costs and the addition of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million of variable consideration as the uncertainty associated with two development milestones was resolved. The adjustments to the transaction price and total budgeted costs in 2020 resulted in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million increase in revenue recognized in the year ended December 31, 2020 related to performance obligations partially satisfied in periods prior to January 1, 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During the years ended December 31, 2021 and 2020, the Company recognized revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million from Roche, respectively. As of December 31, 2021 and 2020, deferred revenue relating to the Roche Agreement was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;14.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. Accounts receivable from Roche under this agreement as of December 31, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;25.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;CFF&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In September 2016, the Company entered into an award agreement for the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program with CFF, a non-profit organization dedicated to finding a cure for cystic fibrosis, an inherited disorder that causes disease in the pulmonary airways leading to morbidity and mortality. Under this agreement, CFF contributes funding to help advance the Company&#x2019;s CF research program. The agreement was subsequently amended in September 2017, August 2018 and February 2021 (all four agreements are collectively referred to as the &#x201c;CFF Agreement&#x201d;). The total amount of the award under the CFF Agreement is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. As of December 31, 2021 and 2020, the Company achieved milestones totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million under the CFF Agreement, respectively. The remaining award amount will be paid by CFF based on achievement of certain development milestones by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company expects to make payments to CFF equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_ae6a1cea-4dc5-429f-b6df-a8af5d5155a4;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;six&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; times the actual award received by the Company in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; installments within the first &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; of the first commercial sale of a product developed under this agreement. The Company also has agreed to make future sales-based milestone payments to CFF of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_55f2fc27-7ef4-4149-a482-d2ca9293554a;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; times the actual award received upon achieving specified commercialization milestones with respect to the first of any product developed utilizing any compound covered under the CFF Agreement. The CFF Agreement also requires the Company to pay to CFF royalties of a mid-single digit percentage, up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_ebac0ee9-675f-4dde-a1fd-3d4097e446f6;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;six&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; times the actual award received, on any amounts received by the Company from the sale, license or transfer to a third-party of rights in the technology developed as a result of this collaboration. Any such royalty payments shall be credited against the payments owed by the Company upon first commercial sale. In the event of a change of control of the Company, CFF will receive certain payments, depending on the timing of the change of control and the size of the transaction.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;To date, the Company has not developed a commercial product in connection with the CFF Agreement, and it has not licensed, sold or otherwise transferred to another party the product developed under the CFF Agreement or the underlying technology.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;If at any time prior to the first commercial sale of a product developed as a result of the CFF Agreement, the Company ceases to use commercially reasonable efforts to develop or commercialize any product under the CFF Agreement for a continuous period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; consecutive days and fails to present a reasonable plan to resume commercially reasonable efforts, the Company will grant to CFF an irrevocable, exclusive worldwide interruption license under all of the Company&#x2019;s interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Under ASC 606, the Company identified one performance obligation within the CFF grant agreement for research activities. The Company&#x2019;s contract with CFF does not include a significant financing component.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company concluded that the transaction price should not include the variable consideration related to future research milestones as they were considered to be constrained as it is probable that the inclusion of such variable consideration could result in a significant reversal of cumulative revenue in the future. The Company re-evaluates the transaction price and estimated period of performance at each reporting period. For the year ended December 31, 2021, an adjustment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million was made to the transaction price to reflect the achievement of the fourth milestone related to demonstrating GFP expression and determining a cell specific expression profile in human and NHP upper airway ALI cultures following apical transduction under the CFF Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During the years ended December 31, 2021 and 2020, the Company recognized revenue of  $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;) million, respectively. As of December 31, 2021 and 2020, deferred revenue relating to the CFF Agreement was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. Accounts receivable from CFF under the CFF Agreement as of December 31, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to the remaining performance obligation was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. Based on current timelines, the deferred revenue is expected to be recognized as revenue over the next &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_6a54b9ee-b4de-4717-a1a2-a0f99f73deb0;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; as the Company performs research services through the completion of IND-enabling studies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The obligation to make payments to CFF upon a change of control meets the definition of an embedded derivative that is required to be bifurcated and separately accounted for as a derivative liability. See Note 16 for further discussion of the embedded derivative.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <fdmt:ScheduleOfCollaborationAndLicenseRevenueTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_5b07e23f-85c5-4a03-8be1-aaded0327e33">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Collaboration and license revenue for each period was as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.014%;"/&gt;
        &lt;td style="width:1.584%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.804%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.584%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.675%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.584%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;uniQure&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Roche&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;CFF&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fdmt:ScheduleOfCollaborationAndLicenseRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_0c74490e-c642-49f7-a178-c5c00a711057"
      decimals="-3"
      id="F_fc216c33-542d-4737-9a42-62104d828e21"
      unitRef="U_USD">736000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_10bf4f98-2380-4a78-bf83-b60685bbda33"
      decimals="-3"
      id="F_cbef46ec-792f-4da9-995c-e47bae11a32b"
      unitRef="U_USD">742000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_efc3ff61-873a-4027-8905-9906185f858f"
      decimals="-3"
      id="F_c1531654-9e7c-4e85-afd6-a45beeeb743d"
      unitRef="U_USD">17181000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_7224f03c-f6e9-4042-a275-59c886ca1970"
      decimals="-3"
      id="F_72d27bf0-1b8d-4c90-a9b8-adffdf447be2"
      unitRef="U_USD">12897000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_bc671fd0-0ba3-4f31-87f7-95c143537ef9"
      decimals="-3"
      id="F_e3051771-0a68-43f0-bc4e-14a80ef7d7d5"
      unitRef="U_USD">121000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_f311e2d1-83ec-4e94-91c6-bb50b44c9a4a"
      decimals="-3"
      id="F_cbcc57d5-c980-4e00-a01c-6a56ce30cc11"
      unitRef="U_USD">-27000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_dfd0d18e-816a-44fd-b58e-bba6ac6a812a"
      decimals="-3"
      id="F_49d20e62-d675-4001-859d-29840e9ea6a8"
      unitRef="U_USD">18038000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_46bb51b8-c564-4f79-bb7b-808fc09a2915"
      decimals="-3"
      id="F_62db0d10-1569-4f3b-90b6-e9c8884de1a8"
      unitRef="U_USD">13612000</us-gaap:Revenues>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_3fa9c27c-c36e-49dd-aa8b-e9c67363a8da">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred revenue for each period was as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.124%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.019%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.041%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Deferred Revenue &lt;br/&gt;as of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;uniQure&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Roche&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;14,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;CFF&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;19,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_019809d7-3321-4394-ad06-f1dce3e3dcd3"
      decimals="-3"
      id="F_da584672-5c48-477d-87fe-1b3c5e99214e"
      unitRef="U_USD">3661000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_d7e7e417-5edc-4abf-a76c-5be707bce23e"
      decimals="-3"
      id="F_3b87ec64-3b54-4624-a58b-3e87ce82c969"
      unitRef="U_USD">4396000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_fb67bb6e-bab1-4045-8de0-aaff307da3a9"
      decimals="-3"
      id="F_d4d92cfa-88d1-4bae-97d3-1f93950481bf"
      unitRef="U_USD">14318000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_b3cb484d-807c-45d4-a35e-ca7c2f3f9313"
      decimals="-3"
      id="F_2a55cdff-3b25-4fec-b873-461932621d46"
      unitRef="U_USD">1429000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_84be53f3-486d-4f0d-90b0-07d7e83acbf6"
      decimals="-3"
      id="F_1ed6c1a5-bc9b-4533-a21a-6ae2dbee883c"
      unitRef="U_USD">1098000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_09501158-5bdf-4c85-aa6a-a115b9b1b586"
      unitRef="U_USD">5090000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_800ba7cf-728a-4b1e-9a47-0c949e4836a9"
      unitRef="U_USD">19812000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-5"
      id="F_a6257806-6f91-4a8b-9d36-89e3a2a3a8e9"
      unitRef="U_USD">15100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-5"
      id="F_f1c744b0-108b-4c74-ba71-6a06fdd75114"
      unitRef="U_USD">3200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <fdmt:CollaborativeArrangementInitialResearchTerm
      contextRef="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b"
      id="F_bb29245f-b4b9-483b-a085-2af4e50f44e2">P3Y</fdmt:CollaborativeArrangementInitialResearchTerm>
    <fdmt:CollaborationArrangementsUpfrontPaymentReceived
      contextRef="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b"
      decimals="-5"
      id="F_6ab1d663-3b33-4749-9c26-788062e40063"
      unitRef="U_USD">200000</fdmt:CollaborationArrangementsUpfrontPaymentReceived>
    <fdmt:CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct
      contextRef="C_e3231fac-0339-4b86-8552-33d99ccf5b90"
      decimals="INF"
      id="F_8de4e11a-6828-4ca5-bf30-bfbea03e10c2"
      unitRef="U_USD">5000000.0</fdmt:CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct>
    <fdmt:OptionsToPurchaseOrdinaryShares
      contextRef="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b"
      decimals="INF"
      id="F_21ce308a-63e3-4144-a6bb-c96d3d0e027d"
      unitRef="U_shares">609744</fdmt:OptionsToPurchaseOrdinaryShares>
    <fdmt:VestingPeriodOfShareAwards
      contextRef="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b"
      id="F_5503e1ff-f02e-4778-bfde-0646259dce92">P3Y</fdmt:VestingPeriodOfShareAwards>
    <fdmt:CollaborationArrangementsUpfrontPaymentReceived
      contextRef="C_7e8a43a5-741a-4ee4-9c36-c8a517700a3b"
      decimals="-5"
      id="F_f2ab2148-948c-4517-af8c-90f59b0a8b46"
      unitRef="U_USD">200000</fdmt:CollaborationArrangementsUpfrontPaymentReceived>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0912072b-bcab-4ad8-a96b-b69214a4c085"
      id="F_a7385807-61f0-4cb2-9c70-b6d343847868">P4Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <fdmt:FairValueOfOptions
      contextRef="C_98081424-857b-49e5-aa11-1c55ddebeec0"
      decimals="-5"
      id="F_3375892e-4452-41e2-bba2-6d9a34dbf3f4"
      unitRef="U_USD">10600000</fdmt:FairValueOfOptions>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0912072b-bcab-4ad8-a96b-b69214a4c085"
      id="F_b9c50cad-48ef-4f7f-8629-89184360247d">P4Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <fdmt:ContingentPaymentsEliminated
      contextRef="C_af32b9d1-9efd-44e5-8ceb-eb4bf3e5244b"
      decimals="INF"
      id="F_1744dcc9-e611-47c6-b496-de94829fc3a2"
      unitRef="U_USD">5000000.0</fdmt:ContingentPaymentsEliminated>
    <fdmt:FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight
      contextRef="C_490d082b-4c24-4ebc-97b4-1f4ca133afe2"
      decimals="-5"
      id="F_9d9ce441-b867-4d97-a011-7525776c151c"
      unitRef="U_USD">5100000</fdmt:FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_6589222f-c96b-40f8-a688-38fc97e550be"
      id="F_34edb21a-11fd-4948-ab7d-f57cd0dde3e3">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_2975534f-c7d6-40d2-b4f0-8396ed62ffe5"
      decimals="-5"
      id="F_51ca3e43-41ec-405d-be55-67cdc1b581e4"
      unitRef="U_USD">700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_d8f5fd72-5501-4424-9c3c-155dadbc1f06"
      decimals="-5"
      id="F_c95f5f4a-ab7b-4a69-82fb-e2d27822e3a6"
      unitRef="U_USD">700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_019809d7-3321-4394-ad06-f1dce3e3dcd3"
      decimals="-5"
      id="F_2f2ae6ed-bd7b-4b9a-880d-93b8a63bc9ec"
      unitRef="U_USD">3700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_d7e7e417-5edc-4abf-a76c-5be707bce23e"
      decimals="-5"
      id="F_e789f3e6-e2bb-4a46-8aaf-1f7daf1a71a3"
      unitRef="U_USD">4400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DueFromRelatedParties
      contextRef="C_019809d7-3321-4394-ad06-f1dce3e3dcd3"
      decimals="INF"
      id="F_5481060e-da52-49be-b43f-99401d939fc8"
      unitRef="U_USD">0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="C_d7e7e417-5edc-4abf-a76c-5be707bce23e"
      decimals="INF"
      id="F_776464d6-8401-4f7d-8b59-3b28b3e8fa3f"
      unitRef="U_USD">0</us-gaap:DueFromRelatedParties>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_4a392933-0525-4a24-bd80-f86924e2bcf6"
      decimals="-5"
      id="F_d7d93f51-73ee-40d1-9307-c692d5fbc307"
      unitRef="U_USD">3700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0e28aeda-24d7-44f2-b175-686133e42282"
      decimals="-5"
      id="F_e01080ae-67f4-43da-90a9-1f15165ef8f1"
      unitRef="U_USD">4400000</us-gaap:RevenueRemainingPerformanceObligation>
    <fdmt:CollaborativeArrangementInitialResearchTerm
      contextRef="C_e21eab0a-797b-4380-9011-1aea8fabc1b5"
      id="F_c41616fa-c147-4043-8a4b-14ebde92c61b">P2Y</fdmt:CollaborativeArrangementInitialResearchTerm>
    <fdmt:CollaborativeArrangementContributionUponDevelopmentMilestone
      contextRef="C_44ba6365-051f-4e87-afa2-47586cb35c9d"
      decimals="-5"
      id="F_8ee68137-e2b3-4015-acb4-d0fe59b6ea4c"
      unitRef="U_USD">2500000</fdmt:CollaborativeArrangementContributionUponDevelopmentMilestone>
    <fdmt:CollaborativeArrangementAchievedMilestones
      contextRef="C_6795eac3-18cb-415a-b6be-fd09406f11f7"
      decimals="INF"
      id="F_0849f39d-5c73-42e1-895e-bf3e8c90a7e0"
      unitRef="U_USD">0</fdmt:CollaborativeArrangementAchievedMilestones>
    <us-gaap:DeferredRevenue
      contextRef="C_46645de8-496d-4445-bcee-79e0f6a7e2e5"
      decimals="INF"
      id="F_603c5045-732b-402e-9f02-9dbde56318f8"
      unitRef="U_USD">0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_be527709-9a9f-4be1-8ea5-1064c24e61fb"
      decimals="INF"
      id="F_4126d7d8-0d1e-4590-8c51-f16515b4566f"
      unitRef="U_USD">0</us-gaap:DeferredRevenue>
    <us-gaap:DueFromRelatedParties
      contextRef="C_46645de8-496d-4445-bcee-79e0f6a7e2e5"
      decimals="INF"
      id="F_d25478d7-4607-4780-b0d5-1e72ca9b4ef5"
      unitRef="U_USD">0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="C_be527709-9a9f-4be1-8ea5-1064c24e61fb"
      decimals="INF"
      id="F_781891e8-144d-4d35-8b28-93f085967666"
      unitRef="U_USD">0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_46645de8-496d-4445-bcee-79e0f6a7e2e5"
      decimals="INF"
      id="F_27be9389-24d8-4eba-979f-3ab79156651d"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_be527709-9a9f-4be1-8ea5-1064c24e61fb"
      decimals="INF"
      id="F_bcf6bb67-7818-452c-8e80-4343bc62a03d"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <fdmt:CollaborationArrangementsNonRefundableUpfrontPaymentReceived
      contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0"
      decimals="-5"
      id="F_35e7ed47-d744-4780-87d9-84fb083135ce"
      unitRef="U_USD">21000000.0</fdmt:CollaborationArrangementsNonRefundableUpfrontPaymentReceived>
    <fdmt:CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree
      contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0"
      decimals="-5"
      id="F_a34f90ab-cc58-4dd8-a619-bf07b026c321"
      unitRef="U_USD">1000000.0</fdmt:CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree>
    <fdmt:CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct
      contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0"
      decimals="-5"
      id="F_c261faf2-96ed-4321-a39f-bad4ca819af6"
      unitRef="U_USD">30000000.0</fdmt:CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct>
    <fdmt:CollaborationArrangementsMaximumDevelopmentMilestonePayments
      contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0"
      decimals="-5"
      id="F_9ba89443-94cc-4815-8476-92c355d0e6ec"
      unitRef="U_USD">223000000.0</fdmt:CollaborationArrangementsMaximumDevelopmentMilestonePayments>
    <fdmt:CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia
      contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0"
      decimals="-5"
      id="F_be6f3545-19eb-4ecb-94ad-db1f36669595"
      unitRef="U_USD">86000000.0</fdmt:CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia>
    <fdmt:CollaborativeArrangementMaximumSalesBasedMilestonePayments
      contextRef="C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0"
      decimals="-5"
      id="F_cf296114-2d59-42d8-953c-58d272335f94"
      unitRef="U_USD">123000000.0</fdmt:CollaborativeArrangementMaximumSalesBasedMilestonePayments>
    <fdmt:CollaborationArrangementsNonRefundableDevelopmentMilestonePayments
      contextRef="C_62a5478f-6648-41ef-8d95-7e857719eae5"
      decimals="-5"
      id="F_439d306c-91d8-40d5-9a77-e14e42d5ab33"
      unitRef="U_USD">10000000.0</fdmt:CollaborationArrangementsNonRefundableDevelopmentMilestonePayments>
    <fdmt:CollaborativeArrangementAdjustmentToTransactionPrice
      contextRef="C_62a5478f-6648-41ef-8d95-7e857719eae5"
      decimals="-5"
      id="F_045e178a-da5e-4269-b282-2f7d1b9848dd"
      unitRef="U_USD">8700000</fdmt:CollaborativeArrangementAdjustmentToTransactionPrice>
    <fdmt:IncreaseDecreaseInContractWithCustomerRevenueRecognized
      contextRef="C_62a5478f-6648-41ef-8d95-7e857719eae5"
      decimals="-5"
      id="F_1d138d56-dcf7-4c37-9bfb-0ebd22566f97"
      unitRef="U_USD">11100000</fdmt:IncreaseDecreaseInContractWithCustomerRevenueRecognized>
    <fdmt:CollaborativeArrangementAdjustmentToTransactionPrice
      contextRef="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0"
      decimals="-5"
      id="F_9c344b02-b591-4c5b-9084-ee0ef12102ee"
      unitRef="U_USD">17000000.0</fdmt:CollaborativeArrangementAdjustmentToTransactionPrice>
    <fdmt:CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts
      contextRef="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0"
      decimals="-5"
      id="F_eafeeb0e-5692-4de3-abd8-1555548a06f1"
      unitRef="U_USD">7000000.0</fdmt:CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts>
    <fdmt:CollaborativeArrangementAdditionOfVariableConsideration
      contextRef="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0"
      decimals="-5"
      id="F_35599517-32e7-4952-92b8-17161479664e"
      unitRef="U_USD">10000000.0</fdmt:CollaborativeArrangementAdditionOfVariableConsideration>
    <fdmt:IncreaseDecreaseInContractWithCustomerRevenueRecognized
      contextRef="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0"
      decimals="-5"
      id="F_c2a58457-236e-4191-a615-1c63ecfb345c"
      unitRef="U_USD">4600000</fdmt:IncreaseDecreaseInContractWithCustomerRevenueRecognized>
    <us-gaap:Revenues
      contextRef="C_62a5478f-6648-41ef-8d95-7e857719eae5"
      decimals="-5"
      id="F_ebcb2ba1-1d65-4c2d-8d42-f5fe63308b07"
      unitRef="U_USD">17200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_613b38f3-e2bb-4451-b04c-3532c4bb63d0"
      decimals="-5"
      id="F_e2cca2c2-e8d6-45a0-8bab-1c73716d19c9"
      unitRef="U_USD">12900000</us-gaap:Revenues>
    <us-gaap:DeferredRevenue
      contextRef="C_7974df26-e7b0-4ed8-86d9-17fbf7835f1a"
      decimals="-5"
      id="F_e6b4c719-df5d-46b9-99eb-e6c6cccd1033"
      unitRef="U_USD">0.0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_ee124165-31e9-4e1d-8df3-5e051998cafd"
      decimals="-5"
      id="F_11b4f6e5-2b58-4d98-bc93-5a029921eddb"
      unitRef="U_USD">14300000</us-gaap:DeferredRevenue>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss
      contextRef="C_7974df26-e7b0-4ed8-86d9-17fbf7835f1a"
      decimals="-5"
      id="F_acd2c390-cb2b-4158-a132-527f3ab2de40"
      unitRef="U_USD">0.0</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss
      contextRef="C_ee124165-31e9-4e1d-8df3-5e051998cafd"
      decimals="-5"
      id="F_bc4fe13c-c5df-4196-842e-193f3a8487de"
      unitRef="U_USD">1100000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_7974df26-e7b0-4ed8-86d9-17fbf7835f1a"
      decimals="-5"
      id="F_4840b47f-dfb6-450d-84ae-a6ffa49b4059"
      unitRef="U_USD">0.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_ee124165-31e9-4e1d-8df3-5e051998cafd"
      decimals="-5"
      id="F_1ee36f20-2ec5-4623-85b1-ce74bd4e0053"
      unitRef="U_USD">25800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d"
      decimals="-5"
      id="F_ec0017c0-21b7-4f93-b355-f7953dab236d"
      unitRef="U_USD">3500000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <fdmt:CollaborativeArrangementAchievedMilestones
      contextRef="C_d34de791-bc33-4d58-b8e1-f57a6ba20191"
      decimals="-5"
      id="F_20a801fb-0f30-40b6-9620-329f76b43c9b"
      unitRef="U_USD">1800000</fdmt:CollaborativeArrangementAchievedMilestones>
    <fdmt:CollaborativeArrangementAchievedMilestones
      contextRef="C_067e587d-dfef-4587-ad79-844c454aeb5e"
      decimals="-5"
      id="F_8e534614-2d73-4e1a-9101-a6a352a38a9e"
      unitRef="U_USD">1300000</fdmt:CollaborativeArrangementAchievedMilestones>
    <fdmt:NumberOfInstallmentsToPayActualAward
      contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d"
      decimals="INF"
      id="F_54b939ab-17e8-4113-8a78-cd314b453408"
      unitRef="U_Installment">3</fdmt:NumberOfInstallmentsToPayActualAward>
    <fdmt:ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct
      contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d"
      id="F_16a62b7d-6633-4ac4-a53e-8b745e5bd40f">P4Y</fdmt:ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct>
    <fdmt:ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct
      contextRef="C_eab566a6-1468-49d2-aaec-a715d312418d"
      id="F_21d691c5-9ef9-4aa2-82e2-0fe3a5c32434">P180D</fdmt:ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct>
    <fdmt:CollaborativeArrangementTransactionPriceAdjustment
      contextRef="C_d34de791-bc33-4d58-b8e1-f57a6ba20191"
      decimals="-5"
      id="F_7b9a1e31-c89d-4599-9491-e3ecec645de2"
      unitRef="U_USD">500000</fdmt:CollaborativeArrangementTransactionPriceAdjustment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d34de791-bc33-4d58-b8e1-f57a6ba20191"
      decimals="-5"
      id="F_f39a574e-cccd-44ee-a928-67f6f5800b02"
      unitRef="U_USD">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_067e587d-dfef-4587-ad79-844c454aeb5e"
      decimals="-5"
      id="F_1d3606c1-bcdd-43bd-b69a-dc8e6022d176"
      unitRef="U_USD">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="C_1001d586-4a93-4bdd-bca8-c247e6d58d1e"
      decimals="-5"
      id="F_e5e1b3a1-5de2-4d25-9a89-baebcb56c79a"
      unitRef="U_USD">1400000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_4a794422-dee1-4707-8185-703c70506d97"
      decimals="-5"
      id="F_c76260f4-db2f-47af-8e72-c69c6eed6dc4"
      unitRef="U_USD">1100000</us-gaap:DeferredRevenue>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss
      contextRef="C_1001d586-4a93-4bdd-bca8-c247e6d58d1e"
      decimals="-5"
      id="F_149c6150-1ec6-4319-a0a6-0bd5074f9c2b"
      unitRef="U_USD">0.0</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss
      contextRef="C_4a794422-dee1-4707-8185-703c70506d97"
      decimals="-5"
      id="F_e5d18d0e-775c-4bf0-ac07-f3b9f65f31d6"
      unitRef="U_USD">400000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_1001d586-4a93-4bdd-bca8-c247e6d58d1e"
      decimals="-5"
      id="F_89f5f052-4365-4b8b-9abe-a79e4cdef12d"
      unitRef="U_USD">1400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_4a794422-dee1-4707-8185-703c70506d97"
      decimals="-5"
      id="F_ff381a6a-0ed5-475e-b0c8-1b0fb83d274d"
      unitRef="U_USD">1100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_b4e47e36-ad9e-4007-bb25-cc82fae064e6"
      id="F_5dad5432-6235-4f6d-b59d-c2c3bc02404a">P4Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <fdmt:LicenseArrangementsTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_b0f29c8d-e2e6-4bac-9c12-c8d77ba7ef47">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;8. License Arrangements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company has exclusive, worldwide license agreements (the &#x201c;UC Agreements&#x201d;) with the Regents of the University of California (the &#x201c;UC Regents&#x201d;) relating to the use of certain patents and intellectual property surrounding its core technologies, including Therapeutic Vector Evolution. Pursuant to each of the UC Agreements executed prior to January 2019, the Company was obligated to pay a (i) non-refundable license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; upon execution, (ii) a non-refundable license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents, (iii) reimbursement of domestic and foreign patent filing, prosecution and maintenance fees, and (iv) either $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;50,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; or issuance of a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% equity interest in the Company upon the closing of the first qualified financing at the option of the UC Regents. The Company&#x2019;s first qualified financing occurred in 2015 and at the election of the UC Regents, the Company issued the UC Regents in January 2016 an amount of common stock equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of the equity interests in the Company pursuant to the applicable clause in each of the UC Agreements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Pursuant to an agreement with the UC Regents executed in January 2019 the Company paid a non-refundable license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;50,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; on the one-year anniversary of the contract effective date and each year thereafter, until sales of a licensed product are made and royalties are paid to the UC Regents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, (ii) low single digit royalties on the net sales of its developed products that consists of a minimum annual royalty of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million per year for the term of the Agreement beginning in the first calendar year after the year in which net sales first occurred, and (iii) sublicense consideration in the mid-teens to the mid-twenties-range on any future sublicensing arrangements the Company may enter into with third-party licensees.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In July 2021, the Company entered into an exclusive license agreement with the UC Regents and the Trustees of the University Pennsylvania to license intellectual property related to certain vectors. In July 2021, the Company paid a non-refundable license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; to the UC Regents upon execution of the agreement. The Company is obligated to pay a non-refundable license maintenance fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; on the one-year anniversary of the contract effective date and each year thereafter, except years for which the Company has paid royalties on the net sales of a licensed product. In addition, the Company is obligated to make certain contingent payments including (i) development milestones up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, (ii) low single digit percentage rate royalties on the net sales of its licensed products that consists of a minimum annual royalty of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million per year for the term of the Agreement beginning in the first calendar year after the year in which net sales first occurred and (iii) sublicense consideration in the mid-single digits to the low twenties percentage rate range on any future sublicensing arrangements the Company may enter into with third-party licensees.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During the years ended December 31, 2021 and 2020, the Company incurred expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively, under the provisions of the outstanding license arrangements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</fdmt:LicenseArrangementsTextBlock>
    <fdmt:NonRefundableLicenseFeePayableUponExecution
      contextRef="C_cc9158f0-cc85-4a61-9faf-16e23bce0c56"
      decimals="0"
      id="F_6d187497-f3c7-4faf-a0f6-14f971a18fbe"
      unitRef="U_USD">5000</fdmt:NonRefundableLicenseFeePayableUponExecution>
    <fdmt:NonRefundableLicenseFeePayableEveryYearAfterExecution
      contextRef="C_cc9158f0-cc85-4a61-9faf-16e23bce0c56"
      decimals="0"
      id="F_06c07edf-49ee-4f7d-8b43-0d6eb95b8b38"
      unitRef="U_USD">5000</fdmt:NonRefundableLicenseFeePayableEveryYearAfterExecution>
    <fdmt:AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption
      contextRef="C_cc9158f0-cc85-4a61-9faf-16e23bce0c56"
      decimals="0"
      id="F_45380fa2-e155-4f73-a2ea-5df730d35bf9"
      unitRef="U_USD">50000</fdmt:AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption>
    <fdmt:PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption
      contextRef="C_cc9158f0-cc85-4a61-9faf-16e23bce0c56"
      decimals="2"
      id="F_b0e8f5e4-e08b-48cf-bf69-a9d35ef8eb42"
      unitRef="U_pure">0.03</fdmt:PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption>
    <fdmt:PercentageOfEquityInterestsIssuedAsCommonStock
      contextRef="C_b7f143b1-ffa9-4263-bc77-01c55254624d"
      decimals="2"
      id="F_7af32fc2-7432-45ab-8077-78e611c5043d"
      unitRef="U_pure">0.06</fdmt:PercentageOfEquityInterestsIssuedAsCommonStock>
    <fdmt:AmountsPaidNonRefundableLicenseFees
      contextRef="C_47f11691-274e-42ed-9d35-7150a1a1bafe"
      decimals="0"
      id="F_b5858459-8280-408f-808c-9d2ee8279148"
      unitRef="U_USD">50000</fdmt:AmountsPaidNonRefundableLicenseFees>
    <fdmt:AmountObligatedToPayNonRefundableLicenseFeeAnnually
      contextRef="C_47f11691-274e-42ed-9d35-7150a1a1bafe"
      decimals="0"
      id="F_94170475-5ebe-4a1f-8859-988a0eee0f75"
      unitRef="U_USD">5000</fdmt:AmountObligatedToPayNonRefundableLicenseFeeAnnually>
    <fdmt:DevelopmentMilestones
      contextRef="C_aaf1e58d-3b1c-4821-9e56-aaa8b373ab63"
      decimals="INF"
      id="F_8dda1be6-1f92-4b9b-b801-41052de7f133"
      unitRef="U_USD">3100000</fdmt:DevelopmentMilestones>
    <fdmt:AnnualRoyalty
      contextRef="C_bbcc2364-ba79-4bc4-b41b-1b1dc9a8eede"
      decimals="INF"
      id="F_98ee2840-e3dd-4f77-97a7-67b97ed12e24"
      unitRef="U_USD">100000</fdmt:AnnualRoyalty>
    <fdmt:AmountsPaidNonRefundableLicenseFees
      contextRef="C_b92a1f3f-887c-4ea7-a989-5b92852b7259"
      decimals="0"
      id="F_83750204-8583-4a51-ad60-30ddbd7dfe72"
      unitRef="U_USD">100000</fdmt:AmountsPaidNonRefundableLicenseFees>
    <fdmt:AmountObligatedToPayNonRefundableLicenseFeeAnnually
      contextRef="C_b92a1f3f-887c-4ea7-a989-5b92852b7259"
      decimals="0"
      id="F_e95c3816-4630-45d9-a62f-3b84b33e3728"
      unitRef="U_USD">10000</fdmt:AmountObligatedToPayNonRefundableLicenseFeeAnnually>
    <fdmt:DevelopmentMilestones
      contextRef="C_485d52ae-2831-49f8-b4f8-3e103c72940b"
      decimals="INF"
      id="F_a25ce4a3-d176-4aa9-8432-2f01122204c7"
      unitRef="U_USD">3900000</fdmt:DevelopmentMilestones>
    <fdmt:AnnualRoyalty
      contextRef="C_00c84e7f-1487-4fcb-b57c-626e653667be"
      decimals="INF"
      id="F_4dfed9be-8669-4789-a977-c2ad06332087"
      unitRef="U_USD">100000</fdmt:AnnualRoyalty>
    <fdmt:IncurredExpenses
      contextRef="C_bcb74483-fa99-4ee5-a6ea-6a4843de5d40"
      decimals="-5"
      id="F_1a88edb7-a1b8-49cc-b9d4-119f57aae794"
      unitRef="U_USD">300000</fdmt:IncurredExpenses>
    <fdmt:IncurredExpenses
      contextRef="C_71c68b91-969e-469a-ac31-ed7554ddc8fc"
      decimals="-5"
      id="F_6ef6f1df-d176-47e8-951b-a28abf0120f3"
      unitRef="U_USD">200000</fdmt:IncurredExpenses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_9b2a5aa3-d027-4c8f-97cd-a0f2660d40a6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;9. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Operating Lease Commitments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prior to the adoption of ASC 842, the Company recognized rent expense for its operating leases on a straight-line basis over the noncancelable lease term and recorded the difference between rent payments and the straight-line rent expense was recorded as a deferred rent liability. As of December 31, 2020, the Company performed an evaluation of its other contracts with customers and suppliers in accordance with ASC 842 and determined that, except for the leases described below, none of the Company&#x2019;s contracts contain a material lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;5980 Horton Street Building Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In May 2015, the Company executed a lease agreement for office and laboratory space in Emeryville, California. In January 2016, the Company executed the first amendment to the lease agreement for additional rentable office and laboratory space which extended the lease term to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;March 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and updated the option to renew the lease at market rent from the prior additional term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. In October 2018, the Company executed a second amendment to extend the lease to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;September 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. Additionally, the second amendment provided a tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, which was paid to the Company in November 2018.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The 5980 Horton Street Building Lease is considered an operating lease under ASC 842 as it does not meet the criteria of a finance lease. As of December 31, 2021, the operating lease right-of-use asset and operating lease liability was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. The discount rate used to determine the lease liability was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;5858 Horton Street Building Lease and Expansion&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In October 2018, the Company executed a second lease agreement for additional office and laboratory space in Emeryville, California. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The new lease has an initial term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; months beginning on the rent commencement date with the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;option to renew&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; the lease for one additional term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; at market rent. &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company did not have to pay rent until October 2019. This lease agreement also provided for a tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, which was paid to the Company in December 2019. The Company amortizes the tenant improvement allowance on a straight-line basis over the remaining term of the lease as a reduction of rent expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In May 2019, the Company amended the second lease agreement executed in October 2018 to add additional office and laboratory space (the "Expansion"). The amendment extended the term of the lease to December 31, 2029. The Company did not have to pay rent until December 2019. The lease agreement also included a tenant improvement allowance, which was increased to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in February 2021 pursuant to a second amendment to the second lease agreement. In November 2021, the Company received the first installment of this tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. The tenant improvement allowance funds improvements to the additional office and laboratory space, which the Company has determined to be lessee owned. The allowance is treated as a reduction of lease payments used to measure the lease liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The 5858 Horton Street Building Lease and Expansion is considered an operating lease under ASC 842 as it does not meet the criteria of a finance lease. As of December 31, 2021, the operating lease right-of-use asset and operating lease liability was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;14.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. The discount rate used to determine the lease liability was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total operating lease expense for the year ended December 31, 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. Cash paid for amounts included in the measurement of lease liabilities was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Neither of the leases include a general option for the Company to terminate the leases.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table summarizes the components of lease expense for the year ended December 31, 2021, which are included in operating expenses in the Company&#x2019;s statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.996%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.88%;"/&gt;
        &lt;td style="width:20.34%;"/&gt;
        &lt;td style="width:0.78%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Variable lease payments include amounts relating to common area maintenance and are recognized in the statements of operations as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table summarizes supplemental information related to operating leases for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.998%;"/&gt;
        &lt;td style="width:18.536%;"/&gt;
        &lt;td style="width:2.457%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted-average remaining lease term (in years):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table summarizes the maturities of lease liabilities as of December 31, 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.996%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.538%;"/&gt;
        &lt;td style="width:20.543%;"/&gt;
        &lt;td style="width:0.919%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;22,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: Amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: Current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;15,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Indemnification Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions, such as with vendors and other parties. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently maintains directors&#x2019; and officers&#x2019; liability insurance that would generally enable it to recover a portion of any future amounts paid. The Company believes the estimated fair value of its indemnification agreements in excess of applicable insurance coverage is not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. There are no material legal proceedings outstanding at December 31, 2021.  See Note 14 for details of a settlement with a former employee in April 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_9a196306-24e0-483e-8634-0a715c3d21e0"
      id="F_512ed984-a676-4540-9b0f-1f26dd34fa27">2023-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_a504b7f3-7605-46fc-8597-53b18af6a1d1"
      id="F_c5eac9d3-379b-4226-ab04-ab746879c995">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_68843b0d-f738-4525-bbf0-8acf1ea83427"
      id="F_8019d16d-a0ad-4207-8c22-af641cdb0936">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <fdmt:OperatingLeaseTermExtendedExpirationPeriod
      contextRef="C_5b1c1ec5-d872-44ae-8bb5-78aa34f73511"
      id="F_b70744d4-5b3c-4188-8438-d328a427f269">2026-09</fdmt:OperatingLeaseTermExtendedExpirationPeriod>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="C_4fafc5e1-de72-42ab-a39e-911d607b5701"
      decimals="-5"
      id="F_663b1d4f-27de-4cbb-8951-fa4d001b3d5e"
      unitRef="U_USD">200000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_6c273596-2f89-4f1e-8401-1a71be26008e"
      decimals="-5"
      id="F_e5e52f91-2fba-4d50-bc54-51a34279db67"
      unitRef="U_USD">1900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_6c273596-2f89-4f1e-8401-1a71be26008e"
      decimals="-5"
      id="F_dde76680-63b8-463c-ac54-646be6db78bd"
      unitRef="U_USD">2300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_6c273596-2f89-4f1e-8401-1a71be26008e"
      decimals="3"
      id="F_e5c0aead-7561-4e73-abdf-d14351675cee"
      unitRef="U_pure">0.075</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_e1dda0de-9512-4575-b09e-7dc96d5fda59"
      id="F_b783d2e6-4887-4e59-9cc5-e6bcb35c29ca">The new lease has an initial term of 87 months beginning on the rent commencement date with the option to renew the lease for one additional term of five years at market rent. </us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="C_156eea03-1e5f-4d20-bdd5-c6922ae709bd"
      id="F_981b6188-1663-4e7b-846f-616cbc5bf3d6">P87M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_6b9c4496-5f5c-4b08-a9c6-6e3811f8ebe6"
      id="F_6b5d5b95-995e-42ae-b8b0-eae77b551c08">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_156eea03-1e5f-4d20-bdd5-c6922ae709bd"
      id="F_cc3e33b1-5198-402b-9d22-db74b655531b">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="C_3b2169b0-5a83-4d78-862e-5aacb257dffc"
      decimals="-5"
      id="F_dde7ced3-6273-4875-b1ea-c1eb62fc61dd"
      unitRef="U_USD">400000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="C_a5af98ab-cbe3-47d9-a7e7-15b8be38cf21"
      decimals="-5"
      id="F_a31d4b82-8121-45ca-b189-385c89d1c3ae"
      unitRef="U_USD">2300000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="C_cdd81399-daf3-42e2-bc69-e7aaf154c086"
      decimals="-5"
      id="F_840c1ffc-e82a-42d5-ac69-68e84567fa1a"
      unitRef="U_USD">600000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b4b6884a-ce1d-4bbf-9756-4c19b608736e"
      decimals="-5"
      id="F_eb80e1a9-4743-4bc1-92b8-0f249e024730"
      unitRef="U_USD">12600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b4b6884a-ce1d-4bbf-9756-4c19b608736e"
      decimals="-5"
      id="F_5dede44c-b1dc-4943-9282-e180338b95e8"
      unitRef="U_USD">14200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_b4b6884a-ce1d-4bbf-9756-4c19b608736e"
      decimals="3"
      id="F_4b3c73f4-0c10-4dcb-a80a-8b1136b6011e"
      unitRef="U_pure">0.078</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-5"
      id="F_60dff6bc-f09e-4bd5-8bb2-835a1160da55"
      unitRef="U_USD">2600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-5"
      id="F_ca7dd366-656d-42e4-896e-f3a8c7a81842"
      unitRef="U_USD">2300000</us-gaap:OperatingLeasePayments>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_920c49b0-f0be-480b-88c8-aef07c35dc8a">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table summarizes the components of lease expense for the year ended December 31, 2021, which are included in operating expenses in the Company&#x2019;s statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.996%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.88%;"/&gt;
        &lt;td style="width:20.34%;"/&gt;
        &lt;td style="width:0.78%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_ef6cee05-aeda-43bd-be7b-101434b7b0e6"
      unitRef="U_USD">2631000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_49dce5b4-d1b4-4c37-843b-5571a1045de6"
      unitRef="U_USD">914000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_43b94020-5236-43ed-a070-b7a843e7ec80"
      unitRef="U_USD">3545000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_64377ffd-064c-430a-9d1b-bf2f03744d47">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table summarizes supplemental information related to operating leases for the year ended December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.004%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.998%;"/&gt;
        &lt;td style="width:18.536%;"/&gt;
        &lt;td style="width:2.457%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted-average remaining lease term (in years):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      id="F_943e8fb4-225d-4fb1-bc5a-9a8fe0b43609">P7Y7M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="3"
      id="F_c192ff88-e188-4180-b0a6-4d62572fff3b"
      unitRef="U_pure">0.078</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_a2870369-0371-4ac0-a239-310ab7a95696">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table summarizes the maturities of lease liabilities as of December 31, 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.996%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.538%;"/&gt;
        &lt;td style="width:20.543%;"/&gt;
        &lt;td style="width:0.919%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;22,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: Amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;16,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: Current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;15,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_471209be-32b3-4f8b-9ef8-6db6cfc161a9"
      unitRef="U_USD">1230000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_6cdeda0f-2acb-4a66-8f14-5a3352205151"
      unitRef="U_USD">3058000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_6d0c68f4-a4f5-4338-9135-d08a20b9162a"
      unitRef="U_USD">3149000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_2b5d867d-100c-4015-abf2-3eec68c317dc"
      unitRef="U_USD">3244000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_5b34a016-8184-46ff-96e7-24be2500f296"
      unitRef="U_USD">3135000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_572f979e-faf6-466a-a5cf-c516166e304d"
      unitRef="U_USD">8686000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_c7b4faf0-f78d-4862-bdea-69f213df6396"
      unitRef="U_USD">22502000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_bd0558df-510e-4edd-81b5-3079f091b1e2"
      unitRef="U_USD">6054000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_1546f684-c45b-4fb6-a03c-2abe02eb0ae9"
      unitRef="U_USD">16448000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_9bc9f3b1-ab11-4a22-bba1-faad915e3d60"
      unitRef="U_USD">1231000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_5142529a-c1b9-4b2f-a4b3-cf12b2e23908"
      unitRef="U_USD">15217000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_1844990d-6eb5-4b0c-b17c-31545d840c2d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;10. Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;t record any income tax expense during the years ended December 31, 2021 and 2020. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company&#x2019;s ability to realize these assets. All losses before income taxes arose in the United States.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The effective tax rate of the Company&#x2019;s income tax expense (benefit) differs from the federal statutory rate as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.429%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:11.297%;"/&gt;
        &lt;td style="width:3.384%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:11.297%;"/&gt;
        &lt;td style="width:3.384%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;23.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;22.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The tax effects of temporary differences that give rise to significant components of the deferred taxes are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.081%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.912%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.912%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;37,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Intangible asset basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;54,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;50,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total net deferred tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Income Taxes,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#x2019;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million during 2021 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million during the year ended December 31, 2020. The increase in the valuation allowance for each of the years ended December 31, 2021 and 2020 was primarily driven by net losses incurred, stock-based compensation expense and tax credits generated within the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company had net operating loss (&#x201c;NOL&#x201d;) carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;177.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;100.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as of December 31, 2021 and 2020, respectively, available to reduce future taxable income, if any, for federal income tax purposes. $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million of the federal NOL carryforwards expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and the remaining $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;168.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million carryforward indefinitely.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2021 and 2020, the Company had federal research and development credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively, and state research and development credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively, available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. The federal credit carryforwards begin expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and the state credits carryforward &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;indefinitely&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Utilization of the NOL carryforwards and research credit carryforwards may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in the expiration of the NOL and tax credit carryforwards before they are utilized. The Company has experienced ownership changes in the past as a result of its Series B redeemable convertible preferred stock financing. As a result of the ownership changes, some of the tax attribute carryforwards may be permanently limited as they will expire unused and such amounts are excluded from our NOLs as of December 31, 2021. Subsequent ownership changes may result in additional limitations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The reconciliation of the beginning and ending unrecognized tax benefits amounts is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.722%;"/&gt;
        &lt;td style="width:1.927%;"/&gt;
        &lt;td style="width:1.542%;"/&gt;
        &lt;td style="width:16.039%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Unrecognized&lt;br/&gt;Income Tax&lt;br/&gt;Benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Additions for current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Additions for current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The entire amount of the unrecognized tax benefits would not impact the Company&#x2019;s effective tax rate if recognized. During the years ended December 31, 2021 and 2020, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;t recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will materially increase or decrease during the next 12 months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company files income tax returns in the U.S. federal and California tax jurisdictions. In general, the Company is no longer subject to tax examination by the Internal Revenue Service or state taxing authorities for years before 2017. Although the federal and state statutes are closed for purposes of assessing additional income tax in those prior years, the taxing authorities may still make adjustments to the NOL and credit carryforwards used in open years. Therefore, the tax statutes should be considered open as it relates to the NOL and credit carryforwards used in open years. The Company has no ongoing income tax examinations by tax authorities at this time.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was signed into law. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The CARES Act changed certain provisions of the Tax Act. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminated the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021 and increased the amount of interest expense that may be deducted to 50% of adjusted taxable income for taxable years beginning in 2019 or 2020.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; The Company evaluated the impact of the CARES act on its tax provision and concluded that there was not a material impact.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;On December 21, 2020, the U.S. president signed into law the Consolidated Appropriations Act, 2021 which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant. The Company evaluated the impact of the Consolidated Appropriations Act, 2021 on its tax provision and concluded that there was not a material impact.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;On March 11, 2021, the American Rescue Plan Act was signed into law and contained provisions relating to extending the Employee Retention Tax Credit, additional funding for the PPP loan and Economic Injury Disaster Loans, as well as expanding the covered employees under Section 162(m) for tax years beginning after December 31, 2026. The Company does not expect the American Rescue Plan will have a material impact to its current income tax provision.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;On November 15, 2021, the Infrastructure Investment and Jobs Act was signed into law and contained several tax provisions including changes to the Employee Retention Tax Credit after September 30, 2021. The Company does not expect the Infrastructure Investment and Jobs Act will have a material impact to its income tax provision.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_6e121d45-1019-4ada-99e3-ce7d54debfe1"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_68bcae6c-40a3-4a5d-bc79-3bcd2bb3a85a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_cec1d1ab-26df-4adb-abc9-fa0b5724938d">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The effective tax rate of the Company&#x2019;s income tax expense (benefit) differs from the federal statutory rate as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.429%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:11.297%;"/&gt;
        &lt;td style="width:3.384%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:11.297%;"/&gt;
        &lt;td style="width:3.384%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;23.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;22.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="3"
      id="F_81f64c70-6f6f-4377-9082-7ad6cb5753bb"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_a93ec866-2d29-40d3-ba09-8ba416800945"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="3"
      id="F_354c2613-7e65-4d19-9faa-5ec38e534c38"
      unitRef="U_pure">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="3"
      id="F_ffe8ece5-4926-459a-87e4-dfd5182ecdfb"
      unitRef="U_pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="3"
      id="F_a88ca701-2786-42a8-bf6b-041a2914cd91"
      unitRef="U_pure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="3"
      id="F_ed2aea53-7465-47ea-866d-888cdce312a5"
      unitRef="U_pure">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="3"
      id="F_6e5ad598-8086-4ca6-9232-66b5b3263fe0"
      unitRef="U_pure">-0.235</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="3"
      id="F_4a220096-9315-45b1-85bc-090d86919ee6"
      unitRef="U_pure">-0.221</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="3"
      id="F_bdd83099-c679-4806-95d8-9c48cdfe2957"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="3"
      id="F_0fff3ebf-6cf6-4787-af0c-a5cdf02b5a9a"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_ee9df346-49a7-46dd-b246-a0a59b76b1bf">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The tax effects of temporary differences that give rise to significant components of the deferred taxes are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.081%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.912%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.912%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;37,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;21,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Intangible asset basis&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;54,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;50,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;32,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total net deferred tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_bf4c4b95-f618-4643-9ef3-c5920f25c41a"
      unitRef="U_USD">37295000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_46cc3001-e2af-4283-a5e7-760fbcec2867"
      unitRef="U_USD">21132000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_f67e5cdd-9d15-4b86-829f-6e2e2c1d7483"
      unitRef="U_USD">937000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_d17427a3-ac44-4cd2-ad96-5ef0416a6235"
      unitRef="U_USD">422000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_1a30dfe8-b40c-4dbe-9a34-7ae763b51027"
      unitRef="U_USD">993000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_1da83b6e-0c59-41ad-b9a3-b495524ad9d1"
      unitRef="U_USD">3111000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_adc4195a-e627-4717-92fb-00338f557329"
      unitRef="U_USD">8078000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_ea914ef5-d076-4bdf-aa0f-43954da85d01"
      unitRef="U_USD">6018000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_4234f2ca-6452-40ad-b541-30f72f9dbee2"
      unitRef="U_USD">2618000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_a1351eab-56e9-4cac-94ad-84bb24d7150f"
      unitRef="U_USD">1151000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_0ed4c5f2-5c79-44d6-9fb8-7ccde2e2b3e1"
      unitRef="U_USD">907000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_c6d52395-f8e9-42dc-a804-48668350fe6c"
      unitRef="U_USD">977000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <fdmt:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_c107e1ba-4445-443e-921d-40548857d7bd"
      unitRef="U_USD">3460000</fdmt:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_e211ea3d-36bc-4893-8db8-36f116851f78"
      unitRef="U_USD">54288000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_b9e5b6fd-804e-4a05-9ae3-bc047ad7632b"
      unitRef="U_USD">32811000</us-gaap:DeferredTaxAssetsGross>
    <fdmt:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_ac748a02-2e95-4c50-8c50-14090fd9defb"
      unitRef="U_USD">3064000</fdmt:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_6fea1618-a8d7-4865-b223-6ca2ff9796fd"
      unitRef="U_USD">992000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_6bfcdfe3-2ede-4523-9420-d898ce545feb"
      unitRef="U_USD">4056000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_b3485fd6-9cc3-46fa-8b83-121457e2d946"
      unitRef="U_USD">50232000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_69943c47-909c-4b2d-b2a1-5aae5395d830"
      unitRef="U_USD">32811000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-5"
      id="F_ba3e45e4-c843-4a03-b565-b757ccb365cd"
      unitRef="U_USD">17400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-5"
      id="F_3bc8955f-1ca2-4635-a50d-c9268b6701cf"
      unitRef="U_USD">12500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-5"
      id="F_213e6572-891f-4bc6-ab50-80acdb31db3e"
      unitRef="U_USD">177500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-5"
      id="F_538d6b66-6a1f-4e6c-8220-59523b6dafb1"
      unitRef="U_USD">100600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_da1fd0ee-2a34-41fc-9e75-f7316c4ea264"
      decimals="-5"
      id="F_4dc0a330-8513-4d4a-a447-80e2e7ec2261"
      unitRef="U_USD">9500000</us-gaap:OperatingLossCarryforwards>
    <fdmt:OperatingLossCarryforwardsExpirationYear
      contextRef="C_3af24779-857a-4d8c-8ca2-daaa220bb8ed"
      id="F_6add8906-6c62-4b1f-a4eb-63af932bc43a">2037</fdmt:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_da1fd0ee-2a34-41fc-9e75-f7316c4ea264"
      decimals="-5"
      id="F_0c8ac0d4-a356-4ef8-baa9-c75f74235c39"
      unitRef="U_USD">168000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_da1fd0ee-2a34-41fc-9e75-f7316c4ea264"
      decimals="-5"
      id="F_0ae6d2c6-c363-4d4e-952c-19b79577b4c1"
      unitRef="U_USD">8600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_a7b36ed3-eaae-482f-82c3-37d423f79c62"
      decimals="-5"
      id="F_fb6d18e2-a296-4237-b43f-5e07e6c6407e"
      unitRef="U_USD">5700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_3efe0308-17fb-42e4-98f2-745c68439aa1"
      decimals="-5"
      id="F_c4d61fe1-6511-4d6e-9e38-a78ee90130b4"
      unitRef="U_USD">5900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_49564e79-c36e-4c78-aae6-91ada470dc34"
      decimals="-5"
      id="F_d97da949-d676-433b-946e-0da846a6d48b"
      unitRef="U_USD">4300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <fdmt:TaxCreditCarryforwardBeginningExpirationYear
      contextRef="C_3af24779-857a-4d8c-8ca2-daaa220bb8ed"
      id="F_fcb9177c-acaa-4e8b-bdb3-ab21a0719493">2035</fdmt:TaxCreditCarryforwardBeginningExpirationYear>
    <fdmt:TaxCreditCarryforwardExpirationDescription
      contextRef="C_0befc9ee-bbe3-4743-91fb-e5d8d3675f92"
      id="F_749f4c31-27ad-4bfc-b161-87102a3a8004">indefinitely</fdmt:TaxCreditCarryforwardExpirationDescription>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_9a4315ba-6950-4ad5-9ffb-ff354bbf877e">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The reconciliation of the beginning and ending unrecognized tax benefits amounts is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.722%;"/&gt;
        &lt;td style="width:1.927%;"/&gt;
        &lt;td style="width:1.542%;"/&gt;
        &lt;td style="width:16.039%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Unrecognized&lt;br/&gt;Income Tax&lt;br/&gt;Benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Additions for current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Additions for current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"
      decimals="-3"
      id="F_cc0709f7-adef-4c4c-a506-ebd855713b0a"
      unitRef="U_USD">1566000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_70a8f81b-7711-40aa-a6b5-764bd1fd3a8d"
      unitRef="U_USD">1729000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_9292fffd-8152-41b4-8807-c66c71ab7b26"
      unitRef="U_USD">72000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_cd410d17-8ea1-4990-aca8-8332de9d367e"
      unitRef="U_USD">3367000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_b1666a41-061d-4574-abac-2695459aba6a"
      unitRef="U_USD">2219000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_b227918f-8816-4acb-bd6c-f22d83bee72f"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_6d4fa379-c897-410b-9cbd-d7b897516feb"
      unitRef="U_USD">5586000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_553c5206-d5b0-4a1e-b032-f337bee1c918"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_c42afef0-1e6c-45ea-ba4f-f59cc4b0a81f"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <fdmt:CARESActReliefDescription
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_ed8f9a8f-0481-4321-b5cf-b39baab1990b">The CARES Act changed certain provisions of the Tax Act. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminated the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021 and increased the amount of interest expense that may be deducted to 50% of adjusted taxable income for taxable years beginning in 2019 or 2020.</fdmt:CARESActReliefDescription>
    <fdmt:TemporaryEquityDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_9be8fbde-8236-49d1-9c0a-b7b35f4e84f6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;11. Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2019, redeemable convertible preferred stock consisted of the following (in thousands, except per share and share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:14.981%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:12.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.541%;"/&gt;
        &lt;td style="width:11.985%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:16.982%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.541%;"/&gt;
        &lt;td style="width:11.996%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:2.675%;"/&gt;
        &lt;td style="width:14.446%;"/&gt;
        &lt;td style="width:0.781%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Shares&lt;br/&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Original&lt;br/&gt;Issuance price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Shares Issued&lt;br/&gt;and Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Liquidation&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Proceeds Net of&lt;br/&gt;Issuance cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;909,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;909,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Series A-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,311,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,311,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Series B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,154,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,154,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;90,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;84,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:middle;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,375,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,375,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;108,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;102,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In April and June of 2020, the Company issued a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,200,353&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of Series C redeemable convertible preferred stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;72.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million. Upon the closing of the Company's IPO on December 15, 2020, all outstanding redeemable convertible preferred stock automatically converted into shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of redeemable convertible preferred stock outstanding as of December 31, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Funding Agreement with CFF &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2014; In April 2020, CFF made a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million investment in the Company's Series C redeemable convertible preferred stock financing. In return for the investment, CFF received shares of Series C redeemable convertible preferred stock, and the Company and CFF entered into a Funding Agreement ("the Funding Agreement"). Pursuant to the terms of the Funding Agreement, except in the event of a technical failure, the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million received from CFF will be used to advance the development program for 4D-710, the Company's lead product in cystic fibrosis, or any other therapeutic approved by the Program Advisory Group ("PAG") to alleviate pulmonary complications of cystic fibrosis ("the Funding Agreement Product").&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;CFF committed to provide an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million of funding upon acceptance of an Investigational New Drug ("IND") application or its equivalent to allow for human testing of the Funding Agreement Product ("Acceptance").&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The IND was cleared by the U.S. Food and Drug Administration in October 2021, and CFF made the additional investment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million in cash for the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;125,715&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company's common stock to CFF.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Except in the event of a technical failure, the Company is committed to providing an amount equal to the funding provided by CFF to be used solely to advance the Funding Agreement Product. A technical failure is defined as a determination by the Company, after consultation with and approval of the PAG that (i) the Funding Agreement Product has failed to reach its intended endpoints due to safety issues, lack of sufficient transgene expression and/or efficacy, each despite commercially reasonable efforts and (iii) the exercise of further commercially reasonable efforts is unlikely to correct such failure. Under the terms of the Funding Agreement, neither the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million investment in the Series C redeemable convertible preferred stock, which converted to common stock as of December 31, 2020, nor the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million of funding upon Acceptance are restricted as to withdrawal or usage.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</fdmt:TemporaryEquityDisclosureTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_9bed7306-e8ac-47f6-9b61-3a810db78a9e">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2019, redeemable convertible preferred stock consisted of the following (in thousands, except per share and share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:14.981%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:12.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.541%;"/&gt;
        &lt;td style="width:11.985%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:16.982%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.541%;"/&gt;
        &lt;td style="width:11.996%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:2.675%;"/&gt;
        &lt;td style="width:14.446%;"/&gt;
        &lt;td style="width:0.781%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Shares&lt;br/&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Original&lt;br/&gt;Issuance price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Shares Issued&lt;br/&gt;and Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Liquidation&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Proceeds Net of&lt;br/&gt;Issuance cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;909,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;909,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Series A-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,311,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,311,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Series B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,154,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5,154,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;90,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;84,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:middle;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,375,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,375,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;108,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;102,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f"
      decimals="INF"
      id="F_90347b89-3ed1-42e4-ac8f-1893c7636f44"
      unitRef="U_shares">909312</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:SharePrice
      contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f"
      decimals="INF"
      id="F_fdc45cf8-0289-4e83-a98d-9f3de404a82e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.70</us-gaap:SharePrice>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f"
      decimals="INF"
      id="F_f82b029d-ec64-40cf-a0c7-68ec0f3b0a25"
      unitRef="U_shares">909312</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f"
      decimals="INF"
      id="F_3501e2fe-8c6e-4915-b0bc-36f78d6cdd54"
      unitRef="U_shares">909312</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f"
      decimals="-3"
      id="F_dbc7d53a-dde8-4c4e-9ad7-f4fac87bb4a4"
      unitRef="U_USD">7001000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_2c8b71c8-25f6-4b37-939e-19643fcd4b9f"
      decimals="-3"
      id="F_0d00704b-eb8f-4ec2-9b1a-25ddcdf36bb6"
      unitRef="U_USD">6960000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706"
      decimals="INF"
      id="F_45599f15-b200-4f20-aec8-8de31392f6dd"
      unitRef="U_shares">1311687</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:SharePrice
      contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706"
      decimals="INF"
      id="F_b4e1ff7e-0cb2-4681-8919-cfd17e3ee577"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.84</us-gaap:SharePrice>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706"
      decimals="INF"
      id="F_2ad1f5ef-d8b6-4b7a-83ba-e05ce7d8acfa"
      unitRef="U_shares">1311687</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706"
      decimals="INF"
      id="F_495b6c7b-c270-4b49-a489-0d7a3af8a7d6"
      unitRef="U_shares">1311687</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706"
      decimals="-3"
      id="F_ee77f994-d63e-43b1-b4f3-f7c14f2c676a"
      unitRef="U_USD">11595000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_8fc037ec-2e59-4454-98a8-7a703d7f1706"
      decimals="-3"
      id="F_6aaaca1f-eeeb-4246-a1bc-f462836a6a1f"
      unitRef="U_USD">11548000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77"
      decimals="INF"
      id="F_0ca8d32d-4d91-40e0-857e-ab8f94729d48"
      unitRef="U_shares">5154639</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:SharePrice
      contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77"
      decimals="INF"
      id="F_5c69965b-d250-441e-9c4f-cb3aa92f567f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.46</us-gaap:SharePrice>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77"
      decimals="INF"
      id="F_a74128ef-2fc6-456c-8ea5-c8ffd5b0ed99"
      unitRef="U_shares">5154632</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77"
      decimals="INF"
      id="F_155fb8a1-fefa-442d-ac5b-b7d4797692e8"
      unitRef="U_shares">5154632</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77"
      decimals="-3"
      id="F_d5d6856a-474e-441f-be30-529ec96240d5"
      unitRef="U_USD">90000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_e5c170a8-c607-4fca-ab72-c7b6add90b77"
      decimals="-3"
      id="F_661ab383-328e-4013-8bd8-a61e684803b3"
      unitRef="U_USD">84472000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"
      decimals="INF"
      id="F_d6867444-bf83-4ad5-bdfe-c21b55f4f7ef"
      unitRef="U_shares">7375638</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"
      decimals="INF"
      id="F_35a4b7af-742c-417f-80ab-bfc334fded49"
      unitRef="U_shares">7375631</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"
      decimals="INF"
      id="F_8e81bef4-5659-477b-974a-023613db582f"
      unitRef="U_shares">7375631</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"
      decimals="-3"
      id="F_03701b7d-da35-4fee-94c5-686428f73e66"
      unitRef="U_USD">108596000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_034d1a9d-6368-4975-b6f6-9934f04efcc1"
      decimals="-3"
      id="F_e37777d5-0d12-4dfb-9859-2d908ffc1df5"
      unitRef="U_USD">102980000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_893705a7-019f-4880-8fba-130e464feaa6"
      decimals="INF"
      id="F_fa2d0b54-42b7-4d16-b63e-e9367c167d4f"
      unitRef="U_shares">4200353</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SharePrice
      contextRef="C_893705a7-019f-4880-8fba-130e464feaa6"
      decimals="INF"
      id="F_8dfdcedb-406d-40ab-aea8-a06c5db22731"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_b20ba5e2-9962-466b-938b-74b85690f0f0"
      decimals="-5"
      id="F_d4110d5e-701c-4e0c-a0a3-981a9672d63d"
      unitRef="U_USD">72500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_f3739e33-d3f4-4f2b-8774-6c87ccd17eea"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_9e6231ea-e398-4095-b6a1-1e695c8b0912"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_40669389-a7ad-4950-93fb-0a77d4c10a4c"
      decimals="-5"
      id="F_4bcdc944-bc1e-4513-a2f8-d2442cf15ffd"
      unitRef="U_USD">10000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_40669389-a7ad-4950-93fb-0a77d4c10a4c"
      decimals="-5"
      id="F_73c30aa9-1063-406e-8e7c-552912ece342"
      unitRef="U_USD">10000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <fdmt:AdditionalFundingCommitted
      contextRef="C_5d804358-02f5-4c3e-b83a-38d656050858"
      decimals="-5"
      id="F_a85bef32-742b-4851-b99c-fc60ea6fb2e7"
      unitRef="U_USD">4000000.0</fdmt:AdditionalFundingCommitted>
    <fdmt:AdditionalInvestmentInCash
      contextRef="C_20cd7796-d782-44fd-9c7c-a0d741c85cea"
      decimals="-5"
      id="F_e0d9a29f-d089-431d-964a-038512ff5420"
      unitRef="U_USD">4000000.0</fdmt:AdditionalInvestmentInCash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_963e934f-bc6b-4dc6-a918-158ec67c6212"
      decimals="INF"
      id="F_2e9f1b3d-a50c-4a9b-b83e-aa283999c35f"
      unitRef="U_shares">125715</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_40669389-a7ad-4950-93fb-0a77d4c10a4c"
      decimals="-5"
      id="F_157ea075-404c-4a49-8d91-c9be59ca797b"
      unitRef="U_USD">10000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <fdmt:AdditionalFundingCommitted
      contextRef="C_5d804358-02f5-4c3e-b83a-38d656050858"
      decimals="-5"
      id="F_afedce41-1e99-4b54-84a9-edc96f25b09b"
      unitRef="U_USD">4000000.0</fdmt:AdditionalFundingCommitted>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_e4367f43-6b98-408c-9632-981eb7837618">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;12. Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of each of December 31, 2021 and 2020, the Company&#x2019;s certificate of incorporation authorized the Company to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;300,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock, at the par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share. The holder of each share of common stock is entitled to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;one vote per share&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Common stockholders are entitled to dividends if and when declared by the board of directors, subject to the prior rights of the redeemable preferred stockholders. As of December 31, 2021 and 2020, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; dividends on common stock had been declared by the board of directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2021 and 2020, the Company has reserved common stock, on an as-converted basis, for future issuance as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.356%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:13.674%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:13.674%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Issuance of common stock under the 2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,690,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,606,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Issuance of common stock under the Employee Stock Share Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;498,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;252,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Exercise of options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,881,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,194,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Exercise of common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;53,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;98,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,123,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,151,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_1b48eaee-274c-48b6-9f49-38b47b262447"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_1faac0f2-2b25-4eb9-89fa-5483a626a81e"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_3835f731-dbaf-43f6-9953-797a2863a48a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_635ea2bf-8a3e-426b-94ec-74205487d6dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_6c1d29ac-cbb0-40c0-b696-92d096d0891d">one vote per share</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_d890d2ac-436a-4287-843f-f12cfc667cd2"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_e4097c81-3392-4867-bfbd-757a3d58458b"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <fdmt:ScheduleOfCommonShareReservedForFutureIssuance
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_df8237d6-e583-4b1d-9b83-56325f48cbc6">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;As of December 31, 2021 and 2020, the Company has reserved common stock, on an as-converted basis, for future issuance as follows: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.356%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:13.674%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
        &lt;td style="width:13.674%;"/&gt;
        &lt;td style="width:0.771%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Issuance of common stock under the 2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,690,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,606,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Issuance of common stock under the Employee Stock Share Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;498,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;252,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Exercise of options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,881,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,194,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Exercise of common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;53,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;98,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;7,123,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,151,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</fdmt:ScheduleOfCommonShareReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_84f39b44-5422-454e-b43f-0e6094e9de94"
      decimals="INF"
      id="F_58f70912-13ae-4a98-82c5-b0aeb0a7c49c"
      unitRef="U_shares">2690097</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b47d4e9a-a1c9-42dc-ad5a-046908180aa8"
      decimals="INF"
      id="F_5ba942a7-c6d6-4326-a9cf-b9099d0cb8a4"
      unitRef="U_shares">2606546</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_22fd50bb-c8c9-4334-a1b4-281b0e9b354f"
      decimals="INF"
      id="F_badac09f-5f0a-43d1-9bfc-e59f568c6961"
      unitRef="U_shares">498747</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_79e057b2-8bbb-4970-a6fe-1330e9256ec6"
      decimals="INF"
      id="F_405a79d0-772f-4907-a40d-cdd7a0dc791e"
      unitRef="U_shares">252337</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0fd3c166-54d6-4e85-a12d-b5c2352e23fe"
      decimals="INF"
      id="F_f4711f51-d646-4188-a831-2d36c24c8c96"
      unitRef="U_shares">3881274</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_229b1105-6f81-4be3-bc0e-35524c07bfa6"
      decimals="INF"
      id="F_32e8ac8f-ebf4-40d7-a448-1f73fc7f1e3d"
      unitRef="U_shares">3194113</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_614c9897-40b5-49d5-891b-2e8c91231c75"
      decimals="INF"
      id="F_c271f282-2bd1-4060-9f3a-bf73de7c1d4b"
      unitRef="U_shares">53669</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_76054bca-7f31-466a-af59-aee060457d1c"
      decimals="INF"
      id="F_343c317f-558d-455f-a684-d3272c80167a"
      unitRef="U_shares">98669</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_40354756-5166-4581-bf96-d516d0245d0f"
      unitRef="U_shares">7123787</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_c12c46b1-b9e0-4d06-bddd-c184664b1db9"
      unitRef="U_shares">6151665</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_76728b4c-ca3d-4490-a5b5-b52bde14682c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;13. Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2020 Incentive Award Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In December 2020, the Company adopted the 2020 Incentive Award Plan (&#x201c;2020 Plan&#x201d;), which became effective on December 10, 2020. The 2020 Plan initially reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,606,546&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance bonus awards, performance stock units, dividend equivalents or other stock or cash based award granted to employees, directors and consultants of the Company. The number of shares reserved for future issuance under the 2020 Plan will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company's common stock may be issued upon the exercise of incentive stock options. In 2021, an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,334,099&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock became available for issuance under the 2020 Plan, as a result of the operation of the automatic annual increase provision. All options are exercisable over a period not to exceed the contractual term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; from the date the stock options were issued. As of December 31, 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,690,097&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares available for grant under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Following the effectiveness of the 2020 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the &#x201c;2015 Plan&#x201d;). However, the 2015 Plan continues to govern the terms of options that remain outstanding under the 2015 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;2015 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The 2015 Plan&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;provided for grants of stock options, stock appreciation rights, restricted stock and restricted stock unit awards to employees, directors and consultants of the Company. As of December 31, 2021, options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,519,217&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock were outstanding under the 2015 Plan. All options are exercisable over a period not to exceed the contractual term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; from the date the stock options were issued and are granted at prices not less than the estimated fair market value of the Company&#x2019;s common stock on the grant date as determined by the board of directors. If an individual owns stock representing more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of the Company&#x2019;s outstanding shares, the exercise price of each share shall be at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of the fair market value on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; additional grants will be made under the 2015 Plan, and all outstanding grants under the 2015 Plan that are repurchased, forfeited, expire or are cancelled are returned back to the 2015 Plan and are not available for grant under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In December 2020, the Company adopted the 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;). Under the 2020 ESPP, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;252,337&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company's common stock were initially reserved for employee purchases of the Company's common stock under terms and provisions established by the Company's board of directors and approved by the Company's stockholders. The number of shares reserved for future issuance under the 2020 ESPP will increase annually on the first day of each fiscal year beginning in 2021 and ending in 2030 by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of the shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as determined by the Company's board of directors, provided, however, no more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;15,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares the Company's common stock may be issued under the 2020 ESPP. On March 28, 2022, an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of common stock became available for future issuance under the 2020 ESPP, as a result of the operation of this automatic annual increase provision.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Under the 2020 ESPP the Company's employees may purchase common stock through payroll deductions at a price equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2020 ESPP provides for a series of overlapping &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;24-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; offering periods comprising four &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; purchase periods. The initial offering period under the 2020 ESPP is longer than 24 months, commencing February 15, 2021 and ending on May 14, 2023. Contributions under the 2020 ESPP are limited to a maximum of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% of an employee's eligible compensation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table summarizes the stock options activity for the year ended December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.854%;"/&gt;
        &lt;td style="width:0.225%;"/&gt;
        &lt;td style="width:1.167%;"/&gt;
        &lt;td style="width:10.332%;"/&gt;
        &lt;td style="width:0.867%;"/&gt;
        &lt;td style="width:0.225%;"/&gt;
        &lt;td style="width:1.435%;"/&gt;
        &lt;td style="width:11.274%;"/&gt;
        &lt;td style="width:0.867%;"/&gt;
        &lt;td style="width:0.225%;"/&gt;
        &lt;td style="width:1.349%;"/&gt;
        &lt;td style="width:9.251%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:0.225%;"/&gt;
        &lt;td style="width:1.349%;"/&gt;
        &lt;td style="width:10.632%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:0.225%;"/&gt;
        &lt;td style="width:1.638%;"/&gt;
        &lt;td style="width:13.03%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Available&lt;br/&gt;for Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Outstanding&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;2,606,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;3,194,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;11.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;8.46&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;97,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Options authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;1,334,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;1,566,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;1,566,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;34.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;563,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;6.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Options expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;4,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;4,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;36.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;311,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;311,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;29.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Balances at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;2,690,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;3,881,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;19.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;7.97&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;24,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Shares exercisable, December 31,&lt;br/&gt;&#160;&#160;&#160;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;1,592,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;12.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;7.07&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;17,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Shares vested and expected to &lt;br/&gt;&#160;&#160;&#160;vest, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;3,881,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;19.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;7.97&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;24,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table is a summary of stock compensation expense for employees and nonemployees by function (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.671%;"/&gt;
        &lt;td style="width:1.424%;"/&gt;
        &lt;td style="width:1.541%;"/&gt;
        &lt;td style="width:12.706%;"/&gt;
        &lt;td style="width:0.781%;"/&gt;
        &lt;td style="width:1.424%;"/&gt;
        &lt;td style="width:1.541%;"/&gt;
        &lt;td style="width:12.706%;"/&gt;
        &lt;td style="width:0.781%;"/&gt;
        &lt;td style="width:1.424%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During the years ended December 31, 2021 and 2020 the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,521,150&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1,267,743&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; stock options to employees with a weighted-average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;34.46&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11.84&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share, respectively and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;45,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;54,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; stock options to nonemployees with a weighted-average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;47.42&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;11.05&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share, respectively. The total fair value of options vested during the years ended December 31, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. As of December 31, 2021, the unrecognized stock-based compensation expense of unvested options was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;37.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and is expected to be recognized over a weighted-average period of&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; 2.7 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Stock-based compensation expense recorded for employee options was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for the years ended December 31, 2021 and 2020, respectively. Stock-based compensation expense recorded for nonemployee consultants was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Prior to the Company&#x2019;s IPO, the fair value of the shares of common stock underlying the stock options was estimated by the board of directors at various dates considering the Company&#x2019;s most recently available third-party valuations of common stock as well as a number of objective and subjective factors including valuation of comparable companies, sales of redeemable convertible preferred stock, operating and financial performance and general and industry specific economic outlook, amongst other factors. The fair value was determined in accordance with the guidance provided by the American Institute of Certified Public Accountants&#x2019; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Subsequent to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock is determined based on its closing market price on the respective grant date.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company estimates the fair value of employee and nonemployee stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of the Company's stock options was estimated using the following assumptions for the years ended December 31, 2021 and 2020.&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:18.506%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:18.506%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:18.517%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:18.506%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:18.517%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Employee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Nonemployee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Employee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Nonemployee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.0 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;80.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;84.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;83.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;82.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;83.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;82.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;83.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Expected Term&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.  The expected term for employee options is calculated using the simplified method as the Company does not have sufficient historical information to provide a basis for estimate. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The expected term for nonemployee options is the contractual term of the options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.  The expected volatility was estimated based on a study of publicly traded peer companies as the Company did not have sufficient trading history for its common stock. The Company selected the peer group based on similarities in industry, stage of development, size and financial leverage with the Company&#x2019;s principal business operations. For each grant, the Company measured historical volatility over a period equivalent to the expected term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.  The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues whose term is similar in duration to the expected term of the respective stock option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.  The Company has not paid and does not anticipate paying any dividends on its common stock in the future. Accordingly, the Company has estimated the dividend yield to be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5f7ac562-47e8-4c80-b681-d3d1fbda0f72"
      decimals="INF"
      id="F_c0574c5e-1f66-4721-954f-1548b42fe9db"
      unitRef="U_shares">2606546</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance
      contextRef="C_c922aa7a-0ebd-48c9-9a1f-066c43a04ba3"
      decimals="INF"
      id="F_04e86558-d168-42e0-a2f2-c02d46d0d989"
      unitRef="U_pure">0.05</fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_87233471-231c-4c4b-ba05-554ef259a531"
      decimals="INF"
      id="F_54c129e6-b10e-482d-b547-99edbb2592b6"
      unitRef="U_shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_da9eacae-140f-4ff4-bc19-21fffcc55707"
      decimals="INF"
      id="F_0eb64582-f34d-4088-84ec-22ff84d6d3a7"
      unitRef="U_shares">1334099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_7aabaf7d-fcee-40ec-a3ce-91d93ae55155"
      id="F_052bc20d-6a5a-496f-8d12-242f5cf32f87">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_da9eacae-140f-4ff4-bc19-21fffcc55707"
      decimals="INF"
      id="F_13afcfda-6b6c-41a7-8dc8-381798f9bc35"
      unitRef="U_shares">2690097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_87699b30-eed2-4ea5-86f4-0a39c1e5772e"
      decimals="0"
      id="F_9ab9d2ce-08c0-425c-9248-4a2c60ff456b"
      unitRef="U_shares">2519217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a55673c8-51f2-4439-9f29-f4ac123dd97d"
      id="F_e6d054fb-905b-4130-89d5-73e1d679f4af">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <fdmt:MinimumPercentageOfOutstandingSharesHeldByIndividual
      contextRef="C_a55673c8-51f2-4439-9f29-f4ac123dd97d"
      decimals="INF"
      id="F_5b373e00-f692-45c3-98c9-8b6ee11c8551"
      unitRef="U_pure">0.10</fdmt:MinimumPercentageOfOutstandingSharesHeldByIndividual>
    <fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum
      contextRef="C_a55673c8-51f2-4439-9f29-f4ac123dd97d"
      decimals="INF"
      id="F_16491420-d581-4d04-a16f-f342e75a92b7"
      unitRef="U_pure">1.10</fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_87699b30-eed2-4ea5-86f4-0a39c1e5772e"
      decimals="INF"
      id="F_6a0423ad-96fb-4e69-9acd-0fe51f74d50e"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_87f2bd8f-07bf-4e4e-8992-26041f581ddc"
      decimals="INF"
      id="F_3c5418f8-d2d0-478e-8b65-b8b640fc96f8"
      unitRef="U_shares">252337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_a0611f15-32cf-4702-b60f-3cf600264460"
      decimals="INF"
      id="F_d5ed3b90-c9ca-4737-afa4-a0b781b54fb4"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_26af25a4-cb52-44ca-92d6-ccc8fa01b65f"
      decimals="INF"
      id="F_c4531022-101c-46e6-ab8d-8dd3388e6824"
      unitRef="U_shares">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_bbdb060d-8326-4e8e-bfca-89985b0ee2d1"
      decimals="INF"
      id="F_1fbcc6a3-c783-45da-9cb9-570a560742f7"
      unitRef="U_shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_5dc42fe3-b34c-426f-a35e-e9d6777af922"
      decimals="INF"
      id="F_d8115124-ebe2-40da-92cb-0dc34fd5d609"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod
      contextRef="C_5dc42fe3-b34c-426f-a35e-e9d6777af922"
      id="F_590c5746-1d09-42cc-908c-46fab70f964a">P24M</fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod>
    <fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod
      contextRef="C_5dc42fe3-b34c-426f-a35e-e9d6777af922"
      id="F_db277b06-2014-48c1-a3d7-40bd3a2919f3">P6M</fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_87f2bd8f-07bf-4e4e-8992-26041f581ddc"
      decimals="INF"
      id="F_0bca7b3e-26fe-459e-8d9d-117f96eb47cc"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_e50467e6-ed6f-4185-9c5d-2ab353119547">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table summarizes the stock options activity for the year ended December 31, 2021:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.854%;"/&gt;
        &lt;td style="width:0.225%;"/&gt;
        &lt;td style="width:1.167%;"/&gt;
        &lt;td style="width:10.332%;"/&gt;
        &lt;td style="width:0.867%;"/&gt;
        &lt;td style="width:0.225%;"/&gt;
        &lt;td style="width:1.435%;"/&gt;
        &lt;td style="width:11.274%;"/&gt;
        &lt;td style="width:0.867%;"/&gt;
        &lt;td style="width:0.225%;"/&gt;
        &lt;td style="width:1.349%;"/&gt;
        &lt;td style="width:9.251%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:0.225%;"/&gt;
        &lt;td style="width:1.349%;"/&gt;
        &lt;td style="width:10.632%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
        &lt;td style="width:0.225%;"/&gt;
        &lt;td style="width:1.638%;"/&gt;
        &lt;td style="width:13.03%;"/&gt;
        &lt;td style="width:0.61%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Available&lt;br/&gt;for Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Outstanding&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;2,606,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;3,194,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;11.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;8.46&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;97,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Options authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;1,334,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;1,566,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;1,566,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;34.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;563,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;6.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Options expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;4,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;4,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;36.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;311,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;311,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;29.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Balances at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;2,690,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;3,881,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;19.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;7.97&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;24,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Shares exercisable, December 31,&lt;br/&gt;&#160;&#160;&#160;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;1,592,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;12.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;7.07&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;17,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;Shares vested and expected to &lt;br/&gt;&#160;&#160;&#160;vest, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;3,881,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;19.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;7.97&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:8.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"&gt;24,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_496c064a-a099-494d-9dcf-209ddaf9e905"
      unitRef="U_shares">2606546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_c37d5d8f-2ca5-43ab-9aea-93ee955ac292"
      unitRef="U_shares">3194113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="2"
      id="F_05cf165e-ee79-4098-a436-4acca00dd4cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      id="F_1c01fc38-cdb4-4342-9d8c-2d0768373af9">P8Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-3"
      id="F_9d46f5f5-fa42-4fca-8f99-5f6bf3e1896f"
      unitRef="U_USD">97105000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_828bef5a-856c-4ab2-9522-8d019081d451"
      unitRef="U_shares">1334099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_00ae9c83-ac57-4065-a641-1ba3e730372c"
      unitRef="U_shares">1566150</fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_5ac50414-b0af-4b5f-9384-95c3d78cec3f"
      unitRef="U_shares">1566150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="2"
      id="F_bc116b5e-cbca-4f75-aa4f-0ec08e36affc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">34.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_d803e3b5-6c8a-4969-9fc1-59201e3eba24"
      unitRef="U_shares">563387</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="2"
      id="F_1bce6bc1-0889-47b3-bbab-24852aa2b466"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_5e17d572-2b9f-44d7-b06e-590aa839d4a2"
      unitRef="U_shares">4324</fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_d982f946-efbe-4468-b162-474a42f8c06d"
      unitRef="U_shares">4324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="2"
      id="F_10373e25-5cfe-41b2-8d18-e622d6d97cc0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">36.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_6fc103a4-fed4-429d-bb67-ee5c4d5f1439"
      unitRef="U_shares">311278</fdmt:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_49c0dab8-9044-42c2-8ddb-c05cf11b1cbb"
      unitRef="U_shares">311278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="2"
      id="F_c6960332-df40-4aef-b711-dd38291e2827"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">29.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_9659f0a8-a870-4e0d-b8c6-6931f68cd69e"
      unitRef="U_shares">2690097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_62d0707b-064a-4344-bf16-426aed159729"
      unitRef="U_shares">3881274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="2"
      id="F_8bcd202d-61fd-4ecd-9646-76d077c4ee75"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_ec932bff-78c4-41e2-9c81-853571879787">P7Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_f46325b0-074d-4aeb-93d1-ff4ee76778e3"
      unitRef="U_USD">24666000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_8fd5ac3c-0206-496c-9a2a-8f4cce32bebb"
      unitRef="U_shares">1592139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="2"
      id="F_4a48654e-208e-4a09-ac09-ce7f5bfa8d58"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_07237b00-8582-4bcc-a26c-8d89bb49f05d">P7Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_781a4cff-f8a7-4adf-a77f-64a1912419cb"
      unitRef="U_USD">17280000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="INF"
      id="F_ffb2923d-3435-409e-a02b-2ccd407787c7"
      unitRef="U_shares">3881274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="2"
      id="F_2e016c50-ae7d-4303-8d95-133f525767d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_5fc5a0a8-abe9-4c9f-9453-1fb21c5d4bdd">P7Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-3"
      id="F_3d17a2f5-337d-4563-b59b-b9d5f4972206"
      unitRef="U_USD">24666000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_177f7628-9184-4ff2-a315-55fa67f4b4d2">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table is a summary of stock compensation expense for employees and nonemployees by function (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.671%;"/&gt;
        &lt;td style="width:1.424%;"/&gt;
        &lt;td style="width:1.541%;"/&gt;
        &lt;td style="width:12.706%;"/&gt;
        &lt;td style="width:0.781%;"/&gt;
        &lt;td style="width:1.424%;"/&gt;
        &lt;td style="width:1.541%;"/&gt;
        &lt;td style="width:12.706%;"/&gt;
        &lt;td style="width:0.781%;"/&gt;
        &lt;td style="width:1.424%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;13,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e63d3fbd-6765-47dd-a387-c3545c1942c5"
      decimals="-3"
      id="F_dcfc7b83-583e-4092-8b87-1e37e299c72c"
      unitRef="U_USD">6847000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e44911fe-c20f-4f88-b1c1-84fcf30c91f4"
      decimals="-3"
      id="F_45a96e4f-8dad-4d50-b80a-32dd88c92fc0"
      unitRef="U_USD">2670000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_649adcbd-b0e6-4117-97c9-7ba0549ac8dd"
      decimals="-3"
      id="F_1f138c00-c53b-49a2-8b41-71d5732a1f14"
      unitRef="U_USD">6952000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7d63139e-3006-4754-b5ec-c678676f6695"
      decimals="-3"
      id="F_9c7ffd73-fe00-431f-9777-de895db5a6e8"
      unitRef="U_USD">2314000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_dd3bed8d-cf1c-49e2-a389-7e28c44e31f4"
      unitRef="U_USD">13799000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_a3108fc0-d185-4523-aec4-f007dad60079"
      unitRef="U_USD">4984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e"
      decimals="INF"
      id="F_99c77ba9-dc1c-48b1-a5bf-6cc313d6a748"
      unitRef="U_shares">1521150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1"
      decimals="INF"
      id="F_9fa66707-4410-4827-bf24-81eafe676da3"
      unitRef="U_shares">1267743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e"
      decimals="2"
      id="F_2c6a4420-df8f-46fd-ba3e-5ed766459cf4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">34.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1"
      decimals="2"
      id="F_fe9a2032-9160-42f7-b57c-4535ba4ad8d7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93"
      decimals="INF"
      id="F_b818a15c-1dc9-42db-ac5e-28be4e38edf9"
      unitRef="U_shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4"
      decimals="INF"
      id="F_2d2d58f0-ea4a-400f-87a3-7366f46532ca"
      unitRef="U_shares">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93"
      decimals="2"
      id="F_55ff7fbd-b2b0-4266-84e3-ae6480ff83e7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">47.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4"
      decimals="2"
      id="F_1691a14c-afa9-4cc7-a8bc-b199d27cb68c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-5"
      id="F_f0e0b9a7-9a4b-406d-b6d3-86cde1319384"
      unitRef="U_USD">13800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-5"
      id="F_a0c48a39-206d-4334-9c04-acc05ca2ee27"
      unitRef="U_USD">5000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-5"
      id="F_e52647e9-32a3-42d6-99f1-d0658392ef81"
      unitRef="U_USD">37700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_669f6064-583c-483d-92dd-91cb9cdc3fa4">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e"
      decimals="-5"
      id="F_f3221b54-143d-446a-9b3b-3c2b8f8a994a"
      unitRef="U_USD">13300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1"
      decimals="-5"
      id="F_af6f4f13-33e9-42d3-ad96-52fe8b66d35a"
      unitRef="U_USD">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93"
      decimals="-5"
      id="F_b7d7b276-23c4-48d9-a264-75f77be91fa6"
      unitRef="U_USD">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4"
      decimals="-5"
      id="F_3b40fe98-1924-4baa-8543-47aeb2d0690f"
      unitRef="U_USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_854479c6-2140-40a8-8a73-dd3e9b8e0829">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company estimates the fair value of employee and nonemployee stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee options is recognized on a straight-line basis over the requisite service period of the awards. The fair value of the Company's stock options was estimated using the following assumptions for the years ended December 31, 2021 and 2020.&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:18.506%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:18.506%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:18.517%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:18.506%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:1.242%;"/&gt;
        &lt;td style="width:18.517%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Employee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Nonemployee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Employee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Nonemployee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;5.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6.0 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;80.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;84.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;83.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;82.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;83.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;82.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;83.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f96a58ac-dc2a-4623-8894-1ced49494bd0"
      id="F_61de5221-0c2a-456e-b7be-c068fa8cd96d">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fed81344-7c82-4eb4-9718-d25d585ff1e5"
      id="F_e493bee0-9c9c-4372-a7cc-0aff96b2d78f">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93"
      id="F_957dc219-ec33-418c-83a8-c80567cd9a79">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e916e9be-dd44-4775-b1f3-058f8afa1981"
      id="F_305765d3-6d5f-43e6-b533-c1a564003f2b">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8c6ae4c6-838d-4e8a-a05e-7a077c423abd"
      id="F_4d95ecc3-37a8-486f-892e-1d98caf2e372">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4"
      id="F_fa478f47-5395-44ae-985d-9009ba747561">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e"
      decimals="3"
      id="F_426c593d-6a6d-4e00-97b0-2fe27fd70079"
      unitRef="U_pure">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e"
      decimals="3"
      id="F_b6e5ac3f-3ae9-4f39-a9fc-0a492dde3077"
      unitRef="U_pure">0.843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93"
      decimals="3"
      id="F_07da280a-0bdc-43be-ac17-3a608ffd1b86"
      unitRef="U_pure">0.835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1"
      decimals="3"
      id="F_90faf74a-abeb-4088-b7c4-ae400bb8b1f2"
      unitRef="U_pure">0.821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1"
      decimals="3"
      id="F_9489f985-ee5f-454e-b9ba-446dcc45eeb6"
      unitRef="U_pure">0.838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4"
      decimals="3"
      id="F_0039717a-b07f-46e9-b982-add6980fce4f"
      unitRef="U_pure">0.821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4"
      decimals="3"
      id="F_afa25bb4-9a99-47c3-ab49-54693a5ae10a"
      unitRef="U_pure">0.831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e"
      decimals="3"
      id="F_053c9414-8a85-4864-90fe-32d2af2ffe78"
      unitRef="U_pure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e"
      decimals="3"
      id="F_9ada536e-1e01-4a3e-b13b-61daf88c96d4"
      unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93"
      decimals="3"
      id="F_136b2db5-993b-42c5-9c57-f0a8c8ca732e"
      unitRef="U_pure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1"
      decimals="3"
      id="F_857d842e-4d2a-433a-9026-87d12a2a0026"
      unitRef="U_pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1"
      decimals="3"
      id="F_4b5d37b2-b81c-494f-901f-660647ce1e07"
      unitRef="U_pure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4"
      decimals="3"
      id="F_f7b150ff-c2f4-42ea-97ec-e2a6ba7f60cb"
      unitRef="U_pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4"
      decimals="3"
      id="F_e6efed02-1999-44be-80ae-14a6f58da712"
      unitRef="U_pure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_41177fa2-9b3f-4111-9b72-79dd315c5b6e"
      decimals="2"
      id="F_ec9f4360-a4ba-4cba-bd4b-b84ea9a99719"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_d3baf353-2444-4e1a-a27d-448df6997e93"
      decimals="2"
      id="F_fdaa87a1-7480-4360-b17b-b3d5b6a0b4a2"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_f509df6f-30cd-48cb-a9e1-308f964642f1"
      decimals="2"
      id="F_e3a7eaaf-799b-4f5a-8b89-dd67830d3fe0"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0deaebff-c017-4132-ad32-5d55ae62b6b4"
      decimals="2"
      id="F_dfeb1404-9982-41c3-8b49-2c2e8dd0bf7b"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="2"
      id="F_e2686b15-3389-418f-b548-b6b36486a7f7"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="2"
      id="F_360591e1-ba9b-425a-bc0c-495c0c2ee93c"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <fdmt:CommonStockWarrantsTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_a76e48fb-f377-4379-9c74-d99097280acb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;14. Common Stock Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In 2016, the Company issued a warrant for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;45,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company&#x2019;s common stock to a service provider with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.14&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;15,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; warrant shares become exercisable upon completion of an offering of securities in a private placement by the Company with net proceeds in excess of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; warrant shares become exercisable upon completion of an IPO by the Company. The warrant expires in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;15,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; of these warrant shares became exercisable upon the completion of the Series B financing in 2018 and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; of these warrants became exercisable upon completion of the IPO in 2020. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;45,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of this warrant were exercised in October 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In May 2018, the Company issued a warrant for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;23,669&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company&#x2019;s common stock to a service provider with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3.19&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model, expires in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and upon issuance was fully vested.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In December 2020, the Company issued a warrant for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;30,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company&#x2019;s common stock to a service provider with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;18.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share. This warrant vests over a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and expires in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. The fair value of the warrant was determined at the issuance date using the Black-Scholes option pricing model.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In April 2021, the Company issued a warrant for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;40,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; shares of the Company&#x2019;s common stock to a former employee with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;9.41&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; per share as a result of a settlement agreement with such former employee. The warrant was exercised in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;May 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;. The Company previously recorded an accrual within accrued and other current liabilities within the balance sheet at December 31, 2020 to accrue for the settlement and the related expense was recognized in general and administrative expenses for the year ended December 31, 2020. Upon the issuance of the warrant in April 2021 in connection with the settlement, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million was reclassified from accrued and other current liabilities to additional paid-in capital within the balance sheet as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company recorded less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million expense for the above warrants, within operating expenses in the statements of operations during each of the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;</fdmt:CommonStockWarrantsTextBlock>
    <fdmt:NumberOfWarrantsIssued
      contextRef="C_da021c91-4acb-426f-8a80-77705578bab8"
      decimals="INF"
      id="F_cf4ece7a-b144-4a6e-aa9b-cb0cda812926"
      unitRef="U_shares">45000</fdmt:NumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_aad92407-2080-466e-ba91-9ebcedf0142e"
      decimals="INF"
      id="F_36bfef34-d72c-4f3a-8c71-1958d3636c10"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_f1e25908-cccb-42b0-b877-3c97c0b0e8c4"
      decimals="INF"
      id="F_8ad85cf0-d9eb-4646-8d8d-71d941b07228"
      unitRef="U_shares">15000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_da021c91-4acb-426f-8a80-77705578bab8"
      decimals="-5"
      id="F_25d0135f-bfd5-4426-b1c1-b04252625462"
      unitRef="U_USD">25000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_925a7886-495a-4170-9b11-97befb205b58"
      decimals="INF"
      id="F_cf738967-ad02-4559-8a24-e36cee95e949"
      unitRef="U_shares">30000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <fdmt:WarrantExpiresYear
      contextRef="C_da021c91-4acb-426f-8a80-77705578bab8"
      id="F_b43cbaba-7d1d-4cb9-88c1-2595d2fd1beb">2023</fdmt:WarrantExpiresYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_2316f0b3-fa95-4376-836f-ea0ad0fecdf7"
      decimals="INF"
      id="F_cf9f2c13-8b4d-4f34-80e2-ff5593f91f71"
      unitRef="U_shares">15000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_925a7886-495a-4170-9b11-97befb205b58"
      decimals="INF"
      id="F_2258bf9e-a29c-42dd-885f-c3e0ae4f7655"
      unitRef="U_shares">30000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_3050ecb2-11ee-4119-a548-6cdd89f1f561"
      decimals="INF"
      id="F_19a44626-93f7-43ac-9fff-bae9bb3d1672"
      unitRef="U_shares">45000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <fdmt:NumberOfWarrantsIssued
      contextRef="C_4a6c44c3-d641-4e5e-b729-a73d0337615b"
      decimals="INF"
      id="F_48eabb48-818a-4090-a5d3-b9b450fe939c"
      unitRef="U_shares">23669</fdmt:NumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0652071b-4c72-4479-b886-fe246ac1708e"
      decimals="INF"
      id="F_111bd410-c6a2-4460-baf8-75ed917b6187"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.19</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <fdmt:WarrantExpiresYear
      contextRef="C_4a6c44c3-d641-4e5e-b729-a73d0337615b"
      id="F_d8d851a7-ba2e-402c-a1e6-eea4984e033c">2025</fdmt:WarrantExpiresYear>
    <fdmt:NumberOfWarrantsIssued
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_5f7af4c6-5118-4ff6-838f-9d5a18a205b8"
      unitRef="U_shares">30000</fdmt:NumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="INF"
      id="F_b40e2aaa-0dcf-4b64-897f-487846e3f655"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <fdmt:WarrantVestsOverPeriod
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      id="F_f7d89bce-c595-465e-801e-487ab7fde171">P4Y</fdmt:WarrantVestsOverPeriod>
    <fdmt:WarrantExpiresYear
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      id="F_f3a818c8-76f7-492b-b1c5-715124f9682c">2027</fdmt:WarrantExpiresYear>
    <fdmt:NumberOfWarrantsIssued
      contextRef="C_5b3c671f-d9c2-479a-878e-5392aef7d177"
      decimals="INF"
      id="F_2b16d311-cfd6-4a69-bb8b-b8f6d600cb35"
      unitRef="U_shares">40000</fdmt:NumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f933dccb-0084-4f9e-bd98-0601bbc462d4"
      decimals="INF"
      id="F_e4145173-c1f7-41b5-a8ca-8ac12f3f1387"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <fdmt:WarrantExercisedMonthAndYear
      contextRef="C_5b3c671f-d9c2-479a-878e-5392aef7d177"
      id="F_14fd1429-0b08-4de4-b6c7-2937a32e2fa4">2021-05</fdmt:WarrantExercisedMonthAndYear>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_899d20dc-a0cb-4505-b8f0-3ed14460cfce"
      decimals="-5"
      id="F_f3caa09d-aeef-4dd6-9790-e125dbb660f3"
      unitRef="U_USD">1100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0dd3438c-f8c5-4fe9-8672-19340e3bbb9d"
      decimals="-5"
      id="F_7c213d2a-24d8-48dc-b8d7-2028b01f8ccf"
      unitRef="U_USD">100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_363a526b-afc7-4132-8b3a-387a13ab7bb1"
      decimals="-5"
      id="F_04cd2c97-9d04-4ece-a9f9-6039458dcb87"
      unitRef="U_USD">100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_d146a0d7-1e73-45f4-8580-1cfb2b0039cb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;15. Net Loss Per Share, Basic and Diluted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.422%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.276%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.552%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.602%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.552%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;71,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;56,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted-average shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27,730,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,430,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted-average shares outstanding used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27,730,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,430,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Arial;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.98%;"/&gt;
        &lt;td style="width:2.997%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:13.509%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:1.552%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:13.37%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:1.552%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,881,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,194,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;53,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;98,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,934,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,292,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_e86ebf83-868e-4d11-b907-756b88e5c5fc">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.422%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:13.276%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.552%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:12.602%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.552%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;71,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;56,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted-average shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27,730,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,430,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Weighted-average shares outstanding used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;27,730,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;6,430,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;2.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;8.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="-3"
      id="F_00c66517-1c87-4257-8fa4-2c90f3e94a2f"
      unitRef="U_USD">-71317000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="-3"
      id="F_fd36e61f-d69f-4e26-ae74-1af7f2887bad"
      unitRef="U_USD">-56693000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="0"
      id="F_046945ff-23c5-4d1e-8263-b467f14aa219"
      unitRef="U_shares">27730420</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="0"
      id="F_8d8c7574-3f14-467b-999a-6d5dbdb31dda"
      unitRef="U_shares">6430555</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="0"
      id="F_c144d0e8-02e3-426f-9334-d75d53a103fd"
      unitRef="U_shares">27730420</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="0"
      id="F_effe1611-6b84-4e59-9acf-bf3f791dbecb"
      unitRef="U_shares">6430555</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="2"
      id="F_16efc342-c84d-4c68-87fd-0438f959c8a8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.57</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="2"
      id="F_3029ef58-fd5c-446f-b09a-6a4fbbe8e9de"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-8.82</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_3fe7230d-a99a-47bf-907d-c2507ba08f52">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.98%;"/&gt;
        &lt;td style="width:2.997%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:13.509%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:1.552%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:13.37%;"/&gt;
        &lt;td style="width:0.76%;"/&gt;
        &lt;td style="width:1.552%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,881,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,194,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;53,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;98,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,934,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3,292,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fe322eef-bf6e-4784-9f7d-22ae2b365638"
      decimals="0"
      id="F_216b4514-b963-4362-824f-dd6afd9ff072"
      unitRef="U_shares">3881274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2f3dd1a0-d4ca-4297-8f43-1b41c1131161"
      decimals="0"
      id="F_3ce97aa2-73aa-439b-8d72-e6274e3f2dc5"
      unitRef="U_shares">3194113</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_17493eda-6778-49b9-933d-bb5807fea6cc"
      decimals="0"
      id="F_4560a767-9e61-405d-b3ad-7314aefc1e43"
      unitRef="U_shares">53669</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e4af4886-82cd-4423-a392-44aee99ef576"
      decimals="0"
      id="F_39d2f24f-5edf-4f65-92e1-5823999e95f4"
      unitRef="U_shares">98669</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="0"
      id="F_bae366ad-a64a-4aaa-b68f-72a3fc0d1f06"
      unitRef="U_shares">3934943</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="0"
      id="F_727b394a-67ad-4f62-8381-f57f2b017012"
      unitRef="U_shares">3292782</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_7ea07b3c-2d84-4d28-a8bb-ccb23ae7ac22">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;16. Derivative Liability&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;The Company identified an embedded derivative resulting from the change of control provision in the CFF Agreement. Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as separate financial instruments. At the inception of the derivative in 2017, the Company recognized this derivative as a liability and revenue was reduced by the initial fair value of the derivative liability. The Company remeasures the derivative liability to fair value at each reporting period and records the change in fair value of the derivative liability as other income (expense), net. The Company uses a present value analysis with multiple scenarios, which incorporates assumptions and estimates to value the derivative instrument. The Company assesses these assumptions and estimates on a periodic basis as additional information impacting the assumptions is obtained. Estimates and assumptions impacting the fair value measurement include the change of control payment to CFF (range of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;10.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million at December 31, 2021 and December 31, 2020), the probability of a change of control event, the probability of the product achieving development or commercial status at time of change of control (range of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;17.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% at December 31, 2021 and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;12.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% at December 31, 2020) and the discount rate (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;14.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;% at December 31, 2021 and December 31, 2020). The Company determined the estimated fair value of this liability as of the inception date of the CFF Agreement and concluded that the amount was immaterial. The Company determined the fair value of this derivative liability was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <fdmt:FairValueAssumptionsChangeOfControlPayment
      contextRef="C_d2425f46-763c-4d4b-b2fc-1ca90612499e"
      decimals="-5"
      id="F_1806b053-9601-4457-b12e-a95b1a9e431b"
      unitRef="U_USD">0.0</fdmt:FairValueAssumptionsChangeOfControlPayment>
    <fdmt:FairValueAssumptionsChangeOfControlPayment
      contextRef="C_dcff2890-ab1b-4492-8304-4e459fc72f25"
      decimals="-5"
      id="F_992aa15d-d04d-405d-9986-dad451b30f79"
      unitRef="U_USD">0.0</fdmt:FairValueAssumptionsChangeOfControlPayment>
    <fdmt:FairValueAssumptionsChangeOfControlPayment
      contextRef="C_363a526b-afc7-4132-8b3a-387a13ab7bb1"
      decimals="-5"
      id="F_d5aa5939-58aa-49c9-8d5b-5a25f8a0860a"
      unitRef="U_USD">10600000</fdmt:FairValueAssumptionsChangeOfControlPayment>
    <fdmt:FairValueAssumptionsChangeOfControlPayment
      contextRef="C_0dd3438c-f8c5-4fe9-8672-19340e3bbb9d"
      decimals="-5"
      id="F_9ed848ef-cfe6-431e-a3cf-8a7645a2c0d7"
      unitRef="U_USD">10600000</fdmt:FairValueAssumptionsChangeOfControlPayment>
    <fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage
      contextRef="C_dcff2890-ab1b-4492-8304-4e459fc72f25"
      decimals="INF"
      id="F_ec956af1-710d-43f5-b529-7e13219368ac"
      unitRef="U_pure">0.048</fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage>
    <fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage
      contextRef="C_0dd3438c-f8c5-4fe9-8672-19340e3bbb9d"
      decimals="INF"
      id="F_9c28d668-515d-44a5-924b-197a757e33a4"
      unitRef="U_pure">0.172</fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage>
    <fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage
      contextRef="C_d2425f46-763c-4d4b-b2fc-1ca90612499e"
      decimals="INF"
      id="F_ebcefe0e-192e-486e-8fbb-d664d3958740"
      unitRef="U_pure">0.034</fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage>
    <fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage
      contextRef="C_363a526b-afc7-4132-8b3a-387a13ab7bb1"
      decimals="INF"
      id="F_0041cc01-cbec-4daa-9909-d9ebf3ebf242"
      unitRef="U_pure">0.123</fdmt:FairValueAssumptionsProbabilityOfChangeInControlEventPercentage>
    <fdmt:FairValueAssumptionsProbabilityOfChangeInControlDiscountRate
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      decimals="INF"
      id="F_4b5b37cc-0b6d-45e5-8f6b-d87663c05141"
      unitRef="U_pure">0.140</fdmt:FairValueAssumptionsProbabilityOfChangeInControlDiscountRate>
    <fdmt:FairValueAssumptionsProbabilityOfChangeInControlDiscountRate
      contextRef="C_c809c8ab-34c1-45aa-9199-72b4b861d30e"
      decimals="INF"
      id="F_91681762-6fc8-46eb-8a1d-5ab01fb3fa37"
      unitRef="U_pure">0.140</fdmt:FairValueAssumptionsProbabilityOfChangeInControlDiscountRate>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_46423923-3058-4aaf-ac32-c74922d40a3d"
      decimals="-5"
      id="F_2bea9d2e-e238-4f8d-aa5e-ed62a7acbe96"
      unitRef="U_USD">200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_bf1c55da-f533-4e8b-9709-41e08427872a"
      decimals="-5"
      id="F_2885585a-5b36-4898-b750-329bf360e1b5"
      unitRef="U_USD">100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_c647d8eb-7c02-4779-8dad-49bfc5871506">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;17. Related Party Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;During the years ended December 31, 2021 and 2020, the Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;85,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;93,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;, respectively, to David Schaffer, Ph.D., the co-founder, director and Chief Scientific Advisor of the Company for consulting services. In April 2019, the Company entered into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; sponsored research agreements (&#x201c;SRAs&#x201d;) with the UC Regents to conduct research in a research facility on the U.C. Berkeley campus, under the direction of Dr. Schaffer. The SRAs have a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; term ending in May 2022. Under the SRAs, the Company has an option to license (on a royalty-bearing basis) all intellectual property generated under the SRAs. The total amount the Company is committed to pay to the UC Regents under the SRAs is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, which was fully paid as of December 31, 2021. In March 2021, the Company entered into another sponsored research agreement with the UC Regents to conduct research in laboratories on the U.C. Berkeley campus that are under the direction of Dr. Schaffer and another U.C. Berkeley professor covering investigations into how machine learning approaches may enhance AAV capsid engineering (the &#x201c;Machine Learning SRA&#x201d;). Pursuant to the Machine Learning SRA, the Company has committed to pay the UC Regents a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million was paid as of December 31, 2021. The Machine Learning SRA has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; term ending in 2024. Any patent prosecution costs incurred under the SRAs will also be borne by the Company. The Company can terminate the SRAs for convenience and without cause with 60 days&#x2019; notice. While the Machine Learning SRA is between the Company and the UC Regents, the payments under the SRA will be used to fund the lab under the direction of Dr. Schaffer. As of December 31, 2021 and 2020, accounts payable to the UC Regents related to the SRAs and Machine Learning SRA was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively. In the years ended December 31, 2021 and 2020, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million, respectively, of expense related to SRAs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In August 2019, the Company and uniQure entered into the amended uniQure Agreement and the Second uniQure Agreement. Under these agreements, the Company agreed to transfer incremental rights and services to uniQure in exchange for uniQure eliminating the exclusivity clause in the uniQure Agreement and transferring other rights back to the Company. Further details and the accounting for these agreements is discussed in Note 7. As of June 17, 2020, uniQure was no longer a related party of the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_f8c80726-14a0-4e92-b15c-36f91786d60a"
      decimals="0"
      id="F_01ae6d35-49cc-4fb6-9f5a-6498eeec310b"
      unitRef="U_USD">85000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_d8cb6a3a-516a-44ff-a6c4-14639dae2312"
      decimals="0"
      id="F_ad5fd97f-c0ce-4dc3-a32b-b02de3ba60da"
      unitRef="U_USD">93000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <fdmt:NumberOfAgreementsEntered
      contextRef="C_dab250fb-28e0-4123-8e2b-eee2d878a7bb"
      decimals="INF"
      id="F_ebbf6a89-7e4a-4875-935b-75c9a84314dd"
      unitRef="U_Agreement">2</fdmt:NumberOfAgreementsEntered>
    <fdmt:TermOfAgreement
      contextRef="C_dab250fb-28e0-4123-8e2b-eee2d878a7bb"
      id="F_50642d9e-a892-4dd8-a263-16882493d220">P3Y</fdmt:TermOfAgreement>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_5f4f9f3d-c2a5-4a7a-b39c-2a675787b677"
      decimals="-5"
      id="F_78a4896c-7091-430b-8283-b7e38521887f"
      unitRef="U_USD">1500000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_43895722-c889-4f5a-86ef-d1095b190b17"
      decimals="-5"
      id="F_0edfea58-ee21-4211-a06d-1ee4d56d004a"
      unitRef="U_USD">1400000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyCosts
      contextRef="C_7407984c-b650-4ccb-99f5-f9cd63af7b7b"
      decimals="-5"
      id="F_4d4345f3-0145-481b-8cd0-79fc79d1034f"
      unitRef="U_USD">400000</us-gaap:RelatedPartyCosts>
    <fdmt:TermOfAgreement
      contextRef="C_ac7b6ce7-cd1a-4e4d-84ee-87d64c2d5f60"
      id="F_18904104-e407-4848-8f27-3210390c8abe">P3Y</fdmt:TermOfAgreement>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="C_646334cd-512e-4567-85e0-49ec256638ec"
      decimals="-5"
      id="F_96bc063e-3b4a-4057-9038-efa0abd74eca"
      unitRef="U_USD">0.0</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="C_ffdd2326-026c-4d95-8076-5a7d7c11f527"
      decimals="-5"
      id="F_ee0aa60e-857a-40cc-9f40-e7d9ceac7ef6"
      unitRef="U_USD">200000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_67c79b0f-725f-4422-a99d-21b85901d3c0"
      decimals="-5"
      id="F_151ba881-1651-415b-b366-c426aa7c9d40"
      unitRef="U_USD">900000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_d24dc914-f653-4ead-88fd-297fac82aaf8"
      decimals="-5"
      id="F_7372a372-b9ff-4200-a7ef-a503edcba042"
      unitRef="U_USD">500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_7421a1ac-23e5-447d-aabe-10f3efe826be"
      id="F_38de6bd6-f2d9-4031-ac42-19667999398f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"&gt;18. 401(k) Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;In 2014, the Company adopted a 401(k) plan for all employees who have met certain eligibility requirements. The 401(k) plan allows employees to make pre-tax and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company made contributions to the Plan for eligible participants, and recorded contribution expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Arial;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"&gt; million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_b63ba5ca-290b-449e-9c24-797545392bb5"
      decimals="-5"
      id="F_2b53fabe-30c9-4c9f-9b4d-0616474cc422"
      unitRef="U_USD">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_77581bff-7745-4be8-a763-3227bbf42da1"
      decimals="-5"
      id="F_20c03885-a2df-4c40-abdf-1cd4636d02e4"
      unitRef="U_USD">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M3-ZPFCS2B/54&M$P'5=!AQU)4TKQA,"!>)B^":)EP>Z+TH&18[\#G[ ?4#T
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M;7YCJ^?<\:5*&'^%39O;"R"MC55E"Z8.2BZ;.WMN?=@!1,D>0-P"XH^ P1Y
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MML@IS.1[-_*A7,"T%+^-T2OCDAQRH"/('UC F= IOX,!?8_07+C%VZL/Q6-
M-$9@QD*ND!M6W]'HJ2(,[K6AL80T7Z-?P+!G<C+!/48+B@FB-[?WBVVY+$].
M3\H?GQU_0Q\S<=VO WWNF:1!(/<B!-"D053?CO]8]_=![D4X$V\<9+$3'^S7
MM/\+=#.F:GFH?:Y?DZJ/2S$0'%9WE$:R7Z3^49%]/4&XHY/B,3.2=7Y<GI[<
MKYY#4@]J*86?*S"R&"<_N;ZR(D\.*HKE'GJ9DXLMA"WI_"(^TD;S-$IU,0TI
M@1L^I8CK)\,XV%>TJ+UK$\(OX\KHO@?ER]ER+(G_3PG0#8Z.@<ORG?[<ZXKG
MQWZ!-KE]]YEPO;&ZAAP1#(3$?9"-6:Y:CEO)T(@:X(=H<"S-2<CK&IGK7*F^
MQ<AAMG$VTTK'L>)/9XNIXF7(TV$HK_' <=@_UF0T>CRZ=P/>6#L)0PJ9+Z!^
MO96&QCS@4/N)8M(T1-9SKCB(K[L23'+H:X;(_&'J'H@6M-?(N>B,M!;![(7+
M2P'(D S,.XE;PHB=*.8.CS,,!M30[O 0;;.>3C;A[F0S>DT6B,]P?Y84YJR!
M )T?.D>V.Q37'DIH&PG16!$;[_I-DR<S\L68.'=0PUV>RI3"-.<-@7W N4%I
MQC('EA(^-?3]XDB\0-5R/9X-V!#*F:6'ON\IQXHP7$I)B4YDZ5[)#O,H?&V,
M-Q+R6Q/ZA.SPF@%PWCB4 34W.3RBP[[#J;(NIL-$/I[DJ;0EVU,.:_3&MH#P
MO;0X?:1ZYMI1=QE%-?W-HD!JT.BPDWT--#/&0)0D6O>Q]W1(+HLM[?229_+>
M?&4M,@B$Y)D[KEC^&*J$NSMR]4GJB9#A."6BA^(R:,3Z!T*B:@]U<N\Y#HL,
M\XC <:CW2;Y<=>5XHN.DQ8/L#C#" <JL<;LI45KHT],]/JHP+^%!;J4V*7[&
M3;X-W#)PD$W/AD$VN(#S.G5L8S!\L _YXB4CG_OE^VTBRB^3J62G(WXY*YX[
M+*6.ZBF]]R@+],UAJKN>Q\:7>UE8:XRR=C\FE58GO4JT(\3']2XKS%<@R#-D
M).R^\,<#/I>@:KCQ)2;7?(A%00JW_B-/()#VM<^@^=XW:$LX[O*7-I<FYD3^
M')V>3A_SE_D;]FYY_D\ 3NH;#2$:JK%U,3L]*83/7]?Y)KHN?=&N7<0A)ETV
MA..TYP5X7SL7QQMV,/V+X^*_4$L#!!0    ( ).%?%0!"R9@;RD  +&%   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;,T]:W/;1I+?_2M0NNQ%VJ)H
M47XF<5PER_:>4_&CK'BWKJ[N P@,R8E!@(L!)'-__?5S'B @RWO9NJO:=402
M,]/3T]/O;CR[:=K/;F-,EWW95K7[^6C3=;L?[]]WQ<9L<S=O=J:&7U9-N\T[
M^-BN[[M=:_*2!FVK^^=G9X_O;W-;'SU_1M]]:)\_:_JNLK7YT&:NWV[S=O_"
M5,W-ST>+(_WBHUUO.OSB_O-GNWQMKDSW:?>AA4_W_2REW9K:V:;.6K/Z^>AB
M\>.+A_@\/?!7:VY<]'>&.UDVS6?\\*;\^>@, 3*5*3J<(8?_7)M+4U4X$8#Q
M=YGSR"^) ^._=?;7M'?8RS)WYK*I_F;+;O/ST=.CK#2KO*^ZC\W-?QC9SR.<
MKV@J1_]F-_SLPP='6=&[KMG*8(!@:VO^;_Y%\! ->'HV,>!<!IP3W+P00?DR
M[_+GS]KF)FOQ:9@-_Z"MTF@ SM9X*%=="[]:&-<]O^+#R)I5=F77M5W9(J^[
M[*(HFK[N;+W./C25+:QQS^YWL!Z.NE_(W"]X[O.)N1?GV=NF[C8N>U67IDPG
MN ^ >FC/%=H7Y[?.^-(4\^S!8I:=GYTO;IGO@=_] YKOP<1\(]O,_NMBZ;H6
MJ.6_;UG@H5_@(2WP\%^"WMOG/I]G=Y\^>Y$[Z_#!#ZUQINYRNA2_;0Q<C*+9
M[O)ZC\^O;)W7A<VKS,$C!JY?Y[)-?FVRI3%U!A=_E[>FS&Q-X]H2GC9 L]TF
M^U3;#GZYPG$N^XNI39M7U1ZA,3O\)0:KM;#*KH('C__]WYZ>GY_]]&E^-<_^
M<G'Q@3XO?CJ99Y^<08A?N<YN:=*\+K-?^G(M<"'T#!'O!IX=A1^ +9H:.9CM
M]@*LK@:<Y>^]!9S K:ISGCGK&OCTV60F6?GWL'*WR;LL7ZV M\#?!B;9-2WN
M,=_B%@G1N7.F<[.LLOG25K:#4YC!@]>F[@W-9[X :W7&_42?2NN*JG%]2WL&
M>!%1" S/0\]$4\'7^!PN7@*$^O?8_I%.BDVT&<!]U9>&!YO. %YJC\'>F55?
MP5+7\"3@## ,(J %Q!',@*P=SCJCT0@FWI4,)X&OVKQV.?/;76L+WF?1.,8(
M,*LJ7S9R6OFZ-0S@##=S YP9_QO U"WEMLVN\ZH7Q&RW,!@88_$Y.X9% $(X
M+GSPS8?W)S/YI=GA&HRUTK3V.D?N#SN'N]WS&>)/@(EF"XC(OV0]$'+;@1A#
M[,Z!6+L>L B$ ?S=P;)]A6<$1]YFJ[;9PHJ-BRADGKT$  42N!A-G5_;M@_T
M??G^KV]>GBY^4/+.X,J59FL+PB2<^@8V3Y<L0+)7RFA[V@]2,LZ_KIHE &<
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M6[4YVI\%N3#8AZK;B8Z/@1;_!H'3HIY3H[I3$VOLV^#B&E.=)S%*QP'3N+X
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MR]9*9;H-1=51_M/!E04>V%,=U/")82X*_YH@;XJ9'):0GLT88'0MZE%+UON
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M_BKBJWZ4]L*7&O&!+P';YV 8,<V?X!);WP1'GJ.F]>J^%QR2VM!I:$^VG^V
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M"V409P? 81R%$HY/(WTT6EF=OMCYC8IPQ#Z+G<Q2<I[CBRMNF&';EI->V!D
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M /R.=TL_X )HUQ!XS_\'4$L#!!0    ( ).%?%1%02W_K 0  ) ,   9
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M@F!%\\UN[%Q"-:9J@WH7$%#E:?A-,*T]2-5:UNZ4/2=!.:L+IY$JK'!EK'?
M21[7+I'@CZ=:.Z"[CGXLD1XLCM9./VCOCZ\CXG!4>>_8_1"V;F+JR;5_;QA*
M""FO+^5FMGG2+.J;_-F\?@_1V;YV52=P1:[]7C+J@J[?&/7 JM+?ZTMEZ97@
M/W-ZEJ%V!K2^4LH>!BY \]";_P-02P,$%     @ DX5\5)XV&6$U P  _@8
M !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULK55-;^,V$+WK5PR$'C:
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M$>FQZ=$KJGB>_.BVQ&>:U*'>>>4U=!@':4=Y.EE/XKX>->W%??PS/#"]X]*
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MH_-L&(!NVFDSL6KG6]A:66J(?KBE?R#4+H#V2Z7L8>((NO^T^2]02P,$%
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MKUY</GI]<P/_721/D^5E\NS1DV1QE<[/KF#$XBR] )EZ(]>RKF&A;R35C__
MXT=IA*4N%O#O>7KVXL+2^>__=K5<++]/%O#EXHH)3<^7+^#O^8LKH/0Y_#M'
M0E^D5T#H7V!,HQM1)*+4;=4D>NUI)IIDLD>VR0';2+[3Y'ZK8%>X'55E18M/
MP;B\OW_1)+^(J@6#FH2A, @(>3Y;@,DH"CCEV>^D9_[M],P=/6>S92#',?MM
MY1]?SH&W1,AK7>Y$M2?1= ^NE-YM!=CAY,?9IUGR%,]C.?_>_DR?%M\_ _(;
M61-IC4[$B*B_LZ)^O:DEZ4/RM+''&Z8+O_J)8;K,3R83S2S+E<GTG:R9UDI7
M)QDHILJ S;771G0\JE'2P'<%#,YQLFB?)%J7WQL\HUKL9-NH+/D$;@M$^Z<[
M7;1$_ Z&HA-&KNLZA[.!63:RDD0/+G\G"I7CASL::T@W\ DXI4(1E;@P^.X&
M"9?@S RXFV9KSQ\8 W:N2&#*.]"8Q.Q-(TMK(& X<$IO)#Q9\S'U>':C9)$[
M?K' #=B9[&I]IU!VW$^X/AR4YY8S12 R]^"K\5]1)?(+B)P!(F K=X D=C09
M4I;ILI1UIF#O?^=3=C,$RU#KWX CP)]:"1C&F !HP"?6;8T[BN=EVN$8&Q6?
M(P@6,-_ UF$SI"S&4@\'LJ.E<4*W,6"U_-* .A&ONK-H.),&L T-@.$BSQ5.
M ,OAO+/DURJ3HR+BYP%QJ)(M<"?35AU3OS00:70ABST^OM. H%8%KT7'#&Y9
M@:KF\9Y3 !55NP99;6M5;298"S8#9^@QE SN3L->B6'P:]["KQG,0?)H9JCF
MOX),HD4!-;\(I,HON()!C85Y+!L/L6Z<8S@DLB-7?(3.CI!/*(R&J?[6JIH5
M$-%BD"O@%9VE9R&K1$>V1RW%3W8&U>R3UX5HC0PJ<-O6ID6)L_H^4(>NN:O!
MZ (IH!N[=:U16<2>/3;P_4DR#_8SI?/!;2'/FX)W9,>#SWMF#WDCXUF< (!.
M*#AY4B'R A%LB-4+%I, 0"M)!+0[7 /\W&SNR @J9G4N]X?O=:RMR%3AL@&#
M,/U/%1!:Z[THR#A:EAL@NT#+NE%-0B/0V*[;!CEG1,'4D!@>$#E:P+0K9PPR
MU()<6D=@EP*$ $(%O^/.Z,-6U6RHW;IX+FYM-QOI1P2HNL)F!<T>929V._*.
M$SPV8&MATF0M854,+W)<%4\/$6<+>UNW17%"QD*6NT+OP?;4M$, /-9:O*41
ME0UT2(Z)/[*FJ UMB0;:-[1Y$QW)A$"N-3U"C#Y_ S@>SK(M0,LB!V72Y-V[
MUV&CJ%F@ JS!Q-!="QL6:,J!C1M884..<YU<S%^DE^?G)%26 '!HJD+E->#C
M)=I8\%%W('T)>E<BRMEC,K\GK/1D2UD8A-N"]3Q=%1IH$"D/$(^>-$?[-00R
M5L/PH4VE_LXG(Y#Y LTI'!;864\>T*I*<NXQVRTHA=6!I[5U&F 8G$KB(K54
MY0HLA0Q:ZL4ETZ9!1UC+/AWPQYP $FN):"*&=SYV H[-EKLT7X[L(KNQ@LTB
M=LF$P15+\!B693VU[6I1BFS#)_"<4"=@@%L<. ,XZ'. .D,D(-B\L[L2SC33
M3\Y0;77AQ+#I[8QAA%.?6*9[@K 6JD9DU$HWC9<YGBY&MN$0F2T HN>SBV!U
M>_+ HK!/Z%N6FF^1!\L)F,9H\+8X!D\!+ U;*_EE9Z.S#GH$TYQ]]DSQ,N($
M>M+DV.G(;%RWFQ:4#%SFBVGHW<74,*CD( &?@9BS(:*^%FF[2281MSL7$:U6
MN]4FC!<^(T H=H) \=?2]!'85QT@:9;\U8F9B03-]%B'W_,I@>88,"L8,;%H
M(Y[$/)'U3TYZX=D(>  HV9+_B>$D(/@23"0I6KS[(?Y@>;)+$YC3A'#MPBL!
M4M,-0*)])9/G$C"; Y!$]U;<R2Y"=RX7?F04D%Q??T)'"*8C0,8NWRU8^&1_
M]5'7& R;C1,"ZCH$O2G&HX@LT9"F^)C5A ' E18;@_4#6\+G8V$%8>Q&@ .R
MO!_0RZ9&3+'.'UY/<D?.KK?AZV#,;CA0*74MTPC'=R$>^<U8&/L8$;QBZ6?_
M)P/"(9_(B$7,.@CB'HC.K-$&(C#BP^T?AGY@HC$0%AL6JU+E)QU(:K]K[I&M
MW>=C/9JR)7QV8*!H<+ 58TR'2/S^J/*\AV<&>D-R +X>W'HS%%?[\WJ-RIG)
M&F4[:40-P;T)![7:>^K' I^_\/-'5#5&QJ-A:4]#G4AZ=EBG'>^R.^L&CKJ)
MM&[*%@F_TZJEU-;(S*,;/<!@YF"\;<N58*,>LND_R"R-$7R,T,Z.WSFEO;4K
M=+,Y(4[%53&D]MX,=M!9=31\[I!BEV?7!+]4XVQDA5II&]),>B</HJ;U+F2<
M@.Z5["0#P(!V0W$?E6*HH.LBOT>X*:JJI019$R+1 =/P;,70;@0[0?%;BA:+
MLBB86;22:78R4VM%40C.A<ANUB6<PLLCU'=L8==HHGYU?AY+,@'0DP5:@99C
M:R =/)0]:F_9V^.8(=&'C2'C$%7GP2 V'&)!?"7!Q$H6BV-&N"N?6T;I"BC'
M1&P4^I+>$78&7]T_$4IC61)3QU9'<A"(CD]Z (/=V?[SF-KECL\7!K#P[5H%
M$:5N0;4QA,PRK"O8M*HPE.0$P[52%04TG-'@10^,BN"['^.]]G#]#5CY*NPD
M!MJ>IP<Y;\.*@]D90ZXT5QCFQN2,0?D=1()*MP8,OL?@K*6.^$, R/&;A@K.
MY^QJ3!#1SB@_M-I3],]5'-HYF (P"S8HA"E$@;P'1UZ@ /)XZ^T>$(FLY''*
M#TO,E+3,P$DH,O@HF7N+S+IVK 32&\P$#3)V8RDN^45F;9R:_G:MP5H ZZX!
MD@A51X'[:M_!;8X3NA<' MQ"VN@4G'4-:4H+5=F6[ ^CVUR:K%8K!,$K?2>G
MDAE8<II@&:M&A.*Z05_ 6@?T ^$+(OQ.(5$=]! XQ!$2\DMX@B=HD*4YD)H0
MQH!KI=.M +$5C:PQY 4@9UEGP]N4[ ;F##?%GM,R][5J@,_ ES69D<R*U4.6
M=0F6HW70Q0M7&PI:-%35<'1V0K1G %-W6S[+X[G'GE7S #I'02)\0 K.'M';
MV/%\KY75ZX^ODXOYA<NJV!HN&PTK@<9)2 SETL"V8 TKZUO QW82ZK]IA583
M JN:/6-9XJE(7Z[]Y>/K@"D_N/*S 1'!YZ/46NO!B:IV+82>$I0M#QERFQSG
M_*A/@Y+_B-PZ*@G5O%=M#GB2_)#A>E73<8GEKI"( !"3C[-QEOSHUB9$C@NB
MZ(2,H2HE-F78;-#@3&&7*&=9R"Y&V^UG$,4.A/8+S0R.A,J%<#3WVF8,R0,-
M>@:Z?CZ7F!XGP1CW*('%M3*?$Y'_UAHD#M'M#@^]:JRM$94H]ICM=L=8O[_]
MY$,A/AI=Z W5EWD(&6>7L@KF.93]0N8C"UDKC@9PU[4*#LK7&%;[K@%C(1[:
MV0#6.JD0PARN2!8G0IAQN"F2)5WON,CO#I<E'HQ36[K\=F?E$%#ZT&PJE\I$
M6..3>NZ?>.[##"NQ4@454];@'S*T75@$VKMAE.$(#1$9U6-"%2QU-5H_#QF2
M3A3AP\WNH$D+26J3]M@<XB(.ABR3HAQVKWQL9PD,;L07&PS1@MA,@: &OYHE
M;[@23>DD*SXL_1,M,S0'-ISTBZH^7>\TC&M!ESYK]5!<<P@_S))K"@>GR4J'
M-H$R^B1% 62Y9IE 'D[P)#F?G8="!.82)#4T%GN27APH*=]CD2%XE;8KY8?K
M?@>!TR1H$D?V_!"N<-'&U0=#=]*XU1)% 5%=5 8!1VQS(!/^[QL8^OK##59'
MWH,M+FW/PO-NDK_79^059]TR\.,\3J?\,%IRP)6&S48>W[[>ZEH3DBJ5" U^
M-Y@,XFF?AHE"Y83*>8A[U@K/;R,JIX)PQ,JS;ZTLL>C..!V<Q0NF%(M340(D
M3.$HT%';?(0V)4/+C3&/ABT8RKC=*>K7+;0!36^+QOFP0HK<2KISMPF<496#
MQ[01ZD9CM,X'W^$+^DXD#K^D\1 7JE7;2,]N+$3(8A<8)_([E .7TA[+<G2V
M&C76X&9$.4A=]EMI!)G1C+=;BL_NU#LAB3/_^+ EPU7QHK8PA@..+00;$8A@
MWI",8BT;W\/GR^!1[1OYXF7C%AN#L$W)HP5;G0C<=-C/,Q*I[3I7I FGC?+\
MR]GS8#%W:,YM9B-V%-IB%T !4;G 5J8!V2 CXHHRYFI$VVB0$I5QUX\A#^L7
MYG:K7K^/F30L&(/%A0JJ3ZTPD62K''D GF@9V+-&7H*C(F4Z##L6%UQZ(PQ3
M5OJPI1_*]W$S^M[9=5K!FW9=NX,*QOUKI^;^UIZYNSQH[K+)#N+ -%+%FUGR
M,T1D8).KDW?"+O6NX<K.\)>W53:+NPRM;:,?XTY,UW;9*9:,I<6Q.E[2L58@
M6ZY=DCJBKS_9'DNT+5EKL3U@*K!L18EPED"5;Y2T"(6LGV$ 2Z;'UC@SM(^
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M['456L%B$V!-IJ/;0_:;;M'Q-T*R! %R?A^J&6#4!YVQA;Y:8".G?X,,-GZ
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MR)Z-*91LPB44U?[*D^J\VU+&"Y"<NOG8!;"&L'C2_YZ^;E>][M5'*'-[#3@
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M3%J ]Z <%[_0 >VO<M[]#U!+ P04    " "3A7Q4RJ_9DLT&  "0$   &0
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M7[<7[2US3][>U7^7!D,ZMY@,K,-H-@V$:>^_[<+IVM\Y5]IA6O.O.=H1&2;
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M!K3:T=S7-V"=.(D?$B]L)T%0]($C<6982^*$E'8]^?7]SB%UFYU9.VF ]J&
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M\;K-3R+>8Y' )+N /,VS$WB3P<])Q)O\NY\?C0^NI<(*'H21\ 'E2ID5++A
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MC:.3XT&3J6[A315>'#/C\7X)/W,\&,FR +YG!C&W"W;0/T$O_@502P,$%
M  @ DX5\5/!PB>?5 @  #P8  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&ULG57;;MLP#/T5PMC#!G3Q)>E6%$F IMVP8B@0I+L\#'N0;286JHLGT4WR
M]Z/DQ$N'M0][B46:YQQ2)IGIUKH'WR 2[+0R?I8T1.UEFOJJ02W\R+9H^,W:
M.BV(3;=)?>M0U!&D55IDV;M4"VF2^33ZEFX^M1TI:7#IP'=:"[=?H++;69(G
M1\=*;AH*CG0^;<4&[Y&^MDO'5CJPU%*C\=(:<+B>)5?YY6(2XF/ -XE;?W*&
M4$EI[4,P;NM9DH6$4&%%@4'PXQ&O4:E Q&G\.G F@V0 GIZ/[!]C[5Q+*3Q>
M6_5=UM3,DHL$:ER+3M'*;C_AH9[SP%=9Y>,O;/O8,2M6G2>K#V"VM33]4^P.
M]W "N,B> 10'0!'S[H5BEC>"Q'SJ[!9<B&:V<(BE1C0G)TWX*/?D^*UD',TG
M6?[Z\QM8*F&F*3%A<*?5 ;SHP<4SX+R .VNH\?#!U%@_)4@YDR&=XIC.HGB1
M\0:K$8SS,RBR(G^!;SR4-XY\XV?X5DC2(3<1P0(-KB5Y^'%5>G+<#C]?$)@,
M I,H,/F_^WL9G%^,(! \] 1P:[CN?'(&U"!<6]T*LP=1VY:P!G$,;4,HCR,(
MI0!UJ^P>T<.VL="(1P3-HURA(YY(0"4WLI1*TIY'Z%=WN P_@B\L<4K(9';K
M3_C(<I\](/"LOR6Q V%J:*VG:%3\V9TLNS!9'KHV1(>DN3.E[G3/)DJ%(+3M
M^/8])U7N8\RM(71&*%CA(YH.X1[=HZRPS^E8MA8U_B5ST%@>Z^^+8XU6.)*5
M9!SYLYBHP\HZ;LDG#( [WF6>:[-K> 79Z)PG2JFX'!@3/)/!$P2"VAZ%XVL)
M_0W<G:A+=$.'1AP?LC-6]"W&%:/VHW\U5GHRI!K=)JXBSPGR]?3S.GB';7?5
M#_F?\'Y5W@FWD7PA"M<,S4;OSQ-P_?KI#;)M'/G2$B^0>&QX8Z,+ ?Q^;2T=
MC2 P_ ?,?P-02P,$%     @ DX5\5/:NMZ(@+   2)8  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&ULS7UK<]O&DNAW_PJ4[MD;:8NB1=J6Y;RJ9#G>
MZU02NZSXG-JZ=3^ P)!$# (\&$ RSZ_??LX#!&#9R=;>JI0CDL!,3T]/O[OG
M^_NZ^6BWQK3)IUU9V1].MFV[__;Q8YMMS2ZU\WIO*OAE73>[M(6/S>:QW3<F
MS>FE7?EX>7%Q^7B7%M7)C]_3=^^:'[^ON[8L*O.N26RWVZ7-X:4IZ_L?3A8G
M^L7[8K-M\8O'/WZ_3S?FUK0?]N\:^/38C9(7.U/9HJZ2QJQ_.+E>?/MR>8DO
MT!-_+\R]#?Y.<"FKNOZ('][D/YQ<($2F-%F+0Z3POSMS8\H21P(X_BF#GK@Y
M\<7P;QW]-2T>%K-*K;FIRW\4>;O]X>3J),G-.NW*]GU]_W^,+.@9CI?5I:5_
MDWM^]MG3DR3K;%OOY&6 8%=4_/_TDR B>.'J8N2%I;RP)+AY(H+R5=JF/W[?
MU/=)@T_#:/@'+97>!N"*"G?EMFW@UP+>:W^\Y=U(ZG5R6VRJ8EUD:=4FUUE6
M=U5;5)OD75T666%L<JI_G7W_N(6I<8#'F4SSDJ=9CDRS6":_UE6[M<E/56[R
M>(#' +,#?*F OUQ.COC*9//DR6*6+"^6BXGQGCA$/*'QGHR,-[3B_WN]LFT#
MA//_)B9XZB9X2A,\'9G@96H+BWA^UQAKJC9%JAS"Y%<,D_R^-4#@6;W;I]4!
MU[ NJK3*BK1,+#QBX!RU-MFF=R99&5,E<(+W:6/RI*CHO2:'IPW07KM-/E1%
M"[_<XGLV^0]3F28MRP/2A-GC+R&JF@)FV9=('O_[?UTMEQ???9C?SI/_N+Y^
M1Y\7WYW-)Y#WS"'OV>2J/UB#:_[)ML6.P$JK//FYRS>\LB$T_JD!":&,)$8P
M/#N(4L!?5E?('8OV(/A3! #7^F=7P#;!@:U2'CEI:_CTT20FFOD//W.[3=LD
M7:^!;<'?!@;9UPVB/=TAUFGO4VM-:V=)6:2KHBQ:(-89/'AGJL[0>.83L&UK
M['?T*2]L5M:V:VC- "_N'0+#X] SP5#P-3Z'D^< H?X]M/YY<MMEVV Q0 YE
MEQM^V;0&\%(Y#';6K+L2IKJ#)P%G@&$0+PT@CF &9.UQU!F]C6#BV4MP$/BJ
M22N;,BO?-T7&Z\QJRQ@!/EBFJUIV*]TTA@&<X6+N@>GC_SV8NJ2T:)*[M.P$
M,;L=O P\-_N8G,(D "%L%S[XYMW;LYG\4N]Q#L9:;IKB+D7! BL'7M'Q'N)/
M@(EZ!XA(/R4=G*VF!1&)V)W#^6D[P"(0!H@."]-V)>X1;'F3K)MZ!S/6-J"0
M>?(* !1(X*S657I7-)T_<C=O__[FU?GBA9ZX!+A ;G9%1IB$7=_"XNG<>T@.
M2AE-1^M!2L;Q-V6] N ,H+_>\4-^XT%4?#2XZW@\;IC;),".JAIHZ3YE^L+O
M[-YD*$L2I,DV 41F19-U.Z <Y#-$X_>T;CDC\%;2[8G<8*%%&VU60^>#40L?
M4B3UP@I1$5+2IB&VY_821Q#JAC>.B1O$A]FM .$J0N;)/[9%:01A]ZDL*D$0
M&EQ[ :O-6MT&63QB?/'\.SO,'$:FHET)-Q@F.239-H5#2?1:@3)#B(/WLZQK
M:!?2/"]PHQ"4BM4QVC9X9H4[:O*(UFM<"!!XUM:-!825*?(0A5X(QA$*[T@F
M.X)TB?306[O5U\<XX;IKD<<PQ\+M@,-=U+F=D@"73@)<3C+L6T,$D+SQ:Q_B
M^E\\2$3*R(T<3V:F;8F45IV%H2QO::5+3%<ELR%^#U=L>8;HA#@BR;:%60-O
M-EE'+*->PQ$QS2RYW]:XD43*](P?,(>#1*2.4J,A+H^::; '(34@[TM$#3@'
M3=*@REH(L^V:/? 5%B!E66<\ 6QWW369+!K/C+6Q!@&PT QP<H%Y\?O(%I ]
M L0'DP*%&=3KCFF=GH0_+F8XIY[7/F+*NMJ<HUC(]=#>XRDD&%E)P;=BQ82@
M+4LG]O#( B35R/-3-/C<T>#S2?*YJ0$%*)54H-V "E6TR?O"?APBQLG1T-[Z
MUL*Y,C^<[%&7:^[,R>04R>M@S[VPH:.[KUOX4)"B9KO5'ZH]*&7#R47"Z V>
M\> -#@X_ J6T]'5JMRQ>\0]DT,!769JR!"#"MT#&C?!4W O6"I'79 9>@$=&
M3@$."C2Y-<!L /3VOHZH&;ABV[&('=QX /!Z!XPE2R?&#X!.4"X5%>@<0DL@
MY,U!5@(\J\I[ BTM;2TO$ BDT/T.-B]H4*1IH:)@&CX;*9P.447@>"'W2%;U
MT9!;D2>HE\$8L TYR4G0RNA$5L1E<N JMA"%9FP/1.5RSX+LF!$:P5@&V,RG
MS,#@:Y.+V@X([5#3+PM04>TPRD#-;4'-%W4VTJ1(-<Q0F0RT*F)8P /9!$D6
M%_^&4G97-V;LA+=UF_JSBCN2(E<"-G1OOWWTGW!PV3*,.,@CXB#(/1[=D"D,
M7U\G+YXE_T;_^"]?)O^>_/NCWVD.]S-\]PNR;#@?%8 (7_Q/+GW@>!RAX?-K
M7US@.IX_C1>/WRTOX3O& #_$_PXM.=H+D&V'9&/J39/NMZ (-&8#BY^1JR-'
MPL0EL; (]"V9>]9;0G)*)[;N+"#/GCUD8W\SJ*B4^'SRM^3YDTO\]^GRT2W8
M4O_B'Y+%\]GB:I$LEK.K%\\?Q=Q@ 0.=)LOGR9FL7FGL;\GB:G;QY K_>#*[
M7"R3"0EPY23 U;0$T%-)?_SD3^40^__*H2+&05PY1_I$6;<M-ELXTF4!3^?"
MHH0JT?*LFV)35*2GM\J::<> >)'KH?\%M6%29-K(P /E !102]KWR@PPG9L^
M5PWDQ0!#G<#U"X?K%Y,(^M6+FELG:H;P/#G,L)@='#OY=5"XA8*QQ_AG?:Y/
M&]J3%RP=20:1;4PR"$9OR *'WRH0R_J1M)]8=F0E? O&E*BB(Q(8_KM+BQ*_
M/P?-[-RFHINB;81/P&[O<-=#FY?%#MA[9)61%W&>O/8/%-X,RY..U,("#O,>
ME3V %NUP4GI%@70\XY]=C6^0G6[9QT0*K]B/I#I:D$<E< >_B#D(>L!:6?P+
MWMV 22.>"2<CD6!'EM^$CA(K2C"0947[1H;[MB[Q('U#5 SV[VEN0/TNVC-Q
M@G6[CHTD-IUP@,9LT0%]9P@(WI9TA\8-@HC.!R+_09  =VG^1T=*!ZY7WG-\
M% ;?%6 1J_+4&/T%W34L*\A91$?Y@$9"D9'B%-(16/*@*=M6W0V"I< NJYTU
M 70\3]Z/(KA/HE\\=$BT;/F!CH8JB$%J8O?0* &C@DJV!ZR31()X08BQ=9XN
M$-B$5!]VPJ#<E<=!S -D>!R; A4?@*0 S6<^PE#OX#&05,Y&AB6KQPJ)VH&!
MXCZK-Q5,CUX*'I;,2."8S0:TW#>1X'>C&-'-V1>6(6,B4JL"SOV-#0]D(7;[
M.2[F7!=S8(<8>XA0=\3G'$Q,[Q%<A*/B<]LUP:(7%SY\<#')I-\2CM Z$=X7
MNKH&XP1_8KR^V\D9.C69,/Q&Y&Q3GQX\ 9I(>3@'=&R,6,B%<5A:%<"PLFU5
ME_4&5>8<SBWBG<\#D ,H1%U+*CSIT>1*F<&NWIFR)J<EJE$X+)QBHB9 -KIQ
MW*AX%&"XJKYC_,_0^=E*;(K800WL$LY%<_ O'7 *YK89'<"/AHZ6K:O*E#-
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M,)Z!SB=.UL8>(\!*\3#%XK:SDB@/M,TQ"=C9%<:Y[XG@I$9>@>^!SGLV\6K
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M6?HW0R)XF33K'D3=;+ANGV-(G5Y5%3TSB,%9OU?/YS'"<26OJ)M/$DMRRFB
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M(6@0AJQ[XH"_.%\L9TD4*E.UY.D%'.E;JH_V9_HZOG4@>C&D=Z(5JY%_S#:
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M4H6-S$!73EO6*=XIMC5E?M[6YWJ--IR.51M$*&?TH'0ID')ROX(-:'^8!RW
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M:M0T^ #\CL)5/^ $Z-@@\'[\+U!+ P04    " "3A7Q4:-;M4%@$  #E"@
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MBLHJT/>EE&:SL03MS7;Z+U!+ P04    " "3A7Q4M) +H>$#  #="@  &0
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M.NL'H)OQWFRLJOU(72I+ ]HO"_HBHG8 \J^5LH>-2]!^8Z>_ %!+ P04
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MJ5;-Y&XV1F[<M%Q)@[/7+4O\V8&R!OB]D-+L-I:@^WTN_@!02P,$%     @
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M*9_3P==PD&'UGMV1_AH)TA_NCW%W:&1(CL>AQ,"'X^*Y5D4-I!OE@#B@EYG
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MW,A+J@U*B1FLM$B?X/+1N*BKB:>)U(1ZZ9Y@T1*$)PB"$.Y%I7,%MU6&V;\
M'F7;I1P>4EZ$9Q%O,.U!/W A],/@#%Z_*T'?XO5/X#UB60M)+Q)NGQNNW^"&
MJ[00JI$(O^9KI24]G=]GB**.*+)$T0FB5?OP06S@_\K^7K7/4I@6'JN:I3AU
MJ$<5RA=T9G-E**EL6*Y1[DL7C%QJJBZ+]"B+NLM"V<NG/<65)IU@=(ZP$04U
M,Z^V<,DKLHA&L2I3+N!KBK6&FEA4SJA^9#Y(I6@JK:[&%RNC*_@F^997K("]
M?J=40Q1?.%U"QFS++J5($3,%7VDZB<W%"B4GSSF,_)';IY?U 8:]H7^LNKX?
MT#IP1P._\_\80$ .@3M(AK29])+HR$!+/(KM$B6'F 7$;A!'[J _HHA@V(L&
MG24D0N+Q(8G<:!A>/ I-QQBZ_6%,NTDGF40"/R'T@95"=Y3X\-Y#\HX:N$2Y
MM6-*4>&I9&TO=]9N$L[; ?#7O1VC]TQ26144N*%0OS>,'9#M:&H5+6H[#M9"
MTW"Q8D[3'*5QH/V-$/J@&(+N_S#[ U!+ P04    " "3A7Q4?6.PN?@"  !3
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R-5=MNVS ,?<]7$'[:
M *^^YE8D 9)>L#X4"-IN>QCVH-A,;%267$ENFK\?)3M> K3%@""FY,/#0TJD
M9WNIGG6!:."MXD+/O<*8^C((=%9@Q?2%K%'0FZU4%3.T5+M UPI9[IPJ'L1A
M. HJ5@IO,7-[:[68R<;P4N!:@6ZJBJG#"KG<S[W(.VX\E+O"V(U@,:O9#A_1
M_*C7BE9!SY*7%0I=2@$*MW-O&5VN4HMW@)\E[O6)#3:3C93/=G&7S[W0"D*.
MF;$,C!ZO>(6<6R*2\=)Q>GU(ZWAJ']EO7>Z4RX9IO)+\5YF;8NY-/,AQRQIN
M'N3^.W;Y#"U?)KEV_[!OL</4@ZS11E:=,RFH2M$^V5M7AQ.'2?B!0]PYQ$YW
M&\BIO&:&+69*[D%9-+%9PZ7JO$E<*>RA/!I%;TOR,XLK6554G$<CLV?X\L0V
M'/7766"(V@*"K*-9M33Q!S11#/=2F$+#C<@Q/R<(2%,O+#X*6\6?,EYC=@%)
MY$,<QM$G?$F?:.+XD@_X;EZ:TAS@]W*CC:*[\.<3SK3G3!UG^@'G([5(WG $
MN85C(0NF$!Y0HWK%'*AKX+8Q#>W=:=TPD>%[Q?TTC.W+2UVS#.<>-9YC]A9+
M;:-2E;#:H.HK!4SDU@A], 5:5343!RB8!G44E;52M3US'VQKT$]_RZ1X164(
M0->\U+X3OVW%EYUXPM$VIU;6EX/3X ,7W 8>'!.U^DY#04-70SE9%@?=B=P1
M5-C6A#4G(;$_FH9^.!U;*QSYPW3T/XPW5<WE ;&[R>TQK!N54>8=<SJ=^..4
M>(>QGR3CP<T;JJS4CE76=D9HER<5P!:1)I@V9)1B!XD_F41^/$[)BJ:I'T7)
MF?N9J#U3B@FC89CXH]$4*"P]!D_2,'Z.[$]D[$=QXH\G8QCYT3 B_!#>NY_!
M2:-7J'9NG&DB;81I>[[?[2?FLAT4_^#MN+UG:E=2QARWY!I>C(<>J':$M0LC
M:S<V-M+0$')F05,?E070^ZV4YKBP ?KOR.(O4$L#!!0    ( ).%?%2I/><H
M0 4  " -   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;)576V_;-A1^
M]Z\@O'1K $76W7*6&$C:=-M#VR!-6PS#'FCIV"8BB2Y)V?%^_<ZA9%E)':][
M2,3+N7SG3E]LI'K02P##'LNBTI?#I3&K\]%(9TLHN7;E"BJ\F4M5<H-;M1CI
ME0*>6Z:R& 6>EXQ*+JKA],*>W:KIA:Q-(2JX54S79<G5]AH*N;D<^L/=P9U8
M+ T=C*87*[Z 3V ^KVX5[D:=E%R44&DA*Z9@?CF\\L^O$Z*W!%\$;'1OS<B2
MF90/M/DCOQQZ! @*R Q)X/A9PQLH"A*$,+ZU,H>=2F+LKW?2WUG;T989U_!&
M%E]%;I:7PW3(<ICSNC!W<O,[M/;$)"^3A;;_V::E]88LJ[619<N,"$I1-5_^
MV/KA1QB"EB&PN!M%%N5;;OCT0LD-4T2-TFAA3;7<"$Y4%)1/1N&M0#XS_61D
M]G!&=N7LC2PQUII;=[V^Y[,"].G%R* :(AYEK<CK1F3P@D@_8.]E99::W50Y
MY$\%C!!?!S+8@;P.CDI\"YG+0M]A@1?X1^2%G=&AE1>^9/22*VB-ON5;S#'#
MKI3BU0+L^J^KF38*$^;O(\JB3EEDE44O*6O2G<DYL\YF'U?D8,VN*"&%V1[R
M\%&15*CG>L4SN!QB)6I0:QA.[Y? YK+ *A/5@AF*7EMJXA_0S."UMOIEJY^W
M^I%+V>LM<,6 8L;0XU#.0'5>/Q_L8'^LC3:\RE'+X$-MB="T_>JK+03(SWJK
MJ\5"P8(;&%SS@E<9XN'F.R4>"YS$2YPX2ECH^)/(\?V0G3#?=[V8I2X>G[#)
MV/&]N$/#:[.49&'.?"<,(\>;3-C//Z6!'_S:$2TPM(B#O4::.$D</_;8:6\=
M1FX:=M3P""H3E!NM'.2+D] )TS%R)6Z0]$A70B%AY(1!A&3-]Y2%B1ON!:)_
MYR (0.C[3C!.D7*W.F7!Q/7'1_WBDU\F'IHV1K^D*7%&Y)>)FY)+QBY>G+ @
M<I(D&=CD[JR@-'">2D2[)X'CAQ,2$;CCV(KP2(0_=H+4VXE8@R;0&&LR%-LH
M;HS\;PCL2-7$7=7$_Z]JGC2GFT=:@\W<FW)5R"V0ZQ#H!UE!=S#;LG=U9=O_
MH2([BN#'BTR@YMU0([Q-E65]O-##"T_P5L_PSEN\[+6HL"AEK9%*GYX/_J3B
MO/FN. =-?F#Q#.X0)%?9TLK-88T#=V7;V0E+G#2R\7&2L3?X#2I0O+!T/,>A
M(JC;T71$PDD<(%GH1X-[:9!(]P;$09LP"4)G/*%LBIQ)&AV+?M)%/SD>?7Q[
MY#7Z%MUYI=&W;25])A3HF.N"(RBDDCBBV!=>U VF]S*'@G+T1AN!(QO8.RZ4
M)8#O&O"AE#@*Z^64H.3DU99!J[9IMW/2O=[IWH7Y>=B?=>5:V\Q"]J=&-O=L
MI41&!"59ZK+['U>S4X#IJB"3B\HV37H8,0H_M>HS,I@>.4@CU]!,!07?:J&Q
M?3$R6&3 5J"$S$D9W?,-5[D^!,7L/?.+?F;FANO.6WG/Z'UQ\5[<^Q-*OS2B
MK,54">Y+Q=*0';GT!KMNTF\D[-#AX*9KB:!*%KMI,R[\7W%$A"W2_2IVXX/W
M7K/:2UO+ G.YH+F<>GC]JF-+(^1[Q=(01>$G</W^98@ #IWB=G G],/97*$!
M N<@9JYABHK#<Y,>L6_%-V>>&_5N/'=\^&P/.\>G1(Z!85L!1<X(=__O4$\8
M]5ZM):B%?9MK;#)U99H';'?:/?^OFE?OGKSY[?">JX7 /"E@CJP(#5N[:M[C
MS<;(E7T#SZ3!%[5=+O$G#"@BP/NYE&:W(07=CZ+IOU!+ P04    " "3A7Q4
ME;)A':\#  #5"   &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R55MMN
MXS80??=7#(0^)(!J69+E&VP#<9*B"W2SQCKMHBCZ0$MCBP@EJB059_^^0TI6
MG*YCI"\V+S.'Y\S%X_E!JB>=(QIX*42I%UYN3#4+ IWF6##=EQ66=+.3JF"&
MMFH?Z$HARYQ3(8)H,!@%!>.EMYR[L[5:SF5M!"]QK4#71<'4]Q4*>5AXH7<\
M^,KWN;$'P7)>L3UNT/Q>K17M@@XEXP66FLL2%.X6WDTX6R76WAG\P?&@3]9@
ME6RE?+*;3]G"&UA"*# U%H'1US/>HA 6B&C\TV)ZW9/6\71]1/_%:2<M6Z;Q
M5HIO/#/YPIMXD.&.U<)\E8=?L=7C"*92:/<)A]9VX$%::R.+UID8%+QLOME+
M&X>/.$2M0^1X-P\YEG?,L.5<R0,H:TUH=N&D.F\BQTN;E(U1=,O)SRP?*.^_
M2:UAC0HV.5/HPXIIG@(K,[CCHC:8P=4CVPK4U_/ T)O6,TA;_%6#'[V#'T;P
M698FUW!?9IB]!0B(;,<X.C)>11<1[S#M0QSZ$ VB\ )>W$4@=GCQ.WCW3)6\
MW)]$ /ZZV6JCJ&#^OH _[/"'#G_X#OZM+*K:,%>#<G<FN#^FX%R8+SYB6W>F
M*Y;BPJ/>U*B>T5L^Y@@[*:CO2!\8FT+0:#0=*I.#H>OT+;EM1RYKR95$3EAR
M%9'3+CI7O"1?66NRTS[@2XJ5:>^LZZME1A5Y/>O]B4PUZ0=*'A9;,J $]FP"
M;18'O8>Z0,6,5+V'XWO,&,6W=</:2,NT()+4$.E3+D6&2L-/< 7CT(_#,5R[
M33+R1],8KGMW6$KJ%@?YS74F9C^S9WIDCPTY#?03I0T1ML&)QOXX'OC#:  C
M?TBK)$D^Y%AK4D4!:0)I3WZ,F'\FKF<??/B0JQ4:]9.CYDE_$M'R0J4F7:4F
M%ROURXFN32MU!VMIL#2<"?&]*5GZ%84-IK7BAI/)_4LJ:IO;G9(%_*?:_U^-
M7Z3WD1H_S8SN%%0G"K*C OVJX(!4J_A&QIG>N- 1U$_.@TZXS.C&TBNM\193
M1B5"%6+171O25*5)58L,<JHKLD":343OR&S6>Z=)OE26B@:N=4W0MB1.]<;^
M9!+ZT7A(JW Z],,P[MV>- T<F%+TD(8D]D>C*4PG]JOW* T3Y#.-A_YT&-,J
MFD;^F(KJ7$D%)Z.&>G;O!JJF6-6E::9.=]K-[)MF5+V:-P/_,U-[3GH$[LAU
MT!]3^E4S1)N-D94;7%MI: RZ94[_.U!9 [K?24ILN[$/=/]DEO\"4$L#!!0
M   ( ).%?%25&+S)Q 0  #H3   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q
M+GAM;,U86V_;-A3^*X31AQ9H(Y&R)#MP#,1VDJ58XZ!IMH=A#XQ$VT0DT2.I
M.!WVXW=(*9)MR8J!==GR$(O2^<[EX[E('&V$?%0KQC1Z3I-,G?566J]/'4=%
M*Y92=2+6+(,G"R%3JF$IEXY:2T9C"TH3A[ANX*249[WQR-Z[E>.1R'7",W8K
MD<K3E,KO$Y:(S5D/]UYN?.7+E38WG/%H39?LCNG[]:V$E5-IB7G*,L5%AB1;
MG/7.\>D5\0S 2OS"V49M72,3RH,0CV9Q'9_U7.,12UBDC0H*/T]LRI+$: (_
M_BB5]BJ;!KA]_:+]T@8/P3Q0Q:8B^97'>G76&_10S!8T3_17L?F)E0'Y1E\D
M$F7_HTTIZ_90E"LMTA(,'J0\*W[I<TG$%@#TM -("2#[@/X!@%<"O'U < #0
M+P']8RWX)< _%A"4@.!80%@"0KM9!;MV:V94T_%(B@V21AJTF0N[OQ8-.\(S
MDXIW6L)3#C@]_K9B:"K2-<V^HT_H/(ZYR1":H.NLR'.3+^]G3%.>J \@<G\W
M0^_??4#OD(/4BDJF$,_0?<:U^@@WX?K;2N2*9K$:.1H\-':<J/1F4GA##GB#
MT1>1Z95"%UG,XA;\[!4\Z5#@ #45/^2%GPGIU'@CGDZ0YWY$Q"6XQ:%I-WS&
M(H!C"W?;XCD>WF;]XI]9O^R&?Z;9"7(/6[\ZVCH>=FR%5Z6J9_5Y!_3-Y9)F
M_,\B)<^S&-U0G4N&Y@LTR14(*X5^^QE^T;5FJ?J]PV2_,MFW)OL'3)XOEY(M
MJ68H@ZFPEB)B+(8\IPO-)'2\.(=.FBU1#MDF-Y+;1<Q5)/),*P1%@"*1IER9
MSEVLQ6+!I!&+A-)M)3(K7 JL2V:2/(TQ[I-A,'*>MK>^*49</_ 'E=A.Q'X5
ML=\9\3S72H.?QL.RO,4"9D[,8 0^) S<SIZ8U-Q<P_"#8. A@CX5/;:51V'-
MW_+2W8UC]JK$Q:L2EZ]*7#4E0B_T P^WTQ54= 7="1)%>9HGD"&Q&8 \XKJ-
MA:"YI9X?A,,]*IIBQ V&C9U_5=M.*&$52M@9"DR!% KKKKF3.^H&E;K!6U7K
ML#(Y[(S@)D\?H"PA7\O,52*);=%! >;M\V38R(O^(/1#[.]QWI0;!H$+?^VD
M8[>>O^[1M*._8.Q"$X'Q>YL_)#P"MHINT<$.WAKU^*VV!)/:*/G1FS(M51[/
M=CU"L-?I34'SG@O0QW@$W0S<M#ZVNN0U:]/;RY%NF5V/ZPF$_W\C:(K;ADL_
M/,A_/5UP]W@IL^'EQ;&@/U]#/A9SQ7[A'#5PK(96WYNM'F,_](>#_OY^'2&Y
M&V<]%G#W7-BKZHMG)B.NF EM#M'0)!$:/N@TFJ]--7956MV_<?AFY5UW>3SX
M\>4]:/).NLJ['@"X>P+LT7XI@.?-IWEV3!\E=<LF[EL13>KF3?"_TKDFI=Z=
M6O;;B29U5R?=7?V_Z$J3TJ?=-V.,#Z4-J:<"Z9X*C22VM,:%]VA=C&+1FD*E
M9U[S-2+T6S+:V?I23YE<VD,8A2PMQ9=0=;<ZZ#FWQQM[]R?X=(I;[L_PZ45Q
MC%.K+TZ5OE"YY,!UPA9@RCT)P5M9'-04"RW6]IS@06@M4GNY8A08, +P?"&$
M?ED8 ]5QV?AO4$L#!!0    ( ).%?%0. 1_ZN 8  "TC   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;+U:6V_;-A1^[GX%80Q8"]BQ2$J^%$F Q$ZQ
M#,T:U,CZ, P#;=$V5TE422IN@/[XD9(BVK%,:0OL/C2239[SG>MW*.M\P\57
MN:94@>]QE,B+SEJI]'V_+Q=K&A-YQE.:Z&^67,1$Z5NQZLM44!+FF^*HCSQO
MT(\)2SJ7Y_EG]^+RG&<J8@F]%T!F<4S$TS6-^.:B SO/'WQFJ[4R'_0OSU.R
MHC.J'M)[H>_ZE920Q321C"= T.5%YPJ^OPD\LR%?\0>C&[EU#8PI<\Z_FIO;
M\*+C&40TH@ME1!#]YY%.:!0921K'MU)HI])I-FY?/TO_D!NOC9D322<\^L)"
MM;[HC#H@I$N21>HSW_Q*2X,"(V_!(YG_#S;E6J\#%IE4/"XW:P0Q2XJ_Y'OI
MB*T-_OC !E1N0"\V('A@ RXWX+8;_'*#WW9#4&[(3>\7MN>.FQ)%+L\%WP!A
M5FMIYB+W?KY;^XLE)E%F2NAOF=ZG+F=%@@"^!#.V2MB2+4BBP-5BP;-$L60%
M[GG$%HQ*T -78<A,>$D$;I,B24VPWTZI(BR2[\[[2D,R@ON+4OUUH1X=4 \1
MN..)6DMPDX0TW!70U[94!J%G@ZZ14^*4+LX AEV / 0?9E/P]N=W,[K2N:T^
ML(0D"T:BOV\3J9C*#/H:S)/V&KQ20XV4J5O*;R0Y ]XNSAHI-ZVQP'&ME!TG
MXBHK<"X6-V3%I^:L^/.CW@MN%8WE7P[-?J79SS7[!S3_GL5S*DPZ"IIRH<@\
MHD 6\9/@!RA#69=IA> @%VSZX^,E/.\_UF )*BQ!2RRZ+PN2V]T.2M 6RJ""
M,F@)9?F<Q(#9))9@0>0:, G6- HUMK:I?CW80XKJD0XKI$,GTJM(<X_638%N
M$"#DV5PMLT@30IXZL@Y#(7"PA<&K,!0%Z5JQ@W)4H1PY47X13-$>7RZESK.H
M"*WB($MT/\TYS*3=,V:]9$'9HTG%.OBC/1>^A.]:L0-_7,$?.^'?QBEAHDA$
MG1,13U:]2!-N"(B4M-[+XT8OC]O"A)YE%\^=#1LB0NV_;QF3VN.Z?,0CT[FA
MZXGQL)8OW )]\$2)D(Y. [>H#SIE?:JJ.J)ZUN@"8:8*G16]3%*')TNQVZZ$
M?C#0L]E+CY8K';DQK1,V"/!P6]BN?<C:A_Z+?2!B9,XBS>!4=O5L(<2![E6*
MW6E?",,:\_87[IFWOT03WOBP=9:B(/[_UIF* #U%10P,BQQH?J6&'4,#!(<U
MENZOW+.T1MC "T:'3;6<"-VD.*5+JJ-E"JDV8E-8PWU>_N^ :DN!T,V!'W/?
M,MW/$S/15UY^JH41[.5RX$)AV0^ZZ6^F^.+KFD<A%?(78+J)>@)$*<'F63$B
MZ.:=DH,)O<]R&(ZA5Q?H&D(,!GBTO_2F7+IM;6^(QD.'P99$80.+VDG[GK"P
MQQ(P(2E3)')U/LM^<'3B^0Y:ZH)N[GIM+/=Y+$"# .&:6.X3&AXC;["_]*9F
MJ:Y=_V DD65 U," !R.IQ[1)%F=F^M"%=;-<ZKFC"^YS9C2L?A7RU.SLZJM_
M]$EP?]C<A61Y#\$31Q]93D)N3GI=]&]*Z3LUAP^S";)L@MQLLF7\3)$D-&/+
M0QH2/;.\[5S-'CKOS!%KT/.0RPVVHR/_U"&P+1VY6_ID39*5Z>G/ ZY1EPK=
MXUEJI][\L%-Z0H(L=T47$).3+\_IY;'<K56)C+K@6RY ;BYX-7SSR,+<UAKA
MUIT?VF'WIS=OS*G=98[M],C=Z5]C#M-)I&<<<QBD>?NH-<FMORDNEE.0^TC5
MKH)&/6_H4F=I!(U/7$'8]G3L[NE'JJ &K0V1PK;_8_>YYZ@5U*![IX(\ESF6
M4K";4MHF'ARYU&T]&COULS%L:0.[#P+'2CRWUJ;$L\R#C\P\SL1SZV[=NK%E
M(GP\)FK5NAOT-\7%<A!N.&VTJJ!Q#[J&'VR9 I_Z]($M;6#WZ>-8%>36VA I
MWS*/?V3F<550@^[6%>1;)O*/QT2M*JA!?U-<+ ?Y;@ZZ8PF+L]@ERQ*,?_(?
M7[9^?7&W^GMA?NHP1[(DS$]GJ3EU=@&5BAEWAR"3U#S/C]BR/H?<\G'CXUO?
MLHGO[NAWY'N3SVTK]P>G]KGMOKZ[^[[>YV[Y0;//;>OVW4-^Z7/P [0?]\WB
M4ST$\2T1^*<^/P2VBP?N3OJZAR"34OK.3P9UCUG[6Z\%Q%2L\O<Q),@-+'Y0
MKSZMWOFXRM]T>/'Y-7P_*=[<L&**%TGNB%BQ1(*(+K5([VRH2U84[V84-XJG
M^<L'<ZX4C_/+-27:<+- ?[_D7#W?& 75&S*7_P)02P,$%     @ DX5\5"T=
MY?_R @  I0P  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULM5==;]HP
M%/TK5J1)F]21.'RU%2 !W;1)JX1 VQZF/9CD E8=F]FF=-)^_&PG)% 1LW;P
M OXZY][CDUS=]+9"/J@5@$9/&>.J'ZRT7M^&H4I6D!'5$&O@9F<A9$:TF<IE
MJ-822.I &0OC*.J$&:$\&/3<VD0.>F*C&>4PD4AMLHS(WR-@8ML/<+!;F-+E
M2MN%<-!;DR7,0']=3Z29A25+2C/@B@J.)"SZP1#?CG'7 MR);Q2V:F^,K)2Y
M$ ]V\CGM!Y'-"!@DVE(0\_<(8V#,,ID\?A6D01G3 O?'._:/3KP1,R<*QH)]
MIZE>]8/K *6P(!NFIV+["0I!;<N7"*;<+]H69Z, )1NE15: 3089Y?D_>2HN
M8@^ .S6 N #$SP&M&D"S #2=T#PS)^N.:#+H2;%%TIXV;';@[L:AC1K*K8TS
M+<TN-3@]F.7V(;% ,[KD=$$3PC4:)HG8<$WY$DT$HPD%A=ZCF7F(T@T#>WHL
M> )<2^+<, M3JA[0VSO0A#+UKA=JDYV-$29%)J,\D[@F$QRC>\'U2J$//(7T
MD" TLDIM\4[;*/8RWD'20$U\A>(HQD<2&O\[//*DTRRONNGX6C5\4W@$O@'T
M!XV=KR"?7:*[P;W=H2=HJPS:<D&;-4&/1/CQQ9Q!GS5DZJ<G0KN,T/;*.HP@
M380KM 9IUTP=./8<^/ENVHTH>G/,KI?C#@1U2D&=L_KD"=DM0W8OY-)U&>'Z
MS"[Y^>I=>CGN0-!-*>C&2U14*(6FD !])'/F').04OT?[Q6.JL(97<@SO%><
M\9E=.T&(HZC.MQ/(;NN$<3BN5,67LF[D2Z JQ+AY*>NJNHM;Y[;.3UAOG!\7
M=TX95U5Z["^QKS?.%[ZJR[AS*=NJ0HR[Y[;-3^A[XUZ!S&6%>PV?N=VEZX,5
M<N[D_5&Y6O;:0]=A/EL?V1[<-9(53=[ WQ.YI%PA!@M#&36ZYM&0>4^<3[18
MN[9R+K2QV U7YCL"I#U@]A="Z-W$!BB_3 9_ 5!+ P04    " "3A7Q4&"]9
M?F0"  #L!0  &0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6R55&UKVS 0
M_BN'8=!"%[\D[49) DVZL<(*(6';A[$/JGVV1?7B27+3P7[\3K+CI24)VQ=;
M=[KG>>Y.TDVWVCS:&M'!LQ3*SJ+:N>8ZCFU>HV1VI!M4M%-J(YDCTU2Q;0RR
M(H"DB+,DN8HEXRJ:3X-O9>93W3K!%:X,V%9*9GXM4.CM+$JCG6/-J]IY1SR?
M-JS"#;HOS<J0%0\L!9>H+-<*#):SZ":]7E[Z^!#PE>/6[JW!5_*@]:,W[HI9
ME/B$4&#N/ .CWQ,N40A/1&G\[#FC0=(#]]<[]H^A=JKE@5E<:O&-%ZZ>1>\C
M*+!DK7!KO?V$?3TAP5P+&[ZP[6.3"/+6.BU[,&4@N>K^[+GOPQX@O3H"R'I
M]AHP.0(8]X!Q*+3++)1URQR;3XW>@O'1Q.87H3<!3=5PY4]QXPSM<L*Y^:8[
M/= E;'BE>,ESIAS<Y+ENE>.J@I46/.=HX2ULZ X5K4 ?O=0J1^4,"Z=!CC6W
MCW!VBXYQ8<_A;,4,[=?HB%&<3V-'V7K-..\S6W2994<R2S.XUT1@X8,JL'A)
M$%.90ZW9KM9%=I+Q%O,1C-,+R)(L/9#0\M_AR8ETQD/KQX%O<H1OC4^H6H3?
ML SGC.954T-']W879-RS9RY;>4)^,LA/@OSXB/P!K>^?*0;N'$K[XX3"Y:!P
M>;+ EPJ&%"Z@0>-]-" .W8C3?&DR2I(WAP[N_W%=0?'>PZ$.5V&>6 AWO[M7
M@W<863?AI;[R+VB4=9/G+TTW!^^9J;BR(+ DRF3TCG(UW6SI#*>;\#P?M*-C
M#LN:QC$:'T#[I=9N9WB!8<#/_P!02P,$%     @ DX5\5- ?^%/Q @  5 D
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M -^WG*OGB;Z,UK]6++\!4$L#!!0    ( ).%?%0XRN)I7@0  /\8   9
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M3,P/ $KK8-9G0NC-Q'Z@_*7H_0502P,$%     @ DX5\5!):^ZRI!   Y1D
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M$M"/CV"-[C1+U'\#N=PZEUOD\H[D^BHTC5'6)IP]Y>HCLHPV*J*9<_LPQY,
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M44:]S\, =#.AC6%5[9M\J2R-C%^6]*BA=@YTOE+*'@P7H'LFLQ=02P,$%
M  @ DX5\5$I\?-W7 @    @  !D   !X;"]W;W)K<VAE971S+W-H965T-30N
M>&ULC95=;]HP%(;_BA7UHI4Z\@DI54!J0=,V[0.5=KN8=F&2 ['JV,QVH/WW
MLYV0I1"BWH!/?-[CQV^<XV3/Q;/, 11Z*2B3$R=7:GOKNC+-H<!RP+? ],R:
MBP(K'8J-*[<"<&9%!74#SQNY!2;,F2;VV4),$UXJ2A@L!))E46#Q>@^4[R>.
M[QP>/)!-KLP#=YIL\0:6H)ZV"Z$CMZF2D0*8))PA >N)<^??SF.3;Q-^$MC+
MUAB9G:PX?S;!YVSB> 8(**3*5,#Z;P<SH-04TAA_ZYI.LZ01ML>'ZA_MWO5>
M5EC"C--?)%/YQ+EQ4 9K7%+UP/>?H-[/T-1+.97V%^WK7,]!:2D5+VJQ)B@(
MJ_[Q2^U#2^!'9P1!+0C>*PAK0?A>050+(NM,M17KPQPK/$T$WR-ALG4U,[!F
M6K7>/F'FM2^5T+-$Z]3T+DU%"1G"+$,_5 X"?25X12A1!.0UFI5" %-V^CMG
M:1U^0,OJF""^1H<2+2&ZG(/"A,HKG?JTG*/+BRMT@0A#CSDOI:XF$U=I? /A
MIC7J?84:G$&=0SI H7^- B_P.^2S?OD7S ;(.R^?OW]U[ZW<U9XWQ@>-\8&M
M%YZIM\"O>$6U5<9::R&F$OV^6TDE],?PIV>)L%DBM$M$YY<0G%*[@@"*E7Y)
M\*(;AH1.^ZMJ(UO-M(O=-!R/H\3=M5WJ2(K"N$EZ QHUH%$OZ.$$I7J"I+@B
MUEVLB:4JLU>4<JDZP:OJPQ93Y,5'W*<Y-Z-Q-_:PP1[V8L\XD[J]$+:I@?D:
MI.F'F'91#D\(_&$<'F&>)H7#..KF'#6<HU[.ZKO&M<E])V!TBAC'WA'B:5(T
M]KL)XX8P[B5\Y,J\]58OXI;YT&_H_];2A1V?G,DXCHX.[NPTZ2;TCNWO2HJ/
M-^>VVJVY&[]AL2%,(@IK+?,&L?9&5/=-%2B^M1UXQ97NYW:8ZRL:A$G0\VO.
MU2$P3;VY]*?_ %!+ P04    " "3A7Q4:E: N6L"  !C!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-2YX;6R-5<MNVS 0_!5"R"$!4NOM!($LP+%1M$73
M&G'2'HH>:&EE$:%(E:3LY.]+4K*@!K+KB\0E=W9G=OE(]ER\R!) H=>*,CES
M2J7J.]>560D5EA-> ],K!1<55MH46U?6 G!N015U \^;NA4FS$D3.[<2:<(;
M10F#E4"RJ2HLWNZ!\OW,\9W#Q"/9ELI,N&E2XRVL03W7*Z$MMX^2DPJ8))PA
M <7,F?MWR]CX6X<?!/9R,$9&R8;S%V-\SF>.9P@!A4R9"%C_=K  2DT@3>-/
M%]/I4QK@<'R(_M%JUUHV6,*"TY\D5^7,N750#@5NJ'KD^T_0Z;$$,TZE_:)]
MY^LY*&NDXE4'U@PJPMH_?NWJ, #XT1% T &"<P%A!PC/!40=(+*5::78.BRQ
MPFDB^!X)XZVCF8$MID5K^829MJ^5T*M$XU0ZSS+10(XPR]%W58) 7PG>$$H4
M 7F-%HT0P)1=_L99UID?T+K=)H@78["!Z^42%"947FG0\WJ)+B^NT 4B##V5
MO)$ZKDQ<I848.F[6D;YO20='2"\AFZ#0OT:!%_@C\,5I^!?,)L@[#E^>G]W[
M%^[JZO<M"/H6!#9>>"3>"K_A#05IBVS[@:E$O^8;J80^%K]/I C[%*%-$1VE
M7(!N1XY,2\84M_"IA9N;8I?Z07B3N+N1I%&?-#J9M-T7=:MNK,G12%*OS]D2
M:WWB@<_4C\=YQ3VO^"2O)ZXP1=RRH\-=R_I=.\8V_C_;Q8A//'VG:,3G-@[>
M27(')]I<OP]8; F3B$*A8=[D1D<1[976&HK7]I!ON-)7AAV6^A4 81ST>L&Y
M.ACFWNC?E?0O4$L#!!0    ( ).%?%3Q9H4#% ,  &@,   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4V+GAM;,U776_:,!3]*U;4AU9:29Q H!4@\;%JE=JI
M@W9[F/9@D@N)FMC,=J"3]N-G.R&D?'556XD78COW')][#W%NVDO&'T4$(-%3
MFE#1L2(IYY>V+8((4B)J; Y4W9DRGA*IIGQFBSD'$AI0FMBNX_AV2F)J==MF
M[8YWVRR324SACB.1I2GA?_J0L&7'PM9J813/(JD7[&Y[3F8P!ODPO^-J9I<L
M89P"%3&CB,.T8_7PY0#[&F BOL>P%)4QTJE,&'O4D^NP8SE:$2002$U!U&4!
M T@2S:1T_"Y(K7)/#:R.5^Q7)GF5S(0(&+#D1QS*J&.U+!3"E&2)'+'E%R@2
M:FB^@"7"_*)E$>M8*,B$9&D!5@K2F.97\E04H@)0B>X&N 7 W034]P"\ N"9
M1'-E)JTAD:3;YFR)N(Y6;'I@:F/0*IN8:AO'DJN[L<+)[@@$$!Y$B- 0J5HD
M9,(X,17N<4[H#)1G4J!S-,Z-1FRZ$:>1-W&@K 4T@@70#-#I$"2)$W&F@ _C
M(3H].4,G**;H/F*94 C1MJ62KT7802&UGTMU]TC%+KIE5$8"?:8AA,\);)5W
MF;R[2K[O'F0<0E!#'OZ$7,?%.P0-_A_N')#CE5YXAL_;PU<IZP*>E[^G:OR5
MT6!?!+I70T',HR'0SQO%C*XEI.+7 5WU4E?=Z*J_K*NP.RGLYKG=N[S,*7U#
MJ<^211>W'*_5MA?5 N^(\GSLEE'/]#9*O8U7ZMWX>QZHB5_NX1^55\U25_/]
MO<HI&R]XM2-JOU>M4F_K;5ZAORBC\;>,'W+MHMSMXJA<P\[Z&';>W[>"LVI)
MT_,W;-L55-_C&JZ\-O";?1LQU70<JHZ[WLT]+M_61S;V/L W;_M1:N(6WG1N
M1YC;NFCN\6Y]G./7GN?;W@VNK@[59WT4X\9Q.;<^P+'_ <[YVR\L=\NW[:!S
M=],UN]*SI<!GII45*& 9E7D'4ZZ6[7+/-(D;ZWW=1IM><$V3]^"WA,]B5;H$
MIHK2J36553QO:_.)9'/3&4Z85'VF&4;J4P"X#E#WIXS)U41O4'Y<=/\!4$L#
M!!0    ( ).%?%3O#G3ELP(  #\)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4W+GAM;,U606^;,!C]*Q;JH96V@B&AH4J0VD35*FU3EK3;8=K!@8^ :NS,
M-DGW[V<;2DF;H!YZZ"78\+W'^]YS;,8[+AYD#J#08TF9G#BY4IM+UY5)#B61
MYWP#3#_)N"B)TE.Q=N5& $DMJ*2N[WFA6Y*".?'8WIN+>,PK10L&<X%D599$
M_+L&RG<3!SM/-Q;%.E?FAAN/-V0-2U#WF[G0,[=E28L2F"PX0P*RB7.%+Z?8
M-P!;\;. G>R,D6EEQ?F#F=RF$\<SBH!"H@P%T9<M3(%2PZ1U_&U(G?:=!M@=
M/['?V.9U,RLB8<KIKR)5^<09.2B%C%14+?CN"S0-#0U?PJFTOVC7U'H.2BJI
M>-F M8*R8/65/#9&= !X< 3@-P#_K8"@ 02VT5J9;6M&%(G'@N^0,-6:S0RL
M-Q:MNRF8B7&IA'Y::)R*%R"!B"1'A*5(>T')B@MB';X2@K UZ,R41)_1L@X:
M\0S-( ,A($4+V *K )W.0)&"RC-==[^<H=.3,W2""H;N<EY)32W'KM)JS3O=
MI%%V72OSCRB;07*. OP)^9Z/#\"G;X=[^W!7>]0:Y;=&^98O.,+7\68+^]Y<
M:>N^<Y8<JT!W>BB)7;<2_?ZJF=&M@E+^Z=$5M+H"JVMP1-<=5X2:A5LG(NI$
M#ME=\X26Q_R[M_'0B[0UVZZIKXMP-,)^6[6G<=!J'/1JK%CQHQ+0T^VP91I^
MJ!3"5E?X3BG4/,..P4$8XA<IO"X:!%%X.(2+5N)%K\0%UT= 3ZNCEF?TH2*(
M6EW1^T0PC5ZYBP<!'AVV%WO/.ZG7*V!Z<]/3!N[LR/A#&8R?MT#LO],J;XCV
M]I&!'[U8YH>JO.AE$&[G=#.?%M^(6!>Z/0J9AGGG%SI)49_6]43QC3WP5ESI
MX],.<_V% \(4Z.<9Y^II8L[0]ILI_@]02P,$%     @ DX5\5(?!(!,'!0
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M80#/EU+JW4TQ07WX._D/4$L#!!0    ( ).%?%3H\]/>6@(   X%   9
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ME% X4+K\2&%+<ED@J3K1!PU"ULP7?#\)V+,H)0=O]%OYP7[]\92ZML "69;
MV_0?.%H.G5[PJ<P,5CS<Z@SV"\WK!+P&&9*XJK"]8'1,L)4P?.$EN*(;JA2U
M*>J8]M*[.!UY?,JOQVJ88*MEV"]FBR2Q:J7K/436O)_C]&3T$X*G)N-!?JVH
M8;^JW5/;:#*QM5O*]08"<DVN.=NZ+J%7R6K,R0L1[;$:C&C4:EGD5Q?;T_Q
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M5Q87H.IQB7LV:"> WS.E[.;%&6@W]\F_4$L#!!0    ( ).%?%3ZS&G%D@4
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MSAE-F#0#X/U,"+V^,0;J?UQ,_P-02P,$%     @ DX5\5$NQ8)E= @  B04
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MWMZ/0WP,^"&Q\0<VA$HVUCX'YZ&<)5D0A H+"@R"?R^X0*4"$<OXW7$F?<H
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M5S'#Q8YD4FL2,Z6^8Q6?F.H.6V4Q*BW:6CXN@XD_"^?N\3(Z;2F?TL!OI'[
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MCX)W9ID4V"VX=O;LT3+7_M"!)PTXX5[C>5;V* >'YJ) ^:BJ*IJRI>(QU?N
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M \6I9 CP?"F$WB^,@NI_*:;_ 5!+ P04    " "3A7Q4J\1DE,P"  !:!P
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M7.G19Y>%_CB!, 'Z_H9KBYN-2=!^[M(_4$L#!!0    ( ).%?%2/\B-5]@(
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M?/SP"7P  Y"L"*,)\"/P$OD\N1 /Q?6?JSA-2.0EEP,NX,I)!_,<VNT>&FJ
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MT?"(QSP&,PI*,O%&!,4V:U.H]YF(.]%V@35E?JQUAAD. CM*6 )&((PCODH
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MX^P7O^6)J "4GWH R@'H%. T )P<X)P"O : FP/<4X#; .CE@%Y;@)<#O+:
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M KY'B#0)<'\E8-RT&W. ^\*9_ -02P,$%     @ DX5\5(R%X%L) P  1PH
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M5?2,*\H<!5(>QD!/NUZ >J#^]AULK6 V."/IM_,C7MW4/2O#RAXH!EF;T7<
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M)%D61@ +*T@2#(&G$4<P!: !0Y+$G8,[YU&\/J?BS6]$H]]02P,$%     @
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MXFZ7[GQ5EN_IV.?ZPNEB\\.\S8\*W_X+4$L#!!0    ( ).%?%12-<:CB@(
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M+GAM;%!+ 0(4 Q0    ( ).%?%1C>1O-[P   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ).%?%297)PC$ 8
M )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ DX5\5 L%ZO5)!P  !QT  !@              ("!#@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ).%?%2DE9'W*@8
M &(9   8              " @8T/  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " "3A7Q4>W[U/!4#  "N"@  &               @('M
M%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ DX5\5(ZS
M<]5%!   /@X  !@              ("!.!D  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( ).%?%3]=0JR3P(  "L%   8
M  " @;,=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "3
MA7Q4E[RF&)L"  #0!@  &               @($X(   >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ DX5\5._$"D(*!P  '2,  !@
M         ("!"2,  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( ).%?%1;R?_PH0(  'P&   8              " @4DJ  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "3A7Q4)#QE-','  #R'@
M&               @($@+0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ DX5\5$1&1@8P!P  [A   !D              ("!R30  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "3A7Q4 0LF8&\I
M  "QA0  &0              @($P/   >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( ).%?%1%02W_K 0  ) ,   9              "
M@=9E  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ DX5\
M5&"/8"8\!   ] D  !D              ("!N6H  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " "3A7Q4GC89834#  #^!@  &0
M        @($L;P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( ).%?%0\YY& \ (  -\&   9              " @9AR  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ DX5\5.R2B9P,&@  T%P
M !D              ("!OW4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " "3A7Q4FJA6 "@&  !7$@  &0              @($"D
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ).%?%1;R)!S
MS H  $\?   9              " @6&6  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ DX5\5-%HDG:H#   H2,  !D
M ("!9*$  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "3
MA7Q4RJ_9DLT&  "0$   &0              @(%#K@  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ).%?%3GXH(EL ,  %8(   9
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M970R-2YX;6Q02P$"% ,4    " "3A7Q459Z;7<L%  ".#@  &0
M    @('0U   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M ).%?%3P<(GGU0(   \&   9              " @=+:  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ DX5\5/:NMZ(@+   2)8  !D
M             ("!WMT  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " "3A7Q4:-;M4%@$  #E"@  &0              @($U"@$ >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ).%?%2TD NAX0,
M -T*   9              " @<0. 0!X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ DX5\5+PD\[%5 P  ;P<  !D              ("!
MW!(! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "3A7Q4
M8#GLN?X"  !3!@  &0              @(%H%@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( ).%?%3KYYP#$P,  $H'   9
M      " @9T9 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ DX5\5/W__U/4 @  KP8  !D              ("!YQP! 'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "3A7Q4"1Q0L=,#  "2"0
M&0              @('R'P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( ).%?%047H9'] 0  %(,   9              " @?PC 0!X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ DX5\5"C[MZ;T
M @  *P8  !D              ("!)RD! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " "3A7Q4?6.PN?@"  !3!@  &0
M@(%2+ $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ).%
M?%2I/><H0 4  " -   9              " @8$O 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ DX5\5)6R81VO P  U0@  !D
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M=#0T+GAM;%!+ 0(4 Q0    ( ).%?%30'_A3\0(  %0)   9
M  " @8Q* 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
MDX5\5'H'!>0K!   N1   !D              ("!M$T! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " "3A7Q4.,KB:5X$  #_&   &0
M            @($64@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( ).%?%3O9C1YT0(  -L)   9              " @:M6 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ DX5\5$2SQBL7 P
M7@@  !D              ("!LUD! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    " "3A7Q4$EK[K*D$  #E&0  &0              @($!
M70$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ).%?%3!
MYRQBYP(  "T(   9              " @>%A 0!X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ DX5\5-=-DLR; P  S0X  !D
M     ("!_V0! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ).%?%3O#G3ELP(  #\)   9              "
M@4MT 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ DX5\
M5(?!(!,'!0  "!8  !D              ("!-7<! 'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    " "3A7Q4Z//3WEH"   .!0  &0
M        @(%S? $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0
M   ( ).%?%2C>8TI( ,  /$)   9              " @01_ 0!X;"]W;W)K
M<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ DX5\5&5*SMSZ!   KA$
M !D              ("!6X(! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q0
M2P$"% ,4    " "3A7Q4LRL$ \H$  "($0  &0              @(&,AP$
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( ).%?%0^V<R'
M= (  )(&   9              " @8V, 0!X;"]W;W)K<VAE971S+W-H965T
M-C,N>&UL4$L! A0#%     @ DX5\5&)UX4]!!   Q0\  !D
M ("!.(\! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " "3
MA7Q4^LQIQ9(%  #$&   &0              @(&PDP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( ).%?%1+L6"970(  (D%   9
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M970W,"YX;6Q02P$"% ,4    " "3A7Q4IM#K%^ $  "Q$   &0
M    @('RJ $ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    (
M ).%?%2KQ&24S (  %H'   9              " @0FN 0!X;"]W;W)K<VAE
M971S+W-H965T-S(N>&UL4$L! A0#%     @ DX5\5%?RT!>)!   U!(  !D
M             ("!#+$! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"
M% ,4    " "3A7Q466FYHS@$  !:$P  &0              @(',M0$ >&PO
M=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( ).%?%0O&.'AC0(
M /H&   9              " @3NZ 0!X;"]W;W)K<VAE971S+W-H965T-S4N
M>&UL4$L! A0#%     @ DX5\5(_R(U7V @  * H  !D              ("!
M_[P! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " "3A7Q4
MTU? !#H'   &)0  &0              @($LP $ >&PO=V]R:W-H965T<R]S
M:&5E=#<W+GAM;%!+ 0(4 Q0    ( ).%?%2H;I^A3 4  $08   9
M      " @9W' 0!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%
M  @ DX5\5 J2:@#\ @  % D  !D              ("!(,T! 'AL+W=O<FMS
M:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " "3A7Q4XMYRCP0$  !7%
M&0              @(%3T $ >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+
M 0(4 Q0    ( ).%?%3:5QE6O@0  *X3   9              " @8[4 0!X
M;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ DX5\5%=>/L?R
M @  %@@  !D              ("!@]D! 'AL+W=O<FMS:&5E=',O<VAE970X
M,BYX;6Q02P$"% ,4    " "3A7Q4>*'GB>8"  #M"   &0
M@(&LW $ >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( ).%
M?%2,A>!;"0,  $<*   9              " @<G? 0!X;"]W;W)K<VAE971S
M+W-H965T.#0N>&UL4$L! A0#%     @ DX5\5+T)K%7$ P  &0X  !D
M         ("!">,! 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4
M    " "3A7Q4NU>T)UD"  !_!0  &0              @($$YP$ >&PO=V]R
M:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( ).%?%2X$@,(&P,  # 2
M   -              "  93I 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !> %X R1D  "7Y 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>251</ContextCount>
  <ElementCount>441</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>91</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical</Role>
      <ShortName>Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrent</Role>
      <ShortName>Accrued and Other Liabilities, Current and Noncurrent</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Research and Collaboration Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements</Role>
      <ShortName>Research and Collaboration Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - License Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangements</Role>
      <ShortName>License Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Loss Per Share, Basic and Diluted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted1</Role>
      <ShortName>Net Loss Per Share, Basic and Diluted</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiability</Role>
      <ShortName>Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100270 - Disclosure - 401(K) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlan</Role>
      <ShortName>401(K) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentTables</Role>
      <ShortName>Accrued and Other Liabilities, Current and Noncurrent (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrent</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Research and Collaboration Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables</Role>
      <ShortName>Research and Collaboration Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Net Loss Per Share, Basic and Diluted (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables</Role>
      <ShortName>Net Loss Per Share, Basic and Diluted (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted1</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - The Company - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails</Role>
      <ShortName>The Company - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impact of Adoption of New Accounting Standard (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Impact of Adoption of New Accounting Standard (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Marketable Securities - Summary of Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Marketable Securities (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent - Summary of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Liabilities, Current and Noncurrent - Summary of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent - Summary of Other Liabilities, Noncurrent (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails</Role>
      <ShortName>Accrued and Other Liabilities, Current and Noncurrent - Summary of Other Liabilities, Noncurrent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails</Role>
      <ShortName>Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Research and Collaboration Arrangements - Summary of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails</Role>
      <ShortName>Research and Collaboration Arrangements - Summary of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Arrangements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1</Role>
      <ShortName>Research and Collaboration Arrangements - Additional Information (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Research and Collaboration Arrangements - CRF Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Arrangements - CRF Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Research and Collaboration Arrangements - Roche Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Arrangements - Roche Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Arrangements - CFF - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1</Role>
      <ShortName>Research and Collaboration Arrangements - CFF - Additional Information (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100650 - Disclosure - License Arrangements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails</Role>
      <ShortName>License Arrangements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Commitments and Contingencies - summary of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Commitments and Contingencies - summary of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Commitments and Contingencies - Summary of Supplemental Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Supplemental Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Income Tax Expense (Benefit) Differs from Federal Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Tax Rate of Income Tax Expense (Benefit) Differs from Federal Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences to Significant Components of Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Tax Effects of Temporary Differences to Significant Components of Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Beginning and Ending Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Common Stock - Schedule of Common Share Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Schedule of Common Share Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Stock-based Compensation - Summary of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Stock-based Compensation - Summary of Stock Compensation Expense for Employees and Nonemployees by Function (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Compensation Expense for Employees and Nonemployees by Function (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Common Stock Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails</Role>
      <ShortName>Common Stock Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>100850 - Disclosure - Derivative Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails</Role>
      <ShortName>Derivative Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>100860 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="fdmt-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>100870 - Disclosure - 401(K) Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails</Role>
      <ShortName>401(K) Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="fdmt-20211231.htm">fdmt-20211231.htm</File>
    <File>fdmt-20211231.xsd</File>
    <File>fdmt-20211231_cal.xml</File>
    <File>fdmt-20211231_def.xml</File>
    <File>fdmt-20211231_lab.xml</File>
    <File>fdmt-20211231_pre.xml</File>
    <File>fdmt-ex23_1.htm</File>
    <File>fdmt-ex31_1.htm</File>
    <File>fdmt-ex31_2.htm</File>
    <File>fdmt-ex32_1.htm</File>
    <File>fdmt-ex4_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img227133604_0.jpg</File>
    <File>img227133604_1.jpg</File>
    <File>img227133604_10.jpg</File>
    <File>img227133604_11.jpg</File>
    <File>img227133604_2.jpg</File>
    <File>img227133604_3.jpg</File>
    <File>img227133604_4.jpg</File>
    <File>img227133604_5.jpg</File>
    <File>img227133604_6.jpg</File>
    <File>img227133604_7.jpg</File>
    <File>img227133604_8.jpg</File>
    <File>img227133604_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="773">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>117
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fdmt-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 35,
   "contextCount": 251,
   "dts": {
    "calculationLink": {
     "local": [
      "fdmt-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fdmt-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "fdmt-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fdmt-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fdmt-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fdmt-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 684,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://www.4dmoleculartherapeutics.com/20211231": 4,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 15
   },
   "keyCustom": 95,
   "keyStandard": 346,
   "memberCustom": 38,
   "memberStandard": 47,
   "nsprefix": "fdmt",
   "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - The Company",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompany",
     "shortName": "The Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Marketable Securities",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Property and Equipment, Net",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:AccruedAndOtherLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrent",
     "shortName": "Accrued and Other Liabilities, Current and Noncurrent",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:AccruedAndOtherLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Research and Collaboration Arrangements",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements",
     "shortName": "Research and Collaboration Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:LicenseArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - License Arrangements",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangements",
     "shortName": "License Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:LicenseArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Commitments and Contingencies",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Income Taxes",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:TemporaryEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:TemporaryEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Common Stock",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Stock-based Compensation",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:CommonStockWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Common Stock Warrants",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrants",
     "shortName": "Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:CommonStockWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Net Loss Per Share, Basic and Diluted",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted1",
     "shortName": "Net Loss Per Share, Basic and Diluted",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Derivative Liability",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiability",
     "shortName": "Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Related Party Transactions",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - 401(K) Plan",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlan",
     "shortName": "401(K) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fdmt:PrepaidExpensesToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fdmt:PrepaidExpensesToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "fdmt:AccruedAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentTables",
     "shortName": "Accrued and Other Liabilities, Current and Noncurrent (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "fdmt:AccruedAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:ScheduleOfCollaborationAndLicenseRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Research and Collaboration Arrangements (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables",
     "shortName": "Research and Collaboration Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:ScheduleOfCollaborationAndLicenseRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "fdmt:TemporaryEquityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Redeemable Convertible Preferred Stock (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables",
     "shortName": "Redeemable Convertible Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "fdmt:TemporaryEquityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:ScheduleOfCommonShareReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Common Stock (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:ScheduleOfCommonShareReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Operations",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_c809c8ab-34c1-45aa-9199-72b4b861d30e",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Net Loss Per Share, Basic and Diluted (Tables)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables",
     "shortName": "Net Loss Per Share, Basic and Diluted (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - The Company - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
     "shortName": "The Company - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_542e8a0a-d3fd-48d5-aca9-2b0837fda539",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_d724d8a1-6a4a-42cb-a720-853feca51dab",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_d724d8a1-6a4a-42cb-a720-853feca51dab",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_f0620193-2d47-4e0f-b17c-1fa3385b38cb",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_f0620193-2d47-4e0f-b17c-1fa3385b38cb",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_02f4bd8b-251b-482c-a9fc-56da777a2727",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Summary of Significant Accounting Policies - Schedule of Impact of Adoption of New Accounting Standard (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Impact of Adoption of New Accounting Standard (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_1874832c-8de4-4a7f-a27f-f1dc966227e4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_d1ec6218-dc19-4a0d-9c16-9e9cf05148c8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_d1ec6218-dc19-4a0d-9c16-9e9cf05148c8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_04e47ba0-ce07-4a2d-aa4a-280a066c7c65",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Derivative Liability (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails",
     "shortName": "Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_78089c61-9c63-4f0e-ab4c-7158c1adabeb",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fdmt:ResearchAndDevelopmentExpenseRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Operations (Parenthetical)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical",
     "shortName": "Statements of Operations (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fdmt:ResearchAndDevelopmentExpenseRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_f91508fa-5dfa-4192-91eb-1afaa64ddaad",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Marketable Securities - Summary of Available for Sale Securities (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
     "shortName": "Marketable Securities - Summary of Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_f91508fa-5dfa-4192-91eb-1afaa64ddaad",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Marketable Securities (Additional Information) (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "fdmt:AccruedAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent - Summary of Accrued Liabilities (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails",
     "shortName": "Accrued and Other Liabilities, Current and Noncurrent - Summary of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "fdmt:AccruedAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "fdmt:AccruedAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_bf1c55da-f533-4e8b-9709-41e08427872a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRentCreditNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Accrued and Other Liabilities, Current and Noncurrent - Summary of Other Liabilities, Noncurrent (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails",
     "shortName": "Accrued and Other Liabilities, Current and Noncurrent - Summary of Other Liabilities, Noncurrent (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "fdmt:AccruedAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_bf1c55da-f533-4e8b-9709-41e08427872a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRentCreditNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
     "shortName": "Research and Collaboration Arrangements - Summary of Collaboration and License Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "fdmt:ScheduleOfCollaborationAndLicenseRevenueTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_dfd0d18e-816a-44fd-b58e-bba6ac6a812a",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Research and Collaboration Arrangements - Summary of Deferred Revenue (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails",
     "shortName": "Research and Collaboration Arrangements - Summary of Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_fb67bb6e-bab1-4045-8de0-aaff307da3a9",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
     "shortName": "Research and Collaboration Arrangements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_0912072b-bcab-4ad8-a96b-b69214a4c085",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details 1)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
     "shortName": "Research and Collaboration Arrangements - Additional Information (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_0912072b-bcab-4ad8-a96b-b69214a4c085",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Comprehensive Loss",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss",
     "shortName": "Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_e21eab0a-797b-4380-9011-1aea8fabc1b5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:CollaborativeArrangementInitialResearchTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Research and Collaboration Arrangements - CRF Agreement - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails",
     "shortName": "Research and Collaboration Arrangements - CRF Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_e21eab0a-797b-4380-9011-1aea8fabc1b5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fdmt:CollaborativeArrangementInitialResearchTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Research and Collaboration Arrangements - Roche Agreement - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails",
     "shortName": "Research and Collaboration Arrangements - Roche Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_c5195dc7-61ee-4ec1-9b9c-32cef44fc0b0",
      "decimals": "-5",
      "lang": null,
      "name": "fdmt:CollaborationArrangementsNonRefundableUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
     "shortName": "Research and Collaboration Arrangements - CFF - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_eab566a6-1468-49d2-aaec-a715d312418d",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_b4e47e36-ad9e-4007-bb25-cc82fae064e6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details 1)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
     "shortName": "Research and Collaboration Arrangements - CFF - Additional Information (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_b4e47e36-ad9e-4007-bb25-cc82fae064e6",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "fdmt:LicenseArrangementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_cc9158f0-cc85-4a61-9faf-16e23bce0c56",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "fdmt:NonRefundableLicenseFeePayableUponExecution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - License Arrangements - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
     "shortName": "License Arrangements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "fdmt:LicenseArrangementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_cc9158f0-cc85-4a61-9faf-16e23bce0c56",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "fdmt:NonRefundableLicenseFeePayableUponExecution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Commitments and Contingencies - summary of Components of Lease Expense (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails",
     "shortName": "Commitments and Contingencies - summary of Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Commitments and Contingencies - Summary of Supplemental Information Related to Leases (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails",
     "shortName": "Commitments and Contingencies - Summary of Supplemental Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Income Tax Expense (Benefit) Differs from Federal Statutory Rate (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails",
     "shortName": "Income Taxes - Schedule of Effective Tax Rate of Income Tax Expense (Benefit) Differs from Federal Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_034d1a9d-6368-4975-b6f6-9934f04efcc1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_59d3639a-d9e5-4bdd-af89-ba17bedfea32",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences to Significant Components of Deferred Taxes (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails",
     "shortName": "Income Taxes - Schedule of Tax Effects of Temporary Differences to Significant Components of Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_bf1c55da-f533-4e8b-9709-41e08427872a",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Unrecognized Tax Benefits (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of Beginning and Ending Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_034d1a9d-6368-4975-b6f6-9934f04efcc1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "fdmt:TemporaryEquityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_034d1a9d-6368-4975-b6f6-9934f04efcc1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "fdmt:TemporaryEquityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_893705a7-019f-4880-8fba-130e464feaa6",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "fdmt:TemporaryEquityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_034d1a9d-6368-4975-b6f6-9934f04efcc1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "fdmt:TemporaryEquityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_034d1a9d-6368-4975-b6f6-9934f04efcc1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Common Stock - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_46423923-3058-4aaf-ac32-c74922d40a3d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Common Stock - Schedule of Common Share Reserved for Future Issuance (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
     "shortName": "Common Stock - Schedule of Common Share Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_84f39b44-5422-454e-b43f-0e6094e9de94",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_bf1c55da-f533-4e8b-9709-41e08427872a",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_bf1c55da-f533-4e8b-9709-41e08427872a",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100790 - Disclosure - Stock-based Compensation - Summary of Stock Options Activity (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails",
     "shortName": "Stock-based Compensation - Summary of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100800 - Disclosure - Stock-based Compensation - Summary of Stock Compensation Expense for Employees and Nonemployees by Function (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails",
     "shortName": "Stock-based Compensation - Summary of Stock Compensation Expense for Employees and Nonemployees by Function (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_e63d3fbd-6765-47dd-a387-c3545c1942c5",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_f0ae8a23-d71e-4828-8ac8-78470326d77f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_f0ae8a23-d71e-4828-8ac8-78470326d77f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100810 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails",
     "shortName": "Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_41177fa2-9b3f-4111-9b72-79dd315c5b6e",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "fdmt:CommonStockWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_5b3c671f-d9c2-479a-878e-5392aef7d177",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fdmt:NumberOfWarrantsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100820 - Disclosure - Common Stock Warrants - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
     "shortName": "Common Stock Warrants - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "fdmt:CommonStockWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_5b3c671f-d9c2-479a-878e-5392aef7d177",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fdmt:NumberOfWarrantsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100830 - Disclosure - Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100840 - Disclosure - Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fdmt:FairValueAssumptionsProbabilityOfChangeInControlDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100850 - Disclosure - Derivative Liability - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails",
     "shortName": "Derivative Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fdmt:FairValueAssumptionsProbabilityOfChangeInControlDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_f8c80726-14a0-4e92-b15c-36f91786d60a",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100860 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_f8c80726-14a0-4e92-b15c-36f91786d60a",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_b63ba5ca-290b-449e-9c24-797545392bb5",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100870 - Disclosure - 401(K) Plan - Additional Information (Details)",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails",
     "shortName": "401(K) Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_b63ba5ca-290b-449e-9c24-797545392bb5",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100090 - Statement - Statements of Cash Flows",
     "role": "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "fdmt-20211231.htm",
      "contextRef": "C_7421a1ac-23e5-447d-aabe-10f3efe826be",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 91,
   "tag": {
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND",
        "terseLabel": "Switzerland"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_NL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS",
        "terseLabel": "Netherlands"
       }
      }
     },
     "localname": "NL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r761",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r761",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r761",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r761",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r761",
      "r762",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fdmt_AccruedAndOtherLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and other liabilities.",
        "label": "Accrued And Other Liabilities [Text Block]",
        "terseLabel": "Accrued and Other Liabilities, Current and Noncurrent"
       }
      }
     },
     "localname": "AccruedAndOtherLiabilitiesTextBlock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_AccruedClinicalAndPreclinicalStudyCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical and preclinical study costs.",
        "label": "Accrued Clinical And Preclinical Study Costs",
        "terseLabel": "Accrued clinical and preclinical study costs"
       }
      }
     },
     "localname": "AccruedClinicalAndPreclinicalStudyCosts",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_AccruedResearchAndDevelopmentPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development Policy Policy [Text Block]",
        "terseLabel": "Accrued Research and Development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentPolicyPolicyTextBlock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actual award payment period upon first commercial sale of product.",
        "label": "Actual Award Payment Period Upon First Commercial Sale Of Product",
        "terseLabel": "Actual award payment period upon first commercial sale of product"
       }
      }
     },
     "localname": "ActualAwardPaymentPeriodUponFirstCommercialSaleOfProduct",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fdmt_AdditionalFundingCommitted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional funding committed.",
        "label": "Additional Funding Committed",
        "terseLabel": "Additional funding upon acceptance of investigational New Drug application"
       }
      }
     },
     "localname": "AdditionalFundingCommitted",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_AdditionalInvestmentInCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional investment in cash.",
        "label": "Additional Investment in Cash",
        "terseLabel": "Additional investment in cash"
       }
      }
     },
     "localname": "AdditionalInvestmentInCash",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital vesting of stock warrant issued for services.",
        "label": "Adjustments To Additional Paid In Capital Vesting Of Stock Warrant Issued For Services",
        "terseLabel": "Vesting of common stock warrants issued for services"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalVestingOfStockWarrantIssuedForServices",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_AmendedUniQureAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended uniQure agreement.",
        "label": "Amended Uni Qure Agreement [Member]",
        "terseLabel": "Amended uniQure Agreement"
       }
      }
     },
     "localname": "AmendedUniQureAgreementMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_AmountObligatedToPayNonRefundableLicenseFeeAnnually": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount obligated to pay a non-refundable license fee annually.",
        "label": "Amount Obligated To Pay Non Refundable License Fee Annually",
        "terseLabel": "Non-refundable license fee payable annually"
       }
      }
     },
     "localname": "AmountObligatedToPayNonRefundableLicenseFeeAnnually",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount obligated to pay upon closing first qualified financing at option.",
        "label": "Amount Obligated To Pay Upon Closing First Qualified Financing At Option",
        "terseLabel": "Amount obligated to pay upon closing first qualified financing at option of UC Regents"
       }
      }
     },
     "localname": "AmountObligatedToPayUponClosingFirstQualifiedFinancingAtOption",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_AmountsPaidNonRefundableLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount paid non-refundable license fees.",
        "label": "Amounts Paid Non Refundable License Fees",
        "terseLabel": "Amount paid non-refundable license fees"
       }
      }
     },
     "localname": "AmountsPaidNonRefundableLicenseFees",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_AnnualRoyalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual royalty.",
        "label": "Annual Royalty",
        "terseLabel": "Annual royalty"
       }
      }
     },
     "localname": "AnnualRoyalty",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_BuildingLeaseAndExpansionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building lease and expansion.",
        "label": "Building Lease and Expansion [Member]",
        "terseLabel": "5858 Horton Street Building Lease and Expansion"
       }
      }
     },
     "localname": "BuildingLeaseAndExpansionMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_BuildingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building lease.",
        "label": "5980 Horton Street Building Lease",
        "terseLabel": "5980 Horton Street Building Lease"
       }
      }
     },
     "localname": "BuildingLeaseMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_CARESActReliefDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Relief description.",
        "label": "C A R E S Act Relief Description",
        "terseLabel": "CARES Act, relief description"
       }
      }
     },
     "localname": "CARESActReliefDescription",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fdmt_ChoroideremiaResearchFoundationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Choroideremia Research Foundation Agreement.",
        "label": "Choroideremia Research Foundation Agreement [Member]",
        "terseLabel": "CRF Agreement"
       }
      }
     },
     "localname": "ChoroideremiaResearchFoundationAgreementMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_ChoroideremiaResearchFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Choroideremia Research Foundation.",
        "label": "Choroideremia Research Foundation [Member]",
        "terseLabel": "CRF"
       }
      }
     },
     "localname": "ChoroideremiaResearchFoundationMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_CoFounderAndChiefScientificAdvisorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-founder and Chief Scientific Advisor [Member]",
        "label": "Co Founder And Chief Scientific Advisor [Member]",
        "terseLabel": "David Schaffer, PhD,"
       }
      }
     },
     "localname": "CoFounderAndChiefScientificAdvisorMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_CollaborationAndLicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Revenue.",
        "label": "Collaboration And License Revenue [Member]",
        "terseLabel": "Collaboration and License Revenue"
       }
      }
     },
     "localname": "CollaborationAndLicenseRevenueMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration arrangements contingent payment for each nominated product beyond the first three.",
        "label": "Collaboration Arrangements Contingent Payment For Each Nominated Product Beyond First Three",
        "terseLabel": "Contingent payment for each nominated product beyond the first three"
       }
      }
     },
     "localname": "CollaborationArrangementsContingentPaymentForEachNominatedProductBeyondFirstThree",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration arrangements development milestone payments relating to Choroideremia.",
        "label": "Collaboration Arrangements Development Milestone Payments Relating To Choroideremia",
        "terseLabel": "Development milestone payments relating to Choroideremia"
       }
      }
     },
     "localname": "CollaborationArrangementsDevelopmentMilestonePaymentsRelatingToChoroideremia",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration arrangements maximum contingent payment upon exercise of the option to convert a product.",
        "label": "Collaboration Arrangements Maximum Contingent Payment Upon Exercise Of Option To Convert A Product",
        "terseLabel": "Maximum contingent payment upon exercise of the option to convert a product"
       }
      }
     },
     "localname": "CollaborationArrangementsMaximumContingentPaymentUponExerciseOfOptionToConvertAProduct",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborationArrangementsMaximumDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration arrangements maximum development milestone payments.",
        "label": "Collaboration Arrangements Maximum Development Milestone Payments",
        "terseLabel": "Maximum development milestone payments"
       }
      }
     },
     "localname": "CollaborationArrangementsMaximumDevelopmentMilestonePayments",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborationArrangementsNonRefundableDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration arrangements non-refundable development milestone payments.",
        "label": "Collaboration Arrangements Non Refundable Development Milestone Payments",
        "terseLabel": "Non-refundable development milestone payments"
       }
      }
     },
     "localname": "CollaborationArrangementsNonRefundableDevelopmentMilestonePayments",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborationArrangementsNonRefundableUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration arrangements non-refundable upfront payment received.",
        "label": "Collaboration Arrangements Non Refundable Upfront Payment Received",
        "terseLabel": "Non-refundable upfront payments received"
       }
      }
     },
     "localname": "CollaborationArrangementsNonRefundableUpfrontPaymentReceived",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborationArrangementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration arrangements upfront payment received.",
        "label": "Collaboration Arrangements Upfront Payment Received",
        "terseLabel": "Upfront payments received"
       }
      }
     },
     "localname": "CollaborationArrangementsUpfrontPaymentReceived",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborativeArrangementAchievedMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement achieved milestones.",
        "label": "Collaborative Arrangement Achieved Milestones",
        "terseLabel": "Collaborative arrangement achieved milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievedMilestones",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborativeArrangementAdditionOfVariableConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement adjustment to transaction price due to variable consideration.",
        "label": "Collaborative Arrangement Addition Of Variable Consideration",
        "terseLabel": "Collaborative arrangement adjustment to transaction price due to variable consideration"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionOfVariableConsideration",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborativeArrangementAdditionalResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement additional research term.",
        "label": "Collaborative Arrangement Additional Research Term",
        "terseLabel": "Collaborative arrangement additional research term"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalResearchTerm",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fdmt_CollaborativeArrangementAdjustmentToTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement adjustment to transaction price.",
        "label": "Collaborative Arrangement Adjustment To Transaction Price",
        "terseLabel": "Collaborative arrangement adjustment to transaction price"
       }
      }
     },
     "localname": "CollaborativeArrangementAdjustmentToTransactionPrice",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborativeArrangementContributionUponDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement contribution upon development milestone.",
        "label": "Collaborative Arrangement Contribution Upon Development Milestone",
        "terseLabel": "Collaborative arrangement contribution upon development milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementContributionUponDevelopmentMilestone",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement adjustment to transaction price due to increase in project scope and expected reimbursable costs.",
        "label": "Collaborative Arrangement Increase Of Project Scope And Expected Reimbursable Costs",
        "terseLabel": "Collaborative arrangement adjustment to transaction price due to increase in project scope and expected reimbursable costs"
       }
      }
     },
     "localname": "CollaborativeArrangementIncreaseOfProjectScopeAndExpectedReimbursableCosts",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborativeArrangementInitialResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, initial research term.",
        "label": "Collaborative Arrangement Initial Research Term",
        "terseLabel": "Collaborative arrangement, initial research term"
       }
      }
     },
     "localname": "CollaborativeArrangementInitialResearchTerm",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fdmt_CollaborativeArrangementMaximumSalesBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement maximum sales-based milestone payments.",
        "label": "Collaborative Arrangement Maximum Sales Based Milestone Payments",
        "terseLabel": "Maximum sales-based milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumSalesBasedMilestonePayments",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement research and development milestones entitled to receive for each licensed product.",
        "label": "Collaborative Arrangement Research And Development Milestones Entitled To Receive For Each Licensed Product",
        "terseLabel": "Contingent payments entitled to receive for achievement of research and development milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchAndDevelopmentMilestonesEntitledToReceiveForEachLicensedProduct",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborativeArrangementTransactionPriceAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction price adjustment.",
        "label": "Collaborative Arrangement Transaction Price Adjustment",
        "terseLabel": "Collaborative arrangement transaction price adjustment"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPriceAdjustment",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangements future sales based milestone payments percentage.",
        "label": "Collaborative Arrangements Future Sales Based Milestone Payments Percentage",
        "terseLabel": "Future sales-based milestone payments percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementsFutureSalesBasedMilestonePaymentsPercentage",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fdmt_CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangements royalties percentage on actual award received.",
        "label": "Collaborative Arrangements Royalties Percentage On Actual Award Received",
        "terseLabel": "Royalties percentage on actual award received"
       }
      }
     },
     "localname": "CollaborativeArrangementsRoyaltiesPercentageOnActualAwardReceived",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fdmt_CommitmentAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment and contingencies.",
        "label": "Commitment And Contingencies [Line Items]",
        "terseLabel": "Commitment And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesLineItems",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fdmt_CommitmentAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment and contingencies.",
        "label": "Commitment And Contingencies [Table]",
        "terseLabel": "Commitment And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesTable",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fdmt_CommonStockWarrantsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants Policy Policy [Text Block]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsPolicyPolicyTextBlock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_CommonStockWarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Text Block]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsTextBlock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_ConsultingServicesAndServicesAsBoardOfDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Services And Services As Board Of Director [Member]",
        "terseLabel": "Consulting Services and Services as Board of Director"
       }
      }
     },
     "localname": "ConsultingServicesAndServicesAsBoardOfDirectorMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_ContingentPaymentsEliminated": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent payments eliminated.",
        "label": "Contingent Payments Eliminated",
        "terseLabel": "Contingent payments eliminated"
       }
      }
     },
     "localname": "ContingentPaymentsEliminated",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuous period where the Company ceases to develop or commercialize any product.",
        "label": "Continuous Period Where Company Ceases To Develop Or Commercialize Any Product",
        "terseLabel": "Continuous period where the Company ceases to develop or commercialize any product"
       }
      }
     },
     "localname": "ContinuousPeriodWhereCompanyCeasesToDevelopOrCommercializeAnyProduct",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fdmt_CorporateBondMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate bond.",
        "label": "Corporate Bond [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "CorporateBondMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A.",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B.",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_CustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer.",
        "label": "Customer Member",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomerMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_CysticFibrosisFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cystic Fibrosis Foundation [Member]",
        "label": "Cystic Fibrosis Foundation [Member]",
        "terseLabel": "CFF"
       }
      }
     },
     "localname": "CysticFibrosisFoundationMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_DeferredOfferingCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs.",
        "label": "Deferred Offering Costs Policy Policy [Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredOfferingCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, operating lease liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, operating lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Operating Lease Right-of-Use Assets",
        "negatedLabel": "Operating lease right-of-use assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_DevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones.",
        "label": "Development Milestones",
        "terseLabel": "Development milestones"
       }
      }
     },
     "localname": "DevelopmentMilestones",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee.",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_ExpectedPaymentsPercentageToEqualActualAwardReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected payments percentage to equal actual award received.",
        "label": "Expected Payments Percentage To Equal Actual Award Received",
        "terseLabel": "Expected payments percentage to equal actual award received"
       }
      }
     },
     "localname": "ExpectedPaymentsPercentageToEqualActualAwardReceived",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fdmt_FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.",
        "label": "F Hoffmann La Roche Ltd And Hoffmann La Roche Inc [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "FHoffmannLaRocheLtdAndHoffmannLaRocheIncMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_FairValueAssumptionsChangeOfControlPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assumptions change of control payment.",
        "label": "Fair Value Assumptions Change Of Control Payment",
        "terseLabel": "Change of control payment"
       }
      }
     },
     "localname": "FairValueAssumptionsChangeOfControlPayment",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_FairValueAssumptionsProbabilityOfChangeInControlDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assumptions probability of change in control discount rate.",
        "label": "Fair Value Assumptions Probability Of Change In Control Discount Rate",
        "terseLabel": "Change in control discount rate"
       }
      }
     },
     "localname": "FairValueAssumptionsProbabilityOfChangeInControlDiscountRate",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fdmt_FairValueAssumptionsProbabilityOfChangeInControlEventPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assumptions probability of change in control event percentage.",
        "label": "Fair Value Assumptions Probability Of Change In Control Event Percentage",
        "terseLabel": "Change in control event percentage"
       }
      }
     },
     "localname": "FairValueAssumptionsProbabilityOfChangeInControlEventPercentage",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fdmt_FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of non monetary consideration of intellectual property right.",
        "label": "Fair Value Of Non Monetary Consideration Of Intellectual Property Right",
        "terseLabel": "Fair value of non monetary consideration of intellectual property right"
       }
      }
     },
     "localname": "FairValueOfNonMonetaryConsiderationOfIntellectualPropertyRight",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_FairValueOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options.",
        "label": "Fair Value Of Options",
        "terseLabel": "Fair value of options"
       }
      }
     },
     "localname": "FairValueOfOptions",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow on public offering.",
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Follow-On Offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_FundingAgreementProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding agreement product.",
        "label": "Funding Agreement Product [Member]",
        "terseLabel": "Funding Agreement Product"
       }
      }
     },
     "localname": "FundingAgreementProductMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_IncreaseDecreaseInContractWithCustomerRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in revenue recognized related to performance obligations partially satisfied in the beginning of the current year.",
        "label": "Increase Decrease In Contract With Customer Revenue Recognized",
        "terseLabel": "Increase in revenue recognized related to performance obligations partially satisfied in the beginning of the current year"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerRevenueRecognized",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_IncurredExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incurred expenses",
        "label": "Incurred Expenses",
        "terseLabel": "Incurred expenses"
       }
      }
     },
     "localname": "IncurredExpenses",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_IssuanceCostForIssuanceOfPreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance cost for issuance of preferred stock.",
        "label": "Issuance Cost For Issuance Of Preferred Stock",
        "terseLabel": "Issuance cost for issuance of preferred stock"
       }
      }
     },
     "localname": "IssuanceCostForIssuanceOfPreferredStock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock upon exercise of stock options and warrants.",
        "label": "Issuance of Common Stock upon Exercise of Stock Options and Warrants",
        "terseLabel": "Issuance of common stock upon exercise of stock options and warrants"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUponExerciseOfStockOptionsAndWarrants",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_LeaseIncentiveLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease incentive liability.",
        "label": "Lease Incentive Liability",
        "terseLabel": "Lease incentive liability"
       }
      }
     },
     "localname": "LeaseIncentiveLiability",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_LicenseArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License arrangements.",
        "label": "License Arrangements [Abstract]"
       }
      }
     },
     "localname": "LicenseArrangementsAbstract",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "fdmt_LicenseArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License arrangements.",
        "label": "License Arrangements [Text Block]",
        "terseLabel": "License Arrangements"
       }
      }
     },
     "localname": "LicenseArrangementsTextBlock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities.",
        "label": "Long-term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_MachineLearningSponsoredResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machine Learning Sponsored Research Agreement [Member]",
        "terseLabel": "Machine Learning SRA"
       }
      }
     },
     "localname": "MachineLearningSponsoredResearchAgreementMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_MaximumMaturityPeriodOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum maturity period of marketable securities",
        "label": "Maximum Maturity Period of Marketable Securities",
        "terseLabel": "Maximum Maturity Period of Marketable Securities"
       }
      }
     },
     "localname": "MaximumMaturityPeriodOfMarketableSecurities",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fdmt_MinimumPercentageOfOutstandingSharesHeldByIndividual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of outstanding shares held by individual",
        "label": "Minimum Percentage Of Outstanding Shares Held By Individual",
        "terseLabel": "Minimum percentage of outstanding shares held by individual"
       }
      }
     },
     "localname": "MinimumPercentageOfOutstandingSharesHeldByIndividual",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fdmt_NonCashIssuanceOfCommonStockWarrantToSettleLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash Issuance Of Common Stock Warrant to settle liability",
        "label": "Non cash Issuance Of Common Stock Warrant to settle liability",
        "terseLabel": "Issuance of common stock warrant to settle liability"
       }
      }
     },
     "localname": "NonCashIssuanceOfCommonStockWarrantToSettleLiability",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_NonRefundableLicenseFeePayableEveryYearAfterExecution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable license fee payable upon execution every year after execution.",
        "label": "Non Refundable License Fee Payable Every Year After Execution",
        "terseLabel": "Non-refundable license fee payable upon execution every year thereafter until sales of a licensed product and payment of royalties"
       }
      }
     },
     "localname": "NonRefundableLicenseFeePayableEveryYearAfterExecution",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_NonRefundableLicenseFeePayableUponExecution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable license fee payable upon execution.",
        "label": "Non Refundable License Fee Payable Upon Execution",
        "terseLabel": "Non-refundable license fee payable upon execution"
       }
      }
     },
     "localname": "NonRefundableLicenseFeePayableUponExecution",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_NonemployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonemployee.",
        "label": "Nonemployee [Member]",
        "terseLabel": "Nonemployee",
        "verboseLabel": "Nonemployee Consultants"
       }
      }
     },
     "localname": "NonemployeeMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_NumberOfAgreementsEntered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of agreements entered.",
        "label": "Number Of Agreements Entered",
        "terseLabel": "Number of sponsored research agreements entered"
       }
      }
     },
     "localname": "NumberOfAgreementsEntered",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fdmt_NumberOfFinancialInstitutionsWhereCashIsHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of financial institutions where cash is held.",
        "label": "Number Of Financial Institutions Where Cash Is Held",
        "terseLabel": "Number of financial institutions cash is held"
       }
      }
     },
     "localname": "NumberOfFinancialInstitutionsWhereCashIsHeld",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fdmt_NumberOfInstallmentsToPayActualAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of installments to pay actual award.",
        "label": "Number Of Installments To Pay Actual Award",
        "terseLabel": "Number of installments to pay actual award"
       }
      }
     },
     "localname": "NumberOfInstallmentsToPayActualAward",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fdmt_NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of marketable securities unrealized loss position more than one year.",
        "label": "Number of Marketable Securities Unrealized Loss Position More Than One Year",
        "terseLabel": "Number of marketable securities unrealized loss position more than one year"
       }
      }
     },
     "localname": "NumberOfMarketableSecuritiesUnrealizedLossPositionMoreThanOneYear",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fdmt_NumberOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued.",
        "label": "Number Of Warrants Issued",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "NumberOfWarrantsIssued",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fdmt_OperatingLeaseTermExtendedExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease term extended expiration period.",
        "label": "Operating Lease Term Extended Expiration Period",
        "terseLabel": "Lease extended term period"
       }
      }
     },
     "localname": "OperatingLeaseTermExtendedExpirationPeriod",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "fdmt_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards, expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "fdmt_OptionsToPurchaseOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase ordinary shares.",
        "label": "Options To Purchase Ordinary Shares",
        "terseLabel": "Options to purchase ordinary shares"
       }
      }
     },
     "localname": "OptionsToPurchaseOrdinaryShares",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fdmt_OrganizationAndNatureOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and nature of business.",
        "label": "Organization And Nature Of Business [Line Items]",
        "terseLabel": "Organization And Nature Of Business [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndNatureOfBusinessLineItems",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fdmt_OrganizationAndNatureOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and nature of business.",
        "label": "Organization And Nature Of Business [Table]",
        "terseLabel": "Organization And Nature Of Business [Table]"
       }
      }
     },
     "localname": "OrganizationAndNatureOfBusinessTable",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fdmt_OtherRisksAndUncertaintiesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other risks and uncertainties.",
        "label": "Other Risks And Uncertainties Policy Policy [Text Block]",
        "terseLabel": "Other Risks and Uncertainties"
       }
      }
     },
     "localname": "OtherRisksAndUncertaintiesPolicyPolicyTextBlock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity interest upon closing of first qualified financing at option.",
        "label": "Percentage of equity interest upon closing of first qualified financing at option",
        "terseLabel": "Percentage of equity interest upon closing of first qualified financing at option of UC Regents"
       }
      }
     },
     "localname": "PercentageOfEquityInterestUponClosingOfFirstQualifiedFinancingAtOption",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fdmt_PercentageOfEquityInterestsIssuedAsCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity interests issued as common stock.",
        "label": "Percentage Of Equity Interests Issued As Common Stock",
        "terseLabel": "Percentage of equity interests issued as common stock"
       }
      }
     },
     "localname": "PercentageOfEquityInterestsIssuedAsCommonStock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fdmt_PrepaidExpensesToRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses to related parties current.",
        "label": "Prepaid Expenses To Related Parties Current",
        "terseLabel": "Prepaid expenses to related parties"
       }
      }
     },
     "localname": "PrepaidExpensesToRelatedPartiesCurrent",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock.",
        "label": "Redeemable Convertible Preferred Stock Policy Policy [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockPolicyPolicyTextBlock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_ResearchAndCollaborationArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Collaboration Arrangements.",
        "label": "Research And Collaboration Arrangements [Abstract]"
       }
      }
     },
     "localname": "ResearchAndCollaborationArrangementsAbstract",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "fdmt_ResearchAndDevelopmentExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense related party.",
        "label": "Research And Development Expense Related Party",
        "terseLabel": "Research and development expense, related party"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseRelatedParty",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_ScheduleOfCollaborationAndLicenseRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of collaboration and license revenue.",
        "label": "Schedule Of Collaboration And License Revenue Table [Text Block]",
        "terseLabel": "Summary of Collaboration and License Revenue"
       }
      }
     },
     "localname": "ScheduleOfCollaborationAndLicenseRevenueTableTextBlock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_ScheduleOfCommonShareReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common share reserved for future issuance.",
        "label": "Schedule Of Common Share Reserved For Future Issuance",
        "terseLabel": "Schedule of Common Share Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonShareReservedForFutureIssuance",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_SeriesA1RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 redeemable convertible preferred stock.",
        "label": "Series A1 Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-1 Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesA1RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_SeriesBFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B financing.",
        "label": "Series B Financing [Member]",
        "terseLabel": "Series B Financing"
       }
      }
     },
     "localname": "SeriesBFinancingMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_SeriesCRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Redeemable Convertible Preferred Stock.",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award duration purchase period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Duration Purchase Period",
        "terseLabel": "Duration of purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationPurchasePeriod",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award exercise price as percentage of fair market value minimum.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Exercise Price As Percentage Of Fair Market Value Minimum",
        "terseLabel": "Exercise price as percentage of fair market value, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsPercentageOfFairMarketValueMinimum",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award percentage of outstanding stock increased annually for future issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Increased Annually For Future Issuance",
        "terseLabel": "Percentage of common stock outstanding increased annually for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockIncreasedAnnuallyForFutureIssuance",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Shares Available for Grant Expirations In Period",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Shares Available for Grant Expirations In Period",
        "terseLabel": "Number of Shares Available for Grant, Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantExpirationsInPeriod",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award shares available for grant forfeitures in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Forfeitures In Period",
        "terseLabel": "Number of Shares Available for Grant, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantForfeituresInPeriod",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award shares available for grant grants in period gross.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Grants In Period Gross",
        "negatedLabel": "Number of Shares Available for Grant, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantGrantsInPeriodGross",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fdmt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award stock overlapping offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Overlapping Offering Period",
        "terseLabel": "Common stock overlapping offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOverlappingOfferingPeriod",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fdmt_ShortTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term marketable securities.",
        "label": "Short-term Marketable Securities [Member]",
        "terseLabel": "Short-term Marketable Securities"
       }
      }
     },
     "localname": "ShortTermMarketableSecuritiesMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsored Research Agreements And Machine Learning Sponsored Research Agreements [Member]",
        "terseLabel": "SRAs and Machine Learning SRA"
       }
      }
     },
     "localname": "SponsoredResearchAgreementsAndMachineLearningSponsoredResearchAgreementsMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_SponsoredResearchAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored Research Agreements.",
        "label": "Sponsored Research Agreements [Member]",
        "terseLabel": "SRAs"
       }
      }
     },
     "localname": "SponsoredResearchAgreementsMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares stock options and warrants exercised.",
        "label": "Stock Issued During Period Shares Stock Options And Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "fdmt_StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value net unrealized gain (loss) on sale of marketable securities.",
        "label": "Stock Issued During Period Value Net Unrealized Gain (Loss) on Sale of Marketable Securities",
        "terseLabel": "Gross unrealized loss on marketable securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNetUnrealizedGainLossOnSaleOfMarketableSecurities",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value stock options and warrants exercised.",
        "label": "Stock Issued During Period Value Stock Options And Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies line items.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fdmt_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fdmt_TaxCreditCarryforwardBeginningExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward beginning expiration year.",
        "label": "Tax Credit Carryforward Beginning Expiration Year",
        "terseLabel": "Tax credit carryforward beginning expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardBeginningExpirationYear",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "fdmt_TaxCreditCarryforwardExpirationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration description.",
        "label": "Tax Credit Carryforward Expiration Description",
        "terseLabel": "Tax credit carryforward, expiration description"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationDescription",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fdmt_TemporaryEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity disclosure.",
        "label": "Temporary Equity Disclosure [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureTextBlock",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fdmt_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "fdmt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of redeemable convertible preferred stock, net of $3,138 of issuance cost (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "fdmt_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period value conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement.",
        "label": "Term Of Agreement",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fdmt_TwoThousandAndSeventeenRocheAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and seventeen Roche agreement.",
        "label": "Two Thousand And Seventeen Roche Agreement [Member]",
        "terseLabel": "2017 Roche Agreement"
       }
      }
     },
     "localname": "TwoThousandAndSeventeenRocheAgreementMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_TwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen equity incentive plan.",
        "label": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "terseLabel": "2015 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_TwoThousandFourteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen plan.",
        "label": "Two Thousand Fourteen Plan [Member]",
        "terseLabel": "2014 401(k) Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenPlanMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_TwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty employee stock purchase plan.",
        "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 ESPP"
       }
      }
     },
     "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_TwoThousandTwentyIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty incentive award plan.",
        "label": "Two Thousand Twenty Incentive Award Plan [Member]",
        "terseLabel": "2020 Incentive Award Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyIncentiveAwardPlanMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_UCAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UC Agreements.",
        "label": "U C Agreements [Member]",
        "terseLabel": "UC Agreements"
       }
      }
     },
     "localname": "UCAgreementsMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_UCRegentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UC Regents.",
        "label": "U C Regents [Member]",
        "terseLabel": "UC Regents"
       }
      }
     },
     "localname": "UCRegentsMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_UniQureAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "uniQure Agreement.",
        "label": "Uni Qure Agreement [Member]",
        "terseLabel": "uniQure Agreement"
       }
      }
     },
     "localname": "UniQureAgreementMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_UniQureBiopharmaBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "uniQure biopharma B.V.",
        "label": "Uni Qure Biopharma B V [Member]",
        "terseLabel": "uniQure"
       }
      }
     },
     "localname": "UniQureBiopharmaBVMember",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fdmt_UnpaidOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid offering costs.",
        "label": "Unpaid Offering Costs",
        "terseLabel": "Unpaid offering costs"
       }
      }
     },
     "localname": "UnpaidOfferingCosts",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_VestingOfCommonStockWarrantInReturnForServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of common stock warrant in return for services.",
        "label": "Vesting Of Common Stock Warrant In Return For Services",
        "terseLabel": "Vesting of common stock warrant in return for services"
       }
      }
     },
     "localname": "VestingOfCommonStockWarrantInReturnForServices",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fdmt_VestingPeriodOfShareAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period of share awards.",
        "label": "Vesting Period Of Share Awards",
        "terseLabel": "Ordinary shares vesting period"
       }
      }
     },
     "localname": "VestingPeriodOfShareAwards",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fdmt_WarrantExercisedMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercised month and year.",
        "label": "Warrant Exercised Month And Year",
        "terseLabel": "Warrant exercised month and year"
       }
      }
     },
     "localname": "WarrantExercisedMonthAndYear",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "fdmt_WarrantExpiresYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant expires year.",
        "label": "Warrant Expires Year",
        "terseLabel": "Warrant expiration year"
       }
      }
     },
     "localname": "WarrantExpiresYear",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "fdmt_WarrantVestsOverPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant vests over period.",
        "label": "Warrant Vests Over Period",
        "terseLabel": "Warrant vesting period"
       }
      }
     },
     "localname": "WarrantVestsOverPeriod",
     "nsuri": "http://www.4dmoleculartherapeutics.com/20211231",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r60",
      "r62",
      "r114",
      "r115",
      "r283",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r121",
      "r131",
      "r139",
      "r233",
      "r452",
      "r453",
      "r454",
      "r492",
      "r493",
      "r541",
      "r544",
      "r546",
      "r547",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASC 842 Adjustments",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r121",
      "r131",
      "r139",
      "r233",
      "r452",
      "r453",
      "r454",
      "r492",
      "r493",
      "r541",
      "r544",
      "r546",
      "r547",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r121",
      "r131",
      "r139",
      "r233",
      "r452",
      "r453",
      "r454",
      "r492",
      "r493",
      "r541",
      "r544",
      "r546",
      "r547",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r202",
      "r328",
      "r333",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r282",
      "r296",
      "r405",
      "r411",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r650",
      "r703",
      "r707",
      "r755",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r282",
      "r296",
      "r405",
      "r411",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r650",
      "r703",
      "r707",
      "r755",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r202",
      "r328",
      "r333",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r198",
      "r328",
      "r331",
      "r652",
      "r702",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r198",
      "r328",
      "r331",
      "r652",
      "r702",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r282",
      "r296",
      "r359",
      "r405",
      "r411",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r650",
      "r703",
      "r707",
      "r755",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r282",
      "r296",
      "r359",
      "r405",
      "r411",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r650",
      "r703",
      "r707",
      "r755",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r114",
      "r115",
      "r283",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r3",
      "r118",
      "r119",
      "r120",
      "r123",
      "r124",
      "r128",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r139",
      "r155",
      "r235",
      "r236",
      "r455",
      "r493",
      "r542",
      "r546",
      "r547",
      "r548",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r3",
      "r118",
      "r119",
      "r120",
      "r123",
      "r124",
      "r128",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r139",
      "r155",
      "r235",
      "r236",
      "r455",
      "r493",
      "r542",
      "r546",
      "r547",
      "r548",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "auth_ref": [
      "r3",
      "r123",
      "r124",
      "r131",
      "r139",
      "r235",
      "r236",
      "r455",
      "r493",
      "r542",
      "r548",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r3",
      "r118",
      "r120",
      "r123",
      "r124",
      "r128",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r136",
      "r137",
      "r155",
      "r235",
      "r236",
      "r455",
      "r493",
      "r542",
      "r546",
      "r547",
      "r548",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r199",
      "r200",
      "r328",
      "r332",
      "r705",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r328",
      "r332",
      "r705",
      "r739",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r203",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standard Update (\"ASU\") 2016-02",
        "verboseLabel": "ASC 842 Adjustments"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201807Member": {
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-07 Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.",
        "label": "Accounting Standards Update 2018-07 [Member]",
        "terseLabel": "Accounting Standard Update (\"ASU\") 2018-07"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201807Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201818Member": {
     "auth_ref": [
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.",
        "label": "Accounting Standards Update 2018-18 [Member]",
        "terseLabel": "Accounting Standard Update (\"ASU\") 2018-18"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201818Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "Accounting Standard Update (\"ASU\") 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r123",
      "r124",
      "r125",
      "r126",
      "r209",
      "r210",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r267",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r492",
      "r493",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r606",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r46",
      "r618"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "verboseLabel": "Accounts payable (includes $0 and $173 at December 31, 2021 and 2020, respectively, attributable to related parties)"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r46",
      "r112",
      "r611",
      "r613"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Related Parties, Current",
        "terseLabel": "Accounts payable to related parties"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r112",
      "r610",
      "r676",
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties.",
        "label": "Accounts Payable, Related Parties",
        "terseLabel": "Accounts payable, related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r28",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization (accretion) of premium (discount) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "negatedLabel": "Accrued and other current liabilities",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12",
      "r14",
      "r49"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Consulting and professional"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r44",
      "r253"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r66",
      "r67",
      "r68",
      "r691",
      "r715",
      "r719"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r65",
      "r68",
      "r75",
      "r76",
      "r77",
      "r118",
      "r119",
      "r120",
      "r516",
      "r710",
      "r711",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r452",
      "r453",
      "r454",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r123",
      "r124",
      "r125",
      "r126",
      "r139",
      "r209",
      "r210",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r267",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r490",
      "r491",
      "r492",
      "r493",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r606",
      "r653",
      "r654",
      "r655",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r412",
      "r414",
      "r458",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r311",
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "verboseLabel": "Issuance of common stock upon initial public offering, issuance cost"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r281",
      "r311",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock warrant in connection with settlement",
        "verboseLabel": "Issuance of common stock warrant"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r414",
      "r439",
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r35",
      "r206",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Write-offs relating to uncollectible accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r109",
      "r181",
      "r190",
      "r196",
      "r226",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r512",
      "r517",
      "r564",
      "r616",
      "r618",
      "r669",
      "r689"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r57",
      "r109",
      "r226",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r512",
      "r517",
      "r564",
      "r616",
      "r618"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r215",
      "r244"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r212",
      "r216",
      "r244",
      "r673"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r415",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r527",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued and other liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r40",
      "r98"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r93",
      "r98",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r93",
      "r574"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing and financing information"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r118",
      "r119",
      "r122",
      "r209",
      "r210",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r267",
      "r448",
      "r449",
      "r450",
      "r490",
      "r535",
      "r538",
      "r539",
      "r565",
      "r567",
      "r568",
      "r569",
      "r572",
      "r573",
      "r588",
      "r606",
      "r653",
      "r654",
      "r708",
      "r709",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r118",
      "r119",
      "r131",
      "r209",
      "r210",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r267",
      "r448",
      "r449",
      "r450",
      "r490",
      "r535",
      "r538",
      "r539",
      "r540",
      "r543",
      "r565",
      "r567",
      "r568",
      "r569",
      "r572",
      "r573",
      "r588",
      "r606",
      "r653",
      "r654",
      "r708",
      "r709",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r123",
      "r138",
      "r211",
      "r234",
      "r455",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle accounting standards update, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r107",
      "r109",
      "r143",
      "r144",
      "r145",
      "r148",
      "r150",
      "r160",
      "r161",
      "r162",
      "r226",
      "r268",
      "r273",
      "r274",
      "r275",
      "r279",
      "r280",
      "r294",
      "r295",
      "r299",
      "r303",
      "r564",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r320",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrant shares exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r320",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r504",
      "r505",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Research and Collaboration Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r52",
      "r263",
      "r677",
      "r695"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r264",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved",
        "verboseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27",
      "r618"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value, 300,000,000 shares authorized at December 31, 2021 and 2020; 32,224,524 and 26,681,983 shares issued and outstanding at December 31, 2021 and 2020, respectively.",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r70",
      "r72",
      "r73",
      "r80",
      "r680",
      "r699"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Total comprehensive loss",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r202",
      "r561",
      "r562",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r202",
      "r561",
      "r562",
      "r721",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r202",
      "r561",
      "r562",
      "r721",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r165",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r170",
      "r171",
      "r202",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r168",
      "r170",
      "r171",
      "r172",
      "r561",
      "r563",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r202",
      "r561",
      "r562",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r322",
      "r323",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total",
        "verboseLabel": "Total deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r322",
      "r323",
      "r329"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r322",
      "r323",
      "r329"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r322",
      "r324",
      "r329",
      "r740"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.",
        "label": "Contract with Customer, Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable",
        "totalLabel": "Contract with Customer, Receivable, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r25",
      "r26",
      "r306",
      "r312",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares converted, number of common stock issued",
        "verboseLabel": "Number shares issued upon conversion of redeemable convertible preferred shares"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r360",
      "r399",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r169",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains on marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Realized losses on marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Available for Sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r22",
      "r478",
      "r670",
      "r688"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r583",
      "r604"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r23",
      "r584",
      "r604"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Total"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]",
        "terseLabel": "Summary of Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible asset basis"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "negatedTotalLabel": "Total net deferred tax",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Net operating loss carryforward indefinitely"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r484",
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Research tax credits",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r484",
      "r486",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r480"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesToSignificantComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "401(K) Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r96",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r96",
      "r251"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r58",
      "r62",
      "r63",
      "r528",
      "r632"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Estimated fair value of derivative liability",
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r537",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r530",
      "r531",
      "r532",
      "r534",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r522",
      "r523",
      "r525",
      "r526",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Embedded Derivative"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r319",
      "r686"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Common stock dividend",
        "totalLabel": "Dividends, Common Stock, Total"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r112",
      "r271",
      "r273",
      "r274",
      "r278",
      "r279",
      "r280",
      "r610",
      "r674",
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from related parties",
        "totalLabel": "Due from Related Parties, Total"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r112",
      "r271",
      "r273",
      "r274",
      "r278",
      "r279",
      "r280",
      "r610",
      "r675",
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Amount due to related party",
        "totalLabel": "Due to Related Parties, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r151",
      "r153",
      "r154",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDiluted1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r110",
      "r468",
      "r497"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r468",
      "r497"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r468",
      "r497"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r468",
      "r497"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Research tax credit",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateOfIncomeTaxExpenseBenefitDiffersFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation, expected to be recognized over weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation of unvested options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Share Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to Purchase Common Stock",
        "verboseLabel": "Options Issued and Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r75",
      "r76",
      "r77",
      "r118",
      "r119",
      "r120",
      "r124",
      "r134",
      "r137",
      "r159",
      "r233",
      "r311",
      "r319",
      "r452",
      "r453",
      "r454",
      "r492",
      "r493",
      "r546",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r710",
      "r711",
      "r712",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r96",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value of warrant shares"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r550",
      "r551",
      "r552",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Assets, Level 1 to Level 2 transfers"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Assets, Level 2 to Level 1 Transfers"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r550",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r284",
      "r287",
      "r288",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r399",
      "r551",
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r550",
      "r551",
      "r553",
      "r554",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r284",
      "r360",
      "r361",
      "r366",
      "r399",
      "r551",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r284",
      "r287",
      "r288",
      "r360",
      "r361",
      "r366",
      "r399",
      "r551",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r284",
      "r287",
      "r288",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r399",
      "r551",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Liabilities, Level 1 to Level 2 transfers"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Liabilities, Level 2 to Level 1 transfers"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r555",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r555",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Fair Value of Level 3 Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "terseLabel": "Liabilities, Transfers into Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Liabilities, Transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Assets, Transfers into Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Assets, Transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value included in other income (expense), net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r284",
      "r287",
      "r288",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r399",
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r558",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List]"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3DerivativeLiabilityDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r223",
      "r224",
      "r225",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r286",
      "r309",
      "r537",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Liabilities",
        "totalLabel": "Financial Liabilities Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r96",
      "r250",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairments of long-lived assets",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r249",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r256",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r469",
      "r476",
      "r483",
      "r495",
      "r498",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r111",
      "r136",
      "r137",
      "r180",
      "r467",
      "r496",
      "r499",
      "r700"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r465",
      "r466",
      "r476",
      "r477",
      "r482",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r95",
      "r651"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r95",
      "r599"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r86",
      "r179"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r668",
      "r684",
      "r738",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r601",
      "r603"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease extended term date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease, discount rate",
        "verboseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lease existence of option to renew term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease option to renew term description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Lease initial term"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r47",
      "r109",
      "r191",
      "r226",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r513",
      "r517",
      "r518",
      "r564",
      "r616",
      "r617"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r109",
      "r226",
      "r564",
      "r618",
      "r672",
      "r693"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r50",
      "r109",
      "r226",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r513",
      "r517",
      "r518",
      "r564",
      "r616",
      "r617",
      "r618"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r678"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Total"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r9",
      "r48"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, long-term",
        "totalLabel": "Marketable Securities, Noncurrent, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r93",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r69",
      "r71",
      "r77",
      "r79",
      "r97",
      "r109",
      "r123",
      "r128",
      "r129",
      "r131",
      "r132",
      "r136",
      "r137",
      "r146",
      "r181",
      "r189",
      "r192",
      "r195",
      "r197",
      "r226",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r548",
      "r564",
      "r679",
      "r698"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r128",
      "r129",
      "r131",
      "r132",
      "r140",
      "r141",
      "r147",
      "r150",
      "r181",
      "r189",
      "r192",
      "r195",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r121",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r131",
      "r139",
      "r155",
      "r209",
      "r210",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r267",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r490",
      "r491",
      "r492",
      "r493",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r606",
      "r653",
      "r654",
      "r655",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r181",
      "r189",
      "r192",
      "r195",
      "r197"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r597",
      "r603"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total operating lease cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Annual rent",
        "verboseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of future minimum lease payments",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Present value of future minimum lease payments",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities, current",
        "negatedLabel": "Operating lease liabilities, current",
        "terseLabel": "Less: Current portion of operating lease liabilities",
        "totalLabel": "Operating Lease, Liability, Current, Total",
        "verboseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r590"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, long -term portion",
        "negatedLabel": "Operating lease liabilities, long-term",
        "terseLabel": "Operating lease liabilities, long-term",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r592",
      "r599"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r589"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease, right-of-use assets",
        "terseLabel": "Operating lease right-of-use (\"ROU\") assets",
        "verboseLabel": "Operating lease, right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r265",
      "r581",
      "r582",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Lessee, Operating Lease, Disclosure [Table Text Block]",
        "terseLabel": "Summary of Supplemental Information Related to Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r14",
      "r15",
      "r49"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r64",
      "r66"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Gross unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "negatedLabel": "Other liabilities",
        "terseLabel": "Other liabilities",
        "totalLabel": "Total other liabilities, noncurrent"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Summary of Other Liabilities, Noncurrent"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r20",
      "r671",
      "r690"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other payable"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentSummaryOfOtherLiabilitiesNoncurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings",
        "terseLabel": "Other-than-temporary impairment on investment in debt securities available-for-sale"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Exercise of Overallotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "terseLabel": "Purchase of marketable securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Acquisition of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r415",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r26",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r26",
      "r618"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized at December 31, 2021 2020; no shares issued and outstanding at December 31, 2021 and 2020, respectively.",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r38",
      "r39"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets (includes $285 and $169 at December 31, 2021 and 2020, respectively, attributable to related parties)",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs",
        "verboseLabel": "Issuance of common stock upon offerings, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Issuance of redeemable convertible preferred stock, net of issuance costs",
        "verboseLabel": "Net proceeds from issuance of convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from offering of securities in a private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r91",
      "r442"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Issuance of common stock through 2020 ESPP"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities",
        "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r69",
      "r71",
      "r77",
      "r92",
      "r109",
      "r123",
      "r136",
      "r137",
      "r181",
      "r189",
      "r192",
      "r195",
      "r197",
      "r226",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r511",
      "r514",
      "r515",
      "r519",
      "r520",
      "r548",
      "r564",
      "r681"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r44",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r258",
      "r743",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r43",
      "r252"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r254",
      "r618",
      "r685",
      "r694"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r42",
      "r254",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r36",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable\u2014Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyCosts": {
     "auth_ref": [
      "r83",
      "r112",
      "r271",
      "r273",
      "r274",
      "r278",
      "r279",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.",
        "label": "Related Party Costs",
        "terseLabel": "Payment to related party"
       }
      }
     },
     "localname": "RelatedPartyCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r384",
      "r609",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r384",
      "r609",
      "r610",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r609"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related party expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r384",
      "r609",
      "r613",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r607",
      "r608",
      "r610",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development (includes $935 and $579 for the years ended December 31, 2021, and 2020, respectively, attributable to related parties)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r319",
      "r455",
      "r618",
      "r692",
      "r714",
      "r719"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r118",
      "r119",
      "r120",
      "r124",
      "r134",
      "r137",
      "r233",
      "r452",
      "r453",
      "r454",
      "r492",
      "r493",
      "r546",
      "r710",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]",
        "terseLabel": "Retirement Plan Name"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]",
        "terseLabel": "Retirement Plan Name"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_Disclosure401KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r503",
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Collaborative arrangement total amount of award"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r177",
      "r178",
      "r188",
      "r193",
      "r194",
      "r198",
      "r199",
      "r202",
      "r327",
      "r328",
      "r652"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": 0.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration and license revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r82",
      "r271",
      "r273",
      "r274",
      "r278",
      "r279",
      "r280",
      "r722"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Collaboration and license revenue, related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Aggregate amount of transaction price allocated to remaining performance obligation",
        "terseLabel": "Aggregate amount of the transaction price remaining performance obligation",
        "verboseLabel": "Remaining performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Deferred revenue, estimated performance period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r78",
      "r109",
      "r177",
      "r178",
      "r188",
      "r193",
      "r194",
      "r198",
      "r199",
      "r202",
      "r226",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r564",
      "r681"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenues",
        "totalLabel": "Total revenue",
        "verboseLabel": "Collaboration and license revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenuesByGeographicRegionDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r600",
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "negatedLabel": "Decrease in right-of-use assets due to reduction in operating lease liabilities upon modification",
        "terseLabel": "Decrease in right-of-use assets due to reduction in operating lease liabilities upon modification"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Investment in redeemable convertible preferred stock financing"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r170",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherLiabilitiesCurrentAndNoncurrentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfCollaborationAndLicenseRevenueDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsSummaryOfDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Tax Effects of Temporary Differences to Significant Components of Deferred Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Tax Rate of Income Tax Expense (Benefit) Differs from Federal Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r414",
      "r438",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockCompensationExpenseForEmployeesAndNonemployeesByFunctionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r414",
      "r438",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock Compensation Expense for Employees and Nonemployees by Function"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "auth_ref": [
      "r85",
      "r88",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.",
        "label": "Investment Income [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r127",
      "r131",
      "r157",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Schedule of Impact of Adoption of New Accounting Standard"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r44",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r611",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureLicenseArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r415",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r421",
      "r428",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r53",
      "r107",
      "r160",
      "r161",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r303",
      "r309",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r475",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of Beginning and Ending Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r168",
      "r170",
      "r171",
      "r172",
      "r561",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration of Risk"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Options exercisable period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of maximum contributions of employee's eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of Shares Available for Grant, Options authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized and reserved for issuance",
        "verboseLabel": "Number of shares authorized and reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Number of Shares Available for Grant, Ending Balance",
        "periodStartLabel": "Number of Shares Available for Grant, Beginning Balance",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Shares exercisable, December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Shares exercisable, December 31,2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Shares Underlying Outstanding Options, granted",
        "verboseLabel": "Number of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r423",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Underlying Outstanding Options, Ending Balance",
        "periodStartLabel": "Number of Shares Underlying Outstanding Options, Beginning Balance",
        "terseLabel": "Number of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted-Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Shares vested and expected to vest, December 31,2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Shares vested and expected to vest, December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Shares vested and expected to vest, December 31,2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of aggregate number of shares of common stock outstanding reserved for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r413",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Original Issuance Price",
        "verboseLabel": "Temporary equity, shares issued price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r433",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesValuationModelToEstimateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Shares exercisable, December 31,2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (in years), Shares exercisable, December 31,2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (in years), Shares vested and expected to vest, December 31,2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Employee purchase price of common stock as percentage of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Shares, Issued, Ending Balance",
        "periodStartLabel": "Shares, Issued, Beginning Balance",
        "terseLabel": "Number of shares priced under public offering"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Stock sold and issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Stockholders\u2019 Equity (Deficit), ending balances (in shares)",
        "periodStartLabel": "Stockholders\u2019 Equity (Deficit), beginning balances (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r107",
      "r109",
      "r143",
      "r144",
      "r145",
      "r148",
      "r150",
      "r160",
      "r161",
      "r162",
      "r226",
      "r268",
      "r273",
      "r274",
      "r275",
      "r279",
      "r280",
      "r294",
      "r295",
      "r299",
      "r303",
      "r311",
      "r564",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r56",
      "r75",
      "r76",
      "r77",
      "r118",
      "r119",
      "r120",
      "r124",
      "r134",
      "r137",
      "r159",
      "r233",
      "r311",
      "r319",
      "r452",
      "r453",
      "r454",
      "r492",
      "r493",
      "r546",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r710",
      "r711",
      "r712",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r159",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Receivable for common stock issued upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r55",
      "r285",
      "r311",
      "r312",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r26",
      "r27",
      "r311",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock - 2020 ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r311",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Purchase shares of common stock",
        "terseLabel": "Issuance of common stock upon initial public offering, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares sold and issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r311",
      "r319",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r56",
      "r311",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r26",
      "r27",
      "r311",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock - 2020 ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r311",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon initial public offering, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r311",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r32",
      "r33",
      "r109",
      "r208",
      "r226",
      "r564",
      "r618"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Stockholders\u2019 Equity (Deficit), ending balances",
        "periodStartLabel": "Stockholders\u2019 Equity (Deficit), beginning balances",
        "terseLabel": "Stockholders' equity attributable to parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r310",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockWarrantsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r16",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r268",
      "r273",
      "r274",
      "r275",
      "r279",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Redeemable Convertible Preferred Stock, ending balances",
        "periodStartLabel": "Redeemable Convertible Preferred Stock, beginning balances",
        "terseLabel": "Redeemable convertible preferred stock, $0.0001 par value; 0 and 7,375,638 shares authorized shares at December 31, 2020 and 2019, respectively; 0 and 7,375,631 shares issued and outstanding at December 31, 2020 and 2019, respectively. Liquidation value of $0 and $108,596 at December 31, 2020 and 2019, respectively.",
        "verboseLabel": "Proceeds Net of Issuance Cost"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Temporary equity, liquidation preference",
        "verboseLabel": "Liquidation Value"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Shares Authorized",
        "terseLabel": "Temporary equity, shares authorized",
        "verboseLabel": "Preferred stock, authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued",
        "verboseLabel": "Shares Issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Redeemable Convertible Preferred Stock, ending balances (in shares)",
        "periodStartLabel": "Redeemable Convertible Preferred Stock, beginning balances (in shares)",
        "terseLabel": "Shares Outstanding",
        "verboseLabel": "Outstanding shares of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockSummaryOfRedeemableConvertiblePreferredStockDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of redeemable convertible preferred stock, net of $3,138 of issuance cost"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r16",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Summary of Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r223",
      "r224",
      "r225",
      "r286",
      "r309",
      "r537",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r123",
      "r124",
      "r125",
      "r126",
      "r139",
      "r209",
      "r210",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r267",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r490",
      "r491",
      "r492",
      "r493",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r606",
      "r653",
      "r654",
      "r655",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfImpactOfAdoptionOfNewAccountingStandardDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCFFAdditionalInformationDetails1",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsCRFAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureResearchAndCollaborationArrangementsRocheAgreementAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r113",
      "r360",
      "r399",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFairValueHierarchyForFinancialAssetsAndFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r464",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r163",
      "r164",
      "r166",
      "r167",
      "r173",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates and Judgements"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance, deferred tax asset"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r598",
      "r603"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonShareReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares outstanding used in computing net loss per share, basic and diluted",
        "totalLabel": "Weighted-average shares outstanding used in computing net loss per share, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/StatementStatementsOfOperations1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r140",
      "r142"
     ],
     "calculation": {
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.4dmoleculartherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e725-108305"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e765-108305"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130534-203044"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL116876444-165333"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL116876444-165333"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL116876444-165333"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL116876446-165333"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL116876446-165333"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r757": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r758": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r759": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r760": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r761": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r762": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r763": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r764": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r765": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r766": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r767": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r768": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r769": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r770": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r771": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r772": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r773": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r774": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r775": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0000950170-22-004794-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-004794-xbrl.zip
M4$L#!!0    ( ).%?%3-.G#X!,T$ *&5.P 1    9F1M="TR,#(Q,3(S,2YH
M=&WLO?EW$TFZ(/K[_!7YN#-SJLXC(/:%JJXYQD WTX"YMKE][WOG'9]8<7;)
MDCM3 CQ__?LB)7D!+[(M62&3U"G0$HJ,Y=O7W__7MZ-!]24V;3T:_N4)>8:?
M5''H1Z$>?O[+DZV][;=OG_RO/W[_OQ"J7KUY^Z'Z$+]66WY<?XFOZM8/1NVD
MB=4O>^]_K=X.!_4P5O_Y<O==]6KD)T=Q.*Y0=3@>'[]X_OSKUZ_/0JJ'[6@P
M&<.CVF=^=/2\0F@Z]W83;?ZX>F7'L7I!,:4(,T3U/I$OF'I!V3,L#/N_,7Z!
M\=FO1L<G3?WY<%S]XG^M\H_@R<-A' Q.JC?UT Y];0?5WOR13V&-_EFU-1A4
MN_E7;;4;V]A\B>%9GO*__7XXAK. \QBV?WER;MU?V;-1\_DY,<8\_Y;'/)D.
M>O'--8-0GX[-;[N1%&/Y?/KEA:'C2X>*Z=#Q^:'UA06<'\V>PR&.86MQ/AZ.
M_<]KAN>OG6U/AW_[8?R%_>5OYT/K;U?-2_(R\GWGZYX/'XZ&'^#:F]I?_K,P
M;IZ/3X[C<QB(AM.19X\:7_ZCL\<\'S=VV*91<]2!2EZ%0)@B*L]-@MIX\>GP
M_MGGT9<;Y]&(D=,C:NO+#@B.DSS_S_?O]OQA/++H^WL(\3M0F#\:OH#?4O(O
M/A\Z:=%G:X]/AR?;NNX1LR^ZX0B3<VNJVQ&G1%T'%],1\Q]$.&%Z&<!1_#Q^
M&\=A6[M!1+&[B.XD6D0S^L]V,VY0OJSVAKO,\^65TM.5IG!T\2YY.!H-HI\,
M;#,^A&<=1\!'/Z4 >:.$GFW3CR;#<7-R^4'.ONQ^-/]!VXQ_/$;X\)(CG(R;
M*X_//(=OG_SQWZK?#Z,-\&_U^[@>#^(?!*.___Y\^CI_>A3'MB-J*/YK4G_Y
MRY/MT1 .<XSVX32>5'[Z[B]/QG#&SZ?$XGF>]OELWM_=*)QT,X7Z2]6.3P;Q
M+T]"W1X/[$G&H/C;DS]^K[^]R,-C,WU9AQ"'W<LS%*OJ\)<G;PX48Y:0X%"2
M7B%NN4!&:8><Q-@G1X3*^Q_:H_R46+]X/82MG&S#$AL[>#L,\=O?X\ELV=_&
MNS'!A@X4P)$EUB/*HD"<JX"L=1$1G%A,45/IXI,_,*"#%%AR_?OS"TN[?*72
M"NY,C,CQ$!%71"%X!D46)V.28B$Z/%_I# U>[,8O )]Q%]"M'@)'^AB;#F\!
MZW;<H/[<@>WK;\?1CV/8KX]@R$[:@T_;9'W^#GY0CP+Y?H.>DJ0DBTCCZ!#7
MW")K.$$I8IN(LLIC]Z2:DHB_/)F1E1=ATGP=-:&-PR=_C ^;&*N3:)MVH=UK
M'#B)1B.I14#<:]BXD1(9.%!)#(]2ROGN,P*]V!X-!M:-,F9^B5L-D*S/,;/4
MK1#JO#,[R,S+-OYP/S9'WV\P4A*MPQ8IHV"#3&-D,"&(V&AULLX3)^Z[P3?-
M](QG.Q0BT>2I0BHFCCCA!ED.VPS46T,-$X+;A7;8OIF,0:K8LX/8O@3&%=[7
M\&H,J/'1GG0#X%8]_&L_Q^_W39W7@ T*"< "6(332-O $:Q&&BM4]!%8SF18
M3W_PZ> 8GO2D"M'71W8 M(X^J5IO,TXB>N& 7@"=#*/Q;.23/QC&\W.9'\05
M!V.CM,1'BWCP@$W4),#.D)#5-HD@B!"67SB8.4#_N-W]T>M_3>P !+#\]U?;
MA%W8$1Q?^ $ K!-26@D[EW 0)@"\V>B1540$1B@G.BSG(.35!W$1!3P60IA\
M-R3EPV !2!4S<!B>6Q6IQ'D;%PG QV9T')OQR<>!!= ?!MA^?9P/Y5,;TV3P
MKDX_@$#P*5%M,+*. .AS0Y%F&" R<F&25S11\>2/C^R_%L);QCBFF0!R(N&O
M!$*I99H@9P30,TF-5N*AJ):A+G$*2"T$PYF"$KC.%! 5+/(@E')6PL[(8CO3
MC%.*@P9Z'.%TN!- CP%,I$T)$Q.4\#_L[(VMF_^P@[PW/VD:6#@@:-U^&HY<
M%J0M"!1OA\<36#"LW->#NMOJN]HZ>#T^^2N<Q[M1V^Z-0<K/M[B30"(?'<77
MI_+(N[H=_X#4B5&;@D)$=>P( ^ (>!LU$-24(L?,/?GC9E'JWW:R^/%A-,PP
M!2L;?IX__1B>'A<C<]%9CV,T2"J1 (J!EUD"E\ "QT9%SF5:C)"WNZ,3.QC7
M\1Q^[PP?%K7Q]9C];%'4!EB4+@&Z86T!EA@#LAL#1L!.+2R+*AI_@*4MWXES
M< L #L, &VX_'0< C.N!P6MLO+8.,>X)XL):9$!S08HZ[K0D@>&X$#!<^7S0
M!S16[^.1B\UB,($MQ0[$%Q0X+(P3 D@%RA20"RN !0GN^0^BS?;HZ*@>=X
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MU29&G0DY&"#EK&! 5NU!1X^.N\2BH)P7IYD_.+*N/@ZA"-YQH?)'UR!U&=0
M\\B5LQCYB'/'RFG-1HNHQC9;^I67Q1KP-JJ"]!(E<AP" PKN4=*YA6&*!FD)
M8B QC./(G .24=J=W1E)-].^L%@/J]5>T6:<5#+2"@TG%3RUB,N<#:T-!WDT
M!F[@/U=>;X0[VRH7FKF F*#U@ (E4A-C-9)8 "_2T2(K#$8Z&4J%L]JJE7N<
M;T?4:0Y9H7H91#VD@ /1$6DB;>[U%Y 3\-8Y*ZV75A-:I/6XC^.]D*)CA.11
M&>29C#D24^=NH!(98H/E"@?/BBUU5V9$RS+E)JFBT,"*0XH)<7B);,B).)Q[
M+KB-3A2G^99E]"] )0:95V-%<[]=T%IX-!0Y(CQB,AFBM P2%T<G%X]GR?%\
MDT'7!G=*3MNNE\KL9?MR9)NPDU[53?3CT=)JDMXZJ&5[U$%9;'*CS\,ZICU?
M3X_';X4O=7OCTC:3NE.OG2)>(RJ21-PQA0PS(-4;R5GR@3N32H6]4_-9IR'O
MI*X4YOFJ.7 . &*[,<1XE!/  !2_Q&:<V]5^[+J<-C&LO*WG,HN:*@/R4\@2
ME0(ADINHD$M.(I%+Y,3H3(S%%EVYQ%+Q?>#OK$?AJ^C&*\W5^UFJ%!M,-0_
M4PS+R,V(1=J+"%2&^.2=3B05IXC>*69\%C/9G)P?N"DRG'/>4R8Y<A8D-^X\
MO.+$(>)(\* [1J!?I=W2ZLP%?:+<7=0 HA45FB(C<^J1P DT;:M13,Q88R66
MY>IH"Y8CWXUC"R@>YL6XEF&6VIX<30:=&?UU2B!^?NR.''22,#H^DV(7&AG^
M.9EFH6^**)'K:S 5/:(QE[,!91$9#2"CK,(LJ$14>9$6MQ3\R".2_ 2G45ML
M46#9;:J#0-9;@ZC#FJD4K&#%I>+?$L-S=XH<@'OSK2S^Y(EKZU#;YB0WT+H
M**<FHH\[*S<J$/KP1@7L8O*@#R#G(D-<<88,20Y%$71@4HED-C;L\ '-=B4P
M=XT9Y9PB'WT7,<&S>0^4/F^!DEG"M5YYQ?D[*WUG2M?IR[_!C%FR.WF7Y;HK
M]*ZWP^/)N.U&D!5H@%=5:WD/A.ED6C'FS608>N7S'J9I[#6/*B$ 4(4XZ)L@
MDZI<V%U&*9B4:O7^XEZM61[E4XOGO*ME4;X4F"<RV[>"1#QJ$'H(S5Y$4)@%
MC92EXD#HM"IF#KW^T5+Q(/WL5M1I-3A!6*X!E7+U?^Q!MM" T#@8:WFD4N)B
MLZ=+Y4-%,X,EVK@LEH0D(A"C/H$TBBER$B?$?)(84PGR3+F6R+*Z<?U8BX3R
M!>DR#!7+H,N1A&!QB,@(@! NE$ N-TE4P1L91-9&BU5&WP$:Q3F3G=A!+A%X
M[F9?3FJ89_BY&Y:MR=^.;3?#HU0M9+87)E M0"$$!HL=1X:R+*@)%S@E3(AB
M0V5OY2!X,VF&]3A',P_#F_I;?K4QL;%$*ZZ!;N86&!QQ"R*UI?!7RNX!*2E5
M<>7&W=L*'1> ^5Y:A"$4*^IR+JN#S0>-K)'P5AI*N.4>Z^(@=$7I GWV_H-F
M[S_FA*GDDN"8<B0-R&2< BMW)'$DM&$N<FN5+K9*U=*MR<40>B-9-(PGH'5
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M%!8V.VES5HK6&.GD+"(,1RYYBK:\SAL/7@'UOK>UM @<YBC))! )JQGB0>5
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M.>_/F13JJ>IYO5CQ9C1ILGUZ 5%B,U4"J8R(UC-$M'>Y&IU%3KJ(4L"&8YF
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M].JVS?0VCZUSB\]I2XKK#B[5@-.#ZB3:IIIZ6EY%'SMNQLA4-GQVP2GXO?8
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M_8BGQCPEACW.*WILM'.)R4$]X=L02?:V<=I]H'9/%7NJN%%4L;<"%* 7=%8
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M&L94;54LP[X>]O5N[FLON<5DU!S T0W,P"1 VP :C)IDNF0\$D) %A7%85+
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MT7=@=;"RQUNY<!1?<(9X;6;)M)0<Y$-!LV,,U]J,CS7_=PY/$SV%TSH?EW,
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MO5&DNQP\4.QW>W>:W))I.T?"\0P<=N=GD]\4M'M$O,[)G+MEE "H-14UQ1?
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M::_SDGN#KT]9^TRTL.,U!)Q8<G!G%JEW@C>)J/&)(?8DEODA>^*R)<M4+!Q
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M0DR<W_T@^.:1,B,6OELUO$7/G(88JY,JU1V7['$XT7 \>$]= A]B6/!$J%7
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M).@DQAR(VJ>3>4X'?B(VXY2(>'U0K2#JA3W&N"24?*[R;2YDA J#B>@DA];
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MK:*A2*H/P9PLYF>MNZ0E8?DQBZ[\X(B,1S.EH;-LC)897?%XSE+*;1,K.^W
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M.'-8_9W.$9S:(;RC[>>]LE7-N@I6BUD+3FACR77KF GTF<JSV>3@.NVV$N!
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M3TKYWZ*4S?F-&2,$(5SG)0[.ULV'V"W3$**]_N><-4!ZJ=M:MW1WQUB4<#C
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MDP7;,T&#W>!I$'G/PWXT@3"XW:$A;*.(3)(ZN("]ERA.%>Z-E]^Y#@>OMCA
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MY1"B#()+-'UFB@TB<J@MC$0,L1^DPB-, 268RN20"#SQ),@PNN>;)$CV>S1
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MA["G'Z,Z^_TAUEIBT):0J5+F9VJA7'>:I8C)_A,"6$YF.0^CO!IB%=)B#)T
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M_X*BQ[(;P!F343P^"648-(8</"%")C^UWGU*,V[B$9[;)/>.?TM' 3. $T'
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MU,[2<3EJID;?B(<C5P*-N&#74I&S7YL@NC2FW<B1&C=Y\U._AMIC=M6(B38
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MM7#I%>>BY768\F/\_IO8LF9 \(W,D^,I98WE-';]F,*SD^QTR@*^&$Y<M+0
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M*Z6=V<_2 +J9E$I[HJUZX1'E!PR&"1MGNFH2.DLJEFQ?]EF_\"WL'048X.X
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M0S"J%[!I6EY6)(H2PD4<2LH:=]6@M0S"7L;YJL[*.OQ9=Y%U6J."X8O6MQ2
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M3<\80QO0%#\M8H(",PU:V(2F^ W6.H+CM%#<KQ3 /)P>ON-1DOUR'"*GS%0
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MM#1+H8JD:U1';[X45QS(Y)-'E\O2[G(%>C7N3>$P\3R*Q>L%[B?M&YFVIOR
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M)]YW1?.,$NXC$CL3$7WX@87J7<>1ZBGT8=?#YK\!5\6$;;MI') =WM'XH]0
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M4+@$-3F!+GL=K=QVHHR#R"O] E>Z^4<*HZ6N1W]::F.T$[ESIX4(<H 9[.3
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M[.8#PC<T4_B#<36P&%:\.2:"#>83!:\VW,&SZ>$PX QJ'\*S$WK>W'KUAT)
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MW;JQK%+VHI[D:>L:,VF(&,@?Z+<9I95D8A074#)0SSP^C(=ASQ CB(>@KK$
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MU>[,;B*YR4TK RAQ%B5B%IINJ2.O"&SJ->Y;;[(V$"/K<.:+K)X7,HA86)%
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M-2QW'9>BEB+NT)3S;'Z5-U4PVRX-/'D/.B"U,(L>P-H:5W"IM%IRT.[P!')
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MD"H'8,J)(EAH+)MC&]9*EX'8<\P'V]P-_Q[2_8\KFT,^*+T12:MIQO?$8,S
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ML!^(2BR-E%-<R22<J^S0A':JKV-1<9V>??#Q6F<"H2PCQP)U%VT$^ST3J(\
MCGBF+Z^U;(5R$PCHD9=+\1;V%0G7N%MM;A-*8!>5J,WO<.A2+N15<G>&B=H+
M>E,@92ROMWK>;& 6+E7X0NG&K1GVPA8<N4VB$0X.\>#,S%]!:PZJLD']@7I6
M@#C>Y"_QGS GH$1&)KSJ!8;ZO9%7M#Z-C:6:;!D.M[JAJ\NR2!#KSLZQKP-
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MW%W%I[]5:T-SM]<!2ORB!E]"*K[VD5P;44JO9CYD&(&FY(0I]F^E06!>:I6
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M_'146I"_$N(\47TYZNT+7&'MV;?:!,>!Y827TXR]KU7F6/.<>_2 A9G;SRW
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MDIOQL^D_*(#NW5A:AY"8$$>;7I3YOSA5P1HZ2#)@;[N58Y$=VKW_W<&#66"
M(UNM6D%^^A,S1-G?YJR092(A9UOB7V9J9MB#Y#"C1$2]:H7$[ERGELFAH#>#
M9_H:'OG8+BO-DO6L(!\W>C5\&6P$(=G*EH@%A=/C^%NQ$QLM'G6!#=I>1F-,
M3CU\AO\;>2A=$_C@*J^ZIL 6P(4A[* \VR&\&)(R@J?Q5,'>@PP(UW ="/D
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MKDF9:S+D7!/.-7FD@-:947K.E!-=AG0V<J"M%E1]B(SXIRH</:K08^.2I*3
M4>SILN+L,X=-XD0+4MJ.ST_$L#O$8 JHG*@"YJIO>?QY/IR(2:H6R9%XZ;\2
M/A*"3K6JNPH.OSD%X2XC4)11\RH<6.:AN1OQ#=P%;E.XJ?*[P*EL_(=WW@U/
M7K-6'=^H.%WT*8^+KMQLJ14&RI$!VZ2R&J!POOR5Q<'JYJ!&@QV2I[N0PQ"P
M3##0A,GV,;DFR^>9>R1PD1^FN<J>1UD2P$R?[7C_JU>8[1"MXG?C[H56<<N[
M%J[.7)5P :,@,%8@(/6&-(.7\+0J6\#C<FX!C$+Q$MDD>85F!*:J)MY2* GF
MP.;'UEA]8!VZJD/G-/97HIE@56*0,)W!ZBYU/ %D+YJ]K<+[C\455RJ(=*I7
M'J[$$#>\L<E)+KW=VJ-0]:6#<98N%SIN7_&*HQF7QTI0BICG)KG6GBIG%@(R
ME\N6E@]%-$+[M,LEY9*@I?F;MFLA'="WNB(0</N%2N\K<J!08 (=N:E)$*B$
M/5#,Y9%8]/'";^B:S1W^L-1LS>U?%;#PVF@.!.6+1B";T8Z.M$=C1:X>87E,
MK#RXG;;6%V#>&L0-.,)3^)K% O%:^&8+P\"PZ_'NE5J/TEVR6%UP'OZ&;8W6
M32[37 76 >6I!P$8]KGM,?T7HG5E_!EY& ,SU&'?X/NU1/E3K"ZS0*91K+.R
M$@GK,NGOR(!KOI<X6LI YW2$^EIBDG"YPF+H;HDC-W.0NXY7 $9?0HYMCE?Q
MLMK[@=XR=#HE-^MH*/9"D?)%BF0A^><:]P_RIW%XF6_*H"HLJS*4"GB\+,WT
M4>1':)*E?G"KK,:ES94)+A$P!J22D/EKM"HHZ<V7H-_$GT\QP)<[YA;($_#R
MFP\9O3- HF,=$V5DXDT"_YM"WPNYXW YLX@2[/+S0UO#F^_8 6F(JUK>A!M
M09(1F,"FR%%TI&A%0Q/9<;*8#&Q-GXTOA?5N><&13F>@9=!]J3 +U[JR*!1N
M65@X>&3 IU,#3J?C6W8)4E/FBA]YOLO ,ZI"J!^A$U"6JAPJAQ7=,->8G RV
MU!POA5W@:T;,8.N2L-$L1NDM6O<EOC3ZF-XM:92B4V>30G:':K0:>[Y%*:,E
M%;MF11-KZ6W3ND/IPY?12IJ/@>!_JD(8ZE<L%-#"ZXZO7"YE\][.->(;+PS2
M5SM[%>4HZ9?7KB5Z(9)\E&8 /%'UBF_S2...N^W9IKP)97) -RJ5:RW=?,R
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MIR74?+>?*R4^@S8C[+PJ<:-OM)@NJH)$7<]TL>F**-#5)86DJ/D$1>&[O[U
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M0"X2=90H##ZG14PW)ESHWB_P^;" 0F>] O-?=[TXRK]O+H*KW.+]Z7$3>AI
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M*UZ;SOQ$?(#'"ZO;_OLK#E2S8YIQ95P95\:5<65<&5?&E0/5'*ANE,>*4>1
M=4V 9 <JX\JX,JZ,*^/*N#*NC"OCRH'J PQ4]RP.5#?':U;_0+4IK^Y9C2NO
M1J0]P!J_JR/0"@NM0\=?R$"\_ZZ<+/6OE/CBP54J%HLL3C(9IB*-Q%D6 &A6
M3[:M_DOYBGJF6P/7_$8+H?N=PTUB/_7AXO??'=VW_=BAFFYKTNNWA$R$=*,%
M=FFOWA^^1\OJ=>U\:><RGLI0)>TOWP.US.]B=[LVQ\K9-\ZX,JZ,*^/*N#*N
MC"OCRK%RCI4WRFG&*'*LO"9 L@^7<65<&5?&E7%E7!E7QI5QY5CY8<;*[;K9
MOQPK?PZQ<OM9Q<H_^*&$'^$GCI4WVH?;@%W.N#*NC"OCRK@RKHPKX]I(7#E6
MOG_W3H.#DXPBQ\IK B3[<!E7QI5Q95P95\:5<65<&5>.E1]BK-SN6/]9-P.8
M@^7-#Y;;C2XL3[:I+,>(^+;1=&LL_NB<=TXZ1=S;Z@VZ]P;')]TA!\?9&<ZX
M,JZ,*^/*N#*NC"OC6D=<.3B^?W].@Z.1C"('QVL")#MM&5?&E7%E7!E7QI5Q
M95P95PZ.'V!PW.I:G8^?S^MF G-XO'GA\1IQ]<<07U#\S]NS3^)CF*0R=)1X
M%SG9'# 2__&G[W;7ZKVAF+.??^SF'[L1O'T8I4(N%DK&< 5=^!%%I70H//Y.
MIE)\\ ,EILJ166(>E<K+1,A8"36?*A>'BE_[Z:SX?KFF_%D=WG=-V7>,(J/(
M*#**C"*CR"C6%T4.*G-0^9"B>(PB!Y5K B0[.QE7QI5Q95P95\:5<65<&5<.
M*A]@^ V#RN<G?ZV;"<R.,PXJ[RBH_%5^C\)HOA3OOZ<J3+".^=R9J;DLHLS,
M_$UA?D:14604&45&D5%D%.N+(D=V.;)[2*$T1I$CNS4!DCV.C"OCRK@RKHPK
MX\JX,JZ,*T=V#S &AI'=D^-/=3.!V7'&D=W'B^R>R,#) CUA^I,??IO*1'&<
MMW%;@5%D%!E%1I%19!09Q?JBR'%>CO,>4F"-4>0X;TV 9/\CX\JX,JZ,*^/*
MN#*NC"OCRG'> XR(89SWW?L/=3.!V7'&<=['B_.^4YX?^ASF;?9.8!0914:1
M4604&45&L;XH<IB7P[R'%%=C%#G,6Q,@V?W(N#*NC"OCRK@RKHPKX\JX<ICW
M  -B&.;]=/RV;B8P.\XXS/MX8=Y/<JH"CO V=Q,PBHPBH\@H,HJ,(J-87Q0Y
MPLL1WD,*J3&*'.&M"9#L>61<&5?&E7%E7!E7QI5Q95PYPGN L3",\)Z>O:^;
M"<R.,X[P/EZ$]S16"8#%'9L;OA<814:14604&45&D5&L+XH<Z.5 [R%%UAA%
M#O36!$AV0#*NC"OCRK@RKHPKX\JX,JX''^@=/..0V.#60&^_;N;OG@AQK]/L
M-@AK:_X>)D>?1(":.)672GQ$Z2:=U+]2XIU,I?C@!TJ\5/.I<EWEBFL_G?FA
M2&=X:1D:=DW$]Q7OC*;L#$:14604&45&D5%D%.N+XH^'?!\=U;V&?&^CSITA
M7_BOG :*?KP-Q5\KC[&ZVW@4K*?F3:M"[%L>NH%-Z_[23\(X&Z#+.>=/8-*X
ML/M2>!%X!3"'T*01#ER*)I&(8OAYOE!A(M,H7HI%(,/.3O ='@2^P)"]_AMQ
M C).@@T)N'H^X@.?BD448PYQ(E[ZA@:NF"[%%(#_IM)$R- 5,@%IXR??DE=B
M)L$^G2H5BFCNIWBQ!PL!L]1/A/H^\Z=^RI39GC+_*;Z"0>_@X>,A^$0)F:;2
MF2G$7;S7F(J>W;$ 99D*Z>!>D.%2@WX<AAF0\4PA(444B@](#ZO;_KN0L1*N
M@KT$1,KBT$_HGD#/,$J%YP?&JT ^A7/E9+&?^DI3_/UW9R;#2R5.HOG<3RCE
MG#@!;HG?3B-@ N&'3A3#<W.FB96G8A4Z^ E<@6N$Q_CAI8@\T7\G?H\">$P@
M8WQK@$UE<.8F+=C]3D< #52\OI9CW/V>L":]7@OAD" 87.6V4"2L75HLN?Q.
M?_4[US,%WXE!Q+C(P\"X"N\CO=0\V(47P:_> VQ+^'&LDH72WAKX K[II0KA
MG8(** @:2*K+#/T[*,Q@\P%0L .3S)D9:':S6ZSQ(VT7X;N_O9#PSQ-LG&D4
MN-MMFX^I E(,.TB3'+_ZK,YLO_-L#A OMZ'OH#,<CE@>OOCSYRA4.]H1]LX!
MVZ/6?0=D5F^X!MBL"%LM0/)H6Z=-4NY(!M=RF<"V?EU[I?39:^)/QT[;BZ[S
MCW_Y?/SUC[/WYSL26X^P#>LHMTZS.,ED2(H1:A*Q^G?FQV3&)*@@G*.N .J
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MFW- 'W3I?9]N@D$W =T$=!/JSL1]Y5X0]LO<5[_,6[-RF-*NPO7#CLOCAGZ
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MLJJU_FS63O/+Y7,W+SX]=_-VF>H;PU.0+# W[U:+\.\BO.<?G92?3\MV>]_
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MT[;@\"XM/TQ#VMY)^"6%Q?OYYK=LKB?T<A-!3*SIJ[X<R63X9')4I21HL+7
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M"75DV"N IG]HX%%'4$=P,_6M(\/;5:-;%-P-AP9^>)L I04W4UW 8XARZ!5
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M"ORT6)YW^6Q[N0Q@-#;S/&J2.*H+;6BD:*082*"Q(Y (Y-$!B?2+]'LTQHY
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M^/S9W;6O]1Y^G5;_N+PV\S<WG?^\:-LW\W=NEM[DOU_>GGEW>7GF[M?7VF)
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M,<&ZA??.G3U[G5:OYF%QFKI:@7[K 32=<'K0&2&CX;<:RP;0'SAB<4+(T1]
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M3;R_>OW35Q/NG$T8$Q/)Q.'[\B&EU$LIZ)X<? F&8OP85*,@'UZ0$_5"6:&
M*%X$F:<(ULD WK-HM:2"6M6+('?-=D\6LV(![8__64]7'^]^(OXU748Y1BU
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MG_OV^@ZJ,^?6>%")$A!>97 \,K \QR 3US[HZ_4=6C#JJ O >)(@A([@G$]
M2>8I)\.43]?K.]XN%WFZ&N,(Q)HV3(UTML]1Q[6O!:KT:,P:51I5>F\J+;P4
MSF0#EJ5N7H+5X)5A($V1;T%2<D9<5^E@B W&>> B4!#2.;#46M#,"V\4C9SL
M3:6EFBC;5SLGI+-]J32>DM6^;,_C_Z[;U;:,9;5HEJEP0)C.4C,_3Y%T7^T^
M[JIPFG6;8C.=XVD:)LKK\Q@P48X8(TD@28S+@!'C79VF7<6.BLWO>)!;>;4J
M\OSW''I9:O0T-PUZP+O.A>QZ;Z1YZS81:OJC^SAA+(=9OJ.&<H!,/]A\F,]6
M1Z(3:.(B"&DD6!$]9,]\4C'J'%,?IU:;^:%_[3COQ17*ZZ4S&>43;2VFQ$:Q
M]Q%*A+(^*%&1]J=(S#/N.&&05-?STE@*/FD'WI.@@[4RNAM3-QYR0K-#11(3
M:_J::XU;_]"%2!@>[Y45_IG:S8'*(G?1\>FB>[ 2,#>_N^72S5?=J<LRK=;+
M>;<#FS8M/TP#'KI4HJX(:#V HM.R/Z>%1T%H]@%,I H$IQ8L$02,-)DS88Q-
MY#%A=(ZGJV?GS/@FO]CPXB:/^*\M*[Z:_[+AQ)\6RW?GC-B+)V,J:/A=D]6.
M@A@04 2T;D!1NO88;UO53;G4$%0,(%PNJD64!2JICXDI1K5_3+Q]*.D2!J5K
MV'$X'E ?AB=>G+CY^]0%VME-E\T'-UNG+AR/:3G]X%;3#ZF93=VV S$FM8:8
MST8H\6A@@*Z*TD):*2(H+QB(2(NK4N)F4-PR*5FBBM\HWGC(8?6K>2C+WJ:7
M:?O?5_.7E]3W\SGS37MR4RS#@X)1$ %"B5#6!R7*T_[D*9@0LO0*)*4:A/(4
MO/0&LB#.9,*99JZ/D^M]RE/731CE:9CQ,YYC'Y(C7J;R*\)T>[7;S6/C3A<%
MU__;? $S455(*@):#Z#HJ>SQN%IQ+W(N@307&81V#(S/ 9+1@23"BT]B^PBD
MKW+@\WE\?H4!^[GZ/9&LKV8(R 7U< $"BH#6#2BJU3[CZE04RG*@VA,0G!BP
M25D(P?)$C$TL]'(C?/=J)02JU<"#:CR4/E!_GBN[L3N,WE <+#*LV]2XMDTK
M;&)\:#U%*#'9?RQ.22;<42T,Q&Q\":$3!<^$ &J82YHR15@O9]%O+CJ,_=RE
M^G_IGOY-_D>;GG>4=Y44?]QVC^C+4['8"G@<I(!0(I3U08E2M<=K4Z:H"TL<
MF%,,A$T6C-(&F"=<>BV3$;V<2^]'JOXO+1?1M2>=T?[!"!4_H% --9C&$^I#
M#_^Y>BC=?.="6*;NP^^[$+O\@=/I^K3Y+D[;4!YS5;XZ;\H;_7=:.3]+39O"
M>HD];^N18@2T'D#1P]FCAT-()$EFB(PK$,QD\(IPR)1HFFQPP?,^@O'G%_QX
MU9MYDU^>\V/[?![?;DFS?37_D,[[B?<]IZ>O7F?(%O6P!0**@-8-*.K9'O6L
M1-TIJ0A4FZ)G*6FPK,@;4UQJK;DN,M='Q+YK/=M+W(XD<>BC<!Q"TVOE=7MM
MLLSF<'MSA7SVJ;H#<UP5C8XXEA0X'C @ND@)2 G#-%I$%X]O1N0LEN!M$Z1U
MLPK3]$-W(H,!5!7LA(#6 ^@ 27^P:2LG/*71<.CF*'?#E1D8Z\LC4IDLXX1R
M^:@NN%]N@'#!A;]<4F&_ARYT(C@>NXR/'1!0!+1N0 >H7X<6I^\N%FD4HAI#
MMMF8 %&3#$):!=83"CXSKYDV/(:PFZY"CQ'5KVBI)-B9M_K@\GNLHASCLKY=
MIC,WC1>C9K>G2HO525HV8;U<%JBPEK(.EP&AQ&0Q^EV'G(L@B$I<!S"A&^GC
MRK^\TQ&B2T8:3Q6GO?1(NNEWG9/TR_(3A9+C>;7,\WE\TQ'UIIJFIQ$)$\8D
M5L_4*]>W>F%'NA8#T@Z$$F489;@?&>X:)V?BN['T1(.(R1<9SAHT8R&20#*3
M<C?IC[W),)M(I5"&!R;#>(UB'(N[V<V/RGJ,. TYN.,2!!3/GP;KZR3IB+26
M0,@^@E#,@1>! 9?=8(D4.&$[NC^Q(<'7B_EY$O@QS@W6^1P!*R"@"&C=@*)N
M[?&* C7<,6: L6A !$+!.EO^Q9W2)IFL_(ZN*#Q2M^[4;Z&O##FRP[W8 2\;
M##VROBQ0.',?'UZ=,,J,UH R\ CE,1]F#-8G<4X1FPT'X9GNFEXR,"0RR,$P
MKED)LUTO+:&^?&WR[9;U>CHB8 9/ZL?! @@E0ED?E*A->SS3#E;;;J"13Y&
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MB 4-H4=?X@@2*HQ[I5C4D!(M$JRR!B^-@*R2S49I3\2.6O(]6K9K;U2#7'/
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M\SC1?N[Z0;:)?!$/11HF$<N#$! V##G+W#!A>1:'GJO"-'+E%O(1H WV?4+
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M=4TZ%]2JLR8;#Q\$-CB*8D=<5-I6"SF_E@22F;- H U-IR:47>_*G+L4P,A
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M2Z*HG&LQ7V^/07H%+T$_7-DD5[Z>#?LB&\@"4[TVSKUB40-;NVH=S%A<? 6
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M'H1;<>$X#5R7*^SEFH/9X.$<X9##(U(>1H$7@2P-OM(FO%V#]$Y)1#Y?%3!
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M6P#8YG!,RKD0Q<+ ;EX"5.IF#-6>[0-\*PU'@:]%6.!9+8'?+NC@ZA7H:)=
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M^\ P!GRW6*,< W$*HJNL+F#[1BNKG5=F0JI\^^Z?'VOSMWK[VNC1S?V@$@$
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MV/#P#9CPV8-"L4]+\4=Q]V59$D9I(%@<^Y(%H:=8&NF,18D(E"_C,(G]8\2
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MH'W+0,2:1ZY68Y/YE&C54MC@/V-:)NJ/CS^U77(MBD,1"#20O("L) U4",9
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M?D,7%NM0"PYG* UW0.&@8TF^_JD\72[\1EU>LO=HMVR\)R>;>T^6A^&L^1^
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MY07(/-C<IW)>R-M?X;'?STOY^W>.!N&WQ+.OUOH.8?+D]/]4PB0KY^HP*K/
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M57'5@^4AJULO6M"+^22YQBZYSO?H''B4HE$.D2.+5G$CQH4Z%! N?-VJ>ZA
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M'+OJ"RI8J_6_UZ9<@'10W3:*I6:@Y7IEVPZT9E^C4%N;Q Y\[[*+9TT$JQO
MWE$(\O:Y@0\^!_#5%N]J4T_6!JZ<5\69/C/E=;IIC@I_EU7]>F;);SD7LIUQ
M49CN[*T12$;!.P"_.[,G8J0,=NJO+==MF^&VK\$U+)<(#$>M>R;1K$GF)I/>
M[@"G7Q9DIQ@>0>9-KVNLN6K0V[R%(P("["BZ&^XR;56UN6<07J.UV.<KIRF)
M:\H9S;K-SC;2S:D+0].]4F\>&4!]A=.\VP/I^C,VW<WQSL8^H4LV&NT*^W9<
M;K\3E$F&@P-\C8TI:%I#F;-UW>].+.Q+!VV/L(G1L.T1=3>";5A04CBNYT@P
MS\!U4C(Y-:NEU+O5C9YCJAYJ<;BX"SCLN9T VD"]L)5\O1,KJZXSAWTX+O95
M 5L9 JDPJ]W;/3_?A0FT\2OLI_3?'6VT;2X?\NB-50)J_]2'4'=T SC C00$
M3-K?"GQ;/P=5$FP1T\[MF%!YP^5<PHY_K.>W!V5@>*?BY#L5;FYG.%$+,D)J
MF\>W75%AVL!@7^BZUT>!LO_@KJ9(PS!(T?;N[GP;]@LTC?J%#W3M$LN,VSX"
MIIP <)M>8[,PK$_)"HE1](R>-+6[IXAJW5:&]$0YE<!@B5!9KA;8"L_*N)V*
M=.OHVC3R6E2#QYF$CK]E%6;\F7]'1VN[>,3=]9@_@VS_?R#,-LHQGQ#==ZJI
M4UGHH?A_3FI"TQ,23A5W -*Q*F\PM\H@^*QI%$EH_H_UU1(PNUHY']>5\ST6
M%:#D_8Q?K9<U8,NJZS+YCX_??\9OVE:3#7?NTP^P5&K"-: @5&9!-%?ZND"V
MVU.-ED,<1*46%$-LZP /6JXS^-1C_KV&9ILWXO0"',^]\03J\:B[1PQSHV@P
M_+R=3("Z'Q$[G#/9&'VI9.5!-\.B <>&5TA12R'D/^L:-YMI@%&3"6\?CW]B
MJMJ4-_Z2\L:CWG%.>>/'R!N?-)NM@O_[_$^>?RH62]>SX$/;++EF[\Q\FI_,
M*!MKSO@\>CUS_CDL#1]>"9QWYP/'!POKTVHRQDFC[!Q<O1!K&R+'4[7C\NI6
M=2TJ H09ITJ]YFS:P*XFU#VGDKF! N)V_@^;E^7OU,^IF=)#D?)N4"NY:(R_
M"7LOM\^WDWAZS9#L=*'>(*+^:!'K5*!F2K;^OEETF>=LZ%.QCX(U69^U2?8P
MV1#H"BM!-,^<2SU7P K8E5AAASML 9JM>OWN9G0A=5TJJ"@-ONEV<+$6-&+1
M+A:[*A74\*F-V!LG IW8C48PU*@4*&W3W%'1J$WS*G$MBCE^9@!75HNYWER+
M<7O@_ \[$<7 :;8!MJ8O:0LZ&P!8+/3 _[$JE;B=V5R)=MK1YE,VVEDW<Y9J
MG.9TV=30M_U;NW[DP[.R9E&_92$PI8]R5>Y(E[HNK4)E-$$RL=O0;5.9/["J
MSIR6T+NVK,?+C>!G=V7?#W7"KIEATU(7VU#8254V3ZHQ'>TND*Q:'Y1U$.X*
MQ^QT(3Q<NC9L9+=,W6[[M_-;4%#VM-WB#RQ-CUT5Z4@SK@/- B]*6<)SS5Q?
M9)D?>@'/CC+9XCUPO/_ !NX_='&LJ<?6@QM:[9+$/C P[(]/X.V+V:?OMW6O
M"^ H.!N+6'D!X)\'% 3X)UTFW#ACV@L2S\\SWU-'::#\65X"8YWKCWF+O><D
M,\\7ZJ=ND*"%N/JX^ 7Y*_9NQ#:2]:\H31Z(XY,WI-?K-R]1W!'7)D&-P3CC
MS]V3T-U-B;@L=(4#%&_[@8Q.YT%MH?NR/Q2RK_#TITXLJ/VY/5[;-=>XK5MI
MY=M,&7HZ%J YKT@4E>L:OJE?OQFI"_I$[-3]3&)+DEKS_6^$-LWS[9+PU6_$
M>E6^S;"91D5OA#-]X[ZERQGH/.5Z]89:4KV]*=3J$D!",+(W4+GGLM9OFE$I
MS6XI"FF>_5WG0EBU+H3KHBY,'/)-\XS>A7"E:F%!KPV2,YXF?T9 _76E[K@0
MC@.YQ@'7<=\[X+KT+ @.N<X]BPZY["LL+_;'O#S_H%-[IN5YWID?'O+ G>N#
M#]4NW+:,P6A@NY'Z'I%R ]1E'&QOC)L-OWA+?8+!5+",PS"47:QD'VMK> 8Q
MD>00UN9^!9_K/<PM>8B5L.?0C@C>$8'S$9+BBX )H,-?__=WGOO=5X"L%2'M
M;D,7UNK4Y;Q0SE ).#D4?P*S:/_)DL)-NMX]IM 34= +/N?38F7W'@0/PUGS
M/X  G,B(3N#9N!__&LSOY%#]65E:CY&1H?G$A'-RA_65Z&)2>,=T&I/">UHL
M_P7K0<\J'%[]I*_UW/%>CTV=.MWS/"V.->FU$Y/[1I@<GYC<Q.0F)C<QN9?,
MY/R)R4U,;F)R$Y-[D4QN*T=F;#1VNN=Z*FY/[L8S'KC Q3CAUB&G!W <TP$\
M4S+H_B,TV8B/IZ7'G,GD,3U8!'T!>'>2_5@ 3GENHU&Z)BB/',HC@NG$*B8D
MGJ \7BB/"*83JYB0>(+R>*$\(IA.K&)"X@G*XW(WM1Z8/A"]@)[S*-]3OWS,
M/F>$;.=)RC;W'_(_RX6^=6#=OV-;35C%4^?=CXA\GEHJ?'/ ?&9<_]/S)60_
M4%8<5M'[%83%_6!\YC/</81>:ZGC,%&,>ZE@01CD3+@XCMZ+LB!60DHL#AOV
M%W 3U^=!P)G4DB;/!2P)@HB%4NA<"R](DF2SOX!QW^_HC+%W%KT_F$7OWSF+
MWH]F81CM'4<_\9")(4_ '"\P)^DVGO/9*=R>^8!,VY-@HIJ)!4W / %@3OQ\
M/.<S\?-3H9J)!4W '"<P)WX^>9^^CO>)9T'NN0D+,@_^"<.$B214+/+<U)=^
MKL-DNR.K3'DD$H&]6P5VM]0L\W3$LBS7GH[=5/!T\CZ-CH><2C!M(\(YA=2>
MD$F\*Z^N=$5]2I<X*7U*MAB18C.!=$P@G6S.)[<Y)P(8$P%,()U .GZ03J;D
M4YF2:2BCQ'=CYN9^Q@)/NTP$@69IX$=>H%.=1]&F*2F5ZWE1'K- 17"/CD,F
M9*98'@:QC'3L2:Z>V)2,9Z$?'M&4G-C!F-C!!-()I.,'Z61;3+;%-TT $T@G
MD(X?I)-M\52V111)G<0\!#LADRP(W9R)))8L#R*9NFX2:=?;M"T\U\TCY0H6
MZRQ@@9MJEJ1)S$(O":(X@?_X6T/8)MOB9;.#J?+KA82IJF6)P]"<K)S*OL8B
M22=@/C<P)[MQRH/\YI!^ N8$S'$"<[(/G\H^Y"[WTXR[C,<Y#NG.?)9P*9F;
MQ:XK@L#3_E81K>?GD>:1Q-@39X'.$Y;Q-&/2BY(L$YZO_.AI[<,TF"51,*4Q
MOB 6, %S N8X@3G9"I.M\,TA_03,"9CC!.9D*SR5K1"G0>R&VF5)G@<LR%./
M)5HF+%5NG@KM94&8;I4\I6&B5:)9$J=@7Z0Z9EF>12P,W"#4.DNUEI.M\*VP
M@*GDZ07%DG[[[/P*$ 7"+/0TW6),<O0+0'KX")X)^,\(_,D&/:4\QXFHQDQ4
MT^"^,9S"1 )C /YD3#^5,>WYOIM)K5@0^9P%@0!C6@B?98G20JC$"^16_Y!$
M";2F(Z9Y$+$ 3&>6B52P.)9!$F5NEHOLB1,S 5X\'4=BYL1BQLQB)BD[AE.8
M2& ,P)^LM\EZFXAJDBLOYQ0F$A@#\"?K[:FLMT!S+X^D8AS^RX(TBED"-AAS
M\X0G,@Z3)-EJV>$G?N1G8<94+K$>3_M,J$BQ* 5SRE,YY]EDO4TLYED+\'AR
MG*"I?<X(C^>9V<FOY4K,IUR#4<CD1P%SR*?X&0^13ZERG<WU:3&J;ZPU]@,.
M;M*CGDJ/2K$==IY&+ @SQ0+/\UGJ!Q[32L:N&\DTS/Q-/2K-<NY[GF;*QQEN
M+BA3J5"<A0F'+T(EY9/K4:/HHOUR.--+DPB3CV)"_$DD3R+Y)$1R%$5)) 5G
M@N<)9GF[+$F#D'$=N+GP4^[J?%,D1USE2<)=IF,,3"N=L"0+%8NCT)-IH+PD
M?V*1[$5\%O!DDLF32)AD\B@/X%00?Y+)QY?)4QA[I$<ZH@/\%GC@)(0FQ)^$
MT&08GH1A*%T_=UWALLQ-% O"&+./,\Y\[0O!P>;C/M\T#)6G9<2]A"GII2P0
MKF*I]"*6ZE3F;N@%B4R>V#!,DUF:/'O][\MA3:<2[WY,;L)FB'N$X/\:K"(K
MY^K_L_?FS8T<69[@__LIPC1;,Y(9G>7WD:HNLZR4<E9MNE;*JMGY:\S/)%H@
MP$8 F6)_^GT>$;@(\$@F"$0@O:TZ11(1 8_GS]_OW>])6_CCR+K1>#0O!<!'
MUY: @/G3?_L*9.Y+D7=X!MX0\_L*E8NH***B,'&A<D^HW".:%E%1F+A0N;]4
M[A%-BZ@H3%RHW"^?T]X:B]*8[H7=U]_%V>B#G8\^Q&K<.:AN2\E%+Z34 7SE
M RX-^Z*C>*4APKEED@SX))Z9 "QY)(7M"P 5 "H -)23>&8"L !08?L"0*5U
MSP#2&)6G0@GID*=:(JZ,0589BH05E OI@]MMW6,,)U0'BE)2$7&A/;)81L0D
MEU9H;;E,=],8WXXF=N)A)1M)4B^5U$A)SQ(:!RRBS@P9"C(7MB_(7)!Y ,@L
M@S3&!8)<P@EQ #5D#1:(62]"9-(JO-M43YJHO6<H" _(C.%RDZQ"&HQ3CWV(
M4NW,(B[(/$P1-92H[P-#R4I_O7[WURNI0'U*3#F?(JGA:E?'V;[B?Q]N1_PA
MG\OSE(K%YN_%-@SE$!1P*N!4P*E_Y_(\I6(!IUYLPU .00&GTO^F'^YI[9G&
M23,DI1&(VRB0DTHBY87&S@;LJ=YQ3W,1/'<<11\MXL(GY#3E\(746)$P/(J?
MCWNZ"*RSA8N"VKW8AJ$<@H+:!;5[@MHI:L&51I0E@S@G!&GL'1*$66R2"4Z9
M0W2M*Z@]:(%UA-@R_&R!+O?3X2^??,S)L>E Z-,)L7SMYJWW!;'M8CY=LE#^
MQM'D_2O\;7,Y&MO;Z6+^*HW^C.';CZ,POP*2-#3J;@ &'MN;.KZJXXV=V7E<
MOFTCO-IG?[4OK/]A5(_:FN!7RV?<$]UOOY:;2TW-7S*A[CM7[87X4F/VA.O(
M)1-/>9Z^5%(\Z7M!5CUM?90?=GU*]GM]1IUF??HISX.S)(E^]@)?KEG!,WM'
M+,5)7\3\6K'JA5WP+/+VB)PGZR]#\",-9HZ7 #H,%C]I2]A_V'I49^6URMIO
MU:B_U4_19N7W&I;[&8UBRSX/69252H47Z:[U9:#V247:AB"S=35-1SXX@]NL
MH>1IE]WH'TKTB)SG)?+/6 \Z*3A\_6/\$,<5^:9OZM1P]W-8$JOHM47(?2%"
MCA8A5X1<$7)%R)VSD&-%R!4A5X1<$7)G*>2^BSY>NSBK&+FH**:X;V=LN/LZ
M%+=G&81Y^&/5SJPM?2=Z"D%E.$K/,]\+E8NH***B,'&A<D^HW".:%E%1F+A0
MN;]4[A%-BZ@H3%RHW"]WT\H#LTG$,@/SA8MA?YI.XFT%Z_XCSJL$JSAVWGV/
MCD^OV@.\L->\YV0?;E^ XT4[2D. %VT($*64C"F+@M&YC4_ R!@N$<.2,LEC
M%!'?;0B@G<?),88B80IQ*1VRR1-D/65$ACP5AMYM"-"&!%ZL!8"2%XK*TEN^
MX$')5.@?_8?"]@6/RT#0PVQE&0A:!& !H-[0?RAL7P"H % !H#Z<Q#,3@ 6
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M")A*&N-]>[X_C5%Z$G72'F&F$N),$62\4L@')9GQW%B=[J8Q^B0XC8&@*)U
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ML9'H31 PNQ8SDL^O*EO5BVMXK=MER*P-0-75;KBON^#-]!I>[[:MC##?UJN
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MU5@Z(TA"(5**.#<&64PETH2F8!7QFNQX&EX 6@<;VRY@.WC!5(A:P/;+)?\
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M5C>-8*PK6$.=S8QP>8Y'$F-II -6H]PIQ%,0R&KO0=5/!@ G"._976[EDE.
M)(88AK/,K4W(>D;A&'-#:>#8LK %.2!^ 5[W8\RVE^[7:3W*J_LI^^H 8'^9
MQ/\-\GR+@[M[;S^)C7^>3N*0^!:TC,R$;Z;7L+;;_U%7H\F'6,^O@1/SS_<I
M-:#0-. !5\ K+5:T;;B^NNFHV_#X-9"X56* - UJ-ABT_$H@;LY:!2TQY*OF
MU6C>/#ZORKK1&#8 OB+ -\UA3=5\6EU-LT9UK\+5/&0-;WF%#5^-)HOIHKZS
MP 7\?:5UW>9C.XM^"H;4[04\:-$LHT'+^FS!TE.A"<&@_?D$]K>Q!FDL/"+*
M2:RTEMKM9,(]!T=^R:3,9^U=O,Y3K6:W/P #C&:9U?*1? QG_/3])+/8#Y/O
M[6PRFKQ_ ;SI[3&=M:_?;!L<V7QNIIF>*!\L-%]2M!JM2)H9/Y^A?."J"$9;
MV+4_+O>]\<N_S"&,2W(<.[H?V_]ZK_F(+S9%=V-*GJ%XHBE2J4R.]'F+>)0.
M&6PYPE[;%+2WR>]D"+E$O!#!HB08@WLTW*,P*,DD8LVITHKN=%/=;Y=^,0)F
M+Y9>;OG)]KG!_J^J^AO\]_-=$M999J/'2&L/NI["#&F.(]AM2BAM!:B)_A H
M].ML"@KW_/;7L9W,7T_"]_^Y&-UD>?G=J/:@&RQ 'X1O^,=XZO_XJHJUMS=9
M.,T6\:NE%A'#Z_E3E_Q_R .NU$<DG#ZAA/N\>( ##>TI?-=>DM?Q:C2')7I8
MG+BLEGO4Z'VK#;J ]YP?#+ ^9XE; +:?^^FG<3^3C+- -5*18[#E T461]84
M>6HC!(TTOBCWW\?SS_=SR\%R[Z?(S2U6C6M6G43X!_:K'M5@T2^MK#0=CZ<?
M076MOFZT,[!'X+[ZFU<]U<,>E5''<?$?B!+WG\DE)9:QCYM5#*A#Q-UZ5+N8
M3Y>AM;P*V-17^-OF<C2VM]/%_%4:_1G#MQ]'87X%I&MHV=T +S2V-W5\5<<;
MF^?[+JG2!'7;9W^UKSCWPZ@>M3;QJ^4S[BG1;;]6RDM"0)/^ZOY(8[>^2V'$
MTZYCY"G7T4N#GW(AOC3T20\\_ *U>?X"'ZF>;J'[6<73SYSJL#PWO0G;KE,F
M!ISHTR>"'CUO"HB7/_VWK^17/>)=?2K6/8*BK._=KDW;_W2C8X:Q48\<BON)
M_%D-,XK(+R+_?$0^78O\5F5M7_#^-E(OEK#VQ-Y5PQ!-)\60[/%_TF$J.]Y[
M,'KZ?NTF=QYSXYZ?6GJ$'7N&>/VL_2K2];RE*R[2]3RDZXN/VWM6.[P^:J.G
M]K__9/T5O.+LC@.^]!'N59'=&1/UU ?@,^KG/F-72FG<\1)@A.(Z$9.0-2JG
M&1B#='(>)2R,, E'0^G=V#!+@EBK)0K2PCV&RYP^(Q'7QB?OL0R&/3DVW!2Y
M'Z0@3EP8=<AZ]C.6*T58%Z(.@ZBGEIH% <\= 941$5,6D28.(^X!"XT5@( $
M2Q%PB,GN5#H93#4/N;<^2X![C%BDO8@($P((Z !1$SX! O(+0PH"GE18OV#C
M^V+6'T@._!AM'9LZG]'US6SZ(3;U2"42V!-MII#S].0L"L@13? D*9=!(<&U
M13Q)4$ (Z!:$L@#6-+=8[TS9$]30:(U#(H&^PI5E2!N!4102A\2EPUB=0 &A
M%X(><H!>$06G%P6%G(6<_25G :KC 55TPE*OP326@B.NF4.6X(BL"C0!B%EJ
M=BQEZ:R*AF+$$E4 5"D@"T8JHA9PC0@+>)4*4)V>4X=M(Y< ^,O(@;>+&9RU
MQ2PV ? $!PE^_@Q+N3B4BO?_[(E:5)+CJ226:*JEDDA)3T"]$!09K!0RWDIC
M7;#"[]C.1#G!#(;]%%@C3L!V=M$;%(3QTK&(63Q)^%KV9,QMG[CU;(1"(6HA
MZC"(6N#KB+%GGH@)42.L*< 7"P&9@ 4*.!HF K-$[<"7-)+8Q"EB&?<X=AP9
M"J:X$\*%/.-,"/%"\/5WK@XY][.<_!Z8SB6\?.BC_DM*(Q\/D2Y>O$JG=S 7
M<A9__4"U"QJIYB00A(U/B.<4;:<=1I@&FZR*TO-P5[OPB;L8DT94$P?W&(R<
MCP$E)K@F2B0I3V$<$RF*M_ZL!$$A9R%G?\E98.IX,*5UL(%2BWB0.?\I&J25
M4(C2F QF6,#_[Y8@2984ET@0F4N0,$";B@H1%P5S.#@OZ4L9P02??&IFGYAQ
MV.9OB1R_S%'/?<,7(#?79G 30JZG:?[1SF)Q&O4*(PM1^T74HGX<T4KFV,1$
M.&(L><0Q)L@239"P#G2,)+&R9F=V4.#>J.20\#PBKFGNCLT3"IR1Y$&=(?ZE
MU(\'Z[]HJ?XZ7Z%0B%J(.@RB%O@Z'GPYQ6*(3"!.%4%<^HB,3@%%GQ0CT3F&
M=R;8!!:Q4A1L9NX OJ1B2(,)CC3 FLL5ST:_F/7,2IK3N=G0)81\>.MY4L]G
MB^Z<3ZJ;V?3]+-:E1KDOX/@L<CZ]56(A_(D(7S27XVDN21'-0F((JY1KF(U'
MH'Q0%+5@(7BFK-YMO")HP,EKY&T.:3/.D T<(RSSG%^GL G^%.%IH-I!]9HB
M7\Y*OCR_4779@<+ZYT'X JW'@U;LL5.&)\2L9P"3-B"MC,K#'*-/"5NP\>]"
M:^2<D*2S"SP&Q+4+&8XUBA),]F2EHYZ<HBR*F8*K?1<N)2X_%,_"N^G<CK,_
M8<]@T>*&ZQ4>%Z+VBZA%@3F> F,DMBQ1AF1, G&G!')1$F22"UXX';TB.T%Y
MR2DS< _#0B-N;4*@_5#D%3>4!@Y/#*?P#9@+14K,XWSE0B%J(>HPB%H0[(C>
M;<%H%-(C[W#*<?DFK8PCX0C3\)F63-U%,)>(%R)8!#>#V1ZU0T9A@SB)6'.J
MM*+V! BF+PPY9+.T(A9Z8&"OSL<F&0EOGO,L:[NC5J;*\CE]W*%32XL?8UV_
MJEY[O[A>C.T\!CB'\% _LHWPR :YO9X"I?^K^4.)^/<$=HOG\#P)/T"=Z-0B
M[.OE9IZ'HL:T3$)&A)T I<O&B%QB'*D0I))&$T%V$BB?XVK8$/G?;4A\^'D<
M\P^@N[W>$/SWZG4'FI7&Z,DKZL]'.IZ:L[_IV\Z5A(=3[\!@SL[9$KYH%E^X
M9B%YU$T>A>2!(] ,"+(F$$23DY8H0BW>J2Q\C@NH5YH%N]"<%\WB[#6+%T_Y
MV-P-J@_CE^J>4S9Z=Z-_W9L2<E%-8LD+Z9?:\AE$W9:+])**+!?#=.'&L0C&
M 0P&_H0-'*#Z.5A-SWHE).ASR%(1$5=$(JN31#XPQF6*V"?_HNDJ/\?#:&^$
M7S#3DR829R2LSA0LBI>G)QLQF(-P:O%=4+N@]KI*AMMH(DU()HD1-S$WQ,AY
M.EHH:C16..P4H!XT1>=0J W2MR^#&<Y(5ATCEP=^MD"9OR\W[^?%=9R-//P>
M1A_NI\]?/ID\I ?DN?NE^P@%9(A_^O$BQ.>^/:$'?_VU).X3EKU%^[SEIUX5
MT1O;V7+YWZY6WL$;^SZVH@39!#1]9<<?[6W][5?57[]$;O_K)KOO%0% P?UT
M$9=2JE-2ICFK&1Q'DX7=M(6=939ZC+3V8-<JS)#F."(CE5#:"I:,_S^D9V?I
M]?B^HKC*SF)U;4>3.?Q_#+D;S_PJ5O\$U(;??I_;>:POJ\VX2Q7_O(F3.E8?
M;5W]WV<5T5)2FNBH1=0[CGC2%HZQIBA%IF1(3C/,[FI,BE-BB?6Y^%@@SE7N
ME>DB(CBQF**FTL6[&M,F.>_5D.26AB0>]FM<WI_MTB<^K."W\3(/]+QXQSI'
M#-$&:8(#XEA)I%4D"(2"ICIJ!7)A9QJ)QL9KZQ#+>CD7UB)#C$&*.NZT)('A
M8_#._?',7O(.O$LCHVZCG=55!+P((*!\O'9Q5C%R45%,2<-A\ .^J&:QOHGP
M7A_B^/9R!4]WI/O>5W[Y=]I6)OX&D+CG(-#'6+'#U*44TX%Z!=:>#J:9.J#A
M)VL04S;&0(&K@O@<*9;"]3P'Y6>+&,#<^P7V8O;CR+K1>#0?Q?H=//4?XZG_
MXZLJ CO>9&"'2Q\PAQY1>/51-*"78&\W'8>G,$)[25['J]$<ENAA<?*RZFC<
ML')#Y6J#S!?5F\5LMFP\__-TXMM?#\;'G[/X3;X^#%,#]FKG1.9G3Q'WDB+M
ML$8V4$,8$]3RG98?SX'FW_U5#(MQ_"5UU-_D[&S+?B)[/T&/E8/E[T]203MF
M'J_IF;>K'M59T9RF1J2GZ7@\_3B:O*^^;A31Z:(&[JZ_>75RZ=QKZ^U E+C_
M2"XIL33Q;E8.GL:_LR\7Q2[FTZ6[+*\"-O45_K:Y'(WM[70Q?Y5&?\;P[<=1
MF%\!Z1I:=C? "XWM31U?U?'&SL &65*E\="VS_YJ7WK.AU$]:MCK]M7R&?<D
MZ;1?*^4EX>8OF:#W^1"[]5U*+)]TG6#D*=>Q2TST$R[$ETH]Z8']6N C^5/Z
MD].GGI4HM^?<],8GN]_K-K!TX3X1].@!42!>_K0QMWJ2B?U)7*Y/Q>1'T+7U
MO1N[:2KV-F]W<%OZR$&[?SL^JS"\P$B!D?.!$5I@9#@PDIV,!3YZ#A_#JP\]
MP@X\0\!]%OV+?!NH?,-].U;#W<K3J,>E,7%OW-^_VMO9=#QN@C6SV'9&ZA(I
M/F/L42E >P&5X(R)>NI3<)K\]))T?KPT&!)-)(Y@I%ABB#OMD28RHD2),S$2
M'<-!.AM_?WTSGM[&^%LK2S>BM%U8_$#5_L8<LMK_C$5+D=>%J,,@ZJD%9P'!
M<P=!;["W47&DH@V(1Q6141% ,!J1%->!)7F(RJMC@2!GI3_R2>5U&6K<?[&^
M3'#S\**9=(VIGW.UE[_7\T6XA5-?S\N@X[ZH.86<IR=GT4R.IYEPS+WG2B(6
M7=8M0-4PPDM$B+)"L1 I#Y]CGF_6!KSI!-_K2?AU+09_SU+P31:"!U%..#ZD
M:E+$P>G%02%G(6=_R5G ZHAF-'-!1JF1R-5LW"2.G'848>()I8X+2G9J?C[%
MC#XZ6&EY\F&_?>+685O0)5+^,K+@S712+\;S7 366M#3%.L:CHH=%Y]3KP"T
M$+5?1"VZR?%T$VRU",9$Y)T%/<,$!7J&84A)BJV3 5NY,__PF6-ULGKRZX84
M?!L/Z]\G%Z(O[=7ZQ*]G(Q8*40M1AT'4 F#' S"EM3%)>#"N+4%<&HY,LA)9
M29BGPA.6](&FM[PT@#$ L)*E=6;F=0E0'UH.M"V$;!>F_OSD\^)_.KT[^GPF
M09TMX8M2<SRE!A0:*W4$+48IA[@(.?&.!"2P"BY*X:,_2/9Y(TIW&X0=UBI7
M"I\Z6E#$2U_%2YE-<NH=**Q_:L(79#T>LFI,$F,V("T%1]P[B0P."KGH&9-&
M,0#.0[@+CH"L_* 3P(IP&8A#X8'YJZIYV&>/7U5K@O5LETXM4]Y-YSDA?J.?
M\;1Q1G0]BS>;PA:W7:\@O,Q*ZL/Y*7/=BBJVCMP$;15/#LG$,0(]RB+'0;?B
MGDEB*%'1[ZABGY%Z\$):F+I0O"=!FS,25&<*%,7;T9.-&,Q!.+7H+HA=$'N%
MV(D0ACF/B# B$1>>(H>)1MHY@Y7&AN)#YEJ\$&+K"Z;*[/2A ,47,H;U_IDE
MN^0YR""BI+'T6>?&$G/$%3.@24N.HN<V$J$<G,Y##")J'*'KL4XO/X;H\'-E
M^XC+;1+,>'..UF1%Y#*0J'^G]HP&#:FGC-,Y^!P?>FFTZON@H:>,8"J#ALJ$
MB%X0],P&#0VNF?:7.CYH<!M5A@(5D5]$_N>)_(VA&:W*VK[@_1DCIT[%&H9H
M.O5LC:?-#GIPQW>#(J=-0!T<#PQKZ%"/R-F'"4)%&)Z/,'S:H*$B# <H#$O?
MI:%XQK^+*<YF,8\GFLQ+%N:YY'3TG:BG9OLRC>&)V1>GWJC__M_^I)CP<HJ*
M:"I$'2Y13RU&BKP_]VR[B*GQCEE$M*2(:Q*0T9&@H#67RH.]R<PALNV6"O-O
ML&UOX+^C^3I=YT M &@9O-.?++K2UZB?$KU-Z;JQMSGEIZ=.V7,[%Z4N^DLE
M?-%DCJ?).!44YQ8CJCP'K80[I!-V"'L+.DEB@1^PG='O\/*SVXT\XT-K,[3_
M[8Q*G5G!RR&1L^!E[PE?\/)X>*D<4<D!0#*!$^*2)*2I94@30H('P*0$'ZQ)
MT4OCI22BX.5@Y$SI5W1.+H6V7]'TH5JQXH;K%8J78N(^G)O2]:!H8RMMC&!A
M7 @1$>H<Z%/$@B)&)4J.2A6Q=]I_UJSA+6UL*'Z+TB9G^(!1B%I0N*!P0>%!
MH+#!CA&:*$H82\0QP<BH@)'"/FJ&G5'R(-D0+XW"%UK0@L-#@XQ/Z$*T]Z]P
MZQ?4Z.0P'8I\TB2*/ 2%*@5G%@Z[4S+!/]8)^$A13@_1H>A-[GL"A\'.1Q_B
MZ]G,3M[':]B;[T:U'T_KQ>Q3FQ0]NJ?R*'MZA&JH>\]3>TE>QZO1');H87'J
MLOHMUM'._%73.GN#[B#E-PB_ZIV]^39'7^Y6DZ*#,+1P6$7*$M+" W-:S)!V
MD0"'AA@PHRHR]CD,G<+U_-7O_BJ&Q3C^DK;H^WH2?ASY/"GMM_@A3A;QA;IO
M#9>U/VVV^R;K9F8>M\2M9BUULPI010N<?@,,, W51UM7\+^V#U==NG!]RFX?
MB!+WG]8E)998=C[=N@1H;?QI3:[T$Z][:K<NC9_RP*=WZSKX J423UJ@H<]?
M8&GQ4EJ\G+%9=(2N7J5=P<NT*_C?H(A7WP-%0G7"5F!GO+O#ZLKR@BDRY]7(
MI2!Z0?0O!M%I0?3A(/J3N[&5K2SP_:7"=Y%O0Y9O3VNP5K:RR+<O5;Z5/G5#
MB2$M)J/_=S'[C$+_DOG7K\R_OA/UU Q?.A:=>XY>\I1(SQ@2G(8\4TPA8SE%
MDA+,@Z8ZTITZ?^P5YP9'Y"5<R4U2R!*ED1<>8ZL(P4+=S=CI4ACJPPSP9;(?
M^7A]XLLBE M1ATO44TO'@G3GCG3>Q<1E]$@9FA /UB!CA$>1*V<C(991=Q?I
M"':))Z,191HC;@'D7-(,.8FE%LX%F]/_7A+I>$\RS_O$ET4H#YRHI;5A_P'Q
MMZF_*BT-^R)D"CE/3\ZBK!U162."$2DX,E'Y7 8HD$U!(LN%BS$ZQ=E. 7],
MGJ4D"=**6<0Q54@;+$#+PY)HD;30Z465-:(NB":G[IS4)Z8\@U-?R%G(V5]R
M%DPZ'B8I&JAR"2/B=$#<&XRL<1K9D%)(G"L7=XM;*>4),X^2C 8PB=-<&BN0
M,%YKZ2TQ"K\L)M$+;0[9R;^<^M.?^B^5G"538BC>@S=OWQ:/6J\$S<&ZCI16
MS[TE?]$&CZ<-1H8%48H@;*5&G(%>Z#R/B'"K<4PJJ"!VFAMYJ4@*&&%G&>*)
M95]%4L@(3S@33,5D7E@;/*1[HHB4LQ4II8U4/_:A'(-^D'^ R'IJV/QZ7X><
MP<*]=]X+@'3D3<X$B1@CBXE'T@KI01?PGNSD20*^DT@#@#R+.8AA.#+$2^2<
MP(YS;RS?Z67XZ7!? P? 3P_B/NW)+,?SD7>GYM)O^KE_16\H.2Y'[Q)V_Q;M
M=@DK[MG!>;M+>^X^9#F_]-8-4,,>K#++3: X2HJ"5 )QC$%%%28@:C3'T40K
MK;ZKS(84<" Z(DVD19PG8 (!OSH'5WNX@>PVYCZL[TI?8*9/'<D\(V%T=C!0
ME,^3;\%@F/_4@KD@<4%B0&))@P-8Q8@(:7)$R"&#G40QYP=I'B+916(NG1/$
MY7I;R>$>90"$E4,:Z^2QL=00\;)(S"XD.61=TI<NC,X.!@H2/V,*29_[N1]P
MV,AA!C.P9(VGRB//9$1@T.0A"]IEP2D5D\SJ8 \Q:>0[^& VBZ$3H/^X/<2T
MD2<,93C.MIX:%)?4+3,8R@R&/LU@D)>$/FUT@<3RD",.&("E.>@,AL,OD#_E
MPOT++)V82R?F,U;VRFR%P78J76DBG:)7_<W-JK_^'72/:2K3%H;4SK1@3,&8
M+P9C2C?L 6%,Z?8_ /@HW;!+M__A'HI3R[?2[;_O\JW44 _%.5ZZS?<Q8GK&
M1#TUPY<>O.>>[A*LT%PJBH3G&G&E0BZ CH@XYD4TAA(>=[K-$Z.Q"0HQ1@GB
MS'!D Y8HD> CBRSXL-.#]PT\(7_S_QK-K]XL:J!LG/TXLFT,Z" Y,.Q"RI[4
M4O>)78NL+D0=+E%/+30+ )X[ #*G5?22(^8$1UQ2 #.A'6)1*Q\U]4::G<H+
M%57D1"$1@T?<NH2LDAX)%Q56SD?*=M*67AX ^04S90I+;W(+2XEI/T5Z::/>
M)]VED//TY!R@NG%J(?+?_]N?%!->&'_0C%_(6<C97W(.4"P/U@H,/!CJDT5:
M!X*XLQ$9%1@BR3 C,-?$I9UF4DXJYV1$SCJ2.XD+I$/$R-J4&%;!,KO3._+E
MK4 "9B Y>5%^GSAUV 9@B>6^C!PH_;#[!I*EB]WYD[_H-,?3::@5PH>4$'-4
M()ZB1TXKAK@DAE%)2>!RIQ\V\XYK'I#&><J7"!Q9)B+R5GF:&&A#Y 2A77+!
MJ>F'9[M(FGY+FM+GH!_[4(Y!/\A? /=X@$MBD)Y8@9PW#L"3,60IL4C:2(.+
M46OF[P*NYBX*E@"5M0P TCCD=D,88154U,QZE^0I !>;0_H0BJ09E,_A_(+.
MI:_Q6;%\:6#6=_=:Z:985")0B; 1F!"AD7 A(>[SU' K+;+P1V<<<4+O^""X
MY)09RA##<".W-B'K&45><4-IX-CF2>/'5HG G#3XU&&5,Q)09P<-Q?-P\BT8
M#/.?6E@7="[H#.BL,796^804U19Q1R(REBN$O>$F<LVDW<E]=XEX(8)%*?LW
M>-0.&84-XB1BS:G2:G?JP!$<%N9"EP;( \"&TGUWASRE(>U#[/3N*E;SZ=R.
M*WL-JYCG[F_+WK1-[]E8W48[JR+0+6SUA:MR=Y^+"E;CKYJVM:.)'R_R57!?
MN-OGULZK?[>3A9W=5NM;X:855)Z%Q+>2"J6Q1#(9 K95EMZ!2:1-9)9:9G7<
MD?C/:=+\H,3O&OK]%OWT_01>(]P+ 7(+ L3#$" N[R__[1-'5_#;&!9WV:?%
MW944&UV5^["\PT@#_'QI@,]1&H JISAW&(XR" (.OR#0!PF2%LL4@A*$\+O2
MP&MLO+8.,>Y!@@AKD2'&@ KIN-.2!(;[( W8Y?W:8)\8^D%A\&+]PA\X[5DC
M ;K%/YO3\5PMK/O.0RHGQVNO]2G[]Q;UD:N(V=C.5MO^V]4J,'ACW\?6I$$V
M 4U?V?%'>UM_^U7UUV%KW4^!M3WFR0'870]6%[_32^[IW:\^6U ]_9L?'_#P
M!'-)[MLB ';-UO\WA W[%#GPPV2EQN1RQ8M&07HSO88EWE9V$JIN3RLWFMY<
M67AP]8_+?UU67[?UC?[;[O/VU_#M-U4CA!NE:3ZM+#QK/+9N.K.-5I&?^.,(
M!'4=J]?O9[&9R5)]G;_TS@/7'Z\?#0_TJ\?%:MJJ<V%4^^F'.&O7"W"./.QA
M]KV LE:#K@?J7,;W#Z/Y"+9K%L=P<\@/VWC7]DO,MW4%"B00-"[F(U_]*_KY
M=%9]_V$Z7C3KOX%[LTZ15<+&E9,?\SY.8K.@_/T?8*]#_N5#<V_=C$?)5X!F
M,AXUR\S?#+)UGE<>;0UK^@AJ3Z><9A";P=+AD1^FB[JJ;^MYO&X>W=P.Q)J^
MCW#EK-VKNV1[.XKCL"+92RH-+WP:]RL(9WX<L_6R<P"JF]GTPR@;(LN/,K_
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M5R1L<6\+O_9K!-]WCQC-;ZLW8[NH8\&Y@>+<KXM9O<BPTFEA.YBWK8C.HH_
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M^@@>C_*<U4$+5'"ELT-;8OA'@6WM<  &BXIZ:QR/21SDH#TM9GG XZ8TT8;
M*@GGL,K !-*.:E"'$];"2 7J\$&.V]'?C"H7#=,F1R)T+E:VR"A8+[-.&0)B
M1)"=!OO/W+,\.G/SO=ZTE7&O)^'GZ:0KDWO1=\VA.N>D0GD[06A2#SL"3,H9
M9\Y+:C';>==G[N(1W_7G)PG308K;+J:=-9)54'XZ6_ITUF'Y3Y2ZIZ]&*&&I
M)P:(?IOZJ]C3P-2CELG>P-0 M^LSPE3JP3"5WYEHL.QNLK9<FO#)V\OJ_YFF
M!#29H!]MU7!%]>.\;;N\^\D/$W]9?3V?OH^Y!NUB%=QJ/MUH/#EMRY2:.NJ-
MAJ'[FD+FT2'7C74U@0VHWL?)LG%*;BWZK^CGTUF."/E%5_L]O;F:7]GQ=:ZE
M:RJZX*MRQZ1Z61[5Q*SJMGJN"1AUS>M]CFH!-;?C<IF6W=OMF^.P&1=J1EDT
M5S:=!!MKOXD_+2O(IM5DVO:MWJAQ6]/BXOX.FGT5G<5-L)]RK]O&$+%I$YI#
MH:$;O9S_NH^E+NY$(!OHC36\7QL?[*Y?S=D>V[I>9=GS[Q A>/5AOG?5]0SX
MJ[EUFU7;#A?;,<R<,9>[039M'A[KA'8S&[4*P<WH0]._P<,&-\>MGL.IRCT6
MUL?AD6_;Z.6TU0QFLJ_\<1TI;<9N+WVZ%]U7K5L2YRY56W/R[N_J-N]2^II;
MFQC"/3._FP>" OC',G6O<_IL[]U:/]J_T\V+=4&*'%J8399],BZR5(HWZ^EV
MRV88JWK055 ;#L8B5_2W153-FG96<G92X^R22_[Y"*NT?[BR&7"[*5J91_*1
MJ)NAI4\XAWEZ08?N65!047V]9*_Y+-KY,B_B__OQMU^_V9QTF'MO=]]U,D]U
M0:!G4N[7Q:Q>V&6;UOOXZTXE9=LAH,T8FL6<4-,PV=E/<68BJABX0D%QWCK0
MM H&:9X<< EAPL>[#@HOB!'!YXF].:<Y>H*,,QXQZF/B/'GL\-.F./\\G?RV
M(O8+CG2F9&BS8NRZE5S7XFD+\A^:?K1O9-*ZX<37HV_.C(4MX\E@ZY#W0B,>
M\O!-20QR"2N'J?2,[F1#'XZ%=^8<O9W.OK?^ZN?.W@E=V_)_Q%O0^]Z.9O7\
M7<X:.,S<UZ&Q]6H$4BN/ET;A>A*2:\C4\'?*M*J:%(L+8%O@VW/,I_)4DF03
M1;DX'?%<%F:92<C9P+W5Q-BTX^<_'/?^9/\<72^N=Y@X)U=]WRE RU'%[Z9P
M&1CK\]<=2Q^FG 0/C8<;,VFI'6Y/W^[$;R;2NC?.EK!><_R&4=;P_Z/:+!P!
M. -[1]6M!?V99AT:9[7AG"'#O4=<$P$:BI+(4,^$"#C*W=+P@Y^2?=F&R^%V
MAU%3*!O88;C(#-?:3>?%<"[*Q 07B)CH,O,X8#T;4' D,2FE$68GL'PXAGN(
MTW[KXO\@CC<]'@=A0"T'QG^;0[>W75%+#V&>>+QY5=LC[NX$QOK;YH:O1Q^^
M:;N1H;:;Z_79#P/UB1I)"$<T"(,X!>W9".:1T($JRIA(9J?#SN<P^E:*9"=8
M?\\4;UK8OHQ<)8.3J_O&">SP;'9LPUK?7^W+X]WKWS@OUN7,!(:E1X;D1)*<
M]V.L4B@2'H&1A75LM_$LM3EC*"$IN<Y=I1+2P0BDHA9*@;"W\=YBG =\%R^N
M&I#!J<G9U'M$6=V8=;CI=6L#-OO<=NUTKM%R?D\N:QBUU0GM&)B5%V2['&?9
MM',YUV*U@+R;V2FR&FAS=P[6JO%X,PRK&8F[]"!O#2G;Z%6^/I\7S23Z;.UZ
MD&V;\\A:8%I.(,N7M5W]FWX(JT!'KFU;/=WV:(9,Z6PY],Z6M'2V[$-GRS./
MQ&R5#J\G1-BGSH=8BMI.LG[2P(=___U-%T??FO:VD8^3BY\[MTT8A2;F-XO+
MWM7V3AOIK22"C>+I:3>AK1':+5HM'];!5/.Z[R?PZCX'I=)H J_9S:"X 3B<
M;#^[2HM98Z+L&5.WVV*GFR.W^77YPF;@L!O?'=FT80;M1>;E\(G;MEO7SBR;
M_ =80[-E-@^D:&(/;:OH<=P:0I?;<[>UW_4"]NN>!?FNIW:]&#<%(]NDRAGO
ML[JMAO>+Z\6X'8BS&EK1;G0['V>;AMUQ#54W[V\_#?8;>IM]P5>=P%?!X>78
MOHW:EX]7W1#-Y:,[K<#[Q:Q=UI[62+E"?C6>XZ893- T -\X"%DQ@A,8<T?T
MUF,X;[4)X-+I;-ZU4<HW-J7URP[@.7P=8UA.ITYMAM=5UEM7<WUK/[U9N2YA
M_[)>DD_7Z-HM9FUXO9L,5&\T5L^)*Z-68VFG .<E[-_9'B@I15)_6@[EOR\F
M\2';L=&1EV&;^7*B8C,EP*Z,U.FB:X?Q4,97>RA6HWV60\!WR^C;^QY.*EHM
M8374:#1K#(%9S"WP)]7O\6;>&L=$=J,HVK(S.&BY<WRC8>]>=+%ZUVH\A;,S
M:RNC5PDE&9NZ[+.].27;WJA<A0WOU)ZCK52VBY6G:J/)QOI+-P.[2S-F$R4V
M'52SC<D%Z]UJ(L?_OAC?[MG<O)$-)+?O>E^+D"9+=!W>@'._B-M%YG?>MZDO
MMIU@O_@T^^;BSESRCLC!SENGWOX!;%UV[-: W^U<WP9--IK1=6]Y63V6B31*
M=[=G<R1DVX@D=\,#L?NQ^O4JFWKDK]2N(SCS1HU8,\R=\/T*P:<?V[U=FJFK
M$P"KW[(VV\? QJ:+Z@KN:C)H-Y]Y/?T 5P98HY^/FP?956"I7<WJ*1>K<]O&
M6Y?3KM9OV.4K/O:"=U8 8-0D(G;)B7LLZ\WIT-T;=P.L]KUL 91! <K&^5\U
MB-S B@?S@?-PWT:;.<^4*\Q%)$K;W#<V(DZE08YJBFA2@3BCN0X[-6&?X[;<
M;DJP(NR[Z;NU6OIKUDH/$T(:6GO(;,)<V[":/KNKK&_HT>WTO'80=8:U+96Y
M35E>:@/W%[YW&LC6@^[IH)I5@WU# I=?\FA'U?8(MKH1$/^\3A()A.D@) H^
M*<0]4\BXY!".+E":"]+-3G/53SY)/W1SQ[_K=NN'R;Z6WR\S,H&0@0W)74UI
M;P_'LF)]92L_VA2"DDT+O3%/]S-VX_3Y_]E[V^8VCB1=]/O]%0COSEX[@L6I
M]ZZ2]TP$+5M[M.&U="UY;IQ/-^I5Q X(<-" 9.ZOOUG5W7@A (FD *(!U>S:
M)HE&=W565N:365E/FD1#4><6?\/5(IK_-.-YZC>]6&ZOOKPH\=D['NT8YQ93
M9(4FL%R$11HKCD+ (1(*D"1LU/I*PBQ3D;4T^EP09#%WB E&';=6,O^PK=Z#
M.QY2G=H.V:,\CUE96V>GF<'$$"P.2$A-$?>!(6.]2AULA.#*)-JE@VEF9^#?
MQ+=-)NQ=RHY=C7W72_3W%2?_,KG?O>CKR:GK9W*'+>-GVT%X"RCJ<AQ=!?OY
MJ3 30FM!*L1H "RB!46:6E#ABDC"*PUPXY#&M1'KF_CW-AW[<C4;^XU6((".
M[=AW:'MLS\?M8<39W>9)PT\[-TG:0YV34:(Q:QA"%\ZMWFW,=X)Y6%BYN=L:
M5C^SY>$ =BLN*D29A*"7   QD@A$G&3!1<NXV"C@??3R."94YY?RM%;'5R-U
MO(K4MZ/T>BM,AULW&U?U+L1^?NF^LSN_V_:P?'CORHUMI;-O7AFLL]0:@HB7
M N(MZI'RG*(H8I",864W>[\\)CUQKTW'G@H-JTMZ6H;L#/N[4.<,=10%E3J8
M"H.1LL:"LZP8P$E/M--?XRP/HSCT4I^6XBSW2.^WK/O*%IW)T-W?ICZ_UE9!
M6N[ )"$?$V&WM!KI=%@F2">=<Y[@S?+K2E?<1RI1J"Q&/$",KZ37$"5%&RO%
M1"3FJ82@C^M%>V*QS/D9.4(LCS((1&T^MJT5LDXS!-:.:DU)\'ZSE48@E!-P
MIHP$#>I#DD<%FR<"%D1KY4ST^U*?OQ%^R4Y*23:LF'-->\&F<"3'P2M5/%VA
MQ!IK\Y>8#,_0CAGGJ6,:HX36$N&[0H8PB@2M(C.6^L W2.*?8L>VQZ+=S%RE
M2NNKT6CR*<50KR;3EZ"SP]FODWH_[KE8O*,KFG4\!L(<<L+'E -)K59I0$0S
M4#3%5>4W4H1/L7C'5;13V[)\//8K75 ??5)/<6QY%0$JVA308-!B;@(R,D;#
MM>58; 0T3S&QS]>PLIC3HRL5"8')2#&BP0F(/RA#2EB"7*BX]3Q@+#;BCZ>8
MT_TJU=^HN%0GI3H[>IV6XX?E^.$31T59.7ZXQ^.'3V1Q/XDMB4>T$W[5UW;"
M3V-M/XGI>>09H^4Q&XK309O=1.T 6#Z9J5_)3'0EKV\6M.A7(-\)NEINW/]]
M.)TWM;&_S@%>_W(+ 5 8#<W@/\(X *0?@0>;W@U6R!H&;YLVM\V>/ZC05W4-
MOJM3S\0XM--)/<PG>[[4,[AE:.]V6V_GHYO)..V#FN$T&;W5AL$WDZD=^D2G
MGK <_#8SB5Q]>8!E-9%SD5YFI4=PO=$DN.T-O/W$S\M7.SH!F[6$]I*_>@2C
MNFFV (?WYKFZ&%S-/Z3S(/"+RH-_%>PT;_?FR.K[=. G3N;3Y=WK?/HQ'>#I
M<$<JA&LR[DD]FOJ-1=OG5]LZ2+=G+W/%Q7J0UJC62C./5_?:+)\74 X.PRPX
M ,K$5HA'S9!E0J!8:<&\L93)C0,'P5@AI9&(<)FZ[GB*C D.F8H(SQ*(5KN
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M8CY8W+?D^,D<._J:PS3;RE"%-UYP1I&D#!9_E#ZU(X37HXY9ARG'?".38WD
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M[%0G/5$5URD'[!)#I(DI>$K'OJ*NP/RK:#?8TYS31*B($PH'QV D03I]D<A
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M,"]-'F]YVVP?]\_)1FCP6G%D9,IO"(Z1MC@B A#;>\:CH1L[$=H0+1F6B/*
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M:&.(]>=-<_)M$E$BRC  DF8Y[+A_V2+7=H8=,X((@L9T<#Q:D[IS8F2= "Q
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M2'W2X-,&)B4G<H!:?)!?:O!5T'I/O.>3Q%GHL7LO^ )MGA':5#3J2@>X.DJ
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M5"^[[T=BCUN2R =3A_WPQY6TU_'SY@]OEE8$?_PN=04+'1H+$5P%8@V$^5S
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M#X9*_LRZK$_-*G8YAE;3P!7?\\  F8;3C.B>J&^+&6_SHUT-G/%>:0S&RTG
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M/0$__+C%?^T^=;'5?VG#&1'6(*D%1MQX@70$7Q0C$]S:J*K-Q,13RG+?N6M
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M@K>(8^GA7\8B$XQ"!DLGO*6T8F0?NK<_X@MU^9FS.KU2L]LP;50M+9W!.,Q
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MC44PJR[6 SM.RJ<QUIE P87'VF/$J?#(4)XK_JF7&-P5(7=RM5I)8QS#*,9
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ME^L.?L-[/)BH$WZ3?LS)?JF'7@LYGW J-C_H?-GS.H1)+/-E[X>&=YXO^U^
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MF.139(LS6.5I@:7RE+ \L)WR %:T!@AT.N33MU0[3)+V/NTVC@Z,,^T1?"K
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MF1(*/O8.%-8_-N$+P#X?P.J@O1**(P9PB@!5'3+&6"2#""XX1D*PATCA/@O
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M_13G_XZ3>%EY>WZQ;$9=)?8J!Y)E:E4Q_78^WDAA%]/,2ZK.;"Z'?J@@W.+
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M5[<4]I?5O!Z3\M*/)XO;J6E\K?J'=<.90.:)O72KQ:).^>CW#EBO63/!WU;
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M@^+3P*%'ZUA[;<M\B6V9YH%MF6_?A"[=O/ON[9N+Y73R[E]02P,$%     @
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M3Z-[A\["*V(PV&_PQM@41@$V%4UU%X0,73? )6S<8VVJ[A#$"L1#XW<*?A:
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M\=JTYK#PAW48PYW2NR4X/A[#M*31X>3B]4WC:IT4_L9S2:$A+7C120' (P6
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M].45BV0G1G:^MZ+*X1 ]Q(7M+&D7SL-/%D,<BN6K&_1UY$?+?J*$L7P?#=]
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MSRB^"8_TKV[)7@X^72+LOSC47[/G=R>]YH?[]N@P?G;P[X0$HA4_T.G-9O_
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M63SYQW<Q>MZ4')U%.3JI2HHK'&VXB0%[6B-F-/YL2^:33,_NQW??OCM+8T)
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MOMC]A*)G\L6U[R[1,Z%>]QU?PI/S_(S1\SX.EU-Z(J;K#[JT==/W)DTS9;S
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MT7/H_Y$MBD)=C ^*P#T*\T>PB63>7Z&=N2Y.$2OGK,^(ZJX%S997#S,W6:+
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M$#!ID(>IQRY/P)1!UH?N1&!=^O'OUQBAFS!!&,7)R.*!]_D) SR>:.!]?KH
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MS]F3F/$=>FP'N.)?]VGF;3'GJS;KJ>/0:1YX>2X</'2;Q>XST[LAXGC0"=A
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M1HJ*^AP%'HT3+/;6.SGWHF)PEXK4P52"Y%T&_IJ9X1K(WL;GQT5XV <YMF&
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M54PP(S#!6YR!X!0S G.\747Q6S;+C*!;\<AD#?85\\CD4[=H,4%"HA4)0,X
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M*_8&H,S-YAW^F"KKH^1G ]=W@N.#H!=*45IET] QMHT].7/EK'$/)+@'\G6
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MJNWUX1E\?7)%4UL4GL],BJG!EE+!/HB<_FM9EI(NNL_&&/#C_T0/Q:A=[IP
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M_#AMV^U(J;ZH7-1;L+N$=68+_-QU8Z85G;-?8/??T&.3NN)?]VGF;;$!0U\
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MZ0WE<MQOF$47(2*XT"%E5]+^%Z:8BLBYR/W=_#BE"G0"R7E(KA#G,]E6??1
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M[XB4SBL_<9T 4"@-8 ?)S&9.%$$T+>,'F9(B&$. /"[J),_P?WCC+TX D6G
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M%&<Q,*'$[Z[\54II"/J?$L8S%<$[_0/AE)5 GIT0GFVYFB+-*SX7FB*EB/-
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M"5X<P-W%%CU&K<F,)O)#Z/\EBVE/3."*FR#C1 O\7UL&OAGN<^7:)V6V;<,
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M,A3[8F_\D%ZSR^W0:ZV@1'X!6@2)68W+]V:]K.\/S+\FL_N NNC:/O-5#*=
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M@E*42_LZK6+,8C7@TGGEV=Q%S4V4).=.'&_9(082'5Z>)^H-L6!;I*8KO3[
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MV'CL7KE\3=GW M[V&_]@8[2@3G+RA-,GOQ0SL/. *?O<SVU3S[<C:PV*9:O
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M)"S*5Q59;NBL_TK"_(;NI4$RQRNAAP"HG3E3?'/V*<M49L$S?5_"F+X_R'H
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MIS7;2=OKQV:N9MY57'I0^(ZM2+;SV)WQ./%9*)MCL/+TLU6.=HP!&=422%8
MAF10YI72=)X4/1HG;419 SO.D[MO\FQ[_8W.A4H^EQ5]F+9T6A?[CR1[R</=
M:[Q>@G%N%.\U'S'8T"$#,68@!P4-MQXVP'$G=7!/N"*V*IA\"LVU>" O3D^G
M-3YPH$M T%U@4D4IQ80=D^ZF*.<B9,G5!OR!-TGV=6B,8"V>0D0,.!F1JOL
M0:Z&/)""A/GZE7XG#CL*DW%1$ETHDCD?$;]?5(_I#,#*.:/"XLP9%",AQ( R
MUO2UT=VS;K(4/*@?6!G0(3HCA/E#UJR,*H("P'&.2F16%%?DN:RS;Y=O89S
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M(OK[JL*B:C>4T,!*._]^OIPDXGS#, 9X9#G6 K[D,\%@[ 76@H/BI:X*PC4
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M64KD+ZA4>5.E:\?%$=6U2:-:P:X=P -KEBDZ^P4O?.R^7AG89NCEN'S)"3-
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M(5LLVG )4,EY&<//K4HXA$DWS\SZ4 0_4!F0Q4O^>&[,JY:FONP_2UO3>:]
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M]O+F(>!D X5N (3GSDCBC0<F7T/*4;[CL$<(Q7 )B=;Y_C*+AJ74,_%=H[_
MG"R""*ULE "&.1O^DAFPIJ6+M(,6T;!PS8NO,L082N0U+ A8:@8=,VYP8P&N
MBN'Q7?#AIP\_!=>/]_=GSB[_OO;8U86(3A-#"J0@/BB:P]PM@JG0^3#8.T.Y
M]GE//VG-W&6T\*@+KZ ^&*?O'/1!A G2O8R&^U$TJ<^D#" :$4X(<[WP\!)6
M/CY.JM*E3V(TGL3=SNG5[#C6=HL<<+]V_ )9ON2$2_?T$2$Y IP,=CVHQ%S[
M'9SRH^LG#:9<62+2M J3!T33/]J6V;02(2T.S;]W9A8:,F-A &(SY43F.%'-
MG*.MJZ/9\D#!ITR\]JL\BM,P9W&,0P.311ABF07B\%!AD@W ':"N]LO(C/$=
M)!AZRFKQ2!#F/OKSX,<4+-KQE=QH,TNZ52+T$P[4EB4AAZKEH,DFT\RS[05!
M4?YB?YF$Q:!"[((BQMVB>O!,E4&@ZKY@^8C<:#&:@J658.G".4L@2-RSTC:K
MG-=W&^!COE>JY'!JSIS-8TU=_02&^3LL[).E,FJ3@=)P@*B!=D>5KD#E^8&3
M_G&2Z-?1.=->!V.*U/]P"C0KDU/Q7#*81)ZG2J+WIZ/G*GFI/+Z.0S!*XF?$
MUO@YM^YC[LW;=&A&@?WXG0M'AP^<HYQ$1^PH9J$>7\FYD0AEY.?#.+W/EKRM
M7TE10DXJ,YC*6+=3;Z(1$)!EAAR;FIH>5R<<?_\+JN'#U2F^] [,N%+SAB--
MF7G263UNW&2;@Z7DSI;OKH* #M_HL'A=IA'\ ]YCNID@ V7) *#HS86;]%3Q
M@Q)%01=_4,@COJ,8P?7!=<*A)HD(-M?P ZG'.#>>E"?LF$_G_"USPBT#_GDL
MP[P\B><:FNTB3!PGH[CC_SJ-3N+^&E./W+/>49IVS$HRG95H_2#7N.9<3P19
MHZ!E6P$WII6GN 0+UVV*U1JJ,(%G%$%Z0(QYC7=/&0O1&.0TPU% /*K'<>PV
M<\R7AJ/89LXO&#)5>B("!BY0OX?INOW!HK5!!0;Z3-"AQU@0S7Y(\FV8PFF-
M8CI\3N@9=2AH3,:B(GN,]>&=R24,?.YK]O2:505],I^^TM'VUO"E4>"RZ7!!
MR<<+2APP(")ZB1FWI"=K1P=UAE+HF&UQ:U-VQ3@!&Z@S6,LUKK9KMAL(!*["
M\#AL8KY=;61(QV"4S7P++U HZ+G#QQPT;;&Q8+JK32#IS'.VFJM7$ GH;[<.
M[WJQI9E;R@S]]!FLZV!?0MM6@3>L^G= 5_R<E7\E)5S6+VG\.Z]XR,U@(]@/
MC>6:Y;QT<^$"P2?I7\M@3\J@GI/[<J>S7$YU7WU)<TG37N:;'NU*+"VW,#J+
M]U!14>  77\K";SP-? XLYX.CM$19OD$+8QPK +"QU*1QYF.["Y>QQ6_PEND
M@[\P &@QAHHHST8Y.S:U/!_D4'Y$_*0[1VQUA1-?#J^1-X-P[A.Y2%H,J&'1
MEZX!P,;\'H>CO#EEY]9/$^QL(3%E!TG9*E!OC;GK3I1VR5+++\:*I2(,M88F
M/ %;K  AKVF>\1KGHY=V%\4894GS3!8Z]U'5W0'3FA1LY]9A+7>)-Y*6<01)
M$/&;<KD,CNA7R6J7RT2H0F.SI0=S=_#FCJ7['*(NRCWHXE#?%3P9F-%\-Q #
M0Q!>H,&AE FW+%UZ&JR/\9EKQ"8B=<[@T@.#&#K#COK@\LDL#$?<&U,@D(XR
M^W9@E/-RIJ-,NQ4 U5YY]ZEQJE5ND&C4,#:ZEXE&F+J6MZW/GZ7 393?"FA:
MJXUBGAD0[VV'\X#[5_W?;-.5KR$$":F=7&.1C<*N';+C%)Y=89CP&*<1RDAR
M2K.<:!-=AQ-S!I(S:+*)OJ !H^+&L_U(7F!=/I+L)0]WK_$Z3 :)ORHAQT[Y
MT::N[F*5FIMI@ZR\VGP*_Y[EX@L/2R$6V\3M:H\V[6GNC+%B?'DQ"U8(J,SC
MM(C7PZ-\ER\O.7D!_[<D*DP '".9U.,N@BNRQBL@^/G]XL-/'][_$9;+X"4:
M&F5^K:YI8^%GN*32!0UU5*#$G<1XYM$0HPB3=8@!#-."D D+L+G#:%#)@_X5
M:U!MT7[*XM3_""LWWF:LY76QW#I4NO,()Y$P6F#11!B+^6M6FX>X^,?%'OY[
M$Z[++!\:@2E'8EPJ8\$O8)P%+!;\$+ 1)ZV@,L%"&!-U;8OACE/5*_P4?KL@
M*=G$92&2'P EODK G7>39UNZ+[.<.>]HV_NLB(<X^36'- 1]B<'A N;9('+X
M8$/'#W "HB(I=)%S^+Y62),'HH@100#]DC*]$V1A>^QP2:!HMLNZ;-5S$4<Q
M@#&$,DU]@)H/5.I$>]<:^VBSU\ZLRL($_I:Z /9@F&#%7Z90=8R8Y(0ABQ=0
M]3.ZT7@NJVV5H.V%A:^R([_:+",6-#-0:Q/$ T9](:X\NM_$"(Y5.C<,ZOI=
M#RZ=^E;6A$0%W-H")%$3!X>50;'B+B+R;@:QW !8ADG/T$841J&-"Y?&_]'9
MKMUE2)>]TRKWJ@Q[1GR957+X6CL^U"((-[15P&/2J8Q2I1')OX+CD_Z/B-YO
MX 5G6+VP!^@WQE<;T>;Y#NCQO9?Y6EN),%\+1NB/!WCA+?X-(NG)KGS'/A?O
M#M_JB.*?MMJ?:DQ M17*_HX>:1+]FL$9AP19".G_%'Z+M]56?MG,Q^BX$_[-
MVS+?;G=TQC#]U>8N2U_NZ T8,>?9+R2!<DQ?"F):H5X=/3&'EFUA-V V:94%
MPY\]?P4,(*PC$J_H]GAO6G13.\]3/_FDX'\ F$ "\1I9'I.^[Z5B;H 'LLMR
MG)4IE=*X!GTZ^CQK7]+X+U3$O8BS'?T6V_#B5\NILS7T_&5,,8&0./DES9ZA
M7ARS$N\J#!14LL DWH*,-;M-2Q9^]K/I0[H89RY+I]0#Z(S#ZUR7OD0\,UV'
ME6=%@>GIFRS') H3=_;6/L^L42Z%(B"B*CHW37"GQ#*-?L,"'F71.M6GD_+\
M'9_(%L#W\STK7L$\6LNJ?,UR,+"9/N:!+IX80L1,5OKA+ENSV %E\H8_>UYY
M 3+SP#!F3"O=:#*7(\\S?0L!]M=YXIN-?1[XNWB-((6UZ%08I8Z#C>?RXC!M
M@S^ET2J5L?88:M]Z4_4G]6*/W1& E)F/.A^FD<>:RV9F2>[P+G5NX[J9;W75
M7GA>+V=N5%G[=O9Y2H6#)4QN*L2Y@2<U+DO]-3K0U/-7TKR&X#&$*$7[(>MH
M[O$Y93 IUUN2O]"E_9AG7\M77D*T^;1V-/7^S.;Q&YJU%<FZCHDV/[N=7?Q?
M  P*I';8=#W$'<U]OV)Q2D7F.$QN4SJ?2H3N&A\A<U/_7Z)QF][G9!?&D9#;
M!"@R+[_)7M!^]W(?2I[99Y7E5QMFE&%YGVBE,;)H;^W;)G6J>4UPQ!4@I?KO
M1]#L1C7E'1C+\Q*:,G^9;<ZT"/;6GMG@"UX\9<LU56US8LWW,K'5O[=/X<I6
M!W49_;TJ2OCI*4-+$WT? !D (M]:8M<I1#PQC<'G4%.P&7[>?&HZ&WJ7)J5-
M"54QLPBIM_$N-U+9G%Y5!:[I*J>'X2U.];UTJ*W'+?- WF*&G*]$D-4 C72B
M:03FRR^[B$ZYWO=MH_]P:KX]<[4,;'3(U7_V>:^)!Q($Q#!)^$U,[^3ENJSH
M(89'M'6/]>GDDRD%]@SJ%X,5L"0D?<C6KW5-.(N?Z8B^WF\W\VL"5G+0NBQ_
M5AZ8XD[D7YMOQO'HGZNL:@K*P*!INA%NH0 @*4H(R7 >"6(:U/>BRFI/O3##
MEDG"'0B@S(A(9':G UX8JQ-E7$@7 WFUIS-=%4Q7BK%DW[J++.V\&AG1B5K<
M4QV;W@$/9%/1)Y@N)[?ZWQ#2=O+UZ#,;8Y?!8E(H3W7[T3B1A.^W QP*W+?:
M85YMM?(][;I(TKVHD82S8_H]*YH-[N.ZS)+%;'PL&=]N%[!>P267DU=Z9B2R
M,21UA G<;[]D"1CR/]*/!-Z655H;"98YE:+3%[5R^6=2KC9/X3>C[\;16-[/
M^'.IS%,Q!4$*Q -GS>;0ZM_;,YN_D?CE%9 YZ<8-7XAF %M590$Z$W<^KJD@
MQTMDFU@^C9)G]A]D137K(;??X;T[>V;2J@)_^.G]G][_R<Y@KXX^Q0M<8W;_
MJE<(2L.60" 1*=164X<0\WY9;:CJ%&&EIOBY0FM@$J9<_LW!)Y43].#F>[61
M/5!N&$7OIQH#>2 I BM2@+Z4VRPKUL8^-_8-U9:SKZOTOGI.XO6*9TU8;!!=
MC3U_B8\DI:]!0H_,,MK&:5R4S # '6WVJZ=71]\:[7C($(W'\X& ](R!%JSV
M6A4F@"EL#UR?=AI>39!FG9 R!K_@P:#KJAF9>&S?>;S9$)Y-8@SWHG+QI3V8
MHJN][P $/;2-'FE-O6T%NC%[8:[%O5F-/:,1]WV7Q"]IO(G7X,.L"V*!NS8F
MYNC)XWKZU\3M-23Y"UP;WRQ*^!$4?']-:8)41(J]:NJ^V&M_.6S+/(*01Y_D
M)7@9J=Y_F44M'Z3ZM]E\'[-)717WX79A+VIM7L=E[CZ5HX[@7[U E?8I_,:N
MV8^YU>YA:CG'2(SB(=N'"0;%2#"G5:IX)-E+:M 3!U.<V]>DDD*O;TG;>9[Z
ME\>G'-_T?6U<L^L0]M;ST$\[,SN:;7P_X*^PS6]3M5IGG*[C74(Z(BRRG<58
M.("<[Z?CD)NVL/EI^6U_D^4;$I<  "/JI#?4+F%5:D6%^9J#[[W7)?H=+2MZ
M9P92)T1@!,R4[G22KBW6J8[FOAEAWCYN"EWE#[!_[CHC1#I[^#[74F SEXNX
M_K9.JHA$8">$4U>5/&;@.LS!1 *//IZYGF+A6*/,(1I,!CH5UQAO8@\!:[7T
M.7U%3-NP)%L1+L-]NLM""?=L\71<=Z]N$KGK^(1@!ST02"0D *!R4\%3()*K
MVXZ1H[K[/L=F+PYSU7\F7_%/QNNI7T_?=L&&*[F^.G27L]%&V+.O[_P "Z:5
MQ<5JXO1($KZW+/T6!9?WJ8YE5VB,#3U/'BVH]&+738]]P&;Z]?0:O;9>Y_0V
MN*2_QQ2%-*+[9LW_UV-917L,$&Q'L/7KYWO;==UWULK/QU^==E)^D80@\4\X
M2\W?T=#&N^6@MO7: _':K7SK"B>H^[?;+?UO'H<)P\D<RXS0I.MS$]H!>VKL
MM;^2L.WR[]O1NZE11+DJP:WT.OR%1)# OES3/S$!I%>2]0!R\[QKT7-91XUJ
M(DJW+#>(H/^$[FQ+9!;@X;3Z5E/?7]/@W#G6$M?#Y3>0^'?@]N\T)XTZ@.\D
M?U)>AL4KIF1&)+K8?Z%?]#:]Q9KTVM5F6HG^O7W+ >$N+NG#"T%<D; _(]Y'
M=%&5G[/RKZ2$O _C6]^SKU=#2T6%BWQ/CVY74(9Q5Y_2WZO\?%G;\FP8G*TF
MON_M4U/L5%.?$LO.0KP=@#OW&,_S4@JECJL:RLW;$:1VL-.\HU5-+!WHXOL-
M%KEERE(;*E$87]=^7?W;"LW@'Y:8AJ[VOM_&+J=EQZ'JT\]_"NCJ.8FAE$"$
MB?^6.-QEFE9ADK0S6T^@X=M.S^-Q>6BQGEG OPI/C#\<U-N;B/<M+-U=:FJD
MS:]M:.K=7B&08-/RDOX;EX<@[.SM?<LZ0F<&W U0HC%\H)6EV:5\'TEB)M].
M(O$=0%3I:N_[\F@XZAK9I%L Y_^=(#H!:K%]G'V':/C.6-8 4C$R9+6A:BSJ
M]B;^.COXO@?Y,]S"&[6[]@YT\;TANQ)!?_KO)V:0BHX>X]7YB=A??UNC*P%*
M.JM\V-KXQ,R".5@ L.H_>;6"G*KV6F 7:Y>&C%9L6T[<CSG'*':!: J09]G?
MR;I\7%,%!Q0;7@KJ@<3;YRHO6):ZR<DY'FG?RFZ5IV@7I'.\B;^AA=!^,]E;
M^S<%URCH<E\^98K$_)HE$<D+A%*PV(./(>%W8_.(UE( >UXG\39.0Q,.>5=C
MW_(+H*#TAKZVM_;Y+7A@+EY]I##ZG=M-?!_Z$PL=Z6454&B4E7]6%92:&[VV
M4L\A9RSJ_>?[#Z>)>K*C=QU1!! 4/0+4[*U]ZQ=H:CA&N^CJX/?ZSZ'(44DN
MLC2RN)$,;3QJ#%?9&N-.F$QXG497#3Q':Z-Y15V(\DRV6@ =S;T"!A=B1NWP
M-V,#[ZL./G@$.J7C7-*IO4#]+EQ+^WD]W&LFRH@>CM*2SZ@V=1VN7S]G7$BC
MF@04#;X@^PRD[KPHGUYSTHE\/LX(_A]5" CNYR6U-O8-%<=D/_NNU1K,*%!6
M@4L09=(@,4!%40#Y3>UB8F\@R7DNB.WZ[VCN6_AI>HZZRRAV-/?MH9&!?@"5
M*9!+GL)O%R0EFQCP!)+DAH7U'@,X<2PUWSG]8&*Z+LH8PK*->U%OX5V%:* B
MZ'ZD+D^3I<M<-.BC*@W*" .!ZMIR%EY_*\%+B,[YHKL8K].1?1N&S)7_.M[_
M[AXSD&0(!WH$#R)/3X: ( Q58+E.V[C:%K40:W90GD1IGJ]H X7IR$?5T-OW
MTR2.E KI;>/*VMC[MRH(;?X*8,-@6<LPT(N+:RS1'F.CL8I4!+7@LC4I"G!E
MF#_>R>2\.N-(3C6(BY. CD\BX/N"DF5]BJ=,O!Q$\X@\9:9H>7GMUM'R7<$Q
M+L;Q+EDW[(-4=%R_;L.\"_/_0!_?NV$8RH8='WD4PC[OA4_A^C5."94Q<&:/
M._H.91C*QJ^Y X6/CNP_$WM5P\--/UJ8B!D#LNT1WO%67Y\L_LH2?9B]F6>.
M87A#V]]O;^K1KGM9;:N$!<YC4JZ8'6)^&<P4??O,I*S8TU>Z9?:R- _+\4A"
M@P7XN)YSTX6A_K%>2E>+QDDC88PPA^O81"\7X_C<&0*2!.9QD^4U0HD=V>28
M?O/9%6J( ^E,]#W8R7>^$UXQ,N:93A-*JC%W1$6O4R[5969\C/Z]?2M^THIX
M;'9MC:3=TTPYP@#SV>@2(+7G'F^U]\P*E^;RO9H39??T=#3W"3[-+&0W<;$.
M$XA-LGCG;>U\JU]4683_AP5]"Q-$%*:R6AY#L"7\@2ZV_@NE)1-^V@7NN5E"
MQ"[#M=,!IS+I#+PFI451C-5KDMJV>)L"1ZU'U][4:TW(+'T!I>.3H<J[1:H\
MW,6[P8ZC^/.J(W1';;)\BR(.2_WC[E;8?4\0^/E"]1?ZVV+#*Z#C%C0621F+
M]JR\"39YN=UJ)GK03;R!ZL@"+9,K-?TTH4-]/7^9.T*?=**O_#750$N"$CH#
M7G[*T#=E=%0?1< 3L^B9R?=_^WRG<E#_UJM2Q<% 1#Q&6WMJ-/ M/<9%^/*2
MDQ=9>QAO*"LN4%=[[])C^T7I#H#O[N'3$ 5[F>0[<,1!HI?1\&1HX]O.S72H
M+G^%UN(LT\.N*J8D2PS)D5/!S/1]:^1=T)IC0L?UI#B7:)41DR]NTS*;-MVC
M'M$K^F3^$J8\\ )@)$)(@EMM+JJ"ZO9%N^9:[TXS%,5D&(W('+L"".5OY=-7
MDKR13UE:OAH/RZFTYG),V+6/>^W#$]MS[^4VM+LWC^GO^^G305)ZU$C46WI'
M,((<(]!CUA9W:W?+.3I6A<EDM?DUS&,>,U+$$3=R]W:R'J#CVUY71Q;?A_DJ
MQS@HAL JW/SFB(F#W7QK)N;:SW;-I*.][^!B<RRTL%*">;-*X&+'B UV(3!Q
MB+:^SXK8ZM(9A[)WX1+J:J419'<E_XM*>$44K[M3DPYT\<T0"K$*9**1A6:C
MV>2(82$.[E,IE:IUW1#)?7O[?JBE(1U@6L&$CH"NEA([_7OYK2(0_P4P) X$
M2YF;>3>W=P2TLH1GLR7]8+>Y"+\]',H'D@TN]G7\/40WVP,AG0_J<YL+S[56
M"N-@H9<CN\X@J1NR;9O>8O5O\WDH;E-^V=>6U-:UGT:7)"_IUJ$*&\:FL^0C
MB=W:&:CA:JQY)(^;S+J-/_L6PK,M!&JN+YESQ2Z0&1MZ5VK5>#2\%LT:;:N9
M[U67D!]W7:4'#,UFY1B6[\<!&*)#G7Q_C8J ]J3CWAJ_AZFA;U6D+O792N@_
M)D[N4&_?4CU>]%U6-[7!7"3#IHAERVWK[.#[=)@=PMT7UX$^?BM*/)"7SG(2
MVM_/TH795=A!F(XB 6'>HS*KGWGXCL56"PJRN!B[>&1M/$OM6_ETEQS7_RGC
ML6KT,R!N8'&Q!UW$GF0\ F'OIO5V30.J(Y,85>;EIB3Y,DFRK[ 9Z>P9O!FD
M7)H-[B<2\RU P,E]/GRXGYN'F^URU<#Y&P%\;'JBWZC ]U)'08JEH<<<(D,_
M6*VETT[#N_925P\&Z'34?$O$@%YM3)%+9MWF2"+>;0L\,X5;\KA#PVP:,#;U
M?6>$Q>L-/<:@O= ?Z^)G$#J*M6R.+S@YE*;OA[*1=8QHO_ N0.*R&2[I0!??
MRL:PK.N+O9F [2EU.)Q7M_UKEF?@12?;.!3BPDT&I73P:C_@S#BNNV\E25IJ
M.MS76A._2?E8VTT\%"*C^=";<VQ?SV':C00ALWS&TS6$B[W%[HETYB#3G:*P
M<6$*DO=!,9,@_$\9_$J1L99<O:<+4N9Q2F]OJ_G5VV2\WPF-/$Q[-6U+N$O?
M[CX/FC1=K394?/F4I?06R/=: !4 II4D20B*WJ(V'M;2:9VW8>1\'[LZY-F8
M':;^W;<8V\2K/!#,TM7>/^[4<BCN5'\"OK\; S_C&+BK'+=]!VZ2O;EO[3<)
M4U/FB^GOOM6!]9IAP)#HBNQRLF;Q$_3GA/#X=!5<T%K\TRC[CT3;]\TW\(V_
MR?(-$=6VVPDW#H?QO7#2 6>+3BYXZ4W+GU6 1ZON,?XHOI<M!&;P6M9D V9P
MA5 H9<;&%3F&@'<;OJI=X#5PN*K(P4ZS* %$\G5,CRHFL] =V%T,R-!X+N$0
MIFQ@:R/?)MC[54=)"/%'[\E5'< #OO$&Q#P:CH;/%2P<Q[I3!>0NV^^Q-#RS
M7"=EI1$5G=_B-4)8R#+NMRF=9L7P2NE$"O.?[ +KF/1]BXTJ=*LEOES1"%74
M-;.9>  ]WTO1726XEH$_YEE10,Y+F( 9#2P=%V23Y> &,J[)&(1]RS(#A5J[
MYU,\F?=YO'9BFNLYM/]2ER,@,1]/Q?>ALU7*.UPRH6=7K]ZE/40CW\3/]&#'
M1>T7LGF3.IM[%W8ZLK^%I^5P,.<)9.8B/[=,VE95]D"7.9KGM+M0_K'@?RV,
MIN*3"/F^<$Y\C*'"BI-77B,\LR")KJ?&UG:.2?C<'PR?I4 QX5-,?RJSE C8
MBO9=?#*IF2R 7BSPRXZVDI4"A0&IB^L^_>?\)"F )&"$>?J:'?T<M4GX%Q+K
MDAH6^:]NX/N9:9;#N.N*QK>W]JWY2+.T&;E:SU<])IOE>'IS^Z(L/AA^ZO5)
MZ^;>C=4=>=MVNV./;C-(W&58SLQQ=$-_IQVWSH:^S79D"\6M\SW/J#5CLV'@
MQ6?R%?]BO$I.H>-;*I6Z+#I #M5;LK;VSX:0<C&+ @PV.7D%;5S<<O PT5=J
MM;&)T<>1\'C>KND7*/?+*,JI#,'_@4?K??.\61OZ?MG&,ZPQCX!CZQT;Q+?,
MV:MN]>P*5C>U-5W*.$;/,_?T':B39QM[UE/]5^\"U'8+UA%PB%"5PRYI&!O.
MY:Z[S^B)3/YWO+O,HA9$B+VE1[2+I[@$@?N67B-O<52%B0GSPMCH7*]H%;2R
MVK*K% 3OFYQ  #*A7Z<$;8.;,T:]N8\<^UR7N/U N0\SMPXV$Z.39BHSJTO2
M7E;@59% J#RW)]UD^76X?KV+UZ!01?3:CJIU._S:\7B^!8R>%JDAUBR/5S%?
MY#IT@A@"+3H;SDM+1>\.>%81_W=9,MA/M-ID]Z%-/CR:B'>#"0;J69+LV=_.
M]1X7T4QUM J+:UI6Y6N6-Q.N)AC.MQ+?"K@-S3&V=O'U2!*^=XZTR [ B^@1
MUCR4NL\W_J**DT@\*2S-C7Y%>RC#@?;^_2@]PV2&!=G,1"K377DFV4C(!H@:
M1EEXRK3,YOY^PA.(^];)AQ3ZDR7]KN)BEQ5A\C'/JAUB!!1K5M*41-WU4*<<
MW_=%*S EN=1#'TZZ/>"-L.17=7;P+J?S^.X^,4_&IK[?>16,[G"YI$9#SY,7
M11 Z0_!;C;Q;T![(2PSKEY:0-FBVG>EM? >_]?#!W$/J'WT&#&I+U[8:B;1'
M7?9Q3:A@&V?W.7F+LZI(Z+>C:AV]IMM249_VWJ]G>BF]9@E]EPMVX7[.2M(3
M([EW9^^ !UI87B-H[T$)RC-QV;^W[V]YJGJ*_WD@] L6<4FXY:6CF*R3@7S*
MS?1P[L)85L8$8Z&*I&MP^AW1S?L#A/;W$*..KL(R-'!SJ*UW%KAOZ1+0X_*G
M[&MJGGVKF<>'XE/X]RP7.#PM:=?<PK=TR N$U>B0'>8>2]MSO0--#BR!Z_-K
M!DHLV-/1A16GD[C/.D?W'5K0*XSQ&PO^,ZIYQU&8PZXZ!0.TZ[L"U*?]>74R
MFL=[G-?%>-QOG[.D>7MK?_3N]I!O^%XU6_>4B8_H/D^#: WR.23[L(.*=QM.
MA[_T2QJ!$0WJ6U.Q;@VQ>]8:H2<1\BGEKKI+U]Z90O6/ZNC;JMN,/>\&"N]H
M[E474:#IF5(MXF>^[++TDMXA''@@+\J_5%3YW,1$0>,M6=1(6U<9A:Q7YP:7
ME)>V3%K][[YE:052_2JKGLM-E;1EYJZZ(<<0F*73B<=Z7:)/ BI7<%D%-IS(
M&%UMV,9ZRCB\W;)'!-"(PWB4B+""Z/UKEI)V)+7I[[XWM"WU_L-/[__CIP\'
M-<7NCKX%_)8ELY^]T^>Y>_J:/;UF54'7]":K\I(0+#MLN1T[6WNWSS809>D/
MXG?<N 9Q%/D;%MK#@E!A4J OP6RP/9F<YX6P%%4V,6EIZMMUI$G#ID3K[I;>
M4PI47%46H\6RR$PLV%O[OJIQUTMK0*UZVCV]AL8^*U7"XVZL42G^X-TB_;@-
MDT1H0&9KM-;D+,MUL:)15%Y*PMT.]0-6Q+8-A.IRG!E>"@= J0]TF>%SR^RL
MQV._F[OZ?H44>P6 J&9)' GC!?TT!>C!#+!=8O3)J*-.8]<HA&=A_\)7M^@!
MU]K1W+?,#L>J&T%N#B!O\F7EU=!Q+\A?_A)3,2A?O^Y[5%;O0\"WY-$'"M+H
MWC!'!2@HP=;\*M=C^K[,WEA]/N3P4+5':V/?9U4&Q+=>$'IUGE@9^"A2\WES
ME2DV D@.O+CVCKZ!F[=T,CENN5P$):\V=QE5[@ QBGV<'F_-*72\^QQD^9%?
M,U!G&>*=V=]@;.I=NK44;OA2D$V5W,4;2^GZ@]T\,W81)F ]?WPEI 13*HII
M%E>0K>T,10>V_7L<IMZ=Y\)D_8[7")*=C)DZ>/6O@@41'(GP$'VA;?.22F1X
M71_Z:*?T]_^BQ2G(4RF+TX9"#O04=>[)0WU\?CT1*"-,D;7#]"FCMUN8++&L
M%P]AM6 IGD)D-J+99_)509G*LY3^N)8)G9>O8,4I;E.U34QUW%U"9:U^$ML8
M(WC?]J):IE(1KOZE#  Q;_]^?7WOB$-FO.( 8L5'O(I%(:/1L=_'&][G??,K
MBX^"RD=2+N2OV"W53,LJ3R'%@,,@M&Z:X[K[WE%U42/(;UIME,@XN^'C<*]Y
MP4(<\A=U-/<=SHL3ZD0$TUKXWDY#;PCZ3,<\/=;;+77D''RK^*URP^UWRY(Z
MW[/K/,-^[[KPBP_UF86E_S RT')3DAS KF_H%['[ (XDY-NNP<MTVI\7O<6\
MGI*+/:^S@*^?%6?D<"_?YC%E/IU'R=C0:W15+T!A]H8;D8E/I^(WF!,!)+*J
MX$_2*\D)O'!ANK]$)^!3QO$^5GF-6!G_3I;IWAZZ.9RH__>/92EQR"8J"UEL
MB>:6WK76NH2O63.M_^[;WZ4],_1.8*]/S_2;_KUG^#A#CA8H=*E5##_<R^?E
MT<<3*_5636/%*[%+W1V/M'<0DZ1BJH*([V^Z,9D9[#:U9QX=2\-W4$"O3(;?
MZ%5)=?R-N<3D<21\ZZ>G5C$XA[(%LGXS2,ULB@!;!Q]G]9S$+[@Q9=9IO&4G
MDOZVV##UZ+&D^M(559QL+^BX(_B5IK"@'\G1NAV3S>,ZIE=8O(G7R^@M+C(#
M'/A1'?TRUS0\FMT !QO[9$(@<WX*\W\0Q!JJH5[TJJSW68&/SB>HVD:OUU5*
MC%7!!U.<92[79XB6VD!Q2LK0T,)B/8C-)+'FZ2N=TU[D2X(KCTZN7Y;-@:Z^
MGRBC^;*_H=.W=4>+?Z*7)/K.-= Z<]3*P6Z^OXOTE9K7G47*,PLR3ZWO48!U
M.%7OW]L2;@09VQTFOL/=O$M39KB(+E_,H3YGF6JB.3N6A9JN#LYR]IJR>*8V
M_L[$0\_ =)#EIY@.NGO-RP1^^%;K[.#['A]8](/O26#)79VMUB#S1*2I42A.
M@>@V]#[7O<&1#JZWNR3;$_)8/1?K/,9O">!9HVZ1 V/Y]BM1=3(N9>"8@'Z
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M2T%I @LW9KMNVE6&G[)'4I:)N2+2R43F(O?WM(IUM?=N%MCE9!T+&]UR"W
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M5HC*544E'G,+=J[MDA;!T5$QO5,)70LR8=.'3H9I;H.T6O644+&2HJF2>NA
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M[)QDR$EGE;N;\O/)1OP2HL4%P\1.XP9^"**-/*;+P(.['X3Y]H4H.GM('9Q
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MJEG J+9VPT-MR>;Y,D8\]G#SXM-$#.=EM"3:IPVG/NF6?.PVT&S@4P&8[0?
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M]Q[*E$/_;,$)W<!;W1'=2='1!KXSI-$H_Z@#!,[].XGB]%H.2A?S4^C:0F&
MU'$&B!:V0X"RI>X@X_HWL.-G.S@!>-<5CYDVP#V^)&&$ %\&D1@EMAA]L(#'
M]>Y7*W2S#Y?R0[:)?"0-)6TM!8ZW(/OOO8_+\,>JA=AI*-69.!@Y-.;HS2[E
M-#.I&Q'P8@>5R(7G!5_1VT8H]BWAG-WX(8C(NDS;\523E(&5*N?0$:T#RH3,
M<(9C.0<I#QIZ*VJ_,QC$.=);!U^J!).CH<C/\;8F"DUS>.+P7*2]L7S>CAZV
MHZ/MWO 0QCFJ5+LM47I,Z$;S.<ZT!^1;.9_F"%7YD=4\#K$YAK5OO8N+ \V%
MWZ0^J*$Y%>?2<'V\BQ9W@,YEXOI[2D9TR\XEX=J#WMI_/!>&:X=ZTWG=2RTX
M;Q(@DMZ$R2WX-B&J[! "4$ _ZYV#E#24JE26N(6Q;\:&JFPXSF#S^:G;])ZZ
MS8^1QOP829]';?.32>V?3/(==00>@1%=_S;\E+!0UO\ZZ+0^00GMF!R)$ZO^
M?7ZOV-M[15UJ.HZL.C(?D6>>%C*15_X^WKV;4#W..7Y,C>U@#KJ?0W7GR/"Q
M@CB_2Y@?QRC'$JN@71A=64TR'8 FD6!4,D-!T,H9,1=4GU\&J#CI5;W44!"&
M4QU*MXKA0=NCK@ALJE]]Q(\;>@WL'IDC?KE:F9.Q=3:<BQE?42)ITH+NWFPO
M<2"3J[1MAAG1+:]2OC"5S(%S,,?LEI^>6WYYCN"]MG)?PB!R(ZX"UO0>L_-=
M3^>[$K^D%G$!XZN#2YAQH?X4;\:@CF0C>7 /ML'='XGE+>P8_>]7*W1HB81;
MC2-M%8\)VL?U[MZ/8LOSTAEL SB7TE=QL^;J)VV6I4%SF#+C''I;GR8V6 ;'
M(WIB;WGH567ZW(F4$K?U6+W3>K1*8JBJ4-Z%7FE#Y!0(C=O_*C?!V?)059'K
M5]<^YV'I/JC$]:%$#TF01!G]_ 854P!IYV3YYR5ZAP3/0_[&=!U>:<K]$RS\
M,S5ELX1Q>]_%^OO-Z]M.D6VCC**'/MC4P"Z:VB*"6P$/T]9ZX]'[.$>:$WW.
MB3[U3/0Y+#&&$'C$+%:6&_YJ>0F\AZ^_?'"M%]=SXS.12CF[JS8<#^0#E6/;
M,M0-.@<4JJ'].11)42@2R\AD*'QS]%&;F 330- IZ&7&5EZ\AVFQ,ZU"!4T#
M06W.'G+]ZQGG%CBWLY?/X5RZ1@Z9NB6]'@(^=XOAX7*](MS>532G.I5_B8JY
MM.:DISWL +^[;<YYV@5^&=[ .0>J_ - \U3.N4[EN1=X7:5]I#I]!>%+,!74
MB1DC3;4GC2!CY&P1&"1CI%2=<V),@]>C/D@25+->!@V5EW-^&J1AA(U!.;7F
MYS7S\YKY>4TE<'5^7C/&YS5JWK",\DFEQN^5YCR*!B@><QH>K5S!TXQ(FF--
MYUC3.=94]_ UTT"87Q;H171STK4Y"%=#+'M.NF9JG-Z(0R>GXEIY<&W@1U78
MC$FP5KK82Z6D2VLMW,K;(#_)JR!<(R2CFS-22*@V!AEC*[3#M)X^FCRV&)?<
ML:79_' D3C'QT9IKX,7I BZ7]Z;S!Z1MW.?E)>TZWEM!:C7&4]6PT,D[5 \=
MW+2DG$2!OP$[9"J .YZ?F!5 $</H%RB0^^X-WDM9:$ASST2ZS]X2K9.1]>7R
M:D5X=Z\@//\+GI,T(JP#"9(&FH*/;'%$=5MR?0:J,>CM"SJ22R@Q0H4F?:'Q
MOQ/+<W<N<%:N#[4?%$ :KT\DK#N.*&UEI?#ZW=T?"93M[U&!&A#%I=FL=RU6
M*&GD 58:W4=1 IQ%A"+<D4(:V+^+K0@[@F3JBYXLUR$<46QZ09YNO9X0PE<7
MO@^WVZNGP6D]C+0UE(0(>N)&?$-Y6*8KRU[ X%&J-)#VW7O?3I "CZPU$&/L
MTAMM5!M4I"JT5<.6%'704*LUKQJ)=PITU]@,A;4_Y582:9?/C.%[(-4>=/$M
MXS3X&4AN$\#U3;J(NFTHP'-NI#EJ0>DQ(QH7)N-:E7D]3\,]/>>(ZOO,=K56
M3<8%KYEL_3"9;$6]D+TL4Z;A>8P&QAYO7#4\:U&/;)UA!C8\&=%@]R73=FUX
MVJ%>@"88V W/']0/S59]!(:G!.H%PJ:[HX\D/QH'.J(;V8V+N- L%]@>0&D(
M&!3P^(#2F!7D 8_,%H1'2@PCL;FR "K<C*BQAI0.TER%-PD\JY!:TF^1 ]%P
MS>;@I?[#6,83O'3E0746A O-Y.HRP-P:EPK?_![4)X=)3R*\\=SL/1=Z=T%*
M]()MJK!T%O&RNMYHA"#F=F,H6VJ19!;*,%O@6WY\?SR%P6OF,R0LC=ZG'[X/
M,83D8?D1-1D)JXM14:,$V-8G@ Y1#@*ZD.]RN>AZOK*, 3@$!7HKH]GJ'#?N
M_A"O=Y_AAD<1(!U'>A]-EL*JVD9JK9##0_A =5J(NR$;QP;R<"*W9W13NB"H
MS34. 7I"Y]/8/4='K78I,T!O@^QT"^Q3K:-6B[J#XB*<E0W6N];K(X^AU5(W
MP =?,WU+8''E7IKPO-PBPL7QBK::3+V0@[CF?FFLVK[%,E*4'8PT>T ?$2Z>
M%A9 MA7D8M?#VB8,C?V9,Y;,$6"<9A$<+D;'\8K:<!I,MF$F,12H3B:64B4+
M!OT9BI[HX6/?^7W$O*F]Q;L<188US/  P;9R#\XV9RA4<P*M%ER(_T0:&HK8
MAB4)VW)G[!KLG&$H-C3X4AYBS9HG4H,HM2@OTTUR9YF_#0V1[ H:R\1N:,"C
M;%JK&[D-#6Z4#1O%36!H;*-L!"O>AR$B&4>&&<'%T4L9PM'?HB2GRB"5 U6&
MR')%QSXGQZ,5GM'M>#P%/FJRWI7):I21LA.*L*J2]S*(^$)4TH;*)OVK%;KI
M:Q3&G)OM5,<N$Z=*F.*8;-\TDNK#XJW%U2(--0Q-&VJ@DP99$RJYYJ4@MKQ1
M7L;/R>GDI6Z!RJN5#?"R5WTI<-%\->M]->-4&^YH/T9'K18E/29SG,R,O=N&
M^HU[Q1!K\91ZI3;ED/'<%)^L.($HP%_E:EMA5'?G^V&,]\/%)U(8*FX3\ @W
M9?L5>*_@$US*@?S>L^5PV@. TG)MOP8=UUV,,H[EPB^+W*7T<4:QY%60U-\Q
MM1YF' MV7V5L<3J,]@M.T^I)6G5U+.V7WG&UFB[PL^_DDAD*%[%ATRSY3)O5
M$L?2Q*PZNI=SA DM4980XA8Q.NFV&%3]K<UZ2OV,5)CX1,A9%96#[$4VG8V]
M$@'-I%]#8PZ50)I)UX;&)*I!-!5D#4__.!BB-?W T,C&P6'M*=BQYEDS%DFR
MDB,U&/*G#%8?I%D[#0&6%>PM-PK2((ID*6^&1D3VC5]97QPH5%*C#)GW/FP+
MMM8;B*Y9X^]V.V"CRNGP]\B_MMY=FN7A?S? !SLWOG5ARS!:P8U: 0B=Y3W#
M22=0XS^C?J/T-%V6RNU7HO509AVY[.%E=FA'-L"&Y [I/CNY<7W7*HT)RY4Q
MLM:PP%\NX>%VB3E6! ?1>K&0_<'3EL!FJ-H--2U.Z^&T!F!Y0"]K[_W;G*?#
M1NE+O>A7RTLR8O:\X*OEVUUP$?F*9G!E5VT"+\[\!@U\L8.!'4"U.,'!YLO"
M@Q1V:KAQM0=(RZS8<$MJ#^CA>;OAYM,><!2Z(@RWI4J!%W^E]&(SU2C8FT?U
M0BI6"ED$?P;'4Q!:X3E3L]#;T6@;/+M[W]VYMH5J0EP?9Y5H<Z0A?J45E*(5
M'T',4+_8_2363\=]BIKP@5!>O<4XRL3"!ML3VI-F%WT6<D4\B**E%8;G71!^
MM4*')."*C*!LF898,/"'Y"D$)\LME;01X GUOCHL+2,C!'W^NWQVJ"!0^ J0
MK7-AVV%B>5%:[H>7, 5&U >&XA<9/?(NM=9+^7(NIZE$>HRU8+LH7XBX*41K
M\P;N4A*XOS2:^$4M;G5G$7IKM;P:[T*2+OQO1DF^D[L?HN<#U%=NH+#DE!M0
MGF/W\BE]@/LY")ROKN?!>=]#0=_?(\4?*X:V&J(/.;HN1M4>*S&D9U9OC;8F
MA (B]R:DC56K^MP*6:G\91O]2*I95,>8"1X%JFPT$=)39J,R%;H*U(9C)71@
M!=4LJ=9W'0]I>T(C86U>EFMI#$U$WS7<[],9R[K2;+A_IQ.3PZOF4A&K\K:M
M/@&(76]2BK.K#^3, .U1>LIG;>E+QJ6 M6H8[E'MX3)M82XQ_,%*9Y"IIA7#
MGZ7P@B=LVS$TX[8\HLN,1KUDV!Y%8,3"@==!NKY2OKM11C>033BX,O"\O=3[
MF!=)?$A)LER:CN1>KC96/_EQ.\C)Q/%0SWS-35;7GNIWI_K6A+4SM=;JIW\A
M]FHU*^;9R)NK<UW ^42092_1B\;PC*TD3V^K,(%T746M7ZE%*"<U*8WP,,H6
MC"+-426T!_@-[_]-0C=R7!O-G+IKK%X:<C1A1B;/64G^QK4<%GJACG-5<O?5
MQU%)GO)C$#\G+_\&=HQ*EQ33[QXI1QA7'TCPA@EDL8:ZP*%;V,5E%&GTBOU.
MJ=(KB.S0/6&V3K1WOS.^ 7O7]R&]L$^94']E9/79#X$=['WWSY0H"J/,10!X
M E#-07IQ9F( 4)^)4U<(< @DUF5$:9NW7&SNGA=VO &>"W8,ZB(W5JVK<^IG
M976=I ,9[F46-(DS@34<+@$M#4M<=2W(<+A8ZE/%7H;75":'4-GT0F=0!9:&
M0]2"F7,=4\-#$5JR*G&MVW <17@84X,W'*N6-,<1$6EJ (P@8H(V#,.=[2W)
M38*5Q' 'NRQ@6;86PUWM;0ZWB,''<(^[-/B(UB=#JUUW/,:=;%N&EK_N0I,4
MH]H0:1[U# :I)F59[RYG%!+5G>_ 'PAD.,J $4."% A;(F;1UF[Z$.HP+;8)
M!9/$0X<;Y<#,4[$^ 7@P4>NG(')IZ=(D#3X.<)X0M^H'&M+0N@$CMM8O/RB_
MN@1-_<1E]V%N/*7[_1S#FT6/>UX.6,*<Q7#[4)^H$EF2X18D.9A"_M2+M2@[
MV%"@TU,@W0 '@"-R(RP#_Q6$:7+%IV*%SW%@_VY.U/+2LZ)HO4M710UCQ#24
M%F'P# D"1$L.X+%1;^W&4!O2A]+<W_V1H/3^EQQ_E !K>A]U^82KLZ$2$+ZM
MK*E'85R:-OQ7?<KP5U\VX)2$]@%>$XM]"%(\4\\R""%+C<^/UA%@ER#65U[@
MS1GYOE?N2P@OKF@%O^98Q-!/GAZ#@EU'!T/=Q&;*"'H1ALB1612A>(0L_OJ;
M+?PILE+?740-OQ4=11K%K)+42G*AT*<P0-F!R01#[Z!L&[;P"^M="48*:\2W
M53?U(J=KQN]NSN6+D_82B*.C+HMJF#7I2WE0_^2D-J/TG6QT'T7DT$M:#UV6
MP6TX9/=3+PV5R9U'$FJT5[8$5+@H\,GR*;F=.M01.4/MF)CGL=1 V23A960#
MX*35A]#)0X%'ZQU1KB>L1'0470YWQG'621S%5GI)BS"J<C=U1&:AA.<IJA#N
MR'7R3/ ;8 /W%3AKOR0+D>A0: QI@M15P<\EI*PX6=RX+EBM>YC1/:3<**V3
M=N\OK:C^/(756B&GAYN8W:"W20A1R@QS&<$^@J_IG\ALGZNS:L,;V9QR\?R*
M&SL,C^7ELH=42D[@K0Y]P*0V&ULKF\4UQ(!A/C"4K%BV!X2/(+#F459'>\>%
MQA@&!T-)C,M,4>98PC";2W'\]I$R@ 2D)P-3P^)2 8=FW##]"/):1"B 86G0
M<-R89I<R7CBIUG!\J)ZM"C9-XX_AT(AQ<+(X9F[V9!'F7;;$]8%(LSCY2( 1
MMO[U$=.C,WJ<HA.%TQL>!=59AJH87_N(A#*)O/#6FSY0TY+)\RHR1)HT_/F@
MT)THYCB8D6.Z(4Q_5=D"HZ8;Q?"GDT(GD--7T\=CR1)['U=4\'-R/$)XUSN.
MMJ,,%C8S#"C/X?&G6"A0J9<NRS$A',C(\#D38IST>2>PD/!.0& ,V;/_(&/Z
M H/,,68Z!X92:>5& JD(C*'7)HPY\JTA^<#_9,$7&?" 7&";JZLN"TN372#_
M?YKV;1''H?N2Q(C6ML%3JI#PK9)CG#%I3TPQ<S)^Z]D?._MCAPVL%)$.#<>L
M+W_1C)>01=_4Q W\1U)$Y3$<-)U" T8*"T^XF[E! -RG3D1YG ,!% <"F $6
M0<_MPS^KU9GL !F/!MV'[[:)GT:^ME),I3F9=K+]9GAF:HUT>-+,Z22C]=!A
M&? PK<-4MW%0.0/P!,)TGNSE$'OJL*Q? Y3K;./N#\3L@Z36ZLJON:^N P]C
M5)H98>[8IJK9/?XD$X+"AS'^:20_"*%#/I6&*SQ"*%4/N>'".AL9//\80BS7
M4T9ZM@_ 2;PT.C[])3I!J*!"^ J<51"NDACEV<YCZ$<I/)6UWH9X38E >% ?
M<U3:J*5U<F/+RZX$X@:QKW'.<12G!1R)J'L]/2FVN=67%FI$ZZ$^QFC.*JFP
MLO!OZ;MN?,(]?!L=LO.@-WGK72FFG@HY1T=UI',\><$9 '8R+EQ+=9FN/,LG
MY,C$-E$^42J!U!JI9XESV.6@DVX;M2;>7UZ!\J_!]A DD>4[VZ^0 G+K[#T4
MH_S8?06(I,F1=@*]U66V106)4!H-R@&HME$;.'IC1<!!]SJ =TNF?EYSJ-R<
MKVV>K'.:$ 3-_;H W^%B5;U\2H_;;WTBYHIFMU>W]\E+Y#JN%9Y+8@:-9Q/;
MJ[9C4%56@J&'5T&<O F1JK09C@Z'PBK^0-M8L#1.+J@13-SI;FH*KN&P\.O(
M%1+"*:&&(X738"O97&K2F.%PS.'<7:+86BB2AN.%5V:N%8X%U%?#D<+JN8VH
M6NG:I>&H]JF2$Z_.J@;;!\):11$R55]"BARB9&(Z38KI037&8'A\B:B22*8]
MP\--!(&JRKF&AX*WM3007XZ9FJ)+$"B":7"('%T:13!E4#5D"F,"OJ\K30.S
M+BO<  _%.RZ#*(Y2F>FE)#-%C*B9CH/J$&736I3DC,GI./ZP%4G1I+ ^FOI?
M!YW6)^O-/29'XL2J?Q\>,4(MT>O?# ^0X/5B7PP *7T+.K&)G96#JWV8#),'
MD5C0 R.V5<+ <R!LOPQJBX23]>[>=U"8>F)YO[GQ(;V>X4Y%!_>T#>[@L8K/
MQ%+3HB-(XQ^%]87,)&HMU )+N 7P[>2EYFI[!)] B!BJM8>3*STHSE*M^G8(
M4(>%[\,9>V?685 ZE6%E$=>GRR*5OTO;YL? !\SCT&S4QUV^<G<Q '[;D#1F
M]_%=DS3ZS653V1<HSR=[#$<LV\6?\KIUHD&)C#'&1P;I__P*HOB2H/J#[&W'
M?6)\0#TF:(=SW3A:O%JNAW1=R-E_1M$<LD%C?6Y\ &:NJ'(>D&R-LI$C?D<:
M:\FO2Q([2W?L%^ Y-^>K (5C+ZW&42^$W;W!";M1EE9I$96GO[+<\),5_@[B
M]"EROD"I<I?XU\=W5&J'GY4W0OYWU$+VPE[*2T.V*"YC1!:75[SI-9U1" V[
M?CZH_J1F(0"O(/2LTPFRE/5N!ZZ5**0>2\:GU&-QFV0%<"[[)A\#PB?&QW]R
M8?PB[28OD1VZZ;VZL6)J+O(^/C<^ ',9)!75HGL_(X2?PR"2;I2D?,D0V'X#
M*&D'<!:0N<!K/OWC+20+=-NG]_P@D+)G,;X[,U\H4LV 4RSTLB"J'MC'Y]2_
M^0+A*[S,\83S&*3%KD"FSD;;(+:\\M^1V_@QB/\%X@VP@[V/Y*A2"![IX _S
M;?.@S:DG"/-?H78DBAUX$NK>IWKIZ,#!K_#N#?U(8I><G<=WJ5PXS"**DF-V
M(-!J;+C6(@U2'U(-]W=51U[)";(A/"WL&JEB:  N(7"EJ/9="QXQ'81ZA'8#
M'4,!:/LTA1R3,A&@YB=R_40$,L.TC4526K21AFD)M'BBTR&NY\((Z\$UAA(E
M,U*GN".%\304L'Y.L=I0)4,?5[$$WVJDDJ$@]'I_UZ1J0R&4<9U@XM,,14M<
MT6 'S!D.53\28;_A>H:_,Q7.X,"*^#,<K]ZN%X)P.L/97MN6P6Y,?TJM%T?&
M1L[.6S#D%C!C<DU_,Z_7=I C?(=XEF_,/G2(,<YQ_NN,<^_VG191T/GN_#CO
MCH++H5D][&_S/HCN0T^1V?F&_#1O2.]LBQ427EAU9A=!_WM!"DDO]F VK0UR
M43"CW8O],-:PH==^T(+GBZV0JF!KX1\?TV9PA.07&S6KWH,(6<Q0_F(_9A5<
M9#\&>AE0;,ZLMVNQ.82W!<4NS?J[R"[Q/DHHT)6JE<\WNXQW$<76]*J?:Y]5
M]3DY'JWPG.><S7GWPHXA5/%YSJXZ^NRJO3FAL##U]KGQ GA-6]PTV?:#(>6+
MZA,6$#:8_:9\L,]JBQ&\QMS,M':9\1 8X3ZK+4;POSO@HICC03'"?7:\+$L/
MGO_E/T8(X0C3@6D"V52SBJ0O)Z"N I#CY.*RRLY$628O//-$L4%\H-'2"OLF
M[/-+HX6-?3GV^:71PJ:,F7_Y,,:4HE4V@V[T7E%K?F>TD&5^CH7O% :K;8!^
M-13]<7]^M "7EE)S]E7BWOH_W]2OZPLO\0$ CS]5"L029S!>F(MU*$5:;!)C
M!KLA :J!6VP:XP4<(SNJ %QT&OH";L*E^.7#3^-%N"2B*D"8]^NCA9<MMRI
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M[O!5T:7>I:A9@4ZBD3TX+">P 1-KMC$4V(S>=N32"&Z&]1]02P,$%     @
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M0W/0)&"*@%'\*=$I_EBUGS/%LDYP A'7@M& QQ,RYV8*$]0)\ZV"V&\"JLD
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M"C6AY#I^;*:09$GOQ; UOD_/]=YI0)HVL._YG'(&.\WB;?(Y@L5\X]VYN&Y
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MPJSI">>(P/H.N!:YBRYBRDG;\ )F\H87.,3AMX#U+@IF,;)F1LD!K4#8Q(-
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MB_P%.'OZ!/?)IU0GS@$GSYZ@.GN"W X( < )ZA-_7,!?KQ,G*6NDH3U-1\]
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M9Q>\[MFX" HGMY&DP9%'-7',[5[$4%5-CP+;'Y-M:C^BMS:U%1-3%8$WISZ
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M?K8RMHL2X]%93&.N/IE"+;:25<,(/VX'4LOGX(;7.;-YPH12'=$FMU46@N>
MJ@%SE/S6&7QSOVG"'1M^L&#8-28'89;3%D&(TF9SJE>&-]2TH9(U)!ZX97JK
MHNEKR)Z=Y_JLW+-JF4=RU*OET'UU63BC5IE6"3B0??]*G_=B4Y*DR%DI+1Z^
MU]=\)VXFG>Y5Z<30!=%B4X?6+<9<]_I9S*<@787.Z3Z9N[ZEX4\091*I_CW@
MOO571=%YPJQ@_J$1A82$Z[41V3?36M,)BIX_= IZ%0I?Q'+=L]2.CCF51@>D
MH%T^OK)Z1>-E^&E47<5BRB798(;H91)SS^EQ?>5(D-B8;[_8Y=.YK[7$J$U&
MV&47@5>7O(RV;(XG @Y)O+QE5G(^&'0W;LQXK!4RWLH<8TN-ZWJYVRW@]374
M0AB[<)K32.Q5IYN$_EN.&T)U)Q4> %=T&WU+)N!M<N&D"XUXB\<?5J;/H\5Q
M[U/]SW\>S7EGV<6^<^LKNY7LDOL%EG'N?DWKS$54%T.OV:UAJS9;Z=!UK<^!
M#530V</WNN?]@T:?OF0QUI\O6@%6@ \==K@RC,6 CWFCQ!P,Z<WY=G<LH2TI
MO/;*]^UOX2R;PHUE3S6HKG$#]$)7X90,PD^-AR[>_AE/RAXI=77&,)"$5IO/
M8_V>[7UMU/2:2V"U_/']:#&\1]_53F:MY$;Q$SN9ZQ>\IR>'LS/<%'<JLBOZ
MTOQ+831H\(AL-5T9]1N<S0NMH'7YK-E9+M\N(7D>F_Q7MR];+UP29= <;5:#
M^6E6H*4;)>>H2?W/$4\4Z((N#F%^M([W/+6NHM$=6WI"[9XFX29U52-R/BU"
MU>@]+.$V=BMFPP=!/R@M+9LS4$BCXL-XZHEJZ?79297G??Z]S.E'^D@X!"\T
M-&*I6K,8Z+NK&C%WF:.]/#YZ(T^]B[WCN'N/XT=M"RK*K:?KBZVD>#R8H">+
MPD^=(_#@PS_#.ZCFLE"[I^K)P+S/0('@LIP8LGQL39 &76W@UV5[ <?9X/4>
M'P@>2?TBH#ZVJ61F9ASI$RTO&PWH3KU]^XP;.&G@T\Q%3!KK\*WU>X5O]1N8
M>O(![7-AMW4@(_!-H8?:#^>TC6]\5O4@3,N"O9V\>U7VRV8V'#P6(4/B<\D2
M&5" 8JXL&XP$J?AX0*5RU*U+JDU2QKR KVT1P@N\7;@@$(^J:\'T:GK"L[UA
M=)FLC*.^/ICIIR9'Q62'V%U-^A>MVB52A,:%=TF&!EY*YYO&K=R'R,!5A#;(
M168+<U3N(O0\A'.XM%&"&#>/,)Y;;T\=JS7%63N%<@^I&,EEU(6W>5J>HZ$5
MJ? 80KH(5:B-9CA^=)'HF+!.5_L01BQA_(I"96VZ&L_I,XOZ+GIK_[0'G1_*
MMZ^9:!WR)@.QO'($48@#5K 9-"M8TU!=CIF=3([Z=2?"A@Q(], #\&J?=_.3
MP?@6N6@%F>!&6B09<'+AM7-FR\;KE/GZTTRY]G$Y,BWF$J8;1VPM)R!IV:L/
M/=O 'B1UK<-F*IB9_F?<2%G)O,WM[^ZG#T-_S7J+!UH(J;C.63!]4;='?+%I
M?/AR5J](F@PXFF\0)&8@+/A(JT:T=)#>E<F^U'2+S\E@__@G,33>9A:)]D\B
M#F_N*I>%W<69=4Q!]1L_C9"8NDHU_8MZ/_:,-9]ME!V[<N'F0C%/Z[.2[/JK
M\87R<@0MW)9)AM&Q>SCAGI\=;+2GWGI"8-+"DL__[(PB-F62LU_FOBN)]<OR
M^=>/54JZ:]VS]Q9"[X97Q:QC%C0E-C ?7'@_5)Z)FZ<31U>I608KW6\>]JZD
M?96*!:NUK[V42C,Q/VTR4_YP*!>+W#A^'W3KF4L(+ZX_^;VV;$YCXUC5O,N^
MV5FK*MQ+#C&/Q=L?VWH8?1_\LE7V30G&-6@-RR&?$,XB=13V*\_7>2)F2R+U
M')*419,436\RRB;K?KAR2:,86<T<@W;>^N",8D VJN0V-0TS%ZRJ<]7'TT*C
M&HL?N[:\S1_?+I:^&0_P*&<,UW8@&FMK4/$=GFA4ZR9<#4FRRO*;!X<?I3T+
M A7:NAPC?*3BM(\-LPV35.69W$14:I?/\-\Y+1H+: B/\=C6SF6*S@O%J4K-
M9C-#!1EQ"HN1D:Q.50>N)Y?[S!<D7_NK-GZ^&\T%\F;T[E2&X.^!6% K&C@P
MB>YW*GIK6P;V\J/#4 U<=J5#! Z[>6A#2G,2C Q4$!@$"VE??7%+E8^]\"0L
MY;#/H]?7]C+QS:Z!4*>ZW'79XN 2F,J=FB9=MTF7GQ9KG%N\U8@!*N!5S_>V
MDUHM_!%4;T<:.7 Z;;6<!GDP4#N.KY_):C7ML;PRQOM.S)*V%T_+]_AWL?<5
M<02OZN$@BT#FR" (.TE*V\!)-NR:_A=[UL?)WR=./SA]\03_\Q:%E"FT\1#F
M955>?G),4R^*AR""-2PN#=+#'H26$K0<YYBI]42I40W11P*&8O7Z#B9TK/+&
MJ8GTR!Z^E/7H, .\Z =G.'7!&$$S'V*%+SPV/  '6FUZ8FY#-=B?7CGK+!_B
MVB9T+:E(XPO$TC&.LF'9JI4W5(VHRLQQOV_Z;-70\@%VYT?US^]^4CT#-^)$
M&/69VF=VQM+S"KMP)8;8U]-\9."%G'734'ZZU2L%(;KJG[CNB[E?<;W23.<N
MGRV\V,:G+:GS5KM/O]"H.Z6A4PZI68#KWT#GK@B>QY5.G"\,+H5IZJ)])"(6
M0Q&]'_)<H@T*!JCX%RH^?4D\+7KJ$I]EY$:@8!@BZ%S-R+E1X9HQY,R0JO90
MT0M-/VGH]1C'B]K]DM\YE=O:Q)^F&W1UQ3';XLZ7/Y[%<&H%SMW0+N-K&VHT
MR[Z6O!S5>B\"B#VC+$#W884UR!?;5U>TSJDNB//;C\@)%,SS$N]\+C^G_V;Q
M2GZ#[;F<L$IO >[X%]'ZV>!@2LD).R2==D^&>.R1@>=$_TK'.>07R!F\3LO1
M5E35-SE6;OG>Z]L3<IM2P=KCY].W]?WGN)X6Z>U_% WZ?*&_:IG#H6O? SM:
M/A->%V-=AP[2"?RP4NFL'["ZKQ(SV5[O5YOX2?43QI&!C^U9.\W,@AF$FS1
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MN(6=;H 66O^ <AY<=N%B<GYR]UWC]])>GE./S2^67_QR-GH;S(AGML([EEE
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M9T_"Z9NE9Q0318-A^0/-;"N\,B,C/]?]D+8_V_:=97VZ"YO@$B*-.4NL' R
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MMKK'IIZZG0Y,$),KX21LZVR9(Z$_@MS>59[K9D0'R&=M-[!L6JUPAG/$0W3
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MG*5/S[Y90^+WZ0CE!K&G-;XXQ!B+)&;3+H)X=XE*ES%X755,7]^<I@\7[MB
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M)M(!__7E[?6SS9#/-A*TJ8,.S":1?82+?ER?Z@]^(B,66%BHV\! .+J0N^@
M+W+T_?J<'6\Z''YC(&[L ([&QD2@;L'3@0&MOK]>.3J(:+=C667P@C;_JQR/
M_K@Z]PG+9 $#;0N<RVQ"#3H2J-+(2K75HYP@A<&<#E2L+W$?H<!.2&'S#!T
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MWYCM 8O4.^C$L66F3^8&GT-U8_D\=/>8H9%J^*9''S(SLCV_-6W;P5Z8MS5
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M&6)Q7ASR-(MSD183K'T=/H)Z(J<W,$$"OZSF0-Q,L/?:W(H\\^,.F0W-7R?
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M4M!<UR]V$JB,Y+C@@K6[4UA_]3N%94V$HM)[-VZ1$)EF%_DJ-J]U6>S4<JC
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M:R?6T?C#PL,ZH=_#B / PL;%PR<@)"(FP?IK)18 &^=[)3D "Q<+!QL7&X\
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M'7EUUQYZ>#4W7+[X7C)YVT_T=5KT1R)!KZ5,'';3-,4'0^7S3P<KGWX%T+5
M25Y5'3 R)>H(LK$'J3V(6AS)_W0[J_;CWI<W'OHXHA$1VSEI5G:8Z5IY,T*7
M)\]%/RUL(K\(?VG]O!.CA?^DTBS_IA,13/#M;9L@#W^J#_-F#U-\L^^$:627
M2XBFZL0_"R%M?7EGY[? JI1B( >&V*LE7DAO+G^GLZ;;U-R]H>VFOL'8U1=?
M <M? 8-?1L:1@<Q,-@: 4SJE4SJE4SJE4SJE4SJE4_I?2E]7=(=<T&A/.6%A
MA+>0_?$CJ) CTD/8W]Y36%1(1!B@<-'?T][1'89F<8 YNR(4V?9:'[*QN$(5
MV<PD]43T/-5@+J[:@2B8<: ^Q#'0W5$6RG91B5C!7\[?P],#AK9G\?> ([SE
M_!793HS+'9T?LX796$Y$T.Z*;"</OBSF>H8L:D@4C$522%S04414E$5*2DA4
M0E)*2E2 14Q$5$Q8Y.A/2E!40DY22DY,FN5W8E,B/MHKH*!.<F!US=_ACDJ*
M;+^WR\_/3\A/7 B)<A86E965/38C)B9X)"'H'8! V_L+(KS9OQGY;D<=YNV(
M<CU9U68Y+ML[('W0BFQLQ"P_T3<@J.,/'$\?%/P$!>HH#(/#/& (M/=1#$6%
M?Q@_M@]UE$.[HN$PI3\9.X%5@:/_S/U> 7<]1I.#VR.<%=G\!7]?+&%3^F?>
M>B@(?[/P%SSAOP,J"/_"MV-_G9 H#WNTDJN'O3-,&.;I[70B^3N7^&>#/P7N
MOQK0HS'Q(Z*_')%_BN:1M)P:"F:/1J(@2"1<Z=M0 L+A/MYHU#&714Q"2)R%
M1\_>T15Q_'J)5T'XKSJ_,@=3/_HI'<=04%144$06(BHK)R$E)RHC*"(M)R+R
MDY%ODG^QH8>$NCH%_,*&I-3/!GX2^ZN!HQ2!VJ/M_W,3/PO^-_2%GMY_W!L>
M'L*_TO1&@V%._[&F]_%"GC 8YHWT03G"CL39?VU(PQ?]_V)(P_<H[]C_.DCT
M]([:C3I*#J@F"NEQTFY/>Y3WR8*M(MMW7;:_),E)*^1<$=YH>\3Q\K'2D24A
M5U>HG(J,NHR4C+BTB(B8N(:JJ*BLC(RZJJ:DN*RTF*RXK)BJ@O#?5']E&8IT
M]#F>)GZW##VV+*TIJZFB(:VI+B;V'UG^2?57EK^M9-O#U?\0TQ01T125UA05
ME1*5$1>759$0%Y.5U=!4DU4[8JJK2W^W_ O5G^>(OP7S[Y'6=O4^RJV 7\QP
MQC"O?SC#_7-]\J.51\-"SM[Q9'1[VQ^Y<NS^3[Q_K/2+[I35_,^#_A?5?VS?
MSP6&^&O*2LB)2G_/VI^D_K$1;Z03VL\>!5-Q/NJ!WV>U/UZ0JQE+L?"8N2*@
M2#]OWN\6_ZSRCTT[NAQ=1F!0)>'OBM\9?^N87UXY_BT]YHA$'+\5^'_HM2,<
M^Z/[AJ.+FY+3<09_NQBY><*<6=!(%GM/3[BKH_VQ#6%?!/3W2<+S>\"^H_QD
MY'^PL=!ON?)?:>J/.+'\7VOTOYR3*B*G.?D_FI/_>H])_+?WF*38:8_].V?1
M_V0*.9YE?K[K___'+/I_J-'_>DY*GN;D_[%95.J_N<<DY<1%3WOLWW\O>CQ;
M_*^_+?MWWXO^GVCTOYZ3_\1#^6E._J_JL7]B@>9?ZC&IT^XZO1$]O1']M=*O
M$E+V-"'_J>[ZQOWS0NGW5=>_+ZS^ON(*_*\$_&^J?U\R_Z^L3_]-]6]F#?XK
MB]/_4/7?_=+C1_[]^JW#C^J_OXSZ425W\H_*>D@H3$E"0?A7[/_0Z6]<L+JF
M$O%1N[^_2/W5D/OWTRG(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(
M*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@I
MR"G(*<@IR"G(*<@IR"G(OQF$^(]/D\$04$4V/[:+2E\7 &H K'^1CHW\JS:P
M3KZ=C86##<;!HOC^[>Q.P 4 %@ +!P_KYX_LXQ,281U_')N8Y$@ 30X X!^I
M8>/AX5(0DYTY"\#Z]N%L "$%)14U*Q$-+9OH.3IV%2,.,7LO3BYQ*1-3,_-K
MB:GWJCNF9E[1<TNK@GU3TAJG)36TC!W\,,GY!0T3L\3G)=2TH3!4;O?8Y,J^
MC*:3LT]H6,3U&TDY>86/CE 9L;Y]L/NG#\/]#DMX5.M$<>0S#@X6'@X^/C$I
M,0$^P5$E!0"7%8]25 6?BLW(GMKK&@$-NUCB/5I5</78*PY.<6.(B4-RQ\HY
M"34T)JEN?&)R:I]04MT1ZAV:4E-+IV&*"@O/X8+YI.8_6I5RBLBMS_OS%[$_
MO1]//MI2''P63($#]$^]AJZ8"DG0,=6MGX?I/[SQHEIFU'K=I?!6SK44ZP5A
ML;1 P>[!.L5YTQ5!U6M(@\0BEK%R)1-UJ-D=$V<CL]3P>PW!K!KKQ1IN'#LW
M('%WC\(+Q2CB&=+(-S,8M*\MRGU9RZB)R=YH)#*8[\9:7#0-#$#6(RXR/8$^
MVT_GFYVL)V9,&JJ#9?:'QXNP$P<%A6GYJXYI1U_/XORMSP\F2/W$ISQ#5G;&
MJ+^ZUS4U=7.>9_[ZY!Q)"AYU6D(HX1)NTSDV@ S%]-T4979\(I81X!N9=Q\B
M5XOGF)XCKI!]UE =</2?8-NI1;[-W+BSZK!97Q4_[/_T LRC9H0]:2NR$G=_
M /^#,#)5X"&C=DO)_LZR6*F.WN4<4+%QO%+)6]_DNW<)79^3N(@KCD?;ZD_1
MKRLDJW<(/NK4IN&T\F))R%KL[*#J3(Q2-%";+HDD?=U<UMS21.WV;KN//4P,
MJN_?2[=;'&&X8&W$5OV$9\#?FV!JY_5;TA%K6U!@NI?GDT\8JK=N1ALIZZ8:
M$1Q@;D>ZWO*7QGIU@[R"[WIW1U<N76X-BBOO E"6WP/*&^&)\NX[H]N-C'#U
MQXEP/5A"E)\YL_3&B[]4;/A4L<@!RWS_9,\GP6%&''G]4+W#@N_\?2.5QZ1(
M[:6-1MRG5>XY;94/PRR7($4J:DN;4D0RA>)2<IW;K_B$EQR;B[7VMW=X:,)_
M>^Y^O[-/K.*%7$HW*T>_@;)R9I&:%^/SGCIF625E-)-;[.U%VF<BT>"9\->V
MQL..YDO,K_>#@AW=0QY'231/B9P9\R-)*_+I-+NW:NEQC9^TZTF4.0%* &8D
MW@%/4I_GF!NHLYX\#[/CD%I 3;4\&B_$Y9W)4#%:7$TBKQUGV1=1QRAGVQ4E
MTK/@*5,\9[;^Z% J..H4]W@9CC1,O(O(L>(=?+9('U03$>>&8+3)Q[8E%KHM
M?39#-)>'6,';JV=+*8M38?3<M0>2GN4M&27>ME7N;&V#(A/Z,GZU55*;8&4^
M@T B0UXC/FXT6>>UYY%A0"Y"PU#QCGF#-=(W!]RB>Q4,0I^]&>AVNDWSEV2*
MGPTZ7J^ZPNFG7C%I;3UDL60*'@B09^9,<*U_O[F]5+-O7@4Q[0F(+P:$\:ZV
MW:/(X;I.=+=*BEZO!.AJAX3U,'H*HZ_TJ#)XYAMC";$4Y2LGJ.>-T !1'%=$
M0%!L$8@CS@I+TEN?6PTI+0IWTE!G9MU,2R5NWQ"2VFG%IZ]@L\VPM&Y[YKSP
M#+[0('RS6=>T@+_*-]"XK\E=,7YVOL#74! <^T!B?_1R=Z)#_\0@9UW;7?:7
M=&!6JQ"UH>)'G#*B6.)*3K+8Y7,XHJN95W2CE-XGXLS(E)5NT986)/]]*]5?
MG-K<('%<:! I?J(7C1E.=P#'R2<Q:)KE<[/2J:PQ/%-!VA2P(V,SBZ5;EJ!N
M>JRKMK-WN>>DHSG#.M1:,A54QMK&*?/:ZD/N+MBK4&JN%I+'=MS2-MWVI@\A
M*H$XX':(W^&AO"I]^$:*IEEWJ*E-^ ZX&_*YZQ:<W(11K?[E^HZWS_V'K7FT
M4^E^P.3]NNW=59O&NV;;+XT7I^^5'J82.[CXWQ!9CY>HPXSMT0;9VWX2E&IX
M5T[$J:^ X;1J:!AGU%8FCEH$IF"S,XD3<^@R PXVM0^_!#?)K<8-/I]OZ$<-
MKXOA9B/JE_+XP:(RN0L\V^?$@;70VTIJF3VWYN(%\U?XGO9CUDT'?RL^OWO^
M]?F/#GHX!=H-9YFS1J/@TCL\,&)X'M,PM=_=_#H6P:"8JELAZGF1;)JR(?FX
M*7P&>6?RU*D'7\=?=N_N"4#*PPJLI&.\FC\_-6D80EP5V-%2;+C9_;XE@A5F
M0+OSSCL@M33!=EPLE<#'[9[5 43P++E-GB,UC(+\2:N]12S,3<8FY;>\>WE!
M0-*&O'=D#^;X?*Q 3V"864-///SH:6D*3NU5W4@\$#:U5A30%"!#+-[-A1M(
M[O;L/F/:YQE,52=";W BO:#_8 I_[I-%T(>&CR#=:DQF58/%6\F(QZ.)?MK=
M=E.U'%F-O2\I#L)?.3+/FNT_F[J=S'J6FKT%P%3H[)] -(]U*1""BP'RFHX1
M\T5F))07\[%"L5I$\C6! (Z^;D>.9=);I:UJ[ K-/0.=JBJV+A-/AA^DN0N[
MY0MD!KMP+W<E1%<PDBK$ADUF^R>S&06O3+#5^0.G$W<9WG/6GG.XK2&R53EK
M6U4:TH>8_E#?M*+..YDZJC'@$34O1 *$S>$O]2@;&8A-MSVK6%I*R4IMSGD:
MI[A0L'LH2-.YL( @)!44EC&Q]_*\N^QI01*Q*%[M>K_1KK 5HNC4*[UF%TL$
MBTN^I5C*VN] ^Y;;I-N'PRF?R/VZ1/BX*-#R?'9%Q^-&/"S61990P4A\-NPT
MSC4_6('K5T"XY>'M%S#30._S\[,:\WMQK9I#7=>I/]1XVC2%<^/Q&!F):+,Y
MAD[+Z\VS'P0=7"V=LWY*YECG=S_2V= /Y*A^[AW/M"5L2:55PEV@5-N^IP]R
M[K:.!TO"]"-*7&.CH0"]-Y.DNN7Y(P'\4MR5>J+>5!9$^%LZSKJ/@36:.DTW
MHT&*G?WU'^NHU5M? #3IM?:'.=SMQKB=3#Q2AF_DW3O3-%7-8U)1BWK<Z_-J
MXE[\B*O9="E4KF)?@&MWY5/J?!/^NLC!^69P Y=LG'BC3;GOZO3TEJFY5Y95
MM9S/86U#H%T+S.\K@)>I<GNWW#6PU=W(K;7K9:!-_)T@[T)<\Y+=J:W[ F)I
MT2E>M/+UB<G7-\A=17C9-;H3Q%/8_,U?I[+9;%@^^_#X4>9.O%^!R;;..>S8
MQ#LL*LA1#(>>1F1!Z'A_GX>O/:+!5/@P*,9]G'9Y;V>A:6(T%9/,RZ<::HNF
MG$^H1^)X\@(K5:?J=QSFGV^H- C[<BMO7\\J?M$G8$7A&/S;[7GNK&!>78&'
M]Q<8S*1LSLT#G2AG53-!]YXW"[/)]<@&<7$F3$>F=?%(')IPTD77)'H/:([S
MIT+FYPDWF3H_CM0(A+<4:3!C@TGC'-=9=:@GQXF:Y8=RT$.2Y^-C\IDNWG>W
MX!-Z^NX=ZR=T\U5OMWP+7*7;Z%P#CZSA@HW"Y'S6#;E5*S!(5KYB\FW*\+#O
M0CV9;_C<TEL)#HL71+7C*;!BH0GE<1^T9)G?VS.;?$%U?M+1;F.6-D_N+"TL
M6G!-Y;?=(.L!G96$=H.KR7V;15F% X8&+].ZRC1UMKL;SET^9!N+XR UY82+
M52>4W=;IT2;F!0$?/;R"GA;O7WN^N?YP[HLHO.U+:<#$)X4;APP^"C7U-HLN
MD9/P>J=><[-:A;6N&[=!K0T7/)++<&WR2SIJ=_;</'8]!'RLVGS#-BBVF$?<
ML,?'B.0T;B)V@RZ6OC5Y)?C8=LZU<$$RP!5M*"RT?:G%Z\RY-ZTQ*1^:*2<R
M6:59Q54:H=LWXHN:>RNKGTV6-WWD/FM@Q%IYE4U<"JC==H? N6 (BCY0AVR
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M#=AC2QH4[+:"+*QI51->:#85\(+WCH8Q;]K7CA=,O1""YKKWSE]K(\".!J>
MS(AY.53FB\#:Z?%M*L4=W(/*O:_??5KESXU^ F?@N'3 SVAO\%C_@":4GZWF
M09,!U3VSE#8S$NA; T&>\,$-$(U F)EB%9 @(:]TK_#N=)9)JQ5)[GV;)F;3
M"\IXL(Y&*"AJ'J1Z&YMHWK=[+#*2@LYNI%.?>^GCET,;R('4V(&#>1KW9):C
MN^&SHAC?,YV-M"GA,T&>%:JU-?,(F6$I#7\'):05?(;>?"//_8 +1EI3GW)V
MUF0FG&\TK^W)&QZ9[!V5KCR,5%'R78&HN/&\0C_9J*+DI$V80K#VIZ8MB,_U
MK*KF=\D?Z^\PV=-+5BT]87!/UI[3=:>M%7!%)!1,H?"N4DY/F][?_%BK-:4%
MZ:-+)35S!FSTCU*0F2JLI&NY/EB.(&\T\">)X03M1QF"IQ+,WA_H'N*NC^)&
M DCM[/P#VP]>XZR*=EX_\'8KZ-%9EY6H]G=4\$CU\.T4J#%YL;YUN#A%GP W
M,KUMXF.6&,'7V&,A9SO"+$7\DG' P)J+DZ%'(2$IV;R"EVG9=JQ-$+B K1I-
MN/P5P(Y4BV1.X9)E#[O&Y,01F)W],8]NXTL:;<L6+SMK_-KY";&ZV-P4J"MB
M&2GY>26X7"$J\*K]1FF9&(-N:4#AW)TZ8([/:,/\EG%\&Q\E!8J8N-[#5U79
M8C$!]P(1",(NS@#.NZE>=(;PD:9!F]8\RUDQ[B=DAM7BS#?YJE@);'MF:XAV
M/2+= OB2\;&279TRRP3=?/MN9U[3B^WIJIYRTVKJZ:5H'?BL3N;O?%[1,^,!
M+\T4S[M^W)1R%>(._@0:^GG0W=*+T<"P#2 %2S"[DAKCIQ*-K%X&<7-7JZCJ
M"^=*-C?G54%I*7F;N J3I=;\.OU^9L+DV5ZXXH)1-XOQ!I)(J0-SD:8B02[Z
MPA$;4QK+!+%UTN]EU6\9!%JI=+8_T7$UNW/#%Q#)$!!"'+D.T/7:V]22)+"J
MS(YM"]$,.+-EV-5(5,P8LLM9-;3,+S"L _X*@.=H+C W628_4+C$P;+;$U<-
MU8B:?%WR$<Y9 N'YH,%A%EO9:%%OA:#$W,PC7.# 8]YS,S7"G%D4A(G*\*V2
M<7*=X?CHY'!5TOI OF5!=9@OCL%)SONF1YG,;JX1>FXB976;EK':-+EYS:6W
M.=PRF_51X_E)@=A8MHA LD5BHBJ:*+:7N9(O=FU"@^I5_:CBL:F3BWI$J.^F
MOY8IYCCC/E6_&X0[GI@ [DJ@E_9A\$[N*5'MZ9PMW#F[FY!(,?%:\L7YE"O,
MX#'891HB029^]NUM]1R!6RUZCR.,62&4RJHC1!#JB%!U;(PVOCY+0N"'@'&M
MK0_W?TL1GMXVDIJEBY$@B<A2'=&J3XE!K<2\[YJ!'E(*+6GDYEO68!R*DV0U
M-"OGZGVO?=!#4QH6L(#5*<^R=&PJC86]DE28:2S*E_C39I7JT++3TL$%)TJ?
MGZH\PYUC80'=WXF.8DVPMWS,M:GG#USP1I?63GULE0;3%'N5]5FF10HD9S*L
M*I=MO G,!]7Y147<+1;SC>"T M["Q6')9+PF(PEDLWLFYB4ZHO2Y2Z5NZUWN
M6S6*OH52$S=<)39,2-':/8ELXIKQU8KZOKZHA7+F-'"EA>AGCNO:-U.J+ 5\
MH[=IY(0ZM9)\B8":>LD)R9XE[TP77IB#HIX0IZSXD,Q"I7)R(HJDRG"SNKC8
M/-6KU&-C/;$2X^]4VK8%F5_!L3,HO&O\&*+ -CSBE51CF9MN5MT6C/NAS/_*
M8]O$FI:,6,M6)DZK1B.!&;GUW%N?V%UN,UKG+<A2GZ<PCE[/=VN*X'5#AX<0
M1T>1+YMC WMY/92CV"C!P452JP"J3*R]D9Z]-<FE2F>]U$54,GM@HAW\@Y)O
M]V/.ZBHSD<-IV&,=QUF2>.R;;?JV["X5]J54PVXT00W"R(NPS.C@P'!H'@53
M8$B7'G#W#EFQ)CB$F%"(11OO#'4X300/PM(,BX/&/SQ!&W0U;RUS9U#?BSE'
MEJ8O+/\MIU[E%,H)  LO]FE[DI*90+O)Z<"7SX34C!_O<FE(!;[6OC4NR@EK
M(\L 0U.Q;A(>KJVKM%/,Z:;?<U@N!OJU&6G.@:*3[S6%QU(&<& QHQF4B0%G
MV0%:+X8"]]X]K!]7ZP&=_R#R4:S+$6E8P4\57;/]<E?\[):4CAM'@>3U>TI^
MWE&6I>":H8S'IJJV;>:]-W2*><"^GS Q?OUMO(#PB!3>[H0$[!"&Y/I\EETV
MRAPB+@ WM2$Q$!>;M) =WSAQ)AESUCS1A(KAP<*!]]LFIAP*VOJM?4/*["Y!
MC>IB'$,@W[9):#.%Q,:2C]R.U/1TI>A9B>YTJ;=L3\:956Z/A@-S7A:Y][8\
M;/#QZVUN<GW7^N1@Y4QRR[M [2#4H\9R(2'5P>2RP:0N-P1:D/9C1Q;;:^!$
M1=V @=-;#Z75L1OPG8B[( \2VBT//8E2:+YBARK8\MI2\BLV8-M"U=L1^"0)
M8ZI"'"=8^4USJCB$*#*C]V*NE0+)>_/TQA2GE*BO #L/WQN(;7L;3!(HM?9#
MU">LU?1\099X51\R5WZ]1\*5C;M>[<O-7CI+J/'S7NI[X Z?ZU:N*LI(CX(%
M,0:0)M\GWCD_#[VDK.RQ%*A%0Z/44VE+DBNK_2N?6C7#@%#VUH;6EN8F>WDM
M/\]/(RP$3%Z@LK(*WP!(3._TW/LR_W%QG$H:[5[*]6*98.IW$Z*>-6.2+!)H
M\:[UI\VQ#U1XDAEYH4MY0?*:T5)Z$\L(5_W2<HJEF$_C0K27%IY6T#XD%,)J
M L#RWC?+4R4!8D#;SM#DAD4S9PD3F:ZJ6@]G@T9^Q,1+AR6^W;Y=Y<O+J0^*
MSC0!L-RR6^$]M59T=?>%WF+*[EL^-L[!<BY"[?MMWH]W/2=45"7F0[3YF'_J
M\B2&-$NVE+2,G7J1HF5 HT@17ZF<[1W$([]J:6F>'BUG.B[$2"8@=RL0G+*M
MN&I6/WFS@J;>+M;4>"EK>Z=KZ?Z7[JC\BY==!"<\? \C:M,$N*9 )I7HS7E^
M@UJ:8M]/NE7YE-./G)KW6J/GSRA>ZT+YD2A"$SX0,L 6U6/UY+J\@AQ,G3JL
MX,//3:Z7F#[G[ ;9]J3POZCS#:/.NZ.]<(8PQ>0LZ_R]0A\\P8.%R@A9Y+89
MP?W=1SN&<0\&7X(QU/U6,/96(UXB51:R'#'K<8D;%/"%%H^8N+E-OFE!RE:G
M3+V&DK61MOO $,.@TN<76II]_ 0?]Z-6#GFA+34E/@KUU45E73C^04RZ(4/O
M;H&2<]T/P\CF2OTD6 ](P[/%<IDWT+=SNIMRFENUC?->3%TW2[=\DQ7)<IU8
MM+5[9Q19ADI[2[OAYL$1%V5N29R0O:_!R@<V!:<@.'0IO:T4"+-16F!Q^O;0
MX*:7+TTN(X5VB-IBT7H60Y+IF[*VEO@MO_'=$!IOFA'>(*&I81O-DIN,@\FU
ME6>,N%_UB6L!FFP\I4NJA),)["[<]SP4'S?<A?'U8[%D)G.0W0U5"6%W86-C
MIS!B_PHHD=F\,J(4W#8$?I\FMGV#%5\:&3-OD@@3Q#P3FHU:B)5$W#/;J.E:
MO8.!)S62>HN[Y9BQY N^[==IR^=F=RA7\OS-C=ER&);=Q-&_X6<<%8Q\VI80
MGF]7ZC6+24@N0G"[:>MRK(C<PJ%FT,959HP'R.?U,K<-Z@?W46M)PI54N1)Q
MJ?QOC>+WBU[EWEZ:_"Q!)%;AXY.6N^K$[QQP"21(7U900Q\;5RZ0S!XD1_EZ
M5]5DPLK*)S^BL<.(UY,<0W.8QUDSRVICCZ<7>='L<:P]+P4C70A[6<?KU2LT
M,\_M;HG="[S7,^FYPU>T^I(IKL)_M3R.RAH^<XNX3?! JF"!V91?&"8T/IK"
MV^O.)K#,\BQ42+2#B<".069;_<$J)L<:'(T399EL$ &R5"$VZBPFH6#!*+KX
MYJ%QRK#:WWM=0$^GEQQ6-[F)\V[/@<H'QKS+2QZBY9*L EIM9A?V>O1SX]V,
M4V^]V$;*/1/ZO%Q08+39;SG?-6]3%*N!HBLI&8T=3^8\Y,F_OY"0$D82J0IN
M-,5:Q!_%GE06T5_K&[RUOO]J"_O*RAWA"+,IZXBZU;&M5,M^ZEDW6^K[D/TA
MZ\*[0%,"6BCI/2:CLFE^"IHYN4GH?254S[GTDE%^CGG!T+AY&Y.X5*,<-QV.
M.#PAH"Y/RMT*?-71K'XNK0@@7HVF=G+O2R#!]-FG-M94B'F$DQ:'[LKY2=Q:
MDAC*W$3GOAME;]Y;WS@G+>Z+D;4VL"SV>9$90_?1MRLX*="EL7;P\^4,A,K+
MR/(HDZ>051LXBTS1S9+L0SZP#(":T\W8B3(1EZ-=GX48(*;N/!H<Z'39J='A
M<VZ="3>*,X:J4@OZECCMO-5OJN7@"VK3ZSQ-Z02O]O5N\'!:PXR;.M92A]=S
M+<0C:H;8S52<AY(T,IP\;50QVYQ\3U0@^;A)Q"B.<"J64H98;#L]Y=A2YD+&
ML[Z.3U]U0H !]1^EN^J=Y:PW9VV=G[-KU>IH0D4>@^8Y:VCE.9WDI';$W2[3
M@))ON4-@QE4]:M;Y%9WQ<;&121R2UP8@9WRO>7)M"8:^("WGY5F\2]Y6C"6F
MC*_"NR"F'COJ$=4-W7_[^:)N &0GI4S>LEBV9^X&=WU/!;>)J>0#GGH\$_FL
M:2.T8WX!VVU'I_K9@ 7TZI #IS/,DA4,?;_#S@&[E! E@=YQ7 !9F[[*&A5;
MQ@>L;?7AW'W.19"B+_HJ-L!Y)3HVKZ:[9X\>TRHH:%MI66O-Z=:L2 %/:/=+
MC^'D:^4:[Q V]Q'U\8[/9%4F=],1;YIN $9R;^.Y&NJUPFR%-$J)+O-P\K$2
MH.R%\O ZB,#*3Z370Y03 I8IV7'7G>1N7BT\##!A>VLU=L^V;$WW8[D9LC D
MJ4?DG8+1Y=@NHXD*@YO5LJZ0CVO]1>HF'+",3P#:$CV'AY13.50IKQ4<R6@[
M:F(9I5W-]>8LT_&6^BP3\OS" ?F4$"(^HE P!"CBZ*7HQLG.'LJE_!S9!(S/
MWC;9<_P<9MXWE9JZ&9H$ZKAOL^#[O I2GIPN:A(3<5X&SWW&!70846)7HX5K
MZD,;+92$73&Y)2WG=IM)F\<(%))(50\T'+Q3%GK7X%:FOMM=J$&6:4M!00;X
MSUL3DR3\L/8Z8A0X8.;"-S?@,\%6U(1H)LWH%4AO[S3B-!9-,A)/!J'HND0(
M":]G.1<M'S)=E<%/H6OL,+?(+RCV1T95]TO+,>+PU7--9XFUZ=" ZNGZUM%P
M,A2T>H7U+!73!5:6CC#\,^2(H<RPM^5)0(**)-/RK="LS?E</H982EV,>H<8
MUHB1$4XOA+I&GK-Y5W">(-=A('4U]QE=J2!<BSK(6)@ 7JPL92K8]E9/M9C=
MMG)I:ZH;'BHFYS#</<%$%\9A(04DAZN4^;U49M4! 5A9>")!L;?T7\[G0-L!
M@^G/$L3LG+/%Z:B>,YI<X'9_$ZA4TOFLD&9;WCFT[-EM$[EFE\C.GA8]\6$D
M\F": >J#X".^(^KJ@\3TQFUX##_IU)0!Z[L8>*DLW"2/K4GQ:%:-5DK!K:/-
MP^0-</*R)+' %QJ<E!_I>D&RPKC$BG"O]?44<@%?<WR8"J)/EO()KE;M:F^Z
MNU1&'XA*2XMT^\*ZDP>#'W+'+7L=_K;'366=X&Q6;98O&DA.(]NZU21K_C(X
M6*1:AYO=U"CW/+&-=E(3+DC, ;L0I>DO'[\LNBH^I)MO[7]#AE(TP: HU@<W
MJ"3"O2DKI)%+^%7-^XTZ1:&'-GUTPWT'SC)/DF+O>C/Y?.!_JX[4*N0VZ+(/
M*AWI9\,1E[4(8*?B^7 NRM]GFF72\/T2:[LIB)JC?\#M8YYNJ1N&$)><$!=*
MK+UL,+6.)IC)NZE@!RG'BGP; [[3LORQ@>>Q25]P1SR7LQ@>-@Z3F<,L5,"A
M]="M]LJD>'R8)JUOR\O#ZDFKWG2<BMMWLZZP]:DSM1I.%NLG,(%3??FP^Z-X
MS7%#B,0(B42\* 8GUU@(>Q*V+N:T]3$]V5&R&YN,LHXAX.H^) ^[2/JVTM4/
MXD7DW&Q1+1%D9;U:W\57WTT;5&\Z 8I4?<I)GA*JS_F);E61A\ &:+_&1U9B
MZ$Q^CA5K/*_ +ZN850.(+Y?@1H1#<+.5BWT@4\-P=L= :]>VOR*/Y\V@L/T
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ME"X":'ZE<GVL-B[$#0#'B&U*%:'2[(-]/+I.8FS]V>P\3G90M_#''9^CLK=
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MR8+.'_X@Y_K#AA(WM/WS+I0$M$7L$\]E>_V#:L+A[HVV+I\!EY?JFY&/Y_\
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MBZOAC2$/US-?+ONV0Q_''ORJ>EL0LB>2VKTV')?7S'7O:Q]S?I0/P9TB)4H
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MM)W;+-.,@9C/[0B,/)#ZUEX(HY-E;C[[(<5V]*#[KX3[F%S*RCTJ!@_*[Q4
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ME]NKRHU^_+9"/#[YRB1Q26).G&PR%%!EZ>2QQ,@(DL#T;=YG9C6'S]76_@'
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MWAG-C<N^C@'JGW!O90M60T_.L83J\F,#QL3LDB-=U+Q@N][CCNZ)>P_?Q (
MH'5O)S</:?&RSDXH$1B0 5<75#%JXT.T'H\Z*&3 \)!T&'JIC)D2'90V)DL)
MJ%*#0>#^S@Y74_@7^Y:<_<*[)5W%1M4?/F8DD *U-;1T>?VQ*@:^=)#4 &?5
MD:+J?F_E3AA0K"$E%R-=E3""A 7$=3D4]6XIMYGW$O1$K<TY_6SO+^).2FW^
M\M1M^%;,=.:V#Z14JH0NKOST-+N5MGO[[O:9\,MISPK_[#^,5]<G;W_+Y][_
M!X@R_P>0#+X-F+BX,=*)Y9;Q&=C!61TD#),VV2W69I**)9K(%%MOW4L4TM(6
M+O-0<,#Z?SDCU:Q[^JY;+UMC*?-WJ]ZU39!:SZE/F]1EJ/]2)+IUT;Q'2^2W
MZ[=G'AOMAF/0VK76J5)=^KRHC.Y8L/1SV:!@BU6N;OG\Z:R?S85/FLKGYK8J
MYF;S(PXXNOR(;/*BI)L66&I19M_)?GX@=4X*2&ZQ+CG:RKLA>9X\V:9NMU^Q
M07MH^9$G;W1OU(7YUTC](N_')2T5U1K0F!KO! V[B8-C1@_FUXE(QLW/4!%6
MD)\6TVM[#T]6$1<=J]:=R_JU)/AFA:%K=",R=/.XHO=>'6)=\>P?0//$]F.?
M1WD;Z7KWQH!%YS-C%T&:SAC\VM1IKXNSDF'$4X1+61E4A4C,I$UM-88PK=BL
M[%QRL(RM;&>T_G.K'P+'AGY_0C":XET]/E+3Z8]Y0K1KHRU[8WO0_@2&6+5P
M4]&VB?)WV2V02RTK#U4N2$LMS%%P.?/X!Z#DT)E2O'QFL50[M^H9^A]AWZZR
M'(C)N8MDFBOS0#W"PX;MC2+.GUY$!::,#?OOW/;""R./KUU^A5$_HEFN-5SC
MPKN_D'SR#W#O[<$_P-;;ROBM?X FIC_WQ/X!5I/<N/X!'C__=ELH]S<YJTJ+
M=O/NWK)P2L&NE7(^?W%&E-=LJ9W#N&2E '_ C^J2MT]#EC#\?,X)@[_[;<24
M'R>G(EZ!#WIT5A^E_;Y]4-ZJZ1L<G&[-/<*83[T7#<=-3%6Q_75/J3]V@V9Q
M@R5HC[EX;\.O@[Y>N=QO>&@@Q?'$=#9_MK"CM</4-;7JZ\)BJ,V.'E_&$?E3
MQJ3',I^(\0JCBHO#?[+W"V.FCF7"OGD?+/\#'+SJ?.8^&W04I"SQ86HY^V=D
MV7#(6ZE0KJ_R51^FNBMDDU0^4IQ'5E$Y ?[85N0WV7V=(G^=]]%=,C$ZY0MJ
M9^57G F3UA_ZA5#LS,T0)M#R.9-AQ!MK?=2%L+U?48JP[@2HBVU")L%= M7M
M UZU#CK7\AEJ]WC2TMTM@[0P=K'?:\YV$.GFH%:\;:ORE36:U4+=H?A8-BI*
MO:;6LI#3:]E!9;UF^5LAJ8K)M+)3JYZAM7S"0_*VW[D8_OQY-$KH$RWNKO52
M*+;;O/%4&3N2S-'>-69"8%,J>.B!7L!.ZRI]$TMNAI4@3.T)*[^ROASN+GL2
M) YT=F,/FW*PA^<W;IFU1XPICWE[VSUVJQ8R)\8 +"H+H\#N5^L4WAXJD7%H
M'"&],OZSJ\>Z@IW/1G7\/<:Y2#6%=;PN8]2;VS&M9T&074)[&2D6I&XGF#4B
MB8N&GAS+AJ>7"5Z),RIX5? !B(Z]6*;TK?[$]#8B*O^C].CU[RX]6'DSBQ(X
M>, ^INCRVIF\'")9!*&!:LBFC6W?1AK_%5G4CBC,\TC1A1WYV"5]Q,M0Y&R<
M.>4\LESRO/VT\^'@O?XSR<<Y!:G?YQO(!\,6;PM?5#0>O9'<,"W<N?-TY,FO
MB9_'>FF*LS>?6@).SSE?/K@)=DSXXT0([O/L/?\'^-[0L7.H9[/X,L'O\=N;
MX57%SNMQV<H&[J?6LY.*29C2R!9"L"_;/<TR/4']+.($#@P++R5DZH\@'Y19
M/BJ06@E ?K1B=I2?:R][[_Y% "@>'>!BJD4,H]V>&QM55.)L:^B=ZU$ZF_'X
MVF:"!Q-J+N<VR(P"V?P$^\]E=_WJ_SYX'YP=X\9O&0::]A&ZMT77+)\M'O['
M4*V*N1I,5?Z,2"_M(I8>H/29,Z3-\PKS=6="L^6(5=4%C30],9XC3D=);,WM
MGF>/)MHQ6&>^;I#,2,CE,!XPPN/]%/SZB6GD8X_QY!^U<T9?S51EFU1PI#*.
MBB[EY,$6D[DWQ(M].C37]NWHW"C2S*_5Z.-;+'=J?M#I$56*UTOFB>G[<?!*
MMOH&CXWPF<:?W!W.^YV)'=+NWG'VEI%A7#IJ>SICA!^ K"4UM]4U,G7M26;<
M]S%(+V+]*LGF]MO_-+3NON3JADK=Q\Y.IGM%4;BS\;D.8OVME2;<-CXI7A_;
M(I-2']8-2G'VP#F>0Z6<XSUR>$-Q!HRCZ73*##"H&_[#-!X&T)%XD!YVHSZ#
M ]WC4O0]>5RV;'0PUC7:IECHH+$="!,9)*0M@8F?]P.HA5C7R#:IB+P:R97A
M*HG4>"-4/*XMR?Q_AH0S!IO'9%#JR_JQ)7'4)=75/N5X5+F!W(*!:AQ2;103
ME_R<@KZ,Z#]X2;L0C@(0HT3_@W2* 'F\%ZDRE!@%((+A 0 ?E"R *FW/A"A3
M9L7:<6O(D&2D<8Q16?Z$J?NM5XN5X1-S'F8&+\C)=$+/RL<4H4X/(W/67_R+
MYRB%WCM+V[B/W3W-C0:>)T-R 4G=#O7+]Z&[N86U"6 RD.<C>TK0)6:]4YA/
M;QWK/A,MQ<?_8Z=] 0Q\%?MC@U;<:$%4/,.*S\ZEN3-_W0FT\>9BQRJ62?-^
MAJM K=6.G9G! =5G;&="E I+@IP\J'Y<X)GU:_<SL\3DN\-;+-Z^Q;MLG^>_
MO>ER4U_*FC?I,2J_B_.3J07G%X]P^HW0!>DM6WI*KL8[9'*V*Z=%^D:O>OHE
M7'&$O,CS_.&1:[JIYSOAK.K:*K:ILH;9TPR>ZFODY<X-^TS&.9ULL<C@7_Y@
M7(.4SCNY;IJM(^C6E\I65DK%N23/^%TC)74C-WN)-%F24L+4<K&VEYKT:POU
M>:J$<J7>9K'??.$.)1J;N>7T)$O#_/2M 5K<UO,)Q#H]'/[C/V9=RX*E=B$>
MA0I&E0>= 5="L;MEH&\8BF]LRD./#;3)J%5O0EY>N&&H?M^D\%I6;U3]/T1O
MJS ';LL7WHN\S1[!!=ZULW4?T!3>/[[O7C7"X.;)[[GH:V _M9(#N][^HHFN
M+N(W+EY_J 94&[#UZQ;P.]>Y"O3J>;FF(QG-/;.BX-'&8ZN+?$>F"".V9YV<
MC=2T<N_Q[=&73/@E&-#S2><T(]IID.YGVJ30N&/MI+UX<[G';'L\IFB+EEYY
MB;^1QG<\W0ZGLZ5!(8_<5F>P+2Q_#K4SGG7&10##FQJ^MAU7]<R,M+8_8O4"
M164IQ&": W.^D3=#-*<[ ".<JZ/#9%][?H;#RC68V'UD0Y]F9(C;9*Y4N1%/
MB'S\\0+?#^U\<*B,Z_O3@*,2IP9;M_X#\&1Q/JCU(HY8H2MHS$5.EUS$]G<[
MA6N?W&CW8[/W+)-=S]2S(7XQ<W)B8:-1T8*"!'(Q@.<S<?H*>O+89:)=\>XR
MRZ9V5\Q 2_IH2L*@/RWY0RFC1:=C6M /I?YKQNG\::ZB019^ P2+$2CKI[).
MT2H9X1ODI8-8+)#C+8J8DHA7%I&B577)17F]M]4YH/36EC>+"]4/E2[D3R^>
MF9X?=W@NV!RU]D!VDSV/WI3V8V+7:"5>F2'C3SA (KH4;V'])3Q+SU$YYP]8
M"<.\XL*\4  <?=2</4@H)_KF2)RHR]=<C[@)32 YZ*E*(H0</&-+SZ),&G3'
MI&>.;A950H#Q*\=6U8;28I=3NMR@!6QQVJ#)O6WHG1SMOV"-MS]@YO.Y6I5T
MLE;IQB,V@&"-RI*9R-^./R0 ;.4VO_Q1#[[MO=#[LRS $,(&K74+P!/I_7'Q
MI%F@U"?/+W81!GN9L0%CZY%=BO6YPP[>[4%NF%1=1@5A=5OD2>S"\(O=K]JN
MUT'TSD-&A*>)/,K"OV-JO(H01@/X!'$&UK1!VKAN&T@)@(XZ#T)APFNCO3C@
M#J)R6W8,$":I6HNBK_QE9+C0V;XT4;3;O$H<JVUT;!B<&ME,[26"4<28A3>*
M#[=XQ']DH7RWDNTWD$[2CYT:!FOBZ:<)@?J;E8"GG9EJ$6'?@$\O%ZB_[D8C
MG!3.>0<$:"VNYNU5WGK6:Y]".=2C,[3[8;)X>YM?CM*#X8@=-T]/J.J+/&/B
M#Z5%K\@NJB3CE=6AZCY@,LF'2<W'L-F8U!M>$__'VKRU?*^:F)(%*?<&_7CD
M!%+Y#'_U!['.R^<Z1U3)USMZS@3*WM0\ID;]!"R^6S8J((+>UTIPYR$E(3:^
M0H'+X<HD3)]<'U.H][/Q'8QJ_LX+)&I+;$Q\?V0 #)/7=0S9MQGCK:5+LZB(
MA-G^>#\&Z$P3]7*B$_M@>)J3?SSRPD:O!Q+IJ=3KVV1,>S#99V./9B<*-P30
M$GW-$.6JU:0=_5-F*Q\YF,KY9Z3RHDZ]7VEOCROV$17=?$6>_4)ZRH/F,P#)
MR/L(FC6B7]1-QT^LNO]KNNF]L*?XFQ2KWH;WFG)M:SGQ+O*.<>EVY*#F$^0A
M-"]/_@ZX)L$AU8IG&Y>6_L6Z.+^8<W%5+S+QA,O]XI8B$YSQZ0DEZ:NK /<:
MSTU/=DH#)(3&/ZK*%00&@. ?5UVF-X!UZ+OB]?0V=2HV5\ZX4B 8%4Z3Q]KH
MEG2S$6S5LMR5FOG]F&C+1A\Y>4S[#7-.KFT3[03/,J<<U.+C[\UKFFR4I"1I
M8\!K#K6%S;KFK+XI-7B1"2G]>JG#AVHA0X(,@97RY8F"\('F9J7"4JG9M57+
MM6CI<>D,@<'M<:/MHDDZYJS\4G=MY;'*.G.5*RK3<JM#E@'/\6YT5H/Y([7M
M&A<3:F6UA6<\4T])]:WY,$:AN^/=_'+& O()9=*-)6?OT'-??&7[KCL,?[([
M/+5<Q9 %<-M\U0L8CW;XF@= )E:D5]J1"I#'=^9Y]PI%$\V;4<6FY9[8$_%(
MY7CZD+XI5:<B5??I]'+\^O5$68RF%,=\7>);[X1)V<"QD)=\>0(/Z Y::UF&
MO%'Y^%4K8&JD+2J+R!.VO=>GB"2:0R$PL9'57;,&7G<R^T4/>;_H6AAE#<2<
M:E[#4F4!CN(&Z!Z3YKNA^055,'/9@))B.LOWW8[=0B7>.OXI9H^46RYIV/+D
M39Q_--^I&-.&?9&C>N8V__..#F:Q9X)IWMOSZXDW'*.(&L#K-S)&PS;+5)SF
M*/<+'-8"[G@6%=N0D%?R* -ML+*\Y\N%+T<70YZ!4<%"0WBAZ,DEN4C&!"1J
MO!>8;L0J[KA>+IJ"MG7([U1POE0#/U8^UOA3R^CG\7A$HTW&]%NF)3X="*M;
MSH24!7AP0S.$1W*4]M!HQ^J.#O_#8!;='0A*-!VKM%[F!=RIO6!(24SH=+M4
MD_^16M.@4LV.18@EOK!I4G1GQ[[*+72&*8@S8_45K5\8 A>/W0.STQD%:>*/
MW_0M_,3T6(+?W!L*QF9&ZZS%[AN= :1WXQ1806OAUC#/^OC/VAWM<,,TKPLZ
M4M&/1G\%!48ZJF3%H #7-:LWJ"H,"FOOO%+D*ZT.'%7AURT62[3E!Z@*5D6-
MF 4%:?-#O&< ^N=77(C'WTM Z%C%#,%;!\&?GZ$U9RW=VB8+ E4LQ +C2OV)
M1*>3'\J,T[4/@@;1M$$)%QM+P4,_+N(BA;>)) 3#MC_5$.=9+2_Z<LRZ[TM^
MHDK6]8.5[-%# [HYZ-IS^K"&7Z?Y]P>4@@;VT-QEM%W6 X.9]B0M("51Z<H7
M;IP[NAV]Y&](.Z+>UZ5 8K:COU.1P J91+W-80-K*:6.V)MNR08;C[KLRC.5
M!F%E\7XL"!89DRH>B^/=MQMM/B2W($?]]EWR#!0<W;F'MSOER#M)3ELU JYV
M[C#%N7?^3!KP[_ZH.U/&O9!\N/_.FPLYEZP-SB!.G7SLTL%H;B52172O:%Q[
MDE@.-4)^(O6PRV<CUV^CQYI_RI*G)H;:2M (YXF%9QMGFAO&(7-0_*J")3%B
M:!5Z[:< (@X_71&18BT++"0JHPHMFEX&J%+7+*($%J+[ 6F _T"DCYZRB1;^
MRAD@I+K=#O-YV8O94YP:," 0T=$J1T19#O2EZ;_A/T&.!?4)4]ESM*CT3^X+
M7K]T?FA@WB;4/FNI/M^%;N $6A*RR;M<'LH840'*JMK?D5-3,/2TS=$W<,SU
MM$8\6$4*'?^,%7 >MN,)8FWN 2[D)2R+GY\UTRUI'D; ^/E>,]U'KNNMPWS8
M&:1_?.W_!] 6^S'::K,^?$*8I?N%S1UMNZMQ=OO!N:_'?_]P#.&%!Z_2UTK.
MT407@RD ND0P"K9+"X_6*,FHXB)%!6^$.*71;IIB94$38#F%TKMQ<<\PKVKJ
M48/96@8L+92S"6FN$<L\HHLPSQDT3NRQ'SR0,&GVR"M7%HM=KZH7T<UG#6NI
M=-&[DR^]->&6VBKT%.ERP0-Y50]Y6^I-@:1$/H<#@'6-Q-&>EJTWTMU1G8F1
M/7SL>V3*0,_O[R(&;8Q/;'5.3/<7W:S'3W*-^9-AZFQ:D'K71&RY*-.9LA3U
MUI[1W^]9QP_-+R H0LDI_TK<G#/GNY6WZ1-WE9$M2TJ-?0@MEU"X>7/@ )"X
MA.EK]:/S>A&\6O%.C_/,XR^>S7?:";V3NO,<7_X!6L8[S_*274_.9,.762AH
MH#+N]E#N[^!K5-7U\;*(^%'I+ZF#:[:?D_^[Q;>$A7+:$?X6-F>T5H,'H(:
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M0J6T-C>IQN7A=]+]D!/]^M&K)T!@PQ. O[K^^O^6*:;W',S8PG@.MB/IQ:"
M[Q(>5:0*[+&A16!P<9PB(&N AR !P$4*N"2=)NA3T-W'XRI*3E83Q /.M9X2
M(-[_O 3O"A*H:[IY$*@F"REO<V!\9L8*.]C!QDN4ZWYCS-$=Y%Q)4M;Z1>&
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MR0'A"A2\/9='S%@I_QY,].* B:F#@0_7"6WYK']3(FCQY%(X9" '!WHVM,(
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M_2*5H;$>/F5L\I!XLE/8V^:DCN:7:TD5[4=QZB[%A+.S+>V-Y&E (B4P(H8
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M(5NCBT\ V/^#^;>&'+2N_ZX.? )4!3]4A+QLORR0<WM01<MY?_X?N>=OG)\
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M?AJ/B)D[]S\GWVOW")^ 7(W?'G[=#E_[!!\=[,XH@WH?%.K570=3AR]@XD]
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MC19;:VH3;;WB.*?D7>82Z8UTD#U#H+R)I"7^."3H*')N+J(98<(=<VY@=#C
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MYE2.&6*&=@LVM+<X'H5QKZ&W'"CJ-?7DG11E'1DJ<^,&-=LH^L=SS/=:$<,
MM/1&JA. -H*?B&DP'CMNF#?M])3D.BZG@V0I3,YWUL:%B=$P;VNU?&L%[ 7P
M&_)VM[3=3&C&05Y,G[#N[DN>)\XD9A3B_3KLV_Y:F8SC-10R]'T.3\GP@$3$
M@DM1!X?I4!.6H;8=UX?O; '4?);2@U?(8)^A,RHAO>W*:*0R'R)[%V2[;NVO
M#G+&4]O^R+X5_>;"IS-<Y;R(Q^CVOJOE>BTE"/-WJ<IEX&1<(8_/3V:JF%*2
M.-_X+[%5:J];EVLG/;/"R-V^@JA?%N='JU*_%[9B]LI/ZZ%X??LAFO*#_MR[
MYQ[?RF.F<N%$$,UPVJ.:O(OFKLP671Y#0TJ5YHZL627EU"2RAB75THV5/$0L
M KH+H?G]*4J8:+79Z^/JV)#B6R^V:=G88&)UBMK,,Q" 0P=BBJSVM2*6JN0Q
M>P*<P_TR7IO[DHG>:Q4_ 2$5?DV'K"<.# ,9J==B[^_$<I]C,U0^M^*[E^N3
M]'L"-&-S0PC]R/;]-FQSCSA\"5KGM6;4NOZC8TF6; AGFWO1F3.IKA%7=H9\
M5?3,1?6HYIDC2A"$+]8DD%C]A/@W4^$D1NQJ(U7)@V..Y(?M8[J7!EJV@MPJ
M#RH#28?V#:&:14UC';HT,(UD:O=!8\T96')U/ULQN_*1(FS)YM9.S(562<E]
M5BROE>Y#7K4E!,38)+2D"8U/8F1/9NM#*@]6N]MS)%6%$=7(7BZ-2YU^_,S0
M7_GGDY'ICF/"$W!#5^6!3A-G%,+P&/I/3>N\J=*5?U'\W\.<P>OHD.?Y+AW>
MB]%[,8S>&[<Q-300:$1$FWNA6%[:K7\9!A]#*K_FUZK:A4:J:$/>"9C([HEH
MOL"K'F%_:)O^.M3\-JSL +N&LVG?Y.#9>]^C7L0EG3K1.VL1;:4.>\?[[!+<
M#\P*6.0HY9216K](.BU0<4B%,UX$IK9.+E2F#6&/?R*94OYV47N[LKC2R:[L
M[HVQ)Y.9Q79*7X?NA/_IP:HIT^W$9'4-@07IUPC8)?.B=5L58453T]E$NON^
MKMT^*OO5P_WK6ZZ])B-A:0AQ%A^40#&/$R2>1M-IL%D>6:*OJ!A@'8"K*][U
M?->,GR0')JD;^6*64S@U'=-CH8SMY-44$>15;]:XFDHA921<QZOC9\14?M\:
M?:S<:'Q! [J( -$;6L2&LDOA,S-4_\6,,YPD'8QH,^.5-5,[6K?TOR>)OUC%
M3[4]#6VE'U*]D$Y<.JC84)B&/T[H@$>AB]R \#-.LL!(9]<NLH]QQZSRRB"V
M9!=A?CB:..,B?(^3HG];,0L2:Y TR-AO-D/Q<Z<R;?U=+-%J=!RC(-U:.I2F
M<R&-:0&!2$9AT"<79L%.YSJF+_SWZPG/G?"*?_<NL.-B%92P9V&LM[*)H*F&
M22B>T[O0%*D8HZ>'>WS?)- W>N6C*/G:XE.V %9>A:RA2<"1YQ0+3KWVPX=
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M;,C/ CM^MW6*Y7(%+FZ^4/ISQSCAQNDHUL_\UU<:SI]?+ST/;VH&[7T3C9^
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M'4*76P&HM7Q$CWWDQ.3P3E%FC[/ZS+!CVZF&[QYZ$QNLMY785470M\*E])^
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M)165\6!+4L6=7&'Y"\*;O5K_@,?.<VY@:?B[0EHK$>. XQM>"FV=51&9(*<
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M'3!J4>_(4G2^36A"E+<(CTX(LH8-(>X5>=:7E656AV%SF#_/)V^_ G#=8>>
M[>4JW_Z(_T6S[:A8Q^'?SG,!UJ+YS([_K%139=';6<NPMUI%IN/P7%@NK1ZZ
MT>5+69UH#[ZP9/B-6[:$5SIMX2MM(Z+*D(LK11D*'!^<^XM;K!&^8*_:NW!
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MR&O%C6BFABHVV_(34;XX7"S!:T\KG@&$CT NM5>D.&5C<L?<,GR\2BKW9I6
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M(*MDZ06E 3>'Q>=;08HMW &X >G=;^64V4$JLB,9DQ\YMPHU:>>2WV'V7 ;
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MSXS=2:7/;[!Y[((2JX,5FEU_#'6J#4"/N"GF3HZ@?V8$@$0U ,]N_5O= GO
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M=[G%3-&IS>/4S+)X-A0/[IE]YR #Q,R89=(OS38Q$X[!1Z'K00>&-;OM[*<
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M9GNJ,]U;UHP\_Y]S^O5_ %!+ P04    " "3A7Q4%D+;7PZW   '[@  $P
M &EM9S(R-S$S,S8P-%\Q,"YJ<&?LNP547-VV)KKQ)%A(<"=HT.!>A! L! @0
MW(-KX0Y%! E."!#</5B@*-PMP3VXNQ:N5:_^T^?<_OO<<_O=?J_?ZQZC_SG&
M'*RY]MISKKEDKF_N6B!_(Y> AZ_D%.4 -!31H]$# '+Y8;*LEXTE "@K ^P
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MG!DT62^L<]EOYYU 32651RS0[[MBG#V=6GPS\[,JPY]IIY?(V$![85%H%$A
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M?HWX*+<VS8C3'G!_K)'J_'#O9UG>C5NV+FAXY[?$:7N4Z$6AU++15OAJ+MP
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MK?QH\46ET/F)H4&5T#9K8UI^@EPWG\Z=&-Z##)7D@Y4NYG&N;&C2U7'VMU_
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MIAS)\U:,T80RE6/[;R5,J%A:1*Y)HZU;,<*%-5CD4B$W $7#2IJ]*<YACJ[
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M,J@W!+O<(-004X[07>A*/=GL6LH->X_J%.-XQINJV@3?KC@B8HPAR]A:^N5
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MEQ_>OE^Q(4X8E(VO>7Z*!#3'SB[*0I<WF=U\OOYHE-6SS76PVO W-=B,SDP
M8\T+L(WZ)]OYUC%*?X%W2+CT9GK^8L3S'/!;1P*X(2L$= AV&Y!9VPT)[.?I
MW=3) ,8J8>=#%3]EAE]+&!8.;6<H_5.GY\77I3+&>_;:B0N^B5'V4/ CO0%3
MBRQ\N?O9BFZE*@MW9DJZH2N*TB8*&M#@";^H>\77B<'NFW#F@:\>+U95)P3#
M\;7\%5Z'<2$&*PY??#I@3IY&W\<,.%J+;+S,A9#=^I,E/.Y\74091!1.95)
M=]X7W8&>B" C[*1FO7T[ZE<0=\X!SMB]*5\/ Y6\D:JL-#*&W&)L.4A2'JZD
ME_N#D0#M9+U#TZ<R,8F;M43P+1H-Y'#=7?/XW:TA_/JEFH32DR]=X;A4;U1\
MD$ ?I^_I@-3?=$O]H;OG(TIWW/9-^6;R/W1[GP61'+^_[((##2AP]@7H0 OH
M<@BZH&L8VDR6@8>LW&>D98DQ=7K^HV;M&@D4[U[[JIWIO;^+##N^00)+=#IJ
MNK@YQIP>#_R4BGFA+F.B45/"@17BYITB !KLPI> D"G=NF:D/!,:]A35PJ#1
M\X5'LLZ^3&^@2?NL*6[%&1. B.#X"H_TX6"HMMN(NI/_["XKK$))1C2ST8_-
M:N\=@OG0 W'BW;KT<8#,1_!L8&*\XC+Q;;7BB):(:=1X7AV6HODB+B^K#8ZW
MZ4D-<.6$5BYKKI1CK,C$F<X\\81HYAO%(W&#5S<*)RG/XEJ8A,CNQ]-Q\^'5
MU!O.M_SVF_=\4W?#D[1Q53D;#3W8WG (-0,[I$C-S#^G?*LE6Q/IC_5=36G%
M4'U]M?YQ]6B/+>U+#&S2V7N&(47T.*>F:D.9._S^!7UPRTJ<M&?Q$K7?AV):
MA _&W' X3@CT7?W"3_SW AU&=/\S_7;F.3=<O,-Q)[P\OA&^;H"<99S $25W
M5K#KEG,VC%=A ]#1@WU$Q\9N?=#0M-^0\$#4G'^YIRJ_O0R5K_TT8G*G%/MC
M8<<YF+\KN1/QNEO[Y$D5K<]M2X-_!1[/+V_#TA/8P(43&DSVG>K_?9^WI>T$
MM"^T'QG/J1+?2#38D/+2-&,3M!>3'^QX\KN.880!5?\"N^%0T75*06=3TCC:
M9Q!9EM.\!AU@<L5 !#/><JAD[48#B4,O^8<ZBK8=CFZ!>97S,47K_$D)79.=
MT8PJW2W=8(:Z4**$B+3F)$></%\!^6=9?71?73HP[ZS1QE%QVF7J6O!VD<3-
MX1V;L(Z^3>(;):$S*L.%)SD4/WNUUO"<M1S],)9N^HH<RR58LX:<^9.8$PR%
M2+W)4Q/>:3-]<5$L^Q FQCQ[>W@=HI_N< ."_+Q_=''7B 2V7T.W!3<6JS9O
M8S(((;-#B*]]1G'_\5VV?[ W-A0),-S)()ISD<!PI,_=/U4(8+&S97_[\RM4
M 01((/;'$ ('"60*^D1Z>WYL6;.O0@+OD< 6OE&.8B *>@3^J^OZ=O5R>;D6
MLC1*U _"]VM:3DX([VY)HE?M(MEGVQ,)RW^GW& P*3(!_BNC;$:K6?0($GD$
M"?@#9,N@ZC;Z<AA')^H'F_5OOO0@%>DR<-<D@J6Y.KGC.6R,"5H/\\KW[?O,
MZ,YY[\JC:,\.K#S&>>HOQH'/-\]5:HHI_\C-(!4)\*NT-"I+*=<UQM.,+K#$
MQV/K!%&TTC:JQW\_K%CUW:[;W%T>HC+<F@&%%^IO/9O^K6R_[PR6R'_^Q$)4
MDPU@XA:[*%<HDWHU=6M:S)4V?+20@14T^5.X)E?O962%:S7+_;9!?L,@_1:C
M-0ZWISOURL%U>0,%MN>Q1KJ#P)?[VNR_Z:-[ ^6ST(NDE^D(];U<E-%I: ?<
MBEPW]+QES% 32S/X7%3BB,,R[$N8F%QX_A:EK<TUUU<AK=@O6FS:&$QK&2[^
MRDX9%%(;*+!0.:2"!&;B_YCP/U=\1=L6^#L<\%N^D8'\E*Y$ A4&D&LAO>/B
M,^,9*L0K_.B[#ZM(8.3'5+QVN?RE]4U_R]TD[7M98JT>IS]!1[0+5.IJ1'15
M^)^'FG(7#WLDG!HKO__X8!91@;?DWGH8$0; !Y340R_)-.#XFQ$\WQL5'[\&
M_4KL(J70[-7!I.A^!@SRW^J6F\&\F:"?-U6YM9X;\J<54(>=&#)V4CHT%1MX
MA;3/0!$PP"WQ#8CNW0F@<L_D(Q"!1S=5=#KAL$6.SL?_X9DUFO4?"ZP<-"X!
M*=)7++:MD+%THZ'34!9:-Z0>8N ,.R[!GLG2;9UYNXD3JU1XZWKIGKN3J.>1
MM<+#<C!H]<$+T>4T2T->@A?:*T)_3,"V#=EMV:&QU_HGA'E$^+&%O/'^LO&G
M:Z'(<KL6\W$NU+83HJL<O/%498Q.>O/QN$*"]FP6TB%]RXL$LE)0628WY'(>
M\%$FV5@\&H;@0;8L42 1-P,A+'\K0-=!=TW1<OP"!5<CAW%R1XP<D  ^SE$/
M(AA\&U.'!%;=_L]2]$]QQ^Z?FWAW%\'-VK0IF]:.=O5SOGBZ@7_T\^$^(IS+
M#]QF*Y-'D"9^;-E"O?"E"@(GAK2/'GG>84L=:X$13[[1N)/T(H$_5T5?ZAFA
MHEAF#^+5 !+H?(-C*.LB=53=2(,$I*-OXU$V0W/^6XUH4VH&T;=</#B08110
M9T9YN\*&!(+RE@ZO\2!KWQ=O90$?U?\V$!I+7-JM7+RO1@(/9PWF=P,,GK:X
M^G]QC<C""$S:L6M" L$?+U&Z9(01"@9( %[_FE QNW$604FX''V'MWC%X(H$
MNK?^7:OG_V+,]=.)+U$]H=KY8=-,/@F:]R1F\8S>JY+_A%>L8@CL]'6[#@#N
MU?^4,+AD/#J=+35N]?30>C8@,*J$38IVLO3J4^PID-%>#&FO1$U'5D:7U*4P
MY*ALIG8V@\(8%O58_L</&*G:/*[H 4O,5;#6^WRJ-\[5 )_B8>OABSU0B'+N
M=E_NMM/OO(&!T?9[CPU_F<?^<#WAW9V,-!D4$%^U[H\+]Y;(?[L@XR#"X'LR
M4W2IH0\A\K*=54]@#E/$S2D6TG81?2%]<-\@K*%$<&9KJC0_$(Q)8(+3F**R
M.$5<;'_P\#)V'412,\Q@R, Z*F%!<_WM8Y)9/1%GJGFZ1]!0#:]1AQ%//BQD
MU9!@LT-XBM^KW>Z;UIF>-Z4-R'3S\W J%H;GFV?/NWQE;;B:(1.A^DC ^+/&
MVPG.:D,^!QF-5&F[>UAK[/H4] " ^4410/O)\F-/PGEY0%6F:6+?7:$K_OV3
M_0VYH-)>"H:15@N1,^KS4@<YQ)#2F"//F>@JK+HFHH_S!S4[^[%B^;V6\>I#
MHDNK3A [;)SS@""G>/MB*MD"VJ[$2>G>6)B5)\L4S,C=>DI.4_Q LJ0#P3IR
MJV;'U1WB>?XIZ+9.,]LK7:B5GD\$C^\>(V/L:.U01,8) ^3W9@%D_U6IE97#
M:CF-5]NII.W!K%)M945-W-L1QP_B!G*'#,?K0,0G]M*(H]]EX!X0@ 0^:6L>
M25[<,J>S3?H-D?Z6.?<W4[]YJ91@UL@]$GSEG/'"WQICOO#O)_15QWDP:L%_
M1"TXDUHD<&H/7=?<::D6OOU*17>#A4I@<RS*V<N-HH]&+I(@-]\E47ET:=32
MGZ[68!R\8LMN9#QY\Q]=O?EG+G/M6B#)Z+2S *44@V*+=!K(><PB>M4,3*<<
ME^Z)T+B.UHNQ8?3;!U!Z_>I0B1J<79'M?-B=IR4P]G6?MB? ;HQ12V?"$%8!
MD';S^=MU6<'O^L5H&UB*5G09)LPK\$G"L.2KZA_U2GQ]+NQ$XJ+B)3HDN$^Z
MSZ'7.?7@T;O WLPC*NKHP4"F/WH^A,H_BN:4B[>?#5C=O?]N:U-DT- 0'MIK
M;O7Y#?<H>>95.#J?EZ3=<+V:+!4'Q+#E^:[K0(O5T!4#B!8)P#+NGB8TL33.
MGONAQN_Q\N&--Q(83;(;M?[;J!!VHQ)\U499U+ V9-P13\";_&-7(5>L"T]0
MY[/A$"+,]G*A"8^U?:@8%:A"I%"CQU%]_>=QPIAKL3R\2I+:GT("=MIUVL&(
M@<43/LAL.6*RW*6<E>A6RT_.#G$EE;CV(8SM.^&S__@_)O\U<_2"F/6G;=)9
M*,M#.;G G!MLE:7!F>=3!>NS'VF?)Q8!$0_)P\["5STX6<5<VJ=\";^P,C$X
MSH9NTKTZ.:^9W(1W5WHN-_&T'WH[CC!W#6QG#.*]TPA\$8,MU7!YHE1X35,>
M8EZ5V%&CG*\S8&JSCD92/?PM79#:I&C[SF>D9%&NQG,R8>H=QUF5=^P;<"SV
M/8+'+5))Q0BB2:NI6QZ[PH5[I"LO=MEG#WY_+WO[OB%]0K\+]* 2_B+)O*ZA
MHNFA *Z[E;A<%]6E#L9)F7<;HGK'<([!PNQQ^X(@S)=&#+>)L!/CS1>1Y>0=
M!RZ$QQ*9#>^8Q-IYV77M .-RIX_Z-*1+=454.5-U/DVQDP=&[>V/GNJ_J,)1
M51R?1-04K(RG322@T?VE>UYM_"$$0TVZ8%J?5&@RYH6. YB;OHXV!/V[FKH:
M";2T*16=2H'Q _,VM0*)_!+'(((/TA^$!,S2TY  E&/4;J#YSQ5L&*/6_\NV
MW1_O= NT4-B*B9)1?@W1&6> UBKUN8TIIG>_%0D5"..321==38U TU\D%-R=
MW?<1-UO!GLJL'7UTOCUK>L/\TTFBLAH_\\,BPYK]Q7<J'B)KV(SQC)\\G-"H
M:IS.NRYX^-OJY_?TG] 9CZ^IO_A,E4_/S,R^5,[E[6:^FHY%3R*\B,)A70CD
M_!MR-( BJB"$7894\F'^-61B%N/''94JF_*A3P?YGE'4XE!/RN7!S6[$-1M0
M8/833@^9L672\HUL663S4X]*JA'8[2_G&-\/;%L9D!/8UK^';?_ZPR">%!7J
M[ 3!R>X^'$!.-;2[S\[E(Y' 6H97.*+-4^KZ:<FJS^FS#%Q0"2."^NY%&%O9
MV-:?/QX2NMREM&R8HS:^\5VIT;H1U8TPI/\G$G!LN=%K^M68*@_7A5.4WZPA
MC+\\8,NND&C]'YB8OW$Y&1P4FYE!OJ-LM61GJ'3'S>&;DA+Y<E8.]HA[.0A8
MHBY3]1#<]6G?B<S[)4 &54)(Y#=J6?<PBN(.O9Z*]ZHQ)K5YI^!.WOBT<-$.
MS?0&DS2N$9;B8^%IAGNW&N$SN@,*R;PD=9;Z:!]:!:T\[H_U3QZ!R9/^I/#X
M.!?AXILZV5S$U4\INS9)=+\LY_T,^1"\5OUM "N)?'N"L!XXR)Y+$%=?7.E;
M=F>,3A&1G(L*&1,"=%5">=<TL!A\QN'[2+:_YDLNLSZFZ ML0D>;B5U3C7F#
MX[3'W62>XO:E$M+>17:/;4D=*YYUL,?@MQ,#F+)7/9+WJ#>:DAN%%G7@I&E9
M"URY/G>CRA;$GL)3I.BBG)8X%PTJ&"1$P:*;F 0N=L/-5/."@]&%WF2)PC/F
MGH/)[@-]58TQ^\8KCCK8<VB@>$,D4-:'H&K.W;=# H:0Y<'VNMC5?>K+1V-=
MOHX!75Y%Y]:8NNE6'C.QQ1A]CYRP(=3:RD;\-OF+L[</C[!6=>8JA\M+>0X=
M$DCY0A-]ZNY'?&GH,*.XLGTE*=P1P%H-%X3VZ;>Y6[E:\7[8^77\+$Z_&0-H
M?22J?H\^1GK7 -*M>A73LN<ZUG*>)Y]UZ:L"/\]:U=\W:K=I%"]7MB(F&ORA
M#VV%22?Q'M>J7P+PM/3X/J_-9?#'1J+B2SKUH^[H<ZHZ/WU3C)_G1;F_2"T9
M"=;<-3<I5@(E9_ZQ %.EK,%7;$)2Y[C12$"NSTC3J.3?97PH](A/YYV(!.H[
MAE%QYO?!@W]\LT0Q: UURK1+"?ZY[K_/WYO G<G&(0FD$_E?&$2?2'$O*+I&
M6!T\[5&;#)1H>0LG"P\)6M0<]WMY;>"9,+;W 9_#&9:FB(Z^NJ'%F(,"&OR[
MYT&1J2S*-_UV#?WD]JNU-+L]U7?ZLHVC6$.AMQ8K#?ZR'2FQ]H[O/A.HLI70
MHJ_&[D^E<TP_Z?F2HFA:;0+3.,O$T<3_O]AYS[BHMB9O=!,4E*CDC((@67*F
M 26)B"@YY]3D'&T!07(4D(R2<\ZAR:A(SCD'R4VR@:;[ML_,?>^<<^8^YYEW
MYLL-']:'[M_>5;5J5=7Z5ZW:2T]V3'#G/H&K<O7$EZB&7,^DGWPE9E08 9V=
M>UH[V?@<,02<2T+C?M+)#P4KJU)_Z.$VFC ]&-J'17WJ$[\HFWN<DP<M7_GK
M*>#T7TX*_X&23>#+2*5?H=!]"C0<_Y+:+EQ1+>&(?O.ZQ^@"#YW+C*H8T4Q_
M?@_7.==A.-[>1;_BD?6'.KUO\OXB"N!GO6E& 0>VO]B/EV=;D):JU^[H?'WR
M4&-C#10^'#H(668]0<2JR9$%;/UMR>9/@VH.,5?6'NS*^J'L8<N$[!IN?NS#
M^)=\JI7;=+#PTRQ"':_U9TU9:JW';M3Y->Y(Z*LL[4A>NC@*AWLXO^1\VDBY
MZ+K=33,3G/W=\[J%RLSKA>V(4AP2[LC2H@ OC,PG-H)I864"'-<1FG*9-#;T
M0@F'(7<56><%/8IWXQ=D<@U5S' SMT3H/H>B )I@9IXU6ZOCZL\PIN\(P1*X
M#U*%>VU[3;...T?\V;"Y0Z*9S4M^^DX&+ DS4)3/,8"/$;##T=>#9%,>?%11
MM_AZU7%NS,ND?OR^H(LYO=N+[RDQQMM;3$Q,4VWQ=;Y^LZEH,\S.KA""HP,M
M'\5-M(\G<J)"Z8^_L]%)U+_O;]M$?RYX%"-'ED]>V4'V*1B044FMQ6T^H&Z%
M)0L4<%AYAJ9=+Q[X'T-\$]IECF,&9?\+_1)$'$TPP\_@X\,]V<:&:7.8:3>S
M=LB<I4<RZ_W<8J']PR<^SN'G>!:)7*9Z(41/I)E-1NI%01EOI@5;0(0[X[NI
M:8KU(X!^/Y7'QHJ3Y*!JP7)WD4[>8&.B1B.;@ I)T1E[!_';+^\X1^5>3=8M
M,LD$L$X+*G,)L=&8*GD[Q98(\;_3CDPG_(CQ-GS%3VW+QI#E&''%75 X7+2;
M&E]4#YZ.QZGKM%&-?]E1W$;YV.Y@8RNMR NZQE5?XGD[Z[CE8"KNQ<];TPAF
M<MCE#F6P?[!+$Z6(1.1:=#)A/<>_>(Q^F^'/N^@UTU^PKP^E:G"61AP*('S[
M68Y4R^;L#\77IK?_$=H2_'&??<D$+X5'3M^<0'B^H8U?F][XOWXF2@IH":X=
MW8>8ZZI8$>27/)KLK;GDGYEIW2,AEF8N7 D:XL@K3BTV&,A94LAOC(9E.V-E
MK?H7V"!@;WB"$^F&V8Y[DX-?I*HGMU/ 9/=HOO MZ,MYJ:O$)9GJ.0B[?NT3
MUZJ<3JT(K:/34AIUDY0:U@_2"UE;/J@>)HTKM8W$S]L$<90 W52B7RN>ESVZ
M0@%QJ7>[859A.<?U,733L^9MS4V-T6-#8T)WQX<?=.6O=T7G)HQ@@EV:B$*;
M7WXNM/%1N8BQ=72H-= E4-X/[]1=)>9K9A.AJ6]BDNQ5>GIF1*^G2E]!$6X:
MU-V0RAE7=J)OR"$;\?@VZ_W8[!(K+$;:0%Y]4&\,-5Q+#8VF.*Y!/<V2R[.M
M>B;.H#@(R:4:]\V8$,VF6ER\%U5Y0O=;.G1Z'M%S]2M<X %!2&5]_=2590&I
M"[\"P.H7EO1*N5Y:(BI[6AAFUFE(-@Y=O8L</IZ*L;G((I_1&][0?I9IIP)U
MLP^^_+AB3D_X&&L$M&H&9T)^X"%" 2MC1$CV&+@V$A<%?![H1@%P@2 4$)Z#
M).L/!.VH'*, Y-T5%+!FC0*"G5=BKDC\0"@@L!$$3P7^9Z@<\T2W,X^<0VAG
MAW/WQ/S/./*_""1-*ST,.347^1[/'RCRBVPKR[$&!60U@HY6*JI!J_I>3,CW
MR[^YEA,A66+@6O2_N0K_YLJ!YAI67FBJ;YIC-O<Y;2)'Z8V:+@/-3?LP\BV:
M/S0PIF$6!0PO,/PZUIIE."Z7N(<"9!T_H(!C+1P40** X(C!AHRDK:( !%DG
M"NB9O'$P0#M2 SODH93PM7\6X@;]+^06PW])GIP]EWV&^410W']#D-'S)@^B
M@^]97V.BD,M6* #D!%GN5)C?1P';AT37<([]_X3M7Y1_M=""<[&INB&# O 8
M.AG.1+T@*.!V+ 2F#NGJ/U:X(31D0 &=N0P(C7]!HNE[IYW_$W1&,/Z6BNM;
MD6.*H ,!1?.ZX_PPK+3@6SGCGU_+3ZT_ +]'.X]J=]89,(9F<!=T7& L"4&2
M@]#S=OD];P)&]+P+T487@S8ZVE:TT04I@N#%)T3P9PA1%"!-P(,"@)S?M]2L
MDAQOWP "4 1F#.)Q)3WT;X7RQD$\?(O>F[-OHW'=.[03!S,<A\%=D>^HC9 8
M"DA2;2*CO_#]L\>T!B'O@0@A(UC***#C,0KHBOFS7)PX%>B__ZS4*@1:J4^3
M?RO5!JU4,D/TBN)F?0#M8.2A*9-"5A7^+!LYUN^O+?_.7TLA=_U Q_;](?:/
M&H^3@CFCH-Q7=IRJ0]U%NC-_\5SIO\JA@."$H!=W\_?B4J-EZD6SOKN.5B,+
M'*W&6TX0F "DJQ$]F3OMOR>CSX!0 ?Y*Q>!6W0^*I"H#G4':BU/&>#93IV\/
MXV*_*V 3N^"60_YLU>#L^OK H2D./1&SP"72>[VDBF1,KYZ02:\ MP%2C'\T
M_KF^Y9W2DPV9NN#271KMYHM0_C3P:*:#V0+#G?VV)R#][:N$66[YF[YZ?J5'
M(3EV@I29(\^CW/.+E0045Y\2L4T<O:GU7_Y$AHTU!(@2W5O<E7K2:GTV[QOG
MSIT2H2Q3=/-I_KL2R/IU+N>.>CF54M\"L3#UN9?&&.Z4U2GS72P1R@7G;_VV
MI]Z(-\?MJO@RV<N&_5P9Z0^90\#>K3M=Y7Q2KW9G#I^ :T;.O>OT*=T&!GRQ
M8^ZX^DDTL3CPA@X/1IHGV1>(=(A^!69^@ZG$YF-QU;6??G)$88(1X*:'Q-A1
M7(8B:SCB)#\"P@.]140ES(]Y)]7DZ#CI'/YE<&T.KQY:?W5L66=A=B]U:ULU
M\[$I/FE+K1V9BR(6<T"\=$5*\LI1S^W9+(*O+37I2_-^4*,ESXM!?R,Y\,O:
MHGU/$^=)IZ)BC^FF$Q<$ SS08[O[?OE+0D?[MT:NU\NGX33H=>JYUT)/F5CI
MQ.L+/O6-64(!Z=.3U FU/AKS.606P5^-G63FO"MXCRLN>L0LPTH[S=8XM$UJ
MKE\6.!?OH@!P] F(,5V!*O-UJ7X)5MT3#/K)@JF"$G\0FG#<Y$U-^"B'P:4/
M)&5C\-AW[6X-QFH*Y>.5B'D[X7$^=*A\;@1_ R4&[>@E'#J@@)AY!R@Z$="9
M/OM582_%"U-I)<_;M^/9GG3;;J\.'!(FN#U.KQ8$.G*JWN:H>>0<$&M; V]Y
M,^$VCT&W6#$_=[&VF$N>K)G_D(LYSF_ RMUX%FO3TH()G]#IJ5=JF- 5:4VZ
M\J2>$4_*NC):%CR^H-44TB<;:?-V/-/W40"/KAP<!,,^& YYI)].NS2':-_^
M!=TFVQ?3BA TX)Y72'N32?,I)+% V=\):2W.$C?2/O[@E<R,LAGS[6%CEF9X
M6(EBL\N,S'T:N%5;N/K8845 @/G\_?T@9HK7=UR<) E$3=GEY@<K&A,S3%-5
M7\8X7"#;K2*%T6$VE,E#@I?#>,7T8GKK%T,;"A M$.Y<#L6#TM/$U:]3MM5?
MMF>U'AR%7WV0@R9KC)16'')N5:=N8<<KVTR4=/68%V%CXDJXL)^SAA5F?)IR
M#VM0;80M!TE1P80#A]INVE;G"Y&CV*\[S!KK(8(YRY]"'JU&PP*=6FDKUZ62
M;4J7]1=U>X5#ZI2?95#EIMIP/=>+U;[EG\!_WR-0Z#:#V$9,&O69EL3&-K>E
M=^+>RS:%U[XU]PE\U=+VEZS>GX=*_(Q4W5*V] N^A'A=6XD:?3IN2=MP3#[<
M4LZPO,+3L8CHULT;Z'<SUC:-GY (O?ULH-FXA4CZ#M'NE[J=(EX^&IUV[:,9
M+["ZF>VJB<RC<D<,4V&%E$H R_-(B)8>0T*-O,:?.8$##E8/5;!EU?+F<N8X
MP/FF_^(E(K[)CD4=,=,I=O;JMEQ^C;^K.YATB7J2Z[Z;9;Q-;AV;@XPQV<6+
M'TISN#.4?GOQ4G9XI<L"'OA^@L5LS2XU#^*GA8R?T.3VS# &M?SR'<)AI.<P
M# =ZD$L3D.IV=#C&S:S:]E[2FFF=!PD[+%RFG%[8#U,NMH"ZHVWEIQR3Q"_H
MJ2<IYQJU7RF!TSJTHT:W[ !@\7KP \X[5;(*M-/*E2XK,7]'4O_N20F;7%+6
M?WXM<Z)%0@)E+M>[DP@2>J+$7>-/&UN,GOI')5LK*R4N9Y(#UF]V/P@1[YKT
M\[7]9KY1HV<FNR<\2!?$0& ;[I!>^M6\;O 3_NV?O$*XC(<W2Z<!7W'"8ZY]
MU9#?KXT0#WWZ,[:]C4Q/[1"++:Y;5L.S#1)F'F@,0BA:UOROE--*BO64O'.6
M]&1$&Y*LZ04^00;XU-\M?]!5F=4':YD2@'4_/*T+MRFKX(X<YV2CR[VMQ?RK
M8T=DU_:,K_28N9"2,YP2YW4NUBX1XS4U3$]<CZ.DC.>@_?&HGDYM<UU]3?CT
MJT=<)E$A-UG+\2^(7<37);3J)_64$_QE?W^#_*^FJ_^T5$O32RW9UY#7;V\+
MRRGMDC5GQK]E,L.@NPE:-=J%GL+0P,R_ 0UR#,/D .]E!,>-%O(M)PHXJO]W
MZ LI1F.^WJR;BV6$BL\CTD.<#/3F#IV$;*\-(Z\=_X$=KRH0"!T4L&S_&V)]
M49/K.(7^\<]1]):* C30^#,"='T A:>>/7_<2._YYW__*A$%EKC,^.;8F;BO
M>(A\O.3L8R7:*LF.\S+JQ[E_:+S1*'>G458N 8/30M<S#[[+T#"DRMY6Q&K'
M$;1L@I):4R?E%-GHM@>Y@@ES\E*>@;TB1Q6K"S5Q;+#OO9-AF'K'/"7ANAJ%
M]89<K*_*'NRAY1Q5_3PZQQDX&&[G-[CE71$JP84V??2\H_ST%SN="VWOCMOZ
M1/68'S&?:$BSWA51&W&_J'A6^RSZ.W9HC7Q5X>M%Q7ZJ[#N%7PIMYWKKHS!5
MO,GV(YCL,(?ZP/DX5)NF\HR^<>$ 5,Z[(J:4J1JF$.+> L:UG[+771(OTQ5R
MK"MT3#29D;X9I\N.FJ%B=? NT4U&<#,<Z$'1D!D-46H0V]<\<^W36Y=ZT8/7
M7HL-5/U40X_UC#8O(9\D#V[<_Y)PNQCA^;'YK\2$-!M]J-.QWVJI.6WMK[>T
M'KK,Z,,#?)X<3#7/_:_C'+LJYI'6UU'?'B::I)O3$VB%+PTHC8XM>NC-S$DS
MT9LAJOI*HI7IWQ'F3A9O(1RT?_KXJ:  ^E/;I+B%T\[([R)2O?5!^]9[#A=&
M!;LTX+GU-[_SN]+RC ,RKMSW.6V]"Y&5O;'S9MS]WU]),[*,X&*[D::21ZQR
M[%$ZU+*93#Z(7MW2JYV@WV_-YZ<A_]A"(4Y93IF.[]91L.=3.<XI* ZEG+6)
MA?M,2G2*-MDLO7@RWTP>"KA&FJ2E:SH&N9>1(U6T>O!*;7S/[ZPJA"Q=L=V"
MTCQ4L#"5F!K>DHU<?U3F0"3;VQZTDD*P'&*2-+5F9LQ9;D>C9F.I9U=U5[W)
M'<N[<QUX1PB44;7R9MM>D"O1*GRMCNRT?Y2X$%O-V/6INZ<C\5*:_26A**T6
M;Z&1S3A"9F1EM-PN#RQ^J=*7X(@1LLMFP$SDRBK*>[H(F'8V" -'</7J/</'
M(1(W29(O*-NP!'AKWT$ZOH%>6^N6H  ]-*K$R4%"R[,FZW:X[(VK:L*GAIA#
M<%\IT%H_*<PV!B39=1_G-?Y72WM_&%9[:TRK;8KZI15WZI)_:+^]-/CPP!\V
M5LM!TB.6WNSWLD%78_(P14".)6F AU/GJZA,R'ST7KRD^,0W0RXR"AL6E_9[
M'WH&<G9ZO,#=L-G+)W%/&J6L8["V.EXX]$OZ_*J0JV 8=T"2ZR[+IHI.L;35
MN5OOKU+L?^_8(/@0TP$SS,M=,EB>HXE8E#P[/K@NM' :L^_7P@J6],*^\25@
M/BI*U1QIT\<&$5?DPM_D>T7L:Y[8SI7"YG3G,0?N92I%*B5\NRL%NZ+>K3T@
MJ+W1/83O7F7,-%L^G-LR'NE.&KHG&PCLB$IHT1"]._="WMNY8I>L!OM(_M":
MND[_I*M=P'?+]+931URZ<Y9M?) "O*Y@=G;/R>MP;5EUHA;O0_AY679L#^PR
M-.Y[N' EP58?[[<A7ZT'ZUGAAH2P]I(5?^%NZO[Y\C68_?LCAEG+&%RJC^G-
M&)/)D=NIAWZW5GRC> PG$7H5?57@YIY3BD VX;S66PGFOE6GQ$RO]:(+PH^L
M_QB1B_8PSVLYSL>,!J!"8WA6[(2S'AD?<(*&Q*;3E_QD)PP0!.YFO.1:]:,&
M8-%GJX^\/DN[M+Z]>/V2MTL0\$DDVQI8!^^T0EPO%N7%(40*$%?[ZTDY#6TN
MM0W3F2&)/C18[/)U-HA:*G+W7Z429"#04W)UE6S?$]FBES%=X+C'>"D]Y$V'
M\U2:AE0K ?VLSIH1[BQ85R'L/,W 2#W*7J4\EUS<*UN8<(?\%0E>C4EL0GJ%
MB8%"MZ2>QJ0?#Q-8-R._CI/BM1Q]B>7/S<5LNZ JX.3[MLUKT =1T6S"KK^V
MR>/TI4X>!JTJ#RRR=X'WZL(0=:'%H:'RCKP#3J3V9\SI *$UED]X?^W4Z^E.
MH:NI"@Z[&%7EDA1-OG[,)T/SZE83*W<M<];I\)[']OOZD;5_;S!6H%%J%G(*
MB\K>J"$F4^!T?><L3>.FQ2?%N,,P>V(@T1"G1/K38<I%^T6#(3A0#?N69WS'
M_2=/I%DE:.4H>K((%EBR+G0.#\TGF/BZ;[5%CGTE,S)+TGBM!<:D$>G,)BS_
MSZJSE:TJ+-41E@+B-^R#&[%]RW,/AE-[_(K3=+Q7&[<:P.&PLA^Z5A&(1\6[
M*IL_/7Y1W%/A\/^:%_^DBM^'J)7/QR&;T*KW%)R<:O'KPSD*H/22^E80R5DE
M$=_[,"B$P>=I)&P&9ECA2!$')M493@IPS6RDK!" 9]BL1HEW2S%.<NO2E"GK
M!C UR,\<M&G9?JKD QAX10\,$ZWC>RTP]:4N-04)EY>,14$9@/+O,BH'7%D^
M6=] %VS#W*PCL:G#;6']^H79#^*DD^YU>.#V4GWAE^@DHC]<<%+(8U=V3L-F
MS\-TOY/OP(TY,J9P@\'Y:]%>"(PB3-" 00-&\.4EWY4;B8UXCE&\E<?[Z"SA
M(5.)[2.?5_Q-6 #&_,2HH14H0G 9_HQ1'3I?HCUK>]^6!,\-4Z%>,T9<\8&G
MHEH'Y8J/LP$H4$(+)T) \9#K13('J5IN0Z>ZG, \AM,GB0,)DG?\':PXA',M
M;B@@"/GL 'Q^PU6PYE9W*R.J/0LC9 S$134G?QG&^:/W4[PW<SPX <8\=Q$!
ML?%U+!<<7]SEU>O,Q;..9PW[Y+A]6W8W+;W2"<JS6(K>N.'51L2[FIYC\$!K
MS0NE0)MXFYEZ-_Q5<M$+_.]D3Y\L+?>>1&?K1NWXT)&J*?ZU-+]92V>DW0R;
M:BFPS2=MJ*NO2UK"E?=K.W@LZF<1AEM028<CJS)?0:X]Q_)YJ]-U:V91SG;D
MO<%):XM?=?I*4*N+XH[K6$8S1I.<*SE28OQ0$'=-C^.\.G5S?W4B4OG"V^JU
M3*1)P[DFD'A7L8,Y3H,;R3QK,R"^V\Q=8T*MH^*/IR]#*<S[#,._F+:Z'O?2
M'-<[5UQ\9K^P6/=E]E5^>K*CB;O)EDN5@=V25HT)U3MLUT#7W5L&.:9O&O_Y
M]=?_-Z/<L7>)  6\;]B'P-3@0<^NN5' )>:R?]K08L,1HL!#"/8S84]_&L$&
MO2I$ <2@8V\4,//JWSOU[CHBBT$]1 AZR 4II"L-!13'P+!0 $[63?#O-KVR
MY&[QG;,*BEF#A?G$B2^^]H]BZ^T_G[*D2BXX:2K%O#B.4/[G-)Z"NE+<R_"D
M*V'XE2WS ]Z>A<J.'$77*GW;1%0=0[,T3!Y2.^MU[F,%$10=COA$!<)A[^EU
M7^QW+>8.272?Q/-)V3<RTHO23O/\<S9\RYW4&^U48+P,_N>!)W@S@B*'N1/F
M+>"]3PN\_ EWB2GQS:T<*?4!#M].0YH)M[8W/=1;M?53TZF;8R^FA!P,:=RC
MA'A^2"_L2UG:X6<N:++^45MJ?^2.\5- *^U/(C <YZ. W1R$-!H<;*, D]^?
MR7DW_)&,.K5"@%N+$:7>W#SB!2SI<Z$.6:OOG3JHD-"S6,SJPA?V7">)S/?Y
MCZ3I/\O];OM[CWB) KXTH8"D232\)OMWD@] )-"=<LAFG?V_U;YP57N.KCBR
M+NWU(#!UC)^""OI5"6^.+W),L-@'W,&<C_5C/Z?@4O4[_*.,R;KF>4,VC*@O
M@_XN%-Z!HW,#.5<4P%7BB&1_)PX6MZZ%WI6Q+Q8PU,B+[W?IV10J-HF1K"1:
M-=18'086X!&K-Y-=!H]^C!EV"11Q4RN.@6F$.1Q*M;8QIGT=:)''PH+0/PD$
MZ2*!B2/#MY%ZFLL(#>"-$> 50D.U-5ZZ+_#-@=M$F%PH=7+&-\UK3*:J G<)
M*A'P[ADMYAWQQJ;CY=7#JE6.DCON.IRX]97-]19UJ4I2-@Z(\TYW['>MYND;
MGGL*?Z>,?ZS3?Q2 X7]/J0*:K,$";9Z*8[E!/4@FM!Y##O*YDXU,E W"ZJ15
M0A5%'D3[(&8.]-S^UZF3NI9FTJ^I:CW#3KJ>^^6S#Q.Q.&)DB6[G?7GWI#8&
MVPLLTRKL(Q]A W:2H;?-U\::P/1Y2];RY],KC3H.T $=^V'_@3!YEDWPZK5<
M:=JC")>X-AJXMA7C!:-6%AH1_-EI?UO.'VU1X2^^/RVXQH,CMT9TWUJL9;$6
M1RDE8^U.G$L!&)N5B=)-_N@7&$TT6!B=ZS&LX2")0-=W0:OHG&%2 1Z CO3#
MR*[@G!=BV@L)'<YMP^'Y>K\8CF.E3=1Y-^WYZ?L8K;86G/H+GE>M@G!8WULT
M*=/D"6G=>YJF\<$T]VL M9SHBHC&]_5 _LR_Y9&_E.4DZ8F$EM#<@VOU.'NU
M;^M)/1@OU]2<Q1?658^>JC2W?#SK0"8CLEF_D6[%"#RJ.5:?FF[V<[&U88G+
M6ZB;3/PR=Y!(^P&0:#G^WFYFC/UFG'EE&P])NGRC#@EE@$N@@/W'?Y*!/.D$
MIPPQ_(_>W'_V''"6RC$(_:/ 1;90_+.;^R,&MLNDK9Y@/,6J$J7RFVVSX%="
MYO&J,M+T97*6<%]YM/5 9!K&0;5U!*I?%Y')1:K;JBQ;7*=2MYW3"<4 #I+>
MMW2PZ(KB?E"(A#O:$L^_=-T[@%0_:%ZZ_I2\M'$O5MVL8"#S#&/J'P'\GSG;
MO]G"GPS^3S[S"L?*YO--<F]J9MU%%#K_;&@(^C8;E:D6N^WA/9PRCD5YE-K5
M-@JIDV+777K&G=-0U4#D17U;VS+1=</>!7#YHJ,T]Q)7?V5*]9^[T%&QR6CY
M9AI/,+D0]6ASO9B^4T08]VN3G&>.B0LU9@?,F1@.3P)"< ;56> @9T^J:\,V
MAW$48*5OLVQM(')9W<]^BX"IMG2H(_+\KHM32;RM(USV+2MD5!\%#-C._^,0
MD#@K;/E,"W0R][L.4OAR'D<O,PK_K3H;O6N5[/8T9M;?*.O!(PNS,>L*H;^)
MD0&9"7+.4O3'#=%G!SY+>X;PB)N:@OZ6P2ID=^#RX/=8D%<!1\B#QKU(S_*Y
M?['1YM\&K]^;-:)] EZ"6@;P1,4C\BERXY5A?JQWJA8 N>5^L8IW]*)C;[-J
M]X&4ZGU;'_VYX+*-!D\Q_X&<KZ/O^UZZ*+"6@\?/C^[LM#]*G3*P_3'\*!.&
M53HF/WK4MT]J,FV-*$FJ@INY?YZ%N_N)ELG8.W\I^\IG,"O9]=+R[IWY;3;]
M6W24X<#(\8NYD.12V\S[DQ4;$QOCIH&[2TA+,\Z1'_HF)ZH_RFCPHW&9 K3?
M<HF51ZS?\&LG]U#<NRE&XBE+/J!6LV*^%6?AG?: 7#4C?+OH;C:O8!OX^*0+
M5E'N9\V)4/+UYW1D&C0OPC<5M(@RBTR: SPWJIA;7.?2BKU8WTR8-8U3&$;S
M$"T,D*21F#5KFZDTA;/Y=9 1=D9^9F+%R0<HW>TM01'T\E^*[/,4<@R4L7E?
M#(V3IF)L-1]GK\3FQ&-((&8HI8C3=&NF6B7+=WUZ!_>E^*,RSBXM/$(Z?Q X
M!1)KO\/,85M/".0=:_EV1I;5.W4U/R3473!H;O_#>X$Y7GBQ1;*UU8QVNX(L
M(->+XO4X@Y+2^5='+@'*1S'/@_;EA61?]85HG1*EU/-I!;_82)"FD&(UTO\)
MQ6M]ZFLBD?3KB?97F#+)1W-CL4!1G)_Z/,%UB@)$%'K]7[S6KOO)7747E"#W
MFL#3M8KC/LW[IAB6&)CKK)YT'*-^3U?W*DB],$]E)KC7&EJ@U2>L32$/OY:K
M.UC(RC")=K!4@)N5)A&BA38>OU2-?R6-R38\B4E]^%U^=3PN2^V<%*/;*V(M
M:C$SIJB;(N2<@TN7YEES"%[RNZ3@7.V!C'A$+CD#&V-D=.O$]AI=4E2I+7F"
MWNZT;L;FQ8S;3UW&AQ9U]9Y1!KDGH](?>0< [7;^/NO^8Z<<HU:?Z$3S:5WG
MZCOY.U"K*-4TVD!->C!__:N@I(U[D69I8@U=GI-UYU.'@LI4CN0'AY'"NJ\R
M9P?FY[MV1VM3F&X8G+HQ\0A?+L02D,(SP&Y3FG.6847+ML*6FU*]]]X+\&#$
M_-!R993I*7YZFS%HFAESF0A^ KGO-8>GK,)^R,5G_]C@3OY,OBA^9"FM(VM@
ML A.K'<?@<XQ"@@@C"BQN0I:TDGA8FK5#!E0459,&[96G"M^B1D*7$;P#G-U
MD!X1PA]"B,":TY6[<8.D'BZZ@R2ZL4/4GBDZ>I"!(!;<!S71$Q@,$>=T#O.]
MAE2!DV9!S]/>*&Y_>MFE]*F7[>2"4(B@B3DA7AZ'JLSY"V6K#7F9(^T]O9MP
M:PM<H9KO)_+SH5B9Q!OG/]^ ?5@O!OL2>.8DLO;GSUO[!I<LF=SF)\R.MB7.
M?NK6 EIW8"]_EI7Y"5.E:40OK>MJEY,H)JEGJE\+'-1Z/Q.E27R)4U#GZ9Y5
MM#/57->7)C@:*Y7FP<,X,T.#:(C)4JN71SA+TWL7@,4J0E:G!6G<)DAD,:?$
M0?#G1ZDDM+V?GE]O<C%&8C%\=U$V?[SU^<,:2UO%@@VOC5)^B=P:665+/%Z*
M1-JGP9(7+7@*+91#7KL1@4_O2Q+U&-+7PQY%"OWB7YAK:^O2GU_0;=1Y$.<:
M0H7MQFP<*%IJW4[S,W;KV82[49W09_K<:4<G^C=B\J9#.HJ=LNKEO-&?.K()
M-=ZR2R:6940%MS4V\BJ[<MAJ:=TG@%HG"<J91\W$FYH-849B9,[QP%CUH+5M
MK2-N-&:.)KF=Q0M<-^-R++3/=8DQ&3YY*R0$7$Z-^XF.?]'S&!?DTE+.I%PB
M;ZQNU/ V\Z96B4ED?#?40XQ!)2(Q"6^ERNMV+'Q*U31;: .S&7?\U.*M5E(<
M.YC0<K]>B57B%0X-:XR$C(EP6!U+=>"V:B!8L.X-<]2%>1*SZ0F[_,L1&E<S
M5@FWK>8C/*\B]^4[[36NCR*8651.;*9!UF&)H@N$&#@,71WW7BFOX-U.VCPX
MYWH]LL",=4.]PIIT7*@>]]:HK4XVUB7777=LQ$_0*EM[48:T9DER_\#9T]FC
M<R-3]K.2'0!U5S<&GCS&2G ,]5E,BKM=4;+C$3MKJTFR^'./8%XB?+1CO-05
M\QWFUTB7W)5(UZFZ5LFU#,OKGB<VS1?)5M8\;N.%<W5E \\UGCZL5DHT2OL5
M[L(G=F69$[2:%$?6HJ?L7VR@^RBWWB-IFD(\_CL;<0YNXY '77:5*0YFP^H(
MY\KD@2 SG_>%AXH9O=[FR6Q<M+S8EN#VGC2]:XF2Y%$/"K@WKZ\+;U%KJ(\>
M_Q;S;))^24187MGB&2PRGG_D3##&N_BI5857O(HMB+8N*8WN4Z2.;0+/S,B<
MO/;S9ZN>&_$_//$W$B:F<Y>]J/&@Q(9@\N:IJOP%(TZPV*S^0Z9]@Y+.IS.I
MT%POPP'%>*0,5^]&:GA/@ZK'ZH]V?65BUG=WV+.S7JL WMNAM1FZ/.]3WU:4
M@L5JQ?:5K/#C=6Q/Y2,K7").<=.9VK\]T2=493RK>#DF\,E-CZ%Z7M5;S(&K
M_>)0.87/US$NPFQ>I+1J)>.)EQ (GXH[[67X,^L@Y>2HUVKLC';^D^P #NAQ
MG^W4Y[Q=8:G'8X)X!B^5?6EXGS37$)PL'.JSR(/>GTK3_+/[%7X/.K'I5#J(
MQD0[$^?QDA)YF%"4GUVVK-:@=2:CE<1I? _/E\B@4ZV\)_AYVIBXG3AM+B7'
MPUVOP)6V4]2/HH)[R$\ZO@R-/4[^]6G@.&4)8*0]IFJS@20@WLBQQ W,/)4*
M.U[O;F>KG134<=R([BT?.WV3N24>QR]?WO+(0X/5F[$0FUC<7,O,'9+C53^T
M-:XP/3BOTPC^)& @1V[9YTPC5K_QC2Z%4.$5OX8;%) Q<2S07=Q+K2\RR?>&
MF%>W7HN$X1MCFVT^B]QTXFV,2Z<UQ]*;J_\TEU>L0/_9MV" YD.TKRAF=?J]
MK\;?NS,C<WW-[X[9"QW4+9^C "!TD3D3!4R?^P_1*+5/Y<'!93W-'R\:KMRF
M%==66_=*1+J2H_D?, L$/*>[- F:C!&HNLGIT<U/R%NRI4XG[EV=:.?3-53&
M4N(G;DD9#? S3J>-;&"<UK-9C5 V($<!JC:'K/8*WBTM'RLR^)OWN3T*7SD!
MP&,LK/ "_Y42W]PJ(9_\O/Q!"YN+!Y(Y<NW:3GPQ;9007%& V#607Z=E$=%^
M+7A9>WV^X(A  0(H@'D:@=D?<,X19=;AP_+9#VDQV/M1E2-KS3Z'%28Q3>#M
M;N.\SD/673B\UN1@W!3&^48IX16O0IKU5\KWE^R>]]]"#+W*48#B&,OHH>;4
MF'$J5]M'H8LD+^R^;XW\5E2;'H1*.SZ>6:JC]F>+RF_: C9M!$6GO(-B-73,
MM#OT"6\3NP^+EB2FI^F)(\TBJJOZ#.'K>L?)'SA98-P9YB=/'1T:Q@:*<OE5
M.-[1? ME(Y09OI7 3&NNP<% ;:NT3B>[W$/,,?>T0C(O9WY9[!*W7MZL"?-Q
MK+$5ONJ/[>MP59DR/Z%Q]Y:VUS;N7,\G!5_E[])XAG*(!6,$"5CTWX4^MB^@
MK=!-1X#&:7J(BNLFURE:K\&Z23'?^2YO8[[=VB>5B)KYBFV6GMPVO[A\-([$
MC5=6W;-T&?5S'-\<WVZ)7E;-\L@2/,]K*R^C';]'[<@[%-X4''JV),(8Z\7G
MU=+?_K!FK+RLS*W%'Z1F5*5*<]/P0S/0IL><9-.O(J[V'2Y&-65<^(YJ][S"
M:+E;6%V9I0&?GG!UR&B!=-(HWT'7*H8+#O#5B*YXJ&[%7E@_?DTYY7 M'JQM
M'_3LVW45:;NMV*;B LTT4_1'WP9-)+3L=OWTU3SR3D4AUUGS&SREG-HF=F&E
MAA^XH @'YX3(E;C(E5@?+8[5:_ PB1_]&/8O>O_SWG0^P=Z!^SK5=YA7TF,)
M/"*HT+:_84.XF#=/Y2"6#O"?D:G*CAX@0-FS-D*J3/.SLI5]8[':[Y[P26.!
M@KD$+]]^V3'*/OL2GEQ)+YR],.C_V>9T9QQ>#KE7M[+,>?1VR@(;GN"<?$-;
MD!QW<CKN*#@#IA=O&47(@,U<\V8Y*9(#OQ-<?8E(=AU%Q'[8&.+S/ 0V*FQ_
MNJG0+TN/9H_;+2F$$,SKOL:CK3)+!\2RGF^K=AL('RSY[.JF/FL.G8B?-62,
M>.*_G<7CR\9\_&-F>"":[<( M/H>28%.6%91P)M/(V\?+LQ:"_E41)3-*?5E
M%2X)3$V7JN?R?SG@M7_&Z0G<N?[L@^BG6(=#'2ZTMC@,Q) G4X\MH^EXM)1S
MXY@3S;H52>V<M"T4^YGPO9DLB4)\!)R]^8=]W>T8F^L5'[G=C=,7:RED_]QH
M?JDD2B61R6N#(*&;RI+,+RK?HP[\83HW32(O\9DV8(+]"_NY6I*Q=LQ:\;CJ
M7@D*> ?:.T$!@:Z9#V -H5]:&\;MW?;TQ.'N$2+<.//*_9PDY.Q8WCK8!P_:
MU:)[2XRD8?NIR^'Y8PRJ#74G2QHG<S=OIRGEYYN5/30>Z%%IRJYC6U&5S#4$
M<@J"KR.V6UH;FE+!-CVQU6]_KG"^*C1GRN@7Q3G^0G1K/K_%OLA@MQF=E\UL
M>I<>E&\J*%LY:837=SY8_00,=5@%='1%-:, 79ZIC9;EJT,4L$*\1\_36CM9
MA\=%HV"@<,V^R.VX>-CS2".(N"JJK.TX=^4CG90#F%LU++Y5-_@BZTO94$)!
M66V-@>!6OU=^E!$;?7?2JV[&2LH=UU[[/2F\NLESMB,2M0FW7RWO]);R/A:6
M>!(/D35PD/5MT<26&)__5&(-<$L>=P?CSJW1^&L\5+HOI+;):5WXF:^ ]O%>
MJO*/@LT;].IB?X-GN;K2&M*$3-B^?C15&:?BF&](8U.@RO*F4B1>P@5C\\/S
M?IA"2@Y">**\[$!"[4N+P1S338-VTJ['4[';)W/B83HNE)%LV%?T'(TPAA!3
M&*TF1L61 #HX?G9WE,Q*;M/GX'GXS)V)T%=#.>MV?4Z>2L&>X</).A&+)"KU
MH?JOH[6O[]Q>YB9=2:0:\OH9SG2%I";S?W-RH_-C)\JJV*NW%@40+,+#:NMJ
MDR0-)9_O7@F%S=M\,&DT81>E&7J#1>?=JW/,$L> >"3%XNU.8+I^S:-Q+9GK
M*=8[\34NS2O-1B&VY&3_K;&J5%?SSS,\G59E^_+<!!EO;"ZLRQ>8"_(O9171
M4?V$-Y#0N_-ABEFV7.ZW,GV;<>6+*-V51=&XY#NL25514!XL7"+1;=!SFUFC
M;TCP&73CY94W,J2-3$\E?)> ?8I+?L7 H/\NYVGP76:GVUL= 'YZ)E B($GW
MODY&CO0UY?].R_B?ASI%<GVS>U'3!+=)78".^H!$ "FY<3&?US=FC%U%,DEC
M^+!<<H\4+;4?KQSWWAZ;>;2=O?5Z<[@2QK!1'$WTS6-,1835:IA;Q8$(0BZ/
MADCXZ[76O-D)XH>5Y?ZZAVB_OJO&D9]K=F?V@FVJQV?"TM@LKC<O3-R&'V 7
M ^]/G)<!0B6LU!^-Q]2V/A>MORJX\A+/ZFMDI_B]7P[2OHAJP;KY?-YQ5F;/
MVN4Q=SO&WZI WV"!)L_!89N/V&/%^((48VA7B@_&-?R^E1U)63.^-7V^)]#"
MYD%E'_?L^8F;4\?FQ.-O1YGOI]56C^[)E,+%Q@W3;NC9[%M_-JS@?@^"-E%B
MT[MX'>E'3;]W5Y0 K3[.'[7SDTU]F<19?I;6]%'>XF0-TV(A3YDG:>_K$+/(
M(6$J7$O=,<@32=.8 JEUL./^HLHM^YJ$^R2.@_9^*-4KMTMUM^R[,/BX5M+F
MPY/::S.NC(Q=_\)/QPE+E!=5/%%(S2?0TY'U] #=5,<>$(&1C4]('DN-B:.5
MF<]%O K7#]O/'U=H#YFV.CEVQ;5 13M:2]SQ=([/HQ_5MU2/U>?4CX70K$J$
M*YB2,-'GD"5#T!FCCN]1+0&;@VG5%(_#6D/#I'D-^-,AH<;D.F-)_R^G!>+!
M0<!'8(G]^*95R&6XW&:TWS^FNL6 D8**D> #2)B9D+TV4^RXF4!:H>)GC7)^
MS\GB4[(%.UCQS7[4@C%LV#5\2X)K1;F-0[NJ/4&EMEJQU%%=YJ*)1R(L/Y/5
M*/.U3O2]B'L!\4ZB@ZZI%-VJQ/V0W+;#++KFV3G]N06)U,^IHM2*5)YRF,7]
MI+['3H!$M)2AM*2P'.QM1"G\[;)&A'KUR49]N#=DC(0X[(Y:RY;X6W>+C7--
M.IDB9ICGAX?Q,.;ILUXP&9<;P0*D$>/[?02BT5A]&TH''H2N$L!<;;C,;D?9
MX,P+1 D-K2Z=.V/-#;/9W6*0.G=GRN=S_=HY/BE%;Z0/-^Y)JE)QIPCCKO.H
MCX8=1"VH"N2I#])3Z7.&=EP\QEA[)W:=1::3IL+S9NSP@,<MHJ6N/O7P#G9X
MRTGH4[;^J[%PGW7/-5$03G^>H=<H3VV4D#\UKFGJXREET23_9U78 Q*EC4R;
MWT,L3?688UHT-HXWKB !YP0"/X-4VF"$17=E[&_R!/??;0H_/U'LWU:/6CA8
MP::-YQBM!;..NW'@49F?&D[-B>C*NC86OU-=#P=:_ILW-M[&EA(Y1EP57/AY
M#EE=OYF-M\^[%S9=:BG;@N6#OW$Q*+7<.V<_]:5>30^,QR'5,;:3'->?Y4W-
M^,XW(<:GCYX 2@V)VYH[0@'O(W=S#^V\#3T0_LMMT8O\2_7V"*;\N5T.7[*A
MRK&2(SSN!F]F[U]1>8\5JB@OOHBSH( R"@1#XR.80+N1+PH(^)5RD<DQ42ZX
M?$]7*?= A?L[1YHVUI;-P&6KL+B6E';'=M"W;QTE*S'4^EX):O&+AV>#SWFJ
M\L95\S')1V?6]T^V% 8B2;*2/U_*Z;<=9PPBJ]9L,G\:-TRY?;7[XA5V^M#B
M?H@I;\RE-6_0S%F.[(B[=JL,84%)7F)A3:68WY.9H3'.@28]W\-G<_(+MVBJ
M&A'] I--T/+A\P:$8"]7+;(>!03=: ?U2#UI'5_6%#/W.")/NJA\;JDIGI_Z
M["LE4W!4YU7EV6:<GVPM_:-Q 9>M8R/!5?",W5:XB%^8D)TH/A_A4Z$5*?V5
MV[K#[2,.CNY&9-:QK<Z#10:SN_5'O ]T!7@Y@QCI93Z@  ;]\\(/W1DOZ@KC
M?355KDJU:"S<.0@V@B<3-C8GS-B=1$'"M!4UD#W'TY'QQ;V%GR1K%"'T0UO[
MNRJTY"-I'^+U;,R(B!F]XP[5ME@4+Q.<-ER5G&%$W4FQG W"PG%%,8-.;O,9
M(_WQV/$\R9]&8IV&WTDSW^>(8< [UZE-.6 ECQ#0)+"REVCN/5\Z>6Y1_]Q#
M.I>5_?.U\3O1>5A#<*OJ&L\!'@?-GG.^X:PW;HPW5U-# D$2!S7)8U,MQN9W
M./+8@9L65?<FKWL7A=?H4_PK=IO=O@FV>@@[Z72+RW#/?TB4T:?[1,45\.WK
M94T@^_FO:#]0@4%;V>!&_B:WRN= &J5\C^2!^W8:SQY%]^%$(D.:('#I\QW=
M$V7/\50E;CN>U66)=P+UL"\"*J'P-S4/^E1!GN$UN7!^?55* E=-?TGEW?BE
M5LV3EGW-6D79P*]\3WD,^437\P22S]$H+>B7_ZDG]'P:B3$Z#Q^0;9D,27/T
MZ=O,M8Z+:@UDC9-9I/Q8*.\<])&@T1C66:[<0]T6TI(M1]B2K5RT2[PP;,$8
MH9)YN#2EWL$OX/R!B5TC =YN=YNVCCOA>&U/92J;Q%N+VK_]\Z,K598*GY<O
M(E?ELDWN5G+].I'I\S"?EEGQTCDX]]>CC-":V&A^9U4JHRG@F(/;361)QL92
M]P\;^T7FD9DUA0*."0[8!3\HU(2+LB3>Q];P#>9@ G*2\#$(=G%Q!&W#V1H\
MG1]9&'\)9_NO'Y3_S9#3D G&D%?JH!MF2?J_.BTP[A89*V)7/(W^6/O?:.?Z
MGQAD*X9,\+TU>Z9>L?(T>[/<6B'/&KV^L:=LIH6;,B*Q^"L^FHX( >%P%+##
MD -9#H/ -]TX!>7+?4:_.[]6RFT_W;GBV":"6SN2H8 1D#P*@-Y' ;#OH-7/
MK5HH0/J&!HE01@'];#>ZV2B@"F:0O.3/(.>'SD ("-:@5S@[R[_6C)"B"G]B
MP:!9R# #+Q\XDHKYTNZ$ D)"8$8W6&>.US >%$";@Z2FZ86<$8U"CWJ@")>8
M$G6B?3\MBU]9"J-&(I#NIUX5R( KX1MX,@J(5OLSI\EBG LICNKKX9R=BO0_
MB_GX+ZQV)[&N&<AF_;='S[2&&(Y'ECA00/;;*!3P]A$*6/_X9V[GM@$W,>'[
M_ZI:'E_522/[>SV,O,_\R4X__%D+?V'GKYL-,5MKX6F]D@J_[/Z3&O["3:KL
M%>C_5+DW5TRO@<NV:D.FLH&$0!5'I?8R$)=U-('VC9JZK,N+2O1+CBB@=YIW
M@[Y SML*P7E@A?0O!1W-HRFY0;J&IB#;<]W(&R@*H)#^_Y_XRQ,:8X>9UPHU
M+1\?QWO=E[\K<NLC28R#[>2_U?VTR&!O^G0_!""X[(MLGLRK"#24. RX1'XG
MS:E_JXDCJK8\U9K\Q\6L#Z8:-* /8>"I"/T@P67VKUD3.[+LU?+_*ZSU_Z$!
M(@CNNAX3YNXOJ\AMYY:G$=K(V\TH^I5N0ZIN# 7\P62TGW,3)6:ZV_)_5AO/
MW#D7XQ@ K5J!0:<')FCE+:. B!PDN4<-"I":8OAU@ +@S0DD$SL5G"@@.*,4
M!0S7?;BYAB"Y8^ Z<\.(:VW(<@,*6-O!^O_H(^4\G4N\$Q)/2Y5M? FJY6.I
M,,*T:4/4%F-H4P_^\X\AUB&_[VZ1@5'<!'-#SL":= Y>R\CG1*'0?397%)"C
M6[DW'],5,UJ( @BE0M';>([TWWU>,>W'7V!@6Z])GG3/NZ:MFLR@T_4]]HDB
M64&Q%T1]5(/F=:VUYM-@^^\=62\"Y6V-0L3?+N<?#2U7T:Z72Q2/7;_-D"RE
M9@DR\_2D;:!W+=L(S_N$"=!X835):+U'Q QJI0RH!U+IDJ>8N=XGINK**%:5
M5ETU* M)-,,)K:5ZO33;._=M2X&FI:?T_4E>M.K+2[(4?.)=:JG<O?OS)-[8
M)F9Q%_CQ=QBKOEV='82#*OHZ7 6T]+SS=YR-E$T-%Q^%N$?S4J5_8_V!A;/0
MXDTEJF^VE%5D(V:<8! RUVLL9MD?UE/>V\E(9I>9?M&932@5ON]>L?\11I_F
MZ&]%UI8UNV9#3[>R4K1>SILP8[54>7[-4+DD?ZOV23^SR>C!I@W31W/$=^T$
M.(FT@X6: 9/.SRO[]OAD<I"]+[RG6M'<XO&=OHF[TE]_#>JWCKH=T#QO3U)6
M;X]?5KL6$X@7"PS&Z)Q3 $V?%#CN'6/%E,T@*"H&;!O83#ZE8(6<YFPZIZ^[
M:\&X,PB3U_#2E V6GA^8X[M(LQ/RPZ?EUD#[=$D,<UES(#!R*,)J%@'EH109
M.O09NQ8FK'_">)S?X%K ==X6H>0PT*1CH,1TL[!]5C +!QE :Z)WQ_I_A,A\
M=!2]K3!2#RX>UU.-GN^N$'\A>*O>U;JEJ^<@(=@L4%YU59N>['X,F8'_9XDF
MO[!?^;RU!Z*DDC272*!.>1.>0IT?46A=K4!?X+@A\*XZ:G>6(4!0-OS 9-2M
MB,?-%\N4OU [S#S]^77B14(L?_0B+M-/!>6 7O4+#]?E)06P=:;Y6/K##?RL
MHK4ZSI#,^G!N4+5?9_I-SH'OU:_9$Z2&53=2%<'J ;*\!B5OX?NG_9C]Y>N=
M);RMXF@B2<*[[Y9V\!P^.S-?.U[NDAW-.\U\S"9(QW>JU'PME8,EP\V'P;CA
M$R@B..KE^UT3AIU<P5AUCRSC 55<-8+LRC4=]LJK80"L0J_,&CM+\[J2L_L^
M-TW&\HT#NP_/7I.!+K*9/@L=IB_)W:!7IQ'H&$F6H[/$@ +BK-"!LD($>H:A
M*]#S>_OS5CT@0 ',5_W(KCAT""\";U-?B?_CMBI_,Q1@HH@"SM3K3J-\/CFN
M9EDEH(#F"DWT:VZ9C7]30,,8\V) /GT#F6Y"[R-);:^'NW07;\(-=;53C)V>
M5R;>EKY@E2SYCB!" 0^*H'L+:-;*AFL.;A$@(KC/MKK>5B:S9X!]>+"('Z+G
M].=8:ZD"C&'@1(I!$ 7X9PV<*)#NP!1'O^;1*>&7/I$YRP42WO&IN%_YIQL^
M;$G:0O;AWMI[\9,WI;7/^,XE*:VQ<[S"NL8A0;,72*$WDF8[57H,<S4 __8A
M3;FDBR2O_MZ/4X-FVHDJ)>PR4EBM"ULW4Q$V@Y--XMRN[LL,1\^B)0-*;:ZC
MV, 3I5GI.<KT?.V$0^?SXOQ^N0]R$W5XVN27#YJB'MC0R]%HXP?>'G-R'<8)
M5W;<N]JE>_DZ_#!9M7+L4+ W_#N;F1YVIN"G*K86*OU 0M&]Z:5J+LY2GE80
M<Y)0[""$,FX[+,_=S6C5NL^I@S![8_Q6T9":[A+=>/9$'17YGG,X+KW',Q$^
M>ZKYS-DR>P;E<??&STU"RN#-I7[\..;HU^:N(P[,(?3]>>(0HW?E+NZ^RJ-'
M=2E+=$)$8L\,?@@7KUC1?2W+4% 97U:>S*NK)1^SF39EMHA+^_&ZQV\^;#LZ
MA[0=[X2WU+_FQXE4!](J,6K>A3\2EJILM/=]W0=B:$$EP536"R'XF*3=F**3
MHRHH92QVVD(:LRKI("DO3E%IT9BH_#!9_PF=TVS_GIX4#;(/!;S/ %6_7=[P
M3W(4/Q 7]E]>G>]7U2U9(Z^7HAY_(W]?*;\TVF\VC8_S0_$3+*QHKSWYSB9#
M52QX^.,Y)0$$>^ //S@<"WE+_\9-Z@$*B"7Z@ +V)J%G8A%=%T+)TUI?KAA$
M'U3'6QALOK7H$R7U/(&NT$'+?HAQY#35C$\-*$YHXH$M6NZ75KT8JV7\W %B
MXQF>*C&"6-U$JS)=,_WH'[B U!WMS4,&+D=NNR51\&K+^<#6EBP?QS2Z*!B*
M37:N9AC_A,P][%*M/EB&,HG[>VR+_.K5;T?[$-YSM ^E0//<S?4@X$\2>S$'
MT/UAGL%Y9%14RG#%RQO^IZ.@O;Q.L.->6:1C".B$7Q\RG0;9L3$L,-0Y[D?*
M@V.N3AUO"#@F=O[[^]_2,238H=6@(B^X^NL#.;Z%'Z'ZO92[3F*9'9XL;<5<
M(MI^SX_]FCU2G MF6&+8G]7(JO?-&]37*RP?RFRUDJA,U:E0Y=HSO6ZMM $(
M[:VL(P+&Q14'/<G1*,B10G>DXLB>FX?D>8W0R5.N4X;:K^I%'^,+\&7.6)<J
MR^X,K)XB4K;6G>#A-0YB)8*.R;N&QP4]7. ^J8<-Q]N14L.E/Z\2+O&KY^6C
M[C B=M3D<5>0="4?)B382N:5_+GJ4_R="W15."'VRE:\9/+LVHV4!\."H_TP
M$H71U10$W<J>/\VKQ+M<9PT5;C#,)\]Q&-@Z)9 A3<PP\CKZ]"L_G]ZK61'C
MBP&7-:$%EUG]E8V$+%WGB->M&M *)EN!77D']?4!"GNIZS8! ZGU"7M!R:>&
M<)ZRP2*A9%\;1\Q'F6F6H=4_K_4</W47TCKL*FW7N>IZ(F(-K)#=Q.AHA)G=
M!+L)A[^]&GAZW%N>X%LD6VEDT"W.]S6H4#%T+N6BU->1Y":K0RN3^IKEJ,[P
MT?2<WX+]'&^#@^C55D&\X7G2P5L"HZN%OB3Z+T8$;6<'^>%+NF\K7,?/_)61
M]RY;R5;UQ)6]!09=!EDF$C\37>2G,25)(.HVJ#<_^CB&NM-0OMPY*,\+)G2-
M+9=&:DSO9)'T)>9J]WIFS]M2YR?2].;OWO^A/E_B=@OH7F]XV+2HNZ?0?'R8
M?@$#7:P/\.^2I%"&8=CERZS00SUC#%7)*+_SVU?L7OE_;>42^V@K97U44#*Y
MB,2#/ETPF2QW&P1U'?BOV9,/=*_+!U2X#72%^ 94;A23+<BL./G2<Z!3#<+Q
M\S8.[2D)D+^+6754>2J5W7/9L!867N[U9 VFJ&SZOBJ$ZIH17.EV C+LPG'_
M0(J#YSP-,9ARV8QO)2EZ-?W4$<:])(EM4V,]7BFF-#;_'3I+/^:ZQ4XY1/M+
M5/2BZ,(U:I/N_.:%C4G)2+C;5/GT/'0-,<A\_#;(HMR+FTMH3<>A3M&TT0):
MI6.2["S1'";/.VX\?#V9874\MO[FU)$E'O8@[57JU+T"&T>GDJI*@PZ3S7PO
MVJH+D>*+96+[> BAH8'UR8!_MGQL#VP).UK]33H?Y;<A0CZ:XV(7>-? Z['-
M\?,#%KU"\A.]%JWZ%N(!QRW::@?>2@L)=UV/(@CTE/M);WE;^1EDL&'%!MHM
MXG; Y8"0*9-,R-"H[28E-_0<$I/RK!B(]G?>]2K18B"JC2+I0CY,,VAK%IZS
MV/?XHFR-]26D&Y.T>=N)293)\7,I!>PCQZHXU^UIE;@'-9-22_'?7.A".VD(
MB?%/?T&?CTVT,\N4UD,)"W*>V]6EA9;[M?AVQ,O""HW:S8P[UJ^_)&A 2[PA
MG0S<O-\,?D*X*I *M\6FO6$Q2(5:=&S"@]Q@-J*C]WB=HU=_#PHX3MKK?GW-
M.LOK2"MEE 8]Y.9/)X0^GU-JDKMHFG^L-!TY]0W4GXR(I'[\I5:,2.]X\WPH
MHV!F0>?;YG>NQ*?V.('OZ-LG;<<.??$:#^V9>0>IOE=2]6_K-*LB NR@>TN@
M&VR-YN.80176Z7,*L.7I)$%)\OO^NZQ)JOKV6#$.B;17O0<])+)'U/WB'(IQ
M'7$A'.D,'PF]!>7#@=%D?>@GUG28XL^&^W6MEJK)!<,-SC_W5!)T)Q[%PY;6
MN?R 1G&*;:SC]>/>5R5S]N&+$6$%G/535=[QB;O>786_F .DB9"+$T1QS=JS
MV:\*#[#MYIWDQWI=Y(F>QFD<N>-ER#[S;<*B''G(GBTG1Q=8"!#EV1KLO.HS
M(?XF9:2BUR61PZ*- HB^2ZD=^FB('^"]'C<+5!Y04K-ZI;XO@KU]5_57XY#8
MR*\)[+II03R1^Y2L&$R/<I;O-T5FYBEC:AWW/IO+6)]I2QO2O<-RNJB-J0.+
MFMV[&E/*-^IVIB717N@7@.ZN6VOSW]P6+2B/*:IY6)[AH2O]' /+XMU>M&@V
M;D5%N2!-0W-;PH^4#OQYZ:';.%C1@75?8!6A#^J5O?Z/[KXR*LJN;?M22J0$
MI4NEI+M+1$HDE1Q2&AR&GB$'04!:0$!II*6[&>F2[FZ0[G28>;G?]XGUW+=K
MW=^O;WWO]V]8L]C[V.=Y[#/V7->Q]\_:/A#K=$?Z8O.>V\;&!>09]SF2-F9F
M[8Y6?%/WJ]F-J)4,T/;$ZYK"C(O)B_IA3<4GS"/")K*Z$::Q2F>6,VI?]*8J
MPD8)I#5#"%!C.X]ZCB[,) 2=Q2Q<KNRJ!E"I<?J8R!/*\R9!MS6R8W*[VLU*
MZM[0=#QKZ<3'?G&RA6/[QF:B3(9Q:&I60H.$,>K-F[R(6I%E7\9XS6A#,@*1
MW*.EV"Q\QZ2/(ILC(5&N<W)<A?9D*R13G6M/9\A7#8C#S%)R"H7VFLV&=[EW
MIQ)8RZD#15D?G](_N\. !@I?/R'TBXE6VGZE-Z]FZDX[EG'I_-PIW-?!)RC$
M+P3#:3>BT#M[07 NO%56W,KY";V0M\SBB"NMZK%VW2_Y#'$U+AY<P,0#$"'5
M# '.C6_*R*[R+#0PD61\!112]1^@ 62HF/&U>SL:2+L[]#_:;:S7Z8C5U!MO
M3VI*7Y-R>JT8*_@,+ARI%<!W6.E1(7%-CL6O")#\.T?P<ZVMEL:,9A1FJN*!
M?+G@?#Q4J#3/>J2;D'.RX(D\&8_CC\BD71I?G$)8#2--!(&;/GW;_CT;[:M/
M4(^(K%SJ7N'J@*Q11C0@[SPLU^].-WDU'FO&^FQ(K/33]NN0U_7YUS\W3^DI
M+X*:%_"1M'3^7F_#VX2EG#XS.+WHXCT?7:$43%S.UY.P6B(@;QNOTRRJ='=E
M2CJ8? 8?KBI:7,)6?8HC@HK5G.F<QI^G&CXI)KYXNDV47> G[O]-B1!:M>SV
M[5HL9K@,*;LRIZ#;5!;S4FYPUV6-W0R<4QO9-7<>L>2G>RX!E]CHNBP&VY]>
M)E64G#(PKA!J)R5ZV'E.V>1O-HUSPIX9W[O0:;>S()]JD,XU>J@!+9!9N\3M
M9H308,^$K:0D:2]$+.OZB.H&5(#<^*?YZP R-R;GAQBEJ-C>32/.T-UXDHM.
M%<@#QL-OED='<@F2F5%51KJ$J@H>*E8=K[:-!"HGLBLBGNS2/<+*!!]E.G[4
M$C:;*1)'D7J5G86HP(TGNH9?V[ZHR.D]TS_U\$)=-UE!L0KKD4Z'1NFN]O$L
M+_S6KR@,S 4^9$!H#Y/&N<,@:X?&K9(L[51E':X6B.@.I6&>%!=/9:ZGVQ&Q
MD?2119RHQW.P[.GNVW/UE^.:4FNP6=./53@;(4-P*FNQ\;R,S8DK&@^K@+<O
M(\YX#11W^GN<UK[CJSJ^NTQR:7_UZ;5]E?(:&'4==AVN^SI<%33%6<^X3Y]X
M226-M5H7C%1A3O6$F+K4F?(:&I00M\S46#+> \ZQ<P['^F.+N<(M"K?/Z@+K
M\9VH\Z^I1@UPRQ3B[]U5YW?= S;&:PIQVG'3].W&!Z<$AK;&PVVSLJ=-,0_4
M>J#>(KE(IF6Y@XXL9Z>S2"<N3O,J9E;DE\?S4E=2A.,4V_[Z+Q*=-U!U\1P"
MUQ7;A5?@HF#(3-=VQ4#@M&M.*/?)G,?>EF[Z,+6F?V_UY(]Z>+CRFI[:@56T
MJ.GK0B3#=?62(0DGE3*4?+JA:DB%\V/(HJ]O#$/0VUS@8T9.7A8\^&.R#ZV<
MBXT0W#R9#99P<I\1]MT"PKT&R7T[Q@ZYZ20M;.H,4X)R&FM&!,D:@_?LG[?[
M<PV'O]?8[NHT[L@>,UZZ1 Q&&)@IG5Z"EN"%X=92]V8-Y_4RA:%G9\=&U$H6
MB.&$N8^[ECIR5I>#NPRBF.;F6M@7<).'H%YO6[M\15>M$6Y'2P;89!+V4X-
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MQ_IJ&+Z*9W$#X_"F97M<.*;"@GI:97RZ3X_R8YN#*:RG__'L!V@:E ^3!@7
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M\==<B+%*?>3'D^&;X+7Q#>9T_GJT K;OFD]Q<IG#K+BKU5NAD5I'<[(0D>9
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M6U!H-0%M?Q \)]>P!11?;<'"L'8]6^#<[V$649GQCR?DT5/_!5!+ P04
M" "3A7Q4)@;#DQ+-  "J,@$ $P   &EM9S(R-S$S,S8P-%\Q,2YJ<&?LO'=8
MDUVW)WPC(MU([T0%!*5)5THB*B BH(!4(2(B)=([!((BO41!0$&)=*F17J5W
M1*1+J %%.@DU0$B^/&>^F6_F?>>/<[Z9<V;FFF>3E>O*G76O>ZV]UU[KM_;>
MA/*3,@^<NZNMJPW0T-  *=0_@#(%W )H3YWZZT5MIZDO.@8ZNM.GZ9CHZ<\P
ML#"QL# S,3.SGF4_QWJ6[2PS\SGN<VP<G%Q<7"P@'EYN3EYV3B[.OX30T%+O
M.4W'2$?'R,G*S,KY;VZ4%H"-X13]:2Y:FHO *38:6C8:2@< !@ :.II_:<#_
MVVA.474\0\_ R,1,9:@Z!YRBH:4]=9KV+ZVIWP93OP=.L]&Q7Y#3/,/QP);^
MH@>G_(LWF0PB-\M:N8R&\*(*3SQ?,C)Q\_#R\8M=$I>X?$5125GEVG756[>U
MM'7NZ-XU-GEH:F9N86GWU/Z9@Z.3LY>WCZ^??T!@V*OPB,BHZ)C$I+?)*:GO
MWJ=E9>?DYN5_+B@LKZBLJJZIK:MO:^_H[.KNZ>T;'AD=&Y_X.8G%+2S^^KWT
M9WEEE;"]L[NW?T \//K++AJ EN8_M_^N76Q4NTZ=/DU[FOXONVA.^?W%P'::
M[H+<&7;-!_2V'AP7Y5\P<-Y\DUG6RBBB8(3G>N(YQ,0MJH@3(_QEVK]8]J\S
M[.7_+\O^BV'_GUU8@(66ACIXM&P %#@.FG=KF8LXRF^%1DZDHD&-TGY^'K@-
MB%.I^)!+AJYU2;;4MTYY7=%$0R-X#06(0!*M*<#MJ38H\6(5!5CT#AFD -N:
M30+(GU5Y%&!%RF?N/CTM!6"A /@&<G3-*R1>"TX!NI;_^5:?N0<W!$$D!0K0
MMG5T:9:- K1R82B 0#:9CP+@_$XXW!@HP'S,! 6(GPC6 MRA>.JCF)N7T_UU
M*,!ITV:2*XKH0 '"YW;U&T4HP$M)&%G%>H^3IH4"M$-),A0@RP4')K%94@!"
M/12')O,@AY3Q*#)#"9(XXS?ZMY9_:_FWEG]K^;>6?VOYMY9_:_FWEO_G:/E'
MA\29CFM^A: ^CFF-3'T^TW(:&(NL1%" ]0U5 :2*VZ3OYL_L:],_!^^A+26S
MJ<_(0P[(48#:?#+VP0VPU3^C5C/:8R@%Z#U#=*$ 3\;3*4!.V43P#3K.!__S
MR9T"<$&D5Y!,WB=RI<4^K&[F8YM-G;F.@>H7X?V'^ZE78BQ,KA16*#1<^<PG
M:N9A(TM8TR&<>;,(C9QCJV0]M=89BW-R^S3JK:_QVKK?R8]=1-]5,#Q Q/'U
M^C2SY#7Z:Z=I,XDP0N'4@M!F1:XS1'"\D6-!7_C:G\8ADB:GWL762ULR3U/$
M_7/BUCV2O5[FG),L+2.@(_?T)9Q]+3?3 _+>(UX$T$V[,;Y^?<J-7J#\1I=7
MHN0?:#0VM0.*%< AXZ6?D_E7+64CDA7WJX;V5HP&32=>^3E);]1I7C!_XG^N
MH^$GC\/UMHGW<-B9W\1XV6A9A!(^R @/?N%CU<PR.>WONMHEP"?[NV;,U"J]
M LZ1'"]2H\;\@0?88[X!?FY.G&K'?D@+M%C#VD^M7M0N-Y<5\?(4N?:Z.^)P
M/Z/!*V%/YOW" (=E8Y"&FL7(UN:PV,>2#==$76YY=\'"Q)M)/W8QJ$LGZ9&1
M)/W@0D<PR&YD<P,BX^2'=1E(3M,>QVKWNU4V\E( ,U>+4I7"Q^RP\Q.TQRI$
MF8-'^,'VH#D&Q*7:D;T!=HUG!T8$ZXDD-WA)JY29QRU'<5-9B12SR"LM#+<#
M%IE?@YIVJ0[O[V=:VUQ3-K';,!6OSMT8,[M]G?\GRZ\>6GNYL FA*Q^;.U@5
M[A-84][GZ;D5:5VMY9B=G)UJ]"V_?>[0M>G9=L<=4%\^[V'U+X>= ]Q$&TI@
MVG^[^V$L+B$75]L=5C5P95\-QCCIF/)F1L^QR;H^P*A7J6]3OTBJV.2#W>FT
M_??-U$FT/L=*4AS:'3SU"+O2WL+?&5'EDL507,HZT_GQ@SU+1V@-.^\THV"&
M\9+Z??JQ--F82A@[=M G!\[-7U)YUBX%+OGVO<AC^8<QB32T99^+$0ZX$^.[
MP4;]UB.NNV-)O? >61'_V^]I;=T]&D19'*Y?;&+%Z[0V"]D@5(CO<1L"+7YV
M6O4CZVQ@"_Q>:H2/BUE/HUFZ(;*\][<!ZKF8H7HQ4C%=][$N/_DB\;ILAPNT
M6P7"350I\&=NM:PJ#<^=)CIOMC'S*>E%53G^3EM<_U+'5#:U:7RAU=U GCL4
M\GO(YT2A(P7Z?%A)0-]TT$L<*Y5OD3U]EF$Z)RYLU,1EP45(Z=>0P,,R:Z?%
MG50#E<O[$:CC!?7-J>Y'3QK1\Y'MU\@""$MB@W 2KK91!6=]<^U>[4AF>8U5
MT/5'%J\^+L1?_;1Y7P!XFN %@ZZA&7RB29K%1)\0=F<.DEXCH7M_#]W)%0.J
MN&6__^O])95TTJC<U.6P]1:O&N#<Y"=0?A,/*7 8(N,_TF5Y*<S61QH5(4-N
MA50ZU,"#8E\<#"M:W*LU?E/WYN$7WZ0P0WS-!AU.EI]TG\#S8M<J&K-5R7PA
M !G,&5!IO%3IPM1+<LT]N_$I7)VC]MSUK4DT+@<&RB.F7\=W-D?FCZG;?7YT
M2]3T3=N$:?K;MLD'.^+?CKU&I-?,,O'?BQR.#9T#?Y>^;=>!,+[L$\A2MJKZ
MT91QBQLW]*6O.R$^#<#,@[$.AH3N>,5FT#01VBG,H^_)MZG(JO.H,H'7QQ$'
M]#PPU4Z\R!G)+'_!_OJIFJTF-?\@?>)&/DFB+F)?]MPJOY[S?@WDOG+Y>3]C
M;M(OW:C)+]H,QH-<"TT"-00=%-)QBXE8+ALQ>P4O&R7%'>3&#5LS*_#(T77Z
MQ6D5)-C3IAV0PL/>]N9CV4<*$,2YA0JA(WB1G,<1?K@MUMDUGA"A'XH?;]VU
M<@>::E\>S4];9",#-G[[4( 7)4 0-"Q$W=^M&\I.\ILON>Z:<M":-7=\=W_A
M:DKQ<)'RSSFH\L KN1: \'/"VG[1$+1JJ;HZGK:9[I-;F7&_*6););3)H\;?
MI6Z0][L7C'=U#D \2X.AI)$XWH8)\(-A=:7@0LN (J:U\KQ,#[]"B^+PT.E^
MD4N,P,M" U;-(@2?6S1MQT$@J'6*FKB(]):CC7(N*N&8X@L502O251QB,XN6
MMW\_T0I_P^S^Z,*U\TS 47LG3$B="R< 8IVSAH^;<=N<'[,;EI(I<7V2*/[Q
MP!/FJUPZDLC8VK)E3%(E-N,H0/2YNU*N[-]/9##2S16N>7'65ZMK@_S>:O-^
M#,^^YG93(:P34;,H&[K8;G-Q/&^DB5?I(-Q[*SI0N\HI9R7MJ;S._JU\':%O
MXS\$)6!J FTO^I+"8D;P;BT"\6>.6X3%(ENE'18ZB*E%,&?+\JD7OO7> R&T
MNI?\ EA*SO"H!1C'_: ?AG%!I)Q@C+OIS+%K5B=61F,RX^UZ0][O;D^D'M#I
M!7ADGG]\I4)!CJDPI^Q469,0R;^,D+R/R5UK H]#P/ CDP>/IE="Q,SM+C&:
MYQCK*!JI4]U(<KON0@0#/5\/\3C3_V5W)Q@4<H$8=*N68)+!UM!P[!OY=+G&
MC#OU*F].(NLO23T^AE9&@51_>E':/Q2 4VDK"@UNXO;?9E7 I>1F+KM/6NKE
M61!#=5R*5E/=9[K5/W^)M$^0$[0RJ:/[6-O"2;.;^R=:,1YB85<_)E62$U78
MD_3H(J<4XWU-]:>2;*N<1R;<(0IX<JY2CNE?KB']NZZA^H[KHF_:.7?[&Z!O
MH13@W$+3=0+HQ1X%2 "S[PEYF1#M2YUF^<;4C7%Z8?88RZYR?2<XUQ^TZ%#1
MEX=F/BPY22_EK_XL4(1-MKFQKJ71D6/G18<Q)>0KJXFQ4W!%G>HAL>K&V]CV
MMY52A 6EME^HE%!($>&@4QI$'?'0/1C7]".93'N[/,/"8F[YKNV96^QN7N>D
M:#T2O!*T#95RFE3Q1W-.XSS\W]$.A<YLQ=58G\YI)Z_SMF^JY:?2\?2Y"&F/
M>0H0!9$@PJD"F=#ALR+#I21Q_&*'L$#&PNJUQJ*B/S4U"=<VJJ_+H'ZS8UJN
M=]N94X!*GG:HL']%9Y/(RQ&<]?)HYICW<8.0GC:^\VV)GPMCM5ME?V'_Y?=/
M:7@#SF5=_0F(LCO2;GQ46<1$(C2+X&FN$7/8@S3AAK-AGSNY!NIY1=\\B&M6
M#_.40 @B.M^,/8QY8]T8N/]>^F,NUED9!?=?$ZI<4WW[/GVS4-F]8W[^;"WF
M32F$:]47RHZPHXL,E2D1JR5F9OK'.>_OLXE]_1UJKE*;;&#>?='@>_&9X=]U
M4G"SMF8ZA+4;P7*K#6P;K-8B#$HWFB!)%WSYQNH3\DJ3">-6KECS*I ^5DB"
M=E4(VH&%E!38K(RKEL0O93ZY.8.=FLY)G$KZ<2?TM^$HTXX;"BJ,@= Y=3],
MPFU%D<PRVX&T+>.AW HV;"+NE/R NJNN:/"82$;5#G@=A1?IL $1<W&Z>U_%
MN[ V5;@UO2@?J_X2#IV*$5?K!8GYV9:LA1.;>ZJI4IHT[\(^G$"/'_I[/23X
MK5. A1.1VU_0)F,RG\(?5U9;#]^Y32@#@FF@X8 KT6SA31/^ W8KSEN@.>)!
MM]<^LH*8M3V@Q\):*GPY!\6B"W!_-R$,%Z]2 &Z20A;B!GXB3,:'U\R*P%I\
MD,(6;?S\36>%>$JO]!+K)]H&^.)FVK8L5J^MR:$31$>LL"%Z!!&L6BU]/P;;
M*T?;.K'NIOB5-UZ2Q)3?;;6G8S<_8'D[E_$J;9L"T).$":"76TT<SC4PYMG-
MA=F)#KSY2N>%6M53,P85*]6I/#31,8HH1-"/-WR>V6$WP.9P-%>C0LXR1'S4
M90^N\<3P[,]!)-(VWUI+NL.)7:'\+>MV&?;&3 )<MFN.;QW!@_>5C=*Y,^JC
MI_NI(HU5_IO.?H'ERL*=;($98]^5U.N/57=@]/XZ.-F$*C"GY>HYDLQHXS6=
ML*J3*T<"4"KHJ2Z;T;>-*OG1*95D?=D'6][7J8O59N8_:E_D:=^ =:++A5-Q
MUW:+UCX:Z%F?G5WJ&DM3>V6^*7WOI_WY BTST9<,V#LK-X3 +RF (SS>J]O2
MX17)$+]%C4-[&C:7<X9_C<?G_+#A-5$O*YHRE)DP4?M"[*$7DOSQAS 7^1AE
MB=P8@&@/V3GY\"[6QV<,F; CAAI^S8._)B3ON-2LKWG@O19?PH@V[>947+Z@
MS[VF5SY>97UWS;@._Q$?]WIUIV>]>@( .NS#.L+4K&A[*<"SN<F)1R.(!_F6
M:[-"A/"F_-SEU/H0S$G!I^7Q-/V=?E<[_]E-+@YGAFW;T3J[[0C/LYXT^W/M
M%" FA)^*M%A%.M(NY;M)1^0_KG][=T<\[77&9F;"</YOM\W7FK],D[L3U*\_
M^R'=':58RX\[_3I:UL[XXEL9/L_I^-!J'=N,9 (TE 1=P$1"./!OQZ'TI#L;
M/OA9)/U WL])JU:QZB+!W/=_8%>OM,M)M7DT^!G)C^7GD >QR1.AZD$>!42V
M4O4[S4R[P0(Z*0M#PM[UULI+E^=#T77GGYD\?[Q]QN,&V,&1+#JL?GOBUMVQ
MYU4*</%D=ZE-=I@8!:@_UL4&QSN9?4>>"6&V)$D3)QT\J!&+X18.#1J8%Y!4
MZY5R26&P;TKXW63A>W+X4JY?V3RL5VG7'N!\H/7O1@@>"D!WCP*DV5$ #\.3
MRBP4\8H#:01\'(/<R.6DV:NA3F(*("J JSF)M70C)W9;[[E#*R@ Z;5;Q-R^
MM%/SD9Z0WRCP0(OSWXU,W2(1UW.).MK5PXK6D+F[PQN:YE(;(FR=O*)E3-DO
M>L4))5<D (P,'ME]PM,%XU>WP*]BOR\)S#!Q)2LQRNT'+0G0M6E-5[)*W25O
M,VV1=#];KT"$QF2+I43'W$I*[--FV]BY-I^:B-D9W0'* ,\;2TVW\/GKW8MS
MX>TX3,<UDM:"+!>QK?\A_&M0._L@?)_7;G2*?"E#6T3G2<+:^3D1AYYY[T^@
M0F]8=,@Y@GB4DC2]+L$TMA">YD9".E4'OE)XA)V?/RPKXC9 -M*9#I%EB1P=
MRI9?EY(782!GW[3KD@6/+%:_W$VY[<,A7\>V"PT2DOR%"F^F1=CAFJ,\5U21
MH556LG0Z]H78V4G_S-TZNP2UJ%\=@<_RW<COHT4E!+[;<";J7J%[ZB\[#^H(
M0M&3;N"K/^*L]?1^_,%[8Y5>A2A&ZEKMUFO?<H/3;:0.*)5RW[!TSQ&*3+0,
MA>#&U#UP,V<MLD:I!89A(E?X;[VBGD6)\K([L6=$:"8M3-"-FK37B@? "P<O
MU#5]LJ><0A3Q^[D>Q:*)3E^PSE_N'A3Q7;S%8';I1LZYNW]XKV.220_Q!]TP
M 9)^T2IVKFUM@UZG&<)631X8*RUYEN+HHF3QK%%>RE,^W 2Q*%H^ORCN.-)P
M\F%/&FKS==0;36=E^8@"M,V-[/V4*<E^(:28$T,CU>>5'*?R\2VON/3VQ^G0
M8*U\DA8^KV2A:([%G)BNTT@02]RJ']K86@CJX4FP.3<UZJF:L#MX%G$7CXI3
M<M&[^P-AG+46F)<VY59<N7%3(+K$ZEK'Y[B[@B\ACU7-NJ"TR&=H'G^S!?$(
MJ4:='/^%H.:SJZEI86OZ!8Z$9:]H]:U9[5[ZJ1P%QAN.'^)XGCS:X%NA /84
MX%63(M&/ #>HJ<:'E'PB2AJ,;#[_ ^/6R7W4[U!;$".D2IXXN>@8*_M-_,%V
M8:+>??KAP)I.%Y5;Q'?J(DCP3^K8#R[P5<&C$]7\;6/\%^P]#<%K*J[J0%[6
M5^(0+A;#O);6'*$TP]SIEMWS>N:6?0FV\);(M?N)?;"G.A]"?SGP"J9M;V$Y
M<.CH1KM%$,^,$[]ZZGY-,XM2\%EZ"[;;J17Z'#KTW]I3F P,!3VUW&'L%,!!
MVF96R'.JE<S\\OOX&HZ<G,-0N1=Q.F63]?:=)R+N_:(6:BC>>>%1FDU+Z,8%
M'(H33KXP5,F<KJ%W'T_%6"6-&I]O'GVLE$))&,Y^=N@'OO5P;"ETK9[1\MEO
MYFKD"%YD5!=W6V0]L]@IMSF7V5G0-E'T(NG=+3?>K4[$&A*?WPG&?VFTHFM^
MN12!75RPB5R(\GFG7][N\Z3 M>+<K</T+,>GSTP?'&PW1"LMC<.80B3A,%X$
M:W !"=HP<OX'R15;LIMFGX=RR+GU?/A>%MPO+KT_1?*\@Q,3^/UVL3X0[(1#
MQ_MF7")RB'<L[Q9%28W<JQ^E !496O(;H;IOIR&/T%+SQV-%T(0,>FN1]@G5
MP1A%P[,PN&]*C>F1:T%!*VN7*X>W(]<[;KL=FA>]Q@G)+0@-8L""!GA?KA;O
MLY0L*GS)#>1L:F?@<'/)Z339TI6U1CSPH%MIR7)B?:Z0&-D^=PYMC-=ORBZR
M1D@-[[)>T<N)T(5,"?) GK.5N;UY%<\XT_)]&$0-JQ\RKOZP'=G3.U0JT9#R
MKK-D/DZIUQ2B.OO3Y(I7C_ET65^J@"R+Q#O<&#L7B(T29/&AD4[VSC\Z64JD
MFWN+77Y1?FXB@G^$)/]0 20KP>=/)ROH7O6(^E8D6<9:UIB *+^'7IY(<RY@
M*W>0D:FVTNYPB!+0@ ^:[;L07I+@8UECE<V"<ZU!BS"BKHO/5_'[0[BA<7"E
MU% C1I0U,%&[Z/>[U LO ;Z'M<#Q17",#4LMX5(F;KG1.E,/LS*D.%%OZ7P_
MO<AQU#[C3IBK%FWB'<!,:!Z)3<>AXDDT#HMTA(3H[!45?=4BY[3<2C'U@L:\
MF?=7KSL.P@Z=T;-<..'31.BB+!-YB+M\.81Y3'&.A0*XPN968?C$O&1DG@YK
M]X=A_7SK/%DC"WZMDY&"^T*C'PL5#'%NZSO%T_HX9EEVTC4K<W653/]L?:_
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MMN,&48T\BQL\K:EDY9=@9FC$G@98K[8F87OFV^L!SL^7WK!->*JJ?&/H>RW
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M7("&M!][D:[;'B]7%7F1Q]Y!>]>,1O9_$*U\XE8GW!W(@9.Z)S281[7XA/
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MEZP"1HM&1F0S\9%][RGB(MO%"0:TMYC6G:B'..>\<9>I]TQM\K].-UD]0=Z
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M /7)PPR 4,9?Z89MB!; 9_ZO%03U5[KA*\1YZ+].+.R_$8M%6#_V!1/(K3$
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M5RZS\N^ MLY(BKU!R"2I%$Q0HK=7TP</O'?0(^!R5W 9?;(2-JK>BFW=)#,
MTDJNZ\.)VW?%63H0)@<W*)HM 4)]Y<DFV]^>];GFU/1O.V)JJC"29I\^_A2I
ML3B29JZBEU2Q>LCMU54K:UH"71AJ"R1-!D_WK6U!9=G#>'2K>A4E(P1J-,XW
MI;E>]'H7!D9)>:?H&R@N;3TXIAQ8"\I @$EU281NH!/9R5<FZ?B;H3[!U2C6
MYS&Z*JVB,;JB*7H^DW\X'KV,F8&4BU']$9(,0,F_GGKN_;_8_O%?KH>7@V0N
MPK.T8L2,"J.O\0H?%ZG*Z;T%NH+0I-BAZ5T!XDE$UL90/!)XQ]NY&GB)0S[F
M%JA^0>?*VC>T/\6&?$^3@B%\Q$1Q([:L(BR.;[IDXL;<J*C;*ES#I6&<!8"V
MQB,<[[00E61- G<-2:=I@ZI#>?36DJVNX,N7RTHHE2>Y-W+<624'X<3OXFW7
MR],,\?Y,)TZW'S91\$LUZK66;0!'[(-:0.Q,!-,^.]9R>/S7G<;.2H2G>KZ?
MLN9>^%K!FQ=Q*M=;+3(N)[Y\K,5I?/SO;^A0A0Z%\"$ND!K&ZK"%C3"WR*S/
M.AU5R/33R'.OU\UXVV#Q$BM.RNDW+4D0O-D.*H*@E^1H>>$>BFL,5\4M$-,F
MWZ<M](L!.$D7BZZ-PN&ZPU+Y+_O)!JOSQ.KV_5IQ@1FRO%[BI8;[!V\^< :5
MF&81A8 /!KS6^:R=)Q22E754/RD10D@ES\M8^D5X5R3[,T)RM)W-L[\K'W1F
M'.593YY?F3S0'J5:] _K#/'?A'!;XA),!(S(K!9G7H(G;,=UA-2ZZFR9"/EQ
M%#^8_=?>Q,6!0NK=B&KHLI+P':36[4,_%C^_\<]EPDD'\B8A1YV?'(2->'YN
M#;^D(_MZ=/<33=!X,"ND0&FA4U8L9ZS!\&UJ=7>N(_KC15H!U68JQ%S] O5Z
M77_+"YB4YO'N.@$))"M:AQ2RJDL:;;&UU"#REB^'7#_C[.PR2M\'7Z&R>W2?
ML#Q)K;09PKX__3E!<T@\UT56>GVUS\]INBJHQ?2.];74-"Y%MT]!_X=;,H+@
MOVFOFA$OF%&I)G']@/4>M0 30KN/7$/-W@*Q_F55N(R_:. !\'?Y&]L#UL _
MVJI_S2+A^L,Z-2L>_JM=JEO"-?^5FR@=2)Z D\L0=L1=!N!L'7>@BS??-6=+
MJ7L?Y^_/MGU9 AJEAF_:EI">3MM&D&,;L<]+'D/S1E_)>HX([+Y3SJ5O"'?N
M30VGF]4C,<4)K*_H$@ITP1(L:=GYY7/7M:*QYJ,$9)W(Z.HNSET#Y[',1 $N
M&#[J/8=]>3A]<]POU=<0<HYZAO8UB^00$JM#CBK:*;*#AJYB)%\(&]]W$TP*
M'8_&J> $A[_#O7>^4IX2SZ<AM*L14;B$W-NDU(XH;-%CLZ.VL=#XY>K+QK/"
M(6A#"TOE\'((AS8ZRWGH1HS<3Z7*$V(;B@76THH9UTZ*I[_[=Y6#2W"7P[)A
M4^]BXUGV3M%(+F/?&%^S$(0F#:T*(JB,ZO>\K9,9"OL5OP^[ZKH8>/ET0#A_
M18YVEH.S\ZRVC)7PLJT)67(GGJ3<"%8Z573?.3&=3$O-)EJP^%[M&J#J^Q>T
M(0E<E''RP=PP>IBP&WR9 4@0/V21K'8RL):)BD9T,+XYC9"1A!^3[(B:"'\%
M9WSZAA?[G1/6ROG%2CE3\NLVMFU1(&+;>BD-LL?3SDN]OY%!7(_"@NH,@$[+
M4T"V>[C1XA,6R08OFES!I*,L$S6P$&PISUM5R1?5T77]<*SET^_S _I/QH<O
MJGZFF6/\,%S7FKO&RA,D-FBV4TMJ&6E"WVM-WV7*_?:ND1?_OB7-1.<+2Y:N
M%E?#L]\5]YIYC"->A>-95#"?^3..!2T?7,3O3>5" I0VA1F 1J6OUF"KB#,N
M,_O4CZSD8]\EPONXQ/0F3C?J%:$^KC$ 3\<-&BJ!WJ1=W'YVH))[Q:[47?]3
M%_BHQ@,0T@=Z+XBM2U'O9#ON!@+A,_1*(?,T W!YJ'N0W5]3RXOF[MZ7;[1M
M29M+Z:5E><RKL>S\(K5;1\AR.?I6!L$T&L/2KGU1VP<TTO?03T@YS>#C%**B
M"[#),N!+)P,@E?'Y!'@],)@F:08AI400"Y[""A>5?#-%G[J,G1*;?=\,QT5B
MG\H>6N[M5(]B[PY1%,ILV/$H"8,(GHU*D:?UL?,T#(Q?!W]'?O2+V5 +-"*W
M!&;"8_5[9+VLH"X.#TRA5BJ@LW=9K8&S*577.UW-9M&1JB#B)!ME\P!H%KX#
M.:MS4<>U;5TTUB,4?WE))TU(K03R8!$K0+]&5>Y?G2*'-+9'N0\=.;D?5(P8
M8JDIA1E-OBK.'T%*/5GLO+DO6_7-$%/8G>^(3D7</'@.!QJ]?S1(&*B]Z?'Y
MVOCHNA;8N)7Z VU.ZF:^-;S>>&%"M!\V4JTCU! &7G^C"6RK7?KH.T"_7OZ,
M(+X6G1\N7NS^_[7=W>E_]]03LO4"V9L6F$4WP3?2L\&[.AM?@('8?UN>PO"O
M8KI7ZA5_HX-?,>L?JUF_4K6$X%T':YTN?WHZA>)<JN.K' P.\B >2#IF?@W>
MA4?%/HKM@O?=YI@S;Y,\=H2:.<!^8.JX/ U;:20@SP"9D1'3(C<H,@ G<N*
M.PX[\0R ;"ONT]S*)MAKWB? EKGVO!!DAP/PLK  .;D%]9@T:HL,C9CF&5+
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M5@;V02\%$G7=X35O=?L)C?:F\2ESH7=V61"=ZF@)'#C6+(2YI6Y<JSBSK*?
M[9%>C4;6:_\')M:=SQ_!B0*J'(<WE+C+W_E@!X^%9S=X68D\C17+BXP;IQ+3
MD@W' V@KGX-GOK3?/@LUF.>;W[O,*6<X+$5G$S,@6]A>;YVN*M,Z)9,4;2LR
MTO#>\+>L@9WZ^%#=[*)-:/YW1AEA\WM%S/W)BA7P>7E.P"#A#+!-CY?B/4=.
M1HY+]#J&A">_V@I;Y.,%/B4^W7W! Q_8[MI!Z=QN3^_)]J/2V&'I@,N=5,--
M\N B8SMDYR7(ZGOX)9'8ER>&-@]O"$V=#C*#71CY2XZ4FM,XO,VOS6T+L*R?
M<IQDO"!+U1@(U23 'RRP1B\,%,,,2J+-7<=LJ!GKMN/U;B;):<2(*1;O4%/2
M5H9\/F*MQ]%3=X]!%-_Y875>NY-!S /?=X."HI>TT^J:]@$H:_NDM\2QT-LR
MB]C/^SKC9'OY)#1%\-)Q%;4&BLC-FHY];1F^@#7<Y7:Y\IIA>%6XF^-S6,>N
M0-9W=/"Q%@FOHM]MRTJD?NW>QD%*-9Z6@61+>U1HEO8@GA[%7[/N&KLI.0!(
MTRRFZ?YNO9]D2S3:VL<-<[I9_CSZ<IAABIV.S"?T#)7K"M#2>0_P?XXO\/[,
M^2#\W85RM>K[TP?:J);)K5^Y3&0UHDX\<EYUM5>?7M,4\A3*U]B2N*(6PZQ;
M\@66^B7YE=\5=+SQ13,$TK0$6C&_ 2'L[1E%R@7ND@50O)*GXZ_OHRZL6#9T
M#7,EM'SU8UO@"M.X)FVRWHXT/3>WV=V;P.ZX/PC.T;]^H\$%I'0#4_$A00W/
ML0'W:PTN0^ZXNT)1(AZ ]?F0@2/H<,R.\+G7&\34DB37+'BO-Q'N#P$/7J(6
M/-\U[DI]9> (?=,E^,U*A!N/3NWZLT$!)D!5G@0;*MFTY2501Z+U _"T05P)
M(5_W[ZL^;>IH2."WJOJZOS-[]S+KVN76^- @_U<(EVBTO^^2A.JL6CJ]'8;!
MC7'#S\C[\F@(YM2@X\WV[_XFAVC/YOG61K$_2&G$05.2 5$ 7UPBSA9R?4P&
M2.>2T=AR45K<:BUG;X--%,,M3<&^EO3FY:8EHGZX*]A.BQ1Q_KI\C R0I/5+
MBMGVPXR+01#/3&WC/5[[C/@_Z+WDUC,?)Q_>\7GW,O<:V/F] )ZW!#\[._3P
M=,J(T17KEZTX^QL6([[CT*3]H.Q[EL95[UM4M]6XPTXG+8OC"DAC4LQPY991
ML@WNN$IN;%&]?I(?;:-MH$YNO95!\<0X@ZXF^376T-Q>F7D168TBH!Z32BKA
MVF-78U3>'\04N;;Q-$WB(**2DA(KWEV'S\N[.O4;XINYV*']@&/G!+"S#6V?
M_*EL:]N$KU@ V8 W\WCS+NM=F=];/"N-.5187<\=KM7^WVJ]=X!BP*UP>R][
M/(>O!P\IUYPH5Q/\K$(J1C@(MK-5\V+9(=+E"3^#*+;G@>.5:^;VJS(4PS"[
M@Q^CY_%CE&)-?*Y6&%2J.[#05%4T]][DHX>H\:K").^%;G&OI(;>R\8;+#PA
M/N&H7#^2U;+8GR7$J,:5=4I=I&&N2"%(7+#JAO%^4>OM/4MC ,U6MGF)DC]4
M\ TDM.4DBPV3P_5Q5-EQ.9<!-M7A5E;NYND6-G]]4AF),1W38M:-<:]DU>04
M71C<9[S,L@B7(EPX?QQS(Y].UB"#:*F2Q0LGS)4_6F4(B\H#Y,7=-&Z\:)SD
M$-Q7XW'\[WFV 3#1@ON+)"K#6Z3(D@B2H2SP(Z(+<A)Q!J"QB)US;9]!8'-G
M9A&3O]M=AG?10R<A-DUYP%K1&B!IV LOQ0$W)WAT![/U!&:$-1R?2!M/(24>
M:5V+6V><W\8GTN28SQNS-<WUN0KR<3MD[2U2D5K[S@ <OSRNPA70Q)TBW.Q[
M"=G]2E*2>N2"V+Q!PXF6>-7GW80QOD[RP(4:P:=0JE#5KG]LX5%U.A0B,X7V
M(A1/K6'\338X=W)+[7X<9HQJUU;-8FT&/=:V;)F;HF^;= CBF^VP^KWI@2%%
M2PJ+1M/.-@(]Z6:']18_S%#7^B[TR*TQZC")V0<2"G,"/5TH%T5K_DS&Y!&H
MR8=$ZE/&K#^34";G"%A]"?A[%P\D"\G:G6KG <T_H'-/.<,[0/N+&!#IOEL[
M.4&'+$L="EYKCP83_IA$_.8,57D>2_2@/YUL T[ P<7S;HVG?&/(NU7+*1M]
MIPP))J?#-XPM5;IFJ5W[^W]6@4AN0 !B&'$-@;MQ#GGW9 &!/2PK9P#"!._Y
M#N:<\IU'P(^>G N/&QA7JDQQ!E AJY];N.**,T#_!,4FLUGJ&:#;&$9Y&D0*
M/P-<-C [ R27_M-*C*DK36R-_G$Y!?^P$C7>6BU8\:=C,YAVKY) ,984_C#
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M=+C=$/UYJ%7T"8HB%G!P4^PSPBDW.O ,@ %&?H<_;QR%;6J<;YRR)OU;C%@
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M %A?@K)\T7H(+6D>3YL=9(6( P/)1@'XZV76% ?O-?73R"3HBOV7]'&+>FR
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ME([N$?V^[A14!89$$=B.[3L/6X"8>=-I/'U"MQIAO40OLL]H')ZG(5&HE_'
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M19T'DR)\!GA+W_-UN]NM;%\%T</I3>8DFKV&)DP.1TLA"XEKW;2E4(<[;F<
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M.Z??OOZ>4/!Q<?$)\(D("(A(" @(2,Y.!"3?52[],P:^-0,N89TZ_P2(P@A
MO80"O(3R;>:TH3C?VE"D3KU$1SFGW\((!*"@HJ%C8&)AX^"B_+D2!8 *_%%)
M!$!!0P&BHJ&B8V)@H0/Q^$\K+P'1&"[SHDNKFQ,S.OGS89!$9Y3+,#&3:K18
M\ O  P9D,5EB-#^^W08Y"UYY6A%X]5:LEJ7<RTR$$-F@]COPI\I[K4/(A1UY
MUD=9055Q;<.+N]G5KT;>[^E8N03'Y]2TCW[8%U;0A;B&/,ZM[1A;.K@$0$4]
M]1;MW"=,#'3!<Q<8>"^CG7K@Q$B,SN<?37+F08O&P$=^9HNW\( 864U2D+/
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M78DKHVE\J)!"XJ.'SW:4Z+$[U*>OHGR\5#.1MH=\1VR,83SY24&R@40&8D\
M0&CJ:9>>/8:=R*7,E1;$6&.4%OI8FH'M8;K9*'#,1ZAVZY@I.#PJ:I&!8M4K
M@O#NP52?0-_ZY[!=9F3)5<@(NGRS$2_%9N%&8-8Z]&N(80RV_%IT:%DW^'4W
MNK,G8]P$42AY*TW%DTL!5[2$AKKN5L@9;;<GN4C?M>WFON?G4ZN9 F)?2;*D
M2^A;/=GC7)L]:7>13"C*-O:)SQG)M"NRO;(+8"!64@Z:?#TV^3#)@IW3WH=^
M#<EYCS#W.9@S7YV<-T"GE[N/@TC+CZ"-&K$1=;O7::I;0L$6F')X6;*K\4NX
MLDCV]X/4B['@Z^+.R;1&WO >2IBZ?16[?B'$2+TEA[&[)JO@TG-W-+W/1=G]
M,4,Z?=LKJP%(N7M$UO-]BH^KTL@G-!%P$J;<GDQ@X%[-QZU"GV10:7K<3?K=
M/3K(@E2@GC%F_C,5L:1W:W8)ZRE>VO7)$N%F9&XKHW/ZJ;EI#;BH_(+5X EB
MP>:MFA+G[=$W>5,UC!JZ'R8[L1%\Y?P53U<LVKC:S(B'F!=@ZM'[_=3[3.^D
M(*:5>V-7ID8BU4+L:&A0]ANG+)SKWM SO;M%T";;/K=>-AY6['80+R0HNKQ9
MQ.%)Q0015(]_&6N<4H>Q_QH-YV7Y$IIJ^"T;RM#W%<(HD6:>#%_V\H9O' 'W
M4[QGUA@45Z_FZIIYFXB7>/)KV=,[/%;$=ZL+?=^KWU(P91'1.^%3L9GGXQEZ
M(FRRLJ88D[YM ,F+ND)3+TV&PAV0 (A7PZ8G3MW7(&A.(6JE.2)B<VZ2X%\Q
M%8M41Q[(WM_V:*T"B0TI%;]6'XK&-.5[^6D'W<97M9*<K&,</AI)ZW7\YIGE
M)1A('WLC0/1ZNM7K=[HX1-B='PO*UP;*%-2D4OC?/^<3VNN5U'[Y^C#GY:IN
M4;S7ARU.0IB6CK7C>QOV:SY1TR?+NUL9=>6,@4J^-/1C+I0X8I0#&\/B%+"-
MPC5+C.O8#S8?AT?5B5P58AN7:&EI$<&L_TPHD8<E(3Y_\J+TO89M[^>^9>'@
M>;XO]B4)JS'QN(T-+?R!$)OV$$VGAY(] 9N[(Y@I^";I@KEY9?8LX/P!TI0J
MJ/3=4)SDB!2\& P/8$IJY3B1$%,^C4*JLI>09(;3YXY]NZZL\:E1Q EG>*F9
MR8"6G[(VQ<CG\B-T?IA3S=[2)1>7NZN-]-G4%-<DE0P./VW=*H][=PM'11C(
M"A2=\[+W\]Q8.IWQQ8EK5,1Q'D$:51I6-_OX0<G#BX@X"K]]5HT5AHRHA&4.
M3BY;5,YLJRI*L7I:Z4="UP:2S;+X1!:\!CH^58NB(::I4WQ*;[@/#XNE#PL*
MCKJR>DAB5H"$R]C-&YO!-*:/N%5+GL04-"V&8T5I0SELK^45!E07V<?E="WQ
MT8=,C&@UR577%&+U5&W*9T^)1<RC$O#6H<5XF%$/0XZ%YMXV$7:.38C/=!>_
M6: 9-J[%KRFH6'U7_C[('\M*QXJP9V2EAS-GGVA)FI0TN"8)^QDZ4S%3W!+$
M$&D4G7@MAS19(ZJN%[MW/CH\Q(CN[D92N*%_8.S4QB?)N'MY>]ICE!SC1S?>
MJ.PH189P)XZM(AZYVZABXFH6=VINV9H/XKV<@H)[W'$//=<,J(,<"M[%-W1>
M+I:Y3!P0]< ZD2*NK(AB#%/4(JP3,4\=T'63E4)0E(Y;<@ZVL#<JUY3G$6#0
M^[:*\F/%T^71ZX;^':5Q[R7SAP/F<+U30&F=B$=74"]OM]05IIE956*T5P^V
MZ_&W#3QHE<]V!+>G)U? IMT>[:]$BEF:I>Y3B--Q;"Q]VJHUB$9&>N_Y.L["
M=NIH<!WLQ0:_\"?EJ;F;F>WC J\>8'+<#Q.XY9Q*./RRX)4G%;OZRYA+++),
M3S2Z= U6C0XT9_T"^S^42)IKJES_ZZ'UZL!]D;_!8:*+FO0XWEAXV+UI:;CK
MFEDG@[NQHG$*BQLB1A&"EVTBQZIE/5Q^-^#9M7%MF5<@_@><3Q9)HBDZVV+(
M@SUY!F)<)KQ 3K'E4SD@"6\,7]/- IFQ,2DCT.$U4S7CC)#UM-+V\15G 5)2
MUV^ UTV9ZK8$4?0E'T;Q34=2(\<%/T+X)H1G-VKPRVLPI:4CV^VXL3,<]UH9
MIH(JJ]I)+*,#XBV>WLRD0A=;D.\6>F1T76/]B; &DUJ[2JO('%U9]-I8SE[<
MU.'K;G/!D^S;OEH'-.WL63&A)N.;U"-6& O 4)P=*MTF0UDVIG611IW9DL?<
MCC2IV_41U<\BGB'87+(6@N\.6$2M:CE [PS:#1"37>:59\_"1T?R:F9=F2;H
M0 TJ<\J.5&XF/_%NW/C8^WFJD_5^@@6].X4 <?MK\R36FMLYH?*9"_'7R4M
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M$5)I7PFX+9XKU_B,YC$[WL?4G(=45R:J_>7,G8@YZ/,?#&1KXAPZ91I>KK=
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MS&=-)LN#UTW]IB,/RR60<6HU S>;EE![TG1<\%X]4'N";XC/5L##6W-SKD^
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M#5X;?9@3D[3_D<9X0_">%=G3XMQ)?:>\&,5!A-MM<E:VV^26(KT\6+U8'7I
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M><[F6I>\EYR_G[A.;8.O'A1ZR2*8?+GS<&;N]LV>V]H MA+')RC]*/ZA/7@
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MK7,X4[4ZS9I+F63<(Q$^T.:Z807R%CJJ%!A8;MB?*W[2M,))JHK4?C@:-7?
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M$0<-N^"6K#?22=?VSF]_28L=,9YO/%R %454#G:8C-HA1$RVA5;2DIR3"D\
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MI'904KOH "72=?[N04Y[?(#LQ-8Q#%GAO$PH,%=RW#5\()YO+2/C@WQXLMA
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ML7D^.Z(<,VR=^S;A;W"<]A95%D/U%R)MO-RAE!W*D2<'717"HZUMS9Y-S[Y
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MO?T%G+_^J=1;:_MOWD6/,"76MK/6PSSQGQ+CT_\Z:77CQ-X__*^5TW]S"?+
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M-%3'N5FOJ=Z JNG[W.F+0],];YY7S/:AZK ]2^=DG5I-"PJ&5!8K?9/9YN(
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M >$V-26PPRHNG=2V0WNV&LTJRZE%A"\&GQ&0:FHLXH%<].*SPXVN1\I!"$B
MD$X=U>1WPA%8TXI;/<A296DWU#NQ@1*!=ZF5MZ$+=WI/E>DAH]OK>:/RC>AG
MF)B':4<VQ*V#:HD9S(%R;X,^'HV$&N+8S)KCR[<DG?9]@W-!]3/BW!%Z[V8+
MD=.-6 "?@*CT:JI/+R*7ZH22-)CQ1W]\7\O:/0+CA%GY-X$>'CJ$\W=WV#HV
MS*;4RI[KF BEK3@7PH-&&!)ZUR;KEASJET/ FBRNG8C-S14UT7YJ!E0>I8W&
M@Q-V53G7:?7:A(^Q^P]HB86>E)P!7TUVLJ-T?%&._SDV&\W 1J^& %="#6OS
MT:2=GB9,1.]*J6S(%'*0]DE0M"%XQK 6TEQ,^S[$S#2XOMV'I+%3Y2:#74AJ
M0EQ<*8-T8+)!2 ?1RN1634H%83FEUXOA38*T=B7BO12!R_"H/(6*HVLC?S')
M*!=NK07)LEQ#K3T=7ZW,?PU5^Y<_<UEBBG=,[E],_D=OIKZ(SK.X,'P7ILYJ
M./Z&+\7[K\QEPU9-POEK,)-52[?.MX:UV]<[?F/\<TM],Z7^\XL3DA"A.BH9
MB#!Q<^<"0X*[H<HB;VFBB* G*UFE-9X[G."-6$/\(R4+?! G\E#AS2U5YD8)
MGW'XJQC\J<_%!UZ_:LSW#G8)*S!/\1V#KN;EGUY9F_%*-\EG/90#<]F-%-O4
M(EH*J!4T'BHDC:<T5*.K\T-</)\:L(@5-3IQ->%K9K%0C-8?3H^#2*@]A?,+
MXGO!!3$+1_)O[[Y7UQ<U];0M.[B*3 7<O9[GM5E--)XF7A7N-4M?*N5M"+]0
MW 8X)V8R 6RO7HT<1^8PEJ!ZW0WIAH<F:B$R ,P0A1H(X+C=4XR?P:*P4%W$
MIZ#M#Y+%B1B!!R8@SQ^3WW.[7;5E%BRN'0+7_%!CMB)&NNZQ]7WY?+'M-(TW
MPAR\?/D^]T4F=[R_>TES@C?M82P!V/R;1R1C2L&*?42'8;+4A!P AQ@+0%']
M08:#Y292^03Y\70'N @\B5WR13U6,FX@+RM>>*@,,,?$R;QR/7BX=)358,="
MLSE"Z^<F.U? 2B$%2?_4@B[B''_/=!U-)HY7P9T-Y4G'DO$-GOU.%J)X 9U5
M]4)QQ+-'"^%TOR_HFFQ3\*8E0D6B^K!+86L1@FIN+D^@/C@Z1O"YH9=L?-]"
M?Y2KS[H%%_\L=^7Z3V#G9.^F1N[_471S'-ZK213 SA]>.&"7]VJBH7D-/WFN
M2CWNOCZ+MG62L7Z"HPSO1&BRNO-I.1.57K.M9RL^OBC>>GXIN2,NZ3L=B.G/
M%#)P\.=7YOC*V1/S_!< R.8L+8)@<*(!F2\9%ZL!%F1BZW(PJWPIR_D0J%GX
MSZ0\$D&XSMC5QJQ7.BRI<;%0A/C\C[V!TVB)MS;E$NK;.;D)".6=?9V43.I6
M/>(U#Y0QSR7^X"V+AK.EDS;N%-=LV M7WI).)[K)^I/4JL-FI*F4!R-(]6=8
MM+G]5;IF#OV78:$X=D*WPG$<G';A;PER:0R/&8B[,?@T.(J"#/%;48]/M^N>
MI'/V/3O%D6WVG1_[.#]>U#HV9_0F<.41!U440=5R3RFM6^MJ_0383#'?;-=5
M<@WSK8>,M/3"DI<GT"%%=1 -2B[ =*.C@*UUM*QTL!-#6CR<2\W)5&D$]SH*
M$\E6!)2/!C?N 8W8.=_W3Y^3W[I8Y*)Q.5OG?KMO?&@5-ADYM4[:6W'#5D+6
M>6!O67/K=Y05;:;V/O1BM$=EB969,!_A4SL'C$4M4D7,&0\$4H)K0@KG08$8
MC?%9;AHN6P]K-!]NN@*L85;"T2?$ PP$.:1@!-#R$8,E_#M*D2!Y_] ^_;.Z
M\J&EX-4.G%:+8]FE&+TKPX\-\]9W^E\KH[+6H>S-0F@;L2O?F_J35&]86.$)
MR>GI'LD9W%A6'.T%!TA/D%'&/:FD&_^@-?H0E/__@AIP2P5OV@$4JAH:P8J[
M.'66K./C5DP?+VAFF:(FNBB4&"^*.R&$/T&!,_ID::'#()>T@F.5^0,K5)#)
M4U +@)%N3H!55N^ENU#B'BY5&868Z_L!L4$, $CV12L%OMAO:1D9F1CILNH_
M!18-,E],ZF9";J#!:(.Y7$?W+99JY5U-Y/LOW9G;"1;"GZ]VR]E'XI&E\Q ^
MCTY*JYQQ>T38)B:+0U A!M?OQ]&BLQM*,]VYL6#!# KEE8)IRQY 3H7#E?N!
M)+':>9VH7;([QWLMURS$!8'I7FLP*0>WO!2Z69*U[>JHGI!6WZ<O(AKR7!R8
M]!1EPM$']$$?*5M_8I)AFS+$_>,I+(D(*H8*R3[1G>I<GBHG6NKOG'2Y6=FQ
M_E26N"#+6%)"_JL?G>X=?3;IOF6#,CZ,04.>_O-TLA#Y89W%1L7/GJI:=RW"
MJHJ*[I\X4C0AJ((T9U*44I11D J:("E$'-1_2_3TB([R%75U_ZT@];^C:O9V
M6Q=LH^A%;*.)2GO?X[Z2%]I=@_B(^0$?R$W*&@"0)N-S3%Q/ID5<DWW'"0>4
MFT'?(6GD]I([F$ NTWISAUO&*L$J-[L6P2HKS(7W#Y:P@3U7?2^Y$Y*2(4D3
M"S%.D8)DI9:*.SJ7O^V/KY484"*'\D75% A56D=<E.U(@3-;:^#2/3_+.39(
MF5V':^J.*,P//TI^3LE3+8<+;-U'<(S/D^5I]?TC4-.\7>N;SD,/B74:Y?P+
M )M&1&#K.,5D9]]?*I>/?K&Z%"<3D/_RO6EE_](V''6"/O*$%G4B.KILHZI_
MND-M;1#Y &^2&_D=?4 _(IEEH(B_?V]@KUQIJWB1;T0*8\KF+WY3&W<1$^J@
M@D*BR7QYH8K+ZNCYCV%15<SV#!:CW:!-K?,RYGBJF<')J)$.LT'!<H)T6T%P
MZEJ*%#&_[JZ1:I7"NQ^S9>QCN"5F!XFY= V(.CGW*3!J:[&$D-G3C4 !JP%0
MW47 XL;>T\8',A#9Y@0G)@6.=*CF@PXRN2U!9;;N$,1E.>! O+K=G<2_9ID,
M0SNGTJ,GB@A2GX6A$?L=^L4*BN1CD?B\>%(>/YR56)$LDZU GRC-2";C_HQW
MQ<S63GF)UXEOL UUG7+"9HM=R,SF$8N;@?%6G3 H:A6^FZ+ACKC^ (K,:?Q3
MN'%MXO0HT21*^_@5_T>NS;H3TWE .45C%S&ST.X?KX@K</2J NFY$]M[@Y]I
M3A:>.EP(Y*).)*<"IK[K:Z:O2NM@+CW_F"L^\OBJL8UMTN=US!;O@"P%N.3C
MF05.>LXT,YL:U7B4E:T\+1LO\CVJ[TV3BU'DRRYS9J9[QM-,I,JPI&&FW4VW
MMXT9^I8DII30F4(]QO9V8WJ&#"Z4I/*(#=W:Y@#N<(:Z*;&*/SVN)M9?63*H
M1F;Z'PU>A"S.4>K_8/T%Q*H)D+3FKV([UNK-$1=$85%*-+6JNTQ!-.FFOEVC
MD_>^M]:M 2NO@I:HJNY>"UI/@0-/L><N.;[QSXT-#$) 0TGG$]4Q8D(M' FA
MA+AK:#AO^+JX[?8!6ZWM>0BAIKZH,Y1$4 UKS^N;#W#.='N:A5Z.T(KB:YCB
ML)7(!\$06=Q1,& <_/B\YK7^=8H)Y[YM@]I*D'>3:'26VK;P3Y4B[X+1#+!U
M[DGT?A0&S7$E:T1,\H[%)Z^\PS'+\K'U .C[*)X@R-IDW6D%L%$"-6ZQ"KP^
M2HM0^,J#L>3AM"!4#AGBX*3D5+V;V(]2CD#3A08ZV91I2#'X[$#[YH6>I-W3
MQ,[1\>* 2<Y40%3[-));#K"CT(:%0"3\;6(LS%><_$FQJZ_^3\.V %9+7-][
M0_>XJQ@&/$/"/<7!@)1=XP6&-4=U43F[]E"88#AG4A'WJ9!U946 EI> )3^<
M<#7$]]<+L%SC3M[ZWA 6$+YJRCQ[-FTI(LB]'B55UI5$BH.51%[:QRY</^Z.
MP$W<2QKE9?P 94<?F.HCV>N6%KQH/R+;I6!S!-)UNF.C]#H0=??X0$!I>H?S
M2#4?K"Q76)+28A\AV$_F]VLPA/%[5BB']05$4*"^=_C%Y%PE?_Y%WF_ ]&''
ML9TB<-[@2A6)L@UESQGHJNO.=YU/R]:3JL-&V21/&^^CT9YRFS0X"*E1&!"O
MPS-1MG[($F,+(?M5]8+P.7O!\+/9_6R$]ABJ,+K*]7)SAFFS+A.OMYE?&MMP
M;F!W03(L/%ZP> ]^_]O8V.6CU0YV- V9,?D0!$3;N:>-V)"NTQ9_S)0/_;&<
MY,Z@L7TNC$U7\,;JF.W7!7W-RA^".B28"J(T;U(G;*M%G0>4WL>$N08R#8EE
MW7\CQH7*#EOO?M%U>6-&K .Q[8TA-/;<?1>+NC-NGGG0N>L]Z3<+D; +&3M5
MQ9!(^X@S0^7;^2,I_&D'N/,)<53\@[@=0\:>1:!\SYMAG\ ^/^N08!_A;B5M
MEJ 77F^#8GSL9&N&!JPF,GTZRY7$XGN6P%4#"=^S\_JV$$?SV[@?ZSGP2MY!
MH%E\YDI<B*]9Y9RPN]L@0G]G A%$@[4P^(#,:P,W60&$>U_>_7.MY/]<?*_2
M:?V6;>[.>Y9D$:+G6&MCXI [-HDN4X='NIY@KHB^NN>3/=:!6X(AA&&2C.Q>
M.UBLPZ,PB968%/1U%6B ,DVR1C(K)41R.KZ7C#LIJ730U: !I@2P5/Q&5!C^
M@Z)?QD:K5<7N8\301X /Q+JID^^A]\L]\G>MFM@U/'1_/8L;/TA-!T;51K8U
MT+!CK=-0'9GZ.OE:4%>@[>-P&[@N!0P( >!B;X_;,J!Z!*3G"OLA-D,4O8?R
M+%5-![X=\389K:0]M7H4#V.L^4HM<=\6^1F3+(:#I+ZTT\2]!I(\^G_@JUB&
M \!S<PN,KHM=R8V!KER7!"(ULI^:9-;$_$LI!])"Z]K6E[%T$3N02?9D-4-H
M$=J"!&GLJVG"O/<2[DFV?=X8<>)WE8(0&X %?#911QW"18XI'2)YLP[S+E!T
MV(]D%3>"7W)P,FG^$;SCA0!.80P/HL@/.M+_"=>5U%\0C;\=C_5%3\TY\><Z
MI9YK\%@>'?*3_^+8'3294.-C:(D'I7I>Z_)ZK?;VS A%M**@'M#2&UN1?@;*
MMGVFLP2/S^Y38SQAZX?.[T^VL, :#D?MTQ^6 D:+95?MDK.[FGASL \-FGW'
MD(KJMWX )DZK^SNZHY]/? T; M*=9D/KFM,*1U&7^?W<?LF%D8>-,P_@ 5 =
M*Y"THH36<W$[1O_E2O\R@3RF[SNDLYX(U'WB'35$*2MS%?;?PZW$Z7D\]* A
MD[7"6'5G(Q"@J9_V&IF:R_;J6VN3<N)IELO'8"C!DR#+W=$&SRG/D2<C>LPL
MS&@\[MUF$@PI,I$&*RCW +^!2AZY!$_>62+C3,*V=O]73WR3WRIIC^J&:*=M
MC?9N>%),C+2X^;"+L^-I-=L)\C(V9G_QIE8494I8NH.4;&ZE:4WO_"JG2'&]
M*0(.M^1Q(MSQP3OJ )['5^.NM^<VG__6>_L/3/E\?-E&#91CE@'I67D!2+,F
MLKHE1'2Z"[:LWRK;X)3A754),>J P<M!WRC:-=02?7:S:I(*7>2$X\8FTRB6
MP,;DQJ=0YRI4FEJ2+,ZS.;2+Y^29FD%#Z"\WQ!7]S]#5=75]FXL+(/ 48JM8
MVQ95F7DG-,Y9B8K'R5//<($2T*>.4 Y5&]N_OJH VVC?EBE,GG#!A?D9Y$RJ
ME8'BB^5=O;S*1O2.153K<UC)_:K1#6)V@1R\OJ<(M9,LHX<1,V++]_2\WE#A
MS-@+.7Z8*18,U*:B"1<?V3$W!W%-$/\+Z*R9=%RUH)41(S2E6_N<P,P9S\RC
MH*+(=IX;EB@Q9\&%K]3*7]X%14P18\CV'@N/6HYX'\I)&TP;@4KS(TX,E1YE
MZ&A9DYL^!!)]TE^-K-Y?#2!5H DA :"*X" [()FD#!O:LW3)E= >=:&SFD55
MM1.$_J ";C[0%YCI$=I_(K1O %7)^>+]"*R2*%?X3ELL=-T+W2.NM6#"%, C
M9X8LONEBH?HU?]M57$^J:(^65RVW$;'A&_L+&-JD<(4YVQ$-,NYKYU(%PCG[
MUM)E>LO.;+7<KC+#C[.%N1GI&RC7)5M^0:MJE]9<O-\N"."[-[$YX^7GDSKV
MHRJ:(_%\AK#-5DG)-=96X.2*9F]RZBO\YE&:-!OA+F*U9VK4%24;57IB2'HU
MD+#O*=R]Q[TZ5=[Q:HX763>C6YV!X+'>V5YJL(ZU.K0O'I(F?Z8X350@.356
MBWU3[ FZ#XW_=$Y-\N-3P/"%4[OLX7I*]'7J[D.;*.KW77R3*^_V6$.JIW8_
MN5K0I2>^K6,]4@Q1C/:M? FDWYK3<4/6NJ78,Z",L]O&[O(D*I6[S55V@P?.
M-6,-63;1Q6DRC-6[A+.=)3[5%"76ENB##M]]UP;)S*C37J(18YC.._>AQX!I
MU5SA+= 97,3>JFY&$GR8-BKEJ+Z<I[6[]M?QHX.;76];"K*+E7:9[D G2@F,
M^] -55PPB*GYCV)['Q7\982K@W*Y*N,PR:8:07+W!^DQ#%>Y&+(C]]Z,5V$[
M"WIP=DUG<^TV_.=PO57/.EM%*0CRSW">)KTT ZH)9B>\U<AUB;TO**R3W^KS
M"&ZFZS,FQ-=<?X9L0R&@6&TSV?Q>TB$R!]GXZ[H%MHM/W]M#>+L\LRPB=!?
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M-W(N<HF43>L%-\YG?-.BGAM?K=O]-EX4!P1-FKJMIVM"9B]#710@M+M$GS>
MU<[6W6+LEOR->O(@7G:Z)$ML#)7T,F2,O$#IY%!LFMFI_;$,%!W4\$1_K8E@
M%G^S5 AOAPTPQ%:MB"5U CW?O+?^W7R691;5@SL$8MW5T=[5X<XXLGRSJ48+
MIY*B>LX;+QU4;-#$3X!$V@\ &5>'7\&H,(>\OZ+L)J([D0\Z@@2=L5LQ+MC.
M'$'[+<U!H@D,L70A'_8QZ;OJ#9N:++,B>;5.7)7^9]2**+?[PDK=\1W]/FJ9
M),T.JICQGB+FRZ=Z+$P!:700&62HK?WK!T07(HVY&'H_,"4UL-+YME4./'(0
M[#]4#K7+IJZM.?&A%BW"EY5^9&@485 ?KOE%IF=$KS%5&<QWV%-_#X.JF0H"
M>^=?+,: [2@H$;)!V\9-KVS3WQB2]#<&T)3=O< LLO2R( >,)<&XR>^:YA_0
MZQ8)?Y6+-)[F]W7>T:YJ/5^L4\'7MW!OT_\%X(5U'&"@Z.9A<*_^-+'TY]'6
M&JK@SG804;"&('-C1BN0+_T%# 2N1+7GC@6Y\B6$]G%$G;99^GG--]H=]F8Q
MT@DH8C-:#CLE4\A-CO9$'J*LY[.B('?L]BY=Q9PZV](0B]+M;9R_C[C!FZ$J
M3>)NP&51?*<WK?(^7D'A9S'-8\&S3 #>JJ:G[/5;B?"R?7ZYYJ>&9 .E6%PJ
MR5V99X5YJQPSBGLD;%W>S,>ZS$\E"VN2QQA^M)[,9UXM>,I#NZHH@8NN*G[)
M4<%X"'D'('U0/9P;NPJC.C$-#8.1LZ-8INYC;.UHC;1+3<R>U3:0T 1M7_-'
M%PL"_"29'&XEN_0J7U])^7S*P*D(T7/^R1H2;)L87<1I\V?F7+:K$=NI.CB0
M'36!)'KBYT:;! %1_80>3[&P0/]F9$/@2OH>^E-D5,2N0]6U"B))/]I81C+2
M!.HI#=&H^0(N"W)LA' .S-F*T-LO7V3H]II?J\G)4R8\>(P'@1]6J?V01!2)
M++#XI+_.W?50+ND4?.2)Y2'H=M4>TXC&14MBFWTO#0G*:*&M]UI6)JFD=)A*
M4D[F^APMDS1Z8?/3F*T(^CKXHQ:&U';E=.8BR9JGF"B%+!D4FY2(Z1RZL?./
MGS@#SQ]G4M?XT?1/&#(8 <^;K?W*<4R#>UNEAWW!MQUH9B7//;?KE-:>/_(W
MIV20*\I1U.AFE::/LW:9#&BRN7-D 74>KNE:O^Z*T9[,''_S'-IT'K8UYB]L
M38 )VU!ZLL[F>T8S^[4 "&&>ILD=*"Q)/$T7!'A<AL8B3VI_"EZXO?6O+^W;
M=="=>#@C(TNG9QE2#RJ3=9,%DA>W*%7<#+>!1-?*40=)1FFJE&_M8HRRM1MF
M49>S'?B?UEI*#1R"N>]QY:MQ$+_N >,W/!OSYY]'S!MGJW)_GYV6W@^:)BH=
MF/_X1U["-C:,L; #09?61/>S-.9S7("JS+^ .$GH8%?1Z# E4)+!<VFCS_H@
M_P0JN(9MY[C'LPDGG*H0M*RK(AXA7?616Y:^,\*P8IEE^CC_Z81:/4MKXW;U
M),<GQRQ9AP#T)2K"]Y0D$VIBXJ!C!O!<>5_"$>^):8G:I,3;@(]/C=@P?F*H
M%NY*A>U^D:LZZR 21SNH5(@LK8 17U(2DT:3:CU OM=)P1/C<L'EQ-YNM:F3
M:,]B_'XV TZWN!)NH;Y_-Y6"K,UG#A+W/Z=O_]^@Y7EW^G4==Y7L%ZDA,K=;
MD8GYJ^61WG8<><FW.9WX>@0DB5$9983MRY',!#^]<X?+CTQT\^.E+7SK<Y+!
M>$2,!J0,3<I)R<@X/_"3A99DK+M1-SS8JODYP<0^J?!8OC2QR#!QKEY^KNSI
MVEWD7+$1O#C5IA&2\]SL+\FN5DF)=*P.'\,RJ1&5QN8(4M30&DE))I9@^#O6
MR@>+$<SIBJC 0_IT'M*=H4I8^I%99VR0BQ=IU96^$I6JI3 ]%CR*948F*A4G
M_G!.LH)[<(>($]ADN<##\T%:XIU=UNU ]\79VU3]%0F>_##L9Z&$H/AR.JVO
MGVF!E(T%*NDB):;AL7G+;IZS*%;^;"J?F=/YE8,!%AOEQJ;K*3LV7TO<UA[Z
M^@7\)E^S6?J&$+(%CPJ?(-H[&7EAHVZ^B;T,XEQA70Q_NJ,H@TUC _V,EO3-
M&[$]R3B1D>:B#\%HPR? V6#Y+P9U:PM*S'[UN;MIP>=$)'GPBH?[$ /.:YAP
MSV0".U<^CU)2U/JJ<U+%L#O%D4],&S=;2IZ/G\ICO8+XDT?=VV2&/ M/+G=*
MLJPON>S\0Q0\4OS9AT4LK@O/4M^4=+A4//YU"!QR3:]F]?)_!+94?;^M;/]X
ME?#*/P6:ZQQ?&XE .S=W3S@C"G6@TUI;(T).&(\*B*UQIB2_/Y0E"(;1B].9
MI1/WQ$/Q(M,9G*L6Z5H?H9D(?: $XQ444[7TNRK!/HV E#@!G[!-#9C=?0?,
M*!#2F]/8'& 5N;8,)A*A7>/7UMX0>T\5A069-]S9.74L/7UTVT67%\,I73WG
M:_85S:^%SU<',:HF^C-4I2/+6:.A,J1=54R0VQ0*#2#4B[GQG+Z@S)EI4)K4
M)/\L'U)>U4-S8#TO^^&K>]JVP<-=$&D=?(F5?^+@P H(+NKH@)\<5]VL:H10
M=#[NE_R^XU=I],!=AHXQ#8-;X2MI@A--TB\ $@2 V*>X+IY6R;DM[:^ROJG.
M7CNV#F&G,]KV440&*7E+F_*\M#N8LF5,S%9PYI1&>GQ64T D5]<U./8@;]8#
MA=HS>PZS]_$$23?WP!KH $*;BWSFV,=6S]\S<$P58^E_ 0DK!A]GP+S_4X%2
MFK:7MH%RT^DG?G<J<'A@U./)CJ&L=47-9R=OXC1/&;1S$LV'4F3<W0A)?@M)
M!,96"$.5)U2#^9^7T9G, [X#!.>&\.0^6]I0XQ[U*6D7[/N:= @0\TU#[Y&S
MVF/?/[*$'G]H,RI."[EYUWDQ#-D&&W_O9'*Z[TAZ:7\^R46_6QV@_)(]O:/5
M''KR$\\O%IK*O%BLI[T9)*?XS*U32(--))RLRH*BX4>U]:<I[SE!C<-PS^TM
MX842 \^H]&!T/<,F!W;<FIHWLP'N%/E489P9>?S"FW"UNDP !.V$LY<Z?FPC
M$O&MYBKFKVW\$F>\F2]#$S6*C$J*YOFS*:Z?=-A*7JWF73]RSN7IB2KV$*C[
MS[,VXW:*W_-F#DSL[>7SNK;J\D]^,ZV"G;9EHP ',6QG\[;"Q=#8.3"?43IO
M][UT\A'I9U?DP3/B%*"7I:8J>",I)=X<H3&<A,9;2HA%<BLS--G-DUK4M-[_
M_H\/P-=KQE%'%9S@NM^:SO\:8SU3?SAH4<EAL '+D$VM3N0R?U4U[GX/$6V-
MEV:/%)'>6CCXZ$<AT!=4<1V<429]U\3\.1:"C*4EI\!P0CDJA4!R?BK)__;[
M]YUXUE\ VJ;:)S%8]K_]UV;7]Z1Z/@F;?G"?-O@M>>1:LTG*.$%.5<]2#9%9
ML:\3-H4JS($)=:PV-[#?*]0-G0-#GCWE7G-'Z!&]-4/RGFT&H:;PK6[#\&[(
M_#.2B %_ <#]\U_"=H\Z% 4*>:%)%0(<RP&%G]3IH(N4,4NVNW.1X-B:577%
ME=>)C,J*_GVN6QQUV2A\ 6@[' T>,]HEQ1\!LL8H")UBCN@*@\/GH%(%Q$27
MC?D\F0LL@K^ "@4JCP'2@=,EB<! O_@=N^J'>M\YA=_"A:(X"'T(83B=(5=2
M]^Q]5>'DNY[Z%*!?J[K]G^AN@596?%L&7/P[2(RQ^JAG5OX1BW#H=R&<T!,O
M%,"/A_4SGM;]\J09U1?GZ[OCX^N;.=6T$H<E\>J];A7/D#T+1T^"K=J26:BZ
M;]2%K^,%@BR[7Q'/H"%C+.DB^S<$L?K0+Q7C%KQ$V4SZ:R;&:F:F,"+HL-ST
MJ!2-!9+<24E2^@2]( H"=9<I#<(.I9_-W8$_5WL_H3WI?'Y9P??E-&1HJ95R
M]Y(^=^KVK[/".G[:S7MBDV/&4O:W]$1.%T*.J?E?OZ&9#4^/CFXMJ^B9XG,R
M<,,[94(J6!W'>:S!0?*2_O*"LVIU1E6N:VO[+_<GOA:DM16W?P&AW:>!3?@<
M14%2;%\-193EKD*7MD!TB&QC=F?W=X"IZ@5DS*VG[YJ_@HE&9\>M$S^%,?18
MTO8N,HZ,6X^?$6 $B5>%SR(/"596%_^/:Q;^&RT<JQSE*CH5VT4%',TKZ_LR
M,_HC#;6+:+)^R-7-M;5-$#NB>FA+**'.K6=X_??YSF.JNV]G@EY<LU^K[P4V
MWAC/=(@"F8<<O^]I*-OPY:[B ^,N/<\6-GD_9Z8=Z.DK>P]VCG"=3_KO]4H\
M@?XDO$@\.=R+B:7=AT;ON B"!&O;2.OW6N4V<]AI$8GYN6;<,1<SG8"OV\^'
M3$'=& -#)=>=U=B3D<>2MU8K>9@1_<^5HTB]"V>^IQ_CQKI$;%QQ??Q0PP0^
M5M>LV</T9/B:$;1A_9.GA<=G3;MZ<7:ZG"/SN1,83?]>8.+EE'-+01J'74_Y
MO46"RS;IH*-SK?4>W<6VR$5 4JS+!9FW4DP6U<JED^FWD@C%1G-.M3]X4JDQ
MLR_.3TCWK#?49P(-.X\FWUR-.9Z^I0]N8[%Y6=Y<,V0_1+G:/=8.M(9L&VMZ
M>34"%];'""L43:48D/BZ_99T2K$:[CX?9V6S!5@_T(,V$Y-,!%=T<#I%B^8=
MUF5]LL8=W?\"N 8W"&5-?->="RP?K(&%U11M9*L.*L_E9/<I42\2HS,]S?<Z
MZE>!JA&VZSDKR0M[5NWHW)D'7W@&?3"=IMR^KXI)#E 3A_KQ##WN(,7_O!'Y
M]7[_<QL?GFY:3?1.3<Q%[OKM9..$ T8PXT_:UD3(H;:=9Y_B,W4/[\'U(V[$
MZGWL#?@/!_Q*R=8"0T\D;@;*=@;&- B=*%I!I95WM#,N0;=):I*@!IS1I2TQ
M+A;WI]O/Y)RZV=!I\'>XRY0">[*V'DW$74%X2U^700E[DPJ9%_B3M:)Y;.T0
M7D,#G)K;T8W5V1G_JI35GM#N ?V'9![&GQT,GE,,IG**60,XCQI(##3N,\1]
MGF='U42MZ:(^C,$=N*@-2:44$Z@N:RITG-R+S4)$\+E:MDNRS.>+0)<>&F^9
MEUX]\:RS'315#@>1F6%MXMT$[ ]1R[]LSW$8VLX,O UH"22Z(E.$#;V;W]S^
M5+U8^#TQWW>%R_8_(ER'[7O>&!HQ+J=4JUKW)5GO=I,,D7U%6X$?ST 2_*90
M(KF:7!=OQ'6<9_C:<V+]LO1Z@?4S@2.N'CI&.(^8O<4 +-3+';QMI-;4$D%>
M8K.M5@_6_!)(C9LTN->,UQ,^]?4F=/BB[SUU<B#3^5\ 4OI4@JM7\VZ;W1"$
M,"ZVT7 &47YK8U:1*9J*$G'1R)B9N[D[XEF9+;LK,5#UD>EPZ::I7RSU/N^Q
MH(F?"'_;I2^P(7U#I*RIS6"J-/IHARU_X4(P;MJ!L&1>EIH^?T$A5\ZMM'5(
M]A='*9"_RZA#]L(JIT'[5:F0ZDP0ODA 3?3WNOZ7Y!/%,^,;U&R;S^C.;(D#
MLZ11%L[F:2%K;P*[.V\?>GH+@ER$"J 0O RB;AG9I[&TX>2EJ &SDA%$<QW4
MQOJL] -Y+P]<1'DE^_Y7B_.U@TAH@F7[0-/N0[?<S>I?0 0WNMU!JYVW=UXL
M2X@N:"%?/8G5@/=JC,8P4@] <F$P+U$2WW>;MG2C878G 'LGL KO>'D!^5FK
M+3RJ_STXBFR E28>)[2."#F.P4W5[ O)H'5F!-]"M,1"0.%]V5_ QH2C\V-X
MLLNQQBBB 1]>9)A2V6ZRDXL.-^ODCWQ->0!\#L5=3_*][QCT@F)!SU#9@X.!
M6&.&.3:4-@Z'!2A)%ZZI!=ILBC"'"I+/S"+Y5OT_CRI<D]9$?!;_WW^U_Z^H
M#JA?7#.TXF](NXJ3<3^^B-14BXW^)#.PIO!QNVHYYLJ/?U5?D3?Z5W%=R-3F
ML%]QLDAZ@5+*QC%2F:JE0>PW4WF7F%R;+!(/- $;%@ 3?(4QEF'Z@UET#<=D
MJ@5]BHLV]YA%N4QNN;4@6O $C;-&S!2RSB"S:@MR)TF4HL)'>KWY[TF$C4/X
M>D"-EE]K56/TY"P?662!#9\(G"/THTI;M8 *XZ/\Y#C^NJ=K8KXK;8)H8*1K
MYVJ1RUA'__L+E RE<,=JDZ+3Z@C%<@*+@6^\:9WVUUKS7XQLE&,^R9L^CQ'2
MQR!#)KN952H8,@*9]2CNRI4>)_/E+\-2.V+=;FH&F>+&X9)59.F:8H]7:Z8J
M5=5;6V@@+-W[60[,/^VLM-,8)17E$HX_AQ34E:[HEJ^8=I+@?+)X9C@^Z_Q#
MSJK['D7'QLK%^F=A>/B!.NB@@;;3\"!YX ]4W::&/CF_=5+"Y?Y."LZ1(AG>
M>U'$"Y^K]G0,W:$MBH&H\?@#.UN29$2 R+'//KR.AJ*\IQQ#]-H08OX1^32:
MH9*Q0\44RL%FUT]O! _+$&DS.1*,Z-AB#$S#[F(CM/]\YMBS*D?GQK7F-.7<
MC[752I"X[&?2.U*?(FX!+/4UZ,*Y[6%'S0=%)I*J>QCB(GV:'@/DFPGYCWV0
M9%+>=>S9.QAMY-:G%W M!D*++5IQW99O>=7Q)R _OT&2;63Q<4XEZ#M'^4LZ
M5G6)V&HV2/7@P\86T;"[@Z'RL4%!@;H93L%M_9;N;]>XU"2< 'I510_R;JM1
MUV+Z0?D5D?W%8L'-M^?6+XT!0 ?VAY*\V**&SEQ,.3\?.Y\5T)=FPO4JYY%;
MZ.G-V:_YT\\GU17[\@N;1:\R9MK3));P6EQ6>]J2A9=Q44,8\*HHTJH'>=='
MN5]HGO>/8@-W.,17DDY4SVY'&LYJ+]PKOL]T->SBS8Y9R_G1B(FU1M[QCZNL
M+'L27:U]XQOHB&D*_YZ/SBUN&^>W6R>-3%%I%J&#5MH4&FO5=-<V/O'+4ZR5
M?E<5A@4+'- M%',"8Y "9\L=Q:OK='2^K*^!^<C(A,8;&+#JJS=^-3M@@*D-
MP_ VYTR.+_8HK"?C;#'A[>C%1]/159ZXB3\4<AEKNTP"\#('4RKB(V11?OI1
M2)K*!Y9XB,5CK1\7C#K00NXJ%QZ96OAE0.XXO&M:)-:A*&6E5*T79HSU9=\;
ME"41&?QJ/V#B;+ZZ8=U@$BTVVI'QO-.*)V)R-(57&(<+GBL(7!<Z ^R@V-N3
MW\&6YJYW E]9/B\;E[E2;M4VS_VHYHW4T#&ON.<"*=79^NROKNFUC6;(L9;F
MG&Q9?/$)[2*R2T;1R2U*X[.3B4243;>%:O*86D7OT^2&:Y\G+8SY+Q_Y^V#\
M^4H>T#[JZVC#M[ST?VN?:EHX%Q8PQJ[9A]>"!O1R9^Z#[",W=#2X5WWM&VO,
M:@-6NNLUEYJ?D&TAS<WY9">W:<K\NJ,1.L6D,,$)\GVQ/Y6/+PYUC7T*FONJ
M_E=@1!U-TF?NJ25#+4^C ,/]S02#0.>!@L(SC#*BMX</N+?)-G5W(^'2SSF)
M?(Y$(9L826/X?2GUPN,3ZP1,-#A8/^HGQOM1RI[;1BSR2^""=P2/U^A)80^:
MMR;ZQ2&>O3DF6</:!E8UI>4DL6..(Q73)R!]-=6/E$[V]W.822S#A\XN:YS!
MI,IW"-1:-(H$X_X,'V.DI8M9\2#?(TH&2&W479/YN9(%7AEGA=\Q4?HW)8SU
M+YN0GD:Z]]6A3O\%?-1"9YO_QQ$7L LOJKA>GS)O_(S,XA8&\L>.+WZ+*/UJ
M@%1*<(B1-B\80FD^.QX%?)H,?<\X@72#8.>,#(65*2 %N&$)C.YS8OD^>LYB
MFQC>CSF+]W#IP>;T5Z4/(U:M.W?X2L@_KA^">^62 V%H,2I":5\A%TV=9R<W
MKN'!:UK(;1C*W&B$K=,S7 )0US*\9&4] E$9R63T'RSIYIJ)OHZE[OE=!Q](
MA,1!>IN6E^TP^G/Z^V??3USY%8P[ZO?-$5;?QW3-.^N-A[ *Q5JL8_3X0&6Z
M.>!L]TJ>MCQG$TYM'#5MBMLNMI-*^@!0BP+\-,E1K#<+@@T3Z0" 8K_8K'>%
M*JL2,=<2Q^NU@+H]:<T].@U,[+M]V?Q1?6/O8TEE&T(KVOAV0H-GR,8>>]99
MU6S#DF))J6&@H^@34;H.WVIJ377;@K1DE;]UK4HQQI"KE18IAB(9'P9<O.FR
M,!?3^ %6CHVO<X+)V*G([9-V!>X.Y9;7QIKN[)R(SK$7M1TX[;W(?MZB#&Y<
M:0[Q5EM:,Z?]5_*S*NPQ/L9=9J?+VF8^CFK*M/3,$T'=??C.!MA40CH)SBP8
M .>?# EKY12VIX$+W7PBWK^$U0T=K:^9&@F4+H"$0ZM:A9_O-1W ><X12_8L
MQ62F4+WBWFFM#:.U>FG#&R1;;2L"'CG:RVS$.+JTV22(UJ(D1K\-63RW>P)M
M0?@G/8K_12OX2[2.WE] J?*B]E_ *DH9> A\<5.-#TI:B5NW1O<_S6QZ/CEA
MP:1I/ (IE-K)H"WG+_LE,647'8#K*XF8D! .XH<Y2MZ4Q" -]QP;2</>"=A^
MC^SGC+L-.:[8W7I38%>GZRW)IM2X$HK>C_$>>M$^J Q!<;^I)]<:*3[")*Q,
M(EVV&7+%_91;]C[-\D2Q[[4V=G\[MW+P'X_&.'4GMTV365V #[51FZ:B!NL8
M)0W6SNZ8%-FHK, I+#<C=D2U FKY5NHEK>E9_ESW5T:0(Q:E.FC8%X>4P&&'
M:5@7W+E(K"Q!HTKVT^NOJ,B=WI;5P-YS"%*3$;:U(,>?@;1EJTS)N_K\76Q.
M##X0=H8@8?;JLC>PG]X9->E]P<:EI5A=V_W>&[J$^;F@4;&LQZ9LG6G\XO/I
M-[A^G=]AQQ3$BMPP!7:(H*/GM=S[SZ[T+]F*/8B^\EN'96=.BQP][SKF'AB9
M4PFUE-ZG\[#'$EN9 #NI)L*J]63QQBT^@*K,(ZJ,AC89OUMSKTUVML_EOH!&
MS:,-J#"9$.*<VGE&@"GR8GU YD9AL_KW6UGJ-?6&XPP/(+P]?'*2U1^!G??4
M$9_<,2])(F,WQ<J)\4OX;^2%VVTOL"KKI"=HG/2B;5,'" =L$U489-[S_7B>
M/(&]-'*+I:&X;&LNW%JA@A$C<1Z2=;4)WY^51KS4FD?OP>68B95EY_=8-#(1
MW<.IBZ74!&HW%K++Y'J.K=?9/&80[E$0;5Q[=TE*&_@U]@PO;@ _#PP;[Q$,
M.WW?[/[DF1V6B,B.V.A_'M"UVPM]D5SE%]@T7WC-#-'S6>,ZC?^)ZKS7FAQ(
MC:$C.<;9V=6&*RNBWQL><I1508+?$EB^\=FW\3CGM5?NY+=@-KW*;+?!+K58
MFM:=$$$K/]TZ 6-D_R<[.+Q^E'J(*P\>W.($I[0B*2'W'UCXRR?05V<'QIY\
MHME=BWSD;#9VBP29Q.$R46$%B3 +%1O<L91I*]NWM+."IF23+1,_*2;<G[(N
M:URR% W*C(O&WW!W\FA2BT@LV#!X1AC*-%,T,J5L-_HNQ).:3GJ;Z*W\NLSH
MP5.YUF'"\]A9@]^)5I9W/Z9GFX^!O]&O9Y#3QO?[;V)JC.=%# _['3Z;-!HZ
MD5Z*#7C;3SQMVXXT=5]]F&.5?W]H&?$9A#')QRGE'FE6RTY@)T'UI^D%;OBU
MMG<WPU-\$8LB?UJ>K>>U9YG8L(1K1^G&E9WZH@U1S0?',IBN(WZB5"%85!H'
M2BGB*5')@E5_!NL];-_TE#F[2&E;F:LN)?/QN&NQ^N LB(E;9L]R<O;KN+"W
MBBK6I58MH!K.#5\OVQ%'KG=R!ZI(%Q/I8C8HR)#D)^YXF:0[FJXZ_EXA>Q$I
MJ)NX#4^>5>D2GA=4.J1J0K]:UXRKC#2&GQ%][5D06SJ3VS1!D+S3%072E^],
MW:)3(W"=P9%NPQ>=J46-E)H[7;NU]]".*7T&X%WR TZ0SM\Q=W&(4QJPY1A]
ME"V>64TRYF5U&F#Z@DVD@-UHP7*Z(:0AJ$.K%J[X]4AB4J=9.W_^10JR.G"6
M@!EO3.ZRF.FSQB/E+N1C.%2K5,P5+U&:\N%[2Y ']N+7%!,;IY[\'[).SON]
M%$JZC['_%V-O&10'%T0+#JXAN#N#NSN$H(,&=W=WA^"N@[L[@[L&=W<G>'!W
M2/9[;W=KM_:]'UM=]]_]<ZNZ;I_3<AJ:Q9-E!^FR"&,D9[^FL@^SXV@TW*04
M!%?=0.KWU!OU_RSU4E8HZ^WZFM.PL/%=;5^S1.8/K)DCI;5,'H61*2:(,J[B
M]=A4GVIGI:'WA#4?,6;H*2)^XYU_@)5O>E^.N2>KT.HWXD(7B/)[=.$VN@4(
M!V0)@,FGT"?%&63A&T5OW5N9)E1P.5(_HC;]$7G'3RV.^9T*O>J_<-Q66RIL
M\C?+(>S!UGYY25"Q\V):\I>1OV1J_6M&TT4$:SI@N4YDO51G(XSD*"FE1O9-
M>8XF&08Q8U)@M-Y+[LDPB07!_=7L]Y9<[ V]_07EGJ?]8"WYOOPDE3.:=#<0
MT7YACPN$59;I'DQ2_X..2<CRB'-#CG4\ &MOBS.V9+5NJ&;X@>/F43..Z;4,
M-TF,<V!?PBPQ8R"G"!._0\)G9O4?H!/N 2S9<W%1FD?4OA!15_7 J7X66E*0
MNXDR5:SX81$KP%\WS)+%04PX*&GK(/\]EP&]-;8PFHZ:\0_**_%3GAP:F4^;
M$*/^Q\K8RK4KN:W5U0XP6MM,RX #+RML@<=C"P[--0$S@$EDJN;S,UOW]EO:
MCVT!/12O"?UQB\;N>8DBHXDIRI^J,ABZH-7)M:R?AG]/=1?Z/G7!FW*+^O,T
MK>^FICD] _%;39MBVC(3WR^OAY:4++C]-S5Z/_#4-/QQK"W61K0T6$N1^9C'
M3A/&+)MW<U@@ 7PW#3@])9X@;XIN]8QIX+PT4J@.@>E/\^ZJJS,J2>2C&1GL
MW;OEBSNG+@?*+='H\[P[.1 SO],])?HPZL(4]<E=KK<F>K=-3>5VM)T8U0/&
MBG!4SF5O9]]3O.2Q*/,Z7T[M/P#7.49O=/_Z9QPZ(8.Y$'62.NIR;0.!+(X9
MV"C3D&SL'\"QXZ>HOZ4HVJ_>O54*C9.([:UU/3A[6=J6+#GO9A[X$LR1LYJ@
M:M@@0]VFSNBWE8T[:'D\CQO][UK&L9H83/.X>KE,INY,Y85\XY6K#,M9_Q^V
M_#]M7][JALD^2VM?NT2F$&0>SYTFJ7XS-G\EZ9N*H4ZXI!D ^_D1FWM3TPI:
MNRBNMD,<$;K-RY6!1X*I.[@]?3]?1P[3OWW/2GH7D8PR& (3'&%MU3PS%/M/
M7CXS>-T_W1]YPP7V7R9RGOVL %RY;E[_L08OGFP^/\U>3?LT[QG>,EI&3>?_
ME1QGLEE/7VOTBE(^2V(=615]\OL[J7<]+G2CR)DH!HN*+G;KKQ=K[N)!V*!<
M09I!'E<O==).:N8NX+K;7JNJ3AQ9^<JZS9]JQDOPJ1M]_S^5 ^B'&;\4FLNG
M>-SNTIW*45M/M;Z5^TKIG* P*KYN'_52O*FG'QJZ>#FFWN4)_1<K)--H0L%L
M8%1J3P<C\K*@D+2Q,7S^NV&;'(FY">H%$_;V%-[E.;7P+X=LBCX8ZKTZ^B4$
M9^3-#^$V"SX^F6E+WVWA6O S;8<S^NLDFP4*?ZG0.V3106P1*4TV5BJ-D>4=
M,ZK3&:T6MUJZSQTJF=XHD_BCQXHTD,:\3#/@K!Z2&B$V):>:#%#8]CJW]I=I
M7K%O!8'-%;?GTNR%R3E)^+W59U!%W@3I<"D\KI.+>$:I6/0/4T732+9IL64Y
M/QJ3OJ$M*Y=VCTCK@,B1I.%4,B+XBFF=J83*\?F"8H\X]>L-G(PIO.4U)?WX
MH*8A6_6E@<ST?E;Z_)BP1TEO,ILN>B-B"1+?=>VER9MH>\2GF;!?3#%.M('Q
M!CU&:.U=P,_O%T8/RKS[XT_*J1V7WZ5&R!^[VG\'UY&4Y?Y]HB(J18-BPPT%
M/0(5+%@-$+F4T=)@>>$HO5 MA3;UQDF55MI<,XM(.$Q2F&X?H0C/!5.4L_V_
M#+3_93D*=?%FFA")%HMK8#C&HW69A(>',G4K!ON]J!F2F=_T^GE+&#XRL#*^
MOA&3B1_ZVVQ[_X\*E[J$$D-%U(?F14XPU/G+S&YK:N$#D2@H^V</Q]_?=SY=
MM'DK3_"45;OB:UD&C2PSI%.=M9>G=9R$.C7^"F'ACNU5U:>"1+QLK;_8M8,1
M2YS<8T/$\\F\,2L98].@QA#Q/_'-QN%<^'TRE8Q\<@)MN*&1!-%>^_"%_\)7
M?8)$0JG(;/'1DK^)2,O%GRGTA =T\31+F-E,E5145,XL;HHVV* 201@;>YIU
M:^Y?#@AB(X$=<LCK2%5Q1HDL\(D8X6)4[%\>&G;AT(H(M,P.@Q'O<>*Q8%%-
M>Y$^O3=OCW2E(UL>^J,["D4)UOFC[P2_ZU+<8:->,9K>ZS!"7V.DNYK6I^GL
MWQ7O:)T9YZ9'G%1(MC4L85E,4M)V-C5^;S!+"4>-B[R%I !J-VT$7&/=EIP
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M]K^*K^VGKN2??GG86_M;(GZ64V>P?&A)3M=5J-BQ;0Z_?/Q'KN<L>T+HE'1
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M:,Y\;VJB$#6<:-12H%E<*R-3S[\WP.5DM]6N_H95L!%3ZM"]__.+P[Q[/"=
M,:7.)MP]*N$*5P9?D)DFC%%4N3A+K]PRECEC/@@^O%<G*# 54* %9@HJ!=3S
MS)1]AX][2 -\A9=\Q=X-$R%OX"MAHNHGAQ2,/_KG_@FP^4'V.M5WI#(1(5.
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MVOR52$;#0?V!!R"T-Y!RE,3<K6&^4?9PO*(P),Y3.:TS:5$=70%?(5Q3;S!
M@;\"GHG\@U-HE309@*\_!.^11CY:,[.58,-CE$I P%G=21EQIO7>X,Q7(O?,
MSK8H+BTMC<V#OYJV7SW_DG0<7FV1&%(+"H"LMW5<VO_O_*I/))>F4\]_@]X
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MI7UW"[X]2/*0A+K)](C\=6DY .T@\K66@F3;_WW /I*90QG'^.F9=NR 6$[
M9/IS CG)7'CM#2 3WM"Q'C Y@3*9*[7[Z)?I_AUWFF//BHIZ1JY&![^W]W?K
M'R-*YZKX92<L(_1P\XG4<5J2W-W_&+W:5MR9Z8%NX\@,G/CP)2$T%9B'_B^^
M=NG=E"O475:C(7<VSR=R+I?%0@UR5B>O?.L8DLR:JC3O7WB%B4Q9MX(^S%@]
M.3TQ4?O'.X>==GN',?)=M?GLLJ/G[8H@V&0.@K!8E83+YBWB!Q[:$S/2TC>J
M -90R7/JK] IW4Y\\*E#-V^#)0P;B!!/IET54O;[.N85<KGRT#(TQ*0K(Q/
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M^7(.+7+[/Z^430WIY5@NAX[]@2;&<UEA<WV+VUP;C:B*@[?B6-GF2SNH(F!
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M4/4N59K8E#!"[BS;*OT0*^8\Y/<?,2UXAQPM!)>OT#92^4)I#A8=#_LPQ6&
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MZD4\2E=I3^Q?,S!)K^2"8N-%[1$;;\G*4EBR_;3!G5C"YNA+T>0ZKCK"Y!M
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M9>%D7_ZK#1@N]^I(@1K\+>(4*RPZ+<R=&B9OBZL"Q=/G2:%L$!N,,_MP&9_
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MRTE" -: _?D'H-. %BJ#2S[^I92ZPV@6>^(S:]EG<W\>Z;\)]QH5Q$=+SX(
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MXRG^/:OXF9'T$_]'IS.*??X%LNA6K%=1W\'$&1@I1A!SE@;V%QK3?L\0]0]
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M=B75O@*E,-1--T61PJVE_^6,CN%,^U\U$)^<\2GX"FC28K(.WRIS!".!"AB
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MS]<[MWKIX)>7S:/ERJ/'7I)Z31I)>! />FN\3VI3FO#[[-AJ6'*G4I"65##
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M 2AE^2Q:Y^[[K ".QES^]%;'J^[E%8*OU,?MA]M-.I6N3B9*V57N75X6%Q^
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MX* !A/Y5(D=_($"6(8W!E*QEOWKK@?Q%5=5*[RL?@6WFV)Y@<V( Y25@7@-
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M,8ZRPYJ V9H S060U[.^HG3-QBT_J;U6VQ?AY2/X-UES*T>V(VM3-E;6]07
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M/KX &A.1EOGJ"*>K[08J972ACXT^=QR/&C(_$(PAZP]'3M+NEMA/(Z3^#[$
M\8M:H66V7M)NSV&-%3JY1VM@^/[\!:SSA!X!22+<%WG%/PD,0)='LEI3=71@
MSI!S&TMHJ55[VI(NRAE'"*=8%BSK9Q"S$/SX%H/ B0(5KO -]M\/2/$Z%F8
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M)\@7QU>[7V*]OJ*2"E&))1*I2_C,UJ!8V^C1T-W&Y&DFK.:Y" 5@(-4.,R%
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M$,^B P-C<Z.,CUXV-E4VSMK.W,ZX/"!Y$M0WUWE]>&SOX4+&0,2^BX:G B,
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M[*G4OJ[-8W),#/O.4).I$._MULIMJ[HBI@K&:NV37 E'VC:3+U6,L:K ;3M
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MU,LND@1S-,0,4XO+CV7#5'6&U5XY^R[O+DR>\C;=718/=D][,$<I(7:3DHO
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M?:Z:7K-7&NJX;L/^ZCC7GA9>#+V[3F*=*A%'WKGY;Z%DTUQY)TWV_6RAG*(
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MWIZOM?1[04*=/M_>@MW#;$?YVQK/U$T)-.5BE[$H!("E,I62,_<=B-QG&LD
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M+S@![:,;(@#?F^-O;C.OEQ   = A& 'X46RWC@",KP8-_WY.RE5<[IC$JT4
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M(%6! "  [[]5J>Z/7LC_XL^!%XCRH"ON2O"FP0RN>96^RX@\XZS.3PU(1C!
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MI?@"B65*GP'HY(#3!+'1:R+JL<$#&NP9Z(^Y,>%Z!*"N@TRD(.J]P^'\FIT
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MF4."V*3S85 W<%SEV?I%6ZD(M#]6^NK++]U'VEZE".:0_!@W?^C$Y;:;/4
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M?WHHPG[A1_D1)S-U5BB?W#AL<H"-O2">R!(G9IND^1A4]QS[Q?11\/>.?,S
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M\3=O7(,;]]4MVYIO0(OXJ6YB[6.NUKK.(Q?&RQ]DZ2P)"U+!VH;+:'J$+"*
MG3<8$0*1>"V[MS/@L*J,#"RA%3PK6/@9Y]N$&@Z4Z@HHS4RQ[OI!-SK:QBA^
M/^JZD*6$X5>#?@<BZ9F61D[SUV+SNS^H+?!=.FN9M>9C7P<G*!/%X*-AW-ZV
M\OIL5:%'FO17>E7W,X:/+"J04^A%#BZ]E]$:0)%3B$K:8$2J,M!5E!:8JKZN
MSPF:%C>0J/7SIIQMH4\85J_Y)8+&P9!^\6.>\@=:7)XM-:7Z^"*1LI3>_H='
M[#?K;N)O390=[4*,AIH(*/5"@:5$,<E#RIYAA1R_6$6LM<%J]A+< 5WBN75)
MEXLTPJZHQ>@,RBEU/IADF#C&PJ\KF#^:\> ;XJ>B?C/'\G;>-[I2L3W"+!M_
MJ)Q?L348.!R&2SU4/,P)SLR89;W^@A+8?FKSHP =9/WA'5.W8]2AL'T?\349
MQU+6T7/2X"E1CQ "(*AET$/_WF6JWR=-"P?,.FG/(]>Y5?:B\\I!?_>E/0+
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M"BMN<%4*TE1=O'V@E@)28BR.:RAV+N<A56IL<C*=#@HR]@L+[.1DFFR1)G3
M/YJ&HH !P6/.4O%2N9I-"  MSW!E4TS]'295U!+I.[&>.>)9:/YW2<WS>DSJ
MRQ"M>](@]Q#6\-I-4*)!:>R.ZR@EUA\8%WZ=8\S/-E]_P\F%[>JS7>1RA;7J
MP_C8CYJ:FB223.ILS]$C?T*0*$.0T,>O"H7?_C,YK]1' !).:T2/.FHZDA
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MDP/,F$D/O17U]/D"AM+)\=PU5(<V1TY"83T)LIU"C;6)OU K4 N?>^M2W0>
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MV&VA;0BR?S4>(1]F?@$R4?ND=.G514&.5=U*E5-=C+JCP@=W>4* @<4WO$@
MJADI&%&7ON5AUOZ);^39Y@5 Z+KR<^>ZMLNY1^ZQ9>9I^N8%H-D==363?BHW
MDS<=<W968,^JV>\H_W]B7'DLD.O=%/*42#DG%X:&AMT5%MY*2JHT%#X?B_&1
M@@&\X#NUPJ,;FZU3%RG]Y:7I'>L,V$?8\3,PD:DX&X^323JO,&:U:C;.<"_+
MTO4NK3!YIO/CZ/"?->WZWG5/\Y&@!3E7-T>LG*;O\<>LU6#+=DP0D)+M*\D>
MHJ#Q\(*?/S:/$O?'MS K/#"Y]==Q='J,0E&YQ%A"Z4-9).=/])57*ND-/"&F
MYQI "_3D;G$#:RT=RO2F$EH0R?64AD7)_E+ "%X&AC^)D8#@G+D5I_;.JW(4
M([G;$9+'(MV+-1O,=SOP!%NJB\Z.@_IJLPE'EFQ5;EM;NUET\L%QQ1&*]HS(
M[OY%.;X.(@D"1CB<AJ?-"!R13(1&ZHY[R-UX@6E626)*L_*DLQ_#6P97G,J;
MLOBZR5< ZK <RE=C[8=F##,+VQ0'63LG-;@28H,_CL2RF'3=C@B]Z9 &->]4
MMBP[#+_?GJ(C>I1% B=SGFL_K04&N2MU'!/05F\U8DFSHR66@EVEYLL^G;UC
MI8;-^6]D^*ME-QJR;\H'=@E8];W2U>=E1+FJ\4OF'X2."D.,DHRV3#9@I*3,
M> (,N,:_BN-F2^T3MR2U<Z-TF=E@]/#C&[A\!:M8WRN_WG=.Q1HIS C=TCTD
MPF(T 9_9H"<SHQL35X97YZ46[\>3U9K8-EM/KI]> #=..$H/1]=''WTH6[TD
M'$>T5TJ*KQ]\T&<7.(B/UE:BH@Q*G*&X?S_W])4W=YJ,A7<0R6JG]S5QU-WS
MW0LFCP/"!;=XAF"D%H$I74W 8D_KV.=^WN''TY\??.46B 'NIF3VB>/.945.
M9177T\'!7WE[6CZPLK:AS$7*@.*6;B7SFK7^9'V:^7LH%_55TM+C16XOT=6)
MH[CT$2B/PE\ 6LD@Y!/XKO(4<9MPH^0')L$.I.!A,GXSR<37]JERL9%N2'FJ
M'-:9F8QL/QXROSVC%:;=^IQMB?D"* %(QT]37[PG[@\B#,'T_H9@KDW?,5D\
M<_HG2_FP4_DT,ZF''A#4DY$M1H20'U8?-@X!"WTIS38Y #$5K)22RN28 )E#
MQ^KZ&RK8^>]+,6I5Q,4N5ZH-'7J&S*('2=0:#\!9)68!>JG4E+'KW3P_V%2P
MKOO03Z&OHZYK.V8WK_-BT%OVB 1_C2E_E+]')QDT"Y/NOIT,4NZ,N@;;?_JR
MV&=C=\A='\R^C^W26T@D-7)?2NI!60LXTM.=%'>M<R04W5;;=3'8QLB[<L?U
M<5N:KW("WKX WNI%GT_9Y((RY\\>^5S]D>+6S^19$50G +KL](/YNW(D*L$-
M%8KO5?/J>JDH&=!K:>[P['Y$-3 LFJ!8]4\Y):ME7O-;JE3"EIETDSKHD>7/
M*;5-4$TW O@[,6 RS,@R)^$*>%-4W1S'<EYESDF]8U5T%9R#Y@J_0RFSM%=^
MC.4[!(4G8&$>\U!V"TS3NKJ9\5%K;.2M7I>R[?]8&2\Q>,KFC1'M$NU:L3]Y
MZGOD#ZE3>H:V/E>L@-TMEGS,3 9> /HJMZT-+9.0D^*::M)IS:_OTC6&HRLJ
M?7,B-E.GPF?]HM' N)2G>4UYU2:\\[TFIZNTRG8U49D)&EPC?&/DYNX@XX9J
M *$JONPL3'8Q%H&O.-XQI6]88.,:X?;6GM$MS:;)VYNX)VW@_.E9U7NEYVC
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M^DX38VR_-S;TFDQO2%[XJ(I*&_J*)4-YA^.LGL8*+0HF(SUY=T+V8^X/7XB
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MI_>5+P#X1>O.WX0ZK?7I\;^W^0)0^AL-98\J?Q<I^OSE;P:^\S\Y>LCSKQ?
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M008PK;C +!GN0;TQXT;9J(;S_8Y4!L!>;N0C]<%= 0YLN #!HVXGB+7MU5]
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M0J!%:6TO^OXHIH7+V@Y/(Y, VG0@T>[7[BN6N;Y8#HT4ESC['?G&K38(V'*
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M#V][1FKQIIME18Z,E#*BC3,RM?\N_R]02P,$%     @ DX5\5 -8(H9DB
M#+8  !(   !I;6<R,C<Q,S,V,#1?,RYJ<&?LNW=44]V^+KP4 6F"]%X$1*19
M*"(E(M)$B*#T$A6D14!ZJ%&0(E5 0$% FH 0(EUJI*MT0A$00N](0@V0<N.[
MR]G[O?L[^YS[C7&_\\>WDC7&#.LWR_/\RGSF&@/R#_(,P');6T\;.''B!/"
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MLH@,&&8O%[_]RYIHO.8$^.V0!+V<]_"6NR@G&AY!D<&O9."3O,(0GM9ZQ-O
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M3-TBQ>X?P)UTOS-RQVQ^ Z>I^*]"KN_.>"/LM%]G&#* M\%[ES,#RF^C \A
M9D()&?C'P,C[4QP<WHQ&K^W"$X,[(?\R3OX<57E_&+?L?<3T]?_[H=61.H=<
M/X7^+X],2^"@VG\N34L0XP5!CJ@T(1>,D=.0HK]-D$Z9H)S@2 :HI?%[.?A*
M,S2B42.?F#6Z.)?@FT"GHC%_OASUC].7\=W%>P7.9S,13.L'5=74ZY _8-%?
MM?>?RE>VN U.\3REU1*W^];UT+9P+N%%ED M+O*%K+NW 4@#JYWX87+]>N;B
M:.B^;]J))[-PR:VS4V6W*NMSZ)_%;3[SL":\%LV+)J7TI:C>JK[WVU^Q$'P
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M?G#6N=/4F#4J8!MH;JR[1_WH9F=:\],7S0,%<RUW%C\N!$2^!+_8PU<Q0?3
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M[7-AMW4@(_!-H8?:#^>TC6]\5O4@3,N"O9V\>U7VRV8V'#P6(4/B<\D2&5"
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MN6@%F>!&6B09<'+AM7-FR\;KE/GZTTRY]G$Y,BWF$J8;1VPM)R!IV:L//=O
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MN5_M5"NE\DB\$]S357B[HQG/7 "#@/'AN2Z*!Q/]\005N+P.N!H5/[*YP:D
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M+/-)252"(3*N[F;UAPAV(VL)F)$6._!_Z3YQN'Q\Q\7WNM*F1YGM&I?S8_X
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MJS*Y=PS3:R8QN<%"#B\+3$S3Q"ZJ;&$G2VS,O/N\2)Q,8T2Z:3$R@&*!X]9
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MM]E#+<&A[.T0:;5,\.$A7C3ASW 2_AENR:?<!&?P(8A3L*^00""<[4*V,WP
M$FAA"4)[G<PD-7TR0$?\O3Q1RO(N499'B,$I+'[!*7ZB[OD27 ,_=,+L##:M
M*VW6@G9VE(A$=QQR:+X%FP2>D"-0DX%MG<7M>>5.0_5OJ\1%,O U^Q,&F_T'
M/-#QSF]X>22VX]_9K4/)[@>_LQN_LS^9?7B802+5X@?_HSD"+QZ@^(LBT4_
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MB!_A?R85-4H1$3>J05@6,F""(5)3:/J2T"\]F$YD(O424U&HF6R*QB-=3-C
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M=X-Z!O5V[_O9CADDV#<R$,3[=PL;ZNQ'UR^"*WO)@"JE$C<S"?W=1C:TOUR
M0^+OJTSX#R,N#<<?_Q))S/O_ R!##P+NH_X^K?G&+_%$(YDEOT<<)G:/]-0
M[O7;*T'(\KV#C>?'UGJSXZ6J=//Z']+T$U.9Y.Z_2H4Z2# P1A;?A)F2!"/C
MLX/,OL$K0!O16=3Q8YTA\E46JKKS/>7HQT!95O[37RK?X3@,$HR0PF8)%X<6
MQ[W^!!W9=>_>VSJDB-VV*MSPI\OQ"NN#/OK]1^CM"[G1A\FKWRFH14ZCUI/A
M"B4*%J@%$2ZBI_M2M<.SOP7$WVXIFW]\\X+P(U5,DNK)P ;"U(EJQGTB8[\.
M'^8_O\4:I( /IH?Y5Q6R6*]-N\2\?'FWJ]NNW8ZVQBIVP71K(^'8"H]N%U1#
MDW@(-VK"C)J31IUSQ^P238:U>#S/=WU?IMIB9 E81D!)0_#RD(8Y=XXU=16\
M7_&-H\6?K6M;6L-?[V?=.)G,CFK5I5H,4>MP">D#E3_)HAVAC0[R#Z8I+#-P
M54/M&WR,J(Y6'L@O$16T%S</I6$/W$-^2KE3N\9?+#59V]3K2@11S>>!+YN3
M' ,AJ(;NR:/A%9_LR1-N901-YO!&U?I\1:4)K?#PO;W!VC CZ.I"9-_-LPE)
MI>_4SY!TN5M4ZB,WJ9%XL&4=%O.R48114,)\\]?&S- >E8=[D96>4E*GA--@
MZBW/$]I&F5_"PBR.#C; ,U)3C[9,!F8A#)"J^J!]8^>:Q!,/Q?-C9W--C=4]
M[U]290FM;Y ;/QHU>&00:(T3+)X#L7X31Q+N;'&*;;\/A2@\B+XV:"SON/B)
M@0WSW-91T3;=%XW8"LGRW8)_V6K7O)K"\]&X:F-CM]9V/1B!KI.&\$5&->H5
MK@IR#_7B&R,>R<EE;N9:S-_8/'%(]_,]X>=37?X=2]))7&$4P:+81=(_;[7&
MU#)X892+M2UH^]M2YXGOQ5$G"Y\NO HN"2 #K9QIT^*#/J\V3]5#)NBU>)\E
M\;RFE>FRO;HG3P88\:;,##5E#]+U4%75=#YTJCU!\;.>>0(1$PN9=Y0JJZ]!
MW6K=#D)BH-Z7<R)Z.<7USUKBC ,OY,]W\SD[D&0?-VVX#FIQ+&7?#7D4\G^J
MJ8)//.DNQ#.TF;UX_3GYIGZ@[RYQHU.[J^(5"@MR620#58]06.+(FYYD"S8?
MFMEOADG,"YCG'TD\^,1<%ULAM#<SAWD5?'R0#RKP:/S=H1&7X_9BE-!;/Y6@
M]1W&79<0A!UTUJI$QEC7+<,P]8YFD7E/6JH?/<R>*5SXE>[%'P^S4EB:I%JA
MTPW0RDWWU/7@?OH:ZM&R]8Y"6E1:X"K&+5WFCDI<@*N*1EWCM$CJC@^BOE-Q
M]MJ.=0BW!FDGX#Z&3N'\R-YZH,'&D/.JOV=,5KE::8G$PB0S@:[8AXD&W6%[
MONG38!41?+=B*#)QR5J?HZ"ZZC:X5[[PJ75FCYZH&%929%3U,G:O,.U&E0&X
MO4)3IG;_8[_2N*OQ+:>%LU(/>CHL(O9-C-Z%J_+6)^U7_13.>(UB.-@L7(=F
M_6)F -,,K\GG"74<^HWMUGW1(2%"0C-U:0: 57W;NKFL@^,S3)@JWXBZ"<LA
MK)N SB^K1,@',F#G?GB4O0/!(GNR?SB2#'5ND &D53^19>0(#HGSB"3$BI(X
M#BOWIYG(0.(35"<9$#,]YH/W#Y.!=#(0+O2W[B7R9FW9OO\/C^Y2NY?7$HC@
M0R3>:%^1#&13#IP*9("^4@OX;_98#I%T/NK+FU&[#_-=LS+P/=TQDGQS,>A_
ML?<FX%"V??_XU4HI*ENR3(44(452,JF0)"%[3*42&I)D=X60=4(H8LHV=HDA
MZV27);O).O9]&?M@YIK_I>>Y[Z?<][.\_]_[OL_[6XZCZ3A<<YW?[_?\G-_U
MG'/Y>O?.X;*>I+5G>T<KBIPL_2#1S\:S3-?1%U&[*36V7M3S,:I<G:9V@(&!
MYZW[3E^+&GBP?5?&[$$CE&.#"TA<-!Y'_2F[E2+2P+*/)()Q(K#]H;N&[R5/
M\S-2_G=-O2+.9XU9\G=EU[(>$NL]=*:"FRO-:^G%;+HW/YGD52#^005D\5GT
M)]I*\W%ZIPWB/0&NM_(=3CEO2O<*(43PTO'1^E&DGQG)59#F%Y'#A#[4Z<K9
M4Y5&LK,XC\7T;56I3V2/+TM#^UKNSZ&'<]=NN#U]5BRAPN197'E(3ZVGJISL
MU]&6.W .R6Q7V<^<F<TTL\<Y>JE2$RVI(J#1_D@]PY-?[?2%Q*A-J\W9V8M4
M7@\ZL&561R[EST!//T?9T2_2#9;F=5F/S]GYJC7;^/KNEC:(,'6<N+?#Z_C[
MXQZ&L1B[_9;BY^L<T(="BGX36>E[)^2"HQ*IPG5LF^;PQ*E&,N%Z?E23@:A3
MC27_Y:&G:T^DCQWLG5YDYZ1*XTH(*[.S#!!3ZOJ4#86U#/8"I\P1BVM(R,^L
M+KW#N"3W:73$\%I]F5!YKM^]IJ'F*AJL>IX+%!TZ("=WD X4V_R87]I(BCH7
MG4Z[64,H7 Z$<AZ@NM<P#22*I9H'.#_0ST+E-/@Q!U7JX"0"@X[8 _;FD>B
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MNO[^ND2[;(5H+*$(BB!A_< \L'._^,B/UI?!NP.$0+!7'<X+1LQ$1K$;><5
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M%WZ:A0O.-GG*XWF&W09@W:H4F_HM+Q\V=07@O_OCHNW2"0F[%],!?([OS+T
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MCXT(RS_I:!!I:9(R8FG%@ZO,V??B=L^M4.TX X8S_-6CYL5_&QP]\#=U<&F
MJND _KK'VA6*SI,5!TO?1\:(#GW%Z<B"[YDUBFK]L;U+0MWF<^)+>RD[!E O
ML:R/9 UBS#B-]C<\/?><>+:%?[<$)/*PN*^&F5OF!HN,P);5,9207\Q.J5NF
M! I#7\&EYZ7W*425W>=PJ82PFE7B9W4%]B].Q3]M^4S^>9G_IK^>H/3;9YLY
M83&4M BC=]\L4ROMIV0,L*NL3.^H_((%'@UA=(J@9J+;-.9R<Y6C>Y3'2MGM
MU1RYYVW8+W2@PP#^#R&9%5&:]\I7<Z\75JF@S/;&:F3N2@MH_T0N4J07TQ'Q
MA0BR$!YBV.S"R@^(I+G#]4 'ZI;!2O8GH5#?YQ3A-$;DL>+^;((QZ)5'![SE
MSA0/@+M&)TQBO^NA+H2_:!LZ'FKB$;37U9\.R'"[6?O-B4P,A?1I,W0>.]>Q
M7!0V13-S>F%]38=8Z!L0AD^9L8"[X36:ECN 9;:[+X;5(2[4B:(OHQ];B@WX
M?MVWCU_\LW^^ST>N"?> $+[@V2TEJTMO:3'Q=ACE%DDZ('G!(M72..C0H=Y#
M]^]*(Z[C9Z]GDD_UIWO*JO9S=ZNIN5?LZ1HOXFV5,IC@-HW[W-+!E,AW:?.Y
M*6[.33$5#?F;7>L<C#+(,S<IWK,'ELO:^!@+R?4>TQ^:%SIKF*HT>IS5VR9J
M';T\]D_JQAS_T+G+=J_?)J.[7QKRKJ=ATJ(,Y2RGB:GY5EP!1R*Y6G!7YY0[
MSDX0M%RJH3Q4>K,^[F56ZJZ$%AL1E<U539NLSU:&H JZHMSYA7J2QES.D*=S
M[$+#GQ7&DPS/'/]H8%C)_VJ[\DYF\V^I+JPUL,U[\W$23J'LW"1X!Z6EB9,"
M<[?G6N1W3+G.6_ME?)5J<A(GUXQF4I)4(F70?.AGX^8F$@FB3%L[JI7([PX,
M1?+('IM7M'U&L$A%$U3>-%0^D,H0CKPJO'?8='I!W2_=YG[J5+M4_KGJ]?WZ
MXRQ_EO..4-FLO*A2BKGUU,]ZX&@@2F*:#[^\']5[J1'19"].]7T,^P#,H.,1
M]P'43LI(B0.+5X&R5)M'\L/LNOO&"0*EDZ<NWS,]79O/%>.4RV=2&[NMZM:#
M!!+%H?.+R\%,M*)!YWX3!M.H;I/L?-<*XMRP=W55G/+@SKG(TK8\2R;JY599
M<?,C4;L.Q'N=LL0JM01_P[^B W9B3_RA#G9+A]&" 3[=PG-\[O[ZCQ_'B=N0
MU PGX03PYM,\@L>C H7^XKY"Y@%-XO;P QW<SG*E##N5@_2XNK9N\Q;$ ,9-
M69*=I!U.7.'3\VJ?\XBR=P3CRH,4T'9!NOK'&R75AJM863_J"!PW>7B;>=Y/
M1[0_W2<\[&7J=,JCU"DGF>BNJOL1JDV7#E\?''GZK:P AR3=9;@MXM]UWCQ2
MPQKB/S/@$?DP[J7#LYEQXF 1>:R<S>+'&L$6ATJXRB)?QZZ<K6<&B9'+4'"A
M"X$XR$!EC87=G+:=-50P0UB(G%B$BC0EH;,+<!)/AF 5#WP-?B&<9E-7L&<H
MWL:F?N&W#X]M!<OV'NH%BGFZG:-J5$\'M J\JK')K];>E2*-WCHP-&7DW$]Z
MP7>:\H&WF^@CQ;NS8IJD%E5Y-;/I1?U.V6'D2=/8QUP!WTL\=@)?!:(DIF_>
M8/@F=Y#VCJJ4.&[$'][D?+A&+:_M8-O!YE!%2_S5]$.O:T0NZ[&[)S-6A6@K
M"-SFT83+-1/4WLZ) TPI#EM,SZ+?9<<WCKS^>EC%7/*DDD#_7@&?7;Y9TS?8
M;A\\>&#UHH^A#)A6W#92N\^E5DXPMW&!R;$F4FSJ^.V\CV>=;$4M7AE\/6[)
MFE*S25SX94GFI*(%\Z2;6G/@L0!)C2<W-P59JT4G]7]45V#S7)_.=5)/ (O%
M9%E2S#AUYNQ*RQB7-64GDU[=YKA;QA+<\YX.>&E2."$O\;T@Z00XR[[4(K/G
MO2S/S9#.Q2ZE>:SB9U^IJ]7Y5&05Q0OB5>M%K?(4P&6]$UPQEL$!F1E'%J<Q
M&\%^N.@V'>@7F1H_1G/<2QV@ [KSENO;^%GFUI<W_\*"#2Q-I#+1@4MA+PDS
M;Y 4GS4''[G"E]#C?T\C'G=HAT&OLCL=*+_?+QY23:LZ!WX11E%LD*[@Z)-9
M3MKZ,9Y[46;?W3@>^;DL$B+U8B:^8T98%C'KN\-FX)#*WX_8\+82]2SV"V%!
MQLX76C_\]65Z3L+_;HWZRNB FS9E+RYH?6Y$80YP&>2=A\I5_F3,=>77T,65
M6X\@]3.5B!F(;X@)OO6]>*0^2*D,21X'-].!AJ%^\;5A%N@P9B.NENK_M W6
M$BYW$\EP3)$M$IME:Q39/-N_K2=W\)X0UV)Z]N@/T3E7*\/I0/TR!0S$]"$8
M1Z$MY&Y/U_>ZE^)-.2084Z=NWQ).@.Y%*<L&*4ME*+"7=5I,KHPIU^4J=W^,
M]CFV3_NGV:JD29:E%TH\]NN)Q8U_G%A,NYXTN&VR3%@[ELRV2<F@(6MFWYCM
M 8O4.^C$L66F3^8&GT-U8_D\=/>8H9%J^*9''S(SLCV_-6W;P5Z8MS5 BG=S
M0B]+G&YT9'=J@[9.(7[GT>A7)7"1]Z/0\Z4#II[*<B=1"K2(^.XK;4O5J5;Q
MG?7\^SYOL?Y@O%#W.$R.M>4X]::3C+17UN4VV6+.]F_!]_W+;5DB:BHD>@K5
M!N12C>'PV+%O1HO@U\7$?<;$C61ZV+0,S-?FCYX>Q"Z9!V$J.\XO>\N*I'89
MR$78Q.?+V[*=&V9AW%K1]R;(X'BU_.0V%V6_\C;=)._^.(1S\C&IAST=3U>>
M7EV2W3$@L?===+*RP,*M>LL)RTMOFIU$G),?+I^-RW;]<#Z6>SY?Y9..\W/.
M[YZR10WR9WBVW!0_?AUK:2R[*N89:%0Z\H74SF'RQ$($N^CT!)<>9U.T?_9!
M,.ZA-HN-;./XV:LD 8[D'??SUB[>47;J>Q9D'?5^E\ZY_MWZG>I-3E*6FXP%
M/:/0N*[/FZAC"(RZ)P\Q3!/A[2]UM!_G*)X-.3MV&U33KAF=8ZVQ,=*A ZQS
M\XMK:??MV^C  F,CDJQJNIXMSZ?2@=&]T6!O>#.<8]^4U&%9BD=";D)TP%6%
M6@MF26#G5U$45CIPTO(L"7(]( 3M2$526OEL"+3-DFI45GUP-LG3!XF7@*GN
M15)WHH81'?OK5VCBU!UTX.THN-D)&4?)[ \(N0/&ZRDPA,FZ+DP\S7A]PCO#
M^S8C97 VG^%S>C+8ITQ1@YP7D51>$C@[ON*[=)\.!'V- XF%E9"OU 1#R=G@
MT7#"R\/M6V_T&')Q-->9^\9QVLO=_G;")_;Y^ZAM+EZOANW>]'9&O.X>G!Y<
M4%8J7(L:9CE1[LB=%Q1,F)>KC*8#)<%D+'5M'*2<*X++H1;PU[];J^W6RMKT
M%^L6H1 7L<GC"U5ERZ<GKUEE&I9\V7>F&Z\[D,">F&:(]"LPCS6R,]!_J8:^
M\Z2A-L6HO4MYCT0UPPWY57<WD;&>A],M4BYJ-L_2B@8:[#W,L^*[4Y>BX#R)
M'P6Q85_0@1%/'!UPSY^!SBM1CR%AC.IWJ]$!!EL2U>&SH^/^K,+KCLB]/=U&
M=C8VCICLKJY3C(.?3Y08SULUR89]67OOL3TV/Q/?XM)ZOV\M(AG<]37)= QM
M93:Y[YS_U/";_72 D=9^9L4:Z_#U0>L!H^E\@PC#]$Z+L!F+03KPL%]J.2IL
M3>U#!_BG6)!;X'S#UGG]U%W_V2.)::JIANTD!9O=W5&1/+;-NLF;SB?FJ<Y?
M"A@^T;YE&/6&N2(BG7?[&4L&UV[5W"9+YK@ES@?/E0:Q1W,LI5TDJ+K=X8(1
M7X4$LHO",KM34X?2T8XL:Q<+I[ZMVH!M7K#N[50K >=GUL\BG%[[RW'_/YZ4
M:M*!XNYE.L"7HFI;%B[]\GC!&<$6CIG2O7)U6JF#@AQJ(LN'[Q:\$'TWXC=5
MSQ[L*)AEGISN&9M+!UX</_^>8+YOB'79?V1EJ[5_A/3DV#>9.G--2:M@=5M4
M_UPA'2AM6EYA6E,L3(N'.RM$X<5L' 4,1<,%5G>L\V\/<KM/(UDF6.W<5<DT
M?&$L1V@CJM/,0:OYS+ZT_K>WT#I;>0)LCQ5/&.)*'4]C2K(=/,K2K1+& ^,6
MN^8>ZRO=>,Q 3O([JMZP<_1#0*2]'MJ\6QK=,9F7?G$@H$PY[MNZ%,T0+Q>!
M'$N%C4YN%0LQSQ#6C_K]]6_;ISI@%O:9Y6(2'9B?I4WV(7^UF0U_3H_&=*CE
MLZ3"=H_%S)CL^+MP_^V)CJT"7Y/S=V<S I4*.IY1VXC#'X#)SSNZ%#Q=.J$%
M:_7 6GL)6!)$?M-K,'X;_&[Q7\;B'QMQ=Z,2#!)"/QT.HHB>;ZQ_M3G2[SH5
M\X<G:=,^YV/7/JZV@BL4:.DQ]I^.@_J44+=76S*L,Y7+F2]0;G+[;O5W:G#)
MG&G[5]ZG QY"?<B5Y=]M+>$/3Y+SHS&F<I-R>!3D@BQ\)_17#2W:Z#A^?V#8
MS>:HO'SGOU,UY/9UJ;7CCT?AUO[O&6IXH/C[1(N+ZA('=YG\7]1OY%8G@>]U
MV?&/GR#[_S=6V0VP.SH^Q>?X,!;OK?C :<UQ9LL6@3F7^-CHN&J-[K??4J]B
M>2(63:I(!R8?610A4:I)LLIQ[>V=75W>OF@;K3ZY6QE=9<S;'ZM:K>*>/W64
MRLU#:US:']1_(S1AUUV!'BWV^ME7K.[M>=K8J?-T0'!=OG0#D+:Y /=P@9UB
M<5__G95-G[!ID:GY/)QHY:1;#YA?E4B6''#6&P7)J4^7;NV^K@6*V)E(O)Q]
M31N>_NKY:(M;.0N_JUZ4*+G5RW/AJ:YA?'[X* N)??Z#UJ600]=/*&M3%:S6
ME.+0=B;%>3A?L9VF;>W^UP7R7K_P1"Z_FZ4P.R?7AUS1NO4Z48]P[LV1N%CC
M1'^%IWR"9+'D/KLVQY=-X\5?CCD_[+DG=-Y['-?^/,WE<]P.^8ZK%1J^OIGR
M"FPW]SF@)H= =+R30;.8V#0_WO7VY^W*;X3]*JR^IF> ?=+D91J#)!V@[E";
M37^%?&"C)R=A*O_ZQ)S8&7[D7"VQ@W#?"[*KA&MF'QK*0TLMH28DW7MASLBD
MZ7Y73WDG867_Q( :L^*)O+;P&)DOG^5IINLT9WZGF0I^*J4#LL8_=L+]3FJ-
M6WNZ: 0R29RQ/<E=T<-[_^"$@Q6#V^YJT)]IP)(YZ;E4X9E-7S8/(2OP4 T+
M=79]RZ5S*&)E $&;.XJWF)@&A_F6K84@5I %;+"&=>/+:SIPP(S27!HX8H''
MB5V_+G;#>J6MLOT.'8B26-]5A_F;&!RIW<[UU-*>Z7M@";JOB?%L3Z0[D2:(
MK/"83??:>S$M!R<< ' >PXSHPV72;Q++_2:&?H[-,G*>Q3$W($J2W&6\(]4T
MZ10VM(]A$0>66/;-K#+#*1)E'W9 G_0/V@;3@1T$+\*HS/H^MZN@/X(<07&$
MW,-!:"N.TI;SC\0F3=^#<^*?.2E1CT!\=.#],!;6R6.05.J2+CCB!RY7Q4Q^
MA&UW__K^1H5D6Y0U'3BQO/86^3.OQ@V"F/^.\MIQY'S%^AY;LVYB%QVH/0\-
MJ_W*2/)?[C#XH\.5?[?#[S@^KAQ;>[,*/M6$_A]6@3^P G_G([Y!YF<5';R9
M+N/(Q50J?UL*[9^:!?(7(T^U_#.#%#7(6\.N>!&ZOL+I.*F4M,"SOIL3M@D,
M194*NT+Y.B0=V*Q)-3?X&TY*?X/>]X<YWYE9/OFK1XG9($K;[TC]AGMT:WYZ
M[OIZ)EHM]E=6#S=(@B_Z>YZ #ECS0ZP89CKP-TZH7XF939YNH.6-+$LLJ/7Q
M+9K\SQGL?Z=V(\CO[&Q_X]6T@99.> =BBI%@C5B-A_:.XXW_A$+^_X/L5\C2
M4C_,BZY#1IK&3(=G_$''N_^7=/S?;-=G?F;V9E O1D>1V4]:Y%C5P>7XWZ05
MOOZ.>9LI'YA-7)P_0-#L3^]PA%0X8NB 438=6-UFK^60_B.Q\OT]L4HB,-:!
MI DZX(-Z.TO!#*BU1H7U$CS;= X8AB8GGBD*&I,=E1P*KC&,>+F;WT9&V$6+
MJFH;[A$WE1T5VMCYXG:^T\L;2CR,]AU)9[BF'=J4/+/3/:GGK X/<QM*W',Y
M4__V2",E/%C;H,Y8S6=1_KF;AG9@MGC&2 LH/"]R4UW#LR?2,8=FX*B[D%AQ
M A<]JI43II'QP*LFE,UERU17DMH#S=)#TRQMN<ZHXK:\U\V52T_)T*>7TZ*V
M6[85*QR_&*^B^)@E"6N&.MW$%1<U#&8I/)+^5.&B(U.2YEP_%NZK0N34)TI&
M!'_^MJUEW[3,F,60LEPL.'HD[T1HD/_I"-5)DBI<#^R>;[X4KN&7%?CE6-?[
M@(6L[W2@%=>@F?QZ7DV3]A8<_&2*6IRQH@/1=<X9*%:HEC"G)YF^NKR^..-!
M(:XLZBPQ#8_:ISB6.!HZ@=MBSJTP9'_[EC"7[<C,&2$^]X#<]&:*-3N/V*9Y
MD1X-ZF'L(AU@=F;>'ATGGT.B8BRC"\9Y;]@ARP/;%5)(Y@Y/0S6ZNN5/<>>F
M7OWTPD:8J2]G;T[46][=RHG\$WRR#81,&U7M30)@A_1C^QD>%8L8LT,O7=VF
ME6[Q\.M\IZ$E@_1[Z@R=(7,J]H&#"U$I/GF5IB8?79 ]H$<HR G]9GB]OX,)
MRUIW1[#ER630T8N9PB(@L][%$5)/'LGK;,BWU-XU$=_$\&'#I@HQ[I2DH),B
M6 TM^7JG5O7RBJQ<C3&P&$G+=3GO=<!'8PC*.:M_-#K?W\WGZ'MFRWYI_P\4
MV]Y"S;)3'5^=CC<ZY>M>T8[2L;DRL)4L?>[HU[%WQ'/Q%%PYQ(%94^IGLGM2
MJ?2J?(^S0->ISCH!GY<!WT[4A *$ZDV5^\>:*<O*#7C2]O$EOB-!^[.X?9^I
MY%H<V1-K2ILYQ7^'8>MI1<;M!1AM<FT>L=30@5>\7\7I@KMZUEFIZ'';;,4F
MA%0;__&@RS[W [?<NS?X"N!ZU(0PANW?8[ZW71S/9. XD=S^2'0D+]=<A2ON
MRH!WK/;=8HD:A8-&+G>]V+6) S.>P_B 5<5<MV_]W]J&.WI49,JI=>>J J,[
M5QR]+8\/F,H4GP'NM=$!3[N&\A&O7;;+KTP[^$)7M0K]1/99^G]XB'7Z(%NQ
M:W^&1KF*QZ-[UKM0F75)!M^K(:'6P;8LBNC!C-9G7_BZ#+B<8CXJ913I17(_
M/N<Z:8\CKL)%S7,Q+#&,RMKRM/"BJ,'U[$*/^U?2^/<)U[,J'-QJLLMOD^8X
M8U6REHJRIXK!?K0) 7UU?.O-\.$+/G.GY>:%@4WG'P/LS][ (_)C_=&6XB.T
M-">DL6QV7;39HX;\RU<D>D,$3&8<-9%]'PM@1W!!5',>LW[H9I@-9F67&6)Q
M7ASR-(MSD183K'T=/H)Z(J<W,$$"OZSF0-Q,L/?:W(H\\^,.F0W-7R? !:1>
MICC<@F5J)XT.;!DG41Z)P]Z2Z>;ZSWD_CK0L@1T8@%?[AH2$BS2B,8L1)R&;
MY8-00SJ)+)?ZZ_>87QHG#ZT?"?J_0CXAAY8N>YX1I 2.>UF'3B"LH445V.X]
MX."QR0S[#J1J.<4I("9.WZ=.3,O3/J (O<X&OWZ/('\W6H]3'(DKL&,OUZF^
MJ0YE/D!]*QI$=+"O00RMA%]?4/^O):^#(I.6W,@S9?YZ"Y^-/S>++TU[BM3%
MU/.6O%+C;TYU4E)SLT>;!-@)V)EXNU<*/-(*=*TZN"2%YSM:61(=HAC'E_35
M15#I1$KL.[S2*!4Y2[->4)O0-J\AF- !/C-(CAP;%EX>7&ZU0U=[F5N##+@\
M/N_(8Q45,BZU6L2]=Y?6?B(N*V11+N!=ZY7$R@=LZ@I/PW_^S9P] KJX%R0>
M@<RUS3+!JHOBJX.D.K.Z/VP6TO[YA$LI_1G:_1R:#1UHUT]IV"JM\UC70,7*
M6O+9TNPQ>\$0M^BCX\JRF]1\;H9+!DGK\3_F,KQ^:4N#^QCJ#8C'89SNSQH,
MH'QE=R10/ VE2_0-.SHZ] SBO\?=]FE_M5DZ6W>NS+4"2,5^K^^O]"GBH^IF
MD<^37L:W.FW/E@[;5RFK>NQY,=,5I\ :\>ZUY%?.IU"*<WHITCDCM]J&<T+7
MEN6>R+3P"7U_XI@S5-@&16*:S$3Z.NL[ULJ@4[/;,W&F>3CJX8$;K9(BJOM:
M'\G6)(A.B]T+Z(N?YQ<^<G1O=A3GP5VO6L>,#E.\!DB TX5<\@%*%,N^KBX#
M/3,._;C6U^HJIL.&]KNW55=L_D38E<)NX,73>V  JDV)_7 DV*7(2+MI>#'3
M@>WAM\((/T>#>A54*B;^:#HWG\1L4>$ FN5:7H[<GD\$G_'=$1JF'0_5]>*V
MN?(97>=LN1?5BB<7J>T9[XC*/8WKUYN96JC3&+ANH(WWX%"XD&_HDR"SDF]5
M?D>6)[$T2L, 1=#.$['(?W.C_MA=<V')1#6],]VQV7\]R#+GP]A-=07[D48L
M&]1,FM/%(U87<^"<7Z0ZN14TG5DYKH^A.732@5'V(2W*$7.(#J"H&M1Z_S+P
M@$O*DC]'OP$&&&TR'<^1N&0Z:/@ZY-*EH[8=*:=>G6@?<\>:C8SD%=G?<YL5
MFIOFK"$=O)M$^F+=G(ZX:.[:+*52QS%IJ-NE;'YF?S?7^'G&4:6,_KRCBS6P
MMYM',(_K]?>3'F?!*5F6^YOZO"%GCR=/FE.ESL>-9([ATK&DAE9M#>5'C2KZ
M;C3T0'-OUMMAAKK/)3PB@7.)Y[<WKF;@G)!-^//(F_DMEKVZ3W4/O59]VGR$
M/ZS&:O\6F0>"V5,\?4EH??3I3HW\/$*!W+'"(,5[SZ_1 6,_UN('O57.G@RY
M*:HJ.GFMX:>L#\[U[_=A;!!09[DL7X*)>YJH45+_UJRM!E</,?3>$5'4F53W
M0_O++^!@'#T9$G]-)8IJBAI3I"2.%GS*R=M7.?AUY')ZD>S(G:I!DW<Z%=A,
M<6JHJ@A4.(U<T$O/%EE,8_<)W7SU*C1/#5S(M22CTE?8)+$L8^%;+?G>XO3'
MQ@YU39COK-B_^FY3^*?L5THV@M6E![JN)&&.JN>^-@&B>N]!#^*CBQH5)90%
M,\9C0U]^L'EO&M:F<]KV@'-66X[8O7!.[ZM7R@8S=SUYPB#7:M'3(W*%WXVQ
M:;_Q#6\>,W8M)0 XNS/(A\V8\ZE;S>-H'^$?JT7L*Z?8/Y#L@GMQ/@MU)]O,
M.]>2U7ENR'.&3SJ5CV++ SXOI8M0WO:"K _;/HVEBBYEX,I-36R.),<]S+@D
M:9&7PMS)L?^;WF%MY_<\4]^81<;RCDY8+63,$STP9:D.JW#HR<*/2B8;G+\X
MH1H^UW%&L.CAM/':@>Y0S-!QC^);_"=OOSLP(C0K5*9$+L()AB;W?RR]GHV]
M$:;>V"[HI3'_NL8</52BJSA6J))T)8/Z@C48=5-=26UB%8X>\C001=0<%C4O
MXY/-S'>_Z59:%GJC+M%T3B[,$I=04.B?\IX9\SCPY/: BX,S.U/Q84]NZS1G
MJ5\??!_M<VS7T6@?@&*K0=D],.%_=4Z7*GU.26#N;$XDI[#N*Q<Z$*<#9Q];
M9AD@#SA,SBR@J(;.=990G%R(H-.EON/<MDM!5&35')AI:@MZK2!VPF6-Z_I!
MS!=;Z,#RJC@DAJ'<0.X!1_6QL$TIP-Z?V'U3@P[<? S.SZ&\5IC63H?94L!
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MI0T@3TPG'?W;6# LH<7^L@ &M1$,8W+ITKTV/-I.I;]3NFG!]PG7^WFVKT_
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MC]\WLV;-[)S]3\X^^^SKOJ^[G;7NJY]7RP Z72T=+0 ! 0$@[?H'N)H#W <
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M1W>7+<4T&52+\GD[%.;YEHR4#Q!(K@DS+=H5*I[%"TRJB^"BNF[FPY2<T%<
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M>_S1=_D*0+7)XA]&T@)S!35!UQHM;MFI9G:8BNF^ >)BKFW8@?FP(FE7$QV
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MJ[XB=&&/E5>BC$2!F[2X)S9TJ3UM<M-[+H*MC=B(6I\,I")#6N33,06QTBL
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M>(*/:%5--7;^HN!2&);>U1P5@N==41V0@]KW@3\]I79%T\O^[,OUE<V#EV_
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MJ=:(4+ZH@WM6XM5PMWE*5G:-#A^V0\'3"Y423'*+EFE4I63*(A.3%(=N85>
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ME8=(%=G/X2$PD'DX_L9% >AN/NZQ]&Z<WBC[%FHF$8'4L&MW3&2D$"NYFP)
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M.^E2J?>Y#O3J7&W\#+*@BR$]5&2^*_*O'LKQ?^%+U)X*$/=HG:,%^S9F*3E
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MV;^J@6_]4!^:\ !-=H*CH-:40&P\A9$V84?T;GZB JG.M#%2<I/6'*>&$:G
MV:WZKNW3!31D(EHHKWS6;78SYLSC&WQK]NMS@,,<Q2F<U;F$5<O\'-[;,W!1
MSRZ?Y0%':3LJ<+6""GQ^^N-L^9=I(^Y&7"S"PW.9W)7=GIL90HKIWUJL#KUC
MM*)\D[:-<BKY,!]9E]?S'150\P*1CH-("6O>J:OH!G*73BQ,B@QKS="P7"OM
MVE[[-Z'=,_:I:S-N5. IW8]+$;2%(F305T63-8D6<JC,P[65MOS1G\6I+$E3
M_)9A!'X84<8-- 4+V0ZY2+'Y@8AF:,VOLCI[03.=,[1<I?]Q+5&:8D(#T!4Q
M;07?/F7W9X5>I?L6< ?I^ZNHY"Q85W(7Y0 S12C2EHSX@?*4U5<TW^KY;I/J
MGT1Y8VW)V\-48.SRCXL/T[ O5(!Y[9@1N?V'-R*>C/)1@>BV">?=0W-6NVZ6
M\%^T+P)=K?P&;W)F_^#CN#HJGIKU+@O2='X^H/OCQ<7MZ]N?7-VB>EG?3&YG
M+->0JWP2-"_V;,6-^F.BN@W_?14@EK]K*ZWV;SJP_DLLXY3]TV)W?-TSA!"_
MBOLU/KY2@5A:RO#D;\=/4#2X+F[]) S^<]3Q=&U;C5/N?T&_"P!-&J;_(T(3
M6BB@0O1"'FSV2L$ORQP@%TIQ96;XGDD^V2>ZGU5;=F6E8J8"%F@AFM-DX?N;
MN2F_GK LS-'-^G$/J5-IN=AT[?4D0&^"TF'RR_8]X:D7MW[H>K[(=N6W./\;
M^5/[.V!2WG])B;]QJ.)OF=;P>Z*E;63^Z<R)3/Z7P/HO$*J5 ,V@Z/ %@A9Z
MC6C$_03C:][ULJCT'"E_[$7\S5K?,F1?]:LXXA7^(VR$]I)IX7#72Y$;V%^S
M@$-[36?$=]O3\E%T:*G_%"K5Z^^H,##\F[J/_/YBESRO]\+ OP*(#)>-/^LS
M+:'PA#_/=UZ\%=.1L7\^*X\U9/YY:I ?D<THH@(MB["-)69*&-@^\6;=3V6C
M?\_!4<6BI79@/+$U)#;IF!PC<]6<:86:QW)M375UQRD3@:UX/4J )NO?V+'T
M+Q0C_6]L%//GZ2A2?_T?BEKI/R_ZE>#&]#_B!A0?6._[TC^B.N]PZ)\-GK\Z
M!6 9_VM%D< C!X)XX6G<'5([[FIG>HUE0XD&!<$NQ:^^N^Z;C*2D%^<+M^YA
M2+!WF0I%'C^(*?)=+3$=48I]-$$)^3<Q'_YF:OQ998>A,]DW_A6DPY.@ZO!G
M=?"929#ZLP>W=?IVQW2A_Q6U2FR&_'2]:]>1"J2%IIG%N]E3@4$?%SG409!O
MZ9%FK8[. '#&+YXLR&T;&O>M'<&]R[R>3]:QP7WZF_7YK\I^I+[E^L/^/UE'
M_J&&35'FT3_BJ]0YS8F%?R0=U/;LEB+[_SXS3?Y.$]'ZPC'_B/IE_V=L.//,
M4?XK1TE%EZH3??8N<J%_[%$$BDD,/>M; 4:IH88VU-1(KZB 0&<-%;#JI0*S
MS46>E1(O4U=5%G ;>R!*N,,,9*- @G!F%BVPFJ1/G)FG:94>2L^#T?XJM#%Z
MVW6%[IQ;*V]Y)H)AH)9O;L>K6?]HRWBN<R1ZIBT7(N_LNHK'?(P1IG/YDD=L
M\LU\,EY\LF"&LWFX"*N<G;DK\6[H9=K1B\=.H*5J\SH@3BL!*>H:ITQ<&CU2
M&4"3GB54H$B>;^?<0G?\,CS3N^NO^WXK89KA-;"A_+6H#5/G7=1>-14X'T83
M$>?S5+,7I3 Q$+J]U:359 PJ90]%KC#JJ&4(A:7/]9B3W+[NC68Z+<F_?97"
M=K]42M[U: HR IS2B;6<?C.^Q&U2O,[V8WV6'2)Q_;27*<&Y:>EV$T4%G4+G
M,GX$J5WZ\FTU^*&(>QAKY?GQ#T,1'2/?-Q$Z*%)^[MUY-KF4<X0/HWQ*F:5;
M7(^?[2A'B32QQ+Z/=X!?U U\K68SMA9EVL+"Z0?FNA&>49:=_FV?ZB%(NXH(
M,8_F5['Q&(_Q"^ZM?KK9.KX?E!U86FVB%5Y$G'HOL;R:?7%X?9*NZ<E.2*/S
M*6CO^$H#^H3E+ M8WQL/$4:B>I&G<9!;MMS<KCGAC/O6V.ACEJXVUF-A5OUU
M!LFTKJZ0"K3NB(?SV/*87!@#\>CBYSR&1/8NE#I::U2S><4]&S/7BHMXJ*4-
M<,?&AMQ3;RV"W4[1V/M0K7H\JE&X'E/T8-B3C5TR\/I<JD]WOWF>3K[TIM.2
M6DC68\>JLN3:<GQTM4A+"GT9 =>H?]1JEJNV6")R(^*Q+G^\0?3U1+U;NE^J
M!1?OLDCF!Q[#5T=#1O2D7'I"W5P=93_>N'A!9NOH^?0RZ:/CU2 J<"ZF&;?)
MU(/>G*Y*^,,'Q:E-?%;?>I1U>C>TW#1.&3??+QWC>>)C^#Q\(G2[]U:_RNWQ
MU @TB]_M#-7.X@_V GIP(P+^1#/$N$RT=RBR5U-S*6,E]SZ&%>5,O*K92SD+
M;6DBXK1S25X4%L>+\T.++] I#U,\-"*T/WL^R.]4'%LO A6(#.8[4('QSO@K
MQI48#=*0?N/649$.<8K(@I(H1HX+]P+]R>.=3'NRSLWGN]K"P2NM!CW75B_"
MQ34.G)!4YZR3K2+D-W%APLDG,R%*T_&0S"Y_1Z:O$(C'3$$.,=^YN;LD9DO/
M9<%,L_2<N%'%F]PO(N^20^)VW8J+%T(=_;+'(PZUF)$R\%555  @(1I1QTEE
M#^'FO1O&H9W]1J]S[,@;K?K5EZ^^]L5\Q/HYZ"PLB%U493,FBF+[.Z/4HE$,
ME2/W;@L,LPU]X?CZN)KQW:F'QC+$HR;3O3OKLLGT?"%65;29%BC^S"EC$DB^
M3BJ1>*5"1Y1N0+$=R5@ .X5LKJR+Z2G7Y*R40*KO>;OF\F2K0H6J?*E 6-1L
M)3/<:4@GVIET-?U%Y?88=\W G 0]G_!HB^)<0N;+Y\XH,FC[Y**M\T([N4OK
M_;,:39$N1("87-C$"O,L5S#\=$T1TK6LS$O@UJMESJ^/+D]_9ZH7>%;5-J]T
M#W.$$(_7S!W79S"M+7S?(1$BKJ+CG4T%G,1VV@5==?S/:EKNES^\]?K=2%1+
M>RCOV:/&!S7UY%4)SZI90D5FX/3DATB2[]BNF-+DT(C#3EQ)0;45-B':M(['
MT/+Z$>\D.<4S1I<5-^ED%V',*A[61(%Z.3 E)>(4^\$)N^3G')-:YQ<JH/<X
M]3B>:!Y>,-(K=;!#L=Z0RL[_/G?QESL]@G^^"Z0PDU"B\ _<]V&J=H[H%#+6
MH>J,W'O0<NV3+8M8<YI2 Z?K$8:*EYR?57QO.9[SE$GTU"P[TDFO5YI7,,A_
M@M[\Z&K7RYT/7J-2)&6/^U"A3]4#4QYQH^8M*H^^&-]^_>0+5 #I:BE%&"2]
MFP"]BG'@JLW.EG\A.F9Q_.ZHME-<";+$7+;-B%^9K9X\R'TGW$0F'SLGLK!C
MCI5!/!I!CR_Z WEWQ_;K(R]$-$N%2_>&CLE N$'AJ?35:A3A8,TPH]Y"9Z<X
MSLDRM4=-KEZ:7S[;)M%9ZA 6QB]C_-CQ_I#Z7!4E3V3^-?<]J=U;Y8/>F4/:
MI8V];+;J3^J&GBR5NG><*!3$7*RT<\GF5K.%P"RZLN12H"H>'Q"IM5RD9U_:
M+7K=NTY !@8\L18CC3YJ2:A;NCPQ;0+B*CUJT+0#==QJ=.4QG%CD.I/]C>Q2
M$^E<W5[/WWGC?'J@@L0I6)LU@7[/QP&](\ZU GE&U"+'@0 8)BN?"J2/%VT6
M9Q/U,>N:,23KN=_N&+26_/V1/0T#U5[C"(;Y."7/$L1<I=$&<?_ P.K<V6B_
MLNYB[7:_%AXOF:0W1M][G*\Y+?V%[(*,G5AU_ _Z(;,+I] OW/G"LHWZ4IM\
M0EY9EU4$%0T/U22A"ATW+QWR/'BGCH-SN*+#5[ZYZ_#<J" AJ1<WFX!YI9=8
M:2>3?&QOR3:YDYT_OPB?$173HG  (PI1U"BMIFBN?L@03%S=3MY@G<&54-+<
M\LC<!&3'<HY'6%:93?3<X+O5TR%Q4X$/9@%-P?TW$M:Y9E_\?^R]=UA3:=<]
M?*P(*$CO1&DB""@=!*(R@(" @/02D4X$!$4Z41E NH" (A"1+B72.U'I2&^1
MWHO4A!I"2+Y8YOF-SHSS/+_W?:_W^[YK_N"Z".&<>]]KK[WVV@?.2<54^DBC
M]FQ,Y,U7(0(MGS&AJ?V4Q^%. %L2 80=;--XX*YOK['L&MZOB0B8=Y':?4GN
M>&,-:,&NEFQ]_QJ./U.)4 (>8TAYUI/NP7WTT;'%"V.U5EB1:2';R?S(HWF(
M<8UL#VK3 1''H?7[YX8X4$,SX5(Q1$!X_>9Q(G (I&CF_!#O*1)X;]^IAU)F
M:]19'Y.18Y]I&/K@X;;DMDU4(:WX)55I^0=D$DWLUZQB^Y&(OD]QG-J.0C!$
MU_:B8%.U :;.J+N80^,4NNT^X6ROFR ;98WL*E9<(%[G2(C=K-[^5.E5]H-I
M[!'G?9ETRI'Q[V3#A@+2O)Q2MLG;2M$CGDMTGHYO8QQ65SJ..+)VQ^YZL<BZ
MAK]8=!9W2N5EIG;10) &"ML5!7E07:7*XUP_9FQ!2?,F7X79K3U#(5O8F=AH
MFN.=Q1_P,I%AVPBS7H*$TI0]-^3X)S(3K65#M^!9:'U9Q,>V8<M 98N V^0L
MP7LY+!,S%(W)I]6DXB+G"<HE_-(M64O.6ANVZ1.)$[8<=@C**FPTG"9? 60V
MW+3-XNAS^]Z'\A7G(_54GQPO\/)>(^<^_=3_X>94Y8K(-(]Q9B">*2><ZVI3
ML)M^SP!(CL[I\C/G,R I7'*B[VJU7A,-N>2UK XP"K'+&7;@#&#5[9]HF8!>
M8_,QC#=#=]8['S>WSTZ%,OJQ5O;1+2<DNM^.FGR2FW%>+OORN^$8E+\>7@D#
MNJ$5*!OX,-].S$XJGG"RLJI7Q )I$@MO*3FJ=.LE\\R!V()F;K"DDGI]W<M^
M<COO=H9)KZ 5CC0L9P=*/9K2NZE'/.=LR9GROJG29VL/(8[56C$7 W8?MVX!
MM)J"P[EK7'WG5E97AGV8:'*[2R_$WCPFC:,Q[LUA35!:#)O7O*[:XJ1ARM2H
MM7N U'$;'06)@)I^U=!$K2BLF;H.N2UF#\'I%.MCF;_[B^\1>NU+7_X),J*&
M'R&)Q<"\00'W? 4ZMGVE]KQ-"WN$180@5@67!>%BEC!*T?R1".7%X _1PDI7
MY'JTY<\^S:X[2%W#ZRGROEW"AQQSL5'A6&^^\!QZ)2\\+MO:V=-UYX3=!@OM
MU?Z1N*%K%@_./-+PZM>0V6C<9I]N77X4PI]W];=''HB,P9I!I%FC=!S'_)K!
M;X-P"6>[3^H%70W7<[/Q8*G=(K47^/B91V$TCY3%>D)V*U'UG-QHD?JUX#&1
MLK@E0W12<AE'?M&K?+.5B;USYT2$FEXS7NQR,U?ARLB#6$/SFC1?9'O+1Z;=
MN4,E+<^/H.DE\-CCR,)K>3T>\L4;]69JG+CW\78:E7!:,J-A]+FD5._S\P_[
MDF,+ID3"$CH#Q<=I+F=C]<37:.UQXD/]2=E]^M[0<LNI*[QZAT5II?C&7,]K
MNO+>.@TMK E;L]YW)-CFZ%9G#B>%1U0TW/0@,^C?6J.RW\&-O7!.'QM184_6
M*$$-T<1&&2JLY(3-X*NG^U#M1.#8)IN\;B/=HI0"@-%'^"7SU9)/V97HFRD(
ME0G3%RN[K&< W!8X5EW$AP^M9<=ZYG2JAGOQG3EVG_V%Q)PLN'$6E=9][O;F
MV3G,D1E4U[B]X)U7&N#EY[1QM\Z[$HP1EWS>NIZ'AF*#,49X"_1.(TY]2"4=
MRGINR%)C'YZ=/F/"6QD)J#,SNY3$QK![)?;&<9&;P8Q-N:\X#B(6MQ4>O:I>
M,\:V,,9.$@$VAWG5:"7T0+YXQJ^:!\IY4SAO7O33WEM-W!_WBH.$1%I@).O>
MLT;$<*3T)7LLY]-IAQ@-MU[9FRW3KN1Q(X/2WFV\U&Y0&I@0LYSY<:U9X([R
MB<,,TMQ'J^DFW.M]=171U ^%W&HHK+M+U(-Z'4O>^155:?8T6V[<:IS1/Y7E
MV)1H=7S ]H&?U) 'W23"_UZP4LEJD;NMFU?[Z\5L:]KW93JGV@J/CBQ[Z!W"
M:EX]6&B89225 9\EV$127RPN*?KRYZ*(5V_PU%-[()"'BCJ&*I''1/X*2(+V
M^J%,'M%$ER>76=C9K?1GW3+2\B/N)YH]YT7B9HF ?,ZP8/T*$4")[*Z8#T+
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MEDD/"_0#]':\BW XE"/AXSN)9YQ6- $4%%8W);M1!7-%/Q$+ >2 J?^_\+P
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MNHP)A&?AA?KE.'([MY4#82M" @LI;G0' @/>D!]X*"U_0 YUX4Q8B;W<::9
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M?#C2.:3[(<ZQ02[]]D3MA')WQ^7-[+"^4N%[UIHH"3O$1<Q\XPF1JUCK*2)
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M5QQX<[FI"R4V@0BWG]8*E-TN+P4-FO-WY:;[:EVN LNGOW]O==WEPR\31PU
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M<\R/EQU/85VH2&HHW1!4$\V&.!R.0Z\J7!Y^^*D:;1#1E5EW<HUU6(&<E*/
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MZ7#2?@_5W_,+CXB]-1Q($8'&?\3>J40%M3D(2")'0HOJ[E,$U]V6(VA4X/(
MM+'$Z8G<2\V/X57R6C>KM\$FDO<CE)18/M1)7@&QE GW<E.(W$V=6/MLA1,7
ML-8BIZN5%1:?-V_-&>_T%3Q]$O]11XDFM\T! L;=F<=5=>,!:>,9X!I>(*&M
MZ3"#C3 T[IGJA1XJN77.PT;<^K*Q-&L$I:#643I_W@7&E.C<E,*2-,_(B>P]
M+;7?Y.7KE/55[O'1J&*O*?]PV;5)A(10EM!8RU&J6.H.#2@UFWW2W8!H1GXV
ME2Z[)%N2V]%P,48CTC"QV0?6ES'XJKAE;)/5SXU-\1J9GA_U>D)<"1(/"&J@
M9N6*:1JWA\A,W-?H] @ P6X\"@O9Y>,Q>G[Y\^4/\V_X5O0K F5UGI1<G\CS
MOD/Y\=H]2R<92V;+_E(XE@XY9:A6UK_M3B:R>Z_L<\6GJD_AR" BHD=4K^;[
M2P\\AUA23%PU]4;V9K9M(B#@=@M>S(L"")V& GN,1I"VN3W?!PV-BE <UP4'
M7@Y)X0LT+YW.)3U7X6:F"NL$7X&$MEV!"LD$A0GM><88#+MWUDY07#]?Y6 =
M:QF+2.<ZN-#1-IT!\(:G&JJ5F(;*OBJM--Z8MW7,-'HK1OJ9^*[4D=ZL%;D4
MC?IN4P/;8%EZEOF*B>-PPF-)-LN$?LF@+HX2WP!+%X[H9]&:K-V'N#**@CO'
M=V:\"'*7<!)YMFY(O/?B.-0(_3A\3NVCIE"K</' ,*E59=WEN#R< PV_%Y]+
M<9',;L(VS)XO/Q_V2G3<U*(]TV3-)#PKQ3<'5-7JX,#Q477'\5I &TV$RF5O
MFI5LA(RL\=38!ZZ6<?.JZ+F9C=7%KL\\E]?#A,\8QISVK1H6%3YLJ(B;7J/?
M<ES2C584(5&Y/WA3CFH_NV-CZ)![G6HY[,@3MHA3B8-2H1^G^N9!XILK9;+"
MYV39* 3RQM85V"I,?72CV=D^/3&PHJ#7.51#!GK##?-D!/VS(,X@#3)VK;+^
M KTX4P=Z6OHF>:TA@-706E4VS6.WH>BDR;0" NF,WQA2$3AQQ)\LB0<4/X[!
M RK%)T;^PY<HW!U!R)3LM8CI$)Y\X>][&(G6J<!\,U<8PY?>9U5\RFDB4G/.
MYDAC=YUUH7=K7AX<25ICHXY7Q-CYSH.#%2Y%(NAD[I5>TA3<@< YWH\!0#>>
M?[;A*))Y?D'.,'_X<3W2EZE56XFX/,-HG?+NQ'P$;HI+[XGET\ODY+*#:I*?
M)+)YE+^ZK#>"M69>H/VRL^P,@*7U!0>,11_RG=#61>5S&KY<.F*TE_BB_WA0
M=UYIG*+!8="/#(- 5. != H2F(8)@^)/J*N@1\&YVU3&91,WU2N)&J3V6<NW
M34 OL?(?1Z?&[!+(WV<;3Z'=G!ULF%UZVQ0\B,B:VL5*,)((U(I0:GNJ77!:
M=:==O@U]I6720GMXQ@+10/E#1BT!V8UG-,)O<AF4LO.Q3*#M 44$S('B*@2$
MHZJ%D8J-"V15SDL&J.5-TP\Y"E"^=,J(*3H;GMLK+96/D\9X(35->A%>#2R#
MSN)\4R;C_>V@3Y_JN!#Z$8/$@4NK@*/YYV0++T5?@>=HUADK$9$7'$92' @-
M5+J]I"DM4&:M^0:;?1COXEL4"<"ST)3LDF9_0_>!@,QP[T:Q;QS%=1H0%[/_
M8A;)UVK )O-3WM-$QXI');R480]]\F=ZCTOEO Y\,=79F(1U'%6H)J^&M<0G
M^Z=K5\!*;O++VQ6: N/<-^]M>3UY@FZW/SCN'8#*9JQ4&E::^,5;/_2 XJP'
MARM6F28E#S^\/=N^;D*3<37DD[2#%@W7XGFK[\1ZK7? AC[]OH?I_>\9_3SH
M(1[ -CRS/P3<^T-M0T^!0Y8@WF]BET\]8:>D0_:?<F$=ZKNX6B NP+Z<9R/H
M_OS#[W^.3>,_#Z1<\V/HCUY71W4?AFR9Z#"4#"R%W*!1Y:@6*3:[?&9$;GB?
M^MU<OY?]<C#4%BT1 U_Q]#M3A>M%'93,=<S5#L7K5@6*9IGD_Q%M;)0DUL@3
M#N#FCFH>N836T(T&,4.U'9G:CH$O'4T1!U'FBGD%;A^<A/[XJD8D?&1HMW/(
MM6.:9/@M800!)H5$'VM,@9MK!'-]N(@FIT>5Q,)?O(BSYIAU,8#7T2"G[I\
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MCF6>5#A/JU<)9$,WYZ^Q14RO#LBP6CBRO3UOK</>'@]5"I2R(*31W!@SFL5
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M: @1S<.D_-IN8DXQ/23MBU?C)'1<XG!NU!^J_4VS?TRQT/\ES?Z;8O]=+QA
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M4 INJ'_V;X-GYNB.[5&GRK1M_<8D>*)VZW.'X$=]Q-IW-8R^B11WHC44I:Z
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M82Y)03G/E9 9,(H7'^]:S/!;C>=PSEF$#*'S_!Y^0E.+@LUR<\3Q6(R)=I]
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M3!UEDEX2RR<UG-_X\]:"1+:-@?UM?55-ZF#"*D VIL:FS-0YK=S32=;L_HH
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M8CIN/)[J47:W(>-H)\9^[KZ-P_L+8V$JN8BNR5!D0%.8S$)]5G*![HTY([#
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M'/7;D7F&\F*4JEDD7#=H?U-Z2;>RTJN5\_XR>85'LXG<0*FR=.KC24U1Q6
M$?891IZW+8<.XX?4$49J6)B6"^DAX$AOGK8ZNI3MC 2>#M-X3+]O1#A6O033
MJEP[6^]7WSEY5$!M:C:8_9USIY=;$J=8E>8%CBJMBHY;CY ]*^?A2RG^/(?/
M58N<.5)O*G_N!__\XK'TV/;.%<U+)?S_57.]#1XWP$8B9OVZRW#UXOG)O"$[
M.N%:DSQ>\3>^_PU0=*3$I$A^VT,%M7H5(M3Y5V_VZ@U$\09((NZ%GI(TW  3
MVJ9_ 4-9-'&/G'<\B,^GV#Z=:L'D,'[#0IDC[J H7#5-5C^2@\;#8(-RD"-Z
M9Z\COQ2^-RM#9]B 7EY84IO0<1$GU*0,O_<-1*&.QP2<4_<$/*K'N"-'GO2=
MR?F?13E9X%8,^I>9/\'O65@:Y?#[&V,?Q9M=P!!'*]U+P\$Z2:L NS16LT3D
MY$IM2"QA3%;-ON7V?32MD%#X_'W+\>OQ"];8+N@]F&]XZ5HG^;ZAB=-L?O[N
MW)R<E7-M)G)2EFD:_<LZ(25O-SYD$K9LH/K^/4FEJ'ZX,MLGG.U9*$4 G;T8
M)@ ^98Z"S6>"TS4:&G-6U/[H7G3RTB0S^.$DV*-RP^1N@"@L.2+AKGU:)B9+
M=0;KXU^@DS=L0Y_&E7FQPXC7] ?4M=]ZY#3XL['=G[T PH_2#8=E2/ES]S#1
MI7\=TG38?RS-4,)S<CZC?.6@I4BP(PHW@9?$O$F;;?QP?==@X8[J1^//OPH9
MR)L_'[)L1ATIL8L:7X_G<#K4,)$J]OUQ,+'!<OJF=1;M&9[2-2RT-";F.=A.
M;8F>(-\8_1[5&'%9PFI@(A#\>'P6#6BIK8HUTUS*174?&])ZK_3$<\9[KYS?
M"8CQ6O-L$O["D3KXAN5#Z;1-C="'2C[8ROZ@::TC1S%:1_*,:''(]:S=;]:E
M7R3L&V:[V_O"XM,I_'[UJ>4;V+0>>:: V\Z82VJOH-[='E$]A5>#'"\(Q\X4
MZ:^Y=P+HV^:$3LQ=#":DXBRU)__ZJYM,.O[=U9-=%P$-,Q<YG 4/)(@=#R=^
MG/_IY]*U2H'I-&A$XR?$I)KX*Z -)HVK'3?:;"U$N\R**Q@F>IV[<;R%IX)&
MWF&Y,=2N"$:0,EVC4V$W8OGY+/-K5%HVSYFOO:.@R3MAQ:C>AZGZ]^Z0E6:>
M*))@GJB@S(.^CTLZD%*-9/F$Z#9H4-0>J@2EW'J3'R-C@+8)D])1^ZF!?EU^
MOQUM\D>S)7-O=.69FI"UMR<.X:B7^F\0;)TYZ."P37^=$=;)LDN-U8SI=5JK
M,#*1CSE0F/,J[2!_M&Q&\ )/]K[@D[K/2]L@<@]=@AVQ7]^K8]Y\K]JWUT(N
MB MG:-6?#U[T% 5???2=9N-"$8:#S/WL?*K!WMJSPK]'G;8[Z^)M8KY@BX.X
M<\!YY%E2Y+&K%""=0DQZ'YWO BIO$D18"B[W<'U+\L/96CN*C<^.IBFN+5'T
MKB.%LAZ9/S<B-[;MU0U K$=.OI^)W$\S:0S+1],H+0SBU'WZQ0TNG!>?2%R+
MN_SL=#DHM=>80S/A2>3)Z.R1)1 E)?#6QO=XL9#Y,\%O54[N+>7VZU>#O_SM
MC4"*)29[E):]I2;]?K3?OL<C.%]R*=U]2^%H?5])WM?Z!>$HE/7]C-55$41<
M,H%VIX.L&4IDR6W/=-*BB\O9$B+VM35OY?E=69# 1X<1R=4XPPX<#+V5S=K!
M.VWY(Y*%/9(T$Z<V>B^Y3UZ-:C(=R4@(I8M [;VDM\=]PDJTI^0Q'0R8)X-3
MIC^1+L2VUYQIRUHJ%\6QA@12?#S\GH_8M<RU$;FA4C%^S'Y'Q+:-B49]XR:J
M"KG456V.HD.!U;0::T']@ ]9,5JWS]=FP$G6!38_UR-7E':::=Z0P0K[)6XN
M59YTX)QPL5/R@;G04UYZC3(E$P$B1[LC%>.QBG:5>T'/@VKF]RA7%LW,["9Z
M[9]2?>?]RI-K)\Y]?U#S"94,RWTQ2YT%["-43FZ5J?UI!^/$ <S42+6-?GR^
MKTZ5P3R?MF<#:'OCA<PB[U6\:[J?;O++@GYB?>8PI*K_PN@IWR?1WD/_9OD@
MCHT_.;:XFX_)D="H-EY4\]OQFH/*]]]0NB%%=1F_D8D#9S(*SXJC&#WYN_0^
MR@X0C7A9*&"ZUQ/"'-#LFG+?P<G;V@EJ.8-ZK;!@PGK3W8UP/827FIZBB%MZ
M%W.'%P>UQ0UP ]R[ 7K9;:1O %2"7< 391=[JTL6OV>BTCO< PJ_G7[$1_LP
M5-1A;#1:FCN;LK3K,OU5\!O:DK4]/C1%>3O%JZC_*G1_PZ9@M:_$YH22Z<N1
MG):RI-S-$5P6@GU='"L=\_=\<[9I3<;Z05M:+ P?1PW>C!?OM55N[G KHV'W
MBZ\JQ+N+,2[=%7XXGQ#<$DM-.2[=0A/N\S:S[3(]*X2HHZ"#S4;484C)SHMG
MW44)S^LU<)/&ORE)8&Y54 >C*29A &X9J6+Z#/_3A4+Y>W 6HN-;.HG5VV B
M8UJ-,3R)D+,RW(W'B@,6G)-MK]ZBJ_>[<CA@]":+EI;[4X*6[V^ 4"_P)$,!
MG/U7G^VW7^*=?CX[[N8#=4@A[V[?FL%<AAT+\0BMZ^%9I\-W$R6P8%LIODO2
M<LHZRJT/+U1$TGX&*Y^W&,X:,JG&S:;<3Y?*;FMQ3,RRJ0-_ZIF@A5OQQSHM
M#HC%&E!@3-<FJDSVV5'1MIWPV:]1^&?S7'\*7K\HHSW=< )PQ@"2%X1Q.FCO
M?E_R_L?*4@X+SAX_APZSE"?J,4(EP5L:CMCM[ZES9ZCEBHJ4U@<_NX#I 'I,
M%C(+?$WG,(69'.M/PB"WY/UJR!?A3YC@@HF@*MXZOB,Q'/.:K;2A42^6>V>F
M4%R,VU1?,B:<E% GPB)#2_.KNAW34DM.WA#!^OFTKV[O$?$.T_)*70G876OJ
MQ*'MJN!B]L>CK70^/O>OP6X^LJ!QPE'+.O:$&H\X1<0-$'$H]4 0^Y@ON/I$
M4?AC9 E2_BJL+R(WE6'#AD%6BK"WDQG<BR2/NJ9<M0\ M4^^G0'Q^Y0O5]73
ME>/_FC#K*N5<%_C#_2?^-7DZH^,5NS=JK(<I/+?$:!ELJ=[T?8JA/:ZM@5+2
MJ_*Y9IP60O9OP1FB--132.;95#56K'!I]\+*I1:6.7 _?J;=2J])MY<&Y\_M
M(!Z+M:1JLT0ZR1B"TX2HUOLD[ Q;_)='LTFK*HDE^F@),TYKZJMGG"I%SQ^]
MN)=Y +4?NB42"NV>,YD6<5WSTZ4R&4-JI&KS+=P9HMQZ>99O'"NX3AAT8/$E
M@!6LWZ9S Q QHF:3(<JW:MO>/URD?KL$,M):%W]>=9ZO'6G!_](Z:KJ".[8"
MMQO/FP:G!PZ^1)14E=G2I?D>A;L<%4/L1$V6E"5;&Z@_ZVMR;XQQLQB.K>)B
MU9'0.QAR!/X/3)(S2!%)?+DL;L[E\"#4H(SN\'V&->XOX2IRV7=%8@#)AXXT
MU%'/& 'XR:OTE^-MO/D[\-"%/\*5DCMO4NN^;*8J;_/]J3B])AUW<O)8-/(P
M5Q!P$G\E%<OO&"1DS1D$'E!0>=(T-+BB4(]SG'15T&;H<,L^TFW^-DCH!Z_V
MB&%B5&>D=!1F5PS<!2,M'EF-'3(\>&^LAHYW(_52$,8DW9:@$;[I,9*U-;U(
M_D)4; !/8W/;]V!<ZY[M'U^XJF<\*)/WJC67 NED:VP;,>IK?D^S.5!>(7>6
MGO"V5;!EW8OB3FJ4DZ9/M1HF##%69 B@*>US(;8PL=L:TYTIB6?V;DKCCJEX
MFFKMQV\NBB02U0_.B=5]?)<P;!5B@$E!7)$Q&NK-P8C9*3!II (:T[ XZ9_/
M6[5UOV<83\KJ/9K5Y"60M&OBN$//0]",'*,%=U[3YF158I*X;^]P0J^%[!3R
M6X:S4%%S)M'[>*[T.PNQ=MSJK@_%JW&836U'?&5ZH$%N8)OG:*&$J*J_6=F$
M!J*1$'['R16[AG=2G!D!$\/B5$6!7PO?K=G<;Q'27;M.=_5!F+)*]SZ?@ @4
MK$(=.K+>.G\[/[,5(]!7>O'5:,@O3>,25XDMXA_-;F%YJ0L=[L1L7W?78/M]
MP_['[_MI?V"?H7(RD$?W=,@JH,))I+&U>Z[V'^4*%[1QB?3>&-&>:VV$XVN,
MJGKJ&[Z>_'W2KN#'JC++O,\_9]UP=I=-EG[B$TJ]-H\\18$5 Y]#C$6+>%:T
M/[PTCK;"'UST)"Y#ML+JIYVCBWNZZWU2S)YU.$8'>:EQ*B<7.TQ!'>X6W+K)
ML,=;KD_<#'Q_KL\K!9/&JS?D& B1_*KP5ULL[,L;E,"LIPCACLE 3>E>XX5P
MKE_Y[K:T=SK=T!_3&V!.AEL 8U!4RX,&Z14,,P=7QHHSL-WE;LHCHQH;7"4Y
M<1@CAR_L=S!VMJ8I248*.7.DZ2R2D3PL2CK>3AHW#(10H>FCL,1KEJ&-KI@X
M9TER"@=Z^+,6P0;7NU7K(QL5#W\0?C8W8?G2,,D05\A84PQZC*KI#J"<X9W^
MJTADZZM0*/PLW8O)0_3'PJC;C[P_*>>S<9TA'LRF.G*SK/2ZT8LZGY>,5=*&
MJ."O6D48!FCCSS;<_["; .>ZUTP"_=(7(GU$DK>%Z=+>[#>P_#65$//K&<E+
M4SN2',>H+54:GZM>?)(*T=7N4>7JUGYV*@4.K.(T1*>DNI,P<OO6;9+@M!6'
MGP_>7-+$?*S]12$\OD,9\[69SPTPVFK_2AZ:0P@SGF4GM!6-0J81/?5U%-A2
MY_P5.6^AG\##1FJ-M<#HL_<IWK,TMAN8TIDI"1=XY<G#=W8:\W#HU$V. DFD
MDOJFM)!Z3 M 91U%WX*$*").6A)>S7FRRO>Q\< F/>*TC:8$Z_?+#G3JM(YY
MW(ILJX\3^)E</J%44N)6%E$REN@/S7G[="O"E'$JO2_\P/<O52O317">>L@0
M.XXP:<E0*'5Q"#@Q5NJ&KM[91/4G1 FV:;H4C>39]^#%]'A526UEV7+C2=3
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M+^,>]'9GRZ4:_EA]U].+.(V$:.BQ^P@ ^6F#?M(O1Q;B8U6P9W#AOOADK4+
M>.23'L,L6D6GDUO<VH,$_%O-P6\@EQ'DCMJ$>.:1O@ ''SV;E720-[='PE>(
MG/([]<R&%#3$8XM?YMIOJ2XGREXP7U,HDKZ-."7("I?N[YS@WEB\ 0:;0="?
MBFO71X[Z60GW=AKCODI>J,8>?.52#[!N5+LT*7M8(:P^"O  "UV2.%T04C1A
MK*<L2+T4T^0L+:$R*[YLMJ )F= (3?J8%FNEQ_A\%L>;?S=1YQU?- ?LJE"!
MP]YW [FHC4H/<URA3\36JDJ,"?W*\\WE$M4M>F-8 ;;JSB0,=ER9ZH7?S\V'
MM[J /?9?!QFW:[P0#X"-WJICI]Q(D(\+DH@+U@IKF<I5G_58W E-7($?BC_U
M2E2V3O'&>U.9L/, =Z.&"%S79T&!#@]"NYN@I#L+LDWU<W0I]]/#1;ZS/D07
M:K_N<D.\(;)7VV2XVO*=L^*+:E-&7:RN$\;\M:2M:IZ".'"5AFW"PC5.^-XW
MO*([Z/CH@XNO$PHHK<7.S6:F);RMM/-F>G^5VGZ8[4H9[J =F8I,%A?5_Q1+
M&3\3FTL*XF:/+)R;Z[F0VT\*I-:C$_//_R@J=G]YB4SN;QXYQ72'&+BU>T41
M;6^?&7%:J;+XNA6UE5#:C3>;ON]P%UJ707V&-E=[0D1[7(5]Q$VS+Q+)QCNU
MA6(VPR#'!F8[I&'9SAX8(8Y(XX3OH!O ME$L;D5//')>RPB[/P1B]_Z&4HSP
MZ*0PWV_P)<NRJUH.%I9B<.+6CE+>;U&285GS?/R5E1ZQ&@:1A?K[%X-=-*=$
M1(),*V*T'R"3/S[7\-+'#P+]46*7A^!A$OSS,38]<!YX57M.G!.J8\PH6+;/
M'K\K^;6/3",/OE$W8]?022&B)A9DO@Z-5"03\=1EM30R7<40K)HVUX4S6P<?
MKHU1?*(%#S$?BQOBNX<])%=468%(H,+S'8KARV!3M9:&R?3WH1)&3W?MFP;F
MN\TXNEA(/&@N.R,4:#H;)SF:4;,IKF0)C9=RLHZ%;VT:&8Z#+%,8V+U9"8L!
MR#D*NL[>5\.\;\$T>\3U>OS$7PTY>C%PN/X\?&5".?&AZ==.>.S.4'ZRDC=D
MFSC(/.) R?&@NH-ECXTW<@QU/69)M?]UR(+FEW##]^?R/74T0KGIO.X6I>2]
MN?=,P9FZE*J(JOM" 2K&)T^_QYK5<N-E2!\.GXPX+RT^\7'AH:?D06D4L_'3
MB+?DW.5 J0(?W<%'B)5:G](%H_T<EFG/<HZL2V%F[<_W<^_0";^[I_FR3I8;
MEW8-B@\Q1KI$7.-@1$X3:/KY(B#*A>:#0D6GE)%_-X-'#KDS&%VY4RD3NS^'
M$P;"_M:$7]-A)+KG7BW;*E!/2)IF!3ZML[OP$)4/F:;Z2L0R&\KVCV+^V\1Y
MFU+R)U/3>B0;E!J"$@OOABLHO4Y]-*#,%:CP\C:?1*)#%2@P\:<6'$UM?JQ\
MFC-_=72-OM5'(]+VW&)7GEJ*?'I-\&+M$>G82_/TV X>S#JBHQB-JYK2IUW-
M*J,Q!2OS%(BYRYWY@[]ZA3DOJ7HZW=HU/<YT2^@X^9SV]VSG70CI6Y):4[",
M<F.T;5L4E9 T+3G;#2#QMN>XM<O18VCD+=8>H]9)A94'R8&_PZ:WDE</=-R9
M']H;U,JZOP<E(75Y8]A"UW(B>"C(:5HPN6A%Y:F_,9HNL,4B-%]DM6#]P1.]
MJ=^2EYO?HQ=_Z23]JNUG^3[<KOZ%2(!-'^>-@+H%VC!ZL:>3W'.,HHB[GTDW
MX>!OV49C4V.R797-?7KCL%9).\YHRVR:]0?,N$$64:B:-3O4=1"25:0_T<XW
M)^&KV: D&Y.N]-GSJ1D*?LJLV%KA7I\UP)=L.^ /0CC[?CM"\GO=U-]<8K"7
MG12#1P4#GC;O[A.6Y[=RN:R&VS?M(30BD5SY?V5+Q'_;&O&O57"M_UXHMX.K
M_N\M#Y7D$3? ,2?8Y;H[;?6"WR'@/W:EWO$- />[OBT@!Q5/2:%; M,"/V\
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M8UZ6E(H.-9&^G;%M$IYE8.._/SFMY[3VW[L_BI;Z,,0AST'R^+M_Q0^0 $K
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MSYGFC+WLA$T:;TX[??C^4-C9N?< #->3N%<]?WKL'F3D=2O;/9WXUJ:O:2=
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MAKXUA_<]EZ PM%,!'!F'YMWPQ5Z*'G";Z=]2_RWU?YY4*()$&YH_M!U(/-I
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MK$@,[-%! W _#%+^J6^__?]Q[:)'011][B^071)\YR2*'V5Q&$?CM;@Z5BH
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M-6_X40&O_FI%-QP5L$=O<0C\%;SV0&K4XL\JM&V7KRN)1_1^K8R=5KQ #(2
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MB+EZV>#>W5U)TG_+4L;\RZN'UCK>'5*&J2;^8@%"38HJND+-@:?K'G#"?GD
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M&??O7I:8EMX]P4E1*N"3YA0ES'\9^O.BHN$]G*W6C"85<(K6$#+2X-_5IJ@
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MU,N+"!:<J.#0DEWGR[6:\%:\LQC=,#Q(RMX:Q/4V!V0-%KGQ!+_^/%B8QNG
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M\3G.+7JI8J7UJNK[O+\_"^O+-'QF@Y^B7) @::++-N$501.'R?.!+_0:@J@
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MF)M3QF4D+"5>P\FT;^</28B?NJ@M2JPI\MJ5V(AA5J7]XQ$JT<HLS4]O Z@
M;JD?O(EW-9"HM016EOC_I==NN!T,>/_/@72BY+XR%U98HBW$%;<X5;XP2,#,
M.XF&E1=6R0!>KHE:5/]I9'H#\X^73C0YI235(7>\8K%$L5C:(YUK$SG,"AX
M>MD5+(FQJ/J@?NPO>$('_"-D;QH&R<O M./_9FQC84&N>$S,"!O6R'FM*(/3
MQ_-L"G?$ 9-S36V!\X:]-U\8L$&J^MQ%(5 !=?/]H@D+.;\UWZ$<7+/[Q>!V
MPS?1H0R^8LL\G?Z2BGU_),5_>CZE_L_#56AHY"MKF_KBD[<4\J+\99BF70N;
MZ[2/&&8?-@+=RMTRS#Z5)B.SI8J6E]U!$/EK '$[DZWC;YFYA%&9I8:$6(Q
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MSX(B7D$#J[_>Y4JHYM^;.CV5R-0X>F'/.;E8PD^*2<R7:, )#3PR#/MG.#G
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MLM3<J*H?QR>Q%W(.[?BTF]':^+ECAC1(7B8Y5/A69.OA< 8:8!_#E!Z*+]%
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M=J?&KA-!.IB4$(42]/^C=7".T^L(B0G7;I&>T1X86+UX1D-;$VTU]5JW+;"
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M84U5. Q5<CB0W%ZMBZ;]@B?Z6E9YT_ZU4]FF7V%CQ$KLB./1B"&,]$/3X]J
M>^/QBI-#Q=]GJ9(V -?0K5)H.AS7O?2/=?[#*9FM=_X^[]HHN.K_^6+: 'RP
M71P<;;=? J%S@!IX/Z]H3EMZM?Z1[,4M!:E&';7"CFR-.A81=:0B(JOP4@4U
M<WUJ6RK!EF*0(*C*3$JZ(SSG7O7LR*#@YDG+)0./;J+#>IS:FBX:(/\^'=_)
MONWH4;OD9^:>)JN'ZW= VWZ'^<:&-ALBQY*)Y7/K/GA9(>8!> X-M$2I<R8L
M>(WTZC-G\&YFYLC;YW7L5JFZLJ3RV'0=)*V[:Q,%"@./#?(+4"SPSEZ?GN:\
M>Q70L]HQ_FS;Q":KV>=O/B>H_Z#$)L.SJS@A!?'Z6'V\%1*&))BR?_6R<LSM
M5XFB>F/T0,^T<,KJ[JI1;%?$XZ&A%P!.0>'RTV![O4XO;1/&NC@FW6>X^JY+
MO)V]M *&RF2:-6W;9K'FIKYA'\U/].A9/DC?U9OORG[6.FF_)!K17SR'5R_@
M[7PY5BZ;RD9L;N'QZFN(HI;0;LWQ$V]'JBX*PF_)U$KKBAQ&2GVO?=\1"''^
M#WL_,?NO@*F]UG1G5FIFFAXW:*?8#<6X5WQ.?K(?Y[$.JRC_>5FW8QRF>IQT
M78;8'MO@1YA<C.7@_%+LQ&14%'@!-*1M\C]&JD9*!KEC*P1 =Y4/N"RJN"22
M)-^LD=! T4"H.RD9/%(]3'G,CNW$P9&/D)!BG3C-=3*HM\34*VQ-Y)T?-[29
MS7A*4MG"/M?V9EF>:EVC\8V7*UT11*"!)Y=/VGX9SNSC';5VM5+O^W%G6UU%
MI^;N4,]5^Z07\&7B&(8_!9K(O8'\!'VCD&#QH^"R9\<Q^*AA$_(6I@4KD7/Z
MQ.!28[BUD"K;B^A597MJU<?[XUI6/]E#Y[S2'F.%4_966V)8DIK')$K,BTC^
M*#IF-?*0\J?^-GWS@-[/Y;YU]A.!Q^\9S1F+<#X]JMZBJEAK_6#,!+?,C#+K
MNLKQ>9$RT6M7-5 \G^OZ7H:20ED2P/.;+PT8!%&@V*V9:<8EK==4[YTS<2I.
M\A[PE_+,7:FD-O8SJ=A)O[S![5\8MR41R935:$+G=Q\>MCH29(PSQE<JZ+O,
M /?4FA B*LAM3)2P':D88O#\PL9#+R_/N;%2\2L".%O&03X]6NXJN:>JTBG>
MW5)A35F"6X)U-^N3NZ(L#IN+Z&M2UB_+%)*"+9S@6VC MO,:PC2@U_R%V.BM
M%TE'YAK=HP<!S?@E7K=J$9)(I9G2)L55[>G3Z]OZ,&J(I7?^=@K'>OE\<P*D
MJB/6/Z>W/I?GUUTS6@UU!=$;I3]1/P(>Q7?W'+Z$X=0D^[O:7N<)ZJ<5^;H2
M^PC6/-=_&H73=\_-R0E_L/'=(QD6%743KF&$F)^V/_^3N)-5JNG<PO#2G*FH
MTCR.+]:/*#U<97H> (^Z28=R'QKK,<1Y>W9EA**XX."CB=Z ^_3G5;YK]6=K
MWM#NBI;Z^A"1Q;N06N%+ O)P[COS@<4+*P @G5_JVZU2J)RW^ROK\;WJ.?..
M[IR>,6G2Q!=>/7ONW_U$CHJ7\(^8PS*-3!9L:A.U"YB&SR9+>))NDR>S\_1*
MUIOM$3 5Z2M32!DZ6I@L@,E[82_Q0^%OCT>>'#48>BDJSK#")A2M;V3?J[?P
MO\<>MTKY]8"(+*Z.A V[V$OC":'&+HA"FMVZH:<LC\A7KW2?K3[\:0K5W'RQ
M\WQ2!'SH(W1:64;M+M:;QNO0D4;_0I;+7RS7I_<1FJ"3:1!B^R5^.%Q@M3?J
MS-Z%H-1/S-O?43B$9,_#3-7V@?::3_$[:PLP+^&"'KF*A>9Z >VC71"EI#61
M+=98]:SIE/0@#WYGK0YHUN--#I%[LP%-P&O=NA@LR86T]T('+#9A*)]>-.!_
M4WJ*%'D6@[JBQ%JE;I&&9^1OUZ8$3I2X7=KO[^%ZN%H+5!DJ2_:(L:,!W9M<
MWV>)O7@:/Y@^2BDJ\'L&3\K>7;I;D3@^#JW>T,TFWT[Z>-S[Y4FK:DAVK(RW
M;AO[,J(Y.VUK*>!W%7_8A[,U&,,"OP)1/&X7ZOW LRYNU^#?Y,/4_6Z!S?%V
MGSGOL=\ 9<Y7')R/[KP!]Y$O)O?4>4I,O5DNXDS4H//YU(1X7X?&]2_Y[[SE
MYGF9EYK&(N) =/.*=!]34(U@\OAAIN(<IJY-K\ 4ZK*!DMF]RV3(-[D[Z41U
MXZ=PNUL%CEO+JNYO7#T^J58*J[Q5TFQPY+VSI,AL+!YK. ;/A7$M,80U39C5
MUM3%.S7&R-=]VBF/W/GVUJHS,>U2^3:LEN'B=8GOUI\:8B!R:$#*#'-+" '\
M^H\.>Y;)JT=NP7V?UE;6(>0,%!E?+EE=\')T*$4?>LT0M[,>+^/T@[\$?=R8
M(82RT/HI5TS>:&5J[OWPO:E\PK[,[L M?&]H1EI^37IX"%>"77<L>IS!:=W"
M=F?D3SU_N@^X_+[<8RPY+<1+JI\^9]N_6NO%L"=N=%9X)P[Q?"FN"ZKL]@JT
MR$ZE/0*[N=/"""_J0@G @[,6?E$G.3\Q;<BM^UK,4:5LZE8>1QWW>*CPTOJ3
M7^^U@9M$B&_8WUOHQ5<!,^BM.??<9R2?72PM/*_J%@D[9%>]M_A\23-D F1-
M<>F$'/O(F1HG)48(.62"ZVC#6#X4[Y5)SU2N/F%,I-$AJ_--U1C$U<6M-Q$8
M)*D&>Y6)7N7]O>_H\A:DID*JQ]FZCI^6]K/:6;!C/S%,8[%+TXJ(_/L>'%E9
MOP>/^GD^>*L8?#'ZC= JO^5?,(A5T^JA=K6]_".O,+'V84C\10&JHO6#S^3R
MGVN;^'^JI8S].E/0A'S9B],HO5<WRBW(JH@OK@&<RC/<9%X<5"D0V_9J8JG9
MX.][/_2CR?UU99^6;3P-G4X^IWTNS#HS0+M.1E?K<;ICQ"3_^[RS_^PN0S&F
M_J_9 ?<??MYE\J>/GLX\O"[D7\I;=%QE+I*ASO\;X['UN?C_%DXC,-[HDGQK
M^UN1!;TY)HX:?-\A-#<IF14Z.LM*;0<#2+W W357WUL%47=#[,Q@>#-S^P;/
M"&;LCP]B&5O[BIT#L7"85'UI_AXZ*O+_?=.P_WQFIV50E!\PS'_XZB!CE3F!
M_W_*V3C=DNK0#$:6\);;(Q$E&\G9K<(7*MDDB44UDD4D<--.@$)Q4<K5N#_'
M8$E_QV-TE\;6W^<#[LP#FL^5(AZ$\;4[*1G_JWC#2?[C<5=A@IEVBD#!_\'>
M>T9%N2P+H!^"DB0'"9($ <F20:)*$F'(.:@$20.20<(("$A.DJ/DC.2<<\Z#
MY"A(G@&$(0T/]SY;]]EGGW?7N?>M]>Z/NQ:SOAZFJ[JJNKJK:G5U?7KX6](R
MMI>CZNX3R#.DXQ15Q"![M[+"H>KY]NGH>L[)U&$^_A;<9B:Q?8$'*D;F4@5&
M[:@Z\PRB]G6HKN,Q6]ER6ZT,P.2 &=U_DX'UQK7D]6^08X5]A1AO,+Y)%IFK
M.YAF5Y:&Z%@4WJ51'6K"-!-[..K.^F*!&:Y0W SF2#0_9M7UH+,R&,#H4O_R
MB!P7JX368WS;($3A,.HG"5DJUIE)J8:Q:^J"++;*AANGH>F)O_V0,0C:+]G0
M3L#]IX1\;4\+B =$>!QV%#CCA>+U"._)#T_OKK/(XG$'+-'R"D!IT,S5ZLR7
M6Z%B J6L/@,SKJ\\B+%+NY&'C<=UQGKK3#/1)4&<\((0[NA[XLV[?3XH/-RZ
M:%DSOC^X>^',TYNK6_BA<(RP',PF^:C*5YR#QR#V_/F%-IRI#=% @.>G0EH[
M51F5\WPXJS^W)Y?]:^S#V<Y[/%5&=U%'HF9J4OTAE5^A)=0^;BOREE)53;#O
MC1U5"2+<<H\LQK8XC=F5'MVFZB,N\( .Z:+R]3@D:*:2(1_HM#OGSIE3Z/N]
M6V!J&($>GK/LN1:RT\6\B"U_6GP[B#:4EY*+>[G<QTM7_C)=[)Z<F+]-@0O;
MYO4:&"%G-VC[ZMUM+U*Z6"XKIG8P>>\%S4V1X3@^ISN0RAROG=VUB-7)H.EN
M6_X"K.FO1W%+M>>\@W8";TCU2GH;PC$!KX1V.-.N:LXTHF_FD8?PP7:KDO8V
M*-?P\GW/E(JV"$'9S+M3$\U(J5=]Z.3H0 )P<"X>8H@OQKWHXBG(P3O+7P97
M3#Q/YL8,ZHZIETM1UPY(&$ +L\J4+B-\^ZI1OH.&Q)-V$3EL0  '1W\8$9%T
MS=.6*60>6Z\]I\JK/=CX**%X^4EZ18A.KO5;.UY;,YD8F3MGW90C#G;KV^30
ML!R$7;=J[>2NSJ./@4/:C/BZ74WV+U%9PR/<XYD 1]'+L%W)9=82,EV$@265
M,PAJS%PVNV#^E6(Z$_>5M@1#GJ-"R]([<F<2)F*4M29J1#Q<H$7 DXM?C*8&
M#FX\+EAAK6<UW]E3L>%>8#;V,>+!I_M8?C,8\-1C)>IT*VE9I'3QZ4XA2+@"
M.C2JG$[,[48[CA^P6;*Y$7@9AYN0D9K0DM)PZJWAVH N"T0>%/*^,3\SJ,VU
MX+8HRBA.M;0ACJQ8F2RN><D9H]:1N2:.]F)I2@HVM=I][5E:*$^;P2VXY,1B
M<2LM3J!-*G,SLE_1 GI%A*/IW@FU MXXP%L^I02MI8D4;7VC /8@GEH4M5N]
M#"G>)5#T@ K$]R!1C39=XHF5NG%3KQWC\*YJK):\X&:8'SKY;M+(S50\1,%3
MN$E<_:BC+KO.=!!SS)!CM%WF+7*5M\:>1M!B"YWHE# C]J^7 _Q.$8!QBC-&
M4)17I,O="$,Q<W%<3Z;^8XS[]0WC#IT)@J@0L\[+3U3A=57W&1,>^D?UAIK<
MSKG/?T/^4(\ZAR98!+2R#N,O+5[4W_J\6:I3G'+RNK^N!N.^283Z.Y;2W*AA
M8[KD*NN>3L CHN*MNIDCZZ.@[43FXI>1>Q/TH!LUG/CN']F$@Y=61=]8#B#)
M$&[=.OH; ;,=PB%'4\[4KZ?7ZVH#+8F8XNE"9>D-4_B^&-VD-#MU0?L:EF!V
M!=Q&,GX9A+C9XE8RQ$I/\MVLAM^V73"4IVK(-PGTC&B[_Z9-/-;GY T_%_H$
MI4S6]9_[KL?2<# .8WZDA7.U;5^"I1[(,H^!\+GRC7D9TP8VB<^+M>^M%+_V
MHI%LN]M^<CFP046HX&!^QZR<Y2&.U5394N[D4/ITST2A=$ +7?6"-FE7" UX
M&S]1V)59YUK[WK!"VA;<X.K'U2J_NUW-</LL(3DSE%_*5/VUH#K#C6[REN]+
M-'U-ME> KRZ<2!E^4><[WY4%1+ZT<<Y_4L@2 %8X2="8)M[S>DJG5HS"X&AT
M2&CC;WCGY<B+0!S3@U5E\$,#N3U'8M=[S?R:MD(A'TXU!RQ5'G9)BB_TH(\V
M&7N:!=F=)CI;]0P)OZ;^>)DQUN0,YVQ?#,1O+>S,LA .&7M:SAC/>9R ':\V
M_X3-G"&S (WEO@:=STW!N^]P4WQ@4UUY*_5Q^XXX%N//:B9S)CBLP=^ACC%,
MU=1JRCZ'M'(NM"Q^+2+!@<")C'&(=EQ^?G",-4!=P<H06)BEK67,M4:P;2@@
M!SM?<=QJM7>J^^3FU@^M*M>'O EA*@M1ZOG:[!XQQ];,>AP.5A)3%IWR0G)<
MIIQ1ZC\^7K@L- FP(5(/UBFC--%Z%8C37!]__S2X$1?ZU<=7"2_]..P9?]BS
M-23EM[,%G\PM?IW)N9-TT6=K7P8=Q5,?5'#&^32K2##8]Y"10$=N@*D_7O]5
M*/V_--!(T\!18:=FBT/9,Z(LE(;U3)<.-ANJ_P);N6X@..[).8<(=!6A+T:(
M=3]A25$3;HJWYVL!9SAMR$7+SB?9CJ7;?=6LO,1-$B4Q<"^VH+9K;$8;?CXC
MRCPCRNJ/L#&"4PQ9'JXVZK8G?'R>=RR9]F706NFP&1)/OT832];]1']0L#_>
M ,I8R2=MC?5,8ZO$II.._S=^=5B"T:[)NX.ZJVQ[@7,!S?G3%1"T^M^TF9T8
M2/SGACT-?I&[D7-Z6PI&\^C1KI9BMIQCO;8U'=>NU;O2.OS9JL.D%]1"Q:R/
MQSR%NHN^B)6N@%!!F87?K%?*QSC&7ON_62!(L$,E&<)$0_T"5<E=9;6K>DO\
M)J( -",\&A;5> 6@3:V\71_=E![=E)>R<%WY*5*!%QXQ!N+OKP"66+.CW.)?
MU2=1_L$-\\\&*KT2_'Y,XK5AEHZ3.QY48'3SR/O8(2F_)UKS,A!Z+;9NQWUO
MQNUN YK:ZHD&28XD4G@)1Z)6U$"U*?;7#[W@/K(]-,X7/&.-AC+C1-)CNX5&
M"2LKCQP("JM5XDU>/"I/T3I/ *HKWBI7O%49E<#\HW$WNU!\Q=RV^WKYI07F
M:?Q,5&+)<NPVMI=_DQ[($H#5!W\=P-9 LJQOU*$3'GLN\*PR\F"ME?J$(#T&
M7-"EB/X<6N1Z9Y<$9GRA#%-L9 _9:^";&&.J*AUWN-3?!7-DT06RC1K3?PW%
MW7O8NE*50?8L/43&V$1#-9C2NUY4\WE3D,;83B4&*K9;#WUMT(!^4>D$]YJ3
MX+U"S51W*H2J#6Q8LAH[SW*JNIJ??W1>LM!BS*#;YA[MW.<"0GJ4 !I.,M2Q
MQEO9Z<'&$U2C:G-9Q&N%;8',A?U88[ KX *2>H)W2)+XIU.Z;$-LED<1+N?+
M$-\FYNDO,X@<V2 -ORY(Q2PFU4@[QUC]9(07NB77]D+92P0Z[&!104&,$W,3
MKMUMG/!6BH($&VO@M1*7'=FSYU[=@_5)Z_5GK.&;@IA(E O1VLKQHBQ8=@IL
M\[R#1>F 6I(U !?RED+B;H# C;FD%/,#=VP8_;9F70ULA\!"P-N6O8-;COP2
M_N2A4N&-.\R^@4N1M4Q\"\H2U*Z<.^>P/4O!73Q?-HUI-NG$M>Y:DB*?>#0K
M5)R61SPWIFG+[QY86JHC7BY[6'9P6\9>NU%;D6U5AT.%F\<?)KC4H]5\/P*#
M(4NK3"03HQ+4'LO-[\3QW&D\3-PR$#I#;5M#3V,69/NC*-G8;T3$B-XSE43V
M=K_4-2!'F"Q#;NEIZYDEL#<E\Z4DU2G4MR=UFQ4;:TF#YF_+75CFI+_#^L3@
M)ZKWDOQZT5T((K\;%KMUQBAOZ5B7FK,8R)%TQ?(JUKG=K*7S0GLJ1^;IJ9I2
MDX83MX^63R$X(R5*CA5QZB.WP11GV&/#Q8']T@Y]8ZS)!.8N)@1+XF<UR;'4
MD?:A:KS ;TW_Q@\3O>@_AEQ[J/.3[PE)"(-AA:_FJS>P7H4T,1E:1!DH9%OX
MJ$X>N5EB?Q,O5P=;QSPHB=2,?(SBVP$BRM6S>8UJCN8+G+W7BR''[Y')[4:,
M7:9=AQ#DXG1(OI7%6\4-KJ]7L-EI]$+7VY^6C[^L]NM2X#S1)9VABL1.<XF"
MQ!51OLX!4&I6MZ@%$279,BOD]&/?]9\)VE1BL*WYRX4X^UCMOB[C\?L2Z:OA
MQ%;XQADLJ(27YCD"V0A.#;\"*,1^MDZ18+<5QZY&NKJH#M(SD]!&;-X9ZPC<
M^^5NKMT?2\MBWI1C./=@H@F^T+RIT=C\08S-0KE-HUNYNE8^8#GT>%\A;"AT
M0<YAI7#K1I>V^CXZ*DW=EFT,<$:_BXYTZ3W%@V>>:\C=>(!))7/7LW)I!!&U
MBB8\7]D0(;N)QM-MLVY.]VEB3:Y86:'C@\QTP-.J-Y)8SI&H'I/.[24(1;"[
M$%Q 5U[TV6''E"5:%9/V9WG^%(>R$&T-6O5G!=X92?QB\/,)E'T:,_'#+E /
M).1GPT4OA1D1<3Q/X@ O-M 5].D%/WGJ1^2R_C7FJ\W#ZIV^"#"S&L=.U&'J
MQ[&P#AK2G:/9)[E-N= I5G-;5U>CC"?WYV/@#@Q^S*ZXJ#*6-=&FRJS4<3,H
M1W@S>!?PJ .:59D_&@;X,R>=0;MVR%&3AL]RCK+@2>D/P3%5IE_50'<[HNU&
M" >*:@J(VGQ;,]*W#.]P5#)#C[<URFLG[HU-A.W4Z$ G!8@;P@F;V1JL9SK>
MW<7'( -H'O]4!%Z/GRJQ1-%5"A>J#'D\S2$B11IME/=%L,'_V;LY!2#&;.^I
M1:YZ!JTDHYCI3,=&?H&#(;Z[>D7-V.Y0L@?*Y6*L*>^W&:C9C+;GR E1S#SQ
MA_IGS.=?#&AL_\R0@F4IM8#T=I1736[OT3:TH:!%N+JC=:F9(/D5WBX-?F>V
M[KQYJF6EO$GDGKS$@<3C</[,14X&@DC,5;Y^A)LB/">XP6.I?]"1S[(176Z"
M@RD4K/G,#RIC__K=6 <*=IE*/V4P4=042ASJ8M/86U?NU^-A\.QN]T@_YL)E
M.0V6OC<R2JY+4P/".3Z>3 L&+HD=3C-&LP(A] E0W4=NW?(U=,%[Y=HH*+1B
M3^T?ZVLM[WU, O>,-91"^>1M"%R<6\5Q[[0+&Y2"7^=DK4'Q<KAOO3Y7T2-(
M;GVIB<V">O@LC0CZ3BST7%+D@S']]9Y+85A!<[K*M";>56/C[22\X7]!(2)4
M,AWDEHSK5%J=($0A^[H2X*N7WD$!EY9UR0%[ 07-:1A_MW82 H$<L- LTY[Q
M^>Z7MY<6-G\@CIS:Z[T"]"E/)XY0_E5I5)4E\/]NDOF(_YN=E2I;S]4@M5%[
MU2^WFK[;?8(@SH(NNY"6$NC_L['5OX?8*\(N(QHF.8LJMB5:GY^H%)IA?A-X
MB,I8LWC#W7"T0?\Z+.S/-W\SWYTW^-H$33-PV)%PU3BPMG=^6%$P#7?[CUT@
MXX]&7NZ_%66>XQO/0<YK6>9\/CJ;:/YC+=_Y(REKXG\J2KU;I?#R]AE(4(4^
M-[N-=$S;IK7GM//QVA4@9=:VHSJ$\DK+_G)FW\IFMU)>T'IG[UY]9?R3;A$.
M*BK08XRE0,#Y/QF^9ZN,*$^/*E3H+KYXG>A623RRW3-U5=/Q+QZ,;=/K<YPS
M2 CU[P_AP$\XA^)?;,8OS'Y_F$]N+)*+\9B)8UPP%2[H6YP]-:"M'L]N&C_R
M> Q_&?G](U5^7O@ N=]B;*/>@[[,C[3%TT1)YIU]BKU45\#O8\K\_M K:6\.
M6*!"1&?,SIG-[$7E+Q05$BW,;%8'"%6ZXE,5$T<V\R\/GR@X?LPBESSHER;X
M:%J;ON=WFKHCL(GD=?W]L<4B3[D.^;R8@X"F^B<ZI7EJT-!M?R=)_K/_HONP
MV_['_<#P32SF:W/\QZ<=3EH+7D[TD-=J(*14$%>,V7M)N.<1X;U;X2R('CA7
M>#J9.<G_+IABS@^7&V-^[)U(C.&,W$Z1E6DCS#3'C-%WGVG>'I- IS"F=X-N
M_GS@LDA,V2?ZY3!:/^<N_IG%?&^>B\H6I<FD\<@N!SO':HU\_]*M'DW R&TO
MR'9)F#LEOD3B,P*R?,DQ6538()2NH_OYQ2OO-M['Y-%Q+VZ_^/C88]3CIDEU
MFP(6N^7S"3:';:K[5ON42I'0MC%!H_J:+UN1"A4F@:Z17%> >?D$%K *AIBK
M11Z"NWTYBW9(U0@-V.>X;P:4&/3(?:;J/MD^D1@:3VG05%@J">KN,B"8N)"8
MN3D4\=K&NKJJS'#N:81^RS?]NW+UF"VGU6^:LNLR8<6)U/SF%#JKUOPSN5WW
M#V6LQ]Q7+TL22_A(_+V//#AFE:K+1HZ"Y#TD8AK\L'F?UC()<0-<I[W;*=GO
M1/:&CS\(=R5,41CZF=:F+"K6-#?Y67Y[A8^QG@+D@KCW(F<DHPUNC;G26?BF
M[K*!C;R^>]PPRZX+[*6K*H]GI+&J>]]K8WV7)JY/4ND+0(VG-Y4CLT1UB[SP
M*PC/K( ]JB&F#)MA'E6HO^RN>U880VA.D4*V"X_LZ O\S3/JB)=8=8*A,X/T
M2CUR3]ZAL\BU[J8PH_9;70%FIT6S:O43#K<,\<R5[D\B"V,?-"TP-M16N]Y&
MO1\I7E[.@YJ<EN14M'_'_;KW>U KD@9.M1#BC&6A,74'G%TU+,+@5*:8*_>"
MY(/DMO<;6VBUNS(L1PJN\*$RLJVKXZX, ]2I)[*Q-DZ>O>G"6(;UQEW<3XFU
M@PXZ,?[@(NF(+5)2@6]>WD4#-R0$'FBTO'B;1WOF+06X#@<TL5NHNK-!*QMY
M0!Z<>N-\+@ZUA3DQ3-2O9^E"1N3Z7D8JDAW-;[%B*UQ^*N%L4'8&XT;='QC/
M)-5(X '=?O5H(N;2.J"6R5RA*O4!^= M@&%UZCJ@>.F1L_!%;_,MN#-D.YZC
M**M*(]2)@7 H\V5 R]H95H[X.P?*(J[-<1=GJ5C0P:K_3I@1>9"Q2;!E1?!+
M^8>HI4:A%2@;3HN5MT(<;U-XFYVT2]YCWFCB?GJM<K0\A:^ SGDGO*9:O13N
MM,]S"'$XMB;\N&2E>Z+H5K(EF#U16_NT]/EH)WN^?!2#.V%G>7"2 UK@]E3K
MF8I%U4S"MSJ5+8V1RP3L5C-OL_16:ITF[CMHP:C!1(K7QO#]T2)FNX@.8T36
M-[@BTBKOI<5GMK!@ZQ=IQDLH41*4#FHTF]2EGM)A1V%:S?021*-*D,RWG:<4
MXF.BKRY" )"4)#)B^\Z:V14@^SWH@!=%E 3]3*;0,"+CDA[*V3."=O3/\#?_
MJ "^E5P]P]_K0[-HW0W-^G? W]>IA1'H+U>'"88+02M7 *4YX;-<ORDI^.WC
MF/Y*B;XN?R#)^"SAZ'?D,K_!YB;1*^L\V]"@(=+%%C=_K%=B%(RPA,6,+W^<
M.M!U">LX@S>H:1@26!(N?JC:6^?:^,KD++CMM:D_^<^,K)+<["?Y1%(PT:'F
M:-%WX"'W+?=WEG]G)[<EY:>1E?L-T(+Q7&8F8UUDU[I[0NEF'PO>GVA*P_QG
MZ'>$YZ#*B=V!.S$C\VVRC$*KN+54N#AV"]@(RQP7:0\->YO7MGS0'+X+0O;\
M#-V"58*\C;VEHVZ#Z,G_2/@W?M4H4Y<OJ?!(T(N#5QR+13/]/5%,Z6G_0/3[
M*,!:I8WOC&+6RCR1ENXCC!>?Y:,3IG;,I%JCU6Z SN_+K5$W%I145P4.H7EC
M1&(84:H(3K#D'@$.V5? ?T(ENL"O.L4L707KU_NKWFM3.Y[@*\!!';0 *3V;
MTG.2X:VFD>(Y2=WQK/ \O R#YC[9#D7DP885$*E+C<[2-56?PY0F>$\+P=_E
M$QE2Y!]O23@R6),Q":)IZI\/'XOKB+LBN[<U,?L(54*_!4CS! 57F7+Z-%!F
M(3BERLK&C\XIM=,K_1;<@AX]]2J^;7;''DPN)"02!:TV3VVX HR^9_PV<A83
MDY-@IY0V7GK\+Z0J2F=_BN.C?_MA K9W!>RBUEOS4Z<JJ[+'K=:.C?[+92'E
MF*?^:N8,)K+0N7*>NP"JG5S!9%B1.6D*[;EU+.1.JI&K\?%A9VVLN[53V5=9
M>MJ(UC0\0ECJKJCM:A!E$)@1YYZ^Q8F6][C<%2#'>6-:CZ%,4K1K/()6WK5:
MFLO92B]DFL*3'W'BN 1!6QBHR_&K7"1Z4G %F,A0\$SK^LM>;*JH1WS)^!#Y
MW+V#]'IN&@./DMV6_7T;%$MQY*6KDZ0LCP6/]X*[\1TB'D?3FVN&D&O99;IG
M&J^+XUVPPKI]O]OLRE,)A6:[#TY5:ZKJ#71"^5X-LY8R63TL!M$IH7AU I+Y
M[EJC%5< !@+2H?3$HT![>Q!K$V[^V77\N4E EAZ'#(R5:-BB&S2#W78BW]2&
MHZOJ._"PE3TE9:>:2)Y0_BZS(@]=J$3'W9M8YQ\Z=>&:K8U,!B,7XNG3>V-'
M(3R:R'$W-_.LD"22Q+?T&04R,7&I'Y< ";*52@:$\K+TJ/&8JDSH0NM7/UNJ
MBC!L*8:'F;8B5L$4_&HAQ,2T\#T[E Y$V''H6%%H>!U[Y?Q^LK,-=>:A=D]!
M3M?^O3KY2*SGMU6 I(,&F*3H;<A=$7%G5QL3(W"^A>;XZ?.J*J?G!Q@+9-F'
MNI^EY%;FY)9J4!D+\;RI,75#A-5'H#PO\)\&V')G[' H]7D=#[3TTLW3&L4:
MI5BPXGF)88RM>ED=!8!3,-_#!ZD_V3%J$&3JN@_S. U&I.\,C1'8"1*C^&<A
M1V<8LW :]K.VH-Z;#/PQ*C,Q=76.-?C,(<31=(D,)GX P](-2U40XONRA[SN
M^%%-K(KVWH*@]M=2AU"H.;49E#R AB'%I"&OXL3P,8Z^C;<8MDD2Q"ABG8?+
MI#Z)3/XY(R,A#1<2=HO:8.[N*CF?/0BAL,S.N7.M'Z,9'UJ.#S)<RXB:[D3*
M)D5.F^+Q%FJME=KI\E[++&.UL(D*L9F-$ 9]9@QA4V8[P2WC;7+W5B@MR)NY
M/W_L_J0R.=*(45UI2GVE)+B)"F9=#\FR,#T0VG'X/I$=P1Z?<3 #8B<!P>O%
M^V[X>$LP&)MZ&"Z=O.=;),!Q.I$EW"JPI5K18^_(*UOA4]>>5&\K3"11=4$)
M#,F,7LF!,[4U8R/:U85#*[-"I+_--,;Q@!X\#8'7O[*>*7PCYHA2<Q?&C(HU
MM;KA;_/)]6495)M]9ZVQB4G1]AAC?. Z'DOQ#>8&S]8_LA_Q-C= CE&3EYIG
M>(CKG3_G#W-FH)DN)B>6/KC7Y+D906^J!P\V+I9RX':GA"6-L45^F0=Q3J<,
MR9E.%"?OT8%/Y>)ZX]\=TE";[M:'SJG/#OL94#9--E>8C,_NLEM5V7W8,Y'=
M\%6/5C&;]'X&.*&Z6!FOO!-Z)#Z#)YO"LVXNW#U+?B^"-Y<M07=2VLO4U,$
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MW\G4Z>PQM+SX1#>]9\8X;!']]/Z+-4*19*DNC[PD).^.W!(/;'HHE>TBTVY
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MF(691T]P"O,C&AX.,$JUJA@]ZE[XD$'0RO!"\^T,;MRB)7N.#I'K]1(1\H)
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M86]QD'EIB/V.!)>R&GQY\WQS87?576/M>W$L71!G!NO"')&PK+?B%W1B+%=
M>E ^9*FN^]IU&T&WU1:N2K0IDG/.F<^)-W<VACU_%U%+R=).GX,V]>@*P  %
M-G]+WTI%<%RK^BJ?)A*_F1CR(VW0US_?^L ^=6>69A\R10$4O#Y_A&!9F*2K
MJ6B<Z'O,WC'C]XEW#.,IB/ I6=7C_)YSB2[R(+S$A!2;=TW$==4/N";OUWSL
MX2A)5*LY5UBS8V&+ #%[C$EK,$^]%$2Y]5 3LHP)U[PDUE>] FY"Q2],PQ"/
MW=6O *D[:E= JV/8%4">AGG$Z2M& UL,Q*W/Z;2_V1)JME)YKN8'1>&A'WCU
M/CE7/T/E#3KM64*)!\RPK5KSSATE[3ESS1.*CPGEB^:Q=KJ@XWAZK4R/;RW+
M$1*L(ZN"P[S-L/>( F0@1]X5X+U-@^21^1=QW93??X<DFMBSV:@+4TJ1/^]W
MFTT_"]X8,L/D*G"?2X\*%TOQSJE L"[7DXT)4JH&8KR.7!F[.9%SL!._&L-_
M<,>)GBQ!\4ZVM/!MN;_*EA?21K12<L9<EX/$+H0@!@$;A'B;\&LO$0&33V:P
M!@K'A+*.2-DQ@8'.N)A7<O?C4KM#64UK(/\BEPPD?BH)9%1J4ARF;W0%=)FA
MUJ3_7[=_ZE;ZT^B^47)AZF0K"?N0D+-H<^KWY7H_G:*(_6\/7R(,C]W9A4VM
MD#:+5:^ ;FV^[2KBSO]_FKO.J";39_]2%*4NTFM 4!"D2.](%Q3I'41Z)Q)Z
MD="EAR)%1$)3>@\!Z;V(( *"A!J0I0@8.@B2&^_NN;M_]Q[=3_?<#_F0<R:_
MF6=^,_,^<]X\\ZC[>E+R=^KSA'E^!.2)FW]%O'(>0YFZ^5I>3%5DANSE1KEU
M!!; MWR"!2Z>46%*S:9E.-!E+/AW1^,@DX[Z;^BD%5:1RR=3#N;_2.[W_]"T
M3-]IRC.0]:%TZ?J&8>I3N.'V^:$OM1'%KTS2B9G]JWUV2< "$5R]EOLZWEIG
M=,:X+BLKIH5J"8Y0E4=;.S]#+>R1U1R ]OM"I%&\3_XA*O]#8H=(Q_X;*5$9
M?\QRMSS5OA^BBF8-V;3]@GIIA>\+%:0\U$0)%B1,T3,%RC\?DK\<)%UNO-$$
M#D$$RJKV>;U&-B9>8;Q!&<Z;&!"&=\;K^2-G_]#\1K]D<$_C1KM24[H\G2*\
M]J6I#LSN>L:<Y[^* 1>]B&WN2M OM0";?XT$*PMOQ&C%&LXK!E]UCG"3QWGO
M>Z7E^E]*M<HC+/#+$D7DH9DBFBZFQI0<19RS.$7URSH#P8$.R%^47\M>@Q]]
MP@() 4:103<*_4#=AP&LX47=+YUHK=))I+U1R6&]T02S-?()GK\LE),Z+^\_
M;[F:,;!=!>M=RL^++KOQLB+[^=GTK,Z_B%/1DJY_$Y6 Q=\FNPX[/Z#8X=F@
MBCH.+TD?&#P?KMT'[;\I@W:Q+VE]Y6:$GY.XMA]_^._!()Z5^:]!Q\HRN!*L
M0H"+L$ZWC.^W1)Y34ER!OK\]@7.'F1V.M=(([P_)RP*D,\?+G4VK455%.21D
MUB-FO$^0#VL)DS5JS,.$PV<9!W#<*O7 ][5%Y<]HIZ$[I088: Q#"*O\Q* L
M,/Y=IR@7;=;:]:=IS\;6?7@+U[X&/Z=.4;^0UN+SGH'<N)1-6ZL-**/!P72!
M<):"#OZ$D4?_ML/UC9I,"Y<!2,LSY[0OQ?XLWO\M]Q\K F&B_5+/8R\6X:B8
M$3@7O3W2A&B1Q^7JZK?NLUY<0W]VE16WP<P/Q7&UB!S"T6NDMBA+9#AV4)2.
M!7KILB:NT^J /1S 5TH&3NH8;[QS=6">N&LOL>T0Y'[L5A"DT88Q0+8N#<'(
M4<8;"R[(NKIF,Y.J+X2N;)>O*UU4-.FX?U^V+ RSL/E\L2&E6_-)K[CI7$/D
MF9I8(5)32I/SLMC@I_%MXRNF8B^L&[M#($0V9G!</>LT6TB8 I%['6^MI*J/
M'^SYE\S.S)'X;UT]O?DF57EZY""M@,/]OMH]^Q:XPK'PSG+7Z'%N96G4J<&.
M%JJJWH(]]^X+U?>NNO3NE*S*^N!;-(7Q39_"XZN(GJ[+7@1]'%*+8F#'\9)R
MDA=)2 O,*#/2)[YDS5TR9![INQ,6Y>JFZ\>9:D$7@@7L]X\#EZ;K*^1[4IOZ
M;8JGC96N90=6],Z--CGX$PD+#4C,)5)(RN28[G5#F;[4+S\\FG(JFK4\^5*F
MX@\F5G-'23X9VIW(,*1;:&%7(&"+X@C50W_IAL5)>;>%TQR6++'(]:MAREVN
M160-(_JP@$G"1QHGC0%#6O.'AX0.22J $?CC:4<.:<TH7SV892.&62JXP.HQ
M:UT)]Q-=1&/,_/%-UPY%$BQ02*O5I$W5+UK$M1GKW3M157G.X1R0,'<4-=--
MVY1B8L895S0P8#PP &0I,3Z]POQ04H)SBD2\:R&1E;/&Q+OY(ERG6NIMEFU&
M0"1BR[W!5#**VY=6>L?+V&Y7L /30O[NG!(+Q$T^8-LQ^-":^)HOWS%I>IV6
MI +5[^3A6T^ZE]J(8!D3,9@)>:N1?N&V-.P)M&X[ 6/99PJ+%:FZXESV2JM0
MQ>JQ7;G%\VCD3':W0-8J-P<LP&9[2[;F0;V#_\4\IPL?RG=F42-Q-_44T6/*
M5FEV5IV$ORG0["; NN$)1@L?CQCWL^I7AE\]KW2:N?JA8E(LQ<1@\WJ6;*^M
M%C?]1Y;A-(:!02F45D2PE(FSJ;[][AWK,!)C6(:O*_*&<Y/]8.XMO,;9Y^^>
MV5HF\4L";FP@+2.!Y5:-Y>\GKJ*]2=1EGI=ILO[N9]LA;:'S[#X%$2%Y?7<0
M/N9+#YAL$$J4*,HT?!^ER:N1<@-<:?UB$@L,6 7GYM(KL-WSV3!J#7AZN.Y=
M+..I7-MYK49-G0Y2S77ACLQO:LX QN!;D:BL>!>8U\_S5.,KJH.F->M0PKJY
M,7%^S"2.6]?&HL%D1#XD'B_<XOKK4P6+-2FQYM)9/VMVFX)9T<(Q%E-!AV?L
M)H5WC.S-(VZJW=N41$E6Z8")URI(E+WB"*AX.=B1FB]-\ 4Y6(A+2PZ(B13N
M@8G6^%XE2"(T)=;1#21*3J"G3.ZSFWW"#2OKX[' GH71812M2_%=%_2>/V%
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MWR?VESVV .=@Z/M,)JYFCN#GJ)_VC[4RILSWF,ST@B^TIQ)RU_0S7J>A)KU
M4 W@Z?K_L0I-]1N#@[S0!S9%=)>*&_ZQG/+ABX89N.YG^0P+-$(S2UG_L-=4
MBM2]H:>VFHE"9YO'[ON5V/"2(!:,>TVQ^<(#1[&]N=D[=NF&OD.W-OR<*[
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M"N#D,4NA*'-AEJ"J]8PJ_L;G[S-9RW8QT:]^'1<9235YZNPWSE@YUIS.3/]
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M1:.H=! %D1H5!!0!I2LE^BD@ B+2:T0Z$9 >(! %Z4U%0$"(TGNDA$Y"1T5
M>B<D])Y00B"%R[?O/7?L<_8^O]^]Y^Q]]A]SC+QC9.7-6.\[G_D\:ZTYI_%[
M]KS'K8QJ%8:F=XG"?4//R$%XB"5E-\^L-]^J6VWGBP#TMRZ_/IGI)U6"87>[
M@YF@I$4?(8AE4 S6&D!M]=*BEI@SJR6DJ.SG'3]=V/$Y\J\_/KX3^IJ9#XFF
M<UM#3;9QF$A@"UV+>DW203#0K.:OBEA?@6<2(LH ?V0,W)$SD93%3V;%L8L_
MH64UF>,%! 3TJ[1*70+E04[#BG? U=^\+D<#V#^J'"#K0H"0R(Y9MD'?A]^L
MR?8S?XG2?Z*C[=+'DG;N(0$T"89O2&9B_V8](0B'Z;C1Q(>7X5;,+)GZ_=[J
M!TDNPS) \'2)*$X5I2Q2XIE^X'HH26>Y@X\'MV&KMJ/VXD5P&[-7!_;7S>U&
M%7I\-1,?QR6?6WJ,IL:=$N7Z4R#ZC!$#>T8>FNL/"V$Y!KQ#=J8O\+M'=5[@
M^\1G@9MVN"!ZWT+3]H_$W4(T-\R38-K5S]2#UV=:?[_&;]U8;:JIX7P=Y<OG
MD*YT*N>*]^ZI;H6=S.;\1+S,I"')B+#'VVU#2$F:ZRESTDGW;9NVNG5#T%M6
M6.GLX9NU_*9E4N6HC+H@U8A6A"-,)^:WEU!5AU "(S77'UJA^B<F#1/B7K[,
M/>@%!,<3YDF=9&VB7?<06:E=^%;,,< *+/?3)/0QKFF'?@R86'1@5IRE,".=
MD9''  @GVRJ<$^Z(>9M>$.EV;<B#*H5G9Z1<+?MT(TX;)?H@X;&O79W_M@V2
M\I3*0^XGZG3P2V';.6,W"5/Z*!04*76V().4QKJ@'O3"\[Z@/I7'^Q]F?9@N
MR6RV4E3I?^"<QP G-;@%\:"[AM@=89LUXC3 'AW;[YCVEQ!VHX*=;+HZ]L^2
MV'D$ICI%!WX3172$_1[_8I4.G"/U:FL M#P]>(:EN(FB TI&'Q[>V/YS(GWO
MGPV0B8>QED)%.E)M5,EP5VD9IZO[6+:2,['F]^\L=6>)-!@,-"@+6%9Q6F2C
M"@R&_"U]K7\7&QKS9-& =@B"3$(U/&I6H&9,7B7)T^F.O<.')SIG8EX3GT1^
M^O#TX8T%+DO3#P\\G51-;R:^6NFY^?/@"5<H9XV<S5TBY#&(:0L%BD$+-:*&
MXNXPJS[,G?E]M7H$9\-P&JJ3)RAR#  R39SATB%YTO*JP9-A^L3TA_FTT#&]
M!HKLE)6RK)Z3*-1<E"'\ELFS^Z( 1K$&AXA/14T:U[>DJ$V8.;JEX$!'EP(/
M"Q(;%'!X#&@Y!D2JZ>"V(G%P#K+)8'=K#>D2&OA7%]/>8#Y;RO6H*_/EWM;7
MO<$<5 $<!D!^.J1)2,YKS@IG]HN0=%'*-X]^*2!^5_2@/*7>5:6W>FH?N^1K
M:!*J9SGD\=Y @R?M[Z2,4X?7CP%G;V38))'B,A7TE5V*; %##R\N'IH=QBS'
M;?=YSC9UD\S(EXX!U<!.B R;GEIOUL>*YM[]D4K[;OY$PQ;1]U\1%D<@4D4=
M?!)"^D7 MENK+ _MI>H(I+T4+-=/\SH1P0Z:ZMGH/;(EP; 5?G:O_A;LZC?+
MU1N*JH>I4O(=/M++2=22[6)'L$'+\]SD8N75Q>4C1,%('ZC*ZY>\D9O)L\$9
M%:7EL>%6LA9%AJI,ECSCU)XE5,L?&J=8 %5=SS^8Q?JOU/&L#1N V9^7KNMD
MY6:$."V-0(R0TH&57L'CR3M.FTJ4TV1__) 5.;8U'\@*;:>Y['3U6-:N[Q92
M$N!H3)0:9/V)I)6Z6/FED,&XTF- 6>_WNE_DFS%ES.;TD()ESC;0E$ WMDH_
M6H0,)];JH.N'RGXD2/UEC/4][70JS"=+U;_/<WH/^4>?D3STD'CRV#9],9RN
M?D<UJ5Z-.74UKW\%)WX3:ETP!1&]YY#O0I3(;GL>/*L&6(W0%_4&-4&.(MN:
MM <T3D\P@BY!UB>&D1B)JK-B!..]V6N$6Q_/U0FP=AE2:N]PUGD.:E"[GY .
M;T_D5V\^17I4R3S]?01R"NM#Y;D:4X+3 OW@8VE'OAI0I0T<Q1:J1 JOB!EE
M3GU$?"[F-.#^Q?WEO6JI$X[-NR_4&=0+52@<;N\=*A&0AW6)<)JR&@R6"9M?
MR8Z19/CR]QFU16KP5ZA.QZ5[,!N9FJ%R-]OF&,B#(AX6Z0>T"2M$<U;RL*D4
MD:&%?HDXDH#PP#>J0'H@.N/E929+>F_=N:GO!..R](76WY,K*+I0R3EDG \G
M!SEK"P*)MYD,^KP8(2(1I17_-MEKXOV6<<M=R9@9C>$X.];:<L3B46;URG"G
MQ&#VE[R2VOF"M4#WLA)SYWL.HSE%UNVVMA !';7>]G<)H@S7TQ(!+,3J1'-:
MKIBYF"66@WKSC.S#E%HT\?P:7X/JI8)*P@Y'H]'<Y""5JPSF."*E^I!X[F=U
M/X?EXUI^_="\J^@77JE*9-SBBHGP<W5*QH>-:NOG4^8A8()>0$[8(,>^REYB
M@?]RY6IY4477]Z[",%<)%L#&V7LG,]3+$H.?%"@DZ5_036.OT6"3Y7C0>E#D
M_/7,E=M7XF(<FIM,OI<^>_2^(X=5T)5'ZP_+QW]\'O#_M$FR=EO(D1-;+4C)
M0DU*7F S_5<U!VPF=UF[3"%<?P3WRR;;B7W?"E?56<>V?=XEZ)E,M@6477AY
MFB]%4>)RUM2;KYS):!YG#,JC#1,I#"2$UT:H"ZTI3DH53[1ZJQ>]+B<BF>O.
M=OTU%X1'%Q)4Z5?K"5EI,K%2KTJ;'@TP!'GD_QBTS$U;$%$2]5D'<U*YR-XX
M9!R090]X&5I+2B1:0A$F87W#.;7$1R8&4U;VT5?,M*:96LK52C83(XZD4B-5
MV7-<&OQ0WGA) >?3&L4VUJQI[J;BRRY:6/6]4X-CO\%\ZN=#_H N;,-T<!!@
ME/#%H1 !".7K1Q?Y>DO3:I1G]+6XL,4*D2MRWKW!*AH &)8((NEE>;!3[]23
M'4I;<0A^F$+<@Z^SK@;RHV/G+[][/C5=3.T4TC)>$$XV;0%7\G0ALZFZ:#*F
MU()<U07DDC)I-\[0B?Y675FM<>VRU$-8R]6KM4K7WX# ^85?.=^KBE-$J4]'
M51_,24GBX8D^B LP%3+<5V@KUJE@XB?/5I[\$Y.)[;1H\ S2'I=H<42/D6!8
MX"3?W*:FZ<?"UW?:CP%/GJ,3R7>/ :*1)U&!=+KB&##H@_SR3T\GOU%A^5>[
MAO^CR:&. 1RK-C<'"X84RA2'3(8*+J<,DGA2Q/=^?;\RE@D5)]F1X01L1T--
M%2Y>VOK\6HV>79"=V^L32$]7O+)L=Q$5H7Q34PEHL>_ZBRA$3W;)Z^= PL\A
M(%[QS!\A;SD>L@G>$<D*,ME;&XEY_2Y=W_<8 .CR*?I9U'<#574,"'6$*9*#
MOL)D".&(2)@<@^4*J7-2U"7=,.7E;_\[HCMZOCP_J5($CGA"?ZLB/V/DEK1T
M=:%2DZ&U54:DVX99YG+A3WS#KW1DNI<_NK%YPFCLU@54T_M_R3<TO7["F481
MK&@!<F2G:>F9>]9?DL)!77.VO,27C//6;K"3*3NK3LZ\I2Y$&&L/OO,[=;*W
MI:DA0B[E3HE;]!WZT)>3\"N)88@\&A7C;E!"%A@.];Q.%(@M>)@3>"0%GGL)
M;Y6',?CCD=S0?OQH39G4S.]^)S>YL%UMD8"DNOX1TUWDGR>[B1-8W#LP(YJ=
M;->V\E9:RLUXZ\?EF;]W2-Z=_'PT,#Q0S<8NZN06OI>F9#0J\B&Q1UNROG:$
MC>9+42=>NJM_Y6]?O7EW+F&--\)YU"SW.5(PAL],^&O8L-&G9XP=P&I_ZL51
MK!$ZJ0O(M'1"8OT[GF$F.9($(R3L/?M6K.#%'AZ->^5!<S*;^V507@MA!O*B
MG7<!U@(ST862O^X0EP"HNW\7N#<0DBN,.CIEHT=<)SD1P)O,V1D>Y\V#$4;Q
MCU&C4D92OX4GZ"<\P:'NR!2C=3O<^>;EQ5[AQ$V9774$9_I0AZ'9JU^JA%49
M%!!A%.B>5#*^/NF&_I8_TPZW>QWZV%UJ^M[C@F]G7KLNAH!+$?R@N2QU,29<
MDSYA"^^NOFOQA+/ \ SFVS' %;U.YJ0\@<J0POYT8B,]WEG$N;*/?O#Y:WH*
MX?OW_9T]]U:MQIO0/B*;1>J!'HX8FVXQE9M%$9&UV;0\\>K4]8FL$@UNTX]0
M)W$B+PX9&2+F<N1;$"TUB9_M.I)<?UTE;Y;&^<.+J=\F>1Y\ 62[S4JU)Q<%
MSX/Y(4?H[,$H/&I(BD\*5QL.8,GX;K9;'WW&:ZDY$0]J%P+B$Q#Y$^NR-EJ7
M$,&7OC%7UCN;_>0[?,@U$K!J[>:K6;W:Z:6'!:<6%*W:$D<(+CJ<!@7%>T^G
M0"H0"/>>M9@0HU;ED-NLB]3FU<<BD&@+<Y9"@+O?]<]SON)BY0,:7EG>[D__
MSA$X\[]?R>@_WGCF0>?1:L["#*,*4@SXD ^>N'ZVV7,18QU*3(Z#V]<<6K7M
M'U B%^(K7PA_':LRXAU5G,S,K:E-(5I/_FJTC_#A2%!CR6+ZRIEJ2U:B *TM
M6 OWL!%E#-*;^*/ITVKP45/K.7#"+&.6FUP+XIS\!WR/FEK*K+F/\8W<U6<1
MA[73'[Y_7XCZ4P5TG6R@)= 9L1!&(P3.-%P4([/$EY#**[4>9[>'-!RH5E-I
M;X#Y\1N'EZ?9 :=KJL)?QH?$?#UUG[?P7P6^0X9_<BA"<OF? ^]7CK9_E23R
M;PQS$0[QB,X2(T<2>SJEROM]V0*#]VK\&F )?I:/XHS.VH0I3^L;IM,JD;_
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MM75%B&7 L#P-EL7;-*NU)@;BPS8$MWSR,$P2:0XQR;7/<'G@0[*G_ KY:FH
MSE)7/_%&'W(/#ETZ>Y6L@*=\4!6'^1E."T#R2.:F+#3R*V-]1CH6?#&$Q?4G
M#AN'/E_?M)/0[K] 2]_@W(9[&6S=V4<*FUM!RF'L&B#Q7/16P=M;Z9>3^U-&
MC'EWFD71UOH#Z9(]:"[Z()937='R*J$_RFT1+9DZY*Z?Y),U)9"TS\>SIH ;
M+KCW?*&PE-K_I40SCUG9.#;6^O+?*Y%1_ZL50/ZSS#05YC9 929"VF9%R&YX
M?2Z-@FG]?-1FAV)#Y(< B+OLV3Z&T^>%<ZD%WY &Y9!.8=:J4:G]H!Y)J7O8
M#O]TGW188%YG]I-6INL&/_F<#UY\4N4'D&7:,*?@#FK -@N_#T74D.9AMDOX
M6;AXM]O9IA:V\]=,)XNU" F2V\!P4@C/$%UXY5(6HZ(;3B#H4:SNO:#(L)\&
MX>,M7Q+N+:>3P4;DM]GTWZDF]SPV@02EUMLNJ88"06!^LI9N3?K@7-Q[>Y3D
M4M=CH;='IC,8#E].]K59Q@$/V%6A)AN^NAKS5Y<&.:]=Y5IPTV7/F3K]YMX]
M">0GM$C(&)P+!IC<CG$@7R_$M#6?V[*$T+R"GTH@9Y47) Z>37*E1*J&FEVX
M^Y6SQ!G)2OY)>38)Y6VW8?)@<JXD8SNS5!S [,[O?U^A//G<429?CEV;?W2E
MRBYN!!0!0L7GH[Y!Z:"H0)$3K@M^8[=+?9BG[57+E7M.3M2[5:([0^#-?65!
MXNP;]3?9Z&<$SLTBO)1.!YT]M1O(5@[CG-,7M@I.;3NB'H7JW?I8F1(N_0UP
MF:U8MBG]R,F"Z!>.J[>+-1FMIDEK\WI=WQQ^G<H0>O^EK 3#HL<_7T1)AL\5
M"=\ES#92^,GE8WI$CN1":X69:#,IC^P//WAO?+E9(88N_O^G %@L1K\V/$V$
MP[!^H[/:"<$\.O G5%VR9)X53(^6IZK&7E6L7P1!N%QXW!CZ?LGJP[0GN!Q1
M71N%:(,#F@**-:>N1VIG/EL&RDFW@(AKU,$3[_6%.H+/APP\FVGAUL];3?5_
M7?WFD_F30V?+*5G3\05L?2M>\M"2 %\*G%!JC"N+.@8@?/+I7BXR/Q'%0'9Y
M#/<*^CRJFIA2 4%"5@;YD*5S.W:^MYX T#UOR::&5@7MK/#+%F397R"A&9<Q
M]/6S] '%E/ K(IY3;X(VNR ER*028H_;D=N.J@7\-'89\YNZ3ZL]!CBH])]9
MEX/9D'U?B3RRDT;EM0L;>!_D&ZT8U,^B#_>1_4&4O&9TEF^$BD-RS^'MN&OV
M>PS?>2C?* ^@^B;$$VK-MW*/.T+-@O+THR1,\-(K)R<JTVE,? @?UGGLR+U(
M.L/720W]33!+9_(GGSG/;GR>_MU^5]K%JYTZ7 ^Z<AH3LOQ6O?>:4MDC^FR?
ME"O<,&K_10QV&Z0-!@7D[*G0F;7+UVOY3>/WT@PRVE-V'JK*WL9)"[QV8)PQ
M?JI6LG<:(T)G)K=WP[_W=W!R8*%5NO4U!&1,F4A=8]5=E6SQ2 :R8^)=R3'V
MA/VCSF_K*<)B QLH-^DUE9E[))ZL6?RE7S_B9)E 3P[CMF+-4FT47V?U!CC3
MG98^EN;%=CQ/?AJ@Z=6X':"(^!88(X',E/^?\<B[G-$6H-C]3)!N8NOD8GZX
M/P_U^<Q/?X]E9K>WM(47?N()D/+RAWCCVGCW:MIMZ+5=W:HF2[+%/DIY8J3,
MF]*IZ_/*CF?<I)(L4@L&(U8\9'#=QF-CRT=G7Y"[6[*$R&&Y/_.A21J5HZ56
MYVV;WBGS[8DGJ\_S-&L\LL=O\SHZ\#UA?R+]FVR'7Z9>E'S24!]LAXMH!D7L
MB]K=\E/Z*/>70!*E7JOOR]$RSS*_Q^9%RD/Z3R5/%SB7_%VJ-FY\7#-5:>(]
MSUS(UJKWN"#C3^3@6EGA:DUZYZ<:_]'OLQ9/&NU#\;=7YDA7")"I@HRG!B1H
M7?&'7>Q"?TY>YO GXUL^/&8!6\W7Z^<PY^#N^A' R^\NY1@= ]Y!+),8*$IF
MML)F)&WU]9 7%-,_3UJ'9=__TGP@& 86ASF<^(07587\S@E-&$N;*[.M;-^P
M"\ZI;7I$Q1 NJ"?OKE;0\H\!+P^9:UU@EG,K^AKL0<Z\J_1*8/OIZJ.4BWSE
M' 6W,"G@' 5Z?\O\?HOQ8NJ.OG[]/DA/XN^2>R?J5EOUU'Q-1'OG]Y]S9>9H
MP^NMN[?&*8_/F=+/,(ZB*P;W(5)>79(S]W98U^]J/@]R.1/5/AX6L^-YXD;F
M7J.QX#'O]LX7%9=O>.&OS!_"LCH;)++K.<[_5S=)^&]6+M(%/"_/DV%#R+6Y
M@1IH,N!(E,YNH0Y.3,TA)Y\<&*O2>:;&TJDAQ+Y,0B3.(Z;)4SV)M)[!KFB
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MF S7YM(:ROZCMI^V>0@3-99 O4'T)BW%?9>S7!.^Y:*]3JG^7+O (TD"/FN
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M6E6'2,%A0_<0?!!UKB%?/3F#^OHD+1]3_UA;W:WG*EDSZROIASWS>:2"N6/
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MN9Y84Y%>5 90WEU-R^Y/')?UY0U!E[SH]L;!E%G]JCNM^$6#!IZ18BWBKE:
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ML.9% ;3DZ)+YWN)KR?Y*NX=$ [)(S8[!" IGT5,(:EAG87T<H%H/)!I*$FU
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M-9]W_9D$#O[\<%K\Z4%J7 T$FAX_00&(\B%QX+")"X3T3+=5T0>;*(]U$YL
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M$#*<ZOI],$!^]*1FL[ADXP0;WB/H1$*VV@M9R,/-]%?>IB;G0==4F)6&FBB
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MM^J*K7ON5\E. =A8G,7=Z;GW(E8D :GML>=^T&G_Z%K76:[WKPWEJGWS\RB
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MW+I,>]>(IL6T0B>D6UE[2DM9$K>W[?-&0CB U5C*O*7R]F=K1#/Z_J^E<BF
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MVP;S+_[]+=E$A;_H=^-(FWXEY8[T3S=['9G<SQ-=<4YQX&IW&4:TX;3"8TS
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MLE(NRYB8V4VGRO*R,JV9<B=3#L:"F0W7P5>R=G\[[T^\06;@6\(R^XE!+U(
M3<Z>W11 G\+R.E=G#TP^E>C(^;57MDI<Y&JJC$ZLT>*IUOF<;W>E6_HWS63_
MG/+1"GMTR>^<UU@2_0[O+CFZYJ@5I4M\A"T !WUS)2?Z@38>+R\O)D<N<5Z*
MEXN]>B&E>>E4X?N DRIJK,;JW<58IL5%Z]3%G4K+\*<?2@O]'T=H*PJ(O#JA
M![#Z(V HFD.T%K"@MNGST8,4M4%;@BB_;$QL@FVN28=-IIF:KXW22NS$G)2
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M_\/1@ CGITNZ_,D@F S1G0_!.UX;AJN)U5/+$!F<N'4"(*0*'=GFR$9RJ4K
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MOJ^>V:L:.F:@OX%*+\ISGVLD/1=F.NX7#K;W(Y0?EN9M4='KN^LCD1G7:%>
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MC8:YX:G<B?>U_]6T^M_X-_X5D%P;_0]02P,$%     @ DX5\5+":KC]06
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MK  M&4+&VRRF0="$)1IASO;]8RX%L<E5A_3  /2C08:#D.BI@@1SY;L4^LF
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M]BG&U^;PBOX)R&I9^ONJ8)#$4WCU]^B2S:GC*JR:MX4_9=Q:@I" IY3<Q<Y
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M/?6NL@$WP$HF"122Z="_+WH_6$%,QHO&C6EWQJ' -)AJ:]ZRF;(Z+T#H&RV
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M1CF%S%D%?M9M30JO20CBPX(75S8R)PJBS;<=F.911@W]5Y_.>U_VYEX)K8:
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MNM<IS+>>GJH#NNX=HX48"7#<7MSV(;]4;\D1C<DPKV79?+'4+"_V%?>M2Q/
M;T* F#1^/B.F SFTVY[M#Q#97E'"K51ZX[,JWQ#[:RFW?I3HZ:L/6#: <,]S
M*]:PKV@7S&[IN03^_%^\Q\;[TD7X*U88ZV*&0E0M)<RX* G-)+W0(@<)OA%1
M[L3?976RVW51M.-ZE>]K-VIGIE9]%H]-W"WG7D H%[WS <WB/;^:0Q?&8,=2
MVTOYQU+EJ$T7_NT+R#BI72?C%)^!@;B3)A)(:!N<(WPJSWG0%HFW)/E+DH7)
MJE6?->^!;W^"Y3K^DQNE:8?)4Y7.X,,JATTJ/3,/MKV 2*9 _@13Z$Z/B$G,
MD;^&;<%B-PIS+.O3537O]E_E2QK>$:.)R\M@?"BD8R8%M/!-I+_.%30FJ#;$
M'W(>F;5%65 M\+VC%Z3?^T9\5GZFBLV^MHJ"1CCXB[U@)\-D?[9;A2'_S&G%
MB5"FMI6G*U4D1ET-$UK6G!9*A>P R)V@Q@R'!TVY4!7W.VW-QDRI9.I!X /A
M91!PQ_KS5K38VVK1+X"MGP;G:7/:D?R:<MGDX-:FJS@JS/;U^?ZQ\OW_37%&
ML6()'KC)VEUC+BCJ:+LA'B$7CX[?-MJ2<L^MGM;9;PX-">#70$L0[R]7X9PH
M4AM562A;E+I!/K&LA!Y=B2FB632UERR^$@U-@#LDA('.*#J10/<[)'"KS !=
M8G@ _LT=@ 3>+R !>&9U^0Q"YY(:"5B9=^W\Z-SVZR"#_*T1"-(H@2*+/XUO
MD !F'1* \0485Y]T-8/J7JR>;INX_7N/DJC6N3+YQ;#P\?CJE+LEYUC&6^Y6
M8.![[C7N*GBM$8QX^O<N=,IOJX\(#WYXW5ZE_QKW*FAG1-"80U3N,(^[H 8@
M)/#PKSW\0QOL"RM1A/_(D77;A#'Q7TU5^-<>9O:0 /M-R TO'1*0L+SD7?Y=
MC8,$PN?A&DA RN_XEAQ5\/5._*V;O7-PZEWW748\$LCEN<DX.M,)!?>\\W^&
M!/(Z+A&XUDA@W>;OW9S[=@TCUA _!L#C&0$_+GW9O__=MG_KYKKC?W5SW4%-
M?7L^B(A*E29(%1"DBW0)!$2:B!$1(;30E X_>B<_"QVI$J1&1$"D!$()/=)%
MZ2 E8.@@("6 $"$D&]W=MSO^WIOGSNS,SKX_[YF3<^[YGD\[=VXN= GV!^P_
M=B@8W F-X> _$\H:-.]^$QO2:.!L&]WN9F19C7IM\!'UABJ;11\ ,/0*AF[H
MSJF![VRSOZP=%4COQ%<GR<?P38&R.SFSHY1W+QE?</^<HFHJM,"$S9I-3_3E
MJK;RWSP\,LQ82'[%86K$.]30<,6!ZGF)>)(F3^Q"'B'N2+K]M&;^&=X;FJ)9
MMQM2 IOJS1\XI*&^X.RKX'?IY%@ZQK;S-H^V _;4;JE;N=Q'1A4/!*"&QT8V
M@TFT>3U']H%>;I*;H H_I\7&3P^'[=$-F<,XL\6$JXN]PB^"A!^UZ=?TZ_+$
MKI=CG!A81MH5#T<SPU]*+8]O J\)3?'A@3)7Y1 (;CEJFQ5@@D3')4+.D7P?
M"$MOGH(+>X,+0\F^*7B?U+U$!I0S\CM=OR?B_Z<>X&%AXGSWURG>3[WS4IK/
M.M==P-S=X4-A!7%5-ROA$Z6W$O3OR-5]:I!=/1/6?6/G\/9TG4O<$L'#'[$]
M%7ZZ;OMS"]+1]JUE*7P_5=]MGE.X-B2F5X(-YQ K9*-AIX\U2GLD, XK"7T8
MV1>JX%X4&&(\_JTON+5&6;[LFH$WWD(@,311XF:E#9>]491J'+UC6:#)02=H
M$G'G\>77E;D@Z;'^/F%T55.D$7M>7\4N<V1O6)9J'37P?E%TN!II "<^LA>G
M=M?JYI+O<]E)RR"E'A\6]K,?5XI9F-\QO*O\_"A[/O55>=GM&P,R3UPGY]Y>
M*MO,6BTR&0^K7@NV2MQ0G5W?XI2)($[FC8-JI>6#))><.I)>V 3A KCKXES.
M-9:'!)1#[QS7$+GL9R7XV9_)F*8,KQNEWSZ29=:5=TL*R[.,?"[&HE63= *"
M?M-U6P(^JJX4WM]0B%!+ZU R=%=;/'P:71O@9-@Q6,W2D]9*D^]OS7@E\"T=
M'K1ODZ!_08I#PB&9WI.F-M6+39*>14,_1N-ZEYC#W8D>6B0U@U&BN;<X5]@E
M1TD%:./X[L@PSK$2&CX2SC@<:CAOQ4<&;(RYOW36-6FH@U-5IMDGZ%_48%P0
M%QZ$&^8?V^PI*Y !"5A$9'6.]"$EB:-CW/OSWV@5MGOL3IP!3L:6JI !>N^F
M^]#(#_<VN[GPZ]!8:!5O=LE5Y[,'JH6.#8A;]?"@I@FL& ?$\GP:%V>Q[B6O
M!&7.P6'2M? !<_54ST*+VI=C]P\&7>X4="B-/*][6AS3K@>IR#*ER\GG%0OA
M-A^$>65]7.#VGGNKAO0E ^C45+]]M[#&W#^N"%5[E<B6E4-W-Y%T;FIB;[W&
MM43!4Z50+YAKY\T%S0QNNC^#BCTPKEOT%JO^XPLWQGKE.HOZ&LSF(@0MZI92
MY"03!?2Z+MK";3A1-*(*;<@NV.20G\&QEOL1."P\LZ!-7JF/[K-PB7C?$NM2
M)"[6F\V14X7'A$M=)+QW>#7@@E=5DP7WTP2QEPETBQ"A>#T6D7;ZKI,H!D0
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M-E0CUZ?LGZS)>;:^9+1HRV7']R';^%D(KG?1]7#HUZ>&"@[PBS+9JZ(9S'[
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M2P$"% ,4    " "3A7Q4S3IP^ 3-! "AE3L $0              @ $
M9F1M="TR,#(Q,3(S,2YH=&U02P$"% ,4    " "3A7Q4M2&<GG ;  #W5P$
M$0              @ $SS00 9F1M="TR,#(Q,3(S,2YX<V102P$"% ,4
M" "3A7Q4:> ).Z80  !JYP  %0              @ '2Z 0 9F1M="TR,#(Q
M,3(S,5]C86PN>&UL4$L! A0#%     @ DX5\5-Z5AU?</0  5 (% !4
M         ( !J_D$ &9D;70M,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M ).%?%23PJKR/>H  ,)Y"@ 5              "  ;HW!0!F9&UT+3(P,C$Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    " "3A7Q4%BU+T;!E  !8;0@ %0
M        @ $J(@8 9F1M="TR,#(Q,3(S,5]P<F4N>&UL4$L! A0#%     @
MDX5\5#X>GD1G @  LP<   \              ( !#8@& &9D;70M97@R,U\Q
M+FAT;5!+ 0(4 Q0    ( ).%?%34'\]Y]@@  .1<   /              "
M :&*!@!F9&UT+65X,S%?,2YH=&U02P$"% ,4    " "3A7Q4JRL-PPD)  ":
M7   #P              @ '$DP8 9F1M="UE>#,Q7S(N:'1M4$L! A0#%
M  @ DX5\5&(#_@Q(!0  238   \              ( !^IP& &9D;70M97@S
M,E\Q+FAT;5!+ 0(4 Q0    ( ).%?%3X3GMQJ!X  "SM   .
M  "  6^B!@!F9&UT+65X-%\Q+FAT;5!+ 0(4 Q0    ( ).%?%0#6"*&9(@
M  RV   2              "  4/!!@!I;6<R,C<Q,S,V,#1?,"YJ<&=02P$"
M% ,4    " "3A7Q42*1XR"^6 0!K]@$ $@              @ '720< :6UG
M,C(W,3,S-C T7S$N:G!G4$L! A0#%     @ DX5\5!9"VU\.MP  !^X  !,
M             ( !-N ( &EM9S(R-S$S,S8P-%\Q,"YJ<&=02P$"% ,4
M" "3A7Q4)@;#DQ+-  "J,@$ $P              @ %UEPD :6UG,C(W,3,S
M-C T7S$Q+FIP9U!+ 0(4 Q0    ( ).%?%0'D:%,\R0" &B) @ 2
M      "  ;AD"@!I;6<R,C<Q,S,V,#1?,BYJ<&=02P$"% ,4    " "3A7Q4
M U@BAF2(   ,M@  $@              @ ';B0P :6UG,C(W,3,S-C T7S,N
M:G!G4$L! A0#%     @ DX5\5%%&7>&I( $ ,Y ! !(              ( !
M;Q(- &EM9S(R-S$S,S8P-%\T+FIP9U!+ 0(4 Q0    ( ).%?%0 $51933X
M .=.   2              "  4@S#@!I;6<R,C<Q,S,V,#1?-2YJ<&=02P$"
M% ,4    " "3A7Q4B<T?F9"8   IQP  $@              @ '%<0X :6UG
M,C(W,3,S-C T7S8N:G!G4$L! A0#%     @ DX5\5'3LX')MF0  #[H  !(
M             ( !A0H/ &EM9S(R-S$S,S8P-%\W+FIP9U!+ 0(4 Q0    (
M ).%?%2?^G3_6],  *GL   2              "  2*D#P!I;6<R,C<Q,S,V
M,#1?."YJ<&=02P$"% ,4    " "3A7Q4L)JN/U!8    9P  $@
M    @ &M=Q  :6UG,C(W,3,S-C T7SDN:G!G4$L%!@     7 !< O 4  "W0
$$     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
